<SEC-DOCUMENT>0001077183-22-000017.txt : 20220225
<SEC-HEADER>0001077183-22-000017.hdr.sgml : 20220225
<ACCEPTANCE-DATETIME>20220225165025
ACCESSION NUMBER:		0001077183-22-000017
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220225
DATE AS OF CHANGE:		20220225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEOGENOMICS INC
		CENTRAL INDEX KEY:			0001077183
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-TESTING LABORATORIES [8734]
		IRS NUMBER:				742897368
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35756
		FILM NUMBER:		22681266

	BUSINESS ADDRESS:	
		STREET 1:		9490 NEOGENOMICS WAY
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33912
		BUSINESS PHONE:		2397680600

	MAIL ADDRESS:	
		STREET 1:		9490 NEOGENOMICS WAY
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN COMMUNICATIONS ENTERPRISES INC
		DATE OF NAME CHANGE:	19990120
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>neo-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:c83854c7-f1f3-424f-996d-5603fac85cdc,g:4d64aeee-8493-464d-9030-1629fa1fd3ef,d:a1854a760084469581a7ceab463d6c8e--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:neo="http://neogenomics.com/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>neo-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV80L2ZyYWc6Yjc4N2ZkYzRlMGZiNDk4Y2FhZTI2ZWIwODI2OWFiMDgvdGFibGU6ZmU2ZTZkOTU4NzNlNDY0ZThjZWE2NDVlNjE3NDYwYTQvdGFibGVyYW5nZTpmZTZlNmQ5NTg3M2U0NjRlOGNlYTY0NWU2MTc0NjBhNF80LTEtMS0xLTMwNTcy_398bec22-73fd-4d8a-b23f-0a149f9ace2a">0001077183</ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV80L2ZyYWc6Yjc4N2ZkYzRlMGZiNDk4Y2FhZTI2ZWIwODI2OWFiMDgvdGFibGU6ZmU2ZTZkOTU4NzNlNDY0ZThjZWE2NDVlNjE3NDYwYTQvdGFibGVyYW5nZTpmZTZlNmQ5NTg3M2U0NjRlOGNlYTY0NWU2MTc0NjBhNF81LTEtMS0xLTMwNTcy_26417d5d-877a-405e-8968-296d40f554d0">2021</ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV80L2ZyYWc6Yjc4N2ZkYzRlMGZiNDk4Y2FhZTI2ZWIwODI2OWFiMDgvdGFibGU6ZmU2ZTZkOTU4NzNlNDY0ZThjZWE2NDVlNjE3NDYwYTQvdGFibGVyYW5nZTpmZTZlNmQ5NTg3M2U0NjRlOGNlYTY0NWU2MTc0NjBhNF82LTEtMS0xLTMwNTcy_17ca2c2c-cb98-4c6a-996d-ecc689136777">FY</ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV80L2ZyYWc6Yjc4N2ZkYzRlMGZiNDk4Y2FhZTI2ZWIwODI2OWFiMDgvdGFibGU6ZmU2ZTZkOTU4NzNlNDY0ZThjZWE2NDVlNjE3NDYwYTQvdGFibGVyYW5nZTpmZTZlNmQ5NTg3M2U0NjRlOGNlYTY0NWU2MTc0NjBhNF83LTEtMS0xLTMwNTcy_c37f700d-b6c2-4867-b2cc-6a1812c6457a">FALSE</ix:nonNumeric><ix:nonFraction unitRef="rate" contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDkvZnJhZzphMWI3YmRiZGMwOWM0NDZkODg4ZGNlZTJlODAwZTdmYS90ZXh0cmVnaW9uOmExYjdiZGJkYzA5YzQ0NmQ4ODhkY2VlMmU4MDBlN2ZhXzkzNDU4NDg4MzYxNzE_3abe204f-2ab3-4a36-a712-176a29c29383">0.0151172</ix:nonFraction><ix:nonFraction unitRef="rate" contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDkvZnJhZzphMWI3YmRiZGMwOWM0NDZkODg4ZGNlZTJlODAwZTdmYS90ZXh0cmVnaW9uOmExYjdiZGJkYzA5YzQ0NmQ4ODhkY2VlMmU4MDBlN2ZhXzMz_86d6751e-70e8-4d23-a1f1-365b34121927">0.0275198</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="neo-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16bc87396d614913bb00f167e8f21276_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i46c8412ab640433d99f2e270ea75b9ff_I20220221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i306577667f484778bf45986f95823aa8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97aa2adfd61943129250ed16f5aef4cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i70ebc9da32df40f79360ad5da5aef714_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79d415270f85409cb33c97966be628d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b900d497a954a51b916af633f093d2d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e7e38bca0a483382014babf710343a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d041f360e72469b85c9fb255e34af5c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4187c911d534ee0a8aa9f97ffb938b1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa4741509064ec490975a24aa59cd1f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78002a692994bf9a3d0e7bbfb10684e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id547d59cc8974dcda13cff3fd0b89721_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a0530d49904cd080aff3e02d8c44dc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b950b832fa47e2a4081c8b4e114d98_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8efe0d97fc1406cb5ef0d9c377ce77d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09eaaff3cf3e4c139b248da5aa23a90d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff84eeb2c41c49b5bfd127f0c4245c57_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d2ab56c92948dfbdbcf7f735be5cea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i688fe6bfb720405dbb35c980f41b1802_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ecbb3fba22b4fce8d7cab8d90245383_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e73e76fb9d740ce9295635957e3246e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9052537da8546a7aa1dbd81390401be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9645b439ad4fc3b4c672c2c734a7e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d0917029a34ef29e913c208110630e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id918e17d65804ec2aaddb4bddbbe04de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dd25891418746beaebca51736f0026a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d0596343524d0a9e26d27762aa2791_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83026cc4bc5d41b4ad74488ad2199f77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f50257a2f734bc48f00930c77961bc5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice51bbf0728a42838fa6df2fe01bcc47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if407078fb14144a49b4fde832c9c9fd0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ac84e649b24f039e093f75604210c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib815884d2c9841e7b4cf247a74f794da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe82c466a4049f6ad31f72b2eb34e2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eb531e73f524c3299d26ea0b0cc94f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79509cebd90244a19cdc2cf04c78f592_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18eda084cbb54f798854f0d69e97920e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a51adbb970403990c2ec023fc31d62_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>neo:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="id8fa1647fb744e689ec47a53eb568d0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e0ce2e60c5f48469d701fa7b04e3fdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i254845f3a44141fc942661d21925077a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3530310efa1a411da896298ef26d7531_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib644839f440545ae8408c532800708e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d57451dc3554d079ea8b73a036cab7f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i703a879602c940af8370fab4717a800c_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ee856eea894002ad4ee9f50ed2417f_I20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-07</xbrli:startDate><xbrli:endDate>2021-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8259a282355a443fa5a631a8aff168d8_I20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie972fa406763417d8f2c25acd458f794_I20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e1304c1c784732a549e74c73206cf7_D20210407-20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-07</xbrli:startDate><xbrli:endDate>2021-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b120b1a036d4eb488cfbc0aaf1ae278_D20210407-20210407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-07</xbrli:startDate><xbrli:endDate>2021-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f7ed50e5ea746629e2bf83cd1f470c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide651db4d96d4bcdb658a4ec18230410_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5dd1dfb285c4701b75adf82d4eff717_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50f0b20cb9b84704a2839897bfab2b29_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4da2d058964b75bd9d1986bbd5843b_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0bf694fe7e54138828b3af7f759dc6b_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056163c254b84758b521f7190d147b16_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60818069430f4235a500d9ef12d9797d_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic894cd7e3581485ea84cafa3847d68c3_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53250a94560e4680a9724632efeb9b7b_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09d7da96f3244a2ca7446eb12f52373a_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26e3bddf7f4f43deac1e105c9da91f6b_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a298c3d0be247f28f61c6f6bc44daec_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a906e75b19e4b31bb630f84fb76671b_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i241e751eb6ae41b0a89e6a8d1860ded0_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa897a9364d4ba0bb0ed58d1af8a907_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if693f0a2a745494496eeae35fb96dea0_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6cc8a93c1f0462e8fac56d280a8d2fe_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d155bca1e34d069f969cab67f80b2f_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5d9574696644e1f9309d0cfefa33d29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb76b6a1b0eb453db2e735dd98b1f29f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ca084f388f4e8697369585c4417521_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43d3909305b4bfa99fb106a2a366787_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6716adac8aa646019b124b8d827b9826_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3652099553bf4bfeb2731eeab20bbca8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab89ab574c9d401982c77a3b962e16c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d2c1e8a5f54322b16d387e79522764_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff47caf8efa84cd9b3978e89517a4e53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54d50e147b9488787c8e53018d0c7a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia677c5c475564da488a50b112b59dccb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89815183f42497fa9138d9ca4e8f7b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2bcfcbd104942f4850c679c537fde09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ab7a0601cb455db099d018b5e7ee2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3fa8f61db574f89a67fc8c16cf3711d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76224457309a40699695790b0f50e4f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffbb9a38583e4074b4296919f28d1a77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i638518a143ae4d87a72a11c64fcc3765_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc964799b214b28aed62721500a4078_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i697bd4c12c7545578588a80fd60c5a2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fff7b93030247d7a7ec551b5888bba9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec309e8b8ca4034bede264e6e054708_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if66997f44a6d49358fc4baf034b07e2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i704a124a4a974f0fa8f723461b30609a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93f36a0218f438aaa218be2623ebb81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746a7393ab77458f87d791a8c09ccaa7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42b094c7c0f04992a913df6000efec8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf91dd30bbfd452691bc71a1f3018647_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5abf1dd36ab74c1ab535b08da51fd03e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1fc88b8c4af4d838d278264c23593de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb1df97244f7467cb5339af566fe6b01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ad6cd969fd4b7995ef71a5a45c8429_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cc69c67cfe341499445ae00f2e71e27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie66912a44f91463f9626b1399dcc65b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374016e58cd24f058ea5bda9bf666837_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558037007551470fb27b3d37558ce693_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51cad3ea1be84d3fafc2dceed5c35c13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec189eb73b74704b15fcb292ea00266_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b095f6dcdbc4f00abc2c61aefa9f5bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c09dd584b74333a5ee8cfd4907e771_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02504c45cdee431f96d72f6ef0b3b993_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819a50dc28e74d5181cf147448558684_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie905db35afe34f1baf538346e1229ce2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4854e1e15ce44e82986165ed1c077b3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib160d83770f74b9b8af5700509a86741_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee0c00ad27f2434d8b93b095e710a55f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id904fbd917124e16bb45e001aecb4dd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9633971e98a74fa18caf2e387613ffcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50a6890d5edf4d9894153bf7442085c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf875c7bc1374e99ae736ce591a58b2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04f461e673034df49706dbcf7f464bbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b59437edee2408ca9c79c95d8d4ab63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4317cec7404a430cbea079ef5f61f530_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0773373ae2a84f8e978c278d271d8702_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida715c03157f4228b0751ab8b032c92f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa881d72ef684b53bc9c3d9157e723c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8469e26fb441bd917912f9f3502f1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i998bda56c93d4dd6a54740477cd3e347_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic657212cfb3b42ed8189daaa3097f436_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4421d3ac76904ead8fadef3b2ee78bdf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe0ac1d20e94e4c8366764e3173c3f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbde1cab9dcf4d98a6860b20663b33c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia43aad3092004bd7b9ca33e6dee09b34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea7bec6dbe545609392aa55eb5b135a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d680608e3bb4da6945d179588c188ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af0c8ccd543458fa9a3298f3d4ce64d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf8f52ad9b840b585d5bd5a88b2922f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7bf89c9ebb4ba3a93af970a63499c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c8bd802f0224b98af017ab422589382_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7609acc1e0564279a18161c77ee0a661_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c926b150cdc41c987af0ca6157a147b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic11934a2c2474130860676bb9c52078b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i882fb0fa1ed04909a0884aa6e36e11d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc5bdf0bd65547809e7e35cef332ded7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a20a06d1fb4012ab3ed6acefa4763e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08a6bbb0803484290d41e899ab2e80c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76551b3aac0541058270850f80fddc5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if012ec1a006545bd8bc701a1f1a66681_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i636c4a523c7044148f591fa542ca2a22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e0ff94327434437bddf706a1455ce54_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d92940bce5d4fc1a139df4991f04954_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff03a902a6dc4195b028b950ecde4819_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieadec132a5f64c42a09fbe4ba6114c84_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if418afdb92d045b3a3f7ed0f7f4d1122_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1c7ceda81e3493eb7227ddc4cd896f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e2cb12c76b947e78ab4acbe3ee1f639_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54d9161759f74b8f932b20183ffd720f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73a0aa5156842af960bcd14bd338f8e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84d1f59ac1cd467a8d62d4b587435dc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">neo:ComputerHardwareAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d1a2450d964986952b0cb1d7a972d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">neo:ComputerHardwareAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i880abad5544f42bc928b73e22ab0195b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">neo:ComputerHardwareAndOfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96c96643a9a49e897b82d45077534e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">neo:ComputerHardwareAndOfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ea353bc69b4538a77ec069769583e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc1b463b713a4a888492c941c54b0d54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0af911d8233f4962aafb743c2dd6a5f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e31541c268a47789bfebfdbfe3302c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea2775d83b054b66a7b7488b3b99b796_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib569323910c44cd88620b55283478461_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22d7d272d9234119b3defb42cd98b2ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie55f1b1da3e0488c9a6e5f436542cf5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cc823b18b445a48f1d7b22e1ae4708_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95ed315fe6ca4ac4b52bb55b50e60ce8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d27cc71a1714b4ebf592be7df20c267_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic20fd6415e784db381b4c4dc75be37e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i291ce8a7f66b4b84a5b2060a8fcc1069_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i151d387283274e48b13d8617c7cb5641_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b8f4e448e449b8833a37c30148dc54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6385c3880aa64c458d744783c9ed5858_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74fa1e58d23f4919baa197fafbd39ade_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia467e61d4253433b840909b9672e06a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c550d928cb64f8baa867e835a056792_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic957ae942d964cf9b7a556c4a93531fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac08cc60a5e4cdab6616035137f9346_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28d75b24f2140639b3049878575785f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6711068bbac647fc86549e4223bb1234_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1de0a4a163954f2cb05b76ae300bf20b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8170c0aaa5d7434fa9c612d65b268c2e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i637576e87f3d47aa8bf8b7d26b13ccaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98525a6e8714275ab1c829b7a50b6e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if411244f1e50462093c1aae195efef2f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if43301d85c4e4b128360590c43b56712_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04841638dcb14d26aca6ddbca52a8008_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84706daee59246f5ab9cf3fb66b19a70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0eadb39e524028b1b5befa8894385c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd218dd4ac047aabdc29a8180d928bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a9e3c3f614b4a54a8fa244038abc68c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a182d543fcb4f498a67a90731372126_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eff1173507945b488259b30471cc6bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a929c3ad7fd4b79ac34b701ad8c5f50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie027d3283ba246829bb5659c80860729_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9911279c90843e3b12761e1e6b7cd04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id70e96f3c16a456f80d98d1ca756c591_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626362dd9a22429d9bb4e5026984bc8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i211b3436a4454faea569497baa14b01c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i724957d1dba34eadb214d693374d40ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8e67a3847ca48b39b6ee1a91b870b20_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b55aa860d546afb934b299f66c83bc_I20200522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5c1aae3c584667a244f89cd8a59dce_D20200522-20200522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-22</xbrli:startDate><xbrli:endDate>2020-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3649585fd6c4174aa308719cf6e9e80_I20200522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b0aa1a691324c869b66196ee345f501_I20200522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4115d538e4cb482997d79b54d6ea7e82_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ef4e3b7e4349c09dfb58d45e01d6a3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2746f4168df4e39b0b9c9c32fab75aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55719c5ae1624deeab13abbd59d52c69_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a973dc561984ddf97bf05e50b7774cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0bd3a8ae9bd414ab4804e5744d62945_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd5b0ed6e13f4301a82540f21d96736e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0157f74f12948d5b65dae57eda95f7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie482047107814fcebaeb573c8d125f94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic34c607907124e1797f9b2a94c22f26c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67744929d544b18bcea0c016670b483_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c717cc90b34c8396331da311fbc8a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e5bb53850794a1bb9fe4a1d9392f790_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21e0442b30f14bb3be7f6da7309905fa_I20210522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5bd8263f7e1453fae593718fb321be8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e7531437724368b82772116041a856_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562c64b34e6c47f5ac6fe747404a6e3a_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93dce16f064a42eabc5af5199673306a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icedf740a0317452ea709d14ef5bf92f4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa9ea29f0bc44568dcd39d50b79abda_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id314aeaf3a3e4fd28f10f5c449698ad4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d9fb9ddce7e450f8b051082329851b8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcc7b5e165b64262a42245b5258953e1_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6ac5e675db4ac6837f4c1270b3e2de_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f1df0f3964f4e5f8fec10eac6e0e19d_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4c011915eac47c0998bdadb7a8c7b5c_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808a9ed8cc11448da4c70680cd987939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a23e34f1f24675a50fd9548060e01b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">neo:FinanceObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f65e6d59d9d4339974d98eb93610ffa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">neo:FinanceObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9236c81b3c974578a313916abc4fb1f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8457e19cdaef435383fa565c271d3716_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88a97a83c09a4c2fb216eb170e5f0549_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b91282517d4c9ca4fef081647caa7a_I20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc25a561b9d845e1a4b085174856869d_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c92183f6c1545059fe96165a77e5108_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>neo:day</xbrli:measure></xbrli:unit><xbrli:context id="id52cd4fd62d54923a9542f08f3e9e0b5_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0c47f77f104125b2614b3cc70b4781_I20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8316e135f82444fd960aa45a363a320e_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317802a689f346709fdb8f5e9f54cf2b_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e44ba920e9419596aae3ab89649f48_I20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34af75623b2843a0a57023612b0339a8_I20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia164ece2fda645d18a4614a36f3dde97_D20200504-20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-04</xbrli:startDate><xbrli:endDate>2020-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9736d15d029c4d79a63118c242b0a06d_D20200504-20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-04</xbrli:startDate><xbrli:endDate>2020-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8fa3e8e2304733b69c9fd8dc90960b_D20200504-20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-04</xbrli:startDate><xbrli:endDate>2020-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ffbe19f2b94211b4716f57813e319e_I20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-04</xbrli:startDate><xbrli:endDate>2020-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e141e5dc5ac4d099c050eacf32e2ce1_D20200504-20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-04</xbrli:startDate><xbrli:endDate>2020-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e710b5650c4cd790dff15ccb7d0cc9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47acf3b6354b4627a7978853e4d3e47f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapJune2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fa5b7dff3c2469793b45a7b9c0a39e3_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapDecember2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i872473cddd404138b10ac6c363634e0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapJune2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f2d85c36fbe4f798381a1b1b4a59d9d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapJune2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25aa5942e458401b9ff510cbfb4e37f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapJune2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a03a2c735740e0a62ec8fcfd378af4_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d84ea5eee6f466492f6a5f7b9c99c5f_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i909533f6893842af88add72e0b80061e_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0072740fba4f1f957dc041083ebbbf_D20210106-20210106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-06</xbrli:startDate><xbrli:endDate>2021-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7813f0e28ca47909409d4d71f3f0cc2_I20210106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-06</xbrli:startDate><xbrli:endDate>2021-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b6939f2ae8d44b0b65a46676533cb9a_I20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59836b2a553946d0a448161d3100d995_D20200429-20200429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f5d1a3736b248a992304f0788d7d8b5_D20200603-20200603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-03</xbrli:startDate><xbrli:endDate>2020-06-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i681790e0336945d58f151a6d5808acd9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i831056d6c8b04c6c8f9562bb6f5192df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie255c1c51fd744cca5a778a0da0a5155_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a253449c87943b39413bdd71acbf134_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be580f98fbf4b08bfe75fadf6a6c0a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76afff429474a7f9ebd89074d5938d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib552bd7af98f40b89fa495c675994501_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85dd1e5d4a554aae80eca8c6f52b6874_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971c2719748f46e78600d16ad130da2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b827dae344b4efeb7a3cec6f619da89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i657183ed33254a23a110400913bd73a3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ebf39f1a9949e98894465429e942a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e0d681c2fc34b14bac44c4021fc624f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c7e18a3aebc410cb31023371db1e1f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be2f6f601ad4f47b7a64f324453f4ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f7aefd0c1144fcda962a595d1d326e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f2175697164b01b2aab1f8ff1898cb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83965d652d1d423f8ca32d729d617473_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec0d080a2339420d89dc78184ef8b898_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if16aafa54e7c4291827eb4a4a779b7fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d981c543aef4926ad686ff97522008d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb9f08a180f4313aa2080d8df018f76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed4a1d011e94710823acf48d3e17a2e_D20170525-20170525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">neo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-25</xbrli:startDate><xbrli:endDate>2017-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b45da9a6c9a4f8c9594977540bd40f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">neo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679ecadf68b64358a44f898cebaed8f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">neo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4de4fe398a4353b1bfc64e3f2090b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">neo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i667bb3b470c64da985250798b766a649_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d47d42a743b474492f4e32571a3f05e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f72e0eca1d419dab353fa6c8a23098_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i321637f0a7b540bdbb4033a0247f471f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if213c108cbd74502ad64e78f83030eaf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id558c0253e714d4fa8959f36f7ace8af_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a5278b10f214b99ae816d90c219b11f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib515a6110c0c4a03b0ab671c0fd68174_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie847e09d489543aea8789c0dfbead017_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0e7f7754324dedae9666c62419ea78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67fff1172685496bbaf7a54a6396eb92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e92c7aad5c4209a4df55556c23b848_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ccf651c92142fb87ac4f3feb892173_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeeb6ff7726a404aa5ab12499665bd21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37460a8ce1e41cfbb99f9a168dcda88_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a4237d1df945f78f4dd92cf2d83177_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83dc4513b1f24e378f0be8c6c7f73c50_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ba577adb2b4ee4a77b0a9e0248c94e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dccccc0a21b4ef3be05781945900129_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24a99cf2affb44979b10edd8cc9305bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:HerMajestysRevenueAndCustomsHMRCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7819d6cd0da4e4da9a9fdcae4fb87ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if495aff7c41d4b8aad8f6a3241978f33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0dff7a9994470f9689008656bb381b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c214db41910419cb07bdbcc42d83756_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia87bb3f8d04745f2889e0a2f39c141d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife334d7e97604dfb939dddee1cd879c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1225c352b00e4cb690a7adb7cdcbedde_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a9dd7cfafdc43d091c918725cbc192d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f155818af974561b4f8f18784fa25f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57a16efa8cab4c0c99d0598296108afd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i091d1f087aa54fdfb74ce0705a97ff6b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d1360a007c47328b217b42d2e1ff65_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e3dba7dbe87474f82bf542453f20492_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i383f1d1042d44cf1b819e519a1682405_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a0708e137d04355b6f919e001c59cce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf2957894b7a4d2f897b45f006d71ee4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fedbf43609e4de1a63dab08b8a57324_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74606006218e4bd29582caf14fce1a54_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeda459a54ed4faf87cd1bc16a70d854_D20210120-20210120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:PatentInfringementComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-20</xbrli:startDate><xbrli:endDate>2021-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>neo:patent</xbrli:measure></xbrli:unit><xbrli:context id="i4f4073899af34688810e3b224590c74f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a97ccd6ccc4b63a539db53fa7f8e61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:StrategicAllianceWithInivataLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie359835360d14552b460dfe2e09d74a4_I20200522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1bd7c4a65e8470fb2e0bcb4e07683c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i837dec7e8fdd48c7a1722bf1b1f3b0e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd5c1eb69c64cc799674374d18d6cc0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if43b0047444b401e8e1b445dd63adc4b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c1b9b8d04e54ea9b259cbdf629ff3dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2d0d6a9a7bd4a269a7535713c120fbd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd350be96f284665bf09aeefccfc73cb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83673f0de9224acfae001662ab57801f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i627f74b4ec984553bf1664500f452ad0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:WriteOffForCOVID19PCRTestingInventoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7798d7199db145cf9eee4dd9052c2e1b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia1854a760084469581a7ceab463d6c8e_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.735%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV84NA_3b14177c-437e-486e-9bfc-3324d9cd8a69">10-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.735%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:1.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6NjQyNDQ3MTlhMzBhNGFhYTk2NWZkNjU4YTFhZThkMjgvdGFibGVyYW5nZTo2NDI0NDcxOWEzMGE0YWFhOTY1ZmQ2NThhMWFlOGQyOF8wLTAtMS0xLTMwNTcy_c135a572-3c08-4ac5-b4d3-5b9673953dec">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8xNjQ5MjY3NDQ1NTIy_f4c62f32-ae18-4ca5-a0be-d62a514031e4"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8xNjQ5MjY3NDQ1NTIy_ddf6511c-72ab-418e-8066-6bade8e3e507">December 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:1.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6MzBlYzJiNGFiYzc1NDk4NTg4YmU4MzEyNmZlNzEzZWYvdGFibGVyYW5nZTozMGVjMmI0YWJjNzU0OTg1ODhiZTgzMTI2ZmU3MTNlZl8wLTAtMS0xLTMwNTcy_6ea81aa3-9726-40ce-bf64-ff7576aad72c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from _________ to __________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yMDY_7f63959a-37bf-443c-9a9d-2260c63afd12">001-35756</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.735%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yMTE_78d20d25-0824-4113-84d4-4b455ae816a1">NEOGENOMICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.735%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YWExZDg0NTFlZDcxNGNlZmE5OGY3ZGU5N2Q3NTI2NDYvdGFibGVyYW5nZTphYTFkODQ1MWVkNzE0Y2VmYTk4ZjdkZTk3ZDc1MjY0Nl8wLTAtMS0xLTMwNTcy_a0546f9f-3442-4a57-b1ae-d5482c03f872">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YWExZDg0NTFlZDcxNGNlZmE5OGY3ZGU5N2Q3NTI2NDYvdGFibGVyYW5nZTphYTFkODQ1MWVkNzE0Y2VmYTk4ZjdkZTk3ZDc1MjY0Nl8wLTItMS0xLTMwNTcy_ed6802fc-bf60-4af8-acdf-06a043fe85a7">74-2897368</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yNzQ_0aca73b0-7698-4458-a54a-e25e1725df9b">9490 NeoGenomics Way</ix:nonNumeric>, <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yODI_8f34a45b-7daa-4de8-ae3e-0ebf2faf5b46">Fort Myers</ix:nonNumeric>, <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yODY_66e88b67-1be8-4008-8e7e-afbc7ecb3fda">FL</ix:nonNumeric> <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yODk_4dd3caab-696e-4f9d-a3b6-a5577f147b21">33912</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address of principal executive offices, Zip code)</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8zNDM_709ec07d-bce0-4d58-bdd1-8afa495b288c">(239)</ix:nonNumeric> <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8zNDY_b08b9746-b138-4e26-8152-b24efe35d8e9">768-0600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:33.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.676%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Trading Symbol(s):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6ZGNiMDdkOGU3MDdmNDZmMzk1Yzk4MGExZGEyZTRhYjcvdGFibGVyYW5nZTpkY2IwN2Q4ZTcwN2Y0NmYzOTVjOTgwYTFkYTJlNGFiN18xLTAtMS0xLTMwNTcy_7cbd30a8-ada5-4530-bdb5-3703a39d7a9c">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6ZGNiMDdkOGU3MDdmNDZmMzk1Yzk4MGExZGEyZTRhYjcvdGFibGVyYW5nZTpkY2IwN2Q4ZTcwN2Y0NmYzOTVjOTgwYTFkYTJlNGFiN18xLTItMS0xLTMwNTcy_91102c49-cf89-4dce-b8db-2d7ec50d7270">NEO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6ZGNiMDdkOGU3MDdmNDZmMzk1Yzk4MGExZGEyZTRhYjcvdGFibGVyYW5nZTpkY2IwN2Q4ZTcwN2Y0NmYzOTVjOTgwYTFkYTJlNGFiN18xLTQtMS0xLTMwNTcy_180000df-95ea-4ba7-b6a2-b5688af3356c">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: Common Stock par value $0.001 per share</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV82Mjc_a5a83d14-8a68-461d-abf7-1f74bc7b3d2f">Yes</ix:nonNumeric>&#160;&#160; &#9746; &#160;&#160;&#160;&#160;No&#160;&#160; &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160; &#9744; &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV83Nzc_2ffc1aa3-f6a9-4aae-a2ec-deb3fc4afbdc">No</ix:nonNumeric>&#160;&#160; &#9746;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8xMTMy_8599e90b-c18d-40e0-bd91-8cdbbbee810f">Yes</ix:nonNumeric>&#160;&#160; &#9746; &#160;&#160;&#160;&#160;No&#160;&#160; &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8xNDYy_1c65f964-6648-4629-b83c-7acc25ea303f">Yes</ix:nonNumeric>&#160;&#160; &#9746; &#160;&#160;&#160;&#160;No&#160;&#160; &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:34.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YmU5ZmZlZjQ3ODE4NGQ0OTkxMDg5OWIzNjI1ZmE5YTAvdGFibGVyYW5nZTpiZTlmZmVmNDc4MTg0ZDQ5OTEwODk5YjM2MjVmYTlhMF8wLTAtMS0xLTMwNTcy_fb3f3b38-a82c-4f01-9ee8-21ac7d96cd4e">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YmU5ZmZlZjQ3ODE4NGQ0OTkxMDg5OWIzNjI1ZmE5YTAvdGFibGVyYW5nZTpiZTlmZmVmNDc4MTg0ZDQ5OTEwODk5YjM2MjVmYTlhMF8xLTQtMS0xLTMwNTcy_5f1d4b26-160f-4d02-8ac5-14eaa364336f">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YmU5ZmZlZjQ3ODE4NGQ0OTkxMDg5OWIzNjI1ZmE5YTAvdGFibGVyYW5nZTpiZTlmZmVmNDc4MTg0ZDQ5OTEwODk5YjM2MjVmYTlhMF8yLTQtMS0xLTMwNTcy_e9688f98-c271-40d6-b422-252c28f93850">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.    Yes&#160;&#160; <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8zMDg2_35717111-9c72-433b-8809-2c2ddd29240e">&#9746;</ix:nonNumeric> &#160;&#160;&#160;&#160;No&#160;&#160; &#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act):&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yNTQ3_6f151634-4478-40d0-a654-5bbace0bfbba">&#9744;</ix:nonNumeric> &#160;&#160;Yes&#160;&#160;&#160;&#160; &#9746; &#160;&#160;No</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="usd" contextRef="i16bc87396d614913bb00f167e8f21276_I20210630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yNjgy_ad7a9f9f-4603-4dbe-af9e-6d90368c3391">4.1</ix:nonFraction> billion, based on the closing price of the registrant&#8217;s common stock of $45.17 per share on June&#160;30, 2021.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant&#8217;s Common Stock, par value $0.001 per share, as of February&#160;21, 2022: <ix:nonFraction unitRef="shares" contextRef="i46c8412ab640433d99f2e270ea75b9ff_I20220221" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yODc4_69e914cd-085b-481b-bf1d-3237ab031673">124,025,766</ix:nonFraction>. </span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8zMDg4_420766c4-18e3-414d-996c-5110fa0a6d0b" escape="true">Portions of the registrant&#8217;s Proxy Statement for its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-K ANNUAL REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Fiscal Year Ended December 31, 2021 </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_13">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_13">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_16">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_16">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_19">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_19">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_22">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_22">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_25">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_25">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_28">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_28">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_31">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_34">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_34">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_37">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_37">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_37">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_40">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_40">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_52">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_52">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_52">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_55">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_55">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_55">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_148">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_148">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_148">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_151">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_151">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_151">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_154">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_154">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_154">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_1357">Item 9C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_1357">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_1357">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_157">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_160">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_160">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_160">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_163">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_163">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_163">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_166">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_166">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_166">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_169">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_169">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_169">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_172">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_172">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_172">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_175">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_178">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_178">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_178">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_181">Item 16. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_181">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_181">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_184">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_184">102</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements. These forward-looking statements generally can be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements address various matters, including the Company&#8217;s strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, projected costs, prospects and plans and objectives of management. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the risks set forth below under &#8220;Risk Factors Summary&#8221; and in Part I, Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements included in this Annual Report on Form 10-K speak only as of the date of this report, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time and it is not possible for management to predict all of such factors, nor can it assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors Summary</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The coronavirus (&#8220;COVID-19&#8221;) pandemic is highly dynamic in the United States and throughout the world and may adversely affect our operations and financial condition.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to rapid scientific change, which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased competition, including price competition, could have a material adverse impact on our net revenues and profitability.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face the risk of capacity constraints, which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to develop, or acquire licenses for, new or improved testing technologies could materially and adversely affect our revenues.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials and research services create a risk of liability.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinicians or patients using our services may sue us, and our insurance may not sufficiently cover all claims brought against us, which will increase our expenses.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to make, on a timely basis, necessary changes to our internal control structure resulting from the acquisitions of Trapelo Health (&#8220;Trapelo&#8221;) and Inivata Limited (&#8220;Inivata&#8221;). </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trapelo and Inivata may have liabilities that are not known, probable or estimable at this time.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Servicing our Convertible Notes will require a significant amount of cash. We may not have sufficient cash flow from our business to pay our obligations under the notes, which could adversely affect our financial condition and operating results.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend substantially upon third parties for payment of services, which could have a material adverse effect on our cash flows and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on key personnel and need to hire additional qualified personnel in order for our business to succeed.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on information technology systems and maintain protected personal data, and a cyber attack or other breach affecting these information technology systems or protected data could have a material adverse effect on our results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Performance issues, service interruptions or price increases by our shipping carrier could adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide our specialized diagnostic services on a timely basis.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use biological and hazardous materials that require considerable expertise and expense for handling, storage or disposal and may result in claims against us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The capped call transactions may affect the value of the notes and our common stock.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conversion of the Convertible Notes may dilute the ownership interest of existing stockholders, or may otherwise depress the price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Regulation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory changes, such as proposed government regulation of Laboratory Developed Tests (&#8220;LDTs&#8221;), could require us to conduct additional clinical trials or result in delays, increased costs or the failure to obtain necessary regulatory approvals, which could harm our business.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in laws, regulations, contracting arrangements with payers, or payer policies, including steps taken by payers to control utilization and reimbursement of healthcare services, may adversely affect coverage or reimbursement for our specialized diagnostic services, which may decrease our revenues and adversely affect our results of operations and financial condition.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our net revenue will be diminished if payers do not adequately cover or reimburse our services.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party billing is extremely complicated and results in significant additional costs to us.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations are subject to strict laws prohibiting fraudulent billing and other abuse, and our failure to comply with such laws could result in substantial penalties, including exclusion from participation in Medicare, Medicaid and other governmental payer programs. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The failure to comply with fraud and abuse laws, including physician self-referral laws and anti-kickback laws, may subject us to liability, penalties or limitation of operations. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to comply with the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) Privacy, Security and Breach Notification Regulations may increase our operational costs, and we are subject to security risks which could harm our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;NeoGenomics,&#8221; &#8220;Genoptix&#8221; and &#8220;Clarient&#8221; names and logos have been trademarked with the United States Patent and Trademark Office. We have trademarked or have applications pending for the brand names CHART, COMPASS, FLEXREPORT, HEMEFISH, MULTIOMYX, NEOACTT, NEOARRAY, NEOCOMPLETE, NEOFISH, NeoLab, NEOGENOMICS LABORATORIES, NeoLink, NeoLIQUID, NEONET, NEOPATH, NEOREACH, NeoSCORE, NEOSEQ, NeoSITE, NEOSMART, NeoTYPE, NeoUniversity, NEOVUE, and PATHSITE. We also have trademarked or have pending trademarks for the marketing slogans &#8220;TAKING CANCER PERSONALLY,&#8221; &#8220;UNIVERSAL FUSION EXPRESSION,&#8221; &#8220;Unifying Cancer Care,&#8221; &#8220;UNIFYING,&#8221; &#8220;NEOGENOMICS EUROPE,&#8221; and &#8220;WHERE PASSION MEETS PURPOSE&#8221;. Any other trademarks, registered marks and trade names appearing in this annual report on Form 10-K are the property of their respective holders.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NeoGenomics, Inc., a Nevada corporation (referred to individually as the &#8220;Parent Company&#8221; or collectively with its subsidiaries as &#8220;NeoGenomics&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the &#8220;Company&#8221; in this Annual Report) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;NEO&#8221;.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 a novel strain of coronavirus was identified and the disease has since spread across the world, including the United States. In March 2020 the World Health Organization declared the outbreak of COVID-19 a pandemic. The outbreak of the pandemic is materially adversely affecting the Company&#8217;s employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 pandemic will impact the Company&#8217;s business, results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#8217;s results of operations, financial condition and cash flows are likely to continue to be materially adversely affected, particularly if the pandemic persists for a significant amount of time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact from the COVID-19 pandemic and the related disruptions have had a significant adverse impact on our results of operations, volume growth rates and test volumes in 2020 and 2021. Demand may fluctuate depending on the duration and severity of the COVID-19 pandemic, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business disruption, reduced revenues and number of tests, any of which could materially affect our business, financial condition, and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken significant actions to protect our employees and maintain a safe environment while ensuring continuity of critical oncology testing for cancer patients. Among other actions, we have de-densified our laboratories and facilities, adjusted laboratory shifts, restricted visitors to facilities, restricted employee travel, implemented an emergency paid time off policy, provided remote work-environment training and support, and managed our supply chains. Importantly, all main laboratory facilities have remained open and there has been an uninterrupted continuity of high-quality testing services for clients. The Company&#8217;s top priority remains the health and safety of employees and continued quality and service for all clients with a focus on patient care. We believe that we are positioned to recover from the effects of the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on risk factors related to the pandemic or other risks that could impact our results, please refer to &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a network of cancer-focused testing laboratories in the United States, Europe and Asia. Our mission is to improve patient care through exceptional cancer-focused testing services. Our vision is to be the world&#8217;s leading cancer testing and information company by delivering uncompromising quality, exceptional service and innovative solutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. We currently offer the following types of testing services:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cytogenetics (&#8220;karyotype analysis&#8221;) &#8211; the study of normal and abnormal chromosomes and their relationship to disease. Cytogenetics involves analyzing the chromosome structure to identify changes from patterns seen in normal chromosomes. Cytogenetic studies are often performed to provide diagnostic, prognostic and occasionally predictive information for patients with hematological malignancies.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fluorescence In-Situ Hybridization (&#8220;FISH&#8221;) &#8211; a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes. The technique uses fluorescent probes that bind to only those parts of the chromosome with which they show a high degree of sequence similarity. Fluorescence microscopy is used to visualize the fluorescent probes bound to the chromosomes. FISH can be used to help identify numerous types of gene alterations, including amplifications, deletions, and translocations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Flow cytometry &#8211; a technique utilized to measure the characteristics of cell populations. Typically performed on liquid samples such as peripheral blood and bone marrow aspirate, it may also be performed on solid tissue samples </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as lymph nodes following additional processing steps. Cells are labeled with selective fluorescent antibodies and analyzed as they flow in a fluid stream through a beam of light. The properties measured in these antibodies include the relative size, relative granularity or internal complexity, and relative fluorescence intensity. These fluorescent antibodies bind to specific cellular antigens and are used to identify abnormal and/or malignant cell populations. Flow cytometry is typically utilized in diagnosing a wide variety of hematopoietic and lymphoid neoplasms. Flow cytometry is also used to monitor patients during the course of therapy to identify extremely low levels of residual malignant cells, known as minimal residual disease (&#8220;MRD&#8221;) monitoring.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Immunohistochemistry (&#8220;IHC&#8221;) and Digital Imaging &#8211; the process of localizing cellular proteins in tissue sections and relies on the principle of antigen-antibody binding. IHC is widely used in the diagnosis of abnormal cells such as those found in cancer. Specific surface membrane, cytoplasmic, or nuclear markers may be identified. IHC is also widely used to understand the distribution and localization of differentially expressed proteins. Digital imaging allows clients to visualize scanned slides and also perform quantitative analysis for certain stains. Scanned slides are received online in real time and can be previewed often a full day before the glass slides can be shipped back to clients.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Molecular testing &#8211; a rapidly growing field which includes a broad range of laboratory techniques utilized in cancer testing. Most molecular techniques rely on the analysis of DNA and/or RNA, as well as the structure and function of genes at the molecular level. Molecular testing technologies include: liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases; DNA fragment length analysis; polymerase chain reaction (&#8220;PCR&#8221;) analysis; reverse transcriptase polymerase chain reaction (&#8220;RT-PCR&#8221;) analysis, real-time (or quantitative) polymerase chain reaction (&#8220;qPCR&#8221;) analysis; bi-directional Sanger sequencing analysis; and next-generation sequencing (&#8220;NGS&#8221;) analysis.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Morphologic analysis &#8211; the process of analyzing cells under the microscope by a pathologist, usually for the purpose of diagnosis. Morphologic analysis may be performed on a wide variety of samples, such as peripheral blood, bone marrow, lymph node, and from other sites such as lung, breast, etc. The services provided at NeoGenomics may include primary diagnosis, in which a sample is received for processing and our pathologists provide the initial diagnosis; or may include secondary consultations, in which slides and/or tissue blocks are received from an outside institution for second opinion. In the latter setting, the expert pathologists at NeoGenomics assist our client pathologists on their most difficult and complex cases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reportable Segments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have analyzed our reporting structure, the information available to our Chief Operating Decision Maker (&#8220;CODM&#8221;) and the information being used to make strategic decisions and have identified two primary types of customers: Clinical and Pharma.&#160;Our Clinical customers include community-based pathology practices, hospital pathology labs, reference labs, and academic centers.&#160;Our Pharma customers include pharmaceutical companies to whom we provide testing and other services to support their research studies and clinical trials. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, our Clinical Services segment accounted for 83% of consolidated revenue and our Pharma Services segment accounted for 17% of consolidated revenue.&#160;Please refer to Note 19. Segment Information, to our Consolidated Financial Statements included in this Annual Report for further financial information about these segments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical cancer testing services we offer to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. We believe our relationship as a non-competitive partner to community-based pathology practices, hospital pathology labs, reference labs, and academic centers can empower them to expand their breadth of testing to provide a menu of services that could match or exceed the level of service found in any center of excellence around the world. Community-based pathology practices and hospital pathology labs may order certain testing services on a technical component only (&#8220;TC&#8221; or &#8220;tech-only&#8221;) basis, which allows them to participate in the diagnostic process by performing the professional component (&#8220;PC&#8221;) interpretation services without having to hire laboratory technologists or purchase the sophisticated equipment needed to perform the technical component of the tests. We also support our pathology clients with interpretation and consultative services using our own specialized team of pathologists for difficult or complex cases and we provide overflow interpretation services when requested by clients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are is a leading provider of Molecular and NGS testing. These tests are interpreted by NeoGenomics&#8217; team of Molecular experts and are often ordered in conjunction with other testing modalities. NGS panels are one of our fastest growing testing areas and clients can often receive a significant amount of biomarker information from very limited samples. These comprehensive panels can allow for faster treatment decisions for patients as compared to a series of single-gene molecular tests being ordered sequentially. We have one of the broadest Molecular menus in the industry and our targeted NeoTYPE </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">panels include genes relevant to a particular cancer type, as well as other complementary tests such as IHC and FISH. In addition, we offer molecular-only NGS targeted and comprehensive panels which combine DNA and RNA into a single work stream in order to report a full spectrum of genomic alterations, including mutation, fusions, copy number variations, and gene expression. This comprehensive menu means that NeoGenomics can be a &#8220;one-stop shop&#8221; for our clients who can get all of their oncology testing needs satisfied by our laboratory. This is attractive to our clients as patient samples do not need to be split and then managed across several laboratories. The acquisition of Inivata, provided us with oncology Liquid Biopsy technology capabilities. InVisionFirst&#174;-Lung is a highly sensitive, targeted plasma-based assay for patients with non-small cell lung cancer, and RaDaR&#8482; is an industry-leading liquid biopsy assay designed to detect residual disease and recurrence in plasma samples from patients with solid tumor malignancies. We expect our Molecular laboratory and NGS capabilities to be a key growth driver in the coming years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition we directly serve oncology, dermatology and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic testing services. We typically serve these types of clients with a comprehensive service offering where we perform both the technical and professional components of the tests ordered. In certain instances, larger clinician practices have begun to internalize pathology interpretation services, and our tech-only service offering allows these larger clinician practices to also participate in the diagnostic process by performing the PC interpretation services on TC testing performed by us.&#160;In these instances we will typically provide all of the more complex, molecular testing services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services revenue consists of the following three revenue streams:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials and research;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Validation laboratory services; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Informatics.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research.&#160;This portion of our business often involves working with the pharmaceutical firms (&#8220;sponsors&#8221;) on study design as well as performing the required testing.&#160;Our medical team often advises the sponsor and works closely with them as specimens are received from the enrolled sites.&#160;We also work on developing tests that will be used as part of a companion diagnostic to determine patients&#8217; response to a particular drug.&#160;As studies unfold, our clinical trials team reports the data and often provides key analysis and insights back to the sponsors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services segment provides comprehensive testing services in support of our pharmaceutical clients&#8217; oncology programs from discovery to commercialization.&#160;In biomarker discovery, our aim is to help our customers discover the right content.&#160;We help our customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing our discovery tools with the informatics to capture meaningful data.&#160;In other pre-clinical and non-clinical work, we can use our platforms to characterize markers of interest.&#160;Moving from discovery to development, we seek to help our customers refine their biomarker strategy and, if applicable, develop a companion diagnostic pathway using the optimal technology for large-scale clinical trial testing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether serving as the single contract research organization or partnering with one, our Pharma Services team provides significant technical expertise, working closely with our customers to support each stage of clinical trial development.&#160;Each trial we support comes with rapid turnaround time, dedicated project management and quality assurance oversight. We have experience in supporting submissions to the Federal Drug Administration (&#8220;FDA&#8221;) for companion diagnostics. Our Pharma Services strategy is focused on helping bring more effective oncology treatments to market through providing world-class laboratory services in oncology to key pharmaceutical companies in the industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we are is well positioned to service Pharma sponsors across the full continuum of the drug development process. Our Pharma Services team can work with them during the basic research and development phase as compounds come out of translational research departments as well as work with clients from Phase 1 clinical trials through Phases II and III as the sponsors work to prove the efficacy of their drugs. The laboratory biomarker tests that are developed during this process may become companion diagnostic (&#8220;CDx&#8221;) tests, that will be used on patients to determine if they could respond to a certain therapy. We are able to offer these CDx tests to the market immediately after FDA approval as part of our Day 1 readiness program. This ability helps to speed the commercialization of a drug and can enable Pharma sponsors to reach patients through our broad distribution channel in the Clinical Services segment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to connecting patients with life-altering therapies and trials. In carrying out these commitments, we aim to provide transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and have invested in leading technologies to seek to ensure the data we maintain is secured at all times. We are continuing to develop and broaden our informatics and data-related tools to leverage our unique market position and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology expertise to help our stakeholders solve real-world problems such as identifying patients for clinical trials or providing clinical decision support tools for physicians and providers. We also offer testing and informatics tools to help health care professionals in the rapidly evolving field of precision medicine, such as Trapelo&#8482;. Trapelo&#8482; is an end-to-end, clinical decision-support platform designed to resolve the complexities of precision oncology &#8211; from test ordering to therapy selection to navigating prior authorization. Trapelo&#8482; helps oncologists determine which biomarkers to test and in selecting the appropriate tests from laboratory offerings, and then assists with interpreting test results to identify appropriate, evidence-based treatment options. Trapelo&#8482; also collaborates with health plans to embed plan policy at the &#8220;point of decision&#8221; and streamline prior authorization to optimize the efficient delivery of precision care for better patient outcomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Markets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical testing laboratory market can be broken down into the following three primary markets:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical Pathology testing;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anatomic Pathology testing; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Genetic and Molecular testing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Pathology testing covers high volume, highly automated, lower complexity tests on easily procured specimens such as blood and urine. Clinical Pathology tests often involve testing of a less urgent nature, for example, cholesterol testing and testing associated with routine physical exams.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anatomic Pathology testing involves evaluation of tissue, as in surgical pathology, or cells as in cytopathology. The most widely performed Anatomic Pathology procedures include the preparation and interpretation of pap smears, skin biopsies, and tissue biopsies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genetic and Molecular testing typically involves analyzing chromosomes, genes, proteins, and/or DNA/RNA sequences for abnormalities. Genetic and molecular testing requires highly specialized equipment and credentialed individuals (typically MD or PhD level) to certify results and typically yields the highest reimbursement levels of the three market segments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeoGenomics operates primarily in the Genetic and Molecular testing market. We also act as a reference laboratory supplying anatomic pathology testing. NeoGenomics typically does not operate in the clinical pathology testing market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The field of cancer genetics is evolving rapidly and new tests continue to be developed at an accelerated pace. Based on medical and scientific discoveries over the last decade, cancer testing falls into one of three categories: diagnostic testing, prognostic testing and predictive testing. Of the three, the fastest growing area is predictive testing, which is utilized by clinicians to predict a patient&#8217;s response to the various treatment options in order to deliver &#8220;personalized or precision medicine&#8221; that is optimized to that patient&#8217;s particular circumstances. Personalized or precision medicine better allows clinicians to know if a patient will or will not respond to certain cancer medications like Herceptin, Keytruda, PIQRAY, and Opdivo. This is designed to save the healthcare system money by helping to ensure that expensive cancer drugs are only given to those who will benefit from them. This type of testing improves patient care and potentially saves lives by identifying optimized therapies much more rapidly than what was possible in previous years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. market for genetic and molecular testing is divided among numerous laboratories. Many of these laboratories are attached to academic institutions and primarily provide clinical services to their affiliated university hospitals and associated physicians.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe several key factors are influencing the rapid growth in the market for cancer testing: (i)&#160;every year, more and more genes and genomic pathways are implicated in the development and/or clinical course of cancer; (ii)&#160;cancer is primarily a disease of the elderly &#8211; one in four senior citizens is likely to develop some form of cancer during the rest of their lifetime once they turn sixty, and now that the baby boomer generation has started to reach this age range, the incidence rates of cancer are rising; (iii)&#160;increasingly, new drugs are being targeted to certain cancer subtypes and pathways which require companion diagnostic testing; (iv)&#160;patient and payer awareness of the value of genetic and molecular testing; (v)&#160;decreases in the cost of performing genetic and molecular testing; (vi)&#160;increased coverage from third party payers and Medicare for such testing; and (vii)&#160;the health insurance coverage to uninsured Americans under the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, each enacted in March 2010. These factors have driven significant growth in the market for this type of testing. Additionally, there is an increased focus on developing tests for monitoring purposes, including MRD and recurrence detection in cancer survivors, which could also broaden the use of certain tests and influence the market for cancer testing. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Focus Areas:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to sustainable growth while transforming patient care by being an innovative leader in our industry. Our focus for 2022 is to sustain a purpose driven culture that maintains excellence in service and performance while growing through innovation. We expect the following initiatives to allow the Company to continue on its path to become one of the world&#8217;s leading cancer testing and information companies:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Growth through Innovation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successfully launch new test offerings and secure reimbursement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expand development of new cancer treatments; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerate precision medicine in the community.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Excellence in Service and Performance</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Achieve turnaround time targets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Grow consolidated revenue and profitability; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Design next-generation Laboratory Information Management System (&#8220;LIMS&#8221;) platform.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purpose Driven Culture</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drive an engaged and committed workforce; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foster inclusive and effective leadership by expanding our culture of inclusion and developing our future leaders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Strengths</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the competitive strengths discussed below, we believe that our superior testing technologies and instrumentation, laboratory information system, client education programs and broad domestic and growing international presence also differentiates NeoGenomics from its competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Turnaround Times</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to provide industry leading turnaround times for test results to our clients nationwide, both in the Clinical Services and Pharma Services segments. By providing information to our clients in a rapid manner, physicians can begin treating their patients as soon as possible. Our consistent timeliness of results by our Clinical Services segment is a competitive strength and a driver of additional testing requests by referring physicians. Rapid turnaround times allow for the performance of other adjunctive tests within an acceptable diagnosis window in order to augment or confirm results and more fully inform treatment options. Additionally, we believe that our rapid turnaround time on testing and our project milestones are a key differentiator in our Pharma Services segment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Innovative Service Offerings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we currently have the most extensive menu of tech-only FISH services in the country as well as extensive and advanced tech-only flow cytometry and IHC testing services. These types of testing services allow the professional interpretation component of a test to be performed and billed separately by our physician clients. Our tech-only services are designed to give pathologists the option to choose, on a case by case basis, whether they want to order just the technical information and images relating to a specific test so they can perform the professional interpretation, or order &#8220;global&#8221; services and receive a comprehensive test report which includes a NeoGenomics pathologist&#8217;s interpretation of the test results. Our clients appreciate the flexibility to access NeoGenomics&#8217; medical staff for difficult or complex cases or when they are otherwise unavailable to perform professional interpretations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a comprehensive suite of technical and interpretation services, to meet the needs of those clients who are not credentialed and trained in interpreting genetic tests and who require pathology specialists to interpret their testing results. In our global service offerings, our lab performs the technical component of the tests and our MDs and PhDs provide the service of interpreting the results of those tests. Our professional staff is also available for post-test consultative services. Clients using our global service offering rely on the expertise of our medical team to give them the answers they need in a timely manner to help inform their diagnoses and treatment decisions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have one of the broadest Molecular and NGS test menus in the world. Clients have the ability to order single gene molecular tests, targeted NeoTYPE panels that include the relevant actionable genes for a particular cancer type as well as large NGS panels. Our Pharma Services segment offers a full range of sequencing testing including whole exome and whole genome sequencing. Our menu enables us to be a true &#8220;one-stop shop&#8221; for our clients as we can meet all of their oncology testing needs.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Direct Sales Force</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our direct sales force has been trained extensively in cancer genetic testing and consultative selling skills to service the needs of clients. Our sales team for the clinical cancer testing services is organized into five regions &#8211; Northeast, Southeast, North Central, South Central, and West. Our Pharma Services segment has a dedicated team of business development specialists who are experienced in working with pharma sponsors and helping them with the testing needs of their research and development projects as well as Phase I, II and III studies. These sales representatives utilize our custom Customer Relationship Management System (&#8220;CRM&#8221;) to manage their territories, and we have integrated the key customer care functionality within our Laboratory Information Services (&#8220;LIS&#8221;) into the CRM so that our sales representatives can stay informed of emerging issues and opportunities within their regions. Our in-house customer care team is aligned with our field sales team to serve the needs of our clients by utilizing the same LIS and CRM. Our field teams can see in real-time when a client calls the laboratory, the reason for the call, the resolution, and if face-to-face interaction is needed for follow-up. Our sales force educates clients on new test offerings and their proper utilization and our representatives are often seen as trusted advisors by our clients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our clinical testing volume is dependent on patients being treated by hematology/oncology professionals and other healthcare providers. The volume of our testing services generally declines modestly during the summer vacation season, year-end holiday periods and other major holidays, particularly when those holidays fall during the middle of the week. In addition, the volume of our testing tends to decline due to extreme adverse weather conditions, such as excessively hot or cold spells, heavy snow, hurricanes or tornadoes in certain regions, consequently reducing revenues and cash flows in any affected period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Pharma Services segment, we enter into both short-term and long-term contracts, ranging from one month to several years. While the volume of this testing is not as directly affected by seasonality as described above, the testing volume does vary based on the terms of the contract. Our volumes are often based on how quickly sponsors can get patient enrollees for their trials and seasonality can impact how quickly they can get patients enrolled. Many of our long-term contracts contain specific performance obligations where the testing is performed on a specific schedule. This results in revenue that is not consistent among periods. In addition, this results in backlog that can be significant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our Clinical Services segment, the genetic and molecular testing niche of the laboratory testing industry is highly competitive and, given the opportunities in this industry, we expect it to become even more competitive. Competitive factors in genetic and molecular testing generally include the reputation of the laboratory, range of services offered, pricing, convenience of sample collection and pick-up, quality of analysis and reporting, medical staff, timeliness of delivery of completed reports (i.e. turnaround times) and post-reporting follow-up for clients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors for our Clinical Services segment in the United States are numerous and include major national medical testing laboratories, hospital laboratories and in-house physician laboratories.&#160;Some of our competitors have greater financial resources and production capabilities than us. These companies may succeed in developing service offerings that are more effective than any that we have or may develop, and may also prove to be more successful than we are in marketing such services. In addition, technological advances or different approaches developed by one or more of our competitors may render our service offerings obsolete, less effective or uneconomical.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue our efforts to gain market share by offering industry-leading turnaround times, a broad service menu, high-quality test reports, new tests including proprietary ones, enhanced post-test consultation services, and personal attention from our direct sales force. In addition, we believe our flexible reporting solutions, which enable clients to report out customized results in a secure, real-time environment, will allow us to continue to gain market share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services business competes against many other clinical research organizations and central reference laboratories.&#160;Many of these competitors are much larger and have a greater international presence than we do.&#160;Over the past few years, we have expanded our Pharma Services business into Europe and Asia at the request of our clients and we believe that our state of the art testing menu and our high level of service along with our international expansion will allow us to continue to gain market share in this segment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services segment competitors are numerous Contract Resource Organizations (&#8220;CROs&#8221;). These competitors are larger than NeoGenomics and have global operations including operations in some regions where we do not yet have service capabilities.&#160;These laboratories may be more effective than us in gaining business for global clinical trials.&#160;Many clinical reference laboratories have also entered the space in support of clinical trials and the related laboratory testing.&#160;These reference laboratories are often willing to compete with lower pricing for smaller, more limited studies. We believe our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strong scientific and medical team is a key differentiator where NeoGenomics is used as an advisor to the sponsors on their trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our extensive experience in anatomic pathology continues to result in our winning clinical trials business as sponsors trust our medical team and want them to closely oversee their trials.&#160;We believe our service focus and our leading molecular and IHC platforms, as well as our exclusive MultiOmyx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform will continue to lead to rapid growth in this segment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suppliers</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We order our laboratory and research supplies from large national laboratory supply companies. While we do not depend on a concentrated, limited number of suppliers, we do rely on certain suppliers for specific reagents or other equipment, including sequencers. We have seen an increase in supply chain disruptions and delays in obtaining reagents and basic laboratory supplies in 2021. While we do not believe a short-term disruption from any one of these suppliers would have a material effect on our business, it could result in short-term impact on our turnaround time or gross margin depending on the nature of or extent of the disruption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations of credit risk with respect to revenue and accounts receivable are primarily limited to certain clients to which we provide a significant volume of our services, and to specific payers of our services such as Medicare and individual insurance companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dependence on Major Clients</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our services to pathologists, oncologists, other clinicians, hospitals, pharmaceutical companies, academic centers and other clinical laboratories throughout the United States, Europe and Asia. The Company&#8217;s client base consists of a large number of geographically dispersed clients diversified across various customer types. For the years ended December 31, 2021, 2020, and 2019, no single client accounted for more than 10% of revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payer Mix</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our estimate of the breakdown of net clinical revenue by type of payer for the years ended December 31, 2021, 2020, and 2019:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.946%"><tr><td style="width:1.0%"></td><td style="width:51.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client direct billing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and other government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our Pharma Services revenue is billed directly to clients or the pharmaceutical sponsor.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain professional liability and numerous other insurance policies. We believe that our present insurance is sufficient to cover currently estimated exposures, but we cannot assure that we will not incur liabilities in excess of the policy coverage limits. In addition, although we believe that we will be able to continue to obtain adequate insurance coverage, we cannot assure that we will be able to do so at acceptable cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internet website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.neogenomics.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Annual Report on Form 10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), are available free of charge through our website as soon as reasonably practicable after we electronically file with or furnish them to the SEC and are available in print to any stockholder who requests a copy. Information on our website shall not be deemed incorporated into, or to be part of, this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the SEC maintains a website that contains reports, proxy statements, information statements, and other information regarding issuers, including us, that file electronically with the SEC at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had approximately 2,000 full-time equivalent employees and contracted pathologists.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">World-class Medical and Scientific Team</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our team of medical professionals and PhDs are specialists in the field of genetics, oncology and pathology.&#160;As of December 31, 2021, we employed or contracted with approximately 130 MDs and PhDs. We have many nationally and world-renowned pathologists on staff, which is a key differentiator from many smaller laboratories.&#160;Our clinical customers look to our staff and their expertise and they often call our medical team on challenging cases.&#160;For our Pharma Services segment, many sponsors work with our medical team on their study design and on the interpretation of results from the studies.&#160;Our medical team is a key differentiator as we have a depth of medical expertise that many other laboratories cannot offer to pharmaceutical companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">World-Class Culture</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote a World-Class Culture through Employee Engagement, Training and Development, Wellness, Work-Life Balance, and Communication initiatives. Human capital management, including the recruitment and retention of a talented, diverse and highly motivated workforce, is an essential component of our strategy for long-term value creation. The Company&#8217;s active approach to human capital management values and promotes diversity, development, and equal opportunity, among many other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to maintaining an excellent workplace includes investing in ongoing opportunities for employee development in a diverse and inclusive environment. In addition to gender and ethnic diversity and inclusion on our Board, diversity in gender and ethnicity is well-established within our workforce. As of December 31, 2021, women make up 59.0% of our global workforce, 20.0% of our workforce is in supervisory or higher positions, and of that 20.0%, 53.0% are female. With regard to the Company&#8217;s top two management tiers, 44% of our executive team and our vice presidents are women and 33.0% of our Board of Directors are women. Ethnicity is also strongly represented: 52.0% of our workforce and 11.0% of our Board of Directors are ethnically diverse. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that a diverse and inclusive workforce, where all perspectives are recognized and respected, positively impacts our performance and strengthens our culture. We continuingly strive to promote a workplace in which people of diverse race, ethnicity, veteran status, marital status, socio-economic level, national origin, religious belief, physical ability, sexual orientation, age, class, political ideology, gender identity and expression participate in, contribute to, and benefit equally.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also committed to rewarding, supporting and developing our employees as they work toward our common purposes of saving lives by improving patient care. To that end, we offer a competitive comprehensive rewards package that includes competitive salaries, performance based bonuses, equity grants, healthcare benefits, retirement savings plans, family leave, paid time off, wellness programs and discounts, tuition reimbursement and an Employee Assistance Program. We also drive high levels of performance and improvement by prioritizing training and development, and we motivate and develop our employees by providing them with opportunities for advancement and offering robust onsite and remote learning opportunities for employees at every stage in their career.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees&#8217; health and safety is also important to us. During the COVID-19 pandemic, we took measures to support our employees, including de-densifying our laboratories and facilities, adjusting laboratory shifts, restricting visitors to facilities, restricting employee travel, implementing an emergency paid time off policy, and providing remote work-environment training and support.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laboratory industry is subject to extensive governmental regulation domestically, at the federal and state levels, and internationally. The applicable laws and regulations change frequently and there can be no assurance that the Company will not be subject to audit, inquiry, or investigation with respect to some aspect of its operations. The failure to comply with applicable laws, regulations, and reimbursement guidelines could have a material adverse effect on the Company&#8217;s business. Significant areas of regulation are summarized below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensure, Accreditation, and Quality Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates laboratories domestically in Florida, Georgia, Tennessee, Texas, and California, and internationally in Switzerland, Singapore and China. The laboratories are licensed as required by the states or countries in which they are located. In addition, the laboratories in Fort Myers, Florida, Aliso Viejo and Carlsbad, California, and Nashville, Tennessee are licensed by the State of New York as the laboratories accept clinical specimens obtained in New York. All of our domestic laboratories are certified in accordance with the Clinical Laboratory Improvement Amendments of 1988 (&#8220;CLIA&#8221;). Under CLIA, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) establishes various operational, personnel, facilities, administration, quality, and proficiency requirements for testing performed by a laboratory, intended to ensure testing services are accurate, valid, and timely. CLIA certification is also a prerequisite to be eligible to bill federal and state health </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">care programs, as well as many private insurers, for laboratory testing services. The sanctions for failure to comply with CLIA requirements include: suspension, revocation, or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct business; cancellation or suspension of the laboratory&#8217;s approval to receive Medicare and/or Medicaid reimbursement; and significant fines and/or criminal penalties. The loss or suspension of a CLIA certification could have a material adverse effect on the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Company laboratories are also accredited by the College of American Pathologists (&#8220;CAP&#8221;), including our laboratories in Switzerland and Singapore, and actively participate in CAP&#8217;s proficiency testing programs for all tests offered by the Company. CAP&#8217;s proficiency testing programs require participating laboratories to test specimens that they receive from an approved testing entity and return the results. The testing entity conducting the program analyzes the results and provides to the Company a quality control report assessing the results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a Quality Management System that meets applicable regulatory and accreditation requirements and industry standards. The quality of care provided to clients and their patients is of paramount importance to us. We maintain quality control processes, including standard operating procedures, controls, performance measurement and reporting mechanisms. Our employees are committed to providing accurate, reliable, and consistent services. Any concerns regarding the quality of testing or services provided by the Company are quickly communicated to our Company management. We also frequently revise and improve our tests and we work with laboratory equipment vendors to ensure that our laboratory has the highest possible quality.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with licensure, accreditation, and quality standards are verified through periodic inspections by agents of relevant regulatory agencies and accrediting organizations, and we believe we are in material compliance with all licensure, accreditation, and quality requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance and Ethics Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care industry is highly regulated and scrutinized with respect to fraud, abusive billing practices, and improper financial relationships between health care companies and their referral sources. The Office of Inspector General of the Department of Health and Human Services (&#8220;OIG&#8221;) has published compliance program guidance, including the Compliance Program Guidance for Clinical Laboratories in August of 1998, fraud alerts, and advisory opinions. The Company has implemented a robust Compliance &amp; Ethics Program encompassing this guidance, which is overseen by our Board of Directors, to support compliance with the myriad of international, federal, and state laws, regulations, and governmental guidance applicable to our business. Our program employs a risk-based approach to the development and implementation of standards of conduct, training and education of employees, monitoring and auditing Company practices, investigation, and response to reported or detected compliance issues. The Company provides a hotline for employees who wish to anonymously or confidentially report suspected violations of our codes of conduct, policies and procedures, or laws and regulations. Employees are strongly encouraged to report any suspected violation if they do not feel the problem can be appropriately addressed through the normal chain of command. The hotline does not replace other resources available to our employees, including supervisors, managers, and human resources staff but is an alternative channel available 24 hours a day, 365 days a year. The hotline forwards all reports to the Chief Compliance Officer, who is responsible for investigating, reporting to the Compliance Committee, and documenting the disposition of each report. The hotline forwards any calls pertaining to the financial statements or financial issues to the Chairman of the Audit Committee. The Company does not allow any retaliation against an employee who reports a compliance related issue in good faith.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has a Compliance Committee that meets regularly to discuss all compliance-related issues that may affect the Company. The Company reviews its policies and procedures as new regulations and interpretations come to light to comply with applicable regulations. The Chief Compliance Officer reports quarterly to the Compliance Committee on the effectiveness of the program.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Laboratory Developed Tests</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has regulatory responsibility over instruments, test kits, reagents, and other medical devices used by clinical laboratories to perform diagnostic testing. High complexity and CLIA-certified laboratories such as ours frequently develop testing procedures intended exclusively for use by the developing laboratory to provide diagnostic results to customers. These tests are referred to as laboratory developed tests (&#8220;LDTs&#8221;). The regulatory framework governing LDTs is evolving, complex, and has been the subject of ongoing debate. LDTs are subject to CMS oversight through its enforcement of CLIA. The FDA has also claimed regulatory authority over LDTs but has generally exercised enforcement discretion with regard to most LDTs offered by high complexity CLIA-certified laboratories and has not subjected these tests to FDA rules and regulations governing medical devices, including premarket review requirements. In 2014, FDA issued draft guidance announcing that it would end its historical policy of enforcement discretion regarding LDTs and outlining the first of multiple frameworks that have been proposed for their regulation. FDA announced in 2016 that it no longer planned to finalize its </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">draft guidance and that it would continue to exercise enforcement discretion with respect to LDTs. On January 13, 2017, the FDA published a non-binding &#8220;Discussion Paper&#8221; proposing a framework of LDT oversight largely consistent with the draft guidance, &#8220;to spur further dialogue&#8221; and give &#8220;congressional authorizing committees the opportunity to develop a legislative solution.&#8221; Recent agency announcements made in the context of the coronavirus (&#8220;COVID-19&#8221;) public health emergency have produced a shifting policy landscape and further uncertainty regarding the FDA&#8217;s role in regulating LDTs: in August 2020, the Department of Health and Human Services (&#8220;HHS&#8221;) announced that the FDA would not require premarket review of LDTs absent notice-and-comment rulemaking, but in November 2021, HHS issued a statement withdrawing that prior announcement, indicating a return to FDA&#8217;s longstanding approach to the regulation and enforcement discretion toward LDTs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress has also considered a number of legislative proposals in recent years that would amend the regulatory framework for LDTs, including, among other requirements, FDA premarket review of certain LDTs. The most recent such proposal, the Verifying Accurate Leading-edge IVCT Development (&#8220;VALID&#8221;) Act, was introduced in both the House and Senate on June 24, 2021. A competing legislative proposal, the Verified Innovative Testing in American Laboratories Act of 2021 (&#8220;VITAL Act&#8221;), was introduced in the Senate on May 18, 2021. However, it remains uncertain whether Congress will enact legislation regulating LDTs and, if so, whether the legislation will be similar to the framework described in FDA&#8217;s 2014 draft guidance or Discussion Paper, or either the VITAL or VALID Acts. It is possible that legislation and resulting FDA regulation may result in increased regulatory burdens and costs for us to seek marketing authorization for and maintain ongoing compliance for our existing tests, any modifications thereto, or any future tests we may develop. We cannot be certain as to which of our tests, if any, would require FDA approval or clearance under any of the proposed frameworks and, if required, that our tests could obtain such approval or clearance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Laws Governing Source Relationships</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal laws governing Medicare, Medicaid, and other federal health benefits, as well as other state and federal laws, regulate certain aspects of the relationships between health care providers, including clinical laboratories, and their referral sources, including physicians, hospitals, other laboratories, and other entities. We are subject to the federal Anti-Kickback Statute (&#8220;AKS&#8221;), as well as similar state statutes and regulations, which prohibit the offer, payment, solicitation, or receipt of any form of remuneration in return for referring, ordering, leasing, purchasing, or arranging for or recommending the ordering, purchasing, or leasing of items or services payable by Medicare, Medicaid, or any other federally funded healthcare program. The federal AKS defines remuneration to include anything of value, in cash or in kind, and thus can implicate financial relationships including payments not commensurate with fair market value, such as in the form of personnel, supplies, professional, or technical services, or anything else of value. For additional information regarding the federal AKS and similar state anti-kickback laws, see Item 1A. Risk Factors, Risks Relating to Regulation, &#8220;The failure to comply with Anti-Kickback laws may subject us to liability, penalties or limitation of operations.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the federal AKS, in October 2018, the U.S. Congress enacted the Eliminating Kickbacks in Recovery Act of 2018 (&#8220;EKRA&#8221;), as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (&#8220;SUPPORT Act&#8221;). EKRA is an all-payer anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. As drafted, an EKRA prohibition on incentive compensation to sales employees, payments to group purchasing organizations (&#8220;GPOs&#8221;), or group practices is broader than the federal AKS. Significantly, EKRA permits the DOJ to issue regulations clarifying EKRA&#8217;s exceptions or adding additional exceptions, but such regulations have not yet been issued.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to international laws and regulations, including the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and the U.K. Bribery Act, relating to corrupt and illegal payments to, and contracting practices with regard to, government officials and others. The scope of the types of payments or other benefits covered by these laws is very broad and regulators are frequently using enforcement proceedings to define the scope of these laws. These laws include civil penalties for enterprises and criminal penalties and imprisonment for individuals. The obligation of the Company under these laws is to screen third parties who are hired to carry out certain services on behalf of the Company, to monitor for and report suspicious transactions, and to monitor direct and indirect payments to government officials and others. Because of the broad definitions of applicability of these laws, international clients or vendors working for government-owned entities are often considered to be governmental officials. The Company has implemented a program to comply with these laws and has educates employees and its relevant vendors regularly on the requirements for vendor onboarding and conducting appropriate business interactions globally.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Physician Self-Referral Laws</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal law referred to as the &#8220;Stark Law&#8221; prohibits payments for certain health care services, referred to as designated health services (&#8220;DHS&#8221;), which were rendered as a result of referrals by physicians to DHS entities with which the physicians (or their immediate family members) have a financial relationship. A &#8220;financial relationship&#8221; includes both an ownership interest and/or a compensation arrangement with a physician, both direct and indirect, and DHS includes, but is not limited to, laboratory services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stark Law prohibits an entity that receives a prohibited DHS referral from seeking payment from Medicare and Medicaid for any DHS services performed as a result of such a referral, unless an arrangement is carefully structured to satisfy every requirement of a regulatory exception. The Company endeavors to structure its financial relationships in compliance with the Stark Law and with similar state physician self-referral laws.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have promulgated self-referral laws and regulations similar to the federal Stark Law, but these vary significantly based on the state. In addition to services reimbursed by Medicaid or government payers, these state laws and regulations can encompass services reimbursed by private payers and paid by self-pay patients as well. Penalties for violating state self-referral laws and regulations vary based on the state but often include civil and criminal penalties, exclusion from Medicaid, and loss of licenses. Our financial arrangements with physicians are governed by the federal Stark Law and similar state self-referral laws, and we rely on certain exceptions to the Stark Law with respect to such relationships. While we believe that our financial relationships with physicians and referral practices are in compliance with applicable laws and regulations, we cannot guarantee that government authorities would agree. If we are found to be in violation of the Stark Law or a similar state self-referral law, we could be subject to significant penalties, including fines, exclusion from participation in government and private payer programs, or obligations to refund amounts previously received from government payers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">The False Claims Act</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act (&#8220;FCA&#8221;) prohibits any person or entity from knowingly presenting, or causing to be presented, to the U.S. government, or to a Medicare program contractor, a false or fraudulent claim for payment, knowingly making or using a false record or statement to have a false claim paid by the government, conspiring to defraud the U.S. government, or knowingly making or using a false statement to conceal an obligation to pay the government, or improperly retaining overpayments from the government. Following enactment of the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;), claims related to violations of the federal AKS and knowing retention of overpayments are also considered false claims and could lead to liability under the FCA. Further, FCA liability may lead to exclusion from participation in Medicare, Medicaid, and other federal healthcare programs. The FCA&#8217;s &#8220;whistleblower&#8221; or &#8220;qui tam&#8221; provisions are used with frequency to challenge the reimbursement practices of providers and suppliers. These provisions allow a private individual to bring an action on behalf of the government alleging that the defendant has submitted false claims for payment to the federal government. The government must decide whether to intervene in the lawsuit and whether to prosecute the case. If it declines to do so, the individual may pursue the case alone, although the government must be kept apprised of the progress of the lawsuit. Whether or not the federal government intervenes in the case, it will receive the majority of any recovery. The successful qui tam relator who brought the case is entitled to a portion of the proceeds and its attorneys&#8217; fees and costs. As most qui tam cases are filed by current or former employees, an effective compliance program, as defined by the DOJ and OIG, plays a crucial role in reducing the Company&#8217;s exposure to liability. It is also a criminal offense, under Title 18 U.S. Code, Section 287, for a person or entity to make a claim against the United States or any department or agency, knowing the claim to be false, fictitious, or fraudulent. The penalty is a fine and imprisonment of up to five years. The federal FCA has been an effective enforcement tool for the federal government and many states have enacted similar false claims acts as well.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company seeks to structure its arrangements with physicians and other clients to be in compliance with the AKS, Stark Law, state laws, and the FCA and to stay abreast of current developments and changes in the law and regulations. However, these laws and regulations are complex and subject to interpretation. Consequently, we are unable to ascertain with certainty that any of our transactions will not be subject to scrutiny and, if scrutinized, will not result in sanctions or penalties. The Company has taken, and will continue to take, actions to endeavor to ensure compliance with the myriad federal and state laws that govern our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Payment Guidelines</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various billing arrangements with our clients and with third party payers, including the Medicare program. When the Company bills the client for all, or a portion of, a laboratory test performed, these client billing arrangements are priced competitively at fair market value. These client billing arrangements may implicate the Medicare program&#8217;s prohibition against charging the Medicare or Medicaid programs fees substantially in excess of the Company&#8217;s usual and customary charges. Given our participation in Medicare and Medicaid, we are subject to Medicare and Medicaid regulations related to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">billing those programs as well as agency subregulatory guidance regarding the same, the federal Stark Law, federal and state anti-kickback statutes, and the federal FCA and state equivalents.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the various federal regulations and guidance from the OIG, the Company seeks to price its products competitively while endeavoring to meet applicable statutes and regulations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Health and Safety</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to licensing and regulation under federal and state laws relating to the protection of the environment as well as human health and safety laws and regulations relating to the handling, transportation, and disposal of medical specimens, hazardous materials, and infectious and hazardous waste. Company laboratories are subject to applicable laws and regulations relating to biohazard disposal of all laboratory specimens, and the Company generally utilizes outside vendors for disposal of such specimens. In addition, the Occupational Safety and Health Administration has established extensive requirements relating to workplace safety for healthcare employers, including clinical laboratories, whose workers may be exposed to blood-borne pathogens such as HIV and hepatitis B and C viruses. These regulations, among other things, require work practice controls, protective clothing and equipment, training, medical follow-up, vaccinations, and other measures designed to minimize exposure to, and transmission of, blood-borne pathogens. For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject to regulation by one or more of the following agencies: the U.S. Department of Transportation, the U.S. Public Health Service, the U.S. Postal Service, the Office of Foreign Assets Control, and the International Air Transport Association. Other countries where the Company conducts business have similar laws and regulations concerning the environment and human health and safety with which the Company must also comply. The Company seeks to comply with all relevant environmental and human health and safety laws and regulations. Failure to comply could subject the Company to various administrative and/or other enforcement actions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Confidentiality and Security of Personal Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA contains provisions that protect individually identifiable health information from unauthorized use or disclosure by covered entities and their business associates. The Office for Civil Rights of HHS (&#8220;OCR&#8221;), the agency responsible for enforcing HIPAA, has published regulations to address the privacy (the &#8220;Privacy Rule&#8221;) and security (the &#8220;Security Rule&#8221;) of protected health information (&#8220;PHI&#8221;). The Company is a covered entity under HIPAA and has adopted policies and procedures to comply with HIPAA, including the Privacy Rule, the Security Rule. The health care facilities and providers that refer specimens to the Company are also bound by HIPAA. HIPAA also requires that all providers who transmit claims for health care goods or services electronically utilize standard transaction and data sets and use standardized national provider identification codes. The Company has taken necessary steps to comply with HIPAA regulations, utilizes standard transaction data sets, and has obtained and implemented national provider identifiers, or NPIs, as the standard unique health identifier in filing and processing health care claims and other transactions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH Act&#8221;), enacted as part of the American Recovery and Reinvestment Act (&#8220;ARRA&#8221;), extends the scope of HIPAA to permit enforcement against business associates for violations, establishes new requirements to notify the OCR of a breach of PHI, and allows the state Attorneys General to bring actions to enforce violations of HIPAA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the HIPAA Privacy Rule and Security Rule described above, the Company is subject to state laws regarding the handling and disclosure of patient records and patient health information. The HIPAA Privacy Rule and Security Rule regulations do not supersede state laws that may be more stringent; therefore, we are required to comply with both federal privacy and security regulations as well as varying state privacy and security laws and regulations. These laws vary widely. Penalties for violation include sanctions against a laboratory&#8217;s licensure as well as civil or criminal penalties. Additionally, private individuals may have a right of action against the Company for violations of a state&#8217;s privacy laws. We believe we are in material compliance with current state laws regarding the confidentiality of health information, and we will continue to monitor and comply with new or changing state laws.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The California Consumer Privacy Act (&#8220;CCPA&#8221;) took effect on January 1, 2020, and imposed privacy compliance obligations with regard to the personal information of California residents. This legislation creates significant new requirements for identifying, managing, securing, tracking, producing, and deleting consumer personal information and the CCPA takes the position that consumers &#8220;own&#8221; their personal information and provides specific rights, including the right to opt out of their data being sold to a third party by the Company. The CCPA defines personal information extremely broadly as &#8220;information that identifies, relates to, describes, is capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular consumer or household.&#8221; Like the international privacy laws, this creates greater complexity in implementing a compliance program to support these requirements. This law became enforceable by the California Attorney General on July 1, 2020, and the Company has implemented significant mechanisms to promote compliance with this law.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s international expansion, we are subject to a variety of international laws which serve to protect the personally identifiable information (&#8220;PII&#8221;) of individuals who reside in those countries. These laws include the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;), The Swiss Federal Data Protection Act (&#8220;FADP&#8221;), and Singapore&#8217;s Personal Data Protection Act (&#8220;PDPA&#8221;). These laws are much more complex and stringent in nature than HIPAA and are not limited to protecting patient data alone; they include employees, clients, and other individuals for which we have collected their data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like HIPAA, these laws contain regulatory requirements for both robust data privacy and security programs and require data breach reporting should PII be used or disclosed in a manner not allowed under the laws. Penalties for violations of these laws can be significant, for instance, GDPR&#8217;s maximum penalties are up to the greater of 4.0% of a company&#8217;s annual global turnover or &#8364;20.0 million. Although the Company&#8217;s business is conducted primarily in the United States, we do receive some clinical testing from countries outside of the United States and we collect data of individuals internationally as part of the Company&#8217;s Pharma business, which obligates us to comply with these laws. We have developed privacy and security programs to meet these international obligations and continue to reassess and improve these programs continually.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various risks that may materially harm our business, financial condition, and results of operations. They are not, however, the only risks we face. Additional risks and uncertainties not presently known to us or that we currently believe not to be material may also adversely affect our business, financial condition, or results of operations. An investor should carefully consider the risks and uncertainties described below and the other information in this filing before deciding to purchase our common stock. If any of these risks or uncertainties actually occurs, our business, financial condition, or operating results could be materially harmed. In that case, the trading price of our common stock could decline or we may be forced to cease operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Our Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The COVID-19 pandemic is highly dynamic in the United States and throughout the world and may adversely affect our operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks related to the public health crises such as the global COVID-19 pandemic. Economic and health conditions in the United States and across most of the globe continue to change rapidly. Due to the COVID-19 pandemic, the Company has experienced significant volatility, including periods of material decline compared to prior year periods, in testing volumes in the Company&#8217;s base business (which excludes COVID-19 molecular and antibody testing). Demand may fluctuate depending on the duration and severity of the COVID-19 pandemic, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business disruption, reduced revenues and reduced number of tests, any of which could materially affect our business, financial condition, and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state and local jurisdictions have imposed, and others in the future may impose &#8220;shelter-in-place&#8221; orders, quarantines, executive orders, and similar government orders and restrictions for their residents to control the spread of COVID-19. Starting in mid-March 2020, the governor of California, where several of our laboratories are located, issued &#8220;shelter-in-place&#8221; or &#8220;stay at home&#8221; orders restricting non-essential activities, travel, and business operations for an indefinite period of time, subject to certain exceptions for necessary activities, which was followed by similar orders in other states in which we operate, including in Florida, where our headquarters is located. Various orders have been implemented and subsequently relaxed; however, disruptions continue and have carried into 2022. Such orders or restrictions have resulted in our administrative headquarters closing, work stoppages, slowdowns, delays, travel restrictions and cancellation of events, among other effects, thereby negatively impacting our operations. Other disruptions or potential disruptions include restrictions on our personnel and personnel of partners to travel and access customers; delays in approvals by regulatory bodies; delays in product development efforts; and additional government requirements or other incremental mitigation efforts that may further impact our testing capacity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic is affecting the Company&#8217;s customers, suppliers, vendors, and other business partners, but the Company is not able to assess the full extent of the current impact nor predict the ultimate consequences that may result. At this time, we have not experienced significant interruptions in our operations due to supplier delays. We have established a COVID-19 procurement team to partner with our suppliers to reduce the risk of disruption. Distribution channels have not been disrupted as incoming and outgoing tests are delivered via major carriers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the potential economic impact brought by and the duration of COVID-19 may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets and a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our common stock. The ultimate extent of the effects of the COVID-19 pandemic on the Company, including revenue generated from COVID-19 PCR testing, is highly uncertain and will depend on future developments which cannot be predicted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business is subject to rapid scientific change, which could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for genetic and molecular testing services is characterized by rapid scientific developments, evolving industry standards and customer demands, and frequent new product introductions and enhancements. For example, new tests developed by our competitors may prove superior and replace our existing tests. Additionally, certain technological changes, such as advances in point-of-care testing, could reduce the need for the laboratory tests we provide. Our future success will depend in significant part on our ability to continually improve our offerings in response to both evolving demands of the marketplace and competitive service offerings, and we may be unsuccessful in doing so, which could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Increased competition, including price competition, could have a material adverse impact on our net revenues and profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for genetic and molecular testing services is highly competitive and we expect competition to continue to increase. Our major competitors, including Quest Diagnostics and Laboratory Corporation of America, are large national laboratories that possess greater name recognition, larger customer bases, and significantly greater financial resources and employ substantially more personnel than we do. We also face increased competition from laboratories that more are specialized and focused on particular areas such as liquid biopsies or large tissue based molecular panels. Our competitors may develop products and services that are superior to ours or that achieve greater market acceptance than our offerings. Many of our competitors have long established relationships with their customers and third-party payers. We cannot assure you that we will be able to compete successfully with such entities in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laboratory business is intensely competitive, both in terms of price and service. Pricing of laboratory testing services is often one of the most significant factors used by healthcare providers and third-party payers in selecting a laboratory. As a result of the laboratory industry undergoing consolidation, larger laboratory providers are able to increase cost efficiencies afforded by large-scale automated testing. This consolidation results in greater price competition. We may be unable to increase cost efficiencies sufficiently, if at all, and as a result, our net earnings and cash flows could be negatively impacted by such price competition. Additionally, we may also face changes in fee schedules, competitive bidding for laboratory services, or other actions or pressures reducing payment schedules as a result of increased or additional competition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face the risk of capacity constraints, which could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the market place primarily on three factors: (i) the quality and accuracy of our test results; (ii) the speed or turnaround times of our testing services; and (iii) our ability to provide after-test support to those physicians requesting consultation. Any unforeseen increase in the volume of clients could strain the capacity of our personnel and systems, leading to unacceptable turnaround times or customer service failures. In addition, as the number of our clients and specimens increases, our products, services, and infrastructure may not be able to scale accordingly. We may also not be able to hire additional licensed medical technologists that we need to handle increased volumes. Any failure to handle higher volume of requests for our products and services could lead to the loss of established clients and have a material adverse effect on our business, results of operations, and financial condition. If we produce inaccurate test results, our clients may choose not to use us in the future. This could severely harm our business, results of operations, and financial condition. In addition, based on the importance of the subject matter of our tests, inaccurate results could result in improper treatment of patients and potential liability for us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to develop, or acquire licenses for, new or improved testing technologies could materially and adversely affect our revenues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is subject to rapidly changing technology and new product introductions. Other companies or individuals, including our competitors, may obtain patents or other intellectual property rights that would prevent, limit or interfere with our ability to develop, perform or sell our solutions or operate our business or increase our costs. In addition, they could introduce new tests, technologies or services that may result in a decrease in the demand for our services or cause us to reduce the prices of our services. Our success will depend, in part, on our ability to develop, acquire or license new and improved technologies on favorable terms and to obtain appropriate coverage and reimbursement for these technologies. We may not be able to negotiate acceptable licensing arrangements and we cannot be certain that such arrangements will yield commercially successful diagnostic tests. If we are unable to license these testing methods at competitive rates, our research </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development costs may increase as a result. In addition, if we are unable to license new or improved technologies to expand our testing operations, our testing methods may become outdated when compared with our competition and testing volume and revenue may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical trials and research services create a risk of liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct clinical trials, which ordinarily involve testing an investigational drug on a limited number of individuals to evaluate a product&#8217;s safety, determine a safe dosage range and identify side effects. Errors or omissions could occur during a clinical trial that may result in harm to study volunteers, or if unnoticed and regulatory approval is received, to consumers of the drug, or that may undermine the usefulness of the clinical trial or data from the clinical trial and may delay the entry of a drug to the market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with the pharmaceutical firms include provisions entitling us to be indemnified or entitling us to a limitation of liability. These provisions do not uniformly protect us against liability arising from certain of our own actions, such as gross negligence or misconduct. We could be materially and adversely affected if we were required to pay damages or bear the costs of defending any claim which is not covered by or exceeds the limits of a contractual indemnification provision, or in the event that a party who must indemnify us does not fulfill its indemnification obligations, or which is beyond the level of our insurance coverage.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The potential loss or delay of our material Pharma Services customer contracts or of multiple contracts could adversely affect our results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our Pharma Services segment clients can terminate our contracts upon proper notice. Our Pharma Services clients may delay, terminate or reduce the scope of our contracts for a variety of reasons beyond our control, including but not limited to: actions by regulatory authorities, negative clinical results, lack of patient enrollment, or shifts in internal priorities. Delays, terminations or reductions in the scope of our contracts impacts our ability to convert our backlog into revenue for the Company. If we cannot realize the full benefits of our backlog of contractually committed services due to delay, cancellation or reduction in our client&#8217;s contractual commitments, this will materially impact our revenues. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinicians or patients using our services may sue us, and our insurance may not sufficiently cover all claims brought against us, which will increase our expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, marketing, sale, and performance of healthcare services expose us to the risk of litigation, including professional negligence or product liability claims, were someone to allege that our tests failed to perform as designed. We may also be subject to liability for errors in the test results we provide to pathologists and oncologists or for a misunderstanding of, or inappropriate reliance upon, the information we provide. Damages assessed in connection with, and the costs of defending, any legal action could be substantial. We may be faced with litigation claims that exceed our insurance coverage or are not covered under any of our insurance policies. In addition, litigation could have a material adverse effect on our business if it impacts our existing and potential customer relationships, creates adverse public relations, diverts management resources from the operation of the business, or hampers our ability to otherwise conduct our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our investments in marketable securities are subject to certain risks which could affect our overall financial condition, results of operations, or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest a portion of our available cash and cash equivalents by purchasing marketable securities in a managed portfolio and direct investments in a variety of debt securities, including U.S. Treasury securities and corporate debt securities. The primary objective of our investment activity is to maintain the safety of principal and provide for future liquidity requirements while maximizing yields without significantly increasing risk. Should any of our investments or marketable securities lose value or have their liquidity impaired, it could affect our overall financial condition. Additionally, should we choose or are required to sell these securities in the future at a loss, our consolidated operating results or cash flows may be affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be unable to make, on a timely basis, necessary changes to our internal control structure resulting from the acquisitions of Trapelo and Inivata. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trapelo and Inivata are now included in our reporting under the Exchange Act. Under the Sarbanes-Oxley Act of 2002, we must maintain effective disclosure controls and procedures and internal control over financial reporting. We are in the process of migrating Trapelo and Inivata&#8217;s operations to our system of internal controls. Therefore, we may face difficulties or experience delays in developing changes or potentially necessary improvements to their internal controls and accounting systems in order to ensure compliance with the requirements of the Sarbanes-Oxley Act. We may need to commit substantial resources, including substantial time from existing accounting personnel and from external consultants, to implement </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional procedures and improved controls. This in turn could have an adverse effect on our business, results of operations, or financial condition, harm our reputation, or otherwise cause a decline in investor confidence and our stock price. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trapelo and Inivata may have liabilities that are not known, probable or estimable at this time.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trapelo and Inivata are now wholly-owned subsidiaries of ours and there could be unasserted claims or assessments that we failed or were unable to discover or identify in the course of performing due diligence investigations of these entities. In addition, there may be liabilities that are neither probable nor estimable at this time, which may become probable and estimable in the future. We may learn additional information about Trapelo and Inivata that adversely affects us, such as unknown, unasserted, or contingent liabilities and issues relating to compliance with applicable laws, including federal healthcare laws. Any of the foregoing, individually or in the aggregate, if not covered by the indemnification obligations of the Trapelo or Inivata sellers or our representation and warranty insurance, could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Servicing our Convertible Notes will require a significant amount of cash. We may not have sufficient cash flow from our business to pay our obligations under the notes, which could adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we issued $201.3 million aggregate principal amount of 2025 Convertible Notes, and in January 2021, we issued</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$345.0 million aggregate principal amount of 2028 Convertible Notes. We may also incur additional indebtedness in the future. Our ability to make scheduled payments of the principal of, pay interest on, or refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. Our business may not continue to generate cash flow from operations in the future sufficient to service our indebtedness and to make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt, or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance the Convertible Notes will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not have the ability to raise the funds necessary to settle conversions of the Convertible Notes in cash or to repurchase the Convertible Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Convertible Notes have the right to require us to repurchase their Convertible Notes upon the occurrence of a fundamental change at a repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any. In addition, upon conversion of the Convertible Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of the Convertible Notes being converted. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Convertible Notes surrendered therefor or Convertible Notes being converted. In addition, our ability to repurchase the Convertible Notes or to pay cash upon conversions of the Convertible Notes may be limited by law, by regulatory authority, or by agreements governing our future indebtedness. Our failure to repurchase Convertible Notes at a time when the repurchase is required by the indenture or to pay any cash payable on future conversions of the Convertible Notes as required by the indenture would constitute a default under the indenture. A default under the indenture or the occurrence of the fundamental change may also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Convertible Notes or make cash payments upon conversions thereof.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accounting method for convertible debt securities that may be settled in cash, such as the Convertible Notes, could have a material effect on our reported financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which we adopted effective January 1, 2021, and which applies to the Convertible Notes. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments such as the Convertible Notes, which could reduce non-cash interest expense, and thereby decreases net loss (or increases net income), which could affect our reported financial results. Additionally, the treasury stock method for calculating earnings per share will no longer be allowed for convertible debt instruments whose principal amount may be settled using shares, and the if-converted method will instead be required. Application of the &#8220;if-converted&#8221; method may reduce our reported diluted earnings per share.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The capped call transactions may affect the value of the 2028 Convertible Notes and our common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2028 Convertible Notes, we have entered into capped call transactions with the option counterparties. Upon conversion of any of the 2028 Convertible Notes, we will satisfy our conversion obligation by paying or delivering, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock, at our election, and the capped call transactions are intended to reduce the potential dilution upon conversion of the 2028 Convertible Notes and/or offset some or all of any cash payments we are required to make in excess of the principal amount of converted 2028 Convertible Notes, as the case may be, with such reduction and/or offset subject to a cap. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these transactions, the option counterparties or their respective affiliates may modify their hedge positions related to the capped call transactions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the maturity of the 2028 Convertible Notes (and are likely to do so during any observation period related to a conversion of 2028 Convertible Notes or following any repurchase or redemption of the 2028 Convertible Notes). This activity could also cause or avoid an increase or a decrease in the market price of our common stock or the 2028 Convertible Notes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conversion of the Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of some or all of the Convertible Notes may dilute the ownership interests of existing stockholders to the extent we deliver shares of our common stock upon conversion of any of the Convertible Notes. We have entered into capped call transactions with respect to the 2028 Convertible Notes to reduce the risk of dilution, but to the extent that the conversion price of the 2028 Convertible Notes exceeds the cap price of the capped calls or to the extent that the Convertible Notes are converted, such conversions will dilute the ownership interests of our existing stockholders. The Convertible Notes may from time to time in the future be convertible at the option of their holders prior to their scheduled terms under certain circumstances. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because conversion could be used to satisfy short positions, and the anticipated conversion of the Convertible Notes into shares of our common stock could depress the price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other manufacturers may discontinue or recall testing products used in our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily on reagents, test kits and instruments manufactured by third parties in our testing services. From time to time, manufacturers have discontinued or recalled, and may in the future discontinue or recall, the reagents, test kits or instruments used by us to perform laboratory testing. Such discontinuations or recalls could adversely affect our costs, testing volume and revenues. We have had certain tests discontinued by manufacturers and have had to develop alternative solutions for our clients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend substantially upon third parties for payment of services, which reliance could have a material adverse effect on our cash flows and results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business consists of clinical laboratories that provide medical testing services for doctors, hospitals, and other laboratories on patient specimens that are sent to our laboratory. In the case of some specimen referrals that are received for patients that are not in-patients or out-patients at a hospital or institution or otherwise sent by another reference laboratory, we typically bill the patient&#8217;s insurance company or a government program for our services. As such, we rely on the cooperation of numerous third-party payers, including but not limited to Medicare, Medicaid, and various insurance companies, to get paid for performing services on behalf of our clients and their patients. The amount of such third-party payments is governed by contractual relationships in cases where we are a participating provider for a specified insurance company or by established government reimbursement rates in cases where we are an approved provider for a government program such as Medicare or Medicaid. However, we do not have contractual relationships with some of the insurance companies with whom we deal, nor are we necessarily able to become an approved provider for all government programs. In such cases, we are deemed to be a non-participating provider and there is no contractual assurance that we will be able to collect the amounts billed to such insurance companies or government programs. Currently, we are not a participating provider with some of the insurance companies we bill for our services. Until such time we become a participating provider with such insurance companies, there can be no contractual assurance that we will be paid for the services we bill to such insurance companies or patients, and such third-parties may change their reimbursement policies for non-participating providers in a manner that may have a material adverse effect on our cash flow or results of operations. When new Current Procedural Terminology (&#8220;CPT&#8221;) codes are introduced by the American Medical Association it often takes time for commercial insurance providers to recognize the new codes, which can significantly impact the timing of payments, if any, and can increase our days-sales-outstanding. Medicare has also, at times, issued codes or coding guidance that conflicts with the AMA CPT coding, which can cause confusion when secondary insurance is involved. Insurance companies may also try to steer business away from us </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">towards in-network providers by sending letters to physicians and even imposing financial penalties if they continue to send us business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may fail to protect our facilities, which could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are dependent in part upon our ability to protect our laboratory operations against physical damage from explosions, fire, floods, hurricanes, earthquakes, power loss, telecommunications failures, break-ins, and similar events. We do not presently have an emergency back-up generator in place at our Tampa, Florida, Nashville, Tennessee, Atlanta, Georgia, Phoenix, Arizona, or Rolle, Switzerland laboratories locations, which would otherwise mitigate to some extent the effects of a prolonged power outage. The occurrence of any of these events could result in interruptions, delays, or cessations in service to clients, which could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on information technology systems and maintain protected personal data, and a cyber attack or other breach affecting these information technology systems or protected data could have a material adverse effect on our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our laboratory operations depend, in part, on the continued performance of our information technology systems. Such systems are susceptible to a cyber attack, malicious intrusion, breakdown, destruction, loss of confidentiality, or other significant disruption. These systems have been and are expected to continue to be the target of malware and other cyber attacks. In addition, third party hacking attempts may cause our information technology systems and related products, protected data, or proprietary information to be compromised or stolen. A significant attack or other disruption could result in adverse consequences, including increased costs and expenses, manufacturing challenges or disruption, problems with product functionality, damage to customer relations, lost revenue, and legal or regulatory penalties. Sustained system failures or interruption of our systems in one or more of our laboratory operations could disrupt our ability to process laboratory requisitions, perform testing, provide test results in a timely manner, and/or bill the appropriate party.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also collect, manage and process protected personal data, including protected health information subject to HIPAA, in connection with our service offerings. Breaches with respect to personal information and PHI could result in violations of HIPAA, the HITECH Act, and other federal, state, and international laws regarding the privacy, confidentiality, and security of such information. A breach of protected personal information could result in adverse consequences, including regulatory inquiries or litigation, increased costs and expenses, including costs related to insurance and remediation of any security vulnerabilities, reputational damage, lost revenue, and fines or penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we invest in our systems and technology and in the protection of its products and data to reduce the risk of an attack or other significant disruption, there can be no assurance that these measures and efforts will prevent future attacks or other significant disruptions to any of the systems on which we rely. Similarly, there can be no assurance that third party information technology providers with whom we contract will not suffer a significant attack or disruption that impacts customers, such as supply chain attacks. Any significant breach, attack, disruption, or failure of our information technology systems could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance issues, service interruptions, or price increases by our shipping carrier could adversely affect our business, results of operations, and financial condition, and harm our reputation and ability to provide our specialized diagnostic services on a timely basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expedited, reliable shipping is essential to our operations. One of our marketing strategies principally highlights the reliability of our point-to-point transport of patient samples. We rely heavily on a single provider of transport services, FedEx Corporation (the &#8220;Carrier&#8221;), for reliable and secure point-to-point transport of patient samples to our laboratory and enhanced tracking of these patient samples. Should the Carrier encounter delivery performance issues such as loss, damage, or destruction of a sample, it may be difficult to replace our patient samples in a timely manner and such occurrences may damage our reputation and lead to decreased demand for our services and increased cost and expense to our business. In addition, any significant increase in shipping rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters, or other service interruptions by delivery services we use would adversely affect our ability to receive and process patient samples on a timely basis. If the Carrier or we were to terminate our relationship, we would be required to find another party to provide expedited, reliable point-to-point transport of our patient samples. There are only a few other providers of such nationwide transport services, and there can be no assurance that we will be able to enter into arrangements with another provider on acceptable terms, if at all. Finding a new provider of transport services would be time-consuming and costly and result in delays in our ability to provide our specialized diagnostic services. Even if we were to enter into an arrangement with such alternative provider, there can be no assurance that they will provide the same level of quality in transport services currently provided to us by the Carrier. If the new provider does not </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide the required quality and reliable transport services, it could adversely affect our business, reputation, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We use biological and hazardous materials that require considerable expertise and expense for handling, storage, or disposal and may result in claims against us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with hazardous materials, including chemicals, biological agents and compounds, blood samples, and other human tissue that could be dangerous to human health and safety or the environment. Our operations also produce hazardous and biohazardous waste products. We have an Employee Health &amp; Safety Department that closely monitors the use of hazardous materials in our laboratory. Federal, state, and local laws and regulations govern the use, generation, manufacture, storage, handling, and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair business efforts. If we do not comply with applicable regulations, we may be subject to fines and penalties. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Our general liability insurance or workers&#8217; compensation insurance policies may not cover damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or penalized with fines in an amount exceeding our resources, and our operations could be suspended or otherwise adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price of our common stock may fluctuate significantly.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock has been, and is likely to continue to be, volatile and it could decline substantially within a short period of time. The price of our common stock could fluctuate significantly for many reasons including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change in our Leadership or Board of Directors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future announcements concerning us or our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments and enforcement actions bearing on advertising, marketing, or sales;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports and recommendations of analysts and whether or not we meet the milestones and metrics set forth in such reports; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gaining or losing large customers or managed care plans;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products or services and related insurance coverage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisition or loss of significant manufacturers, distributors or suppliers, or an inability to obtain sufficient quantities of materials needed to provide our services;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quarterly variations in operating results;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business acquisitions or divestitures;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the regulation of LDTs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in governmental or third-party reimbursement practices and rates; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the economy, political events, or general market conditions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, stock markets in general and the market for shares of healthcare stocks in particular, have experienced extreme price and volume fluctuations in recent years, fluctuations that frequently have been unrelated to the operating performance of the affected companies. These broad market fluctuations may adversely affect the market price of our common stock. The market price of our common stock could decline below its current price and the market price of our shares may fluctuate significantly in the future. These fluctuations may be unrelated to our performance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory changes, such as proposed government regulation of Laboratory Developed Tests, could require us to conduct additional clinical trials or result in delays, increased costs, or the failure to obtain necessary regulatory approvals, which could harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We frequently develop diagnostic tests for clients that cannot currently be provided using test kits approved or cleared by the FDA. The FDA has been considering changes to the way that it regulates these LDTs. Currently, all LDTs are conducted and offered in accordance with CLIA, and individual state licensing procedures. The FDA has published a draft guidance document that would require FDA clearance or approval of a subset of LDTs, as well as a modified approach for some lower risk LDTs that may require FDA oversight short of the full premarket approval or clearance process. Congress may enact legislation to provide a regulatory framework for the FDA&#8217;s role with regard to LDTs. As a result, there is a risk that the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA&#8217;s proposed regulatory process could delay the offering of certain tests and result in additional validation costs and fees. There is also an associated risk that some tests currently offered might become subject to FDA premarket approval or clearance. This FDA approval or clearance process may be time-consuming and costly, with no guarantee of ultimate approval or clearance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, FDA issued draft guidance announcing that it would end its historical policy of enforcement discretion regarding LDTs and outlining the first of multiple frameworks that have been proposed for their regulation. FDA announced in 2016 that it no longer planned to finalize its draft guidance and that it would continue to exercise enforcement discretion with respect to LDTs. On January 13, 2017, the FDA published a non-binding &#8220;Discussion Paper&#8221; proposing a framework of LDT oversight largely consistent with the draft guidance, &#8220;to spur further dialogue&#8221; and give &#8220;congressional authorizing committees the opportunity to develop a legislative solution.&#8221; Recent agency announcements made in the context of the COVID-19 public health emergency have produced a shifting policy landscape and further uncertainty regarding FDA&#8217;s role in regulating LDTs: in August 2020, HHS announced that FDA would not require premarket review of LDTs absent notice-and-comment rulemaking, but in November 2021, HHS issued a statement withdrawing that prior announcement, indicating a return to FDA&#8217;s longstanding approach to the regulation and enforcement discretion toward LDTs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress has also considered a number of legislative proposals in recent years that would amend the regulatory framework for LDTs, including, among other requirements, FDA premarket review of certain LDTs. The most recent such proposal, the VALID Act, was introduced in both the House and Senate on June 24, 2021. A competing legislative proposal, the Verified Innovative Testing in American Laboratories Act of 2021 (&#8220;VITAL Act&#8221;), was introduced in the Senate on May 18, 2021. However, it remains uncertain whether Congress will enact legislation regulating LDTs, and, if so, whether the legislation will be similar to the framework described in FDA&#8217;s 2014 draft guidance or Discussion Paper, or either the VITAL or VALID Acts. It is possible that legislation and resulting FDA regulation may result in increased regulatory burdens and costs for us to seek marketing authorization for and maintain ongoing compliance for our existing tests, any modifications thereto, or any future tests we may develop. If the government begins to regulate our tests, it could require a significant volume of applications, which would be burdensome. Furthermore, governmental bodies could take a long time to review such applications and/or document responses if other laboratories were also required to file applications and/or document responses for each of their LDTs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that the FDA begins to regulate our tests, it may require additional pre-market clinical testing prior to submitting a regulatory notification or application for commercial sales. Such pre-market clinical testing could delay the commencement or completion of clinical testing, significantly increase our test development costs, delay commercialization of any future tests, and interrupt sales of our current tests. Additionally, the results of pre-clinical trials or previous clinical trials may not be predictive of future results, and clinical trials may not satisfy the requirements of the FDA or other non-U.S. regulatory authorities. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites, and the eligibility criteria for the clinical trial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions, and contract research organizations to perform the trials. If these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness, or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed, or terminated. Many of these factors would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures. If there are delays in testing or approvals as a result of the failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests and/or to achieve sustained profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare reform programs may impact our business and the pricing we receive for our services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, healthcare reform legislation known as the &#8220;Patient Protection and Affordable Care Act,&#8221; also known as the ACA, was passed into law. The ACA makes changes that are expected to significantly impact the pharmaceutical and medical device industries and clinical laboratories. For example, the ACA contains several provisions that seek to limit Medicare spending in the future. One key provision in the ACA is the establishment of &#8220;Accountable Care Organizations&#8221; (&#8220;ACOs&#8221;), under which hospitals and physicians are able to share savings that result from improved coordination of healthcare. ACOs continue to develop, and we cannot predict how the continued establishment and implementation of these new business models will impact our business. There is the possibility that value-based payment </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">models, such as ACOs, will drive down the utilization and/or reimbursement rates for our services. We may not be able to gain access into certain ACOs. These changes could have an adverse and material impact on our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the 2016 election cycle, there were substantial efforts to repeal all or portions of the ACA. In December 2017, Public Law No. 115-97, which made changes to the tax code and included, among other things, a repeal of the ACA&#8217;s penalties for the individual mandate, a provision that required individuals to buy health insurance or pay a fine became law. While efforts to repeal all or part of the ACA have subsided, in part due to the results of the 2020 election, we cannot be certain that there will not be further legislative efforts or judicial challenges in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in laws, regulations, contracting arrangements with payers, or payer policies, including steps taken by payers to control utilization and reimbursement of healthcare services, may adversely affect coverage or reimbursement for our specialized diagnostic services, which may decrease our revenues and adversely affect our results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental payers, as well as private insurers and private payers, have implemented and will continue to implement measures to control the cost, utilization, and delivery of healthcare services, including clinical laboratory and pathology services. Congress and federal agencies, such as CMS, have, from time to time, implemented changes to laws and regulations governing healthcare service providers, including specialized diagnostic service providers. These changes have adversely affected and may in the future adversely affect coverage for our services. We also believe that healthcare professionals may not use our services if third-party payers do not provide adequate coverage and reimbursement for them. These changes in federal, state, local, and third-party payer regulations or policies may decrease our revenues and adversely affect our results of operations and our financial condition. We will continue to be a non-contracting provider until such time as we enter into contracts with third-party payers with whom we are not currently contracted until such time as we enter into contracts with such third-party payers. Because a portion of our revenues is from third-party payers with whom we are not currently contracted, it is likely that we will be required to make positive or negative adjustments to accounting estimates with respect to contractual allowances in the future, which may adversely affect our results of operations, our credibility with financial analysts and investors, and our stock price. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face efforts by government payers to reduce utilization as well as reimbursement for laboratory testing services. Changes in governmental reimbursement may result from statutory and regulatory changes, prospective and/or retroactive rate adjustments, administrative rulings, and other policy changes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislative freezes and updates affect some of our tests that are reimbursed by the Medicare program under the Medicare Physician Fee Schedule (&#8220;MPFS&#8221;), or the Clinical Laboratory Fee Schedule (&#8220;CLFS&#8221;). The MPFS is updated on an annual basis. In the past, the MPFS was updated using a prescribed statutory formula (i.e., the sustainable growth rate formula). The Medicare Access and CHIP Reauthorization Act of 2015 (&#8220;MACRA&#8221;) repealed the previous statutory formula and specified new annual conversion factors for calendar years 2015 and beyond. If the new annual conversion factor results in negative reimbursement in future years, the resulting decrease in payment may adversely affect our revenue, business, operating results, financial condition, and prospects. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, recent laws have made changes to Medicare reimbursement for our tests that are reimbursed under the CLFS, many of which have already gone into effect. The Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;) made significant changes to how Medicare pays for clinical diagnostic laboratory tests under the CLFS. As part of the changes made under PAMA, beginning in 2017, Medicare CLFS reimbursement rates were to be based on the volume-weighted median of the private payer payment rates for these tests. This led to reductions from prior rates, and without further legislative changes, will continue to result in reductions as the Medicare CLFS reimbursement rate converges towards the median private payer rate. Reductions were capped at 10.0 percent per annum from 2017 through 2020, and this cap was set to increase to 15.0 percent for 2020. However, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) and Protecting Medicare and American Farmers from Sequester Cuts Act delayed the implementation of the 15.0 percent rate reduction cap to 2023 and capped reductions at 0.0 percent for 2021 and 2022. When rate reductions begin to take effect again in 2023, this will further reduce Medicare program payments for CLFS tests. It is possible that additional reductions could be enacted in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS also adopts regulations and policies, from time to time, revising, limiting, or excluding coverage or reimbursement for certain of the tests that we perform. Likewise, many state governments are under budget pressures and are also considering reductions to their Medicaid fees. Further, Medicare, Medicaid, and other third-party payers audit for overutilization of billed services. Even though all tests performed by us are ordered by our clients, who are responsible for establishing the medical necessity for the tests ordered, we may be subject to recoupment of payments, as the recipient of the payments for such tests, in the event that a third-party payer such as CMS determines that the tests failed to meet all applicable criteria for payment. When third-party payers like CMS revise their coverage regulations or policies, our costs generally increase due to the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complexity of complying with additional administrative requirements. Furthermore, Medicaid reimbursement and regulations vary by state. Accordingly, we are subject to varying administrative and billing regulations, which also increase the complexity of servicing such programs and our administrative costs. Finally, state budget pressures have encouraged states to consider several courses that may impact our business, such as delaying payments, restricting coverage eligibility, service coverage restrictions and imposing taxes on our services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain jurisdictions, Palmetto GBA administers the Molecular Diagnostic Services Program (&#8220;MolDx&#8221;) and establishes coverage and reimbursement for certain molecular diagnostic tests, including many of our tests. To obtain Medicare coverage for a molecular diagnostic test (FDA-approved or LDT), laboratories must apply for and obtain a unique test identifier or what is known as a &#8220;Z&#8221; code. For newly developed tests or for established tests that have not been validated for clinical and analytical validity and clinical utility, laboratories must submit a detailed dossier of clinical data to substantiate that the test meets Medicare&#8217;s requirements for coverage. We have received favorable coverage for many of our molecular tests, however, we have also received non-coverage determinations for many newer tests. The field of molecular diagnostics is evolving very rapidly, and clinical studies on many new tests are still underway. We cannot be assured that some of our molecular tests will ever be covered services by Medicare, nor can we determine when the medical literature will meet the standard for coverage that Medicare administrative contractors have set. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, CMS initiated a national coverage analysis for the use of NGS diagnostic tests for patients with advanced cancer. The proposed decision memorandum was released and open to a public comment period. On March 16, 2018, CMS issued a final decision memorandum for NGS as a diagnostic laboratory test and determined it to be reasonable and necessary, and covered nationally when performed in a CLIA-certified laboratory, ordered by a treating physician, and all of the following requirements are met: (a) the patient has either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; (b) the patient has either not been previously tested using the same NGS test for the same primary diagnosis of cancer or has had repeat testing using the same NGS test only when a new primary cancer diagnosis is made by the treating physician; and (c) the patient has decided to seek further cancer treatment (e.g., therapeutic chemotherapy). CMS also determined that the diagnostic laboratory test using NGS must have: FDA approval or clearance as a companion in vitro diagnostic; an FDA approved or cleared indication for use in that patient&#8217;s cancer; and results provided to the treating physician for management of the patient using a report template to specify treatment options. On October 29, 2019, CMS issued a proposed decision memorandum open to a public comment period that would expand coverage of NGS test when performed in a CLIA-certified laboratory, ordered by a treating physician, and all of the following requirements are met (a) the patient has ovarian or breast cancer; (b) the patient has clinical indications for germline (inherited) testing; (c) the patient has risk factors for germline (inherited) breast or ovarian cancer; and (d) the patient has not been previously tested using NGS. These CMS changes to reimbursement for NGS testing could directly affect our revenue for this test type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, Medicare has encouraged beneficiaries to participate in managed care programs, known as &#8220;Medicare Advantage&#8221; programs, and has encouraged beneficiaries from the traditional fee-for-service Medicare program to switch to Medicare Advantage programs. This has resulted in rapid growth of health insurance and managed care plans offering Medicare Advantage programs and growth in Medicare beneficiary enrollment in these programs. Also, in recent years, many states have increasingly mandated that Medicaid beneficiaries enroll in managed care arrangements. If these efforts continue to be successful, we may experience a further shift of traditional Medicare and Medicaid fee-for-service beneficiaries to managed care programs. As a result, we would be required to contract with those private managed care programs in order to be reimbursed for services provided to their Medicare and Medicaid members. There can be no assurance that we will be successful in entering into agreements with these managed care programs at rates of payment similar to those we realize from our non-managed care lines of business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the initiatives such as those described above to continue and, if they do, to reduce reimbursements for clinical laboratory services, to impose more stringent cost controls on clinical laboratory services and to reduce utilization of clinical laboratory services. These efforts, including changes in law or regulations that may occur in the future, may each individually or collectively have a material adverse impact on our business, results of operations, financial condition, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to comply with laws and regulations regarding laboratory licensing and operations, including environmental, health, and safety laws and regulations such as the federal Occupational Safety and Health Administration Act and the Needlestick Safety and Prevention Act, could result in fines and penalties and loss of licensure, and have a material adverse effect upon our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive state and federal regulatory oversight regarding laboratory licensing and operations. Each of our laboratories must satisfy federal requirements under CLIA and to maintain the appropriate CLIA Certificate for all testing performed at the lab. Additionally, most states have adopted various laws and regulations setting standards for laboratories performing clinical laboratory testing, and requiring laboratories to obtain and maintain a state laboratory license before the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laboratory is authorized to perform testing. These state licensure laws address a host of requirements and often establish permissible and prohibited practices involving digital health, including but not limited to telehealth and telepathology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic inspections or surveys are performed to determine whether our laboratory locations are compliant with CLIA requirements or with applicable state licensure or certification laws. The sanctions for failure to comply with CLIA, state licensure requirements, or other applicable laws and regulations include the suspension, revocation, or limitation of the right to perform clinical laboratory services or receive compensation for those services, as well as the requirement to enter into a corrective action plan to monitor compliance, and the imposition of civil or criminal penalties or administrative fines. In addition, any new legislation or regulation or the application of existing laws and regulations in ways that we have not anticipated could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to licensing and regulation under federal, state, and local laws and regulations relating to the protection of the environment and human health and safety, including laws and regulations relating to the handling, transportation, and disposal of medical specimens, infectious and hazardous waste, and radioactive materials, as well as regulations relating to the safety and health of laboratory employees. The federal Occupational Safety and Health Administration has established extensive requirements relating to workplace safety for healthcare employers, including clinical laboratories, whose workers may be exposed to blood-borne pathogens such as HIV and the hepatitis B virus. These requirements, among other things, require work practice controls, protective clothing and equipment, training, medical follow-up, vaccinations, and other measures designed to minimize exposure to, and transmission of, blood-borne pathogens. In addition, the Needlestick Safety and Prevention Act requires, among other things, that we include in our safety programs the evaluation and use of engineering controls such as safety needles, if found to be effective at reducing the risk of needlestick injuries in the workplace.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with such federal, state and local laws and regulations could subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions, any of which could have a material adverse effect on our business. In addition, compliance with future legislation could impose additional requirements for us, which may be costly.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our net revenue will be diminished if payers do not adequately cover or reimburse our services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been, and will continue to be, significant efforts by both federal and state agencies to reduce costs in government healthcare programs and otherwise implement government control of healthcare costs. In addition, private payers continually seek ways to reduce and control overall healthcare costs, and increasing emphasis on managed care in the United States will continue to put pressure on the pricing of healthcare services. Uncertainty exists as to the coverage and reimbursement status of new applications and services. Third-party payers, including governmental payers such as Medicare and private payers, are scrutinizing new medical products and services and may not cover or may limit coverage and the level of reimbursement for our services. Third-party insurance coverage may not be available to patients for any of our existing tests or for tests we discover and develop, and a substantial portion of the testing for which we bill our hospital and laboratory clients is ultimately paid by third-party payers. Likewise, any pricing pressure exerted by these third-party payers on our clients may, in turn, be exerted by our clients on us. If government and other third-party payers do not provide adequate coverage and reimbursement for our tests, it could adversely affect our operating results, cash flows and/or our financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third-party billing is extremely complicated and results in significant additional costs to us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billing for laboratory services is extremely complicated. Depending on the billing arrangement and applicable laws, we must bill various payers, such as patients, insurance companies, Medicare, Medicaid, physician practices, employer groups, hospitals, and other laboratories, all of which have different billing requirements. Additionally, we undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Insurance companies and government payers, such as Medicare and Medicaid, also impose routine external audits to evaluate payments, which adds further complexity to the billing process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among others, the primary factors which complicate our billing practices are:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing differences between our fee schedules and the reimbursement rates of the payers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in payer rules or contracts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes with payers as to the party who is responsible for payment;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disparity in coverage and information requirements among various carriers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing pre-authorization requirements across payers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant additional costs as a result of our participation in the Medicare and Medicaid programs, as billing and reimbursement for clinical laboratory services are subject to considerable and complex federal and state regulations. The costs we expect to continue to incur include those related to: (i) complexity added to our billing processes and systems; (ii) </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">training and education of our employees and clients; (iii) implementing compliance procedures and oversight; (iv) collections and legal costs; and (v) costs associated with, among other factors, challenging coverage and payment denials and providing patients with information regarding claims processing and services, such as advance beneficiary notices.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations are subject to strict laws prohibiting fraudulent billing and other abuse, and our failure to comply with such laws could result in substantial penalties, including exclusion from participation in Medicare, Medicaid, and other governmental payer programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of particular importance to our operations is ensuring compliance with federal and state laws prohibiting fraudulent billing and the retention of overpayments. In particular, if we fail to comply with federal and state documentation, coding, and billing rules, we could be subject to liability under the federal False Claims Act, including civil penalties, loss of licenses, and exclusion from the Medicare and Medicaid programs. The False Claims Act prohibits individuals and companies from knowingly submitting false claims for payments to, or improperly retaining overpayments from, the government.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties of between $10,296 and $51,483 for each separate false claim. Further, False Claims Act liability may lead to exclusion from participation in Medicare, Medicaid, and other federal healthcare programs. There are a number of potential bases for liability under the federal False Claims Act. For example, liability arises when an entity knowingly submits, or causes another to submit, a claim for reimbursement to the federal government for a service which was not provided or which did not qualify for reimbursement. Submitting a claim with reckless disregard or deliberate ignorance of its truth or falsity could also result in liability under the False Claims Act. Following enactment of the ACA, knowing retention of overpayments is also considered a false claim and could lead to liability under the False Claims Act.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act&#8217;s &#8220;whistleblower&#8221; or &#8220;qui tam&#8221; provisions are used with frequency to challenge the reimbursement practices of providers and suppliers. Those provisions allow a private individual to bring an action on behalf of the government alleging that the defendant has submitted false claims for payment to the government. The government must decide whether to intervene in the lawsuit and whether to prosecute the case. If it declines to do so, the individual may pursue the case alone, although the government must be kept apprised of the progress of the lawsuit. Whether or not the federal government intervenes in the case, it will receive the majority of any recovery. The successful qui tam relator who brought the case is entitled to a portion of the proceeds and his or her attorneys&#8217; fees and costs. In addition, various states have enacted laws modeled after the federal False Claims Act, which prohibit submitting false claims for payment to the state, or, in some states, to commercial payers. If we fail to comply with federal and state documentation, coding, and billing rules, we could be subject to liability under analogous state laws as well as criminal liability through a variety of federal and state criminal statutes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government investigations of clinical laboratories have been ongoing for a number of years and are expected to continue in the future. When we submit bills for our services to third-party payers, we must follow complex documentation, coding, and billing rules which are based on federal and state laws, rules and regulations, various government publications, and on industry practice. A large number of laboratories have entered into substantial settlements with the federal and state governments for alleged noncompliance under these laws and rules. Private payers have also brought civil actions against laboratories, which have resulted in substantial judgments. Failure to follow these rules could result in potential civil liability under the False Claims Act, under which extensive financial penalties can be imposed. It could further result in criminal liability under various federal and state criminal statutes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submit thousands of claims for payment to governmental programs and private payers, and we cannot guarantee that there have not been errors in our claims. While we maintain a robust compliance program that includes consistent, detailed review of our documentation, coding, and billing practices, the rules are frequently vague, complex, and continually changing and we cannot assure that governmental authorities, private insurers, or private whistleblowers will not challenge our practices. Such a challenge could result in a material adverse effect on our business. We therefore could be exposed to potential liability, penalties, or limitations on our operations due to failure to comply with significant government regulation and laboratory operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing federal laws governing Medicare and Medicaid, as well as some other state and federal laws, also regulate certain aspects of the relationship between healthcare providers, including clinical laboratories, and their referral sources, including physicians, hospitals and other laboratories. Some of these laws, including the federal AKS and the federal Stark Law contain extremely broad proscriptions. Violation of these laws can result in criminal or civil penalties, exclusion from participation in the Medicare, Medicaid, and other federal healthcare programs, repayment of reimbursement received related to services tied to any impermissible referrals, or civil monetary penalties, which may be significant, as well as potential False Claims Act liability. Government authorities may determine that our arrangements with physicians and other clients do not comply with </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the federal AKS, Stark Law, and similar state laws, and may impose civil monetary penalties or exclude us based on our arrangements with physicians and other clients. The Company, for example, is voluntarily conducting an internal investigation, with the assistance of outside counsel, that focuses on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste, and abuse. Based on this internal investigation, the Company voluntarily notified the OIG of the Company&#8217;s internal investigation in November 2021. The Company&#8217;s review of this matter is ongoing. As of December 31, 2021, the Company has accrued a reserve of $11.2 million in other long-term liabilities on the Consolidated Balance Sheets for potential damages and liabilities associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#8217;s best estimate of the minimum probable loss associated with this matter. As a result of the ongoing investigation and interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. At this time, the Company is unable to predict the duration, scope, result, or related costs associated with any further investigation, including by the OIG, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Determinations that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s operations or activities do not, or did not, comply with laws or regulations, however, may result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, or other losses or conduct restrictions, which could be material to the Company&#8217;s financial results or business operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Civil Monetary Penalties Law (&#8220;federal CMP Law&#8221;) imposes civil monetary penalties and potential exclusion from Medicare and Medicaid programs on any person who offers or transfers remuneration to any patient, who is a Medicare or Medicaid beneficiary, when the person knows or should know that the remuneration is likely to induce the patient to receive medical services from a particular provider. The federal CMP Law applies, among other things, to many kinds of inducements or benefits provided to patients, including complimentary items or services that are of more than nominal value. Government authorities may determine our operations and provision of services do not comply with the law and its interpretations and impose civil monetary penalties and exclude us from participation in Medicare and Medicaid for past or present practices related to patient incentive, coordination of care and need-based programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tests which are reimbursed by Medicare and other Government payers (for example, State Medicaid programs) accounted for approximately 17.8%, 17.0% and 18.0% of our revenues for the years ended December 31, 2021, 2020 and 2019, respectively. The Medicare program imposes extensive and detailed requirements on diagnostic service providers, including, but not limited to, rules that govern how we structure our relationships with physicians, how and when we submit claims for reimbursement, and how we provide specialized diagnostic laboratory services. Further, we are prohibited from contracting with any individuals or entities who have been excluded from participation in Medicare or Medicaid and are listed on the OIG&#8217;s List of Excluded Individuals and Entities List (&#8220;LEIE&#8221;) or in the System for Award Management, which includes the previously independent Government Services Administration&#8217;s Excluded Parties List System (&#8220;GSA-EPLS&#8221;). Contracting with excluded individuals or entities, such as hiring an excluded person or contracting with an excluded vendor, can result in significant penalties. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply with applicable Medicare, Medicaid, and other governmental payer rules could result in our inability to participate in a governmental payer program, an obligation to repay funds already paid to us for services performed, civil monetary penalties, criminal penalties, False Claims Act liability, and/or limitations on the operational function of our laboratory. If we were unable to receive reimbursement under a governmental payer program, a substantial portion of our revenues would be lost, which would adversely affect our results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The failure to comply with fraud and abuse laws, including physician self-referral laws and anti-kickback laws, may subject us to liability, penalties, or limitation of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the federal Stark Law, as well as similar state statutes and regulations, which prohibit billing Medicare for certain healthcare services, which are referred to as DHS, rendered as a result of referrals by physicians to DHS entities with which the physicians (or their immediate family members) have a financial relationship unless an exception is met. A &#8220;financial relationship&#8221; includes both an ownership interest and/or a compensation arrangement with a physician, both direct and indirect, and DHS includes, but is not limited to, laboratory services. The Stark Law prohibits an entity that receives a prohibited DHS referral from seeking payment from Medicare for any DHS services performed as a result of such a referral, unless an arrangement is carefully structured to satisfy every requirement of a regulatory exception. The Stark Law is a strict liability statute, and thus any technical violation requires repayment of all &#8220;tainted&#8221; referrals, regardless of the intent, unless an exception applies. Penalties for violating the Stark Law may include the denial of payment to an entity for the impermissible provision of DHS, the requirement to refund any amounts collected in violation of the Stark Law, and civil monetary penalties of up to $26,125 for each violation and $174,172 for each circumvention arrangement or scheme. Other </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implications of a Stark Law violation may include exclusion from Medicare and Medicaid programs, and potential False Claims Act liability, including via &#8220;qui tam&#8221; action. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, many states have promulgated self-referral laws and regulations similar to the federal Stark Law, and these vary significantly based on the state. In addition to services reimbursed by Medicaid or government payers, these state laws and regulations can encompass services reimbursed by private payers and self-pay patients as well. Penalties for violating state self-referral laws and regulations vary based on the state, but often include civil penalties, exclusion from Medicaid, and loss of licenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial arrangements with physicians are governed by the federal Stark Law, and we rely on certain exceptions to the Stark Law with respect to such relationships. While we believe that our financial relationships with physicians and physician practices are in compliance with applicable laws and regulations, we cannot guarantee that government authorities would agree. If we are found by the government to be in violation of the Stark Law, we could be subject to significant penalties, including fines as specified above, exclusion from participation in government and private payer programs and requirements to refund amounts previously received from government. Further, as our operations expand into new states and jurisdictions, we must continually evaluate whether our relationships with physicians comply with that jurisdiction&#8217;s laws. This may require structural and organizational modifications to our relationships with physicians, which could adversely affect our results of operations and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the federal AKS, which prohibits the offer, payment, solicitation, or receipt of any form of remuneration in return for referring, ordering, leasing, purchasing, or arranging for or recommending the ordering, purchasing, or leasing of items or services payable by Medicare, Medicaid, or any other federally funded healthcare program. The federal AKS defines remuneration to include anything of value, in cash or in kind, and thus can implicate financial relationships involving payments not commensurate with fair market value, such as in the form of office space, equipment leases, professional or technical services, or anything else of value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AKS is an &#8220;intent-based&#8221; statute, meaning that a violation occurs when one or both parties intend the remuneration to be in exchange for or to induce referrals. In 2010, the ACA, amended the intent requirement of the AKS. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provides that a claim submitted for reimbursement for items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal False Claims Act. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions; however, the exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. Violations of the AKS may result in substantial civil or criminal penalties, including criminal fines of up to $100,000, imprisonment of up to ten years, civil penalties under the federal CMP Law of up to $105,563 for each violation, plus three times the remuneration involved, civil penalties under the federal False Claims Act of a maximum of $51,483 for each claim submitted, plus three times the amounts paid for such claims and exclusion from participation in the Medicare and Medicaid programs. If we face these penalties or exclusion from participation in Medicare and Medicaid, it could significantly reduce our revenues and could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, most states have adopted similar anti-kickback laws prohibiting the offer, payment, solicitation, or receipt of remuneration in exchange for referrals, and typically impose criminal and civil penalties as well as loss of licenses. Some of these state laws apply to items and services paid for by private payers as well as by government payers. In addition, many states have adopted laws prohibiting the splitting or sharing of fees between physicians and non-physicians, as well as between treating physicians and referral sources. We believe our arrangements with physicians comply with the AKS, as well as state anti-kickback and fee splitting laws of the states in which we operate; however, if government authorities were to disagree, we could be subject to civil and criminal penalties and be required to restructure or terminate our contractual and other arrangements with physicians. This could result in a loss of revenue and have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states have also adopted laws prohibiting the corporate practice of medicine, or prohibiting business corporations from employing physicians or engaging in activities considered to be the &#8220;practice of medicine.&#8221; In these states, we rely on service agreements with physicians and/or professional associations owned by physicians, to perform needed professional pathology services. We cannot be certain that a physician or physician&#8217;s professional organization will not seek to terminate an agreement with us on any basis, nor can we be certain that governmental authorities in those states will not seek termination of these arrangements on the basis of state laws prohibiting the corporate practice of medicine.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to comply with the HIPAA Privacy, Security, and Breach Notification Regulations and other evolving federal, state and international laws related to privacy and data protection may increase our operational costs, and we are subject to security risks which could harm our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, the HITECH Act, as implemented through HIPAA&#8217;s privacy and security regulations, and similar state laws contain provisions that require the electronic exchange of health information, such as claims submission and receipt of remittances, using standard transactions and code sets, which we refer to as &#8220;Standards,&#8221; and regulate the use and disclosure of patient records and other PHI. These provisions, which address security and confidentiality of patient information as well as the administrative aspects of claims handling, have very broad applicability and govern many healthcare providers, including physicians and clinical laboratories. Failure to comply with the Standards, the HIPAA privacy and security regulations, and applicable state privacy and security laws, could result in material adverse effects on our business, results of operations, and our financial condition and could subject us to liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA privacy and security regulations establish comprehensive federal standards with respect to the uses and disclosures of PHI by certain entities including health plans and healthcare providers, and set standards to protect the confidentiality, integrity, and availability of electronic medical records. The regulations establish a complex regulatory framework governing the use and disclosure of PHI, including, for example, the circumstances under which uses and disclosures of PHI are permitted or required without a specific authorization by the patient; a patient&#8217;s right to access, amend, and receive an accounting of certain disclosures of PHI; the content of notices of privacy practices describing how PHI is used and disclosed and individuals&#8217; rights with respect to their PHI; and implementation of administrative, technical, and physical safeguards to protect privacy and security of PHI. The federal privacy regulations restrict our ability to use or disclose certain individually identifiable patient health information, without patient authorization, for purposes other than payment, treatment, or healthcare operations, as defined by HIPAA, except for disclosures for various public policy purposes and other permitted purposes outlined in the privacy regulations. The HIPAA privacy and security regulations do not supersede state laws that may be more stringent; therefore, we are required to comply with both federal privacy and security regulations and varying state privacy and security laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA privacy and security regulations also require healthcare providers like us to notify affected individuals, the Secretary of the U.S. Department of Health and Human Services, and in some cases, the media, when PHI has been &#8220;breached,&#8221; as defined by HIPAA. Many states have similar breach notification laws. In the event of a breach, we could incur substantial operational and financial costs related to mitigation and remediation, including preparation and delivery of notices to affected individuals. Additionally, HIPAA and its implementing regulations provide for significant civil fines, criminal penalties, and other sanctions for failure to comply with the privacy, security, and breach notification rules, including for wrongful or impermissible use or disclosure of PHI. Although the HIPAA statute and regulations do not expressly provide for a private right of action for damages, we could incur damages under state laws to private parties for the wrongful or impermissible use or disclosure of confidential health information or other private personal information. Additionally, HIPAA allows state Attorneys General to bring an action against a covered entity, such as us, for a violation of HIPAA. We insure some of our risk with respect to HIPAA security breaches, but operational costs and penalties associated with HIPAA breaches easily could exceed our insured limits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA imposes additional requirements, restrictions, and penalties on covered entities and their business associates to, among other things, deter breaches of security. As a result, in addition to the aforementioned reporting requirements, covered entities and their business associates may be required to take preventative and remedial actions, as well as face stringent sanctions for a breach. Our electronic health records system is periodically modified to meet applicable security standards. Despite our implementation of various security measures, our infrastructure may be vulnerable to computer viruses, break-ins, and other disruptive problems inadvertently introduced by authorized users such as employees and clients, or purposefully targeted by hackers and other cybercriminals which could lead to interruption, delays, or cessation in service to our clients. Further, such incidents, whether electronic or physical, could jeopardize the security of confidential information, including PHI and other sensitive information stored in our computer systems related to clients, patients, and other parties connected through us, which may deter potential clients and give rise to uncertain liability to parties whose security or privacy has been infringed. A significant security breach could result in fines, loss of clients, damage to our reputation, direct damages, costs of repair and detection, costs to remedy the breach, government penalties, and other expenses. We insure some of our risk with respect to security breaches but the occurrence of any of the foregoing events could have a material adverse effect on our business, results of operations, and our financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous other federal, state, and international laws govern the collection, use, and disclosure of personal information and may complicate our compliance efforts. Failure to comply with these laws can result in the imposition of significant fines and impact our ability to process certain personal data. For example, the GDPR imposes penalties of up to 4.0% of annual global turnover. The GDPR imposes a number of strict obligations and restrictions on the ability to process (which includes </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collection, analysis, and transfer of) personal data, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification of data processing obligations to the national data protection authorities, and the security and confidentiality of the personal data. Further, the GDPR prohibits the transfer of personal data to countries outside of the EU that are not considered by the European Commission to provide an adequate level of data protection, including to the United States, except if the data controller meets very specific requirements. Following the Schrems II decision of the Court of Justice of the European Union on July 16, 2020, there is considerable uncertainty as to the permissibility of international data transfers under the GDPR. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the CCPA affords California residents expanded privacy rights and protections and provides for civil penalties for violations and a private right of action related to certain data security breaches. These protections will be expanded by the California Privacy Rights Act (&#8220;CPRA&#8221;), which will be operational in most key respects in 2023 along with new privacy laws in Virginia and Colorado. There are similar legislative proposals being advanced in other states, as well as in Congress. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including laws in all 50 states requiring security breach notification in some circumstances. These and other laws could create liability for us or increase our cost of doing business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are dependent on key personnel and need to hire additional qualified personnel in order for our business to succeed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance is substantially dependent on the performance of our senior management and key technical personnel. In particular, our success depends substantially on the continued efforts of our senior management team. The loss of the services of any of our executive officers, our medical staff, our laboratory directors or other key employees could have a material adverse effect on our business, results of operations, and our financial condition. Our future success also depends on our continuing ability to attract and retain highly qualified managerial and technical personnel as we continue to grow. Competition for such personnel is intense and we may not be able to retain our key managerial and technical employees or may not be able to attract and retain additional highly qualified managerial and technical personnel in the future. The inability to attract and retain the necessary managerial and technical personnel could have a material adverse effect upon our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our ability to retain existing clients for our specialized diagnostic services and attract new clients is dependent upon retaining existing sales representatives and hiring and training new sales representatives, which are expensive and time-consuming processes. We face intense competition for qualified sales personnel and our inability to hire or retain an adequate number of sales representatives could limit our ability to maintain or expand our business and increase sales. Even if we are able to increase our sales force, our new sales personnel may not commit the necessary resources or provide sufficient high quality service and attention to effectively market and sell our services. If we are unable to maintain and expand our marketing and sales networks, or if our sales personnel do not perform to our standards, we may be unable to maintain or grow our existing business and our results of operations and financial condition will likely suffer accordingly. If a sales representative ceases employment, such termination could result in the loss of client goodwill based on the impairment of relationships developed between the sales representative and the healthcare professionals for whom the sales representative was responsible. This is particularly a risk if the representative goes to work for a competitor, as the healthcare professionals that are our clients may choose to use a competitor&#8217;s services based on their relationship with our former sales representative.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, non-compliant activities and unlawful conduct by sales and marketing personnel could give rise to significant risks under the AKS. We require extensive, comprehensive training of all sales and marketing personnel, but cannot guarantee that every staff member will comply with the training. Thus, in addition to the cost of training sales and marketing personnel, we could face liability under the AKS for non-compliance by individuals engaged in prohibited sales and marketing activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business operations and reputation may be materially impaired if we do not comply with privacy laws or information security policies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our business, we collect, generate, process, or maintain sensitive information, such as patient data and other personal information. If we use or do not adequately safeguard such information in compliance with applicable requirements under federal, state, and international laws, or if such information were disclosed to persons or entities that should not have access to it, our business could be materially impaired, our reputation could suffer, and we could be subject to fines, penalties, and litigation. In the event of a data security breach, we may be subject to notification obligations, litigation, and governmental investigation or sanctions and may suffer reputational damage, which could have an adverse impact on our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations regarding protecting the security and privacy of certain healthcare and personal information, including: (a) HIPAA and the regulations thereunder, which establish (i) a complex regulatory framework including requirements for safeguarding protected health information and (ii) comprehensive federal standards regarding the uses and disclosures of protected health information; (b) state laws, including the CCPA; and (c) the European Union&#8217;s GDPR.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to implement our business strategy, which could impair our ability to continue operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implementation of our business strategies will depend in large part on our ability to (i) attract and maintain a significant number of clients; (ii) effectively provide acceptable products and services to our clients; (iii) develop and license new products and technologies; (iv) obtain adequate financing on favorable terms to fund our business strategies; (v) maintain appropriate internal procedures, policies, and systems; (vi) hire, train, and retain skilled employees and management; (vii) continue to operate despite competition in the medical laboratory industry; (viii) be paid reasonable fees by government payers that will adequately cover our costs; (ix) establish, develop, and maintain our name recognition; and (x) establish and maintain beneficial relationships with third-party insurance providers and other third-party payers. Our inability to obtain or maintain any or all these factors could impair our ability to implement our business strategies successfully, which could have material adverse effects on our results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to successfully integrate future acquisitions with our legacy business, the anticipated benefits of such transaction may not be realized. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions require us to devote significant management attention and resources to integrating the acquired company&#8217;s business practices and operations with our own. Potential difficulties we may encounter as part of the integration process, all of which could materially and adversely affect our business, financial condition, results of operations, and cash flows, include the following: </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential inability to successfully combine the acquired company&#8217;s business with our legacy business in a manner that permits us to achieve the cost synergies expected to be achieved when expected, or at all, and other benefits anticipated to result from such transaction; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges optimizing the customer information and technology of the two companies, including the goal of consolidating to one laboratory information system and one billing system; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges effectuating any diversification strategy, including challenges achieving revenue growth from sales of each company&#8217;s products and services to the customers of the other company; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties offering products and services across our expanded portfolio;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to revisit assumptions about reserves, revenues, capital expenditures, and operating costs, including expected synergies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges faced by a potential diversion of the attention of our management as a result of the integration, which in turn could adversely affect our ability to maintain relationships with customers, employees and other constituencies or our ability to achieve the anticipated benefits of such transaction;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential loss of key employees, customers, managed care contracts, or strategic partners, or the ability to attract or retain key management and other key personnel, which could have an adverse effect on our ability to integrate and operate the acquired business;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing the combined businesses, including difficulty addressing possible differences in corporate cultures and management philosophies and the challenge of integrating complex systems, technology, networks, and other assets of each of the companies in a seamless manner that minimizes any adverse impact on customers, suppliers, employees, and other constituencies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and challenges related to the integration of the acquired company&#8217;s internal controls over financial reporting with ours; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential unknown liabilities and unforeseen increased expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be assured that all of the goals and anticipated benefits of an acquisition will be achievable, particularly as achievement of the benefits is in many important respects subject to factors that we do not control. These factors would include the reactions of third parties with whom we enter into contracts and do business and the reactions of investors and analysts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully integrate our legacy business with any future business we may acquire, we may fail to realize the expected benefits of such transaction, including the anticipated cost synergies. We could also encounter additional transaction and integration costs or be subject to other factors that affect preliminary estimates.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may incur greater costs than anticipated, which could result in sustained losses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use reasonable efforts to assess and predict the expenses necessary to pursue our business strategies. However, implementing our business strategies may require more employees, capital equipment, supplies, or other expenditure items than management has predicted, particularly as we continue to assess any further needs resulting from the growth of our Pharma Services segment. Similarly, the cost of compensating additional management, employees, and consultants or other operating costs may be more than we estimate, which could result in ongoing and sustained losses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may face fluctuations in our results of operations and we are subject to seasonality in our business which could negatively affect our business operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management expects that our results of operations may fluctuate significantly in the future as a result of a variety of factors, including, but not limited to: (i) the continued rate of growth, usage, and acceptance of our products and services; (ii) demand for our products and services; (iii) the introduction and acceptance of new or enhanced products or services by us or by competitors; (iv) our ability to anticipate and effectively adapt to developing markets and to rapidly changing technologies; (v) our ability to attract, retain, and motivate qualified personnel; (vi) the initiation, renewal, or expiration of significant contracts with any major clients; (vii) pricing changes by us, our suppliers, or our competitors; (viii) seasonality; and (ix) general economic conditions and other factors. Accordingly, future sales and operating results are difficult to forecast. Our expenses are based in part on our expectations as to future revenues and to a significant extent are relatively fixed, at least in the short-term. We may not be able to adjust spending in a timely manner to compensate for any unexpected revenue shortfall. Accordingly, any significant shortfall in relation to our expectations would likely have an immediate adverse impact on our business, results of operations, and financial condition. In addition, we may determine from time to time to make certain pricing or marketing decisions or acquisitions that could have a short-term material adverse effect on our business, results of operations, and financial condition and may not result in the long-term benefits intended. Furthermore, in Florida, historically our largest referral market for laboratory testing services, a meaningful percentage of the population returns to their homes in the Northern United States to avoid the hot summer months. This combined with our clients&#8217; usual summer vacation schedules typically results in seasonality in our business. Because of all of the foregoing factors, our operating results in future periods could be less than the expectations of investors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The steps we have taken to protect our proprietary rights may not be adequate, which could result in infringement or misappropriation by third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regard our copyrights, trademarks, trade secrets, and similar intellectual property as critical to our success, and we rely upon trademark law, copyright law, trade secret protection, and confidentiality and/or license agreements with our employees, clients, partners, and others to protect our proprietary rights. The steps taken by us to protect our proprietary rights may not be adequate or third parties may infringe or misappropriate our copyrights, trademarks, trade secrets, and similar proprietary rights. In addition, other parties may assert infringement claims against us.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_19"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_22"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. PROPERTIES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate an international network of laboratories. Our corporate office and all of our laboratory facilities are leased, except for 43,560 square feet at our Carlsbad, California facility, which we own. During the third quarter of 2021, we committed to selling this property and the associated land and concluded that these assets met the held for sale criteria. For further information about our held for sale assets, please refer to Note 2. Summary of Significant Accounting Policies and Note. 5 Property and Equipment, in the notes to our Consolidated Financial Statements. Our leases expire at various dates through 2041.&#160;We believe that these locations are sufficient to meet our needs at existing volume levels and, if needed, additional space will be available at a reasonable cost.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain laboratories at all of our facilities, as well as administrative offices at four of our locations. The following table summarizes our facilities by location and approximate square footage:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.875%"><tr><td style="width:1.0%"></td><td style="width:71.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square&#160;Footage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fort Myers, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aliso Viejo, California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carlsbad, California</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Houston, Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">La Jolla, California</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge, United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Durham, North Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneva (Rolle), Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nashville, Tennessee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tampa, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atlanta, Georgia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phoenix, Arizona</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzhou, China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burlington, Massachusetts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our La Jolla, California; Rolle, Switzerland; Singapore and Suzhou, China laboratories support our Pharma Services segment exclusively. Our Nashville, Tennessee; Tampa, Florida; Atlanta, Georgia; and Phoenix, Arizona locations support our Clinical Services segment exclusively. All other locations serve both segments of the business. For further financial information about our segments, please refer to Note 19. Segment Information, in the notes to our Consolidated Financial Statements.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time the Company is engaged in legal proceedings, including proceedings that arise in the ordinary course of business. For further information on legal proceedings, please refer to Note 17. Commitments and Contingencies, in the notes to our Consolidated Financial Statements.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_31"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ia1854a760084469581a7ceab463d6c8e_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on The Nasdaq Stock Market LLC under the symbol &#8220;NEO.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;21, 2022, there were 690 stockholders of record of our common stock. The number of record holders does not include beneficial owners of common stock whose shares are held in the names of banks, brokers, nominees or other fiduciaries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We intend to retain all future earnings to finance operations and future growth and, therefore, we do not anticipate paying any cash dividends in the foreseeable future. Our financing arrangements contain certain restrictions on our ability to pay dividends on our common stock. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the securities authorized for issuance under equity compensation plans as of December 31, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:48.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;securities to be issued upon exercise of outstanding options, warrants and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average exercise price of outstanding&#160;options, warrants and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;securities remaining available for future issuance under equity compensation plans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Equity Incentive Plan</span></div><div style="text-indent:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(&#8220;Equity Incentive Plan&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Equity Incentive Plan was amended, restated and subsequently approved by a majority of stockholders on December 21, 2015, and amended and subsequently approved by a majority of stockholders on May 25, 2017, and then amended and subsequently approved by a majority of stockholders again on May 27, 2021. The most recent amendment increased the maximum aggregate number of shares of the Company&#8217;s common stock reserved and available for issuance under the Equity Incentive Plan to 25,625,000.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Employee Stock Purchase Plan was amended, restated and subsequently approved by a majority of stockholders on June 6, 2013, and amended and subsequently approved by a majority of stockholders on May 25, 2017, and then amended and subsequently approved by a majority of stockholders again on June 1, 2018. The most recent amendment increased the maximum aggregate number of shares reserved and available for issuance under the Employee Stock Purchase Plan to 1,500,000.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently the Company&#8217;s Equity Incentive Plan, as amended on May 27, 2021, and the Company&#8217;s ESPP, as amended on June 1, 2018, are the only equity compensation plans in effect.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None for the year ended December 31, 2021 that have not been previously included in a Current Report on Form 8-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning our purchases of common stock for the periods indicated:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period of Repurchase</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased (3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2021 - October 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2021 - November 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2021 - December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Equity Incentive Plan, as amended on May 27, 2021, allows participants to surrender vesting shares having a fair market value equal to the required withholding tax related to the vesting of restricted stock. Pursuant to a share withholding election made by participants in connection with the vesting of such awards, all of which were outside of a publicly-announced repurchase plan, we acquired from such participants the shares noted in the table above to satisfy tax withholding obligations related to the vesting of their restricted stock. The average prices listed in the above table are averages of the fair market prices at which we valued shares withheld for purposes of calculating the number of shares to be withheld.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of Cumulative Five Year Total Return</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have presented below the cumulative total return to our stockholders of $100 during the period from December&#160;31, 2016, through December 31, 2021, in comparison to the cumulative return on the S&amp;P 500 Index and a customized peer group of five publicly traded companies during that same period. The peer group is made up of Invitae Corporation, Exact Sciences Corporation, Laboratory Corporation of America Holdings, Natera, Inc., and Quest Diagnostics, Inc. Several of our closest competitors are part of large pharmaceutical or other multi-national firms, or are privately held and, as such, we are unable to obtain financial information for them.</span></div><div style="margin-top:6pt;text-align:center"><img src="neo-20211231_g1.jpg" alt="neo-20211231_g1.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results assume that $100 (with reinvestment of all dividends) was invested in our common stock, the index, and in the peer group and its relative performance tracked through December 31, 2021. The comparisons are based on historical data and are not indicative of, nor intended to forecast, the future performance of our common stock. The performance graph set forth above shall not be deemed incorporated by reference into any filing by us under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) or the Exchange Act except to the extent that we specifically incorporate such information by reference therein.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. SELECTED FINANCIAL DATA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserved.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included in this Annual Report on Form 10-K. The information contained below includes statements of management&#8217;s beliefs, expectations, hopes, goals and plans that, if not historical, are forward-looking statements subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion on forward-looking statements, see the information set forth in the introductory note to this Annual Report under the caption &#8220;Forward Looking Statements,&#8221; which information is incorporated herein by reference. For discussion and analysis pertaining to 2020 overview and highlights as compared to 2019, please refer to the Company&#8217;s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 25, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Company</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeoGenomics is a high-complexity clinical laboratory that specializes in cancer genetics diagnostic testing and pharma services.&#160;Our testing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include</span><span style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cytogenetics, FISH, flow cytometry, IHC, anatomic pathology and molecular genetic testing. We operate CLIA-certified laboratories in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States and pharmaceutical firms in Europe and Asia.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Overview and Highlights</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We increased consolidated revenue by 9.0% compared to 2020, including increases in Clinical Services revenue of 5.7% and in Pharma Services revenue of 29.1%;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharma Services backlog increased to approximately $267 million;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial position strengthened with $743 million net convertible note and equity offerings;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We acquired Trapelo;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We acquired Inivata;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the Inivata acquisition, we added liquid biopsy platform technology, including MRD testing capabilities, to our comprehensive portfolio of oncology testing solutions; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Transitioned the majority of our testing in Fort Myers to our new headquarters and laboratory facility, providing significant additional capacity for future growth. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Outlook</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advances in science and technology are driving a proliferation of oncology therapies and associated diagnostic tests. These diagnostic tools and therapies are increasing survival and enhancing quality-of-life for cancer patients. As a leading global oncology diagnostics company serving biopharmaceutical companies as well as practicing oncologists and pathologists, NeoGenomics facilitates the adoption of these advanced oncology diagnostic tools beyond the academic environment into the community setting. We are continuously enhancing and expanding our test menu to ensure that providers and patients have access to leading edge solutions such as advanced molecular testing and state-of-the art digital pathology. Moreover, our team of MDs and PhDs, along with our highly-trained oncology-focused sales team, provides ongoing education to our clients to ensure that they remain abreast of cutting-edge developments in oncology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading provider of oncology-diagnostic services to biopharma companies. We will continue to work with these clients across the drug development continuum&#8212;from research and development through clinical trials testing&#8212;to commercialization of companion diagnostic tests. We expect to continue to grow our Pharma Services business through (i) global expansion in both Europe and Asia, (ii) expansion of our test offerings (including leading edge NGS tools), and (iii) our unique capabilities for developing and commercializing companion diagnostic tests.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to develop and broaden our informatics and data-related tools to leverage our strategic market position and oncology expertise to help our stakeholders solve real-world problems such as identifying patients for clinical trials or providing clinical decision support tools for physicians and providers. We are committed to connecting patients with life altering therapies and trials. In carrying out these commitments, NeoGenomics aims to provide transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to help ensure the data we maintain is secured at all times.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe lower cost and increased value of testing is extremely important to the healthcare industry and creates a competitive advantage. We will invest in information technology, automation and best practices to continually improve our processes and drive down the cost of testing. We will continue to expand our test menu and expect to remain at the forefront of the ongoing revolution in cancer related genetic and molecular testing to achieve our vision of becoming one of the world&#8217;s leading cancer testing and information companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to develop our company-wide focus, which includes the following three critical success factors for 2022:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Growth through Innovation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successfully launch new test offerings and secure reimbursement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expand development of new cancer treatments; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerate precision medicine in the community.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Excellence In Service and Performance</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Achieve turnaround time targets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Grow consolidated revenue and profitability; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Design next-generation LIMS platform.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purpose Driven Culture</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drive an engaged and committed workforce; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foster inclusive and effective leadership by expanding our culture of inclusion and developing our future leaders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These critical success factors have been communicated throughout our Company. We have structured departmental goals around these factors and have created employee incentive plans in which every employee will have a meaningful incentive for our success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Environment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is currently considering changes which may include increased regulation of LDTs by the FDA. In October 2014 the FDA announced its proposed framework and timetable and indicated it would move toward greater oversight of LDTs. The FDA has not finalized the framework they announced in 2014. In 2017 the FDA shifted its approach to oversight of LDTs, indicating that they would work with Congress and stakeholders on a new legislative framework and pathway for all diagnostic testing. In 2018 the FDA began limited enforcement activities on a subset of LDTs known as pharmacogenetic testing (&#8220;PGx&#8221;). NeoGenomics is a member of the American Clinical Laboratory Association (&#8220;ACLA&#8221;), which has been in active discussions with the FDA and Congress regarding FDA oversight of LDT&#8217;s. However, recent agency announcements made in the context of the COVID-19 public health emergency have produced a shifting policy landscape and further uncertainty regarding FDA&#8217;s role in regulating LDTs: in August 2020, HHS announced that FDA would not require premarket review of LDTs absent notice-and-comment rulemaking, but in November 2021, HHS issued a statement withdrawing that prior announcement, indicating a return to FDA&#8217;s longstanding approach to the regulation and enforcement discretion toward LDTs. At this time, we cannot predict what the current administration impact will be on the oversight and regulation of LDTs or if there will be any additional changes to current rules and regulations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor changes in legislation and take specific actions to identify and estimate the impact of changes in legislation whenever possible as regulatory changes can affect reimbursement for clinical laboratory services. We do not anticipate significant changes to our clinical revenue in 2022 resulting from known changes in legislation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our activities in two reportable segments&#8212;the Clinical Services Segment and the Pharma Services Segment. We have presented the financial information reviewed by the Chief Operating Decision Maker including revenues, cost of revenue, and gross margin for each of our reportable segments. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets are not presented at the segment level as that information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is not used by the CODM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical cancer testing services we offer to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. We believe our relationships as a non-competitive partner to community-based pathology practices, to hospital pathology labs, and to academic centers empower them to expand their breadth of testing and provide a menu of services to match or exceed the level of service found in any center of excellence around the world. Community-based pathology practices and hospital pathology labs may order certain testing services on a tech-only basis, which allows them to participate in the diagnostic process by performing the PC interpretation services without having to hire laboratory technologists or purchase the sophisticated equipment needed to perform the technical component of the tests. We also support our pathology clients with interpretation and consultative services using our own specialized team of pathologists for difficult or complex cases and provide overflow interpretation services when requested by clients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading provider of Molecular and NGS testing. These tests are interpreted by NeoGenomics&#8217; team of Molecular experts and are often ordered in conjunction with other testing modalities. NGS panels are one of our fastest growing testing areas and clients can often receive a significant amount of biomarker information from very limited samples. These comprehensive panels can allow for faster treatment decisions for patients as compared to a series of single-gene molecular tests being ordered sequentially. We believe that we have one of the broadest Molecular menus in the industry and our targeted NeoTYPE panels include genes relevant to a particular cancer type, as well as other complementary tests, such as immunohistochemistry and FISH. This comprehensive menu means that NeoGenomics can be a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;one-stop shop&#8221; for our clients who can get all of their oncology testing needs satisfied by our laboratory. This is attractive to our clients as patient samples do not need to be split and then managed across several laboratories. We expect our Molecular laboratory and NGS capabilities to be a key growth driver in the coming years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition we directly serve oncology, dermatology, and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic testing services. We typically serve these types of clients with a comprehensive </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service offering where we perform both the technical and professional components of the tests ordered. In certain instances, larger clinician practices have begun to internalize pathology interpretation services and our tech-only service offering allows these larger clinician practices to also participate in the diagnostic process by performing the PC interpretation services on TC testing performed by us.&#160;In these instances, we will typically provide all of the more complex, molecular testing services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharma Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services revenue consists of three revenue streams:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials and research;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Validation laboratory services; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Informatics.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research.&#160;This portion of our business often involves working with the sponsors on study design as well as performing the required testing.&#160;Our medical team often advises the sponsor and works closely with them as specimens are received from the enrolled sites.&#160;We also work on developing tests that will be used as part of a companion diagnostic to determine patients&#8217; responses to a particular drug.&#160;As studies unfold our clinical trials team reports the data and often provides key analysis and insights back to the sponsors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services segment provides comprehensive testing services in support of our pharmaceutical clients&#8217; oncology programs from discovery to commercialization.&#160;In biomarker discovery our aim is to help our clients discover the right content.&#160;We help our clients develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing our discovery tools with the informatics to capture meaningful data.&#160;In other pre-clinical and non-clinical work we can use our platforms to characterize markers of interest.&#160;Moving from discovery to development, we seek to help our clients refine their biomarker strategy and, if applicable, to develop a companion diagnostic pathway using the optimal technology for large-scale clinical trial testing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether serving as the single contract research organization or partnering with one, our Pharma Services team provides significant technical expertise, working closely with our clients to support each stage of clinical trial development.&#160;Each trial we support comes with rapid turnaround time, dedicated project management, and quality assurance oversight. We have experience in supporting submissions to the FDA for companion diagnostics. Our Pharma Services strategy is focused on helping bring more effective oncology treatments to market through providing world-class laboratory services in oncology to key pharmaceutical companies in the industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are well positioned to service Pharma sponsors across the full continuum of the drug development process. Our Pharma Services team can work with them during the basic research and development phase as compounds come out of translational research departments as well as work with clients from Phase I clinical trials through Phases II and III as the sponsors work to prove the efficacy of their drugs. The laboratory biomarker tests that are developed during this process may become CDx tests that will be used on patients to determine if they could respond to a certain therapy. We are able to offer these CDx tests to the market immediately after FDA approval as part of our Day 1 readiness program. This ability helps to speed the commercialization of a drug and can enable Pharma sponsors to reach patients through our broad distribution channel in the Clinical Services segment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to develop and broaden our informatics and data-related tools to leverage our strategic market position and oncology expertise to help our stakeholders solve real-world problems such as identifying patients for clinical trials or providing clinical decision support tools for physicians and providers. We are committed to connecting patients with life altering therapies and trials. In carrying out these commitments, we aim to provide transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and have invested in leading technologies to seek to ensure the data we maintain is secured at all times.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_43"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Our management routinely makes judgments and estimates about the effects of matters that are inherently uncertain. Please refer to Note 2. Summary of Significant Accounting Policies, to our Consolidated Financial Statements for a complete description of our significant accounting policies.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those where we have made difficult, subjective, or complex judgments in making estimates and/or where these estimates can significantly impact our financial results under different assumptions and conditions. Our critical accounting policies are:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business Combinations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accounts Receivable;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recoverability and Impairment of Long-Lived Assets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contingencies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based Compensation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue Recognition; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deferred Taxes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of operations and cash flows of acquired companies are included in our operating results from the date of acquisition. We allocate the purchase price of acquisitions to the assets acquired and liabilities assumed based on their estimated fair values. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounts Receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are reported for all Clinical Services payers based on the amount expected to be collected, which considers implicit price concessions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Pharma Services, we negotiate billing schedules and payment terms on a contract-by-contract basis, which often includes payments based on certain milestones being achieved. Receivables are generally reported over time based on the number of units completed, which aligns with the progress towards fulfilling its obligations under the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Days Sales Outstanding (&#8220;DSO&#8221;) increased to 82 days at December 31, 2021 from 78 days at December 31, 2020 due to timing of cash receipts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recoverability and Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the recoverability of its long-lived assets (including definite-lived intangible assets) if events or changes in circumstances indicate the assets may be impaired. Evaluation of possible impairment is based on our ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value to the carrying amount of the asset.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingencies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingent losses when estimated impacts of various conditions, situations or circumstances involve uncertain outcomes. Contingent losses are recorded based on management judgment along with internal and external advice from legal counsel and/or technical consultants. Estimated losses from contingencies are recorded when both of the following conditions are met: (i) information available before the financial statements are issued (or available to be issued) indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) the amount of loss can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, that amount shall be accrued. When no amount within the range is a better estimate than any other amount, however, the minimum amount in the range shall be accrued. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation costs for all share-based payment awards made to employees, non-employee contracted physicians and directors based upon the awards&#8217; initial grant-date fair value. Prior to 2021, we estimated the fair value of stock options using a trinomial lattice model. On January 1, 2021, we began applying the Black-Scholes option valuation model on a prospective basis to new awards. Stock compensation is recognized on a straight-line basis over the awards&#8217; requisite service periods. The periodic expense is adjusted for actual forfeitures.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our specialized diagnostic services are performed based on an online test order or a written test requisition form. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration we expect to receive based on negotiated discounts, historical collection experience and other anticipated adjustments, including anticipated payer denials. Collection of consideration we expect to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay patients and within 60 to 90 days of billing for client payers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our estimate of the breakdown of net clinical revenue by type of payer for the years ended December&#160;31, 2021, 2020, and 2019:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client direct billing</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and other government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our Pharma Services revenue is billed directly to clients, or the pharmaceutical sponsor. Our Pharma Services segment generally enters into contracts with pharmaceutical and biotech customers as well as other CROs to provide research and clinical trial services ranging in duration from one month to several years. We record revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is usually recognized over time based on the number of units completed, which aligns with our progress towards fulfilling our obligations under the contract. We also enter into other contracts, such as validation studies, for which the sole deliverable is a final report that is sent to sponsors at the completion of contracted activities. For these contracts, revenue is recognized at a point in time upon delivery of the final report to the sponsor. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. We negotiate billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected in advance of services being provided are deferred as contract liabilities on the balance sheet. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. Contract assets are established for revenue that has been recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding account receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and are amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets and all others are classified as non-current assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. All contracts require payment of fees for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for deferred tax consequences represents our best estimate of future events that can be appropriately reflected in accounting estimates. The factors included in the analysis are historical and projected future taxable income including evolving business practices of our industry. Changes in existing tax laws, regulations, rates and future operating results may impact the amount of deferred tax liabilities and deferred tax assets over time. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to realize the existing deferred tax assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we determined that sufficient positive evidence did not exist to conclude that it is more likely than not that net operating losses generated by our operations in the U.S., Switzerland, Singapore, and China would be able to be utilized in future periods and has therefore established a valuation allowance against the deferred tax assets generated by such losses.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_46"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the year ended December 31, 2021 as compared with the year ended December 31, 2020</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the condensed Consolidated Statements of Operations as a percentage of revenue for the years ended December 31, 2021 and 2020:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on termination of cash flow hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue for the year ended December 31, 2021, includes $10.4 million of amortization of acquired Inivata developed technology intangible assets and write-offs of $5.3 million for COVID-19 PCR testing inventory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Services and Pharma Services net revenue for the years ended December 31, 2021 and 2020, are as follows (dollars in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Clinical Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated revenue in 2021 increased $39.9 million, or 9.0%, as compared to 2020.&#160;Clinical Services revenue increased $21.8 million, or 5.7%, to $404.2&#160;million in 2021 as compared to $382.3&#160;million in 2020. Decreases in Clinical Services revenue in 2021 due to the exit of COVID-19 PCR testing were offset by increases in Clinical Services non-COVID-19 PCR test volumes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the broad roll-out of the COVID-19 vaccine and a sharp decline in the demand for COVID-19 PCR testing, we made the decision at the end of the first quarter 2021 to exit from COVID-19 PCR testing which was included in Clinical Services segment revenue. The Clinical Services segment&#8217;s continued focus is its broad and innovative testing menu as well as any future new product offerings. COVID-19 PCR testing revenue was $1.6 million in 2021 compared to $27.8 million in 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma Services revenue increased $18.0 million, or 29.1%, to $80.2&#160;million in 2021 as compared to $62.1&#160;million in 2020, primarily driven by an increase in revenue related to research studies and informatics. In addition our backlog of signed contracts has continued to grow 27.8% to approximately $267&#160;million as of December 31, 2021, from $209&#160;million as of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020. We define backlog as the stated amount of signed contracts less dormant contracts with no activity for twelve months, contingencies and cancellations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Revenue and Gross Profit</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payroll and payroll related costs for performing tests, maintenance and/or depreciation of laboratory equipment, rent for laboratory facilities, laboratory reagents, probes and supplies, delivery and courier costs relating to the transportation of specimens to be tested, and amortization for acquired Inivata developed technology intangible assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated cost of revenue and gross profit metrics for the years ended December 31, 2021 and 2020 are as follows (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue as a percentage of revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical Services cost of revenue in 2021 includes $9.2 million of amortization of acquired Inivata developed technology intangible assets and write-offs of $5.3 million for COVID-19 PCR testing inventory.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharma Services cost of revenue in 2021 includes $1.2 million of amortization of acquired Inivata developed technology intangible assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated cost of revenue increase in 2021 when compared to 2020 is due to the amortization of acquired Inivata developed technology intangibles, the write-off of COVID-19 PCR testing inventory due to the termination of COVID-19 PCR testing, and higher payroll and payroll-related costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit margin for 2021 was 38.6% compared to 41.8% in 2020. This 3.2% decrease is primarily due to the amortization of acquired Inivata developed technology intangibles and the fixed nature of many of our laboratory costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of payroll and payroll related costs for our executive, billing, finance, human resources, information technology, and other administrative personnel, as well as stock-based compensation. We also allocate professional services, facilities expense, IT infrastructure costs, depreciation, amortization, and other administrative-related costs to general and administrative expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated general and administrative expenses for the years ended December 31, 2021 and 2020 are as follows (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative as a percentage of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $77.6 million in 2021 compared to 2020. The increase reflects acquisition and integration costs related to the acquisitions of Inivata and Trapelo, an increase in payroll and payroll-related costs due to increases in personnel to support our near and long-term growth, higher non-cash stock-based compensation expenses, an increase in professional fees, and a loss contingency for the regulatory matter.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses to increase in total but decrease as a percentage of revenue as we add employee and compensation expenses and continue to expand our physical and technological infrastructure to support our anticipated growth.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses relate to costs of developing new proprietary and non-proprietary genetic tests, including payroll and payroll related costs, maintenance of laboratory equipment, laboratory supplies (reagents), and outside consultants and experts assisting our research and development team.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated research and development expense for the years ended December 31, 2021 and 2020 are as follows (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development as a percentage of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $13.6 million in 2021 compared to 2020. The increase is driven by additional focus and commitment to new test development and FDA initiatives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate research and development expenditures will significantly increase in the future as we continue to invest in development costs for innovation projects and bringing new tests to market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales and marketing expenses for the years ended December 31, 2021 and 2020, are as follows (dollars in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.030%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing as a percentage of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses increased $14.7 million in 2021 compared to 2020. The increase primarily reflects higher commissions due to our increase in consolidated revenue, the expansion of our sales team, increased sales travel expenses due to the easing of COVID-19 pandemic related sales travel restrictions, and increased investment in marketing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect higher commissions expense in the coming years as our sales representatives continue generating new business in both of our business segments. We expect our sales and marketing expenses over the long term to align with changes in revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense, Net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, decreased $1.9 million in 2021 compared to 2020. This reduction in interest expense primarily results from the termination of the higher interest rate term loan replaced by the lower interest rate convertible debt in May 2020. Interest expense for the year ended December 31, 2021 reflects the effective interest rate on the 2028 Convertible Notes and the 2025 Convertible Notes which is 0.70% and 1.96%, respectively. Interest on the 2028 Convertible Notes and 2025 Convertible Notes began accruing upon issuance and is payable semi-annually. For further details regarding the convertible notes, please refer to Note 9. Debt, in the accompanying notes to the Consolidated Financial Statements. </span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Expense (Income), Net</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net, was expense of $0.5 million in 2021 compared to income of $7.9 million in 2020. This $8.4 million decrease was primarily due to grant income related to the CARES Act Public Health and Social Service Emergency Fund for the year ended December 31, 2020. Please refer to Note 2. Summary of Significant Accounting Policies for further details regarding the grant income.</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gain on Investment in and Loan Receivable from Non-Consolidated Affiliate, Net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a gain on investment in and loan receivable from non-consolidated affiliate, net, in the accompanying notes to the Consolidated Statements of Operations of $109.3 million in 2021 for the excess of the acquisition-date fair value of the previously-held equity interest, Purchase Option, and Line of Credit over their carrying values. For the year ended December 31, 2020, we reported a net unrealized gain of $4.0 million due to a remeasurement of our investment in Inivata. For further details regarding the previously-held equity investment, purchase option in Inivata and the related gain, please refer to Note 3. Acquisitions and Note 8. Investment in Non-Consolidated Affiliate, in the accompanying notes to the Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net (Loss) Income</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the net (loss) income for the years ended December 31, 2021 and 2020, along with the computation of basic and diluted net (loss) income per share (in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,347)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Non-GAAP Financial Measures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide greater transparency regarding our operating performance, the financial results and financial guidance in this press release refer to certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to the Company&#8217;s core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of the Company&#8217;s core, test-level operating results across reporting periods and when comparing those same results to those published by our peers. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results, should not be considered measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definitions of Non-GAAP Measures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-GAAP Adjusted EBITDA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Adjusted EBITDA&#8221; is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest expense, (ii) tax (benefit) or expense, (iii) depreciation and amortization expense, (iv) non-cash stock-based compensation expense, and, if applicable in a reporting period, (v) acquisition and integration related expenses, (vi) write-off of COVID-19 PCR testing inventory and equipment, (vii) new headquarters moving expenses, (viii) gain on investment in and loan receivable from non-consolidated affiliate, net, (x) loss contingency for regulatory matter, (xi) loss on extinguishment of debt, and (xii) other significant or non-operating (income) or expenses, net.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of GAAP net (loss) income to Non-GAAP EBITDA and Adjusted EBITDA for the years ended December 31, 2021 and 2020 (dollars in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME (GAAP)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,347)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to net (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA (non-GAAP)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Further Adjustments to EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of COVID-19 PCR testing inventory and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New headquarters moving expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,955)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss contingency for regulatory matter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other significant expenses (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADJUSTED EBITDA (non-GAAP)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA as percentage of revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other significant expenses (income), net, includes strategic deal costs, CEO transition costs, amounts received related to the CARES Act, cash flow hedge termination fees, debt retirement fees, and certain non-recurring items. </span></div><div id="ia1854a760084469581a7ceab463d6c8e_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_49">Liquidity and Capital Resources</a></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through cash generated from operations, public and private sales of debt and equity securities, and bank debt borrowings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of our consolidated cash flows for operating, investing, and financing activities for the years ended December 31, 2021 and 2020, as well as the period ending cash and cash equivalents and working capital (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working Capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> end of period</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Defined as current assets less current liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities during the year ended December 31, 2021, was $26.7 million. The net loss of $8.3 million includes $15.7 million of acquisition and integration costs as well as non-cash charges resulting from $53.4 million depreciation and amortization, $22.5 million of stock-based compensation, $8.7 million of operating lease expense, $2.7 million of debt amortization, $6.1 million of write-offs of COVID-19 PCR testing inventory and equipment related to the exit from COVID-19 PCR testing, and $2.2 million of other non-cash items. These charges were offset by $109.3 million of realized net gain on investment in and loan receivable from non-consolidated affiliate. Operating assets had cash outflows of $9.8 million resulting from a $4.7 million increase in accounts receivable, net, and a $6.7 million increase of prepaids and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other asset, offset by a $1.6 million decrease in inventory. Operating liabilities generated cash inflows of $5.2 million from a $12.3 million increase in accrued compensation and other accruals offset by a $7.1 million decrease in accounts payable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Investing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, cash used in investing activities was $632.4 million, an increase of approximately $472.9 million compared to the same period in 2020.&#160;This was due to $419.4 million of net cash used for the acquisitions of Inivata and Trapelo as well as net investments in marketable securities of $133.8 million, $64.1 million of cash used for capital expenditures and the disbursement of a $15.0 million loan receivable from non-consolidated affiliate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Financing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, cash provided by financing activities was $725.3 million compared to $235.6 million for the same period in 2020. Cash provided by financing activities during the year ended December 31, 2021, consisted $408.1 million of net proceeds from equity offerings, convertible debt proceeds of $334.4 million net of issuance costs, and $15.1 million for the issuance of common stock net of issuance costs. This activity was partially offset by the use of cash in amounts of $29.3 million for premiums paid for capped call confirmations and $3.0 million for the net repayment of equipment financing obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Outlook</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had $316.8 million in cash and cash equivalents in addition to $198.6 million of marketable securities available to support current operational liquidity needs. We anticipate that the cash on hand, marketable securities, and cash collections are sufficient to fund our near-term capital and operating needs for at least the next 12 months. Operating needs include, but are not limited to, the planned costs to operate our business (including amounts required to fund working capital and capital expenditures, continued research, and development efforts) and potential strategic acquisitions and investments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2021, we entered into an underwriting agreement relating to the issuance and sale of 4,081,632 shares of our common stock (the &#8220;2021 Common Stock Offering&#8221;), $0.001 par value per share. The price to the public in this offering was $49.00 per share and we agreed to sell the shares to the underwriters at the public offering price, less underwriting discounts and commission of $2.45 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30&#8209;day option to purchase up to 612,244 additional shares of common stock at the public offering price, less underwriting discounts and commissions. On January 6, 2021, the underwriters exercised their option in full and purchased all 612,244 shares. The net proceeds from the 2021 Common Stock Offering and full exercise of the underwriters&#8217; option were approximately $218.3 million, net of underwriting commissions of approximately $11.7 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, we completed the sale of $345.0&#160;million of the 2028 Convertible Notes, including the full exercise of the underwriters&#8217; option to purchase an additional $45.0&#160;million aggregate principal amount of the 2028 Convertible Notes (the &#8220;2028 Over-allotment Option&#8221;) on the same terms and conditions, solely to cover over-allotments with respect to the 2028 Convertible Notes offering. The total net proceeds from the issuance of the 2028 Convertible Notes and the total exercise of the 2028 Over-allotment Option was approximately $334.4&#160;million, which includes approximately $10.6&#160;million of discounts, commissions and offering expenses. For further details regarding the 2028 Convertible Notes, please refer to Note 9. Debt, in the accompanying notes to the Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used $29.3 million of the net proceeds from the offerings to enter into capped call transactions. We intend to use the remaining net proceeds from the offerings for general corporate purposes and/or to acquire or invest in complementary businesses and technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, we completed a private placement (&#8220;Private Placement&#8221;) to certain accredited investors of an aggregate of 4,444,445 shares of our common stock at a price of $45.00 per share. The net proceeds from the Private Placement were approximately $189.9 million, after deducting fees to the placement agents and other offering expenses of approximately $10.1 million. We used the net proceeds from the Private Placement for the acquisition of Inivata.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party Transactions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 18. Related Party Transactions, to our Consolidated Financial Statements for a description of our related party transactions.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as of December 31, 2021 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than <br/>1 Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than <br/>5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment financing obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts represent required principal debt payments on our 2025 Convertible Notes and 2028 Convertible Notes.&#160;Please refer to Note&#160;9. Debt, to our Consolidated Financial Statements for a full description of the terms of our indebtedness and the related debt service requirements.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We forecast capital expenditures in order to execute on our business plan and maintain growth; however, the actual amount and timing of such capital expenditures will ultimately be determined by the volume of business. We currently anticipate that our capital expenditures for the year ended December 31, 2022, will be in the range of $25.0 million to $35.0 million. We have funded and plan to continue funding these capital expenditures with cash and financing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 2. Summary of Significant Accounting Policies, to our Consolidated Financial Statements for a discussion of recently adopted accounting pronouncements and accounting pronouncements pending adoption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, inflation did not have a material effect on our business. Widely reported inflation has occurred, however, and may be ongoing for the foreseeable future. Depending on the severity and persistence of these inflationary pressures, we could see, in the future, a negative impact on our financial results.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk is the potential loss arising from adverse changes in market rates and prices, such as foreign currency exchange rates, interest rates and other relevant market rate or price changes. We are exposed to market risks, including changes in foreign currency exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk on our short-term investments. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid and high-quality government and other debt securities. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term securities with short maturities. If a 1% change in interest rates were to have occurred on December 31, 2021, this change would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we have concluded that we do not have a material financial market risk exposure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in Cambridge, United Kingdom; Rolle, Switzerland; Singapore; and Suzhou, China. Our international revenues and expenses denominated in foreign currencies (primarily British Pounds, Swiss Francs, Singapore Dollars and Chinese Yuan), expose us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. We do not </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hedge foreign currency exchange risks and do not currently believe that these risks are significant.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_55"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_58">Report of Independent Registered Public Accounting Firm &#8211;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV81NS9mcmFnOjIxZGQxM2U2Y2VhZjRhOTZiMzc3NGQxM2ZmYzYwNTg0L3RhYmxlOmY2NWMxNjFmNzhiNzRhODE4NzQ4ODk4MzYwYTQyMmQxL3RhYmxlcmFuZ2U6ZjY1YzE2MWY3OGI3NGE4MTg3NDg4OTgzNjBhNDIyZDFfMi0wLTEtMS03NzUyMi90ZXh0cmVnaW9uOjdkYzkyY2U5YjdiNjQyMWFiZjc2ZDUzYzAwNDdjNjVmXzE2NDkyNjc0NDI0Mzg_d3da63ce-adbc-49dc-81f4-4f2999608750">Deloitte &amp; Touche LLP</ix:nonNumeric> (PCAOB ID: <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV81NS9mcmFnOjIxZGQxM2U2Y2VhZjRhOTZiMzc3NGQxM2ZmYzYwNTg0L3RhYmxlOmY2NWMxNjFmNzhiNzRhODE4NzQ4ODk4MzYwYTQyMmQxL3RhYmxlcmFuZ2U6ZjY1YzE2MWY3OGI3NGE4MTg3NDg4OTgzNjBhNDIyZDFfMi0wLTEtMS03NzUyMi90ZXh0cmVnaW9uOjdkYzkyY2U5YjdiNjQyMWFiZjc2ZDUzYzAwNDdjNjVmXzE2NDkyNjc0NDIzNjY_ff819ee5-055b-4e2b-9612-2f847f98e761">34</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_58">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_64">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_64">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_67">Consolidated Statements of Operations for the years ended December&#160;31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_67">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_67">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_67">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_67"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_67">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_67">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70">Consolidated State</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70">ments of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70">(Loss)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70"> Income</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70"> for the years ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70"> December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_70">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_73">Consolidated Statements of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_73">Stockholders&#8217; Equity for the years ended December&#160;31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_73">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_73">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_73">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_73"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_73">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_73">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_76">Consolidated Statements of Cash Flows for the years ended December&#160;31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_76">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_76">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_76">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_76"> and 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_76">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_76">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_79">60</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the stockholders and the Board of Directors of NeoGenomics, Inc.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of NeoGenomics, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive (loss) income, stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2022, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Services&#8212;Refer to Notes 2 and 13 to the financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 13 to the financial statements, revenue for the Company&#8217;s clinical services is recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience and other anticipated adjustments, including anticipated payer denials. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified management&#8217;s estimation of implicit price concessions related to clinical services revenue recorded that has not been received in cash as a critical audit matter due to management&#8217;s manual process used to determine the estimate, and the significant judgments required by management to estimate payer behavior. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the reasonableness of management&#8217;s assumptions related to expected receipts that were applied in the estimate of implicit price concessions. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to management&#8217;s judgments in the estimate of implicit price concessions included the following, among others: </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of controls over management&#8217;s determination of assumptions used to calculate implicit price concessions.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the methodology used by the Company to estimate implicit price concessions.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the assumptions used by management to calculate implicit price concessions by:</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Testing the mathematical accuracy of management&#8217;s calculation of implicit price concessions. </span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Testing the historical cash receipts compared to the amounts billed to payers, which are used in the estimate of implicit price concessions, by making selections and agreeing the selected information to source documents. </span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Testing management&#8217;s ability to estimate implicit price concessions accurately by comparing recorded net revenue to cash receipts received through January 2022. </span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Evaluating trends in revenue and accounts receivable compared to previous periods to identify any evidence that may contradict management&#8217;s assertion regarding implicit price concessions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Inivata Limited&#8212;Refer to Note 3 to the financial statements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed the acquisition of Inivata Limited (&#8220;Inivata&#8221;) on June 18, 2021. Prior to the acquisition of Inivata, the Company accounted for its minority equity investment in Inivata&#8217;s Series C1 Preference Shares (the &#8220;previously-held equity interest&#8221;) and the fixed-price purchase option (the &#8220;Purchase Option&#8221;) in Inivata as equity securities recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company&#8217;s acquisition of Inivata was accounted for as a business combination achieved in stages under the acquisition method. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used a discounted cash flow analysis to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#8217;s previously-held equity interest and Purchase Option in Inivata. To determine the fair value of the previously-held equity interest, the fair value of Inivata&#8217;s total equity was allocated to its various classes of equity based on the respective rights and privileges of each class of stock upon liquidation. The business enterprise value of $552.8 million and a Black-Scholes model was then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at fair value at the acquisition date based on its settlement value of $74.3 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The developed technology acquired in this transaction was valued at $291.2 million using the income approach, specifically the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology and required management to make significant estimates and assumptions related to the future cash flows of Inivata, including determining an appropriate discount rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the accounting for the Purchase Option as a critical audit matter due to the judgement required by management in the determination that the Purchase Option should be accounted for in purchase accounting at its settlement value. We also identified the selection of the discount rate and forecasts of future cash flows in determining the enterprise value of Inivata and the developed technology intangible asset fair values as a critical audit matter because of the significant judgments made by management. Performing audit procedures to evaluate these matters required a high degree of auditor judgment and an increased extent of effort, including the need to involve individuals with expertise in accounting for business combinations and derivatives to assist with evaluating the accounting treatment of the Purchase Option and fair value specialists when performing audit procedures to evaluate the reasonableness of management&#8217;s selection of the discount rate and forecasts of future cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the accounting for the Purchase Option and related to the forecasts of future cash flows and the selected discount rate used by management to estimate the enterprise fair value and the developed technology intangible assets fair values included the following, among others: </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of controls over the Company&#8217;s determination of the appropriate accounting for the Purchase Option. We also tested the effectiveness of controls over the Company&#8217;s determination of the enterprise </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value and the developed technology intangible assets fair value, such as controls related to management&#8217;s selection of the discount rate and over the forecast of future cash flows related to Inivata.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the assistance of professionals in our firm having expertise in accounting for business combinations and derivatives, we evaluated management&#8217;s judgments related to the application of U.S. GAAP by evaluating management&#8217;s accounting analysis to determine whether we agree with management&#8217;s conclusion that the Purchase Option should be accounted for at its settlement value in purchase accounting.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due to the lack of historical experience available for the developed technology assets acquired, we evaluated the reasonableness of management&#8217;s forecast of future cash flows by comparing the projections to (1) peer companies and third-party market analyses, (2) internal communications to management and the board of directors, (3) external communications made by management to analysts and investors, and (4) industry reports containing analyses of the Company and its competitors&#8217; technologies.  </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the assistance of fair value specialists, we evaluated the reasonableness of the selected (1) valuation methodology and (2) discount rate including testing the source information underlying the determination of the discount rate and testing the mathematical accuracy of the calculation and developing a range of independent estimates and comparing those to the discount rate selected by management.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Refer to Note 17 to the financial statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021 the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;) of the Company&#8217;s internal investigation focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse (the &#8220;Regulatory Matter&#8221;). The Company has accrued a reserve of $11.2 million in other long-term liabilities on the Consolidated Balance sheet as of December 31, 2021, for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the internal investigation. This reserve reflects management&#8217;s best estimate as of December 31, 2021, of the minimum probable loss associated with this matter. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the Regulatory Matter contingency and the related disclosures as a critical audit matter due to (1) the significant judgments made by management to estimate losses and (2) the outcome of the Regulatory Matter contingency materially affects the Company&#8217;s financial position, results of operations, and cash flows. This required the application of a high degree of auditor judgment when performing audit procedures to evaluate the reasonableness of management&#8217;s estimated losses and disclosure related to the Regulatory Matter contingency. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the Regulatory Matter contingency included the following, among others: </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of internal controls over (1) the determination of the significant assumptions used in estimating the Regulatory Matter contingency and (2) the financial statement disclosures related to the Regulatory Matter contingency.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We inquired of the Company&#8217;s internal and external legal counsel and evaluated whether the information provided was consistent with the information used to determine management&#8217;s best estimate of the minimum probable loss associated with this matter, and the related financial statement disclosures. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested, on a sample basis, the underlying data used as the basis for calculating the Regulatory Matter contingency by tracing selections to source information.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We read the voluntary submission to the OIG and evaluated whether the information therein was consistent with the information obtained in our procedures.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated whether the Company&#8217;s disclosures were appropriate and consistent with the information obtained in our procedures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV81OC9mcmFnOjI5Y2U0ZjY5MDFlMTRiNWViNWM5NmNhNzY4OTJiOGM5L3RleHRyZWdpb246MjljZTRmNjkwMWUxNGI1ZWI1Yzk2Y2E3Njg5MmI4YzlfMTY0OTI2NzQ1ODM3Mg_5eeff2ec-8a1c-4ed0-ad5e-97d5add0e4c4">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2019.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_64"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNC0xLTEtMS0zMDU3Mg_40fcad2b-4dd6-465c-903e-acd6afbb5942">316,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNC0zLTEtMS0zMDU3Mg_e5fc6d04-8a58-48f3-9069-cc74ac81c53b">228,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities, at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNS0xLTEtMS0zMDU3Mg_e8b9d36a-5832-44e4-b512-1936665fbe34">198,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNS0zLTEtMS0zMDU3Mg_affc5ebf-6cc0-4583-b596-d893de5435ba">67,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNi0xLTEtMS0zMDU3Mg_eedadbf8-49ef-4867-9ce8-5d406ad84daa">112,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNi0zLTEtMS0zMDU3Mg_d60068fe-a2d9-4bc0-bce4-986395769875">106,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNy0xLTEtMS0zMDU3Mg_6be9a3b0-0662-4191-806d-b1d7863b404a">23,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNy0zLTEtMS0zMDU3Mg_cf10cacc-fe34-4183-bd4a-d6b6f94f3877">29,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOC0xLTEtMS0zMDU3Mg_5c423e6d-38d8-48ec-89d8-ff724e7e6034">12,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOC0zLTEtMS0zMDU3Mg_f247620a-e623-45b0-8318-a0be2bb40ae3">11,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOS0xLTEtMS00MDg4OQ_56d8d31e-7bd2-4652-bc9a-922277f982d1">10,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOS0zLTEtMS00MDg4OQ_44b5de32-fbbe-4781-b6d1-d6e842031a78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOS0xLTEtMS0zMDU3Mg_31b98ac2-ec4b-46b1-b05d-06d739efdc76">8,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOS0zLTEtMS0zMDU3Mg_749787eb-c66a-4f72-9c01-39153dcb602b">4,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTAtMS0xLTEtMzA1NzI_3f679ec7-d363-484f-a731-1d5afc2a95cd">681,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTAtMy0xLTEtMzA1NzI_8672e59e-465d-4cdc-9a58-8eedc50c46e7">448,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment (net of accumulated depreciation of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjpiNjk4MTQwMzk3OTU0NzhhYjBjMjNhZDY5NTE1MTg1Y18yMTk5MDIzMjU1NjU4_7322545a-9505-4d03-b601-765d45a32031">109,952</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjpiNjk4MTQwMzk3OTU0NzhhYjBjMjNhZDY5NTE1MTg1Y18yMTk5MDIzMjU1Njgx_08fe9643-49c5-4e6b-82ec-76171c0f4601">92,895</ix:nonFraction>, respectively)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTEtMS0xLTEtMzA1NzI_b43614c7-554f-4067-8ffb-426c04d1915e">109,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTEtMy0xLTEtMzA1NzI_b64d3e6f-9e38-4ca3-a6ba-30b57ad3d920">85,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTItMS0xLTEtMzA1NzI_d475b38b-c54e-4653-b457-9973ec9eb1ad">102,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTItMy0xLTEtMzA1NzI_380361d1-0487-42ba-bef7-60b63641a0e9">45,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTMtMS0xLTEtMzA1NzI_834db1c9-d1cd-4660-a013-84cd024e109d">442,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTMtMy0xLTEtMzA1NzI_f3d2647c-089a-4212-9df3-8cef84589ab7">120,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTQtMS0xLTEtMzA1NzI_c831c70a-83e1-4157-a51e-796a09c7492b">527,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTQtMy0xLTEtMzA1NzI_b979dd14-0ecf-44e7-ba95-7ea37e83cead">211,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTUtMS0xLTEtMzA1NzI_ff185f29-cad1-44da-a489-94e8fffd0467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTUtMy0xLTEtMzA1NzI_aa4e4b6e-3c61-47f0-9af4-6ccaf6297d96">21,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in non-consolidated affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTctMS0xLTEtNDc2Mzg_d41c2aee-4129-41a8-8526-9f4f4fde2852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTctMy0xLTEtNDc2Mzg_4e50d9d4-1f38-46fe-9eb3-5c1685a73072">29,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:PrepaidRentNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTYtMS0xLTEtMzA1NzI_6e00af3f-5833-4741-ad39-55a6f1032db5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="neo:PrepaidRentNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTYtMy0xLTEtMzA1NzI_61af4a64-6fcb-4f3c-ae84-ce9764196594">20,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTgtMS0xLTEtMzA1NzI_7182d8e9-2044-4b69-9a43-8ee900c2b7fd">7,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTgtMy0xLTEtMzA1NzI_d501d413-86ea-4914-8201-c2fbad2ed8de">4,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTktMS0xLTEtMzA1NzI_6c5ca8f3-1435-4cf2-9d38-7b0b8d9b07c8">1,188,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTktMy0xLTEtMzA1NzI_29471560-0d9f-4535-8b9b-212f9c326a82">539,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjAtMS0xLTEtMzA1NzI_35e6ddcd-652d-4ba8-b64c-7c5474985859">1,869,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjAtMy0xLTEtMzA1NzI_9bda9206-a281-4741-8e9d-e9cea140deb5">988,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjMtMS0xLTEtMzA1NzI_850f6a17-bd37-464d-b4f9-671201377f1c">17,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjMtMy0xLTEtMzA1NzI_2f883586-f58d-47c3-89d0-f843217fef1c">24,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjQtMS0xLTEtMzA1NzI_7345fa04-df2f-4b46-a890-d8180afc3068">38,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjQtMy0xLTEtMzA1NzI_271f12b8-1e91-46b5-aa54-4b87b9a76112">24,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjUtMS0xLTEtMzA1NzI_2637aebb-5ac9-43e9-af6c-021f0028e888">17,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjUtMy0xLTEtMzA1NzI_9b4e7e22-ea77-4c50-9d09-c85bcaf588f6">11,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of equipment financing obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjYtMS0xLTEtMzA1NzI_72d8f26c-ab9d-4cf5-a53f-eb58c4a2cb6c">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjYtMy0xLTEtMzA1NzI_516679cf-df69-4fbb-b4ad-5d3a3c012dd9">2,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjctMS0xLTEtMzA1NzI_8324b0b5-884c-41b9-81a1-15d61b5c22de">6,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjctMy0xLTEtMzA1NzI_d85d17c1-e3f2-4931-a5ce-73820b0c14df">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharma contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjktMS0xLTEtMzA1NzI_a101fcea-1910-4e9c-936e-1592d579de5a">5,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjktMy0xLTEtMzA1NzI_b7f3259d-e80d-406c-bf39-5e70f87ad0a3">4,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzAtMS0xLTEtMzA1NzI_e89c27f2-2543-439e-82da-5c4e8448bcc4">87,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzAtMy0xLTEtMzA1NzI_eb428583-15b6-4ee6-9f98-a15c467f1d4d">73,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzItMS0xLTEtMzA1NzI_899a11ac-c0a3-46c6-a54f-cc6488f9caad">532,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzItMy0xLTEtMzA1NzI_935379b5-c581-4d91-8686-25499e2ab753">168,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment financing obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzMtMS0xLTEtMzA1NzI_e2acf1d1-dbac-4217-aefb-c77295b986eb">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzMtMy0xLTEtMzA1NzI_9ec8432e-ca6b-4f91-9b75-fb95088bd42f">967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzQtMS0xLTEtMzA1NzI_1eea9e20-4fa5-4369-b5b5-bee6d59d4870">72,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzQtMy0xLTEtMzA1NzI_854106b3-86c9-436c-b234-e4a3ebeed02e">42,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzYtMS0xLTEtMzA1NzI_8747a71f-5a39-4083-9ff7-a60c151fb590">55,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzYtMy0xLTEtMzA1NzI_fe4a1a9e-0e77-430f-8b39-1ea471de92d9">5,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzctMS0xLTEtMzA1NzI_9cbcb6f0-d769-4ccf-beb0-c4805a8377e6">13,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzctMy0xLTEtMzA1NzI_6fc1eeac-6581-4252-a9ef-e43f367ae017">4,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzgtMS0xLTEtMzA1NzI_9ade6f64-8c12-401e-bb02-dadde889a0c5">674,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzgtMy0xLTEtMzA1NzI_6917ef04-edd8-4362-9b82-07a3c618a2e8">220,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzktMS0xLTEtMzA1NzI_b6f7ca60-5557-4416-92f3-dffd619e6a09">761,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzktMy0xLTEtMzA1NzI_5d77d574-8ac8-4dc9-9119-4cbdac5e9a7f">294,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 17)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzktMS0xLTEtNzc0Nzk_cfe9a0fb-0af8-4e99-942b-8d214dd47e4b"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzktMy0xLTEtNzc0ODE_0883dfb7-a228-4988-82fe-ef531cef7cb0"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV8xOA_4addb2dc-dfde-4300-a13b-c50a41b16136"><ix:nonFraction unitRef="usdPerShare" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV8xOA_bfaca6e4-f148-448c-ab8d-d7271e4cc38c">0.001</ix:nonFraction></ix:nonFraction> par value, (<ix:nonFraction unitRef="shares" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV8zMw_7927d83f-6fab-43c4-85f7-57e9187aa44c"><ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV8zMw_942f7489-ca75-4ef0-999c-03e627402aab">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV81NQ_6b9cd9fe-5bdc-447c-87fd-4b447124376d"><ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV81NQ_6f0b8999-3e7d-4387-bb3d-2b44cd51b3c3">124,107,500</ix:nonFraction></ix:nonFraction> </span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and <ix:nonFraction unitRef="shares" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV82Mg_7f0ffc17-9ca6-4c69-adef-b42caeedefcb"><ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV82Mg_85d4f6ec-4bf9-43c7-ba19-4bb6d9965361">112,075,474</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMS0xLTEtMzA1NzI_afd19707-24bc-4c76-8eb7-ec2a1e9bd2e5">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMy0xLTEtMzA1NzI_2fc2afc6-e80d-4521-983c-5786227dbef4">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDItMS0xLTEtMzA1NzI_c5b1ebfa-ca21-4557-a2ce-bef4392796f7">1,123,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDItMy0xLTEtMzA1NzI_b8ec7742-e991-40ad-8eea-6de3e7aac717">701,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDMtMS0xLTEtMzA1NzI_bab77008-e581-4307-9e25-cf154dc76ffd">638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDMtMy0xLTEtMzA1NzI_d1f9eefa-03a5-4407-b8d2-ce2584f761bc">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDQtMS0xLTEtMzA1NzI_d22d52a5-09b3-4870-bc9f-dee47bbb5f31">14,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDQtMy0xLTEtMzA1NzI_42c10169-a191-4be0-a9fa-10c815bc759d">7,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDUtMS0xLTEtMzA1NzI_e643cc03-bff7-4fd9-8b03-ac6511e5992a">1,108,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDUtMy0xLTEtMzA1NzI_162cdd3b-459f-4e0d-a4e6-bab66259509b">694,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDYtMS0xLTEtMzA1NzI_ef727e31-49aa-4700-a83f-53d5aa643765">1,869,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDYtMy0xLTEtMzA1NzI_44fa145e-6a37-4b7f-8cfe-52e83a53b46c">988,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the Consolidated Financial Statements. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_67"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:54.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET REVENUE</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ebc9da32df40f79360ad5da5aef714_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMy0xLTEtMS0zMDU3Mg_8fab6d18-f2a6-46d2-a9ad-69a16e6991ef">404,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d415270f85409cb33c97966be628d9_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMy0zLTEtMS0zMDU3Mg_bfaf55ff-0311-47f7-98f5-233b608d570a">382,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b900d497a954a51b916af633f093d2d_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMy01LTEtMS0zMDU3Mg_65549b50-ac61-4f4d-af05-eb7e33e06e55">361,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e7e38bca0a483382014babf710343a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNC0xLTEtMS0zMDU3Mg_0d841b9b-0ebd-4160-9854-69f75cbfe547">80,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d041f360e72469b85c9fb255e34af5c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNC0zLTEtMS0zMDU3Mg_2ba7bce0-b4cb-457e-afb5-444ced712ebe">62,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4187c911d534ee0a8aa9f97ffb938b1_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNC01LTEtMS0zMDU3Mg_ed91c185-7d55-4e29-8ea9-de765b1b2961">47,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNS0xLTEtMS0zMDU3Mg_d8f328a3-0047-42e2-8fb0-ed3d4dfbb20e">484,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNS0zLTEtMS0zMDU3Mg_eb0a08dd-e541-4b74-8a3b-8948eb115e13">444,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNS01LTEtMS0zMDU3Mg_832329a8-f9d0-4acd-abf6-e1a11f8cf79e">408,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COST OF REVENUE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNy0xLTEtMS0zMDU3Mg_005eb7dd-1733-435b-ae3d-6e9471c4906a">297,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNy0zLTEtMS0zMDU3Mg_8bc3f444-603c-49df-ba03-a40a3ac53ca0">258,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNy01LTEtMS0zMDU3Mg_3904072b-56b4-4430-8a4c-7e206c02de68">211,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GROSS PROFIT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfOS0xLTEtMS0zMDU3Mg_d842ea56-c414-4b10-bffd-b5ae70c83c9d">187,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfOS0zLTEtMS0zMDU3Mg_4cf89ac4-abd0-48de-9ca5-82feab4250f6">185,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfOS01LTEtMS0zMDU3Mg_00634ebe-6733-457e-99b1-8989698413a3">196,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTEtMS0xLTEtMzA1NzI_93637123-6e4d-49bf-8ca1-e86d2c2550b5">221,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTEtMy0xLTEtMzA1NzI_9bc3b184-56a3-48de-989e-6b22eb8ac139">143,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTEtNS0xLTEtMzA1NzI_12a887e7-2b6c-4292-bb1a-a1328fa890b7">127,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTItMS0xLTEtMzA1NzI_ad5db4ed-fc96-48e7-8387-dbb8cc12acee">21,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTItMy0xLTEtMzA1NzI_ceaea8cc-8466-41ef-bbdc-4fa9175a3b29">8,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTItNS0xLTEtMzA1NzI_1e18f228-107d-48b0-b467-c4f5fcc04057">8,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTMtMS0xLTEtMzA1NzI_a43833ce-1727-4470-9bbf-3705b998e7f7">62,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTMtMy0xLTEtMzA1NzI_46771ccf-f826-4eec-8777-ee12079c7d67">47,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTMtNS0xLTEtMzA1NzI_3d960a1b-9b77-4f84-8d58-ab21436d2e4c">47,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTQtMS0xLTEtMzA1NzI_10be26eb-09b6-4fec-a784-a3ce76b301cb">305,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTQtMy0xLTEtMzA1NzI_77d99c6d-0c79-4403-9800-908b52b29412">199,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTQtNS0xLTEtMzA1NzI_3174eb12-9ea6-4029-b509-4e196c71d347">183,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(LOSS) INCOME FROM OPERATIONS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTUtMS0xLTEtMzA1NzI_98ec2464-6282-4cf4-89a7-77177febefeb">118,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTUtMy0xLTEtMzA1NzI_32d0f3d5-831c-4874-8212-8005bd630e49">13,992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTUtNS0xLTEtMzA1NzI_30023162-a00e-440e-ab7a-39dfab22f022">13,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTYtMS0xLTEtMzA1NzI_7df35995-03cb-41bc-baff-12c47ff47371">5,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTYtMy0xLTEtMzA1NzI_2e58f105-9fae-416f-a1b4-2630ae2d5261">7,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTYtNS0xLTEtMzA1NzI_74c4573b-9807-44d4-bc0f-ff4f27d7b10b">3,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTctMS0xLTEtMzA1NzI_2ab09a54-e621-4d35-91e3-68dc80a05014">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTctMy0xLTEtMzA1NzI_426375d7-f1d5-4da4-af8e-5edd3ffd244b">7,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTctNS0xLTEtMzA1NzI_32e2ae9a-c76c-4a9d-bf00-00224425a0d1">4,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable <br/>from non-consolidated affiliate, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtMS0xLTEtNTA4NzE_914b1a7d-c2b9-46f6-9b42-fcfbd1a2990b">109,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtMy0xLTEtNTA4Nzk_32b8429f-6b0a-4d2d-9c76-72217bca3c37">3,955</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtNS0xLTEtNTA4OTQ_6481a8c1-d047-496e-9252-7c66fd3dbdc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtMS0xLTEtMzA1NzI_785215b4-dff6-43e5-be64-a0d7436167c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtMy0xLTEtMzA1NzI_a600d601-25bd-43d4-b1bb-edb76dcbd780">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtNS0xLTEtMzA1NzI_fbefaf75-30a3-4c77-8b84-da1677ae5e72">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on termination of cash flow hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:GainLossOnTerminationOfInterestRateSwap" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTktMS0xLTEtMzA1NzI_cba57844-9458-41ff-9a5f-192465ee9963">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="neo:GainLossOnTerminationOfInterestRateSwap" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTktMy0xLTEtMzA1NzI_723c8e74-bd9a-422f-a059-da573395e40c">3,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:GainLossOnTerminationOfInterestRateSwap" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTktNS0xLTEtMzA1NzI_35040701-04b8-48d3-80b7-ab66896f2e92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjAtMS0xLTEtMzA1NzI_f568677a-d773-4d41-8d6b-3efaddc64f10">15,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjAtMy0xLTEtMzA1NzI_cd1249a0-0e10-4e64-a79a-cd70c03e30ca">14,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjAtNS0xLTEtMzA1NzI_c8d6acb9-8ade-4100-aa59-ff33cb422ca1">3,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjEtMS0xLTEtMzA1NzI_18c6a1fc-1d11-4845-99ab-2ce37cba686e">6,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjEtMy0xLTEtMzA1NzI_e099c199-f40f-444b-a0de-9394845d900a">18,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjEtNS0xLTEtMzA1NzI_e52cc0b4-a8f6-4114-a77a-c1f5e5fc6f05">4,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjItMS0xLTEtMzA1NzI_e4d6b368-80f3-42a5-b00e-3be40a7acbfe">8,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjItMy0xLTEtMzA1NzI_64df1ef4-a5a9-4fd8-a0f2-b5767e70cbd2">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjItNS0xLTEtMzA1NzI_f7f92092-9cae-4e49-afc8-43c4ea640902">8,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME PER SHARE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzMtMS0xLTEtMzA1NzI_8c6f5aeb-2914-46c4-b00b-b1d6724a87fc">0.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzMtMy0xLTEtMzA1NzI_09c157bc-b377-4a0e-b493-50103e5a86fd">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzMtNS0xLTEtMzA1NzI_04b0ba43-1514-4e42-a0a0-585f91e792f5">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzQtMS0xLTEtMzA1NzI_56cf0e92-1501-470b-af08-fd863c511319">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzQtMy0xLTEtMzA1NzI_74441f65-fa00-431c-b72a-2255e52f7b68">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzQtNS0xLTEtMzA1NzI_fd7e62f0-b3e0-474a-8166-e99e03c55553">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE COMMON SHARES <br/>OUTSTANDING</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzctMS0xLTEtMzA1NzI_592f56e1-b2e5-46c9-bd4f-16eb4b723585">119,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzctMy0xLTEtMzA1NzI_62d78830-029d-49a1-9d87-005db5f9a68c">108,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzctNS0xLTEtMzA1NzI_a117d89a-10f5-4d1f-9439-f11eefda93f1">100,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzgtMS0xLTEtMzA1NzI_6bda4676-f997-4261-8c56-eff09779b2f6">119,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzgtMy0xLTEtMzA1NzI_ae986b8a-2050-4475-80c2-5572f120a8c9">111,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzgtNS0xLTEtMzA1NzI_4d194ca0-3ccb-4c17-87a2-03a81bfe10b6">103,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the Consolidated Financial Statements. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMi0xLTEtMS0zMDU3Mg_c9d32abe-2c58-4b0c-996b-bf938a27aac4">8,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMi0zLTEtMS0zMDU3Mg_d58023f1-18e0-429c-9df0-e19c9bdd1bb7">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMi01LTEtMS0zMDU3Mg_196bc182-139e-412d-803b-eb795bb918b6">8,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER COMPREHENSIVE (LOSS) INCOME:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNS0xLTEtMS0zMDU3Mg_b3c08451-1075-48ed-987e-087fcf36cd91">648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNS0zLTEtMS0zMDU3Mg_346cfa36-37da-42a6-bc56-8b0cda78000a">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNS01LTEtMS0zMDU3Mg_97a6e77e-1a34-48f5-82b3-be6ab11fcede">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on effective cash flow hedge, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNi0xLTEtMS0zMDU3Mg_6b784425-1300-4aa0-9494-6e428caa4e58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNi0zLTEtMS0zMDU3Mg_a0608759-daef-4582-8c4f-394917157edf">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNi01LTEtMS0zMDU3Mg_cf01fac0-a4c7-4ece-bd25-32cc039627b8">1,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge termination reclassified to earnings, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOC0xLTEtMS0zMDU3Mg_2e4fabd3-27c5-4e76-87dd-4c05798f301c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOC0zLTEtMS0zMDU3Mg_c5021104-e56d-4770-9b1f-6397e058dac6">2,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOC01LTEtMS0zMDU3Mg_665f8ba7-e414-4a54-b3aa-7a29c0cdd747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOS0xLTEtMS0zMDU3Mg_93eda72c-6946-40d1-95d3-c65b4a181799">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOS0zLTEtMS0zMDU3Mg_5f8b1e22-201d-4eef-979e-ce0431bf9580">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOS01LTEtMS0zMDU3Mg_4a79e566-0ace-4e42-9ca0-8276eb59eb9c">1,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMPREHENSIVE (LOSS) INCOME</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMTAtMS0xLTEtMzA1NzI_a8896ff4-183b-48a2-8d82-48d9c973f9b1">8,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMTAtMy0xLTEtMzA1NzI_e5879a28-eb43-486d-a213-53809a02f516">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMTAtNS0xLTEtMzA1NzI_3aa11aea-5681-4d7a-a8da-c2b437c2e006">6,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the Consolidated Financial Statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_73"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.062%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.312%"><tr><td style="width:1.0%"></td><td style="width:43.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.602%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fa4741509064ec490975a24aa59cd1f_I20181231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtNi0xLTEtMzA1NzI_e8bd32ba-aa54-46db-93c4-a52575a03a24">94,465,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa4741509064ec490975a24aa59cd1f_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtOC0xLTEtMzA1NzI_8ab5396e-d121-4a9f-a57e-65819a6881f0">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78002a692994bf9a3d0e7bbfb10684e_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtMTAtMS0xLTMwNTcy_b884b7d7-b8aa-4494-85ec-3e550de74cde">340,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id547d59cc8974dcda13cff3fd0b89721_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtMTItMS0xLTMwNTcy_111efe5d-682d-42a5-876d-3859ef30882d">579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73a0530d49904cd080aff3e02d8c44dc_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtMTQtMS0xLTMwNTcy_fa498221-2e35-4047-bacf-bee0399172bf">19,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtMTYtMS0xLTMwNTcy_9aacb1fb-8f4d-43b8-8aa3-880bdfcb641e">320,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issuance ESPP plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTktNi0xLTEtMzA1NzI_6c7db819-ff53-404f-b053-8665ab5ee54b">141,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTktMTAtMS0xLTMwNTcy_615bca09-d173-4387-83e5-d216e02e5b8a">2,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTktMTYtMS0xLTMwNTcy_aba33fe7-8017-43d1-95c9-6ce624f7c774">2,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjMtNi0xLTEtMzA1NzI_009dd1b5-8b6c-465c-a960-1665b646b016">168,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjMtMTAtMS0xLTMwNTcy_9c11d46b-b0ff-4677-a983-39741d67aff3">837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjMtMTYtMS0xLTMwNTcy_3d71b455-6bde-4de3-8e9b-23437fb9a6c1">837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjYtNi0xLTEtMzA1NzI_d8c17b5f-f48a-4c0a-a32c-dde992a924f8">2,054,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjYtOC0xLTEtMzA1NzI_98417077-4043-4252-9f6f-b731adf97240">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjYtMTAtMS0xLTMwNTcy_6ad96d4d-23a0-4c86-a15d-e3be4a9396d6">9,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjYtMTYtMS0xLTMwNTcy_1b193133-447f-411f-b89a-f90345c703ba">9,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - public offering, net of underwriting discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjUtNi0xLTEtMzA1NzI_15b9d1a1-b8b5-4888-9fe2-d826bd6b5137">8,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjUtOC0xLTEtMzA1NzI_d9c35ff9-4a83-42c7-aca8-d1e85292204b">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjUtMTAtMS0xLTMwNTcy_8ac09c09-47d1-4e5c-b5ef-ac18fb10f168">160,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjUtMTYtMS0xLTMwNTcy_35b9c9e0-3168-48db-828e-7c2f02d6546f">160,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital adjustment related to acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231" decimals="INF" name="neo:WorkingCapitalAdjustmentAcquisitionShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjQtNi0xLTEtMzA1NzI_cd1a0bad-d57e-4012-b817-39bf3aa877c1">99,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231" decimals="-3" name="neo:WorkingCapitalAdjustmentAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjQtMTAtMS0xLTMwNTcy_9c3e9f49-12fd-4d27-af49-bbca216e0f88">1,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:WorkingCapitalAdjustmentAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjQtMTYtMS0xLTMwNTcy_0f00128d-704a-44cd-9ec2-39500d465c40">1,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock issuance fees and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjAtMTAtMS0xLTMwNTcy_8f6e0497-4d16-46e6-812b-8b34443bc4cc">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjAtMTYtMS0xLTMwNTcy_d61525c4-eef0-4528-a52c-502b171af1a5">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESPP expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjctMTAtMS0xLTMwNTcy_8e15a733-9786-4b73-b091-5010214026dc">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjctMTYtMS0xLTMwNTcy_f8eabf50-d7d9-4d4b-b7fa-707ceb702bf1">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjgtMTAtMS0xLTMwNTcy_141f9101-e0b5-468b-aa17-d4e3b85fac75">9,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjgtMTYtMS0xLTMwNTcy_0d6e37c8-cf09-496b-953f-43ce2f69bb29">9,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on effective cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8efe0d97fc1406cb5ef0d9c377ce77d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjItMTItMS0xLTMwNTcy_9ed9029c-b9d5-4e93-8ba1-ef14ef28604f">1,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjItMTYtMS0xLTMwNTcy_8c67202d-dc15-43e2-b7d6-fba6aa96e007">1,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09eaaff3cf3e4c139b248da5aa23a90d_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTQtMS0xLTMwNTcy_4860e2fb-11d5-43cc-a3eb-5a9bfae07e2d">8,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTYtMS0xLTMwNTcy_08037828-0ecc-46a1-82f6-a707e71afc2b">8,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff84eeb2c41c49b5bfd127f0c4245c57_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtNi0xLTEtMzA1NzI_91eeef8d-ed02-40ea-b56a-487582ce1607">104,781,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff84eeb2c41c49b5bfd127f0c4245c57_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtOC0xLTEtMzA1NzI_933a8368-57ba-48ca-bd1a-ed8e99a3345e">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d2ab56c92948dfbdbcf7f735be5cea_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTAtMS0xLTMwNTcy_6b3cbb73-10e5-4294-a57e-e4c8444c7f7a">520,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i688fe6bfb720405dbb35c980f41b1802_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTItMS0xLTMwNTcy_61418455-7c4c-4384-a9de-95a3be79273f">1,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ecbb3fba22b4fce8d7cab8d90245383_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTQtMS0xLTMwNTcy_2a83e27f-ad3b-4c44-a59a-bc371d583dba">11,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTYtMS0xLTMwNTcy_53770167-b3ed-448d-a004-0cf895b6dd0f">507,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issuance ESPP Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtNi0xLTEtMzA1NzI_910aa17e-215e-409f-b95b-709323ef6775">138,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtMTAtMS0xLTMwNTcy_f225c5a5-dde1-4176-91fe-8423eb8aa628">3,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtMTYtMS0xLTMwNTcy_33fe8805-1aa5-4a12-86af-9876067c4106">3,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtNi0xLTEtMzA1NzI_897349d5-ed8f-43a1-ac72-7018e61cbefd">97,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtMTAtMS0xLTMwNTcy_12764d0c-7c7a-4846-924a-28c7f7047735">1,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtMTYtMS0xLTMwNTcy_8562e33a-2ec2-4cba-a853-dbb9c67ab967">1,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktNi0xLTEtMzA1NzI_b41f1e19-e7f3-4faf-93e9-8cd7734917a0">2,306,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktOC0xLTEtMzA1NzI_f1c2b2d4-cd39-4707-8545-31d155917721">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktMTAtMS0xLTMwNTcy_3fd26d76-afad-4f8b-a2e3-e2e4235bcca0">18,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktMTYtMS0xLTMwNTcy_e5ceadd1-021d-45ae-ac88-a49b27c510d4">18,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - public offering, net of underwriting discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtNi0xLTEtMzA1NzI_c50a6785-aa08-456b-a78a-fe5428acf717">4,751,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtOC0xLTEtMzA1NzI_f9b00242-7647-4431-aa0c-21a596362cc6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtMTAtMS0xLTMwNTcy_c7f5b5c3-62cb-484e-9430-33b5250fb9b7">127,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtMTYtMS0xLTMwNTcy_306d32ec-2fa6-4527-a6f9-b2a931da714b">127,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock issuance fees and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItMTAtMS0xLTMwNTcy_9f9a62fe-851b-4d40-b3be-e645988334c7">268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItMTYtMS0xLTMwNTcy_fddcf924-6c2e-4619-ac62-6fd7b13d40a6">268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESPP expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDEtMTAtMS0xLTMwNTcy_c22bb3e9-8279-4c55-a743-e64e397cbbd4">875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDEtMTYtMS0xLTMwNTcy_b3c88f87-7a00-4c6e-8aad-f2883ce615b6">875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDItMTAtMS0xLTMwNTcy_7ad8db40-5e2c-4292-9704-b727b43aba03">9,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDItMTYtMS0xLTMwNTcy_c8b7dadb-30c2-4983-b045-325dd9f4c524">9,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of Convertible Senior Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTAtMS0xLTMwNTcy_c2855314-bec5-4012-8b08-9ebb0aef6296">30,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTYtMS0xLTMwNTcy_97d1d3e4-d793-41d8-acbc-7b102a5eff63">30,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax liability related to Convertible Senior Notes due 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" sign="-" name="neo:AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDQtMTAtMS0xLTMwNTcy_338499b5-7cd0-4893-af5e-4eb3ad4fa8a0">7,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="neo:AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDQtMTYtMS0xLTMwNTcy_4170821b-de52-4b19-a883-a51ce9cb4359">7,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convertible note debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231" decimals="-3" name="neo:AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDUtMTAtMS0xLTMwNTcy_26155a78-4b12-4ec1-bde8-4cd8f9763169">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDUtMTYtMS0xLTMwNTcy_903bfa00-d8dc-4394-a89e-b55f180ac769">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on effective cash flow hedge, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9052537da8546a7aa1dbd81390401be_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtMTItMS0xLTMwNTcy_825f363b-a4e8-4d4e-890e-84510068199c">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtMTYtMS0xLTMwNTcy_c426e666-7455-487e-9602-e85c93309dbf">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash flow hedge termination reclassified to earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9052537da8546a7aa1dbd81390401be_D20200101-20201231" decimals="-3" sign="-" name="neo:OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtMTItMS0xLTMwNTcy_7b4c6ab6-1319-43a4-a6b9-9b4a373d2246">2,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="neo:OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtMTYtMS0xLTMwNTcy_b7512147-3a55-4b65-803e-d00becf79928">2,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9052537da8546a7aa1dbd81390401be_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctMTItMS0xLTMwNTcy_0cf583c2-e763-4b09-80d2-c494ede0e444">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctMTYtMS0xLTMwNTcy_81e6bebb-e4e8-46c9-afd9-e295194abcce">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9645b439ad4fc3b4c672c2c734a7e0_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDYtMTQtMS0xLTMwNTcy_5f07c74d-b928-45c5-a391-9e1b3eb8f62e">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDYtMTYtMS0xLTMwNTcy_8fb2458e-e460-45d9-9b55-b93c3acb4813">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57d0917029a34ef29e913c208110630e_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktNi0xLTEtNDgxMjE_56c66167-d55e-41dd-8d94-d74713e85737">112,075,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d0917029a34ef29e913c208110630e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktOC0xLTEtNDgxMjE_1dd9f1c9-7c3f-4bfc-9dc1-19b37fb1b7da">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id918e17d65804ec2aaddb4bddbbe04de_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTAtMS0xLTQ4MTIx_a64d5d0c-2fc8-4783-b696-903239b08d20">701,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd25891418746beaebca51736f0026a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTItMS0xLTQ4MTIx_2a849d85-9eec-4e62-8732-71597d20f9fc">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04d0596343524d0a9e26d27762aa2791_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTQtMS0xLTQ4MTIx_67f362cd-1a6e-407c-a899-244bfc3eee97">7,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTYtMS0xLTQ4MTIx_84cc517c-308c-4e5b-b855-e04e8e6edaac">694,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative-effect adjustment from change in accounting principle</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83026cc4bc5d41b4ad74488ad2199f77_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTAtMS0xLTQ4MjAy_20f6012f-a92a-4de4-b3aa-b400bfaa9e02">23,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f50257a2f734bc48f00930c77961bc5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTQtMS0xLTQ4MjAy_6b83b6f7-fd7d-4b51-8c9c-384c9d8fca30">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice51bbf0728a42838fa6df2fe01bcc47_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTYtMS0xLTQ4MjAy_6c010d36-d810-4039-9bca-48b084483345">22,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Premiums paid for capped call confirmations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" name="neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtMTAtMS0xLTQ4MjAy_73b9fe4f-a267-4372-9907-85f541717e05">29,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtMTYtMS0xLTQ4MjAy_b5ac1632-75fa-43c5-9e38-fcc05bf1d385">29,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issuance ESPP Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItNi0xLTEtNDgyMDI_8880ea19-6ee9-4448-a7f1-bc4f37022b5c">112,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItMTAtMS0xLTQ4MjAy_3075a0ca-9a54-49b8-a67f-53984d2b7d64">4,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItMTYtMS0xLTQ4MjAy_62125cde-5947-4bef-af0a-3485bc002d30">4,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzMtNi0xLTEtNDgyMDI_6d35bb4c-5319-4600-8f93-788d577747e1">811,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzMtOC0xLTEtNDgyMDI_e96bffbd-2973-4fbf-9ac0-667c307e218b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzMtMTAtMS0xLTQ4MjAy_883cfdaa-2b2d-4ce1-959e-1504a1c0d9cf">2,818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzMtMTYtMS0xLTQ4MjAy_0dfd4f5b-4029-48b7-b2c6-2a076afb6905">2,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzQtNi0xLTEtNDgyMDI_c07c1c2f-c397-42bc-96e7-b6028b21546d">1,372,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzQtOC0xLTEtNDgyMDI_a8c17ffb-cfb8-4319-8a45-831666c1665f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzQtMTAtMS0xLTQ4MjAy_a20e3e13-605f-40a6-aa40-2a37365c197a">13,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzQtMTYtMS0xLTQ4MjAy_96aef084-0be7-4ff3-8c1a-4ca1eacb88ac">13,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - private placement, net of private placement fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="INF" name="neo:StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtNi0xLTEtNDgyMDI_9ad376d2-42be-48cd-bd5e-c3ffbe70c3ca">4,444,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="-3" name="neo:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtOC0xLTEtNDgyMDI_a76b1bed-bf69-4b89-9f76-4ee5cbc3ba2a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" name="neo:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtMTAtMS0xLTQ4MjAy_ecc68e0a-6d4f-40a5-b118-bf4b9d5cf39d">189,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtMTYtMS0xLTQ4MjAy_cf340f78-e5d4-4ac5-a96e-08af72d3fbf3">189,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - public offering, net of underwriting discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtNi0xLTEtNDgyMDI_eb6452b7-ff31-4749-9f0f-19d63e37041b">4,693,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtOC0xLTEtNDgyMDI_bc24b4cd-23ec-4b18-a027-d1356eca0d45">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtMTAtMS0xLTQ4MjAy_6cd378bd-6791-4a77-ba44-49dc556e23a3">218,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtMTYtMS0xLTQ4MjAy_1fdc4df8-6ca6-4f76-9e34-e11e16d396cf">218,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctNi0xLTEtNDgyMDI_6a7a24a6-a257-4276-80c8-3bbd02abc07e">597,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctOC0xLTEtNDgyMDI_cc4caf73-5968-443d-8582-5496ec70d055">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctMTAtMS0xLTQ4MjAy_85e65766-89d4-4578-aae4-22e6591871a8">29,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctMTYtMS0xLTQ4MjAy_1fbe0344-5d59-4d15-b4b5-0cb94b55036d">29,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock issuance fees and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtMTAtMS0xLTQ4MjAy_6bd9fd6b-98b4-4a79-9883-ec8a576b687b">372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtMTYtMS0xLTQ4MjAy_a1549f00-7eac-469c-9eb6-309ac3d830e3">372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESPP expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktMTAtMS0xLTQ4MjAy_5ad9b126-12ff-4d01-8b4e-7db8595d7f23">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktMTYtMS0xLTQ4MjAy_ffbd9bf8-974d-4bd2-97ee-0c3e64c98e41">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtMTAtMS0xLTQ4MjAy_7b439271-25bd-4743-b764-38bc7c0ee611">21,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtMTYtMS0xLTQ4MjAy_82811149-fa2f-4b72-ba21-a0a1e073a57c">21,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if407078fb14144a49b4fde832c9c9fd0_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDEtMTItMS0xLTQ4MjAy_a40998e9-497f-4f6e-abaf-3bf3d4b6fe7d">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDEtMTYtMS0xLTQ4MjAy_16c3c23f-3163-4ac5-8805-56e515767f3f">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82ac84e649b24f039e093f75604210c3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDItMTQtMS0xLTQ4MjAy_5aadab1c-96e9-4994-8462-4814fe9ee99f">8,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDItMTYtMS0xLTQ4MjAy_10420406-8a86-4bd6-bea8-c47835b14013">8,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib815884d2c9841e7b4cf247a74f794da_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtNi0xLTEtNDgyMDI_a087d649-5d34-4001-8cb1-621298669059">124,107,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib815884d2c9841e7b4cf247a74f794da_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtOC0xLTEtNDgyMDI_50ef5c18-717e-473d-bf07-5524704e1913">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe82c466a4049f6ad31f72b2eb34e2a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTAtMS0xLTQ4MjAy_e5b401c5-22a4-4afd-af48-344ba4598abe">1,123,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eb531e73f524c3299d26ea0b0cc94f8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTItMS0xLTQ4MjAy_18252df4-bf0d-498d-991d-7abc8c705997">638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79509cebd90244a19cdc2cf04c78f592_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTQtMS0xLTQ4MjAy_9b38826c-895c-436d-b077-ed4f28d2df3c">14,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTYtMS0xLTQ4MjAy_a599903b-ee9e-47db-a07c-44ce828a4213">1,108,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the Consolidated Financial Statements. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_76"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.062%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.802%"><tr><td style="width:1.0%"></td><td style="width:59.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMy0xLTEtMS0zMDU3Mg_2afdbdd6-93de-4c38-815b-92dc41242afd">8,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMy0zLTEtMS0zMDU3Mg_79dc1126-05c0-4d7d-b1d7-caf76f86c338">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMy01LTEtMS0zMDU3Mg_735c0175-961b-4706-8087-8348af0d4c98">8,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net&#160;cash&#160;provided&#160;by operating&#160;activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNS0xLTEtMS0zMDU3Mg_54dda617-a3cc-42c4-ac6a-f72a97fa6949">30,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNS0zLTEtMS0zMDU3Mg_8f942b4e-5ce8-45b3-9425-453334f5f799">25,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNS01LTEtMS0zMDU3Mg_316f7db4-3e4f-4040-8df7-89c3987dc2fc">20,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNi0xLTEtMS0zMDU3Mg_ed63edac-a250-4755-9f00-9469b33e0c86">23,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNi0zLTEtMS0zMDU3Mg_32e9516e-ca72-488c-871f-3b34eda0c3db">9,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNi01LTEtMS0zMDU3Mg_2db782f0-7a79-49f5-9e69-4a91ff6d2589">9,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNy0xLTEtMS0zMDU3Mg_433d0da2-b468-4989-a8bf-36b743c8e867">22,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNy0zLTEtMS0zMDU3Mg_8d38aa11-4f8d-4198-863e-441626b23b4d">10,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNy01LTEtMS0zMDU3Mg_782c05a9-e976-4e65-bddf-d9e5be0530ba">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOC0xLTEtMS0zMDU3Mg_ca0349a5-b291-481e-b830-71eda137c4f4">8,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOC0zLTEtMS0zMDU3Mg_15d13bba-f5af-4c36-b172-f02ac39b01ec">6,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOC01LTEtMS0zMDU3Mg_8314f6c8-1cc0-4eb6-80df-f13ab9c2f3d8">5,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of convertible debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOS0xLTEtMS0zMDU3Mg_db18231c-a8b8-4ef7-b2e6-3d83f4282dd9">2,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOS0zLTEtMS0zMDU3Mg_bb81d762-c9f7-49f7-bc0e-5a646b8c118b">4,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOS01LTEtMS0zMDU3Mg_9d2ea96c-b089-4c71-9fcd-28ab8941f4c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTAtMS0xLTEtMzA1NzI_74fdc1e6-3364-483c-aedd-36c81963acfb">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTAtMy0xLTEtMzA1NzI_62b441e3-db5d-47c9-872a-a515029472ca">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTAtNS0xLTEtMzA1NzI_15384752-40b1-498b-8d81-0c220be3ef87">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTEtMS0xLTEtMzA1NzI_60f2e327-994a-4b2c-86ee-5d1ce179f30a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTEtMy0xLTEtMzA1NzI_b4698d5a-c96b-4019-b5e3-429340b2de1a">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTEtNS0xLTEtMzA1NzI_0b002233-3b1e-46ec-b6f6-e9c9b0e36822">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on termination of cash flow hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:GainLossOnTerminationOfInterestRateSwap" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTItMS0xLTEtMzA1NzI_a58eba1f-eaec-4615-81ec-fb2266d129b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="neo:GainLossOnTerminationOfInterestRateSwap" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTItMy0xLTEtMzA1NzI_d1647d9c-b33b-40ce-9b7c-22bd0a7f488f">3,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:GainLossOnTerminationOfInterestRateSwap" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTItNS0xLTEtMzA1NzI_d48b236a-4a49-48fc-b5d4-d7be41aca397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTMtMS0xLTEtNDc3Nzk_6399a283-55ed-4d47-a110-04035dbc0eb9">109,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTMtMy0xLTEtNDc3Nzk_cacdf68a-d867-42d9-8837-764e7c90f98d">3,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTMtNS0xLTEtNDc3Nzk_b159f8ba-d83a-4a92-a38d-2e08c1b8f528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on loan receivable from non-consolidated affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:ReceivableWithImputedInterestNonConsolidatedAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtMS0xLTEtNDc3Nzk_c6627e27-5027-45b5-8fd8-ba5f6532daab">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:ReceivableWithImputedInterestNonConsolidatedAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtMy0xLTEtNDc3Nzk_2dc1f869-547a-4b14-bfad-e2fa2872bab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:ReceivableWithImputedInterestNonConsolidatedAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtNS0xLTEtNDc3Nzk_56c8c830-674f-4445-a79f-1b6335bc9a82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write off of COVID-19 PCR testing inventory and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:PolymeraseChainReactionTestingExitCostsCOVID19" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtMS0xLTEtNDc4MDQ_f909724a-748d-43d7-9392-2b65c2788680">6,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:PolymeraseChainReactionTestingExitCostsCOVID19" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtMy0xLTEtNDc4MDQ_7f3301c6-7df1-4f51-84c9-89eb9e24a743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:PolymeraseChainReactionTestingExitCostsCOVID19" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtNS0xLTEtNDc4MDQ_fdd8ba28-0a27-4b69-80a2-5a6d5f71dc25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtMS0xLTEtMzA1NzI_b4eae17d-c5ae-47df-b4f4-306a5eae63f4">2,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtMy0xLTEtMzA1NzI_38dab966-d40f-4ff7-a3d3-acb113c80a56">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtNS0xLTEtMzA1NzI_41630718-6542-438e-a71f-bcb01ff1583b">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtMS0xLTEtMzA1NzI_c84ee165-2d95-4f2f-83eb-264647f64c05">4,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtMy0xLTEtMzA1NzI_3a04eace-e648-4c47-9226-db9dd2a99ab6">12,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtNS0xLTEtMzA1NzI_4710ab31-c047-447f-8920-f21f86127833">17,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTctMS0xLTEtMzA1NzI_32aebefc-8899-4be5-8aef-66a1295c3e15">1,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTctMy0xLTEtMzA1NzI_a55791f9-742b-4d9e-95a4-e9b5a7721e2f">15,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTctNS0xLTEtMzA1NzI_fc303e1e-f05e-43ce-ac9b-e458ca5b57c5">5,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:IncreaseDecreaseInPrepaidConstruction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTktMS0xLTEtMzA1NzI_5906ad66-9dc8-4918-96cd-72e3a425f0d0">4,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:IncreaseDecreaseInPrepaidConstruction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTktMy0xLTEtMzA1NzI_30cad26b-9c5d-48c1-9cec-03d085a3f124">20,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:IncreaseDecreaseInPrepaidConstruction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTktNS0xLTEtMzA1NzI_e32c407f-6bc8-47d8-81b5-0395ec72204f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjAtMS0xLTEtMzA1NzI_e8bac7f2-31d4-45f5-ac19-17fbbc9d3d21">1,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjAtMy0xLTEtMzA1NzI_3490cfc6-50e5-418a-8559-8ef67fc87362">9,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjAtNS0xLTEtMzA1NzI_96451942-62ca-49fb-b9d2-3c7aab80e28e">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable, operating lease liabilities, deferred taxes, accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjItMS0xLTEtMzA1NzI_f691ca07-cbd5-48f8-91df-92cda6c3ff04">5,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjItMy0xLTEtMzA1NzI_1e19dc87-fd27-4ce2-a5a3-9988c55f8682">3,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjItNS0xLTEtMzA1NzI_e4762bb4-a241-448b-a586-3b08bafad72b">9,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjMtMS0xLTEtMzA1NzI_124b9bad-7694-4cf1-87c8-837cebb597b1">26,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjMtMy0xLTEtMzA1NzI_0b464538-3c56-4256-aed0-1539fe1c6e8d">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjMtNS0xLTEtMzA1NzI_3396e024-377f-4c73-9834-dd9a1fe0718b">23,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjUtMS0xLTEtMzA1NzI_e150c2eb-b38b-412f-9583-6085f31e12ce">196,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjUtMy0xLTEtMzA1NzI_a0863e68-cef8-4604-884b-7d26b6de769d">73,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjUtNS0xLTEtMzA1NzI_2e39f7fb-3523-494e-a65a-884da9aef0ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjYtMS0xLTEtMzA1NzI_4a909b03-2921-4457-9e94-f4367b2c373f">62,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjYtMy0xLTEtMzA1NzI_e3eb37a2-aa5a-430e-ab29-e58c5c38eb9c">5,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjYtNS0xLTEtMzA1NzI_b29a069f-94c0-4201-a73c-764d5d09bf3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjgtMS0xLTEtMzA1NzI_4b78a923-65e4-4e35-a16b-9f25c3de4705">64,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjgtMy0xLTEtMzA1NzI_3e88436c-6744-416d-b6f0-6b100dc23555">29,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjgtNS0xLTEtMzA1NzI_9e2da64c-4f0d-4e38-96f0-0eefa8290942">20,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjktMS0xLTEtMzA1NzI_53fd27a6-5166-4d5f-8756-1ab59af55275">419,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjktMy0xLTEtMzA1NzI_e03d147c-d903-4296-b114-bbe2ddff358b">37,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjktNS0xLTEtMzA1NzI_6a19a471-6373-4318-9e58-ef42e2239a13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in non-consolidated affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzAtMS0xLTEtMzA1NzI_f3b3ba4a-6619-4aa2-867b-1ad784a364d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzAtMy0xLTEtMzA1NzI_629e5de4-0aa2-48e3-a7e0-ac458b6cbeaf">25,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzAtNS0xLTEtMzA1NzI_b4a33cbe-c2f9-4c46-915b-ca8dd515cec4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan receivable from non-consolidated affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzQtMS0xLTEtNjQ0Njc_18dc9b98-ee2e-4c8d-b271-0ca446f69b68">15,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzQtMy0xLTEtNjQ0Njc_dca53bb8-cdaf-4465-af1e-195c4ec67a43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzQtNS0xLTEtNjQ0Njc_ccbcf9ff-bd3a-405b-8f39-7c1ee8ab0f46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition working capital adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:BusinessCombinationWorkingCapitalAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzEtMS0xLTEtMzA1NzI_cb4dfbc4-ef1c-417c-a513-3cee749c7210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:BusinessCombinationWorkingCapitalAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzEtMy0xLTEtMzA1NzI_3199390d-06c9-4f84-a2b3-560425ab0f26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:BusinessCombinationWorkingCapitalAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzEtNS0xLTEtMzA1NzI_6b69a7de-edd4-4de4-aa00-613323d93774">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzItMS0xLTEtMzA1NzI_c329c022-58ee-4376-bc0d-133add15dc2e">632,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzItMy0xLTEtMzA1NzI_9db29e16-6463-4a03-9eb8-d233ffec33ab">159,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzItNS0xLTEtMzA1NzI_03449a45-7c8c-42f6-a42f-a940563d2e0c">19,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzUtMS0xLTEtMzA1NzI_d1e799ba-b336-4a07-8a24-ff441fc7f187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzUtMy0xLTEtMzA1NzI_91a9335f-6750-40d5-868f-1494af0ccc47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzUtNS0xLTEtMzA1NzI_8d102f69-cfaa-4b83-a4db-4bd78448691f">5,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of equipment financing obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:RepaymentsOfEquipmentAndOtherLoans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzctMS0xLTEtMzA1NzI_a7f7489a-7b5f-4ffd-87b3-9faf9aaa56d8">3,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:RepaymentsOfEquipmentAndOtherLoans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzctMy0xLTEtMzA1NzI_297f037d-4348-41da-8d6f-86e2dc07c443">5,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:RepaymentsOfEquipmentAndOtherLoans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzctNS0xLTEtMzA1NzI_e6301b30-4ea3-4cc2-b7d7-b2a9f24b3851">7,201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzgtMS0xLTEtMzA1NzI_1d1570a9-130f-4c4f-8349-22a587c81145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzgtMy0xLTEtMzA1NzI_bab77c95-f6b5-480f-9a22-b7995ffb1b69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzgtNS0xLTEtMzA1NzI_8d63f12f-51be-44a4-8b7e-07e1082c8b6e">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzktMS0xLTEtMzA1NzI_8ceda06c-f367-4226-ad6a-4e4ac1a1a424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzktMy0xLTEtMzA1NzI_e6ead933-7d8a-4865-a7ca-81ab800fdef3">97,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzktNS0xLTEtMzA1NzI_b246917d-6913-47bf-a520-414cd953aeba">99,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash flow hedge termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:DerivativeTerminationFee" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDAtMS0xLTEtMzA1NzI_678c91f8-ad06-4c67-bc87-279414fab8bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:DerivativeTerminationFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDAtMy0xLTEtMzA1NzI_33f9323c-f8c9-434b-9206-5bb5747fe21f">3,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:DerivativeTerminationFee" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDAtNS0xLTEtMzA1NzI_835c5b60-2af0-4e24-b3b0-cf461425e6c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of debt issuance costs for term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDEtMS0xLTEtMzA1NzI_52823b05-3592-4b69-a7bd-1a7842fffc37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDEtMy0xLTEtMzA1NzI_c1af376d-923f-4ebb-9f3f-f84522b392cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDEtNS0xLTEtMzA1NzI_8b122d8c-88e7-4256-b31a-0a3a1f4b3bb1">1,059</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDItMS0xLTEtMzA1NzI_d3586fce-cbcb-4fa1-8a2b-c6d397b59cf9">15,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDItMy0xLTEtMzA1NzI_0d08dcab-474c-4ee5-8d2e-33b70500a86f">20,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDItNS0xLTEtMzA1NzI_cf10d085-1d29-4a02-a8f7-11281bdd2abe">11,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of convertible debt, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDMtMS0xLTEtMzA1NzI_deaafea6-a0ef-4160-b6b3-a84b6656484a">334,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDMtMy0xLTEtMzA1NzI_3210085c-1033-4759-acb1-e72f76c0a05c">194,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDMtNS0xLTEtMzA1NzI_d4c57567-0c8a-46ed-b203-c25fa808113f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Premiums paid for capped call transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:PaymentsOfPremiumsForCappedCallConfirmations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctMS0xLTEtNDc5MDg_f2b0bef6-d5c5-4673-bd59-04812d2faec8">29,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:PaymentsOfPremiumsForCappedCallConfirmations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctMy0xLTEtNDc5MDg_6a212bba-b2f5-4561-b486-2901420e37e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:PaymentsOfPremiumsForCappedCallConfirmations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctNS0xLTEtNDc5MDg_ff7df7fc-a044-48a3-8ab6-c8dde1200da3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from equity offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:ProceedsFromEquityOfferingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDQtMS0xLTEtMzA1NzI_df5614c4-b853-4e22-9108-d090bacf4e6f">408,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:ProceedsFromEquityOfferingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDQtMy0xLTEtMzA1NzI_7e4e9033-1846-4601-b08f-30c18e81f16e">127,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:ProceedsFromEquityOfferingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDQtNS0xLTEtMzA1NzI_79f0b9d3-fcf8-43fc-a863-e8d768234a1d">160,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDUtMS0xLTEtMzA1NzI_85736a66-ef45-418f-b5c9-ed4995744986">725,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDUtMy0xLTEtMzA1NzI_c9877375-2005-42bc-a06b-6bc41a53b36a">235,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDUtNS0xLTEtMzA1NzI_cf00972e-e988-447c-95a5-9760754b1902">159,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctMS0xLTEtMzA1NzI_5c0856df-f254-4bab-8ee9-45f5ef6e7b0c">66,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctMy0xLTEtMzA1NzI_b29d5abe-4db4-4c3e-91f2-cd59950f9923">77,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctNS0xLTEtMzA1NzI_5bab8467-a42f-498d-841f-186782f873d3">163,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDgtMS0xLTEtMzA1NzI_03f56cb9-050b-4e90-bba4-2f2b59a78585">250,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDgtMy0xLTEtMzA1NzI_d74e8978-4907-42d7-945c-3bb87da9a296">173,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDgtNS0xLTEtMzA1NzI_4d73c27e-6ebd-4025-86c9-2286df871c7e">9,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDktMS0xLTEtMzA1NzI_fe7476a5-425d-4c02-b31f-fab4da4cc54d">316,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDktMy0xLTEtMzA1NzI_60303392-3911-4208-9965-c8128c16feb7">250,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDktNS0xLTEtMzA1NzI_7d967eee-b191-4c2e-a6bb-802f116cd53d">173,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.062%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.541%"><tr><td style="width:1.0%"></td><td style="width:59.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMS0xLTEtMS0zMDU3Mg_70ab0efb-8c8b-4ac1-9c08-c127558c5d24">316,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMS0zLTEtMS0zMDU3Mg_677d5435-8965-4cd9-aa03-6f0795fd4b11">228,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMS01LTEtMS0zMDU3Mg_a3b16760-8349-4490-88cd-1dbcf814e265">173,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMi0xLTEtMS0zMDU3Mg_88161477-a70f-4171-975a-cb4e91315143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMi0zLTEtMS0zMDU3Mg_df256b8f-45a3-46c9-8014-cebc9cbb6eb6">21,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMi01LTEtMS0zMDU3Mg_68d66e15-8827-4ea2-9063-9f5a65fe6eee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMy0xLTEtMS0zMDU3Mg_a5e56d72-1653-4b71-841e-65a308bae7d5">316,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMy0zLTEtMS0zMDU3Mg_9ebefb80-166d-4c45-8816-4dc2c7cb0c90">250,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMy01LTEtMS0zMDU3Mg_65633075-418b-4e38-8dbd-c5fcc14c9092">173,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNi0xLTEtMS0zMDU3Mg_a4c5b2e6-d374-47fb-9568-0639415192bb">3,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNi0zLTEtMS0zMDU3Mg_7e819478-7ee7-47f1-990f-3035d9a880f1">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNi01LTEtMS0zMDU3Mg_90003fc8-bf54-4803-b336-ea8f805a25d0">4,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes paid, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNy0xLTEtMS0zMDU3Mg_898cc25e-f855-4346-ab24-ce7b0747fee9">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNy0zLTEtMS0zMDU3Mg_8369dfa6-606c-4ed7-8cad-11fded53b2ed">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNy01LTEtMS0zMDU3Mg_ee3050d9-2a9c-440a-9af8-3a4558a92dda">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of common stock issued to fund acquisition</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:FairValueOfCommonStockIssuedToFundAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfOS0xLTEtMS0zMDU3Mg_5c014568-2798-4958-b992-2bbb9ab7adf6">29,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:FairValueOfCommonStockIssuedToFundAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfOS0zLTEtMS0zMDU3Mg_e2ebefdd-5486-4e2b-88ec-2fdc0e6e4e13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:FairValueOfCommonStockIssuedToFundAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfOS01LTEtMS0zMDU3Mg_fbc39632-155a-4938-aabc-e1a503d42113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital adjustment related to acquisition</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:WorkingCapitalAdjustmentAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTEtMS0xLTEtMzA1NzI_dc2a8727-bf0e-471e-b5de-a2141b02615c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:WorkingCapitalAdjustmentAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTEtMy0xLTEtMzA1NzI_9bfe5c5d-f69d-4f46-bc3f-d5506145be1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:WorkingCapitalAdjustmentAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTEtNS0xLTEtMzA1NzI_a0e0f9e6-ed0f-4153-ae3c-72278972e1a1">1,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment acquired under financing obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTItMS0xLTEtMzA1NzI_213d8ebf-9e19-400f-9c22-58d9c886ee59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTItMy0xLTEtMzA1NzI_e13d18b7-9b9e-4d74-bec0-fd013a03032d">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTItNS0xLTEtMzA1NzI_59d41713-0279-433c-8e7e-75aeb1e35ecf">4,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment included in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTMtMS0xLTEtMzA1NzI_d3ef7dd4-499b-4758-a23a-ecf47f1d2a5c">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTMtMy0xLTEtMzA1NzI_ddd2395f-7eca-4bbc-90d4-cd52a9cca4f9">2,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTMtNS0xLTEtMzA1NzI_1855230a-2fff-4fb0-8425-42eef6d66bc5">1,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the Consolidated Financial Statements. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_79"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ia1854a760084469581a7ceab463d6c8e_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTM5NA_fe820508-529d-4ad5-bdb4-bbf64db84eba" continuedAt="i99e9c6a74ac1447fb5b08722a090c140" escape="true">Nature of Business</ix:nonNumeric></span></div><ix:continuation id="i99e9c6a74ac1447fb5b08722a090c140" continuedAt="ia6b2d9dfb5424cae953a1a7f92d1f383"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Nature of the Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeoGenomics, Inc., a Nevada corporation (the &#8220;Parent,&#8221; &#8220;Company,&#8221; or &#8220;NeoGenomics&#8221;), and its subsidiaries, operate as a certified, high complexity clinical laboratory in accordance with the federal government&#8217;s Clinical Laboratory Improvement Act, as amended, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">COVID-19 Pandemic Update</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) was identified and the disease has since spread across the world, including the United States (&#8220;U.S.&#8221;). In March 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic. The outbreak of the pandemic is materially adversely affecting the Company&#8217;s employees, patients, communities, and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 outbreak will impact the Company&#8217;s business, results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#8217;s results of operations, financial condition, and cash flows may continue to be materially adversely affected, particularly if the pandemic continues to persist for a significant amount of time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the cash on hand, marketable securities, and expected cash collections are sufficient to fund near-term capital and operating needs for at least the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the first quarter 2021, due to the broad roll-out of the COVID-19 vaccine and a sharp decline in COVID-19 polymerase chain reaction (&#8220;PCR&#8221;) testing demand, the Company made the decision to exit COVID-19 PCR testing and the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i18eda084cbb54f798854f0d69e97920e_D20210101-20210331" decimals="-5" name="neo:PolymeraseChainReactionTestingExitCostsCOVID19" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDQ3OA_66859e04-1b52-4be0-ae32-1ab9a3341ec8">6.1</ix:nonFraction>&#160;million loss related to the exit from COVID-19 PCR testing. This amount consisted of write-offs of $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="neo:PolymeraseChainReactionTestingWriteOffsCOVID19" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDQ5Mg_5807a833-9699-40a3-a20d-7e0317c901f0">5.3</ix:nonFraction>&#160;million for all remaining COVID-19 PCR testing inventory recorded to cost of revenue and $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDUwNg_2538f730-6d63-4d09-81ee-16f150c1f422">0.8</ix:nonFraction>&#160;million for all remaining COVID-19 PCR testing laboratory equipment recorded to general and administrative expenses on the Consolidated Statements of Operations for the year ended December 31, 2021. There were no such amounts recorded for each of the years ended December 31, 2020 and 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Coronavirus Aid, Relief, and Economic Security Act</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal government passed legislation and the President of the United States signed into law on March 27, 2020, known as the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). On April 10, 2020, the U.S. Department of Health &amp; Human Services announced that Medicare-enrolled providers would receive a portion of a direct deposit disbursement totaling $50 billion. The $50 billion is part of a $100 billion Public Health and Social Service Emergency Fund created by the CARES Act. Payments made under the CARES Act are intended to reimburse healthcare providers for health care related expenses or lost revenues attributable to COVID-19 and are not required to be repaid provided that recipients attest to and comply with certain terms and conditions, including limitations on balance billing for COVID-19 patients. In the absence of specific guidance to account for government grants in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), the Company accounts for such grants in accordance with international accounting standards for government grants. Such amounts are recognized when there is reasonable assurance that the Company will (1) comply with the conditions associated with the grant and (2) receive the grant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="neo:ProceedsFromGovernmentAssistanceCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDUyMA_bcba9233-5022-49ee-895a-39cc8c2d51e0">7.9</ix:nonFraction>&#160;million in grant income related to the CARES Act. <ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-5" name="neo:ProceedsFromGovernmentAssistanceCARESAct" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDUzNw_467040f0-34d4-4690-9b3d-e963436395ef"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="neo:ProceedsFromGovernmentAssistanceCARESAct" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDUzNw_adb7388d-ac73-4d6e-a534-d5fa96898936">No</ix:nonFraction></ix:nonFraction> such amounts were recorded for the years ended December 31, 2021 and December 31, 2019. CARES Act grant income is classified in other income, net, on the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also permits the deferral of payment of the employer portion of social security taxes between March 27, 2020 and December 31, 2020. 50% of the deferred amount was due on December 31, 2021 and the remaining 50% is due on December 31, 2022. As of December 31, 2021, the total accrued deferred social security taxes, related to the CARES Act was $<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-5" name="neo:SocialSecurityTaxEmployerDeferralCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDU0Mw_ff8d27b7-86cb-4899-aea9-b1b085ededfc">3.0</ix:nonFraction>&#160;million. This amount was recorded in accrued expenses and other liabilities on the Consolidated Balance Sheets. As of December 31, 2020, the total accrued deferred social security taxes, related to the CARES Act was $<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-5" name="neo:SocialSecurityTaxEmployerDeferralCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDU1Nw_07dc349d-8bbc-452c-b2b5-2846a58576de">5.9</ix:nonFraction>&#160;million which was recorded evenly between accrued expenses and other liabilities and other long-term liabilities on the Consolidated Balance Sheets.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia6b2d9dfb5424cae953a1a7f92d1f383">Additionally, the CARES Act included an Employee Retention Tax Credit (&#8220;ERTC&#8221;) provision designed to encourage employers to retain employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages paid between March 13, 2020 and September 30, 2021 that meet the requirements of the ERTC provision. For the year ended December 31, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="neo:EmployeeRetentionTaxCreditCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ3NDU1Nw_66d56c97-b45e-49ca-9d76-e43f89c933fe">1.9</ix:nonFraction>&#160;million in credits under the ERTC which was included in (loss) income from operations on the Consolidated Statements of Operations. In the fourth quarter of 2021 the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i17a51adbb970403990c2ec023fc31d62_D20211001-20211231" decimals="-5" name="neo:EmployeeRetentionTaxCreditCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ3NDU3MQ_91276501-a5fa-4a58-ae9e-d3c85fbef4c7">4.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="neo:EmployeeRetentionTaxCreditCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ3NDU4NQ_bc2fa111-e789-41b0-a9c9-76c4ca513718">1.9</ix:nonFraction>&#160;million in expense in (loss) income from operations related to non-reoccurring reversals and reserves against tax credits previously recorded in the nine months ended September 30, 2021 and in the year ended December 31, 2020, respectively.</ix:continuation></span></div><div id="ia1854a760084469581a7ceab463d6c8e_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjI_069ce4d6-1f77-4888-914f-fc7a915b62d4" continuedAt="ib13228290f584ebb92f72de5a397ca6c" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ib13228290f584ebb92f72de5a397ca6c" continuedAt="iaa24050ab1a3488b98a9d4e9f4a81ca6"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of the Parent and its subsidiaries. All intercompany accounts and balances have been eliminated in consolidation.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjM_df485d6b-20c4-4c3b-8339-9c6f8795fe92" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#8217;s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these Consolidated Financial Statements include, but are not limited to, those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDE_5b89be1d-60d5-417a-9f25-234ecc88f301" continuedAt="i05752d25082c46b3b8191e66cc27eb30" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether investments in affiliates are a Variable Interest Entity (&#8220;VIE&#8221;) at the start of each new venture and when a reconsideration event has occurred. A reporting entity must consolidate a VIE if that reporting entity has a variable interest (or combination of variable interests) and is determined to be the primary beneficiary. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i05752d25082c46b3b8191e66cc27eb30">The Company accounts for its equity investments that are under 20% of the total equity outstanding and for which the Company does not have significant influence by applying the cost method. Investments that are under 20% of the total equity outstanding and for which the Company has significant influence are accounted for using the equity method unless a scope exception is applicable. Investments in which the Company holds a non-controlling interest and are between 20-50% equity are accounted for using the equity method. For any equity investments in which the Company holds over 50% of the outstanding stock, or for investments in which the Company controls the investee, the Company consolidates those entities into the Consolidated Financial Statements.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU2Mjg4Mg_7e27b754-4399-4adb-a987-92ad1fee5f8b" continuedAt="i74ef50ea04e9431e8098fa8c92c48986" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i74ef50ea04e9431e8098fa8c92c48986">The Company reports its activities in <ix:nonFraction unitRef="segment" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzI5NA_02f06d13-433d-4765-bb62-11960cfcf322"><ix:nonFraction unitRef="segment" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzI5NA_b2e00182-3d12-4980-8464-6cce9c362eff">two</ix:nonFraction></ix:nonFraction> reportable segments; (1) the Clinical Services segment and (2) the Pharma Services segment.&#160;These reportable segments deliver testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers and represent <ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="neo:PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzU2MQ_266e2bb8-12fd-4b3c-b6eb-a13fe665782b"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="INF" name="neo:PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzU2MQ_4204abfa-b37d-4ae9-afc2-b3f0844545cc"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="INF" name="neo:PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzU2MQ_905d6e65-898c-452a-a590-e0ea29a0477a">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s consolidated assets, net revenue, and net (loss) income in each of the years ended December 31, 2021, 2020, and 2019.</ix:continuation> Please refer to Note 19. Segment Information, for further financial information about these segments.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDAwNw_ea98f009-0bd7-4500-917c-cbcc126517e0" continuedAt="i872a69a88ebd40589ec8c27473951cf2" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions of entities over which control is obtained that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent third-party valuations that use information and assumptions provided by management, which consider estimates of inputs and </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iaa24050ab1a3488b98a9d4e9f4a81ca6" continuedAt="ic93d732568b04e80aa1bfa2eed44555f"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i872a69a88ebd40589ec8c27473951cf2">assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired less liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives, and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the Company&#8217;s operating results from the date of acquisition.</ix:continuation></span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDk_7a792a75-8a82-4485-960c-39359dca3e27" continuedAt="i02a3fb9c02a84abc88bce5878ce1022f" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash, certain cash equivalents, accounts receivable, net, other current assets, accounts payable, accrued expenses and other liabilities, and Pharma contract liabilities are considered reasonable estimates of their respective fair values due to their short-term nature. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i02a3fb9c02a84abc88bce5878ce1022f">The Company measures its marketable securities at fair value on a recurring basis.</ix:continuation> Please refer to Note 4. Fair Value Measurements, for further discussion.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTM_03d13f6f-4837-4ad4-b2ef-5217032601a1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with an original maturity of ninety days or less to be cash equivalents. The Company maintains its cash and cash equivalents with financial institutions that the Company believes to be of high credit standing. The Company believes that, as of December 31, 2021, its concentration of credit risk related to cash and cash equivalents was not significant.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTA_0b4ab91e-202d-4b8c-ba18-e59e84d9c4fa" continuedAt="iefaa53efa2824ed291271b087f0e8108" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all marketable securities as available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are carried at fair value, with the unrealized holding gains and losses, net of income taxes, reflected in accumulated other comprehensive income until realized. The Company evaluates its marketable securities for other-than-temporary impairment on a quarterly basis. Unrealized losses are charged against net earnings when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine whether a loss is other-than-temporary, such as the length and extent of the fair value decline, the financial condition and near-term prospects of the issuer, and whether there is the intent to sell or will more likely than not be required to sell before the securities&#8217; anticipated recovery. There were <ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU5MDY3MQ_0dd6ecde-065a-49dd-a987-c09aa3c2b09c"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU5MDY3MQ_768153d4-c130-4999-b94c-d88bf4577e98"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU5MDY3MQ_f8dd6dac-5856-4724-b4d1-18ae9058aefa">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> other-than-temporary impairments for the years ended December 31, 2021, 2020 and 2019. Regardless of the intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are recorded when the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iefaa53efa2824ed291271b087f0e8108">For the purposes of computing realized and unrealized gains and losses, cost and fair value are determined on a specific identification basis.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTE_f9f6bb72-21ea-48bb-8805-ea88d432744b" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounts Receivable, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are reported for all Clinical Services payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Pharma Services the Company negotiates billing schedules and payment terms on a contract-by-contract basis which can include payments based on certain milestones being achieved.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjQ_c8f9701a-5847-4c90-96ee-f885b255eaff" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist principally of testing supplies and are valued at lower of cost or net realizable value, using the first-in, first-out method. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventories to their estimated net realizable value.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ic93d732568b04e80aa1bfa2eed44555f" continuedAt="id2f6bcc074f74bb59e8b88442d3519f5"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="neo:AssetsHeldForSalePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDAwOQ_a5234236-161a-44ae-aeb4-dfa39960d870" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Assets Held for Sale</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns <ix:nonFraction unitRef="sqft" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="neo:AssetHeldForSaleSquareFeetOfFacilityOwned" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDAxMQ_f5355dca-acd6-4732-b09c-f3841b8f9738">43,560</ix:nonFraction> square feet of our Carlsbad, California facility. During the third quarter of 2021, the Company committed to selling this property and the associated land and concluded that these assets met the held for sale criteria. At December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU2MjkxMg_4ea1919e-b685-47b4-b47b-2baeaf0216b0">10.1</ix:nonFraction> million was recorded as assets held for sale within current assets on the Consolidated Balance Sheets for this property and associated land and reflects its carrying value which was lower than the fair value less selling costs. We expect to sell this property within one year, however, there can be no assurance that the sale of this property will be completed in the time frame we expect or at all. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Prepaid Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU4MDM5Nw_08cd435f-9281-45b6-9540-6d3ddc973d8e" escape="true">The Company records a prepaid expense for costs paid but not yet incurred. Those expected to be incurred within one year are recorded as prepaid assets within total current assets on the Consolidated Balance Sheets. Any costs expected to be incurred outside of one year are recorded as other assets within total non-current assets on the Consolidated Balance Sheets.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="neo:OtherCurrentAssetsPolicyPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjU_590a8d6f-0792-467f-9cf5-83a1130b7d15" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Current Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, other current assets consisted primarily of receivables related to research and development (&#8220;R&amp;D&#8221;) tax credit receivables, pharma contract assets and other non-trade receivables.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTU_d4bcb145-0bdc-4e41-9ef6-5977daf2dcf1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on the straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the related lease terms or their estimated useful lives. Costs incurred in connection with the development of internal-use software are capitalized in accordance with the accounting standard for internal-use software, and are amortized over the expected useful life of the software.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews the estimated useful lives of property and equipment. Changes to the estimated useful lives are recorded prospectively from the date of the change. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts and any resulting gain or loss is included in income (loss) from operations. Repairs and maintenance costs are expensed as incurred and are included in cost of revenue, general and administrative expenses or R&amp;D expenses, as appropriate in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTY_b286d371-3c94-4842-86af-fb246b41980a" continuedAt="i3791fe298f4445afaba0a13feb09c7e9" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases corporate offices and laboratory spaces throughout the world, all of which are classified as operating leases expiring at various dates and generally having terms ranging from <ix:nonNumeric contextRef="id8fa1647fb744e689ec47a53eb568d0b_I20211231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTIwMzE_a4a84daa-7d03-49c4-8b05-f7c1ffee11b5">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i9e0ce2e60c5f48469d701fa7b04e3fdb_I20211231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTIwMzc_ab494235-c0b6-4acf-a7c8-acb11c3a4770">20</ix:nonNumeric> years. Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s real estate lease agreements include options to either renew or early terminate the lease. Leases with renewal options allow the Company to extend the lease term typically between <ix:nonNumeric contextRef="id8fa1647fb744e689ec47a53eb568d0b_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTIzMzI_8e2f963a-e861-4802-9180-535ce1ca5f6d">1</ix:nonNumeric> and <ix:nonNumeric contextRef="i9e0ce2e60c5f48469d701fa7b04e3fdb_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTIzMzk_2ea797b1-1452-449f-981f-3477aafad2f8">5</ix:nonNumeric> years. When it is reasonably certain that the Company will exercise an option to renew or terminate a lease, these options are considered in determining the classification and measurement of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities are recorded based on the present value of the future lease payments over the lease term and assessed as of the commencement date. Incentives received from landlords, such as reimbursements for tenant improvements and rent abatement periods, effectively reduce the total lease payments owed for leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain real estate leases also include executory costs such as common area maintenance (non-lease component), as well as property insurance and property taxes (non-components). Lease payments, which may include lease components, non-lease components and non-components, are included in the measurement of the Company&#8217;s lease liabilities to the extent that such </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="id2f6bcc074f74bb59e8b88442d3519f5" continuedAt="ieff080a4c3bf44918af89074442c83a6"><ix:continuation id="i3791fe298f4445afaba0a13feb09c7e9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments are either fixed amounts or variable amounts based on a rate or index (fixed in substance), as stipulated in the lease contract. Any actual costs in excess of such amounts are expensed as incurred as variable lease cost.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes its incremental borrowing rate by lease term in order to calculate the present value of its future lease payments when the implicit rates in the leases agreements are not readily determinable. The discount rate represents a risk-adjusted rate on a secured basis and is the rate at which the Company would borrow funds to satisfy the scheduled lease liability payment streams commensurate with the lease term.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs represent fixed lease payments recognized on a straight-line basis over the lease term. Operating lease costs include an immaterial amount of variable lease costs and are recorded in cost of revenue, general and administrative, sales and marketing, and R&amp;D expenses (depending on the nature of the leased asset) in the Consolidated Statements of Operations.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDc_0b89b8b7-98f3-4dae-8252-6546250213ee" continuedAt="ia7ce99f3b9f1497e84321c21f80278c3" escape="true">Intangible Assets, net</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia7ce99f3b9f1497e84321c21f80278c3">Intangible assets with determinable useful lives are recorded initially at acquired fair value or cost, less accumulated amortization. Each intangible asset with a determinable useful life is amortized over its estimated useful life using the straight-line method. The Company periodically reviews the estimated pattern in which the economic benefits will be consumed and adjusts the amortization period and pattern to match the estimate. Intangible assets with indefinite useful lives are recorded initially at fair value or cost and are tested annually for impairment or more frequently if management believes indicators of impairment exist.</ix:continuation> For the years ended December 31, 2021, 2020, and 2019, <ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTUwNDk_2df870e2-302a-4532-9fce-949c8bd17bc7"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTUwNDk_8f193cb6-e94e-41e4-9bbb-f40fa703377d"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTUwNDk_cb762ee9-d1f9-4e47-8d27-0ea114bd37fd">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses related to intangible assets with indefinite useful lives were recorded.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company&#8217;s intangible assets were comprised of customer relationships, trade names and trademarks, marketing assets, and developed technology. At December 31, 2020, the Company&#8217;s intangible assets were comprised of customer relationships and trademarks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDU_8078cd1b-e31b-4c9a-bed5-dc4d84a4f388" continuedAt="iedc665f5ec4e456c8d220ad5ded7aafe" escape="true">Goodwill</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iedc665f5ec4e456c8d220ad5ded7aafe">The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#8217;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#8217; data.</ix:continuation> For the years ended December 31, 2021, 2020, and 2019, the Company&#8217;s evaluation of goodwill resulted in no impairment losses. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjA_7f557173-806d-406b-bed2-11fd42bce90a" continuedAt="i14d91021eb854ebc898e2a5aecb7a57e" escape="true">Recoverability and Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i14d91021eb854ebc898e2a5aecb7a57e">The Company reviews the recoverability of its long-lived assets (including definite-lived intangible assets) if events or changes in circumstances indicate the assets may be impaired. Evaluation of possible impairment is based on the Company&#8217;s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value to the carrying amount of the asset.</ix:continuation>&#160;For the years ended December 31, 2021, 2020, and 2019, <ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTc0MzM_9acd79ff-743b-4f35-8d86-4703a56a24d4"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTc0MzM_a1e83a4c-4c29-4183-abda-f9a4ed8029be"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTc0MzM_f7664fbe-aea4-4a8e-8852-27f4f505904f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses were recognized related to long-lived assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingencies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU4MDM5OA_05cebf55-4258-4f54-8c2c-e6658151badc" escape="true">We accrue contingent losses when estimated impacts of various conditions, situations or circumstances involve uncertain outcomes. Contingent losses are recorded based on management judgment along with internal and external advice from legal counsel and/or technical consultants. Estimated losses from contingencies are recorded when both of the following conditions are met: (i) information available before the financial statements are issued (or available to be issued) indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) the amount of loss can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, that amount shall be accrued. When no amount within the range is a better estimate than any other amount, however, the minimum amount in the range shall be accrued. Please refer to Note 17. Commitments and Contingencies, for further discussion.</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ieff080a4c3bf44918af89074442c83a6" continuedAt="i0a2f2be2a077427482efba95b4eab199"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDI_c29a5557-8cc4-4924-b95d-86be89d63f3a" continuedAt="i40438890a6a04b81888eb54323562381" escape="true">Debt Issuance Costs</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i40438890a6a04b81888eb54323562381">Debt issuance costs related to convertible senior notes are recorded as deductions that net against the principal value of the debt and are amortized as interest expense over the life of the debt using the effective interest method. Debt issuance costs related to term loans are recorded as direct deductions from the carrying amount of the term loan and are amortized to interest expense over the life of the debt using the effective interest method.&#160;Debt issuance costs relating to line of credit arrangements are recorded as assets and amortized over the term of the credit arrangement regardless of whether any outstanding borrowing existed. The term loan and line of credit were terminated in 2020 and all debt issuance costs were expensed accordingly.</ix:continuation> Please refer to Note 9. Debt, for further information on debt issuance costs.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE2OTk_4c650d77-f9c3-4043-8011-e59b76557027" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Stock-based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures compensation expense for stock-based awards to employees, non-employee contracted physicians, and directors based upon the awards&#8217; initial grant-date fair values.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2021 the Company estimated the fair value of stock options using a trinomial lattice model. On January 1, 2021, the Company began applying the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) on a prospective basis to new awards. The Company expects the use of Black-Scholes to provide a more ubiquitous estimate of fair value. Like the prior trinomial lattice model, Black-Scholes is affected by the stock price on the date of the grant as well as assumptions regarding a number of highly complex and subjective variables. These variables include the expected term of the option, expected risk-free interest rate, the expected volatility of common stock, and expected dividend yield; each of which is described below. The assumptions for expected term and expected volatility are the two assumptions that significantly affect the grant date fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term: The expected term of an option is determined using the simplified method under SAB 107 which represents the average between the vesting term and the contractual term. The Company utilizes the simplified method to determine the expected life of the options due to insufficient exercise activity during recent years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free Interest Rate: The risk-free interest rate used in the Black-Scholes model is based on the implied yield at the grant date of the U.S. Treasury zero-coupon issue with an equivalent term to the stock-based award being valued. Where the expected term of a stock-based award does not correspond with the term for which a zero coupon interest rate is quoted, the Company uses the nearest interest rate from available maturities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Stock Price Volatility: The Company uses its own historical weekly volatility because that is more reflective of market conditions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend Yield: Because the Company has never paid a dividend and does not expect to begin doing so in the foreseeable future, the Company assumed no dividend yield in valuing the stock-based awards.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDA_0bb8ceb7-373f-45dd-8db7-86d7419ca805" continuedAt="idaabf5b183414c5e8a6e66dc6e3e8139" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent. The performance obligation is satisfied and revenues are recognized at the point in time the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDY_198c1d11-439a-4eb8-a109-2ef2108d092d">Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay patients and within 60 to 90 days of billing for client payers.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharma Services segment generally enters into contracts with pharmaceutical and biotech customers as well as other Clinical Research Organizations (&#8220;CROs&#8221;) to provide research and clinical trial services ranging in duration from one month to several years. The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is recognized over time based on the </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i0a2f2be2a077427482efba95b4eab199" continuedAt="i4bad895141404f37ab7202e36153df19"><ix:continuation id="idaabf5b183414c5e8a6e66dc6e3e8139"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to sponsors at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics provides de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected for services provided in advance of revenue being recognized are deferred as contract liabilities. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently recognized. Contract assets are established for revenue that has been recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding account receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and are amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets and all others are classified as non-current assets. Contract assets are included in other current assets and other assets on the Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDM_5efa417e-cc3b-4ecd-a813-0471d81a06cf" continuedAt="i1a56e355b9eb45b28a0483749960f99b" escape="true">Cost of Revenue</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1a56e355b9eb45b28a0483749960f99b">Cost of revenue includes payroll and payroll related costs for performing tests, project management, depreciation of laboratory equipment and laboratory leasehold improvements, rent for laboratory facilities, laboratory reagents, probes and supplies, delivery and courier costs relating to the transportation of specimens to be tested, and amortization for acquired Inivata developed technology intangible assets. The expenses related to shipping specimens to the facilities for testing, includes costs incurred for contract couriers, commercial airline flights, and courier charges. The Company also incurs expenses returning samples and slides to its customers.</ix:continuation>&#160;For the years ended December 31, 2021, 2020, and 2019, the Company recorded shipping expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i254845f3a44141fc942661d21925077a_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMjYwNjA_fcce48a9-457a-41c7-b07c-5f49045c6575">16.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3530310efa1a411da896298ef26d7531_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMjYwNjQ_40f715a5-07da-4a76-8f91-005c5a93a02c">13.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ib644839f440545ae8408c532800708e6_D20190101-20191231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMjYwNzE_96403c0b-9b74-4fd1-93e6-7f157e11c3c4">14.2</ix:nonFraction> million, respectively as Cost of revenue in the Consolidated Statements of Operations.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTk_63bbf187-3830-4cd4-ba90-8fb44b3a5c1f" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of payroll and payroll related costs for the Company&#8217;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTc_72bbee32-6a97-4ebc-8a76-7f6e3f2857f5" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred. R&amp;D expenses consist of payroll and payroll related costs, laboratory supplies, depreciation of laboratory equipment, and costs for samples to complete validation studies. These expenses are primarily incurred to develop new genetic tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and are deemed immaterial for the years ended December 31, 2021, 2020 and 2019.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:RegulatoryIncomeTaxesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjE_b2e9fc8d-91b8-480d-9023-94952f96a2bb" continuedAt="i1364eeb00526415080cdc078735e6e68" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i4bad895141404f37ab7202e36153df19" continuedAt="ief299bf2f51443698d0c0165982b01b6"><ix:continuation id="i1364eeb00526415080cdc078735e6e68"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods and lives for property and equipment, recognition of bad debts, compensation related expenses, and various other expenses that have been allowed for or accrued for financial statement purposes but are not currently deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations, and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company evaluates tax positions that have been taken or are expected to be taken in its tax returns and records a liability for uncertain tax positions, if deemed necessary. The Company follows a two-step approach to recognizing and measuring uncertain tax positions. First, tax positions are recognized if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon examination, including resolution of related appeals or litigation processes, if any. Second, the tax position is measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes on the Consolidated Balance Sheets. At December 31, 2021 and 2020, the Company has an uncertain tax position related to Federal and State R&amp;D tax credits, including a provision for interest and penalties related to such position as applicable. The Company does not expect a significant change in its uncertain tax positions in the next 12 months.</span></div></ix:continuation><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDQ_b1a2d74d-63d5-4210-a925-c51af36e9118" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Net (Loss) Income per Common Share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic net (loss) income per share attributable to common stockholders by dividing net (loss) income by the weighted-average number of shares of common stock outstanding for the period. Diluted net (loss) income per share is computed using the weighted average number of common shares outstanding during the applicable period, plus the dilutive effect of potential common stock. Potential common stock consists of shares issuable pursuant to stock options and convertible notes, as well as non-vested restricted stock awards which are not considered outstanding with respect to the weighted average common shares outstanding in the calculation of basic net (loss) income per share. Potentially dilutive shares are determined by applying the treasury stock method to the Company&#8217;s outstanding stock options and restricted stock awards. Potentially dilutive shares issuable upon conversion of the <ix:nonFraction unitRef="rate" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDAzNQ_8e3cbf4e-7c14-4408-8509-dfb225d0f239">0.25</ix:nonFraction>% Convertible Senior Notes due 2028 and the <ix:nonFraction unitRef="number" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzExODA_5ee97888-b995-4659-839a-b69bfd456c72">1.25</ix:nonFraction>% Convertible Senior Notes due 2025 are calculated using the if-converted method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDg_5009c4a0-3853-4b80-a841-248492fd1d40" continuedAt="i878b269386ff40edaa4ca1c80040ea84" escape="true"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the FASB issued ASU No. 2021-06, Presentation of Financial Statements (Topic 205), Financial Services-Depository and Lending (Topic 942), and Financial Services-Investment Companies (Topic 946) (&#8220;ASU 2021-06&#8221;), Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10786, Amendments to Financial Disclosures About Acquired and Disposed Businesses, and No.33-10835, Update of Statistical Disclosures for Bank and Savings and Loan Registrants. This update amends certain SEC disclosure guidance that is included in the accounting standards codification to reflect the SEC&#8217;s recent issuance of rules intended to modernize and streamline disclosure requirements. The Company adopted this pronouncement upon issuance and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements, which updates various codification topics by clarifying disclosure requirements to align with the SEC&#8217;s regulations. The Company adopted this pronouncement on January 1, 2021 and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt&#8201;-&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;-&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8201;-&#8201;Accounting For Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible instruments by removing the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such convertible debt instruments. Similarly, the debt discount, that is equal to the carrying value of the embedded conversion feature upon issuance, will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible instrument was issued at a substantial premium. In addition, ASU 2020-06 requires the application of the if-converted method for calculating the impact of convertible instruments on diluted earnings </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ief299bf2f51443698d0c0165982b01b6"><ix:continuation id="i878b269386ff40edaa4ca1c80040ea84"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. ASU 2020-06 can be adopted on either a fully retrospective or modified retrospective basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2020-06 on January 1, 2021 using the modified retrospective approach, and, accordingly, the Company recorded an adjustment that reflects the <ix:nonFraction unitRef="number" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA0Mg_165cc6ee-68ae-4b60-b5ef-ecf93e2bfea4">1.25</ix:nonFraction>% Convertible Senior Notes due 2025 as if the embedded conversion feature had not been separated. The impact upon adoption on the Consolidated Balance Sheets included an increase of approximately $<ix:nonFraction unitRef="usd" contextRef="i0d57451dc3554d079ea8b73a036cab7f_I20210101" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA0OQ_4a337db4-b2f0-4db6-a133-2b021459702c">27.2</ix:nonFraction>&#160;million in convertible senior notes, net, a write-off of approximately $<ix:nonFraction unitRef="usd" contextRef="i0d57451dc3554d079ea8b73a036cab7f_I20210101" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDEwNQ_6fb0b885-78d0-4db5-9dea-974b08ba3c7a">6.6</ix:nonFraction>&#160;million in deferred income tax liabilities, establishment of approximately $<ix:nonFraction unitRef="usd" contextRef="i0d57451dc3554d079ea8b73a036cab7f_I20210101" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA2NA_fe6372d9-e877-4a3a-a1f0-0fe24ba60913">2.0</ix:nonFraction>&#160;million of valuation allowance against deferred income tax assets, and a decrease of approximately $<ix:nonFraction unitRef="usd" contextRef="i83026cc4bc5d41b4ad74488ad2199f77_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA3Ng_94d58871-f5d3-4299-a4ac-d666ebae9d55">23.3</ix:nonFraction>&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment to increase the beginning balance of retained earnings on the Consolidated Balance Sheets for previously recognized interest expense, net of tax effects, of approximately $<ix:nonFraction unitRef="usd" contextRef="i703a879602c940af8370fab4717a800c_I20210101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA5MQ_415fbdff-fb69-402a-bafc-7c040243d681">2.7</ix:nonFraction>&#160;million for amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance, as well as a decrease to the beginning balance of retained earnings of approximately $<ix:nonFraction unitRef="usd" contextRef="i0d57451dc3554d079ea8b73a036cab7f_I20210101" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDEyNg_a1760171-0a8f-4f32-ae0d-b57cc0b895ac">2.0</ix:nonFraction>&#160;million for the establishment of valuation allowance against the Company&#8217;s deferred income tax assets. There was no impact to the Company&#8217;s earnings per share calculation. For further information regarding the <ix:nonFraction unitRef="number" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDExOQ_dde437b4-f13b-421b-90db-305b437e9f6d">1.25</ix:nonFraction>% Convertible Senior Notes due 2025, please refer to Note 9. Debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance (&#8220;ASU 2021-10&#8221;). This update requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this pronouncement on January 1, 2022, and is currently evaluating the impact of this standard on its annual disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#8220;ASU 2021-08&#8221;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the planned adoption date and the impact of this standard on its Consolidated Financial Statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (&#8220;ASU 2020-04&#8221;) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (&#8220;LIBOR&#8221;) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) (&#8220;ASU 2021-01&#8221;) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of December 31, 2021, there was no impact to the Company&#8217;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_97"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTk2Mw_fc866e1f-a738-4213-a472-771297c08201" continuedAt="iab1c387490dd4c558d2ffef1e6db4d09" escape="true">Acquisitions </ix:nonNumeric></span></div><ix:continuation id="iab1c387490dd4c558d2ffef1e6db4d09" continuedAt="ia7e81b3c95db49aa94b3904dbd88515e"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Trapelo Health</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2021 (the &#8220;Trapelo Acquisition Date&#8221;), the Company completed the acquisition of a <ix:nonFraction unitRef="number" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg0Nw_441ea546-34af-4eef-abb2-4312c638daa1">100</ix:nonFraction>% ownership interest in Intervention Insights, Inc. d/b/a Trapelo Health (&#8220;Trapelo&#8221;), an information technology company focused on precision oncology. The purchase price consisted of (i) cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NjgzMg_2fb68294-21f0-4277-a995-1e2248704af2">35.6</ix:nonFraction>&#160;million, which included a net adjustment of $<ix:nonFraction unitRef="usd" contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407" decimals="-5" name="neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg5Mw_0067be10-f44e-4265-829a-f442f4ad656f">0.6</ix:nonFraction>&#160;million for estimated cash on hand of Trapelo and estimated working capital adjustments on the Trapelo Acquisition Date, and (ii) equity consideration of $<ix:nonFraction unitRef="usd" contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg1Mw_c20e8894-1c2c-4538-b342-e63b0b1da763">29.2</ix:nonFraction>&#160;million, consisting of <ix:nonFraction unitRef="shares" contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg2OA_66701302-1bac-4957-90ad-556b573d12fe">597,712</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg4NQ_cf4fbfa3-8204-4562-a09a-93d8e8594213">0.001</ix:nonFraction> per share, valued at $<ix:nonFraction unitRef="usdPerShare" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg3Nw_2f264074-9b2d-4323-9d2d-152cf10cef22">48.81</ix:nonFraction> per share. The Company acquired control of Trapelo on the Trapelo Acquisition Date; therefore, the fair value of the common stock issued as part of consideration was determined on the basis of the closing market price of the Company&#8217;s common stock immediately prior to the Trapelo Acquisition Date. The Trapelo acquisition enhances the Company&#8217;s ability to provide customers clinical decision support to help answer complex questions related to precision oncology biomarker testing and treatment options as part of the Company&#8217;s comprehensive oncology offerings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Trapelo was determined to be a business combination and has been accounted for using the acquisition method. The purchase price and purchase price allocation are preliminary, are based upon management&#8217;s best estimates and assumptions, and are subject to future revision. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTk2NA_fcabd832-7d2f-4dfe-92fb-bf3ff088a53a" continuedAt="i038221d7ba644f97a2ede3b2b8d15c4c" escape="true">The following table summarizes the estimated purchase consideration recorded for the acquisition of Trapelo, the estimated fair value of the net assets acquired and liabilities assumed, and the preliminary calculation of goodwill based on the excess of the estimated consideration transferred over the estimated fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i038221d7ba644f97a2ede3b2b8d15c4c" continuedAt="i58db29d7f06044f2af7141d67babd917"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.851%"><tr><td style="width:1.0%"></td><td style="width:74.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued as consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMi0yLTEtMS00NDI2OQ_452875a7-a624-4ab6-903f-663d76af09c6">597,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share value of common stock issued as consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMy0yLTEtMS00NDI2OQ_ce647117-51aa-4f4e-b80f-b251c3adcb1f">48.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of common stock at Trapelo Acquisition Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfNC0yLTEtMS00NDI2OQ_93bb1757-efc4-4cab-82a8-142dadfd7f62">29,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Cash paid at closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfNS0yLTEtMS00NDI2OQ_ce54131a-23ac-4f29-88c8-5b87af297f6c">35,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfNi0yLTEtMS00NDI2OQ_843c8731-ac32-49fd-92ac-e87316f87490">64,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of the purchase consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfOS0yLTEtMS00NDI2OQ_6d69b8aa-6f5f-42c3-85f1-62a0a499589d">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTAtMi0xLTEtNDQyNjk_edfb843b-a9c9-4b53-9e04-f30d03aade20">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - marketing assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8259a282355a443fa5a631a8aff168d8_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTEtMi0xLTEtNDQyNjk_878d9c11-cc9f-4c8a-b016-d60beab20e65">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie972fa406763417d8f2c25acd458f794_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTItMi0xLTEtNDQyNjk_26302607-bb21-4bf3-8bcc-ed313ed5fc30">19,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTMtMi0xLTEtNDQyNjk_d383f634-73f9-4dde-831b-780047d3babc">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTQtMi0xLTEtNDQyNjk_ed5e4e53-5135-4ec0-bb49-f428310e435c">20,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTUtMi0xLTEtNDQyNjk_a287727c-0da7-481b-8562-bee8fc6e7ce3">751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTYtMi0xLTEtNDQyNjk_c97f2155-6655-48a8-924b-19351167064b">20,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTctMi0xLTEtNDQyNjk_2e34e35d-da97-4d06-b226-127d363639a2">44,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTgtMi0xLTEtNDQyNjk_d2851a4c-4774-43cf-82ae-f3c00a299228">64,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the timing of the acquisition, the following are considered preliminary and are subject to change:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amount of goodwill pending the completion of the amounts for income tax assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will finalize these amounts no later than one year from the acquisition date once it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in adjustments to the preliminary amounts disclosed above which may impact the reported results in the period those adjustments are identified. There have been no such adjustments to the preliminary amounts disclosed above subsequent to the Trapelo Acquisition Date through December 31, 2021.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia7e81b3c95db49aa94b3904dbd88515e" continuedAt="iba069ea541d14aeb959720d6b4706f01"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identified developed technology and marketing intangible assets are being amortized over <ix:nonNumeric contextRef="i58e1304c1c784732a549e74c73206cf7_D20210407-20210407" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njk1MQ_138bb283-2a82-42ac-83dc-bea15b8323d1">ten years</ix:nonNumeric> and <ix:nonNumeric contextRef="i3b120b1a036d4eb488cfbc0aaf1ae278_D20210407-20210407" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njk3MQ_6ff66356-b9b4-4c1c-a920-30e99b71849b">four years</ix:nonNumeric>, respectively, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Trapelo acquisition is <ix:nonNumeric contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NjkyNw_18d0a52c-8aff-41dd-b887-35f2051ea81c">9.8</ix:nonNumeric> years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The marketing intangible assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the marketing intangible assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the marketing intangible assets had the intangible assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#8217;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized, all of which is assigned to the Clinical Services segment, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. <ix:nonFraction unitRef="usd" contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njk4MA_afd78d51-d279-4444-b2fb-fdc68d6b5bf9">No</ix:nonFraction>ne of the goodwill resulting from the acquisition of Trapelo is expected to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and integration costs related to Trapelo were approximately $<ix:nonFraction unitRef="usd" contextRef="i1f7ed50e5ea746629e2bf83cd1f470c3_D20210101-20211231" decimals="-5" name="neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMzI5ODUzNDkyOTIyMg_67ae8e09-6fde-4569-9404-dd87dfd518dc">1.8</ix:nonFraction>&#160;million for the year ended December 31, 2021 and are reported as general and administrative expenses in the Company&#8217;s Consolidated Statements of Operations. There were <ix:nonFraction unitRef="usd" contextRef="ide651db4d96d4bcdb658a4ec18230410_D20200101-20201231" decimals="-5" name="neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAwMw_50642599-0246-429a-a57d-e5219775467d"><ix:nonFraction unitRef="usd" contextRef="ib5dd1dfb285c4701b75adf82d4eff717_D20190101-20191231" decimals="-5" name="neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAwMw_880abd45-6160-410a-b5d2-fbaf56a8d4ea">no</ix:nonFraction></ix:nonFraction> such amounts recorded for the years ended December 31, 2020 and 2019. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of Trapelo are included in the Company&#8217;s Consolidated Financial Statements beginning on the Trapelo Acquisition Date. Revenue and net (loss) income of Trapelo included in the Consolidated Statements of Operations was not material for the period from the Trapelo Acquisition Date to December 31, 2021. No pro forma information has been included relating to the Trapelo acquisition, as this acquisition was not deemed to be material to the Company&#8217;s revenue or net (loss) income on a pro forma basis for the period from the Trapelo Acquisition Date to December 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Inivata Limited</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021 (the &#8220;Inivata Acquisition Date&#8221;), the Company completed the acquisition of the remaining equity interests in Inivata Limited, a private limited company incorporated in England and Wales (&#8220;Inivata&#8221;). Inivata is a global, commercial stage, liquid biopsy platform company. The acquisition follows a $<ix:nonFraction unitRef="usd" contextRef="i50f0b20cb9b84704a2839897bfab2b29_I20200531" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAwOA_57d47251-2b1a-4229-a18a-ef954b804cf4">25.0</ix:nonFraction>&#160;million minority equity investment by the Company in Series C1 Preference Shares (the &#8220;Preference Shares&#8221; or &#8220;previously-held equity interest&#8221;) in Inivata in May 2020, at which time the Company also acquired a fixed price option to purchase the remainder of equity interests in Inivata for $<ix:nonFraction unitRef="usd" contextRef="i3f4da2d058964b75bd9d1986bbd5843b_D20210618-20210618" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAyMQ_cac913d9-0e9b-4316-acd1-4902e4e451d4">390.0</ix:nonFraction>&#160;million (the &#8220;Purchase Option&#8221;). The Company and Inivata also entered into a line of credit agreement in the amount of $<ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAzNQ_82abe24d-6f51-45b0-aa93-0ae5eccdfce0">15.0</ix:nonFraction>&#160;million (the &#8220;Line of Credit&#8221;) in May 2020. For further details regarding the previously-held equity investment in Inivata, the Purchase Option and the Line of Credit, please refer to Note 8. Investment in Non-Consolidated Affiliate. The Inivata acquisition adds liquid biopsy platform technology, including minimal residual disease testing capabilities, to the Company&#8217;s comprehensive portfolio of oncology testing solutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price consisted of cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzA0OA_ecac454e-c557-47e0-b9fa-25cb334b5109">398.6</ix:nonFraction>&#160;million, which included a net adjustment of $<ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-5" name="neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzA2NA_7dc88bec-4273-4bf3-93a7-44b87352170f">8.6</ix:nonFraction>&#160;million for estimated cash on hand of Inivata and other adjustments on the Inivata Acquisition Date, and was funded through cash on hand and a private placement of equity. For further information regarding the private placement of equity, please refer to Note 11. Equity Transactions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the acquisition of the remaining equity interests in Inivata, the Company accounted for its previously-held equity interest and the Purchase Option in Inivata as equity securities without a readily determinable fair value. The equity interests were recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Therefore, the Company&#8217;s acquisition of control of Inivata on the Inivata Acquisition Date was accounted for as a business combination achieved in stages under the acquisition method. Accordingly, the Company used a discounted cash flow to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#8217;s previously-held equity interest and Purchase Option in Inivata. To determine the fair value of the previously-held equity interest, the fair value of Inivata&#8217;s total equity was allocated to its various classes of equity based on the respective rights and privileges of each class of stock in liquidation. The business enterprise value and a Black-Scholes model were then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at the fair value at the Inivata Acquisition Date based on its settlement value. This resulted in fair values of $<ix:nonFraction unitRef="usd" contextRef="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzA3OA_1ae54e1a-2cf8-409d-b6bd-ecc2f333264b">64.9</ix:nonFraction>&#160;million in Preference Shares and a $<ix:nonFraction unitRef="usd" contextRef="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930" decimals="-5" name="neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzA5Mw_33d06b9d-f58e-4fa6-882f-d429553c15d3">74.3</ix:nonFraction>&#160;million Purchase Option, immediately prior to the acquisition. On the Inivata Acquisition Date, the $<ix:nonFraction unitRef="usd" contextRef="if0bf694fe7e54138828b3af7f759dc6b_I20210618" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzEwOA_a330593d-40c7-4258-988c-b2006a14bc10">10.3</ix:nonFraction>&#160;million outstanding under the Line of Credit extended by the Company to Inivata was effectively settled as part of the acquisition of Inivata at the $<ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzEyMw_a85750b7-6063-4837-83d9-781d798e4670">15.0</ix:nonFraction>&#160;million principal amount and was recorded as part of the consideration transferred in the acquisition. The Company recorded a gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#8217;s Consolidated </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iba069ea541d14aeb959720d6b4706f01" continuedAt="i2c5e1e1a9be247858952dec4b21b9652"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statements of Operations of $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzE1MQ_f6699c86-7681-4ce1-9232-f92d3a3c765e">109.3</ix:nonFraction>&#160;million for the year ended December 31, 2021, including a measurement period adjustment of $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzEzNg_59753004-1aa3-4c80-a256-697dedf71916">17.8</ix:nonFraction>&#160;million recorded for the year ended December 31, 2021, for the excess of the acquisition-date fair value of the Company&#8217;s previously-held equity interest, Purchase Option, and Line of Credit over their carrying values. For further details regarding the previously-held equity investment and purchase option in Inivata, please refer to Note 8. Investment in Non-Consolidated Affiliate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and allocation of the business combination are preliminary, are based upon management&#8217;s best estimates and assumptions, and are subject to future revision. <ix:continuation id="i58db29d7f06044f2af7141d67babd917" continuedAt="ie974ca701f614f55a1c669329b2fdb08">The following table summarizes the preliminary calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit and the estimated fair value of the previously-held equity interest and Purchase Option over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):</ix:continuation></span></div><ix:continuation id="ie974ca701f614f55a1c669329b2fdb08"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 18, 2021<br/>(as initially reported)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 18, 2021 <br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMi0yLTEtMS00NDQ3Mg_91748e51-00b9-4c35-8378-13efb9e9a424">398,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMi02LTEtMS00NDQ3Mg_d0e83326-ae64-4ea9-a52b-883e5f72a603">398,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Line of Credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMy0yLTEtMS00NDQ3Mg_08e2a83e-7f47-4370-a55e-83b24be7a765">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMy02LTEtMS00NDQ3Mg_d60b4bc1-7c7f-492d-827b-71bebbe2da4a">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNC0yLTEtMS00NDQ3Mg_0ebae49c-989c-4ceb-b01b-2e382897ded9">413,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNC02LTEtMS00NDQ3Mg_9f15879d-1993-437a-ab5e-75baf89ed789">413,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously-held equity interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNS0yLTEtMS00NDQ3Mg_7f2b6928-0c92-4653-bfb0-12f8bfdf6d34">62,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNS00LTEtMS00NDQ3Mg_c1479d04-4fc5-4112-8e9d-4755e8f00164">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNS02LTEtMS00NDQ3Mg_fab585bc-7f19-4811-800e-fa1300cef2a9">64,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Purchase Option</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNi0yLTEtMS00NDQ3Mg_10b928f2-d913-40eb-b28d-2a4fcbd32468">58,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNi00LTEtMS00NDQ3Mg_361978e3-da30-40bc-9cfc-3e8165adacab">15,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNi02LTEtMS00NDQ3Mg_b9c09994-9399-4a57-ad34-f8d4e97f4430">74,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNy0yLTEtMS00NDQ3Mg_c0317f2a-2506-4c3c-a6ff-fce0bf42be18">535,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNy00LTEtMS00NDQ3Mg_8f3df1e8-1d30-4fa1-b7a3-fc4702e8c516">17,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNy02LTEtMS00NDQ3Mg_70c504ac-e95a-468c-bbfb-372fd16b04e9">552,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of the fair value business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTAtMi0xLTEtNDQ0NzI_03d8cb73-9bf8-4253-b275-2cfcf1ec51fb">14,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTAtNi0xLTEtNDQ0NzI_08d310ec-9f16-4281-91f8-fac4a7630bc3">14,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTEtMi0xLTEtNDQ0NzI_46eb49bf-381e-428a-82be-ee4a4e8af9ac">5,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTEtNC0xLTEtNDQ0NzI_f545221e-0acd-4327-825c-f3523c4b1db8">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTEtNi0xLTEtNDQ0NzI_f64b894e-5a2c-4b0e-a62b-5487bb0382a7">5,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTItMi0xLTEtNDQ0NzI_1c8e5516-b395-4333-8abe-a0051767cd06">1,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTItNi0xLTEtNDQ0NzI_0de12679-1a34-4b27-baf9-bbdb428443fa">1,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets - developed technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic894cd7e3581485ea84cafa3847d68c3_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTMtMi0xLTEtNDQ0NzI_a125db50-d50d-464e-9402-349e8f9aee2c">302,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53250a94560e4680a9724632efeb9b7b_D20210618-20210618" decimals="-3" sign="-" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTMtNC0xLTEtNDQ0NzI_f1debad7-9668-4086-927c-e8df3af35917">11,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09d7da96f3244a2ca7446eb12f52373a_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTMtNi0xLTEtNDQ0NzI_4fc1ff48-dff6-4662-91b7-3887af0a5b57">291,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets - trademarks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26e3bddf7f4f43deac1e105c9da91f6b_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTQtMi0xLTEtNDQ0NzI_6a3225bf-9deb-49a2-aa28-d7d5f20e48ab">31,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a298c3d0be247f28f61c6f6bc44daec_D20210618-20210618" decimals="-3" sign="-" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTQtNC0xLTEtNDQ0NzI_d860e95b-e6a4-466c-add5-318f6fa1df3d">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a906e75b19e4b31bb630f84fb76671b_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTQtNi0xLTEtNDQ0NzI_0b6149ed-c382-4e05-8780-6cfcf34d956e">31,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - trade name</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i241e751eb6ae41b0a89e6a8d1860ded0_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTUtMi0xLTEtNDQ0NzI_0be59029-c599-404a-9625-3b50d9278247">2,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa897a9364d4ba0bb0ed58d1af8a907_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTUtNC0xLTEtNDQ0NzI_8b9520fc-fd62-4af8-86ba-8427e9bbe5ba">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if693f0a2a745494496eeae35fb96dea0_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTUtNi0xLTEtNDQ0NzI_6f24eb76-5ad9-4955-86f0-7501a3f510c1">2,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTYtMi0xLTEtNDQ0NzI_9d006b31-b0ce-420c-ba91-e3caeb74103c">6,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTYtNi0xLTEtNDQ0NzI_9e3659bf-5a98-432a-83a1-8e0e02460154">6,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTctMi0xLTEtNDQ0NzI_185f7ee6-2a05-40a1-b0dc-b658fbd25f8e">364,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" sign="-" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTctNC0xLTEtNDQ0NzI_9d1e7ed6-a29e-4d10-945f-c123f77337e4">11,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTctNi0xLTEtNDQ0NzI_9c9eef69-7429-4667-bc0e-95f044f940f5">353,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTgtMi0xLTEtNDQ0NzI_0df5e3da-27d4-4fd8-bb58-ab7ed7323c2d">4,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" sign="-" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTgtNC0xLTEtNDQ0NzI_5806ef4a-ca5b-4b1b-91d4-241430919761">1,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTgtNi0xLTEtNDQ0NzI_fb164949-7566-4b8e-9576-58efde639433">5,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTktMi0xLTEtNDQ0NzI_d8e8dc1e-7efc-4979-85e4-ed92e9b5e877">64,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTktNC0xLTEtNDQ0NzI_78296606-33b1-4304-b8aa-c3bb09793308">3,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTktNi0xLTEtNDQ0NzI_8751112c-2646-4849-9918-65ee7ec77bee">60,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjAtMi0xLTEtNDQ0NzI_a81f5588-031a-4ba1-a86c-fcea75bbef15">4,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjAtNi0xLTEtNDQ0NzI_27162501-5532-436c-a8b5-649e882c1e7d">4,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjEtMi0xLTEtNDQ0NzI_5b0fb89d-6d96-40dd-bbaf-d7934f5e2eb3">290,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" sign="-" name="neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjEtNC0xLTEtNDQ0NzI_d9e8df82-807a-48e4-a36c-a496a3d9ccbc">9,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjEtNi0xLTEtNDQ0NzI_0cc8060d-cb8c-45e8-9763-d3710a14db19">281,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjItMi0xLTEtNDQ0NzI_b26bc431-a1e5-49d5-b260-11c541695021">244,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjItNC0xLTEtNDQ0NzI_6e5f60d1-d734-46de-9fff-1bef9015f853">27,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjItNi0xLTEtNDQ0NzI_04da9623-e7cc-4608-a860-abd8dba7a3e6">271,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjMtMi0xLTEtNDQ0NzI_b2009f77-be95-4eca-9af1-033d52c88ce8">535,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" decimals="-3" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjMtNC0xLTEtNDQ0NzI_55bf0025-f6c0-444e-a001-6f2d973de0aa">17,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjMtNi0xLTEtNDQ0NzI_d81e603e-5a0a-4231-ab88-f93315e4a70a">552,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to a change in legal settlement liabilities.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangible assets and related future amortization and the change in legal settlement liabilities.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the timing of the acquisition, the following are considered preliminary and are subject to change:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts for intangible assets, property and equipment, other current assets, current liabilities, and other long-term liabilities pending finalization of the valuation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts for income tax liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction;</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i2c5e1e1a9be247858952dec4b21b9652"><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed and the reporting unit allocation of the goodwill; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acquisition-date fair value of the Company&#8217;s previously-held equity interest, Purchase Option, and the Line of Credit, and the gain on investment in and loan receivable from non-consolidated affiliate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will finalize these amounts no later than one year from the acquisition date, once it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in adjustments to the preliminary amounts disclosed above which may impact the reported results in the period those adjustments are identified.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identified developed technology intangible assets and the trademark intangible assets are both being amortized over <ix:nonNumeric contextRef="ia6cc8a93c1f0462e8fac56d280a8d2fe_D20210618-20210618" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1Mzg3NA_8cb2a0de-d681-4e46-800c-caad91f740a6"><ix:nonNumeric contextRef="i41d155bca1e34d069f969cab67f80b2f_D20210618-20210618" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1Mzg3NA_ab7b7845-1978-4795-8eb5-802859f3ca4b">fifteen years</ix:nonNumeric></ix:nonNumeric>, and the trade name intangible asset is being amortized over <ix:nonNumeric contextRef="i8fa897a9364d4ba0bb0ed58d1af8a907_D20210618-20210618" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1Mzg5NA_6d3fc171-f5fa-4f5d-93ac-51abcf36b9e8">five years</ix:nonNumeric>, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Inivata acquisition is <ix:nonNumeric contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1MzkyMA_5d9009b3-6554-4581-a374-ec1807696f6c">14.9</ix:nonNumeric> years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The trademarks and trade name assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the trademarks and trade name assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the trademarks and trade name assets had the assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#8217;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized, of which $<ix:nonFraction unitRef="usd" contextRef="ic5d9574696644e1f9309d0cfefa33d29_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzYyOA_865742fa-3537-47df-ac75-dacdc553ca7e">238.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibb76b6a1b0eb453db2e735dd98b1f29f_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzY1NQ_61396f7b-f858-43cb-b9c0-40ddb707a86d">33.0</ix:nonFraction> million is assigned to the Clinical Services and Pharma Services segments, respectively, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of liquid biopsy technology for oncology testing. The recording of amortizable intangibles has given rise to a deferred tax liability upon the acquisition of Inivata which increased goodwill by $<ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzY4Ng_235aba77-0f6c-4306-8bd2-a716bd180202">61.0</ix:nonFraction> million. <ix:nonFraction unitRef="usd" contextRef="i60818069430f4235a500d9ef12d9797d_I20210618" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1Mzk4Mg_f5b5ce02-2613-4e7b-bb9c-026658365c9f">No</ix:nonFraction>ne of the goodwill resulting from the acquisition of Inivata is expected to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and integration costs related to Inivata were $-<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" sign="-" name="neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMzI5ODUzNDkyOTI0Ng_1114320e-c408-436e-bf8d-0bc7e1bac66c">13.9</ix:nonFraction>&#160;million for the year ended December 31, 2021 and are reported as general and administrative expenses in the Company&#8217;s Consolidated Statements of Operations. There were <ix:nonFraction unitRef="usd" contextRef="i71ca084f388f4e8697369585c4417521_D20200101-20201231" decimals="-5" name="neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDA5NQ_beac7252-a8d8-4e0f-b2d7-277a2a1a72cf"><ix:nonFraction unitRef="usd" contextRef="ie43d3909305b4bfa99fb106a2a366787_D20190101-20191231" decimals="-5" name="neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDA5NQ_e633c066-e21d-4bea-a807-74f6c5b30680">no</ix:nonFraction></ix:nonFraction> such amounts for the years ended December 31, 2020 and 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of the Company&#8217;s Inivata subsidiary are included in the Company&#8217;s Consolidated Financial Statements beginning on the Inivata Acquisition Date. For the period from the Inivata Acquisition Date to December 31, 2021, the Inivata subsidiary revenue was $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDAwMw_9cafa869-1ab4-4f51-9626-4b2613c194ea">1.5</ix:nonFraction>&#160;million, all of which was recorded in Pharma Services revenue. The Inivata subsidiary net loss was $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDAxNw_a50b3d6a-df0a-41a6-8f10-e15b95273763">27.6</ix:nonFraction>&#160;million for the period from the Inivata Acquisition Date to December 31, 2021.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDA5MA_1ff53a11-84f9-4071-b32d-5fa1c0a1c4e2" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.583%"><tr><td style="width:1.0%"></td><td style="width:47.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjFhNmMyNTg1OTBhMjQxZGNiMDdkZmEzOTcxOGI0NWRjL3RhYmxlcmFuZ2U6MWE2YzI1ODU5MGEyNDFkY2IwN2RmYTM5NzE4YjQ1ZGNfMi0yLTEtMS00NDY0NA_63a1067d-398c-4ac6-86ec-f7093c434276">484,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ca084f388f4e8697369585c4417521_D20200101-20201231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjFhNmMyNTg1OTBhMjQxZGNiMDdkZmEzOTcxOGI0NWRjL3RhYmxlcmFuZ2U6MWE2YzI1ODU5MGEyNDFkY2IwN2RmYTM5NzE4YjQ1ZGNfMi00LTEtMS00NDY0NA_0c2c1e71-0029-4290-a417-99aed4868cdf">444,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjFhNmMyNTg1OTBhMjQxZGNiMDdkZmEzOTcxOGI0NWRjL3RhYmxlcmFuZ2U6MWE2YzI1ODU5MGEyNDFkY2IwN2RmYTM5NzE4YjQ1ZGNfMy0yLTEtMS00NDY0NA_80611738-2e5b-4490-973c-0cd98c51838c">129,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71ca084f388f4e8697369585c4417521_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjFhNmMyNTg1OTBhMjQxZGNiMDdkZmEzOTcxOGI0NWRjL3RhYmxlcmFuZ2U6MWE2YzI1ODU5MGEyNDFkY2IwN2RmYTM5NzE4YjQ1ZGNfMy00LTEtMS00NDY0NA_af387b09-b12f-497b-b788-654216b9bbe2">65,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited pro forma results represent the combined results of operations of the Company and Inivata, on an unaudited pro forma basis, for the period in which the acquisition of Inivata occurred and the prior reporting period as though the companies had been combined as of the beginning of the earliest period presented. Therefore, the unaudited pro forma consolidated results have been prepared by adjusting the Company&#8217;s historical results to include the acquisition of Inivata as if it occurred on January 1, 2020. Acquisition-related transaction costs incurred by Inivata of $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMzI5ODUzNDkyOTIzMA_8a488566-3c4f-4889-90ed-6bef1e51f71a">11.0</ix:nonFraction>&#160;million are included in net loss as if incurred on January 1, 2020. Acquisition-related transaction and retention costs incurred by the Company of $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" sign="-" name="neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMzI5ODUzNDkyOTIzOA_1114320e-c408-436e-bf8d-0bc7e1bac66c">13.9</ix:nonFraction>&#160;million are included in net loss as if incurred on January 1, 2020. These unaudited pro forma consolidated historical results exclude $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDA2MA_019a4a7f-f1ca-4cd1-9833-f27dd743a98a">109.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i71ca084f388f4e8697369585c4417521_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ5MDUyNg_da7775fa-b66d-44c1-9034-7ae9ed6958a2">4.0</ix:nonFraction>&#160;million of gain on investment in and loan receivable from non-consolidated affiliate, net, recorded for the year ended December 31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfNDAzNQ_dc0e023b-e18a-4784-a340-ffe13492e7b4" continuedAt="i029ee6c4b36d45e7a8b05dc822d704e6" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i029ee6c4b36d45e7a8b05dc822d704e6" continuedAt="i97f0820d98e946939b83cebd03c3448b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.&#160;These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly.&#160;These are typically obtained from readily-available pricing sources for comparable instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs, where there is little or no market activity for the asset or liability.&#160;These inputs reflect the reporting entity&#8217;s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfNDAzNg_d82c20e4-7cdd-40f7-9b11-cdf9577cc9c8" continuedAt="i622a9b4974c446f68d96187db46e9eca" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses, and fair values of the Company&#8217;s marketable securities accounted for as available-for-sale securities as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNC0yLTEtMS0zMDU3Mg_4d0df595-3351-4c95-9325-d7d15f867878">52,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNC00LTEtMS0zMDU3Mg_2afb4d1e-c01f-4a56-8ba9-025525420bb2">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNC02LTEtMS0zMDU3Mg_b1f1485a-b80d-4a91-a899-39167a639537">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNC04LTEtMS0zMDU3Mg_d0bba0a4-3361-42b4-835e-4eee61c997d0">52,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6716adac8aa646019b124b8d827b9826_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS0yLTEtMS01NTIyNw_aba86d2e-cdaf-410d-ae9f-e0b7afdd99a4">6,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6716adac8aa646019b124b8d827b9826_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS00LTEtMS02MTY0MA_f256b934-3877-433b-9d6e-b12fbad2533d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6716adac8aa646019b124b8d827b9826_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS02LTEtMS02MTY0Nw_8ec1a23a-88a8-47f0-b7c5-2bbb329e2d8a">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6716adac8aa646019b124b8d827b9826_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS04LTEtMS02MTY0Nw_3ec15392-4f0a-4465-821d-706f396e742b">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi0yLTEtMS01NTIyNw_7e31a067-73f2-41ff-a848-b89e0d1681e8">17,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi00LTEtMS02MTY0MA_69861a40-a107-4a54-823b-9a13ad71a87e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi02LTEtMS02MTY0Nw_008e0823-d5a2-4e51-879d-29ed44d5f2dd">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi04LTEtMS02MTY0Nw_d3ec4d5e-636e-4e17-9c9a-641ff6321cc5">17,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS0yLTEtMS0zMDU3Mg_cd431e28-f704-40a1-b646-86682804b204">12,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS00LTEtMS0zMDU3Mg_5ca8369b-0b46-4709-8ef8-a62adcd23d03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS02LTEtMS0zMDU3Mg_a15130d0-72a6-4e72-b11d-f7b2099c7b9f">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS04LTEtMS0zMDU3Mg_c74c90d9-ced3-41eb-b0bc-4bbf8f0d9737">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi0yLTEtMS0zMDU3Mg_c3bf03bf-04ad-4dcf-8c9e-74a660c62c70">17,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi00LTEtMS0zMDU3Mg_80dde007-fa2f-4df1-8a25-0f88b541b658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi02LTEtMS0zMDU3Mg_7c021839-d2bf-45d6-acb6-b75bd711f50b">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi04LTEtMS0zMDU3Mg_b89fd4b0-120d-44dc-b5bb-a2a8ca14d559">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNy0yLTEtMS0zMDU3Mg_bb4af3f1-b64d-42f9-a005-5f3001de1a24">27,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNy00LTEtMS0zMDU3Mg_7c28e3cb-a33f-4b25-9018-3874fe5b4ff8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNy02LTEtMS0zMDU3Mg_97ca3d7c-dc36-416b-92a0-bbc4b580fe16">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNy04LTEtMS0zMDU3Mg_0951761b-58b1-4eff-b44b-14efe8b77ab1">27,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOC0yLTEtMS0zMDU3Mg_7241ad0f-b542-4f38-a329-7e9a5ebffed0">65,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOC00LTEtMS0zMDU3Mg_73e7116f-3e5d-4c26-8613-7a86ce50731c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOC02LTEtMS0zMDU3Mg_a2192750-7d57-4bf8-8cbd-d698ee41b2af">452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOC04LTEtMS0zMDU3Mg_530b569f-e193-4023-869b-dd48ddb752f1">64,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOS0yLTEtMS0zMDU3Mg_f6e0b1c8-9a67-4450-b704-ebd0d8b4648c">199,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOS00LTEtMS0zMDU3Mg_0c5c49b1-dc81-400d-b1a8-126e93a365aa">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOS02LTEtMS0zMDU3Mg_e972ee5b-be2f-4073-925e-4c596ddef8ac">923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOS04LTEtMS0zMDU3Mg_1360e07a-d77b-4332-bcb2-8f4407ca2d0f">198,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i97f0820d98e946939b83cebd03c3448b" continuedAt="iae9548bfc73f4d20bf124ad64785207c"><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i622a9b4974c446f68d96187db46e9eca"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNC0yLTEtMS00NDkyOQ_7f0b8531-a4a3-4a29-99c4-ed4b9bcb4625">21,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNC00LTEtMS00NDkyOQ_1eb8ba91-eb47-49cb-8347-85114ff9730d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNC02LTEtMS00NDkyOQ_c4d87949-cf4c-4a75-837c-bef4d1d0b66c">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNC04LTEtMS00NDkyOQ_af681bae-a15d-4a22-8285-8b9474821bf1">21,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia677c5c475564da488a50b112b59dccb_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNi0yLTEtMS00NDkyOQ_887b28f9-3874-40b7-a534-a6fbc0eda89b">14,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia677c5c475564da488a50b112b59dccb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNi00LTEtMS00NDkyOQ_571dbb12-b94d-462d-8d6a-13e69756d6ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia677c5c475564da488a50b112b59dccb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNi02LTEtMS00NDkyOQ_d388db97-61ef-43a1-b5b7-0aa641e69580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia677c5c475564da488a50b112b59dccb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNi04LTEtMS00NDkyOQ_dc0b83a8-5c6b-4b3b-bcb6-c7d08ec5a996">14,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNy0yLTEtMS00NDkyOQ_8f8e1672-9625-4675-873d-751c7b0ad9ae">14,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNy00LTEtMS00NDkyOQ_2c78f24f-5a36-43ef-aea7-913148be7048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNy02LTEtMS00NDkyOQ_c790c75a-4b2d-4686-bec5-ebee4ce8a7f4">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNy04LTEtMS00NDkyOQ_b1fcc47b-cb6a-44e7-a6e2-a0e38ebfbb7e">14,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOC0yLTEtMS00NDkyOQ_83c2a223-3935-427d-bc6e-b728e08e1c68">17,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOC00LTEtMS00NDkyOQ_4424b65f-466a-4f58-803e-7aceb8714968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOC02LTEtMS00NDkyOQ_98427967-03a0-48e3-a4a7-ec284526a932">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOC04LTEtMS00NDkyOQ_b142347c-aa80-4a39-8bd2-90184bcc287f">17,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOS0yLTEtMS00NDkyOQ_5d1c1d35-34cd-490a-a431-e870c5008bda">67,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOS00LTEtMS00NDkyOQ_2e44eeb9-7e7a-4cc6-b11d-91e9260bef00">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOS02LTEtMS00NDkyOQ_611932b9-91a6-4738-b9c4-b331690dd327">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOS04LTEtMS00NDkyOQ_e66f4e58-48c0-4cb1-a969-e5e6baea4188">67,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfMjc0ODc3OTA4NDAzOQ_aab5c51f-75ad-49d5-90c4-fa0b6c4160a0">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfMjc0ODc3OTA4NDAyMA_81a94423-a621-4e6f-94c8-1ff57d31ee30">0.2</ix:nonFraction> million of accrued interest receivable at December 31, 2021 and 2020, respectively, included in other assets on its Consolidated Balance Sheets related to its marketable securities. The amounts of realized gains and realized losses were immaterial for the years ended December 31, 2021 and 2020. There were no such amounts for the year ended December 31, 2019.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfNDAzNw_e13cd8be-ac2a-4a26-8821-cebe8262c820" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNC0yLTEtMS0zMDU3Mg_0d2394bc-7ebd-49f6-abcf-6755a9827451">22,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNC00LTEtMS0zMDU3Mg_3d63ddbe-0b29-4639-910a-647f17b08b0e">30,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNC02LTEtMS0zMDU3Mg_8f52c58a-d14e-4f89-a988-d54ccdd8ad24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNC04LTEtMS0zMDU3Mg_ca268fc1-904c-4b4c-8854-1b6701b56b41">52,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6716adac8aa646019b124b8d827b9826_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNS0yLTEtMS01NTM4OA_43434d2a-fdd3-435d-95c1-290e66ac9327">4,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6716adac8aa646019b124b8d827b9826_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNS00LTEtMS01NTM4OA_7dbf2057-117f-4a24-889d-f49c9a829978">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6716adac8aa646019b124b8d827b9826_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNS02LTEtMS01NTM4OA_45f99524-753f-45b5-87a0-052eb020ef5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6716adac8aa646019b124b8d827b9826_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNS04LTEtMS01NTM4OA_6349d7f3-63d4-4358-98aa-850a0a58ce35">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi0yLTEtMS01NTM4OA_8e11b4fc-f1b9-417b-8353-37639edbc327">14,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi00LTEtMS01NTM4OA_7e45085e-9985-4435-8d8f-603777f25853">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi02LTEtMS01NTM4OA_99e31c54-11af-4b10-b16f-016cbed48b97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi04LTEtMS01NTM4OA_3cb7d762-e4d5-4d30-a41a-a003e4e9be42">17,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy0yLTEtMS01NTM4OA_53407cbb-7be3-4eae-9b16-5b0de93ccc8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy00LTEtMS01NTM4OA_566456b3-ace4-4ff6-9531-7438d10d7d55">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy02LTEtMS01NTM4OA_71fb6c92-df54-47b6-9300-d2c9579102fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy04LTEtMS01NTM4OA_f0ea8a7b-f413-4780-b670-3599caddfca5">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi0yLTEtMS0zMDU3Mg_87902a19-2cd5-4d9a-a5a7-49214a6de487">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi00LTEtMS0zMDU3Mg_a573491c-0abd-44ed-ab9d-136e26558ed8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi02LTEtMS0zMDU3Mg_cda2bfb8-f333-4e55-a3b3-c3c89bba49ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi04LTEtMS0zMDU3Mg_12c8cc0f-28bb-4c6a-add5-96ab584a8e02">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy0yLTEtMS0zMDU3Mg_b44f8a76-6d39-48ab-8fa7-cf5e289e8fa5">20,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy00LTEtMS0zMDU3Mg_9fbeda79-6004-47d3-b305-2cc3c6ac38b2">6,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy02LTEtMS0zMDU3Mg_3c879067-d8d5-4814-bd1d-6532fdbf17dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy04LTEtMS0zMDU3Mg_7ecc23ac-9801-40c2-a3ae-d73838f4b4e7">27,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOC0yLTEtMS0zMDU3Mg_45c5cce2-5e8f-4972-84f6-caffdd3823f2">25,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOC00LTEtMS0zMDU3Mg_3ae6fc96-48c6-42d5-ad2b-d4110fa5e6ea">39,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOC02LTEtMS0zMDU3Mg_a3611c03-3ed7-405f-afcf-ab93da588224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOC04LTEtMS0zMDU3Mg_eb29e7ec-c474-47df-989d-765a4a1a3a10">64,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOS0yLTEtMS0zMDU3Mg_501d0256-42a2-4bcc-88a4-e019b8f1302f">104,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOS00LTEtMS0zMDU3Mg_93e26198-6315-4d1b-93b6-d9114cd2e737">93,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOS02LTEtMS0zMDU3Mg_beebfa6b-1bbf-4707-8903-a990fdfe76a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOS04LTEtMS0zMDU3Mg_98fb68d4-3a07-4970-8ed6-983be80ee650">198,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNC0yLTEtMS00NTAzNg_c85afa9f-755b-4970-a057-a914c84449ab">6,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNC00LTEtMS00NTAzNg_e7807991-f253-43df-a07b-5274d356b6c7">15,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNC02LTEtMS00NTAzNg_55bb275d-6b4e-44d0-8ddc-43f3f06598d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNC04LTEtMS00NTAzNg_21f626f2-9853-4219-915b-9abcef5b5c93">21,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia677c5c475564da488a50b112b59dccb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNi0yLTEtMS00NTAzNg_c0508af4-abc2-4757-9617-5353444eb9ce">14,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia677c5c475564da488a50b112b59dccb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNi00LTEtMS00NTAzNg_b3e4f6ac-6704-46e1-9a69-11a8d538466d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia677c5c475564da488a50b112b59dccb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNi02LTEtMS00NTAzNg_1b909dd5-368c-46c6-a982-f0e8c6996049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia677c5c475564da488a50b112b59dccb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNi04LTEtMS00NTAzNg_a720a401-7652-4c2b-aa24-18784e5a1a80">14,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNy0yLTEtMS00NTAzNg_a0766c74-5897-4355-ac8b-4f5bb0ad98af">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNy00LTEtMS00NTAzNg_a93d921c-6119-48c0-a2a2-1ed5490f80a4">13,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNy02LTEtMS00NTAzNg_aac70cb3-4bc0-4305-a669-4d0f973786e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNy04LTEtMS00NTAzNg_2b8b17ce-ee44-4bc4-b56f-6de131e16ccd">14,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOC0yLTEtMS00NTAzNg_ee696e3c-c3ee-43ad-8440-933e11df6c4a">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOC00LTEtMS00NTAzNg_2dfeef17-de3d-43c9-969b-5acf59adce35">11,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOC02LTEtMS00NTAzNg_d90309fa-677b-4f68-b2da-9c7909729c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOC04LTEtMS00NTAzNg_42068ddf-a13e-4bc0-b7cd-95a8dc1e4b70">17,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOS0yLTEtMS00NTAzNg_e5014502-963a-4778-86a7-645cfd926eaa">27,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOS00LTEtMS00NTAzNg_68768bbb-8785-497a-98c2-47f1c916dff9">40,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOS02LTEtMS00NTAzNg_9fa44164-2dad-4d7f-b704-bfabca58812f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOS04LTEtMS00NTAzNg_0a65d4db-f442-49ba-89e4-1ec78157e3f3">67,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iae9548bfc73f4d20bf124ad64785207c"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfNDAzNA_4b5dae32-5f08-4ab8-909f-6a7fbd899b0d" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of December 31, 2021 and 2020 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ab7a0601cb455db099d018b5e7ee2e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNC0yLTEtMS0zMDU3Mg_3d32f02f-edf8-4014-b48a-31e4f3f66b8e">254,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fa8f61db574f89a67fc8c16cf3711d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNC00LTEtMS0zMDU3Mg_7c4ea760-bf97-4ce1-aa0a-8d773250f726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76224457309a40699695790b0f50e4f7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNC02LTEtMS0zMDU3Mg_846dfc45-dfcc-4071-a2b5-01894e72a993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffbb9a38583e4074b4296919f28d1a77_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNC04LTEtMS0zMDU3Mg_b78753fe-c972-4f9e-8628-7d4f4834e549">254,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638518a143ae4d87a72a11c64fcc3765_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNi0yLTEtMS0zMDU3Mg_83ba8081-a523-447a-8676-5ea1069c7b6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc964799b214b28aed62721500a4078_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNi00LTEtMS0zMDU3Mg_8b6b77f1-8504-4ef8-8846-9b880b544615">22,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i697bd4c12c7545578588a80fd60c5a2a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNi02LTEtMS0zMDU3Mg_2e620e05-d160-4fe9-8cd8-1f4c10578b8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fff7b93030247d7a7ec551b5888bba9_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNi04LTEtMS0zMDU3Mg_aac1697b-12f9-4c63-ba44-8b3940892509">22,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec309e8b8ca4034bede264e6e054708_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC0yLTEtMS0zMDU3Mg_979ee31e-12fe-4063-a4b8-c1876fa51488">52,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66997f44a6d49358fc4baf034b07e2c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC00LTEtMS0zMDU3Mg_0502e5ee-5eae-4f06-bcc2-a5e9e71b2bc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i704a124a4a974f0fa8f723461b30609a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC02LTEtMS0zMDU3Mg_4d2b01c9-878f-4e85-9db2-6ead77bf0078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93f36a0218f438aaa218be2623ebb81_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC04LTEtMS0zMDU3Mg_dfac5dfc-aadb-4cab-bb4d-2560c54abd75">52,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746a7393ab77458f87d791a8c09ccaa7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC0yLTEtMS01NTQ0Mg_a58cd036-9717-4567-9730-0c264b7028c3">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b094c7c0f04992a913df6000efec8d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC00LTEtMS01NTQ0Mg_d4f0443c-c0a6-4a87-a361-1303ff564545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf91dd30bbfd452691bc71a1f3018647_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC02LTEtMS01NTQ0Mg_6b404d36-5bed-47fc-b7bf-16b975bb855c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5abf1dd36ab74c1ab535b08da51fd03e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC04LTEtMS01NTQ0Mg_7838c64d-9fcc-4e89-91e7-ac663e229ad8">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1fc88b8c4af4d838d278264c23593de_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOS0yLTEtMS01NTQ0Mg_9c35991d-5560-4215-a1fb-7310e4430119">17,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb1df97244f7467cb5339af566fe6b01_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOS00LTEtMS01NTQ0Mg_e2822fa7-304a-422b-89e4-7d6fb1e0d4ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ad6cd969fd4b7995ef71a5a45c8429_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOS02LTEtMS01NTQ0Mg_c3c3fdcf-293f-4a1a-870b-7a753ad0166d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc69c67cfe341499445ae00f2e71e27_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOS04LTEtMS01NTQ0Mg_628bcf7d-ca06-49b9-99c6-d10f4312c567">17,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66912a44f91463f9626b1399dcc65b5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtMi0xLTEtNTU0NDI_ad240757-add5-4dd8-a9c3-89dadbc38c1b">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374016e58cd24f058ea5bda9bf666837_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtNC0xLTEtNTU0NDI_d49d2f56-ab9a-42fc-9d99-a52f5d497286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558037007551470fb27b3d37558ce693_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtNi0xLTEtNTU0NDI_1f13b8d9-2d72-4d99-956a-f33cf3156cc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51cad3ea1be84d3fafc2dceed5c35c13_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtOC0xLTEtNTU0NDI_01fc2d67-3620-46ee-9755-7c15944547e4">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638518a143ae4d87a72a11c64fcc3765_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtMi0xLTEtMzA1NzI_989ff59b-fb10-4245-94cf-9a1074fbd7cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc964799b214b28aed62721500a4078_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtNC0xLTEtMzA1NzI_d55d31d2-de9f-4360-a27d-bc5ee3b71212">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i697bd4c12c7545578588a80fd60c5a2a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtNi0xLTEtMzA1NzI_8bfa1891-580a-4c80-90de-bcc01707551d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fff7b93030247d7a7ec551b5888bba9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtOC0xLTEtMzA1NzI_df839c57-1c34-4b5a-a6ad-706d52a0ac9c">17,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec189eb73b74704b15fcb292ea00266_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTEtMi0xLTEtMzA1NzI_a1352de2-bf85-4eaf-a4db-4ad364bfba7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b095f6dcdbc4f00abc2c61aefa9f5bf_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTEtNC0xLTEtMzA1NzI_491035e9-5029-4e6e-8689-aa1616fff683">27,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c09dd584b74333a5ee8cfd4907e771_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTEtNi0xLTEtMzA1NzI_a9de093d-2c22-4f3e-aaa7-4af7dbd78199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02504c45cdee431f96d72f6ef0b3b993_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTEtOC0xLTEtMzA1NzI_b07736c0-7512-45e0-9ef9-a7a7964b6a77">27,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819a50dc28e74d5181cf147448558684_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTItMi0xLTEtMzA1NzI_6f51025a-25fc-4dc0-bf0f-ef9c9df4eab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie905db35afe34f1baf538346e1229ce2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTItNC0xLTEtMzA1NzI_f5649e49-e05b-4c63-bb18-c487b97d13b4">64,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4854e1e15ce44e82986165ed1c077b3a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTItNi0xLTEtMzA1NzI_d593412b-bfc2-4598-b802-0a714a6b6ce4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib160d83770f74b9b8af5700509a86741_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTItOC0xLTEtMzA1NzI_58e25991-9d85-40cd-ab6b-0bae4a9f422d">64,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee0c00ad27f2434d8b93b095e710a55f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTMtMi0xLTEtMzA1NzI_2da8852a-b412-4cf0-9a36-753ec3271556">342,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id904fbd917124e16bb45e001aecb4dd5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTMtNC0xLTEtMzA1NzI_8b0da9b1-fd7f-4393-b1f7-6815cc8466f3">132,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9633971e98a74fa18caf2e387613ffcc_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTMtNi0xLTEtMzA1NzI_f2ecad15-2205-49c8-933b-da37ec249108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a6890d5edf4d9894153bf7442085c2_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTMtOC0xLTEtMzA1NzI_001cde18-1d66-42fd-aa81-9006b4cbbbca">475,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf875c7bc1374e99ae736ce591a58b2e_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNC0yLTEtMS00NTA1Mg_f6923b6f-30bb-4daa-a1ce-7fad3e64ae03">209,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f461e673034df49706dbcf7f464bbb_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNC00LTEtMS00NTA1Mg_b681d8a5-c3f0-4c2e-ae59-c8e8faf41d09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b59437edee2408ca9c79c95d8d4ab63_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNC02LTEtMS00NTA1Mg_9d15699d-2ffe-41c3-94f4-fb6d9528cbf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4317cec7404a430cbea079ef5f61f530_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNC04LTEtMS00NTA1Mg_4bf9cb74-df41-41e7-95eb-13d51c7d15fd">209,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0773373ae2a84f8e978c278d271d8702_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNS0yLTEtMS00NTA1Mg_c7569650-f0f3-46c1-80bb-29ccb33f842c">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida715c03157f4228b0751ab8b032c92f_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNS00LTEtMS01NDI5MQ_dd82828f-2daf-4d50-a881-112b45973eb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa881d72ef684b53bc9c3d9157e723c9_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNS02LTEtMS01NDI5MQ_a0385ff6-3d70-46be-90a8-3cf818180ab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8469e26fb441bd917912f9f3502f1b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNS04LTEtMS00NTA1Mg_93baa7a6-ec2a-41d5-a6f0-2edbf4cbcb4f">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i998bda56c93d4dd6a54740477cd3e347_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNi0yLTEtMS00NTA1Mg_486bd4e1-c510-4996-8f8a-0af46b9185c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic657212cfb3b42ed8189daaa3097f436_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNi00LTEtMS00NTA1Mg_c116a54b-7a91-4c98-bfd2-b989a0f1c9ee">3,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4421d3ac76904ead8fadef3b2ee78bdf_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNi02LTEtMS00NTA1Mg_63df8adf-0282-41c8-aa44-04fbfb64604e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbe0ac1d20e94e4c8366764e3173c3f6_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNi04LTEtMS00NTA1Mg_b7cfad87-a11a-446b-9f9b-0e828178bf3c">3,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0773373ae2a84f8e978c278d271d8702_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfOC0yLTEtMS00NTA1Mg_48a2f725-3f5b-4a3b-a959-1725e2161a94">21,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida715c03157f4228b0751ab8b032c92f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfOC00LTEtMS00NTA1Mg_e25282cf-6666-48e7-bf23-e2d9a4a59b7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa881d72ef684b53bc9c3d9157e723c9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfOC02LTEtMS00NTA1Mg_57247283-ae93-4c6d-8c9f-049de6003783">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8469e26fb441bd917912f9f3502f1b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfOC04LTEtMS00NTA1Mg_df674c83-1431-43af-8f16-f00600d42937">21,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i998bda56c93d4dd6a54740477cd3e347_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTAtMi0xLTEtNDUwNTI_feea3b30-473d-4edb-ba74-fa7145f5d326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic657212cfb3b42ed8189daaa3097f436_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTAtNC0xLTEtNDUwNTI_f4d95f98-c880-4981-b136-16baa57e29f0">14,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4421d3ac76904ead8fadef3b2ee78bdf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTAtNi0xLTEtNDUwNTI_ecba294f-b46e-4917-a739-d874535d78ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbe0ac1d20e94e4c8366764e3173c3f6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTAtOC0xLTEtNDUwNTI_d77f1bc0-3d60-45f9-880d-a8d3cf7b7e91">14,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbde1cab9dcf4d98a6860b20663b33c3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTEtMi0xLTEtNDUwNTI_45330a30-5c99-4a98-a0f7-05a77eda7d5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia43aad3092004bd7b9ca33e6dee09b34_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTEtNC0xLTEtNDUwNTI_fdc9ceea-9032-4000-b9a0-09569dd13add">14,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea7bec6dbe545609392aa55eb5b135a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTEtNi0xLTEtNDUwNTI_01e84ac3-e68a-4aa1-9aa4-569e72ddc5a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d680608e3bb4da6945d179588c188ab_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTEtOC0xLTEtNDUwNTI_854a96cd-b4c2-49f1-8404-4c53d237dcb7">14,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af0c8ccd543458fa9a3298f3d4ce64d_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTItMi0xLTEtNDUwNTI_129f774e-f28a-4b45-b1c1-42a031fc576b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf8f52ad9b840b585d5bd5a88b2922f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTItNC0xLTEtNDUwNTI_52972b0a-9e66-4836-af9b-dc99cf2555bc">17,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7bf89c9ebb4ba3a93af970a63499c0_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTItNi0xLTEtNDUwNTI_6dda18b1-ee59-4918-a828-dc3b5b08d3be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c8bd802f0224b98af017ab422589382_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTItOC0xLTEtNDUwNTI_8aefebb4-28a0-43f7-a052-068eb656a5ad">17,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7609acc1e0564279a18161c77ee0a661_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTMtMi0xLTEtNDUwNTI_eb0f292a-d8c4-489c-80b2-9d561b00ef63">231,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c926b150cdc41c987af0ca6157a147b_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTMtNC0xLTEtNDUwNTI_30c72ac4-801b-4082-a7bc-992a307db6da">50,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11934a2c2474130860676bb9c52078b_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTMtNi0xLTEtNDUwNTI_4317baf4-acd5-4e7c-8d1a-e7f3d25ea491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882fb0fa1ed04909a0884aa6e36e11d3_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTMtOC0xLTEtNDUwNTI_2cbfaae4-29d1-48a0-9af9-0768911a8b53">281,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the years ended December 31, 2021 and 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash, certain cash equivalents, accounts receivable, net, other current assets, accounts payable, accrued expenses and other liabilities, and Pharma contract liabilities are considered reasonable estimates of their respective fair values at December 31, 2021 and 2020 due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and as such, these are considered Level 3 fair value measurements.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ia1854a760084469581a7ceab463d6c8e_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfNjI2_6550bdbc-e79c-4fae-89c5-199c85761e56" continuedAt="i17e743dca04e4cf5be7fc26724d856d3" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="i17e743dca04e4cf5be7fc26724d856d3"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfNjI3_428273e5-633d-491b-bd4d-24360486d535" continuedAt="ic1b0b6e58ac7477eacedc3073f6e06a9" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lives in Years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc5bdf0bd65547809e7e35cef332ded7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMS0xLTEtMS0zMDU3Mg_be554bd5-b1c6-4aad-bf72-09447dbd87ab">86,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a20a06d1fb4012ab3ed6acefa4763e_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMS0zLTEtMS0zMDU3Mg_36ea077c-e894-4e6d-a51d-a69eeab64d2e">73,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia08a6bbb0803484290d41e899ab2e80c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMS01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjljODY0MWZiNTc3MzQ1ZDdhMzczMWE4NGY3MWE5NDhmXzEwOTk1MTE2Mjc3ODQ_53cbb625-3fc6-42f7-af2c-31a537766ff4">1</ix:nonNumeric> - <ix:nonNumeric contextRef="i76551b3aac0541058270850f80fddc5d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMS01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjljODY0MWZiNTc3MzQ1ZDdhMzczMWE4NGY3MWE5NDhmXzEwOTk1MTE2Mjc3OTA_2657d842-14a4-4777-8429-039af1babc02">13</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if012ec1a006545bd8bc701a1f1a66681_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMi0xLTEtMS0zMDU3Mg_d414ff51-56a3-4149-b1ad-6e0c90dcc0c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636c4a523c7044148f591fa542ca2a22_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMi0zLTEtMS0zMDU3Mg_fb23c28c-c7d6-450d-962f-75b6277a3afe">7,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e0ff94327434437bddf706a1455ce54_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMi01LTEtMS0zMDU3Mg_f5e73f94-2c09-4db2-91b6-5339860ff7fe">40</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d92940bce5d4fc1a139df4991f04954_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMy0xLTEtMS0zMDU3Mg_b441684f-f3e4-4c92-a450-5b8ac839c822">43,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff03a902a6dc4195b028b950ecde4819_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMy0zLTEtMS0zMDU3Mg_bb1bc089-6ea8-41af-93f6-c76bd31de44a">27,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieadec132a5f64c42a09fbe4ba6114c84_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMy01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjRjZDM0Y2ZkZDIwODRhNjg5YzdiNDc1NmVkNzljMWE0XzIxOTkwMjMyNTU1NTY_4042217d-b670-474f-83bf-0c57d11b86f1">1</ix:nonNumeric>-<ix:nonNumeric contextRef="if418afdb92d045b3a3f7ed0f7f4d1122_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMy01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjRjZDM0Y2ZkZDIwODRhNjg5YzdiNDc1NmVkNzljMWE0XzIxOTkwMjMyNTU1NjA_2cdea8d9-fc02-4e13-b04c-8c3df914757d">17</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c7ceda81e3493eb7227ddc4cd896f6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNC0xLTEtMS0zMDU3Mg_156b9061-3c99-4f13-a580-8ba31b6ea256">11,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e2cb12c76b947e78ab4acbe3ee1f639_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNC0zLTEtMS0zMDU3Mg_7b3ae04c-5417-4ad1-b9cc-0567d75872ff">7,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54d9161759f74b8f932b20183ffd720f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNC01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjQzN2U4NWRjMWViODRmMzI4NWY5MjU1NjFlNjhkNjMzXzIxOTkwMjMyNTU1NTY_cc00233c-235b-4763-8cae-d075f9e5e4af">1</ix:nonNumeric>-<ix:nonNumeric contextRef="ia73a0aa5156842af960bcd14bd338f8e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNC01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjQzN2U4NWRjMWViODRmMzI4NWY5MjU1NjFlNjhkNjMzXzIxOTkwMjMyNTU1NjA_a41a72aa-2adb-4007-910f-2f6a61acc270">9</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d1f59ac1cd467a8d62d4b587435dc3_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNS0xLTEtMS0zMDU3Mg_48663088-63c1-426b-b4df-947db81123cd">30,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d1a2450d964986952b0cb1d7a972d3_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNS0zLTEtMS0zMDU3Mg_4648ba54-c519-46de-9b1a-ff83d5241676">22,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i880abad5544f42bc928b73e22ab0195b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNS01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOmEzODU0MjBkNGNlZDQyMDlhNzljYmQ0MDE1YzVkYzEwXzIxOTkwMjMyNTU1NTY_3d2b8645-7a9a-46a6-a961-c1565edf2003">1</ix:nonNumeric>-<ix:nonNumeric contextRef="ie96c96643a9a49e897b82d45077534e9_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNS01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOmEzODU0MjBkNGNlZDQyMDlhNzljYmQ0MDE1YzVkYzEwXzIxOTkwMjMyNTU1NjA_63a8edf8-2ce4-402c-836e-e2e5e181bd5c">10</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ea353bc69b4538a77ec069769583e1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNi0xLTEtMS0zMDU3Mg_7fb8e1a3-2304-4699-b7cd-ba7e996478a7">35,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc1b463b713a4a888492c941c54b0d54_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNi0zLTEtMS0zMDU3Mg_23596519-031f-43f7-880b-8843eaddf9bc">30,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0af911d8233f4962aafb743c2dd6a5f0_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNi01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjU5YmVmMmViYTlkMzQzMGY5OTNhYmYzMzlmNjFmOTY1XzIxOTkwMjMyNTU1NTY_211b27aa-864b-427e-be09-41a003a8818a">1</ix:nonNumeric>-<ix:nonNumeric contextRef="i6e31541c268a47789bfebfdbfe3302c7_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNi01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjU5YmVmMmViYTlkMzQzMGY5OTNhYmYzMzlmNjFmOTY1XzIxOTkwMjMyNTU1NjA_fbb5aa75-9b04-4449-b53d-671a012e77af">10</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2775d83b054b66a7b7488b3b99b796_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNy0xLTEtMS0zMDU3Mg_ccaaa911-4001-4196-bd90-237345b78f41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib569323910c44cd88620b55283478461_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNy0zLTEtMS0zMDU3Mg_6682a16f-1e25-4379-bf75-fb2760383e86">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22d7d272d9234119b3defb42cd98b2ed_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfOC0xLTEtMS0zMDU3Mg_4620aba7-b69f-4c97-ad28-6bcef9c0fedf">12,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55f1b1da3e0488c9a6e5f436542cf5a_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfOC0zLTEtMS0zMDU3Mg_744acc1f-2c38-4cfa-a20e-996d39b63fb3">6,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfOS0xLTEtMS0zMDU3Mg_ebcb8516-d423-4b03-84b7-e6b76b3c4d2f">219,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfOS0zLTEtMS0zMDU3Mg_44514722-730e-4310-94fe-448fa083d6fe">178,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMTAtMS0xLTEtMzA1NzI_7322545a-9505-4d03-b601-765d45a32031">109,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMTAtMy0xLTEtMzA1NzI_08fe9643-49c5-4e6b-82ec-76171c0f4601">92,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMTEtMS0xLTEtMzA1NzI_20f0d62f-10ca-4412-9065-dedb68745e32">109,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMTEtMy0xLTEtMzA1NzI_cee5f204-68f1-4792-a364-29fef63f1e05">85,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns <ix:nonFraction unitRef="sqft" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="neo:AssetHeldForSaleSquareFeetOfFacilityOwned" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfMzI5ODUzNDg4NjAxNA_f5355dca-acd6-4732-b09c-f3841b8f9738">43,560</ix:nonFraction> square feet of our Carlsbad, California facility. This facility, consisting of land and an office building, is not included in property and equipment, net, on the Consolidated Balance Sheets. At December 31, 2021, these assets are classified as assets held for sale within current assets on the Consolidated Balance Sheets with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i81cc823b18b445a48f1d7b22e1ae4708_I20211231" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfMjE5OTAyMzI1NzgyMQ_26af1b72-bcc2-4a9e-a669-fe7ecec6f1ab">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i95ed315fe6ca4ac4b52bb55b50e60ce8_I20211231" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfMjE5OTAyMzI1Nzg0MA_a07448b2-5405-4f05-a379-4a8c5c3c2edd">6.9</ix:nonFraction> million, respectively.</span></div><ix:continuation id="ic1b0b6e58ac7477eacedc3073f6e06a9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December 31, 2021, 2020, and 2019, was as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d27cc71a1714b4ebf592be7df20c267_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMS0xLTEtMS04NDU5Mw_699a51d1-8de3-429f-95e1-b11a2c13951b">14,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20fd6415e784db381b4c4dc75be37e4_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMS0zLTEtMS04NDY2Nw_a24cc798-5e56-47b7-b05b-94d7f6f08c09">15,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291ce8a7f66b4b84a5b2060a8fcc1069_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMS01LTEtMS04NDY2Nw_7ed87d47-1c71-4697-ba4d-9b7ba7568d37">9,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151d387283274e48b13d8617c7cb5641_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMi0xLTEtMS04NDU5OA_09df9a8a-5b48-4719-90a5-e9254d054261">15,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b8f4e448e449b8833a37c30148dc54_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMi0zLTEtMS04NDY2Nw_2280a358-2913-496c-8d64-8ef6aa34ccf4">10,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6385c3880aa64c458d744783c9ed5858_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMi01LTEtMS04NDY2Mw_aa770519-bb2a-4219-89b7-535cfb298dcf">10,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74fa1e58d23f4919baa197fafbd39ade_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMy0xLTEtMS04NDYwMw_1dd14852-1cbe-4e7b-bfca-1db9713c28cf">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia467e61d4253433b840909b9672e06a3_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMy0zLTEtMS04NDY2Nw_2f688020-0a5f-4474-9407-80199969bbf0">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c550d928cb64f8baa867e835a056792_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMy01LTEtMS04NDY2Nw_88c25081-426c-411c-b336-2a8ae07f9758">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfNC0xLTEtMS04NDY3NA_55ed3a6b-4be7-4085-abdb-a09b96319063">30,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfNC0zLTEtMS04NDY2Nw_ed99c7b3-f39d-49fa-80da-42a056de38b8">25,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfNC01LTEtMS04NDY2Nw_3db81bc4-7bc7-46da-a27e-18e455e869e9">20,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTcxOQ_0efa3c5f-1c79-4b86-b978-6528bcd5746f" continuedAt="i540b1630f2f644cfa1462b12fcd49596" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i540b1630f2f644cfa1462b12fcd49596" continuedAt="i42ccd94a9cda42c6b7a74065583cac98"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTcxNg_de21a776-c294-49dc-a5b2-8f613bf98280" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the maturities of the operating lease liabilities and a reconciliation to the present value of lease liabilities were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.511%"><tr><td style="width:1.0%"></td><td style="width:76.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMS0xLTEtMS0zMDU3Mg_5d6b4ab3-76f6-4e76-8b58-36924858c24c">9,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMi0xLTEtMS0zMDU3Mg_e2fe8b40-7b1c-453b-8bd3-b89b60b2d73e">10,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMy0xLTEtMS0zMDU3Mg_dcf61088-0016-4e4c-9f26-76eb3a85059c">10,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfNC0xLTEtMS0zMDU3Mg_9f55fc3a-ce47-4d17-9dbc-29d9372de8d6">6,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfNS0xLTEtMS0zMDU3Mg_83d7aeae-1c83-4a60-9b05-dd8daa6525cc">5,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfNi0xLTEtMS0zMDU3Mg_7f35a3f3-1a1b-49cc-a64a-14a84fe718ae">59,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfNy0xLTEtMS0zMDU3Mg_503ebd6c-7416-4ac8-9251-483005767cfd">102,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfOC0xLTEtMS0zMDU3Mg_f98a54f1-5e57-4412-bb19-a7800b5d0871">23,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfOS0xLTEtMS0zMDU3Mg_5f9fc317-a8d0-4318-86f2-eb6e05a797cb">79,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMTAtMS0xLTEtMzA1NzI_a12b76c4-1f6c-4a35-b1e6-60c19db506cf">6,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMTEtMS0xLTEtMzA1NzI_9c94ca74-2a21-42b6-bd81-bfc281fe6ba9">72,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i306577667f484778bf45986f95823aa8_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMTItMS0xLTEtMzA1NzI_2326eb04-791f-44c2-8950-e32525eae9f5">12.76</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMTMtMS0xLTEtMzA1NzI_beaa564f-5cc0-4242-8aef-de7cb4001408">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i42ccd94a9cda42c6b7a74065583cac98"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTcxNw_792ab530-7aa5-45c8-a7ce-7f5fddfcfbd8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional supplemental data related to the operating leases for the years ended December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMi0yLTEtMS01NjIwNA_71a4bb17-9af3-46c8-b8b8-9af87350b568">11,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMi00LTEtMS01NjIxMQ_97fd0560-1462-4da0-bcae-114a1f0c8173">8,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMi0yLTEtMS0zMDU3Mg_488af37c-2f6d-41ce-8604-c15c24b9cbba">39,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMi00LTEtMS0zMDU3Mg_210bd941-7ec3-4eed-a813-4f3045e2b150">25,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMy0yLTEtMS0zMDU3Mg_bf47da85-5488-49ae-b832-f90f3826f4bd">10,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMy00LTEtMS0zMDU3Mg_3265e365-9b46-43d0-8421-2f9f155dd18a">7,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company has entered into $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMjE5OTAyMzI2NTE2NA_63fea18c-4c5b-43cb-bcb2-dbee1e1d930a">4.9</ix:nonFraction> million of contractually binding minimum lease payments for a lease executed but not yet commenced. This amount is excluded from the above tables and relates to the lease of an administrative space in Carlsbad, California that commenced in January 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company&#8217;s lease of its new laboratory and headquarters facility in Fort Myers, Florida commenced. As of December 31, 2021, the Company had paid approximately $<ix:nonFraction unitRef="usd" contextRef="ic957ae942d964cf9b7a556c4a93531fb_D20210101-20211231" decimals="-5" name="neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTY0OTI2NzQ1Njg2OQ_b8232d0c-9a0a-4775-925e-c269102481eb">25.0</ix:nonFraction>&#160;million to the landlord for the construction of the underlying assets which was classified as a prepaid lease asset until the lease commenced in the third quarter of 2021 at which time the prepaid lease asset was included in the calculation of the right-of-use asset. As of December 31, 2021, the Company had paid approximately $<ix:nonFraction unitRef="usd" contextRef="i9ac08cc60a5e4cdab6616035137f9346_D20210101-20211231" decimals="-5" name="neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTY0OTI2NzQ1Njg4NA_dedbf6f7-55cc-4064-8e5f-7817c0cc437a">17.0</ix:nonFraction>&#160;million to the landlord for leasehold improvements, which are included in property and equipment, net, for its new laboratory and headquarters facility. As of </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all disbursements to the landlord had been completed. As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTY0OTI2NzQ1Njg2NQ_3f8eee22-befe-4154-ae04-ec31c64b96f6">21.9</ix:nonFraction> million remained unpaid in a construction disbursement escrow account for final remaining disbursements to the landlord and remained in restricted cash on the Consolidated Balance Sheets.</span></div></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkyNw_f17ea80c-bca9-4d11-a669-c88f94aeebfa" continuedAt="i3d4451035d514651979ab7ff4ed835fa" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i3d4451035d514651979ab7ff4ed835fa" continuedAt="ib948c8bd27614265a2a12069e40b7cc1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of Trapelo in April 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="if28d75b24f2140639b3049878575785f_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzgyNDYzMzcyMTE1OTY_d6d613b6-a08f-44ba-a456-9e6c49cd1da3">44.7</ix:nonFraction> million in goodwill, all of which was recorded in the Clinical Services segment. As a result of the acquisition of Inivata in June 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzgyNDYzMzcyMTE2Mjk_dabb4098-bba0-445f-81b5-98a6168d6874">271.4</ix:nonFraction> million in goodwill, of which $<ix:nonFraction unitRef="usd" contextRef="ic5d9574696644e1f9309d0cfefa33d29_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzgyNDYzMzcyMTE2NjI_55dce7f5-de8c-4ad9-bf84-4f4d041bcbe9">238.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibb76b6a1b0eb453db2e735dd98b1f29f_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzgyNDYzMzcyMTE2ODk_8865e4a2-f001-40b6-bacf-b766c92b9eb1">33.0</ix:nonFraction> million are assigned to the Clinical Services and Pharma segments, respectively. For further information regarding the Trapelo and Inivata acquisitions, please refer to Note 3. Acquisitions. </span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkyOA_1e21e670-750e-48bd-a593-7be1b59e1f36" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Services </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pharma Services </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6711068bbac647fc86549e4223bb1234_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzEtMS0xLTEtMzA1NzI_1d04c677-9191-47c2-a383-112466384b1e">179,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1de0a4a163954f2cb05b76ae300bf20b_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzEtMy0xLTEtMzA1NzI_8a875527-4461-49b9-9d7d-62647b090602">31,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzEtNS0xLTEtMzA1NzI_ef0347d9-90b6-4b2e-a18d-f73dee87e65a">211,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired - Trapelo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28d75b24f2140639b3049878575785f_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzItMS0xLTEtNDk1NjE_79f84620-8ea8-4161-974f-2547e09cc1c9">44,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8170c0aaa5d7434fa9c612d65b268c2e_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzItMy0xLTEtNDk1NjE_35f03699-6bae-402a-b4e6-0d29ada056ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7ed50e5ea746629e2bf83cd1f470c3_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzItNS0xLTEtNDk1NjE_9b03d984-221b-47fa-865d-ef3739693586">44,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired - Inivata</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d9574696644e1f9309d0cfefa33d29_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzMtMS0xLTEtNDk1NjE_c9ecdea4-64be-41a4-bc20-fd87528d31b0">238,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb76b6a1b0eb453db2e735dd98b1f29f_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzMtMy0xLTEtNDk1NjE_93aff3df-d7de-48f8-a735-a25c39f93138">32,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzMtNS0xLTEtNDk1NjE_3b2b060f-5977-4bbf-949a-e8c09b2b9b7d">271,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i637576e87f3d47aa8bf8b7d26b13ccaf_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzQtMS0xLTEtNDk1Njg_21760519-838e-4bd3-9e45-e51cab6587c8">462,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic98525a6e8714275ab1c829b7a50b6e3_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzQtMy0xLTEtNDk1Njg_8ad09115-fd56-4246-8f92-6f5d687f6565">64,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzQtNS0xLTEtNDk1Njg_59d0862f-7099-446f-a68c-aa0c3b6806d5">527,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ib948c8bd27614265a2a12069e40b7cc1"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkzMg_6631f926-4d2b-41f4-9008-54031f387493" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if411244f1e50462093c1aae195efef2f_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjplZjI3YzYxZDAzYjI0NThlODNhYjQ4N2Q5NzBlNmEyM18yNzQ4Nzc5MDY5NDQ0_96cda091-ac8d-42aa-be3a-797294d4e901">7</ix:nonNumeric>-<ix:nonNumeric contextRef="if43301d85c4e4b128360590c43b56712_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjplZjI3YzYxZDAzYjI0NThlODNhYjQ4N2Q5NzBlNmEyM18yNzQ4Nzc5MDY5NDQ4_de342048-3fd1-4c9c-bea0-0b84ba3baa4e">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04841638dcb14d26aca6ddbca52a8008_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItMy0xLTEtMzA1NzI_92a31186-1737-4907-a6af-784910c9de8b">143,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04841638dcb14d26aca6ddbca52a8008_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItNS0xLTEtMzA1NzI_c967cc55-6c85-4b68-9b07-e3734c52b990">45,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04841638dcb14d26aca6ddbca52a8008_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItNy0xLTEtMzA1NzI_ac948c7a-d7f1-4961-861d-10e2606c1b0f">97,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i84706daee59246f5ab9cf3fb66b19a70_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjowNzdhMzAzOWM1MjI0YjgwOWFiMDRkODkxNDQyYzVjZl8yNzQ4Nzc5MDY5NDQ0_5b064e09-fa95-417c-a731-bec822f224fc">10</ix:nonNumeric>-<ix:nonNumeric contextRef="i2b0eadb39e524028b1b5befa8894385c_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjowNzdhMzAzOWM1MjI0YjgwOWFiMDRkODkxNDQyYzVjZl8yNzQ4Nzc5MDY5NDQ4_0b4eb127-33e6-4364-bddf-41abaeb0d8a8">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd218dd4ac047aabdc29a8180d928bc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtMy0xLTEtMzA1NzI_744b4e04-4d00-480f-b7b1-3ebef60107d5">310,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd218dd4ac047aabdc29a8180d928bc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtNS0xLTEtMzA1NzI_bd0cc009-905b-4ec1-8276-07fc07ba5a11">11,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd218dd4ac047aabdc29a8180d928bc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtNy0xLTEtMzA1NzI_b5c5d5dc-cf37-4c4d-900a-08184d14bfa2">298,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4a9e3c3f614b4a54a8fa244038abc68c_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtMS0xLTEtNDkxODI_d4e47074-ec5a-470e-8276-f0c784252475">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a182d543fcb4f498a67a90731372126_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtMy0xLTEtNDkyNDQ_a2332a94-646d-482f-ab61-5ed99f166d93">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a182d543fcb4f498a67a90731372126_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtNS0xLTEtNDkyMjY_8bc5334e-aec4-41a1-8204-47ab8f2910a3">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a182d543fcb4f498a67a90731372126_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtNy0xLTEtNDkyMzM_ed167cfc-2f91-4ad8-aa84-a6b5e48f08c9">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9eff1173507945b488259b30471cc6bf_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtMS0xLTEtMzA1NzI_09cf90f5-d317-4e73-a017-431968d60f1c">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a929c3ad7fd4b79ac34b701ad8c5f50_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtMy0xLTEtMzA1NzI_fe9ed354-c37c-46b0-bba4-54a5890fdbe9">31,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a929c3ad7fd4b79ac34b701ad8c5f50_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtNS0xLTEtMzA1NzI_8ad9acc4-0860-4842-803c-ee2908e00631">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a929c3ad7fd4b79ac34b701ad8c5f50_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtNy0xLTEtMzA1NzI_21c6f1a0-877f-4f70-8c83-03e189c16c57">30,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie027d3283ba246829bb5659c80860729_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtMS0xLTEtNDkxODI_e77b1439-fe00-451a-aac3-4f9313afae6c">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9911279c90843e3b12761e1e6b7cd04_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtMy0xLTEtNDkyNTE_08d01ecd-c3a9-498c-8c73-1d1b39b081c4">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9911279c90843e3b12761e1e6b7cd04_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtNS0xLTEtNDkyMjY_ee7ef848-ff6b-44b7-9443-319687226786">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9911279c90843e3b12761e1e6b7cd04_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtNy0xLTEtNDkyMzM_02c53770-7b89-4777-b82c-2c73241c5170">2,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70e96f3c16a456f80d98d1ca756c591_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzUtMy0xLTEtMzA1NzI_05f30d36-c717-4b37-8d29-3edea06a4b38">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70e96f3c16a456f80d98d1ca756c591_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzUtNy0xLTEtMzA1NzI_eff48e94-3b2b-4454-9458-82a4a30ab9a4">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtMy0xLTEtMzA1NzI_eea2ef19-216f-4d71-ac8f-a808d47d8ecc">501,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtNS0xLTEtMzA1NzI_9a677908-0d84-4908-84ed-13118a778f49">59,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtNy0xLTEtMzA1NzI_56e9ba9c-d2b3-4ec7-b4e0-f530e063abbe">442,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt 0 13pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="i626362dd9a22429d9bb4e5026984bc8b_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTEtMS0xLTMwNTcyL3RleHRyZWdpb246NmJmOTU5OGExZWIyNDliYWJhOGYxYjk3NjkwMjI3MjRfMjc0ODc3OTA2OTQ0NQ_10a63cf9-1b2b-4ceb-b9c3-46f8fcb66872">7</ix:nonNumeric>-<ix:nonNumeric contextRef="i211b3436a4454faea569497baa14b01c_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTEtMS0xLTMwNTcyL3RleHRyZWdpb246NmJmOTU5OGExZWIyNDliYWJhOGYxYjk3NjkwMjI3MjRfMjc0ODc3OTA2OTQ0OQ_0053aa37-756f-4859-bcf0-66b671685081">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724957d1dba34eadb214d693374d40ad_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTMtMS0xLTMwNTcy_96647ec2-0a5a-4c77-bc3f-1e10b777cfcb">143,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724957d1dba34eadb214d693374d40ad_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTUtMS0xLTMwNTcy_5df2bc71-8a3a-42c5-a8c2-ac059b08bba1">35,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724957d1dba34eadb214d693374d40ad_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTctMS0xLTMwNTcy_77d9faee-0274-48eb-9047-684537e7117d">107,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8e67a3847ca48b39b6ee1a91b870b20_I20201231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEzLTMtMS0xLTMwNTcy_d0109e52-509a-4205-be0b-eee1cc9dc857">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8e67a3847ca48b39b6ee1a91b870b20_I20201231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEzLTctMS0xLTMwNTcy_8b9a3c15-059d-4d11-a417-fc18396a4a2f">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzE0LTMtMS0xLTMwNTcy_2a9c0314-3dfa-49f3-86fd-323c5daf30a4">156,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzE0LTUtMS0xLTMwNTcy_1c9d51e0-5cb4-4bda-a912-c88d0a77daf6">35,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzE0LTctMS0xLTMwNTcy_2041abc2-fb86-4cae-84f9-6597e82c1550">120,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkzMw_75ec7c89-fa8b-4095-8527-2f11148a7f3e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020, and 2019, amortization on the Consolidated Statements of Operations was recorded as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization recorded in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d27cc71a1714b4ebf592be7df20c267_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzEtMS0xLTEtNDg4MDM_405d5aca-7ae2-4625-9801-91d79973a25d">10,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20fd6415e784db381b4c4dc75be37e4_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzEtMy0xLTEtNDg4NDU_6b117663-ad71-40c5-9b82-f2f8412c2db6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291ce8a7f66b4b84a5b2060a8fcc1069_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzEtNS0xLTEtNDg4NTI_2bb39547-00e3-4833-a1a9-82692094325a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151d387283274e48b13d8617c7cb5641_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItMS0xLTEtNDg4MDM_6fa8fc3e-cb2f-427d-818a-6233972af217">12,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b8f4e448e449b8833a37c30148dc54_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItMy0xLTEtNDg4NDU_5454b5bb-9a71-43da-a82f-995ed0f9f90e">9,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6385c3880aa64c458d744783c9ed5858_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItNS0xLTEtNDg4NTI_5dc03dd5-be0b-4580-953c-181af0d2df77">9,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItMS0xLTEtMzA1NzI_71ea2b2f-0e3c-4cd7-9f78-5b2fff5ff018">23,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItMy0xLTEtMzA1NzI_82e4488c-5d83-4c24-b335-5ff549e5a7b4">9,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItNS0xLTEtMzA1NzI_7a6b5db3-381e-4cfe-a700-e2d36d178b3b">9,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkzMA_cc90dc06-4c8e-49e0-9d2f-968180ea7342" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the estimated amortization expense related to amortizable intangible assets for each of the five following years and thereafter is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzEtMi0xLTEtMzA1NzI_1c5ef8a3-41f8-4c15-a929-3ea406b49b9b">33,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzItMi0xLTEtMzA1NzI_bce2d669-a331-431f-a170-174bc6d57bb6">33,899</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzMtMi0xLTEtMzA1NzI_0c66fc8f-6cb4-4062-a7e3-e1b7c8c44f72">33,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzQtMi0xLTEtMzA1NzI_16a2f7c2-2463-4471-b767-31783bc4ce10">33,798</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzUtMi0xLTEtMzA1NzI_bde6ed53-e5f5-4a09-9d34-6f7611df784b">33,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzYtMi0xLTEtMzA1NzI_edffe8cd-c9f0-4005-b684-c9d20ade13f2">259,898</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzctMi0xLTEtMzA1NzI_f112fb7d-3d04-46b2-bfb8-eee7a315ac08">428,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzU1NDM_fe2622f3-fffe-4d81-b335-870b7862dd13" continuedAt="ie52186827b12461a8264c7626fb84b9f" escape="true">Investment in Non-Consolidated Affiliate</ix:nonNumeric></span></div><ix:continuation id="ie52186827b12461a8264c7626fb84b9f" continuedAt="i68d74c780b0442498897e15730e5c42b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company formed a strategic alliance with Inivata and entered into a Strategic Alliance Agreement and Laboratory Services Agreement with Inivata&#8217;s laboratory subsidiary in the United States, Inivata, Inc., whereas Inivata&#8217;s laboratory rendered and performed certain laboratory testing which the Company made available to customers. The terms and conditions of the Laboratory Services Agreement were consistent with those that would be negotiated between willing parties on an arm&#8217;s length basis. For additional details on amounts paid related to the Laboratory Services Agreement, please refer to Note 18. Related Party Transactions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Laboratory Services Agreement, the Company also entered into an Investment Agreement with Inivata (the &#8220;Investment Agreement&#8221;), pursuant to which the Company acquired the Preference Shares for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i15b55aa860d546afb934b299f66c83bc_I20200522" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzExMTA_1981a2a2-a032-4d33-954a-f811edd0456f">25.0</ix:nonFraction>&#160;million in cash resulting in a minority interest in Inivata&#8217;s outstanding equity and an Option Deed which provided the Company with a Purchase Option to purchase Inivata. The Investment Agreement also granted the Company one seat on Inivata&#8217;s Board of Directors. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i68d74c780b0442498897e15730e5c42b" continuedAt="ia6d336c9eb944677beb21afae7b2496a"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company completed the acquisition of the remaining equity interests in Inivata. For further details regarding the acquisition of Inivata, please refer to Note 3. Acquisitions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Inivata Acquisition Date, Inivata was determined to be a variable interest entity (&#8220;VIE&#8221;) and the Company&#8217;s investment was under 20.0% of the total equity outstanding. The Company considered qualitative factors in assessing the primary beneficiary of the VIE which included understanding the purpose and design of the VIE, associated risks that the VIE created, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it was not the primary beneficiary of Inivata prior to the Inivata Acquisition Date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Inivata Acquisition Date, the power to control the activities that most significantly impacted Inivata&#8217;s economic performance was the sole responsibility of Inivata&#8217;s management and Board of Directors; however, the Company did have significant influence over Inivata. As the Preference Shares were determined to not be in-substance common stock, and because the Preference Shares and the Purchase Option did not have readily determinable fair values, prior to the Inivata Acquisition Date, the Company elected to measure the Preference Shares and the Purchase Option at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the initial $<ix:nonFraction unitRef="usd" contextRef="i15b55aa860d546afb934b299f66c83bc_I20200522" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzI2NDQ_1e19541b-9504-44c6-8e95-4a5975ce3abf">25.0</ix:nonFraction>&#160;million cost and $<ix:nonFraction unitRef="usd" contextRef="idc5c1aae3c584667a244f89cd8a59dce_D20200522-20200522" decimals="-5" name="neo:PaymentsToAcquireVariableInterestEntitiesTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzI2NTY_49b26379-2c10-44cd-a47f-ed04c3735581">0.6</ix:nonFraction>&#160;million of associated transaction costs was allocated between the Preference Shares and the Purchase Option based on the relative fair value of each and was recorded as investment in non-consolidated affiliate on the Consolidated Balance Sheets. The initial relative fair value of the investment in non-consolidated affiliate was comprised of $<ix:nonFraction unitRef="usd" contextRef="id3649585fd6c4174aa308719cf6e9e80_I20200522" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzMwMTU_1d6a0756-e31f-4b67-8f73-7f8baaea39a2">19.6</ix:nonFraction>&#160;million in Preference Shares and a $<ix:nonFraction unitRef="usd" contextRef="i1b0aa1a691324c869b66196ee345f501_I20200522" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzMwNDU_04831a49-df19-478d-b6ab-5925001fa10a">6.0</ix:nonFraction>&#160;million Purchase Option. The Preference Shares were valued by determining the equity value of Inivata using the Backsolve Method and allocating the value of the Preference Shares using the Option-Pricing Method and the inputs used included the equity value based on the Series C1 capital raised by Inivata, a volatility rate of <ix:nonFraction unitRef="number" contextRef="i4115d538e4cb482997d79b54d6ea7e82_D20210101-20211231" decimals="4" name="neo:PurchaseOptionMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzMzNjg_00e52521-80d0-4d49-a120-60b3f625da89">84.0</ix:nonFraction>%, a risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i81ef4e3b7e4349c09dfb58d45e01d6a3_D20210101-20211231" decimals="4" name="neo:PurchaseOptionMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM0MDE_856e5342-c1a9-4a12-9fbc-bd462fdd4358">0.17</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia2746f4168df4e39b0b9c9c32fab75aa_D20210101-20211231" decimals="4" name="neo:PurchaseOptionMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM0MDg_0c582e49-be93-4dc0-b0a1-2d8e39cf8120">0.0</ix:nonFraction>% dividend yield. The Purchase Option was valued using the Black-Scholes model with a volatility rate of <ix:nonFraction unitRef="number" contextRef="i55719c5ae1624deeab13abbd59d52c69_D20210101-20211231" decimals="4" name="neo:PurchaseOptionMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM1MTQ_d95820d4-f838-4c80-ac3c-739d7e149aad">84.0</ix:nonFraction>%, a risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i7a973dc561984ddf97bf05e50b7774cc_D20210101-20211231" decimals="4" name="neo:PurchaseOptionMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM1NDc_5209f3a9-2aaf-4e94-8804-3522da4e5a08">0.17</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib0bd3a8ae9bd414ab4804e5744d62945_D20210101-20211231" decimals="4" name="neo:PurchaseOptionMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM1NTQ_44347442-ef99-4679-b528-e912c677bf55">0.0</ix:nonFraction>% dividend yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, an observable transaction of an identical investment in Inivata Preference Shares occurred. This resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Purchase Option was also remeasured at fair value as a result of this observable transaction. As a result of these remeasurements, at December 31, 2020, the carrying value of the investment in non-consolidated affiliate is $<ix:nonFraction unitRef="usd" contextRef="ibd5b0ed6e13f4301a82540f21d96736e_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQyNDE_1d38aa14-37b0-47f8-a439-aa8af937ce88">29.6</ix:nonFraction>&#160;million, comprised of $<ix:nonFraction unitRef="usd" contextRef="ic0157f74f12948d5b65dae57eda95f7c_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQyNTg_0f892b8b-b760-4d1d-98be-ac12b4b8d253">25.0</ix:nonFraction>&#160;million in Preference Shares and a $<ix:nonFraction unitRef="usd" contextRef="ie482047107814fcebaeb573c8d125f94_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQyODg_ce724b64-2a86-4bb3-9d98-b1ed4f3bc8fd">4.6</ix:nonFraction>&#160;million Purchase Option. The Company recorded a net unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="ic34c607907124e1797f9b2a94c22f26c_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQzNTQ_0c949d04-edba-47d6-859d-a56bc8063c82">4.0</ix:nonFraction>&#160;million for these remeasurements for the year ended December 31, 2020 in gain on investment in and loan receivable from non-consolidated affiliate, net, on the Consolidated Statements of Operations. At December 31, 2020, the Purchase Option was valued using the Black-Scholes model with a volatility rate of <ix:nonFraction unitRef="number" contextRef="ia67744929d544b18bcea0c016670b483_D20200101-20201231" decimals="4" name="neo:PurchaseOptionMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQ1ODc_6a85d177-2e34-4b05-ba8f-328fc75766df">84.0</ix:nonFraction>%, a risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="ic3c717cc90b34c8396331da311fbc8a6_D20200101-20201231" decimals="4" name="neo:PurchaseOptionMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQ2MjA_9b6c1150-906a-40ca-950f-1a4faf94f73a">0.17</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3e5bb53850794a1bb9fe4a1d9392f790_D20200101-20201231" decimals="4" name="neo:PurchaseOptionMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQ2Mjc_ea7fbded-af9c-4c1a-89fb-2032acd5641f">0.0</ix:nonFraction>% dividend yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company and Inivata also entered into the Line of Credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i21e0442b30f14bb3be7f6da7309905fa_I20210522" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM1OTk_e775bd91-5178-481f-aeb7-ae8261211900">15.0</ix:nonFraction>&#160;million. In January 2021, the Line of Credit, in its entirety, was drawn by Inivata and recorded as a loan receivable from non-consolidated affiliate on the Consolidated Balance Sheets. Prior to the Inivata Acquisition Date, the Line of Credit contractually matured on December 1, 2025 and the unpaid principal balance was payable on January 1, 2026 and bore interest at <ix:nonFraction unitRef="number" contextRef="id5bd8263f7e1453fae593718fb321be8_D20210101-20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2MTI_c4467156-71ac-45d4-82e6-22b31656781a">0.0</ix:nonFraction>% per annum. In January 2021, upon the draw of the Line of Credit by Inivata, the Company used an imputed interest rate of <ix:nonFraction unitRef="number" contextRef="i33e7531437724368b82772116041a856_I20210131" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2MTc_f7209749-5acd-4c15-b332-7e1e844b1ddd">8.33</ix:nonFraction>% to present value the Line of Credit. The Company recorded an imputed interest rate discount of $<ix:nonFraction unitRef="usd" contextRef="i33e7531437724368b82772116041a856_I20210131" decimals="-5" name="us-gaap:ReceivableWithImputedInterestDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2MjQ_595b36fb-3f52-4c3b-9a9b-0c67aff762dd">5.0</ix:nonFraction>&#160;million on the loan receivable from non-consolidated affiliate and an additional investment in non-consolidated affiliate of $<ix:nonFraction unitRef="usd" contextRef="i33e7531437724368b82772116041a856_I20210131" decimals="-5" name="neo:EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2MzY_e5decf4c-9bcf-43d0-a1d6-5025e87a7a76">5.0</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i33e7531437724368b82772116041a856_I20210131" decimals="-5" name="us-gaap:ReceivableWithImputedInterestNetAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2NDg_35f3f073-f9e2-49ff-983e-dd2896dbf830">10.0</ix:nonFraction>&#160;million present value of the loan receivable from non-consolidated affiliate and increasing the value of the Preference Shares to $<ix:nonFraction unitRef="usd" contextRef="i562c64b34e6c47f5ac6fe747404a6e3a_I20210131" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2NjE_f8771ab1-6e55-48c6-89f1-0f224d56baf1">30.0</ix:nonFraction>&#160;million. For the year ended December 31, 2021 through the Inivata Acquisition Date $<ix:nonFraction unitRef="usd" contextRef="i93dce16f064a42eabc5af5199673306a_D20210101-20211231" decimals="-5" name="us-gaap:InterestAndFeeIncomeLoansAndLeases" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM4NDgyOTA3MTc5NDg_63457d29-df4e-4100-97ab-aa1564e3a13e">0.4</ix:nonFraction> million of interest income was amortized to the loan receivable from non-consolidated affiliate. The interest income amortization is recorded in interest expense, net, on the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, subsequent to Inivata&#8217;s draw on the Line of Credit, an observable transaction of an identical investment in Inivata Preference Shares occurred. This resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Company recorded a net unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="icedf740a0317452ea709d14ef5bf92f4_D20210101-20210331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0ODk3MTM_460f0a9c-1e30-426c-b14a-5633e3d7251f">5.0</ix:nonFraction>&#160;million for this remeasurement for the three months ended March 31, 2021. As of March 31, 2021, the carrying value of the investment in non-consolidated affiliate was $<ix:nonFraction unitRef="usd" contextRef="i9aa9ea29f0bc44568dcd39d50b79abda_I20210331" decimals="-3" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0ODk3NDE_3a4308c8-8609-4354-91f3-2769f1b26300">29.6</ix:nonFraction>&#160;million, comprised of $<ix:nonFraction unitRef="usd" contextRef="id314aeaf3a3e4fd28f10f5c449698ad4_I20210331" decimals="-3" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0ODk3NTY_5c1c993c-8a8d-4c55-947b-c94b8a8fb204">25.0</ix:nonFraction>&#160;million in Preference Shares and a $<ix:nonFraction unitRef="usd" contextRef="i2d9fb9ddce7e450f8b051082329851b8_I20210331" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0ODk3Mjc_219af94a-4595-429e-8862-ca9859dbbfb6">4.6</ix:nonFraction>&#160;million Purchase Option.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Inivata Acquisition Date the Company acquired all of the remaining equity interests of Inivata through the exercise of its Purchase Option. The Company&#8217;s carrying value of the investment in non-consolidated affiliate was $<ix:nonFraction unitRef="usd" contextRef="ifcc7b5e165b64262a42245b5258953e1_I20210618" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0NTA_fbcfc429-e3ef-4ba4-af93-fbf5bd25f45e">29.6</ix:nonFraction>&#160;million, comprised of $<ix:nonFraction unitRef="usd" contextRef="i8e6ac5e675db4ac6837f4c1270b3e2de_I20210618" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0MjM_c7f0d019-942a-44bc-b595-ea6b0a308af3">25.0</ix:nonFraction>&#160;million in Preference Shares and a $<ix:nonFraction unitRef="usd" contextRef="i6f1df0f3964f4e5f8fec10eac6e0e19d_I20210618" decimals="-5" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0MzY_86f55e41-6051-4ab6-bbab-a2ff61a52532">4.6</ix:nonFraction>&#160;million Purchase Option immediately prior to obtaining the remaining ownership of Inivata. The Company&#8217;s acquisition of control of Inivata on the Inivata Acquisition Date was accounted for as a business combination achieved in stages under the acquisition method. Accordingly, the Company </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia6d336c9eb944677beb21afae7b2496a">remeasured its Preference Shares and Purchase Option to their acquisition-date fair values. The Company used a discounted cash flow to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#8217;s Preference Shares and the Purchase Option. To determine the fair value of the Preference Shares, the fair value of equity was allocated to the various classes based on the respective rights and privileges of each class of stock in liquidation. The business enterprise value and a Black-Scholes model was then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at fair value at the Inivata Acquisition Date based on its settlement value. This resulted in fair values of $<ix:nonFraction unitRef="usd" contextRef="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0NjU_3a3e78be-842e-4c9c-8ae0-00bcae97b5ed">64.9</ix:nonFraction>&#160;million in Preference Shares and a $<ix:nonFraction unitRef="usd" contextRef="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930" decimals="-5" name="neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0ODA_01ba7281-6c30-4be9-b175-dfc0633edb44">74.3</ix:nonFraction>&#160;million Purchase Option, immediately prior to the acquisition, resulting in a net gain of $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" name="us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0OTE1MjM_cf81a14b-f0b4-4ab6-9742-178d0bb014b8">104.6</ix:nonFraction>&#160;million for the year ended December 31, 2021, which includes the net loss of $<ix:nonFraction unitRef="usd" contextRef="icedf740a0317452ea709d14ef5bf92f4_D20210101-20210331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzExNTQ0ODcyMTQxMzMx_460f0a9c-1e30-426c-b14a-5633e3d7251f">5.0</ix:nonFraction>&#160;million for the remeasurement in the first quarter of 2021. In addition, on the Inivata Acquisition Date, the $<ix:nonFraction unitRef="usd" contextRef="ie4c011915eac47c0998bdadb7a8c7b5c_I20210618" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0OTU_c7353078-bfcf-4096-8833-740afc956a92">10.3</ix:nonFraction>&#160;million outstanding under the Line of Credit extended by the Company to Inivata was effectively settled as part of the acquisition of Inivata at the $<ix:nonFraction unitRef="usd" contextRef="i21e0442b30f14bb3be7f6da7309905fa_I20210522" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM1NDE_c03d79e7-a3eb-4410-b169-b4837e4dbda4">15.0</ix:nonFraction>&#160;million principal amount and was recorded as part of the consideration transferred in the acquisition resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="neo:LongTermLineOfCreditSettlementGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM1NTQ_77ba9851-5a7a-4062-ad0a-297c605cd4b9">4.7</ix:nonFraction>&#160;million for the year ended December 31, 2021. The Company recorded a total gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#8217;s Consolidated Statements of Operations of $<ix:nonFraction unitRef="usd" contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM1Njg_946c1dc7-efc5-4a32-9a6f-2c8d69a32ff1">109.3</ix:nonFraction>&#160;million for the year ended December 31, 2021 for the excess of the acquisition-date fair value of the Company&#8217;s Preference Shares, Purchase Option, and Line of Credit over their carrying values. For further details regarding the acquisition of Inivata, please refer to Note 3. Acquisitions.</ix:continuation></span></div><div id="ia1854a760084469581a7ceab463d6c8e_106"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEyNTE5_35c7c5b7-95a4-4dd8-a8dd-2cafda71f10d" continuedAt="icc1c8a30e1e346829b6f07e67eb7d407" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="icc1c8a30e1e346829b6f07e67eb7d407" continuedAt="i405677849b144ce695fcc6a7955bf903"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEyNTIw_a07e6498-a704-4109-9a44-9ea9f01b2890" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term debt, net, at December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzEtMC0xLTEtNDU2MDQvdGV4dHJlZ2lvbjo5Y2Y1MTJjOWE2MTk0NmRjYjJmNzdiZDM2M2U1YWVlZF85MzQ1ODQ4ODM2MTQ0_5ae48d67-81d6-4e18-b93a-820661377100">0.25</ix:nonFraction>% Convertible Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzItMS0xLTEtNDU3NzE_be7a78dd-ec0c-4c78-894f-7c0c7a61034c">345,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzItMy0xLTEtNDU3OTQ_1e4721c5-106f-44dc-ba07-48ec2e08f7c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzMtMS0xLTEtNDU3NzE_04f677cb-c5b3-4e7d-b110-7b95e840f15d">8,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzMtMy0xLTEtNDU3OTQ_53540c6a-db52-4b30-9c33-39bd3f1c7640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzQtMS0xLTEtNDU3NzE_7abd2466-40e9-4800-b769-dc16233aa5ae">208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzQtMy0xLTEtNDU3OTQ_2b972e4e-87b5-40b6-a08f-155ad5c482d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total <ix:nonFraction unitRef="number" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMC0xLTEtNDU2MDQvdGV4dHJlZ2lvbjo5N2UwMjM1MzhlNmI0NDY4YjU0YzNkM2E0YjVhYzMyNl85MzQ1ODQ4ODM2MTUw_5ae48d67-81d6-4e18-b93a-820661377100">0.25</ix:nonFraction>% Convertible Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMS0xLTEtNDU3NzE_ff5afe65-4bfb-4b32-80a9-979ed06f2e8f">335,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMy0xLTEtNDU3OTQ_35ea7afc-8219-4253-bfe5-e2aa7860f44d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjoyZGZiZWFjOWY0OTI0NjM1YWRlYzRhMzEwN2JhMGVkZV80_e665d9b6-aa68-4920-aa61-94070387d716">1.25</ix:nonFraction>% Convertible Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzItMS0xLTEtMzA1NzI_1718ce6a-e277-456d-9c06-a339685f76e8">201,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808a9ed8cc11448da4c70680cd987939_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzItMy0xLTEtMzA1NzI_901b26ea-54b8-4880-9e7c-1696368d9c59">201,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzMtMS0xLTEtMzA1NzI_55f6310a-1ce1-42c2-8079-f8343056cdc9">4,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i808a9ed8cc11448da4c70680cd987939_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzMtMy0xLTEtMzA1NzI_631ba16f-996a-4a51-87a9-2bf1b63aa024">32,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzQtMS0xLTEtMzA1NzI_a7687bec-1cab-4906-b8a9-d58dc1bf8ea8">506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i808a9ed8cc11448da4c70680cd987939_I20201231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzQtMy0xLTEtMzA1NzI_f54e8923-7262-494d-af03-54ff49e42ee4">538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total <ix:nonFraction unitRef="number" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjphNzA4NTYyODM0ZTM0YzE2YjU1YmFiYzY3YzBjMTVkZF8xMA_e665d9b6-aa68-4920-aa61-94070387d716">1.25</ix:nonFraction>% Convertible Senior Notes due 2025, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMS0xLTEtMzA1NzI_1007a4ec-44df-411d-97c5-49690bf79ccf">196,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808a9ed8cc11448da4c70680cd987939_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMy0xLTEtMzA1NzI_f71dac9d-f05a-4e27-8f96-98d135eaa95b">168,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:OtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzEyLTEtMS0xLTMwNTcy_58807e70-f225-48d7-a0f5-83b4c3d90308">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:OtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzEyLTMtMS0xLTMwNTcy_4c2bcf6e-f3cd-4f7e-bb1d-6b38215dba86">3,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE0LTEtMS0xLTMwNTcy_b5f4d521-75b4-428d-93c2-77fe73c6c66e">533,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE0LTMtMS0xLTMwNTcy_b2dda87c-8c06-4751-9b5e-c18d9d5174b8">171,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of equipment financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE2LTEtMS0xLTMwNTcy_58897518-12d2-43b3-ae2c-0169bf662b79">1,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f65e6d59d9d4339974d98eb93610ffa_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE2LTMtMS0xLTMwNTcy_b60bf467-dbe3-48fc-9bad-a996440ef96f">2,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE3LTEtMS0xLTMwNTcy_abc72659-afc2-45a0-acb3-8589d6c08718">532,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE3LTMtMS0xLTMwNTcy_e10e7fe1-1666-40e2-93b6-47f155098601">169,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the estimated fair value (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5MDk_ff47dd21-00ef-439d-a270-48be9624f908">0.25</ix:nonFraction>% Convertible Senior Notes due 2028 and the <ix:nonFraction unitRef="rate" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE1Mw_bc74f162-de7b-4ef4-83f7-b9aa4a8e05f6">1.25</ix:nonFraction>% Convertible Senior Notes due 2025 was $<ix:nonFraction unitRef="usd" contextRef="i9236c81b3c974578a313916abc4fb1f9_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE5NA_d02d8084-a070-4cdd-98c0-63445ad6eedf">297.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8457e19cdaef435383fa565c271d3716_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzgyNDYzMzcyNjM1MjI_f4c5e7d0-7622-4a85-a578-fa3ec1d75305">238.9</ix:nonFraction>&#160;million, respectively. There was no such estimated fair value as of December 31, 2020 related to the <ix:nonFraction unitRef="rate" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5Mzk_5c0dbb9f-85ac-4b5a-8e70-e0a114ab810e">0.25</ix:nonFraction>% Convertible Senior Notes due 2028. At December 31, 2020, the estimated fair value (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5MTY_021973cb-d3e4-46e0-b8ef-95bf66e43f11">1.25</ix:nonFraction>% Convertible Senior Notes due 2025 was $<ix:nonFraction unitRef="usd" contextRef="i88a97a83c09a4c2fb216eb170e5f0549_I20201231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5MjM_fce4b947-b77b-483e-a5fe-1b0178727876">320.9</ix:nonFraction>&#160;million. At December 31, 2021 and 2020, the carrying value of the Company&#8217;s equipment financing obligations approximated fair value based on the current market conditions for similar instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2028 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, the Company completed the sale of $<ix:nonFraction unitRef="usd" contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5NzQ_6b94ba52-49de-44d8-9b7d-c80b55d06c0d">345.0</ix:nonFraction>&#160;million of Convertible Senior Notes with a stated interest rate of <ix:nonFraction unitRef="rate" contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5NTE_442e6a77-f9ba-498e-9a15-7d5edf0071d0">0.25</ix:nonFraction>% and a maturity date of January 15, 2028 (the &#8220;2028 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased. The 2028 Convertible Notes were issued at a discounted price of <ix:nonFraction unitRef="rate" contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111" decimals="INF" name="neo:DiscountedPriceOfAggregatePrincipleRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5NDY_204580b1-7b66-41ab-8470-1cde51430bd5">97.0</ix:nonFraction>% of their principal amount. The total net proceeds from the issuance of the 2028 Convertible Notes and exercise of the over-allotment option was approximately $<ix:nonFraction unitRef="usd" contextRef="icc25a561b9d845e1a4b085174856869d_D20210111-20210111" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5NTg_125e99b3-8871-4753-9993-cb0b864d0056">334.4</ix:nonFraction>&#160;million, which includes approximately $<ix:nonFraction unitRef="usd" contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111" decimals="-5" name="us-gaap:CommonStockDiscountOnShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5ODg_ae0fa4f9-c2d4-4519-8bfd-c5044f597488">10.6</ix:nonFraction>&#160;million of discounts, commissions and offering expenses paid by the Company. On January 11, 2021, the Company entered into an Indenture (the &#8220;Indenture&#8221;), with U.S. Bank National Association, as trustee (the &#8220;Trustee&#8221;), governing the 2028 Convertible Notes. The Company used a portion of the net </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i405677849b144ce695fcc6a7955bf903" continuedAt="i599471201bbe41aca6fa52bba0a3886b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from the Offerings to enter into capped call transactions (as described below under the heading &#8220;Capped Call Transactions&#8221;).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to September 15, 2027, noteholders may convert their 2028 Convertible Notes at their option, only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the common stock for at least <ix:nonFraction unitRef="day" contextRef="i5c92183f6c1545059fe96165a77e5108_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMTg_ec3b6735-fa13-49c5-9fa3-afd27fcdae5a">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="day" contextRef="i5c92183f6c1545059fe96165a77e5108_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMTQ_8cf07d97-e338-4680-b39d-1a0d33ba08fa">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i5c92183f6c1545059fe96165a77e5108_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMDM_f05b7cc5-1907-428f-9c7e-7a0af3f860fe">130.0</ix:nonFraction>% of the conversion price on each applicable trading day; (2) during the <ix:nonFraction unitRef="day" contextRef="id52cd4fd62d54923a9542f08f3e9e0b5_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMjc_3a41f8e5-730e-40fb-8066-c2a42d8401a6">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="day" contextRef="id52cd4fd62d54923a9542f08f3e9e0b5_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMzY_f3382dc5-4718-46d7-85cd-e68e11ca2ce8">five</ix:nonFraction> consecutive trading day period in which the trading price per $1,000 principal amount of 2028 Convertible Notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="rate" contextRef="ibc0c47f77f104125b2614b3cc70b4781_I20210111" decimals="INF" name="neo:DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMDk_20dd5be7-06ca-43bb-b7f8-f818d51b972e">98.0</ix:nonFraction>% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day; (3) if the Company calls any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after September 15, 2027 until the close of business on the second business day immediately preceding the maturity date, noteholders may convert their 2028 Convertible Notes at any time, regardless of the foregoing circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwNTQ_2abbb0ee-8c47-4ce6-ac03-4a6caeebe4a4">130.0</ix:nonFraction>% of the conversion price of the 2028 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwNjA_7865bbb1-767b-4897-b243-fd5b9c42fd1b">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwNjQ_0126c52b-1800-48f0-966a-b5c1f0fcdc5f">30</ix:nonFraction> consecutive trading days of the quarter ended September 30, 2021. Based on the terms of the 2028 Convertible Notes, the holders could not have converted all or a portion of their 2028 Convertible Notes in the fourth quarter of 2021. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODYyOTU_76b6f9db-0ead-4294-9f57-ce88e9027fc6">130.0</ix:nonFraction>% of the conversion price of the 2028 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODYzNjU_e71cdf44-eb51-400f-84fd-75b6fcc80578">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODYzODE_c16b5bf6-f2d8-446e-b083-fbac07df663e">30</ix:nonFraction> consecutive trading days of the quarter ended December 31, 2021. Based on the terms of the 2028 Convertible Notes, the holders cannot convert all or a portion of their 2028 Convertible Notes in the first quarter of 2022. When a conversion notice is received, the Company has the option to pay or deliver cash, shares of the Company&#8217;s common stock, or a combination thereof. As the Company is not required to settle the 2028 Convertible Notes in cash, the 2028 Convertible Notes are classified as long-term debt as of December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, the Company will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at its election. The initial conversion rate for the 2028 Convertible Notes is 15.1172 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwNjg_c31c7ff3-844d-4f18-a558-cca2724d1bb7">66.15</ix:nonFraction> per share of common stock. The conversion rate is subject to adjustment as described in the Indenture. In addition, following certain corporate events that occur prior to the maturity date as described in the Indenture, the Company will pay a make-whole premium by increasing the conversion rate for a holder who elects to convert its 2028 Convertible Notes in connection with such a corporate event in certain circumstances. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDkyNjc0OTc3NzY_a8fc00c5-b443-4579-ac66-9a2f35dc8bb0">34.12</ix:nonFraction> on December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2028 Convertible Notes prior to January 20, 2025. The Company may redeem for cash all or any portion of the 2028 Convertible Notes, at its option, on or after January 20, 2025 if the last reported sale price of its common stock has been at least <ix:nonFraction unitRef="number" contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwOTU_ea29b145-37e4-4a3f-af55-3b8055ef4618">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="day" contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMTE_a8a60c54-18e8-4c2f-a992-97181ce0b511">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="day" contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMDE_f66bc178-93fb-4e70-9e4f-450d69a0571f">30</ix:nonFraction> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date of notice by the Company of redemption at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMDU_c17dc497-d695-4bd0-8959-3ad517bba43e">100.0</ix:nonFraction>% of the principal amount of the 2028 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2028 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event involving bankruptcy, insolvency or reorganization events with respect to the Company occurs, then the principal amount of, and all accrued and unpaid interest on, all of the 2028 Convertible Notes then outstanding will immediately become due and payable. If any other default event occurs and is continuing, then noteholders of at least <ix:nonFraction unitRef="number" contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111" decimals="INF" name="neo:DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMTU_222845ad-9ae9-4401-bba4-f471f5cafd2c">25.0</ix:nonFraction>% of the aggregate principal amount of the 2028 Convertible Notes then outstanding, by notice to the Company, may declare the principal amount of, and all accrued and unpaid interest on, all of the 2028 Convertible Notes then outstanding to become due and payable immediately. If the Company undergoes a Fundamental Change (as defined in the Indenture), then noteholders may require the Company to repurchase their 2028 Convertible Notes at a cash repurchase price equal to the principal amount of the 2028 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the Fundamental Change Repurchase Date (as defined in the Indenture).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes are the Company&#8217;s senior, unsecured obligations and will be equal in right of payment with its existing and future senior, unsecured indebtedness, senior in right of payment to its existing and future indebtedness that is expressly subordinated to the 2028 Convertible Notes and effectively junior to its existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness. The 2028 Convertible Notes will be structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of its subsidiaries.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i599471201bbe41aca6fa52bba0a3886b" continuedAt="i6028c4dd0abf4dd899dee24c08c0b248"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2028 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMjA_6236e036-6f4f-42ae-96c8-3e34b2decaff">0.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMzQ_bbde7572-be65-45e5-991c-7b3848a110bd">1.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231" decimals="-3" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExNDg_df1e1c11-2ac9-4b01-8369-24787fcfeb8c">32,000</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the year ended December 31, 2021. There were no such amounts for the year ended December 31, 2020. The effective interest rate on the 2028 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExNTY_8a8cbf59-7dbb-4055-9e64-01e03def838c">0.70</ix:nonFraction>%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="rate" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExNzg_6305f52a-ffe4-4a81-bae8-b3695f15c1f1">0.25</ix:nonFraction>% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, which began on July 15, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the &#8220;Capped Call Transactions&#8221;) with option counterparties pursuant to capped call confirmations at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i317802a689f346709fdb8f5e9f54cf2b_D20210111-20210111" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExNjM_0e8defe2-14d1-4c17-a0dd-208b0a8b1c05">29.3</ix:nonFraction>&#160;million. As the Capped Call Transactions meet certain accounting criteria, the Capped Call Transactions were classified as equity, are not accounted for as derivatives and were recorded as a reduction of the Company&#8217;s additional paid-in capital in the accompanying Consolidated Financial Statements. The Capped Call Transactions are not part of the terms of the 2028 Convertible Notes and will not affect any holders&#8217; rights under the 2028 Convertible Notes. The Capped Call Transactions cover, subject to customary anti-dilution adjustments, the number of shares of the Company&#8217;s common stock that initially underlie the 2028 Convertible Notes. The number of shares underlying the Capped Call Transactions is&#160;<ix:nonFraction unitRef="shares" contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111" decimals="-5" name="neo:CappedCallTransactionsNumberOfUnderlyingShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExODU_926b77a3-cb2d-4780-98df-91596604bed7">5.2</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cap price of the Capped Call Transactions is initially $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExOTg_df2cd10e-d0ae-4e08-b40e-d6fa5064f36d">85.75</ix:nonFraction> per share of the Company&#8217;s common stock, which represents a premium of <ix:nonFraction unitRef="number" contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111" decimals="INF" name="neo:SaleOfStockPremiumOnOfferingPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyMDY_72643e16-2044-4392-bf93-5915b0771b04">75.0</ix:nonFraction>% over the public offering price of the common stock in the 2021 Common Stock Offering, which was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111" decimals="INF" name="neo:SaleOfStockPricePerSharePublicOfferingPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyMTE_83a364ef-9c77-4e75-87b3-04eb65dde1ce">49.00</ix:nonFraction> per share, and is subject to certain adjustments under the terms of the Capped Call Transactions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By entering into the Capped Call Transactions, the Company expects to reduce the potential dilution to its common stock (or, in the event a conversion of the 2028 Convertible Notes is settled in cash, to reduce its cash payment obligation) in the event that, at the time of conversion of the 2028 Convertible Notes, its common stock price exceeds the conversion price of the 2028 Convertible Notes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2025 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2020, the Company completed the sale of $<ix:nonFraction unitRef="usd" contextRef="i34af75623b2843a0a57023612b0339a8_I20200504" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzYxMQ_4a07a2c9-bb93-44b6-b984-b4079df7c219">201.3</ix:nonFraction>&#160;million of convertible senior notes with a stated interest rate of <ix:nonFraction unitRef="rate" contextRef="i34af75623b2843a0a57023612b0339a8_I20200504" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY3Mw_622b03e3-2ee0-4b19-8a3e-65bd28cd0c85">1.25</ix:nonFraction>% and a maturity date of May 1, 2025 (the &#8220;2025 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased. The 2025 Convertible Notes were issued at a discounted price of <ix:nonFraction unitRef="rate" contextRef="i34af75623b2843a0a57023612b0339a8_I20200504" decimals="INF" name="neo:DiscountedPriceOfAggregatePrincipleRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3Xzg1OQ_fabc3782-ba6e-4bc4-af96-3c23ec624960">97.0</ix:nonFraction>% of their principal amount. The total net proceeds from the issuance of the 2025 Convertible Notes and exercise of the over-allotment option were approximately $<ix:nonFraction unitRef="usd" contextRef="ia164ece2fda645d18a4614a36f3dde97_D20200504-20200504" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwMjE_f189d451-692f-4118-a8ff-d1c9939321c2">194.5</ix:nonFraction>&#160;million, which includes approximately $<ix:nonFraction unitRef="usd" contextRef="i34af75623b2843a0a57023612b0339a8_I20200504" decimals="-5" name="us-gaap:CommonStockDiscountOnShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwNTQ_845c0249-b89d-4bd7-accc-5bce06cb986c">6.9</ix:nonFraction>&#160;million of discounts, commissions and offering expenses paid by the Company. On May 4, 2020, the Company entered into an indenture (the &#8220;Indenture&#8221;), with U.S. Bank National Association, as trustee (the &#8220;Trustee&#8221;), governing the 2025 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to February 1, 2025, noteholders may convert their 2025 Convertible Notes at their option, only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the common stock for at least <ix:nonFraction unitRef="day" contextRef="i9736d15d029c4d79a63118c242b0a06d_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDE_ccfbd43e-2f5a-475e-8a10-df7047249a07">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="day" contextRef="i9736d15d029c4d79a63118c242b0a06d_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE3MDU_66c71d6e-f732-4362-bedc-b7d4f9a80c06">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i9736d15d029c4d79a63118c242b0a06d_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE4NTQ_7543efc5-e5f9-479d-805b-a9753431031f">130.0</ix:nonFraction>% of the conversion price on each applicable trading day; (2) during the <ix:nonFraction unitRef="day" contextRef="i8c8fa3e8e2304733b69c9fd8dc90960b_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE5Mjg_7dd89bd4-c16c-4946-a3a2-e2f0077b5e43">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="day" contextRef="i8c8fa3e8e2304733b69c9fd8dc90960b_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE5NjE_f0465a86-6f2e-44e1-8f35-a13e90462b92">five</ix:nonFraction> consecutive trading day period in which the trading price per $1,000 principal amount of 2025 Convertible Notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="rate" contextRef="i80ffbe19f2b94211b4716f57813e319e_I20200504" decimals="INF" name="neo:DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzIxMzc_e47ae969-76bb-4111-9b51-8db5877e517b">98.0</ix:nonFraction>% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day; (3) if the Company calls any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after February 1, 2025 until the close of business on the business day immediately preceding the maturity date, noteholders may convert their 2025 Convertible Notes at any time, regardless of the foregoing circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyNDE_50e3a83c-c630-488b-abbd-3c52cd38a06b">130.0</ix:nonFraction>% of the conversion price of the 2025 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyMzM_0a60da41-7c7b-4785-83ef-dca309c00238">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyMzc_3f9e0435-6892-4963-b762-8aba7bbe71fe">30</ix:nonFraction> consecutive trading days of the quarter ended September 30, 2021. Based on the terms of the 2025 Convertible Notes, the holders could not have converted all or a portion of their 2025 Convertible Notes in the fourth quarter of 2021. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODU2NDA_929f474b-aabd-4d31-9380-a010b7b43641">130.0</ix:nonFraction>% of the conversion price of the 2025 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODU3MTA_81e3e4e1-b665-449c-89da-7ccc28c5054b">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODU3MjY_f0937242-0519-4aa1-93df-2b1f94cb7b7a">30</ix:nonFraction> consecutive trading days of the quarter ended December 31, 2021. Based on the terms of the 2025 Convertible Notes, the holders cannot convert all or a portion of their 2025 Convertible Notes in the first quarter of 2022. When a conversion notice is received, the Company has the option to pay or deliver cash, shares of the Company&#8217;s common stock, or a combination thereof. As the </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i6028c4dd0abf4dd899dee24c08c0b248" continuedAt="ie967fa47afac4ef2bf2da1c101d7cd40"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company is not required to settle the 2025 Convertible Notes in cash, the 2025 Convertible Notes are classified as long-term debt as of December 31, 2021 and 2020. As of December 31, 2021, the Company had not received any conversion notices.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, the Company will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at its election. The initial conversion rate for the 2025 Convertible Notes is 27.5198 shares of common stock per $1,000 in principal amounts of 2025 Convertible Notes, equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i34af75623b2843a0a57023612b0339a8_I20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzMxMDc_8c1ac056-c711-461d-a13e-83ff3da87eff">36.34</ix:nonFraction> per share of common stock. The conversion rate is subject to adjustment as described in the Indenture. In addition, following certain corporate events that occur prior to the maturity date as described in the Indenture, the Company will pay a make-whole premium by increasing the conversion rate for a holder who elects to convert its 2025 Convertible Notes in connection with such a corporate event in certain circumstances. The value of the 2025 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzM2NjA_ffb4a36f-6f03-458b-9852-ab7462a118e8">34.12</ix:nonFraction> on December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2025 Convertible Notes prior to May 6, 2023. The Company may redeem for cash all or any portion of the 2025 Convertible Notes, at its option, on or after May 6, 2023 if the last reported sale price of its common stock has been at least <ix:nonFraction unitRef="number" contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzQzMjY_4b955904-85ca-4b23-81ae-83636590bd9f">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="day" contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzQzODE_caabddf8-7965-4329-b143-bf03be68a5fe">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="day" contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzQ0Mzc_fbde7c50-fb7c-4b17-ac3e-4f5944976055">30</ix:nonFraction> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date of notice by the Company of redemption at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzQ2NjI_6e147508-a558-4a0e-a26d-b24697910246">100.0</ix:nonFraction>% of the principal amount of the 2025 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2025 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event involving bankruptcy, insolvency or reorganization events with respect to the Company occurs, then the principal amount of, and all accrued and unpaid interest on, all of the 2025 Convertible Notes then outstanding will immediately become due and payable. If any other default event occurs and is continuing, then noteholders of at least <ix:nonFraction unitRef="number" contextRef="i7e141e5dc5ac4d099c050eacf32e2ce1_D20200504-20200504" decimals="INF" name="neo:DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzUyMTg_7ae83524-27a0-49de-8eb0-6a0f59d09640">25.0</ix:nonFraction>% of the aggregate principal amount of the 2025 Convertible Notes then outstanding, by notice to the Company, may declare the principal amount of, and all accrued and unpaid interest on, all of the 2025 Convertible Notes then outstanding to become due and payable immediately. If the Company undergoes a &#8220;fundamental change&#8221; as defined in the Indenture, then noteholders may require the Company to repurchase their 2025 Convertible Notes at a cash repurchase price equal to the principal amount of the 2025 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Convertible Notes are the Company&#8217;s senior, unsecured obligations and will be equal in right of payment with its existing and future senior, unsecured indebtedness, senior in right of payment to its existing and future indebtedness that is expressly subordinated to the 2025 Convertible Notes and effectively junior to its existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness. The 2025 Convertible Notes will be structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of its subsidiaries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2025 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDkyNjc0OTc3ODQ_4cee7c7d-82d5-4b4d-b873-e347edc88afd">2.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDkyNjc0OTc3OTg_d8489857-7828-472f-bea1-08cc62b04cf6">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231" decimals="-4" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDkyNjc0OTc4MTI_03008c29-b9ee-46e0-8ef6-fb446b076c91">0.15</ix:nonFraction>&#160;million, for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively for the year ended December 31, 2021. The interest expense recognized on the 2025 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="ib2e710b5650c4cd790dff15ccb7d0cc9_D20200101-20201231" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY2OTY_90f3179b-5a25-47ab-8039-7a57cccaf43f">1.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ib2e710b5650c4cd790dff15ccb7d0cc9_D20200101-20201231" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY3MDA_6f611d20-8807-4576-884a-af18b7f3792d">4.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib2e710b5650c4cd790dff15ccb7d0cc9_D20200101-20201231" decimals="-4" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY3MDc_1d5911d3-f552-4a4b-ade2-0aca05c0ab62">0.07</ix:nonFraction> million, for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively for the year ended December 31, 2020. The effective interest rate on the 2025 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY3ODY_7804c3fc-cfce-4bd9-8742-c2525f47cc73">1.96</ix:nonFraction>%, which includes the interest on the 2025 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2025 Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyNDc_c5cf4263-c680-4f50-a6ef-8c2f6e0d902f">1.25</ix:nonFraction>% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, which began on November 1, 2020.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ie967fa47afac4ef2bf2da1c101d7cd40"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Maturities of Long-Term Debt</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEyNTIy_b351fc9c-f006-4d57-bd76-488e38992b60" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of long-term debt at December 31, 2021 are summarized as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzAtMi0xLTEtNTQ5NjcvdGV4dHJlZ2lvbjplNzk1MzFmNzA4MmQ0YmZjOTA2MjAwMDg4YjI1ODE2OV85MzQ1ODQ4ODM2MTM1_5ae48d67-81d6-4e18-b93a-820661377100">0.25</ix:nonFraction>% Convertible Senior Notes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzAtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjowZjlmMjdmNzk3NWM0OGQ0YTcyNDg5NDYwOWFiOGE1Ml80_e665d9b6-aa68-4920-aa61-94070387d716">1.25</ix:nonFraction>% Convertible Senior Notes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equipment Financing Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Long-Term Debt</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEtMi0xLTEtNDY4OTI_5464bcd9-d04b-496d-a07b-98e871789352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEtMS0xLTEtMzA1NzI_8bb020eb-3d29-4229-84ef-a9412c50234c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEtMy0xLTEtMzA1NzI_03af2d6a-0b1a-4786-9520-bbe7a7d28180">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEtNS0xLTEtMzA1NzI_f8b5f5f0-fd3c-420b-9ce7-1292db4b95b5">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzItMi0xLTEtNDY4OTI_9e3248ab-0b75-4da1-9451-8270450aa6c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzItMS0xLTEtMzA1NzI_6fd2dba9-52ad-411b-b9fb-ae1ddd20e226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzItMy0xLTEtMzA1NzI_f2dcfc5b-bd1e-475e-837a-72811a103db1">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzItNS0xLTEtMzA1NzI_cc7759d3-56d7-4a33-87de-3191ddc00f1b">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzMtMi0xLTEtNDY4OTI_3794ec29-a3f1-42b3-83ed-7ede494c04ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzMtMS0xLTEtMzA1NzI_8fd3f124-e72e-49c2-ad07-296ca826bfb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzMtMy0xLTEtMzA1NzI_369b9695-17a6-4579-bb3d-33531d8efaec">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzMtNS0xLTEtMzA1NzI_94fc541e-ee92-4465-a00b-41e71c7759f2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzQtMi0xLTEtNDY4OTI_c69b1ed5-5098-43e6-87e0-9c5a7097ad50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzQtMS0xLTEtMzA1NzI_c177b344-9837-4231-912e-b15b7135f941">201,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzQtMy0xLTEtMzA1NzI_2cb30602-b494-4084-b51f-ae67a8e9631e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzQtNS0xLTEtMzA1NzI_8365137d-86e3-4b58-bde8-fdb2ba4a1beb">201,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzUtMi0xLTEtNDY4OTI_cdafba0e-eeed-4856-8a5b-a0b2dff46149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzUtMS0xLTEtMzA1NzI_2a1142d4-2fe2-4949-84c6-1d97aa525fbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzUtMy0xLTEtMzA1NzI_a7f6af6c-8c51-4f05-b7e4-21080f42b1c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzUtNS0xLTEtMzA1NzI_0da076c3-a6a0-404d-a6f9-bfce6b7300ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtMi0xLTEtNDY4OTI_f8613eb1-5f0b-4b62-b6fa-f70786239aed">345,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtNC0xLTEtNzAwODQ_65fa3b0d-9362-4adf-ba6a-6e23e0579352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtNi0xLTEtNzAwODQ_14ef1293-437e-4bf6-8f92-a555171a7472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtOC0xLTEtNzAwODQ_1eb6c6a5-585a-4148-98db-d3536777e9ca">345,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="neo:LongTermDebtIncludingCurrentMaturitiesDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzctMi0xLTEtNDY4OTI_db741992-4c2f-4bf4-9cf5-e1c9fc60cc52">345,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="neo:LongTermDebtIncludingCurrentMaturitiesDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtMS0xLTEtMzA1NzI_a10f018b-f56a-4958-8b29-861638988b83">201,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtMy0xLTEtMzA1NzI_f537aaf8-5456-4a57-88ea-fa590b0af011">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtNS0xLTEtMzA1NzI_0f09072b-e851-47ea-90b8-24f6333ea5ad">547,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:&#160;Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtMi0xLTEtNDY4OTI_a11f55c7-ff43-45e7-ae8f-002a5af99d33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtNC0xLTEtNDY5MDc_ee5abe4d-d64e-4252-9896-801ebfe7cdf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtNi0xLTEtNDY5MDc_d8fc0589-8045-4b1a-997d-cec431681dd8">1,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtOC0xLTEtNDY5MDc_981dcd12-4202-4e56-94ed-2e79257aa78d">1,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzktMi0xLTEtNDY4OTI_dcf7df30-1d31-4d85-849d-1453d281e8c0">8,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzctMS0xLTEtMzA1NzI_07a504ea-05d3-4c77-9795-21271cc00db7">4,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzctMy0xLTEtMzA1NzI_9e43a472-eaf7-4849-9daa-a46f0471716b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzctNS0xLTEtMzA1NzI_0c72de7d-4dd5-489a-9167-8dbfb76866b5">13,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:&#160;Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEwLTItMS0xLTQ2ODky_8dc92b83-68d9-4eee-8d7e-9e738ca54206">208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtMS0xLTEtMzA1NzI_8d0a3104-6a3f-4977-907c-9828ea2e607d">506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtMy0xLTEtMzA1NzI_93ea2a7f-b2e2-4a24-8310-f272b1d65d92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtNS0xLTEtMzA1NzI_e14318d1-6b8b-481b-b262-60e43d03ab3a">714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzExLTItMS0xLTQ2ODky_17a618e0-29e2-4b27-83b1-14b4d38acede">335,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzktMS0xLTEtMzA1NzI_7235ed4d-1f70-4eb8-baee-10a38e5a8ae5">196,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzktMy0xLTEtMzA1NzI_f752a93a-ace4-4795-918f-390c8ed29e7d">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzktNS0xLTEtMzA1NzI_22853711-c42a-4575-a428-173cb82e61c1">532,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzIxMTQ_35008f57-c700-46ef-83f4-3758e3575f46" continuedAt="if0475bd38f6045c1aea791cda825574d" escape="true">Derivative Instruments and Hedging Activities</ix:nonNumeric></span></div><ix:continuation id="if0475bd38f6045c1aea791cda825574d"><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021 and 2020, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company did <ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="INF" name="us-gaap:LongtermDebtPercentageBearingVariableInterestAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzE2NDkyNjc0NDQxNDY_5156d0fc-c598-4706-a914-468428dccbc3"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:LongtermDebtPercentageBearingVariableInterestAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzE2NDkyNjc0NDQxNDY_df230200-d66d-463a-97c4-35ea1388eca2">no</ix:nonFraction></ix:nonFraction>t have any outstanding derivative instruments. In June of 2018, the Company entered into an interest rate swap agreement to reduce the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s exposure to interest rate fluctuations on the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s variable rate debt obligations.&#160;This derivative financial instrument was accounted for at fair value as a cash flow hedge to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effectively modify the Company&#8217;s exposure to interest rate risk by converting a portion of its prior floating rate debt to a fixed rate obligation, thus reducing the impact of interest rate changes on interest expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the swap agreement, the Company received a variable rate of interest based on LIBOR and paid a fixed rate of interest. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzIxMTU_218e3405-54b1-4444-bbb5-2a76c5ea019e" continuedAt="i20ae6233ea39427c943528553ff44610" escape="true">The following table summarizes the previous interest rate swap agreement.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i20ae6233ea39427c943528553ff44610"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.767%"><tr><td style="width:1.0%"></td><td style="width:47.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 2018 Hedge</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i47acf3b6354b4627a7978853e4d3e47f_I20211231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90YWJsZTowMGUzNTQ5OWJiODE0ZjUzODE2M2IzYTAzMTk2Njg2ZS90YWJsZXJhbmdlOjAwZTM1NDk5YmI4MTRmNTM4MTYzYjNhMDMxOTY2ODZlXzEtMi0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo3YWM4OTJhODlmNzg0MDhiODU5YjA4ODA3YjQyYTdhZF80_bc0b5847-8470-448a-9155-24e3cd9cee5f">70</ix:nonFraction> million</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 29, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One month LIBOR</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i47acf3b6354b4627a7978853e4d3e47f_I20211231" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90YWJsZTowMGUzNTQ5OWJiODE0ZjUzODE2M2IzYTAzMTk2Njg2ZS90YWJsZXJhbmdlOjAwZTM1NDk5YmI4MTRmNTM4MTYzYjNhMDMxOTY2ODZlXzUtMi0xLTEtMzA1NzI_01738699-4220-45e5-803f-a947bbbc2502">2.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 9. Debt, concurrent with the closing of the 2025 Convertible Notes, the proceeds from this transaction were used to pay off all amounts outstanding under the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Prior Senior Secured Credit Agreement, after which the Company had no outstanding debt with variable rate interest. On May 1, 2020, the remaining obligation to make any further payments under the swap agreement was terminated. As a result of the termination, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i0fa5b7dff3c2469793b45a7b9c0a39e3_D20200501-20200501" decimals="-5" name="neo:DerivativeTerminationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzEzMDQ_691972aa-2c63-4b8f-a1d3-a204e92a3d15">3.3</ix:nonFraction>&#160;million, which is included within loss on termination of cash flow hedge on the Consolidated Statements of Operations for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company did not have any such losses in the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value adjustments were historically recorded within other comprehensive income. Upon termination of the interest rate swap in 2020, the accumulated losses, net of tax of $<ix:nonFraction unitRef="usd" contextRef="i872473cddd404138b10ac6c363634e0c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzE4MjE_2bab34b7-d7fa-4ce2-94ec-50d449241c41">2.7</ix:nonFraction>&#160;million, related to the interest rate swap were reclassified from accumulated other comprehensive income to loss on termination of cash flow hedge on the Consolidated Statements of Operations for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:nonFraction unitRef="usd" contextRef="i0f2d85c36fbe4f798381a1b1b4a59d9d_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzIwMzE_27d0abc1-9917-4778-adae-a06585956db8"><ix:nonFraction unitRef="usd" contextRef="i25aa5942e458401b9ff510cbfb4e37f8_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzIwMzE_a984bfbd-cd03-435b-ac0e-0d896fc005e1">No</ix:nonFraction></ix:nonFraction> such reclassifications were recorded during the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2019.</span></div></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzE4OTU_009a0636-4b63-4318-8e4f-c35887f01741" continuedAt="i4d2abd700fa94d988ae666abb687a7c4" escape="true">Equity Transactions</ix:nonNumeric></span></div><ix:continuation id="i4d2abd700fa94d988ae666abb687a7c4" continuedAt="i7a4fd9ed86b142b28e4b70580647176e"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement Transaction</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company completed a private placement (&#8220;Private Placement&#8221;) to certain accredited investors of an aggregate of <ix:nonFraction unitRef="shares" contextRef="i46a03a2c735740e0a62ec8fcfd378af4_D20210618-20210618" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE3OTc_ff990096-e40f-4776-88c2-26f55ff70376">4,444,445</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5d84ea5eee6f466492f6a5f7b9c99c5f_I20210618" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4Mzk_9143cdd9-7dd9-43c8-b898-8b3c4e058f1d">45.00</ix:nonFraction> per share. The net proceeds to the Company from the Private Placement were approximately $<ix:nonFraction unitRef="usd" contextRef="i46a03a2c735740e0a62ec8fcfd378af4_D20210618-20210618" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4MjM_4502770b-285a-4d72-bd85-1fa11486fa3d">189.9</ix:nonFraction>&#160;million, after deducting fees to the placement agents and other offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i46a03a2c735740e0a62ec8fcfd378af4_D20210618-20210618" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4MDg_f995f037-26da-4770-b922-85d65b62d5a2">10.1</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i7a4fd9ed86b142b28e4b70580647176e"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock Issued for Acquisition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3. Acquisitions, the Company issued <ix:nonFraction unitRef="shares" contextRef="i909533f6893842af88add72e0b80061e_D20210401-20210430" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4NDc_5e160b85-5752-41c2-b334-94d1e7345d21">597,712</ix:nonFraction> shares of common stock as consideration for the acquisition of Trapelo in April 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Underwritten Public Equity Offerings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2021, the Company entered into an underwriting agreement relating to the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="i6f0072740fba4f1f957dc041083ebbbf_D20210106-20210106" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4NTY_147b22f5-6091-4dc1-9597-cd6d968f64bf">4,081,632</ix:nonFraction> shares of the Company&#8217;s common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if7813f0e28ca47909409d4d71f3f0cc2_I20210106" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4Njc_878685d7-d9e6-40c7-b829-28589469732b">0.001</ix:nonFraction> par value per share (the &#8220;2021 Common Stock Offering&#8221;). The price to the public in this offering was $<ix:nonFraction unitRef="usdPerShare" contextRef="if7813f0e28ca47909409d4d71f3f0cc2_I20210106" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4NzU_46426a1c-dacd-401a-af99-79bdade0d4a5">49.00</ix:nonFraction> per share. The net proceeds to the Company from the 2021 Common Stock Offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i6f0072740fba4f1f957dc041083ebbbf_D20210106-20210106" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4ODM_aecc16cc-057b-4ec5-829a-767c9556a517">189.9</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions and other offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i6f0072740fba4f1f957dc041083ebbbf_D20210106-20210106" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4OTk_9eef15ad-d327-46a8-b8f0-d4948cb7e2b0">10.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the underwriting agreement, the Company also granted the Underwriters a <ix:nonNumeric contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106" name="neo:SaleOfStockOptionTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5MjU_a6bd43dc-9df3-4de9-b96f-7a542f3ab038">30</ix:nonNumeric>-day option to purchase up to <ix:nonFraction unitRef="shares" contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5MTQ_45133de9-5045-4363-82b1-0889503ca0a7">612,244</ix:nonFraction> additional shares of common stock at the public offering price, less underwriting discounts and commissions. On January 6, 2021, the underwriters exercised their option in full and purchased all <ix:nonFraction unitRef="shares" contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5MzE_a597f648-9326-4c9b-823c-ab4b24b98cc9">612,244</ix:nonFraction> shares. The net proceeds related to the option exercise were approximately $<ix:nonFraction unitRef="usd" contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5NDA_db633c38-0e37-41fe-8744-51496af77f5f">28.4</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions and other offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5NTU_1da7adda-9c20-4bdd-960e-a466a462d292">1.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2020, the Company entered into an underwriting agreement relating to the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzQ1Nw_af9c3cd6-1cda-41b3-ada2-9ae2ff4146a1">4.4</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9b6939f2ae8d44b0b65a46676533cb9a_I20200429" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzQ5OA_6bd14ab2-6481-44a3-9558-bc0c0397ae7c">0.001</ix:nonFraction> par value per share (the &#8220;2020 Common Stock Offering&#8221;). The price to the public in this offering was $<ix:nonFraction unitRef="usdPerShare" contextRef="i9b6939f2ae8d44b0b65a46676533cb9a_I20200429" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzYwMg_fbab19b2-0444-4c72-8542-f8a5fe87b4e2">28.50</ix:nonFraction> per share. The net proceeds to the Company from the 2020 Common Stock Offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzcwMw_efbe9d38-745a-47c7-bbc7-c62de2ed98bd">117.9</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions and other offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzgwNA_182eb1c8-4953-4b27-8774-7549eb40a339">7.5</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the underwriting agreement, the Company also granted the underwriters a <ix:nonNumeric contextRef="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429" name="neo:SaleOfStockOptionTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzg5OQ_7997cf05-7c39-45d5-b187-bfe32cd43ab7">30</ix:nonNumeric>-day option to purchase up to <ix:nonFraction unitRef="shares" contextRef="i59836b2a553946d0a448161d3100d995_D20200429-20200429" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzMQ_fa770917-59af-413f-980b-fa3c73413edb">660,000</ix:nonFraction> additional shares of common stock at the public offering price, less underwriting discounts and commissions. On May 29, 2020, the underwriters partially exercised their option and on June 3, 2020, purchased an additional <ix:nonFraction unitRef="shares" contextRef="i9f5d1a3736b248a992304f0788d7d8b5_D20200603-20200603" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzExNTU_0a73af93-150d-4491-99b9-b2a2ec33069a">351,500</ix:nonFraction> shares. The net proceeds related to the option exercise were approximately $<ix:nonFraction unitRef="usd" contextRef="i9f5d1a3736b248a992304f0788d7d8b5_D20200603-20200603" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzEyMzM_6a303601-bdf6-4a1b-8c79-8972b9656477">9.4</ix:nonFraction>&#160;million, after deducting underwriting commissions and other offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i9f5d1a3736b248a992304f0788d7d8b5_D20200603-20200603" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzEzMjM_8cf42dad-c0ce-4737-808a-a16bfa9b31b8">0.6</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMTI_7f1fd595-03bb-4c7f-b891-d15978dd16d6" continuedAt="i1a3c0fc9ff1c4800b6264c23316c06fe" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i1a3c0fc9ff1c4800b6264c23316c06fe" continuedAt="i013d1d319cca4650acb6375cc7097441"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2021, the stockholders of the Company approved an amendment to the Equity Incentive Plan, originally effective as of October 14, 2003, and previously amended and restated and approved by the stockholders on December 21, 2015, and then again on May 25, 2017 (the &#8220;Amended Plan&#8221;). The Amended Plan allows for the award of equity incentives, including stock options, stock appreciation rights, restricted stock awards, stock bonus awards, deferred stock awards, and other stock-based awards to certain employees, directors, or officers of, or key non-employee advisers or consultants, including contracted physicians to the Company or its subsidiaries. The Amended Plan provides that the maximum aggregate number of shares of the Company&#8217;s common stock reserved and available for issuance under the Amended Plan is <ix:nonFraction unitRef="shares" contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzg0OQ_1c2523c0-444e-46b9-843e-1fe49fb37495">25,625,000</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, stock options outstanding totaled <ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzkwNA_b4830abf-7db7-4139-b60e-4f1aa8885d84">3.0</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzkxMQ_f38dc419-dbd0-4b65-8d87-9ca6096e4f31">3.8</ix:nonFraction> million shares, respectively. As of December 31, 2021 and 2020, a total of approximately <ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzk3OA_638b3eb6-4527-4618-aea7-50b6cb905120">6.8</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzk4NQ_358ad6dc-0bc8-41cb-b54f-f401658b170c">1.0</ix:nonFraction> million shares, respectively, were available for future option and stock awards under the Amended Plan. Options typically expire after <ix:nonNumeric contextRef="i681790e0336945d58f151a6d5808acd9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzExMTU_528f45c9-5dca-4658-8318-9e5915a038bc">5</ix:nonNumeric> or <ix:nonNumeric contextRef="i831056d6c8b04c6c8f9562bb6f5192df_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzExMjE_d3035432-d42e-4d4a-8916-53be8c8a9223">7</ix:nonNumeric> years and generally vest over <ix:nonNumeric contextRef="ie255c1c51fd744cca5a778a0da0a5155_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzExNTQ_d6743759-0187-4516-934d-de42f54bc992">3</ix:nonNumeric> or <ix:nonNumeric contextRef="i9a253449c87943b39413bdd71acbf134_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzExNjA_411f9e88-ec05-4f8c-a465-58b28e7180f6">4</ix:nonNumeric> years, but each grant&#8217;s expiration, vesting, and exercise price provisions are determined at the time the awards are granted by the Compensation Committee of the Board of Directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock award granted during the year ended December 31, 2021 was estimated as of the grant date using a Black-Scholes model. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMDU_448da517-2982-40d1-9be9-e471c8b62e32" continuedAt="i0e85dbd216264f52a6e31d6f35f00f7f" escape="true">The fair value of each stock option award granted during the years ended December 31, 2020 and 2019 was estimated as of the grant date using a trinomial lattice model. Weighted average assumptions used during the years ended December 31, 2021, 2020, and 2019 are as follows:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i0e85dbd216264f52a6e31d6f35f00f7f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie255c1c51fd744cca5a778a0da0a5155_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo0YmM1Y2QzNTJjMDE0NGQzYTkyMmFiZmJjYTE3ZjY4Nl80_df3fee80-749e-43f2-a3b3-d498e7d43618">1.2</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i9a253449c87943b39413bdd71acbf134_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo0YmM1Y2QzNTJjMDE0NGQzYTkyMmFiZmJjYTE3ZjY4Nl85_f13f4874-935b-4188-b046-0c5ed431ae8a">5.5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4be580f98fbf4b08bfe75fadf6a6c0a0_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtMy0xLTEtMzA1NzIvdGV4dHJlZ2lvbjozNjk5ZWQwZjgwZmQ0ZDg5ODA2YWY0NDU3M2VmNjY4Ml80_cc26de99-91c7-4666-8801-99f3fbde23f3">3.8</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="ic76afff429474a7f9ebd89074d5938d6_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtMy0xLTEtMzA1NzIvdGV4dHJlZ2lvbjozNjk5ZWQwZjgwZmQ0ZDg5ODA2YWY0NDU3M2VmNjY4Ml85_07d17880-cc73-41bc-adc0-3048872e4ce6">5.5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib552bd7af98f40b89fa495c675994501_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtNS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjozNjNkZDBkZTZlNGQ0NTdhOWQ2YjFiNjM0ZDU3ZjFmNl80_102fbbed-a6a1-42ed-beda-4cd8d97dd37c">3.0</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i85dd1e5d4a554aae80eca8c6f52b6874_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtNS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjozNjNkZDBkZTZlNGQ0NTdhOWQ2YjFiNjM0ZDU3ZjFmNl85_12c6481c-9007-4efb-a4b6-8944febfc672">5.5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (%)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzItMS0xLTEtMzA1NzI_42c63142-3814-4eb7-b009-16d4a0e91045">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzItMy0xLTEtMzA1NzI_e71c3857-8bf8-4228-8555-56d461b8b2cf">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzItNS0xLTEtMzA1NzI_72167283-4c94-4024-877e-afe64b2f7818">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (%)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzMtMS0xLTEtMzA1NzI_b0dcaaf7-ace2-462f-a309-0990548b1ae6">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzMtMy0xLTEtMzA1NzI_de64cef0-d517-4326-9148-dbf5f0281860">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzMtNS0xLTEtMzA1NzI_588dcb3f-22ae-4ec6-af98-008534910934">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (%)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzQtMS0xLTEtMzA1NzI_d7b9dbce-1b63-44a3-b9ba-e59a8970bf8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzQtMy0xLTEtMzA1NzI_c133ba45-56dc-48f5-833a-492b0d32d9b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzQtNS0xLTEtMzA1NzI_92744a98-cb9e-403f-8a79-7c4a83269b4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value/share at grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzUtMS0xLTEtMzA1NzI_b0612148-71c1-41e4-a7e2-3728ec3cb0f4">18.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzUtMy0xLTEtMzA1NzI_5c4bfbcf-bdce-4349-a790-ca2b9f34d1ff">8.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzUtNS0xLTEtMzA1NzI_284f2356-88f3-42b0-b854-ea48e1ae2491">5.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i013d1d319cca4650acb6375cc7097441" continuedAt="i9fdee03f7bae4d4685a13b864abedd61"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMDY_5fe3dec5-bc33-404d-9c16-b8ab133afb2b" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of the stock options are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:63.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEtMS0xLTEtMzA1NzI_048a5195-78e3-4e1d-ae08-b6162a65eb03">6,839,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEtMy0xLTEtMzA1NzI_db467ca7-9a92-49f7-911d-52813d0c7222">7.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzItMS0xLTEtMzA1NzI_1c270574-3c24-484b-a447-56392fa39308">969,720</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzItMy0xLTEtMzA1NzI_2c22a362-91f6-4eea-866b-8c3e30713d21">19.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzMtMS0xLTEtMzA1NzI_d0b226e5-8a29-407f-83fe-c9c8635654cc">2,309,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzMtMy0xLTEtMzA1NzI_53983478-6d80-4062-9c1a-75ba3ac94647">6.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzQtMS0xLTEtMzA1NzI_3df756c7-b6c7-4043-bc74-ae2625afbdd6">180,927</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzQtMy0xLTEtMzA1NzI_c0bfb96f-f75d-4b11-a5f7-a186d6fd912c">13.34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzUtMS0xLTEtMzA1NzI_cbf694fd-5be4-464c-8fb7-e655535bad50">5,318,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzUtMy0xLTEtMzA1NzI_d1b24107-148f-4965-8fea-8fd8f88041ab">9.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzYtMS0xLTEtMzA1NzI_beec8459-3050-4fea-9275-fa286767a903">845,120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzYtMy0xLTEtMzA1NzI_113a1b57-cecc-41f6-8168-3436aed09f0d">28.33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzctMS0xLTEtMzA1NzI_5fea29e4-628f-4be5-81cd-bdf4b577ef43">2,310,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzctMy0xLTEtMzA1NzI_a9a5060d-a458-495a-82cb-ae8e1759174d">7.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzgtMS0xLTEtMzA1NzI_9c68456a-878b-42a4-92f4-6f764f0f22d8">67,004</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzgtMy0xLTEtMzA1NzI_1c9da70a-85ff-4def-b678-45caba76f9d0">16.37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzktMS0xLTEtMzA1NzI_ae69451d-ac76-4f3e-bc15-21c795548144">3,785,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzktMy0xLTEtMzA1NzI_64ae3e78-b109-4a54-b4ef-807146a82027">15.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEwLTEtMS0xLTMwNTcy_72fcaa4d-bbfe-4814-b80a-b2e4fcd6b586">1,232,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEwLTMtMS0xLTMwNTcy_3e4f913c-ba3c-40b4-b93e-e17bf360a815">42.13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzExLTEtMS0xLTMwNTcy_c04388d2-9453-4bf0-ace8-f8421e272669">1,372,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzExLTMtMS0xLTMwNTcy_2871130b-6037-4d23-af98-16a8653df0bb">9.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEyLTEtMS0xLTMwNTcy_55607cd6-6f5e-48ff-8eb0-488da1f32229">684,238</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEyLTMtMS0xLTMwNTcy_78c476c6-c85f-4066-b83d-f06bce1ade61">29.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEzLTEtMS0xLTMwNTcy_c8d66552-5b6d-414e-a612-9e3eb1b8f268">2,961,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEzLTMtMS0xLTMwNTcy_6c53de8d-7196-44c2-a9d2-9b7af78ec6d9">25.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzE0LTEtMS0xLTMwNTcy_5cee1865-240b-4a02-8a08-f7a04cb46222">1,668,356</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzE0LTMtMS0xLTMwNTcy_57c12d73-e6f3-4dee-ba00-faeeeb14ba7f">15.29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMDg_40ccb855-35f3-49bd-9878-a2975dfcae4b" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number and weighted average grant-date fair values of options non-vested at the beginning and end of 2021, as well as options granted, vested, and forfeited during the year were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:63.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzEtMS0xLTEtMzA1NzI_380fdd55-b573-484c-9b02-45c35c50b028">2,163,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzEtMy0xLTEtMzA1NzI_ae828293-dfb9-4c5b-8bba-2310b68c400c">6.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzItMS0xLTEtMzA1NzI_35c887ce-1096-4390-b267-70aa1b19bcfe">1,232,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzItMy0xLTEtMzA1NzI_80f9f87b-d56b-43c0-bc11-6e0ec7c2a86e">18.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzMtMS0xLTEtMzA1NzI_0ec034d4-f138-47bb-b0b1-09eba4eff272">1,421,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzMtMy0xLTEtMzA1NzI_91c53556-11b5-44fd-80fe-866b88a4ea2d">8.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzQtMS0xLTEtMzA1NzI_dfa3aa61-8f7f-4479-ac50-f69cf3ca6047">681,984</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzQtMy0xLTEtMzA1NzI_1475499d-12be-4991-a0a1-edb2da6d6376">9.58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzUtMS0xLTEtMzA1NzI_efdfc583-4522-4089-a7bc-f97096ee9c28">1,292,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzUtMy0xLTEtMzA1NzI_1c352141-2fd4-4f01-ad2a-ee3c1a5abb47">13.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMTA_ba42eb3b-04ad-46db-acf0-3ec4e8f5792c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the options outstanding at December 31, 2021:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:32.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prices ($)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life (Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life (Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo0ODY3YzRjMTU1ODg0ZTFmYjAxMTY5NTI3YTQyYWIwZl80_f58ad63e-ddf5-44e2-ae2b-b0ce1a438a6a">7.27</ix:nonFraction> &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo0ODY3YzRjMTU1ODg0ZTFmYjAxMTY5NTI3YTQyYWIwZl85_644d61d3-7386-41d2-9514-da040b2da3c8">8.21</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i971c2719748f46e78600d16ad130da2f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMi0xLTEtMzA1NzI_d86aeda3-17c5-4790-acac-6cbd1e1b8a05">638,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItNC0xLTEtMzA1NzI_058144a5-b3d2-423c-a267-cb1c825df380">0.95</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i971c2719748f46e78600d16ad130da2f_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItNi0xLTEtMzA1NzI_d3807f32-b0ab-4edd-8111-87c978d56dc1">7.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i971c2719748f46e78600d16ad130da2f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItOC0xLTEtMzA1NzI_7ea215c8-2491-4fb8-aa7e-68ab2207b2ec">638,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMTAtMS0xLTMwNTcy_94c93aa7-46b0-4672-8f66-e2b2514b60c5">0.95</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i971c2719748f46e78600d16ad130da2f_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMTItMS0xLTMwNTcy_615cd5bb-ae6f-463c-ba51-d2c7be42fb9c">7.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo4MjE2ZjVkODcwOGU0YjkwOGYyMDk2ZmUxNTliODVhM180_4ef6544c-2363-48ca-a1a6-d86454400d3b">8.22</ix:nonFraction> &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo4MjE2ZjVkODcwOGU0YjkwOGYyMDk2ZmUxNTliODVhM185_8a6aaa95-bc22-4fd2-82af-84d84e6097f7">19.76</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b827dae344b4efeb7a3cec6f619da89_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMi0xLTEtMzA1NzI_bbfaca35-e5de-44e6-a9b0-b7de8093bad9">701,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtNC0xLTEtMzA1NzI_1fe969dd-2abd-45c6-b5a8-f68ff5345571">1.89</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b827dae344b4efeb7a3cec6f619da89_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtNi0xLTEtMzA1NzI_0b6065a3-5ec3-41d1-98ef-10b726b10045">15.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b827dae344b4efeb7a3cec6f619da89_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtOC0xLTEtMzA1NzI_a6c75564-b53b-4f9b-8836-097e675e2622">618,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMTAtMS0xLTMwNTcy_59edafc5-4d1c-4bc6-a6a7-ffb344475d33">1.80</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b827dae344b4efeb7a3cec6f619da89_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMTItMS0xLTMwNTcy_8b7dd06a-9507-4661-a766-3748d8581768">15.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i657183ed33254a23a110400913bd73a3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjpjYmEzMWMwMDg4MDI0Y2RkYmNiZTA0NDdiNDNiMTQ5Ml80_c537eb12-ff09-44d0-8a79-29c52245d2a7">19.77</ix:nonFraction> &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="i657183ed33254a23a110400913bd73a3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjpjYmEzMWMwMDg4MDI0Y2RkYmNiZTA0NDdiNDNiMTQ5Ml85_96d0ba0d-cea2-4c57-bbab-051b39f167a2">27.97</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1ebf39f1a9949e98894465429e942a8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMi0xLTEtMzA1NzI_6b31cd60-da91-4b44-ac71-081764602aa8">359,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i657183ed33254a23a110400913bd73a3_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtNC0xLTEtMzA1NzI_c6782e53-fb4d-47d4-80fe-00ef4666fdba">4.85</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1ebf39f1a9949e98894465429e942a8_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtNi0xLTEtMzA1NzI_51cc4754-c3d6-4330-9666-10ac2044f9f4">24.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1ebf39f1a9949e98894465429e942a8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtOC0xLTEtMzA1NzI_b290e764-6958-4e0d-9fef-ea7342a95ae5">112,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i657183ed33254a23a110400913bd73a3_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMTAtMS0xLTMwNTcy_2460fcac-1087-49d3-9e75-5074167b148b">4.68</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1ebf39f1a9949e98894465429e942a8_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMTItMS0xLTMwNTcy_23e9eb14-adef-43dd-9d65-3a7678f8954c">23.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5OGJhOTllNjJiODc0Y2JkOWQ0MWZkM2ZkMjVhYjllZV80_b595504a-ada0-4dd7-bf2b-aac6f9991406">27.98</ix:nonFraction> &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5OGJhOTllNjJiODc0Y2JkOWQ0MWZkM2ZkMjVhYjllZV85_20ceb19b-53d2-4a80-9ebc-d2d6e5a2b0fc">43.49</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e0d681c2fc34b14bac44c4021fc624f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMi0xLTEtMzA1NzI_38e00fa5-e7a5-4c61-920f-4302b8ebbc56">612,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtNC0xLTEtMzA1NzI_08afcc65-952f-446b-ac3c-f446381e694f">5.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e0d681c2fc34b14bac44c4021fc624f_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtNi0xLTEtMzA1NzI_68b78ae5-1e63-434f-80c5-6c48c915a8a0">31.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e0d681c2fc34b14bac44c4021fc624f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtOC0xLTEtMzA1NzI_78db9f28-f35a-4a09-a5af-37c551f2ad54">298,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMTAtMS0xLTMwNTcy_f1fc68d9-0ef8-4a7e-b1fb-93b0985f90db">5.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e0d681c2fc34b14bac44c4021fc624f_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMTItMS0xLTMwNTcy_5d371170-28f3-4711-ab4b-ed3da3ec0d64">28.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo3YWM0NjljMzU2YWU0NzBjYjQ4ZDk5ZTMwZTIxMzE3Ml80_8c497739-409d-4864-b5bb-695c3acd1790">43.50</ix:nonFraction> &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo3YWM0NjljMzU2YWU0NzBjYjQ4ZDk5ZTMwZTIxMzE3Ml85_13c9964c-490a-4c23-a77c-42b10214edc2">55.40</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMi0xLTEtMzA1NzI_1ad2c12e-c8df-4b9b-ac91-86783d5c5f09">650,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtNC0xLTEtMzA1NzI_1958b782-e793-4d51-9f4a-829470a36984">6.33</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtNi0xLTEtMzA1NzI_6c90ade3-35ef-4436-907b-34d66b13628d">48.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtOC0xLTEtMzA1NzI_9e0c210f-8448-4aba-8dac-28c786546c28">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMTAtMS0xLTMwNTcy_3b887460-509a-4b35-b7c6-2db1cc7717b6">5.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMTItMS0xLTMwNTcy_47fdbd91-8246-4291-a784-95311277b07f">55.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctMi0xLTEtMzA1NzI_d812cfe4-8401-4fdd-9c37-178c74737ea9">2,961,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctNC0xLTEtMzA1NzI_41fb8c19-b9d0-4625-8869-9e3680307b24">3.79</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctNi0xLTEtMzA1NzI_067c3087-7894-412c-9e32-50a6aba14e36">25.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctOC0xLTEtMzA1NzI_e6be3b4f-8bf4-4b47-ba71-5007ebf5b128">1,668,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctMTAtMS0xLTMwNTcy_16fddc4a-144e-4e98-9371-63f24ad67c43">2.28</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctMTItMS0xLTMwNTcy_2f930d86-0ade-43d4-987a-1d5602f92437">15.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the aggregate intrinsic value of all stock options outstanding and expected to vest was approximately $<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzIwMDc_ea6a14a7-189f-4ebd-b416-6a61939a916f">36.1</ix:nonFraction> million and the aggregate intrinsic value of currently exercisable stock options was approximately $<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzIxMDE_5b82de54-638c-4985-8520-8dea316ba54c">31.6</ix:nonFraction> million. The intrinsic value of each option share is the difference between the fair market value of NeoGenomics&#8217; common stock and the exercise price of such option share to the extent it is &#8220;in-the-money.&#8221; Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $<ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="neo:CommonStockClosingPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI2MDc_21654615-86f6-4b9f-81ed-1b33eedeeb3d">34.12</ix:nonFraction> closing stock price of the Company&#8217;s common stock on December 31, 2021, the last trading day of 2021. The total number of in-the-money options outstanding and exercisable as of December 31, 2021 was approximately <ix:nonFraction unitRef="shares" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-5" name="neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI3ODk_6f7b163a-2844-4808-ba6f-8d07d838d57b">1.7</ix:nonFraction> million.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i9fdee03f7bae4d4685a13b864abedd61" continuedAt="i1d5b5cd3c27e49da963e420536298634"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised during each of the years ended December 31, 2021, 2020, and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI5MDQ_b277d9ac-2e4d-4aa9-97a1-2b7dcaac1d90">46.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI5MDg_2067700b-c71a-49a1-a108-8aad53841503">68.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI5MTU_117d42d4-7c92-4457-92f5-5ec5def40562">35.3</ix:nonFraction> million, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options. The total cash proceeds received from the exercise of stock options were approximately $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMxODU_eddf83d7-8ebb-4f5c-bb8f-e3b87b6e5bdd">13.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMxODk_1bfa0a1a-7e7b-4189-a734-770e0b4277cf">18.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMxOTY_9ba58c8a-b8d5-4885-a93a-1f0389f35858">12.4</ix:nonFraction> million for the years ended December 31, 2021, 2020, and 2019, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options granted during the years ended December 31, 2021, 2020, and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMzNDM_b4067974-239d-41e5-ab59-cfe8aff2899d">23.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMzNDc_17fb3b92-895d-40c8-93cc-56910ef84590">7.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-5" name="neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMzNTQ_39444cb0-9c30-4a8e-8777-62f1cd22a87f">5.6</ix:nonFraction> million, respectively. The total fair value of option shares vested during the years ended December 31, 2021, 2020, and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM0NzI_8a7b7c43-b6d1-4652-b6d2-ddd9d7daa404">11.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM0NzY_f0fe9465-84a5-4594-bad8-d9655126d8db">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM0ODM_01233582-9d0b-4d41-baf2-54ff85235c54">5.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense using the straight-line basis over the awards&#8217; requisite service periods. Stock compensation expense related to stock options for the years ended December 31, 2021, 2020, and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM3MzU_77154a54-df02-4587-93bc-7e57db9b52c0">11.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7c7e18a3aebc410cb31023371db1e1f0_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM3Mzk_922e503a-01f9-4370-bf29-18666f459594">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0be2f6f601ad4f47b7a64f324453f4ed_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM3NDY_bd1cafdf-53e6-4c64-8fe8-29bf3b41d7d9">6.8</ix:nonFraction> million, respectively, and is included in general and administrative expenses in the Consolidated Statements of Operations. As of December 31, 2021, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i4f7aefd0c1144fcda962a595d1d326e5_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NTQ_afe0fb10-1849-4c6e-8cd7-72cdeefd51ba">10.8</ix:nonFraction> million of total unrecognized stock-based compensation cost related to non-vested stock options granted under the Amended Plan. This cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQwNTA_6cb11938-da40-4b62-9a76-31b3b0825176">2.1</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzE2NDkyNjc0NTc4NzI_6cfc556c-3289-4785-9b65-22d303465022" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares and weighted average grant date fair values of restricted non-vested common stock at the beginning and end of 2021, 2020, and 2019, as well as stock awards granted, vested, and forfeited during the year were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:59.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2018</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44f2175697164b01b2aab1f8ff1898cb_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEtMS0xLTEtNDk0MTg_0d471a6f-7edd-4c6f-b106-c471b7015932">282,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44f2175697164b01b2aab1f8ff1898cb_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEtMy0xLTEtNDk0MTg_7eef14bc-2c73-4254-b8aa-5b5c54ee3ce5">9.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzItMS0xLTEtNDk0MTg_68c9396d-364e-40e4-9a0f-59d6fc474ebb">230,980</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzItMy0xLTEtNDk0MTg_1a4cb312-804d-44c8-a682-ca091e5fc4a5">19.93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzMtMS0xLTEtNDk0MTg_8af7f6f4-44c2-4a9b-85fa-daa7cf5f72e9">115,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzMtMy0xLTEtNDk0MTg_8f338193-4117-4323-b4dd-5ed8b03a6bd4">9.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzQtMS0xLTEtNDk0MTg_0dd82e77-d1a2-4c57-990e-38239df4a7b4">62,479</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzQtMy0xLTEtNDk0MTg_53a1063a-e2a9-4433-886f-7afdabe42d3f">12.53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83965d652d1d423f8ca32d729d617473_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzUtMS0xLTEtNDk0MTg_4500cc53-8424-45ac-a0c6-1202f4eec97f">335,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83965d652d1d423f8ca32d729d617473_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzUtMy0xLTEtNDk0MTg_c04bc743-1df4-4336-8fb4-db1dbdf5a9d0">15.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzYtMS0xLTEtNDk0MTg_303b2b53-03dc-48eb-af1f-c32a5a45cc74">149,012</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzYtMy0xLTEtNDk0MTg_e2c73f7c-b777-429a-8c7e-00a8444cd154">28.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzctMS0xLTEtNDk0MTg_3cfc1fe0-9ede-489c-aa2e-270ff816864b">184,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzctMy0xLTEtNDk0MTg_97f91c12-8a5c-4dd3-a7ec-9236d645386d">12.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzgtMS0xLTEtNDk0MTg_30cc4641-76de-4017-9112-8ada873617a0">8,292</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzgtMy0xLTEtNDk0MTg_0f23da39-af46-457d-b20f-d6596a8b3471">20.75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec0d080a2339420d89dc78184ef8b898_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzktMS0xLTEtNDk0MTg_737fa22d-f723-4b7e-9184-c800423269b8">291,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec0d080a2339420d89dc78184ef8b898_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzktMy0xLTEtNDk0MTg_bfebe679-3651-49ad-822f-02e572eb0a8c">23.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEwLTEtMS0xLTQ5NDE4_d87adb12-6eed-4f24-9951-7a7d57bbd707">936,648</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEwLTMtMS0xLTQ5NDE4_694dcf76-dcee-4bf3-bd5a-4177f39d1b0a">39.52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzExLTEtMS0xLTQ5NDE4_4ba9d128-3cba-42f3-814b-2c779825c899">213,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzExLTMtMS0xLTQ5NDE4_9f6f92d6-112c-4fc0-8db2-d3138e3e8f68">32.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEyLTEtMS0xLTQ5NDE4_61b94e7f-9aa9-402f-af12-406e0cfcf11a">163,359</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEyLTMtMS0xLTQ5NDE4_2a9a9b13-d11a-454f-9b9b-0bbe701f51f5">38.58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if16aafa54e7c4291827eb4a4a779b7fb_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEzLTEtMS0xLTQ5NDE4_2bf4da74-eaae-47fe-82bd-8bb28929d010">851,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if16aafa54e7c4291827eb4a4a779b7fb_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEzLTMtMS0xLTQ5NDE4_a5f785c2-cca2-4546-8691-58a55116a30b">36.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense related to restricted stock for the years ended December 31, 2021, 2020, and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQxMDY_8489648d-e600-4673-a7b7-5a27fb7e7f0e">9.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQxMTE_d19f4026-275b-41bc-93b6-416842e81585">3.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQxMjA_4f69823e-f172-4a09-b869-35eb26960b00">2.6</ix:nonFraction> million, respectively, and is included in general and administrative expenses in the Consolidated Statements of Operations. As of December 31, 2021, there was approximately $<ix:nonFraction unitRef="usd" contextRef="if16aafa54e7c4291827eb4a4a779b7fb_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQyMzA_36005950-4dc6-49f7-9c4d-a338f90bf7d2">24.3</ix:nonFraction> million of total unrecognized stock-based compensation cost related to non-vested restricted stock granted under the Amended Plan. This cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQ0MzA_92f2112d-eeb8-4259-ac81-1a5ee17e8875">2.6</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company granted certain senior-level executives performance stock units (&#8220;PSUs&#8221;) representing <ix:nonFraction unitRef="shares" contextRef="i7d981c543aef4926ad686ff97522008d_D20210701-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzkzNDU4NDg4NDU1Mjg_05d062af-b644-4c23-9e72-76896e118421">356,548</ix:nonFraction> common shares with a weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d981c543aef4926ad686ff97522008d_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDMxMDU_56f1cd3c-5eeb-40d0-bd3e-e1c2d693ba2d">44.87</ix:nonFraction> to vest upon the achievement of time-based service conditions with vesting through June 30, 2024, and certain performance goals, including financial performance targets and operational milestones. As of December, 30, 2021, these certain senior-level executives agreed to forfeit all of the granted PSUs. For the year ended December 31, 2021, no stock-based compensation related to the PSUs was recorded in the Consolidated Statements of Operations and the cancellation of these awards had no impact on the Consolidated Financial Statements. Concurrent with this forfeiture, these certain senior-level executives were granted restricted stock awards. These awards vest ratably over <ix:nonNumeric contextRef="i4bb9f08a180f4313aa2080d8df018f76_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzE2NDkyNjc0NTgxMTc_3a413eb9-afa5-46a8-a283-7fd94ae79417">three years</ix:nonNumeric> with the first tranche vesting on December 31, 2022. For the year ended December 31, 2021, expense related to these awards is included in stock-based compensation expense related to restricted stock.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i1d5b5cd3c27e49da963e420536298634"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Modification of Stock Option and Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, the Culture and Compensation Committee of the Company&#8217;s Board of Directors approved the accelerated vesting of <ix:nonFraction unitRef="shares" contextRef="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1NjY_a3347345-3bfa-4b66-bf6b-e2ae13e4e7b6">284,597</ix:nonFraction> previously granted time-vesting stock option awards and <ix:nonFraction unitRef="shares" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1NTc_5b1630c9-ea7b-4467-aa2e-62703d91eac3">101,574</ix:nonFraction> previously granted time-vesting restricted stock awards upon retirement of a director of the Company. The Company accounted for the effects of the stock awards as a modification, and recognized $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1NDM_4e1a54ea-6d18-4f92-ac1f-b2f23af4f192">6.6</ix:nonFraction>&#160;million of incremental stock-based compensation which consisted of $<ix:nonFraction unitRef="usd" contextRef="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1MTU_170bdc3c-a12f-4855-bc2d-1bd66b414e55">4.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1Mjk_ca704ee9-38fc-436e-a029-653e82121afd">1.7</ix:nonFraction>&#160;million for the acceleration of stock option awards and restricted stock awards, respectively for the year ended December 31, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an Employee Stock Purchase Plan (&#8220;ESPP&#8221;), under which eligible employees can purchase common stock at a <ix:nonFraction unitRef="number" contextRef="i5ed4a1d011e94710823acf48d3e17a2e_D20170525-20170525" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQyMTY_39bfa8dd-074b-435e-b270-8fba50ebd11f">15.0</ix:nonFraction>% discount from the fair market value.&#160;Stock-based compensation expense related to the ESPP for the years ended December 31, 2021, 2020 and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="i2b45da9a6c9a4f8c9594977540bd40f9_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQzNjE_48a7eb05-c495-4108-bde4-bd7267f49249">1.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i679ecadf68b64358a44f898cebaed8f9_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQzNjU_2599a7b8-17e4-4671-977c-94439bdd5861">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1e4de4fe398a4353b1bfc64e3f2090b9_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQzNzI_1d44bad3-51ed-4098-a0c8-92096effa3a9">0.6</ix:nonFraction> million, respectively.&#160;Shares issued pursuant to this plan were <ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQ0MzE_06cd597d-4649-41c1-9749-670744b73f2a">112,094</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQ0MzU_1a23e509-78c9-457e-ab7c-58e1f03f8f91">138,309</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQ0NDI_e7e1be9d-9142-4b48-8603-558cac6ac6a6">141,908</ix:nonFraction> for each of the years ended December 31, 2021, 2020, and 2019, respectively.</span></div></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgwNzE_bf211c05-ef26-4dfb-8dae-66ceaff65608" continuedAt="id7e18a3bab0147ed9c170887f7467898" escape="true">Revenue Recognition </ix:nonNumeric></span></div><ix:continuation id="id7e18a3bab0147ed9c170887f7467898" continuedAt="ic860b13bbc1d451793e62884c987075e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s <ix:nonFraction unitRef="segment" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgyNDYzMzcyMTY2MzY_224d7d61-7314-49c0-99e5-cfeb47447454">two</ix:nonFraction> reportable segments for which it recognizes revenue are (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s specialized diagnostic services are performed based on a written test requisition form or an electronic equivalent. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgyNDYzMzcyMTY2Mzk_c698fd18-7163-4480-8ebb-4a80ee76eebe">Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharma Services segment generally enters into contracts with pharmaceutical customers as well as other CROs to provide research and clinical trial services ranging in duration from one month to several years.&#160;The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, and/or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is usually recognized over time based on the number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to the sponsor(s) at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics is the sale of de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ic860b13bbc1d451793e62884c987075e" continuedAt="ifb157ba90e6a4f118f9a56b0e6d1790c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected in advance of services being provided are deferred as contract liabilities on the Consolidated Balance Sheets. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. Contract assets are established for revenue recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets. All others are classified as non-current assets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customers, either immediately or according to advance notice terms specified within the contracts.&#160;All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgwNzI_8600ab1a-9ff2-439c-a3f9-917064fc765c" continuedAt="ifbffdc40c0114fbf86629c9be6385ada" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the values of contract assets, capitalized commissions, and contract liabilities for Pharma Services as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzEtMS0xLTEtMzA1NzI_8ff74ecf-b520-4fab-877e-ac1b1ee79c2e">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzEtMy0xLTEtMzA1NzI_8a4fba86-6a7a-4fd8-b2ef-512604bf9065">1,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzItMS0xLTEtMzA1NzI_7d85ffdb-8091-4c77-a692-c88b2f8d5a3e">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzItMy0xLTEtMzA1NzI_1ada9798-cb3c-49a4-9559-0a29c813b2a9">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzMtMS0xLTEtMzA1NzI_20ea7322-e185-492f-b54f-343f4aa0bb23">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzMtMy0xLTEtMzA1NzI_5f01ad9b-f4cd-4004-b1f0-832ca6b1ecb5">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma capitalized commissions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzUtMS0xLTEtMzA1NzI_00d1e0b5-e49f-47d7-81a4-e07ec9bddac6">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:CapitalizedContractCostNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzUtMy0xLTEtMzA1NzI_430a4552-f885-4022-80ce-7a4eb937af47">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma capitalized commissions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzYtMS0xLTEtMzA1NzI_ed21a1e2-6e27-41c1-93bd-1a8eb6648f52">882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzYtMy0xLTEtMzA1NzI_ff37bf89-d47e-4f15-ba20-a7d09dba538f">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma capitalized commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzctMS0xLTEtMzA1NzI_1ea1f922-a20c-4901-a498-8a69b8b46bcd">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:CapitalizedContractCostGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzctMy0xLTEtMzA1NzI_8fc7f86f-9195-427f-a4e0-c35fb28fa246">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzktMS0xLTEtMzA1NzI_17df48fe-9942-4a2d-8902-62aa45117d1b">5,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzktMy0xLTEtMzA1NzI_521904d8-7965-429a-a64e-795afe7eee6d">4,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzEwLTEtMS0xLTMwNTcy_405e6dd9-d112-47e3-b95f-60c10d9bc354">917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzEwLTMtMS0xLTMwNTcy_4bb603ed-a7f8-4cc4-a4f8-3a2fbb09d553">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzExLTEtMS0xLTMwNTcy_0e705834-6041-464c-849b-f91d5e0e8629">6,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzExLTMtMS0xLTMwNTcy_25f35f95-7575-4098-8112-ac31cf3d4798">4,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded within other current assets on the Consolidated Balance Sheets. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Recorded within other assets on the Consolidated Balance Sheets. </span></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="ifbffdc40c0114fbf86629c9be6385ada" continuedAt="i405ec692662a42f8aedfce0539501f12">(3)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i405ec692662a42f8aedfce0539501f12"> Recorded within other long-term liabilities on the Consolidated Balance Sheets.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized for the years ended December 31, 2021, 2020, and 2019, related to Pharma contract liabilities outstanding at the beginning of each year was $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYxNjY_f3758756-a90e-45f4-94cb-f246e9aa20ca">4.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYxNzM_d4986cc5-8f4f-4aae-a35c-3d4d0bac7394">2.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzIxOTkwMjMyNjYxNzA_11afe809-796f-46f5-b616-005964446022">2.2</ix:nonFraction> million, respectively. Amortization of capitalized commissions for the years ended December 31, 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYyNzA_45fd3ace-36f8-48ab-9632-443ad20f3375">1.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYyNzQ_fec6af43-3748-4d9a-9ddf-6ec706728696">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYyODE_e7524103-b5b8-4ea6-b878-3143150b7fbc">1.2</ix:nonFraction>&#160;million respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company signed approximately $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-6" name="neo:RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYzNTc_366ec393-e654-4d9b-8fd1-f2ec6c66489c">172</ix:nonFraction>&#160;million in net new contracts. At year-end total backlog was approximately $<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzY0NDI_ccd18126-b26b-43a9-bc86-7fa0f7f47cc1">267</ix:nonFraction>&#160;million, substantially all of which contain cancellation provisions. The Company applied the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The unsatisfied existing performance obligations under long-term contracts as defined by ASC Topic 606, Revenue from Contracts with Customers, differs from backlog in that these obligations do not include wholly unperformed contracts where the promised consideration is variable and/or the application of other practical expedients.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered various factors for both its Clinical Services and Pharma Services segments in determining appropriate levels of homogeneous data for its disaggregation of revenue; including the nature, amount, timing, and uncertainty of revenue and cash flows. Clinical Services categories align with the types of customers due to similarities of billing method, level of reimbursement, and timing of cash receipts. Unbilled amounts are accrued and allocated to payer categories based on historical experience. In future periods actual billings by payer category may differ from accrued amounts. Pharma Services relate to contracts with large pharmaceutical and biotech customers as well as other CROs. Because the nature, timing, and uncertainty of revenue and cash flows are similar and primarily driven by individual contract terms Pharma Services revenue is not further disaggregated.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ifb157ba90e6a4f118f9a56b0e6d1790c"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgwNzA_aace6c02-065c-4bcd-95b5-d983cbc54d2a" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the disaggregation of net revenue for both the Clinical Services and Pharma Services Segments for the years ended December 31, 2021, 2020, and 2019 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.369%"><tr><td style="width:1.0%"></td><td style="width:37.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Client direct billing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667bb3b470c64da985250798b766a649_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzItMi0xLTEtMzA1NzI_e46c4ca9-eccf-4958-98dc-cfca00e139aa">252,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d47d42a743b474492f4e32571a3f05e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzItNC0xLTEtMzA1NzI_0001c4b3-cf9c-4250-a110-576d934ba8f0">240,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f72e0eca1d419dab353fa6c8a23098_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzItNi0xLTEtMzA1NzI_02e3744d-9670-46de-aa5c-9f4641ba5767">212,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i321637f0a7b540bdbb4033a0247f471f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzMtMi0xLTEtMzA1NzI_c86a91ba-b1c3-4e73-99a7-b19b92ed0e45">78,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if213c108cbd74502ad64e78f83030eaf_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzMtNC0xLTEtMzA1NzI_2445f0a5-ce2b-4d62-8fe2-bfbc2ee76210">76,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id558c0253e714d4fa8959f36f7ace8af_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzMtNi0xLTEtMzA1NzI_b6557800-c4a4-4765-b3d2-db1ce9772965">83,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Medicare and other government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5278b10f214b99ae816d90c219b11f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzQtMi0xLTEtMzA1NzI_15de31e4-19fc-44f2-af31-93cbd9c1704b">72,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib515a6110c0c4a03b0ab671c0fd68174_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzQtNC0xLTEtMzA1NzI_c263cbab-85f1-45c5-a6de-df4350f79ed8">64,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie847e09d489543aea8789c0dfbead017_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzQtNi0xLTEtMzA1NzI_d4fdda24-cfd9-4fe8-a8e7-e8ae6b225924">64,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Self-pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0e7f7754324dedae9666c62419ea78_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzUtMi0xLTEtMzA1NzI_3e93c4a5-9355-4eaa-bc31-a292aef56e53">772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67fff1172685496bbaf7a54a6396eb92_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzUtNC0xLTEtMzA1NzI_926e9060-88d7-44e6-ab65-6f659d956d2c">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e92c7aad5c4209a4df55556c23b848_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzUtNi0xLTEtMzA1NzI_771ca7c5-feac-4f08-a937-c8ab16be1bfe">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ebc9da32df40f79360ad5da5aef714_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzYtMi0xLTEtMzA1NzI_8f16d2dd-15a0-4c21-9c42-2a9c4c218801">404,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d415270f85409cb33c97966be628d9_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzYtNC0xLTEtMzA1NzI_5276b1ac-d21c-4300-9086-93825ec2eeb8">382,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b900d497a954a51b916af633f093d2d_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzYtNi0xLTEtMzA1NzI_9c3ed9d1-5638-4b64-ae5c-ae7527c66ed7">361,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e7e38bca0a483382014babf710343a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzctMi0xLTEtMzA1NzI_68bc80c7-f777-4530-96aa-28c89ae8b9a7">80,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d041f360e72469b85c9fb255e34af5c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzctNC0xLTEtMzA1NzI_fabce891-25e6-4d45-aefe-845d78ca5300">62,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4187c911d534ee0a8aa9f97ffb938b1_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzctNi0xLTEtMzA1NzI_3879a177-cfe4-4639-83c9-c20779aa7d6a">47,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzgtMi0xLTEtMzA1NzI_63eab7bf-f623-469c-9c96-17980a384cd1">484,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzgtNC0xLTEtMzA1NzI_adf6059d-a2cb-4c5e-be6a-f2accf609ed2">444,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzgtNi0xLTEtMzA1NzI_a8ab81e6-c2b6-4981-a2b5-2e7f86c5be1f">408,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3MzI_23cb07f9-7402-4b73-a6f4-1656ffb39a59" continuedAt="i7e1ecf3e1ddc4ce9b06064709ed7a063" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i7e1ecf3e1ddc4ce9b06064709ed7a063" continuedAt="i8911a59c9cce4ce6982b75edf72f8197"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act impacted a number of provisions of the tax code, including the eligibility of certain deductions and the treatment of net operating losses (&#8220;NOLs&#8221;) and tax credits. The CARES Act did not result in any material adjustments to the Company&#8217;s income tax provision for the year ended December 31, 2021, or to its deferred tax assets as of December 31, 2021.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3Mjc_ec8fb0e3-c695-4ae7-84ac-176bd4010580" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) income before income tax benefit for the years ended December 31, 2021, 2020, and 2019 is as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income tax expense (benefit): </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ccf651c92142fb87ac4f3feb892173_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzItMS0xLTEtMzA1NzI_da0723fc-1f53-4c0b-aa5b-d9116315e827">24,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeeb6ff7726a404aa5ab12499665bd21_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzItMy0xLTEtMzA1NzI_a6ea2d7e-6440-451d-a609-d4075c232cc8">6,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37460a8ce1e41cfbb99f9a168dcda88_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzItNS0xLTEtMzA1NzI_96e6a9b4-cec2-4b86-aa20-be43ec8a1729">7,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2a4237d1df945f78f4dd92cf2d83177_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzMtMS0xLTEtMzA1NzI_f760f51f-d3c2-4029-95ae-56eba6c865e5">39,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83dc4513b1f24e378f0be8c6c7f73c50_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzMtMy0xLTEtMzA1NzI_52f0d078-efad-4f23-9527-0ef2a167cee5">7,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42ba577adb2b4ee4a77b0a9e0248c94e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzMtNS0xLTEtMzA1NzI_a68028af-a90f-4a47-8a43-88cec3002d35">3,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzQtMS0xLTEtMzA1NzI_a8fbd86d-b2bb-46b2-9280-c8a3ecb8cd93">15,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzQtMy0xLTEtMzA1NzI_ddc81225-8a60-4423-a74d-7696e1474198">14,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzQtNS0xLTEtMzA1NzI_3ee51c0c-b393-4f39-a763-2916f9d0b93f">3,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzgtMS0xLTEtMzA1NzI_260db9fd-91e7-4f70-89aa-4b260def0cf7">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzgtMy0xLTEtMzA1NzI_fc9532a8-7814-4d56-979a-528454f5ae41">434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzgtNS0xLTEtMzA1NzI_2a75bdd9-007c-4baf-a070-b05c1a2ee183">303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzktMS0xLTEtMzA1NzI_405e2c86-9906-4cb1-aa53-db2c7d851d9b">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzktMy0xLTEtMzA1NzI_627fee47-c056-4e66-a10a-c99ded6f3ed9">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzktNS0xLTEtMzA1NzI_4f24f67f-b7db-4e57-ad0d-ece6ff113dc9">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax (benefit) expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEwLTEtMS0xLTMwNTcy_1dae19ce-0bc2-492a-89da-ec7aee7df8b1">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEwLTMtMS0xLTMwNTcy_eba8b3f4-3511-4152-84fd-a3e777188e0c">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEwLTUtMS0xLTMwNTcy_ec365ade-10ff-429b-a82b-d71b6284879d">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEyLTEtMS0xLTMwNTcy_18c6974e-9248-4ea5-84c4-6910f6ac9ac7">575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEyLTMtMS0xLTMwNTcy_e98af8ca-dcc8-45ff-b2b8-1f4bc177f062">12,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEyLTUtMS0xLTMwNTcy_020f7a20-d6e0-4dec-a233-35cdb3d139b5">3,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEzLTEtMS0xLTMwNTcy_b5ce06bd-e5b1-4730-aceb-ea900074c8c6">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEzLTMtMS0xLTMwNTcy_95927d83-b045-4254-a2eb-c723e449ff1d">5,211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEzLTUtMS0xLTMwNTcy_8f73bbb8-20ad-42f1-9289-529cfa95db28">939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE0LTEtMS0xLTMwNTcy_24fd849c-fe22-4a88-aa61-9f0b862643de">7,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE0LTMtMS0xLTMwNTcy_414403ab-d877-4ff8-a383-4792d35a8e21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE0LTUtMS0xLTMwNTcy_73bd231c-e7e9-4682-b7a2-f7041bbf3f3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit provision</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE1LTEtMS0xLTMwNTcy_3e5a2f3a-e7fd-4a5d-9891-f8404608123a">6,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE1LTMtMS0xLTMwNTcy_c8ccf1d3-80ea-480b-8c88-98f8480f7504">18,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE1LTUtMS0xLTMwNTcy_b395fe5b-f12c-49a0-85d4-271a0540a0c2">4,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax benefit provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE2LTEtMS0xLTMwNTcy_4f4f1862-ec15-44d7-a426-4ce61cb4ae2c">6,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE2LTMtMS0xLTMwNTcy_77b482b1-9ae2-4efa-af6a-24fb4794895f">18,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE2LTUtMS0xLTMwNTcy_5aa08925-200e-4e25-9296-fd2780d581c8">4,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8911a59c9cce4ce6982b75edf72f8197" continuedAt="i37fa586ac4414d6986e63e9d096018b4"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3MzQ_685601fa-2ca3-437a-9026-7eb8b35d5df6" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the differences between the effective tax rate and the federal statutory tax rate for the years ended December 31, 2021, 2020 and 2019 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEtMS0xLTEtMzA1NzI_29b7b154-3f42-4575-9074-dfa4a31c8bb9">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEtMy0xLTEtMzA1NzI_5e0e024a-e254-4dde-a29f-fdd9762dee4e">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEtNS0xLTEtMzA1NzI_ec6094c1-2d11-4e9d-9b72-909dd9101cab">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzItMS0xLTEtMzA1NzI_5b502a4b-7b4f-42de-bf89-218a19c2cd2e">17.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzItMy0xLTEtMzA1NzI_89d86896-c38f-4e9f-8f41-5750b4914893">14.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzItNS0xLTEtMzA1NzI_48230148-9632-4032-9a6c-851ed074d492">19.47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" sign="-" name="neo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtMS0xLTEtODQ5NDk_8e98d9d2-e857-44f0-b6e3-8633e5408c2a">10.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtMy0xLTEtODQ5NDk_cddb94ad-c059-448b-b7ca-13488a6941ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtNS0xLTEtODQ5NDk_9e6c7b5b-38cc-4825-8c40-f6a642d93b2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Penalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" sign="-" name="neo:EffectiveIncomeTaxRateReconciliationPenaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtMS0xLTEtODQ5NDk_ba62d00c-8ad4-44e4-ba31-64bd7c70e997">15.61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" sign="-" name="neo:EffectiveIncomeTaxRateReconciliationPenaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtMy0xLTEtODQ5NDk_e7e17c2b-bc3f-4c5f-b909-1e0fc61c1f98">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationPenaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtNS0xLTEtODQ5NDk_09844c69-e443-42b6-a868-bab893831bb6">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtMS0xLTEtMzA1NzI_28b8f649-f275-4a82-954d-a7a78c5bba74">3.29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtMy0xLTEtMzA1NzI_3ead7abf-2e4a-4cc6-9090-fa66228576cb">1.41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtNS0xLTEtMzA1NzI_76745b17-5c1d-4aba-abca-373ade35a0dd">7.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtMS0xLTEtMzA1NzI_f411746c-27d1-4cf8-8faa-0d300023b975">0.96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtMy0xLTEtMzA1NzI_0b3f1317-6021-4f0a-9e71-2d5876afa7a2">65.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtNS0xLTEtMzA1NzI_87998ec9-8da0-4e15-a6e6-189569897fa2">135.12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inivata acquisition fair value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationTransactionExpenses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzUtMS0xLTEtMzA1NzI_86e611ff-e0a3-4802-9579-775904ffd2a8">159.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationTransactionExpenses" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzUtMy0xLTEtMzA1NzI_23f1e190-f05e-4924-b492-3aa8c275780a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationTransactionExpenses" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzUtNS0xLTEtMzA1NzI_c6e1667e-fd31-496f-a3aa-03aa5ab038cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzYtMS0xLTEtMzA1NzI_3e368cd6-8232-44b1-81d2-32d5a7c9bc1c">11.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzYtMy0xLTEtMzA1NzI_1756de7d-7b0d-4560-a10f-4202690d12c3">32.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzYtNS0xLTEtMzA1NzI_a909fb19-93cb-47cd-9329-31d05de08c2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzgtMS0xLTEtMzA1NzI_e8ce3a33-c226-4cce-a7d9-dc128ad5f5f9">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzgtMy0xLTEtMzA1NzI_1917a485-8ef7-4e8e-933d-b192f3d4ecda">1.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" sign="-" name="neo:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzgtNS0xLTEtMzA1NzI_cee452a1-5244-4f50-91f5-a5b107ed7195">3.32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision and other deferred tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzktMS0xLTEtMzA1NzI_29e46b6d-8b1f-4817-a98f-9b57f8346d53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" name="neo:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzktMy0xLTEtMzA1NzI_39d45dc3-02be-4b4d-ba08-83bf9f6b46d4">7.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" sign="-" name="neo:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzktNS0xLTEtMzA1NzI_1b864dab-e971-4353-a04b-c96577b16a6a">13.20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEwLTEtMS0xLTMwNTcy_f3a1b415-a585-4a6e-8343-7f37b58d7fa0">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEwLTMtMS0xLTMwNTcy_26210d4c-9008-4491-8e4b-0844c08794d9">1.64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEwLTUtMS0xLTMwNTcy_dafb83b7-1ab4-4592-863e-8a8cbf775ed8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzExLTEtMS0xLTMwNTcy_2efce88a-473e-49db-b3e3-d2dd2ae5b6e9">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzExLTMtMS0xLTMwNTcy_1b0e31b2-bc31-491a-9e78-f491f842261d">0.06</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzExLTUtMS0xLTMwNTcy_0b0f8428-3f0f-49a4-89b8-7775106cbd2f">2.78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEyLTEtMS0xLTMwNTcy_1990518a-5d46-4798-9f3a-00c2bb132137">138.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEyLTMtMS0xLTMwNTcy_0d4ad6a4-88ef-4c0e-8b19-82319eab01a5">8.97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEyLTUtMS0xLTMwNTcy_73aab69b-a115-445d-978b-18348b941b0e">25.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEzLTEtMS0xLTMwNTcy_faa52a3b-66e5-4106-abd0-54eed7213b5e">44.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEzLTMtMS0xLTMwNTcy_6c715ab4-b3e3-4745-9075-6fe9c7c4722f">129.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEzLTUtMS0xLTMwNTcy_84eb73c5-4777-4466-839a-bd124742af7b">119.66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3Mjk_596c404b-f694-4424-9959-6719e99ab139" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, deferred income tax assets and liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzItMS0xLTEtMzA1NzI_a2c2f144-9891-4fb3-8cd6-5af78f186e71">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzItMy0xLTEtMzA1NzI_cae80814-a63f-4edf-8302-13d67f78cc8b">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzMtMS0xLTEtMzA1NzI_d3cc74a8-c85b-4565-9f8e-673e14c2f24d">6,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzMtMy0xLTEtMzA1NzI_a20a8043-534b-4840-9001-997227408939">5,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry-forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzQtMS0xLTEtMzA1NzI_60e06839-6ab2-4679-85c6-9b6c6a269506">81,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzQtMy0xLTEtMzA1NzI_5ed36733-983a-44b7-a6a9-a29815397c14">33,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzUtMS0xLTEtMzA1NzI_d8887bd1-ec31-4566-b65c-4744430ba6ed">6,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzUtMy0xLTEtMzA1NzI_676044b5-2a6c-413f-85c7-690354d0a6a1">4,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzYtMS0xLTEtMzA1NzI_b41f28c4-ae6d-4013-ac40-cbeee1a9368d">2,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzYtMy0xLTEtMzA1NzI_20c5048a-2fe1-463e-9ec5-8a1744f13dd6">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzctMS0xLTEtMzA1NzI_9fa7746c-e614-46a7-9831-35bbfbe28cb0">19,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="neo:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzctMy0xLTEtMzA1NzI_fad8beb1-e2d6-4cfb-91d8-d0f440c2988e">11,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:DeferredTaxAssetsInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzgtMS0xLTEtODAyNTM_4d9c513d-2734-4046-82ba-d5a9ec44f689">886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="neo:DeferredTaxAssetsInterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzgtMy0xLTEtODAyNTM_e5d98487-0272-4628-ae9c-1cfe70ebf2d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzgtMS0xLTEtMzA1NzI_2e302243-46ec-4161-9772-489e2476e410">2,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzgtMy0xLTEtMzA1NzI_da7e1dec-cc38-4889-8112-81b5d51566a6">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzktMS0xLTEtMzA1NzI_e04690d7-a33e-4cdf-833e-1fa51cb2a4e9">120,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzktMy0xLTEtMzA1NzI_468ff168-b344-4f46-9a76-9c6395cff0d8">60,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzEwLTEtMS0xLTMwNTcy_41cb3b2e-c07d-4464-b032-42cec8d6de71">33,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzEwLTMtMS0xLTMwNTcy_8ef304f1-59e8-493d-898d-48b428802df7">2,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzExLTEtMS0xLTMwNTcy_e8f631fc-fcc4-4586-843e-450bec1ed052">87,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzExLTMtMS0xLTMwNTcy_18d06098-b69e-4fbd-a1c0-ea85f55b5f05">57,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="neo:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzEzLTEtMS0xLTMwNTcy_57eda328-2d10-4c67-b5e1-ff18da4b4b07">19,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="neo:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzEzLTMtMS0xLTMwNTcy_35cc1567-d59c-48da-8ab6-aab0754b7b93">11,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in non-consolidated affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE0LTEtMS0xLTMwNTcy_c3c6d9e3-8d96-4e36-ab2c-3bc3f0df1991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE0LTMtMS0xLTMwNTcy_c672b542-7142-4705-9f4d-7ffedee1f775">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE1LTEtMS0xLTMwNTcy_d86ddb4d-d81b-4c01-9a9f-94b6a8f0623f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE1LTMtMS0xLTMwNTcy_4954083c-ed72-4e85-8b05-a16dd8344596">6,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE2LTEtMS0xLTMwNTcy_6d1f5abd-8945-4e58-bb3b-37531646a032">108,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE2LTMtMS0xLTMwNTcy_b2abc8fa-8f30-4a4a-b192-0885ceffdb5d">29,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE3LTEtMS0xLTMwNTcy_a2c68b5d-aa83-4e35-9632-119e92b3aa07">15,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE3LTMtMS0xLTMwNTcy_d00215dd-b92f-4dbe-ac9f-3da5d921d51f">14,678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE4LTEtMS0xLTMwNTcy_4038249c-6d99-4ff9-9dab-fc3ed42db7e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE4LTMtMS0xLTMwNTcy_310e0e37-a2f0-4d42-97e8-39f327cd5fc6">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE5LTEtMS0xLTMwNTcy_74180a00-0524-4d86-8191-d8076030f891">143,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE5LTMtMS0xLTMwNTcy_fc24d4d3-53f6-4ec2-8d28-0db7f19c3959">62,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzIwLTEtMS0xLTMwNTcy_8f66c71d-db09-4544-8230-130a37edb379">55,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzIwLTMtMS0xLTMwNTcy_2c913921-630c-4bd1-b616-7f638e873e9c">5,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company has federal net operating loss carry forwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzgxOA_6d48d97b-94ba-445a-b8fe-a30ce39528ea">231.5</ix:nonFraction>&#160;million, foreign net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i6dccccc0a21b4ef3be05781945900129_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1Xzg4MA_636bcde4-d8ab-4388-9aeb-d245a83e4c6f">118.9</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="i24a99cf2affb44979b10edd8cc9305bf_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE2NDkyNjc0NjI0NzI_1abf866b-fdae-4926-b9dd-2e6450b183ca">96.4</ix:nonFraction>&#160;million in the United Kingdom, and state net operating loss carry forwards of approximately $<ix:nonFraction unitRef="usd" contextRef="id7819d6cd0da4e4da9a9fdcae4fb87ed_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1Xzk0NA_5c0084f9-6e8d-4984-953b-638a1690516f">112.8</ix:nonFraction>&#160;million. Federal net operating loss carry forwards will begin to expire in 2036. Under the Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, however, the deductibility of such federal net NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. State tax NOLs will begin to expire in 2022. NOLs in Switzerland and China begin to expire in 2024 and 2025, if not utilized in future periods. The NOLs in Singapore and the United Kingdom do not expire. As of December 31, 2021, the Company has federal R&amp;D credit carryforwards of </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i37fa586ac4414d6986e63e9d096018b4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $<ix:nonFraction unitRef="usd" contextRef="if495aff7c41d4b8aad8f6a3241978f33_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE4ODM_e22120f2-16bc-4664-b798-f501856568f9">5.5</ix:nonFraction>&#160;million that begin to expire in 2036 and state research and investment credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="id7819d6cd0da4e4da9a9fdcae4fb87ed_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE5ODc_3320143a-21d1-4f8b-a45f-dde30162b05e">3.8</ix:nonFraction>&#160;million that do not expire. An ownership change of more than 50 percent could result in a limitation of the use of net operating loss carryforwards and credit carryforwards under IRC Section 382 and the regulations thereunder. We have not conducted a formal study to determine whether there was an ownership change in prior periods that would limit the use of our net operating loss carryforwards and credit carryforwards under IRC Section 382. Management believes it is more likely than not that a limitation under Section 382 would not materially impact the realizability of the deferred tax assets related to federal and state net operating losses or credits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing all positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed. As of December 31, 2021 and 2020, management determined that sufficient positive evidence did not exist and concluded that it is more likely than not that a valuation allowance is required against foreign deferred tax assets. Accordingly, management established a full valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i6dccccc0a21b4ef3be05781945900129_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzMzMDQ_181f9c16-94fd-4b36-b88b-7f912a5d0698">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibe0dff7a9994470f9689008656bb381b_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE2NDkyNjc0NTQ0NTU_6a52a8e9-88ba-43d5-8cfb-b12fa68a2a4d">2.6</ix:nonFraction>&#160;million as of December 31, 2021 and 2020, respectively, related to the Company&#8217;s China, Switzerland and Singapore operations. As of December 31, 2021, management determined that sufficient positive evidence did not exist and conclude that it is more likely than not that a valuation allowance is required against certain domestic deferred tax assets. Accordingly, management established a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="if495aff7c41d4b8aad8f6a3241978f33_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE2NDkyNjc0NTQ0NDA_476e8cb8-b917-4c3c-b643-3d127d0ed2b0">28.9</ix:nonFraction>&#160;million related to the Company&#8217;s domestic operations as of December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States, as well as Singapore, Switzerland, China, United Kingdom and in various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment. For U.S. federal and most state purposes, the Company has open tax years ended December&#160;31, 2017 to December 31, 2020. For Switzerland, the Company has open tax years ended December 31, 2017 to December 31, 2020, for Singapore the Company has open tax years ended December 31, 2018 to December 31, 2020 and for United Kingdom the Company has open tax years ended April 5, 2018 to April 5, 2020. The 2017 U.S. Federal income tax filing is currently under examination by the IRS.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applied the accounting standard for uncertain tax positions and recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management&#8217;s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the unrecognized tax benefits as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3MjU_20598b4d-4d45-47d3-bdb4-28cce3d34ce5" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits - January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzItMS0xLTEtMzA1NzI_0f12b6f0-caaf-4b5b-8239-e9f7b87aadc9">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzItMy0xLTEtMzA1NzI_1b814656-54b9-4f1f-a147-12baab2500ad">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in prior year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzMtMS0xLTEtMzA1NzI_f69c23b6-3947-40fd-a529-612a5ac62412">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzMtMy0xLTEtMzA1NzI_2609e56f-2fb8-4902-b409-ca53adbcb39d">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversals of prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzQtMS0xLTEtMzA1NzI_25e8b143-0955-49e7-8cfe-cc92cabe76cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzQtMy0xLTEtMzA1NzI_ffe311ed-aaec-424d-a7bc-116bdef757a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions taken in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzUtMS0xLTEtMzA1NzI_fcc9008f-45f2-45d2-806d-8f5d02efb26e">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzUtMy0xLTEtMzA1NzI_e8d9db40-b4cc-49a4-91dd-3d089488ebc1">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute expirations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzYtMS0xLTEtMzA1NzI_deff07c7-42c3-4368-88a4-9fe0eca1934e">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzYtMy0xLTEtMzA1NzI_a9b2f0a9-d907-4f89-8c5d-2e34b875fd8b">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits - December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzctMS0xLTEtMzA1NzI_a66319eb-0c2d-40f8-a6fc-0de7a616eb07">2,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzctMy0xLTEtMzA1NzI_469fa267-598b-45f2-886f-2d8868d91bf5">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits at December 31, 2021, if recognized would favorably affect the Company&#8217;s effective tax rate. These unrecognized tax benefits are classified as other long-term liabilities on the Consolidated Balance Sheets. The interest and penalties related to the unrecognized tax benefit are immaterial. Interest and tax penalties related to unrecognized tax benefits are included in income tax expense.</span></div></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90ZXh0cmVnaW9uOjc5MDc0ZTc2MjljZTRjMGU4MmFmMjgxMDEzZDExZjRlXzI2OTU_c34c0d72-f26f-49b1-975f-ad3309f025f3" continuedAt="ib776c3903a684ce482ee294ffa47f0cc" escape="true">Net (Loss) Income per Share</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib776c3903a684ce482ee294ffa47f0cc" continuedAt="ideb380e94e514a75bc397b493c22e441">The Company presents both basic earnings per share (&#8220;EPS&#8221;) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing &#8220;net (loss) income&#8221; by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised and if the 2028 Convertible Notes and 2025 Convertible Notes were converted. The potential dilution from stock awards is accounted for using the treasury </ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ideb380e94e514a75bc397b493c22e441"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock method based on the average market value of the Company&#8217;s common stock. The potential dilution from conversion of the 2028 Convertible Notes and 2025 Convertible Notes is accounted for using the if-converted method, which requires that all of the shares of the Company&#8217;s common stock issuable upon conversion of the 2028 Convertible Notes and the 2025 Convertible Notes will be included in the calculation of diluted EPS assuming conversion of the 2028 Convertible Notes and the 2025 Convertible Notes at the beginning of the reporting period (or at time of issuance, if later).</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90ZXh0cmVnaW9uOjc5MDc0ZTc2MjljZTRjMGU4MmFmMjgxMDEzZDExZjRlXzI2OTI_20841527-8852-4416-95c9-9eb8bab86d1c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculations for the years ended December 31, 2021, 2020, and 2019 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzMtMS0xLTEtMzA1NzI_448b75ad-8392-4335-be68-9ae2be63bfd2">8,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzMtMy0xLTEtMzA1NzI_9e4fc407-b4ea-4111-a937-34cfa36d18a3">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzMtNS0xLTEtMzA1NzI_5f81d88b-d839-4892-9154-fbd53825d29a">8,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE0LTEtMS0xLTMwNTcy_b9b2d7b8-f793-45f2-8829-b8259d4983a1">119,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE0LTMtMS0xLTMwNTcy_c6c21d28-6980-40b5-bfd8-9cb830ea6f1b">108,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE0LTUtMS0xLTMwNTcy_ecfc5f31-9f62-41f2-a0a1-1e952d0ff8d4">100,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c214db41910419cb07bdbcc42d83756_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE1LTEtMS0xLTMwNTcy_06778e39-5cb6-4717-9d24-c2fa6482e918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia87bb3f8d04745f2889e0a2f39c141d2_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE1LTMtMS0xLTMwNTcy_ae464660-f4d4-40b6-9a4f-ca0af5e16ada">3,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife334d7e97604dfb939dddee1cd879c4_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE1LTUtMS0xLTMwNTcy_6dbfc9a9-6bdc-4376-9cae-f4b930667c88">2,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE2LTEtMS0xLTMwNTcy_75315111-4d50-40c5-9760-18c87340e3b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE2LTMtMS0xLTMwNTcy_b32c17ea-5bbf-4a54-9a7a-f8399f1ab3a4">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE2LTUtMS0xLTMwNTcy_184b5272-2361-4b85-9779-6a2f9675d59a">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE5LTEtMS0xLTMwNTcy_85bd4989-a2db-462d-886b-c25175cbdeb6">119,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE5LTMtMS0xLTMwNTcy_c660e1d9-124f-4c24-b47f-96cd771ada19">111,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE5LTUtMS0xLTMwNTcy_d4bc0fb0-5c5e-4029-9433-5e9b51193731">103,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIxLTEtMS0xLTMwNTcy_ac548789-24ca-406d-b900-0ed99ebb9514">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIxLTMtMS0xLTMwNTcy_adeb0212-025d-4380-b0d2-e8491e9ae989">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIxLTUtMS0xLTMwNTcy_64341c99-d7f7-4271-8106-e77ec20087c7">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIyLTEtMS0xLTMwNTcy_c18f3948-2546-44ce-bfa0-c8d417397258">0.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIyLTMtMS0xLTMwNTcy_bd18a777-fc8b-46ae-b83f-29ff04d7033e">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIyLTUtMS0xLTMwNTcy_d4f35249-8e77-4153-9966-5f6724c11980">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90ZXh0cmVnaW9uOjc5MDc0ZTc2MjljZTRjMGU4MmFmMjgxMDEzZDExZjRlXzI2OTM_8ea5f04a-2e0e-4417-bf5a-f5d1710b317c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive for the years ended December 31, 2021, 2020, and 2019:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1225c352b00e4cb690a7adb7cdcbedde_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzItMS0xLTEtMzA1NzI_4beaf9fd-a05c-4b72-8d9c-4290c7a17cfd">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a9dd7cfafdc43d091c918725cbc192d_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzItMy0xLTEtMzA1NzI_c35e868d-4df2-4207-be16-2e1079163b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f155818af974561b4f8f18784fa25f0_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzItNS0xLTEtMzA1NzI_b9537113-a0b1-4f28-b03b-f86c9a31a9c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57a16efa8cab4c0c99d0598296108afd_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtMS0xLTEtMzA1NzI_f7592cef-0efd-495e-95f2-e0d6e6e8a987">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i091d1f087aa54fdfb74ce0705a97ff6b_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtMy0xLTEtMzA1NzI_789d2c0e-ed6e-4166-8186-fcb5bc4f0c5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87d1360a007c47328b217b42d2e1ff65_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtNS0xLTEtMzA1NzI_2a8c6e34-f68f-4876-8848-30484a500bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e3dba7dbe87474f82bf542453f20492_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtMS0xLTEtNDczMDE_481ffb95-2cd4-48ef-b13d-c03c8067e68b">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i383f1d1042d44cf1b819e519a1682405_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtMy0xLTEtNDcyNzQ_1120e48e-ebf7-4362-a5cf-9cbae344cb0a">3,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a0708e137d04355b6f919e001c59cce_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtNS0xLTEtNDcyNzk_21e9b3dc-744b-4981-be9b-1e2b9b128242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf2957894b7a4d2f897b45f006d71ee4_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzQtMS0xLTEtMzA1NzI_f848cf69-923d-45ab-b209-cb293ab5d884">5,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fedbf43609e4de1a63dab08b8a57324_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzQtMy0xLTEtMzA1NzI_d41ddcb6-c686-4994-b42b-52c6c5981482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74606006218e4bd29582caf14fce1a54_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzQtNS0xLTEtMzA1NzI_142f52b1-2282-4796-bfd1-d0be2a44148f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential effect of the Capped Call Transactions entered into concurrently with the 2028 Convertible Notes were excluded from the calculation of diluted net (loss) income per share in 2021 as the Company&#8217;s closing price on December 31, 2021, did not exceed the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90ZXh0cmVnaW9uOjc5MDc0ZTc2MjljZTRjMGU4MmFmMjgxMDEzZDExZjRlXzIxOTkwMjMyNjYzMjU_6cf8d81a-c72a-4599-a50c-87374e284f34">85.75</ix:nonFraction> per share. The Capped Call Transactions are not reflected in diluted net (loss) income per share as they are anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further details on the Capped Call Transactions, please refer to Note 9. Debt.</span></div></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzY0NA_b5d4552b-366f-480e-89d9-ddbd0657b925" continuedAt="i0c93f8e273c645feafa6ba7e2672ce44" escape="true">Defined Contribution Plan</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0c93f8e273c645feafa6ba7e2672ce44">The Company maintains a defined-contribution 401(k) retirement plan covering substantially all U.S. based employees (as defined).&#160;The Company&#8217;s employees may make voluntary contributions to the plan, subject to limitations based on IRS regulations and compensation. The Company matches <ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzMzMQ_235b99d9-9a90-4789-ab66-30fc75779332">100.0</ix:nonFraction>% of every dollar contributed up to <ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzM2OA_cf64593c-c6d5-4ac7-8740-59dd65dac858">3.0</ix:nonFraction>% of the respective employee&#8217;s compensation and an additional <ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzQzMQ_f7649f15-3bec-4b0d-8744-3302a7265578">50.0</ix:nonFraction>% of every dollar contributed on the next <ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="neo:DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzQ3NA_798a9882-b293-453b-b7ab-e7517fdb8700">2</ix:nonFraction>% of compensation (<ix:nonFraction unitRef="number" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="neo:DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzQ5NA_8565b6c0-386e-4f98-9526-83e46b484bf1">4.0</ix:nonFraction>% maximum Company match).&#160;Matching contributions were approximately $<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzU3OA_fce51885-ac62-4a41-a7ae-79bcec474943">6.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzU4Mg_79e42fe3-c55e-45df-b3be-02bf80b3e2f7">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzU4OQ_eff40a82-07ec-496c-8f8d-3cfa22acb109">4.4</ix:nonFraction> million during the years ended December 31, 2021, 2020, and 2019, respectively, and are recorded in cost of revenue and operating expenses in the Consolidated Statements of Operations.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_136"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90ZXh0cmVnaW9uOjhiZmE3NTRiOGIyMjRkYjJhMWY0MDYwODY1ODU1YWE5XzI5Ng_89eb2101-708f-426f-9e52-dceefb17f083" continuedAt="i7b0b95184bc54c378e2e11e3b8d821d5" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i7b0b95184bc54c378e2e11e3b8d821d5"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Commitments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements in place to purchase a specified level of reagents from certain vendors. These purchase commitments expire at various dates through 2023. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90ZXh0cmVnaW9uOjhiZmE3NTRiOGIyMjRkYjJhMWY0MDYwODY1ODU1YWE5XzI5Nw_c7edcb77-b9d0-4cb2-94ae-23058aed947f" continuedAt="i4c0f5bf212c541a3832d8838781dc8f9" escape="true">The purchase commitments as of December 31, 2021, are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i4c0f5bf212c541a3832d8838781dc8f9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.428%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90YWJsZTo2MTRhMDFkNjE0ZTY0MTczOTIwZjFkNmUwYWI4MjI2Ny90YWJsZXJhbmdlOjYxNGEwMWQ2MTRlNjQxNzM5MjBmMWQ2ZTBhYjgyMjY3XzEtMS0xLTEtMzA1NzI_f68202e5-f72a-4b7d-b1c8-89ab6bef7f51">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90YWJsZTo2MTRhMDFkNjE0ZTY0MTczOTIwZjFkNmUwYWI4MjI2Ny90YWJsZXJhbmdlOjYxNGEwMWQ2MTRlNjQxNzM5MjBmMWQ2ZTBhYjgyMjY3XzItMS0xLTEtMzA1NzI_c5c26b3d-af8e-42e6-8efa-ccde6cca25d4">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase commitments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306577667f484778bf45986f95823aa8_I20211231" decimals="-3" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90YWJsZTo2MTRhMDFkNjE0ZTY0MTczOTIwZjFkNmUwYWI4MjI2Ny90YWJsZXJhbmdlOjYxNGEwMWQ2MTRlNjQxNzM5MjBmMWQ2ZTBhYjgyMjY3XzQtMS0xLTEtMzA1NzI_78da70bc-2c37-4805-9e7b-d451f773ab0f">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceeding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2021, Natera, Inc. filed a patent infringement complaint against the Company&#8217;s newly-acquired subsidiary Inivata Limited and its subsidiary Inivata, Inc. in U.S. District Court for the district of Delaware, alleging Inivata&#8217;s InVisionFirst&#174;-Lung cancer diagnostic test of infringing <ix:nonFraction unitRef="patent" contextRef="iaeda459a54ed4faf87cd1bc16a70d854_D20210120-20210120" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90ZXh0cmVnaW9uOjhiZmE3NTRiOGIyMjRkYjJhMWY0MDYwODY1ODU1YWE5XzIxOTkwMjMyNTYxODk_00dc71df-5be2-4340-ac34-67175299ac26">two</ix:nonFraction> patents. The litigation is presently in the pleadings stage. The Company believes that it has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. At the time of filing the outcome of this matter is not estimable or probable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, the Company is voluntarily conducting an internal investigation that focuses on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;) of the Company&#8217;s internal investigation in November 2021. The Company&#8217;s review of this matter is ongoing. As of December 31, 2021, the Company has accrued a reserve of $<ix:nonFraction unitRef="usd" contextRef="i4f4073899af34688810e3b224590c74f_I20211231" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90ZXh0cmVnaW9uOjhiZmE3NTRiOGIyMjRkYjJhMWY0MDYwODY1ODU1YWE5XzMyOTg1MzQ4ODc3NTY_a29b0125-c1c4-44c7-8337-a808470c4380">11.2</ix:nonFraction>&#160;million in other long-term liabilities on the Consolidated Balance Sheets for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#8217;s best estimate of the minimum probable loss associated with this matter. As a result of the ongoing investigation and interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. At this time, the Company is unable to predict the duration, scope, result or related costs associated with any further investigation, including by the OIG, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Any determination that the Company&#8217;s operations or activities are not in compliance with existing laws or regulations, however, could result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, or other losses or conduct restrictions, which could be material to the Company&#8217;s financial results or business operations.</span></div></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzkvZnJhZzozMTMyMTMxYTQwZDA0NjIxOWFjZDQ2NTJkZjEwYWJlOS90ZXh0cmVnaW9uOjMxMzIxMzFhNDBkMDQ2MjE5YWNkNDY1MmRmMTBhYmU5XzU3Nw_65092b7b-c969-4623-bd70-c9f3762c89ec" continuedAt="i4a6c888653e34eaa8e62b4d897ec901e" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i4a6c888653e34eaa8e62b4d897ec901e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company formed a strategic alliance with Inivata and entered into a Strategic Alliance Agreement and Laboratory Services Agreement whereas Inivata, prior to the Inivata Acquisition Date, would render and perform certain laboratory testing which the Company made available to customers. In connection with this agreement, Inivata provided $<ix:nonFraction unitRef="usd" contextRef="i13a97ccd6ccc4b63a539db53fa7f8e61_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzkvZnJhZzozMTMyMTMxYTQwZDA0NjIxOWFjZDQ2NTJkZjEwYWJlOS90ZXh0cmVnaW9uOjMxMzIxMzFhNDBkMDQ2MjE5YWNkNDY1MmRmMTBhYmU5XzIxOTkwMjMyNTY1MDk_00df8d1b-329c-42fb-a1f8-fe4265c51bf1">0.8</ix:nonFraction> million of testing services to the Company recorded in cost of revenue in the Consolidated Statements of Operations in 2021 through the Inivata Acquisition Date. Such services provided for the year ended December 31, 2020 were immaterial. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company and Inivata also entered into a Line of Credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="ie359835360d14552b460dfe2e09d74a4_I20200522" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzkvZnJhZzozMTMyMTMxYTQwZDA0NjIxOWFjZDQ2NTJkZjEwYWJlOS90ZXh0cmVnaW9uOjMxMzIxMzFhNDBkMDQ2MjE5YWNkNDY1MmRmMTBhYmU5XzIxOTkwMjMyNTY4NjY_caf3883e-7476-40a5-a61f-4aa2702630e4">15.0</ix:nonFraction>&#160;million. The Company and Inivata settled the Line of Credit after the Inivata Acquisition Date and <ix:nonFraction unitRef="usd" contextRef="ie1bd7c4a65e8470fb2e0bcb4e07683c8_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzkvZnJhZzozMTMyMTMxYTQwZDA0NjIxOWFjZDQ2NTJkZjEwYWJlOS90ZXh0cmVnaW9uOjMxMzIxMzFhNDBkMDQ2MjE5YWNkNDY1MmRmMTBhYmU5XzE2NDkyNjc0NDc0Mjc_ca1b2533-e259-42be-b6db-878c7fb73647">no</ix:nonFraction> amounts were outstanding as of December 31, 2021. For further details on the Line of Credit, please refer to Note 8. Investment in Non-Consolidated Affiliate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company completed its acquisition of all remaining equity interest in Inivata by exercising its Purchase Option. Beginning June 18, 2021, Inivata is a wholly-owned consolidated subsidiary of the Company. As of the Inivata Acquisition Date, Inivata&#8217;s financial statement activity is being consolidated within the Company&#8217;s Consolidated Financial Statements. For further details on the acquisition of Inivata, please refer to Note 3. Acquisitions.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_142"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19. <ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzEwODY_e731f304-5f41-4e91-9544-86b1cd30f67d" continuedAt="ide5064815cbc4093abe07c75d8a119a1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="ide5064815cbc4093abe07c75d8a119a1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under <ix:nonFraction unitRef="segment" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzgyNDYzMzcyMTM1NzM_a633da5e-3cfb-4e90-8325-89f664f83f04">two</ix:nonFraction> reportable segments, (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology and oncology practices, hospital pathology labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and self-pay patients. The Pharma Services segment supports pharmaceutical firms&#8217; drug development programs by assisting with various clinical trials and research as well as providing informatics related services often supporting pharmaceutical commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) includes revenues, cost of revenue, and gross profit for both reportable segments.&#160;Assets are not presented at the segment level as that information&#160;is not used by the CODM.</span></div><ix:nonNumeric contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzEwODc_aeaad366-c948-46fb-8704-269b95ca4f6a" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837dec7e8fdd48c7a1722bf1b1f3b0e0_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMtMS0xLTEtMzA1NzI_0c100457-d1e9-4401-911a-3ae40cfb7967">404,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd5c1eb69c64cc799674374d18d6cc0_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMtMy0xLTEtMzA1NzI_4a3ed6f0-f8a5-40e9-ab7a-2211c085bcd8">382,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b0047444b401e8e1b445dd63adc4b_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMtNS0xLTEtMzA1NzI_31d5c510-e536-4036-b4ad-01f1560c7894">361,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1b9b8d04e54ea9b259cbdf629ff3dd_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzQtMS0xLTEtMzA1NzI_902d911d-d8f8-4a30-9ad5-8a86f8061823">80,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d0d6a9a7bd4a269a7535713c120fbd_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzQtMy0xLTEtMzA1NzI_0caf2fe9-96fd-4763-a6f5-6b00a1da21e3">62,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd350be96f284665bf09aeefccfc73cb_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzQtNS0xLTEtMzA1NzI_868f4a0c-5b00-4c4f-8692-b6fac1a4463d">47,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzUtMS0xLTEtMzA1NzI_4a353eb7-cdc0-4497-8fe9-edb5c9ea866a">484,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzUtMy0xLTEtMzA1NzI_5dc2a469-efea-4193-a0fc-fe89246543cf">444,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzUtNS0xLTEtMzA1NzI_345c342c-06a3-4c64-88b7-5b41ef6b301d">408,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837dec7e8fdd48c7a1722bf1b1f3b0e0_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzgtMS0xLTEtMzA1NzI_9e315fa3-d005-4184-9eec-52ed4231aa5a">244,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd5c1eb69c64cc799674374d18d6cc0_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzgtMy0xLTEtMzA1NzI_bcf02b37-6cdd-4ed4-81b2-557163f6687f">215,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b0047444b401e8e1b445dd63adc4b_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzgtNS0xLTEtMzA1NzI_651535a1-78c9-4d4f-82fb-a8891c78ac8b">185,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1b9b8d04e54ea9b259cbdf629ff3dd_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzktMS0xLTEtMzA1NzI_a2f363be-233c-41de-8dae-e0737817dc16">52,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d0d6a9a7bd4a269a7535713c120fbd_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzktMy0xLTEtMzA1NzI_f0c816e8-8cf7-4334-a2d9-4a217c0e8545">43,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd350be96f284665bf09aeefccfc73cb_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzktNS0xLTEtMzA1NzI_7a777606-e086-4190-906b-3c826b21e3aa">26,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEwLTEtMS0xLTMwNTcy_90468bcb-dc32-4cb0-96dc-648538a05ced">297,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEwLTMtMS0xLTMwNTcy_3e5daead-b070-460e-85ee-428c949e2b53">258,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEwLTUtMS0xLTMwNTcy_e3b6b385-724c-4d7f-b1a0-0ee3ec072514">211,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837dec7e8fdd48c7a1722bf1b1f3b0e0_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEzLTEtMS0xLTMwNTcy_ebec178f-cb24-42d0-8562-e0b970b7870d">159,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd5c1eb69c64cc799674374d18d6cc0_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEzLTMtMS0xLTMwNTcy_f61d0b73-96e1-42b5-98ad-3d4fff845cb6">166,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43b0047444b401e8e1b445dd63adc4b_D20190101-20191231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEzLTUtMS0xLTMwNTcy_81510dd4-a93a-4981-9e97-da40f9e868de">175,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1b9b8d04e54ea9b259cbdf629ff3dd_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE0LTEtMS0xLTMwNTcy_c879185b-dbe7-4c23-8a59-7f5b0a4c9b0c">27,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d0d6a9a7bd4a269a7535713c120fbd_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE0LTMtMS0xLTMwNTcy_e40f371f-3745-4aa8-a7fc-85fad109b576">19,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd350be96f284665bf09aeefccfc73cb_D20190101-20191231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE0LTUtMS0xLTMwNTcy_bdf8ae62-c04f-471e-8a33-1de43ec7a2c2">21,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE1LTEtMS0xLTMwNTcy_7e5253e4-bf51-448c-8ffc-904a7af3bc9c">187,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE1LTMtMS0xLTMwNTcy_bf416814-273e-4c73-ad2c-5b9ba3070363">185,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE1LTUtMS0xLTMwNTcy_2292ca8e-a582-4e17-8a29-2a3f97a91119">196,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE4LTEtMS0xLTMwNTcy_3cd0033c-5842-4229-ace5-c9339f9ee8de">221,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE4LTMtMS0xLTMwNTcy_f3ca9269-9a5d-4b8b-bdf5-d8b771aaee88">143,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE4LTUtMS0xLTMwNTcy_e6338950-ec3e-4473-8848-8924c10ea993">127,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE5LTEtMS0xLTMwNTcy_d034dfac-1949-42b8-8220-5dd428000152">21,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE5LTMtMS0xLTMwNTcy_5cf504ee-35c9-4136-a6ba-00669ca001dd">8,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE5LTUtMS0xLTMwNTcy_81dfe844-9027-4e30-866f-8e6f734185b8">8,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIwLTEtMS0xLTMwNTcy_84835d9e-836f-4937-a37a-85a66eb441e5">62,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIwLTMtMS0xLTMwNTcy_19e81398-39c9-4a6e-80cf-8a70fea4b76b">47,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIwLTUtMS0xLTMwNTcy_992935f3-5e99-4aee-aa2d-ef7a2122491b">47,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIyLTEtMS0xLTMwNTcy_2c3050f6-20dd-4683-9401-fc0eddf05d40">305,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIyLTMtMS0xLTMwNTcy_5474d547-9c6b-4999-8b61-95b2604682cc">199,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIyLTUtMS0xLTMwNTcy_1a3e7d92-701e-4623-b346-d34aebe87cf7">183,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIzLTEtMS0xLTMwNTcy_590114a2-1655-467e-bff6-c81d87342bcb">118,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIzLTMtMS0xLTMwNTcy_29699726-4b6a-437b-8d72-16c7a9c386b7">13,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIzLTUtMS0xLTMwNTcy_dc91817d-2bda-4246-a843-1f074243f145">13,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI0LTEtMS0xLTMwNTcy_86c8d6f2-5cad-4cce-83e9-df1f20b7a352">5,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI0LTMtMS0xLTMwNTcy_62efc069-842b-4451-88d3-26e339fa89e7">7,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI0LTUtMS0xLTMwNTcy_5852f9f7-9b11-45b0-b4ef-09451a39bfe3">3,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTEtMS0xLTMwNTcy_da80cf80-9dc3-4bcb-9127-a0ca6157baf3">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTMtMS0xLTMwNTcy_91a68dfc-79e9-43cd-a9fd-5462b314c461">7,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTUtMS0xLTMwNTcy_e1f80808-a1a3-441f-a718-8352fa3e3055">4,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTEtMS0xLTQ3NTcz_c01529da-5de7-40ec-a969-d22e3675bec6">109,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTMtMS0xLTQ3NTUw_f0f4f16a-0137-42d7-8509-232a6b9cf11f">3,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:GainLossOnInvestmentAndLoanReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTUtMS0xLTQ3NTUw_f413755a-bfb1-477b-a882-f32a01425c23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI2LTEtMS0xLTMwNTcy_aa876043-7ba7-4329-b27f-8128e1d2df69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI2LTMtMS0xLTMwNTcy_03a0dd2b-d2c2-4f3c-a97e-ab8ba014233a">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI2LTUtMS0xLTMwNTcy_6c522b81-fa16-4c9e-954c-3a252523cff6">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on termination of cash flow hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" name="neo:GainLossOnTerminationOfInterestRateSwap" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI3LTEtMS0xLTMwNTcy_512c824d-6a2b-40bb-b437-5cc9a78eab93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="neo:GainLossOnTerminationOfInterestRateSwap" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI3LTMtMS0xLTMwNTcy_be4ec4b4-1df8-4516-aaba-aac5376dae3d">3,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="neo:GainLossOnTerminationOfInterestRateSwap" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI3LTUtMS0xLTMwNTcy_62eb997b-73de-4dda-a931-b5e3455f67af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI4LTEtMS0xLTMwNTcy_25cf0e67-c10c-4d67-b643-aa977ae0e518">15,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI4LTMtMS0xLTMwNTcy_70383002-a99c-48fb-b2d4-521ec7fe5ab3">14,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI4LTUtMS0xLTMwNTcy_dfc69bd6-49ca-4c8d-9de7-04bb9e186c01">3,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI5LTEtMS0xLTMwNTcy_8aab509c-ef9f-409c-9492-38a4cd9df34d">6,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI5LTMtMS0xLTMwNTcy_1012dc97-494e-44ba-a44d-02d360db9414">18,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI5LTUtMS0xLTMwNTcy_a1ecb0b6-efff-4cad-ab45-85bca65bb2f7">4,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMwLTEtMS0xLTMwNTcy_2c902fc5-ff34-49b3-8e35-3d3d6f80a747">8,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMwLTMtMS0xLTMwNTcy_0def2ada-652c-458c-85a4-a1439ea1fcaf">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMwLTUtMS0xLTMwNTcy_d154042f-a7d4-45ad-b769-2be520134586">8,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical Services cost of revenue in 2021 includes $<ix:nonFraction unitRef="usd" contextRef="i83673f0de9224acfae001662ab57801f_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzMyOTg1MzQ4ODg3MjU_2e6abf7f-e690-4d54-b045-16af499cd98f">9.2</ix:nonFraction> million of amortization of acquired Inivata developed technology intangible assets and write-offs of $<ix:nonFraction unitRef="usd" contextRef="i627f74b4ec984553bf1664500f452ad0_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzMyOTg1MzQ4ODg4MjI_8cb38e91-cd11-4c43-9710-7d2bb6f60ec6">5.3</ix:nonFraction> million for COVID-19 PCR testing inventory.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharma Services cost of revenue in 2021 includes $<ix:nonFraction unitRef="usd" contextRef="i7798d7199db145cf9eee4dd9052c2e1b_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzMyOTg1MzQ4ODkyODQ_0e9e2c15-0cc9-4d8d-89eb-6208aa6bc26c">1.2</ix:nonFraction> million&#160;of amortization of acquired Inivata developed technology intangible assets.</span></div></ix:nonNumeric></ix:continuation><div id="ia1854a760084469581a7ceab463d6c8e_145"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_148"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9A. CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021.&#160;Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2021, our disclosure controls and procedures were (1)&#160;effective in that they were designed to ensure that material information relating to us, and information required to be disclosed in our reports to the SEC, including our consolidated subsidiaries, is made known to our Chief Executive Officer and Chief Financial Officer by others within those entities, particularly during the period in which this report was being prepared, as appropriate to allow timely discussions and decisions regarding required disclosure therein and (2)&#160;effective, in that they provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officer and effected by the Company&#8217;s Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures: (1)&#160;that pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, however, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control&#8212;Integrated Framework (&#8220;2013 Framework&#8221;). Based on this assessment, management, with the participation of our Chief Executive Officer and Chief Financial Officer, concluded that, as of December 31, 2021, our internal control over financial reporting was effective based on those criteria at the reasonable assurance level. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired Trapelo on April 7, 2021 and Inivata on June 18, 2021. As permitted by guidelines established by the Securities and Exchange Commission for newly acquired businesses, management has excluded these acquisitions from its assessment of the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021. Trapelo constituted less than 1% of the Company&#8217;s total consolidated revenue for the year ended December 31, 2021 and less than 1% of the Company&#8217;s total consolidated assets, excluding goodwill and intangible assets which are included in the scope the assessment, as of December 31, 2021. Inivata constituted less than 1% of the Company&#8217;s total consolidated revenue for the year ended December 31, 2021 and 1.5% of the Company&#8217;s total consolidated assets, excluding goodwill and intangible assets which are included in the scope of the assessment, as of December 31, 2021. We are in the process of integrating these businesses into our overall internal control over financial reporting and plan to include them in our scope as of December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deloitte &amp; Touche LLP audited the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021, as stated in their report, which is included in this annual report on Form 10-K. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we transitioned from our existing Great Plains Dynamics enterprise resource planning (&#8220;ERP&#8221;) system to a hosted, cloud-based Oracle ERP system (&#8220;Oracle&#8221;). In connection with the Oracle implementation, we performed pre-implementation planning, design and testing of internal controls that became effective in the third quarter of 2021. We continue to conduct post-implementation monitoring and process modifications in order to maintain effective internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, we continued to monitor and evaluate the design and operating effectiveness of key controls. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that materially affected or are reasonably likely to materially affect internal control over financial reporting.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the stockholders and the Board of Directors of NeoGenomics, Inc.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the internal control over financial reporting of NeoGenomics, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by COSO.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2021, of the Company and our report dated February 25, 2022, expressed an unqualified opinion on those financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Management&#8217;s Report on Internal Control over Financial Reporting, management excluded from its assessment the internal control over financial reporting at Intervention Insights, Inc. d/b/a Trapelo Health (&#8220;Trapelo&#8221;) and Inivata Limited (&#8220;Inivata&#8221;), which were acquired on April 7, 2021 and June 18, 2021, respectively. Trapelo constitutes less than 1% of total consolidated revenues and less than 1% of total consolidated assets, excluding goodwill and intangible assets which are included within the scope of the assessment, of the Company as of and for the year ended December 31, 2021. Inivata constitutes less than 1% of total consolidated revenues and 1.5% of total consolidated assets, excluding goodwill and intangible assets which are included within the scope of the assessment of the Company as of and for the year ended December 31, 2021. Accordingly, our audit did not include the internal control over financial reporting at Trapelo and Inivata.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2022</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="ia1854a760084469581a7ceab463d6c8e_154"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B. OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_1357"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_157"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ia1854a760084469581a7ceab463d6c8e_160"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 10 is incorporated herein by reference to our Definitive Proxy Statement relating to our 2022 Annual Meeting of Stockholders. We intend to file such Definitive Proxy Statement with the SEC pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_163"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 11 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_166"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 12 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 13 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_172"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 14 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_175"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ia1854a760084469581a7ceab463d6c8e_178"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Statements (included in Item 8 of this Annual Report on Form 10-K): </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Consolidated Financial Statements of the Company and the Report of Deloitte &amp; Touche LLP, Independent Registered Public Accounting Firm, are included in Part II, Item 8 of this Annual Report on Form 10-K:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm &#8211; Deloitte &amp; Touche LLP</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets as of December 31, 2021 and 2020</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations for the years ended December 31, 2021, 2020 and 2019</span></div><div style="margin-top:6pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive (Loss) Income for the year ended December 31, 2021, 2020 and 2019</span></div><div style="margin-top:6pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2021, 2020 and 2019</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows for the years ended December 31, 2021, 2020 and 2019</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Statement Schedules. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not applicable or the required information is shown in the Consolidated Financial Statements or the Notes thereto.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Exhibits.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits required by Item 601 of Regulation S-K are listed in paragraph (b) below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Exhibits.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed herewith or are incorporated by reference to exhibits filed with the SEC:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718320000022/neocharter-exhibit31.htm">Articles of Incorporation, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on February 28, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000156459015009957/neo-ex31_614.htm">Amended and Restated Bylaws, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, as filed with the SEC on November 6, 2015</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718320000022/neoexhibit41descriptio.htm">Description of our Common Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on February 28, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718320000108/exhibit41formofindentu.htm">Indenture, dated May 4, 2020, by and between the Company and U.S. Bank National Association, as Trustee.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the SEC on May 4, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718320000108/exhibit41formofindentu.htm">Form of 1.25% Senior Convertible Note Due 2025 (included in Exhibit 4.2).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the SEC on May 4, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718321000050/exhibit41formofindenture.htm">Indenture, dated January 11, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 11, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, as filed with the SEC on May 6, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718321000050/exhibit41formofindenture.htm">Form of 0.25% Senior Convertible Notes Due 2028 (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 11, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, as filed with the SEC on May 6, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107087605000038/neo8kregistration.htm">Amended and Restated Registration Rights Agreement between NeoGenomics, Inc. and Aspen Select Healthcare, L.P. and individuals dated March 23, 2005</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the SEC on March 30, 2005</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107087606000068/neoregrights.htm">Registration Rights Agreement between NeoGenomics, Inc. and Aspen Select Healthcare, L.P., dated March 30, 2006</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Annual Report on Form 10-KSB for the year ended December 31, 2005, as filed with the SEC on April&#160;3, 2006</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000156459016014868/neo-ex1050_400.htm">Amended and Restated Equity Incentive Plan effective as of October 15, 2015.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC on March 15, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000119312517135093/d307655ddef14a.htm">Amendment No. 1 of the Amended and Restated Equity Incentive Plan, effective as of May 25, 2017.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Proxy Statement, dated April 24, 2017, as filed with the SEC on April 25, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000156459016027730/neo-ex1052_264.htm">Form of Indemnification Agreement between NeoGenomics, Inc. and each of its executive officers and directors.</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2016, as filed with the SEC on November 7, 2016</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718320000206/boardappointmentletter-s.htm">Board of Directors Appointment Letter Agreement between Rachel A. Stahler and NeoGenomics, Inc. dated August 24, 2020. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as filed with the SEC on October 29, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718320000206/boardappointmentletter-k.htm">Board of Directors Appointment Letter Agreement between Michael A. Kelly and NeoGenomics, Inc. dated August 11, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as filed with the SEC on October 29, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718321000121/ex101securitiespurchaseagr.htm">Securities Purchase Agreement, dated as of May 4, 2021, among NeoGenomics, Inc. and each purchaser party thereto. (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the SEC on May 5, 2021.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as filed with the SEC on August 9, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718321000121/ex102registrationrightsagr.htm">Registration Rights Agreement, dated as of May 4, 2021, among NeoGenomics, Inc. and each party thereto. (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the SEC on May 5, 2021.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as filed with the SEC on August 9, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000107718321000120/ex21sharepurchaseagreement.htm">Share Purchase Agreement, dated May 4, 2021. (Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the SEC on May 5, 2021.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as filed with the SEC on August 9, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="neoex1011executiveemployme.htm">Form of Executive Employment Agreement between NeoGenomics, In</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="neoex1011executiveemployme.htm">c</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="neoex1011executiveemployme.htm">. and each of its executive offi</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="neoex1011executiveemployme.htm">c</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="neoex1011executiveemployme.htm">ers.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1077183/000119312511192483/dex141.htm">NeoGenomics, Inc. Code of Ethics for Senior Financial Officers and the Principal Executive Officer</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Current Report on Form 8-K as filed with the SEC on July 20, 2011</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="neoex211listofsubsidiaries.htm">Subsidiaries of NeoGenomics, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="neoexhibit23112312021.htm">Consent of Deloitte &amp; Touche LLP</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="neoexhibit31112312021.htm">Certification by Principal Executive Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="neoexhibit31212312021.htm">Certification by Principal Financial Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="neoexhibit32112312021.htm">Certification by Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided herewith</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1854a760084469581a7ceab463d6c8e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denotes a management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The certification attached as Exhibit 32.1 that accompanies this Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of NeoGenomics, Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div><span><br/></span></div><div id="ia1854a760084469581a7ceab463d6c8e_181"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia1854a760084469581a7ceab463d6c8e_184"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date: February&#160;25, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Mark W. Mallon</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark W. Mallon</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Mark W. Mallon</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chief Executive Officer <br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark W. Mallon</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ William B. Bonello</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer <br/>(Principal Financial Officer)<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William B. Bonello</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Cynthia J. Dieter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cynthia J. Dieter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Lynn A. Tetrault</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lynn A. Tetrault</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Bruce K. Crowther</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce K. Crowther</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Michael A. Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael A. Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Rachel A. Stahler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rachel A. Stahler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>neoex1011executiveemployme.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib983aa366c7f4e99bba8fbc56109c3d1_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is made and entered into as of &#91;&#9679;&#93; by and between NeoGenomics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and &#91;&#9679;&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Executive possesses certain experience and expertise that qualifies him or her to provide the direction and leadership required by the Company&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Company desires to &#91;continue to&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> employ the Executive as &#91;Job Title&#93; of the Company and the Executive wishes to accept such &#91;continued&#93; employment&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants contained herein and intending to be legally bound hereby, the Company and the Executive agree as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Position and Duties. </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Effective as of the date hereof, the Executive will &#91;continue to&#93; be employed by the Company and NeoGenomics Laboratories, Inc., its primary operating subsidiary, on a full-time basis, as its &#91;Job Title&#93; or such other position or positions as the Company may determine in the future. The Executive will report to and be subject to the general supervision and direction of the &#91;Company&#8217;s Chief Executive Officer&#93;&#91;the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In addition, the Executive may be asked from time to time to serve in similar capacities for one or more of the Company&#8217;s Affiliates or as a director or officer of one or more of the Company&#8217;s Affiliates, each without further compensation.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control may be by management authority, equity interest or otherwise.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Executive agrees to perform the duties of his or her position and such other duties as may reasonably be assigned to the Executive from time to time.  The Executive also agrees that, while employed by the Company, he or she will devote his or her full business time and his or her best efforts, business judgment, skill and knowledge exclusively to the advancement of the business interests of the Company and its Affiliates and to the discharge of his or her duties and responsibilities for them&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Executive may, without advance approval, participate in charitable activities and passive personal activities, provided that such activities do not, individually or in the aggregate, interfere with the performance of the Executive&#8217;s duties under this Agreement, are not in conflict with the business interests of the Company or any of its Affiliates, and do not violate the terms of the Restrictive Covenant Agreement. &#91;Notwithstanding anything to the contrary in this Agreement, the Executive may continue the activities set forth on Annex A&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">3</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Executive agrees that, while employed by the Company, he or she will comply with all Company policies, practices and procedures and all codes of ethics or business conduct applicable to his or her position, as in effect from time to time.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Executive&#8217;s principal place of employment shall initially be &#91;        &#93;.  Notwithstanding the foregoing, the Executive acknowledges that the Executive&#8217;s duties and responsibilities shall require the Executive to travel on business to fully perform the Executive&#8217;s duties and responsibilities hereunder.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Compensation and Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  During the Executive&#8217;s employment hereunder, as compensation for all services performed by the Executive for the Company and its Affiliates, the Company will provide the Executive the following compensation and benefits&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   The Company will pay the Executive a base salary at the rate of $&#91;&#9679;&#93; per year, payable in accordance with the regular payroll practices of the Company and subject to adjustment from time to time by the &#91;Board&#93;&#91;Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#93; or the </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Note to Draft</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;  Insert for current employees.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Note to Draft</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;  Insert first bracket for executives other than the CEO and the second bracket for the CEO.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Note to Draft</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Include bracketed language only if applicable. </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Compensation Committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in its discretion (as adjusted, from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Bonus Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For each fiscal year completed during the Executive&#8217;s employment under this Agreement, the Executive will be eligible to earn an annual bonus.  The Executive&#8217;s target bonus will be &#91;&#9679;&#93;% of the Base Salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), subject to adjustment from time to time by the Board or the Compensation Committee, with the actual amount of any such bonus to be determined by the Board or the Compensation Committee in its discretion, based on the Executive&#8217;s performance and&#47;or the Company&#8217;s performance against goals established by the Board or the Compensation Committee.  In order to receive any annual bonus hereunder, the Executive must be employed on the last day of the fiscal year to which the annual bonus relates, except that, if the Executive&#8217;s employment is terminated by the Company for Cause following the end of the fiscal year to which such annual bonus relates and before such bonus is paid to the Executive, the Executive shall not be entitled to any payment hereunder.  Any annual bonus, to the extent earned, shall be paid not later than March 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the year following the year to which such bonus relates.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Participation in Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Executive will be entitled to participate in all employee benefit plans from time to time in effect for employees of the Company generally, except to the extent such plans are duplicative of benefits otherwise provided to the Executive under this Agreement (e.g., a severance pay plan).  The Executive&#8217;s participation will be subject to the terms of the applicable plan documents and generally applicable Company policies, as the same may be in effect from time to time, and any other restrictions or limitations imposed by law.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Vacations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Executive will be entitled to vacation and&#47;or paid time-off in accordance with the policies of the Company, as in effect from time to time.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company will pay or reimburse the Executive for all reasonable business expenses incurred or paid by the Executive in the performance of his or her duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set by the Company from time to time and to such reasonable substantiation and documentation as may be specified by the Company from time to time.  The Executive&#8217;s right to payment or reimbursement under this Agreement shall be subject to the following additional rules&#58; (i) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement shall be made not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred and (iii) the right to payment or reimbursement shall not be subject to liquidation or exchange for any other benefit.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Confidentiality, Non-Solicitation and Non-Compete Agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Executive agrees to the terms of the Confidentiality, Non-Solicitation and Non-Compete Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenant Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Addendum A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and has signed the Restrictive Covenant Agreement. The Restrictive Covenant Agreement is hereby incorporated into and made a part of this Agreement. The Executive acknowledges and agrees that the provision of employment under this Agreement, the compensation provided under this Agreement and the execution by the Company of this Agreement constitute full, adequate and sufficient consideration to Executive for the Executive&#8217;s duties, obligations and covenants under this Agreement and under the Restrictive Covenant Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Termination of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   The Executive&#8217;s employment under this Agreement shall continue until terminated pursuant to this Section 4.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">By the Company For Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may terminate the Executive&#8217;s employment for Cause upon notice to the Executive setting forth in reasonable detail the nature of the Cause.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the following, as determined by the Company in its reasonable judgment&#58;&#160;(i) failure to materially perform and discharge the duties and responsibilities of the Executive under this Agreement after receiving written notice and allowing the Executive ten (10) business days to cure such failure, if so curable, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that after one such notice has been given to the Executive and the ten (10) business day cure period has lapsed, the Company is no longer required to provide time to cure subsequent failures under this provision&#59; (ii) </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any breach by the Executive of a material provision of this Agreement or any provision of the Restrictive Covenant Agreement&#59; (iii) misconduct which, in the good faith opinion and sole discretion of the Board, is injurious to the Company&#59; (iv) commission or indictment of a felony involving the personal dishonesty or moral turpitude of Executive&#59; or a determination by the Board, after consideration of all available information, that Executive has knowingly violated Company policies or procedures involving discrimination, harassment, or work place violence&#59; (v) engagement in illegal drug use or alcohol abuse which prevents the Executive from performing his or her duties in any manner&#59; (vi) any misappropriation, embezzlement or conversion of the Company&#8217;s opportunities or property by the Executive&#59; or (vii) willful misconduct, recklessness or gross negligence by the Executive in respect of the duties or obligations of the Executive under this Agreement and&#47;or Restrictive Covenant Agreement.  Any termination for Cause pursuant to this Section shall be given to the Executive in writing and shall set forth in detail all acts or omissions upon which the Company is relying to terminate the Executive for Cause. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">By the Company Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company may terminate the Executive&#8217;s employment at any time other than for Cause upon written notice to the Executive.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">By the Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Executive may terminate his or her employment for Good Reason, provided that (i) the Executive provides written notice to the Company, setting forth in reasonable detail the nature of the condition giving rise to Good Reason, within thirty (30) days of the initial existence of such condition, (ii) the condition remains uncured by the Company for a period of thirty (30) days following such notice and (iii) the Executive terminates his or her employment, if at all, not later than thirty (30) days after the expiration of such cure period.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the following without the Executive&#8217;s consent&#58;  (i) a material diminution in the Executive&#8217;s Base Salary&#59; (ii) a material diminution in the Executive&#8217;s title, authority, duties, or responsibilities&#59; (iii) a change of more than fifty (50) miles in the geographic location which Executive must perform services&#59; or (iv) any breach by Company of a material provision of this Agreement.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">By the Executive Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Executive may terminate his or her employment without Good Reason at any time upon sixty (60) days&#8217; notice to the Company.  The Company may elect to waive such notice period or any portion thereof.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Death and Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Executive&#8217;s employment hereunder shall automatically terminate in the event of the Executive&#8217;s death during employment.  The Company may terminate the Executive&#8217;s employment, upon notice to the Executive, in the event that the Executive becomes disabled during his or her employment hereunder through any illness, injury, accident or condition of either a physical or psychological nature and, as a result, is unable to perform substantially all of his or her duties and responsibilities hereunder (notwithstanding the provision of any reasonable accommodation) for a period of ninety (90) days during any period of three hundred sixty-five (365) consecutive days.  If any question shall arise as to whether the Executive is disabled to the extent that he or she is unable to perform substantially all of his or her duties and responsibilities for the Company and its Affiliates, the Executive shall, at the Company&#8217;s request, submit to a medical examination by a physician selected by the Company to whom the Executive or the Executive&#8217;s guardian, if any, has no reasonable objection to determine whether the Executive is so disabled, and such determination shall for purposes of this Agreement be conclusive of the issue.  If such a question arises and the Executive fails to submit to the requested medical examination, the Company&#8217;s good faith, reasonable determination of the issue shall be binding on the Executive.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Other Matters Related to Termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Final Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of termination of the Executive&#8217;s employment with the Company, howsoever occurring (except as provided in subclause (iv) below), the Company shall pay the Executive (i) the Base Salary for the final payroll period of his or her employment, through the date his or her employment terminates&#59; (ii) reimbursement, in accordance with Section 2(e) hereof, for business expenses incurred by the Executive but not yet paid to the Executive as of the date his or her employment terminates, provided that the Executive submits all expenses and supporting documentation required within sixty (60) days of the date his or her employment terminates, and provided further that </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such expenses are reimbursable under Company policies then in effect&#59; and (iii) other than in the case of a termination by the Company for Cause, with respect to any termination that occurs after December 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of a year and prior to the time that annual bonuses are paid to employees with respect to such year, any annual bonus earned for the fiscal year prior to the fiscal year in which such termination occurs, which shall be payable  at the same time as annual bonuses are paid to active employees of the Company (all of the foregoing, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Final Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Except as otherwise provided in Section 5(a)(iii), Final Compensation will be paid to the Executive within thirty (30) days following the date of termination or such shorter period required by law.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Severance Payments (Other than Terminations Occurring During the Change in Control Period)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of a termination of the Executive&#8217;s employment pursuant to Section 4(b) or Section 4(c) above, other than any such termination occurring during the Change in Control Period (as defined below), the Company will pay and&#47;or provide to the Executive, in addition to Final Compensation, the following severance payments and&#47;or benefits, (i) an amount equal to one (1) times the Base Salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) an amount equal to one (1) times the Target Bonus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (iii) provided that the Executive timely elects to continue his or her coverage and that of any eligible dependents in the Company&#8217;s group health plans under the federal law known as &#8220;COBRA&#8221; or similar state law, a monthly amount equal to one hundred percent (100%) of monthly COBRA premiums, together with the two percent (2%) administration fee, until the earliest of (x) the date that is twelve (12) months following the date that the Executive&#8217;s employment terminates, (y) the date that the Executive and the Executive&#8217;s eligible dependents cease to be eligible for such COBRA coverage under applicable law or plan terms and (z) the date on which the Executive obtains health coverage from another employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Health Continuation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and (iv) with respect to any outstanding Company equity-based award the vesting of which is based solely on continued employment or service with the Company (each such award, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Time-Based Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), accelerated vesting of the portion of each Time-Based Equity Award that would have vested by its terms in the twelve (12)-month period following the date the Executive&#8217;s employment terminates had the Executive remained continuously employed. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Severance Payments (Terminations Occurring During the Change in Control Period)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of a termination of the Executive&#8217;s employment pursuant to Section 4(b) or 4(c) above occurring during the twenty-four (24)-month period that follows or the three (3)-month period that precedes a Change in Control (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), in lieu of the payments and benefits set forth in Section 5(b) above, the Company will pay and&#47;or provide to the Executive, in addition to the Final Compensation, (i) an amount equal to &#91;two (2)&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#91;three (3)&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> times the Base Salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Enhanced Base Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) an amount equal to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; (iii) the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Health Continuation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and (iv) the vesting of all outstanding unvested Time-Based Equity Awards will accelerate in full as of immediately prior to the date the Executive&#8217;s employment terminates or, in the case of termination during the three (3)-month period that precedes a Change in Control, upon such Change in Control, and all outstanding options to purchase common stock of the Company will remain exercisable for one year following such termination (or, if earlier, the end of the term of such option award). In the event Executive&#8217;s employment terminates pursuant to Section 4(b) or 4(c) above during the three (3)-month period that precedes a Change in Control and Executive receives payments and&#47;or benefits under Section 5(b) above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pre-Change in Control Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), any payments and&#47;or benefits owed to Executive under Section 5(c)(i) through 5(c)(iii) shall be reduced by the Pre-Change in Control Severance Benefits.   In no event shall there be a duplication of payments and&#47;or benefits under Section 5(b) and Section 5(c) of this Agreement.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;  means the occurrence of any of the following events&#58; (i) any &#8220;person&#8221; or &#8220;group&#8221; (as defined in Section 13(d) and 14(d) of the Securities and Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)) together with their affiliates become the ultimate &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 of the Exchange Act) of voting stock of the Company representing more than fifty percent (50%) of the voting power of the total voting stock of the Company&#59; (ii) the consummation of a merger or consolidation of the Company with any other corporation or entity regardless of which entity is the survivor, other than  a  merger  or  a  consolidation  which  would  result  in  the  voting  stock  of  the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or being converted into voting securities of the surviving entity or the parent thereof) at least fifty percent (50%) of the combined voting power of the voting securities of the Company or such surviving entity or the parent </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note to Draft&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Insert bracketed language for executives other than the Chief Executive Officer. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note to Draft&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Insert bracketed language for the Chief Executive Officer only. </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">thereof, outstanding immediately after such merger or consolidation&#59; (iii) the stockholders of the Company approve a plan of complete liquidation or winding up of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; or (iv) during any period of two (2) consecutive years, individuals who at the beginning of such period constitute the Board, and any new member of the Board (other than a member of the Board designated by a person who has entered into an agreement with the Company to effect a transaction described in subsections (i), (ii) or (iii) of this definition) whose election by the Company&#8217;s shareholders was approved by a vote of at least two-thirds (2&#47;3) of the members of the Board at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority thereof.  To the extent required to comply with Section 409A (as defined below), a &#8220;Change in Control&#8221; must also meet the requirements of a &#8220;change in control event&#8221;, within the meaning of Treas. Reg. &#167; 1.409A-3(i)(5).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Conditions To And Timing Of Severance Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any obligation of the Company to provide the Executive the payments and benefits set forth in Section 5(b) or 5(c) above is conditioned on his or her signing and returning, without revoking, to the Company a timely and effective separation agreement containing a general release of claims and other customary terms in the form provided to the Executive by the Company at the time that the Executive&#8217;s employment terminates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Separation Agreement must become effective, if at all, by the sixtieth (60th) calendar day following the date the Executive&#8217;s employment terminates.  Any Base Severance or Enhanced Base Severance to which the Executive is entitled will be payable in the form of salary continuation over the twelve (12)-month period following the date that the Executive&#8217;s employment terminates in accordance with the normal payroll practices of the Company.  The first such payment will be made on the Company&#8217;s next regular payday following the expiration of sixty (60) calendar days from the date that the Executive&#8217;s employment terminates, but will be retroactive to the day following such date of termination. The Bonus Severance will be payable in a lump sum payment on the Company&#8217;s next payday following the expiration of sixty (60) calendar days from the date that the Executive&#8217;s employment terminates.    The Health Continuation Payments shall be made on a monthly basis, commencing on the date following the expiration of sixty (60) calendar days from the date that the Executive&#8217;s employment terminates, and any accelerated vesting of the Time-Based Equity Awards shall become effective as of the date that the Separation Agreement becomes effective in accordance with its terms.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Benefits Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for any right the Executive may have under the federal law known as &#8220;COBRA&#8221; or other applicable law to continue participation in the Company&#8217;s group health and dental plans at his or her cost, the Executive&#8217;s participation in all employee benefit plans shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of his or her employment, without regard to any continuation of the Base Salary or other payment to the Executive following termination of his or her employment, and, to the extent applicable, the Executive shall not be eligible to earn vacation or other paid time off following the termination of his or her employment.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Provisions of this Agreement shall survive any termination of employment if so provided in this Agreement or if necessary or desirable to accomplish the purposes of other surviving provisions, including without limitation the Executive&#8217;s obligations under the Restrictive Covenant Agreement.  The obligation of the Company to make payments to the Executive under Section 5(b) or 5(c) above, and the Executive&#8217;s right to retain the same, are expressly conditioned upon his or her continued full performance of his or her obligations under the Restrictive Covenant Agreement.  Upon termination by either the Executive or the Company, all rights, duties and obligations of the Executive and the Company to each other shall cease, except as otherwise expressly provided in this Agreement or the Restrictive Covenant Agreement.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Timing of Payments and Section 409A.   </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding anything to the contrary in this Agreement, if at the time the Executive&#8217;s employment terminates, the Executive is a &#8220;specified employee,&#8221; as defined below, any and all amounts payable under this Agreement on account of such separation from service that would (but for this provision) be payable within six (6) months following the date of termination, shall instead be paid on </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the next business day following the expiration of such six (6)-month period or, if earlier, upon the Executive&#8217;s death&#59; except (A) to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation Section 1.409A-1(b) (including without limitation by reason of the safe harbor set forth in Section 1.409A-1(b)(9)(iii), as determined by the Company in its reasonable good faith discretion)&#59; (B) benefits which qualify as excepted welfare benefits pursuant to Treasury regulation Section 1.409A-1(a)(5)&#59; or (C) other amounts or benefits that are not subject to the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">For purposes of this Agreement, all references to &#8220;termination of employment&#8221; and correlative phrases shall, to the extent required to comply with Section 409A, be construed to require a &#8220;separation from service&#8221; (as defined in Section 1.409A-1(h) of the Treasury regulations after giving effect to the presumptions contained therein), and the term &#8220;specified employee&#8221; means an individual determined by the Company to be a specified employee under Treasury regulation Section 1.409A-1(i).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In no event shall the Company or any Affiliate have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A.</font></div><div style="text-align:justify;text-indent:90pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Representations of the Executive.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Executive represents and warrants to the Company that (a) nothing in his or her past legal and&#47;or work and&#47;or personal experiences, which if became broadly known in the marketplace, would impair his or her ability to serve as the &#91;           Job Title&#93; of a publicly-traded company or materially damage his or her credibility with public shareholders&#59; (b) the Executive has not been convicted of any criminal offense related to health care, or been debarred, sanctioned, excluded or otherwise made ineligible for participation in a federal or state health care program by any federal or state agency&#59; (c) there are no restrictions, agreements, or understandings whatsoever to which the Executive is a party which would prevent or make unlawful his or her execution of this Agreement or employment hereunder&#59; (d) the Executive&#8217;s execution of this Agreement and his or her employment hereunder shall not constitute a breach of any contract, agreement or understanding, oral or written, to which Executive is a party or by which Executive is bound&#59; (e) the Executive is free and able to execute this Agreement and to continue employment with the Company&#59; and (f) the Executive has not used and will not use confidential information or trade secrets belonging to any prior employers to perform services for the Company.</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Compliance Agreements.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Executive agrees to provide services to the Company in compliance with all applicable federal and state laws and regulations, as well as all compliance guidance published by federal or state agencies, including, without limitation, the Medicare and Medicaid anti-kickback law, the Stark self-referral prohibition, and compliance guidance published by the Office of the Inspector General of the Department of Health and Human Service, and to assist the Company in remaining educated and in compliance with respect to such laws and regulations and compliance guidance.  The Executive acknowledges that he or she understands these requirements, and shall remain educated and informed regarding the applicable federal and state laws and regulations, as well as all compliance guidance published by federal or state agencies. In the event that the Executive knows or suspects that any activities of the Company or any personnel or contractor of the Company, or any client of the Company implicates any such requirements or guidance, the Executive agrees that he or she will immediately inform the Company and cooperate fully with the Company to investigate and address any compliance issues arising as a result of such known or suspected activities. The Executive further understands and acknowledges that compliance with this paragraph shall be a condition of employment.</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company to the extent required by applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Section 280G.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any payment or benefit that the Executive may receive, whether or not payable or provided under this Agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), would (i) constitute a &#8220;parachute payment&#8221; </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then such Payment shall be reduced to the Reduced Amount.  The &#8220;Reduced Amount&#8221; shall be either (A) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (B) the largest portion, up to and including the total amount, of the Payment, whichever of the amounts determined under (A) and (B), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Executive&#8217;s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in payments or benefits constituting &#8220;parachute payments&#8221; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order&#58; reduction of cash payments&#59; reduction of employee benefits&#59; and cancellation of accelerated vesting of outstanding equity awards.  In the event that acceleration of vesting of outstanding equity awards is to be reduced, such acceleration of vesting shall be undertaken in the reverse order of the date of grant of the Executive&#8217;s outstanding equity awards.  All calculations and determinations made pursuant this Section 10 will be made by an independent accounting or consulting firm or independent tax counsel appointed by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) whose determinations shall be conclusive and binding on the Company and the Executive for all purposes.  For purposes of making the calculations and determinations required by this Section 10, the Tax Counsel may rely on reasonable, good faith assumptions and approximations concerning the application of Section 280G of the Code and Section 4999 of the Code.  The Company shall bear all costs the Tax Counsel may reasonably incur in connection with its services.</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Assignment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other&#59; provided, however, the Company may assign its rights and obligations under this Agreement without the Executive&#8217;s consent to one of its Affiliates or to any person with whom the Company shall hereafter effect a reorganization, consolidate or merge, or to whom the Company shall hereafter transfer all or substantially all of its properties or assets.  This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of their respective successors, executors, administrators, heirs and permitted assigns.</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Severability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Miscellaneous.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement sets forth the entire agreement between the Executive and the Company, and replaces all prior and contemporaneous communications, agreements and understandings, written or oral, with respect to the terms and conditions of the Executive&#8217;s employment, including any prior employment agreement the Executive may have been party to with the Company.  In the event of a conflict between the terms of this Agreement and the terms of any equity award agreement as it relates to the treatment of equity awards held by the Executive on a termination of the Executive&#8217;s employment, the terms of this Agreement shall control and shall supersede the terms of any such equity award agreement.  This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by the Executive and an expressly authorized representative of the Company.  The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement.  This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument.  This is a State of Florida contract and shall be governed and construed in accordance with the laws of the State of Florida, without regard to any conflict of laws principles that would result in the application of the laws of any other jurisdiction. Executive consents to personal jurisdiction and venue of the Circuit Court in and for Lee County, Florida regarding any action arising under the terms of this Agreement and any and all other disputes between the Executive and the Company and its Affiliates.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Arbitration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Except as provided in the Restrictive Covenant Agreement, any and all controversies and disputes between Executive and the Company arising from this Agreement or regarding </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any matter whatsoever shall be submitted to arbitration before a single unbiased arbitrator skilled in arbitrating such disputes under the American Arbitration Association, utilizing its Employment Arbitration Rules and Mediation Procedures. Any arbitration action brought pursuant to this Section 14 shall be heard in Fort Myers, Lee Country, Florida. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Notices.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to the Executive at his or her last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, attention of the Chairman of the Board, or to such other address as either party may specify by notice to the other actually received.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, this Agreement has been executed by the Company, by its duly authorized representative, and by the Executive, as of the date first above written.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE EXECUTIVE&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;THE COMPANY&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;_________________________</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Executive Name&#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;</font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Annex A&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Insert Outside Activities, if applicable&#93;</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>neoex211listofsubsidiaries.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i13357c3b3c40471bba6919f60980883b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 21.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF NEOGENOMICS, INC.</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Clarient Diagnostic Services, Inc., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Clarient, Inc., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cynogen, Inc., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Genesis Acquisition Holdings Corp., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Genoptix, Inc., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Inivata Limited, UK Limited Company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Inivata, Inc., Delaware Corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Minuet Diagnostics, Inc., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NeoGenomics Bioinformatics, Inc., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NeoGenomics Europe, SA, a Swiss soci&#233;t&#233; anonyme</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NeoGenomics Foundation, Inc., a Florida Corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NeoGenomics Laboratories, Inc., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NeoGenomics Singapore, Pte. Ltd., a Singapore private limited company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Suzhou NeoGenomics Pharmaceutical Research Co., Limited, a Suzhou, China corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Trapelo Health, LLC, a Delaware Limited Liability Company</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>neoexhibit23112312021.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id1c2c08e5f5b45db856b2803d7afad6d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in Registration Statement Nos. 333-231608, 333-237912, 333-251901, 333-259246 on Form S-3 and Registration Statement Nos. 333-125994, 333-139484, 333-159749, 333-173494, 333-180095, 333-189391, 333-205906, 333-210402, 333-256704 on Form S-8 of our reports dated February&#160;25, 2022, relating to the consolidated financial statements of NeoGenomics, Inc. and subsidiaries and the effectiveness of NeoGenomics Inc. and subsidiaries&#8217; internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2021.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2022</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>neoexhibit31112312021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i31fc8c91bffc49078edcd11c30e3093a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark W. Mallon, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of NeoGenomics, Inc.&#59;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.287%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;25, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark W. Mallon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark W. Mallon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>neoexhibit31212312021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4884bcd76af44ee2a6804373a54ac4ce_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William B. Bonello, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of NeoGenomics, Inc.&#59;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.287%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William B. Bonello</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William B. Bonello</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>neoexhibit32112312021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2cc4363cb9564ba78d6a68180f4ac8bf_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of NeoGenomics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the dates indicated below, hereby certify pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;text-indent:28pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;25, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark W. Mallon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark W. Mallon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;25, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William B. Bonello</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William B. Bonello</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>neo-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c83854c7-f1f3-424f-996d-5603fac85cdc,g:4d64aeee-8493-464d-9030-1629fa1fd3ef-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:neo="http://neogenomics.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://neogenomics.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://neogenomics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://neogenomics.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://neogenomics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://neogenomics.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossIncome" roleURI="http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://neogenomics.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://neogenomics.com/role/NatureofBusiness">
        <link:definition>2101101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessDetails" roleURI="http://neogenomics.com/role/NatureofBusinessDetails">
        <link:definition>2402401 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://neogenomics.com/role/Acquisitions">
        <link:definition>2106103 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://neogenomics.com/role/AcquisitionsTables">
        <link:definition>2307301 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://neogenomics.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2408403 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsScheduleofProvisionalInformationDetails" roleURI="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails">
        <link:definition>2409404 - Disclosure - Acquisitions - Schedule of Provisional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsProFormaInformationDetails" roleURI="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails">
        <link:definition>2410405 - Disclosure - Acquisitions - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://neogenomics.com/role/FairValueMeasurements">
        <link:definition>2111104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://neogenomics.com/role/FairValueMeasurementsTables">
        <link:definition>2312302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAmortizedCostDetails" roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValuebyContractualMaturityDetails" roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Fair Value by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails">
        <link:definition>2415408 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://neogenomics.com/role/PropertyandEquipmentNet">
        <link:definition>2116105 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://neogenomics.com/role/PropertyandEquipmentNetTables">
        <link:definition>2317303 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" roleURI="http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails">
        <link:definition>2418409 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDepreciationDetails" roleURI="http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails">
        <link:definition>2419410 - Disclosure - Property and Equipment, Net - Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://neogenomics.com/role/Leases">
        <link:definition>2120106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://neogenomics.com/role/LeasesTables">
        <link:definition>2321304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumLeasePaymentsDetails" roleURI="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails">
        <link:definition>2422411 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumLeasePaymentsDetails_1" roleURI="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2422411 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofAdditionalSupplementalDataDetails" roleURI="http://neogenomics.com/role/LeasesSummaryofAdditionalSupplementalDataDetails">
        <link:definition>2423412 - Disclosure - Leases - Summary of Additional Supplemental Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://neogenomics.com/role/LeasesNarrativeDetails">
        <link:definition>2424413 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssets">
        <link:definition>2125107 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2326305 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2427414 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsRollforwardofGoodwillDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails">
        <link:definition>2428415 - Disclosure - Goodwill and Intangible Assets - Rollforward of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails">
        <link:definition>2429416 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails">
        <link:definition>2430417 - Disclosure - Goodwill and Intangible Assets - Amortization Expense of Intangibles Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails">
        <link:definition>2431418 - Disclosure - Goodwill and Intangible Assets - Estimated Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinNonconsolidatedAffiliate" roleURI="http://neogenomics.com/role/InvestmentinNonconsolidatedAffiliate">
        <link:definition>2132108 - Disclosure - Investment in Non-consolidated Affiliate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinNonConsolidatedAffiliateDetails" roleURI="http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails">
        <link:definition>2433419 - Disclosure - Investment in Non-Consolidated Affiliate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://neogenomics.com/role/Debt">
        <link:definition>2134109 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://neogenomics.com/role/DebtTables">
        <link:definition>2335306 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofLongTermDebtDetails" roleURI="http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails">
        <link:definition>2436420 - Disclosure - Debt - Summary of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://neogenomics.com/role/DebtNarrativeDetails">
        <link:definition>2437421 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofMaturitiesofLongTermDebtDetails" roleURI="http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails">
        <link:definition>2438422 - Disclosure - Debt - Schedule of Maturities of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingActivities" roleURI="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivities">
        <link:definition>2139110 - Disclosure - Derivative Instruments and Hedging Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingActivitiesTables" roleURI="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesTables">
        <link:definition>2340307 - Disclosure - Derivative Instruments and Hedging Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingActivitiesDetails" roleURI="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails">
        <link:definition>2441423 - Disclosure - Derivative Instruments and Hedging Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTransactions" roleURI="http://neogenomics.com/role/EquityTransactions">
        <link:definition>2142111 - Disclosure - Equity Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTransactionsDetails" roleURI="http://neogenomics.com/role/EquityTransactionsDetails">
        <link:definition>2443424 - Disclosure - Equity Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://neogenomics.com/role/StockBasedCompensation">
        <link:definition>2144112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://neogenomics.com/role/StockBasedCompensationTables">
        <link:definition>2345308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2446425 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>2447426 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStatusofOurStockOptionsDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails">
        <link:definition>2448427 - Disclosure - Stock-Based Compensation - Status of Our Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails">
        <link:definition>2449428 - Disclosure - Stock-Based Compensation - Roll Forward of Non-Vested Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails">
        <link:definition>2450429 - Disclosure - Stock-Based Compensation - Summary of Information about our Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRestrictedStockActivityDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails">
        <link:definition>2451430 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://neogenomics.com/role/RevenueRecognition">
        <link:definition>2152113 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://neogenomics.com/role/RevenueRecognitionTables">
        <link:definition>2353309 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://neogenomics.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2454431 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails" roleURI="http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails">
        <link:definition>2455432 - Disclosure - Revenue Recognition - Summary of Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>2456433 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://neogenomics.com/role/IncomeTaxes">
        <link:definition>2157114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://neogenomics.com/role/IncomeTaxesTables">
        <link:definition>2358310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails" roleURI="http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails">
        <link:definition>2459434 - Disclosure - Income Taxes - Significant Components of the Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails" roleURI="http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails">
        <link:definition>2460435 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate and the Federal Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails" roleURI="http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails">
        <link:definition>2461436 - Disclosure - Income Taxes - Current and Non-current Deferred Income Tax Assets And Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://neogenomics.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2462437 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>2463438 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShare" roleURI="http://neogenomics.com/role/NetLossIncomeperShare">
        <link:definition>2164115 - Disclosure - Net (Loss) Income per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareTables" roleURI="http://neogenomics.com/role/NetLossIncomeperShareTables">
        <link:definition>2365311 - Disclosure - Net (Loss) Income per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>2466439 - Disclosure - Net (Loss) Income per Share - Computation of Basic and Diluted Net (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareScheduleofAntidilutiveSharesDetails" roleURI="http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails">
        <link:definition>2467440 - Disclosure - Net (Loss) Income per Share - Schedule of Antidilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlan" roleURI="http://neogenomics.com/role/DefinedContributionPlan">
        <link:definition>2168116 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlanDetails" roleURI="http://neogenomics.com/role/DefinedContributionPlanDetails">
        <link:definition>2469441 - Disclosure - Defined Contribution Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://neogenomics.com/role/CommitmentsandContingencies">
        <link:definition>2170117 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://neogenomics.com/role/CommitmentsandContingenciesTables">
        <link:definition>2371312 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2472442 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://neogenomics.com/role/RelatedPartyTransactions">
        <link:definition>2173118 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://neogenomics.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2474443 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://neogenomics.com/role/SegmentInformation">
        <link:definition>2175119 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://neogenomics.com/role/SegmentInformationTables">
        <link:definition>2376313 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://neogenomics.com/role/SegmentInformationDetails">
        <link:definition>2477444 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive" abstract="false" name="LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne" abstract="false" name="LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo" abstract="false" name="LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PurchaseOptionMember" abstract="true" name="PurchaseOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_GainLossOnInvestmentAndLoanReceivable" abstract="false" name="GainLossOnInvestmentAndLoanReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_WorkingCapitalAdjustmentAcquisitions" abstract="false" name="WorkingCapitalAdjustmentAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" abstract="false" name="OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_FinanceObligationsMember" abstract="true" name="FinanceObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_AssetHeldForSaleSquareFeetOfFacilityOwned" abstract="false" name="AssetHeldForSaleSquareFeetOfFacilityOwned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" abstract="false" name="BusinessCombinationStepAcquisitionPurchaseOptionFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ProceedsFromEquityOfferingNet" abstract="false" name="ProceedsFromEquityOfferingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PharmaServicesMember" abstract="true" name="PharmaServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_GainLossOnTerminationOfInterestRateSwap" abstract="false" name="GainLossOnTerminationOfInterestRateSwap" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember" abstract="true" name="AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_PolymeraseChainReactionTestingWriteOffsCOVID19" abstract="false" name="PolymeraseChainReactionTestingWriteOffsCOVID19" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts" abstract="false" name="PaymentsToAcquireVariableInterestEntitiesTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_CappedCallTransactionsMember" abstract="true" name="CappedCallTransactionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="neo_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_StrategicAllianceWithInivataLimitedMember" abstract="true" name="StrategicAllianceWithInivataLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="neo_ClientDirectBillingMember" abstract="true" name="ClientDirectBillingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities" abstract="false" name="LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_RangeFourMember" abstract="true" name="RangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_CommonStockClosingPrice" abstract="false" name="CommonStockClosingPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="neo_PatentInfringementComplaintMember" abstract="true" name="PatentInfringementComplaintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_RangeTwoMember" abstract="true" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_InterestExpenseDebtContractualCouponInterest" abstract="false" name="InterestExpenseDebtContractualCouponInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ClinicalServicesSegmentMember" abstract="true" name="ClinicalServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_LongTermDebtIncludingCurrentMaturitiesDue" abstract="false" name="LongTermDebtIncludingCurrentMaturitiesDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_InivataMember" abstract="true" name="InivataMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_InterestRateSwapJune2018Member" abstract="true" name="InterestRateSwapJune2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" abstract="false" name="PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" abstract="false" name="InterestExpenseDebtAmortizationOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_CommonStockOfferingMember" abstract="true" name="CommonStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_WriteOffForCOVID19PCRTestingInventoryMember" abstract="true" name="WriteOffForCOVID19PCRTestingInventoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" abstract="false" name="BusinessCombinationAcquisitionAndIntegrationRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_SocialSecurityTaxEmployerDeferralCARESAct" abstract="false" name="SocialSecurityTaxEmployerDeferralCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_CappedCallTransactionsNumberOfUnderlyingShares" abstract="false" name="CappedCallTransactionsNumberOfUnderlyingShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" abstract="true" name="ZeroPointTwoFivePercentConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_ProceedsFromGovernmentAssistanceCARESAct" abstract="false" name="ProceedsFromGovernmentAssistanceCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_FairValueOfCommonStockIssuedToFundAcquisition" abstract="false" name="FairValueOfCommonStockIssuedToFundAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ClinicalServicesMember" abstract="true" name="ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PaymentsOfPremiumsForCappedCallConfirmations" abstract="false" name="PaymentsOfPremiumsForCappedCallConfirmations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_SaleOfStockOptionTerm" abstract="false" name="SaleOfStockOptionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="neo_RepaymentsOfEquipmentAndOtherLoans" abstract="false" name="RepaymentsOfEquipmentAndOtherLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_SaleOfStockPricePerSharePublicOfferingPrice" abstract="false" name="SaleOfStockPricePerSharePublicOfferingPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="neo_SaleOfStockPremiumOnOfferingPrice" abstract="false" name="SaleOfStockPremiumOnOfferingPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationPenaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree" abstract="false" name="LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_DiscountedPriceOfAggregatePrincipleRate" abstract="false" name="DiscountedPriceOfAggregatePrincipleRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="neo_MedicareAndMedicaidMember" abstract="true" name="MedicareAndMedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_SelfPayServicesMember" abstract="true" name="SelfPayServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_ComputerHardwareAndOfficeEquipmentMember" abstract="true" name="ComputerHardwareAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_AssetsHeldForSalePolicyPolicyTextBlock" abstract="false" name="AssetsHeldForSalePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_CommercialInsuranceMember" abstract="true" name="CommercialInsuranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock" abstract="false" name="OtherCurrentAssetsPolicyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_RangeOneMember" abstract="true" name="RangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_RangeFiveMember" abstract="true" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="neo_RangeThreeMember" abstract="true" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" abstract="false" name="CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses" abstract="false" name="EffectiveIncomeTaxRateReconciliationTransactionExpenses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" abstract="false" name="PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_TrapeloHealthMember" abstract="true" name="TrapeloHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_PurchaseOptionMeasurementInput" abstract="false" name="PurchaseOptionMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour" abstract="false" name="LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" abstract="false" name="DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="neo_PrepaidRentNoncurrent" abstract="false" name="PrepaidRentNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" abstract="false" name="DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_AgencyBondsMember" abstract="true" name="AgencyBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_FederalHealthcareProgramRevenueMember" abstract="true" name="FederalHealthcareProgramRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent" abstract="false" name="DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_BusinessCombinationWorkingCapitalAdjustment" abstract="false" name="BusinessCombinationWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount" abstract="false" name="RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" abstract="true" name="OnePointTwoFivePercentConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_WorkingCapitalAdjustmentAcquisitionShares" abstract="false" name="WorkingCapitalAdjustmentAcquisitionShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="neo_InterestRateSwapDecember2016Member" abstract="true" name="InterestRateSwapDecember2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive" abstract="false" name="LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_DeferredTaxAssetsInterestExpense" abstract="false" name="DeferredTaxAssetsInterestExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PolymeraseChainReactionTestingExitCostsCOVID19" abstract="false" name="PolymeraseChainReactionTestingExitCostsCOVID19" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_IncreaseDecreaseInPrepaidConstruction" abstract="false" name="IncreaseDecreaseInPrepaidConstruction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="neo_YankeeBondsMember" abstract="true" name="YankeeBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_LongTermLineOfCreditSettlementGainLoss" abstract="false" name="LongTermLineOfCreditSettlementGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" abstract="false" name="ReceivableWithImputedInterestNonConsolidatedAffiliates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_EmployeeRetentionTaxCreditCARESAct" abstract="false" name="EmployeeRetentionTaxCreditCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ScheduleOfSignificantAccountingPoliciesTable" abstract="true" name="ScheduleOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="neo_PreferenceSharesMember" abstract="true" name="PreferenceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" abstract="false" name="StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="neo_PharmaServicesSegmentMember" abstract="true" name="PharmaServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_DerivativeTerminationFee" abstract="false" name="DerivativeTerminationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_InterestExpenseDebtAccretionOfDebtDiscount" abstract="false" name="InterestExpenseDebtAccretionOfDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ScheduleOfSignificantAccountingPoliciesLineItems" abstract="true" name="ScheduleOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>neo-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c83854c7-f1f3-424f-996d-5603fac85cdc,g:4d64aeee-8493-464d-9030-1629fa1fd3ef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_7160817f-1c16-4a32-8419-9130d5854108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_9c52c5df-89bf-405b-a933-1193914077b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_7160817f-1c16-4a32-8419-9130d5854108" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_9c52c5df-89bf-405b-a933-1193914077b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e4172d64-1fd2-4a41-b1da-83b9eeb93ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_7160817f-1c16-4a32-8419-9130d5854108" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e4172d64-1fd2-4a41-b1da-83b9eeb93ec4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2a187ea-c123-438f-a1b3-fe157595baf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_7160817f-1c16-4a32-8419-9130d5854108" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2a187ea-c123-438f-a1b3-fe157595baf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f2409f4f-bad0-4f23-9d80-3a8febccfc92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_7160817f-1c16-4a32-8419-9130d5854108" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f2409f4f-bad0-4f23-9d80-3a8febccfc92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_628731e6-8dc4-4bdb-a1bc-9e61cf60d2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_7160817f-1c16-4a32-8419-9130d5854108" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_628731e6-8dc4-4bdb-a1bc-9e61cf60d2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a412732b-11e7-4673-b418-e4364aa4a342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_397326c4-d916-427f-8eac-95c526b24cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a412732b-11e7-4673-b418-e4364aa4a342" xlink:to="loc_us-gaap_AccountsPayableCurrent_397326c4-d916-427f-8eac-95c526b24cd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dbcc6f99-6674-46a3-9bd8-24a0186c1e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a412732b-11e7-4673-b418-e4364aa4a342" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dbcc6f99-6674-46a3-9bd8-24a0186c1e9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_360485e4-c771-4b88-9c2a-7eab3a2b0b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a412732b-11e7-4673-b418-e4364aa4a342" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_360485e4-c771-4b88-9c2a-7eab3a2b0b94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_4dbe1716-fc71-40ef-93fe-ee37fd4f66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a412732b-11e7-4673-b418-e4364aa4a342" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_4dbe1716-fc71-40ef-93fe-ee37fd4f66e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3c42ecd0-7b13-4a7b-87a2-199bb54d7a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a412732b-11e7-4673-b418-e4364aa4a342" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3c42ecd0-7b13-4a7b-87a2-199bb54d7a84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_90f357ea-0805-444d-abbf-22731ac26771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a412732b-11e7-4673-b418-e4364aa4a342" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_90f357ea-0805-444d-abbf-22731ac26771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_e981ab8b-4be7-4b12-95de-1da12edce384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_49da755f-879f-4391-b814-d0d9e69cea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e981ab8b-4be7-4b12-95de-1da12edce384" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_49da755f-879f-4391-b814-d0d9e69cea7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_de583289-f1d5-4329-a8b8-6ca91459b768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e981ab8b-4be7-4b12-95de-1da12edce384" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_de583289-f1d5-4329-a8b8-6ca91459b768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0e7d1464-bd9c-481a-a8f0-9d6885366045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e981ab8b-4be7-4b12-95de-1da12edce384" xlink:to="loc_us-gaap_Goodwill_0e7d1464-bd9c-481a-a8f0-9d6885366045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6be795c6-c444-4bc9-9e27-bf8271fafe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e981ab8b-4be7-4b12-95de-1da12edce384" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6be795c6-c444-4bc9-9e27-bf8271fafe49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_125a8727-4d69-4f25-a7ed-c9ced5ac00b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e981ab8b-4be7-4b12-95de-1da12edce384" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_125a8727-4d69-4f25-a7ed-c9ced5ac00b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PrepaidRentNoncurrent_825b5283-b48e-4e04-849b-df758c94ddef" xlink:href="neo-20211231.xsd#neo_PrepaidRentNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e981ab8b-4be7-4b12-95de-1da12edce384" xlink:to="loc_neo_PrepaidRentNoncurrent_825b5283-b48e-4e04-849b-df758c94ddef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ea5f0f99-09b4-4b78-8619-5f18d8f39e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e981ab8b-4be7-4b12-95de-1da12edce384" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ea5f0f99-09b4-4b78-8619-5f18d8f39e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5cceb0ab-1c80-4512-a740-ee764d9f0be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e981ab8b-4be7-4b12-95de-1da12edce384" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5cceb0ab-1c80-4512-a740-ee764d9f0be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e55f930d-cc32-48f7-9d36-dd452107e514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_af762e10-b154-48d5-84e1-408a3019547f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e55f930d-cc32-48f7-9d36-dd452107e514" xlink:to="loc_us-gaap_CommonStockValueOutstanding_af762e10-b154-48d5-84e1-408a3019547f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_da6b4203-02b1-422f-b2eb-fd060a63ad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e55f930d-cc32-48f7-9d36-dd452107e514" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_da6b4203-02b1-422f-b2eb-fd060a63ad0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_23088e2e-ff0f-44fb-9234-f709a0bb8e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e55f930d-cc32-48f7-9d36-dd452107e514" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_23088e2e-ff0f-44fb-9234-f709a0bb8e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cfa47303-7197-42b8-9d17-94e77428eeab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e55f930d-cc32-48f7-9d36-dd452107e514" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cfa47303-7197-42b8-9d17-94e77428eeab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_108e0b01-dcb3-4ba8-8661-65d0167ff17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d6338478-9a7d-40f0-b2c8-2ed62caf324d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_108e0b01-dcb3-4ba8-8661-65d0167ff17d" xlink:to="loc_us-gaap_AssetsCurrent_d6338478-9a7d-40f0-b2c8-2ed62caf324d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_b5de8bbc-9fc5-4187-80ce-f332986f5621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_108e0b01-dcb3-4ba8-8661-65d0167ff17d" xlink:to="loc_us-gaap_AssetsNoncurrent_b5de8bbc-9fc5-4187-80ce-f332986f5621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f7eb2539-7d69-4a5f-ad2c-9e448e040ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ad9f1717-1c67-4f38-bf45-b664e481333b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f7eb2539-7d69-4a5f-ad2c-9e448e040ff5" xlink:to="loc_us-gaap_LiabilitiesCurrent_ad9f1717-1c67-4f38-bf45-b664e481333b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9d04404f-a77a-4be3-850e-b2fac1fcc10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f7eb2539-7d69-4a5f-ad2c-9e448e040ff5" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9d04404f-a77a-4be3-850e-b2fac1fcc10a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa8aa70c-cab9-48db-9e36-7dec1166820b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_99f8d512-ceb5-430e-95e1-bbb0e42d7ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa8aa70c-cab9-48db-9e36-7dec1166820b" xlink:to="loc_us-gaap_Liabilities_99f8d512-ceb5-430e-95e1-bbb0e42d7ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3e41caea-2253-465e-a2c6-7316ee7a4b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa8aa70c-cab9-48db-9e36-7dec1166820b" xlink:to="loc_us-gaap_StockholdersEquity_3e41caea-2253-465e-a2c6-7316ee7a4b1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8b9a02d9-f9c9-4f7a-b019-cef7250bf108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa8aa70c-cab9-48db-9e36-7dec1166820b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8b9a02d9-f9c9-4f7a-b019-cef7250bf108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_35b72123-05fc-440c-b14f-b8174fbb61cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ad4c88d-f2ba-4686-acdb-ec0ebbff0a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35b72123-05fc-440c-b14f-b8174fbb61cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ad4c88d-f2ba-4686-acdb-ec0ebbff0a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6812436a-f630-42c6-a53e-a3199450beb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35b72123-05fc-440c-b14f-b8174fbb61cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6812436a-f630-42c6-a53e-a3199450beb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d889d4ea-dc9c-49f8-b621-d607c53e7bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35b72123-05fc-440c-b14f-b8174fbb61cf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d889d4ea-dc9c-49f8-b621-d607c53e7bfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d1dbf2e1-0356-4076-ac12-7bd01db9d4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35b72123-05fc-440c-b14f-b8174fbb61cf" xlink:to="loc_us-gaap_InventoryNet_d1dbf2e1-0356-4076-ac12-7bd01db9d4f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_37771de9-9e9e-4df1-9cdb-9ea99df78b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35b72123-05fc-440c-b14f-b8174fbb61cf" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_37771de9-9e9e-4df1-9cdb-9ea99df78b97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7da3a4e1-caff-4b8f-8f00-0e2f8c14d489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35b72123-05fc-440c-b14f-b8174fbb61cf" xlink:to="loc_us-gaap_OtherAssetsCurrent_7da3a4e1-caff-4b8f-8f00-0e2f8c14d489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_383e2b30-41f4-45e3-89fa-d8e29f66bfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35b72123-05fc-440c-b14f-b8174fbb61cf" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_383e2b30-41f4-45e3-89fa-d8e29f66bfc0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_72606dfb-f761-47eb-8ff2-a46d8bf7bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b00366f4-246d-4749-9fdd-65d33097dd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_72606dfb-f761-47eb-8ff2-a46d8bf7bbf4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b00366f4-246d-4749-9fdd-65d33097dd35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e30538b0-bf40-4a0e-96e0-d88c58eb8c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_72606dfb-f761-47eb-8ff2-a46d8bf7bbf4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e30538b0-bf40-4a0e-96e0-d88c58eb8c85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d77cd389-3bd8-407d-99b0-08708fae8421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_72606dfb-f761-47eb-8ff2-a46d8bf7bbf4" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d77cd389-3bd8-407d-99b0-08708fae8421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_67d616c1-b1a5-4576-991a-a3da4821f3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_9c3a22a6-3cd7-4891-8b3b-f2f56fba301b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_67d616c1-b1a5-4576-991a-a3da4821f3b7" xlink:to="loc_us-gaap_GrossProfit_9c3a22a6-3cd7-4891-8b3b-f2f56fba301b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c15075ad-5dc5-46de-bae6-ae19834c8950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_67d616c1-b1a5-4576-991a-a3da4821f3b7" xlink:to="loc_us-gaap_OperatingExpenses_c15075ad-5dc5-46de-bae6-ae19834c8950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19de34cf-903e-4083-abe3-738c0fddb30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_475a1c20-5abe-4154-b3b0-740d9b1168f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19de34cf-903e-4083-abe3-738c0fddb30f" xlink:to="loc_us-gaap_OperatingIncomeLoss_475a1c20-5abe-4154-b3b0-740d9b1168f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_542361f2-38e5-4d13-b20d-f467c1713c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19de34cf-903e-4083-abe3-738c0fddb30f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_542361f2-38e5-4d13-b20d-f467c1713c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d338b5d9-bd11-40ba-9703-c5fdc2969de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19de34cf-903e-4083-abe3-738c0fddb30f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d338b5d9-bd11-40ba-9703-c5fdc2969de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7bc76866-03a0-4399-9d51-dd75df78dbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19de34cf-903e-4083-abe3-738c0fddb30f" xlink:to="loc_us-gaap_InterestExpense_7bc76866-03a0-4399-9d51-dd75df78dbdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnTerminationOfInterestRateSwap_3094a3e5-6385-4bf1-85bd-e4c538550c8e" xlink:href="neo-20211231.xsd#neo_GainLossOnTerminationOfInterestRateSwap"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19de34cf-903e-4083-abe3-738c0fddb30f" xlink:to="loc_neo_GainLossOnTerminationOfInterestRateSwap_3094a3e5-6385-4bf1-85bd-e4c538550c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable_8b6e958a-174f-460a-abc7-f7783823372d" xlink:href="neo-20211231.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19de34cf-903e-4083-abe3-738c0fddb30f" xlink:to="loc_neo_GainLossOnInvestmentAndLoanReceivable_8b6e958a-174f-460a-abc7-f7783823372d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e7d71e4-997a-4c37-97cc-99f0361098e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0db01aa4-4420-45bb-9194-e7ca5e422e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4e7d71e4-997a-4c37-97cc-99f0361098e1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0db01aa4-4420-45bb-9194-e7ca5e422e3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4d54e63a-4759-4403-95e3-ffb3ee7ed894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4e7d71e4-997a-4c37-97cc-99f0361098e1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4d54e63a-4759-4403-95e3-ffb3ee7ed894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_d9922827-1e31-4659-b049-3a4202b861d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6a886d9c-1eb5-4909-8575-9f5aa6fd4e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_d9922827-1e31-4659-b049-3a4202b861d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6a886d9c-1eb5-4909-8575-9f5aa6fd4e16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d8af22a3-1522-4bbf-bdd2-79c4fa900fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_d9922827-1e31-4659-b049-3a4202b861d7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d8af22a3-1522-4bbf-bdd2-79c4fa900fcf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedStatementsofComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0494961b-cd74-4429-9eb5-3ac9531991cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8584162d-85d9-479d-b69d-83a082685ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0494961b-cd74-4429-9eb5-3ac9531991cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8584162d-85d9-479d-b69d-83a082685ed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_97f16ab9-84ea-413a-a2d6-cafefa24a3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0494961b-cd74-4429-9eb5-3ac9531991cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_97f16ab9-84ea-413a-a2d6-cafefa24a3c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_ca0c97aa-2081-4d73-9d6f-62baf084e86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0494961b-cd74-4429-9eb5-3ac9531991cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_ca0c97aa-2081-4d73-9d6f-62baf084e86b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a07f88bc-7d3a-4ca3-a7b2-ebaec2a30326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5fa0e7c0-35b5-46ed-8bd4-22af02a71c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a07f88bc-7d3a-4ca3-a7b2-ebaec2a30326" xlink:to="loc_us-gaap_NetIncomeLoss_5fa0e7c0-35b5-46ed-8bd4-22af02a71c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cba50aef-bccd-4ccc-a2ff-813e5468de72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a07f88bc-7d3a-4ca3-a7b2-ebaec2a30326" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cba50aef-bccd-4ccc-a2ff-813e5468de72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_06589efa-1ad4-4d4a-89a9-7f4366b3613e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_06589efa-1ad4-4d4a-89a9-7f4366b3613e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f5cc9921-eb18-4836-a14c-25384da45922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f5cc9921-eb18-4836-a14c-25384da45922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a3eeddd3-e67a-48f1-bcb4-abcccc55d0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_OperatingLeaseExpense_a3eeddd3-e67a-48f1-bcb4-abcccc55d0bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_fed364c2-16bd-4921-93c9-1a2a3db173cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_fed364c2-16bd-4921-93c9-1a2a3db173cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_90a00be8-8b95-4271-b170-2b021484c307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_Depreciation_90a00be8-8b95-4271-b170-2b021484c307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5a998446-62f8-4772-ab39-e918288897fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_ShareBasedCompensation_5a998446-62f8-4772-ab39-e918288897fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b1c4c459-60ce-4de6-a709-a926f567abb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b1c4c459-60ce-4de6-a709-a926f567abb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_13472c60-b1e7-4369-ad14-863c859d1984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_13472c60-b1e7-4369-ad14-863c859d1984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_03e82d56-9a14-40e1-a9a9-550e9bc82a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_03e82d56-9a14-40e1-a9a9-550e9bc82a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncreaseDecreaseInPrepaidConstruction_01cb30a8-ef9a-4c94-9230-05d052c20c2a" xlink:href="neo-20211231.xsd#neo_IncreaseDecreaseInPrepaidConstruction"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_neo_IncreaseDecreaseInPrepaidConstruction_01cb30a8-ef9a-4c94-9230-05d052c20c2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_078e6c03-a929-4b61-b781-dbf128225e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_078e6c03-a929-4b61-b781-dbf128225e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnTerminationOfInterestRateSwap_2f8436c3-49ea-47fb-9198-6730c1b72b39" xlink:href="neo-20211231.xsd#neo_GainLossOnTerminationOfInterestRateSwap"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_neo_GainLossOnTerminationOfInterestRateSwap_2f8436c3-49ea-47fb-9198-6730c1b72b39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88728de7-d700-4451-9e89-eccbf8a403e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_NetIncomeLoss_88728de7-d700-4451-9e89-eccbf8a403e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9becd0a2-357a-4d99-8294-193bb510465e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9becd0a2-357a-4d99-8294-193bb510465e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_403e004e-d99e-47b0-98e6-a9035cff7fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_403e004e-d99e-47b0-98e6-a9035cff7fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_86d5930d-46eb-41b3-bf81-2ec4d4c42dda" xlink:href="neo-20211231.xsd#neo_PolymeraseChainReactionTestingExitCostsCOVID19"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_86d5930d-46eb-41b3-bf81-2ec4d4c42dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_fd502d1d-ef03-44a7-8c6f-fe60bc49638c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_fd502d1d-ef03-44a7-8c6f-fe60bc49638c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_f5edbfa4-3bab-40a5-a16a-5a1e6bba74d8" xlink:href="neo-20211231.xsd#neo_ReceivableWithImputedInterestNonConsolidatedAffiliates"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6895e79e-0789-4352-9621-b069cf71f5ed" xlink:to="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_f5edbfa4-3bab-40a5-a16a-5a1e6bba74d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d7fc86f-d7d3-4bad-bd23-9eb83d9d5d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_eece82b9-a58f-4866-b293-5aeeb86d31de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d7fc86f-d7d3-4bad-bd23-9eb83d9d5d52" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_eece82b9-a58f-4866-b293-5aeeb86d31de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationWorkingCapitalAdjustment_cd9ef636-0143-4798-a2d6-ab1881b83479" xlink:href="neo-20211231.xsd#neo_BusinessCombinationWorkingCapitalAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d7fc86f-d7d3-4bad-bd23-9eb83d9d5d52" xlink:to="loc_neo_BusinessCombinationWorkingCapitalAdjustment_cd9ef636-0143-4798-a2d6-ab1881b83479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_63115bde-3126-4a54-9ce1-c97ab80a099b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d7fc86f-d7d3-4bad-bd23-9eb83d9d5d52" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_63115bde-3126-4a54-9ce1-c97ab80a099b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3bdbb521-db17-4083-a66d-fcd98e8ee440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d7fc86f-d7d3-4bad-bd23-9eb83d9d5d52" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3bdbb521-db17-4083-a66d-fcd98e8ee440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0a9d9a72-b497-433e-b3bc-92f52e54aa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d7fc86f-d7d3-4bad-bd23-9eb83d9d5d52" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0a9d9a72-b497-433e-b3bc-92f52e54aa9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_051c3202-8228-4356-b1db-2c0df1b87a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d7fc86f-d7d3-4bad-bd23-9eb83d9d5d52" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_051c3202-8228-4356-b1db-2c0df1b87a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_bb5ecdae-20d5-43b2-8a63-6bd88ae51b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8d7fc86f-d7d3-4bad-bd23-9eb83d9d5d52" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_bb5ecdae-20d5-43b2-8a63-6bd88ae51b78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4e9f1472-f672-4e28-ac19-97f7a70612fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ae26bea-369c-4925-b6ff-61f80186545b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4e9f1472-f672-4e28-ac19-97f7a70612fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ae26bea-369c-4925-b6ff-61f80186545b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23fceaf4-2db6-4b91-b8e8-81af4caef72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4e9f1472-f672-4e28-ac19-97f7a70612fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23fceaf4-2db6-4b91-b8e8-81af4caef72d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_275d1d55-0af3-4f0f-844e-d0a7297684a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4e9f1472-f672-4e28-ac19-97f7a70612fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_275d1d55-0af3-4f0f-844e-d0a7297684a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1ec20235-96bc-43d7-8c09-5585e95d5742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1ec20235-96bc-43d7-8c09-5585e95d5742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ProceedsFromEquityOfferingNet_884c43c0-7955-4707-9d79-109c74e9dd6a" xlink:href="neo-20211231.xsd#neo_ProceedsFromEquityOfferingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_neo_ProceedsFromEquityOfferingNet_884c43c0-7955-4707-9d79-109c74e9dd6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_eb61f052-0b28-4e8e-a967-357d21c54bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_eb61f052-0b28-4e8e-a967-357d21c54bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DerivativeTerminationFee_6401ce94-15c7-4154-a169-8c01bd37c208" xlink:href="neo-20211231.xsd#neo_DerivativeTerminationFee"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_neo_DerivativeTerminationFee_6401ce94-15c7-4154-a169-8c01bd37c208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_c62b76a4-5181-4ca1-a520-67f60b9079f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_c62b76a4-5181-4ca1-a520-67f60b9079f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_a3b2bf76-2da2-4b5a-8ea9-a8606339793a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_a3b2bf76-2da2-4b5a-8ea9-a8606339793a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RepaymentsOfEquipmentAndOtherLoans_4bcd633c-46f0-4c56-ab07-521a6d60bf7e" xlink:href="neo-20211231.xsd#neo_RepaymentsOfEquipmentAndOtherLoans"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_neo_RepaymentsOfEquipmentAndOtherLoans_4bcd633c-46f0-4c56-ab07-521a6d60bf7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_469b8582-9231-4def-9cc2-b480c9d49b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_469b8582-9231-4def-9cc2-b480c9d49b21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ccdf7c0-0bef-41d7-9cf1-640a2d97cea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ccdf7c0-0bef-41d7-9cf1-640a2d97cea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations_b06e22e1-0912-4e89-a087-fa102c014caa" xlink:href="neo-20211231.xsd#neo_PaymentsOfPremiumsForCappedCallConfirmations"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2546a6e9-45e3-42c5-b7c0-c9ef05ec29bb" xlink:to="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations_b06e22e1-0912-4e89-a087-fa102c014caa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#AcquisitionsScheduleofProvisionalInformationDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_77074a68-69a7-40f3-8ff4-19ad89a48e35" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities_93f97eb3-232f-4c15-a952-3b841f97e1d2" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_77074a68-69a7-40f3-8ff4-19ad89a48e35" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities_93f97eb3-232f-4c15-a952-3b841f97e1d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_832752d3-63e2-4ded-b598-4eafd05fcec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_77074a68-69a7-40f3-8ff4-19ad89a48e35" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_832752d3-63e2-4ded-b598-4eafd05fcec4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities_14017e68-e93d-4ab4-a11c-e970fc8116a2" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_77074a68-69a7-40f3-8ff4-19ad89a48e35" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities_14017e68-e93d-4ab4-a11c-e970fc8116a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_72629337-ddb3-4be8-aa1f-38a8a69f2429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3428665b-590c-41f7-9f22-4bbf63f121a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_72629337-ddb3-4be8-aa1f-38a8a69f2429" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3428665b-590c-41f7-9f22-4bbf63f121a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_735916b9-3f7a-4d74-bb26-9139d58b6bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_72629337-ddb3-4be8-aa1f-38a8a69f2429" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_735916b9-3f7a-4d74-bb26-9139d58b6bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_b1e1fdf1-6f94-4d19-8137-e39d1bbf452e" xlink:href="neo-20211231.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_72629337-ddb3-4be8-aa1f-38a8a69f2429" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_b1e1fdf1-6f94-4d19-8137-e39d1bbf452e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_74711ef0-6e84-444a-b8cb-14917e792892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_8e2b5483-5b9a-40b3-8b41-0006c7cb8a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_74711ef0-6e84-444a-b8cb-14917e792892" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_8e2b5483-5b9a-40b3-8b41-0006c7cb8a96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_2e405175-bef7-4be5-b99b-037d01401ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_74711ef0-6e84-444a-b8cb-14917e792892" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_2e405175-bef7-4be5-b99b-037d01401ef3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_cb6d9d71-9f25-4223-b8d5-9cf65852053d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_74711ef0-6e84-444a-b8cb-14917e792892" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_cb6d9d71-9f25-4223-b8d5-9cf65852053d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_a5d0aff4-6613-41cd-a177-aa20d8d3cc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_74711ef0-6e84-444a-b8cb-14917e792892" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_a5d0aff4-6613-41cd-a177-aa20d8d3cc25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a8ae2e80-9930-40b2-8ca2-c09afe14f129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bf1c144-8431-46e8-9e31-2769d9eb33e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a8ae2e80-9930-40b2-8ca2-c09afe14f129" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bf1c144-8431-46e8-9e31-2769d9eb33e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d4b38d6c-bdea-4ddc-b1b8-4fe962eaf76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a8ae2e80-9930-40b2-8ca2-c09afe14f129" xlink:to="loc_us-gaap_Goodwill_d4b38d6c-bdea-4ddc-b1b8-4fe962eaf76f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_acf46ecc-9f67-4007-a384-6a998fa9525b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_e9c0132d-902d-43d5-b925-d4b31197ecb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_acf46ecc-9f67-4007-a384-6a998fa9525b" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_e9c0132d-902d-43d5-b925-d4b31197ecb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_703beded-04e4-4948-8b98-9eed6837a16c" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_acf46ecc-9f67-4007-a384-6a998fa9525b" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_703beded-04e4-4948-8b98-9eed6837a16c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4b8a9586-e388-4e33-9a43-7ecad67392e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ad51877c-1157-43e3-bd73-fa3b81bd286e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4b8a9586-e388-4e33-9a43-7ecad67392e4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ad51877c-1157-43e3-bd73-fa3b81bd286e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_97e79c62-cfea-4bd5-9e4f-18b02b38366f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4b8a9586-e388-4e33-9a43-7ecad67392e4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_97e79c62-cfea-4bd5-9e4f-18b02b38366f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_46763dca-108e-46ba-8917-32d139fe6f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4b8a9586-e388-4e33-9a43-7ecad67392e4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_46763dca-108e-46ba-8917-32d139fe6f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4b9b415e-9f6c-4cf4-86c1-eef4ef1e6d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c5ada5f5-e16f-453b-915b-77b29edd0049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4b9b415e-9f6c-4cf4-86c1-eef4ef1e6d1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c5ada5f5-e16f-453b-915b-77b29edd0049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_803ede0a-181e-4c31-9c90-1ecfcdadbbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4b9b415e-9f6c-4cf4-86c1-eef4ef1e6d1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_803ede0a-181e-4c31-9c90-1ecfcdadbbd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_ca71fac0-601e-4a0a-b465-c022dec0e01f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4b9b415e-9f6c-4cf4-86c1-eef4ef1e6d1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_ca71fac0-601e-4a0a-b465-c022dec0e01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3ede2c4d-a912-48df-b104-ca7f85f8a508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4b9b415e-9f6c-4cf4-86c1-eef4ef1e6d1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3ede2c4d-a912-48df-b104-ca7f85f8a508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_c1401ad9-69b7-45be-aa92-58be63459de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4b9b415e-9f6c-4cf4-86c1-eef4ef1e6d1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_c1401ad9-69b7-45be-aa92-58be63459de2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_f8324987-b76a-4e61-b3e1-1500b24f88cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_1d597f8c-b67f-497a-a1b0-cd0ce29fbda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_f8324987-b76a-4e61-b3e1-1500b24f88cf" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_1d597f8c-b67f-497a-a1b0-cd0ce29fbda7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_cd369799-7882-42da-b0dc-31363acb3556" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_f8324987-b76a-4e61-b3e1-1500b24f88cf" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_cd369799-7882-42da-b0dc-31363acb3556" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsScheduleofAmortizedCostDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_f07a1545-a23a-4c00-be8d-05820c2a1a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4b213967-122a-4243-88eb-bb53413c57fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_f07a1545-a23a-4c00-be8d-05820c2a1a46" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4b213967-122a-4243-88eb-bb53413c57fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c70cdcd-1bad-457a-9549-a43df92a3e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_f07a1545-a23a-4c00-be8d-05820c2a1a46" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c70cdcd-1bad-457a-9549-a43df92a3e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_983d3a1a-8161-412a-a51d-ca17793bf1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_f07a1545-a23a-4c00-be8d-05820c2a1a46" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_983d3a1a-8161-412a-a51d-ca17793bf1e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsFairValuebyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d75afc84-7ce1-4680-8765-fda98226d19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_04fb89ae-fa2d-42c6-9189-63863844e2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d75afc84-7ce1-4680-8765-fda98226d19c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_04fb89ae-fa2d-42c6-9189-63863844e2ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d09d8595-91bb-466f-8c6a-7f4b649d6e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d75afc84-7ce1-4680-8765-fda98226d19c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d09d8595-91bb-466f-8c6a-7f4b649d6e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_621a6f9b-5e9a-4940-9340-257389f89485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d75afc84-7ce1-4680-8765-fda98226d19c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_621a6f9b-5e9a-4940-9340-257389f89485" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3879b35d-34a4-4d5d-946a-ec60fcf336e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_caa988c8-4fe5-4992-baa2-304d3c88da98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3879b35d-34a4-4d5d-946a-ec60fcf336e1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_caa988c8-4fe5-4992-baa2-304d3c88da98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_16067527-a2e2-4415-a7ff-29b41b6e2d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3879b35d-34a4-4d5d-946a-ec60fcf336e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_16067527-a2e2-4415-a7ff-29b41b6e2d20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf71f1f9-eafa-479a-aae0-5dc5b0bd5dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3e63f3b3-d057-46c2-a604-f282bde2d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bf71f1f9-eafa-479a-aae0-5dc5b0bd5dc0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3e63f3b3-d057-46c2-a604-f282bde2d79d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_44b280de-f07c-4640-992c-6f6bbbafcacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bf71f1f9-eafa-479a-aae0-5dc5b0bd5dc0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_44b280de-f07c-4640-992c-6f6bbbafcacc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#LeasesScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30b6d9ac-9bcc-46ae-a895-fc88f11aeb19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1f526243-498d-4b64-a07e-42fd4a4a07e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30b6d9ac-9bcc-46ae-a895-fc88f11aeb19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1f526243-498d-4b64-a07e-42fd4a4a07e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_86394f9f-c32a-44bd-a3d7-a686547d6028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30b6d9ac-9bcc-46ae-a895-fc88f11aeb19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_86394f9f-c32a-44bd-a3d7-a686547d6028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6bfef535-a13a-4a57-a742-5f401e5b219b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30b6d9ac-9bcc-46ae-a895-fc88f11aeb19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6bfef535-a13a-4a57-a742-5f401e5b219b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_722b8e6c-e1d4-4fc9-9fd4-965f7c2a7c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30b6d9ac-9bcc-46ae-a895-fc88f11aeb19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_722b8e6c-e1d4-4fc9-9fd4-965f7c2a7c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0adee0dc-c73e-43a2-88d7-35458ba6a777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30b6d9ac-9bcc-46ae-a895-fc88f11aeb19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0adee0dc-c73e-43a2-88d7-35458ba6a777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cec29d7a-e22f-49a8-9a26-c0587814988b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30b6d9ac-9bcc-46ae-a895-fc88f11aeb19" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cec29d7a-e22f-49a8-9a26-c0587814988b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="neo-20211231.xsd#LeasesScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3281780-50bf-4551-960c-5017fed37e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_91119ecf-9486-4c21-a1f5-4b525fef523b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3281780-50bf-4551-960c-5017fed37e70" xlink:to="loc_us-gaap_OperatingLeaseLiability_91119ecf-9486-4c21-a1f5-4b525fef523b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_827068aa-1f14-452c-8022-df65052f6bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3281780-50bf-4551-960c-5017fed37e70" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_827068aa-1f14-452c-8022-df65052f6bd2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d172c263-62d5-4b54-9204-ebd21f3a4a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3413d827-ba07-488c-9898-595d18706152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d172c263-62d5-4b54-9204-ebd21f3a4a1e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3413d827-ba07-488c-9898-595d18706152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_03da990a-8264-416d-b82f-36bee53d3440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d172c263-62d5-4b54-9204-ebd21f3a4a1e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_03da990a-8264-416d-b82f-36bee53d3440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_268c9afa-2e0c-40ab-92ed-a5b936b1231e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b0a7d468-e315-460e-b088-58ba5a155b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_268c9afa-2e0c-40ab-92ed-a5b936b1231e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b0a7d468-e315-460e-b088-58ba5a155b9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_837710d9-0c22-4203-a1b7-828688f9b279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_268c9afa-2e0c-40ab-92ed-a5b936b1231e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_837710d9-0c22-4203-a1b7-828688f9b279" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ec071760-ef9d-4ddd-96a3-97dbf4d03922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7bc21a3b-c087-4c23-8b60-1b095fc377c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ec071760-ef9d-4ddd-96a3-97dbf4d03922" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7bc21a3b-c087-4c23-8b60-1b095fc377c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5757ec4e-cd70-4997-a32e-3ecc921f6336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ec071760-ef9d-4ddd-96a3-97dbf4d03922" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5757ec4e-cd70-4997-a32e-3ecc921f6336" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_283e6594-365e-42d8-9bbc-918fced65842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ec071760-ef9d-4ddd-96a3-97dbf4d03922" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_283e6594-365e-42d8-9bbc-918fced65842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1a07b131-8097-40d6-9380-416bd139efa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ec071760-ef9d-4ddd-96a3-97dbf4d03922" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1a07b131-8097-40d6-9380-416bd139efa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4efd926e-3cff-4474-8264-ad6071a58394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ec071760-ef9d-4ddd-96a3-97dbf4d03922" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4efd926e-3cff-4474-8264-ad6071a58394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1026c366-c801-4551-be75-74d9e8c679e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ec071760-ef9d-4ddd-96a3-97dbf4d03922" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1026c366-c801-4551-be75-74d9e8c679e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DebtScheduleofMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_871772e2-4d19-4f1c-827c-65b84998eed6" xlink:href="neo-20211231.xsd#neo_LongTermDebtIncludingCurrentMaturitiesDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a4a5d9c5-7afe-4377-bd8b-9807e3674ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_871772e2-4d19-4f1c-827c-65b84998eed6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a4a5d9c5-7afe-4377-bd8b-9807e3674ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3ed1e78d-ae6a-4713-8552-7d5270c0065a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_871772e2-4d19-4f1c-827c-65b84998eed6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3ed1e78d-ae6a-4713-8552-7d5270c0065a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0425f59e-ca76-4ea1-af99-f2bb930717fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_871772e2-4d19-4f1c-827c-65b84998eed6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0425f59e-ca76-4ea1-af99-f2bb930717fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_cc56c63e-f8da-4486-84ae-0fc26f6be714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_871772e2-4d19-4f1c-827c-65b84998eed6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_cc56c63e-f8da-4486-84ae-0fc26f6be714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7b08e6d6-b815-42ee-8fda-4a5af2f9d968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_871772e2-4d19-4f1c-827c-65b84998eed6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7b08e6d6-b815-42ee-8fda-4a5af2f9d968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_75536d0c-9c77-4fae-b21e-1bad5d63bd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_871772e2-4d19-4f1c-827c-65b84998eed6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_75536d0c-9c77-4fae-b21e-1bad5d63bd8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f092de8c-e6b9-482d-8c76-816b0f81f07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_66f58b7c-63cf-46ce-acb0-4acb75bb3d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f092de8c-e6b9-482d-8c76-816b0f81f07f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_66f58b7c-63cf-46ce-acb0-4acb75bb3d85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b08313ea-992c-4afc-bb8f-7b2c4b6c2327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f092de8c-e6b9-482d-8c76-816b0f81f07f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b08313ea-992c-4afc-bb8f-7b2c4b6c2327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_dbd60940-8d10-4e54-ab53-399cf86c9de6" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne_ffd30605-a4d2-4dc5-9bae-a936ae5d4255" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_dbd60940-8d10-4e54-ab53-399cf86c9de6" xlink:to="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne_ffd30605-a4d2-4dc5-9bae-a936ae5d4255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo_3b671a92-5ef6-4013-b1e0-4f7cdc470133" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_dbd60940-8d10-4e54-ab53-399cf86c9de6" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo_3b671a92-5ef6-4013-b1e0-4f7cdc470133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree_37871f21-95db-4ca5-be81-0733a44150ed" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_dbd60940-8d10-4e54-ab53-399cf86c9de6" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree_37871f21-95db-4ca5-be81-0733a44150ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour_134e6075-9a5e-4ecf-b6a3-350fd197806b" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_dbd60940-8d10-4e54-ab53-399cf86c9de6" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour_134e6075-9a5e-4ecf-b6a3-350fd197806b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive_47af70a1-9572-4b1c-a0f2-22ea4bf0ad90" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_dbd60940-8d10-4e54-ab53-399cf86c9de6" xlink:to="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive_47af70a1-9572-4b1c-a0f2-22ea4bf0ad90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive_a82bc901-8996-4ccc-8418-65bd7f3d8f1a" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_dbd60940-8d10-4e54-ab53-399cf86c9de6" xlink:to="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive_a82bc901-8996-4ccc-8418-65bd7f3d8f1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d28a6c4c-d03c-45e9-b490-254ab9e03516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_217a3618-81a7-42c3-b7cb-256706fd6cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_d28a6c4c-d03c-45e9-b490-254ab9e03516" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_217a3618-81a7-42c3-b7cb-256706fd6cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b87aa6f9-9cc6-4aa5-a6a7-dea6412231ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_d28a6c4c-d03c-45e9-b490-254ab9e03516" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b87aa6f9-9cc6-4aa5-a6a7-dea6412231ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_f0562576-909e-404d-8de1-25ac4bc2cd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c0a00443-f512-46cc-bf03-f7050a5c6be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_f0562576-909e-404d-8de1-25ac4bc2cd91" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c0a00443-f512-46cc-bf03-f7050a5c6be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_eca548d7-b415-483f-a46b-61b2c657afe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_f0562576-909e-404d-8de1-25ac4bc2cd91" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_eca548d7-b415-483f-a46b-61b2c657afe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_88e53483-e875-4565-911f-2ed2fc464263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_9b890bf5-fb2f-4d83-9dc0-fbfd9961b142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalizedContractCostGross_88e53483-e875-4565-911f-2ed2fc464263" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_9b890bf5-fb2f-4d83-9dc0-fbfd9961b142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_059e1640-9802-4a33-a262-f0544b00715c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalizedContractCostGross_88e53483-e875-4565-911f-2ed2fc464263" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_059e1640-9802-4a33-a262-f0544b00715c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d132b0b2-f0c9-4b13-bfe5-1fa5f691eeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_41563b65-c427-4ce0-a2e8-bee2b72ce9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d132b0b2-f0c9-4b13-bfe5-1fa5f691eeb0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_41563b65-c427-4ce0-a2e8-bee2b72ce9de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_33ef5ce6-3bc5-4a58-ab49-16212a6b859f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d132b0b2-f0c9-4b13-bfe5-1fa5f691eeb0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_33ef5ce6-3bc5-4a58-ab49-16212a6b859f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b35e0abc-e1fe-45ad-a7ac-954a1cde00e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_85b96bc6-961b-4b5a-9233-7eaadcee0d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b35e0abc-e1fe-45ad-a7ac-954a1cde00e6" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_85b96bc6-961b-4b5a-9233-7eaadcee0d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_57a8af52-833a-49f3-9e29-e66661f0ef1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b35e0abc-e1fe-45ad-a7ac-954a1cde00e6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_57a8af52-833a-49f3-9e29-e66661f0ef1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0282cbfc-1789-4c97-b779-f3165364ca71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_323de0c0-d0ef-4b93-93b6-4b333cfd6112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0282cbfc-1789-4c97-b779-f3165364ca71" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_323de0c0-d0ef-4b93-93b6-4b333cfd6112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4f54b59d-179a-4d7b-a3a3-94dbdbffebae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0282cbfc-1789-4c97-b779-f3165364ca71" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4f54b59d-179a-4d7b-a3a3-94dbdbffebae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2fe3dc66-19a9-44eb-8282-a54e1bfe8e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0282cbfc-1789-4c97-b779-f3165364ca71" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2fe3dc66-19a9-44eb-8282-a54e1bfe8e35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses_c436297d-8021-438f-8b03-de077fa42d23" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses_c436297d-8021-438f-8b03-de077fa42d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0ad02bbc-5eee-477a-8273-a7acf537ab45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0ad02bbc-5eee-477a-8273-a7acf537ab45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2bbf6c29-0572-4ec1-9562-982453f406d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2bbf6c29-0572-4ec1-9562-982453f406d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_af6f3ee6-b5e2-4e38-bb66-b3ac0efd3e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_af6f3ee6-b5e2-4e38-bb66-b3ac0efd3e05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2fe58233-9151-45d6-bbf0-376dc3fc0e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2fe58233-9151-45d6-bbf0-376dc3fc0e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bbedb61e-e421-41bf-9dc6-d8acba69b5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bbedb61e-e421-41bf-9dc6-d8acba69b5ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent_b28d1581-8f93-4085-8788-0642c5100dc9" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent_b28d1581-8f93-4085-8788-0642c5100dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f9ec80a1-52d3-444a-a6ad-41955db236d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f9ec80a1-52d3-444a-a6ad-41955db236d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_126c57ff-fa0c-4c11-9db7-ff0140db0a7c" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_126c57ff-fa0c-4c11-9db7-ff0140db0a7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_db070780-bc37-448c-86a7-8f482c6d1715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_db070780-bc37-448c-86a7-8f482c6d1715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_b366eae4-ee89-4406-98ed-aeaa9e0cbc46" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_b366eae4-ee89-4406-98ed-aeaa9e0cbc46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_c9580722-eb05-4eb8-95b1-d3ce1ade25c4" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_c9580722-eb05-4eb8-95b1-d3ce1ade25c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent_59b9092e-c36e-4571-85ff-65a712c353f2" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f217da04-e32d-48cb-b5e9-528d059a72cc" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent_59b9092e-c36e-4571-85ff-65a712c353f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_cd828dfc-471c-4f3c-a722-435f4f04271c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_93a1a80f-ef4d-4afc-afd3-e5b576a064ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_cd828dfc-471c-4f3c-a722-435f4f04271c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_93a1a80f-ef4d-4afc-afd3-e5b576a064ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b5476e16-a32f-4bfe-bc52-ea2d815127ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_cd828dfc-471c-4f3c-a722-435f4f04271c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b5476e16-a32f-4bfe-bc52-ea2d815127ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_42eafe50-06ce-4530-b3ff-0a30cf5587ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_ac0c6bda-9a8a-4120-a4e2-4abda4331a14" xlink:href="neo-20211231.xsd#neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42eafe50-06ce-4530-b3ff-0a30cf5587ea" xlink:to="loc_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_ac0c6bda-9a8a-4120-a4e2-4abda4331a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_0d41f3aa-f386-4498-b50c-01644bd1a41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42eafe50-06ce-4530-b3ff-0a30cf5587ea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_0d41f3aa-f386-4498-b50c-01644bd1a41b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_b00f3078-24a0-4ce8-a7ce-39fc10bb05cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42eafe50-06ce-4530-b3ff-0a30cf5587ea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_b00f3078-24a0-4ce8-a7ce-39fc10bb05cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_53dfdb28-fe8e-42d8-ba07-d1e916993d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42eafe50-06ce-4530-b3ff-0a30cf5587ea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_53dfdb28-fe8e-42d8-ba07-d1e916993d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_72065c67-4dcb-4c23-8658-3ee6f981a4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42eafe50-06ce-4530-b3ff-0a30cf5587ea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_72065c67-4dcb-4c23-8658-3ee6f981a4d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3f5aec4a-a81a-4793-9a2e-05fefabfffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42eafe50-06ce-4530-b3ff-0a30cf5587ea" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3f5aec4a-a81a-4793-9a2e-05fefabfffbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3ed8165a-519d-4b7b-b734-3551fcb28048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7cf97cc2-ea6b-435d-88f3-959835c59c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ed8165a-519d-4b7b-b734-3551fcb28048" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7cf97cc2-ea6b-435d-88f3-959835c59c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DeferredTaxAssetsOperatingLeaseLiability_4f8313c8-48b3-4a41-8f16-94bd28b94b87" xlink:href="neo-20211231.xsd#neo_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ed8165a-519d-4b7b-b734-3551fcb28048" xlink:to="loc_neo_DeferredTaxAssetsOperatingLeaseLiability_4f8313c8-48b3-4a41-8f16-94bd28b94b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_daf6b9c9-2691-47f2-aaa2-bdbe1c1b9c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ed8165a-519d-4b7b-b734-3551fcb28048" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_daf6b9c9-2691-47f2-aaa2-bdbe1c1b9c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_0b591281-79e6-404c-afc4-07ce5f709f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ed8165a-519d-4b7b-b734-3551fcb28048" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_0b591281-79e6-404c-afc4-07ce5f709f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ab638c67-70ce-40c3-ba49-7f79e48ee948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ed8165a-519d-4b7b-b734-3551fcb28048" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ab638c67-70ce-40c3-ba49-7f79e48ee948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4f08b583-fce3-4d55-92cd-aa01d6c059ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ed8165a-519d-4b7b-b734-3551fcb28048" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4f08b583-fce3-4d55-92cd-aa01d6c059ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_384ec4eb-b9da-49f4-8a5e-1b2609bc3283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ed8165a-519d-4b7b-b734-3551fcb28048" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_384ec4eb-b9da-49f4-8a5e-1b2609bc3283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DeferredTaxAssetsInterestExpense_fc634597-2ec9-4bf8-aab3-d00b8bb2aa1a" xlink:href="neo-20211231.xsd#neo_DeferredTaxAssetsInterestExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3ed8165a-519d-4b7b-b734-3551fcb28048" xlink:to="loc_neo_DeferredTaxAssetsInterestExpense_fc634597-2ec9-4bf8-aab3-d00b8bb2aa1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_13cf39af-e304-4127-b71a-350158fc56fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_5ab977d3-f005-4499-a13d-416ff5348b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_13cf39af-e304-4127-b71a-350158fc56fb" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_5ab977d3-f005-4499-a13d-416ff5348b25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_709f0a72-7176-468b-a8f7-cfc2370e034d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_13cf39af-e304-4127-b71a-350158fc56fb" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_709f0a72-7176-468b-a8f7-cfc2370e034d" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>neo-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c83854c7-f1f3-424f-996d-5603fac85cdc,g:4d64aeee-8493-464d-9030-1629fa1fd3ef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i21c06f06da9148abbab0b4aec2be3f14_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_61db20c9-d75b-44c8-9c7a-8e4a5dcda609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_RevenuesAbstract_61db20c9-d75b-44c8-9c7a-8e4a5dcda609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_50bb7924-0d79-4d95-b5e0-9c6b5b9c7799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_61db20c9-d75b-44c8-9c7a-8e4a5dcda609" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_50bb7924-0d79-4d95-b5e0-9c6b5b9c7799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_433929b4-97d1-4502-b88d-274e30a22fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_433929b4-97d1-4502-b88d-274e30a22fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7b9cc24f-b75c-4f4f-827e-9c9372b9978b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_GrossProfit_7b9cc24f-b75c-4f4f-827e-9c9372b9978b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_20bb8941-ecdd-4795-99dc-45fb693a19f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_20bb8941-ecdd-4795-99dc-45fb693a19f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2821bcf3-aa7a-4b8e-abd0-54e401bdbe33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2821bcf3-aa7a-4b8e-abd0-54e401bdbe33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d065cfb1-1775-46b2-8c77-5d5fff90212f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d065cfb1-1775-46b2-8c77-5d5fff90212f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d6f34a06-eb4d-44cb-b93f-6d36070e3fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:to="loc_us-gaap_OperatingExpenses_d6f34a06-eb4d-44cb-b93f-6d36070e3fc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2ed8d449-4998-4fe0-bd8c-fd22956d7d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_OperatingIncomeLoss_2ed8d449-4998-4fe0-bd8c-fd22956d7d39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9f8716d7-beae-4704-9a90-45b67322bd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_InterestExpense_9f8716d7-beae-4704-9a90-45b67322bd8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_59465301-274d-4934-8c84-15606b623b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_59465301-274d-4934-8c84-15606b623b39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable_d0de0f00-b658-456d-be26-efdb3a6da060" xlink:href="neo-20211231.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_neo_GainLossOnInvestmentAndLoanReceivable_d0de0f00-b658-456d-be26-efdb3a6da060" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a049980d-ba41-4a8d-b1ac-5d9f961e7b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a049980d-ba41-4a8d-b1ac-5d9f961e7b7b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnTerminationOfInterestRateSwap_9c5cea23-f381-4348-9b2f-716d5877dfbe" xlink:href="neo-20211231.xsd#neo_GainLossOnTerminationOfInterestRateSwap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_neo_GainLossOnTerminationOfInterestRateSwap_9c5cea23-f381-4348-9b2f-716d5877dfbe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0327eb69-b90e-42f7-9000-fc8ca366db86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0327eb69-b90e-42f7-9000-fc8ca366db86" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ab7feb0b-aec1-4238-b70f-66ab2de2cb19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ab7feb0b-aec1-4238-b70f-66ab2de2cb19" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_054e5f3a-f0d2-4f07-811e-2542a24af038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_NetIncomeLoss_054e5f3a-f0d2-4f07-811e-2542a24af038" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e473dd1d-f8cb-459e-bb49-d9d1bc30919a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e473dd1d-f8cb-459e-bb49-d9d1bc30919a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_54cf6e70-7abf-4923-b3a5-fa55220ffe03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e473dd1d-f8cb-459e-bb49-d9d1bc30919a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_54cf6e70-7abf-4923-b3a5-fa55220ffe03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6ea07730-f8b6-4b1a-992d-a76079ac664d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e473dd1d-f8cb-459e-bb49-d9d1bc30919a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6ea07730-f8b6-4b1a-992d-a76079ac664d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c1fcf6de-03f7-477c-b9f5-dcec9a301b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c1fcf6de-03f7-477c-b9f5-dcec9a301b44" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87bf7323-d422-4fac-a454-17c3e86b9937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c1fcf6de-03f7-477c-b9f5-dcec9a301b44" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87bf7323-d422-4fac-a454-17c3e86b9937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c1a907c6-c26c-4a67-82fe-d9d5436e8287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c1fcf6de-03f7-477c-b9f5-dcec9a301b44" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c1a907c6-c26c-4a67-82fe-d9d5436e8287" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5d25df01-5d2a-4e51-b425-f5526be04bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_StatementTable_5d25df01-5d2a-4e51-b425-f5526be04bd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c1820137-cb79-405f-b4dc-2fb5e21c9ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5d25df01-5d2a-4e51-b425-f5526be04bd0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c1820137-cb79-405f-b4dc-2fb5e21c9ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c1820137-cb79-405f-b4dc-2fb5e21c9ed2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c1820137-cb79-405f-b4dc-2fb5e21c9ed2" xlink:to="loc_us-gaap_SegmentDomain_c1820137-cb79-405f-b4dc-2fb5e21c9ed2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a77c4239-37be-47dc-b3f1-b7c17df4c640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c1820137-cb79-405f-b4dc-2fb5e21c9ed2" xlink:to="loc_us-gaap_SegmentDomain_a77c4239-37be-47dc-b3f1-b7c17df4c640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_8deec9d9-be31-4a52-8d3e-a24b41fd6e37" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a77c4239-37be-47dc-b3f1-b7c17df4c640" xlink:to="loc_neo_ClinicalServicesMember_8deec9d9-be31-4a52-8d3e-a24b41fd6e37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_74de7236-c917-4d70-bb61-b37aa1483cd2" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a77c4239-37be-47dc-b3f1-b7c17df4c640" xlink:to="loc_neo_PharmaServicesMember_74de7236-c917-4d70-bb61-b37aa1483cd2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i3392151954d6486da2bd95d20f7a0082_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c2919226-a7db-40c9-97bd-435d8692b926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c2919226-a7db-40c9-97bd-435d8692b926" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3caa4ead-636b-4040-94a9-ccfb5f62fad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_SharesOutstanding_3caa4ead-636b-4040-94a9-ccfb5f62fad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc6f92b1-6268-4c98-9c50-01a3d371e40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockholdersEquity_cc6f92b1-6268-4c98-9c50-01a3d371e40a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1e07429-66d1-4f89-ba47-2923b70629ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1e07429-66d1-4f89-ba47-2923b70629ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8a4b8e4c-977e-4cd7-b7ae-2b2ee2940cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8a4b8e4c-977e-4cd7-b7ae-2b2ee2940cb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_80da79be-89af-46be-8661-18418dfa0623" xlink:href="neo-20211231.xsd#neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_80da79be-89af-46be-8661-18418dfa0623" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c4a60a02-d2d2-47da-9e9c-250a5bef3842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c4a60a02-d2d2-47da-9e9c-250a5bef3842" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_deadf772-5d7c-4194-8e5b-4e52b510f251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_deadf772-5d7c-4194-8e5b-4e52b510f251" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_6722f08d-f77c-4abb-b37b-83569122eb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_6722f08d-f77c-4abb-b37b-83569122eb72" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e5de00c8-512e-4f9d-87d6-40e91b619850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e5de00c8-512e-4f9d-87d6-40e91b619850" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination_9a4394ac-4237-4dff-9f9e-8310194eeb4e" xlink:href="neo-20211231.xsd#neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination_9a4394ac-4237-4dff-9f9e-8310194eeb4e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f392c8b-1d7f-4e81-968a-79fb27100a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f392c8b-1d7f-4e81-968a-79fb27100a7e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WorkingCapitalAdjustmentAcquisitionShares_61b8f60c-400b-4f78-8c76-59acf63312d0" xlink:href="neo-20211231.xsd#neo_WorkingCapitalAdjustmentAcquisitionShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_WorkingCapitalAdjustmentAcquisitionShares_61b8f60c-400b-4f78-8c76-59acf63312d0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WorkingCapitalAdjustmentAcquisitions_6c50a532-17ce-419b-adaf-14253c143081" xlink:href="neo-20211231.xsd#neo_WorkingCapitalAdjustmentAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_WorkingCapitalAdjustmentAcquisitions_6c50a532-17ce-419b-adaf-14253c143081" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_941e5ced-b982-4f44-9632-3e4d97f4032c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_941e5ced-b982-4f44-9632-3e4d97f4032c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3806dafd-6049-40d9-b528-062ec97e1893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3806dafd-6049-40d9-b528-062ec97e1893" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_026827b1-d66e-4a0b-ad93-ec1b70ee9d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_026827b1-d66e-4a0b-ad93-ec1b70ee9d4d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b2f7660d-4238-413a-8b3b-7c7213767aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b2f7660d-4238-413a-8b3b-7c7213767aca" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_d1334945-44bb-4396-a3e5-02196835e03e" xlink:href="neo-20211231.xsd#neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_d1334945-44bb-4396-a3e5-02196835e03e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_4a60d9d2-0fb8-4ae6-800b-9bdfb586203a" xlink:href="neo-20211231.xsd#neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_4a60d9d2-0fb8-4ae6-800b-9bdfb586203a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_7b1abe9a-dbe7-4fae-b892-9efb4c212533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_7b1abe9a-dbe7-4fae-b892-9efb4c212533" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_6c4d186d-5c83-444f-8233-231d15da642e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_6c4d186d-5c83-444f-8233-231d15da642e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6bf9a84c-d887-476d-8fb6-0de84343911a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6bf9a84c-d887-476d-8fb6-0de84343911a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb8fb25c-8706-4f24-985e-d85d0df1e644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb8fb25c-8706-4f24-985e-d85d0df1e644" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6f51eeb6-b343-4d52-b989-79f9e99b8b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6f51eeb6-b343-4d52-b989-79f9e99b8b75" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment_f861db6c-8725-461c-a688-38752165cfee" xlink:href="neo-20211231.xsd#neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment_f861db6c-8725-461c-a688-38752165cfee" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts_cf0be6da-d167-42ae-953a-6e5db12f3dbb" xlink:href="neo-20211231.xsd#neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts_cf0be6da-d167-42ae-953a-6e5db12f3dbb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f29ad559-5900-4f1f-9382-b753197d6964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_NetIncomeLoss_f29ad559-5900-4f1f-9382-b753197d6964" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_74611909-ec5b-43c0-8cf7-1588e5460180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cb16c0b6-e82d-408a-a101-149ebcc7d855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d616f464-5b6a-477b-a42f-5f0f123eb6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c2919226-a7db-40c9-97bd-435d8692b926" xlink:to="loc_us-gaap_StatementTable_d616f464-5b6a-477b-a42f-5f0f123eb6e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c695c8c9-2e42-4626-adf6-290b4354b34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d616f464-5b6a-477b-a42f-5f0f123eb6e0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c695c8c9-2e42-4626-adf6-290b4354b34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c695c8c9-2e42-4626-adf6-290b4354b34f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c695c8c9-2e42-4626-adf6-290b4354b34f" xlink:to="loc_us-gaap_EquityComponentDomain_c695c8c9-2e42-4626-adf6-290b4354b34f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c695c8c9-2e42-4626-adf6-290b4354b34f" xlink:to="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0bfb1f30-93d4-4581-bffa-83a276f3201b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:to="loc_us-gaap_CommonStockMember_0bfb1f30-93d4-4581-bffa-83a276f3201b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_07e96efb-7459-4bbb-8ddc-72e5ef14eb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_07e96efb-7459-4bbb-8ddc-72e5ef14eb98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a7e0e98-e2b2-4b73-9fc4-ce752e330782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a7e0e98-e2b2-4b73-9fc4-ce752e330782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1f03e685-b79c-4d3a-af3e-d8a5071ddd37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:to="loc_us-gaap_RetainedEarningsMember_1f03e685-b79c-4d3a-af3e-d8a5071ddd37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6ec4048a-dc6c-40fb-9d87-e23abe9785fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d616f464-5b6a-477b-a42f-5f0f123eb6e0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6ec4048a-dc6c-40fb-9d87-e23abe9785fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6ec4048a-dc6c-40fb-9d87-e23abe9785fc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6ec4048a-dc6c-40fb-9d87-e23abe9785fc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6ec4048a-dc6c-40fb-9d87-e23abe9785fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ddd9bf3c-48b2-47d1-b858-5cf00c596010" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6ec4048a-dc6c-40fb-9d87-e23abe9785fc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ddd9bf3c-48b2-47d1-b858-5cf00c596010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7510c1ab-7bc3-4fbf-a69b-6d0c2e6f2235" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ddd9bf3c-48b2-47d1-b858-5cf00c596010" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7510c1ab-7bc3-4fbf-a69b-6d0c2e6f2235" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="iabb4647fdd6a4837a004cd9eab69a69f_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:href="neo-20211231.xsd#neo_ScheduleOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7b941143-4393-4234-a67f-45f69a95d4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_NumberOfReportableSegments_7b941143-4393-4234-a67f-45f69a95d4c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_fcc08df9-efdb-4d82-9071-252355db6087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_fcc08df9-efdb-4d82-9071-252355db6087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment_bef4ea68-3560-454a-9feb-85c856a05ab9" xlink:href="neo-20211231.xsd#neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment_bef4ea68-3560-454a-9feb-85c856a05ab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings_762a9b7f-8664-412f-8409-312c0ac4cb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings_762a9b7f-8664-412f-8409-312c0ac4cb80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_999e45dc-92d0-4ca4-9610-c985672f0f8e" xlink:href="neo-20211231.xsd#neo_AssetHeldForSaleSquareFeetOfFacilityOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_999e45dc-92d0-4ca4-9610-c985672f0f8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_256a75d4-1775-477b-9ae2-f625194634a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_256a75d4-1775-477b-9ae2-f625194634a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4830ef21-3c65-4d6f-8fcf-c35f4224d354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4830ef21-3c65-4d6f-8fcf-c35f4224d354" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_46b07344-bc36-49de-b8a5-f65a9b02ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_46b07344-bc36-49de-b8a5-f65a9b02ff59" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_61dae43e-8c2b-462d-920d-13411c562666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_61dae43e-8c2b-462d-920d-13411c562666" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f7671f27-9a21-46f1-8973-f6a10f1d0d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f7671f27-9a21-46f1-8973-f6a10f1d0d37" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_915c544a-365e-4fbb-94f5-443a97c99dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_915c544a-365e-4fbb-94f5-443a97c99dc2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0ad5071c-19c3-4109-b187-35e1b601c1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0ad5071c-19c3-4109-b187-35e1b601c1dc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f925ffa6-0ad2-439c-89db-10f6ac3ba89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f925ffa6-0ad2-439c-89db-10f6ac3ba89e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_bd4439d0-83dc-4207-94dd-4136e4f7be01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_bd4439d0-83dc-4207-94dd-4136e4f7be01" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bb370116-022d-454d-8eea-37c5d0e4da17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bb370116-022d-454d-8eea-37c5d0e4da17" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_04e86a50-41e0-4c50-b504-f4bfcf34d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_04e86a50-41e0-4c50-b504-f4bfcf34d4cc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b3b820c4-a496-4d13-99c5-3cff44ad6d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_StockholdersEquity_b3b820c4-a496-4d13-99c5-3cff44ad6d5c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:href="neo-20211231.xsd#neo_ScheduleOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3b651ff5-40a5-4e5a-b7f5-6fe4a73f37ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_srt_ProductOrServiceAxis_3b651ff5-40a5-4e5a-b7f5-6fe4a73f37ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b651ff5-40a5-4e5a-b7f5-6fe4a73f37ed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3b651ff5-40a5-4e5a-b7f5-6fe4a73f37ed" xlink:to="loc_srt_ProductsAndServicesDomain_3b651ff5-40a5-4e5a-b7f5-6fe4a73f37ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d186fbaf-4834-4b83-8d9c-ebfb43c37875" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3b651ff5-40a5-4e5a-b7f5-6fe4a73f37ed" xlink:to="loc_srt_ProductsAndServicesDomain_d186fbaf-4834-4b83-8d9c-ebfb43c37875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_c1014e77-1971-43d4-abcf-412694609d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d186fbaf-4834-4b83-8d9c-ebfb43c37875" xlink:to="loc_us-gaap_ShippingAndHandlingMember_c1014e77-1971-43d4-abcf-412694609d48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1dc97c47-be3f-482d-8ce2-bc3c83c3f7a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_srt_RangeAxis_1dc97c47-be3f-482d-8ce2-bc3c83c3f7a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1dc97c47-be3f-482d-8ce2-bc3c83c3f7a3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1dc97c47-be3f-482d-8ce2-bc3c83c3f7a3" xlink:to="loc_srt_RangeMember_1dc97c47-be3f-482d-8ce2-bc3c83c3f7a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7bbcae89-3b4d-44fa-80b5-2e8b54788c4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1dc97c47-be3f-482d-8ce2-bc3c83c3f7a3" xlink:to="loc_srt_RangeMember_7bbcae89-3b4d-44fa-80b5-2e8b54788c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99a21c14-fe3b-4e2e-949a-9cd60d217d28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7bbcae89-3b4d-44fa-80b5-2e8b54788c4a" xlink:to="loc_srt_MinimumMember_99a21c14-fe3b-4e2e-949a-9cd60d217d28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_03b1c2c4-819f-47b2-a3b1-fd414a43756c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7bbcae89-3b4d-44fa-80b5-2e8b54788c4a" xlink:to="loc_srt_MaximumMember_03b1c2c4-819f-47b2-a3b1-fd414a43756c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c64473c5-c80e-4c3a-92c2-984ac08a9875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_us-gaap_DebtInstrumentAxis_c64473c5-c80e-4c3a-92c2-984ac08a9875" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c64473c5-c80e-4c3a-92c2-984ac08a9875_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c64473c5-c80e-4c3a-92c2-984ac08a9875" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c64473c5-c80e-4c3a-92c2-984ac08a9875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_648920c4-7855-40d4-9447-8d91a4715e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c64473c5-c80e-4c3a-92c2-984ac08a9875" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_648920c4-7855-40d4-9447-8d91a4715e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_0ec5ca64-b995-423e-b719-23b0812e3d43" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_648920c4-7855-40d4-9447-8d91a4715e60" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_0ec5ca64-b995-423e-b719-23b0812e3d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_4d4ddca8-929d-4f1b-a544-fb6ec29ae12b" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_648920c4-7855-40d4-9447-8d91a4715e60" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_4d4ddca8-929d-4f1b-a544-fb6ec29ae12b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c4f14262-2756-4d3c-ac09-eb708db14bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c4f14262-2756-4d3c-ac09-eb708db14bec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c4f14262-2756-4d3c-ac09-eb708db14bec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c4f14262-2756-4d3c-ac09-eb708db14bec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c4f14262-2756-4d3c-ac09-eb708db14bec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e822f0ff-4337-4f8d-aea2-7a39ed07afa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c4f14262-2756-4d3c-ac09-eb708db14bec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e822f0ff-4337-4f8d-aea2-7a39ed07afa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_cbaa87ad-4d1a-4731-8a41-281eb4c4c129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e822f0ff-4337-4f8d-aea2-7a39ed07afa5" xlink:to="loc_us-gaap_ConvertibleDebtMember_cbaa87ad-4d1a-4731-8a41-281eb4c4c129" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_05f64a92-0162-4330-9952-e587a3d4f567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_05f64a92-0162-4330-9952-e587a3d4f567" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05f64a92-0162-4330-9952-e587a3d4f567_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_05f64a92-0162-4330-9952-e587a3d4f567" xlink:to="loc_us-gaap_EquityComponentDomain_05f64a92-0162-4330-9952-e587a3d4f567_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c709021f-97bc-4fec-968b-792e14569cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_05f64a92-0162-4330-9952-e587a3d4f567" xlink:to="loc_us-gaap_EquityComponentDomain_c709021f-97bc-4fec-968b-792e14569cfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_21b1ed41-c98d-4b28-9830-aad301adbce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c709021f-97bc-4fec-968b-792e14569cfc" xlink:to="loc_us-gaap_RetainedEarningsMember_21b1ed41-c98d-4b28-9830-aad301adbce9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a526f834-4a74-499a-9102-72ca9b5e9deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c709021f-97bc-4fec-968b-792e14569cfc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a526f834-4a74-499a-9102-72ca9b5e9deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_04b2a307-6e28-4bfe-8edd-47c8e54d64a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_04b2a307-6e28-4bfe-8edd-47c8e54d64a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_04b2a307-6e28-4bfe-8edd-47c8e54d64a0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_04b2a307-6e28-4bfe-8edd-47c8e54d64a0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_04b2a307-6e28-4bfe-8edd-47c8e54d64a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fb94fce4-af81-4b68-9212-0bf90302fcbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_04b2a307-6e28-4bfe-8edd-47c8e54d64a0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fb94fce4-af81-4b68-9212-0bf90302fcbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4a521e3b-72e2-4d17-a73c-d3b3699f0e3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fb94fce4-af81-4b68-9212-0bf90302fcbb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4a521e3b-72e2-4d17-a73c-d3b3699f0e3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i28a7f1fef2794eb1a4d148a3282df1f0_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_742610fc-2be4-43df-b667-5538a3fede2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_742610fc-2be4-43df-b667-5538a3fede2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c7d57c4-0b84-42a3-8d5b-540e48ca6282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c7d57c4-0b84-42a3-8d5b-540e48ca6282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_592b2662-2e43-451a-b4cb-bf4c47bd16d4" xlink:href="neo-20211231.xsd#neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_592b2662-2e43-451a-b4cb-bf4c47bd16d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_db18ae82-592f-4eab-b4f5-f1f03fdb4c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_db18ae82-592f-4eab-b4f5-f1f03fdb4c67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c99bd384-4db2-4707-b62d-8d413f2cb615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c99bd384-4db2-4707-b62d-8d413f2cb615" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7c8ebe78-040b-42ad-a258-58517f004569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7c8ebe78-040b-42ad-a258-58517f004569" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_27bdd9fd-d196-4050-8ffb-46160dd960fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_27bdd9fd-d196-4050-8ffb-46160dd960fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e1f30fea-2db6-44c6-a01d-e95c240c3719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e1f30fea-2db6-44c6-a01d-e95c240c3719" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_36450923-f352-415f-a471-8d41d55d56f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_36450923-f352-415f-a471-8d41d55d56f6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_25eb7133-3bfd-4d97-976f-c806784280cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_25eb7133-3bfd-4d97-976f-c806784280cb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_02f8ff3f-3b8c-403b-8de3-1a29bb00ca83" xlink:href="neo-20211231.xsd#neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_02f8ff3f-3b8c-403b-8de3-1a29bb00ca83" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_7b905295-35a5-4b02-8c9c-02f5e7892d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_7b905295-35a5-4b02-8c9c-02f5e7892d87" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_da81f7e4-a242-432c-ba59-7a562806e95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_da81f7e4-a242-432c-ba59-7a562806e95d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_a04b8cf6-ab8a-4324-8103-235b94cfe3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_a04b8cf6-ab8a-4324-8103-235b94cfe3cd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_340d7a38-cb35-40b9-b1e9-3d7d99d0b98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_340d7a38-cb35-40b9-b1e9-3d7d99d0b98d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_3f5f802a-75ea-40ae-91a1-cd75af37010d" xlink:href="neo-20211231.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_3f5f802a-75ea-40ae-91a1-cd75af37010d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_e6b2c069-f064-4ff6-a66a-d9a98ed168fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_LineOfCredit_e6b2c069-f064-4ff6-a66a-d9a98ed168fd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_757aa534-3d57-4189-b392-5e0c1c06ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_757aa534-3d57-4189-b392-5e0c1c06ca47" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_3b6daea8-5f54-45bc-b6f1-c6d6a0a9f8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_3b6daea8-5f54-45bc-b6f1-c6d6a0a9f8ea" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_46033150-f028-4626-a4af-36617c6219f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_Goodwill_46033150-f028-4626-a4af-36617c6219f4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2b99d7ca-191c-467b-ac21-747115bc7d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2b99d7ca-191c-467b-ac21-747115bc7d31" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1fbb04e8-0a6e-4358-ac06-9c36d5d0a721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1fbb04e8-0a6e-4358-ac06-9c36d5d0a721" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_d38e6d0d-388b-44fe-826a-8468a946a648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_d38e6d0d-388b-44fe-826a-8468a946a648" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_bf44291c-08e7-4479-9f64-dbd82b98c55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_bf44291c-08e7-4479-9f64-dbd82b98c55e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b952a4f0-76e5-4e64-8fd8-eb67fac6dbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b952a4f0-76e5-4e64-8fd8-eb67fac6dbc5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dfee7d91-1dfd-41a9-8230-3cc05f0190fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dfee7d91-1dfd-41a9-8230-3cc05f0190fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dfee7d91-1dfd-41a9-8230-3cc05f0190fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dfee7d91-1dfd-41a9-8230-3cc05f0190fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dfee7d91-1dfd-41a9-8230-3cc05f0190fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c37d9941-9b10-4725-aae3-c31c10540b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dfee7d91-1dfd-41a9-8230-3cc05f0190fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c37d9941-9b10-4725-aae3-c31c10540b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_951c22f0-bb4d-4b7d-8e36-7e32d6cbbfc2" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c37d9941-9b10-4725-aae3-c31c10540b85" xlink:to="loc_neo_TrapeloHealthMember_951c22f0-bb4d-4b7d-8e36-7e32d6cbbfc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_979748c7-bb96-4a48-96e8-d8f7e98b033a" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c37d9941-9b10-4725-aae3-c31c10540b85" xlink:to="loc_neo_InivataMember_979748c7-bb96-4a48-96e8-d8f7e98b033a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b05db42-d55b-44ea-b95a-1f6001f57fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b05db42-d55b-44ea-b95a-1f6001f57fba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5b05db42-d55b-44ea-b95a-1f6001f57fba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b05db42-d55b-44ea-b95a-1f6001f57fba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5b05db42-d55b-44ea-b95a-1f6001f57fba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b05db42-d55b-44ea-b95a-1f6001f57fba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_013c3a36-c9c2-4913-a7a3-5f076bc9cdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_013c3a36-c9c2-4913-a7a3-5f076bc9cdfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_34b3d4a6-453a-44e2-96b1-961ecd833e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_34b3d4a6-453a-44e2-96b1-961ecd833e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_7d09ac04-e0ee-454f-9604-2e9d0aed213b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:to="loc_us-gaap_TrademarksMember_7d09ac04-e0ee-454f-9604-2e9d0aed213b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_f7445748-33ce-47f0-8003-38ccad7d26fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:to="loc_us-gaap_TradeNamesMember_f7445748-33ce-47f0-8003-38ccad7d26fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e5730ae7-6b8c-4142-bdad-f03f48652f16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e5730ae7-6b8c-4142-bdad-f03f48652f16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e5730ae7-6b8c-4142-bdad-f03f48652f16_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e5730ae7-6b8c-4142-bdad-f03f48652f16" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e5730ae7-6b8c-4142-bdad-f03f48652f16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0b568e8c-890d-4f58-938d-666346562e92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e5730ae7-6b8c-4142-bdad-f03f48652f16" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0b568e8c-890d-4f58-938d-666346562e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_15b0e304-f1e7-46d9-9b74-d95062653d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0b568e8c-890d-4f58-938d-666346562e92" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_15b0e304-f1e7-46d9-9b74-d95062653d0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2dfb5324-9e01-4a8a-b827-4ed34fa0bf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2dfb5324-9e01-4a8a-b827-4ed34fa0bf7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2dfb5324-9e01-4a8a-b827-4ed34fa0bf7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2dfb5324-9e01-4a8a-b827-4ed34fa0bf7a" xlink:to="loc_us-gaap_RelatedPartyDomain_2dfb5324-9e01-4a8a-b827-4ed34fa0bf7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_16e340fc-060e-4ce8-a43f-3df35c7fe868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2dfb5324-9e01-4a8a-b827-4ed34fa0bf7a" xlink:to="loc_us-gaap_RelatedPartyDomain_16e340fc-060e-4ce8-a43f-3df35c7fe868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c2e199aa-332f-4eb0-87bf-59e8684519e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_16e340fc-060e-4ce8-a43f-3df35c7fe868" xlink:to="loc_srt_AffiliatedEntityMember_c2e199aa-332f-4eb0-87bf-59e8684519e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dba38153-6995-4508-974e-4634fc5a167c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_srt_RangeAxis_dba38153-6995-4508-974e-4634fc5a167c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dba38153-6995-4508-974e-4634fc5a167c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dba38153-6995-4508-974e-4634fc5a167c" xlink:to="loc_srt_RangeMember_dba38153-6995-4508-974e-4634fc5a167c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae91fa59-cc9b-4f17-82c8-3965203e25d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dba38153-6995-4508-974e-4634fc5a167c" xlink:to="loc_srt_RangeMember_ae91fa59-cc9b-4f17-82c8-3965203e25d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c883138b-26f6-46ad-bab8-120364b43d86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae91fa59-cc9b-4f17-82c8-3965203e25d6" xlink:to="loc_srt_MaximumMember_c883138b-26f6-46ad-bab8-120364b43d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_11b7b0e8-60fa-4ed4-af90-41f4d27dfc34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_11b7b0e8-60fa-4ed4-af90-41f4d27dfc34" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_11b7b0e8-60fa-4ed4-af90-41f4d27dfc34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_11b7b0e8-60fa-4ed4-af90-41f4d27dfc34" xlink:to="loc_us-gaap_SegmentDomain_11b7b0e8-60fa-4ed4-af90-41f4d27dfc34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ac1bb635-22a5-4725-b44b-48ed83e02019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_11b7b0e8-60fa-4ed4-af90-41f4d27dfc34" xlink:to="loc_us-gaap_SegmentDomain_ac1bb635-22a5-4725-b44b-48ed83e02019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_e7dfdae8-9fe4-4e6f-9a49-8f022606a05e" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ac1bb635-22a5-4725-b44b-48ed83e02019" xlink:to="loc_neo_ClinicalServicesMember_e7dfdae8-9fe4-4e6f-9a49-8f022606a05e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_5fb790c0-86ba-45a6-8256-8bb6b24519a4" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ac1bb635-22a5-4725-b44b-48ed83e02019" xlink:to="loc_neo_PharmaServicesMember_5fb790c0-86ba-45a6-8256-8bb6b24519a4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#AcquisitionsScheduleofProvisionalInformationDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="extended" id="ie990aa38f4774d5882adbe77c87e0b3c_AcquisitionsScheduleofProvisionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59251630-6914-41fc-a696-b31c84905b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59251630-6914-41fc-a696-b31c84905b49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_78e11d04-bafe-4921-949c-773980492809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_78e11d04-bafe-4921-949c-773980492809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e37f26ce-81bd-4639-ac40-f7250473e299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e37f26ce-81bd-4639-ac40-f7250473e299" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8bcb212c-ad44-40e7-a6fe-388a31176235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8bcb212c-ad44-40e7-a6fe-388a31176235" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_03e65b6e-8ba3-44ea-b41e-2fffa8c8d0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_03e65b6e-8ba3-44ea-b41e-2fffa8c8d0df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b36f38e9-5c2b-4123-9dab-ef3552a842ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b36f38e9-5c2b-4123-9dab-ef3552a842ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_268846ca-250c-4570-9470-bdde3a2e86ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_268846ca-250c-4570-9470-bdde3a2e86ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_8eeea187-39a5-4434-8fc0-18f51323c277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_8eeea187-39a5-4434-8fc0-18f51323c277" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_6f07f019-0645-4cec-a73e-7bc799f5adb5" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_6f07f019-0645-4cec-a73e-7bc799f5adb5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_948ef23b-dad4-4c7f-824c-390432481d83" xlink:href="neo-20211231.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_948ef23b-dad4-4c7f-824c-390432481d83" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_d72f1eea-d4f5-496c-b17e-74835407f757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_d72f1eea-d4f5-496c-b17e-74835407f757" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_692d3beb-c900-4df0-b33d-414858608592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_692d3beb-c900-4df0-b33d-414858608592" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4c4506bf-ebc6-4286-8488-8480b6a1eca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4c4506bf-ebc6-4286-8488-8480b6a1eca4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_9e4fe129-87d8-4fab-a967-196e78065b63" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_9e4fe129-87d8-4fab-a967-196e78065b63" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_e568a96b-85bd-4cfe-8782-62c8226ca7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_e568a96b-85bd-4cfe-8782-62c8226ca7f2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_afb158d0-9b71-4980-b1fc-005be5506b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_afb158d0-9b71-4980-b1fc-005be5506b7a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_77980575-7a9b-4e25-b2b1-b35302746e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_77980575-7a9b-4e25-b2b1-b35302746e88" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_be43c4e3-f1b0-4b0d-8fa7-32b909440117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_be43c4e3-f1b0-4b0d-8fa7-32b909440117" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_bfbafc65-1196-4ae1-93f3-bea2c91d7b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_bfbafc65-1196-4ae1-93f3-bea2c91d7b00" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_e5ece77c-8d44-4c86-9c04-1346d489183d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_e5ece77c-8d44-4c86-9c04-1346d489183d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_74407460-cf06-4923-8ba6-da79d45682d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_74407460-cf06-4923-8ba6-da79d45682d2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities_47b70221-71a8-4fb4-aa76-6b091b351bc5" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities_47b70221-71a8-4fb4-aa76-6b091b351bc5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_0b47df00-1e1c-4007-b865-cec636a12a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_0b47df00-1e1c-4007-b865-cec636a12a29" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities_242ba9cf-e031-4bb9-9d24-6cb4167054b2" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities_242ba9cf-e031-4bb9-9d24-6cb4167054b2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a0da2871-2731-4b60-baa1-071708ebdf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a0da2871-2731-4b60-baa1-071708ebdf06" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_a84124a1-fcb1-4889-ade3-1059d831d284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_a84124a1-fcb1-4889-ade3-1059d831d284" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_ee34f1a2-dd6b-4aa6-a0ae-446c7219dce9" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_ee34f1a2-dd6b-4aa6-a0ae-446c7219dce9" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_54b80829-2704-4eae-bc6e-98cdb52cf246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_54b80829-2704-4eae-bc6e-98cdb52cf246" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_82fc4fc7-0ab3-49e9-b784-ef80fbcf55ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_82fc4fc7-0ab3-49e9-b784-ef80fbcf55ba" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1eb889cc-8315-4c3e-8c9f-4fc99558927b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_Goodwill_1eb889cc-8315-4c3e-8c9f-4fc99558927b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_deaa7173-f688-40d5-80d3-547fff5ab249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_deaa7173-f688-40d5-80d3-547fff5ab249" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_16858679-4a87-4b76-a0e6-3927592e3748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_16858679-4a87-4b76-a0e6-3927592e3748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16858679-4a87-4b76-a0e6-3927592e3748_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_16858679-4a87-4b76-a0e6-3927592e3748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16858679-4a87-4b76-a0e6-3927592e3748_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_16858679-4a87-4b76-a0e6-3927592e3748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_c35eced0-ad86-4aca-987e-08832d8403de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_c35eced0-ad86-4aca-987e-08832d8403de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6e6bbeb7-73e4-4231-b531-2e379f3c4c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6e6bbeb7-73e4-4231-b531-2e379f3c4c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_cea91ca3-d9c3-4dfe-a047-8603e3674734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:to="loc_us-gaap_TrademarksMember_cea91ca3-d9c3-4dfe-a047-8603e3674734" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9a53d16d-0769-4d69-8d39-53165c8f7466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:to="loc_us-gaap_TradeNamesMember_9a53d16d-0769-4d69-8d39-53165c8f7466" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_24863d05-ce5f-4cfd-8ca0-365d5bd4d272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_24863d05-ce5f-4cfd-8ca0-365d5bd4d272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24863d05-ce5f-4cfd-8ca0-365d5bd4d272_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_24863d05-ce5f-4cfd-8ca0-365d5bd4d272" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24863d05-ce5f-4cfd-8ca0-365d5bd4d272_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a12d2f74-f394-4071-a009-15325d046c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_24863d05-ce5f-4cfd-8ca0-365d5bd4d272" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a12d2f74-f394-4071-a009-15325d046c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_cfce05a9-7375-4f4d-99e7-9bd3038d3e7f" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a12d2f74-f394-4071-a009-15325d046c71" xlink:to="loc_neo_TrapeloHealthMember_cfce05a9-7375-4f4d-99e7-9bd3038d3e7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_d05aa243-b5a7-483a-a9da-2312a2752ad7" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a12d2f74-f394-4071-a009-15325d046c71" xlink:to="loc_neo_InivataMember_d05aa243-b5a7-483a-a9da-2312a2752ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_5d18e56c-ceb3-4550-a096-80ad204e1083" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:to="loc_srt_RestatementAxis_5d18e56c-ceb3-4550-a096-80ad204e1083" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5d18e56c-ceb3-4550-a096-80ad204e1083_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_5d18e56c-ceb3-4550-a096-80ad204e1083" xlink:to="loc_srt_RestatementDomain_5d18e56c-ceb3-4550-a096-80ad204e1083_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_1f3f170a-564f-45d9-a458-34b7982eaec1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_5d18e56c-ceb3-4550-a096-80ad204e1083" xlink:to="loc_srt_RestatementDomain_1f3f170a-564f-45d9-a458-34b7982eaec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_4c623d03-2520-46d1-856d-117c287589d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1f3f170a-564f-45d9-a458-34b7982eaec1" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_4c623d03-2520-46d1-856d-117c287589d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#AcquisitionsProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="extended" id="i3204f187c21345df9aaedf6cfba11107_AcquisitionsProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35a8d399-a7ad-4450-ba89-84f2199e4c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f359d697-28d0-43a4-b622-2dc3a4ad09b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35a8d399-a7ad-4450-ba89-84f2199e4c0d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f359d697-28d0-43a4-b622-2dc3a4ad09b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_146afdeb-9572-4a63-8388-3cd31568bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35a8d399-a7ad-4450-ba89-84f2199e4c0d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_146afdeb-9572-4a63-8388-3cd31568bfa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39b564ec-7060-4c72-ba3a-c0871e44410f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35a8d399-a7ad-4450-ba89-84f2199e4c0d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39b564ec-7060-4c72-ba3a-c0871e44410f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ff3d3383-d04d-4b84-864f-1071963d4054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39b564ec-7060-4c72-ba3a-c0871e44410f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ff3d3383-d04d-4b84-864f-1071963d4054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff3d3383-d04d-4b84-864f-1071963d4054_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ff3d3383-d04d-4b84-864f-1071963d4054" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff3d3383-d04d-4b84-864f-1071963d4054_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61d4e551-f58b-40e7-bdb1-82e17fd6ba5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ff3d3383-d04d-4b84-864f-1071963d4054" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61d4e551-f58b-40e7-bdb1-82e17fd6ba5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_b8eb0c95-31be-463b-94db-4eb506d83464" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61d4e551-f58b-40e7-bdb1-82e17fd6ba5f" xlink:to="loc_neo_InivataMember_b8eb0c95-31be-463b-94db-4eb506d83464" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsScheduleofAmortizedCostDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="extended" id="i483df5d8eee0440f8ae15b7d48e9bf7f_FairValueMeasurementsScheduleofAmortizedCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_bc848177-ab36-4c9f-9f7b-0521b979e6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_bc848177-ab36-4c9f-9f7b-0521b979e6e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_79af777e-06bd-4fdb-8781-0a59624103c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_79af777e-06bd-4fdb-8781-0a59624103c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fd5b9483-01d9-4d4c-874b-adb2edd6c348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fd5b9483-01d9-4d4c-874b-adb2edd6c348" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_78e287a8-46ba-438a-9da1-2a7eba3bb4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_78e287a8-46ba-438a-9da1-2a7eba3bb4bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_909be818-7f3f-464d-ba78-ffe9a21c9ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_909be818-7f3f-464d-ba78-ffe9a21c9ea6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60c2f8eb-4c78-43f4-a3f1-bca5a0f2f661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60c2f8eb-4c78-43f4-a3f1-bca5a0f2f661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1e07a6f2-bde0-4cc8-a824-16aa28057751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60c2f8eb-4c78-43f4-a3f1-bca5a0f2f661" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1e07a6f2-bde0-4cc8-a824-16aa28057751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1e07a6f2-bde0-4cc8-a824-16aa28057751_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1e07a6f2-bde0-4cc8-a824-16aa28057751" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1e07a6f2-bde0-4cc8-a824-16aa28057751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1e07a6f2-bde0-4cc8-a824-16aa28057751" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c3fec692-b87c-43f1-b665-ea4edaa5ea37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c3fec692-b87c-43f1-b665-ea4edaa5ea37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_f99f523a-fc51-43f9-add4-57a830e0775e" xlink:href="neo-20211231.xsd#neo_YankeeBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_neo_YankeeBondsMember_f99f523a-fc51-43f9-add4-57a830e0775e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AgencyBondsMember_a4cd9054-39af-4f40-84be-3119ece9cce6" xlink:href="neo-20211231.xsd#neo_AgencyBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_neo_AgencyBondsMember_a4cd9054-39af-4f40-84be-3119ece9cce6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_bdfb92d3-255b-4452-9821-052782c8c076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_MunicipalBondsMember_bdfb92d3-255b-4452-9821-052782c8c076" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_16911089-9cbb-4791-ae86-ca96197c95a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_CommercialPaperMember_16911089-9cbb-4791-ae86-ca96197c95a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_afdf2680-90e7-49c5-b32d-c19e55e55c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_afdf2680-90e7-49c5-b32d-c19e55e55c3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8c974a71-fe3c-443f-a0d3-9d0508e89966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8c974a71-fe3c-443f-a0d3-9d0508e89966" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsFairValuebyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="extended" id="i7b5d009fb425438c9a177f2ac40d1aa5_FairValueMeasurementsFairValuebyContractualMaturityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_98d448e3-e796-4a1b-b331-f200e7872978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_98d448e3-e796-4a1b-b331-f200e7872978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8a804827-67a7-4eed-a9aa-1862fb936f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8a804827-67a7-4eed-a9aa-1862fb936f22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_58071582-94fb-4302-9192-e838487e951b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_58071582-94fb-4302-9192-e838487e951b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_39184d44-1370-48e3-9520-58eb7226f7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_39184d44-1370-48e3-9520-58eb7226f7b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb9677d2-0534-43d0-ad86-3224aed6bae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb9677d2-0534-43d0-ad86-3224aed6bae7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_913f5411-3d8a-4187-8962-a633dce5e823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb9677d2-0534-43d0-ad86-3224aed6bae7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_913f5411-3d8a-4187-8962-a633dce5e823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_913f5411-3d8a-4187-8962-a633dce5e823_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_913f5411-3d8a-4187-8962-a633dce5e823" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_913f5411-3d8a-4187-8962-a633dce5e823_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_913f5411-3d8a-4187-8962-a633dce5e823" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_90a30b89-cedb-4257-90c2-d0538cdb53c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_90a30b89-cedb-4257-90c2-d0538cdb53c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_137e4f55-26ea-4087-8021-298d07a0d5e0" xlink:href="neo-20211231.xsd#neo_YankeeBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_neo_YankeeBondsMember_137e4f55-26ea-4087-8021-298d07a0d5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AgencyBondsMember_ee615526-c9e8-4475-9898-5e2bd7815e42" xlink:href="neo-20211231.xsd#neo_AgencyBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_neo_AgencyBondsMember_ee615526-c9e8-4475-9898-5e2bd7815e42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_05f887fb-d3d2-4abd-bb9b-8e54117e9e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_MunicipalBondsMember_05f887fb-d3d2-4abd-bb9b-8e54117e9e1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cc171919-e15c-4335-b113-6c0dc96eb3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_CommercialPaperMember_cc171919-e15c-4335-b113-6c0dc96eb3a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_43be28d3-6c7e-4676-8481-898914353805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_43be28d3-6c7e-4676-8481-898914353805" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_e6e19bbd-98cf-4811-83db-5f384778ee7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_e6e19bbd-98cf-4811-83db-5f384778ee7c" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="extended" id="i972c7ee78a794f7187d0ac541c3f0a1b_FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a11ef73b-29b3-4486-b327-8a17105eb61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a11ef73b-29b3-4486-b327-8a17105eb61a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_41161ff0-5409-4c07-8499-a7e4f442441d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_41161ff0-5409-4c07-8499-a7e4f442441d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9271887f-4eab-4ee2-8669-5acd5d566bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9271887f-4eab-4ee2-8669-5acd5d566bd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dba3701f-cf24-4aba-83f6-18e94af3b94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dba3701f-cf24-4aba-83f6-18e94af3b94a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dba3701f-cf24-4aba-83f6-18e94af3b94a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dba3701f-cf24-4aba-83f6-18e94af3b94a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dba3701f-cf24-4aba-83f6-18e94af3b94a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dba3701f-cf24-4aba-83f6-18e94af3b94a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_355a18ff-c200-4d3a-8ed0-ac5b780e9274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_355a18ff-c200-4d3a-8ed0-ac5b780e9274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bfb8cd72-aa8d-49ed-b8c9-6ddeae27e104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bfb8cd72-aa8d-49ed-b8c9-6ddeae27e104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4f7dad44-1a2f-4338-a651-aedcd1c7cb07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4f7dad44-1a2f-4338-a651-aedcd1c7cb07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59d30598-a799-40f2-8d02-a4eeb7764f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59d30598-a799-40f2-8d02-a4eeb7764f33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_59d30598-a799-40f2-8d02-a4eeb7764f33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59d30598-a799-40f2-8d02-a4eeb7764f33" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_59d30598-a799-40f2-8d02-a4eeb7764f33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9975c65b-915e-4103-8897-a8d48a782b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59d30598-a799-40f2-8d02-a4eeb7764f33" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9975c65b-915e-4103-8897-a8d48a782b75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_57bfafc4-4da9-45e6-a0bd-ad8e23d50d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9975c65b-915e-4103-8897-a8d48a782b75" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_57bfafc4-4da9-45e6-a0bd-ad8e23d50d20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5cebf27b-9969-42f4-b492-b5021bb36981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5cebf27b-9969-42f4-b492-b5021bb36981" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cebf27b-9969-42f4-b492-b5021bb36981_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5cebf27b-9969-42f4-b492-b5021bb36981" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cebf27b-9969-42f4-b492-b5021bb36981_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5cebf27b-9969-42f4-b492-b5021bb36981" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3bc1d650-4c1e-4ac1-b428-4b58f7581776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3bc1d650-4c1e-4ac1-b428-4b58f7581776" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b61e33a6-81d9-47f8-b241-1ad927614022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_CommercialPaperMember_b61e33a6-81d9-47f8-b241-1ad927614022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0482e26f-5ff5-48a4-8fc8-ba95ee210967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0482e26f-5ff5-48a4-8fc8-ba95ee210967" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_343b6475-1c4a-4a93-b1cf-c8fd88ae8136" xlink:href="neo-20211231.xsd#neo_YankeeBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_neo_YankeeBondsMember_343b6475-1c4a-4a93-b1cf-c8fd88ae8136" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AgencyBondsMember_b4871f54-d0a1-4387-9208-96b5ac0154e1" xlink:href="neo-20211231.xsd#neo_AgencyBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_neo_AgencyBondsMember_b4871f54-d0a1-4387-9208-96b5ac0154e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_d54f62b3-6803-4d4b-948c-a467e8223539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_MunicipalBondsMember_d54f62b3-6803-4d4b-948c-a467e8223539" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5ea14c28-5660-4604-915c-dd7abc418927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5ea14c28-5660-4604-915c-dd7abc418927" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_148a9f8c-36a9-47e3-a318-d41b95a28bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_148a9f8c-36a9-47e3-a318-d41b95a28bbd" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended" id="id85761755b8942b4affabdacb6f50b33_PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2cb1e81b-53ba-4184-bf74-59f375d8d8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2cb1e81b-53ba-4184-bf74-59f375d8d8a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2f6b998d-63c9-498b-a0db-780ed74cbf66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2f6b998d-63c9-498b-a0db-780ed74cbf66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cad584cb-ebe8-4330-9de0-3f1a641207fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cad584cb-ebe8-4330-9de0-3f1a641207fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f51fe598-c48d-495d-bc54-bb204b12fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f51fe598-c48d-495d-bc54-bb204b12fef1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_323166fa-4af6-49e5-9fd7-7a7be0ce469a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_323166fa-4af6-49e5-9fd7-7a7be0ce469a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2bd1131c-4050-45f2-a93b-52ce0b159a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_323166fa-4af6-49e5-9fd7-7a7be0ce469a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2bd1131c-4050-45f2-a93b-52ce0b159a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bd1131c-4050-45f2-a93b-52ce0b159a83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2bd1131c-4050-45f2-a93b-52ce0b159a83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bd1131c-4050-45f2-a93b-52ce0b159a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2bd1131c-4050-45f2-a93b-52ce0b159a83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_cb099ecc-333b-4bae-a8ca-16bca0a9e274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_EquipmentMember_cb099ecc-333b-4bae-a8ca-16bca0a9e274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a9f06023-7839-438b-b21d-010c57d55b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_BuildingMember_a9f06023-7839-438b-b21d-010c57d55b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_79bc3b3f-f966-4683-a08f-87d0366a2aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_79bc3b3f-f966-4683-a08f-87d0366a2aca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d899afeb-8941-459a-9e5b-2098954c0726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d899afeb-8941-459a-9e5b-2098954c0726" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ComputerHardwareAndOfficeEquipmentMember_791c698c-a3cb-4fa9-aa38-8fabbcce0955" xlink:href="neo-20211231.xsd#neo_ComputerHardwareAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_neo_ComputerHardwareAndOfficeEquipmentMember_791c698c-a3cb-4fa9-aa38-8fabbcce0955" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_74521237-623a-4b73-9144-025580c3a8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_74521237-623a-4b73-9144-025580c3a8f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_393f4c88-1cc9-4b6f-beeb-b813aba3f38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_LandMember_393f4c88-1cc9-4b6f-beeb-b813aba3f38a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_64fa9bc7-e8ce-4256-98db-8dbeffea7c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_ConstructionInProgressMember_64fa9bc7-e8ce-4256-98db-8dbeffea7c85" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_472bd442-b9a5-42f5-956b-f27fd89ef568" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_323166fa-4af6-49e5-9fd7-7a7be0ce469a" xlink:to="loc_srt_RangeAxis_472bd442-b9a5-42f5-956b-f27fd89ef568" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_472bd442-b9a5-42f5-956b-f27fd89ef568_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_472bd442-b9a5-42f5-956b-f27fd89ef568" xlink:to="loc_srt_RangeMember_472bd442-b9a5-42f5-956b-f27fd89ef568_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45a62903-4199-48c3-af98-4170c21853d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_472bd442-b9a5-42f5-956b-f27fd89ef568" xlink:to="loc_srt_RangeMember_45a62903-4199-48c3-af98-4170c21853d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70199929-a423-42ef-96fb-fa03a0f0a3dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45a62903-4199-48c3-af98-4170c21853d8" xlink:to="loc_srt_MinimumMember_70199929-a423-42ef-96fb-fa03a0f0a3dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e76f5011-af6c-4dd1-bfae-01ae4ca5441a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45a62903-4199-48c3-af98-4170c21853d8" xlink:to="loc_srt_MaximumMember_e76f5011-af6c-4dd1-bfae-01ae4ca5441a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#PropertyandEquipmentNetDepreciationDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails" xlink:type="extended" id="i6256c3a360ca462a94c70256dd43c42a_PropertyandEquipmentNetDepreciationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_6c19fdfa-9120-4d22-9685-6493c9901925" xlink:href="neo-20211231.xsd#neo_AssetHeldForSaleSquareFeetOfFacilityOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:to="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_6c19fdfa-9120-4d22-9685-6493c9901925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_dfc168f3-cfdb-4d48-afd7-a8c8dbda8159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_dfc168f3-cfdb-4d48-afd7-a8c8dbda8159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0f915871-9ac9-4b4b-a8cb-f89cccbc5e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:to="loc_us-gaap_Depreciation_0f915871-9ac9-4b4b-a8cb-f89cccbc5e77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bdb3989-8328-4c07-8d63-843619d1e698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bdb3989-8328-4c07-8d63-843619d1e698" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_9104dda9-5372-448b-bd28-00f76e11b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bdb3989-8328-4c07-8d63-843619d1e698" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_9104dda9-5372-448b-bd28-00f76e11b8e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_9104dda9-5372-448b-bd28-00f76e11b8e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_9104dda9-5372-448b-bd28-00f76e11b8e5" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_9104dda9-5372-448b-bd28-00f76e11b8e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_4c89e10c-5613-43c0-a5f3-6a2f2d0d40a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_9104dda9-5372-448b-bd28-00f76e11b8e5" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_4c89e10c-5613-43c0-a5f3-6a2f2d0d40a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_f3d92167-3c79-4ae2-b65a-bdea92f94f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_4c89e10c-5613-43c0-a5f3-6a2f2d0d40a8" xlink:to="loc_us-gaap_LandMember_f3d92167-3c79-4ae2-b65a-bdea92f94f50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_3434d648-f776-4603-9005-2292738181a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_4c89e10c-5613-43c0-a5f3-6a2f2d0d40a8" xlink:to="loc_us-gaap_BuildingMember_3434d648-f776-4603-9005-2292738181a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_da8a2e76-5aab-4455-adb6-15b68e3f2d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bdb3989-8328-4c07-8d63-843619d1e698" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_da8a2e76-5aab-4455-adb6-15b68e3f2d4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_da8a2e76-5aab-4455-adb6-15b68e3f2d4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da8a2e76-5aab-4455-adb6-15b68e3f2d4b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_da8a2e76-5aab-4455-adb6-15b68e3f2d4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da8a2e76-5aab-4455-adb6-15b68e3f2d4b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7f4f5de7-d29a-43a0-ad43-e7894512cf56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:to="loc_us-gaap_CostOfSalesMember_7f4f5de7-d29a-43a0-ad43-e7894512cf56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_bb1e7ed4-d828-4097-b18f-a977f33ea197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_bb1e7ed4-d828-4097-b18f-a977f33ea197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bdacab1b-97ec-4e51-bd79-49e37e24b46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bdacab1b-97ec-4e51-bd79-49e37e24b46c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i18bad5d43f1a44c4a5b4eda18aa12e62_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8eb064b0-85cc-4d8d-8676-34cf03560f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_981baef8-06aa-4d07-831b-f4604467a953" xlink:href="neo-20211231.xsd#neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8eb064b0-85cc-4d8d-8676-34cf03560f1f" xlink:to="loc_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_981baef8-06aa-4d07-831b-f4604467a953" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b361c51e-ae3e-4e71-b84b-fb19ed9d8ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8eb064b0-85cc-4d8d-8676-34cf03560f1f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b361c51e-ae3e-4e71-b84b-fb19ed9d8ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4eec1688-d8b9-4d5d-8f81-6dd6d83593f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8eb064b0-85cc-4d8d-8676-34cf03560f1f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4eec1688-d8b9-4d5d-8f81-6dd6d83593f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd863b86-929b-44bd-a621-79bfb9b7f2af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4eec1688-d8b9-4d5d-8f81-6dd6d83593f5" xlink:to="loc_srt_StatementGeographicalAxis_cd863b86-929b-44bd-a621-79bfb9b7f2af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd863b86-929b-44bd-a621-79bfb9b7f2af_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cd863b86-929b-44bd-a621-79bfb9b7f2af" xlink:to="loc_srt_SegmentGeographicalDomain_cd863b86-929b-44bd-a621-79bfb9b7f2af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ae0b1a78-2f92-409e-92b6-c25f9702b32e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cd863b86-929b-44bd-a621-79bfb9b7f2af" xlink:to="loc_srt_SegmentGeographicalDomain_ae0b1a78-2f92-409e-92b6-c25f9702b32e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_3bfadaef-19c9-46d7-8c5b-c476e2aaf90c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ae0b1a78-2f92-409e-92b6-c25f9702b32e" xlink:to="loc_stpr_FL_3bfadaef-19c9-46d7-8c5b-c476e2aaf90c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c827e501-59fd-47eb-a251-383c9a832f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4eec1688-d8b9-4d5d-8f81-6dd6d83593f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c827e501-59fd-47eb-a251-383c9a832f48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c827e501-59fd-47eb-a251-383c9a832f48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c827e501-59fd-47eb-a251-383c9a832f48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c827e501-59fd-47eb-a251-383c9a832f48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_568b3484-9d3c-4e1b-9089-8dc1099dc566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c827e501-59fd-47eb-a251-383c9a832f48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_568b3484-9d3c-4e1b-9089-8dc1099dc566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c6acfed1-ad0d-4bbd-90c3-8e84ad9e2815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_568b3484-9d3c-4e1b-9089-8dc1099dc566" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c6acfed1-ad0d-4bbd-90c3-8e84ad9e2815" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i6d515f5ef4ec4f11896ea2abadd6512f_GoodwillandIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4f645e17-11f4-4a6f-9482-645ca96756d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_353b11a3-6ef5-4a2b-948a-bd368121f996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4f645e17-11f4-4a6f-9482-645ca96756d9" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_353b11a3-6ef5-4a2b-948a-bd368121f996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa5df5c6-2f31-47a5-8885-26747261b594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4f645e17-11f4-4a6f-9482-645ca96756d9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa5df5c6-2f31-47a5-8885-26747261b594" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3d50b473-35b0-40d7-9cc9-b24c5e6c00fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa5df5c6-2f31-47a5-8885-26747261b594" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3d50b473-35b0-40d7-9cc9-b24c5e6c00fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d50b473-35b0-40d7-9cc9-b24c5e6c00fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3d50b473-35b0-40d7-9cc9-b24c5e6c00fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d50b473-35b0-40d7-9cc9-b24c5e6c00fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0f3d9f0-fe81-4fa4-9da3-0142e141f949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3d50b473-35b0-40d7-9cc9-b24c5e6c00fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0f3d9f0-fe81-4fa4-9da3-0142e141f949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_f8bdb577-d682-4787-9131-91942e407144" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0f3d9f0-fe81-4fa4-9da3-0142e141f949" xlink:to="loc_neo_TrapeloHealthMember_f8bdb577-d682-4787-9131-91942e407144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_1666bf81-5e63-48a8-bb15-70dfeaab013b" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0f3d9f0-fe81-4fa4-9da3-0142e141f949" xlink:to="loc_neo_InivataMember_1666bf81-5e63-48a8-bb15-70dfeaab013b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_96ebf2e8-7407-4775-a740-953145b07944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa5df5c6-2f31-47a5-8885-26747261b594" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_96ebf2e8-7407-4775-a740-953145b07944" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_96ebf2e8-7407-4775-a740-953145b07944_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_96ebf2e8-7407-4775-a740-953145b07944" xlink:to="loc_us-gaap_SegmentDomain_96ebf2e8-7407-4775-a740-953145b07944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1ab6b2d5-79c1-45ef-b28f-23b55ea01a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_96ebf2e8-7407-4775-a740-953145b07944" xlink:to="loc_us-gaap_SegmentDomain_1ab6b2d5-79c1-45ef-b28f-23b55ea01a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_7a04d27c-cc07-4957-88fa-c26a4410bc05" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1ab6b2d5-79c1-45ef-b28f-23b55ea01a58" xlink:to="loc_neo_ClinicalServicesMember_7a04d27c-cc07-4957-88fa-c26a4410bc05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_60cbec60-1458-497d-98e2-778985c0d3ef" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1ab6b2d5-79c1-45ef-b28f-23b55ea01a58" xlink:to="loc_neo_PharmaServicesMember_60cbec60-1458-497d-98e2-778985c0d3ef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsRollforwardofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails" xlink:type="extended" id="i3376433a76df428f93808316b80f97f9_GoodwillandIntangibleAssetsRollforwardofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_cf21cf88-0136-4eff-9ba8-931b43d9d3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_956a7dce-9b25-4745-ac53-ca409ff74a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_cf21cf88-0136-4eff-9ba8-931b43d9d3b2" xlink:to="loc_us-gaap_GoodwillRollForward_956a7dce-9b25-4745-ac53-ca409ff74a2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4a3f2913-c00f-4d1c-85be-11cad6c467a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_956a7dce-9b25-4745-ac53-ca409ff74a2c" xlink:to="loc_us-gaap_Goodwill_4a3f2913-c00f-4d1c-85be-11cad6c467a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_dfe52570-b30b-443c-8cdc-b8dd2f212078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_956a7dce-9b25-4745-ac53-ca409ff74a2c" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_dfe52570-b30b-443c-8cdc-b8dd2f212078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4bedfcb4-de5f-498c-a1b8-b8083cd0bf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_bddfe495-27f5-49cb-83ef-36d18f955cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_cf21cf88-0136-4eff-9ba8-931b43d9d3b2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_bddfe495-27f5-49cb-83ef-36d18f955cac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_45aaca22-39d4-4934-9a7f-bc8d8a4bb695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bddfe495-27f5-49cb-83ef-36d18f955cac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_45aaca22-39d4-4934-9a7f-bc8d8a4bb695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_45aaca22-39d4-4934-9a7f-bc8d8a4bb695_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_45aaca22-39d4-4934-9a7f-bc8d8a4bb695" xlink:to="loc_us-gaap_SegmentDomain_45aaca22-39d4-4934-9a7f-bc8d8a4bb695_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8b572741-d5e5-4992-b2b2-154a1452f4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_45aaca22-39d4-4934-9a7f-bc8d8a4bb695" xlink:to="loc_us-gaap_SegmentDomain_8b572741-d5e5-4992-b2b2-154a1452f4e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_02fe1baf-a9e8-40a2-b592-cc60860f5d2f" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8b572741-d5e5-4992-b2b2-154a1452f4e6" xlink:to="loc_neo_ClinicalServicesMember_02fe1baf-a9e8-40a2-b592-cc60860f5d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_64d63df2-cafa-4fb8-abe1-dad83215ccbb" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8b572741-d5e5-4992-b2b2-154a1452f4e6" xlink:to="loc_neo_PharmaServicesMember_64d63df2-cafa-4fb8-abe1-dad83215ccbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7d890705-3bac-47c2-bf18-36061182d357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bddfe495-27f5-49cb-83ef-36d18f955cac" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7d890705-3bac-47c2-bf18-36061182d357" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7d890705-3bac-47c2-bf18-36061182d357_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7d890705-3bac-47c2-bf18-36061182d357" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7d890705-3bac-47c2-bf18-36061182d357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_044d0ec4-d6cc-4b66-a8f2-d150712f13c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7d890705-3bac-47c2-bf18-36061182d357" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_044d0ec4-d6cc-4b66-a8f2-d150712f13c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_15be5392-9108-48ab-977d-3d3311bc5c14" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_044d0ec4-d6cc-4b66-a8f2-d150712f13c1" xlink:to="loc_neo_TrapeloHealthMember_15be5392-9108-48ab-977d-3d3311bc5c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_407017df-a854-4326-a6a6-463f57f5a732" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_044d0ec4-d6cc-4b66-a8f2-d150712f13c1" xlink:to="loc_neo_InivataMember_407017df-a854-4326-a6a6-463f57f5a732" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="extended" id="if4bd500df3774f3a8abe3756dbec503c_GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f3732043-4762-46c1-a5af-c80126693b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f3732043-4762-46c1-a5af-c80126693b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4e7a8c1c-d7a4-4597-83fc-3ec04a742090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4e7a8c1c-d7a4-4597-83fc-3ec04a742090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_51f60c43-c20c-4c16-9fbc-eda5ce55ef8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_51f60c43-c20c-4c16-9fbc-eda5ce55ef8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_888da769-0d8f-4b1f-b3f0-2f36af2843fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_888da769-0d8f-4b1f-b3f0-2f36af2843fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f335aef-55cd-4705-ada1-0013d8b2cbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f335aef-55cd-4705-ada1-0013d8b2cbb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9172f619-6c2d-4656-9604-2179787ac83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9172f619-6c2d-4656-9604-2179787ac83b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a67bda1-2b26-4f87-b2f5-2297f7c6fc50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a67bda1-2b26-4f87-b2f5-2297f7c6fc50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a8fc790-3ea8-4cdc-a044-1211329cf4b3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:to="loc_srt_RangeAxis_3a8fc790-3ea8-4cdc-a044-1211329cf4b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a8fc790-3ea8-4cdc-a044-1211329cf4b3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3a8fc790-3ea8-4cdc-a044-1211329cf4b3" xlink:to="loc_srt_RangeMember_3a8fc790-3ea8-4cdc-a044-1211329cf4b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d25bde6f-33d8-4549-9476-797a75dc6080" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3a8fc790-3ea8-4cdc-a044-1211329cf4b3" xlink:to="loc_srt_RangeMember_d25bde6f-33d8-4549-9476-797a75dc6080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a8f1972-94d0-4bcb-be30-ed4787208ccf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d25bde6f-33d8-4549-9476-797a75dc6080" xlink:to="loc_srt_MinimumMember_5a8f1972-94d0-4bcb-be30-ed4787208ccf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37f2b519-0c8c-432d-9b6b-d32261edac32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d25bde6f-33d8-4549-9476-797a75dc6080" xlink:to="loc_srt_MaximumMember_37f2b519-0c8c-432d-9b6b-d32261edac32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3e355a59-f30c-4336-a829-a245df707530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3e355a59-f30c-4336-a829-a245df707530" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e355a59-f30c-4336-a829-a245df707530_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3e355a59-f30c-4336-a829-a245df707530" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e355a59-f30c-4336-a829-a245df707530_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3e355a59-f30c-4336-a829-a245df707530" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c63abff5-2aef-48fb-9ef3-e9e3d2d0c2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c63abff5-2aef-48fb-9ef3-e9e3d2d0c2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ae5cb2b1-6bb3-4f78-97b8-ec050b678641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ae5cb2b1-6bb3-4f78-97b8-ec050b678641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_42616ac6-78ac-41be-a84d-f0ce7f89d9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_42616ac6-78ac-41be-a84d-f0ce7f89d9c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_6f01e8ee-2ab6-4c7c-aa30-e8c83f1b961f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_TrademarksMember_6f01e8ee-2ab6-4c7c-aa30-e8c83f1b961f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9c49fbd0-ce2d-410f-ae0b-26f258970f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_TradeNamesMember_9c49fbd0-ce2d-410f-ae0b-26f258970f4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f6988808-bfa5-4a7f-bebf-ab0bbc7881e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f6988808-bfa5-4a7f-bebf-ab0bbc7881e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f6988808-bfa5-4a7f-bebf-ab0bbc7881e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f6988808-bfa5-4a7f-bebf-ab0bbc7881e9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f6988808-bfa5-4a7f-bebf-ab0bbc7881e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9fc0fc06-6aab-4a19-b83a-d8ce1e086e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f6988808-bfa5-4a7f-bebf-ab0bbc7881e9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9fc0fc06-6aab-4a19-b83a-d8ce1e086e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_faa4fd1a-2409-4345-b3f7-31f44c5468f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9fc0fc06-6aab-4a19-b83a-d8ce1e086e55" xlink:to="loc_us-gaap_TrademarksMember_faa4fd1a-2409-4345-b3f7-31f44c5468f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails" xlink:type="extended" id="i3ced7ddf93d247329a3e197ab991d58c_GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5532c6c8-7bd0-453a-9af7-f397ff5f3809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5b44b011-1e84-4611-8265-c586c04c5eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5532c6c8-7bd0-453a-9af7-f397ff5f3809" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5b44b011-1e84-4611-8265-c586c04c5eb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9633d940-0355-4f8e-b5ba-ae1132362844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5532c6c8-7bd0-453a-9af7-f397ff5f3809" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9633d940-0355-4f8e-b5ba-ae1132362844" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a1caae8b-57f7-460c-ac53-e56eea30a048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9633d940-0355-4f8e-b5ba-ae1132362844" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a1caae8b-57f7-460c-ac53-e56eea30a048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a1caae8b-57f7-460c-ac53-e56eea30a048_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a1caae8b-57f7-460c-ac53-e56eea30a048" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a1caae8b-57f7-460c-ac53-e56eea30a048_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2c48b403-4a54-4368-9cdd-13839af3c07a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a1caae8b-57f7-460c-ac53-e56eea30a048" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2c48b403-4a54-4368-9cdd-13839af3c07a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_cfe8386c-0424-4b85-842a-cdc021b46bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2c48b403-4a54-4368-9cdd-13839af3c07a" xlink:to="loc_us-gaap_CostOfSalesMember_cfe8386c-0424-4b85-842a-cdc021b46bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f990ec12-67f8-4064-a03c-7c08504e88aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2c48b403-4a54-4368-9cdd-13839af3c07a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f990ec12-67f8-4064-a03c-7c08504e88aa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#InvestmentinNonConsolidatedAffiliateDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails" xlink:type="extended" id="i1cec11a4de86477fab6c2b8048605f24_InvestmentinNonConsolidatedAffiliateDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_f4a92048-a856-45ef-af6e-dcf9fcbed00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_f4a92048-a856-45ef-af6e-dcf9fcbed00b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts_cf3c607e-7908-4a0a-8504-ce174b64014e" xlink:href="neo-20211231.xsd#neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts_cf3c607e-7908-4a0a-8504-ce174b64014e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PurchaseOptionMeasurementInput_fec50d93-a97a-4690-980b-bd80085871a8" xlink:href="neo-20211231.xsd#neo_PurchaseOptionMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_PurchaseOptionMeasurementInput_fec50d93-a97a-4690-980b-bd80085871a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_05c3494e-b8df-437d-b847-1b72698db5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_Assets_05c3494e-b8df-437d-b847-1b72698db5c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0b5ce4c-04b6-4f65-ac10-6b09879ebda2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0b5ce4c-04b6-4f65-ac10-6b09879ebda2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_56a72c9c-ef58-43e2-8e07-1b650ad01e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_56a72c9c-ef58-43e2-8e07-1b650ad01e6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_655327b2-1196-4e7c-aa71-006969d206ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_655327b2-1196-4e7c-aa71-006969d206ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2cac4d54-3393-464f-b5d5-56ece388772f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2cac4d54-3393-464f-b5d5-56ece388772f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestDiscount_b8dfe3d3-b60a-4687-8658-5eacbe2809c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableWithImputedInterestDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_ReceivableWithImputedInterestDiscount_b8dfe3d3-b60a-4687-8658-5eacbe2809c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment_15c56b03-b784-4023-bff7-740ba5960580" xlink:href="neo-20211231.xsd#neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment_15c56b03-b784-4023-bff7-740ba5960580" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount_b5c7f232-6ff8-4f79-b28e-f837f0da235b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_ReceivableWithImputedInterestNetAmount_b5c7f232-6ff8-4f79-b28e-f837f0da235b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_ba9295bd-7b0c-461c-bc6d-af5ce0bea221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_ba9295bd-7b0c-461c-bc6d-af5ce0bea221" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndFeeIncomeLoansAndLeases_b8717f2f-29c3-47f4-8cd7-70cc359ffe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndFeeIncomeLoansAndLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_InterestAndFeeIncomeLoansAndLeases_b8717f2f-29c3-47f4-8cd7-70cc359ffe6e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_48f04277-68ef-4a3b-9628-025e477a4998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_48f04277-68ef-4a3b-9628-025e477a4998" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_19c67e59-e1df-4157-b8d7-9c25c19f9c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_19c67e59-e1df-4157-b8d7-9c25c19f9c12" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_6d21586e-80f6-4ca0-927d-4c79532024b5" xlink:href="neo-20211231.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_6d21586e-80f6-4ca0-927d-4c79532024b5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_a0d0ce04-193e-425c-8ed0-7839f7ca76af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_a0d0ce04-193e-425c-8ed0-7839f7ca76af" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_350334ad-32cb-4f05-9dc2-df78dc0bfab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_350334ad-32cb-4f05-9dc2-df78dc0bfab9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1c7b76cc-c88d-4343-8730-6041f5a2af9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_LineOfCredit_1c7b76cc-c88d-4343-8730-6041f5a2af9b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermLineOfCreditSettlementGainLoss_12882337-1be8-40c1-b8f7-fad57f2ea536" xlink:href="neo-20211231.xsd#neo_LongTermLineOfCreditSettlementGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_LongTermLineOfCreditSettlementGainLoss_12882337-1be8-40c1-b8f7-fad57f2ea536" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f6c8d3d5-3ac3-4ef5-bfae-0f50e0be526e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f6c8d3d5-3ac3-4ef5-bfae-0f50e0be526e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f9a5e324-b5b5-4fca-9d21-edaf76cf0354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f9a5e324-b5b5-4fca-9d21-edaf76cf0354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f9a5e324-b5b5-4fca-9d21-edaf76cf0354_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f9a5e324-b5b5-4fca-9d21-edaf76cf0354" xlink:to="loc_us-gaap_RelatedPartyDomain_f9a5e324-b5b5-4fca-9d21-edaf76cf0354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b0e3a1ac-5390-47bc-b608-aceb6ed65119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f9a5e324-b5b5-4fca-9d21-edaf76cf0354" xlink:to="loc_us-gaap_RelatedPartyDomain_b0e3a1ac-5390-47bc-b608-aceb6ed65119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_f2496c7e-7882-4b1f-9aae-e8284f6d6385" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b0e3a1ac-5390-47bc-b608-aceb6ed65119" xlink:to="loc_srt_AffiliatedEntityMember_f2496c7e-7882-4b1f-9aae-e8284f6d6385" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ccc21778-5181-4e77-ab20-ac4fbdb338a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_InvestmentTypeAxis_ccc21778-5181-4e77-ab20-ac4fbdb338a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ccc21778-5181-4e77-ab20-ac4fbdb338a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_ccc21778-5181-4e77-ab20-ac4fbdb338a2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ccc21778-5181-4e77-ab20-ac4fbdb338a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ed67b273-ed10-4eae-91c0-4ffe68b478fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_ccc21778-5181-4e77-ab20-ac4fbdb338a2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ed67b273-ed10-4eae-91c0-4ffe68b478fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PreferenceSharesMember_a5e5ae8a-605c-4350-bbfb-59e02b6f72a0" xlink:href="neo-20211231.xsd#neo_PreferenceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ed67b273-ed10-4eae-91c0-4ffe68b478fd" xlink:to="loc_neo_PreferenceSharesMember_a5e5ae8a-605c-4350-bbfb-59e02b6f72a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PurchaseOptionMember_87551944-28a5-4777-a87b-bd67fe2c4f43" xlink:href="neo-20211231.xsd#neo_PurchaseOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ed67b273-ed10-4eae-91c0-4ffe68b478fd" xlink:to="loc_neo_PurchaseOptionMember_87551944-28a5-4777-a87b-bd67fe2c4f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1a3407f3-d5cd-47ed-bc4a-a345a7c8b657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1a3407f3-d5cd-47ed-bc4a-a345a7c8b657" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1a3407f3-d5cd-47ed-bc4a-a345a7c8b657_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1a3407f3-d5cd-47ed-bc4a-a345a7c8b657" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1a3407f3-d5cd-47ed-bc4a-a345a7c8b657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b51ec73f-4f30-462d-b088-4c30e2896357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1a3407f3-d5cd-47ed-bc4a-a345a7c8b657" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b51ec73f-4f30-462d-b088-4c30e2896357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StrategicAllianceWithInivataLimitedMember_808c6a90-a1bb-4502-9bb4-490b274e9195" xlink:href="neo-20211231.xsd#neo_StrategicAllianceWithInivataLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_b51ec73f-4f30-462d-b088-4c30e2896357" xlink:to="loc_neo_StrategicAllianceWithInivataLimitedMember_808c6a90-a1bb-4502-9bb4-490b274e9195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b5b029df-4587-415c-9ba2-df8c6c52145a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b5b029df-4587-415c-9ba2-df8c6c52145a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b5b029df-4587-415c-9ba2-df8c6c52145a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b5b029df-4587-415c-9ba2-df8c6c52145a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b5b029df-4587-415c-9ba2-df8c6c52145a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_498368fe-cc75-4b04-91bf-c3e0850c4f36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b5b029df-4587-415c-9ba2-df8c6c52145a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_498368fe-cc75-4b04-91bf-c3e0850c4f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_c5f3ecdb-1ee3-40dc-b659-2ea80321ff2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_498368fe-cc75-4b04-91bf-c3e0850c4f36" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_c5f3ecdb-1ee3-40dc-b659-2ea80321ff2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e38fddcf-7b3a-4914-9a75-6d77ac37afab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e38fddcf-7b3a-4914-9a75-6d77ac37afab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e38fddcf-7b3a-4914-9a75-6d77ac37afab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e38fddcf-7b3a-4914-9a75-6d77ac37afab" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e38fddcf-7b3a-4914-9a75-6d77ac37afab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e38fddcf-7b3a-4914-9a75-6d77ac37afab" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2eadc3e1-979b-470e-88e5-d42bf4d565db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2eadc3e1-979b-470e-88e5-d42bf4d565db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1ff5a8b8-ce7a-45f5-8c3d-f4ee256e7eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_1ff5a8b8-ce7a-45f5-8c3d-f4ee256e7eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_f75abc45-1837-4d28-a7f3-b83121347917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_f75abc45-1837-4d28-a7f3-b83121347917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_de5379da-ba19-42f0-9550-3e22b62d0347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_CreditFacilityAxis_de5379da-ba19-42f0-9550-3e22b62d0347" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_de5379da-ba19-42f0-9550-3e22b62d0347_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_de5379da-ba19-42f0-9550-3e22b62d0347" xlink:to="loc_us-gaap_CreditFacilityDomain_de5379da-ba19-42f0-9550-3e22b62d0347_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a1993c53-29b5-4117-805e-56feb965a4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_de5379da-ba19-42f0-9550-3e22b62d0347" xlink:to="loc_us-gaap_CreditFacilityDomain_a1993c53-29b5-4117-805e-56feb965a4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5bbfb65b-cf63-450b-891d-c3f1fc331429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a1993c53-29b5-4117-805e-56feb965a4e5" xlink:to="loc_us-gaap_LineOfCreditMember_5bbfb65b-cf63-450b-891d-c3f1fc331429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_959271ad-2927-4ca7-a898-838c8b93b4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_959271ad-2927-4ca7-a898-838c8b93b4b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_959271ad-2927-4ca7-a898-838c8b93b4b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_959271ad-2927-4ca7-a898-838c8b93b4b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_959271ad-2927-4ca7-a898-838c8b93b4b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cca535cb-7110-4976-8784-644ffc328943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_959271ad-2927-4ca7-a898-838c8b93b4b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cca535cb-7110-4976-8784-644ffc328943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_6e688731-877b-41f8-be24-4a6309fd8c94" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cca535cb-7110-4976-8784-644ffc328943" xlink:to="loc_neo_InivataMember_6e688731-877b-41f8-be24-4a6309fd8c94" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended" id="i151532f3060945c48aa322d2f7ff29ed_DebtSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_321459a5-ef53-402e-af49-edb7681aaae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_321459a5-ef53-402e-af49-edb7681aaae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ae613dfb-e99a-45ba-a95b-ce105cf6bad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ae613dfb-e99a-45ba-a95b-ce105cf6bad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4aa05126-a1e9-4d18-afd1-9467d1fba9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4aa05126-a1e9-4d18-afd1-9467d1fba9b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_00c432dc-6c6a-48d7-925f-a9dfedd05996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_00c432dc-6c6a-48d7-925f-a9dfedd05996" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fd809411-36ec-40cf-9a0b-e6501fad4653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_LongTermDebt_fd809411-36ec-40cf-9a0b-e6501fad4653" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_193d184e-bdd0-467e-8610-d5a4fc9e1b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_OtherLongTermDebt_193d184e-bdd0-467e-8610-d5a4fc9e1b5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_a569a56c-d5ec-46a5-a752-42cedf8274ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_a569a56c-d5ec-46a5-a752-42cedf8274ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_fd57bb1c-7782-4b4a-aaa4-9366a2c1c39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_fd57bb1c-7782-4b4a-aaa4-9366a2c1c39e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6dc5d27e-1598-4acc-89d6-5a43f8d2e1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6dc5d27e-1598-4acc-89d6-5a43f8d2e1cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_61bef90f-5c70-4611-8328-c4261262d46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:to="loc_us-gaap_CreditFacilityAxis_61bef90f-5c70-4611-8328-c4261262d46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_61bef90f-5c70-4611-8328-c4261262d46a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_61bef90f-5c70-4611-8328-c4261262d46a" xlink:to="loc_us-gaap_CreditFacilityDomain_61bef90f-5c70-4611-8328-c4261262d46a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1bd65e6a-e363-46e4-b655-c2aac188a879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_61bef90f-5c70-4611-8328-c4261262d46a" xlink:to="loc_us-gaap_CreditFacilityDomain_1bd65e6a-e363-46e4-b655-c2aac188a879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FinanceObligationsMember_cb1a00fc-c29b-4c5f-a359-4d3070407e84" xlink:href="neo-20211231.xsd#neo_FinanceObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1bd65e6a-e363-46e4-b655-c2aac188a879" xlink:to="loc_neo_FinanceObligationsMember_cb1a00fc-c29b-4c5f-a359-4d3070407e84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f47a0ecf-a6e4-4410-8d78-0ace8c6aff2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:to="loc_us-gaap_DebtInstrumentAxis_f47a0ecf-a6e4-4410-8d78-0ace8c6aff2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f47a0ecf-a6e4-4410-8d78-0ace8c6aff2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f47a0ecf-a6e4-4410-8d78-0ace8c6aff2d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f47a0ecf-a6e4-4410-8d78-0ace8c6aff2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_15c7b108-166a-439d-83a8-4a858c36c80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f47a0ecf-a6e4-4410-8d78-0ace8c6aff2d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_15c7b108-166a-439d-83a8-4a858c36c80d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_52bd39f6-3d20-473b-925c-332b33bab168" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_15c7b108-166a-439d-83a8-4a858c36c80d" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_52bd39f6-3d20-473b-925c-332b33bab168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_a53d1f06-77d1-41e2-a147-bfc8ee0628c5" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_15c7b108-166a-439d-83a8-4a858c36c80d" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_a53d1f06-77d1-41e2-a147-bfc8ee0628c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e3ae2f55-37c9-43c7-b4d8-af913dc37bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e3ae2f55-37c9-43c7-b4d8-af913dc37bb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e3ae2f55-37c9-43c7-b4d8-af913dc37bb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e3ae2f55-37c9-43c7-b4d8-af913dc37bb6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e3ae2f55-37c9-43c7-b4d8-af913dc37bb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dc6bc69b-8a75-4cfa-b771-6a275f3bcb96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e3ae2f55-37c9-43c7-b4d8-af913dc37bb6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dc6bc69b-8a75-4cfa-b771-6a275f3bcb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_dbceec4e-994f-4f48-9a1e-ef6cf4993df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc6bc69b-8a75-4cfa-b771-6a275f3bcb96" xlink:to="loc_us-gaap_ConvertibleDebtMember_dbceec4e-994f-4f48-9a1e-ef6cf4993df2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/DebtNarrativeDetails" xlink:type="extended" id="ia57960f3f711488b83ad0c1e2e21cec7_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_08555dd3-4cc8-4070-abcd-4f2707968f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_08555dd3-4cc8-4070-abcd-4f2707968f51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_f89316c3-9d03-4e30-9f7d-4d97762731a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentFairValue_f89316c3-9d03-4e30-9f7d-4d97762731a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_da3bc99a-cb04-4fce-a586-c4fd9f986154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_da3bc99a-cb04-4fce-a586-c4fd9f986154" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DiscountedPriceOfAggregatePrincipleRate_ee0097b1-428c-4c78-8d28-a7553381e594" xlink:href="neo-20211231.xsd#neo_DiscountedPriceOfAggregatePrincipleRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_DiscountedPriceOfAggregatePrincipleRate_ee0097b1-428c-4c78-8d28-a7553381e594" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_353dac80-4f81-4374-a4f7-e5a7d042d2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_353dac80-4f81-4374-a4f7-e5a7d042d2b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDiscountOnShares_1f34a9b1-1de0-4261-89d9-6a8d297b7b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDiscountOnShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_CommonStockDiscountOnShares_1f34a9b1-1de0-4261-89d9-6a8d297b7b18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_04634fab-60e5-4b25-9110-eb90e1956a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_04634fab-60e5-4b25-9110-eb90e1956a1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_56d28d41-c2c8-4ce7-a844-3d3b527ed282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_56d28d41-c2c8-4ce7-a844-3d3b527ed282" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5370d0d7-aee6-455f-8fb4-acf0d7800927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5370d0d7-aee6-455f-8fb4-acf0d7800927" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate_82752e92-a86e-4e26-bc0e-85e997cfea4d" xlink:href="neo-20211231.xsd#neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate_82752e92-a86e-4e26-bc0e-85e997cfea4d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ac441e39-2ab2-41d0-8a7a-c9533bb80ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ac441e39-2ab2-41d0-8a7a-c9533bb80ba4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6255511b-66ec-449e-b0cc-dcb1e237842c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6255511b-66ec-449e-b0cc-dcb1e237842c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_158f6a4d-c278-4406-9be0-6384da059429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_158f6a4d-c278-4406-9be0-6384da059429" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt_c5e667b8-06db-4d06-80c7-b4dd864ecb69" xlink:href="neo-20211231.xsd#neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt_c5e667b8-06db-4d06-80c7-b4dd864ecb69" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtContractualCouponInterest_3f85df46-4d0d-467c-9b5c-6545fd022d7d" xlink:href="neo-20211231.xsd#neo_InterestExpenseDebtContractualCouponInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_InterestExpenseDebtContractualCouponInterest_3f85df46-4d0d-467c-9b5c-6545fd022d7d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_8c4863d2-1f96-498e-a56f-a75203b3b29c" xlink:href="neo-20211231.xsd#neo_InterestExpenseDebtAccretionOfDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_8c4863d2-1f96-498e-a56f-a75203b3b29c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_ca041083-9ab4-4b01-8091-25655e96f8eb" xlink:href="neo-20211231.xsd#neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_ca041083-9ab4-4b01-8091-25655e96f8eb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_07a05626-c573-496e-b44d-449f4641f9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_07a05626-c573-496e-b44d-449f4641f9d3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_404c78d7-3534-4d9d-bd53-32002f2b8076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_404c78d7-3534-4d9d-bd53-32002f2b8076" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsNumberOfUnderlyingShares_b2934c59-e615-4402-84b4-d6baa707ca0a" xlink:href="neo-20211231.xsd#neo_CappedCallTransactionsNumberOfUnderlyingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_CappedCallTransactionsNumberOfUnderlyingShares_b2934c59-e615-4402-84b4-d6baa707ca0a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_70de3d4b-33a5-4a06-9a9f-711da186f906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_70de3d4b-33a5-4a06-9a9f-711da186f906" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SaleOfStockPremiumOnOfferingPrice_ccf331a8-3fc5-42a2-aa94-14da9143bdf7" xlink:href="neo-20211231.xsd#neo_SaleOfStockPremiumOnOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_SaleOfStockPremiumOnOfferingPrice_ccf331a8-3fc5-42a2-aa94-14da9143bdf7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SaleOfStockPricePerSharePublicOfferingPrice_2c2a52c0-ca19-4861-83ff-c1729e38df6b" xlink:href="neo-20211231.xsd#neo_SaleOfStockPricePerSharePublicOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_SaleOfStockPricePerSharePublicOfferingPrice_2c2a52c0-ca19-4861-83ff-c1729e38df6b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5e9959cb-a697-409d-8e47-0f31e8e6b272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5e9959cb-a697-409d-8e47-0f31e8e6b272" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f885ad14-c66e-4ede-b566-b657b5282e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_DebtInstrumentAxis_f885ad14-c66e-4ede-b566-b657b5282e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f885ad14-c66e-4ede-b566-b657b5282e57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f885ad14-c66e-4ede-b566-b657b5282e57" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f885ad14-c66e-4ede-b566-b657b5282e57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c44ad8ef-d995-4ef0-ae79-72ac393772e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f885ad14-c66e-4ede-b566-b657b5282e57" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c44ad8ef-d995-4ef0-ae79-72ac393772e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_c2ed7e47-d283-4b8c-b526-7835b2d243e1" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c44ad8ef-d995-4ef0-ae79-72ac393772e8" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_c2ed7e47-d283-4b8c-b526-7835b2d243e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_c3bed962-73d2-4389-b5e1-2e14a2d89379" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c44ad8ef-d995-4ef0-ae79-72ac393772e8" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_c3bed962-73d2-4389-b5e1-2e14a2d89379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f1430d5f-8ff2-45a9-b290-f399a040d8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f1430d5f-8ff2-45a9-b290-f399a040d8fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f1430d5f-8ff2-45a9-b290-f399a040d8fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1430d5f-8ff2-45a9-b290-f399a040d8fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f1430d5f-8ff2-45a9-b290-f399a040d8fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab45428c-51ed-4d34-a02b-289f39d65878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1430d5f-8ff2-45a9-b290-f399a040d8fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab45428c-51ed-4d34-a02b-289f39d65878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_c33d5407-39cd-4139-8398-05823cf669db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab45428c-51ed-4d34-a02b-289f39d65878" xlink:to="loc_us-gaap_ConvertibleDebtMember_c33d5407-39cd-4139-8398-05823cf669db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_78275dd4-0ce8-4c40-b7eb-3ac1c4e767f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_78275dd4-0ce8-4c40-b7eb-3ac1c4e767f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78275dd4-0ce8-4c40-b7eb-3ac1c4e767f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_78275dd4-0ce8-4c40-b7eb-3ac1c4e767f4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78275dd4-0ce8-4c40-b7eb-3ac1c4e767f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281ca26d-4dbc-447e-aa1c-77f4f8f2b1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_78275dd4-0ce8-4c40-b7eb-3ac1c4e767f4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281ca26d-4dbc-447e-aa1c-77f4f8f2b1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a2e55a6a-769d-44d2-8118-61489175a51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281ca26d-4dbc-447e-aa1c-77f4f8f2b1c0" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a2e55a6a-769d-44d2-8118-61489175a51c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember_6c3e8aba-af51-437f-af7e-eadbd942caab" xlink:href="neo-20211231.xsd#neo_CappedCallTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281ca26d-4dbc-447e-aa1c-77f4f8f2b1c0" xlink:to="loc_neo_CappedCallTransactionsMember_6c3e8aba-af51-437f-af7e-eadbd942caab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b30450a1-d50d-4e52-9073-d63be34f09c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b30450a1-d50d-4e52-9073-d63be34f09c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b30450a1-d50d-4e52-9073-d63be34f09c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b30450a1-d50d-4e52-9073-d63be34f09c2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b30450a1-d50d-4e52-9073-d63be34f09c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_669e4d77-f82c-4665-94c0-f515ebe11e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b30450a1-d50d-4e52-9073-d63be34f09c2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_669e4d77-f82c-4665-94c0-f515ebe11e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5f5261e0-b85b-4766-a793-d66edba5f181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_669e4d77-f82c-4665-94c0-f515ebe11e5e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5f5261e0-b85b-4766-a793-d66edba5f181" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f9cec727-5e08-4459-b7f0-b7b2ccf99c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_669e4d77-f82c-4665-94c0-f515ebe11e5e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f9cec727-5e08-4459-b7f0-b7b2ccf99c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86c0e294-eae7-4776-b9d9-900c45180e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86c0e294-eae7-4776-b9d9-900c45180e76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86c0e294-eae7-4776-b9d9-900c45180e76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86c0e294-eae7-4776-b9d9-900c45180e76" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86c0e294-eae7-4776-b9d9-900c45180e76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a805200-f7fe-4e93-ba2d-77c54baf981a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86c0e294-eae7-4776-b9d9-900c45180e76" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a805200-f7fe-4e93-ba2d-77c54baf981a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8bd355af-ea22-4648-a2f8-8d465125e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a805200-f7fe-4e93-ba2d-77c54baf981a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8bd355af-ea22-4648-a2f8-8d465125e5c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DebtScheduleofMaturitiesofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" xlink:type="extended" id="i16095a87c7ce4341b33d79e0ea076cd1_DebtScheduleofMaturitiesofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c651f7c-45d8-49f8-b67f-28bd051947eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c651f7c-45d8-49f8-b67f-28bd051947eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9a1a248e-98a5-49ce-b8ad-a3490dc276d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9a1a248e-98a5-49ce-b8ad-a3490dc276d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bdaaf991-262e-4a26-912c-4b02367513e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bdaaf991-262e-4a26-912c-4b02367513e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a2ded34e-053d-4e8d-b3f5-5d08917f5f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a2ded34e-053d-4e8d-b3f5-5d08917f5f0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_64410b3d-16ea-49e5-90a2-6bd9012f03ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_64410b3d-16ea-49e5-90a2-6bd9012f03ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_14118fca-f4a8-463d-bf6e-39bf65696d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_14118fca-f4a8-463d-bf6e-39bf65696d07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_337d6f95-b65a-4f0d-bb62-ab4555166e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_337d6f95-b65a-4f0d-bb62-ab4555166e74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_613f101a-afeb-45cc-a262-0224babbb8eb" xlink:href="neo-20211231.xsd#neo_LongTermDebtIncludingCurrentMaturitiesDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_613f101a-afeb-45cc-a262-0224babbb8eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ba1e7cc4-1a4e-4aad-9f7a-9de0595c3b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtCurrent_ba1e7cc4-1a4e-4aad-9f7a-9de0595c3b41" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1f22857f-0ff4-4f7d-8978-25df5bde2672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1f22857f-0ff4-4f7d-8978-25df5bde2672" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b6a1231c-20bf-4ccf-83b1-8fde2f934b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b6a1231c-20bf-4ccf-83b1-8fde2f934b68" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:to="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_68ff690b-4538-4ab6-9d40-b6a3f59da12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_68ff690b-4538-4ab6-9d40-b6a3f59da12a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_5c425a31-41ab-4781-98fc-69b47f1b2db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_5c425a31-41ab-4781-98fc-69b47f1b2db0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_95cabd61-2326-455c-b29e-286b9af659a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_95cabd61-2326-455c-b29e-286b9af659a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cd1d84e2-2db6-4f1f-933c-d7670c5e2b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cd1d84e2-2db6-4f1f-933c-d7670c5e2b80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_bbd909ea-140c-4c3a-a291-4d08233a2e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_bbd909ea-140c-4c3a-a291-4d08233a2e2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_a943746b-82ed-4420-98af-4b890b1e22ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_a943746b-82ed-4420-98af-4b890b1e22ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f781586a-d9ea-462b-a254-3ae3907591fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f781586a-d9ea-462b-a254-3ae3907591fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1e85b152-07c1-41dc-9177-5173720a2a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1e85b152-07c1-41dc-9177-5173720a2a7b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a6afdf8c-e8a8-48ce-b9ef-552abf4f50ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a6afdf8c-e8a8-48ce-b9ef-552abf4f50ea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne_66292b67-842c-4dc4-9b38-64354fb10141" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne_66292b67-842c-4dc4-9b38-64354fb10141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo_c015cb28-86c7-4201-bd35-38c37cbf6b39" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo_c015cb28-86c7-4201-bd35-38c37cbf6b39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree_b779ac18-bd71-4f7c-95e0-e2b04e6960e7" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree_b779ac18-bd71-4f7c-95e0-e2b04e6960e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour_f8b62675-6682-4b2e-947a-ed6c587e72a4" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour_f8b62675-6682-4b2e-947a-ed6c587e72a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive_1bfb14b4-c207-4b2a-ae72-9bd7d9ec63f4" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive_1bfb14b4-c207-4b2a-ae72-9bd7d9ec63f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive_802cc540-ce18-4eea-8937-979c42bd6392" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive_802cc540-ce18-4eea-8937-979c42bd6392" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_73765709-ca41-430d-9312-1adce50f2cc4" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_73765709-ca41-430d-9312-1adce50f2cc4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6ed3664f-e69b-4e09-ac7b-f18019ec84a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_275ea7bd-72ef-4e9a-ab89-a63684a2fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_275ea7bd-72ef-4e9a-ab89-a63684a2fe70" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_11982a78-bcd7-49a1-abc9-118c8167d8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_11982a78-bcd7-49a1-abc9-118c8167d8fd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1a5e169f-f311-4679-9797-669a8f1ca67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1a5e169f-f311-4679-9797-669a8f1ca67f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8a832c96-2d8c-4f2c-8ed8-96d496247c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:to="loc_us-gaap_CreditFacilityAxis_8a832c96-2d8c-4f2c-8ed8-96d496247c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8a832c96-2d8c-4f2c-8ed8-96d496247c88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8a832c96-2d8c-4f2c-8ed8-96d496247c88" xlink:to="loc_us-gaap_CreditFacilityDomain_8a832c96-2d8c-4f2c-8ed8-96d496247c88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4a33ef4a-d38b-4b01-aba9-132589a6428c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8a832c96-2d8c-4f2c-8ed8-96d496247c88" xlink:to="loc_us-gaap_CreditFacilityDomain_4a33ef4a-d38b-4b01-aba9-132589a6428c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FinanceObligationsMember_f3a9f55f-a7b5-4f02-aee0-be20e3ba8218" xlink:href="neo-20211231.xsd#neo_FinanceObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4a33ef4a-d38b-4b01-aba9-132589a6428c" xlink:to="loc_neo_FinanceObligationsMember_f3a9f55f-a7b5-4f02-aee0-be20e3ba8218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_06799a8a-9651-4557-83aa-0796a496853b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:to="loc_us-gaap_DebtInstrumentAxis_06799a8a-9651-4557-83aa-0796a496853b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06799a8a-9651-4557-83aa-0796a496853b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_06799a8a-9651-4557-83aa-0796a496853b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06799a8a-9651-4557-83aa-0796a496853b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_10e38071-2b2a-4bfe-8b7a-61b2e69d3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_06799a8a-9651-4557-83aa-0796a496853b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_10e38071-2b2a-4bfe-8b7a-61b2e69d3c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_37256333-6f5a-49a2-8fbe-d5d3c54d8987" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_10e38071-2b2a-4bfe-8b7a-61b2e69d3c69" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_37256333-6f5a-49a2-8fbe-d5d3c54d8987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_23d5bb35-8047-4bb0-98e2-3a9afe3079df" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_10e38071-2b2a-4bfe-8b7a-61b2e69d3c69" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_23d5bb35-8047-4bb0-98e2-3a9afe3079df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_291f30f6-9bd7-41dd-b501-a1e687b00619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_291f30f6-9bd7-41dd-b501-a1e687b00619" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_291f30f6-9bd7-41dd-b501-a1e687b00619_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_291f30f6-9bd7-41dd-b501-a1e687b00619" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_291f30f6-9bd7-41dd-b501-a1e687b00619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d7f8baec-3ed7-4bc3-b4c7-eae8c86be5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_291f30f6-9bd7-41dd-b501-a1e687b00619" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d7f8baec-3ed7-4bc3-b4c7-eae8c86be5bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a840b7b3-1fb8-4151-92f9-62552bc165a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d7f8baec-3ed7-4bc3-b4c7-eae8c86be5bc" xlink:to="loc_us-gaap_ConvertibleDebtMember_a840b7b3-1fb8-4151-92f9-62552bc165a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DerivativeInstrumentsandHedgingActivitiesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails" xlink:type="extended" id="i91d78c266f5a45bebadc99bb31657f27_DerivativeInstrumentsandHedgingActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount_81abc2f1-3230-46c3-9560-19a9b22d8c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtPercentageBearingVariableInterestAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount_81abc2f1-3230-46c3-9560-19a9b22d8c86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2fa2dffe-2948-4174-b579-45315cce750b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2fa2dffe-2948-4174-b579-45315cce750b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_ad6e402b-8e1e-4ce3-b94b-b7b6272cf6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_ad6e402b-8e1e-4ce3-b94b-b7b6272cf6e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DerivativeTerminationFee_55af2ad8-d304-42e8-a0e1-7bd9e272e6b9" xlink:href="neo-20211231.xsd#neo_DerivativeTerminationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_neo_DerivativeTerminationFee_55af2ad8-d304-42e8-a0e1-7bd9e272e6b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c8b25a85-baa4-4174-9a7f-96d0c1037f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c8b25a85-baa4-4174-9a7f-96d0c1037f6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b3b4aa5f-8112-40b4-a51a-c7befddff442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b3b4aa5f-8112-40b4-a51a-c7befddff442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b3b4aa5f-8112-40b4-a51a-c7befddff442_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b3b4aa5f-8112-40b4-a51a-c7befddff442" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b3b4aa5f-8112-40b4-a51a-c7befddff442_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a3d9a919-9bc8-40e2-a2c5-fff948df6503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b3b4aa5f-8112-40b4-a51a-c7befddff442" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a3d9a919-9bc8-40e2-a2c5-fff948df6503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_768c4c35-5ee8-4917-9b60-ef0ed76fa80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a3d9a919-9bc8-40e2-a2c5-fff948df6503" xlink:to="loc_us-gaap_CashFlowHedgingMember_768c4c35-5ee8-4917-9b60-ef0ed76fa80f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4348ad0a-79b7-4388-9661-b9b592e54caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:to="loc_us-gaap_HedgingDesignationAxis_4348ad0a-79b7-4388-9661-b9b592e54caa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4348ad0a-79b7-4388-9661-b9b592e54caa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_4348ad0a-79b7-4388-9661-b9b592e54caa" xlink:to="loc_us-gaap_HedgingDesignationDomain_4348ad0a-79b7-4388-9661-b9b592e54caa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a31459d8-72d0-4e7b-b504-4e8f98d923ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_4348ad0a-79b7-4388-9661-b9b592e54caa" xlink:to="loc_us-gaap_HedgingDesignationDomain_a31459d8-72d0-4e7b-b504-4e8f98d923ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_41c2e604-3bf1-4036-8f13-ab84af9a9372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a31459d8-72d0-4e7b-b504-4e8f98d923ce" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_41c2e604-3bf1-4036-8f13-ab84af9a9372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fbd154a1-4959-488d-ad8a-014ff658031c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fbd154a1-4959-488d-ad8a-014ff658031c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fbd154a1-4959-488d-ad8a-014ff658031c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fbd154a1-4959-488d-ad8a-014ff658031c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fbd154a1-4959-488d-ad8a-014ff658031c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b7c5c08c-e323-4a38-b77e-687044a506b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fbd154a1-4959-488d-ad8a-014ff658031c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b7c5c08c-e323-4a38-b77e-687044a506b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestRateSwapJune2018Member_7650654c-afc2-4382-a951-39b3aa53635d" xlink:href="neo-20211231.xsd#neo_InterestRateSwapJune2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b7c5c08c-e323-4a38-b77e-687044a506b9" xlink:to="loc_neo_InterestRateSwapJune2018Member_7650654c-afc2-4382-a951-39b3aa53635d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestRateSwapDecember2016Member_a0db1c51-2ae6-43f1-b1cf-d0810fc962d7" xlink:href="neo-20211231.xsd#neo_InterestRateSwapDecember2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b7c5c08c-e323-4a38-b77e-687044a506b9" xlink:to="loc_neo_InterestRateSwapDecember2016Member_a0db1c51-2ae6-43f1-b1cf-d0810fc962d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/EquityTransactionsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#EquityTransactionsDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/EquityTransactionsDetails" xlink:type="extended" id="id80ab52df5074fb89127e2dedb45ad8e_EquityTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f4581917-0ebc-4943-9dd2-980f6c12c909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f4581917-0ebc-4943-9dd2-980f6c12c909" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_07e0e859-d6ba-4e6c-83ab-57466ef1e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_07e0e859-d6ba-4e6c-83ab-57466ef1e07c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1cce3ccd-1f22-4aad-a3ad-b58315192d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1cce3ccd-1f22-4aad-a3ad-b58315192d07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_375986d0-8a71-445c-b1b6-b9d87099ea05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_375986d0-8a71-445c-b1b6-b9d87099ea05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4e074978-2ebf-4530-ab00-9cab3b52d727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4e074978-2ebf-4530-ab00-9cab3b52d727" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c453d9c4-d4e6-4c42-927c-2a85911afb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c453d9c4-d4e6-4c42-927c-2a85911afb4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SaleOfStockOptionTerm_18d40ea5-1e65-4acd-998e-35171326b240" xlink:href="neo-20211231.xsd#neo_SaleOfStockOptionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_neo_SaleOfStockOptionTerm_18d40ea5-1e65-4acd-998e-35171326b240" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e285abd6-8536-410b-be1d-48a3151ee9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e285abd6-8536-410b-be1d-48a3151ee9a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b455593-43d1-40e2-8c84-0c5ca5e03873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e285abd6-8536-410b-be1d-48a3151ee9a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b455593-43d1-40e2-8c84-0c5ca5e03873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b455593-43d1-40e2-8c84-0c5ca5e03873_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b455593-43d1-40e2-8c84-0c5ca5e03873" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b455593-43d1-40e2-8c84-0c5ca5e03873_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7470173d-071a-44df-8ea6-40b10f9d894a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b455593-43d1-40e2-8c84-0c5ca5e03873" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7470173d-071a-44df-8ea6-40b10f9d894a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_16d1d5f2-d6f5-4bce-ba06-d52e17988932" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7470173d-071a-44df-8ea6-40b10f9d894a" xlink:to="loc_neo_TrapeloHealthMember_16d1d5f2-d6f5-4bce-ba06-d52e17988932" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17b222fd-c408-4d64-950b-f73df7c9c52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e285abd6-8536-410b-be1d-48a3151ee9a1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17b222fd-c408-4d64-950b-f73df7c9c52d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17b222fd-c408-4d64-950b-f73df7c9c52d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17b222fd-c408-4d64-950b-f73df7c9c52d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17b222fd-c408-4d64-950b-f73df7c9c52d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17b222fd-c408-4d64-950b-f73df7c9c52d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_362591a6-3730-4734-9ccc-b479d86aefeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:to="loc_us-gaap_PrivatePlacementMember_362591a6-3730-4734-9ccc-b479d86aefeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommonStockOfferingMember_9528905f-654e-487c-957e-ffc16dc567be" xlink:href="neo-20211231.xsd#neo_CommonStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:to="loc_neo_CommonStockOfferingMember_9528905f-654e-487c-957e-ffc16dc567be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3f16c13f-c4d0-4485-8e53-7dc2325d48b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3f16c13f-c4d0-4485-8e53-7dc2325d48b3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="icb749ce8b2034979801ce938682f3f59_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e77a446-a7c7-49a8-8664-ea3808e48ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e77a446-a7c7-49a8-8664-ea3808e48ff5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a1987b7-5093-49f6-9fe3-bd25da668d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a1987b7-5093-49f6-9fe3-bd25da668d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1725a647-da5b-4cf2-be7e-cb226c308294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1725a647-da5b-4cf2-be7e-cb226c308294" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_999eebfc-3754-4758-b42e-bc62e87d847c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_999eebfc-3754-4758-b42e-bc62e87d847c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_32c24f6f-fd4a-4d09-a852-bfdc703d5b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_32c24f6f-fd4a-4d09-a852-bfdc703d5b0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_810b3dd3-12e6-4af1-baf4-ad6832c41660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_810b3dd3-12e6-4af1-baf4-ad6832c41660" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_caf7d901-0946-4127-8730-55eeda1f202b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_caf7d901-0946-4127-8730-55eeda1f202b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommonStockClosingPrice_dfe9a694-58d2-4d7b-b6f9-959f4251e1db" xlink:href="neo-20211231.xsd#neo_CommonStockClosingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_neo_CommonStockClosingPrice_dfe9a694-58d2-4d7b-b6f9-959f4251e1db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber_9120eef7-86e1-4904-b340-8cfaa13f6a85" xlink:href="neo-20211231.xsd#neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber_9120eef7-86e1-4904-b340-8cfaa13f6a85" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16edcea9-4760-4853-8c91-ce57d77c99fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16edcea9-4760-4853-8c91-ce57d77c99fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7a2627cd-092f-49a6-a52b-443e611f3502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7a2627cd-092f-49a6-a52b-443e611f3502" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_1ba2392a-54e0-4c02-943b-3061b9b1d859" xlink:href="neo-20211231.xsd#neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_1ba2392a-54e0-4c02-943b-3061b9b1d859" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9fac3ff8-4930-4f76-8ec6-781e1232241e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9fac3ff8-4930-4f76-8ec6-781e1232241e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d630ecb2-21b5-416b-bf24-8e52be81b6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d630ecb2-21b5-416b-bf24-8e52be81b6d8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8dc7b9bd-4bee-449d-8ffd-f2483df480d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8dc7b9bd-4bee-449d-8ffd-f2483df480d0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f7e26e0e-00f2-492f-ba6b-727c28886616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f7e26e0e-00f2-492f-ba6b-727c28886616" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ee5964c8-0678-4cdd-b903-5140530fc627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ee5964c8-0678-4cdd-b903-5140530fc627" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da4f2037-7795-46eb-8939-3a5d9b70d20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da4f2037-7795-46eb-8939-3a5d9b70d20e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_2c90bb95-5242-4dde-a316-5abfefdf6298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_2c90bb95-5242-4dde-a316-5abfefdf6298" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_8008fe78-1f4f-4188-b4f5-dcd8a148d707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchaseProgramAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_8008fe78-1f4f-4188-b4f5-dcd8a148d707" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_fc800129-2dde-403f-9acf-c26856f469f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_fc800129-2dde-403f-9acf-c26856f469f5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e8c6361e-b311-410b-a968-33c51eab78e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e8c6361e-b311-410b-a968-33c51eab78e7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5bb5238-b2c5-4c04-ad7a-410c44e30cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5bb5238-b2c5-4c04-ad7a-410c44e30cd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de052b4d-8944-4549-adba-6faaa712a794" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5bb5238-b2c5-4c04-ad7a-410c44e30cd9" xlink:to="loc_srt_RangeAxis_de052b4d-8944-4549-adba-6faaa712a794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de052b4d-8944-4549-adba-6faaa712a794_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_de052b4d-8944-4549-adba-6faaa712a794" xlink:to="loc_srt_RangeMember_de052b4d-8944-4549-adba-6faaa712a794_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_733a304b-cef4-43f3-9e2c-bb3536da7c94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_de052b4d-8944-4549-adba-6faaa712a794" xlink:to="loc_srt_RangeMember_733a304b-cef4-43f3-9e2c-bb3536da7c94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a87f8ffa-d664-48e6-a727-1bb2a839fc6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_733a304b-cef4-43f3-9e2c-bb3536da7c94" xlink:to="loc_srt_MinimumMember_a87f8ffa-d664-48e6-a727-1bb2a839fc6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_874a25a5-4ddf-4172-871c-5b8c613502c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_733a304b-cef4-43f3-9e2c-bb3536da7c94" xlink:to="loc_srt_MaximumMember_874a25a5-4ddf-4172-871c-5b8c613502c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cf0f1ade-cc4c-4574-bcdb-2746a0a6ade7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5bb5238-b2c5-4c04-ad7a-410c44e30cd9" xlink:to="loc_us-gaap_AwardTypeAxis_cf0f1ade-cc4c-4574-bcdb-2746a0a6ade7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0f1ade-cc4c-4574-bcdb-2746a0a6ade7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cf0f1ade-cc4c-4574-bcdb-2746a0a6ade7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0f1ade-cc4c-4574-bcdb-2746a0a6ade7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cf0f1ade-cc4c-4574-bcdb-2746a0a6ade7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0e56d401-c4f7-4ee2-93f0-812342f513f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0e56d401-c4f7-4ee2-93f0-812342f513f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f7d816f4-d2f8-4221-a0d5-daabd8f5fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:to="loc_us-gaap_RestrictedStockMember_f7d816f4-d2f8-4221-a0d5-daabd8f5fd3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3a4a874b-e092-404a-b8b1-cf1a4a0dfed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:to="loc_us-gaap_PerformanceSharesMember_3a4a874b-e092-404a-b8b1-cf1a4a0dfed4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EmployeeStockPurchasePlanMember_63553f8f-f9b4-4ba9-b8be-d57caaac046a" xlink:href="neo-20211231.xsd#neo_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:to="loc_neo_EmployeeStockPurchasePlanMember_63553f8f-f9b4-4ba9-b8be-d57caaac046a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended" id="id69917d8258242c5a2a9f2172c3257ae_StockBasedCompensationWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b114d06-a9ac-4158-a694-f52fd2f9044a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b114d06-a9ac-4158-a694-f52fd2f9044a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_572a0ece-af9d-473b-b338-f8715a508231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_572a0ece-af9d-473b-b338-f8715a508231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2f538b75-6002-472e-8d97-cdf9dd4cec03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2f538b75-6002-472e-8d97-cdf9dd4cec03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_99a9263a-e4bf-43c7-9195-d3f2d71f474d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_99a9263a-e4bf-43c7-9195-d3f2d71f474d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_61bdbc85-e84d-4f8f-a4c1-279cc4221e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_61bdbc85-e84d-4f8f-a4c1-279cc4221e07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09dddd74-3efd-4799-9ae3-8202ee98ea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09dddd74-3efd-4799-9ae3-8202ee98ea0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_65daed04-f037-429f-a3c6-f89c1ec517c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09dddd74-3efd-4799-9ae3-8202ee98ea0a" xlink:to="loc_srt_RangeAxis_65daed04-f037-429f-a3c6-f89c1ec517c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65daed04-f037-429f-a3c6-f89c1ec517c8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_65daed04-f037-429f-a3c6-f89c1ec517c8" xlink:to="loc_srt_RangeMember_65daed04-f037-429f-a3c6-f89c1ec517c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f012454c-db92-4dd0-8822-2ed01ad18867" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_65daed04-f037-429f-a3c6-f89c1ec517c8" xlink:to="loc_srt_RangeMember_f012454c-db92-4dd0-8822-2ed01ad18867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fba12a47-51fa-42a0-86f1-b4108c5c3928" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f012454c-db92-4dd0-8822-2ed01ad18867" xlink:to="loc_srt_MinimumMember_fba12a47-51fa-42a0-86f1-b4108c5c3928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2ad287cc-e069-41b8-b6d8-b883d80bc835" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f012454c-db92-4dd0-8822-2ed01ad18867" xlink:to="loc_srt_MaximumMember_2ad287cc-e069-41b8-b6d8-b883d80bc835" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails" xlink:type="extended" id="i74606e76941b42768c504b32e9332c90_StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_54ef2f1e-d694-4f11-9e9c-1666d578a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_54ef2f1e-d694-4f11-9e9c-1666d578a5db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_8838e3aa-43e3-4190-a1e7-5443a756d5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_8838e3aa-43e3-4190-a1e7-5443a756d5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_59937940-1573-4add-abe7-9b7ebd7eb343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_59937940-1573-4add-abe7-9b7ebd7eb343" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_66ce4eb9-0509-4f80-8bf2-37072eb6883d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_66ce4eb9-0509-4f80-8bf2-37072eb6883d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c944cced-99c2-4bb0-8045-485d876e68da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c944cced-99c2-4bb0-8045-485d876e68da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c605d424-aecb-41dd-8fca-290adaccb2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c605d424-aecb-41dd-8fca-290adaccb2a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_8a21f417-7946-448f-8b49-798dfab3b66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_8a21f417-7946-448f-8b49-798dfab3b66f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_3dd35e28-70a3-473f-a0ad-e2b0ce170c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_3dd35e28-70a3-473f-a0ad-e2b0ce170c31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5276962a-6913-424d-8501-706f056c525a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5276962a-6913-424d-8501-706f056c525a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c792b415-e150-40b3-b4bb-ae57cd46d974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5276962a-6913-424d-8501-706f056c525a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c792b415-e150-40b3-b4bb-ae57cd46d974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c792b415-e150-40b3-b4bb-ae57cd46d974_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c792b415-e150-40b3-b4bb-ae57cd46d974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c792b415-e150-40b3-b4bb-ae57cd46d974_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c792b415-e150-40b3-b4bb-ae57cd46d974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeOneMember_298e67c0-dfc8-4b5e-a76a-641138b50fea" xlink:href="neo-20211231.xsd#neo_RangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeOneMember_298e67c0-dfc8-4b5e-a76a-641138b50fea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeTwoMember_f1cfb7cb-7836-4880-8cc7-2fd59f307da8" xlink:href="neo-20211231.xsd#neo_RangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeTwoMember_f1cfb7cb-7836-4880-8cc7-2fd59f307da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeThreeMember_166f4bb7-3365-4b10-a484-b20723d2fd03" xlink:href="neo-20211231.xsd#neo_RangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeThreeMember_166f4bb7-3365-4b10-a484-b20723d2fd03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeFourMember_81e8f163-2a5b-49ad-a7cc-c7f309a25040" xlink:href="neo-20211231.xsd#neo_RangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeFourMember_81e8f163-2a5b-49ad-a7cc-c7f309a25040" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeFiveMember_82e445f8-d1ea-4412-b753-7e6d3e3ab079" xlink:href="neo-20211231.xsd#neo_RangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeFiveMember_82e445f8-d1ea-4412-b753-7e6d3e3ab079" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended" id="iefcec092b9a5472185c4e4e0dbf46c77_StockBasedCompensationSummaryofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dba1621-b9ee-4822-ae3f-0781eb8971fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dba1621-b9ee-4822-ae3f-0781eb8971fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6b2182d-1ab3-4f36-a905-8c9f95fef9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6b2182d-1ab3-4f36-a905-8c9f95fef9e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10e8d0e1-b9f2-46e8-97bd-9c0778cf2bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10e8d0e1-b9f2-46e8-97bd-9c0778cf2bbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8a776866-8c73-4419-bf03-8108363a7c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8a776866-8c73-4419-bf03-8108363a7c56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8dc8ee18-7a24-496e-8630-3a5b2451867d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8dc8ee18-7a24-496e-8630-3a5b2451867d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cb164a14-1bd3-42a3-b6ae-2b748c0a92ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dba1621-b9ee-4822-ae3f-0781eb8971fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_099f2b30-e84d-4f59-a326-65bd17604c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_099f2b30-e84d-4f59-a326-65bd17604c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_395cc04c-a5fa-40b3-a639-5abb4f554cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_395cc04c-a5fa-40b3-a639-5abb4f554cba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5bba3b7f-7ce6-48f3-866c-075a6b4876d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5bba3b7f-7ce6-48f3-866c-075a6b4876d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6a30e2e4-c61b-4ec5-b0f8-09cd17448393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6a30e2e4-c61b-4ec5-b0f8-09cd17448393" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636716a3-69e4-490f-85cb-8a47d512f772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_727e6977-86f6-4923-a6b3-036eda49affa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dba1621-b9ee-4822-ae3f-0781eb8971fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_727e6977-86f6-4923-a6b3-036eda49affa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_447f9d1f-ad34-46f4-88e1-7c7441615f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_727e6977-86f6-4923-a6b3-036eda49affa" xlink:to="loc_us-gaap_AwardTypeAxis_447f9d1f-ad34-46f4-88e1-7c7441615f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_447f9d1f-ad34-46f4-88e1-7c7441615f87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_447f9d1f-ad34-46f4-88e1-7c7441615f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_447f9d1f-ad34-46f4-88e1-7c7441615f87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b411009-9bc0-4c38-9511-4053559d448b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_447f9d1f-ad34-46f4-88e1-7c7441615f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b411009-9bc0-4c38-9511-4053559d448b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_26d498fd-ddf1-4cca-a8b2-ddaccfa503e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b411009-9bc0-4c38-9511-4053559d448b" xlink:to="loc_us-gaap_RestrictedStockMember_26d498fd-ddf1-4cca-a8b2-ddaccfa503e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="i0ab007501d6643e99dcd67fc008d3f2a_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a66c4b47-86d2-4770-a4e0-e16df366cc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_969fe6f6-799e-406e-82b2-121331d9c781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a66c4b47-86d2-4770-a4e0-e16df366cc5d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_969fe6f6-799e-406e-82b2-121331d9c781" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b1aec17a-feb2-4cd0-862e-d31a99415e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a66c4b47-86d2-4770-a4e0-e16df366cc5d" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b1aec17a-feb2-4cd0-862e-d31a99415e54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eaaceeb8-001d-41a9-a57d-9fcfe8e619d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b1aec17a-feb2-4cd0-862e-d31a99415e54" xlink:to="loc_srt_ProductOrServiceAxis_eaaceeb8-001d-41a9-a57d-9fcfe8e619d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eaaceeb8-001d-41a9-a57d-9fcfe8e619d9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_eaaceeb8-001d-41a9-a57d-9fcfe8e619d9" xlink:to="loc_srt_ProductsAndServicesDomain_eaaceeb8-001d-41a9-a57d-9fcfe8e619d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_eaaceeb8-001d-41a9-a57d-9fcfe8e619d9" xlink:to="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClientDirectBillingMember_a1eb93cf-93cf-4f48-a789-799410683cd7" xlink:href="neo-20211231.xsd#neo_ClientDirectBillingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:to="loc_neo_ClientDirectBillingMember_a1eb93cf-93cf-4f48-a789-799410683cd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommercialInsuranceMember_e1ba4c4c-4f59-449f-ae39-992dc8568fac" xlink:href="neo-20211231.xsd#neo_CommercialInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:to="loc_neo_CommercialInsuranceMember_e1ba4c4c-4f59-449f-ae39-992dc8568fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_MedicareAndMedicaidMember_1455f59e-b0fe-4943-8baa-92644d3d7744" xlink:href="neo-20211231.xsd#neo_MedicareAndMedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:to="loc_neo_MedicareAndMedicaidMember_1455f59e-b0fe-4943-8baa-92644d3d7744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SelfPayServicesMember_bd536ac4-6e32-46ff-ab38-a2797b854a03" xlink:href="neo-20211231.xsd#neo_SelfPayServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:to="loc_neo_SelfPayServicesMember_bd536ac4-6e32-46ff-ab38-a2797b854a03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_778bff53-faba-4f99-a9ff-add947e5ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b1aec17a-feb2-4cd0-862e-d31a99415e54" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_778bff53-faba-4f99-a9ff-add947e5ce5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_778bff53-faba-4f99-a9ff-add947e5ce5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_778bff53-faba-4f99-a9ff-add947e5ce5d" xlink:to="loc_us-gaap_SegmentDomain_778bff53-faba-4f99-a9ff-add947e5ce5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c46ac12d-f5c7-4f9a-b077-d4256adee27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_778bff53-faba-4f99-a9ff-add947e5ce5d" xlink:to="loc_us-gaap_SegmentDomain_c46ac12d-f5c7-4f9a-b077-d4256adee27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_56a26acd-90a0-47fd-9db8-60dbbb81ec8a" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c46ac12d-f5c7-4f9a-b077-d4256adee27e" xlink:to="loc_neo_ClinicalServicesMember_56a26acd-90a0-47fd-9db8-60dbbb81ec8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_14a6b6a6-c534-4f46-ad2e-4de86f9c25c2" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c46ac12d-f5c7-4f9a-b077-d4256adee27e" xlink:to="loc_neo_PharmaServicesMember_14a6b6a6-c534-4f46-ad2e-4de86f9c25c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails" xlink:type="extended" id="i637665bb8ebd4884b6043df5d5ea3164_IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f029e03-8088-4c83-89b8-8500cac08dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f029e03-8088-4c83-89b8-8500cac08dfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bc8ef726-7352-4f94-8672-e5955f777426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bc8ef726-7352-4f94-8672-e5955f777426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a11e2ff7-8a66-4c32-83f0-1869fa9a9205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a11e2ff7-8a66-4c32-83f0-1869fa9a9205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a81fe836-357e-43a2-9f44-b096e394b1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a81fe836-357e-43a2-9f44-b096e394b1a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7f1d4bba-91da-417a-8741-c408e88b2366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7f1d4bba-91da-417a-8741-c408e88b2366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f99a0891-48eb-46e8-afc7-ce8267686099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f99a0891-48eb-46e8-afc7-ce8267686099" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ba2e4ece-8d4a-48bd-b406-80713eecf49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ba2e4ece-8d4a-48bd-b406-80713eecf49d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ef80f86e-6fc6-47a4-b70e-0ef18c0eeb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ef80f86e-6fc6-47a4-b70e-0ef18c0eeb0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4acb3f55-3dcd-45e2-994a-93063e8c8ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4acb3f55-3dcd-45e2-994a-93063e8c8ac2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b15faf44-105c-47be-ba73-a655bb4b7381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b15faf44-105c-47be-ba73-a655bb4b7381" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e61e227b-4758-4709-81a8-d908ec960abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b15faf44-105c-47be-ba73-a655bb4b7381" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e61e227b-4758-4709-81a8-d908ec960abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e61e227b-4758-4709-81a8-d908ec960abe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e61e227b-4758-4709-81a8-d908ec960abe" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e61e227b-4758-4709-81a8-d908ec960abe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0297fe40-edd9-4613-bf8f-7a6925438c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e61e227b-4758-4709-81a8-d908ec960abe" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0297fe40-edd9-4613-bf8f-7a6925438c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a2384d61-29a5-44ee-9eb4-f84c2572c927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0297fe40-edd9-4613-bf8f-7a6925438c00" xlink:to="loc_us-gaap_DomesticCountryMember_a2384d61-29a5-44ee-9eb4-f84c2572c927" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_8764f39e-583f-4e0e-97e5-12f1e5093fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0297fe40-edd9-4613-bf8f-7a6925438c00" xlink:to="loc_us-gaap_ForeignCountryMember_8764f39e-583f-4e0e-97e5-12f1e5093fbf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i73e9617f59fe4e988159c309e9f9ce36_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:href="neo-20211231.xsd#neo_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_86dc23ec-7da7-4c3a-a3cb-dd89d60f5a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_86dc23ec-7da7-4c3a-a3cb-dd89d60f5a3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_9324ae8f-e118-43ee-b672-1ba837da96ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_9324ae8f-e118-43ee-b672-1ba837da96ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_5cfa66af-46d1-47c0-adde-a541387f119c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_5cfa66af-46d1-47c0-adde-a541387f119c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b8f1f3a4-7116-4afd-a147-b4a062b98568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b8f1f3a4-7116-4afd-a147-b4a062b98568" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncomeTaxesTable_66897163-43a3-49ec-9a0f-1c8d9ca4684b" xlink:href="neo-20211231.xsd#neo_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:to="loc_neo_IncomeTaxesTable_66897163-43a3-49ec-9a0f-1c8d9ca4684b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2b7c2396-f7e7-4c90-b7ca-460dbe98060b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_IncomeTaxesTable_66897163-43a3-49ec-9a0f-1c8d9ca4684b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2b7c2396-f7e7-4c90-b7ca-460dbe98060b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2b7c2396-f7e7-4c90-b7ca-460dbe98060b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2b7c2396-f7e7-4c90-b7ca-460dbe98060b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2b7c2396-f7e7-4c90-b7ca-460dbe98060b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2b7c2396-f7e7-4c90-b7ca-460dbe98060b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_f8488b18-0e2b-41e2-8992-a9b69970e6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:to="loc_us-gaap_ForeignCountryMember_f8488b18-0e2b-41e2-8992-a9b69970e6b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f1de8fe8-cef9-42fb-92a9-cf32c67143c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f1de8fe8-cef9-42fb-92a9-cf32c67143c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_300b1450-3c70-43dd-a1b2-f84b3e997973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_300b1450-3c70-43dd-a1b2-f84b3e997973" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1df9835c-7c7c-4314-ab36-78f1cdfeb717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_IncomeTaxesTable_66897163-43a3-49ec-9a0f-1c8d9ca4684b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1df9835c-7c7c-4314-ab36-78f1cdfeb717" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1df9835c-7c7c-4314-ab36-78f1cdfeb717_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1df9835c-7c7c-4314-ab36-78f1cdfeb717" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1df9835c-7c7c-4314-ab36-78f1cdfeb717_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc36fdbe-2b9f-484f-be2e-bc455a609259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1df9835c-7c7c-4314-ab36-78f1cdfeb717" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc36fdbe-2b9f-484f-be2e-bc455a609259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HerMajestysRevenueAndCustomsHMRCMember_701483a2-0681-4d93-affd-06034548d4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HerMajestysRevenueAndCustomsHMRCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc36fdbe-2b9f-484f-be2e-bc455a609259" xlink:to="loc_us-gaap_HerMajestysRevenueAndCustomsHMRCMember_701483a2-0681-4d93-affd-06034548d4ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended" id="i79c94eb93ccc4010b50c885b7257f625_NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8486e4d0-453a-42b1-a792-25cc20537adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8486e4d0-453a-42b1-a792-25cc20537adb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3a91003-6d17-4a7f-86e5-3ada5dad7bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3a91003-6d17-4a7f-86e5-3ada5dad7bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d3fb6b51-b8e3-453a-ae61-9a65b49e4c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d3fb6b51-b8e3-453a-ae61-9a65b49e4c96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4cefa21b-268a-4f74-a8d3-81066ccc396c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4cefa21b-268a-4f74-a8d3-81066ccc396c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_62c9a536-1def-42eb-9105-369b5d9ca12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_62c9a536-1def-42eb-9105-369b5d9ca12a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9e51fd6b-c590-4561-a5fe-9061147a335a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9e51fd6b-c590-4561-a5fe-9061147a335a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_e8a856a7-c90d-4f17-ac35-0fe0004f64d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_e8a856a7-c90d-4f17-ac35-0fe0004f64d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9b1858b0-9515-4fed-917d-48d5bd9e3438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_e8a856a7-c90d-4f17-ac35-0fe0004f64d5" xlink:to="loc_us-gaap_AwardTypeAxis_9b1858b0-9515-4fed-917d-48d5bd9e3438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b1858b0-9515-4fed-917d-48d5bd9e3438_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9b1858b0-9515-4fed-917d-48d5bd9e3438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b1858b0-9515-4fed-917d-48d5bd9e3438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8eca6e-db66-438e-8089-5057515a9545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9b1858b0-9515-4fed-917d-48d5bd9e3438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8eca6e-db66-438e-8089-5057515a9545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_62343888-dc95-426a-ab49-a7443cad9d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8eca6e-db66-438e-8089-5057515a9545" xlink:to="loc_us-gaap_EmployeeStockMember_62343888-dc95-426a-ab49-a7443cad9d73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_610054ae-84a6-42cf-9f9a-cefac1e47b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8eca6e-db66-438e-8089-5057515a9545" xlink:to="loc_us-gaap_RestrictedStockMember_610054ae-84a6-42cf-9f9a-cefac1e47b6e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails" xlink:type="extended" id="i9cf6e93a400b4367871770d7adfb6a3d_NetLossIncomeperShareScheduleofAntidilutiveSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_115c32fe-3be9-44f2-a2c6-5e6b3791b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5e8f3bb-2e98-4b57-b796-a9cc095298cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_115c32fe-3be9-44f2-a2c6-5e6b3791b7e1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5e8f3bb-2e98-4b57-b796-a9cc095298cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f28b284e-c28f-4329-96d9-741a3c6407f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_115c32fe-3be9-44f2-a2c6-5e6b3791b7e1" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f28b284e-c28f-4329-96d9-741a3c6407f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_115c32fe-3be9-44f2-a2c6-5e6b3791b7e1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_459f5964-6e26-49c4-8b8c-0244f2dea0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_459f5964-6e26-49c4-8b8c-0244f2dea0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_459f5964-6e26-49c4-8b8c-0244f2dea0ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_459f5964-6e26-49c4-8b8c-0244f2dea0ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_459f5964-6e26-49c4-8b8c-0244f2dea0ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_459f5964-6e26-49c4-8b8c-0244f2dea0ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_311d12b9-b45c-499b-a905-9b6fc1ef29dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:to="loc_us-gaap_EmployeeStockMember_311d12b9-b45c-499b-a905-9b6fc1ef29dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0eee2399-193d-418c-bdbb-06e17e4e1152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:to="loc_us-gaap_RestrictedStockMember_0eee2399-193d-418c-bdbb-06e17e4e1152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_6c4915e1-f5dd-4e54-a4b9-e3b74c622dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_6c4915e1-f5dd-4e54-a4b9-e3b74c622dbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aef538e8-92c3-4859-9b5f-0ad2a9cc6a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:to="loc_us-gaap_DebtInstrumentAxis_aef538e8-92c3-4859-9b5f-0ad2a9cc6a98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aef538e8-92c3-4859-9b5f-0ad2a9cc6a98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_aef538e8-92c3-4859-9b5f-0ad2a9cc6a98" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aef538e8-92c3-4859-9b5f-0ad2a9cc6a98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b347127-3929-406f-8784-3a08c2f383a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_aef538e8-92c3-4859-9b5f-0ad2a9cc6a98" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b347127-3929-406f-8784-3a08c2f383a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_23a29394-e65f-4563-8b5b-0cff5c611790" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b347127-3929-406f-8784-3a08c2f383a7" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_23a29394-e65f-4563-8b5b-0cff5c611790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_81c545d8-2043-4f22-a04a-412434ed4c84" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b347127-3929-406f-8784-3a08c2f383a7" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_81c545d8-2043-4f22-a04a-412434ed4c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_26680942-0e21-4ef3-baba-72595e83a75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_26680942-0e21-4ef3-baba-72595e83a75c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26680942-0e21-4ef3-baba-72595e83a75c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_26680942-0e21-4ef3-baba-72595e83a75c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26680942-0e21-4ef3-baba-72595e83a75c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_527f9985-e87f-43cf-81ab-07a837636e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_26680942-0e21-4ef3-baba-72595e83a75c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_527f9985-e87f-43cf-81ab-07a837636e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember_5eb886da-178a-4366-b878-dad866f3d690" xlink:href="neo-20211231.xsd#neo_CappedCallTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_527f9985-e87f-43cf-81ab-07a837636e8e" xlink:to="loc_neo_CappedCallTransactionsMember_5eb886da-178a-4366-b878-dad866f3d690" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i706fb13ef7984c9b9681af5a11d851b7_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7ebfdbbf-b956-4127-a68b-33fb561dd841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_ee962656-a293-402a-94bb-25f81448cce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7ebfdbbf-b956-4127-a68b-33fb561dd841" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_ee962656-a293-402a-94bb-25f81448cce2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_5a66d273-4374-4f39-b175-9b467c2fd46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7ebfdbbf-b956-4127-a68b-33fb561dd841" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_5a66d273-4374-4f39-b175-9b467c2fd46e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bc051d4d-1417-46ed-a3af-b52a47950b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7ebfdbbf-b956-4127-a68b-33fb561dd841" xlink:to="loc_us-gaap_LossContingenciesTable_bc051d4d-1417-46ed-a3af-b52a47950b08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a4bdc366-ea91-4621-bdcd-f828c4bebfba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bc051d4d-1417-46ed-a3af-b52a47950b08" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a4bdc366-ea91-4621-bdcd-f828c4bebfba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_a4bdc366-ea91-4621-bdcd-f828c4bebfba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a4bdc366-ea91-4621-bdcd-f828c4bebfba" xlink:to="loc_us-gaap_LossContingencyNatureDomain_a4bdc366-ea91-4621-bdcd-f828c4bebfba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d1f651a9-8e2f-42f8-8d91-17a7e4dd97a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a4bdc366-ea91-4621-bdcd-f828c4bebfba" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d1f651a9-8e2f-42f8-8d91-17a7e4dd97a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PatentInfringementComplaintMember_229a04ba-bd37-4e7f-811b-ac9a4fd55a04" xlink:href="neo-20211231.xsd#neo_PatentInfringementComplaintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d1f651a9-8e2f-42f8-8d91-17a7e4dd97a5" xlink:to="loc_neo_PatentInfringementComplaintMember_229a04ba-bd37-4e7f-811b-ac9a4fd55a04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FederalHealthcareProgramRevenueMember_7db5d699-0f4c-4441-8fd0-cdfbdf581ee3" xlink:href="neo-20211231.xsd#neo_FederalHealthcareProgramRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d1f651a9-8e2f-42f8-8d91-17a7e4dd97a5" xlink:to="loc_neo_FederalHealthcareProgramRevenueMember_7db5d699-0f4c-4441-8fd0-cdfbdf581ee3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="ie456058415b048cc90fba81abd904d4e_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_14b0f728-50ff-4908-842a-116e012b936d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_14b0f728-50ff-4908-842a-116e012b936d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bb9fefbb-e2da-4534-beb1-5967fd03ec27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bb9fefbb-e2da-4534-beb1-5967fd03ec27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f26f76ac-7a87-47b5-981c-af91dd7da2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:to="loc_us-gaap_LongTermDebt_f26f76ac-7a87-47b5-981c-af91dd7da2b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9100ad44-45ff-4c3c-8591-781a427e5c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9100ad44-45ff-4c3c-8591-781a427e5c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9100ad44-45ff-4c3c-8591-781a427e5c2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9100ad44-45ff-4c3c-8591-781a427e5c2e" xlink:to="loc_us-gaap_RelatedPartyDomain_9100ad44-45ff-4c3c-8591-781a427e5c2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0b4c9f4d-47c4-416e-8c48-130cffc35fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9100ad44-45ff-4c3c-8591-781a427e5c2e" xlink:to="loc_us-gaap_RelatedPartyDomain_0b4c9f4d-47c4-416e-8c48-130cffc35fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b4135be7-bdf5-42dd-833d-dbc7f7d32742" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0b4c9f4d-47c4-416e-8c48-130cffc35fff" xlink:to="loc_srt_AffiliatedEntityMember_b4135be7-bdf5-42dd-833d-dbc7f7d32742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4faae8df-42e1-49d1-a7ea-78b4ff7c0550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4faae8df-42e1-49d1-a7ea-78b4ff7c0550" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4faae8df-42e1-49d1-a7ea-78b4ff7c0550_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4faae8df-42e1-49d1-a7ea-78b4ff7c0550" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4faae8df-42e1-49d1-a7ea-78b4ff7c0550_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_bd934564-0f51-4097-963e-7572817d49db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4faae8df-42e1-49d1-a7ea-78b4ff7c0550" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_bd934564-0f51-4097-963e-7572817d49db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StrategicAllianceWithInivataLimitedMember_6adeacd8-cc1d-433c-82ef-5dcf826ea745" xlink:href="neo-20211231.xsd#neo_StrategicAllianceWithInivataLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_bd934564-0f51-4097-963e-7572817d49db" xlink:to="loc_neo_StrategicAllianceWithInivataLimitedMember_6adeacd8-cc1d-433c-82ef-5dcf826ea745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e03a8ada-9671-4be9-96c9-12a86c1b1cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:to="loc_us-gaap_CreditFacilityAxis_e03a8ada-9671-4be9-96c9-12a86c1b1cfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e03a8ada-9671-4be9-96c9-12a86c1b1cfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e03a8ada-9671-4be9-96c9-12a86c1b1cfb" xlink:to="loc_us-gaap_CreditFacilityDomain_e03a8ada-9671-4be9-96c9-12a86c1b1cfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c87f8eea-3153-4dba-83ed-3d85f4aec428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e03a8ada-9671-4be9-96c9-12a86c1b1cfb" xlink:to="loc_us-gaap_CreditFacilityDomain_c87f8eea-3153-4dba-83ed-3d85f4aec428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1543adbe-6af5-4877-b226-acd19544780c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c87f8eea-3153-4dba-83ed-3d85f4aec428" xlink:to="loc_us-gaap_LineOfCreditMember_1543adbe-6af5-4877-b226-acd19544780c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#SegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="extended" id="i9c5b10bc4d61486387654825aae105bb_SegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f83e7e7b-da6a-4307-bd0b-3c56516d29f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f83e7e7b-da6a-4307-bd0b-3c56516d29f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7f9369bc-6071-470d-8fc0-15cd8199f86e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_RevenuesAbstract_7f9369bc-6071-470d-8fc0-15cd8199f86e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e9e33ebb-ad86-429e-ab75-561b21b7d613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7f9369bc-6071-470d-8fc0-15cd8199f86e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e9e33ebb-ad86-429e-ab75-561b21b7d613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_3fd3328b-7dd7-48ce-bc65-6cde025b098f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_3fd3328b-7dd7-48ce-bc65-6cde025b098f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b58ad66e-ddd2-4cd6-909a-88b111cfac67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_3fd3328b-7dd7-48ce-bc65-6cde025b098f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b58ad66e-ddd2-4cd6-909a-88b111cfac67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract_06eeee77-832f-4ac2-8f53-a2f9bed6bcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfitAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_GrossProfitAbstract_06eeee77-832f-4ac2-8f53-a2f9bed6bcc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4e222efb-a4a0-4e7b-99fc-102282e97bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GrossProfitAbstract_06eeee77-832f-4ac2-8f53-a2f9bed6bcc6" xlink:to="loc_us-gaap_GrossProfit_4e222efb-a4a0-4e7b-99fc-102282e97bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_030c6946-ee2a-4332-babb-24363595d85e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_030c6946-ee2a-4332-babb-24363595d85e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d89be29f-eb93-4405-a603-cfc657377763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d89be29f-eb93-4405-a603-cfc657377763" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_5f4c690f-6aaf-4804-84e5-9b108a0f4347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:to="loc_us-gaap_SellingAndMarketingExpense_5f4c690f-6aaf-4804-84e5-9b108a0f4347" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_628fa532-208f-43db-a508-162d4b035c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:to="loc_us-gaap_OperatingExpenses_628fa532-208f-43db-a508-162d4b035c3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3b188d7b-48ee-4b6d-9c67-7fa6f061772b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_OperatingIncomeLoss_3b188d7b-48ee-4b6d-9c67-7fa6f061772b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_525c7944-2430-459f-9773-0dc1956adca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_InterestExpense_525c7944-2430-459f-9773-0dc1956adca0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b1ee1c80-6f49-461e-8b01-31078b5622d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b1ee1c80-6f49-461e-8b01-31078b5622d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable_2b573543-5c1e-49d6-a371-79d116b90fa3" xlink:href="neo-20211231.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_neo_GainLossOnInvestmentAndLoanReceivable_2b573543-5c1e-49d6-a371-79d116b90fa3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df615bc6-0844-44e1-adbc-43a458a5cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df615bc6-0844-44e1-adbc-43a458a5cdd7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnTerminationOfInterestRateSwap_8198aecc-781d-455e-a23e-6f458022424f" xlink:href="neo-20211231.xsd#neo_GainLossOnTerminationOfInterestRateSwap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_neo_GainLossOnTerminationOfInterestRateSwap_8198aecc-781d-455e-a23e-6f458022424f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_926adc5a-1cfa-4fce-a86f-8b6c970ababb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_926adc5a-1cfa-4fce-a86f-8b6c970ababb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_29f49142-a621-44b3-b62e-84806d3c6f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_29f49142-a621-44b3-b62e-84806d3c6f7b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99a0a7f6-2ac2-4078-ba30-45e5fd767551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_NetIncomeLoss_99a0a7f6-2ac2-4078-ba30-45e5fd767551" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac619675-8264-4e2e-9333-1b4c96d424e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac619675-8264-4e2e-9333-1b4c96d424e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_facccb04-bcb5-4e94-ba84-2fb37cdb3df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac619675-8264-4e2e-9333-1b4c96d424e8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_facccb04-bcb5-4e94-ba84-2fb37cdb3df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_facccb04-bcb5-4e94-ba84-2fb37cdb3df2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_facccb04-bcb5-4e94-ba84-2fb37cdb3df2" xlink:to="loc_us-gaap_SegmentDomain_facccb04-bcb5-4e94-ba84-2fb37cdb3df2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_355b9017-46f6-469c-9c0b-f50ddfbe0a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_facccb04-bcb5-4e94-ba84-2fb37cdb3df2" xlink:to="loc_us-gaap_SegmentDomain_355b9017-46f6-469c-9c0b-f50ddfbe0a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesSegmentMember_7197ef21-1bc1-42f3-b36b-3eca000609af" xlink:href="neo-20211231.xsd#neo_ClinicalServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_355b9017-46f6-469c-9c0b-f50ddfbe0a2d" xlink:to="loc_neo_ClinicalServicesSegmentMember_7197ef21-1bc1-42f3-b36b-3eca000609af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesSegmentMember_9eee3696-707e-4bba-8ba2-4e6036948acb" xlink:href="neo-20211231.xsd#neo_PharmaServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_355b9017-46f6-469c-9c0b-f50ddfbe0a2d" xlink:to="loc_neo_PharmaServicesSegmentMember_9eee3696-707e-4bba-8ba2-4e6036948acb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d16e97b-3c53-444f-95b6-4142cb120ad1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac619675-8264-4e2e-9333-1b4c96d424e8" xlink:to="loc_srt_ProductOrServiceAxis_5d16e97b-3c53-444f-95b6-4142cb120ad1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d16e97b-3c53-444f-95b6-4142cb120ad1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5d16e97b-3c53-444f-95b6-4142cb120ad1" xlink:to="loc_srt_ProductsAndServicesDomain_5d16e97b-3c53-444f-95b6-4142cb120ad1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b9e04fc-b771-40e6-ba5d-8aea15458a4f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5d16e97b-3c53-444f-95b6-4142cb120ad1" xlink:to="loc_srt_ProductsAndServicesDomain_1b9e04fc-b771-40e6-ba5d-8aea15458a4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember_92b5c685-f72e-4adb-97b2-5889b8ebfab3" xlink:href="neo-20211231.xsd#neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1b9e04fc-b771-40e6-ba5d-8aea15458a4f" xlink:to="loc_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember_92b5c685-f72e-4adb-97b2-5889b8ebfab3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WriteOffForCOVID19PCRTestingInventoryMember_c281e93d-581e-49b0-82e8-5fb15b6ff118" xlink:href="neo-20211231.xsd#neo_WriteOffForCOVID19PCRTestingInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1b9e04fc-b771-40e6-ba5d-8aea15458a4f" xlink:to="loc_neo_WriteOffForCOVID19PCRTestingInventoryMember_c281e93d-581e-49b0-82e8-5fb15b6ff118" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>neo-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c83854c7-f1f3-424f-996d-5603fac85cdc,g:4d64aeee-8493-464d-9030-1629fa1fd3ef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber_a27bd0a3-a55c-4e7f-bab3-10af24582471_verboseLabel_en-US" xlink:label="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding and exercisable (in shares)</link:label>
    <link:label id="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber_label_en-US" xlink:label="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Number</link:label>
    <link:label id="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber_documentation_en-US" xlink:label="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of in-the-money options outstanding and exercisable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber" xlink:href="neo-20211231.xsd#neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber" xlink:to="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_16918352-7027-4910-89b3-c2b5faa58fc7_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e71dbc6c-0b49-4205-ad35-961c5e3505c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_210e3db7-9af8-4cf9-8451-8e883687d2bd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent_9e0d2710-1d7f-42f0-b300-c789435f0d34_verboseLabel_en-US" xlink:label="lab_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional percentage of compensation subject to matching contribution (as a percent)</link:label>
    <link:label id="lab_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent_label_en-US" xlink:label="lab_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Employer Matching Additional Contribution Upon Employee Percent</link:label>
    <link:label id="lab_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent_documentation_en-US" xlink:label="lab_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan employer matching additional contribution upon employee percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent" xlink:href="neo-20211231.xsd#neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent" xlink:to="lab_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_bbf3fa7c-e8fc-43db-93b2-d64152094ce4_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7f91723e-fd48-484a-8ff2-5c7e74786247_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, at fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a81b0c3c-21c6-4887-94fe-34b82d521465_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3e27bf8-67d7-45bf-ac96-a2ca2a88e799_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_71b416f6-14fc-471b-b3dc-a5334fddaed7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1590952a-9876-415c-93ec-e4fbcc0dbea3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ScheduleOfSignificantAccountingPoliciesLineItems_96c13b8d-c8bc-48dc-8c78-0617e0668b87_verboseLabel_en-US" xlink:label="lab_neo_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_neo_ScheduleOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_neo_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_neo_ScheduleOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_neo_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:href="neo-20211231.xsd#neo_ScheduleOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="lab_neo_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SaleOfStockOptionTerm_2fe3af12-0eaf-4cb4-b141-f3eee3f53cf9_terseLabel_en-US" xlink:label="lab_neo_SaleOfStockOptionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, option term</link:label>
    <link:label id="lab_neo_SaleOfStockOptionTerm_label_en-US" xlink:label="lab_neo_SaleOfStockOptionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Option, Term</link:label>
    <link:label id="lab_neo_SaleOfStockOptionTerm_documentation_en-US" xlink:label="lab_neo_SaleOfStockOptionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Option, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SaleOfStockOptionTerm" xlink:href="neo-20211231.xsd#neo_SaleOfStockOptionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SaleOfStockOptionTerm" xlink:to="lab_neo_SaleOfStockOptionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5a43e762-cdab-4897-bc82-24462fd55d3b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_30832696-3382-4f83-8e61-bb3632410889_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c9ae6cf4-90e5-46b5-ae3b-cb72cde9978f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b698e3e7-990b-434f-b0a6-eb44e9f8b329_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8f4af450-897a-49e3-8c11-fc8d342cbb90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_70f9a0f2-474b-4658-b18e-0c764b569461_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_cfb1cb66-b0a3-4ace-bbba-94ca7815d3f9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_WorkingCapitalAdjustmentAcquisitionShares_638c9315-d134-490f-ac13-4b43dabf182e_negatedTerseLabel_en-US" xlink:label="lab_neo_WorkingCapitalAdjustmentAcquisitionShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital adjustment related to acquisition (in shares)</link:label>
    <link:label id="lab_neo_WorkingCapitalAdjustmentAcquisitionShares_label_en-US" xlink:label="lab_neo_WorkingCapitalAdjustmentAcquisitionShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Adjustment, Acquisition, Shares</link:label>
    <link:label id="lab_neo_WorkingCapitalAdjustmentAcquisitionShares_documentation_en-US" xlink:label="lab_neo_WorkingCapitalAdjustmentAcquisitionShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Adjustment, Acquisition, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WorkingCapitalAdjustmentAcquisitionShares" xlink:href="neo-20211231.xsd#neo_WorkingCapitalAdjustmentAcquisitionShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_WorkingCapitalAdjustmentAcquisitionShares" xlink:to="lab_neo_WorkingCapitalAdjustmentAcquisitionShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5fe490a4-4583-4ac3-9a9f-ca507bc18338_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2eefb351-9f87-4c6e-a626-a8e2f8bf5f3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ccecfce4-7652-49ad-b33a-17dce5b4735e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ff1c7dd6-6633-4f8b-b297-e30b24e82c8d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent_47b2e108-ab08-46d3-b193-333ed1fe45f9_terseLabel_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits (as a percent)</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent_label_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Tax Credits, Percent</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent_documentation_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Tax Credits, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" xlink:to="lab_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b454df39-fecc-4b25-9c02-7e8d88725259_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings_b594a396-bd75-41fd-9e86-c3a6b32fa7a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporary impairment losses</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Portion Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_65b500d5-acd4-4b76-b91c-ccc006f4e7f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_febf688c-8e44-4dec-b368-691bbaa9e6b8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised during period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_48dab871-142c-4da3-8ce9-b7cbacb663ce_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_aa69f156-ea9c-425e-8e4c-e2d94283a342_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices, lower limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_dcf318cc-7e5d-48da-b677-b24f21284c8c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_57ab200d-5fec-4b80-a45d-af502bde1326_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0faa5d40-748c-4cff-bf3f-0b477e05bbc2_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_853a1643-e070-46b3-aae2-f86411a197c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_68a24316-b493-4cd5-98dc-fc91ff9333c7_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d38bac64-9dbf-46b0-85a0-0a5e54e1ae6f_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from EPS calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8891f956-39a5-49df-9fd8-fe0f7bf6c245_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e83ff280-3d4e-4373-a5c6-b05c2d44eab4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma contract liability, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_67edb383-d19d-487e-ba36-d3ee7aa77e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_365295ba-d093-4737-9bb6-66c87544cf16_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_429557f7-706e-43bf-91b7-80a7b102972c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_49fe02d6-0a94-4f57-be37-579d32cb525b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_4d25430f-6c54-4f35-8883-fc47958c388a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_b00dfe97-9aaa-4518-b80f-fe7153efc50d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_0ff2726c-c071-4841-a969-4a56123f160b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b76e5e7-f86a-4b90-a448-8cb1bed280e1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97b9555d-203b-45cd-bad0-fff44cbc7869_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_599fd1c7-60b7-4624-a26e-ddaf79d43150_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_9ee20af3-6665-4154-8a43-0bd28ddecf44_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4c579e56-1927-442a-b48b-6d091a2941d3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0a1b2137-69bd-42ee-976a-b8a0e0d15534_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_08936843-62d0-4b37-ae34-fc247de3cb1b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_846bb9d2-ec91-49f5-b8a2-4cc5e903bfae_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_394ac1bc-08c3-4025-9803-3dc8fe0a02fd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_DerivativeTerminationFee_f7ceda8b-55d7-4831-a031-cfce67ed655b_negatedTerseLabel_en-US" xlink:label="lab_neo_DerivativeTerminationFee" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedge termination</link:label>
    <link:label id="lab_neo_DerivativeTerminationFee_aadc7600-f162-4d16-be88-8c130a5a5e2c_terseLabel_en-US" xlink:label="lab_neo_DerivativeTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination fee</link:label>
    <link:label id="lab_neo_DerivativeTerminationFee_label_en-US" xlink:label="lab_neo_DerivativeTerminationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Termination Fee</link:label>
    <link:label id="lab_neo_DerivativeTerminationFee_documentation_en-US" xlink:label="lab_neo_DerivativeTerminationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DerivativeTerminationFee" xlink:href="neo-20211231.xsd#neo_DerivativeTerminationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_DerivativeTerminationFee" xlink:to="lab_neo_DerivativeTerminationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_10c74773-6b3e-4ecd-86cf-5f8e2d89aa75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_a3e644e9-58d0-4547-b712-fdbdfcfac3e4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_1c39d3b2-341e-4c74-8f73-a83d87ba6775_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, fair value of previously-held equity interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_853d6bda-7d23-4bc9-821b-07064302ae89_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition_a312f65b-dace-4438-86d1-a6b5c9ddcde6_terseLabel_en-US" xlink:label="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock issued to fund acquisition</link:label>
    <link:label id="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition_label_en-US" xlink:label="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Common Stock Issued To Fund Acquisition</link:label>
    <link:label id="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition_documentation_en-US" xlink:label="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock issued to fund acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:href="neo-20211231.xsd#neo_FairValueOfCommonStockIssuedToFundAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:to="lab_neo_FairValueOfCommonStockIssuedToFundAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination_19a81b8f-19a4-4438-ab7e-5fe65370dc4e_negatedTerseLabel_en-US" xlink:label="lab_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedge termination reclassified to earnings</link:label>
    <link:label id="lab_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination_label_en-US" xlink:label="lab_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Termination</link:label>
    <link:label id="lab_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination_documentation_en-US" xlink:label="lab_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" xlink:href="neo-20211231.xsd#neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" xlink:to="lab_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_eb206303-f4f6-4076-b369-ace32101b5e6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_249ace00-1790-49e0-95da-75c9a59ed056_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in non-consolidated affiliate</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_54edd110-4691-48ad-a65a-219a02431fb1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_54d0ad78-2789-4f4e-838e-e144fc39b7b0_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing Assets</link:label>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_033f2e7c-869e-4b81-822c-42853f892314_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d16c2f69-2a84-4526-872d-da92650348d3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_a4ddca6f-c305-4765-8650-42f3e2ee7b11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3a09895e-96ae-40ea-aaed-5c386fdf8f7b_verboseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_bd499287-0b11-4d9e-9a2b-8d0682f0b1af_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_cda4d5d0-4b87-41d4-99cc-130f877bcbce_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards that expire</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_4494351a-b13d-45b1-8b81-ae6ab06391f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_c491dcf4-40bf-4dee-b044-de17b1e15dc9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_83a7f08d-157a-4deb-9d55-05ca13068d81_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b30f1ae4-aa5d-4bc7-97d6-e5cf866aa6e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0625dca1-c8b0-4ed4-a5ee-4b2083b89801_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6b16b0bc-0e77-494d-b5dc-093f30e575cd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_33aa7262-51a6-4f89-8df5-785f007ffc4b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_9bfcd30d-6ceb-49c5-a48e-5e89922e67ab_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_93767297-8822-4b78-a648-80875c8d76ce_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_14853c60-f55c-4ffe-a230-bf67dd1e6e5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_84aee6f3-5400-4329-894d-bbde6fceca06_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term pharma capitalized commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_dab15bb1-f6e6-4d85-b4d0-e467b565c250_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_b070c3fd-bf98-4ae2-a7b3-12d46267bf4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b8c837ee-48bb-42c2-bc1c-7478932af85a_verboseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_d08b7127-ec92-4a5c-bd79-ee021a6adbe1_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:&#160;Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_9f1bbb28-c9c3-45e6-8427-f61a468b9d84_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_34eaaea5-6b95-4711-a073-0abb20f86014_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3389c9ff-0168-4110-a413-1f9504f342c3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_cd783c96-b55b-45e5-aefe-83256e69be7d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt outstanding</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ComputerHardwareAndOfficeEquipmentMember_4e2fe602-d808-4331-92c5-4cca87073e59_terseLabel_en-US" xlink:label="lab_neo_ComputerHardwareAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware and office equipment</link:label>
    <link:label id="lab_neo_ComputerHardwareAndOfficeEquipmentMember_label_en-US" xlink:label="lab_neo_ComputerHardwareAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware And Office Equipment [Member]</link:label>
    <link:label id="lab_neo_ComputerHardwareAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_neo_ComputerHardwareAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ComputerHardwareAndOfficeEquipmentMember" xlink:href="neo-20211231.xsd#neo_ComputerHardwareAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ComputerHardwareAndOfficeEquipmentMember" xlink:to="lab_neo_ComputerHardwareAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b64f5bd1-a2ce-4b07-8826-b61978d71ef3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_39d64c9b-3fc7-4577-86e3-093dfc7a0427_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fc25c2b2-6976-42ee-97e4-01c968322092_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4c0b91d8-200f-4429-be19-b2d1dc1f0bc1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases in tax positions taken in current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2945342f-de75-4eab-a1e5-38b0bfb3acd9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce949c9e-527d-43af-a4e6-9f27baea3e32_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_19e63b71-abe3-4f4c-b2d8-e8a8fbe45036_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_daf30090-7fcb-40fb-8c0e-96a4aa012d75_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_483901aa-bb61-4326-ab5b-389ee3e4993c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e0f7357d-6e4e-4928-906b-e355be24b7a6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2bccb5da-1c4a-4f4b-990c-bca5d357ba94_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_618cbea5-180c-40fd-ad99-acf17456533a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0102d730-8384-4263-9c81-d5cb897284bd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f4aa45f9-a553-4df3-87a9-7591c3545d4e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_3364b3f3-d91b-4e0d-a34d-15acbb0ceddf_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_69823153-29ba-4093-a1f8-776f83c3a1b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_1c04cbe6-0af4-427b-a075-d952dc8b7445_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7adc3dd5-56c5-4917-9bc9-68ecbb8f8dea_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits - January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0ab9194a-3fc5-4f0d-92e7-aebdf5502cea_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits - December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_ccd337c9-5121-4af5-9642-129a1753b7eb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_a2d0f3bd-25a9-490f-83bf-5be4cb5fafa5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_fad4be17-e2ed-4310-bbe5-5729060310b6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e9011b52-13a3-4441-aa80-55a17dda2cdb_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1a328ccc-104d-42d8-9d07-f6fbf9888f67_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3b526d48-2220-4633-88f6-1843c91dbb9e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19_f16fe14f-ea3c-417d-9b1a-96d2b2b7501d_terseLabel_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of COVID-19 PCR testing inventory and equipment</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19_label_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, Exit Costs, COVID-19</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19_documentation_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, Exit Costs, COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:href="neo-20211231.xsd#neo_PolymeraseChainReactionTestingExitCostsCOVID19"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:to="lab_neo_PolymeraseChainReactionTestingExitCostsCOVID19" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount_1d1410c6-f405-4fa4-84b8-be0dccf3b248_terseLabel_en-US" xlink:label="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, accretion of debt discount</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount_label_en-US" xlink:label="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Accretion Of Debt Discount</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount_documentation_en-US" xlink:label="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Accretion Of Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:href="neo-20211231.xsd#neo_InterestExpenseDebtAccretionOfDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:to="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LongTermLineOfCreditSettlementGainLoss_23e9f059-be8f-4807-a2ee-9d41c2539800_terseLabel_en-US" xlink:label="lab_neo_LongTermLineOfCreditSettlementGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on settlement under line of credit</link:label>
    <link:label id="lab_neo_LongTermLineOfCreditSettlementGainLoss_label_en-US" xlink:label="lab_neo_LongTermLineOfCreditSettlementGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Line of Credit, Settlement, Gain (Loss)</link:label>
    <link:label id="lab_neo_LongTermLineOfCreditSettlementGainLoss_documentation_en-US" xlink:label="lab_neo_LongTermLineOfCreditSettlementGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Line of Credit, Settlement, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermLineOfCreditSettlementGainLoss" xlink:href="neo-20211231.xsd#neo_LongTermLineOfCreditSettlementGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LongTermLineOfCreditSettlementGainLoss" xlink:to="lab_neo_LongTermLineOfCreditSettlementGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_18fe59df-71b1-49b9-9f9c-fd5eb91ad4e4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_017cd04b-ebc6-4a07-abb2-9d311ba15c39_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_cec3e40d-e29a-4c35-9895-2edcb8cace45_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0c4563e9-1ab1-4008-a2e6-d8201f5f4b3d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_3d86cfcf-d5e2-499d-9cbd-22061f969283_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1c8b0412-93cc-4053-8407-254fcace1dc8_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d6efe544-5e25-4a1e-956d-17b6d516fd1d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_33fdfd45-01c6-4048-835a-e5c1269e4b8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_57a36cac-8850-4554-9591-f98447645080_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock, net of forfeitures</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfitAbstract_c041b66d-2bd2-4365-88d0-4e2ad4d4c38e_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfitAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit:</link:label>
    <link:label id="lab_us-gaap_GrossProfitAbstract_label_en-US" xlink:label="lab_us-gaap_GrossProfitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfitAbstract" xlink:to="lab_us-gaap_GrossProfitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_73f4f8c0-abbc-4a6e-841c-dda350dbca20_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities_a46bd0b3-a6a5-4355-acfd-422cab056df8_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, deferred income tax liabilities</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liabilities</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RegulatoryIncomeTaxesPolicy_76b75969-5187-4e5f-adb2-0f78876fa2fa_terseLabel_en-US" xlink:label="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_RegulatoryIncomeTaxesPolicy_label_en-US" xlink:label="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Income Taxes, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegulatoryIncomeTaxesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:to="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9481cc0c-7d3d-4c3d-b253-d103888ce34c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_e4734882-9af9-447e-98b9-35aadc238520_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3a76241a-dfb2-40b1-af97-077cc3d0bfbb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6fecc843-174c-4b61-b005-2c50e7952670_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7af537e8-9c7d-43b5-9dcb-0f269f43921f_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation, weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_38f60e39-145e-4ada-a580-75de96edf309_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6648a15f-7e3e-45c2-9ddc-3ded7cfd48e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b3af5a72-7336-4274-8ed4-4cd7a335edf8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3977f82d-3cfa-47b4-8874-ffb57c3382a6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_cf7d697c-2d0a-482b-bfb8-22b0f0cad77a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_17a26aa6-638e-42de-83a9-70bd4b311803_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsAbstract_4bd5d939-b39f-4107-a0b4-b7a69c94f279_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Obligations [Abstract]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_CapitalLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_bb6fa0de-9671-4aa8-a65a-9d3f4f0d00c4_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5f9fe873-e76c-4611-8146-c122396b3635_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_6287a031-86db-42a7-a14d-5f7998502460_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationWorkingCapitalAdjustment_65e3c4c9-6d98-47b5-b5d4-e2face3124e0_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition working capital adjustment</link:label>
    <link:label id="lab_neo_BusinessCombinationWorkingCapitalAdjustment_label_en-US" xlink:label="lab_neo_BusinessCombinationWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Working Capital Adjustment</link:label>
    <link:label id="lab_neo_BusinessCombinationWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_neo_BusinessCombinationWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationWorkingCapitalAdjustment" xlink:href="neo-20211231.xsd#neo_BusinessCombinationWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationWorkingCapitalAdjustment" xlink:to="lab_neo_BusinessCombinationWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7afe14df-3256-4e99-ab70-046f0786420a_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of stock options and restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_f7e8c3a5-deeb-4a48-b677-53616a550fbc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_c2ad8334-2518-479f-9a58-083f79995607_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_9894ceac-da8e-448b-b063-a846aa9b3b42_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_5a4c0334-f98b-44be-92e7-5482916733dd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_6794845d-261e-4486-b849-f514eaa8b169_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt discount</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_237ac858-2085-4546-b2b9-658efa6c9814_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_74c95b19-4ad8-40fe-acc1-9d6aa5699e1a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a5f59ad6-ce6c-4886-bee1-192d8ed3da2a_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_25e1ed2e-e505-45a6-bc8b-a890903f051b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investment in and loan receivable from non-consolidated affiliate, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f76cc9be-f005-4c61-9869-8fa86bd0023d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investment in and loan receivable from non-consolidated affiliate, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b846cc6c-9b35-45c0-a2ef-72ff19e7944a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c3a63b55-830d-48bd-997a-634f49bbb38a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cddca22e-362f-4c03-b04d-393f66c79d32_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_304dc07d-01a0-4ecd-9dcf-3d4aaaa0791d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance fees and expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_09aff4df-113d-4379-8be7-c22cd9024c86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_14f73a92-2b14-4804-92c0-4be863a3a063_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards that do not expire</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_d1664b48-8b06-4942-96ca-7141680f6142_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, fair value of Purchase Option</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_e9cb69af-5d54-45dd-b708-9fe72f692617_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_bf71fc40-c179-4c06-aeb3-dc466751ff2e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_d957740c-9bf8-42f0-af02-4a236ce096db_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_876b0d1c-e04e-40bb-9bb2-4f97783a72df_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6777caad-3993-49fb-903e-9bfe0010b779_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0c25d431-be05-4293-8f0e-bad4702dd94d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over One Year Through Five Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e2927cda-c8d5-40a3-bdb3-b805dcb11159_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c3a9d90c-56cc-47fd-91e1-62f7544d3de4_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_dab989df-3aff-417b-907f-e9f14e24035a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable from non-consolidated affiliate</link:label>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Fund Long-term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7a9e00df-48ee-4226-b149-220554546cbf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3338db2b-bd89-400d-8d95-902b0b258f79_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_7159c179-f388-4e41-9198-82f83524fe53_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ee291d92-0942-405e-a8d5-974d182aaa97_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_2ab23fb9-f829-4576-82a7-da11ade4fb22_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_531afbf1-2d98-45dd-85d1-3e521d527999_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestDiscount_301f13ef-4b3c-4e8e-a2a8-ac6b1472ecb4_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan with imputed interest, discount)</link:label>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestDiscount_label_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable with Imputed Interest, Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableWithImputedInterestDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestDiscount" xlink:to="lab_us-gaap_ReceivableWithImputedInterestDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_b2e10856-8566-4fd3-8448-5306d7ea1724_terseLabel_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes</link:label>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Two Five Percent Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Two Five Percent Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:to="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_933ad5da-3cb6-4675-8093-fd830638f938_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_1826b32d-6ad3-4b99-b487-a53393a89af1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDiscountOnShares_cb355975-46c9-4f1c-a9a7-e75da15933bf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDiscountOnShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on shares</link:label>
    <link:label id="lab_us-gaap_CommonStockDiscountOnShares_label_en-US" xlink:label="lab_us-gaap_CommonStockDiscountOnShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Discount on Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDiscountOnShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDiscountOnShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDiscountOnShares" xlink:to="lab_us-gaap_CommonStockDiscountOnShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c6286e94-1a7f-4dae-8c51-7dfde35927aa_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_863c39f4-d490-4c00-bc9e-834df2703302_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c0ba71b0-f815-443c-804c-b5bc7cc0cbb7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8919e545-7706-4f20-b526-26d01fb6800e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_19aeea34-4336-478f-b729-0c5179ba9314_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5b4d5011-aca6-4d9c-bced-ee462c3503e7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_27b39a7e-08ca-454f-a8be-6a380c863b4c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_b8f75e40-1086-4d2c-bce9-dee373d2b171_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue payment terms</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_03938a2d-fe1e-45cc-8fc2-2ff1b45e1a21_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9a5c5a10-9365-4b9e-a38e-510683269ae3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Non-Consolidated Affiliate</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_28037dc6-623c-4e3a-9d3b-45117cdbbf55_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_548efc35-fcbe-47bf-90f8-c56063abb597_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_65a6435b-8175-4d01-bc47-edbc6eddb42b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives in Years</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_12b5750e-337d-4d37-8bfd-5c96ab0e2989_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_78c16215-cc18-4565-8133-2b0dcb34684c_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0deafd8f-379d-4a9f-9bcd-f98e88563a57_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_786cc2db-ead1-42c0-ae7d-bcd37a0bd52e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e9eda665-a71a-4617-8e02-6af4740800fc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_37521bfa-cdf2-49b2-bcc3-af3ca2c4eb3f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_b73bd083-fafb-4fd3-8cfb-f58e16d4e24d_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Debt</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_7c90e285-ecb0-43ce-9b9f-08092877333a_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b248f271-26f6-4609-807b-f6064568a259_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_bf4f79aa-9405-483b-9e2f-e7d87ba3dbf5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PrepaidRentNoncurrent_d6e6cbe1-4331-41e7-9495-9a5f08498227_terseLabel_en-US" xlink:label="lab_neo_PrepaidRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid lease asset</link:label>
    <link:label id="lab_neo_PrepaidRentNoncurrent_label_en-US" xlink:label="lab_neo_PrepaidRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent, Noncurrent</link:label>
    <link:label id="lab_neo_PrepaidRentNoncurrent_documentation_en-US" xlink:label="lab_neo_PrepaidRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PrepaidRentNoncurrent" xlink:href="neo-20211231.xsd#neo_PrepaidRentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PrepaidRentNoncurrent" xlink:to="lab_neo_PrepaidRentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_cdaca253-920e-475d-b7ba-fe7c768a63b2_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_64cf7915-2b1c-4962-afe5-6639b5b86d68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_52ae4068-90f8-469a-954c-726e94f63222_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional matching contribution (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_06d7480e-e499-446e-844b-5a8ec13a3780_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6dfa7b15-c2ed-49e6-a9c5-ff400f0682f8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_67716b81-0456-4d12-9a8c-712e4435a8cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0376098a-925c-4031-bcab-881fc5acf270_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f2a1e52f-98a2-4585-8a6c-d4667da4c33d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PurchaseOptionMeasurementInput_03a71f2b-8b56-4c59-97c4-702d109e2117_terseLabel_en-US" xlink:label="lab_neo_PurchaseOptionMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase option, measurement input (as a percent)</link:label>
    <link:label id="lab_neo_PurchaseOptionMeasurementInput_label_en-US" xlink:label="lab_neo_PurchaseOptionMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Option, Measurement Input</link:label>
    <link:label id="lab_neo_PurchaseOptionMeasurementInput_documentation_en-US" xlink:label="lab_neo_PurchaseOptionMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Option, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PurchaseOptionMeasurementInput" xlink:href="neo-20211231.xsd#neo_PurchaseOptionMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PurchaseOptionMeasurementInput" xlink:to="lab_neo_PurchaseOptionMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_745e2c18-47cd-412b-bb5d-eab5aa61d42a_verboseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_5c1f96f6-a7c2-48b6-a04c-283a3df23a68_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of business combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_05a850bc-749b-4202-890f-e07d24de73c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_50f09e60-36a0-424d-bc7c-3a5b56678c1f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_00b7c7c0-21cf-4409-ac9c-07187b0d3f16_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_f038335b-6407-475a-be32-a67b6e3f9175_verboseLabel_en-US" xlink:label="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options granted</link:label>
    <link:label id="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_label_en-US" xlink:label="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Aggregate Grant Date Fair Value</link:label>
    <link:label id="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_documentation_en-US" xlink:label="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options grants in period aggregate grant date fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:href="neo-20211231.xsd#neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:to="lab_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_74dff33a-43ed-46ef-8918-5dd15b6dd95d_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_8f4f2a40-e96d-4f57-ba11-a42db998c24e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ec21ce58-4588-4683-952c-0ebe8769bc81_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5f2284fb-33c2-4361-926d-7f5c15809a3e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_735d8602-3b7e-4530-ad49-604ba37357b6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax benefit provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8bfcbd11-e412-4e0e-9613-03e461e9cdf3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_efbc25fa-bb35-48c7-84e3-54ff10a697c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RangeFourMember_2f604e72-df89-47c5-9f87-c8704c76fd0a_verboseLabel_en-US" xlink:label="lab_neo_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">27.98 &#8211; 43.49</link:label>
    <link:label id="lab_neo_RangeFourMember_label_en-US" xlink:label="lab_neo_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Four [Member]</link:label>
    <link:label id="lab_neo_RangeFourMember_documentation_en-US" xlink:label="lab_neo_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeFourMember" xlink:href="neo-20211231.xsd#neo_RangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RangeFourMember" xlink:to="lab_neo_RangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_408e2582-d496-490d-a164-c3edb11bb488_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_258345d8-5c96-40c4-a3df-1322fcd517bf_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5fdb58e2-c1e1-429e-a70d-15b1ff73357a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_1a00209d-3859-4a4e-b425-4793690e65c5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c8572bf2-7b1d-4505-b2cc-dafb9b4e25d5_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8e9ea9b4-7ab5-40d2-8039-9bc758370b26_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_53c0a72e-f801-4549-8d10-47ce942418c0_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_34663b5b-937e-4b9d-afe1-fa131c97eb52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_905f4d14-cae9-406d-914a-ea42b631444e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedge termination reclassified to earnings, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a17eecc7-7580-472d-a11e-a446e7365701_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct_79d656ce-ad50-40ee-a663-94fce00b7435_terseLabel_en-US" xlink:label="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued deferred social security taxes, COVID-19</link:label>
    <link:label id="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct_label_en-US" xlink:label="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:label id="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct_documentation_en-US" xlink:label="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:href="neo-20211231.xsd#neo_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:to="lab_neo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c7fef945-2226-49b7-a218-c1f7599282a8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ClinicalServicesMember_c9c55aac-4261-448d-9a37-3e6650f3a326_terseLabel_en-US" xlink:label="lab_neo_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services</link:label>
    <link:label id="lab_neo_ClinicalServicesMember_label_en-US" xlink:label="lab_neo_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:label id="lab_neo_ClinicalServicesMember_documentation_en-US" xlink:label="lab_neo_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ClinicalServicesMember" xlink:to="lab_neo_ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations_58d8bd1f-fcc2-4306-8670-ffc4f6f35b58_negatedTerseLabel_en-US" xlink:label="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums paid for capped call transactions</link:label>
    <link:label id="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations_label_en-US" xlink:label="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Premiums For Capped Call Confirmations</link:label>
    <link:label id="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations_documentation_en-US" xlink:label="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Premiums For Capped Call Confirmations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:href="neo-20211231.xsd#neo_PaymentsOfPremiumsForCappedCallConfirmations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:to="lab_neo_PaymentsOfPremiumsForCappedCallConfirmations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7904cdf6-fa89-40a2-9663-13c934c6b10e_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_8a213f71-5dee-4443-bb72-dddd68c2c5d3_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:&#160;Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c0d33c-e943-42e0-a0e3-55cde7af18a9_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ba9c7fa-4a6a-4889-90f1-95cbf8b11f91_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8242a27e-7230-4f90-9e8e-dbbd768c3f7d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_ec510689-e536-4c4f-ae3d-ee1f3eebf88b_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0ab84802-f755-4010-b80f-093352134a72_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent_12d9ca8c-7aba-472c-9b82-738d45eb3ca3_terseLabel_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties (as a percent)</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent_label_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Penalties, Percent</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent_documentation_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Penalties, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent" xlink:to="lab_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_687b451a-0826-4527-b1f1-9a5d376db679_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5b56df09-bae2-4fdf-9751-51de9280d24a_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_d29ecdda-1ef8-4fd9-8bcf-7434c246b15c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts_f0982497-3b56-486a-9bd5-9b39e292448c_negatedTerseLabel_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note debt issuance costs</link:label>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Stock Issued, Issuance Costs</link:label>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts_documentation_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" xlink:href="neo-20211231.xsd#neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" xlink:to="lab_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_4048e4e8-93ac-491a-ba14-70bf32dc0ef1_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_922fcca6-c7c9-4075-9a48-6bc9a5c199f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cb59f3b7-e1cd-46fe-a7ba-eb4b7c0fec72_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1d3dee40-b2f8-412d-b5b3-3033d2ad80a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_FederalHealthcareProgramRevenueMember_563d4593-2fd2-408f-83db-35841938402d_terseLabel_en-US" xlink:label="lab_neo_FederalHealthcareProgramRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Healthcare Program Revenue</link:label>
    <link:label id="lab_neo_FederalHealthcareProgramRevenueMember_label_en-US" xlink:label="lab_neo_FederalHealthcareProgramRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Healthcare Program Revenue [Member]</link:label>
    <link:label id="lab_neo_FederalHealthcareProgramRevenueMember_documentation_en-US" xlink:label="lab_neo_FederalHealthcareProgramRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Healthcare Program Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FederalHealthcareProgramRevenueMember" xlink:href="neo-20211231.xsd#neo_FederalHealthcareProgramRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_FederalHealthcareProgramRevenueMember" xlink:to="lab_neo_FederalHealthcareProgramRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c6663f75-7337-433f-b8a8-d28eb42e3202_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_0e6f17c5-9767-4000-b496-fb029757b768_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of convertible debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_70d8aeff-9e4a-4be6-be97-129adfd01456_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on effective cash flow hedge, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_89c372e1-d04f-4a08-a4d4-e0387395e939_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_7d6fdae6-8ca2-4f83-a7d6-73d9e7fd0a8a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_7fcc34d2-403a-4fa1-9dd8-fb2d5c192fcb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_017855f0-3af7-414c-9e66-5ea5717186f4_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition and integration costs</link:label>
    <link:label id="lab_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_label_en-US" xlink:label="lab_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition And Integration Related Costs</link:label>
    <link:label id="lab_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_documentation_en-US" xlink:label="lab_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition And Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:href="neo-20211231.xsd#neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:to="lab_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_68e2ab69-c011-4f10-8dac-7cea0db54d7b_terseLabel_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes</link:label>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:to="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_06be39fc-ced7-4701-b4a1-32cb9238be28_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_03e57af8-fa22-466a-a31c-189c6a5a3bb8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_17c245eb-291d-4959-87d5-289c6940b596_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_e841e548-46c9-4c77-b1c9-dc4df4351ce6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of equipment financing obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_ca9b3ccc-3db9-42ee-a9b6-c891845549b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of equipment financing obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_b6bdab94-03d1-474f-8787-cf955ce84c40_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_EmployeeRetentionTaxCreditCARESAct_b65b7b10-9cf3-4a6f-983d-ae1e736ba1ce_terseLabel_en-US" xlink:label="lab_neo_EmployeeRetentionTaxCreditCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of ERTC recognized, COVID-19</link:label>
    <link:label id="lab_neo_EmployeeRetentionTaxCreditCARESAct_label_en-US" xlink:label="lab_neo_EmployeeRetentionTaxCreditCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Retention Tax Credit, CARES Act</link:label>
    <link:label id="lab_neo_EmployeeRetentionTaxCreditCARESAct_documentation_en-US" xlink:label="lab_neo_EmployeeRetentionTaxCreditCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Retention Tax Credit, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EmployeeRetentionTaxCreditCARESAct" xlink:href="neo-20211231.xsd#neo_EmployeeRetentionTaxCreditCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_EmployeeRetentionTaxCreditCARESAct" xlink:to="lab_neo_EmployeeRetentionTaxCreditCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_be80ae59-a0bb-4aec-8b15-fce1619b19c1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_743ec867-da2d-413b-a439-610429a8a361_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ffb295c7-d6db-4e92-b156-2d139fd6c421_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_15c4d89b-8148-4e31-8484-771f44955ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_e09b11a5-9c6e-4100-a1e7-d487a25d888f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term pharma contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_feb4f353-757a-40a4-ab29-7f3644a3ad5e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_039e8cfb-2db8-44f1-8d98-1660a55eab35_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1ef094b2-bbab-421a-a7de-cf769ccca922_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_34170cb1-2213-4b02-87b0-1b7a6d263610_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_GainLossOnInvestmentAndLoanReceivable_c34eddfc-0ad4-48ec-a000-f459bc5653de_negatedTerseLabel_en-US" xlink:label="lab_neo_GainLossOnInvestmentAndLoanReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investment in and loan receivable from non-consolidated affiliate, net</link:label>
    <link:label id="lab_neo_GainLossOnInvestmentAndLoanReceivable_label_en-US" xlink:label="lab_neo_GainLossOnInvestmentAndLoanReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Investment and Loan Receivable</link:label>
    <link:label id="lab_neo_GainLossOnInvestmentAndLoanReceivable_documentation_en-US" xlink:label="lab_neo_GainLossOnInvestmentAndLoanReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Investment and Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable" xlink:href="neo-20211231.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_GainLossOnInvestmentAndLoanReceivable" xlink:to="lab_neo_GainLossOnInvestmentAndLoanReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9e1e72f1-0025-4ff6-a85f-2826a9ceb7d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_f2db2b0d-8332-4ad9-9980-ee1ccc49f533_terseLabel_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to provision (as a percent)</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_label_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision, Percent</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_documentation_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:to="lab_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8ad2453b-07fe-411a-9225-4ad23bcea956_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive (loss) income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebt_7fcc96d9-4e7f-40b3-9ef7-f3230aee954d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment financing obligations</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a8a5b763-8a38-4c35-abaa-7d634b006e19_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d08a161c-632a-42df-8224-ff4659f977a4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_3527b67d-5b9a-4e34-abd7-9a41997cead4_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9de43c94-9b2f-4ae2-8e16-a5d97d8d76bc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_daaeb45d-af27-4a53-b119-791e8d9a447c_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_940689fe-82be-4243-aa8a-2c485ef5b613_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a176c9de-9da0-437a-9cc9-12a20feb30dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_606cb804-3e0a-4f7b-9773-fcd965082123_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RangeThreeMember_1f62424f-d2ac-4f7a-81d6-729d01621442_verboseLabel_en-US" xlink:label="lab_neo_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">19.77 &#8211; 27.97</link:label>
    <link:label id="lab_neo_RangeThreeMember_label_en-US" xlink:label="lab_neo_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Three [Member]</link:label>
    <link:label id="lab_neo_RangeThreeMember_documentation_en-US" xlink:label="lab_neo_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeThreeMember" xlink:href="neo-20211231.xsd#neo_RangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RangeThreeMember" xlink:to="lab_neo_RangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_b6868733-3043-4781-ae5f-988a3dd3f081_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c23e2689-f62c-4798-89ea-ec8709e9cec9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b030ad02-2851-48d2-9f2b-3c2c48444f1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour_fe2b57bd-cc20-4afa-848f-449bcfb6ab0c_terseLabel_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Four</link:label>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour_documentation_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AuditInformationAbstract_label_en-US" xlink:label="lab_neo_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_neo_AuditInformationAbstract_documentation_en-US" xlink:label="lab_neo_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AuditInformationAbstract" xlink:href="neo-20211231.xsd#neo_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AuditInformationAbstract" xlink:to="lab_neo_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6d27c6ac-82f6-4f7b-b832-156b4b37e6cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_af54f4bc-a2ac-4668-ae27-ed9d8e9dd128_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_04c72e86-16a0-487d-85c0-285db340274b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_ac62772d-8a4d-46c6-83ba-50fce358a286_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_48c6f0ed-fa6a-48dd-af56-6b151632cab9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_ba06fefe-3332-4fe3-a54c-a05bab133e9f_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_75674f58-a7f0-4936-8cc1-05b3709b5aaf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_60b7d089-a0c6-4aff-a5eb-16984512b421_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_088b20af-c05c-43f1-b69d-727c1153e9a9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price on applicable trading day (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f90041a7-0b1c-4aa3-8dae-6265f17ae6e9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_98b61d34-17ea-479c-9b27-94bcf412ca3a_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_81b56ed4-0c44-49bd-b870-f04d5176a2e7_totalLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pharma capitalized commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_2ab52ee5-46c0-45a9-be74-05a3ffdc65b8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, expected tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_018b987c-2eda-4b38-9fcf-9b97e558747f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_94684a51-f92f-4d11-ad81-11240daf2886_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock_9a6d567c-4153-4e29-9840-ab0f2ee7f29a_terseLabel_en-US" xlink:label="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held for Sale</link:label>
    <link:label id="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock_label_en-US" xlink:label="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held For Sale, Policy [Policy Text Block]</link:label>
    <link:label id="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held For Sale, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:href="neo-20211231.xsd#neo_AssetsHeldForSalePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:to="lab_neo_AssetsHeldForSalePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_2dbdeacd-1632-4d80-98b8-f207e64d8364_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f5ecc841-3109-48ac-9de2-975996759572_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_30da7fef-3311-4cbe-b0f7-6f5c8bfbae9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_68cddeb6-bd95-40a1-8863-761f6d76331e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PharmaServicesMember_6c932c41-2cb6-4809-a5a1-65a771af8f0d_terseLabel_en-US" xlink:label="lab_neo_PharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services</link:label>
    <link:label id="lab_neo_PharmaServicesMember_label_en-US" xlink:label="lab_neo_PharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services [Member]</link:label>
    <link:label id="lab_neo_PharmaServicesMember_documentation_en-US" xlink:label="lab_neo_PharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PharmaServicesMember" xlink:to="lab_neo_PharmaServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HerMajestysRevenueAndCustomsHMRCMember_1838d06d-d5d0-477c-b715-8f56b2f3523d_terseLabel_en-US" xlink:label="lab_us-gaap_HerMajestysRevenueAndCustomsHMRCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_HerMajestysRevenueAndCustomsHMRCMember_label_en-US" xlink:label="lab_us-gaap_HerMajestysRevenueAndCustomsHMRCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Her Majesty's Revenue and Customs (HMRC) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HerMajestysRevenueAndCustomsHMRCMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HerMajestysRevenueAndCustomsHMRCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HerMajestysRevenueAndCustomsHMRCMember" xlink:to="lab_us-gaap_HerMajestysRevenueAndCustomsHMRCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_abc21305-e716-46c1-bb20-154d6cd3f9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_bf1e21b1-8425-4128-ae6b-8c57a762ae5a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_89fe69e1-ba7a-4e77-99d0-d31301f8f52d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_a488d383-a7aa-4b30-a979-876538eea96a_negatedTerseLabel_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums paid for capped call confirmations</link:label>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_label_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt</link:label>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_documentation_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:href="neo-20211231.xsd#neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:to="lab_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_f97fa1b5-dd8c-4a46-9e0e-9f607c796c8d_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f3beff50-e228-425b-8458-7ac6024809dd_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_da9eeacc-a222-43ae-8295-5e6ba883bf6b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_ab4a78e8-19ba-4cfa-a615-2f395324fab6_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_99efb330-097d-474d-93cc-a40172968985_verboseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_5b2e24b2-91c2-4b86-aa71-255c0c74c607_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Purchase Option</link:label>
    <link:label id="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_label_en-US" xlink:label="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Purchase Option, Fair Value</link:label>
    <link:label id="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_documentation_en-US" xlink:label="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Purchase Option, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:href="neo-20211231.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:to="lab_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_37c21ce1-684b-43f2-924f-d710ecdcb1bd_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid to other shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_a7ea1f74-5643-44ed-a556-47b102f365da_terseLabel_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCR testing equipment, general and administrative</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_label_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_documentation_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:href="neo-20211231.xsd#neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:to="lab_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_7b6a8219-4ac5-492d-b612-2ccecb864f87_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo_993f0016-225b-4b71-981e-847e675f9a92_terseLabel_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Two</link:label>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo_documentation_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_393d8ef2-10c3-49ab-afaa-668a80b9c169_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal income tax benefit (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_caa2affb-8412-4867-a9b0-0438e5384394_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635a9aec-a661-4a4a-944b-d02f75959518_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RangeTwoMember_da47eca8-dc4b-4b43-ae9c-14b1f8ac803d_verboseLabel_en-US" xlink:label="lab_neo_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.22 &#8211; 19.76</link:label>
    <link:label id="lab_neo_RangeTwoMember_label_en-US" xlink:label="lab_neo_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label id="lab_neo_RangeTwoMember_documentation_en-US" xlink:label="lab_neo_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeTwoMember" xlink:href="neo-20211231.xsd#neo_RangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RangeTwoMember" xlink:to="lab_neo_RangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b56dae92-23c7-40e2-b30b-613de6e46204_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8b175d0a-46ff-48e0-98a1-751ef73c07cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d0838320-c874-48ba-99e0-415c67ffc1ea_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing information:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount_3f2e1c91-fdf0-4f75-996c-f72ff8b51ec1_terseLabel_en-US" xlink:label="lab_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of new contracts signed</link:label>
    <link:label id="lab_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount_label_en-US" xlink:label="lab_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Increase From New Contracts, Amount</link:label>
    <link:label id="lab_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount_documentation_en-US" xlink:label="lab_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Increase From New Contracts, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount" xlink:href="neo-20211231.xsd#neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount" xlink:to="lab_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_IncreaseDecreaseInPrepaidConstruction_ba93361b-f640-4c7b-a4b3-ce696eb03e4d_negatedTerseLabel_en-US" xlink:label="lab_neo_IncreaseDecreaseInPrepaidConstruction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid lease asset</link:label>
    <link:label id="lab_neo_IncreaseDecreaseInPrepaidConstruction_label_en-US" xlink:label="lab_neo_IncreaseDecreaseInPrepaidConstruction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Construction</link:label>
    <link:label id="lab_neo_IncreaseDecreaseInPrepaidConstruction_documentation_en-US" xlink:label="lab_neo_IncreaseDecreaseInPrepaidConstruction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Construction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncreaseDecreaseInPrepaidConstruction" xlink:href="neo-20211231.xsd#neo_IncreaseDecreaseInPrepaidConstruction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_IncreaseDecreaseInPrepaidConstruction" xlink:to="lab_neo_IncreaseDecreaseInPrepaidConstruction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8b01ce1e-0982-480a-9d60-f2e6d67d9a77_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment (net of accumulated depreciation of $109,952 and $92,895, respectively)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_02107a70-d947-436f-b4fe-52695f79025c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d0905ba1-905e-4360-8bbb-27ff976507dc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_176ec4dd-6e9b-4455-82fc-c67ae062d8ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_dd91eb12-ef27-4d4d-94ab-592a58c2d8dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_36e94d63-2032-43fa-9d17-8c21da1fedc3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ecf8f7e3-3626-4547-9b3f-36c42db6b685_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on remeasurement</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_5bfadc58-9ffe-4cd5-9147-def5d4517d7b_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_2e1a9960-d49d-4ede-b13f-5d22c1d953c7_negatedLabel_en-US" xlink:label="lab_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="neo-20211231.xsd#neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_e621aebc-061a-4fce-8cf3-6c2631817666_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_213b68dc-4266-4253-9059-37b94bea7e88_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding , beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2acba042-b597-42f1-a065-7e34e7f861ca_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c5004938-5e27-4bfc-a964-b416bfc89850_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_731e12f2-5768-4ffb-a78a-01ab15e54a32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0b40ca55-1898-4acd-86e1-4a920702b664_verboseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_82012af7-b1d3-4c1b-b00e-6f575955c0e9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_32407fc6-be02-426b-ace0-242f0268bf12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f97817d9-1052-4e74-a9b3-a03cc5ec0414_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_94d2dec7-315b-4ebc-b971-563ff3caa2d1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_89940f6d-0083-4be5-b600-84505dd1b9bd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current pharma contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d7a4548f-cbb2-4221-8848-09ba70d91d29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_aeadc96b-073e-4267-94bc-0487918287d7_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue:</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0d83183f-677c-4586-9e1a-9f519ead2057_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_549a0b2c-2915-45b1-9524-6ed78388dae8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_8c16491e-3356-4b06-93a5-cba69d2dfdb5_verboseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a57ac65c-3f51-474a-92f8-ac02d8909c9e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74fea923-7d02-4014-98cf-5faebaee3614_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average shares outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_73621df1-ee4e-4896-85d7-3358926579ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_81caeb59-7bfb-446a-8803-2daa8381be5b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ddf0ec59-00e2-45d3-a4ec-0bf3959de8da_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_59501b8f-5cb8-4175-a490-e3c75a9d6273_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2d62f675-8018-45d2-a2f7-41d2e2691681_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_StrategicAllianceWithInivataLimitedMember_bee6ce98-e420-4063-bab1-9e6de6608b86_terseLabel_en-US" xlink:label="lab_neo_StrategicAllianceWithInivataLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliance With Inivata Limited</link:label>
    <link:label id="lab_neo_StrategicAllianceWithInivataLimitedMember_label_en-US" xlink:label="lab_neo_StrategicAllianceWithInivataLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliance With Inivata Limited [Member]</link:label>
    <link:label id="lab_neo_StrategicAllianceWithInivataLimitedMember_documentation_en-US" xlink:label="lab_neo_StrategicAllianceWithInivataLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Alliance With Inivata Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StrategicAllianceWithInivataLimitedMember" xlink:href="neo-20211231.xsd#neo_StrategicAllianceWithInivataLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_StrategicAllianceWithInivataLimitedMember" xlink:to="lab_neo_StrategicAllianceWithInivataLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ProceedsFromEquityOfferingNet_92636133-b7a4-4fc4-8ce7-2b8bc73ba125_terseLabel_en-US" xlink:label="lab_neo_ProceedsFromEquityOfferingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity offering, net of issuance costs</link:label>
    <link:label id="lab_neo_ProceedsFromEquityOfferingNet_label_en-US" xlink:label="lab_neo_ProceedsFromEquityOfferingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Equity Offering, Net</link:label>
    <link:label id="lab_neo_ProceedsFromEquityOfferingNet_documentation_en-US" xlink:label="lab_neo_ProceedsFromEquityOfferingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Equity Offering, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ProceedsFromEquityOfferingNet" xlink:href="neo-20211231.xsd#neo_ProceedsFromEquityOfferingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ProceedsFromEquityOfferingNet" xlink:to="lab_neo_ProceedsFromEquityOfferingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_70945875-d869-45f4-b802-eb3b2d8e7095_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of Convertible Senior Notes due 2025</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_58b2a57e-0754-44ce-a403-5fc73660defe_totalLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b473cef9-7dfd-45f3-81c4-d4b00f314618_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_5d751e3d-3f35-403f-a6e3-850a5726a96f_verboseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1eb35346-e151-4522-a5ed-265a6dbf9ab7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_55b1d6c8-90f9-4877-96ea-149bc8977e7e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a59d68fd-adf7-4596-a9f1-e4631ca3d08e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_98f0747c-dd7f-4cf3-8981-f21ec53f04af_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuance ESPP Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_01c0173f-ced9-4083-a207-c5a783146578_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation on property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f62eead4-c3df-45bb-ae60-887edf1fcdd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_5f84c7a6-bc7b-4253-88cd-5921b0f0d2a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SaleOfStockPremiumOnOfferingPrice_f833902b-d23d-40a1-9e6a-e9ff93dbda2d_terseLabel_en-US" xlink:label="lab_neo_SaleOfStockPremiumOnOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on offering price (as a percent)</link:label>
    <link:label id="lab_neo_SaleOfStockPremiumOnOfferingPrice_label_en-US" xlink:label="lab_neo_SaleOfStockPremiumOnOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Premium On Offering Price</link:label>
    <link:label id="lab_neo_SaleOfStockPremiumOnOfferingPrice_documentation_en-US" xlink:label="lab_neo_SaleOfStockPremiumOnOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Premium On Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SaleOfStockPremiumOnOfferingPrice" xlink:href="neo-20211231.xsd#neo_SaleOfStockPremiumOnOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SaleOfStockPremiumOnOfferingPrice" xlink:to="lab_neo_SaleOfStockPremiumOnOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_55e5e425-5a8a-4f5d-8169-44aaf6f2b5fd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_59fa9f7c-098c-4a48-b912-e8bc8cbccc02_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5cf13646-1617-40f2-9d06-d4df3dbb6002_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CappedCallTransactionsNumberOfUnderlyingShares_e924e43d-0100-4780-b2f9-207ea27e9aa0_terseLabel_en-US" xlink:label="lab_neo_CappedCallTransactionsNumberOfUnderlyingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped call transaction, number of underlying shares</link:label>
    <link:label id="lab_neo_CappedCallTransactionsNumberOfUnderlyingShares_label_en-US" xlink:label="lab_neo_CappedCallTransactionsNumberOfUnderlyingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions, Number Of Underlying Shares</link:label>
    <link:label id="lab_neo_CappedCallTransactionsNumberOfUnderlyingShares_documentation_en-US" xlink:label="lab_neo_CappedCallTransactionsNumberOfUnderlyingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions, Number Of Underlying Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsNumberOfUnderlyingShares" xlink:href="neo-20211231.xsd#neo_CappedCallTransactionsNumberOfUnderlyingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CappedCallTransactionsNumberOfUnderlyingShares" xlink:to="lab_neo_CappedCallTransactionsNumberOfUnderlyingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7025529e-3e60-4973-82e3-e16ce034da95_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_feac37f4-4ecc-4c1e-903c-80ae94504536_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_ab9b7471-db1e-4b63-9a39-be31a1f0e8c0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ProceedsFromGovernmentAssistanceCARESAct_b7ec4db5-186d-4d5b-808e-536327d57379_terseLabel_en-US" xlink:label="lab_neo_ProceedsFromGovernmentAssistanceCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant income recognized, COVID-19</link:label>
    <link:label id="lab_neo_ProceedsFromGovernmentAssistanceCARESAct_label_en-US" xlink:label="lab_neo_ProceedsFromGovernmentAssistanceCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Government Assistance, CARES Act</link:label>
    <link:label id="lab_neo_ProceedsFromGovernmentAssistanceCARESAct_documentation_en-US" xlink:label="lab_neo_ProceedsFromGovernmentAssistanceCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Government Assistance, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ProceedsFromGovernmentAssistanceCARESAct" xlink:href="neo-20211231.xsd#neo_ProceedsFromGovernmentAssistanceCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ProceedsFromGovernmentAssistanceCARESAct" xlink:to="lab_neo_ProceedsFromGovernmentAssistanceCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PurchaseOptionMember_7fdefdba-e88d-4395-b00b-e124cb5c8e74_terseLabel_en-US" xlink:label="lab_neo_PurchaseOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Option</link:label>
    <link:label id="lab_neo_PurchaseOptionMember_label_en-US" xlink:label="lab_neo_PurchaseOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Option [Member]</link:label>
    <link:label id="lab_neo_PurchaseOptionMember_documentation_en-US" xlink:label="lab_neo_PurchaseOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PurchaseOptionMember" xlink:href="neo-20211231.xsd#neo_PurchaseOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PurchaseOptionMember" xlink:to="lab_neo_PurchaseOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_a0014bf4-3d1b-48fa-a322-fa52ed64956e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment acquired under financing obligations</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligation Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3666d715-6300-4a03-89d8-4628cd06c6ee_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_5d764efa-1f88-42a6-9c45-f8226b1be624_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_46a1ee8b-a66b-478b-a62c-2e654ccf65ee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_51d3d9cc-dbe5-4edc-95a0-71b7b1dd76b7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5ab60eb1-8aed-446c-bff0-99de3eb0a571_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching percentage of company of every dollar contributed (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment_d6f78437-2f98-4f1d-a17c-66cc67d4621e_verboseLabel_en-US" xlink:label="lab_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated assets, net revenues and net income reported by reportable operating segment</link:label>
    <link:label id="lab_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment_label_en-US" xlink:label="lab_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Consolidated Assets Net Revenues And Net Income Reported By Reportable Operating Segment</link:label>
    <link:label id="lab_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment_documentation_en-US" xlink:label="lab_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated assets, net revenues and net income reported by reportable operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" xlink:href="neo-20211231.xsd#neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" xlink:to="lab_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_66b60170-116c-4bf2-a2db-afe39400c88d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_02e295c0-a93b-454e-b5d6-fca43b51e9d9_verboseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_73b7ea55-1e9e-4839-89fc-a9336536437d_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_abb8fb33-b239-4d13-b8ab-ab0b302d9afa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_d21e1bac-b1b7-40e6-8289-22b980ea0b55_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_d277a0ad-210c-495e-b891-e5b1fcc6d43b_totalLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, net identifiable assets acquired</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_a60421e3-6b59-4f35-9457-2ea93125ae58_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_9657d54d-613c-4002-b198-a8b8adb00c3e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_28dd24c3-4c43-4dde-9a09-052fabfdc216_verboseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_d942acc2-0651-46c6-88dc-f900fb5ab2a6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RangeFiveMember_1e883532-76c5-40d0-86e5-736a32e740d9_verboseLabel_en-US" xlink:label="lab_neo_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">43.50 &#8211; 55.40</link:label>
    <link:label id="lab_neo_RangeFiveMember_label_en-US" xlink:label="lab_neo_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Five [Member]</link:label>
    <link:label id="lab_neo_RangeFiveMember_documentation_en-US" xlink:label="lab_neo_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeFiveMember" xlink:href="neo-20211231.xsd#neo_RangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RangeFiveMember" xlink:to="lab_neo_RangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1f805e01-0b94-4118-beb8-d2a5a41a4cd2_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_82570876-b064-40db-bf16-32142282ca27_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_543a8276-29d8-4eab-8e76-d79db0fc5c04_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment financing obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9d661fd1-ac06-4845-9523-a8cc3beb4b53_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_edfe3fd2-1325-4c27-9511-a801ff413004_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_6d26f7fe-7ebb-48e4-9074-e1684f994880_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_036bd566-ecaf-4c75-8180-690b659d7984_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_8fee2ee7-cc95-4653-bd19-1a952ea67ba3_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_520414e7-ec09-40e6-8125-4c7fe9dc779c_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Rate Differential (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_ea505e03-b4eb-4056-ba1e-afb50eff7b7f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_8a50507e-6f5a-4a76-b1fb-3ef41339ea4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_4bfbab51-576e-44c5-9528-8a9431840d0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a823432-e4d7-4d03-ab2d-ec8b70481bc6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net (loss) income to net&#160;cash&#160;provided&#160;by operating&#160;activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_DiscountedPriceOfAggregatePrincipleRate_1667ad27-40bc-4b1e-8ab3-161d174bb5bd_terseLabel_en-US" xlink:label="lab_neo_DiscountedPriceOfAggregatePrincipleRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on principal amount (as a percent)</link:label>
    <link:label id="lab_neo_DiscountedPriceOfAggregatePrincipleRate_label_en-US" xlink:label="lab_neo_DiscountedPriceOfAggregatePrincipleRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted Price of Aggregate Principle Rate</link:label>
    <link:label id="lab_neo_DiscountedPriceOfAggregatePrincipleRate_documentation_en-US" xlink:label="lab_neo_DiscountedPriceOfAggregatePrincipleRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted Price of Aggregate Principle Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DiscountedPriceOfAggregatePrincipleRate" xlink:href="neo-20211231.xsd#neo_DiscountedPriceOfAggregatePrincipleRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_DiscountedPriceOfAggregatePrincipleRate" xlink:to="lab_neo_DiscountedPriceOfAggregatePrincipleRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_fc817819-a871-4077-a014-2d1f1304fe62_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3ddccc04-c65e-4fae-bcf6-5da02123a155_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_e64bd726-2123-41af-8d6b-d757622da645_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock_bd320e0a-50a4-4768-a3bf-2e6847ca7c03_terseLabel_en-US" xlink:label="lab_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock_label_en-US" xlink:label="lab_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets Policy Policy [Policy Text Block]</link:label>
    <link:label id="lab_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock" xlink:href="neo-20211231.xsd#neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock" xlink:to="lab_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_d790808c-bc46-42d5-9488-3a9c74169b48_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_a9cf9655-6508-4c24-9f4f-44f146243f99_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current pharma capitalized commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_75778dd2-84f8-451e-b800-d4b82b6afbc0_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contribution (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_81b924bf-7282-4239-89e8-2ddff4af271a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred benefit provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PharmaServicesSegmentMember_160c9676-869d-4234-8024-5b35144ba257_verboseLabel_en-US" xlink:label="lab_neo_PharmaServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services</link:label>
    <link:label id="lab_neo_PharmaServicesSegmentMember_label_en-US" xlink:label="lab_neo_PharmaServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services Segment [Member]</link:label>
    <link:label id="lab_neo_PharmaServicesSegmentMember_documentation_en-US" xlink:label="lab_neo_PharmaServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma services segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesSegmentMember" xlink:href="neo-20211231.xsd#neo_PharmaServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PharmaServicesSegmentMember" xlink:to="lab_neo_PharmaServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_c7bb9ee4-0e5f-4806-b47d-1dc31fcfb7b2_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts_b4d33100-6f93-4210-966b-6fdc8deb5ef9_terseLabel_en-US" xlink:label="lab_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts_label_en-US" xlink:label="lab_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Variable Interest Entities, Transaction Costs</link:label>
    <link:label id="lab_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts_documentation_en-US" xlink:label="lab_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Variable Interest Entities, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts" xlink:href="neo-20211231.xsd#neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts" xlink:to="lab_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_843f3bdd-9518-4f69-bca9-7ca4468716fb_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c81f49f6-ade9-49dc-8b91-3195abc22571_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_f59fff76-6f98-4bcc-a17b-d647e6f63a90_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7f939cb-f4ab-41dd-9182-a2aca03b0b41_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ffe256ad-ff07-4187-8753-001f7aa3de57_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET (LOSS) INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fe158f45-6b86-45b5-b2c6-e8f7b4fa5d3f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET (LOSS) INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5b7dcd96-807e-4dd8-9e3f-fe71f853446b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ebcf08a6-df5d-4b16-8af1-b5bc3f3be245_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_df85fd33-e063-46e2-9cdd-4f29a9c071ab_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carry-forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3c3dc61d-decc-4758-bd7f-b3ce8ba49b12_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c80efddb-38d0-4ce3-93db-6a85932c239b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_169437f4-765e-4d3c-832e-c537afab4900_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_42adaee0-f3e6-409a-82c1-415e0787995e_verboseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_6cff5024-2e61-4b26-b85e-44b0f9c6167e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5a7d5f32-370b-4d77-b633-43299f0bcd3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PatentInfringementComplaintMember_02ff30eb-dd98-4b30-9598-08e65676d625_terseLabel_en-US" xlink:label="lab_neo_PatentInfringementComplaintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Complaint</link:label>
    <link:label id="lab_neo_PatentInfringementComplaintMember_label_en-US" xlink:label="lab_neo_PatentInfringementComplaintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Complaint [Member]</link:label>
    <link:label id="lab_neo_PatentInfringementComplaintMember_documentation_en-US" xlink:label="lab_neo_PatentInfringementComplaintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Complaint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PatentInfringementComplaintMember" xlink:href="neo-20211231.xsd#neo_PatentInfringementComplaintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PatentInfringementComplaintMember" xlink:to="lab_neo_PatentInfringementComplaintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_7fc58b32-5e1a-426a-b5d3-45faa871af70_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0639c930-c731-4071-9988-7ec7e2593b74_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_85f90271-40a7-4099-830f-6158c7cfbbcf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b17ee5ec-6d77-4c6b-b98b-6b9d05ea139e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount from market price (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_be8164f5-3b60-43bf-b04a-8b84f2821f23_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_f06ec99b-8e79-4be2-aea3-53b427c1c108_totalLabel_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Debt</link:label>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Including Current Maturities</link:label>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_documentation_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_eb468568-ac0b-428a-bb57-c912f7fbb0b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_FinanceObligationsMember_9eb012cb-ac70-47f8-8a6c-2cd2dfb9b7ee_terseLabel_en-US" xlink:label="lab_neo_FinanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Obligations</link:label>
    <link:label id="lab_neo_FinanceObligationsMember_label_en-US" xlink:label="lab_neo_FinanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Obligations [Member]</link:label>
    <link:label id="lab_neo_FinanceObligationsMember_documentation_en-US" xlink:label="lab_neo_FinanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FinanceObligationsMember" xlink:href="neo-20211231.xsd#neo_FinanceObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_FinanceObligationsMember" xlink:to="lab_neo_FinanceObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestRateSwapJune2018Member_b0fad401-bccd-4337-a069-4239cdb5171d_terseLabel_en-US" xlink:label="lab_neo_InterestRateSwapJune2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap June 2018</link:label>
    <link:label id="lab_neo_InterestRateSwapJune2018Member_label_en-US" xlink:label="lab_neo_InterestRateSwapJune2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap June 2018 [Member]</link:label>
    <link:label id="lab_neo_InterestRateSwapJune2018Member_documentation_en-US" xlink:label="lab_neo_InterestRateSwapJune2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap June 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestRateSwapJune2018Member" xlink:href="neo-20211231.xsd#neo_InterestRateSwapJune2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestRateSwapJune2018Member" xlink:to="lab_neo_InterestRateSwapJune2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_9fd996d0-00fa-4dd6-8338-85d5f0552431_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_17452249-d647-4d47-bb82-e37c58d08ff2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_fe2ebcc0-8673-4e5b-addb-27a78ef64a7f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in minority interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest in Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:to="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bbff622b-4886-452f-8b99-784867f6c006_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_721f56c2-2b2b-4eda-9a92-01099c8aac9a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_aa8972d0-2c5c-46db-b049-fa6a0d284ec7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price of principal (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_66c15279-39c9-40fe-8579-dbdc19e976fc_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense - options and restricted stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_692495c5-8d24-4e40-aff2-a5b9e8b4fa05_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction, expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_8e692b97-3588-4083-987c-661f3e408ff0_terseLabel_en-US" xlink:label="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business, adjustments</link:label>
    <link:label id="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_label_en-US" xlink:label="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired From Acquisition And Working Capital Adjustments</link:label>
    <link:label id="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_documentation_en-US" xlink:label="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired From Acquisition And Working Capital Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:href="neo-20211231.xsd#neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:to="lab_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_4062f34c-6c83-4cef-86c9-41103774f0e0_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_0da77ccd-d0e4-4485-a3a3-1306b73cefef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_GainLossOnTerminationOfInterestRateSwap_004e935e-8ab4-4b99-81fc-c61a10bbf8bf_negatedTerseLabel_en-US" xlink:label="lab_neo_GainLossOnTerminationOfInterestRateSwap" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on termination of cash flow hedge</link:label>
    <link:label id="lab_neo_GainLossOnTerminationOfInterestRateSwap_label_en-US" xlink:label="lab_neo_GainLossOnTerminationOfInterestRateSwap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Termination Of Interest Rate Swap</link:label>
    <link:label id="lab_neo_GainLossOnTerminationOfInterestRateSwap_documentation_en-US" xlink:label="lab_neo_GainLossOnTerminationOfInterestRateSwap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Termination Of Interest Rate Swap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnTerminationOfInterestRateSwap" xlink:href="neo-20211231.xsd#neo_GainLossOnTerminationOfInterestRateSwap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_GainLossOnTerminationOfInterestRateSwap" xlink:to="lab_neo_GainLossOnTerminationOfInterestRateSwap" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_49948e99-5cf7-4710-b326-e27e0a417ced_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investment in non-consolidated affiliate, net</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Initial Consolidation, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:to="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_5d209308-7825-46ac-87d5-6cd5a7d28d70_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_055bbba2-93fe-449c-80c0-5e1493a64d9f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_671fd51d-a12a-4549-9ca5-6887d2b927e8_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e7f8d5b3-8316-4789-8757-f2245309ec55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares granted during period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e1977429-1d03-4db6-ba2e-a171bd377849_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CommonStockOfferingMember_f41956f8-0d5e-4217-8531-6aa42fc1799a_terseLabel_en-US" xlink:label="lab_neo_CommonStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Offering</link:label>
    <link:label id="lab_neo_CommonStockOfferingMember_label_en-US" xlink:label="lab_neo_CommonStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Offering [Member]</link:label>
    <link:label id="lab_neo_CommonStockOfferingMember_documentation_en-US" xlink:label="lab_neo_CommonStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommonStockOfferingMember" xlink:href="neo-20211231.xsd#neo_CommonStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CommonStockOfferingMember" xlink:to="lab_neo_CommonStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_bb001372-6d9c-48d2-8755-b44c12604eb4_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5db656c3-bb52-4e58-a54b-b7320bd74e93_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2b315453-4965-47b1-9a73-379fee0de8fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5a220748-d9ab-4fcb-bcd2-bdde1a14b5e1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount_c9b3477a-2dd4-4c47-8129-5f39164df351_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding derivative instruments</link:label>
    <link:label id="lab_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount_label_en-US" xlink:label="lab_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtPercentageBearingVariableInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount" xlink:to="lab_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_eac60913-ef3d-41a5-bb80-0eb02bf894ae_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1a6993a7-9f2e-44aa-b276-0eace05bff24_verboseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ab984a98-b2f2-4405-bd73-eb441675b4aa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_40b0102a-a33d-4c83-8675-fac446242ac7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_540b255e-61ce-441c-a31e-82774e2a16eb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_3d420ff2-0e47-4868-882d-01170d717cf4_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_6020a239-7321-4765-9f21-4d32fc2b65c4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_98786a1b-072f-4cdb-91f0-19fb6aa36430_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a934b4ff-8409-4c34-865e-37a11581c44e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_WriteOffForCOVID19PCRTestingInventoryMember_b5ce46b7-6677-47d5-86ef-df80247e48e8_terseLabel_en-US" xlink:label="lab_neo_WriteOffForCOVID19PCRTestingInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off For COVID-19 PCR Testing Inventory</link:label>
    <link:label id="lab_neo_WriteOffForCOVID19PCRTestingInventoryMember_label_en-US" xlink:label="lab_neo_WriteOffForCOVID19PCRTestingInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off For COVID-19 PCR Testing Inventory [Member]</link:label>
    <link:label id="lab_neo_WriteOffForCOVID19PCRTestingInventoryMember_documentation_en-US" xlink:label="lab_neo_WriteOffForCOVID19PCRTestingInventoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off For COVID-19 PCR Testing Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WriteOffForCOVID19PCRTestingInventoryMember" xlink:href="neo-20211231.xsd#neo_WriteOffForCOVID19PCRTestingInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_WriteOffForCOVID19PCRTestingInventoryMember" xlink:to="lab_neo_WriteOffForCOVID19PCRTestingInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_91617c16-df0c-4234-bfca-3a9f2930a575_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e947435-b782-4bf1-8927-259681d396eb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_df0d16fd-c08c-4007-8d79-9daec6324b5d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_99cbbfd8-a60e-4a11-944c-f5d7be747ac2_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_eda265ad-0255-4619-9037-f79ceb0f8273_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_86ca74e5-6881-475f-9cc1-9c2cd14d00f0_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, other current assets</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_709c515c-0f5e-4bbd-beb2-8e36c5593433_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7c9f4d12-c0ea-416a-891e-41d0e99c0a41_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestNetAmount_7248c026-30bd-4341-968a-ba265893775e_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of loan receivable with imputed interest</link:label>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestNetAmount_label_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable with Imputed Interest, Net Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="lab_us-gaap_ReceivableWithImputedInterestNetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_53e3c638-b12a-4763-a028-a44407c88f98_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dff170b3-d674-4872-a0ae-d0f77fc2c604_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_70789bc2-c16f-482d-a6dc-ca1fb5e8a278_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_d3bb40a0-de07-4f33-92e3-5db578ebeec3_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7237325d-158b-4e2c-98f2-bf62a9e14242_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_cd014660-507e-4d59-864f-c1713c697f51_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_DeferredTaxAssetsInterestExpense_49415678-3181-407e-bd93-fd1a169675a3_terseLabel_en-US" xlink:label="lab_neo_DeferredTaxAssetsInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_neo_DeferredTaxAssetsInterestExpense_label_en-US" xlink:label="lab_neo_DeferredTaxAssetsInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Expense</link:label>
    <link:label id="lab_neo_DeferredTaxAssetsInterestExpense_documentation_en-US" xlink:label="lab_neo_DeferredTaxAssetsInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DeferredTaxAssetsInterestExpense" xlink:href="neo-20211231.xsd#neo_DeferredTaxAssetsInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_DeferredTaxAssetsInterestExpense" xlink:to="lab_neo_DeferredTaxAssetsInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3da62897-44b8-419b-b504-627dd4ce4221_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9b440d90-3dd8-44cb-9267-3b0fb7ca8fd1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_3fe7bd5a-07a1-45ac-8f02-82dc9440bcf1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_4b3edc97-990c-4267-8f02-00ef8bf65c9d_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9767476c-62a9-4895-913f-09fabaa41176_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt_26d6bca9-fab3-4c93-8efc-2fb730d96914_terseLabel_en-US" xlink:label="lab_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership of convertible notes (as a percent)</link:label>
    <link:label id="lab_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt_label_en-US" xlink:label="lab_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Threshold of Default, Percent Of Owners Of Debt</link:label>
    <link:label id="lab_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt_documentation_en-US" xlink:label="lab_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Threshold of Default, Percent Of Owners Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" xlink:href="neo-20211231.xsd#neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" xlink:to="lab_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4e699a04-b093-4740-8431-80e4ae4caaed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_302d9595-98e2-4790-a42f-a8cbb59968b5_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_IncomeTaxesLineItems_2d91aefe-2a34-437d-8d33-e7c3c5481ddc_verboseLabel_en-US" xlink:label="lab_neo_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_neo_IncomeTaxesLineItems_label_en-US" xlink:label="lab_neo_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_neo_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_neo_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncomeTaxesLineItems" xlink:href="neo-20211231.xsd#neo_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_IncomeTaxesLineItems" xlink:to="lab_neo_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_3dcfeae6-fae7-4a9e-a6c5-44d73e8b4cfa_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d24e7fb0-0b15-4e69-aab1-796912226c9e_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_ad8aa55c-d7c1-4618-a432-a609b2c63799_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0816ebbd-de6c-4960-941c-0b4be3d83917_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3ef61134-31eb-4f6a-a2c0-38aedd6b53e8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_a7c62f89-9762-42bd-9573-2a3c40745b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping costs</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3e10f9ff-dcf5-45fe-a24f-3478d6187a7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Restricted Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_be25ad2b-cfae-4294-bdc6-235ba284aa6c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c85cdaeb-987d-4e08-ace3-0164aa88dfe0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_12ff3b4f-5ceb-42b7-b7d1-b0f4924df315_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_c282d8f0-bcc2-4abd-8cbd-85f17b1e8e82_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_78c6e076-592f-46fc-8b07-eda60f5604d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_7a374a0b-4934-4ccc-bbb8-83484b623205_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_49917265-931c-4614-aec2-f0dbee611f9e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_477171e6-2c7b-4b55-8ec9-564d44295e24_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Held-for-sale, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Held-for-sale, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_97aa2d75-21da-42ce-b14f-32bf7e912c6d_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_408b6a8a-023d-47b7-8891-1af8bced1327_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_11d34732-fbaa-4205-be1b-b424bc30be79_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_59a55406-742d-4cd5-b49f-d00c68d8c555_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7f785da1-6f2f-4aaa-bdf7-546b8fbf1aa4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net (loss) income per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5a270606-78ad-453e-a4fd-9b2b49c692cf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_40fa9542-9ff5-447c-a309-9dc7fc74aed6_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fcbfe646-52b2-4289-b4af-2100f08e1a85_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_ba7cc450-475e-4fe3-a908-735ffe68fff1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_fe56bf56-8f9d-4557-bddc-983d17f2dbf4_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental stock-based compensation for accelerated vesting</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Program, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchaseProgramAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:to="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_be12441e-45b9-4b4c-9b21-4d7286abd46e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on effective cash flow hedge</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_426024fa-19f0-447e-8191-065d9f7b03b2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_6e2f2294-aec8-4d7d-abf8-b96737fd49b2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term Debt [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ac51cd14-f402-4711-8db5-575cf319ae2a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fb21775e-7024-4abf-847d-992ce91f7ce4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_78f241ff-646c-472c-8947-670f04a33c7d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_26a5536b-e19d-49da-a003-78b68b86f266_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_e3e25143-a0c7-4fb2-87d0-1f70eab7749f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_077e00cf-ad12-46d0-91fe-d6f2f853a9dc_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03c9846c-fe26-4ab5-8ae5-374ea644a178_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c47633f4-8bf3-4a48-bd7a-1ebde0618df0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_9fd4f158-6fb1-4bce-8e2b-cad1420aa27a_terseLabel_en-US" xlink:label="lab_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum lease payments for leases executed but not commenced</link:label>
    <link:label id="lab_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_label_en-US" xlink:label="lab_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:label id="lab_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_documentation_en-US" xlink:label="lab_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:href="neo-20211231.xsd#neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:to="lab_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_25dea593-d823-4462-b8e0-58f3dbb16d17_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ClinicalServicesSegmentMember_6b5a4808-a5fb-4567-94bf-ea5627851a8e_verboseLabel_en-US" xlink:label="lab_neo_ClinicalServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services</link:label>
    <link:label id="lab_neo_ClinicalServicesSegmentMember_label_en-US" xlink:label="lab_neo_ClinicalServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services Segment [Member]</link:label>
    <link:label id="lab_neo_ClinicalServicesSegmentMember_documentation_en-US" xlink:label="lab_neo_ClinicalServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical services segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesSegmentMember" xlink:href="neo-20211231.xsd#neo_ClinicalServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ClinicalServicesSegmentMember" xlink:to="lab_neo_ClinicalServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fd9123ae-e251-4b7f-b14a-a9245ae38100_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_bc2f151c-e66d-4ea1-809c-6e1a9a8e1277_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GROSS PROFIT</link:label>
    <link:label id="lab_us-gaap_GrossProfit_1c8377f1-4cfc-4807-b638-6be09103bbca_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_34821b97-ca92-4b9a-8361-e280b5a3121d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_d87d64cc-c864-4a4d-b7cc-59429166a2e7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RepaymentsOfEquipmentAndOtherLoans_ac7020e1-ebd9-4767-9e97-28ed0ddc9c75_negatedLabel_en-US" xlink:label="lab_neo_RepaymentsOfEquipmentAndOtherLoans" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of equipment financing obligations</link:label>
    <link:label id="lab_neo_RepaymentsOfEquipmentAndOtherLoans_label_en-US" xlink:label="lab_neo_RepaymentsOfEquipmentAndOtherLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Equipment and Other Loans</link:label>
    <link:label id="lab_neo_RepaymentsOfEquipmentAndOtherLoans_documentation_en-US" xlink:label="lab_neo_RepaymentsOfEquipmentAndOtherLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Equipment and Other Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RepaymentsOfEquipmentAndOtherLoans" xlink:href="neo-20211231.xsd#neo_RepaymentsOfEquipmentAndOtherLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RepaymentsOfEquipmentAndOtherLoans" xlink:to="lab_neo_RepaymentsOfEquipmentAndOtherLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_2ba6124c-2989-46a0-8f8d-3499df610f87_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:&#160;Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_00b583b3-df15-4677-9f74-8de2d970f691_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ada0a419-01b1-488a-a3c0-a7746e204d74_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2934aa82-db30-4ba0-a943-f45b29d5ebdc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE (LOSS) INCOME:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_f898b2ed-da16-4ee5-8338-5f6374d9ce49_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3c3977a9-1d1d-411b-a846-ae44d626d18c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interests acquired (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4340f87d-dca2-44fa-b42e-c1faa5bb5820_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1086ae5e-541b-4b97-9959-6e06853786a6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock - public offering, net of underwriting discounts</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_901d5f62-c6d0-4a5c-b398-91913690d0e4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bb22042b-69d3-4d60-9a6f-35660a71f216_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid at closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_91e3adf4-dbb3-4a2e-99c9-96294ff752b4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus: Cash paid at closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f92c5a4b-03e2-47a8-988f-57f6a9f9938b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_96fe69ec-e8c0-4b6f-b162-aa5aa0355dba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3a6b2072-698c-4ffd-b170-6f2da4bc445b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_0a90f81a-afa6-4924-b9bc-1851b1deb4dd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3126c1b9-2d10-42f4-9338-1a89a2405e6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e2c1610c-23a3-426d-bb31-87bd92147af8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_1162e362-59d9-4777-8468-e9f68d359f87_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_508df53b-aaa0-485a-a78d-7cb4499f96c3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock - public offering, net of underwriting discounts (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_a614f08d-0f3e-4c12-a363-b88619fcc138_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lin of credit settled as consideration for acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_751e39e2-d9c0-414a-a280-4ec526d237c4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Line of Credit</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_0efb9151-7afd-4eef-9982-1e0eb98ebccd_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_c2840790-555c-47a8-acea-a311d4702a79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in non-consolidated affiliate</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_5e477777-d266-48ea-8199-0380976c86fc_terseLabel_en-US" xlink:label="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, amortization of debt issuance costs</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_label_en-US" xlink:label="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Amortization Of Debt Issuance Costs</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_documentation_en-US" xlink:label="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Amortization Of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:href="neo-20211231.xsd#neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:to="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_8ef646af-2479-4621-b9d8-adaa8cde0689_terseLabel_en-US" xlink:label="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square feet owned</link:label>
    <link:label id="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_label_en-US" xlink:label="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Held For Sale, Square Feet Of Facility Owned</link:label>
    <link:label id="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_documentation_en-US" xlink:label="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Held For Sale, Square Feet Of Facility Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:href="neo-20211231.xsd#neo_AssetHeldForSaleSquareFeetOfFacilityOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:to="lab_neo_AssetHeldForSaleSquareFeetOfFacilityOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_f239bbb7-4f96-4141-8428-2818ddcca7d8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_58542cb6-daa7-4d05-8acf-b0f4488f66ef_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_02ea0f36-0e2f-4e6d-a9ea-828c30ed607a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 17)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_ba5d66d4-5620-4289-a46a-573cf388aad5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0b37394e-627e-4d4d-a507-1d4c66a21e45_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b89bfcf4-5471-4205-8861-95a42829dc30_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_bde3c9fa-b025-403b-8f87-84274665fb41_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_4a33d6bb-f418-4402-90a0-dbea32ca2f69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_5fb3344f-7c00-48c1-af0f-de7c4f314e0c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs for term loan</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock_abb5dfa8-88ec-4b4a-b0e4-2bac785b21b6_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_DeferredTaxAssetsOperatingLeaseLiability_3e3f7d22-6769-4671-b783-ef9563791221_terseLabel_en-US" xlink:label="lab_neo_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_neo_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_neo_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_neo_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_neo_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="neo-20211231.xsd#neo_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_neo_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_c47c1963-b85b-4bf9-9df6-c5aebfb211e5_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cda146c6-4803-46c5-97cf-44be8a9b36a6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RangeOneMember_0fc813fd-aa95-46bb-a742-917e300ca858_verboseLabel_en-US" xlink:label="lab_neo_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.27 &#8211; 8.21</link:label>
    <link:label id="lab_neo_RangeOneMember_label_en-US" xlink:label="lab_neo_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range One [Member]</link:label>
    <link:label id="lab_neo_RangeOneMember_documentation_en-US" xlink:label="lab_neo_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeOneMember" xlink:href="neo-20211231.xsd#neo_RangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RangeOneMember" xlink:to="lab_neo_RangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3e00976b-f89d-4ca6-bc93-4736fc5f0107_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SaleOfStockPricePerSharePublicOfferingPrice_398409d5-b3b2-4459-8263-261ffc20555e_terseLabel_en-US" xlink:label="lab_neo_SaleOfStockPricePerSharePublicOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering price (in dollars per share)</link:label>
    <link:label id="lab_neo_SaleOfStockPricePerSharePublicOfferingPrice_label_en-US" xlink:label="lab_neo_SaleOfStockPricePerSharePublicOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share, Public Offering Price</link:label>
    <link:label id="lab_neo_SaleOfStockPricePerSharePublicOfferingPrice_documentation_en-US" xlink:label="lab_neo_SaleOfStockPricePerSharePublicOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share, Public Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SaleOfStockPricePerSharePublicOfferingPrice" xlink:href="neo-20211231.xsd#neo_SaleOfStockPricePerSharePublicOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SaleOfStockPricePerSharePublicOfferingPrice" xlink:to="lab_neo_SaleOfStockPricePerSharePublicOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ad09b21a-d683-4985-bb5f-8cfbc6ef7693_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0463b252-ae79-45b4-8a97-491090f0cc05_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dd7a6399-919e-4d6f-a944-3ebad2708bba_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_c8d1ce85-bf8d-48bc-b2d3-08799874f86c_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_c7a3c2d9-4daf-461c-8d57-e25fbc021e7c_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_6e93e155-18c3-463e-826e-591044f01397_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of previously-held equity interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_269ff0e9-e492-4010-bb24-2be997d9a7a1_terseLabel_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of remaining COVID-19 PCR testing inventory</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_label_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, Write-Offs, COVID-19</link:label>
    <link:label id="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_documentation_en-US" xlink:label="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polymerase Chain Reaction Testing, Write-Offs, COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:href="neo-20211231.xsd#neo_PolymeraseChainReactionTestingWriteOffsCOVID19"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:to="lab_neo_PolymeraseChainReactionTestingWriteOffsCOVID19" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_bd889ea8-0518-4a15-a26e-099281ac812b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_be0fd7cd-6671-475b-bc61-9b7caaa69a18_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_70eb34e8-0a7a-4948-8afb-c8725b02aba9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(LOSS) INCOME FROM OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_e363cd5a-dfc2-4f53-bbe4-303af8c5c2c2_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_f2ca0382-2780-4d88-9443-82f439ee78ac_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Held-for-sale by Asset Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Held-for-sale by Asset Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6c013a31-8139-495d-839c-9aa0b7b4e398_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d949e6bd-4938-4393-b171-a2daa3db569f_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0bf60879-c6aa-45fd-8073-fbf67216a462_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_59b0ff64-28c3-40c1-abf3-b1cddafe2c40_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_IncomeTaxesTable_e8f6aa59-b15d-4cb2-9261-27c6f48854e2_verboseLabel_en-US" xlink:label="lab_neo_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_neo_IncomeTaxesTable_label_en-US" xlink:label="lab_neo_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_neo_IncomeTaxesTable_documentation_en-US" xlink:label="lab_neo_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncomeTaxesTable" xlink:href="neo-20211231.xsd#neo_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_IncomeTaxesTable" xlink:to="lab_neo_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_f83c6a87-d259-4b41-abb7-125df03a155f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_24578915-a872-4431-ae29-9c766ab94812_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestExpenseDebtContractualCouponInterest_4d0439ef-e7a3-43de-a153-2df9066952a9_terseLabel_en-US" xlink:label="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, contractual coupon interest</link:label>
    <link:label id="lab_neo_InterestExpenseDebtContractualCouponInterest_label_en-US" xlink:label="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Contractual Coupon Interest</link:label>
    <link:label id="lab_neo_InterestExpenseDebtContractualCouponInterest_documentation_en-US" xlink:label="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Contractual Coupon Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtContractualCouponInterest" xlink:href="neo-20211231.xsd#neo_InterestExpenseDebtContractualCouponInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestExpenseDebtContractualCouponInterest" xlink:to="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_711397c3-b24e-497e-8a2d-f0441a98efa7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_3addfa1b-aaaf-4a98-a307-1bdb1f53d6c4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3a797fbe-313d-472f-b884-67b1fbfab4fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_48facb1e-70d3-42fa-af21-743b0ce018ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_38baf49b-1f8f-4cbe-b473-68a521c88334_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount of derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_YankeeBondsMember_959d52a0-893d-418f-98f7-13ac2efee06a_terseLabel_en-US" xlink:label="lab_neo_YankeeBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee bonds</link:label>
    <link:label id="lab_neo_YankeeBondsMember_label_en-US" xlink:label="lab_neo_YankeeBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee Bonds [Member]</link:label>
    <link:label id="lab_neo_YankeeBondsMember_documentation_en-US" xlink:label="lab_neo_YankeeBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember" xlink:href="neo-20211231.xsd#neo_YankeeBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_YankeeBondsMember" xlink:to="lab_neo_YankeeBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_236e4394-fc95-405f-850d-4d74c55fafb3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_4e640dcd-d7d6-47d9-913f-f6c42e1ea00a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_89ceb0fd-6c02-41ba-9178-52e0b19ebe32_terseLabel_en-US" xlink:label="lab_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock - private placement, net of private placement fees (in shares)</link:label>
    <link:label id="lab_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_label_en-US" xlink:label="lab_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, Private Placement</link:label>
    <link:label id="lab_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_documentation_en-US" xlink:label="lab_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:href="neo-20211231.xsd#neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:to="lab_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_c00fdbb5-0843-4093-ad03-a3e94b71d680_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c3a353d7-d762-4bbd-aec3-0727d790d048_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5e6d65fa-826f-4bfd-9c30-3439531637e4_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ef1558ae-ba5b-4932-9cea-a61141ac92c1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_4a7f7f13-bf2f-4ad6-bacb-87a8a43cefc2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_a91ae2d5-2356-435b-8397-e00bf8879e38_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7801f4c0-f397-4c63-888e-8c086f12c998_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fdc407c1-25ce-4cfd-82d3-c844d64c5763_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ea907f80-6d7a-4864-ae7a-b1e5dca626c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b007e958-6508-4c30-9af2-b61af017af50_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive_88f35ef0-90f3-4a8d-a093-8253a5252d52_terseLabel_en-US" xlink:label="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal After Year Five</link:label>
    <link:label id="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive_documentation_en-US" xlink:label="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ScheduleOfSignificantAccountingPoliciesTable_c5ddaaf2-f2b1-4ff0-8c28-a03a745f4853_verboseLabel_en-US" xlink:label="lab_neo_ScheduleOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_neo_ScheduleOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_neo_ScheduleOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_neo_ScheduleOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_neo_ScheduleOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfSignificantAccountingPoliciesTable" xlink:href="neo-20211231.xsd#neo_ScheduleOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable" xlink:to="lab_neo_ScheduleOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b5192fb9-35e2-4826-be40-b0d69064028b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_148c393b-6ac8-49e0-8197-686dfa548fa9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e99fb89b-63e3-4b52-92bb-1da315c4719e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_1c856255-c7f5-48dc-83a5-2662ac43c349_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases in prior year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_073dc698-1a6e-490c-aaec-ce889da8ff10_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_0d4cabf6-a404-4f52-b028-920f785ab126_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_70129683-fd39-4922-8098-9691d8d775c4_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CommercialInsuranceMember_92fd7598-aa15-420f-b9fb-2bd8c2fe5d28_terseLabel_en-US" xlink:label="lab_neo_CommercialInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial insurance</link:label>
    <link:label id="lab_neo_CommercialInsuranceMember_label_en-US" xlink:label="lab_neo_CommercialInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Insurance [Member]</link:label>
    <link:label id="lab_neo_CommercialInsuranceMember_documentation_en-US" xlink:label="lab_neo_CommercialInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommercialInsuranceMember" xlink:href="neo-20211231.xsd#neo_CommercialInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CommercialInsuranceMember" xlink:to="lab_neo_CommercialInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_ef3e816b-11b9-490e-a554-bdc63a7ced2d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d0788dce-5f5e-40be-b8a1-401170b448f9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_60161b00-358d-4055-8a9f-a69b1fc0ecb7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8c029bab-4822-4261-8250-6aa92160538c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuance ESPP plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4eef3de9-cdba-4526-9a9e-d3c6c627fe4c_verboseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2269819c-1b2e-410d-8614-56370897de20_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_54f9136b-bea1-4d3b-ac6c-d6b33568a56b_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_WorkingCapitalAdjustmentAcquisitions_11c24591-4211-4494-87df-46473fc8a2b0_negatedLabel_en-US" xlink:label="lab_neo_WorkingCapitalAdjustmentAcquisitions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital adjustment related to acquisition</link:label>
    <link:label id="lab_neo_WorkingCapitalAdjustmentAcquisitions_7d50a80f-9dcc-4fef-b0c4-9e0ef53b7ffc_terseLabel_en-US" xlink:label="lab_neo_WorkingCapitalAdjustmentAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital adjustment related to acquisition</link:label>
    <link:label id="lab_neo_WorkingCapitalAdjustmentAcquisitions_label_en-US" xlink:label="lab_neo_WorkingCapitalAdjustmentAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Adjustment, Acquisitions</link:label>
    <link:label id="lab_neo_WorkingCapitalAdjustmentAcquisitions_documentation_en-US" xlink:label="lab_neo_WorkingCapitalAdjustmentAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Adjustment, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WorkingCapitalAdjustmentAcquisitions" xlink:href="neo-20211231.xsd#neo_WorkingCapitalAdjustmentAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_WorkingCapitalAdjustmentAcquisitions" xlink:to="lab_neo_WorkingCapitalAdjustmentAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_76142f38-59c9-4274-81a3-9eb8e3a498f3_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2af6253f-6594-4a45-b960-297b85734565_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets, cost</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2e865a4f-37a3-4b30-a975-3f306dd2cd40_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1846b2d4-691c-4248-9ce4-c58c49dd4337_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ba01a4e5-0cb4-4a59-b258-649363d8985d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a6ad707f-d18d-4885-8d91-1ca6bdbc6342_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cf015ce4-7922-4c4b-b0c9-7440bf8db54d_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a583afc2-9205-43ef-add5-27b2c433c588_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1847698b-9781-4fc2-83c3-c09a5c289234_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2ea8a113-1151-4840-8182-69c55aa728f5_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_686bd099-8201-4f4b-b949-e7a8d2c297b9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term pharma contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c9049464-698f-4348-a44c-843cf7635404_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CommonStockClosingPrice_71186a6d-1948-4cbb-bd68-91a840aee01b_verboseLabel_en-US" xlink:label="lab_neo_CommonStockClosingPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock closing price (in dollars per share)</link:label>
    <link:label id="lab_neo_CommonStockClosingPrice_label_en-US" xlink:label="lab_neo_CommonStockClosingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Closing Price</link:label>
    <link:label id="lab_neo_CommonStockClosingPrice_documentation_en-US" xlink:label="lab_neo_CommonStockClosingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock closing price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommonStockClosingPrice" xlink:href="neo-20211231.xsd#neo_CommonStockClosingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CommonStockClosingPrice" xlink:to="lab_neo_CommonStockClosingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_dfd05b64-7e84-4a9a-b135-7425f6e12e66_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_49af2d45-c56c-41dc-9a1c-8d0de5cdf3b5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndFeeIncomeLoansAndLeases_ad4d0dc7-fcfe-40cc-9e04-9c4d64328b65_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndFeeIncomeLoansAndLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income from loan receivable</link:label>
    <link:label id="lab_us-gaap_InterestAndFeeIncomeLoansAndLeases_label_en-US" xlink:label="lab_us-gaap_InterestAndFeeIncomeLoansAndLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Fee Income, Loans and Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndFeeIncomeLoansAndLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndFeeIncomeLoansAndLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndFeeIncomeLoansAndLeases" xlink:to="lab_us-gaap_InterestAndFeeIncomeLoansAndLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_97824c21-f3ce-48ef-af41-b142d515312a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b24420d8-afc2-46e1-a1e3-c0e4781169d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c603652a-a373-4e93-b567-f680155570db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_34db54e7-409b-4251-b2e1-d5d0944efcb0_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LongTermDebtIncludingCurrentMaturitiesDue_598c0424-55af-4f4e-9e00-85b15a1af1b5_totalLabel_en-US" xlink:label="lab_neo_LongTermDebtIncludingCurrentMaturitiesDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Debt</link:label>
    <link:label id="lab_neo_LongTermDebtIncludingCurrentMaturitiesDue_label_en-US" xlink:label="lab_neo_LongTermDebtIncludingCurrentMaturitiesDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Including Current Maturities Due</link:label>
    <link:label id="lab_neo_LongTermDebtIncludingCurrentMaturitiesDue_documentation_en-US" xlink:label="lab_neo_LongTermDebtIncludingCurrentMaturitiesDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt including current maturities due.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue" xlink:href="neo-20211231.xsd#neo_LongTermDebtIncludingCurrentMaturitiesDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue" xlink:to="lab_neo_LongTermDebtIncludingCurrentMaturitiesDue" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree_7754950e-4d40-4e94-a7a0-ba7d67298d7e_terseLabel_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Three</link:label>
    <link:label id="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree_documentation_en-US" xlink:label="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_516bbabc-720a-4677-b100-d6953ed4c017_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in non-consolidated affiliate</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_a8c05618-9b02-46fc-a1cc-effb12a07e19_verboseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_2593f51f-8a18-4254-ad3a-4c77a04e8932_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SelfPayServicesMember_ebbea40a-7a08-4481-a39f-dcc47b59d875_terseLabel_en-US" xlink:label="lab_neo_SelfPayServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-pay</link:label>
    <link:label id="lab_neo_SelfPayServicesMember_label_en-US" xlink:label="lab_neo_SelfPayServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Pay Services [Member]</link:label>
    <link:label id="lab_neo_SelfPayServicesMember_documentation_en-US" xlink:label="lab_neo_SelfPayServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Pay Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SelfPayServicesMember" xlink:href="neo-20211231.xsd#neo_SelfPayServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SelfPayServicesMember" xlink:to="lab_neo_SelfPayServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_a9b473cf-563a-41db-a2e3-f725e47cd2b2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_725c79fe-a8c9-4b1d-aebf-7b06e74ffbc1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b661f858-2180-4fbb-9718-077594e9cbd9_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses_83e5e208-6025-4f45-b705-4a29ebb42370_verboseLabel_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction expenses (as a percent)</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses_label_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Expenses</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses_documentation_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses" xlink:to="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_45bac433-e58e-4f0d-b990-040e3399f3da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_c9913dda-7d44-4a0c-a9f3-f20141a1e6cd_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_a8f8ee7b-1dc4-41f7-a179-0a13665bfca2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation, description of timing</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_d66d96e4-cd9d-4859-a958-2b0aa33b542d_terseLabel_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs (as a percent)</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_label_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Costs, Percent</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_documentation_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Costs, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:to="lab_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_09b40e50-df42-4cdc-a3bc-49b0f1a4dedd_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5f4bdb5-1c7e-4702-ae61-b25147f86003_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2e3857bb-381f-4218-941f-8d79b0f475ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_032946b0-8371-4fa6-8f49-f86ac603027d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ff998f6e-5de4-465e-a826-e07bfeb80a6d_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9112c684-2c26-4360-a1de-4daa17e9621e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_d006a5ed-7e6b-42fb-a85b-76c2c33b4c9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f9b8cf9-86ff-45de-821d-f01db7be0646_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_62b12257-9d75-4f2d-8dc5-93602a7ba09e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_a8ac80a3-38d0-4ca3-a497-4c8389faf36d_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_ddf8080c-7320-41b9-918f-3c883bf6dd21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_e97270ac-7409-4b09-981a-7212214ceaca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_93f7795a-51e5-4b88-89ad-10cf9da8b54c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_67fd1eb0-550a-44df-9422-ae07b05452a7_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of investment in non-consolidated affiliate</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PreferenceSharesMember_acea7652-3cff-4921-9ec2-28db1e6a656f_terseLabel_en-US" xlink:label="lab_neo_PreferenceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preference Shares</link:label>
    <link:label id="lab_neo_PreferenceSharesMember_label_en-US" xlink:label="lab_neo_PreferenceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preference Shares [Member]</link:label>
    <link:label id="lab_neo_PreferenceSharesMember_documentation_en-US" xlink:label="lab_neo_PreferenceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preference Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PreferenceSharesMember" xlink:href="neo-20211231.xsd#neo_PreferenceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PreferenceSharesMember" xlink:to="lab_neo_PreferenceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_adf64dac-fedc-4313-9d29-1aeb68196859_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_bf46fff3-c687-44a5-a6fd-440bccf1c0b8_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CappedCallTransactionsMember_170ece1c-3a7e-4cdf-8a87-17ecb75e72a9_terseLabel_en-US" xlink:label="lab_neo_CappedCallTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions</link:label>
    <link:label id="lab_neo_CappedCallTransactionsMember_label_en-US" xlink:label="lab_neo_CappedCallTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions [Member]</link:label>
    <link:label id="lab_neo_CappedCallTransactionsMember_documentation_en-US" xlink:label="lab_neo_CappedCallTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember" xlink:href="neo-20211231.xsd#neo_CappedCallTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CappedCallTransactionsMember" xlink:to="lab_neo_CappedCallTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b17370df-fa80-4108-9e4c-3164bc5fbf03_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne_d35d473a-e423-4dcd-85b0-c0a07e7cb960_terseLabel_en-US" xlink:label="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne_label_en-US" xlink:label="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year One</link:label>
    <link:label id="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne_documentation_en-US" xlink:label="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne" xlink:to="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_f08c3d53-c086-4f70-ab7a-36c59d6d565a_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_b6734764-9b71-43be-b496-2cd3db64c395_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_a2e192b3-7319-4ee3-b21a-ac8c54844c6c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_c01a0599-1d0d-4e2e-b544-16c2c0adf1da_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4b68b4e-7d9b-4572-b146-4b882e1b3934_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_c114d88a-8458-45d6-aade-8fe90c585a59_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f430540a-e5ad-47d1-afad-e4db2c268aad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6ffed4b0-657c-4ce6-adf0-dd18a6d63ffb_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_f28ecb6f-5a67-48fb-aae5-e5da00999c40_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dad1af08-ccc5-4c7b-900b-9bef4d5dec56_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dd4448fb-a91a-43c8-9d0a-8071207b4bbf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1e3a5cab-743b-4b6f-b1a8-4a7fed34da5f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_12da6f62-db56-44e5-a07c-4529e1e4df0c_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_1a007519-4c75-446c-945e-fccad83a84f8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_0d5c4e16-83e4-4299-a779-8ad868d2bbba_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_50f923ea-ce18-4306-a031-bdc8e0c73e8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_5248c7f2-215b-44e1-9f5f-d506980e4d2c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_8f627689-90d8-4183-9025-bb28fe412e29_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4c9b1eae-8ea1-43be-bb8c-7e6cb236898c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPREHENSIVE (LOSS) INCOME</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_756449ac-f10f-4720-a602-4be476768d46_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e6310071-78ff-465b-9aeb-17b9b14daa76_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_6b0f695f-3285-4fe7-bccc-6b893e1d63ce_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_f28f979f-7f1d-411c-b7b4-d1ef3ad3959a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_18eab116-5374-466c-b082-306bd40948e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_ea6c6683-24a6-4a80-b3e6-8a725bbec176_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4df0d5cd-a260-45d4-9c61-dae1bfd35ca8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b649c5fb-c72e-48dc-ac3f-03caf7e45dc4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_6c5c1635-07b9-44d3-a916-16a605af87a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_49c7a543-f3c6-46df-af54-2ce5296529dc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net (loss) income per share(in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_467d12d3-c0a8-4aea-afad-5963656ea49e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_575b3eba-bc40-47cf-ab72-13e2bc48adb6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_d255ba56-0300-4ad3-a6f7-39af90438ae4_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e7424ebe-51c9-46bd-9401-25e0af75aba9_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets held-for-use</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_61a5f7b1-fae8-4bd8-8b5e-4f8f0468503f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember_9554429d-a256-45c8-9e9b-57a747623dc9_terseLabel_en-US" xlink:label="lab_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired developed technology intangible assets</link:label>
    <link:label id="lab_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember_label_en-US" xlink:label="lab_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Acquired Developed Technology Intangible Assets [Member]</link:label>
    <link:label id="lab_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember_documentation_en-US" xlink:label="lab_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Acquired Developed Technology Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember" xlink:href="neo-20211231.xsd#neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember" xlink:to="lab_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_e7eba3a2-4584-4d51-bb30-7403ffbddd49_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss from remeasurement of investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0030221a-06b5-41e1-81dc-b6efdcbd4839_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_dfd822b9-e6ce-4428-a509-3844970355da_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, by Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b134c98c-fa35-4ea1-ae7f-be44fd60c5b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_91c09258-4ea8-497c-9999-1da0f95a8cb2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_948c8e55-a17c-4dd2-b9cb-54ce8357b604_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pharma contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2eeb8f9f-4e23-415a-9eb9-ec57a26b012a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f92e2d0b-8fbf-444f-9f67-ee6f9243d2f8_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_afaa4ffc-86fc-449a-806b-045fac3e9f65_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over Five Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_ab31106b-0691-48a4-a9e6-4f8b541e6fb7_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f1a4e0a9-f5c9-495b-a7a4-88e20abcd0e0_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment_e14ecbf6-bf8d-4995-994c-408717ea6855_terseLabel_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax liability related to Convertible Senior Notes due 2025</link:label>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment_label_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Tax Liability Component of Convertible Debt, Subsequent Adjustment</link:label>
    <link:label id="lab_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment_documentation_en-US" xlink:label="lab_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Tax Liability Component of Convertible Debt, Subsequent Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" xlink:href="neo-20211231.xsd#neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" xlink:to="lab_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_033fb3a8-dfca-4800-a965-4127ca029278_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7d24c219-fbd5-49ae-a4f6-7df2e8de429d_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ClientDirectBillingMember_203dc7bc-0920-4478-81d8-85c25e9b56ee_terseLabel_en-US" xlink:label="lab_neo_ClientDirectBillingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client direct billing</link:label>
    <link:label id="lab_neo_ClientDirectBillingMember_label_en-US" xlink:label="lab_neo_ClientDirectBillingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Direct Billing [Member]</link:label>
    <link:label id="lab_neo_ClientDirectBillingMember_documentation_en-US" xlink:label="lab_neo_ClientDirectBillingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Direct Billing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClientDirectBillingMember" xlink:href="neo-20211231.xsd#neo_ClientDirectBillingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ClientDirectBillingMember" xlink:to="lab_neo_ClientDirectBillingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive_90432cce-01e7-48d4-8fdc-26eaacda3c8e_terseLabel_en-US" xlink:label="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Five</link:label>
    <link:label id="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive_documentation_en-US" xlink:label="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_7a113928-9bed-46e8-8980-6e2d4dac7991_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, total identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_15fae419-9728-4e67-ab14-991f7a60e5aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices, upper limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_10a7ef02-faac-4085-9f69-e0239641cb44_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversals of prior year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_EmployeeStockPurchasePlanMember_45ccfb6e-da85-4f2d-a1c0-b33eb7e5c28f_verboseLabel_en-US" xlink:label="lab_neo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_neo_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_neo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_neo_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_neo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EmployeeStockPurchasePlanMember" xlink:href="neo-20211231.xsd#neo_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_EmployeeStockPurchasePlanMember" xlink:to="lab_neo_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_a442fbad-b588-4267-ab6a-b454dd65d83a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_81b63433-4e04-499c-b379-2157cfe271cb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment_b7a92d9d-1acb-4e54-a51b-da7b70d73330_terseLabel_en-US" xlink:label="lab_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional investment in non-consolidated affiliate</link:label>
    <link:label id="lab_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment_label_en-US" xlink:label="lab_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Additional Investment</link:label>
    <link:label id="lab_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment_documentation_en-US" xlink:label="lab_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment" xlink:href="neo-20211231.xsd#neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment" xlink:to="lab_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0512a451-2ef4-4831-99be-46b538ac15c7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_704f786b-d77c-4b15-b50d-0a7d1574a6d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fa4e1f71-0d27-4f8d-b872-7da22d53ebcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_4d12af7c-02e5-4f76-97f7-ea202146cb43_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_07893641-b831-42b9-b819-9abfc1cae4d7_verboseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_062f2e1d-5c5c-4a4f-afc1-225e61ca587c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_9097a0c1-bcac-4996-8ce8-b023faa37a99_negatedTerseLabel_en-US" xlink:label="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on loan receivable from non-consolidated affiliate</link:label>
    <link:label id="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_label_en-US" xlink:label="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable With Imputed Interest, Non-Consolidated Affiliates</link:label>
    <link:label id="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_documentation_en-US" xlink:label="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable With Imputed Interest, Non-Consolidated Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:href="neo-20211231.xsd#neo_ReceivableWithImputedInterestNonConsolidatedAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:to="lab_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_0301917d-dfbf-4f92-9234-1dd678770ab5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_c2612e9d-1055-45a5-bcb6-5c85e7109308_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_7d132ade-7f99-4194-981d-b08282f094a1_terseLabel_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax position (as a percent)</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_label_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent</link:label>
    <link:label id="lab_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_documentation_en-US" xlink:label="lab_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:to="lab_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_a1b71b9b-cfb3-43be-9525-4e4026cc428f_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities_4f1ee0e3-bb0f-46d8-98aa-c0be4cdddfab_terseLabel_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments, current liabilities</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities_label_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities</link:label>
    <link:label id="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities_documentation_en-US" xlink:label="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities" xlink:to="lab_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_711a32cf-1bee-41b5-a708-dfde8fa0b4cc_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_08357cb8-145e-41a7-b110-d4b9cbfaaa1e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoverability and Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_MedicareAndMedicaidMember_461581f1-7074-4acf-af00-dd5b6635681e_terseLabel_en-US" xlink:label="lab_neo_MedicareAndMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and other government</link:label>
    <link:label id="lab_neo_MedicareAndMedicaidMember_label_en-US" xlink:label="lab_neo_MedicareAndMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicaid [Member]</link:label>
    <link:label id="lab_neo_MedicareAndMedicaidMember_documentation_en-US" xlink:label="lab_neo_MedicareAndMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_MedicareAndMedicaidMember" xlink:href="neo-20211231.xsd#neo_MedicareAndMedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_MedicareAndMedicaidMember" xlink:to="lab_neo_MedicareAndMedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f227f834-5385-4cc3-bfd7-6f2f478f2f71_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_840aae5e-abdc-412d-8106-afecbe38297e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_08b38a7d-ac58-4ced-8398-2b2d8a905cf2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_01f29af3-e321-43fc-9d6c-c9eba7b3ddbd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value per share at grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b6306bf6-5d7b-4d57-a6c6-cd852ebaaa8f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_79aa5edc-a81e-48e5-87eb-6dce0df793c1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_dbb22773-5c16-4e45-8d66-c6b0f33caf92_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_6bdae892-4d95-46c9-8ba7-a4304a1ef998_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_67d260f7-c1c4-46b9-a1cd-d3e9bde63ea0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET (LOSS) INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_eb605619-65ba-4bf2-ba37-258185039121_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_AgencyBondsMember_3e05e9d7-4f6d-4718-98ec-9f3929fafe32_terseLabel_en-US" xlink:label="lab_neo_AgencyBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_neo_AgencyBondsMember_label_en-US" xlink:label="lab_neo_AgencyBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Bonds [Member]</link:label>
    <link:label id="lab_neo_AgencyBondsMember_documentation_en-US" xlink:label="lab_neo_AgencyBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AgencyBondsMember" xlink:href="neo-20211231.xsd#neo_AgencyBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_AgencyBondsMember" xlink:to="lab_neo_AgencyBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_117eb481-a3b8-49b8-9522-c9ea72e1f0af_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b32c4cb-5a79-4aa0-80e7-fa711370c179_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3018cb56-c9f0-4984-967b-8ac2f0c4351e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2e54a9cb-960a-4707-8dc2-758b00162e26_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0aa01071-c498-4209-a3dd-b8a7b9b83994_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e2ed3718-643b-48c8-b949-e3e1c9f9845e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_729b3bba-b13c-4583-a0fb-fc8621b2e425_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAbstract_91c16584-d195-4039-bee0-7213b3fdf7a1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract" xlink:to="lab_us-gaap_CapitalizedContractCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_77793eea-65f7-4feb-91dc-42678cfd0674_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00039fce-ebcf-48fe-9c02-107cb25a08b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e968c5c5-b82f-42e4-81ce-749130e94a73_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30109873-794f-4a3d-82f3-55d48d589063_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c5bba026-cd11-4556-8ed2-f219d8283d18_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a45c1008-964d-4670-817d-a4a1745d9877_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_1a4fb625-59da-44e2-998b-c0587e139512_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_111538b8-277c-4392-ba15-7929b1da90b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Transactions</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_625a85b8-dd16-46bd-9994-f3cfd5bb6f99_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statute expirations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_46820098-ce14-4a42-b4a7-4733e1c5a505_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e1d5c1a1-a887-43d8-9dee-8e8ea7fe4a4e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_a21055a9-6f4d-4b8e-bb29-5b1064c613b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate_78b98f10-9ac6-4490-ba7b-f6266017d549_terseLabel_en-US" xlink:label="lab_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount priced to investors (as a percent)</link:label>
    <link:label id="lab_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate_label_en-US" xlink:label="lab_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Notes, Aggregate Principle Amount Rate</link:label>
    <link:label id="lab_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate_documentation_en-US" xlink:label="lab_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Notes, Aggregate Principle Amount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" xlink:href="neo-20211231.xsd#neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" xlink:to="lab_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_818e19ab-ccf9-4756-9db5-5b63f0da4314_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestRateSwapDecember2016Member_a29d04cd-4148-4c83-b756-b342a5f696e6_terseLabel_en-US" xlink:label="lab_neo_InterestRateSwapDecember2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previous interest rate swap agreement</link:label>
    <link:label id="lab_neo_InterestRateSwapDecember2016Member_label_en-US" xlink:label="lab_neo_InterestRateSwapDecember2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap December 2016 [Member]</link:label>
    <link:label id="lab_neo_InterestRateSwapDecember2016Member_documentation_en-US" xlink:label="lab_neo_InterestRateSwapDecember2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap December 2016 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestRateSwapDecember2016Member" xlink:href="neo-20211231.xsd#neo_InterestRateSwapDecember2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestRateSwapDecember2016Member" xlink:to="lab_neo_InterestRateSwapDecember2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2dbc4720-8f98-4c73-994d-8b99643b15bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0978a517-0d6d-4b9b-ab39-3cc0c03d40ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4e705abf-1856-4545-ab43-af3cac383b2a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_1579dc88-c94c-4379-8f29-1bd497129612_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate on Convertible Notes (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_65d5deb5-3edd-4815-bea7-3bf259b7b149_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:to="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_TrapeloHealthMember_cf0dc956-547c-422a-8f9d-aaf9aad56596_terseLabel_en-US" xlink:label="lab_neo_TrapeloHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trapelo Health</link:label>
    <link:label id="lab_neo_TrapeloHealthMember_label_en-US" xlink:label="lab_neo_TrapeloHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trapelo Health [Member]</link:label>
    <link:label id="lab_neo_TrapeloHealthMember_documentation_en-US" xlink:label="lab_neo_TrapeloHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trapelo Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_TrapeloHealthMember" xlink:to="lab_neo_TrapeloHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_309f84ea-a22d-4577-b1d2-30da0cb771bb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_5ca8c442-5683-4bf0-967a-2ea82d29fb0d_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_ce8261e8-e117-44f1-9d1d-d09c7cd9eb5d_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_a6e2b83f-8a04-4bfd-9c04-fc38f348578d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent_8efb71f8-f4f0-4479-b10b-bac0837ce99b_verboseLabel_en-US" xlink:label="lab_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum company match (as a percent)</link:label>
    <link:label id="lab_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Additional Maximum Annual Contributions Per Employee Percent</link:label>
    <link:label id="lab_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent_documentation_en-US" xlink:label="lab_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan additional maximum annual contributions per employee percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent" xlink:href="neo-20211231.xsd#neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_88bc9494-2cfe-4579-b949-2ac0f8103ff5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_8b3a82b3-036b-4a72-9f65-74acc8035fcb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_9e55942c-6993-4f0b-85d0-6ee66ae3d8ac_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_06084c72-f1b1-4bb4-916c-488abd4b2c4f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_88cd1d86-0d89-4494-831a-6824d06176c8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_cc267c8f-79ac-4c16-87cf-12cbf48d227b_terseLabel_en-US" xlink:label="lab_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock - private placement, net of private placement fees</link:label>
    <link:label id="lab_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_label_en-US" xlink:label="lab_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues, Private Placement</link:label>
    <link:label id="lab_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_documentation_en-US" xlink:label="lab_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues, Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:href="neo-20211231.xsd#neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:to="lab_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InivataMember_6bb28f16-6e38-43f5-b8ee-06fa5c441049_terseLabel_en-US" xlink:label="lab_neo_InivataMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inivata</link:label>
    <link:label id="lab_neo_InivataMember_label_en-US" xlink:label="lab_neo_InivataMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inivata [Member]</link:label>
    <link:label id="lab_neo_InivataMember_documentation_en-US" xlink:label="lab_neo_InivataMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inivata</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InivataMember" xlink:to="lab_neo_InivataMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ed8efa50-0a97-48b0-8260-c8e13950c061_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_15894e1e-f94b-47b2-8e0b-fd9079c50ec7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_62705920-03ac-4b69-832b-7d9653cdc708_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_3187f05b-da58-464a-aa17-a9e08f25366f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, operating lease liabilities, deferred taxes, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_d5ded0ef-4204-4065-b311-2b70e0a9786d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, (250,000,000 shares authorized; 124,107,500 and 112,075,474 shares issued and outstanding, respectively)</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b3620934-edf1-4044-bcdf-2557ffe15167_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Year or Less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_ddfb8f68-2a51-4f21-8d1d-84bfa5c5a641_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets - developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_8e12cd46-9033-4f7b-8bdc-6661d7230ca2_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_dd969cf8-c469-44e9-a9e4-79305368b3a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_0807c9eb-c322-42f8-b874-08b860d40598_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate per annum (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_632a1b50-1dab-4521-88b3-e53167e05f8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3e3971c8-f971-445a-ad63-87abdb6d651a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_99e89506-6c05-452f-ac37-e2b5ce730d50_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>neo-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c83854c7-f1f3-424f-996d-5603fac85cdc,g:4d64aeee-8493-464d-9030-1629fa1fd3ef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://neogenomics.com/role/CoverPage" xlink:type="simple" xlink:href="neo-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1e6a1088-e2a1-4795-9ab8-db967b25cd26" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_DocumentType_1e6a1088-e2a1-4795-9ab8-db967b25cd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_4e4f233a-f471-4e9f-9be7-758a640e56de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_DocumentAnnualReport_4e4f233a-f471-4e9f-9be7-758a640e56de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_65fb9ed2-4fcf-44d9-b643-27bbbddfb5fb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_DocumentPeriodEndDate_65fb9ed2-4fcf-44d9-b643-27bbbddfb5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5cbebd0b-a8f1-4d84-a467-0fdf0f17b1c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_CurrentFiscalYearEndDate_5cbebd0b-a8f1-4d84-a467-0fdf0f17b1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4cde51b6-90f4-45ed-bbfa-9d6dadc76fd1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_DocumentTransitionReport_4cde51b6-90f4-45ed-bbfa-9d6dadc76fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2576f441-d38d-48b5-a278-1861301ec708" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityFileNumber_2576f441-d38d-48b5-a278-1861301ec708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_21361bdf-23dd-492c-9dfb-11ad0f633f5b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityRegistrantName_21361bdf-23dd-492c-9dfb-11ad0f633f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ccbd5f25-1bad-431c-9484-98c5592f179a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ccbd5f25-1bad-431c-9484-98c5592f179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5a4c8053-2e23-45b4-bf80-67ee13d07bbc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityTaxIdentificationNumber_5a4c8053-2e23-45b4-bf80-67ee13d07bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_09ad949c-4e33-4932-90f5-9c46d8e90ecd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityAddressAddressLine1_09ad949c-4e33-4932-90f5-9c46d8e90ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_592722b3-1159-484f-baf2-c5184bdb2253" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityAddressCityOrTown_592722b3-1159-484f-baf2-c5184bdb2253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6162d5cc-51fa-4103-90f7-dd0ee04bb365" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityAddressStateOrProvince_6162d5cc-51fa-4103-90f7-dd0ee04bb365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bb3d1fb5-2fce-48ef-9a95-66f51b95a0f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityAddressPostalZipCode_bb3d1fb5-2fce-48ef-9a95-66f51b95a0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a5d2ede0-d43e-4d4f-a3cc-e27291b031af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_CityAreaCode_a5d2ede0-d43e-4d4f-a3cc-e27291b031af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e628d70b-d738-4f43-becd-eaf79f0c7878" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_LocalPhoneNumber_e628d70b-d738-4f43-becd-eaf79f0c7878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3ba2c39c-ceb9-4013-8963-8e0e5f39da13" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_Security12bTitle_3ba2c39c-ceb9-4013-8963-8e0e5f39da13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f3376726-22eb-46e7-8484-ca048fa229f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_TradingSymbol_f3376726-22eb-46e7-8484-ca048fa229f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fdd570ec-5109-40f1-83af-af175998e06d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_SecurityExchangeName_fdd570ec-5109-40f1-83af-af175998e06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_08cdfe61-81cd-41c4-8a09-09fb28d7d875" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_08cdfe61-81cd-41c4-8a09-09fb28d7d875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_5c81b137-6130-42a8-88be-126733228b41" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityVoluntaryFilers_5c81b137-6130-42a8-88be-126733228b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f0718eb3-5769-4ddc-b820-cf8fd29ac7db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityCurrentReportingStatus_f0718eb3-5769-4ddc-b820-cf8fd29ac7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_165c946b-7c4a-4b22-a1bf-684ce02f57ba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityInteractiveDataCurrent_165c946b-7c4a-4b22-a1bf-684ce02f57ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_dae23a22-800d-4af7-ae6e-4c6c8269c8aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityFilerCategory_dae23a22-800d-4af7-ae6e-4c6c8269c8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_be96de8b-ab7f-4484-8784-24a7bd4cf297" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntitySmallBusiness_be96de8b-ab7f-4484-8784-24a7bd4cf297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9428e11f-86a7-4fe7-bc39-62f960bf0bf1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityEmergingGrowthCompany_9428e11f-86a7-4fe7-bc39-62f960bf0bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_b1494602-cad4-4d8a-9fad-b40a2f4cddf8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_IcfrAuditorAttestationFlag_b1494602-cad4-4d8a-9fad-b40a2f4cddf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_eba2ccc6-54a8-4e64-8091-2eed2349fed8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityShellCompany_eba2ccc6-54a8-4e64-8091-2eed2349fed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_b2250bcd-c5d0-44a3-b764-40ebd8b55d65" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityPublicFloat_b2250bcd-c5d0-44a3-b764-40ebd8b55d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4a27aeea-6463-45f9-b5ef-7fa0b07491d5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4a27aeea-6463-45f9-b5ef-7fa0b07491d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_abc869c4-ba40-46ad-b8b7-ac675f0d9ee2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_abc869c4-ba40-46ad-b8b7-ac675f0d9ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bc010a8f-0fd6-4171-9abd-e84470655289" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_EntityCentralIndexKey_bc010a8f-0fd6-4171-9abd-e84470655289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6cca154e-a4e1-40bf-9b03-02581f328568" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_DocumentFiscalYearFocus_6cca154e-a4e1-40bf-9b03-02581f328568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ad42f00e-99f8-422f-b483-45a3b0f382f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ad42f00e-99f8-422f-b483-45a3b0f382f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3b0a0703-cbe7-41c6-abe9-16b0a58f3fcf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_be1657ae-265e-415f-a206-1c4fb08070a1" xlink:to="loc_dei_AmendmentFlag_3b0a0703-cbe7-41c6-abe9-16b0a58f3fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AuditInformation" xlink:type="simple" xlink:href="neo-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_neo_AuditInformationAbstract_0b46dcd5-a8c2-40b6-9528-344a8ce53918" xlink:href="neo-20211231.xsd#neo_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_a6c5bb22-1c49-4678-81de-f859e8abaa72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_AuditInformationAbstract_0b46dcd5-a8c2-40b6-9528-344a8ce53918" xlink:to="loc_dei_AuditorLocation_a6c5bb22-1c49-4678-81de-f859e8abaa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_c8c80341-4f5d-42d6-b69f-ac90cc54f610" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_AuditInformationAbstract_0b46dcd5-a8c2-40b6-9528-344a8ce53918" xlink:to="loc_dei_AuditorName_c8c80341-4f5d-42d6-b69f-ac90cc54f610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_4fb7b051-4194-484e-b59b-faeb14ccf878" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_AuditInformationAbstract_0b46dcd5-a8c2-40b6-9528-344a8ce53918" xlink:to="loc_dei_AuditorFirmId_4fb7b051-4194-484e-b59b-faeb14ccf878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e93de8ea-9b89-4d4d-a206-bd5191d74cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e93de8ea-9b89-4d4d-a206-bd5191d74cde" xlink:to="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b20df03f-be18-469c-bc5e-676b45bdd87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b20df03f-be18-469c-bc5e-676b45bdd87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_20e2578c-3b3d-43b1-94e8-84541b68ad7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_20e2578c-3b3d-43b1-94e8-84541b68ad7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_99bec19c-4f8d-4678-a9a9-b422e9a953ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_99bec19c-4f8d-4678-a9a9-b422e9a953ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f85c8581-3b06-4b01-93ca-6943a1d2455b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:to="loc_us-gaap_InventoryNet_f85c8581-3b06-4b01-93ca-6943a1d2455b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_9085d483-5108-468a-af56-96b0a37b8f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_9085d483-5108-468a-af56-96b0a37b8f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_a0c13bdd-ae08-4146-821c-42132bccc173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_a0c13bdd-ae08-4146-821c-42132bccc173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a670c83e-ed69-4d03-ba51-4a024f5e2184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:to="loc_us-gaap_OtherAssetsCurrent_a670c83e-ed69-4d03-ba51-4a024f5e2184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0809f039-9bda-4257-873f-4d0077a1d153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f59ec004-3eb9-4b52-999d-054699331f3a" xlink:to="loc_us-gaap_AssetsCurrent_0809f039-9bda-4257-873f-4d0077a1d153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e5fecfff-8335-41ce-828d-57fabb6630b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e5fecfff-8335-41ce-828d-57fabb6630b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7bdf4a81-daa6-4da1-9e90-2d572f83e95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7bdf4a81-daa6-4da1-9e90-2d572f83e95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a158cf42-685a-43c5-9921-2d48c6b8bd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a158cf42-685a-43c5-9921-2d48c6b8bd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_152b8bdd-e69b-427a-aee7-17e41b55d1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_us-gaap_Goodwill_152b8bdd-e69b-427a-aee7-17e41b55d1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_471d474e-2857-4e89-8f96-259cb2df70e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_471d474e-2857-4e89-8f96-259cb2df70e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b841d149-0751-459e-91c1-99fce3bc1305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b841d149-0751-459e-91c1-99fce3bc1305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PrepaidRentNoncurrent_ad00c7d9-8a15-43f6-aad2-25868a194861" xlink:href="neo-20211231.xsd#neo_PrepaidRentNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_neo_PrepaidRentNoncurrent_ad00c7d9-8a15-43f6-aad2-25868a194861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1b116c7a-1f4a-4e34-859c-f414484de0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1b116c7a-1f4a-4e34-859c-f414484de0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3eb3c873-4007-4b51-9aa7-c06421ed0a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_308aec87-b784-42b0-b161-499e25bbeb55" xlink:to="loc_us-gaap_AssetsNoncurrent_3eb3c873-4007-4b51-9aa7-c06421ed0a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c3128ebc-94c0-44da-b5fe-8311ac29949c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e93de8ea-9b89-4d4d-a206-bd5191d74cde" xlink:to="loc_us-gaap_Assets_c3128ebc-94c0-44da-b5fe-8311ac29949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1d2bde4b-498d-4783-901b-93bc139703ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e93de8ea-9b89-4d4d-a206-bd5191d74cde" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1d2bde4b-498d-4783-901b-93bc139703ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_776332d3-c73a-4d55-b2f2-c2f31ff6e1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1d2bde4b-498d-4783-901b-93bc139703ec" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_776332d3-c73a-4d55-b2f2-c2f31ff6e1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2d48696a-7ce3-4eeb-a2ba-d30f2e49028a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_776332d3-c73a-4d55-b2f2-c2f31ff6e1af" xlink:to="loc_us-gaap_AccountsPayableCurrent_2d48696a-7ce3-4eeb-a2ba-d30f2e49028a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_edea1543-fcb2-4e6c-aa03-e8d91a1abed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_776332d3-c73a-4d55-b2f2-c2f31ff6e1af" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_edea1543-fcb2-4e6c-aa03-e8d91a1abed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_c829c118-8a1b-451b-b222-70723095469e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_776332d3-c73a-4d55-b2f2-c2f31ff6e1af" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_c829c118-8a1b-451b-b222-70723095469e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b4588ff4-401e-4d22-8ef0-d936cb896bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_776332d3-c73a-4d55-b2f2-c2f31ff6e1af" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b4588ff4-401e-4d22-8ef0-d936cb896bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c9aebee-b4c1-49b3-aabb-caf7df1b25e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_776332d3-c73a-4d55-b2f2-c2f31ff6e1af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c9aebee-b4c1-49b3-aabb-caf7df1b25e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_004722f2-0489-4ecc-9ab4-54d4834a99a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_776332d3-c73a-4d55-b2f2-c2f31ff6e1af" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_004722f2-0489-4ecc-9ab4-54d4834a99a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_406c4cb5-b052-4dc0-995f-f10ae2f4e452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_776332d3-c73a-4d55-b2f2-c2f31ff6e1af" xlink:to="loc_us-gaap_LiabilitiesCurrent_406c4cb5-b052-4dc0-995f-f10ae2f4e452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0daff0ad-0dd4-473a-9019-246c823e46be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1d2bde4b-498d-4783-901b-93bc139703ec" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0daff0ad-0dd4-473a-9019-246c823e46be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_6a8390f6-0644-4cca-9d5b-595489fee4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0daff0ad-0dd4-473a-9019-246c823e46be" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_6a8390f6-0644-4cca-9d5b-595489fee4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4abc8159-0d1d-4985-b417-6a15f0bb04c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0daff0ad-0dd4-473a-9019-246c823e46be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4abc8159-0d1d-4985-b417-6a15f0bb04c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20db2a7a-717e-4adf-8c3b-feb47d4481eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0daff0ad-0dd4-473a-9019-246c823e46be" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20db2a7a-717e-4adf-8c3b-feb47d4481eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3da2f0b7-b4c4-44f9-a3bf-505ed2fc2ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0daff0ad-0dd4-473a-9019-246c823e46be" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3da2f0b7-b4c4-44f9-a3bf-505ed2fc2ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f1d30305-c17f-4516-b15d-f6d68478dc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0daff0ad-0dd4-473a-9019-246c823e46be" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f1d30305-c17f-4516-b15d-f6d68478dc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c1aa48a9-e47c-4593-b9d2-95f2040ceb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0daff0ad-0dd4-473a-9019-246c823e46be" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c1aa48a9-e47c-4593-b9d2-95f2040ceb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e2bed4d7-e8a5-45a7-88ca-1c197d5060b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1d2bde4b-498d-4783-901b-93bc139703ec" xlink:to="loc_us-gaap_Liabilities_e2bed4d7-e8a5-45a7-88ca-1c197d5060b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_10608597-3a6f-427e-8897-206873ba93ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1d2bde4b-498d-4783-901b-93bc139703ec" xlink:to="loc_us-gaap_CommitmentsAndContingencies_10608597-3a6f-427e-8897-206873ba93ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a263df68-98a5-49db-90bb-d589c9e24c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1d2bde4b-498d-4783-901b-93bc139703ec" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a263df68-98a5-49db-90bb-d589c9e24c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_4345d293-5d14-4ab6-804d-b3ddf13e57ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a263df68-98a5-49db-90bb-d589c9e24c5e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_4345d293-5d14-4ab6-804d-b3ddf13e57ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a4ed2071-b9f1-46b9-9755-96e5d56df401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a263df68-98a5-49db-90bb-d589c9e24c5e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a4ed2071-b9f1-46b9-9755-96e5d56df401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a17008f2-172a-4bb7-9f50-025c88db4563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a263df68-98a5-49db-90bb-d589c9e24c5e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a17008f2-172a-4bb7-9f50-025c88db4563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffb06211-4340-4dad-8bd7-615f44360208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a263df68-98a5-49db-90bb-d589c9e24c5e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffb06211-4340-4dad-8bd7-615f44360208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0dbbcf6-32e7-4070-8656-5823eea2bdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a263df68-98a5-49db-90bb-d589c9e24c5e" xlink:to="loc_us-gaap_StockholdersEquity_b0dbbcf6-32e7-4070-8656-5823eea2bdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7f0ed389-8d78-4d03-9e2a-7599abe199cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1d2bde4b-498d-4783-901b-93bc139703ec" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7f0ed389-8d78-4d03-9e2a-7599abe199cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7335bc-e658-45ef-9669-c710a560dfce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bc03835d-cacc-4252-9a0b-3c727976d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7335bc-e658-45ef-9669-c710a560dfce" xlink:to="loc_us-gaap_AssetsAbstract_bc03835d-cacc-4252-9a0b-3c727976d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_994eb732-7020-4240-9c26-839942b0cd64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bc03835d-cacc-4252-9a0b-3c727976d7ea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_994eb732-7020-4240-9c26-839942b0cd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_946b25bc-f4d4-42c0-93c7-9ae9c128f426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7335bc-e658-45ef-9669-c710a560dfce" xlink:to="loc_us-gaap_StockholdersEquityAbstract_946b25bc-f4d4-42c0-93c7-9ae9c128f426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2f8bb1dc-c398-4b13-b3e1-bc3275a04964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_946b25bc-f4d4-42c0-93c7-9ae9c128f426" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2f8bb1dc-c398-4b13-b3e1-bc3275a04964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1c3520f1-58c9-4fb0-bde6-b9a054a47011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_946b25bc-f4d4-42c0-93c7-9ae9c128f426" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1c3520f1-58c9-4fb0-bde6-b9a054a47011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d742edcd-9a1b-45c8-b2dc-8642f608bc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_946b25bc-f4d4-42c0-93c7-9ae9c128f426" xlink:to="loc_us-gaap_CommonStockSharesIssued_d742edcd-9a1b-45c8-b2dc-8642f608bc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9e23bf6d-f176-4b52-b11d-8043f360add8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_946b25bc-f4d4-42c0-93c7-9ae9c128f426" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9e23bf6d-f176-4b52-b11d-8043f360add8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7b5e84bd-0274-459e-8f8f-e4161ad87018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5d25df01-5d2a-4e51-b425-f5526be04bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7b5e84bd-0274-459e-8f8f-e4161ad87018" xlink:to="loc_us-gaap_StatementTable_5d25df01-5d2a-4e51-b425-f5526be04bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c1820137-cb79-405f-b4dc-2fb5e21c9ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5d25df01-5d2a-4e51-b425-f5526be04bd0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c1820137-cb79-405f-b4dc-2fb5e21c9ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a77c4239-37be-47dc-b3f1-b7c17df4c640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c1820137-cb79-405f-b4dc-2fb5e21c9ed2" xlink:to="loc_us-gaap_SegmentDomain_a77c4239-37be-47dc-b3f1-b7c17df4c640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_8deec9d9-be31-4a52-8d3e-a24b41fd6e37" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a77c4239-37be-47dc-b3f1-b7c17df4c640" xlink:to="loc_neo_ClinicalServicesMember_8deec9d9-be31-4a52-8d3e-a24b41fd6e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_74de7236-c917-4d70-bb61-b37aa1483cd2" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a77c4239-37be-47dc-b3f1-b7c17df4c640" xlink:to="loc_neo_PharmaServicesMember_74de7236-c917-4d70-bb61-b37aa1483cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5d25df01-5d2a-4e51-b425-f5526be04bd0" xlink:to="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_61db20c9-d75b-44c8-9c7a-8e4a5dcda609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_RevenuesAbstract_61db20c9-d75b-44c8-9c7a-8e4a5dcda609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_50bb7924-0d79-4d95-b5e0-9c6b5b9c7799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_61db20c9-d75b-44c8-9c7a-8e4a5dcda609" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_50bb7924-0d79-4d95-b5e0-9c6b5b9c7799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_433929b4-97d1-4502-b88d-274e30a22fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_433929b4-97d1-4502-b88d-274e30a22fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7b9cc24f-b75c-4f4f-827e-9c9372b9978b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_GrossProfit_7b9cc24f-b75c-4f4f-827e-9c9372b9978b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_20bb8941-ecdd-4795-99dc-45fb693a19f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_20bb8941-ecdd-4795-99dc-45fb693a19f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2821bcf3-aa7a-4b8e-abd0-54e401bdbe33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2821bcf3-aa7a-4b8e-abd0-54e401bdbe33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d065cfb1-1775-46b2-8c77-5d5fff90212f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d065cfb1-1775-46b2-8c77-5d5fff90212f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d6f34a06-eb4d-44cb-b93f-6d36070e3fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0afbad85-f4ca-4601-8df9-0b9d3795d8d6" xlink:to="loc_us-gaap_OperatingExpenses_d6f34a06-eb4d-44cb-b93f-6d36070e3fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2ed8d449-4998-4fe0-bd8c-fd22956d7d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_OperatingIncomeLoss_2ed8d449-4998-4fe0-bd8c-fd22956d7d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9f8716d7-beae-4704-9a90-45b67322bd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_InterestExpense_9f8716d7-beae-4704-9a90-45b67322bd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_59465301-274d-4934-8c84-15606b623b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_59465301-274d-4934-8c84-15606b623b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable_d0de0f00-b658-456d-be26-efdb3a6da060" xlink:href="neo-20211231.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_neo_GainLossOnInvestmentAndLoanReceivable_d0de0f00-b658-456d-be26-efdb3a6da060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a049980d-ba41-4a8d-b1ac-5d9f961e7b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a049980d-ba41-4a8d-b1ac-5d9f961e7b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnTerminationOfInterestRateSwap_9c5cea23-f381-4348-9b2f-716d5877dfbe" xlink:href="neo-20211231.xsd#neo_GainLossOnTerminationOfInterestRateSwap"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_neo_GainLossOnTerminationOfInterestRateSwap_9c5cea23-f381-4348-9b2f-716d5877dfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0327eb69-b90e-42f7-9000-fc8ca366db86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0327eb69-b90e-42f7-9000-fc8ca366db86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ab7feb0b-aec1-4238-b70f-66ab2de2cb19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ab7feb0b-aec1-4238-b70f-66ab2de2cb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_054e5f3a-f0d2-4f07-811e-2542a24af038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_NetIncomeLoss_054e5f3a-f0d2-4f07-811e-2542a24af038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e473dd1d-f8cb-459e-bb49-d9d1bc30919a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e473dd1d-f8cb-459e-bb49-d9d1bc30919a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_54cf6e70-7abf-4923-b3a5-fa55220ffe03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e473dd1d-f8cb-459e-bb49-d9d1bc30919a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_54cf6e70-7abf-4923-b3a5-fa55220ffe03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6ea07730-f8b6-4b1a-992d-a76079ac664d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_e473dd1d-f8cb-459e-bb49-d9d1bc30919a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6ea07730-f8b6-4b1a-992d-a76079ac664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c1fcf6de-03f7-477c-b9f5-dcec9a301b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e1cc1de-7d74-41ae-b0aa-9038dd72a764" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c1fcf6de-03f7-477c-b9f5-dcec9a301b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87bf7323-d422-4fac-a454-17c3e86b9937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c1fcf6de-03f7-477c-b9f5-dcec9a301b44" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87bf7323-d422-4fac-a454-17c3e86b9937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c1a907c6-c26c-4a67-82fe-d9d5436e8287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c1fcf6de-03f7-477c-b9f5-dcec9a301b44" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c1a907c6-c26c-4a67-82fe-d9d5436e8287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedStatementsofComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c1fbc8f2-c2e4-45c7-a026-40aa5f49575e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c14d6d0e-fea9-4a4e-8101-a862da6eba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c1fbc8f2-c2e4-45c7-a026-40aa5f49575e" xlink:to="loc_us-gaap_NetIncomeLoss_c14d6d0e-fea9-4a4e-8101-a862da6eba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e2a1e8bd-701a-4e88-a290-504020fabc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c1fbc8f2-c2e4-45c7-a026-40aa5f49575e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e2a1e8bd-701a-4e88-a290-504020fabc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8603f5a6-2289-4e5d-aa60-8b2c7e79114b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e2a1e8bd-701a-4e88-a290-504020fabc2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8603f5a6-2289-4e5d-aa60-8b2c7e79114b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_85c56d4d-5cfb-46f7-b2c2-6a9fb29b6a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e2a1e8bd-701a-4e88-a290-504020fabc2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_85c56d4d-5cfb-46f7-b2c2-6a9fb29b6a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_cdf3aad0-4815-46f2-a676-f4b25d9b5424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e2a1e8bd-701a-4e88-a290-504020fabc2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_cdf3aad0-4815-46f2-a676-f4b25d9b5424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0fc6d199-a705-42a4-bab0-2649a8607837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e2a1e8bd-701a-4e88-a290-504020fabc2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0fc6d199-a705-42a4-bab0-2649a8607837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c3ddc5fb-3445-475c-8a8e-31edce0ed3be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c1fbc8f2-c2e4-45c7-a026-40aa5f49575e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c3ddc5fb-3445-475c-8a8e-31edce0ed3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_11e6f751-3dfc-4a75-9f4f-18390f4ed6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d616f464-5b6a-477b-a42f-5f0f123eb6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_11e6f751-3dfc-4a75-9f4f-18390f4ed6d5" xlink:to="loc_us-gaap_StatementTable_d616f464-5b6a-477b-a42f-5f0f123eb6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c695c8c9-2e42-4626-adf6-290b4354b34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d616f464-5b6a-477b-a42f-5f0f123eb6e0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c695c8c9-2e42-4626-adf6-290b4354b34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c695c8c9-2e42-4626-adf6-290b4354b34f" xlink:to="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0bfb1f30-93d4-4581-bffa-83a276f3201b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:to="loc_us-gaap_CommonStockMember_0bfb1f30-93d4-4581-bffa-83a276f3201b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_07e96efb-7459-4bbb-8ddc-72e5ef14eb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_07e96efb-7459-4bbb-8ddc-72e5ef14eb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a7e0e98-e2b2-4b73-9fc4-ce752e330782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a7e0e98-e2b2-4b73-9fc4-ce752e330782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1f03e685-b79c-4d3a-af3e-d8a5071ddd37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d06eebda-3dea-4bdf-9b5f-2e2f2fccb34a" xlink:to="loc_us-gaap_RetainedEarningsMember_1f03e685-b79c-4d3a-af3e-d8a5071ddd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6ec4048a-dc6c-40fb-9d87-e23abe9785fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d616f464-5b6a-477b-a42f-5f0f123eb6e0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6ec4048a-dc6c-40fb-9d87-e23abe9785fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ddd9bf3c-48b2-47d1-b858-5cf00c596010" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_6ec4048a-dc6c-40fb-9d87-e23abe9785fc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ddd9bf3c-48b2-47d1-b858-5cf00c596010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7510c1ab-7bc3-4fbf-a69b-6d0c2e6f2235" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ddd9bf3c-48b2-47d1-b858-5cf00c596010" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7510c1ab-7bc3-4fbf-a69b-6d0c2e6f2235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c2919226-a7db-40c9-97bd-435d8692b926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d616f464-5b6a-477b-a42f-5f0f123eb6e0" xlink:to="loc_us-gaap_StatementLineItems_c2919226-a7db-40c9-97bd-435d8692b926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c2919226-a7db-40c9-97bd-435d8692b926" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3caa4ead-636b-4040-94a9-ccfb5f62fad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_SharesOutstanding_3caa4ead-636b-4040-94a9-ccfb5f62fad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc6f92b1-6268-4c98-9c50-01a3d371e40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockholdersEquity_cc6f92b1-6268-4c98-9c50-01a3d371e40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1e07429-66d1-4f89-ba47-2923b70629ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1e07429-66d1-4f89-ba47-2923b70629ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8a4b8e4c-977e-4cd7-b7ae-2b2ee2940cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8a4b8e4c-977e-4cd7-b7ae-2b2ee2940cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_80da79be-89af-46be-8661-18418dfa0623" xlink:href="neo-20211231.xsd#neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt_80da79be-89af-46be-8661-18418dfa0623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c4a60a02-d2d2-47da-9e9c-250a5bef3842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c4a60a02-d2d2-47da-9e9c-250a5bef3842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_deadf772-5d7c-4194-8e5b-4e52b510f251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_deadf772-5d7c-4194-8e5b-4e52b510f251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_6722f08d-f77c-4abb-b37b-83569122eb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_6722f08d-f77c-4abb-b37b-83569122eb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e5de00c8-512e-4f9d-87d6-40e91b619850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e5de00c8-512e-4f9d-87d6-40e91b619850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination_9a4394ac-4237-4dff-9f9e-8310194eeb4e" xlink:href="neo-20211231.xsd#neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination_9a4394ac-4237-4dff-9f9e-8310194eeb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f392c8b-1d7f-4e81-968a-79fb27100a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f392c8b-1d7f-4e81-968a-79fb27100a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WorkingCapitalAdjustmentAcquisitionShares_61b8f60c-400b-4f78-8c76-59acf63312d0" xlink:href="neo-20211231.xsd#neo_WorkingCapitalAdjustmentAcquisitionShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_WorkingCapitalAdjustmentAcquisitionShares_61b8f60c-400b-4f78-8c76-59acf63312d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WorkingCapitalAdjustmentAcquisitions_6c50a532-17ce-419b-adaf-14253c143081" xlink:href="neo-20211231.xsd#neo_WorkingCapitalAdjustmentAcquisitions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_WorkingCapitalAdjustmentAcquisitions_6c50a532-17ce-419b-adaf-14253c143081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_941e5ced-b982-4f44-9632-3e4d97f4032c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_941e5ced-b982-4f44-9632-3e4d97f4032c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3806dafd-6049-40d9-b528-062ec97e1893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3806dafd-6049-40d9-b528-062ec97e1893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_026827b1-d66e-4a0b-ad93-ec1b70ee9d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_026827b1-d66e-4a0b-ad93-ec1b70ee9d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b2f7660d-4238-413a-8b3b-7c7213767aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b2f7660d-4238-413a-8b3b-7c7213767aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_d1334945-44bb-4396-a3e5-02196835e03e" xlink:href="neo-20211231.xsd#neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_d1334945-44bb-4396-a3e5-02196835e03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_4a60d9d2-0fb8-4ae6-800b-9bdfb586203a" xlink:href="neo-20211231.xsd#neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement_4a60d9d2-0fb8-4ae6-800b-9bdfb586203a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_7b1abe9a-dbe7-4fae-b892-9efb4c212533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_7b1abe9a-dbe7-4fae-b892-9efb4c212533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_6c4d186d-5c83-444f-8233-231d15da642e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_6c4d186d-5c83-444f-8233-231d15da642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6bf9a84c-d887-476d-8fb6-0de84343911a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6bf9a84c-d887-476d-8fb6-0de84343911a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb8fb25c-8706-4f24-985e-d85d0df1e644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb8fb25c-8706-4f24-985e-d85d0df1e644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6f51eeb6-b343-4d52-b989-79f9e99b8b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6f51eeb6-b343-4d52-b989-79f9e99b8b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment_f861db6c-8725-461c-a688-38752165cfee" xlink:href="neo-20211231.xsd#neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment_f861db6c-8725-461c-a688-38752165cfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts_cf0be6da-d167-42ae-953a-6e5db12f3dbb" xlink:href="neo-20211231.xsd#neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts_cf0be6da-d167-42ae-953a-6e5db12f3dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f29ad559-5900-4f1f-9382-b753197d6964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_NetIncomeLoss_f29ad559-5900-4f1f-9382-b753197d6964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_74611909-ec5b-43c0-8cf7-1588e5460180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_SharesOutstanding_74611909-ec5b-43c0-8cf7-1588e5460180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cb16c0b6-e82d-408a-a101-149ebcc7d855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2594058e-ecf4-4ddc-b9d1-8cf3aa238377" xlink:to="loc_us-gaap_StockholdersEquity_cb16c0b6-e82d-408a-a101-149ebcc7d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="neo-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_4cfab539-0b90-4913-a717-42b0db6bd3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_4cfab539-0b90-4913-a717-42b0db6bd3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0dc545d6-4d13-4448-aa30-784e20797dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_4cfab539-0b90-4913-a717-42b0db6bd3f1" xlink:to="loc_us-gaap_NetIncomeLoss_0dc545d6-4d13-4448-aa30-784e20797dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_4cfab539-0b90-4913-a717-42b0db6bd3f1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_86d5fd2d-7f2e-4bd7-8d57-b362a518d049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_us-gaap_Depreciation_86d5fd2d-7f2e-4bd7-8d57-b362a518d049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_613c19fe-ac72-47e6-9461-5eb90c50a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_613c19fe-ac72-47e6-9461-5eb90c50a4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_05cd73ad-0038-418b-a0a2-ff29dbb13603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_us-gaap_ShareBasedCompensation_05cd73ad-0038-418b-a0a2-ff29dbb13603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e5737647-b420-4f00-85e4-8e3e43b798f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_us-gaap_OperatingLeaseExpense_e5737647-b420-4f00-85e4-8e3e43b798f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_a3c4ecd6-e97f-4c32-aae2-badd32c78f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_a3c4ecd6-e97f-4c32-aae2-badd32c78f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_43f13f73-ecab-4e4c-a428-81f20863b98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_43f13f73-ecab-4e4c-a428-81f20863b98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2d1119f8-8351-4109-8fdc-81b23a199e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2d1119f8-8351-4109-8fdc-81b23a199e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnTerminationOfInterestRateSwap_0eedd6b4-814f-41a1-aa5f-5cd27608572a" xlink:href="neo-20211231.xsd#neo_GainLossOnTerminationOfInterestRateSwap"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_neo_GainLossOnTerminationOfInterestRateSwap_0eedd6b4-814f-41a1-aa5f-5cd27608572a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_8af997a5-9900-4009-975c-86935de08760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_8af997a5-9900-4009-975c-86935de08760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_30b89fe3-7238-4ae4-99e0-51b4a602b026" xlink:href="neo-20211231.xsd#neo_ReceivableWithImputedInterestNonConsolidatedAffiliates"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates_30b89fe3-7238-4ae4-99e0-51b4a602b026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_bfff77d2-1fe8-4b20-940f-140964c61d55" xlink:href="neo-20211231.xsd#neo_PolymeraseChainReactionTestingExitCostsCOVID19"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_bfff77d2-1fe8-4b20-940f-140964c61d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d6d213d7-9cc8-43eb-849a-dfdbfa1b65a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8a75494a-d08e-4384-90b3-a42bbb33db98" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d6d213d7-9cc8-43eb-849a-dfdbfa1b65a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f374ff7-8b31-4fd4-bc1e-6036a03a2527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_4cfab539-0b90-4913-a717-42b0db6bd3f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f374ff7-8b31-4fd4-bc1e-6036a03a2527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_80090a3f-d20b-47a5-b63d-30aba24f6557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f374ff7-8b31-4fd4-bc1e-6036a03a2527" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_80090a3f-d20b-47a5-b63d-30aba24f6557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_08300437-04c6-4b4e-83c5-845eb7e1c39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f374ff7-8b31-4fd4-bc1e-6036a03a2527" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_08300437-04c6-4b4e-83c5-845eb7e1c39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncreaseDecreaseInPrepaidConstruction_5e628672-bc3c-4752-bf3b-d4cfd55f9bf0" xlink:href="neo-20211231.xsd#neo_IncreaseDecreaseInPrepaidConstruction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f374ff7-8b31-4fd4-bc1e-6036a03a2527" xlink:to="loc_neo_IncreaseDecreaseInPrepaidConstruction_5e628672-bc3c-4752-bf3b-d4cfd55f9bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2950bfb9-f08c-4515-a0c5-6230343c71d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f374ff7-8b31-4fd4-bc1e-6036a03a2527" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2950bfb9-f08c-4515-a0c5-6230343c71d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_662f8bad-b672-4ee3-bf5a-aa7e41de3cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f374ff7-8b31-4fd4-bc1e-6036a03a2527" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_662f8bad-b672-4ee3-bf5a-aa7e41de3cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9b8f86-bbf3-430f-aa23-77829a3a4043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_4cfab539-0b90-4913-a717-42b0db6bd3f1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba9b8f86-bbf3-430f-aa23-77829a3a4043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1e272ec9-7e57-47f1-bb7f-303f2b53b21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1e272ec9-7e57-47f1-bb7f-303f2b53b21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6233c72a-a939-4010-8717-538557151aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6233c72a-a939-4010-8717-538557151aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ae98337-85df-460d-8585-3cc192fd4a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ae98337-85df-460d-8585-3cc192fd4a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6c792fde-40bb-47da-8546-c2d04502c82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6c792fde-40bb-47da-8546-c2d04502c82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_5fc3c61e-0cb5-4da4-8422-e42a3d0e11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_5fc3c61e-0cb5-4da4-8422-e42a3d0e11e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_ea03e69f-75f3-45fc-b178-bedc00ed8ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_ea03e69f-75f3-45fc-b178-bedc00ed8ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationWorkingCapitalAdjustment_4197f12e-9bf5-4607-b69a-c4e88cd53efc" xlink:href="neo-20211231.xsd#neo_BusinessCombinationWorkingCapitalAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:to="loc_neo_BusinessCombinationWorkingCapitalAdjustment_4197f12e-9bf5-4607-b69a-c4e88cd53efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_810c8515-c07b-4cf4-b78c-af3fe1777552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ba2483ea-2ef0-4805-be39-804ae2611c2b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_810c8515-c07b-4cf4-b78c-af3fe1777552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_c7cdce08-dd01-43a0-904e-b2b171639f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_c7cdce08-dd01-43a0-904e-b2b171639f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RepaymentsOfEquipmentAndOtherLoans_f316566c-ac24-4cd9-96cd-9550e0c22dd0" xlink:href="neo-20211231.xsd#neo_RepaymentsOfEquipmentAndOtherLoans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_neo_RepaymentsOfEquipmentAndOtherLoans_f316566c-ac24-4cd9-96cd-9550e0c22dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_8e765bd0-b1a6-43f1-8ca4-ac4403a8d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_8e765bd0-b1a6-43f1-8ca4-ac4403a8d83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_8d9334d1-0d6f-4b09-92ef-148332d72c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_8d9334d1-0d6f-4b09-92ef-148332d72c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DerivativeTerminationFee_e338b3e4-9965-47e9-bc66-53f00b36f25e" xlink:href="neo-20211231.xsd#neo_DerivativeTerminationFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_neo_DerivativeTerminationFee_e338b3e4-9965-47e9-bc66-53f00b36f25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_348afefa-79e9-4371-8b3a-9e9b57d1091f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_348afefa-79e9-4371-8b3a-9e9b57d1091f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fe8d1f00-aecc-485b-b7f1-16adbbfa1509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fe8d1f00-aecc-485b-b7f1-16adbbfa1509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0eb21376-6bed-47e0-a5a2-129edcb12fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_0eb21376-6bed-47e0-a5a2-129edcb12fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations_0ada1458-4b8a-450a-b67a-7f12dc8149f7" xlink:href="neo-20211231.xsd#neo_PaymentsOfPremiumsForCappedCallConfirmations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_neo_PaymentsOfPremiumsForCappedCallConfirmations_0ada1458-4b8a-450a-b67a-7f12dc8149f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ProceedsFromEquityOfferingNet_8beefdf9-7d3c-47cf-b87b-72d0096dcaf7" xlink:href="neo-20211231.xsd#neo_ProceedsFromEquityOfferingNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_neo_ProceedsFromEquityOfferingNet_8beefdf9-7d3c-47cf-b87b-72d0096dcaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7501873b-5f8a-4cc0-b0ef-1c20b52ba80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cdefd01e-e06b-4092-9e52-77453243bdad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7501873b-5f8a-4cc0-b0ef-1c20b52ba80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5b179cbd-06ff-493b-be1b-094c685fd18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5b179cbd-06ff-493b-be1b-094c685fd18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e42c9467-a03f-440b-be16-cdc257326115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e42c9467-a03f-440b-be16-cdc257326115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a3fff076-1391-4c5a-b367-385d63f08b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a3fff076-1391-4c5a-b367-385d63f08b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c73ca873-e23b-4d70-b247-4954363f1e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c73ca873-e23b-4d70-b247-4954363f1e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_91d41d7f-e429-4bc8-ab86-25eaa544d85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_91d41d7f-e429-4bc8-ab86-25eaa544d85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_285bc9de-919a-423a-a0a7-e8fc4e662a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_285bc9de-919a-423a-a0a7-e8fc4e662a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4adcdc9b-a40f-4e77-9ab9-bba00a362c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_285bc9de-919a-423a-a0a7-e8fc4e662a36" xlink:to="loc_us-gaap_InterestPaidNet_4adcdc9b-a40f-4e77-9ab9-bba00a362c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_780d25d9-aa6d-447b-8da7-42b389d7920b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_285bc9de-919a-423a-a0a7-e8fc4e662a36" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_780d25d9-aa6d-447b-8da7-42b389d7920b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a891dd15-00f6-4cb2-a4ea-66881bb6c679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3f27a67b-5481-482e-bece-210074882153" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a891dd15-00f6-4cb2-a4ea-66881bb6c679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FairValueOfCommonStockIssuedToFundAcquisition_dc5f394f-bd14-4b4c-97f5-143d3d69200a" xlink:href="neo-20211231.xsd#neo_FairValueOfCommonStockIssuedToFundAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a891dd15-00f6-4cb2-a4ea-66881bb6c679" xlink:to="loc_neo_FairValueOfCommonStockIssuedToFundAcquisition_dc5f394f-bd14-4b4c-97f5-143d3d69200a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WorkingCapitalAdjustmentAcquisitions_7655a504-5e1d-412d-927c-e11aa9e46184" xlink:href="neo-20211231.xsd#neo_WorkingCapitalAdjustmentAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a891dd15-00f6-4cb2-a4ea-66881bb6c679" xlink:to="loc_neo_WorkingCapitalAdjustmentAcquisitions_7655a504-5e1d-412d-927c-e11aa9e46184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_3f8b6361-dfe7-4189-acb6-37901d515727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a891dd15-00f6-4cb2-a4ea-66881bb6c679" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_3f8b6361-dfe7-4189-acb6-37901d515727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6868a2b3-b49e-4f0f-b70d-d95e8edb6c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a891dd15-00f6-4cb2-a4ea-66881bb6c679" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6868a2b3-b49e-4f0f-b70d-d95e8edb6c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NatureofBusiness" xlink:type="simple" xlink:href="neo-20211231.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94b430a5-a5bc-487a-b9a5-ecc8fd94ef21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9c0507f4-a1a8-40ec-9139-d4d2979fa5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94b430a5-a5bc-487a-b9a5-ecc8fd94ef21" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9c0507f4-a1a8-40ec-9139-d4d2979fa5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#NatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d3d9af7-d5a1-4b0c-86e6-4e9b19afa344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_c0c64558-d5ce-435c-995e-c57c6d2b77a4" xlink:href="neo-20211231.xsd#neo_PolymeraseChainReactionTestingExitCostsCOVID19"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d3d9af7-d5a1-4b0c-86e6-4e9b19afa344" xlink:to="loc_neo_PolymeraseChainReactionTestingExitCostsCOVID19_c0c64558-d5ce-435c-995e-c57c6d2b77a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_81577d00-f5ad-4f4f-8953-7e08b850f3fd" xlink:href="neo-20211231.xsd#neo_PolymeraseChainReactionTestingWriteOffsCOVID19"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d3d9af7-d5a1-4b0c-86e6-4e9b19afa344" xlink:to="loc_neo_PolymeraseChainReactionTestingWriteOffsCOVID19_81577d00-f5ad-4f4f-8953-7e08b850f3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_84943dcb-c10b-4c73-bc52-d4fb674fd025" xlink:href="neo-20211231.xsd#neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d3d9af7-d5a1-4b0c-86e6-4e9b19afa344" xlink:to="loc_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19_84943dcb-c10b-4c73-bc52-d4fb674fd025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ProceedsFromGovernmentAssistanceCARESAct_010cb375-f668-4864-9a13-84a75ae8238a" xlink:href="neo-20211231.xsd#neo_ProceedsFromGovernmentAssistanceCARESAct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d3d9af7-d5a1-4b0c-86e6-4e9b19afa344" xlink:to="loc_neo_ProceedsFromGovernmentAssistanceCARESAct_010cb375-f668-4864-9a13-84a75ae8238a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SocialSecurityTaxEmployerDeferralCARESAct_c7bd82e3-703c-46b6-831a-1754d6f59154" xlink:href="neo-20211231.xsd#neo_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d3d9af7-d5a1-4b0c-86e6-4e9b19afa344" xlink:to="loc_neo_SocialSecurityTaxEmployerDeferralCARESAct_c7bd82e3-703c-46b6-831a-1754d6f59154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EmployeeRetentionTaxCreditCARESAct_7943b4d5-8b93-422a-b76b-cb0b645576ba" xlink:href="neo-20211231.xsd#neo_EmployeeRetentionTaxCreditCARESAct"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5d3d9af7-d5a1-4b0c-86e6-4e9b19afa344" xlink:to="loc_neo_EmployeeRetentionTaxCreditCARESAct_7943b4d5-8b93-422a-b76b-cb0b645576ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="neo-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2c7b3701-33fd-438a-bdce-5005d446f528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c5dbfb09-0ac6-434c-898d-cd70344f765f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2c7b3701-33fd-438a-bdce-5005d446f528" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c5dbfb09-0ac6-434c-898d-cd70344f765f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="neo-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1abb19a2-aeb9-4ddc-aed3-df459afc8833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_UseOfEstimates_1abb19a2-aeb9-4ddc-aed3-df459afc8833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_53cc88ca-d150-4918-becb-695f046f5aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_53cc88ca-d150-4918-becb-695f046f5aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a98b8ed0-acff-4a3b-b69b-60e88086d2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a98b8ed0-acff-4a3b-b69b-60e88086d2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_8b39f926-b3cb-480d-a76c-64bd1d68c10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_8b39f926-b3cb-480d-a76c-64bd1d68c10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5c7be0bb-79ab-4052-bd80-44ac8a82ca65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5c7be0bb-79ab-4052-bd80-44ac8a82ca65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_291883cb-93a4-440c-b7c9-23a9d76ae358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_291883cb-93a4-440c-b7c9-23a9d76ae358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_faedba36-e505-446b-be08-6e770278adc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_faedba36-e505-446b-be08-6e770278adc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_adeed756-4913-4429-9f45-3b4b80ed3a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_adeed756-4913-4429-9f45-3b4b80ed3a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_4aa0fa85-82d4-4f8e-af89-0c51cb203b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_4aa0fa85-82d4-4f8e-af89-0c51cb203b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetsHeldForSalePolicyPolicyTextBlock_6c1725cc-b0bb-497e-8f21-43acd0cd13a7" xlink:href="neo-20211231.xsd#neo_AssetsHeldForSalePolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_neo_AssetsHeldForSalePolicyPolicyTextBlock_6c1725cc-b0bb-497e-8f21-43acd0cd13a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_da2338a1-184c-42d1-ae49-dce228b52529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_da2338a1-184c-42d1-ae49-dce228b52529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock_89540ad9-1c2e-4c69-b821-432ca6f3a769" xlink:href="neo-20211231.xsd#neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock_89540ad9-1c2e-4c69-b821-432ca6f3a769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_dea2c785-d199-45bf-92f7-13a75b573aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_dea2c785-d199-45bf-92f7-13a75b573aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_d4dc8ba8-5b27-43ef-bc03-586fcff0693a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_d4dc8ba8-5b27-43ef-bc03-586fcff0693a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_30fcb492-6b11-4203-bdee-d56a7c044c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_30fcb492-6b11-4203-bdee-d56a7c044c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c0a0c526-c33c-4491-b4d5-167442741801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c0a0c526-c33c-4491-b4d5-167442741801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_0860509c-780a-4de7-b061-55dfab8a49d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_0860509c-780a-4de7-b061-55dfab8a49d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_b07cb670-91bb-4f65-8496-fd87d73c3763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_b07cb670-91bb-4f65-8496-fd87d73c3763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_9e53be41-b39b-4425-b126-38609c9d0f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_DebtPolicyTextBlock_9e53be41-b39b-4425-b126-38609c9d0f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_00e1562e-b7ec-4a5a-9a14-1178d0ddc3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_00e1562e-b7ec-4a5a-9a14-1178d0ddc3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7b2771de-abc8-4e76-a97e-a03e8b611870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7b2771de-abc8-4e76-a97e-a03e8b611870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_cd833536-9f19-40b2-8b36-141a76fdc909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_cd833536-9f19-40b2-8b36-141a76fdc909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_fc609447-13ac-42b2-9861-0b41faeeec1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_fc609447-13ac-42b2-9861-0b41faeeec1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_53e6ed6c-7588-4a16-a2f3-19caf0c41426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_53e6ed6c-7588-4a16-a2f3-19caf0c41426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegulatoryIncomeTaxesPolicy_5066cd7e-d709-4012-989f-2f6367b61ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegulatoryIncomeTaxesPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_RegulatoryIncomeTaxesPolicy_5066cd7e-d709-4012-989f-2f6367b61ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0333b29a-5ca2-473e-b59e-1059bae6c984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0333b29a-5ca2-473e-b59e-1059bae6c984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7b68802b-fb45-4ec2-949b-cbe1061cafe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3209626-23c9-482f-93f4-c4b7910212c6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7b68802b-fb45-4ec2-949b-cbe1061cafe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b83c3d4a-398d-4613-b516-a3ec6ea64749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:href="neo-20211231.xsd#neo_ScheduleOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b83c3d4a-398d-4613-b516-a3ec6ea64749" xlink:to="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3b651ff5-40a5-4e5a-b7f5-6fe4a73f37ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_srt_ProductOrServiceAxis_3b651ff5-40a5-4e5a-b7f5-6fe4a73f37ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d186fbaf-4834-4b83-8d9c-ebfb43c37875" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3b651ff5-40a5-4e5a-b7f5-6fe4a73f37ed" xlink:to="loc_srt_ProductsAndServicesDomain_d186fbaf-4834-4b83-8d9c-ebfb43c37875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_c1014e77-1971-43d4-abcf-412694609d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d186fbaf-4834-4b83-8d9c-ebfb43c37875" xlink:to="loc_us-gaap_ShippingAndHandlingMember_c1014e77-1971-43d4-abcf-412694609d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1dc97c47-be3f-482d-8ce2-bc3c83c3f7a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_srt_RangeAxis_1dc97c47-be3f-482d-8ce2-bc3c83c3f7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7bbcae89-3b4d-44fa-80b5-2e8b54788c4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1dc97c47-be3f-482d-8ce2-bc3c83c3f7a3" xlink:to="loc_srt_RangeMember_7bbcae89-3b4d-44fa-80b5-2e8b54788c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99a21c14-fe3b-4e2e-949a-9cd60d217d28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7bbcae89-3b4d-44fa-80b5-2e8b54788c4a" xlink:to="loc_srt_MinimumMember_99a21c14-fe3b-4e2e-949a-9cd60d217d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_03b1c2c4-819f-47b2-a3b1-fd414a43756c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7bbcae89-3b4d-44fa-80b5-2e8b54788c4a" xlink:to="loc_srt_MaximumMember_03b1c2c4-819f-47b2-a3b1-fd414a43756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c64473c5-c80e-4c3a-92c2-984ac08a9875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_us-gaap_DebtInstrumentAxis_c64473c5-c80e-4c3a-92c2-984ac08a9875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_648920c4-7855-40d4-9447-8d91a4715e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c64473c5-c80e-4c3a-92c2-984ac08a9875" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_648920c4-7855-40d4-9447-8d91a4715e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_0ec5ca64-b995-423e-b719-23b0812e3d43" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_648920c4-7855-40d4-9447-8d91a4715e60" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_0ec5ca64-b995-423e-b719-23b0812e3d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_4d4ddca8-929d-4f1b-a544-fb6ec29ae12b" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_648920c4-7855-40d4-9447-8d91a4715e60" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_4d4ddca8-929d-4f1b-a544-fb6ec29ae12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c4f14262-2756-4d3c-ac09-eb708db14bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c4f14262-2756-4d3c-ac09-eb708db14bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e822f0ff-4337-4f8d-aea2-7a39ed07afa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c4f14262-2756-4d3c-ac09-eb708db14bec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e822f0ff-4337-4f8d-aea2-7a39ed07afa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_cbaa87ad-4d1a-4731-8a41-281eb4c4c129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e822f0ff-4337-4f8d-aea2-7a39ed07afa5" xlink:to="loc_us-gaap_ConvertibleDebtMember_cbaa87ad-4d1a-4731-8a41-281eb4c4c129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_05f64a92-0162-4330-9952-e587a3d4f567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_05f64a92-0162-4330-9952-e587a3d4f567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c709021f-97bc-4fec-968b-792e14569cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_05f64a92-0162-4330-9952-e587a3d4f567" xlink:to="loc_us-gaap_EquityComponentDomain_c709021f-97bc-4fec-968b-792e14569cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_21b1ed41-c98d-4b28-9830-aad301adbce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c709021f-97bc-4fec-968b-792e14569cfc" xlink:to="loc_us-gaap_RetainedEarningsMember_21b1ed41-c98d-4b28-9830-aad301adbce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a526f834-4a74-499a-9102-72ca9b5e9deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c709021f-97bc-4fec-968b-792e14569cfc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a526f834-4a74-499a-9102-72ca9b5e9deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_04b2a307-6e28-4bfe-8edd-47c8e54d64a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_04b2a307-6e28-4bfe-8edd-47c8e54d64a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fb94fce4-af81-4b68-9212-0bf90302fcbb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_04b2a307-6e28-4bfe-8edd-47c8e54d64a0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fb94fce4-af81-4b68-9212-0bf90302fcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4a521e3b-72e2-4d17-a73c-d3b3699f0e3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fb94fce4-af81-4b68-9212-0bf90302fcbb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4a521e3b-72e2-4d17-a73c-d3b3699f0e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:href="neo-20211231.xsd#neo_ScheduleOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesTable_2e1f125b-3148-4887-862d-21ec99edd797" xlink:to="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7b941143-4393-4234-a67f-45f69a95d4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_NumberOfReportableSegments_7b941143-4393-4234-a67f-45f69a95d4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_fcc08df9-efdb-4d82-9071-252355db6087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_fcc08df9-efdb-4d82-9071-252355db6087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment_bef4ea68-3560-454a-9feb-85c856a05ab9" xlink:href="neo-20211231.xsd#neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment_bef4ea68-3560-454a-9feb-85c856a05ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings_762a9b7f-8664-412f-8409-312c0ac4cb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings_762a9b7f-8664-412f-8409-312c0ac4cb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_999e45dc-92d0-4ca4-9610-c985672f0f8e" xlink:href="neo-20211231.xsd#neo_AssetHeldForSaleSquareFeetOfFacilityOwned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_999e45dc-92d0-4ca4-9610-c985672f0f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_256a75d4-1775-477b-9ae2-f625194634a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_256a75d4-1775-477b-9ae2-f625194634a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4830ef21-3c65-4d6f-8fcf-c35f4224d354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4830ef21-3c65-4d6f-8fcf-c35f4224d354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_46b07344-bc36-49de-b8a5-f65a9b02ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_46b07344-bc36-49de-b8a5-f65a9b02ff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_61dae43e-8c2b-462d-920d-13411c562666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_61dae43e-8c2b-462d-920d-13411c562666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f7671f27-9a21-46f1-8973-f6a10f1d0d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f7671f27-9a21-46f1-8973-f6a10f1d0d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_915c544a-365e-4fbb-94f5-443a97c99dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_915c544a-365e-4fbb-94f5-443a97c99dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0ad5071c-19c3-4109-b187-35e1b601c1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0ad5071c-19c3-4109-b187-35e1b601c1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f925ffa6-0ad2-439c-89db-10f6ac3ba89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f925ffa6-0ad2-439c-89db-10f6ac3ba89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_bd4439d0-83dc-4207-94dd-4136e4f7be01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_bd4439d0-83dc-4207-94dd-4136e4f7be01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bb370116-022d-454d-8eea-37c5d0e4da17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bb370116-022d-454d-8eea-37c5d0e4da17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_04e86a50-41e0-4c50-b504-f4bfcf34d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_04e86a50-41e0-4c50-b504-f4bfcf34d4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b3b820c4-a496-4d13-99c5-3cff44ad6d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ScheduleOfSignificantAccountingPoliciesLineItems_b12c8bae-6519-4da4-bfff-cad5ab74f56a" xlink:to="loc_us-gaap_StockholdersEquity_b3b820c4-a496-4d13-99c5-3cff44ad6d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/Acquisitions" xlink:type="simple" xlink:href="neo-20211231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_191119e1-b9ef-439d-a7d5-84c4439a1d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_4e0bf02c-ceec-4def-99d8-3e534b16450a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_191119e1-b9ef-439d-a7d5-84c4439a1d8b" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_4e0bf02c-ceec-4def-99d8-3e534b16450a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="neo-20211231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d1f1b0a5-c92b-4a73-991d-af3c6d602a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_19ee6880-677b-4129-bd7b-5cff1ab71227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d1f1b0a5-c92b-4a73-991d-af3c6d602a42" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_19ee6880-677b-4129-bd7b-5cff1ab71227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_b68ed733-11c9-482b-99d4-1441fbed14ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d1f1b0a5-c92b-4a73-991d-af3c6d602a42" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_b68ed733-11c9-482b-99d4-1441fbed14ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bea619df-0622-4680-8475-d3f74e0f3746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bea619df-0622-4680-8475-d3f74e0f3746" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dfee7d91-1dfd-41a9-8230-3cc05f0190fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dfee7d91-1dfd-41a9-8230-3cc05f0190fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c37d9941-9b10-4725-aae3-c31c10540b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dfee7d91-1dfd-41a9-8230-3cc05f0190fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c37d9941-9b10-4725-aae3-c31c10540b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_951c22f0-bb4d-4b7d-8e36-7e32d6cbbfc2" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c37d9941-9b10-4725-aae3-c31c10540b85" xlink:to="loc_neo_TrapeloHealthMember_951c22f0-bb4d-4b7d-8e36-7e32d6cbbfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_979748c7-bb96-4a48-96e8-d8f7e98b033a" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c37d9941-9b10-4725-aae3-c31c10540b85" xlink:to="loc_neo_InivataMember_979748c7-bb96-4a48-96e8-d8f7e98b033a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b05db42-d55b-44ea-b95a-1f6001f57fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b05db42-d55b-44ea-b95a-1f6001f57fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5b05db42-d55b-44ea-b95a-1f6001f57fba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_013c3a36-c9c2-4913-a7a3-5f076bc9cdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_013c3a36-c9c2-4913-a7a3-5f076bc9cdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_34b3d4a6-453a-44e2-96b1-961ecd833e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_34b3d4a6-453a-44e2-96b1-961ecd833e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_7d09ac04-e0ee-454f-9604-2e9d0aed213b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:to="loc_us-gaap_TrademarksMember_7d09ac04-e0ee-454f-9604-2e9d0aed213b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_f7445748-33ce-47f0-8003-38ccad7d26fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d265372d-849f-4d41-91bc-6bde2f575e96" xlink:to="loc_us-gaap_TradeNamesMember_f7445748-33ce-47f0-8003-38ccad7d26fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e5730ae7-6b8c-4142-bdad-f03f48652f16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e5730ae7-6b8c-4142-bdad-f03f48652f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0b568e8c-890d-4f58-938d-666346562e92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e5730ae7-6b8c-4142-bdad-f03f48652f16" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0b568e8c-890d-4f58-938d-666346562e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_15b0e304-f1e7-46d9-9b74-d95062653d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0b568e8c-890d-4f58-938d-666346562e92" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_15b0e304-f1e7-46d9-9b74-d95062653d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2dfb5324-9e01-4a8a-b827-4ed34fa0bf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2dfb5324-9e01-4a8a-b827-4ed34fa0bf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_16e340fc-060e-4ce8-a43f-3df35c7fe868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2dfb5324-9e01-4a8a-b827-4ed34fa0bf7a" xlink:to="loc_us-gaap_RelatedPartyDomain_16e340fc-060e-4ce8-a43f-3df35c7fe868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c2e199aa-332f-4eb0-87bf-59e8684519e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_16e340fc-060e-4ce8-a43f-3df35c7fe868" xlink:to="loc_srt_AffiliatedEntityMember_c2e199aa-332f-4eb0-87bf-59e8684519e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dba38153-6995-4508-974e-4634fc5a167c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_srt_RangeAxis_dba38153-6995-4508-974e-4634fc5a167c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae91fa59-cc9b-4f17-82c8-3965203e25d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dba38153-6995-4508-974e-4634fc5a167c" xlink:to="loc_srt_RangeMember_ae91fa59-cc9b-4f17-82c8-3965203e25d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c883138b-26f6-46ad-bab8-120364b43d86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae91fa59-cc9b-4f17-82c8-3965203e25d6" xlink:to="loc_srt_MaximumMember_c883138b-26f6-46ad-bab8-120364b43d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_11b7b0e8-60fa-4ed4-af90-41f4d27dfc34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_11b7b0e8-60fa-4ed4-af90-41f4d27dfc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ac1bb635-22a5-4725-b44b-48ed83e02019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_11b7b0e8-60fa-4ed4-af90-41f4d27dfc34" xlink:to="loc_us-gaap_SegmentDomain_ac1bb635-22a5-4725-b44b-48ed83e02019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_e7dfdae8-9fe4-4e6f-9a49-8f022606a05e" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ac1bb635-22a5-4725-b44b-48ed83e02019" xlink:to="loc_neo_ClinicalServicesMember_e7dfdae8-9fe4-4e6f-9a49-8f022606a05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_5fb790c0-86ba-45a6-8256-8bb6b24519a4" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ac1bb635-22a5-4725-b44b-48ed83e02019" xlink:to="loc_neo_PharmaServicesMember_5fb790c0-86ba-45a6-8256-8bb6b24519a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f76059a4-3b5e-4cb9-8d91-98c49bbfd795" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_742610fc-2be4-43df-b667-5538a3fede2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_742610fc-2be4-43df-b667-5538a3fede2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c7d57c4-0b84-42a3-8d5b-540e48ca6282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c7d57c4-0b84-42a3-8d5b-540e48ca6282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_592b2662-2e43-451a-b4cb-bf4c47bd16d4" xlink:href="neo-20211231.xsd#neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments_592b2662-2e43-451a-b4cb-bf4c47bd16d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_db18ae82-592f-4eab-b4f5-f1f03fdb4c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_db18ae82-592f-4eab-b4f5-f1f03fdb4c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c99bd384-4db2-4707-b62d-8d413f2cb615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c99bd384-4db2-4707-b62d-8d413f2cb615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7c8ebe78-040b-42ad-a258-58517f004569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7c8ebe78-040b-42ad-a258-58517f004569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_27bdd9fd-d196-4050-8ffb-46160dd960fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_27bdd9fd-d196-4050-8ffb-46160dd960fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e1f30fea-2db6-44c6-a01d-e95c240c3719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e1f30fea-2db6-44c6-a01d-e95c240c3719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_36450923-f352-415f-a471-8d41d55d56f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_36450923-f352-415f-a471-8d41d55d56f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_25eb7133-3bfd-4d97-976f-c806784280cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_25eb7133-3bfd-4d97-976f-c806784280cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_02f8ff3f-3b8c-403b-8de3-1a29bb00ca83" xlink:href="neo-20211231.xsd#neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_02f8ff3f-3b8c-403b-8de3-1a29bb00ca83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_7b905295-35a5-4b02-8c9c-02f5e7892d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_7b905295-35a5-4b02-8c9c-02f5e7892d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_da81f7e4-a242-432c-ba59-7a562806e95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_da81f7e4-a242-432c-ba59-7a562806e95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_a04b8cf6-ab8a-4324-8103-235b94cfe3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_a04b8cf6-ab8a-4324-8103-235b94cfe3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_340d7a38-cb35-40b9-b1e9-3d7d99d0b98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_340d7a38-cb35-40b9-b1e9-3d7d99d0b98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_3f5f802a-75ea-40ae-91a1-cd75af37010d" xlink:href="neo-20211231.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_3f5f802a-75ea-40ae-91a1-cd75af37010d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_e6b2c069-f064-4ff6-a66a-d9a98ed168fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_LineOfCredit_e6b2c069-f064-4ff6-a66a-d9a98ed168fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_757aa534-3d57-4189-b392-5e0c1c06ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_757aa534-3d57-4189-b392-5e0c1c06ca47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_3b6daea8-5f54-45bc-b6f1-c6d6a0a9f8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_3b6daea8-5f54-45bc-b6f1-c6d6a0a9f8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_46033150-f028-4626-a4af-36617c6219f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_Goodwill_46033150-f028-4626-a4af-36617c6219f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2b99d7ca-191c-467b-ac21-747115bc7d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2b99d7ca-191c-467b-ac21-747115bc7d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1fbb04e8-0a6e-4358-ac06-9c36d5d0a721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1fbb04e8-0a6e-4358-ac06-9c36d5d0a721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_d38e6d0d-388b-44fe-826a-8468a946a648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_d38e6d0d-388b-44fe-826a-8468a946a648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_bf44291c-08e7-4479-9f64-dbd82b98c55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_bf44291c-08e7-4479-9f64-dbd82b98c55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b952a4f0-76e5-4e64-8fd8-eb67fac6dbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b48899f0-5458-49cb-b01b-7a03e02865ad" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b952a4f0-76e5-4e64-8fd8-eb67fac6dbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#AcquisitionsScheduleofProvisionalInformationDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_097e0e66-3f5d-403b-a375-6e8b96cd7516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_097e0e66-3f5d-403b-a375-6e8b96cd7516" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_16858679-4a87-4b76-a0e6-3927592e3748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_16858679-4a87-4b76-a0e6-3927592e3748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_16858679-4a87-4b76-a0e6-3927592e3748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_c35eced0-ad86-4aca-987e-08832d8403de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_c35eced0-ad86-4aca-987e-08832d8403de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6e6bbeb7-73e4-4231-b531-2e379f3c4c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6e6bbeb7-73e4-4231-b531-2e379f3c4c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_cea91ca3-d9c3-4dfe-a047-8603e3674734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:to="loc_us-gaap_TrademarksMember_cea91ca3-d9c3-4dfe-a047-8603e3674734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9a53d16d-0769-4d69-8d39-53165c8f7466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a5f3b69-adae-494b-a21e-4dc921941ae1" xlink:to="loc_us-gaap_TradeNamesMember_9a53d16d-0769-4d69-8d39-53165c8f7466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_24863d05-ce5f-4cfd-8ca0-365d5bd4d272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_24863d05-ce5f-4cfd-8ca0-365d5bd4d272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a12d2f74-f394-4071-a009-15325d046c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_24863d05-ce5f-4cfd-8ca0-365d5bd4d272" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a12d2f74-f394-4071-a009-15325d046c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_cfce05a9-7375-4f4d-99e7-9bd3038d3e7f" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a12d2f74-f394-4071-a009-15325d046c71" xlink:to="loc_neo_TrapeloHealthMember_cfce05a9-7375-4f4d-99e7-9bd3038d3e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_d05aa243-b5a7-483a-a9da-2312a2752ad7" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a12d2f74-f394-4071-a009-15325d046c71" xlink:to="loc_neo_InivataMember_d05aa243-b5a7-483a-a9da-2312a2752ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_5d18e56c-ceb3-4550-a096-80ad204e1083" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:to="loc_srt_RestatementAxis_5d18e56c-ceb3-4550-a096-80ad204e1083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_1f3f170a-564f-45d9-a458-34b7982eaec1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_5d18e56c-ceb3-4550-a096-80ad204e1083" xlink:to="loc_srt_RestatementDomain_1f3f170a-564f-45d9-a458-34b7982eaec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_4c623d03-2520-46d1-856d-117c287589d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1f3f170a-564f-45d9-a458-34b7982eaec1" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_4c623d03-2520-46d1-856d-117c287589d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33991390-bb45-4107-b52f-4275c93bdcf1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59251630-6914-41fc-a696-b31c84905b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59251630-6914-41fc-a696-b31c84905b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_78e11d04-bafe-4921-949c-773980492809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_78e11d04-bafe-4921-949c-773980492809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e37f26ce-81bd-4639-ac40-f7250473e299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e37f26ce-81bd-4639-ac40-f7250473e299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8bcb212c-ad44-40e7-a6fe-388a31176235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8bcb212c-ad44-40e7-a6fe-388a31176235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_03e65b6e-8ba3-44ea-b41e-2fffa8c8d0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_03e65b6e-8ba3-44ea-b41e-2fffa8c8d0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b36f38e9-5c2b-4123-9dab-ef3552a842ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b36f38e9-5c2b-4123-9dab-ef3552a842ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_268846ca-250c-4570-9470-bdde3a2e86ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests_268846ca-250c-4570-9470-bdde3a2e86ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_8eeea187-39a5-4434-8fc0-18f51323c277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_8eeea187-39a5-4434-8fc0-18f51323c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_6f07f019-0645-4cec-a73e-7bc799f5adb5" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue_6f07f019-0645-4cec-a73e-7bc799f5adb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_948ef23b-dad4-4c7f-824c-390432481d83" xlink:href="neo-20211231.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_948ef23b-dad4-4c7f-824c-390432481d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_d72f1eea-d4f5-496c-b17e-74835407f757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_d72f1eea-d4f5-496c-b17e-74835407f757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_692d3beb-c900-4df0-b33d-414858608592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_692d3beb-c900-4df0-b33d-414858608592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4c4506bf-ebc6-4286-8488-8480b6a1eca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4c4506bf-ebc6-4286-8488-8480b6a1eca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_9e4fe129-87d8-4fab-a967-196e78065b63" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther_9e4fe129-87d8-4fab-a967-196e78065b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_e568a96b-85bd-4cfe-8782-62c8226ca7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_e568a96b-85bd-4cfe-8782-62c8226ca7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_afb158d0-9b71-4980-b1fc-005be5506b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_afb158d0-9b71-4980-b1fc-005be5506b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_77980575-7a9b-4e25-b2b1-b35302746e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_77980575-7a9b-4e25-b2b1-b35302746e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_be43c4e3-f1b0-4b0d-8fa7-32b909440117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_be43c4e3-f1b0-4b0d-8fa7-32b909440117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_bfbafc65-1196-4ae1-93f3-bea2c91d7b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_bfbafc65-1196-4ae1-93f3-bea2c91d7b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_e5ece77c-8d44-4c86-9c04-1346d489183d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets_e5ece77c-8d44-4c86-9c04-1346d489183d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_74407460-cf06-4923-8ba6-da79d45682d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_74407460-cf06-4923-8ba6-da79d45682d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities_47b70221-71a8-4fb4-aa76-6b091b351bc5" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities_47b70221-71a8-4fb4-aa76-6b091b351bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_0b47df00-1e1c-4007-b865-cec636a12a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_0b47df00-1e1c-4007-b865-cec636a12a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities_242ba9cf-e031-4bb9-9d24-6cb4167054b2" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities_242ba9cf-e031-4bb9-9d24-6cb4167054b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a0da2871-2731-4b60-baa1-071708ebdf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a0da2871-2731-4b60-baa1-071708ebdf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_a84124a1-fcb1-4889-ade3-1059d831d284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_a84124a1-fcb1-4889-ade3-1059d831d284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_ee34f1a2-dd6b-4aa6-a0ae-446c7219dce9" xlink:href="neo-20211231.xsd#neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet_ee34f1a2-dd6b-4aa6-a0ae-446c7219dce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_54b80829-2704-4eae-bc6e-98cdb52cf246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_54b80829-2704-4eae-bc6e-98cdb52cf246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_82fc4fc7-0ab3-49e9-b784-ef80fbcf55ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_82fc4fc7-0ab3-49e9-b784-ef80fbcf55ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1eb889cc-8315-4c3e-8c9f-4fc99558927b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_Goodwill_1eb889cc-8315-4c3e-8c9f-4fc99558927b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_deaa7173-f688-40d5-80d3-547fff5ab249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_54673cde-d144-45c7-968f-d0c11d4f2ab7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_deaa7173-f688-40d5-80d3-547fff5ab249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#AcquisitionsProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4064cc68-a2bf-42b4-b907-87e9d1a606bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39b564ec-7060-4c72-ba3a-c0871e44410f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4064cc68-a2bf-42b4-b907-87e9d1a606bb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39b564ec-7060-4c72-ba3a-c0871e44410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ff3d3383-d04d-4b84-864f-1071963d4054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39b564ec-7060-4c72-ba3a-c0871e44410f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ff3d3383-d04d-4b84-864f-1071963d4054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61d4e551-f58b-40e7-bdb1-82e17fd6ba5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ff3d3383-d04d-4b84-864f-1071963d4054" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61d4e551-f58b-40e7-bdb1-82e17fd6ba5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_b8eb0c95-31be-463b-94db-4eb506d83464" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_61d4e551-f58b-40e7-bdb1-82e17fd6ba5f" xlink:to="loc_neo_InivataMember_b8eb0c95-31be-463b-94db-4eb506d83464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35a8d399-a7ad-4450-ba89-84f2199e4c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39b564ec-7060-4c72-ba3a-c0871e44410f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_35a8d399-a7ad-4450-ba89-84f2199e4c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f359d697-28d0-43a4-b622-2dc3a4ad09b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35a8d399-a7ad-4450-ba89-84f2199e4c0d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f359d697-28d0-43a4-b622-2dc3a4ad09b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_146afdeb-9572-4a63-8388-3cd31568bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35a8d399-a7ad-4450-ba89-84f2199e4c0d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_146afdeb-9572-4a63-8388-3cd31568bfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_596c734b-2123-4700-a991-4a343988af04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_aff91909-f5b8-418c-b517-1c1504039b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_596c734b-2123-4700-a991-4a343988af04" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_aff91909-f5b8-418c-b517-1c1504039b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_46329254-776a-4a2f-ab6a-15709d4a89c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_28769237-512f-4510-8dbe-7db366043f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_46329254-776a-4a2f-ab6a-15709d4a89c0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_28769237-512f-4510-8dbe-7db366043f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0a8f0ab0-16ee-4fec-b7b1-bc78d397ad8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_46329254-776a-4a2f-ab6a-15709d4a89c0" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_0a8f0ab0-16ee-4fec-b7b1-bc78d397ad8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_20878d36-d78d-41c2-8c9d-a59628125421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_46329254-776a-4a2f-ab6a-15709d4a89c0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_20878d36-d78d-41c2-8c9d-a59628125421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsScheduleofAmortizedCostDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4fa07a2c-0bbf-4fec-a1e1-33244ba738d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60c2f8eb-4c78-43f4-a3f1-bca5a0f2f661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4fa07a2c-0bbf-4fec-a1e1-33244ba738d5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60c2f8eb-4c78-43f4-a3f1-bca5a0f2f661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1e07a6f2-bde0-4cc8-a824-16aa28057751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60c2f8eb-4c78-43f4-a3f1-bca5a0f2f661" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1e07a6f2-bde0-4cc8-a824-16aa28057751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1e07a6f2-bde0-4cc8-a824-16aa28057751" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c3fec692-b87c-43f1-b665-ea4edaa5ea37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c3fec692-b87c-43f1-b665-ea4edaa5ea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_f99f523a-fc51-43f9-add4-57a830e0775e" xlink:href="neo-20211231.xsd#neo_YankeeBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_neo_YankeeBondsMember_f99f523a-fc51-43f9-add4-57a830e0775e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AgencyBondsMember_a4cd9054-39af-4f40-84be-3119ece9cce6" xlink:href="neo-20211231.xsd#neo_AgencyBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_neo_AgencyBondsMember_a4cd9054-39af-4f40-84be-3119ece9cce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_bdfb92d3-255b-4452-9821-052782c8c076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_MunicipalBondsMember_bdfb92d3-255b-4452-9821-052782c8c076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_16911089-9cbb-4791-ae86-ca96197c95a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_CommercialPaperMember_16911089-9cbb-4791-ae86-ca96197c95a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_afdf2680-90e7-49c5-b32d-c19e55e55c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_afdf2680-90e7-49c5-b32d-c19e55e55c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8c974a71-fe3c-443f-a0d3-9d0508e89966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931d6b77-116a-42eb-ade3-62b2437eab06" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8c974a71-fe3c-443f-a0d3-9d0508e89966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60c2f8eb-4c78-43f4-a3f1-bca5a0f2f661" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_bc848177-ab36-4c9f-9f7b-0521b979e6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_bc848177-ab36-4c9f-9f7b-0521b979e6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_79af777e-06bd-4fdb-8781-0a59624103c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_79af777e-06bd-4fdb-8781-0a59624103c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fd5b9483-01d9-4d4c-874b-adb2edd6c348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fd5b9483-01d9-4d4c-874b-adb2edd6c348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_78e287a8-46ba-438a-9da1-2a7eba3bb4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_78e287a8-46ba-438a-9da1-2a7eba3bb4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_909be818-7f3f-464d-ba78-ffe9a21c9ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ec7ad68-074e-4997-a664-5ef24e7a16de" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_909be818-7f3f-464d-ba78-ffe9a21c9ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsFairValuebyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8613efb4-968f-49c2-90c6-bbbcbf0422bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb9677d2-0534-43d0-ad86-3224aed6bae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8613efb4-968f-49c2-90c6-bbbcbf0422bc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb9677d2-0534-43d0-ad86-3224aed6bae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_913f5411-3d8a-4187-8962-a633dce5e823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb9677d2-0534-43d0-ad86-3224aed6bae7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_913f5411-3d8a-4187-8962-a633dce5e823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_913f5411-3d8a-4187-8962-a633dce5e823" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_90a30b89-cedb-4257-90c2-d0538cdb53c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_90a30b89-cedb-4257-90c2-d0538cdb53c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_137e4f55-26ea-4087-8021-298d07a0d5e0" xlink:href="neo-20211231.xsd#neo_YankeeBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_neo_YankeeBondsMember_137e4f55-26ea-4087-8021-298d07a0d5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AgencyBondsMember_ee615526-c9e8-4475-9898-5e2bd7815e42" xlink:href="neo-20211231.xsd#neo_AgencyBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_neo_AgencyBondsMember_ee615526-c9e8-4475-9898-5e2bd7815e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_05f887fb-d3d2-4abd-bb9b-8e54117e9e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_MunicipalBondsMember_05f887fb-d3d2-4abd-bb9b-8e54117e9e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cc171919-e15c-4335-b113-6c0dc96eb3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_CommercialPaperMember_cc171919-e15c-4335-b113-6c0dc96eb3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_43be28d3-6c7e-4676-8481-898914353805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_43be28d3-6c7e-4676-8481-898914353805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_e6e19bbd-98cf-4811-83db-5f384778ee7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d6fb3a2b-e336-46fd-a1c4-8ba36f05abfd" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_e6e19bbd-98cf-4811-83db-5f384778ee7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb9677d2-0534-43d0-ad86-3224aed6bae7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_98d448e3-e796-4a1b-b331-f200e7872978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_98d448e3-e796-4a1b-b331-f200e7872978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8a804827-67a7-4eed-a9aa-1862fb936f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8a804827-67a7-4eed-a9aa-1862fb936f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_58071582-94fb-4302-9192-e838487e951b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_58071582-94fb-4302-9192-e838487e951b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_39184d44-1370-48e3-9520-58eb7226f7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7caa507-4e73-4e8d-aafc-da1a720da109" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_39184d44-1370-48e3-9520-58eb7226f7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b3bc4350-22af-40c8-803d-f609560094d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b3bc4350-22af-40c8-803d-f609560094d6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dba3701f-cf24-4aba-83f6-18e94af3b94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dba3701f-cf24-4aba-83f6-18e94af3b94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dba3701f-cf24-4aba-83f6-18e94af3b94a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_355a18ff-c200-4d3a-8ed0-ac5b780e9274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_355a18ff-c200-4d3a-8ed0-ac5b780e9274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bfb8cd72-aa8d-49ed-b8c9-6ddeae27e104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bfb8cd72-aa8d-49ed-b8c9-6ddeae27e104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4f7dad44-1a2f-4338-a651-aedcd1c7cb07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a094d745-a5cb-44da-b5da-51203d0d60f7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4f7dad44-1a2f-4338-a651-aedcd1c7cb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59d30598-a799-40f2-8d02-a4eeb7764f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59d30598-a799-40f2-8d02-a4eeb7764f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9975c65b-915e-4103-8897-a8d48a782b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_59d30598-a799-40f2-8d02-a4eeb7764f33" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9975c65b-915e-4103-8897-a8d48a782b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_57bfafc4-4da9-45e6-a0bd-ad8e23d50d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9975c65b-915e-4103-8897-a8d48a782b75" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_57bfafc4-4da9-45e6-a0bd-ad8e23d50d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5cebf27b-9969-42f4-b492-b5021bb36981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5cebf27b-9969-42f4-b492-b5021bb36981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5cebf27b-9969-42f4-b492-b5021bb36981" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3bc1d650-4c1e-4ac1-b428-4b58f7581776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3bc1d650-4c1e-4ac1-b428-4b58f7581776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b61e33a6-81d9-47f8-b241-1ad927614022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_CommercialPaperMember_b61e33a6-81d9-47f8-b241-1ad927614022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0482e26f-5ff5-48a4-8fc8-ba95ee210967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0482e26f-5ff5-48a4-8fc8-ba95ee210967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_343b6475-1c4a-4a93-b1cf-c8fd88ae8136" xlink:href="neo-20211231.xsd#neo_YankeeBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_neo_YankeeBondsMember_343b6475-1c4a-4a93-b1cf-c8fd88ae8136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AgencyBondsMember_b4871f54-d0a1-4387-9208-96b5ac0154e1" xlink:href="neo-20211231.xsd#neo_AgencyBondsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_neo_AgencyBondsMember_b4871f54-d0a1-4387-9208-96b5ac0154e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_d54f62b3-6803-4d4b-948c-a467e8223539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_MunicipalBondsMember_d54f62b3-6803-4d4b-948c-a467e8223539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5ea14c28-5660-4604-915c-dd7abc418927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5ea14c28-5660-4604-915c-dd7abc418927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_148a9f8c-36a9-47e3-a318-d41b95a28bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e9887ab5-dc1e-4428-8201-6330782c15dd" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_148a9f8c-36a9-47e3-a318-d41b95a28bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05db4ed9-5f39-4b64-b5f1-d7163ce7f25a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a11ef73b-29b3-4486-b327-8a17105eb61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a11ef73b-29b3-4486-b327-8a17105eb61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_41161ff0-5409-4c07-8499-a7e4f442441d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_41161ff0-5409-4c07-8499-a7e4f442441d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9271887f-4eab-4ee2-8669-5acd5d566bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a017b165-1994-45ae-8b64-c2f37c5503b9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9271887f-4eab-4ee2-8669-5acd5d566bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="neo-20211231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f0def0e5-a268-4a77-b7bd-c32acaea14b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c17a5a75-f78b-40c8-bb1f-e28920fa129d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f0def0e5-a268-4a77-b7bd-c32acaea14b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c17a5a75-f78b-40c8-bb1f-e28920fa129d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="neo-20211231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_79767528-ca59-4627-bb7b-f8f84cf7a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ccbe7080-5e5b-496d-831a-2e6e60c5bdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_79767528-ca59-4627-bb7b-f8f84cf7a65c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ccbe7080-5e5b-496d-831a-2e6e60c5bdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cfd7a522-1d52-4bad-afc3-181b0dbadf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_323166fa-4af6-49e5-9fd7-7a7be0ce469a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cfd7a522-1d52-4bad-afc3-181b0dbadf60" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_323166fa-4af6-49e5-9fd7-7a7be0ce469a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2bd1131c-4050-45f2-a93b-52ce0b159a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_323166fa-4af6-49e5-9fd7-7a7be0ce469a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2bd1131c-4050-45f2-a93b-52ce0b159a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2bd1131c-4050-45f2-a93b-52ce0b159a83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_cb099ecc-333b-4bae-a8ca-16bca0a9e274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_EquipmentMember_cb099ecc-333b-4bae-a8ca-16bca0a9e274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a9f06023-7839-438b-b21d-010c57d55b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_BuildingMember_a9f06023-7839-438b-b21d-010c57d55b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_79bc3b3f-f966-4683-a08f-87d0366a2aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_79bc3b3f-f966-4683-a08f-87d0366a2aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d899afeb-8941-459a-9e5b-2098954c0726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d899afeb-8941-459a-9e5b-2098954c0726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ComputerHardwareAndOfficeEquipmentMember_791c698c-a3cb-4fa9-aa38-8fabbcce0955" xlink:href="neo-20211231.xsd#neo_ComputerHardwareAndOfficeEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_neo_ComputerHardwareAndOfficeEquipmentMember_791c698c-a3cb-4fa9-aa38-8fabbcce0955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_74521237-623a-4b73-9144-025580c3a8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_74521237-623a-4b73-9144-025580c3a8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_393f4c88-1cc9-4b6f-beeb-b813aba3f38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_LandMember_393f4c88-1cc9-4b6f-beeb-b813aba3f38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_64fa9bc7-e8ce-4256-98db-8dbeffea7c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f73d4591-527a-42dd-a3d6-5446bf90b999" xlink:to="loc_us-gaap_ConstructionInProgressMember_64fa9bc7-e8ce-4256-98db-8dbeffea7c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_472bd442-b9a5-42f5-956b-f27fd89ef568" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_323166fa-4af6-49e5-9fd7-7a7be0ce469a" xlink:to="loc_srt_RangeAxis_472bd442-b9a5-42f5-956b-f27fd89ef568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45a62903-4199-48c3-af98-4170c21853d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_472bd442-b9a5-42f5-956b-f27fd89ef568" xlink:to="loc_srt_RangeMember_45a62903-4199-48c3-af98-4170c21853d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70199929-a423-42ef-96fb-fa03a0f0a3dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45a62903-4199-48c3-af98-4170c21853d8" xlink:to="loc_srt_MinimumMember_70199929-a423-42ef-96fb-fa03a0f0a3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e76f5011-af6c-4dd1-bfae-01ae4ca5441a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45a62903-4199-48c3-af98-4170c21853d8" xlink:to="loc_srt_MaximumMember_e76f5011-af6c-4dd1-bfae-01ae4ca5441a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_323166fa-4af6-49e5-9fd7-7a7be0ce469a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2cb1e81b-53ba-4184-bf74-59f375d8d8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2cb1e81b-53ba-4184-bf74-59f375d8d8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2f6b998d-63c9-498b-a0db-780ed74cbf66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2f6b998d-63c9-498b-a0db-780ed74cbf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cad584cb-ebe8-4330-9de0-3f1a641207fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cad584cb-ebe8-4330-9de0-3f1a641207fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f51fe598-c48d-495d-bc54-bb204b12fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2de2e08-0ba5-4951-945a-1983b4748a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f51fe598-c48d-495d-bc54-bb204b12fef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#PropertyandEquipmentNetDepreciationDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ecab25e7-e2cb-48af-8b41-19ad1215654b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bdb3989-8328-4c07-8d63-843619d1e698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ecab25e7-e2cb-48af-8b41-19ad1215654b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bdb3989-8328-4c07-8d63-843619d1e698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_9104dda9-5372-448b-bd28-00f76e11b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bdb3989-8328-4c07-8d63-843619d1e698" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_9104dda9-5372-448b-bd28-00f76e11b8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_4c89e10c-5613-43c0-a5f3-6a2f2d0d40a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_9104dda9-5372-448b-bd28-00f76e11b8e5" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_4c89e10c-5613-43c0-a5f3-6a2f2d0d40a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_f3d92167-3c79-4ae2-b65a-bdea92f94f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_4c89e10c-5613-43c0-a5f3-6a2f2d0d40a8" xlink:to="loc_us-gaap_LandMember_f3d92167-3c79-4ae2-b65a-bdea92f94f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_3434d648-f776-4603-9005-2292738181a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_4c89e10c-5613-43c0-a5f3-6a2f2d0d40a8" xlink:to="loc_us-gaap_BuildingMember_3434d648-f776-4603-9005-2292738181a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_da8a2e76-5aab-4455-adb6-15b68e3f2d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bdb3989-8328-4c07-8d63-843619d1e698" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_da8a2e76-5aab-4455-adb6-15b68e3f2d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da8a2e76-5aab-4455-adb6-15b68e3f2d4b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7f4f5de7-d29a-43a0-ad43-e7894512cf56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:to="loc_us-gaap_CostOfSalesMember_7f4f5de7-d29a-43a0-ad43-e7894512cf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_bb1e7ed4-d828-4097-b18f-a977f33ea197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_bb1e7ed4-d828-4097-b18f-a977f33ea197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bdacab1b-97ec-4e51-bd79-49e37e24b46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_819540d7-d5a5-40b4-89c9-c23e6848d581" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bdacab1b-97ec-4e51-bd79-49e37e24b46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bdb3989-8328-4c07-8d63-843619d1e698" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_6c19fdfa-9120-4d22-9685-6493c9901925" xlink:href="neo-20211231.xsd#neo_AssetHeldForSaleSquareFeetOfFacilityOwned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:to="loc_neo_AssetHeldForSaleSquareFeetOfFacilityOwned_6c19fdfa-9120-4d22-9685-6493c9901925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_dfc168f3-cfdb-4d48-afd7-a8c8dbda8159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_dfc168f3-cfdb-4d48-afd7-a8c8dbda8159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0f915871-9ac9-4b4b-a8cb-f89cccbc5e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf968ee-ccc9-4e9f-b1b3-d51d4808b654" xlink:to="loc_us-gaap_Depreciation_0f915871-9ac9-4b4b-a8cb-f89cccbc5e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/Leases" xlink:type="simple" xlink:href="neo-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ffd63cf8-96ed-48f2-8e39-e2cec7672ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_bec7e832-f3e6-4a40-be90-d637349bca52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffd63cf8-96ed-48f2-8e39-e2cec7672ff6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_bec7e832-f3e6-4a40-be90-d637349bca52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/LeasesTables" xlink:type="simple" xlink:href="neo-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_31afa94a-21da-4487-98fd-8a53ec5e48ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d61dc9bb-04e3-4408-b0f2-121362ad0d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_31afa94a-21da-4487-98fd-8a53ec5e48ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d61dc9bb-04e3-4408-b0f2-121362ad0d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_710ae471-ea1d-4a96-aa53-f6e7533e6631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_31afa94a-21da-4487-98fd-8a53ec5e48ca" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_710ae471-ea1d-4a96-aa53-f6e7533e6631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#LeasesScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d997e761-ff63-499b-91e0-01afc879c43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d997e761-ff63-499b-91e0-01afc879c43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f700ef2b-073f-4099-9171-37a7e8f9de94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f700ef2b-073f-4099-9171-37a7e8f9de94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5d52ae1c-f4bc-40df-9472-900ab332f807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5d52ae1c-f4bc-40df-9472-900ab332f807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5046ed6d-2d73-47c0-a120-4189051d2b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5046ed6d-2d73-47c0-a120-4189051d2b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_856c6524-8c00-414f-b238-f35d28eb2ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_856c6524-8c00-414f-b238-f35d28eb2ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_33b88475-9fbf-4d9d-b604-f88a18e11921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_33b88475-9fbf-4d9d-b604-f88a18e11921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0d11d6f-2c09-47bd-a63b-51c9db3cbdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0d11d6f-2c09-47bd-a63b-51c9db3cbdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89d1b8d2-8f19-4cb7-a162-d48441e0145d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89d1b8d2-8f19-4cb7-a162-d48441e0145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_01e72e38-8dce-4296-a603-f6d0acc611e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_OperatingLeaseLiability_01e72e38-8dce-4296-a603-f6d0acc611e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_834812bd-fff2-44ee-b927-6246dc923174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_834812bd-fff2-44ee-b927-6246dc923174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73395b8f-efb5-4061-a5ed-ace52ae5092c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73395b8f-efb5-4061-a5ed-ace52ae5092c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_45326755-83ec-43eb-846c-ac1aa09d0d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_45326755-83ec-43eb-846c-ac1aa09d0d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0399dd62-6e08-4273-a8f9-b1357806124b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b1dc07-cf8d-4260-8583-fab12a7dee15" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0399dd62-6e08-4273-a8f9-b1357806124b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="neo-20211231.xsd#LeasesScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://neogenomics.com/role/LeasesSummaryofAdditionalSupplementalDataDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#LeasesSummaryofAdditionalSupplementalDataDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/LeasesSummaryofAdditionalSupplementalDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fecdee1d-ef0b-4c70-8f40-41f0b61c2454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_176d3427-2ec9-4a9d-a2b4-f5a60f177b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fecdee1d-ef0b-4c70-8f40-41f0b61c2454" xlink:to="loc_us-gaap_OperatingLeaseCost_176d3427-2ec9-4a9d-a2b4-f5a60f177b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35300f10-9291-4876-a2ae-d0758962329f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fecdee1d-ef0b-4c70-8f40-41f0b61c2454" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35300f10-9291-4876-a2ae-d0758962329f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_16606b8d-0a3d-49a9-9f3b-b7b51eed09fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fecdee1d-ef0b-4c70-8f40-41f0b61c2454" xlink:to="loc_us-gaap_OperatingLeasePayments_16606b8d-0a3d-49a9-9f3b-b7b51eed09fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_eb3efee5-811b-4cc3-b8be-cbe139e4a650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4eec1688-d8b9-4d5d-8f81-6dd6d83593f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eb3efee5-811b-4cc3-b8be-cbe139e4a650" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4eec1688-d8b9-4d5d-8f81-6dd6d83593f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd863b86-929b-44bd-a621-79bfb9b7f2af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4eec1688-d8b9-4d5d-8f81-6dd6d83593f5" xlink:to="loc_srt_StatementGeographicalAxis_cd863b86-929b-44bd-a621-79bfb9b7f2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ae0b1a78-2f92-409e-92b6-c25f9702b32e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cd863b86-929b-44bd-a621-79bfb9b7f2af" xlink:to="loc_srt_SegmentGeographicalDomain_ae0b1a78-2f92-409e-92b6-c25f9702b32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_3bfadaef-19c9-46d7-8c5b-c476e2aaf90c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_FL"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ae0b1a78-2f92-409e-92b6-c25f9702b32e" xlink:to="loc_stpr_FL_3bfadaef-19c9-46d7-8c5b-c476e2aaf90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c827e501-59fd-47eb-a251-383c9a832f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4eec1688-d8b9-4d5d-8f81-6dd6d83593f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c827e501-59fd-47eb-a251-383c9a832f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_568b3484-9d3c-4e1b-9089-8dc1099dc566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c827e501-59fd-47eb-a251-383c9a832f48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_568b3484-9d3c-4e1b-9089-8dc1099dc566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c6acfed1-ad0d-4bbd-90c3-8e84ad9e2815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_568b3484-9d3c-4e1b-9089-8dc1099dc566" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c6acfed1-ad0d-4bbd-90c3-8e84ad9e2815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8eb064b0-85cc-4d8d-8676-34cf03560f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4eec1688-d8b9-4d5d-8f81-6dd6d83593f5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8eb064b0-85cc-4d8d-8676-34cf03560f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_981baef8-06aa-4d07-831b-f4604467a953" xlink:href="neo-20211231.xsd#neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8eb064b0-85cc-4d8d-8676-34cf03560f1f" xlink:to="loc_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_981baef8-06aa-4d07-831b-f4604467a953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b361c51e-ae3e-4e71-b84b-fb19ed9d8ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8eb064b0-85cc-4d8d-8676-34cf03560f1f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b361c51e-ae3e-4e71-b84b-fb19ed9d8ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_da6f5170-b049-4ba3-b53d-e4bf2c5d00e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_6f0fa98e-1904-4693-89bc-8e2634d1eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_da6f5170-b049-4ba3-b53d-e4bf2c5d00e6" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_6f0fa98e-1904-4693-89bc-8e2634d1eec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61038847-e6f3-46f8-8c1f-1a93c708c401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_f5fbff48-4c80-465d-8f3c-b2a003be5475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61038847-e6f3-46f8-8c1f-1a93c708c401" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_f5fbff48-4c80-465d-8f3c-b2a003be5475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_c212f544-2261-4b2d-b764-911e8363b328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61038847-e6f3-46f8-8c1f-1a93c708c401" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_c212f544-2261-4b2d-b764-911e8363b328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_2fe845e5-49f4-4722-8cec-16a1d5a13458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61038847-e6f3-46f8-8c1f-1a93c708c401" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_2fe845e5-49f4-4722-8cec-16a1d5a13458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_12b92081-f22e-412b-a972-beec965c77f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_61038847-e6f3-46f8-8c1f-1a93c708c401" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_12b92081-f22e-412b-a972-beec965c77f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5d7c3414-e307-400c-8dd8-feef913f8764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa5df5c6-2f31-47a5-8885-26747261b594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5d7c3414-e307-400c-8dd8-feef913f8764" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa5df5c6-2f31-47a5-8885-26747261b594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3d50b473-35b0-40d7-9cc9-b24c5e6c00fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa5df5c6-2f31-47a5-8885-26747261b594" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3d50b473-35b0-40d7-9cc9-b24c5e6c00fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0f3d9f0-fe81-4fa4-9da3-0142e141f949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3d50b473-35b0-40d7-9cc9-b24c5e6c00fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0f3d9f0-fe81-4fa4-9da3-0142e141f949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_f8bdb577-d682-4787-9131-91942e407144" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0f3d9f0-fe81-4fa4-9da3-0142e141f949" xlink:to="loc_neo_TrapeloHealthMember_f8bdb577-d682-4787-9131-91942e407144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_1666bf81-5e63-48a8-bb15-70dfeaab013b" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0f3d9f0-fe81-4fa4-9da3-0142e141f949" xlink:to="loc_neo_InivataMember_1666bf81-5e63-48a8-bb15-70dfeaab013b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_96ebf2e8-7407-4775-a740-953145b07944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa5df5c6-2f31-47a5-8885-26747261b594" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_96ebf2e8-7407-4775-a740-953145b07944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1ab6b2d5-79c1-45ef-b28f-23b55ea01a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_96ebf2e8-7407-4775-a740-953145b07944" xlink:to="loc_us-gaap_SegmentDomain_1ab6b2d5-79c1-45ef-b28f-23b55ea01a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_7a04d27c-cc07-4957-88fa-c26a4410bc05" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1ab6b2d5-79c1-45ef-b28f-23b55ea01a58" xlink:to="loc_neo_ClinicalServicesMember_7a04d27c-cc07-4957-88fa-c26a4410bc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_60cbec60-1458-497d-98e2-778985c0d3ef" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1ab6b2d5-79c1-45ef-b28f-23b55ea01a58" xlink:to="loc_neo_PharmaServicesMember_60cbec60-1458-497d-98e2-778985c0d3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4f645e17-11f4-4a6f-9482-645ca96756d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa5df5c6-2f31-47a5-8885-26747261b594" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4f645e17-11f4-4a6f-9482-645ca96756d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_353b11a3-6ef5-4a2b-948a-bd368121f996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4f645e17-11f4-4a6f-9482-645ca96756d9" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_353b11a3-6ef5-4a2b-948a-bd368121f996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsRollforwardofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b2ea1ab7-22c3-4d21-81f0-c866bdb7e1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_bddfe495-27f5-49cb-83ef-36d18f955cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b2ea1ab7-22c3-4d21-81f0-c866bdb7e1f4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_bddfe495-27f5-49cb-83ef-36d18f955cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_45aaca22-39d4-4934-9a7f-bc8d8a4bb695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bddfe495-27f5-49cb-83ef-36d18f955cac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_45aaca22-39d4-4934-9a7f-bc8d8a4bb695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8b572741-d5e5-4992-b2b2-154a1452f4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_45aaca22-39d4-4934-9a7f-bc8d8a4bb695" xlink:to="loc_us-gaap_SegmentDomain_8b572741-d5e5-4992-b2b2-154a1452f4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_02fe1baf-a9e8-40a2-b592-cc60860f5d2f" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8b572741-d5e5-4992-b2b2-154a1452f4e6" xlink:to="loc_neo_ClinicalServicesMember_02fe1baf-a9e8-40a2-b592-cc60860f5d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_64d63df2-cafa-4fb8-abe1-dad83215ccbb" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8b572741-d5e5-4992-b2b2-154a1452f4e6" xlink:to="loc_neo_PharmaServicesMember_64d63df2-cafa-4fb8-abe1-dad83215ccbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7d890705-3bac-47c2-bf18-36061182d357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bddfe495-27f5-49cb-83ef-36d18f955cac" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7d890705-3bac-47c2-bf18-36061182d357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_044d0ec4-d6cc-4b66-a8f2-d150712f13c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7d890705-3bac-47c2-bf18-36061182d357" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_044d0ec4-d6cc-4b66-a8f2-d150712f13c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_15be5392-9108-48ab-977d-3d3311bc5c14" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_044d0ec4-d6cc-4b66-a8f2-d150712f13c1" xlink:to="loc_neo_TrapeloHealthMember_15be5392-9108-48ab-977d-3d3311bc5c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_407017df-a854-4326-a6a6-463f57f5a732" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_044d0ec4-d6cc-4b66-a8f2-d150712f13c1" xlink:to="loc_neo_InivataMember_407017df-a854-4326-a6a6-463f57f5a732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_cf21cf88-0136-4eff-9ba8-931b43d9d3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bddfe495-27f5-49cb-83ef-36d18f955cac" xlink:to="loc_us-gaap_GoodwillLineItems_cf21cf88-0136-4eff-9ba8-931b43d9d3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_956a7dce-9b25-4745-ac53-ca409ff74a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_cf21cf88-0136-4eff-9ba8-931b43d9d3b2" xlink:to="loc_us-gaap_GoodwillRollForward_956a7dce-9b25-4745-ac53-ca409ff74a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4a3f2913-c00f-4d1c-85be-11cad6c467a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_956a7dce-9b25-4745-ac53-ca409ff74a2c" xlink:to="loc_us-gaap_Goodwill_4a3f2913-c00f-4d1c-85be-11cad6c467a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_dfe52570-b30b-443c-8cdc-b8dd2f212078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_956a7dce-9b25-4745-ac53-ca409ff74a2c" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_dfe52570-b30b-443c-8cdc-b8dd2f212078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4bedfcb4-de5f-498c-a1b8-b8083cd0bf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_956a7dce-9b25-4745-ac53-ca409ff74a2c" xlink:to="loc_us-gaap_Goodwill_4bedfcb4-de5f-498c-a1b8-b8083cd0bf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c82a27ae-67ba-4359-8fc1-ea9029b9abb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c82a27ae-67ba-4359-8fc1-ea9029b9abb6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a8fc790-3ea8-4cdc-a044-1211329cf4b3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:to="loc_srt_RangeAxis_3a8fc790-3ea8-4cdc-a044-1211329cf4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d25bde6f-33d8-4549-9476-797a75dc6080" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3a8fc790-3ea8-4cdc-a044-1211329cf4b3" xlink:to="loc_srt_RangeMember_d25bde6f-33d8-4549-9476-797a75dc6080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a8f1972-94d0-4bcb-be30-ed4787208ccf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d25bde6f-33d8-4549-9476-797a75dc6080" xlink:to="loc_srt_MinimumMember_5a8f1972-94d0-4bcb-be30-ed4787208ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37f2b519-0c8c-432d-9b6b-d32261edac32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d25bde6f-33d8-4549-9476-797a75dc6080" xlink:to="loc_srt_MaximumMember_37f2b519-0c8c-432d-9b6b-d32261edac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3e355a59-f30c-4336-a829-a245df707530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3e355a59-f30c-4336-a829-a245df707530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3e355a59-f30c-4336-a829-a245df707530" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c63abff5-2aef-48fb-9ef3-e9e3d2d0c2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c63abff5-2aef-48fb-9ef3-e9e3d2d0c2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ae5cb2b1-6bb3-4f78-97b8-ec050b678641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ae5cb2b1-6bb3-4f78-97b8-ec050b678641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_42616ac6-78ac-41be-a84d-f0ce7f89d9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_42616ac6-78ac-41be-a84d-f0ce7f89d9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_6f01e8ee-2ab6-4c7c-aa30-e8c83f1b961f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_TrademarksMember_6f01e8ee-2ab6-4c7c-aa30-e8c83f1b961f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9c49fbd0-ce2d-410f-ae0b-26f258970f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_96c92d1c-bfc9-4fd6-a1a7-8f5b35b3848f" xlink:to="loc_us-gaap_TradeNamesMember_9c49fbd0-ce2d-410f-ae0b-26f258970f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f6988808-bfa5-4a7f-bebf-ab0bbc7881e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f6988808-bfa5-4a7f-bebf-ab0bbc7881e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9fc0fc06-6aab-4a19-b83a-d8ce1e086e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f6988808-bfa5-4a7f-bebf-ab0bbc7881e9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9fc0fc06-6aab-4a19-b83a-d8ce1e086e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_faa4fd1a-2409-4345-b3f7-31f44c5468f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9fc0fc06-6aab-4a19-b83a-d8ce1e086e55" xlink:to="loc_us-gaap_TrademarksMember_faa4fd1a-2409-4345-b3f7-31f44c5468f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fb6b00ea-d6d9-4672-9bb2-fde2855d0040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f3732043-4762-46c1-a5af-c80126693b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f3732043-4762-46c1-a5af-c80126693b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4e7a8c1c-d7a4-4597-83fc-3ec04a742090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4e7a8c1c-d7a4-4597-83fc-3ec04a742090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_51f60c43-c20c-4c16-9fbc-eda5ce55ef8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_51f60c43-c20c-4c16-9fbc-eda5ce55ef8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_888da769-0d8f-4b1f-b3f0-2f36af2843fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_888da769-0d8f-4b1f-b3f0-2f36af2843fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f335aef-55cd-4705-ada1-0013d8b2cbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2f335aef-55cd-4705-ada1-0013d8b2cbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9172f619-6c2d-4656-9604-2179787ac83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9172f619-6c2d-4656-9604-2179787ac83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a67bda1-2b26-4f87-b2f5-2297f7c6fc50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b5dff609-953d-4546-89c1-55e5d23b5047" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a67bda1-2b26-4f87-b2f5-2297f7c6fc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ef1b82e8-6b25-4202-a8d9-3432b030b80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9633d940-0355-4f8e-b5ba-ae1132362844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ef1b82e8-6b25-4202-a8d9-3432b030b80b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9633d940-0355-4f8e-b5ba-ae1132362844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a1caae8b-57f7-460c-ac53-e56eea30a048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9633d940-0355-4f8e-b5ba-ae1132362844" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a1caae8b-57f7-460c-ac53-e56eea30a048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2c48b403-4a54-4368-9cdd-13839af3c07a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a1caae8b-57f7-460c-ac53-e56eea30a048" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2c48b403-4a54-4368-9cdd-13839af3c07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_cfe8386c-0424-4b85-842a-cdc021b46bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2c48b403-4a54-4368-9cdd-13839af3c07a" xlink:to="loc_us-gaap_CostOfSalesMember_cfe8386c-0424-4b85-842a-cdc021b46bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f990ec12-67f8-4064-a03c-7c08504e88aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2c48b403-4a54-4368-9cdd-13839af3c07a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f990ec12-67f8-4064-a03c-7c08504e88aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5532c6c8-7bd0-453a-9af7-f397ff5f3809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9633d940-0355-4f8e-b5ba-ae1132362844" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5532c6c8-7bd0-453a-9af7-f397ff5f3809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5b44b011-1e84-4611-8265-c586c04c5eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5532c6c8-7bd0-453a-9af7-f397ff5f3809" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5b44b011-1e84-4611-8265-c586c04c5eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_90631e10-a44d-472c-8019-bc38ea3820d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_59f082b3-5ce0-41f3-8124-75b96082ff84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_90631e10-a44d-472c-8019-bc38ea3820d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_59f082b3-5ce0-41f3-8124-75b96082ff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9efafdea-6792-4251-8aeb-be9043fbab7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_90631e10-a44d-472c-8019-bc38ea3820d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9efafdea-6792-4251-8aeb-be9043fbab7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_405f7b82-cd11-46b6-9822-f20dd4507e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_90631e10-a44d-472c-8019-bc38ea3820d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_405f7b82-cd11-46b6-9822-f20dd4507e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f82bc23e-3ab6-402a-b5ba-79b35e563bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_90631e10-a44d-472c-8019-bc38ea3820d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f82bc23e-3ab6-402a-b5ba-79b35e563bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_03f59510-2e10-4238-be30-cd3dceefc4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_90631e10-a44d-472c-8019-bc38ea3820d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_03f59510-2e10-4238-be30-cd3dceefc4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f0c5323a-1389-48b3-9165-da3373331292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_90631e10-a44d-472c-8019-bc38ea3820d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f0c5323a-1389-48b3-9165-da3373331292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a38ef7ca-b0cb-48bd-a6d0-8f591141d3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_90631e10-a44d-472c-8019-bc38ea3820d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a38ef7ca-b0cb-48bd-a6d0-8f591141d3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/InvestmentinNonconsolidatedAffiliate" xlink:type="simple" xlink:href="neo-20211231.xsd#InvestmentinNonconsolidatedAffiliate"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/InvestmentinNonconsolidatedAffiliate" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_0e46b39a-296a-4ce0-a26f-4709f4bc95fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_e3f95194-8000-4905-9246-64543706cb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_0e46b39a-296a-4ce0-a26f-4709f4bc95fe" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_e3f95194-8000-4905-9246-64543706cb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#InvestmentinNonConsolidatedAffiliateDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_955bab8c-f7fc-4e13-99b5-b5f5cf642d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_955bab8c-f7fc-4e13-99b5-b5f5cf642d52" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f9a5e324-b5b5-4fca-9d21-edaf76cf0354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f9a5e324-b5b5-4fca-9d21-edaf76cf0354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b0e3a1ac-5390-47bc-b608-aceb6ed65119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f9a5e324-b5b5-4fca-9d21-edaf76cf0354" xlink:to="loc_us-gaap_RelatedPartyDomain_b0e3a1ac-5390-47bc-b608-aceb6ed65119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_f2496c7e-7882-4b1f-9aae-e8284f6d6385" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b0e3a1ac-5390-47bc-b608-aceb6ed65119" xlink:to="loc_srt_AffiliatedEntityMember_f2496c7e-7882-4b1f-9aae-e8284f6d6385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ccc21778-5181-4e77-ab20-ac4fbdb338a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_InvestmentTypeAxis_ccc21778-5181-4e77-ab20-ac4fbdb338a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ed67b273-ed10-4eae-91c0-4ffe68b478fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_ccc21778-5181-4e77-ab20-ac4fbdb338a2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ed67b273-ed10-4eae-91c0-4ffe68b478fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PreferenceSharesMember_a5e5ae8a-605c-4350-bbfb-59e02b6f72a0" xlink:href="neo-20211231.xsd#neo_PreferenceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ed67b273-ed10-4eae-91c0-4ffe68b478fd" xlink:to="loc_neo_PreferenceSharesMember_a5e5ae8a-605c-4350-bbfb-59e02b6f72a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PurchaseOptionMember_87551944-28a5-4777-a87b-bd67fe2c4f43" xlink:href="neo-20211231.xsd#neo_PurchaseOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ed67b273-ed10-4eae-91c0-4ffe68b478fd" xlink:to="loc_neo_PurchaseOptionMember_87551944-28a5-4777-a87b-bd67fe2c4f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1a3407f3-d5cd-47ed-bc4a-a345a7c8b657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1a3407f3-d5cd-47ed-bc4a-a345a7c8b657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b51ec73f-4f30-462d-b088-4c30e2896357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1a3407f3-d5cd-47ed-bc4a-a345a7c8b657" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b51ec73f-4f30-462d-b088-4c30e2896357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StrategicAllianceWithInivataLimitedMember_808c6a90-a1bb-4502-9bb4-490b274e9195" xlink:href="neo-20211231.xsd#neo_StrategicAllianceWithInivataLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_b51ec73f-4f30-462d-b088-4c30e2896357" xlink:to="loc_neo_StrategicAllianceWithInivataLimitedMember_808c6a90-a1bb-4502-9bb4-490b274e9195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b5b029df-4587-415c-9ba2-df8c6c52145a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b5b029df-4587-415c-9ba2-df8c6c52145a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_498368fe-cc75-4b04-91bf-c3e0850c4f36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b5b029df-4587-415c-9ba2-df8c6c52145a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_498368fe-cc75-4b04-91bf-c3e0850c4f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_c5f3ecdb-1ee3-40dc-b659-2ea80321ff2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_498368fe-cc75-4b04-91bf-c3e0850c4f36" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_c5f3ecdb-1ee3-40dc-b659-2ea80321ff2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e38fddcf-7b3a-4914-9a75-6d77ac37afab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e38fddcf-7b3a-4914-9a75-6d77ac37afab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e38fddcf-7b3a-4914-9a75-6d77ac37afab" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2eadc3e1-979b-470e-88e5-d42bf4d565db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_2eadc3e1-979b-470e-88e5-d42bf4d565db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1ff5a8b8-ce7a-45f5-8c3d-f4ee256e7eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_1ff5a8b8-ce7a-45f5-8c3d-f4ee256e7eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_f75abc45-1837-4d28-a7f3-b83121347917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9b5e90b1-0b23-4e11-afc3-cd8946998b07" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_f75abc45-1837-4d28-a7f3-b83121347917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_de5379da-ba19-42f0-9550-3e22b62d0347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_CreditFacilityAxis_de5379da-ba19-42f0-9550-3e22b62d0347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a1993c53-29b5-4117-805e-56feb965a4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_de5379da-ba19-42f0-9550-3e22b62d0347" xlink:to="loc_us-gaap_CreditFacilityDomain_a1993c53-29b5-4117-805e-56feb965a4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5bbfb65b-cf63-450b-891d-c3f1fc331429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a1993c53-29b5-4117-805e-56feb965a4e5" xlink:to="loc_us-gaap_LineOfCreditMember_5bbfb65b-cf63-450b-891d-c3f1fc331429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_959271ad-2927-4ca7-a898-838c8b93b4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_959271ad-2927-4ca7-a898-838c8b93b4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cca535cb-7110-4976-8784-644ffc328943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_959271ad-2927-4ca7-a898-838c8b93b4b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cca535cb-7110-4976-8784-644ffc328943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InivataMember_6e688731-877b-41f8-be24-4a6309fd8c94" xlink:href="neo-20211231.xsd#neo_InivataMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cca535cb-7110-4976-8784-644ffc328943" xlink:to="loc_neo_InivataMember_6e688731-877b-41f8-be24-4a6309fd8c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_4757e966-2d1f-41f4-8059-df3aebd46b36" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_f4a92048-a856-45ef-af6e-dcf9fcbed00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_f4a92048-a856-45ef-af6e-dcf9fcbed00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts_cf3c607e-7908-4a0a-8504-ce174b64014e" xlink:href="neo-20211231.xsd#neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts_cf3c607e-7908-4a0a-8504-ce174b64014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PurchaseOptionMeasurementInput_fec50d93-a97a-4690-980b-bd80085871a8" xlink:href="neo-20211231.xsd#neo_PurchaseOptionMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_PurchaseOptionMeasurementInput_fec50d93-a97a-4690-980b-bd80085871a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_05c3494e-b8df-437d-b847-1b72698db5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_Assets_05c3494e-b8df-437d-b847-1b72698db5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0b5ce4c-04b6-4f65-ac10-6b09879ebda2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0b5ce4c-04b6-4f65-ac10-6b09879ebda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_56a72c9c-ef58-43e2-8e07-1b650ad01e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_56a72c9c-ef58-43e2-8e07-1b650ad01e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_655327b2-1196-4e7c-aa71-006969d206ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_655327b2-1196-4e7c-aa71-006969d206ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2cac4d54-3393-464f-b5d5-56ece388772f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2cac4d54-3393-464f-b5d5-56ece388772f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestDiscount_b8dfe3d3-b60a-4687-8658-5eacbe2809c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableWithImputedInterestDiscount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_ReceivableWithImputedInterestDiscount_b8dfe3d3-b60a-4687-8658-5eacbe2809c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment_15c56b03-b784-4023-bff7-740ba5960580" xlink:href="neo-20211231.xsd#neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment_15c56b03-b784-4023-bff7-740ba5960580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestNetAmount_b5c7f232-6ff8-4f79-b28e-f837f0da235b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_ReceivableWithImputedInterestNetAmount_b5c7f232-6ff8-4f79-b28e-f837f0da235b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_ba9295bd-7b0c-461c-bc6d-af5ce0bea221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_ba9295bd-7b0c-461c-bc6d-af5ce0bea221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndFeeIncomeLoansAndLeases_b8717f2f-29c3-47f4-8cd7-70cc359ffe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndFeeIncomeLoansAndLeases"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_InterestAndFeeIncomeLoansAndLeases_b8717f2f-29c3-47f4-8cd7-70cc359ffe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_48f04277-68ef-4a3b-9628-025e477a4998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_48f04277-68ef-4a3b-9628-025e477a4998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_19c67e59-e1df-4157-b8d7-9c25c19f9c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_19c67e59-e1df-4157-b8d7-9c25c19f9c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_6d21586e-80f6-4ca0-927d-4c79532024b5" xlink:href="neo-20211231.xsd#neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue_6d21586e-80f6-4ca0-927d-4c79532024b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_a0d0ce04-193e-425c-8ed0-7839f7ca76af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_a0d0ce04-193e-425c-8ed0-7839f7ca76af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_350334ad-32cb-4f05-9dc2-df78dc0bfab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_350334ad-32cb-4f05-9dc2-df78dc0bfab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_1c7b76cc-c88d-4343-8730-6041f5a2af9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_LineOfCredit_1c7b76cc-c88d-4343-8730-6041f5a2af9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermLineOfCreditSettlementGainLoss_12882337-1be8-40c1-b8f7-fad57f2ea536" xlink:href="neo-20211231.xsd#neo_LongTermLineOfCreditSettlementGainLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_neo_LongTermLineOfCreditSettlementGainLoss_12882337-1be8-40c1-b8f7-fad57f2ea536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f6c8d3d5-3ac3-4ef5-bfae-0f50e0be526e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ce0e966b-0408-4303-8533-6ef034ea9f98" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_f6c8d3d5-3ac3-4ef5-bfae-0f50e0be526e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/Debt" xlink:type="simple" xlink:href="neo-20211231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9883fa73-b5e3-4eec-88ab-ba84c8debdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4b47f1ee-22f5-42fe-b8c5-d66292405742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9883fa73-b5e3-4eec-88ab-ba84c8debdf7" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4b47f1ee-22f5-42fe-b8c5-d66292405742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtTables" xlink:type="simple" xlink:href="neo-20211231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d4a46043-60c4-45ce-82b2-ca761caad9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2fe31106-56f8-4cf8-8b08-d4a9f9b71175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4a46043-60c4-45ce-82b2-ca761caad9d9" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2fe31106-56f8-4cf8-8b08-d4a9f9b71175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_550c9c49-5ea0-42d9-a283-baa060abef8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4a46043-60c4-45ce-82b2-ca761caad9d9" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_550c9c49-5ea0-42d9-a283-baa060abef8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ad470fa1-ee71-4f41-9324-40755881af12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ad470fa1-ee71-4f41-9324-40755881af12" xlink:to="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_61bef90f-5c70-4611-8328-c4261262d46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:to="loc_us-gaap_CreditFacilityAxis_61bef90f-5c70-4611-8328-c4261262d46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1bd65e6a-e363-46e4-b655-c2aac188a879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_61bef90f-5c70-4611-8328-c4261262d46a" xlink:to="loc_us-gaap_CreditFacilityDomain_1bd65e6a-e363-46e4-b655-c2aac188a879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FinanceObligationsMember_cb1a00fc-c29b-4c5f-a359-4d3070407e84" xlink:href="neo-20211231.xsd#neo_FinanceObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1bd65e6a-e363-46e4-b655-c2aac188a879" xlink:to="loc_neo_FinanceObligationsMember_cb1a00fc-c29b-4c5f-a359-4d3070407e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f47a0ecf-a6e4-4410-8d78-0ace8c6aff2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:to="loc_us-gaap_DebtInstrumentAxis_f47a0ecf-a6e4-4410-8d78-0ace8c6aff2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_15c7b108-166a-439d-83a8-4a858c36c80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f47a0ecf-a6e4-4410-8d78-0ace8c6aff2d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_15c7b108-166a-439d-83a8-4a858c36c80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_52bd39f6-3d20-473b-925c-332b33bab168" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_15c7b108-166a-439d-83a8-4a858c36c80d" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_52bd39f6-3d20-473b-925c-332b33bab168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_a53d1f06-77d1-41e2-a147-bfc8ee0628c5" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_15c7b108-166a-439d-83a8-4a858c36c80d" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_a53d1f06-77d1-41e2-a147-bfc8ee0628c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e3ae2f55-37c9-43c7-b4d8-af913dc37bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e3ae2f55-37c9-43c7-b4d8-af913dc37bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dc6bc69b-8a75-4cfa-b771-6a275f3bcb96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e3ae2f55-37c9-43c7-b4d8-af913dc37bb6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dc6bc69b-8a75-4cfa-b771-6a275f3bcb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_dbceec4e-994f-4f48-9a1e-ef6cf4993df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc6bc69b-8a75-4cfa-b771-6a275f3bcb96" xlink:to="loc_us-gaap_ConvertibleDebtMember_dbceec4e-994f-4f48-9a1e-ef6cf4993df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3f95a7d-330c-4c8b-afc3-72085d13e4c7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_321459a5-ef53-402e-af49-edb7681aaae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_321459a5-ef53-402e-af49-edb7681aaae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ae613dfb-e99a-45ba-a95b-ce105cf6bad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ae613dfb-e99a-45ba-a95b-ce105cf6bad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4aa05126-a1e9-4d18-afd1-9467d1fba9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4aa05126-a1e9-4d18-afd1-9467d1fba9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_00c432dc-6c6a-48d7-925f-a9dfedd05996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_00c432dc-6c6a-48d7-925f-a9dfedd05996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fd809411-36ec-40cf-9a0b-e6501fad4653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_LongTermDebt_fd809411-36ec-40cf-9a0b-e6501fad4653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_193d184e-bdd0-467e-8610-d5a4fc9e1b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_OtherLongTermDebt_193d184e-bdd0-467e-8610-d5a4fc9e1b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_a569a56c-d5ec-46a5-a752-42cedf8274ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_a569a56c-d5ec-46a5-a752-42cedf8274ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_fd57bb1c-7782-4b4a-aaa4-9366a2c1c39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_fd57bb1c-7782-4b4a-aaa4-9366a2c1c39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6dc5d27e-1598-4acc-89d6-5a43f8d2e1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2add6372-2831-4659-b0f6-6ace4b2720ca" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6dc5d27e-1598-4acc-89d6-5a43f8d2e1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1887b55e-2c2b-4da4-8408-c8d927dda6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1887b55e-2c2b-4da4-8408-c8d927dda6ed" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f885ad14-c66e-4ede-b566-b657b5282e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_DebtInstrumentAxis_f885ad14-c66e-4ede-b566-b657b5282e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c44ad8ef-d995-4ef0-ae79-72ac393772e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f885ad14-c66e-4ede-b566-b657b5282e57" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c44ad8ef-d995-4ef0-ae79-72ac393772e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_c2ed7e47-d283-4b8c-b526-7835b2d243e1" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c44ad8ef-d995-4ef0-ae79-72ac393772e8" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_c2ed7e47-d283-4b8c-b526-7835b2d243e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_c3bed962-73d2-4389-b5e1-2e14a2d89379" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c44ad8ef-d995-4ef0-ae79-72ac393772e8" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_c3bed962-73d2-4389-b5e1-2e14a2d89379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f1430d5f-8ff2-45a9-b290-f399a040d8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f1430d5f-8ff2-45a9-b290-f399a040d8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab45428c-51ed-4d34-a02b-289f39d65878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1430d5f-8ff2-45a9-b290-f399a040d8fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab45428c-51ed-4d34-a02b-289f39d65878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_c33d5407-39cd-4139-8398-05823cf669db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab45428c-51ed-4d34-a02b-289f39d65878" xlink:to="loc_us-gaap_ConvertibleDebtMember_c33d5407-39cd-4139-8398-05823cf669db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_78275dd4-0ce8-4c40-b7eb-3ac1c4e767f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_78275dd4-0ce8-4c40-b7eb-3ac1c4e767f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281ca26d-4dbc-447e-aa1c-77f4f8f2b1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_78275dd4-0ce8-4c40-b7eb-3ac1c4e767f4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281ca26d-4dbc-447e-aa1c-77f4f8f2b1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a2e55a6a-769d-44d2-8118-61489175a51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281ca26d-4dbc-447e-aa1c-77f4f8f2b1c0" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a2e55a6a-769d-44d2-8118-61489175a51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember_6c3e8aba-af51-437f-af7e-eadbd942caab" xlink:href="neo-20211231.xsd#neo_CappedCallTransactionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_281ca26d-4dbc-447e-aa1c-77f4f8f2b1c0" xlink:to="loc_neo_CappedCallTransactionsMember_6c3e8aba-af51-437f-af7e-eadbd942caab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b30450a1-d50d-4e52-9073-d63be34f09c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b30450a1-d50d-4e52-9073-d63be34f09c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_669e4d77-f82c-4665-94c0-f515ebe11e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b30450a1-d50d-4e52-9073-d63be34f09c2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_669e4d77-f82c-4665-94c0-f515ebe11e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5f5261e0-b85b-4766-a793-d66edba5f181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_669e4d77-f82c-4665-94c0-f515ebe11e5e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5f5261e0-b85b-4766-a793-d66edba5f181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f9cec727-5e08-4459-b7f0-b7b2ccf99c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_669e4d77-f82c-4665-94c0-f515ebe11e5e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f9cec727-5e08-4459-b7f0-b7b2ccf99c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86c0e294-eae7-4776-b9d9-900c45180e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86c0e294-eae7-4776-b9d9-900c45180e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a805200-f7fe-4e93-ba2d-77c54baf981a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86c0e294-eae7-4776-b9d9-900c45180e76" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a805200-f7fe-4e93-ba2d-77c54baf981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8bd355af-ea22-4648-a2f8-8d465125e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a805200-f7fe-4e93-ba2d-77c54baf981a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8bd355af-ea22-4648-a2f8-8d465125e5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2a970c76-59d4-4ec1-9806-1f226e14e06b" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_08555dd3-4cc8-4070-abcd-4f2707968f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_08555dd3-4cc8-4070-abcd-4f2707968f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_f89316c3-9d03-4e30-9f7d-4d97762731a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentFairValue_f89316c3-9d03-4e30-9f7d-4d97762731a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_da3bc99a-cb04-4fce-a586-c4fd9f986154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_da3bc99a-cb04-4fce-a586-c4fd9f986154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DiscountedPriceOfAggregatePrincipleRate_ee0097b1-428c-4c78-8d28-a7553381e594" xlink:href="neo-20211231.xsd#neo_DiscountedPriceOfAggregatePrincipleRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_DiscountedPriceOfAggregatePrincipleRate_ee0097b1-428c-4c78-8d28-a7553381e594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_353dac80-4f81-4374-a4f7-e5a7d042d2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_353dac80-4f81-4374-a4f7-e5a7d042d2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDiscountOnShares_1f34a9b1-1de0-4261-89d9-6a8d297b7b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDiscountOnShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_CommonStockDiscountOnShares_1f34a9b1-1de0-4261-89d9-6a8d297b7b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_04634fab-60e5-4b25-9110-eb90e1956a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_04634fab-60e5-4b25-9110-eb90e1956a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_56d28d41-c2c8-4ce7-a844-3d3b527ed282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_56d28d41-c2c8-4ce7-a844-3d3b527ed282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5370d0d7-aee6-455f-8fb4-acf0d7800927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5370d0d7-aee6-455f-8fb4-acf0d7800927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate_82752e92-a86e-4e26-bc0e-85e997cfea4d" xlink:href="neo-20211231.xsd#neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate_82752e92-a86e-4e26-bc0e-85e997cfea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ac441e39-2ab2-41d0-8a7a-c9533bb80ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ac441e39-2ab2-41d0-8a7a-c9533bb80ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6255511b-66ec-449e-b0cc-dcb1e237842c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6255511b-66ec-449e-b0cc-dcb1e237842c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_158f6a4d-c278-4406-9be0-6384da059429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_158f6a4d-c278-4406-9be0-6384da059429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt_c5e667b8-06db-4d06-80c7-b4dd864ecb69" xlink:href="neo-20211231.xsd#neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt_c5e667b8-06db-4d06-80c7-b4dd864ecb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtContractualCouponInterest_3f85df46-4d0d-467c-9b5c-6545fd022d7d" xlink:href="neo-20211231.xsd#neo_InterestExpenseDebtContractualCouponInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_InterestExpenseDebtContractualCouponInterest_3f85df46-4d0d-467c-9b5c-6545fd022d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_8c4863d2-1f96-498e-a56f-a75203b3b29c" xlink:href="neo-20211231.xsd#neo_InterestExpenseDebtAccretionOfDebtDiscount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_8c4863d2-1f96-498e-a56f-a75203b3b29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_ca041083-9ab4-4b01-8091-25655e96f8eb" xlink:href="neo-20211231.xsd#neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_ca041083-9ab4-4b01-8091-25655e96f8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_07a05626-c573-496e-b44d-449f4641f9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_07a05626-c573-496e-b44d-449f4641f9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_404c78d7-3534-4d9d-bd53-32002f2b8076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_404c78d7-3534-4d9d-bd53-32002f2b8076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsNumberOfUnderlyingShares_b2934c59-e615-4402-84b4-d6baa707ca0a" xlink:href="neo-20211231.xsd#neo_CappedCallTransactionsNumberOfUnderlyingShares"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_CappedCallTransactionsNumberOfUnderlyingShares_b2934c59-e615-4402-84b4-d6baa707ca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_70de3d4b-33a5-4a06-9a9f-711da186f906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_70de3d4b-33a5-4a06-9a9f-711da186f906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SaleOfStockPremiumOnOfferingPrice_ccf331a8-3fc5-42a2-aa94-14da9143bdf7" xlink:href="neo-20211231.xsd#neo_SaleOfStockPremiumOnOfferingPrice"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_SaleOfStockPremiumOnOfferingPrice_ccf331a8-3fc5-42a2-aa94-14da9143bdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SaleOfStockPricePerSharePublicOfferingPrice_2c2a52c0-ca19-4861-83ff-c1729e38df6b" xlink:href="neo-20211231.xsd#neo_SaleOfStockPricePerSharePublicOfferingPrice"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_neo_SaleOfStockPricePerSharePublicOfferingPrice_2c2a52c0-ca19-4861-83ff-c1729e38df6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5e9959cb-a697-409d-8e47-0f31e8e6b272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_4a0731da-1c0e-46ff-ab9b-b64bdcfeba47" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5e9959cb-a697-409d-8e47-0f31e8e6b272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DebtScheduleofMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a43b0b34-0030-4500-9107-772378691eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a43b0b34-0030-4500-9107-772378691eff" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8a832c96-2d8c-4f2c-8ed8-96d496247c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:to="loc_us-gaap_CreditFacilityAxis_8a832c96-2d8c-4f2c-8ed8-96d496247c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4a33ef4a-d38b-4b01-aba9-132589a6428c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8a832c96-2d8c-4f2c-8ed8-96d496247c88" xlink:to="loc_us-gaap_CreditFacilityDomain_4a33ef4a-d38b-4b01-aba9-132589a6428c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FinanceObligationsMember_f3a9f55f-a7b5-4f02-aee0-be20e3ba8218" xlink:href="neo-20211231.xsd#neo_FinanceObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4a33ef4a-d38b-4b01-aba9-132589a6428c" xlink:to="loc_neo_FinanceObligationsMember_f3a9f55f-a7b5-4f02-aee0-be20e3ba8218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_06799a8a-9651-4557-83aa-0796a496853b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:to="loc_us-gaap_DebtInstrumentAxis_06799a8a-9651-4557-83aa-0796a496853b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_10e38071-2b2a-4bfe-8b7a-61b2e69d3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_06799a8a-9651-4557-83aa-0796a496853b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_10e38071-2b2a-4bfe-8b7a-61b2e69d3c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_37256333-6f5a-49a2-8fbe-d5d3c54d8987" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_10e38071-2b2a-4bfe-8b7a-61b2e69d3c69" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_37256333-6f5a-49a2-8fbe-d5d3c54d8987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_23d5bb35-8047-4bb0-98e2-3a9afe3079df" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_10e38071-2b2a-4bfe-8b7a-61b2e69d3c69" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_23d5bb35-8047-4bb0-98e2-3a9afe3079df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_291f30f6-9bd7-41dd-b501-a1e687b00619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_291f30f6-9bd7-41dd-b501-a1e687b00619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d7f8baec-3ed7-4bc3-b4c7-eae8c86be5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_291f30f6-9bd7-41dd-b501-a1e687b00619" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d7f8baec-3ed7-4bc3-b4c7-eae8c86be5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a840b7b3-1fb8-4151-92f9-62552bc165a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d7f8baec-3ed7-4bc3-b4c7-eae8c86be5bc" xlink:to="loc_us-gaap_ConvertibleDebtMember_a840b7b3-1fb8-4151-92f9-62552bc165a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2aba41ae-323c-485b-9630-45d89cb1059f" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c651f7c-45d8-49f8-b67f-28bd051947eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c651f7c-45d8-49f8-b67f-28bd051947eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:to="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9a1a248e-98a5-49ce-b8ad-a3490dc276d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9a1a248e-98a5-49ce-b8ad-a3490dc276d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bdaaf991-262e-4a26-912c-4b02367513e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bdaaf991-262e-4a26-912c-4b02367513e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a2ded34e-053d-4e8d-b3f5-5d08917f5f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a2ded34e-053d-4e8d-b3f5-5d08917f5f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_64410b3d-16ea-49e5-90a2-6bd9012f03ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_64410b3d-16ea-49e5-90a2-6bd9012f03ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_14118fca-f4a8-463d-bf6e-39bf65696d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_14118fca-f4a8-463d-bf6e-39bf65696d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_337d6f95-b65a-4f0d-bb62-ab4555166e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_337d6f95-b65a-4f0d-bb62-ab4555166e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_613f101a-afeb-45cc-a262-0224babbb8eb" xlink:href="neo-20211231.xsd#neo_LongTermDebtIncludingCurrentMaturitiesDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_neo_LongTermDebtIncludingCurrentMaturitiesDue_613f101a-afeb-45cc-a262-0224babbb8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ba1e7cc4-1a4e-4aad-9f7a-9de0595c3b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtCurrent_ba1e7cc4-1a4e-4aad-9f7a-9de0595c3b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1f22857f-0ff4-4f7d-8978-25df5bde2672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1f22857f-0ff4-4f7d-8978-25df5bde2672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b6a1231c-20bf-4ccf-83b1-8fde2f934b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract_9ae70885-1309-40d3-8215-d4a91e827449" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b6a1231c-20bf-4ccf-83b1-8fde2f934b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:to="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_68ff690b-4538-4ab6-9d40-b6a3f59da12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_68ff690b-4538-4ab6-9d40-b6a3f59da12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_5c425a31-41ab-4781-98fc-69b47f1b2db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_5c425a31-41ab-4781-98fc-69b47f1b2db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_95cabd61-2326-455c-b29e-286b9af659a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_95cabd61-2326-455c-b29e-286b9af659a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cd1d84e2-2db6-4f1f-933c-d7670c5e2b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cd1d84e2-2db6-4f1f-933c-d7670c5e2b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_bbd909ea-140c-4c3a-a291-4d08233a2e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_bbd909ea-140c-4c3a-a291-4d08233a2e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_a943746b-82ed-4420-98af-4b890b1e22ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_a943746b-82ed-4420-98af-4b890b1e22ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f781586a-d9ea-462b-a254-3ae3907591fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f781586a-d9ea-462b-a254-3ae3907591fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1e85b152-07c1-41dc-9177-5173720a2a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1e85b152-07c1-41dc-9177-5173720a2a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a6afdf8c-e8a8-48ce-b9ef-552abf4f50ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_60082e1a-c423-4cf1-9b18-b7a4e9f3f31a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a6afdf8c-e8a8-48ce-b9ef-552abf4f50ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_6065b0af-abd7-4ba1-871b-f6b2c5388269" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne_66292b67-842c-4dc4-9b38-64354fb10141" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne_66292b67-842c-4dc4-9b38-64354fb10141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo_c015cb28-86c7-4201-bd35-38c37cbf6b39" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo_c015cb28-86c7-4201-bd35-38c37cbf6b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree_b779ac18-bd71-4f7c-95e0-e2b04e6960e7" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree_b779ac18-bd71-4f7c-95e0-e2b04e6960e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour_f8b62675-6682-4b2e-947a-ed6c587e72a4" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour_f8b62675-6682-4b2e-947a-ed6c587e72a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive_1bfb14b4-c207-4b2a-ae72-9bd7d9ec63f4" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive_1bfb14b4-c207-4b2a-ae72-9bd7d9ec63f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive_802cc540-ce18-4eea-8937-979c42bd6392" xlink:href="neo-20211231.xsd#neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive_802cc540-ce18-4eea-8937-979c42bd6392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_73765709-ca41-430d-9312-1adce50f2cc4" xlink:href="neo-20211231.xsd#neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities_73765709-ca41-430d-9312-1adce50f2cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6ed3664f-e69b-4e09-ac7b-f18019ec84a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6ed3664f-e69b-4e09-ac7b-f18019ec84a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_275ea7bd-72ef-4e9a-ab89-a63684a2fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_275ea7bd-72ef-4e9a-ab89-a63684a2fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_11982a78-bcd7-49a1-abc9-118c8167d8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_11982a78-bcd7-49a1-abc9-118c8167d8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1a5e169f-f311-4679-9797-669a8f1ca67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_0e3be3d4-e8c3-45e7-a3f8-c616b0854441" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1a5e169f-f311-4679-9797-669a8f1ca67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivities" xlink:type="simple" xlink:href="neo-20211231.xsd#DerivativeInstrumentsandHedgingActivities"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1efac2e8-8684-4745-bed3-fedf2195462b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c692ea86-7e74-43d5-8b42-128e8cfb6cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1efac2e8-8684-4745-bed3-fedf2195462b" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c692ea86-7e74-43d5-8b42-128e8cfb6cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesTables" xlink:type="simple" xlink:href="neo-20211231.xsd#DerivativeInstrumentsandHedgingActivitiesTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b942c104-b4aa-4569-b689-e357d9ef0223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_bd74c415-2d67-4345-973f-11421b1eee55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b942c104-b4aa-4569-b689-e357d9ef0223" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_bd74c415-2d67-4345-973f-11421b1eee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DerivativeInstrumentsandHedgingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6ff20231-164b-4773-a19c-92d6b67732d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6ff20231-164b-4773-a19c-92d6b67732d5" xlink:to="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b3b4aa5f-8112-40b4-a51a-c7befddff442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b3b4aa5f-8112-40b4-a51a-c7befddff442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a3d9a919-9bc8-40e2-a2c5-fff948df6503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b3b4aa5f-8112-40b4-a51a-c7befddff442" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a3d9a919-9bc8-40e2-a2c5-fff948df6503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_768c4c35-5ee8-4917-9b60-ef0ed76fa80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a3d9a919-9bc8-40e2-a2c5-fff948df6503" xlink:to="loc_us-gaap_CashFlowHedgingMember_768c4c35-5ee8-4917-9b60-ef0ed76fa80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4348ad0a-79b7-4388-9661-b9b592e54caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:to="loc_us-gaap_HedgingDesignationAxis_4348ad0a-79b7-4388-9661-b9b592e54caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a31459d8-72d0-4e7b-b504-4e8f98d923ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_4348ad0a-79b7-4388-9661-b9b592e54caa" xlink:to="loc_us-gaap_HedgingDesignationDomain_a31459d8-72d0-4e7b-b504-4e8f98d923ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_41c2e604-3bf1-4036-8f13-ab84af9a9372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a31459d8-72d0-4e7b-b504-4e8f98d923ce" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_41c2e604-3bf1-4036-8f13-ab84af9a9372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fbd154a1-4959-488d-ad8a-014ff658031c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fbd154a1-4959-488d-ad8a-014ff658031c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b7c5c08c-e323-4a38-b77e-687044a506b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fbd154a1-4959-488d-ad8a-014ff658031c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b7c5c08c-e323-4a38-b77e-687044a506b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestRateSwapJune2018Member_7650654c-afc2-4382-a951-39b3aa53635d" xlink:href="neo-20211231.xsd#neo_InterestRateSwapJune2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b7c5c08c-e323-4a38-b77e-687044a506b9" xlink:to="loc_neo_InterestRateSwapJune2018Member_7650654c-afc2-4382-a951-39b3aa53635d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestRateSwapDecember2016Member_a0db1c51-2ae6-43f1-b1cf-d0810fc962d7" xlink:href="neo-20211231.xsd#neo_InterestRateSwapDecember2016Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b7c5c08c-e323-4a38-b77e-687044a506b9" xlink:to="loc_neo_InterestRateSwapDecember2016Member_a0db1c51-2ae6-43f1-b1cf-d0810fc962d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4e0fd26c-8d17-4ce5-850a-02356b8007d2" xlink:to="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount_81abc2f1-3230-46c3-9560-19a9b22d8c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtPercentageBearingVariableInterestAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount_81abc2f1-3230-46c3-9560-19a9b22d8c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2fa2dffe-2948-4174-b579-45315cce750b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2fa2dffe-2948-4174-b579-45315cce750b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_ad6e402b-8e1e-4ce3-b94b-b7b6272cf6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_ad6e402b-8e1e-4ce3-b94b-b7b6272cf6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DerivativeTerminationFee_55af2ad8-d304-42e8-a0e1-7bd9e272e6b9" xlink:href="neo-20211231.xsd#neo_DerivativeTerminationFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_neo_DerivativeTerminationFee_55af2ad8-d304-42e8-a0e1-7bd9e272e6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c8b25a85-baa4-4174-9a7f-96d0c1037f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_5d159575-5df7-4e88-9a2f-f95e740019cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c8b25a85-baa4-4174-9a7f-96d0c1037f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/EquityTransactions" xlink:type="simple" xlink:href="neo-20211231.xsd#EquityTransactions"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/EquityTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_242588cc-74be-470f-abe1-656b1c67118d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ab0c1522-f863-4eaf-83c1-b973ebf9081b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_242588cc-74be-470f-abe1-656b1c67118d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ab0c1522-f863-4eaf-83c1-b973ebf9081b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/EquityTransactionsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#EquityTransactionsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/EquityTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1845a50f-edd7-4fb4-a6f2-7e1a7ef62799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e285abd6-8536-410b-be1d-48a3151ee9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1845a50f-edd7-4fb4-a6f2-7e1a7ef62799" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e285abd6-8536-410b-be1d-48a3151ee9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0b455593-43d1-40e2-8c84-0c5ca5e03873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e285abd6-8536-410b-be1d-48a3151ee9a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0b455593-43d1-40e2-8c84-0c5ca5e03873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7470173d-071a-44df-8ea6-40b10f9d894a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0b455593-43d1-40e2-8c84-0c5ca5e03873" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7470173d-071a-44df-8ea6-40b10f9d894a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_TrapeloHealthMember_16d1d5f2-d6f5-4bce-ba06-d52e17988932" xlink:href="neo-20211231.xsd#neo_TrapeloHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7470173d-071a-44df-8ea6-40b10f9d894a" xlink:to="loc_neo_TrapeloHealthMember_16d1d5f2-d6f5-4bce-ba06-d52e17988932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17b222fd-c408-4d64-950b-f73df7c9c52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e285abd6-8536-410b-be1d-48a3151ee9a1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17b222fd-c408-4d64-950b-f73df7c9c52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17b222fd-c408-4d64-950b-f73df7c9c52d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_362591a6-3730-4734-9ccc-b479d86aefeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:to="loc_us-gaap_PrivatePlacementMember_362591a6-3730-4734-9ccc-b479d86aefeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommonStockOfferingMember_9528905f-654e-487c-957e-ffc16dc567be" xlink:href="neo-20211231.xsd#neo_CommonStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:to="loc_neo_CommonStockOfferingMember_9528905f-654e-487c-957e-ffc16dc567be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3f16c13f-c4d0-4485-8e53-7dc2325d48b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa00deb1-3416-4613-ad05-4644a0f98740" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3f16c13f-c4d0-4485-8e53-7dc2325d48b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e285abd6-8536-410b-be1d-48a3151ee9a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f4581917-0ebc-4943-9dd2-980f6c12c909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f4581917-0ebc-4943-9dd2-980f6c12c909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_07e0e859-d6ba-4e6c-83ab-57466ef1e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_07e0e859-d6ba-4e6c-83ab-57466ef1e07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1cce3ccd-1f22-4aad-a3ad-b58315192d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1cce3ccd-1f22-4aad-a3ad-b58315192d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_375986d0-8a71-445c-b1b6-b9d87099ea05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_375986d0-8a71-445c-b1b6-b9d87099ea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4e074978-2ebf-4530-ab00-9cab3b52d727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4e074978-2ebf-4530-ab00-9cab3b52d727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c453d9c4-d4e6-4c42-927c-2a85911afb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c453d9c4-d4e6-4c42-927c-2a85911afb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SaleOfStockOptionTerm_18d40ea5-1e65-4acd-998e-35171326b240" xlink:href="neo-20211231.xsd#neo_SaleOfStockOptionTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c4874122-bd80-4a3a-bbc8-4b3a9c1f0673" xlink:to="loc_neo_SaleOfStockOptionTerm_18d40ea5-1e65-4acd-998e-35171326b240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0d5fee5-793d-46b2-9ad9-73319f0bd6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_7ecb5301-7fb0-4cc2-9c79-b374e5913e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0d5fee5-793d-46b2-9ad9-73319f0bd6db" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_7ecb5301-7fb0-4cc2-9c79-b374e5913e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b48d806-f1ce-49d1-9dfc-ca6e9d3cc3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_082495f7-ef9f-43e0-9ed8-3e6498dc199d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b48d806-f1ce-49d1-9dfc-ca6e9d3cc3ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_082495f7-ef9f-43e0-9ed8-3e6498dc199d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1335a598-2cfc-4553-b2bb-72a4c4a1312b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b48d806-f1ce-49d1-9dfc-ca6e9d3cc3ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1335a598-2cfc-4553-b2bb-72a4c4a1312b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_22ba7993-61ec-4b1a-bb1e-806283df11bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b48d806-f1ce-49d1-9dfc-ca6e9d3cc3ee" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_22ba7993-61ec-4b1a-bb1e-806283df11bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_679ae25c-4efd-45c8-aa5a-05983257a997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b48d806-f1ce-49d1-9dfc-ca6e9d3cc3ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_679ae25c-4efd-45c8-aa5a-05983257a997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_cfcfa04c-dd85-4412-a858-e7e2ad19ee7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b48d806-f1ce-49d1-9dfc-ca6e9d3cc3ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_cfcfa04c-dd85-4412-a858-e7e2ad19ee7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8dae5df-2643-458b-8bed-bd4fc5de3e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5bb5238-b2c5-4c04-ad7a-410c44e30cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8dae5df-2643-458b-8bed-bd4fc5de3e88" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5bb5238-b2c5-4c04-ad7a-410c44e30cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de052b4d-8944-4549-adba-6faaa712a794" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5bb5238-b2c5-4c04-ad7a-410c44e30cd9" xlink:to="loc_srt_RangeAxis_de052b4d-8944-4549-adba-6faaa712a794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_733a304b-cef4-43f3-9e2c-bb3536da7c94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_de052b4d-8944-4549-adba-6faaa712a794" xlink:to="loc_srt_RangeMember_733a304b-cef4-43f3-9e2c-bb3536da7c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a87f8ffa-d664-48e6-a727-1bb2a839fc6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_733a304b-cef4-43f3-9e2c-bb3536da7c94" xlink:to="loc_srt_MinimumMember_a87f8ffa-d664-48e6-a727-1bb2a839fc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_874a25a5-4ddf-4172-871c-5b8c613502c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_733a304b-cef4-43f3-9e2c-bb3536da7c94" xlink:to="loc_srt_MaximumMember_874a25a5-4ddf-4172-871c-5b8c613502c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cf0f1ade-cc4c-4574-bcdb-2746a0a6ade7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5bb5238-b2c5-4c04-ad7a-410c44e30cd9" xlink:to="loc_us-gaap_AwardTypeAxis_cf0f1ade-cc4c-4574-bcdb-2746a0a6ade7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cf0f1ade-cc4c-4574-bcdb-2746a0a6ade7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0e56d401-c4f7-4ee2-93f0-812342f513f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0e56d401-c4f7-4ee2-93f0-812342f513f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f7d816f4-d2f8-4221-a0d5-daabd8f5fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:to="loc_us-gaap_RestrictedStockMember_f7d816f4-d2f8-4221-a0d5-daabd8f5fd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3a4a874b-e092-404a-b8b1-cf1a4a0dfed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:to="loc_us-gaap_PerformanceSharesMember_3a4a874b-e092-404a-b8b1-cf1a4a0dfed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EmployeeStockPurchasePlanMember_63553f8f-f9b4-4ba9-b8be-d57caaac046a" xlink:href="neo-20211231.xsd#neo_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13488a26-2eb0-4c70-925f-fbc08a0bf901" xlink:to="loc_neo_EmployeeStockPurchasePlanMember_63553f8f-f9b4-4ba9-b8be-d57caaac046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5bb5238-b2c5-4c04-ad7a-410c44e30cd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e77a446-a7c7-49a8-8664-ea3808e48ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e77a446-a7c7-49a8-8664-ea3808e48ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a1987b7-5093-49f6-9fe3-bd25da668d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a1987b7-5093-49f6-9fe3-bd25da668d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1725a647-da5b-4cf2-be7e-cb226c308294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1725a647-da5b-4cf2-be7e-cb226c308294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_999eebfc-3754-4758-b42e-bc62e87d847c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_999eebfc-3754-4758-b42e-bc62e87d847c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_32c24f6f-fd4a-4d09-a852-bfdc703d5b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_32c24f6f-fd4a-4d09-a852-bfdc703d5b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_810b3dd3-12e6-4af1-baf4-ad6832c41660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_810b3dd3-12e6-4af1-baf4-ad6832c41660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_caf7d901-0946-4127-8730-55eeda1f202b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_caf7d901-0946-4127-8730-55eeda1f202b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommonStockClosingPrice_dfe9a694-58d2-4d7b-b6f9-959f4251e1db" xlink:href="neo-20211231.xsd#neo_CommonStockClosingPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_neo_CommonStockClosingPrice_dfe9a694-58d2-4d7b-b6f9-959f4251e1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber_9120eef7-86e1-4904-b340-8cfaa13f6a85" xlink:href="neo-20211231.xsd#neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber_9120eef7-86e1-4904-b340-8cfaa13f6a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16edcea9-4760-4853-8c91-ce57d77c99fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16edcea9-4760-4853-8c91-ce57d77c99fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7a2627cd-092f-49a6-a52b-443e611f3502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7a2627cd-092f-49a6-a52b-443e611f3502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_1ba2392a-54e0-4c02-943b-3061b9b1d859" xlink:href="neo-20211231.xsd#neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue_1ba2392a-54e0-4c02-943b-3061b9b1d859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9fac3ff8-4930-4f76-8ec6-781e1232241e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9fac3ff8-4930-4f76-8ec6-781e1232241e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d630ecb2-21b5-416b-bf24-8e52be81b6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d630ecb2-21b5-416b-bf24-8e52be81b6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8dc7b9bd-4bee-449d-8ffd-f2483df480d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8dc7b9bd-4bee-449d-8ffd-f2483df480d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f7e26e0e-00f2-492f-ba6b-727c28886616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f7e26e0e-00f2-492f-ba6b-727c28886616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ee5964c8-0678-4cdd-b903-5140530fc627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ee5964c8-0678-4cdd-b903-5140530fc627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da4f2037-7795-46eb-8939-3a5d9b70d20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da4f2037-7795-46eb-8939-3a5d9b70d20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_2c90bb95-5242-4dde-a316-5abfefdf6298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_2c90bb95-5242-4dde-a316-5abfefdf6298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_8008fe78-1f4f-4188-b4f5-dcd8a148d707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchaseProgramAdjustment"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_8008fe78-1f4f-4188-b4f5-dcd8a148d707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_fc800129-2dde-403f-9acf-c26856f469f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_fc800129-2dde-403f-9acf-c26856f469f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e8c6361e-b311-410b-a968-33c51eab78e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f17fa748-0447-4469-859f-2f7c824dc813" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e8c6361e-b311-410b-a968-33c51eab78e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb28be31-ac27-4cce-bb81-f3502c1bb002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09dddd74-3efd-4799-9ae3-8202ee98ea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb28be31-ac27-4cce-bb81-f3502c1bb002" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09dddd74-3efd-4799-9ae3-8202ee98ea0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_65daed04-f037-429f-a3c6-f89c1ec517c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09dddd74-3efd-4799-9ae3-8202ee98ea0a" xlink:to="loc_srt_RangeAxis_65daed04-f037-429f-a3c6-f89c1ec517c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f012454c-db92-4dd0-8822-2ed01ad18867" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_65daed04-f037-429f-a3c6-f89c1ec517c8" xlink:to="loc_srt_RangeMember_f012454c-db92-4dd0-8822-2ed01ad18867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fba12a47-51fa-42a0-86f1-b4108c5c3928" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f012454c-db92-4dd0-8822-2ed01ad18867" xlink:to="loc_srt_MinimumMember_fba12a47-51fa-42a0-86f1-b4108c5c3928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2ad287cc-e069-41b8-b6d8-b883d80bc835" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f012454c-db92-4dd0-8822-2ed01ad18867" xlink:to="loc_srt_MaximumMember_2ad287cc-e069-41b8-b6d8-b883d80bc835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09dddd74-3efd-4799-9ae3-8202ee98ea0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b114d06-a9ac-4158-a694-f52fd2f9044a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b114d06-a9ac-4158-a694-f52fd2f9044a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_572a0ece-af9d-473b-b338-f8715a508231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_572a0ece-af9d-473b-b338-f8715a508231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2f538b75-6002-472e-8d97-cdf9dd4cec03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2f538b75-6002-472e-8d97-cdf9dd4cec03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_99a9263a-e4bf-43c7-9195-d3f2d71f474d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_99a9263a-e4bf-43c7-9195-d3f2d71f474d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_61bdbc85-e84d-4f8f-a4c1-279cc4221e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e922c143-5201-480b-8c24-01c2b78920e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_61bdbc85-e84d-4f8f-a4c1-279cc4221e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationStatusofOurStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c87f1a4-3b18-4f6c-a421-cb52a0098098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_3eb1816e-0c54-405a-8691-4b7e5e9090da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c87f1a4-3b18-4f6c-a421-cb52a0098098" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_3eb1816e-0c54-405a-8691-4b7e5e9090da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f2f982cc-45c5-4f08-936b-fd04df002b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_3eb1816e-0c54-405a-8691-4b7e5e9090da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f2f982cc-45c5-4f08-936b-fd04df002b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d66dabab-6227-4a71-a3af-fe4522386083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_3eb1816e-0c54-405a-8691-4b7e5e9090da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d66dabab-6227-4a71-a3af-fe4522386083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97e038a2-e40e-4ef1-80ce-4fe0fda26494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_3eb1816e-0c54-405a-8691-4b7e5e9090da" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97e038a2-e40e-4ef1-80ce-4fe0fda26494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c096de4a-fffd-4154-9fac-65d1d38b90c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_3eb1816e-0c54-405a-8691-4b7e5e9090da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c096de4a-fffd-4154-9fac-65d1d38b90c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c0db4ce6-fd5a-4bd1-8a4a-82803aad0084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_3eb1816e-0c54-405a-8691-4b7e5e9090da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c0db4ce6-fd5a-4bd1-8a4a-82803aad0084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8b34d9cb-2a7c-4df1-9e30-c28bdfef7159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c87f1a4-3b18-4f6c-a421-cb52a0098098" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8b34d9cb-2a7c-4df1-9e30-c28bdfef7159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51492154-6570-4595-b488-21f732aa9d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c87f1a4-3b18-4f6c-a421-cb52a0098098" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51492154-6570-4595-b488-21f732aa9d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e6b25acc-ea99-4f90-98de-544df262bb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51492154-6570-4595-b488-21f732aa9d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e6b25acc-ea99-4f90-98de-544df262bb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46415a26-ac06-4447-8340-d7b7ce8805ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51492154-6570-4595-b488-21f732aa9d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46415a26-ac06-4447-8340-d7b7ce8805ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f3d21960-148e-4e85-8aec-598beeafd1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51492154-6570-4595-b488-21f732aa9d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f3d21960-148e-4e85-8aec-598beeafd1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3c594c02-09b0-486f-a769-c59da55c9da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51492154-6570-4595-b488-21f732aa9d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3c594c02-09b0-486f-a769-c59da55c9da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b1dcd448-4e02-4121-8539-aaa55e0e6362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51492154-6570-4595-b488-21f732aa9d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b1dcd448-4e02-4121-8539-aaa55e0e6362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_07153820-a23b-494a-8de2-97a7b12369cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c87f1a4-3b18-4f6c-a421-cb52a0098098" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_07153820-a23b-494a-8de2-97a7b12369cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb6cc05b-3594-478a-a834-0aa2e9237af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f51454cd-b527-4b28-93b5-9f33b4dd59f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb6cc05b-3594-478a-a834-0aa2e9237af3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f51454cd-b527-4b28-93b5-9f33b4dd59f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_38b7c5c5-3c7f-462e-bb15-b71da9de7e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f51454cd-b527-4b28-93b5-9f33b4dd59f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_38b7c5c5-3c7f-462e-bb15-b71da9de7e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_848687f5-47c8-4c27-9104-17a4e648675b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f51454cd-b527-4b28-93b5-9f33b4dd59f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_848687f5-47c8-4c27-9104-17a4e648675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8a63285f-40b1-4688-8edc-7b36607e8899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f51454cd-b527-4b28-93b5-9f33b4dd59f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8a63285f-40b1-4688-8edc-7b36607e8899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0f86b5a1-f512-4abf-b521-ecc034b21b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f51454cd-b527-4b28-93b5-9f33b4dd59f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0f86b5a1-f512-4abf-b521-ecc034b21b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_5f202e75-1b21-4d4b-9dc0-a7e46f2dfb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f51454cd-b527-4b28-93b5-9f33b4dd59f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_5f202e75-1b21-4d4b-9dc0-a7e46f2dfb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_ae28e058-57ef-4180-8b04-3c9930187cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb6cc05b-3594-478a-a834-0aa2e9237af3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_ae28e058-57ef-4180-8b04-3c9930187cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_5539f16b-58e1-4cc1-b7b1-8a724211b04c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_ae28e058-57ef-4180-8b04-3c9930187cbb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_5539f16b-58e1-4cc1-b7b1-8a724211b04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05e70bd9-b95a-413d-a873-42872e9ecf67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_ae28e058-57ef-4180-8b04-3c9930187cbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05e70bd9-b95a-413d-a873-42872e9ecf67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_7d408002-de73-4a04-852f-bc02d26ca14d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_ae28e058-57ef-4180-8b04-3c9930187cbb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_7d408002-de73-4a04-852f-bc02d26ca14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_ae786c7e-68f9-4b43-9ccc-21ffd6dbfb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_ae28e058-57ef-4180-8b04-3c9930187cbb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_ae786c7e-68f9-4b43-9ccc-21ffd6dbfb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1ace6fc2-ff9f-450d-91b9-a53bb4c325d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_ae28e058-57ef-4180-8b04-3c9930187cbb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1ace6fc2-ff9f-450d-91b9-a53bb4c325d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee0177aa-99b6-4277-8e22-18a8b0b9faab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5276962a-6913-424d-8501-706f056c525a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee0177aa-99b6-4277-8e22-18a8b0b9faab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5276962a-6913-424d-8501-706f056c525a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c792b415-e150-40b3-b4bb-ae57cd46d974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5276962a-6913-424d-8501-706f056c525a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c792b415-e150-40b3-b4bb-ae57cd46d974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_c792b415-e150-40b3-b4bb-ae57cd46d974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeOneMember_298e67c0-dfc8-4b5e-a76a-641138b50fea" xlink:href="neo-20211231.xsd#neo_RangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeOneMember_298e67c0-dfc8-4b5e-a76a-641138b50fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeTwoMember_f1cfb7cb-7836-4880-8cc7-2fd59f307da8" xlink:href="neo-20211231.xsd#neo_RangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeTwoMember_f1cfb7cb-7836-4880-8cc7-2fd59f307da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeThreeMember_166f4bb7-3365-4b10-a484-b20723d2fd03" xlink:href="neo-20211231.xsd#neo_RangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeThreeMember_166f4bb7-3365-4b10-a484-b20723d2fd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeFourMember_81e8f163-2a5b-49ad-a7cc-c7f309a25040" xlink:href="neo-20211231.xsd#neo_RangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeFourMember_81e8f163-2a5b-49ad-a7cc-c7f309a25040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RangeFiveMember_82e445f8-d1ea-4412-b753-7e6d3e3ab079" xlink:href="neo-20211231.xsd#neo_RangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6a79a156-8680-40d3-8cc6-49abee61d0f4" xlink:to="loc_neo_RangeFiveMember_82e445f8-d1ea-4412-b753-7e6d3e3ab079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5276962a-6913-424d-8501-706f056c525a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_54ef2f1e-d694-4f11-9e9c-1666d578a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_54ef2f1e-d694-4f11-9e9c-1666d578a5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_8838e3aa-43e3-4190-a1e7-5443a756d5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_8838e3aa-43e3-4190-a1e7-5443a756d5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_59937940-1573-4add-abe7-9b7ebd7eb343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_59937940-1573-4add-abe7-9b7ebd7eb343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_66ce4eb9-0509-4f80-8bf2-37072eb6883d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_66ce4eb9-0509-4f80-8bf2-37072eb6883d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c944cced-99c2-4bb0-8045-485d876e68da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c944cced-99c2-4bb0-8045-485d876e68da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c605d424-aecb-41dd-8fca-290adaccb2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c605d424-aecb-41dd-8fca-290adaccb2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_8a21f417-7946-448f-8b49-798dfab3b66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_8a21f417-7946-448f-8b49-798dfab3b66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_3dd35e28-70a3-473f-a0ad-e2b0ce170c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d92b704-b55f-43e8-b64c-b7084d80e3b0" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_3dd35e28-70a3-473f-a0ad-e2b0ce170c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd552ff5-1716-40c8-8408-4f3e63f7fdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_727e6977-86f6-4923-a6b3-036eda49affa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd552ff5-1716-40c8-8408-4f3e63f7fdd4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_727e6977-86f6-4923-a6b3-036eda49affa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_447f9d1f-ad34-46f4-88e1-7c7441615f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_727e6977-86f6-4923-a6b3-036eda49affa" xlink:to="loc_us-gaap_AwardTypeAxis_447f9d1f-ad34-46f4-88e1-7c7441615f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b411009-9bc0-4c38-9511-4053559d448b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_447f9d1f-ad34-46f4-88e1-7c7441615f87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b411009-9bc0-4c38-9511-4053559d448b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_26d498fd-ddf1-4cca-a8b2-ddaccfa503e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b411009-9bc0-4c38-9511-4053559d448b" xlink:to="loc_us-gaap_RestrictedStockMember_26d498fd-ddf1-4cca-a8b2-ddaccfa503e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dba1621-b9ee-4822-ae3f-0781eb8971fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_727e6977-86f6-4923-a6b3-036eda49affa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dba1621-b9ee-4822-ae3f-0781eb8971fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dba1621-b9ee-4822-ae3f-0781eb8971fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6b2182d-1ab3-4f36-a905-8c9f95fef9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6b2182d-1ab3-4f36-a905-8c9f95fef9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10e8d0e1-b9f2-46e8-97bd-9c0778cf2bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10e8d0e1-b9f2-46e8-97bd-9c0778cf2bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8a776866-8c73-4419-bf03-8108363a7c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8a776866-8c73-4419-bf03-8108363a7c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8dc8ee18-7a24-496e-8630-3a5b2451867d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8dc8ee18-7a24-496e-8630-3a5b2451867d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cb164a14-1bd3-42a3-b6ae-2b748c0a92ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_209e9532-dbaa-4351-a6bd-e849ab83598d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cb164a14-1bd3-42a3-b6ae-2b748c0a92ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dba1621-b9ee-4822-ae3f-0781eb8971fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_099f2b30-e84d-4f59-a326-65bd17604c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_099f2b30-e84d-4f59-a326-65bd17604c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_395cc04c-a5fa-40b3-a639-5abb4f554cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_395cc04c-a5fa-40b3-a639-5abb4f554cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5bba3b7f-7ce6-48f3-866c-075a6b4876d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5bba3b7f-7ce6-48f3-866c-075a6b4876d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6a30e2e4-c61b-4ec5-b0f8-09cd17448393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6a30e2e4-c61b-4ec5-b0f8-09cd17448393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636716a3-69e4-490f-85cb-8a47d512f772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4b57261c-e922-4174-bd47-aee17b7007b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636716a3-69e4-490f-85cb-8a47d512f772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="neo-20211231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d5603ee5-0335-403b-9ab1-ef64c00752c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1e53d1f7-50ae-4a0c-913c-9e61355f5536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d5603ee5-0335-403b-9ab1-ef64c00752c5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1e53d1f7-50ae-4a0c-913c-9e61355f5536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="neo-20211231.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19a7b7c8-3e4c-4d31-8db2-197a64bc7b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1118b66f-a77e-44c2-938b-42024775bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19a7b7c8-3e4c-4d31-8db2-197a64bc7b6d" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1118b66f-a77e-44c2-938b-42024775bd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_669e09c5-59e1-4f06-99a5-37e64c56ccc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19a7b7c8-3e4c-4d31-8db2-197a64bc7b6d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_669e09c5-59e1-4f06-99a5-37e64c56ccc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20dfc1a7-03f5-471e-b39a-8072b0aad31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7f8aaf16-ae08-4f21-8bea-96bb31a20e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20dfc1a7-03f5-471e-b39a-8072b0aad31c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7f8aaf16-ae08-4f21-8bea-96bb31a20e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_1f5cc711-f4e3-4155-bbbf-2e966ec7fd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20dfc1a7-03f5-471e-b39a-8072b0aad31c" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_1f5cc711-f4e3-4155-bbbf-2e966ec7fd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c3396b33-e1f2-4279-9e91-33f1adafcd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20dfc1a7-03f5-471e-b39a-8072b0aad31c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c3396b33-e1f2-4279-9e91-33f1adafcd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_783b0b27-162b-4556-969c-6abedcd45f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20dfc1a7-03f5-471e-b39a-8072b0aad31c" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_783b0b27-162b-4556-969c-6abedcd45f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount_e3f69b6f-8efb-4c69-b417-7cc04e20db39" xlink:href="neo-20211231.xsd#neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20dfc1a7-03f5-471e-b39a-8072b0aad31c" xlink:to="loc_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount_e3f69b6f-8efb-4c69-b417-7cc04e20db39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1ecf2dba-0555-47ba-9d77-46b127e4cd30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20dfc1a7-03f5-471e-b39a-8072b0aad31c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1ecf2dba-0555-47ba-9d77-46b127e4cd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e07366d2-465c-4812-bebe-e3ec2151d789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_ddf2ff7a-c7bb-4a6a-bafa-0444ab9a8b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e07366d2-465c-4812-bebe-e3ec2151d789" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_ddf2ff7a-c7bb-4a6a-bafa-0444ab9a8b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_59c6c138-77c6-4569-862e-ec2b25321152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_ddf2ff7a-c7bb-4a6a-bafa-0444ab9a8b6c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_59c6c138-77c6-4569-862e-ec2b25321152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_1d00d617-d29d-4ad8-a866-e0bd16fd8e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_ddf2ff7a-c7bb-4a6a-bafa-0444ab9a8b6c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_1d00d617-d29d-4ad8-a866-e0bd16fd8e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_cf268a7a-f014-4fae-b9e1-a87e48b69c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_ddf2ff7a-c7bb-4a6a-bafa-0444ab9a8b6c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_cf268a7a-f014-4fae-b9e1-a87e48b69c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAbstract_9cb54473-c1a8-48a4-a4e4-5d57fd6999f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e07366d2-465c-4812-bebe-e3ec2151d789" xlink:to="loc_us-gaap_CapitalizedContractCostAbstract_9cb54473-c1a8-48a4-a4e4-5d57fd6999f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_a358778b-d026-4c33-b728-d46c15a61000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract_9cb54473-c1a8-48a4-a4e4-5d57fd6999f8" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_a358778b-d026-4c33-b728-d46c15a61000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_639cb415-3c7d-436b-8cc0-c498451d7983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract_9cb54473-c1a8-48a4-a4e4-5d57fd6999f8" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_639cb415-3c7d-436b-8cc0-c498451d7983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_6f113942-eea5-49a1-a608-d66640c4ede5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract_9cb54473-c1a8-48a4-a4e4-5d57fd6999f8" xlink:to="loc_us-gaap_CapitalizedContractCostGross_6f113942-eea5-49a1-a608-d66640c4ede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_98214d60-fc4f-498d-a8ec-f28a6742ca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e07366d2-465c-4812-bebe-e3ec2151d789" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_98214d60-fc4f-498d-a8ec-f28a6742ca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ae65746f-3ba5-43e2-b631-a116c0fdcf44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_98214d60-fc4f-498d-a8ec-f28a6742ca8d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ae65746f-3ba5-43e2-b631-a116c0fdcf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_697c404f-ea2d-410f-ab83-bc0058747732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_98214d60-fc4f-498d-a8ec-f28a6742ca8d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_697c404f-ea2d-410f-ab83-bc0058747732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a201022c-371a-4288-8513-c0fe87ae546b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_98214d60-fc4f-498d-a8ec-f28a6742ca8d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a201022c-371a-4288-8513-c0fe87ae546b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b0462f58-9e0d-48d5-98ac-1cba5e5eecb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b1aec17a-feb2-4cd0-862e-d31a99415e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b0462f58-9e0d-48d5-98ac-1cba5e5eecb2" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b1aec17a-feb2-4cd0-862e-d31a99415e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eaaceeb8-001d-41a9-a57d-9fcfe8e619d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b1aec17a-feb2-4cd0-862e-d31a99415e54" xlink:to="loc_srt_ProductOrServiceAxis_eaaceeb8-001d-41a9-a57d-9fcfe8e619d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_eaaceeb8-001d-41a9-a57d-9fcfe8e619d9" xlink:to="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClientDirectBillingMember_a1eb93cf-93cf-4f48-a789-799410683cd7" xlink:href="neo-20211231.xsd#neo_ClientDirectBillingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:to="loc_neo_ClientDirectBillingMember_a1eb93cf-93cf-4f48-a789-799410683cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommercialInsuranceMember_e1ba4c4c-4f59-449f-ae39-992dc8568fac" xlink:href="neo-20211231.xsd#neo_CommercialInsuranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:to="loc_neo_CommercialInsuranceMember_e1ba4c4c-4f59-449f-ae39-992dc8568fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_MedicareAndMedicaidMember_1455f59e-b0fe-4943-8baa-92644d3d7744" xlink:href="neo-20211231.xsd#neo_MedicareAndMedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:to="loc_neo_MedicareAndMedicaidMember_1455f59e-b0fe-4943-8baa-92644d3d7744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SelfPayServicesMember_bd536ac4-6e32-46ff-ab38-a2797b854a03" xlink:href="neo-20211231.xsd#neo_SelfPayServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_321501ee-78dd-4752-a26f-376ffc818571" xlink:to="loc_neo_SelfPayServicesMember_bd536ac4-6e32-46ff-ab38-a2797b854a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_778bff53-faba-4f99-a9ff-add947e5ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b1aec17a-feb2-4cd0-862e-d31a99415e54" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_778bff53-faba-4f99-a9ff-add947e5ce5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c46ac12d-f5c7-4f9a-b077-d4256adee27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_778bff53-faba-4f99-a9ff-add947e5ce5d" xlink:to="loc_us-gaap_SegmentDomain_c46ac12d-f5c7-4f9a-b077-d4256adee27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_56a26acd-90a0-47fd-9db8-60dbbb81ec8a" xlink:href="neo-20211231.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c46ac12d-f5c7-4f9a-b077-d4256adee27e" xlink:to="loc_neo_ClinicalServicesMember_56a26acd-90a0-47fd-9db8-60dbbb81ec8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_14a6b6a6-c534-4f46-ad2e-4de86f9c25c2" xlink:href="neo-20211231.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c46ac12d-f5c7-4f9a-b077-d4256adee27e" xlink:to="loc_neo_PharmaServicesMember_14a6b6a6-c534-4f46-ad2e-4de86f9c25c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a66c4b47-86d2-4770-a4e0-e16df366cc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_b1aec17a-feb2-4cd0-862e-d31a99415e54" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a66c4b47-86d2-4770-a4e0-e16df366cc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_969fe6f6-799e-406e-82b2-121331d9c781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a66c4b47-86d2-4770-a4e0-e16df366cc5d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_969fe6f6-799e-406e-82b2-121331d9c781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_38a56501-a3ed-4038-a319-d6c5ee9c3ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a872af99-f59f-443f-9b43-de4d20f0ed1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38a56501-a3ed-4038-a319-d6c5ee9c3ae3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a872af99-f59f-443f-9b43-de4d20f0ed1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_01630d4a-3c64-446f-a16d-7fc4c3053ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_e9c4bb16-89f9-4d76-a5e8-89bf149b522e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01630d4a-3c64-446f-a16d-7fc4c3053ad7" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_e9c4bb16-89f9-4d76-a5e8-89bf149b522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3a9415bc-018c-4400-885d-580a680220f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01630d4a-3c64-446f-a16d-7fc4c3053ad7" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3a9415bc-018c-4400-885d-580a680220f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b7baf951-1611-45da-b3d6-8509f1ea0197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01630d4a-3c64-446f-a16d-7fc4c3053ad7" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b7baf951-1611-45da-b3d6-8509f1ea0197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_ce12eac4-219a-4eb7-b188-e58b63ac41ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01630d4a-3c64-446f-a16d-7fc4c3053ad7" xlink:to="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_ce12eac4-219a-4eb7-b188-e58b63ac41ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ceb7ff8c-040d-402a-b85f-d62d121d38c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b15faf44-105c-47be-ba73-a655bb4b7381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ceb7ff8c-040d-402a-b85f-d62d121d38c1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b15faf44-105c-47be-ba73-a655bb4b7381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e61e227b-4758-4709-81a8-d908ec960abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b15faf44-105c-47be-ba73-a655bb4b7381" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e61e227b-4758-4709-81a8-d908ec960abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0297fe40-edd9-4613-bf8f-7a6925438c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e61e227b-4758-4709-81a8-d908ec960abe" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0297fe40-edd9-4613-bf8f-7a6925438c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a2384d61-29a5-44ee-9eb4-f84c2572c927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0297fe40-edd9-4613-bf8f-7a6925438c00" xlink:to="loc_us-gaap_DomesticCountryMember_a2384d61-29a5-44ee-9eb4-f84c2572c927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_8764f39e-583f-4e0e-97e5-12f1e5093fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0297fe40-edd9-4613-bf8f-7a6925438c00" xlink:to="loc_us-gaap_ForeignCountryMember_8764f39e-583f-4e0e-97e5-12f1e5093fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b15faf44-105c-47be-ba73-a655bb4b7381" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f029e03-8088-4c83-89b8-8500cac08dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f029e03-8088-4c83-89b8-8500cac08dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bc8ef726-7352-4f94-8672-e5955f777426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bc8ef726-7352-4f94-8672-e5955f777426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a11e2ff7-8a66-4c32-83f0-1869fa9a9205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a11e2ff7-8a66-4c32-83f0-1869fa9a9205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a81fe836-357e-43a2-9f44-b096e394b1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8e4c5e8a-794c-481b-a681-3ee73c076155" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a81fe836-357e-43a2-9f44-b096e394b1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7f1d4bba-91da-417a-8741-c408e88b2366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7f1d4bba-91da-417a-8741-c408e88b2366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f99a0891-48eb-46e8-afc7-ce8267686099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f99a0891-48eb-46e8-afc7-ce8267686099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ba2e4ece-8d4a-48bd-b406-80713eecf49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ba2e4ece-8d4a-48bd-b406-80713eecf49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ef80f86e-6fc6-47a4-b70e-0ef18c0eeb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b1794263-14bd-4fa5-9466-2ce95d8ae45e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ef80f86e-6fc6-47a4-b70e-0ef18c0eeb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4acb3f55-3dcd-45e2-994a-93063e8c8ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fe24a822-1501-4d22-a0af-8b4ecb302c4e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4acb3f55-3dcd-45e2-994a-93063e8c8ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8b2cd3eb-34f8-4541-abcb-b9b0d15a4a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8b2cd3eb-34f8-4541-abcb-b9b0d15a4a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3c9dcc42-4290-468d-8187-bf454ad6538c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3c9dcc42-4290-468d-8187-bf454ad6538c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_52dbff40-0a4e-4748-be82-01d1315e1128" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_52dbff40-0a4e-4748-be82-01d1315e1128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent_eaf87b63-7350-40cd-a36a-1988dafd050c" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent_eaf87b63-7350-40cd-a36a-1988dafd050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_32708bf2-822b-45de-ba53-ea1d61045085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_32708bf2-822b-45de-ba53-ea1d61045085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_12a8dd90-fb06-47f3-8ae1-e7fee19abf43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_12a8dd90-fb06-47f3-8ae1-e7fee19abf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses_5bfe0170-a0a6-4162-a13c-26107c9828ca" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses_5bfe0170-a0a6-4162-a13c-26107c9828ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent_82ebac76-0422-44f6-addd-7e86e060b4fe" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent_82ebac76-0422-44f6-addd-7e86e060b4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_5959a144-267a-4f41-926b-f0e72ad8537a" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent_5959a144-267a-4f41-926b-f0e72ad8537a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_83882f06-8951-440a-8cea-08c82b43a9de" xlink:href="neo-20211231.xsd#neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_83882f06-8951-440a-8cea-08c82b43a9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e1e999c9-331b-4672-8a00-e37f41dc7471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e1e999c9-331b-4672-8a00-e37f41dc7471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_876f8589-9185-4639-85ec-22fc13f60024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_876f8589-9185-4639-85ec-22fc13f60024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a9740b07-6b26-43be-a1d0-5de7b3f87ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a9740b07-6b26-43be-a1d0-5de7b3f87ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8f1620d6-f1eb-41b1-ac2d-e150be6ee5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb79a0f-1898-4c93-8b1a-21a4188aa186" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8f1620d6-f1eb-41b1-ac2d-e150be6ee5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_12daea78-ddd2-40f8-9d4b-6663db65e6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12daea78-ddd2-40f8-9d4b-6663db65e6ad" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_0ba9553c-9fb8-4aed-b3a7-b96773f54947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_0ba9553c-9fb8-4aed-b3a7-b96773f54947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_879c1109-c422-4c88-8c82-4a37b7f7c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_879c1109-c422-4c88-8c82-4a37b7f7c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2acd1134-ce9a-409f-94df-934e09fb4e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2acd1134-ce9a-409f-94df-934e09fb4e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_737e6a6e-f6a0-4664-948f-3002eb591e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_737e6a6e-f6a0-4664-948f-3002eb591e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_039de690-b937-4d90-8ae6-5e8021532ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_039de690-b937-4d90-8ae6-5e8021532ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DeferredTaxAssetsOperatingLeaseLiability_624b125d-2a71-4698-bf4f-0a9676a463e7" xlink:href="neo-20211231.xsd#neo_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_neo_DeferredTaxAssetsOperatingLeaseLiability_624b125d-2a71-4698-bf4f-0a9676a463e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DeferredTaxAssetsInterestExpense_eacc3c35-05a5-403c-afc9-e94e5da92a72" xlink:href="neo-20211231.xsd#neo_DeferredTaxAssetsInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_neo_DeferredTaxAssetsInterestExpense_eacc3c35-05a5-403c-afc9-e94e5da92a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_9216fdd7-f37d-4629-9f5f-2f5e500efb87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_9216fdd7-f37d-4629-9f5f-2f5e500efb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b08bee06-9b04-4a1a-b3a9-3b32be3a1edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b08bee06-9b04-4a1a-b3a9-3b32be3a1edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f7975ef8-c8e5-4c6a-bcbe-b2b73097627e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f7975ef8-c8e5-4c6a-bcbe-b2b73097627e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_6f39f1fb-b6c6-4de7-bd07-fab5d4528acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_6f39f1fb-b6c6-4de7-bd07-fab5d4528acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_44f615a9-7edd-46b4-b7b2-21db5b875ad1" xlink:href="neo-20211231.xsd#neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_44f615a9-7edd-46b4-b7b2-21db5b875ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_3a6f4c02-4391-4555-a431-e46f138f75fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_3a6f4c02-4391-4555-a431-e46f138f75fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_6df12030-07d9-4f31-9af5-415d6e693603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_6df12030-07d9-4f31-9af5-415d6e693603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_92e83415-0293-42fd-9033-9d11ddec1c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_92e83415-0293-42fd-9033-9d11ddec1c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_001904ea-f27d-40e9-b7fa-4ff13c0b06ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_001904ea-f27d-40e9-b7fa-4ff13c0b06ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d624ba20-d4a6-4c4f-bfa4-d55cfc001110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d624ba20-d4a6-4c4f-bfa4-d55cfc001110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7f11cd79-026d-4d64-ae43-5819b4ff73af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7f11cd79-026d-4d64-ae43-5819b4ff73af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_c56c4590-287c-4cc6-845d-baca6a79e92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6143cb35-ba6f-492b-b255-57436b2dfb55" xlink:to="loc_us-gaap_DeferredTaxLiabilities_c56c4590-287c-4cc6-845d-baca6a79e92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_67881b3e-bb4b-4669-aa9b-9d9b859cd4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncomeTaxesTable_66897163-43a3-49ec-9a0f-1c8d9ca4684b" xlink:href="neo-20211231.xsd#neo_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_67881b3e-bb4b-4669-aa9b-9d9b859cd4bc" xlink:to="loc_neo_IncomeTaxesTable_66897163-43a3-49ec-9a0f-1c8d9ca4684b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2b7c2396-f7e7-4c90-b7ca-460dbe98060b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_IncomeTaxesTable_66897163-43a3-49ec-9a0f-1c8d9ca4684b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2b7c2396-f7e7-4c90-b7ca-460dbe98060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2b7c2396-f7e7-4c90-b7ca-460dbe98060b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_f8488b18-0e2b-41e2-8992-a9b69970e6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:to="loc_us-gaap_ForeignCountryMember_f8488b18-0e2b-41e2-8992-a9b69970e6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f1de8fe8-cef9-42fb-92a9-cf32c67143c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f1de8fe8-cef9-42fb-92a9-cf32c67143c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_300b1450-3c70-43dd-a1b2-f84b3e997973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b117cc56-e33b-42e9-876c-4299bf20490a" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_300b1450-3c70-43dd-a1b2-f84b3e997973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1df9835c-7c7c-4314-ab36-78f1cdfeb717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_IncomeTaxesTable_66897163-43a3-49ec-9a0f-1c8d9ca4684b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1df9835c-7c7c-4314-ab36-78f1cdfeb717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc36fdbe-2b9f-484f-be2e-bc455a609259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1df9835c-7c7c-4314-ab36-78f1cdfeb717" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc36fdbe-2b9f-484f-be2e-bc455a609259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HerMajestysRevenueAndCustomsHMRCMember_701483a2-0681-4d93-affd-06034548d4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HerMajestysRevenueAndCustomsHMRCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc36fdbe-2b9f-484f-be2e-bc455a609259" xlink:to="loc_us-gaap_HerMajestysRevenueAndCustomsHMRCMember_701483a2-0681-4d93-affd-06034548d4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:href="neo-20211231.xsd#neo_IncomeTaxesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_IncomeTaxesTable_66897163-43a3-49ec-9a0f-1c8d9ca4684b" xlink:to="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_86dc23ec-7da7-4c3a-a3cb-dd89d60f5a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_86dc23ec-7da7-4c3a-a3cb-dd89d60f5a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_9324ae8f-e118-43ee-b672-1ba837da96ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_9324ae8f-e118-43ee-b672-1ba837da96ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_5cfa66af-46d1-47c0-adde-a541387f119c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_5cfa66af-46d1-47c0-adde-a541387f119c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b8f1f3a4-7116-4afd-a147-b4a062b98568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_IncomeTaxesLineItems_2b815308-ddd7-4c8e-a009-eb2c50b953e5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b8f1f3a4-7116-4afd-a147-b4a062b98568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f94ec8ac-75e5-4f6b-876d-8ac2331b6f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aba4884e-6c5a-4073-8a3d-e18521dec5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f94ec8ac-75e5-4f6b-876d-8ac2331b6f45" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aba4884e-6c5a-4073-8a3d-e18521dec5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6d974df1-1efe-49a2-a91d-fdfb4e0f81c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aba4884e-6c5a-4073-8a3d-e18521dec5f4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6d974df1-1efe-49a2-a91d-fdfb4e0f81c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9bfa755b-1170-49dc-8ba4-62d5c7a2869d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aba4884e-6c5a-4073-8a3d-e18521dec5f4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9bfa755b-1170-49dc-8ba4-62d5c7a2869d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_07bae919-2cb5-48dc-8bbf-2ee6b4b6df1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aba4884e-6c5a-4073-8a3d-e18521dec5f4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_07bae919-2cb5-48dc-8bbf-2ee6b4b6df1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_77c7522e-1b30-4939-8005-967265e48583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aba4884e-6c5a-4073-8a3d-e18521dec5f4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_77c7522e-1b30-4939-8005-967265e48583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e981a8fc-18a1-4a56-8c0e-2236fb4ad374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aba4884e-6c5a-4073-8a3d-e18521dec5f4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e981a8fc-18a1-4a56-8c0e-2236fb4ad374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_15d072d0-79fa-4094-b9d0-af000855502f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aba4884e-6c5a-4073-8a3d-e18521dec5f4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_15d072d0-79fa-4094-b9d0-af000855502f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomeperShare" xlink:type="simple" xlink:href="neo-20211231.xsd#NetLossIncomeperShare"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossIncomeperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a0b1c086-53bb-47d8-89d8-dd8ea8c5554e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_abe818f5-4943-44d0-9efe-5c12f9759ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a0b1c086-53bb-47d8-89d8-dd8ea8c5554e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_abe818f5-4943-44d0-9efe-5c12f9759ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomeperShareTables" xlink:type="simple" xlink:href="neo-20211231.xsd#NetLossIncomeperShareTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossIncomeperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0c279770-65ee-4990-9ea8-82987755e7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3937c659-8cea-4776-b0d3-5c0ade6362b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0c279770-65ee-4990-9ea8-82987755e7bd" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3937c659-8cea-4776-b0d3-5c0ade6362b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_49801021-5209-4c2c-9c35-df8461201070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0c279770-65ee-4990-9ea8-82987755e7bd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_49801021-5209-4c2c-9c35-df8461201070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b9ca280-1d8a-43af-87e6-33a1f79bca67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_e8a856a7-c90d-4f17-ac35-0fe0004f64d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b9ca280-1d8a-43af-87e6-33a1f79bca67" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_e8a856a7-c90d-4f17-ac35-0fe0004f64d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9b1858b0-9515-4fed-917d-48d5bd9e3438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_e8a856a7-c90d-4f17-ac35-0fe0004f64d5" xlink:to="loc_us-gaap_AwardTypeAxis_9b1858b0-9515-4fed-917d-48d5bd9e3438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8eca6e-db66-438e-8089-5057515a9545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9b1858b0-9515-4fed-917d-48d5bd9e3438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8eca6e-db66-438e-8089-5057515a9545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_62343888-dc95-426a-ab49-a7443cad9d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8eca6e-db66-438e-8089-5057515a9545" xlink:to="loc_us-gaap_EmployeeStockMember_62343888-dc95-426a-ab49-a7443cad9d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_610054ae-84a6-42cf-9f9a-cefac1e47b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f8eca6e-db66-438e-8089-5057515a9545" xlink:to="loc_us-gaap_RestrictedStockMember_610054ae-84a6-42cf-9f9a-cefac1e47b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_e8a856a7-c90d-4f17-ac35-0fe0004f64d5" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8486e4d0-453a-42b1-a792-25cc20537adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8486e4d0-453a-42b1-a792-25cc20537adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3a91003-6d17-4a7f-86e5-3ada5dad7bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3a91003-6d17-4a7f-86e5-3ada5dad7bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d3fb6b51-b8e3-453a-ae61-9a65b49e4c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d3fb6b51-b8e3-453a-ae61-9a65b49e4c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4cefa21b-268a-4f74-a8d3-81066ccc396c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4cefa21b-268a-4f74-a8d3-81066ccc396c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_62c9a536-1def-42eb-9105-369b5d9ca12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_62c9a536-1def-42eb-9105-369b5d9ca12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9e51fd6b-c590-4561-a5fe-9061147a335a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_a80877bb-d060-499c-a747-ff6cf4f42c22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9e51fd6b-c590-4561-a5fe-9061147a335a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_613cda92-5d05-4bd2-9bb3-67079103354c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_613cda92-5d05-4bd2-9bb3-67079103354c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_459f5964-6e26-49c4-8b8c-0244f2dea0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_459f5964-6e26-49c4-8b8c-0244f2dea0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_459f5964-6e26-49c4-8b8c-0244f2dea0ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_311d12b9-b45c-499b-a905-9b6fc1ef29dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:to="loc_us-gaap_EmployeeStockMember_311d12b9-b45c-499b-a905-9b6fc1ef29dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0eee2399-193d-418c-bdbb-06e17e4e1152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:to="loc_us-gaap_RestrictedStockMember_0eee2399-193d-418c-bdbb-06e17e4e1152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_6c4915e1-f5dd-4e54-a4b9-e3b74c622dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_31c18434-2a3c-49df-bbd5-066c50e8ba80" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_6c4915e1-f5dd-4e54-a4b9-e3b74c622dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aef538e8-92c3-4859-9b5f-0ad2a9cc6a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:to="loc_us-gaap_DebtInstrumentAxis_aef538e8-92c3-4859-9b5f-0ad2a9cc6a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b347127-3929-406f-8784-3a08c2f383a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_aef538e8-92c3-4859-9b5f-0ad2a9cc6a98" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b347127-3929-406f-8784-3a08c2f383a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_23a29394-e65f-4563-8b5b-0cff5c611790" xlink:href="neo-20211231.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b347127-3929-406f-8784-3a08c2f383a7" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_23a29394-e65f-4563-8b5b-0cff5c611790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_81c545d8-2043-4f22-a04a-412434ed4c84" xlink:href="neo-20211231.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b347127-3929-406f-8784-3a08c2f383a7" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_81c545d8-2043-4f22-a04a-412434ed4c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_26680942-0e21-4ef3-baba-72595e83a75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_26680942-0e21-4ef3-baba-72595e83a75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_527f9985-e87f-43cf-81ab-07a837636e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_26680942-0e21-4ef3-baba-72595e83a75c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_527f9985-e87f-43cf-81ab-07a837636e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember_5eb886da-178a-4366-b878-dad866f3d690" xlink:href="neo-20211231.xsd#neo_CappedCallTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_527f9985-e87f-43cf-81ab-07a837636e8e" xlink:to="loc_neo_CappedCallTransactionsMember_5eb886da-178a-4366-b878-dad866f3d690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_115c32fe-3be9-44f2-a2c6-5e6b3791b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76210ceb-f8cc-42df-a1c2-bf85755a6496" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_115c32fe-3be9-44f2-a2c6-5e6b3791b7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5e8f3bb-2e98-4b57-b796-a9cc095298cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_115c32fe-3be9-44f2-a2c6-5e6b3791b7e1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5e8f3bb-2e98-4b57-b796-a9cc095298cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f28b284e-c28f-4329-96d9-741a3c6407f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_115c32fe-3be9-44f2-a2c6-5e6b3791b7e1" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f28b284e-c28f-4329-96d9-741a3c6407f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DefinedContributionPlan" xlink:type="simple" xlink:href="neo-20211231.xsd#DefinedContributionPlan"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DefinedContributionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c4f2fe96-7379-47e6-a48b-36187a67d568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5977ab1d-afa4-4838-af94-0a66ea0e80d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c4f2fe96-7379-47e6-a48b-36187a67d568" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5977ab1d-afa4-4838-af94-0a66ea0e80d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DefinedContributionPlanDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#DefinedContributionPlanDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DefinedContributionPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e6814eb-dcc3-4df1-9d92-28c5b215a2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_399d6f60-b9d0-4895-a80f-10ffee669f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e6814eb-dcc3-4df1-9d92-28c5b215a2bd" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_399d6f60-b9d0-4895-a80f-10ffee669f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_f0675a7e-adbd-4738-b042-b55ea64e84ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e6814eb-dcc3-4df1-9d92-28c5b215a2bd" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_f0675a7e-adbd-4738-b042-b55ea64e84ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6c1baa4d-eb03-4179-b201-2fc808f48deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e6814eb-dcc3-4df1-9d92-28c5b215a2bd" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6c1baa4d-eb03-4179-b201-2fc808f48deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent_57224ca0-34b5-4421-982d-45a38304784b" xlink:href="neo-20211231.xsd#neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e6814eb-dcc3-4df1-9d92-28c5b215a2bd" xlink:to="loc_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent_57224ca0-34b5-4421-982d-45a38304784b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent_2d925eab-ad32-45f4-88a5-6b5913bd809a" xlink:href="neo-20211231.xsd#neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e6814eb-dcc3-4df1-9d92-28c5b215a2bd" xlink:to="loc_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent_2d925eab-ad32-45f4-88a5-6b5913bd809a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2bfe9db9-d0ff-483b-af5b-55a5d89c1b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e6814eb-dcc3-4df1-9d92-28c5b215a2bd" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2bfe9db9-d0ff-483b-af5b-55a5d89c1b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="neo-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f06f61d6-fb7a-4424-8a0f-a920ab61bb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_826e5094-fd22-4b6d-8c54-839b2d7962cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f06f61d6-fb7a-4424-8a0f-a920ab61bb01" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_826e5094-fd22-4b6d-8c54-839b2d7962cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="neo-20211231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9230b7b4-ec16-4e2d-9258-0c7f4ac8ec64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock_e7bdd071-bdb4-4785-bcb5-00efae9f92d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9230b7b4-ec16-4e2d-9258-0c7f4ac8ec64" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock_e7bdd071-bdb4-4785-bcb5-00efae9f92d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bc102754-2f64-46f7-b8ec-5bcf7bd3c456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_ffe755b7-756c-4f50-a719-a7b5f6c35745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bc102754-2f64-46f7-b8ec-5bcf7bd3c456" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_ffe755b7-756c-4f50-a719-a7b5f6c35745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_893b4632-6ae6-4c81-b5bd-504420df3f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bc102754-2f64-46f7-b8ec-5bcf7bd3c456" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_893b4632-6ae6-4c81-b5bd-504420df3f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_04e6c352-de2a-4169-bbe8-3f12ed15166e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bc102754-2f64-46f7-b8ec-5bcf7bd3c456" xlink:to="loc_us-gaap_PurchaseObligation_04e6c352-de2a-4169-bbe8-3f12ed15166e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bc051d4d-1417-46ed-a3af-b52a47950b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bc102754-2f64-46f7-b8ec-5bcf7bd3c456" xlink:to="loc_us-gaap_LossContingenciesTable_bc051d4d-1417-46ed-a3af-b52a47950b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a4bdc366-ea91-4621-bdcd-f828c4bebfba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bc051d4d-1417-46ed-a3af-b52a47950b08" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a4bdc366-ea91-4621-bdcd-f828c4bebfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d1f651a9-8e2f-42f8-8d91-17a7e4dd97a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_a4bdc366-ea91-4621-bdcd-f828c4bebfba" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d1f651a9-8e2f-42f8-8d91-17a7e4dd97a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PatentInfringementComplaintMember_229a04ba-bd37-4e7f-811b-ac9a4fd55a04" xlink:href="neo-20211231.xsd#neo_PatentInfringementComplaintMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d1f651a9-8e2f-42f8-8d91-17a7e4dd97a5" xlink:to="loc_neo_PatentInfringementComplaintMember_229a04ba-bd37-4e7f-811b-ac9a4fd55a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FederalHealthcareProgramRevenueMember_7db5d699-0f4c-4441-8fd0-cdfbdf581ee3" xlink:href="neo-20211231.xsd#neo_FederalHealthcareProgramRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d1f651a9-8e2f-42f8-8d91-17a7e4dd97a5" xlink:to="loc_neo_FederalHealthcareProgramRevenueMember_7db5d699-0f4c-4441-8fd0-cdfbdf581ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7ebfdbbf-b956-4127-a68b-33fb561dd841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bc051d4d-1417-46ed-a3af-b52a47950b08" xlink:to="loc_us-gaap_LossContingenciesLineItems_7ebfdbbf-b956-4127-a68b-33fb561dd841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_ee962656-a293-402a-94bb-25f81448cce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7ebfdbbf-b956-4127-a68b-33fb561dd841" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_ee962656-a293-402a-94bb-25f81448cce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_5a66d273-4374-4f39-b175-9b467c2fd46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7ebfdbbf-b956-4127-a68b-33fb561dd841" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_5a66d273-4374-4f39-b175-9b467c2fd46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="neo-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_24e206e2-4eb4-458f-bc58-09710089ba59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7ad3d9e9-0c98-41ae-a41f-0ea3f44ca718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_24e206e2-4eb4-458f-bc58-09710089ba59" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7ad3d9e9-0c98-41ae-a41f-0ea3f44ca718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_17a25056-9213-47b2-8538-8853ebc96b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_17a25056-9213-47b2-8538-8853ebc96b25" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9100ad44-45ff-4c3c-8591-781a427e5c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9100ad44-45ff-4c3c-8591-781a427e5c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0b4c9f4d-47c4-416e-8c48-130cffc35fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9100ad44-45ff-4c3c-8591-781a427e5c2e" xlink:to="loc_us-gaap_RelatedPartyDomain_0b4c9f4d-47c4-416e-8c48-130cffc35fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b4135be7-bdf5-42dd-833d-dbc7f7d32742" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0b4c9f4d-47c4-416e-8c48-130cffc35fff" xlink:to="loc_srt_AffiliatedEntityMember_b4135be7-bdf5-42dd-833d-dbc7f7d32742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4faae8df-42e1-49d1-a7ea-78b4ff7c0550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4faae8df-42e1-49d1-a7ea-78b4ff7c0550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_bd934564-0f51-4097-963e-7572817d49db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4faae8df-42e1-49d1-a7ea-78b4ff7c0550" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_bd934564-0f51-4097-963e-7572817d49db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_StrategicAllianceWithInivataLimitedMember_6adeacd8-cc1d-433c-82ef-5dcf826ea745" xlink:href="neo-20211231.xsd#neo_StrategicAllianceWithInivataLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_bd934564-0f51-4097-963e-7572817d49db" xlink:to="loc_neo_StrategicAllianceWithInivataLimitedMember_6adeacd8-cc1d-433c-82ef-5dcf826ea745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e03a8ada-9671-4be9-96c9-12a86c1b1cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:to="loc_us-gaap_CreditFacilityAxis_e03a8ada-9671-4be9-96c9-12a86c1b1cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c87f8eea-3153-4dba-83ed-3d85f4aec428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e03a8ada-9671-4be9-96c9-12a86c1b1cfb" xlink:to="loc_us-gaap_CreditFacilityDomain_c87f8eea-3153-4dba-83ed-3d85f4aec428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1543adbe-6af5-4877-b226-acd19544780c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c87f8eea-3153-4dba-83ed-3d85f4aec428" xlink:to="loc_us-gaap_LineOfCreditMember_1543adbe-6af5-4877-b226-acd19544780c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_309684ee-4e44-4770-8394-e2ce87fa5cd3" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_14b0f728-50ff-4908-842a-116e012b936d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_14b0f728-50ff-4908-842a-116e012b936d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bb9fefbb-e2da-4534-beb1-5967fd03ec27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bb9fefbb-e2da-4534-beb1-5967fd03ec27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f26f76ac-7a87-47b5-981c-af91dd7da2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c45650bf-df3b-46fa-b135-c3e511842ba5" xlink:to="loc_us-gaap_LongTermDebt_f26f76ac-7a87-47b5-981c-af91dd7da2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformation" xlink:type="simple" xlink:href="neo-20211231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b87ae366-1fb6-401b-baa1-5157beae9767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_dcf268ac-927b-4168-b1af-c55cd16c109f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b87ae366-1fb6-401b-baa1-5157beae9767" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_dcf268ac-927b-4168-b1af-c55cd16c109f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="neo-20211231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9d36d436-6c86-40ba-9eb3-e652b39d2072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_e1ef9c1b-df75-4933-adc5-7f9c4354dfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9d36d436-6c86-40ba-9eb3-e652b39d2072" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_e1ef9c1b-df75-4933-adc5-7f9c4354dfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="neo-20211231.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9ce776cc-691d-45eb-b7a1-4352360a6834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac619675-8264-4e2e-9333-1b4c96d424e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9ce776cc-691d-45eb-b7a1-4352360a6834" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac619675-8264-4e2e-9333-1b4c96d424e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_facccb04-bcb5-4e94-ba84-2fb37cdb3df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac619675-8264-4e2e-9333-1b4c96d424e8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_facccb04-bcb5-4e94-ba84-2fb37cdb3df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_355b9017-46f6-469c-9c0b-f50ddfbe0a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_facccb04-bcb5-4e94-ba84-2fb37cdb3df2" xlink:to="loc_us-gaap_SegmentDomain_355b9017-46f6-469c-9c0b-f50ddfbe0a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesSegmentMember_7197ef21-1bc1-42f3-b36b-3eca000609af" xlink:href="neo-20211231.xsd#neo_ClinicalServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_355b9017-46f6-469c-9c0b-f50ddfbe0a2d" xlink:to="loc_neo_ClinicalServicesSegmentMember_7197ef21-1bc1-42f3-b36b-3eca000609af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesSegmentMember_9eee3696-707e-4bba-8ba2-4e6036948acb" xlink:href="neo-20211231.xsd#neo_PharmaServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_355b9017-46f6-469c-9c0b-f50ddfbe0a2d" xlink:to="loc_neo_PharmaServicesSegmentMember_9eee3696-707e-4bba-8ba2-4e6036948acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d16e97b-3c53-444f-95b6-4142cb120ad1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac619675-8264-4e2e-9333-1b4c96d424e8" xlink:to="loc_srt_ProductOrServiceAxis_5d16e97b-3c53-444f-95b6-4142cb120ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b9e04fc-b771-40e6-ba5d-8aea15458a4f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5d16e97b-3c53-444f-95b6-4142cb120ad1" xlink:to="loc_srt_ProductsAndServicesDomain_1b9e04fc-b771-40e6-ba5d-8aea15458a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember_92b5c685-f72e-4adb-97b2-5889b8ebfab3" xlink:href="neo-20211231.xsd#neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1b9e04fc-b771-40e6-ba5d-8aea15458a4f" xlink:to="loc_neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember_92b5c685-f72e-4adb-97b2-5889b8ebfab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_WriteOffForCOVID19PCRTestingInventoryMember_c281e93d-581e-49b0-82e8-5fb15b6ff118" xlink:href="neo-20211231.xsd#neo_WriteOffForCOVID19PCRTestingInventoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1b9e04fc-b771-40e6-ba5d-8aea15458a4f" xlink:to="loc_neo_WriteOffForCOVID19PCRTestingInventoryMember_c281e93d-581e-49b0-82e8-5fb15b6ff118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac619675-8264-4e2e-9333-1b4c96d424e8" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f83e7e7b-da6a-4307-bd0b-3c56516d29f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f83e7e7b-da6a-4307-bd0b-3c56516d29f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7f9369bc-6071-470d-8fc0-15cd8199f86e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_RevenuesAbstract_7f9369bc-6071-470d-8fc0-15cd8199f86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e9e33ebb-ad86-429e-ab75-561b21b7d613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7f9369bc-6071-470d-8fc0-15cd8199f86e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e9e33ebb-ad86-429e-ab75-561b21b7d613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_3fd3328b-7dd7-48ce-bc65-6cde025b098f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_3fd3328b-7dd7-48ce-bc65-6cde025b098f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b58ad66e-ddd2-4cd6-909a-88b111cfac67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_3fd3328b-7dd7-48ce-bc65-6cde025b098f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b58ad66e-ddd2-4cd6-909a-88b111cfac67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract_06eeee77-832f-4ac2-8f53-a2f9bed6bcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfitAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_GrossProfitAbstract_06eeee77-832f-4ac2-8f53-a2f9bed6bcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4e222efb-a4a0-4e7b-99fc-102282e97bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GrossProfitAbstract_06eeee77-832f-4ac2-8f53-a2f9bed6bcc6" xlink:to="loc_us-gaap_GrossProfit_4e222efb-a4a0-4e7b-99fc-102282e97bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_030c6946-ee2a-4332-babb-24363595d85e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_030c6946-ee2a-4332-babb-24363595d85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d89be29f-eb93-4405-a603-cfc657377763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d89be29f-eb93-4405-a603-cfc657377763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_5f4c690f-6aaf-4804-84e5-9b108a0f4347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:to="loc_us-gaap_SellingAndMarketingExpense_5f4c690f-6aaf-4804-84e5-9b108a0f4347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_628fa532-208f-43db-a508-162d4b035c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66e0b830-f93a-4a47-88ac-081a8e9d7d14" xlink:to="loc_us-gaap_OperatingExpenses_628fa532-208f-43db-a508-162d4b035c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3b188d7b-48ee-4b6d-9c67-7fa6f061772b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_OperatingIncomeLoss_3b188d7b-48ee-4b6d-9c67-7fa6f061772b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_525c7944-2430-459f-9773-0dc1956adca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_InterestExpense_525c7944-2430-459f-9773-0dc1956adca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b1ee1c80-6f49-461e-8b01-31078b5622d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b1ee1c80-6f49-461e-8b01-31078b5622d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnInvestmentAndLoanReceivable_2b573543-5c1e-49d6-a371-79d116b90fa3" xlink:href="neo-20211231.xsd#neo_GainLossOnInvestmentAndLoanReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_neo_GainLossOnInvestmentAndLoanReceivable_2b573543-5c1e-49d6-a371-79d116b90fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df615bc6-0844-44e1-adbc-43a458a5cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df615bc6-0844-44e1-adbc-43a458a5cdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_GainLossOnTerminationOfInterestRateSwap_8198aecc-781d-455e-a23e-6f458022424f" xlink:href="neo-20211231.xsd#neo_GainLossOnTerminationOfInterestRateSwap"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_neo_GainLossOnTerminationOfInterestRateSwap_8198aecc-781d-455e-a23e-6f458022424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_926adc5a-1cfa-4fce-a86f-8b6c970ababb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_926adc5a-1cfa-4fce-a86f-8b6c970ababb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_29f49142-a621-44b3-b62e-84806d3c6f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_29f49142-a621-44b3-b62e-84806d3c6f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99a0a7f6-2ac2-4078-ba30-45e5fd767551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4b85c821-bb41-4a71-bad8-b3b9a8b8cc66" xlink:to="loc_us-gaap_NetIncomeLoss_99a0a7f6-2ac2-4078-ba30-45e5fd767551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>neo-20211231_g1.jpg
<TEXT>
begin 644 neo-20211231_g1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M6 2P P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/\*:5XS?Q'::9X9L;2T\02* VI11VZ(EP<$C+J V03G=G-8_[6OPG\&_&_\
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MM*_8XCDTOX8VGBK3'U&[\5ZH]YJ6OW\FH6NQ;2+*"SMD5-X>02S2A,';M;:
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M)2Z;IH_8#_:YN_L$/FGPA?Q&7RAN\L:5?D)GKM!)..F:[;]C SW'_! KXIQ
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MZU/\%/VP/@!^T!XE\0>!_AWXQF_X2#PJY7Q#X=UC2;G3[^Q ;:6>"YC1RN<
ML 0"R@X) KY(_;.\4?L[>'K7]EJ;Q3X>U/6OBI%%I/\ PK?3K?Q =.T^*63[
M$HGU"7:Q6W$RQ'" .^UER%R1Q'[#[^(X_P#@NM\5X_%?B33]4U,^%;M-2O=(
MM3;VTLH_L[>L<9DD*JK#;AG9ODY).: /:?AY_P %9OA]\2_V[-=^#=D=8LO!
M/AOPU/;)<CPO>SW&IZP;RV3S&BAA>6"%$\Q%,@0$NQ;J@#_A5J7PKU'_ (*J
M^-/&VD?MH^)-2UC_ (1R2"Z^#USX:U.$6(AAA#',J"-T7;YJ*B!F:;(+9)?R
M7_@GC-#:?\%H_P!I&>[E6)$LM7=WD8*%4:I:$DD]!CO3O@Q_RL2_$;_L6C_Z
M;-/H ^S/@A^W/^RY^T=XZO\ X:?!CXDS:SKFEPO)J=@/#NH6YLU1]C>:T]NB
MQD-\NUB"3QC-=#X2_:5^"_C3P]XF\6Z5XNEMM+\&W<]KXFU'6](N]-AL)H03
M,C/=Q1@E /FVYVY&<9&?S\_:='B;_@F[_P %;]&_:(\ >$+O4_#7QDLYK:]T
M33E :\U"4I'- F>-YNOLEQD]3,P%>@?\%??!'C;X0_\ !*^'P=IEZUQ<W'BJ
MRG\>W]HI5+R>YFFNKJ=O1)+]T8 ]-RCL* /JSX9?ME?L\_%OQ?IO@7PAXRND
MU/7=).J>'(-7T*\T\:U9#.;BS:YBC6Y0 %OD).WY\;2&/4_'#PQXH\;_  6\
M7^"_ ^JM8ZUJ_A?4++1[U)VB:WNI;:2.*0.O*%793N'(QD5\D?##]G/3/VF?
M"'[.7[6^N?M265O9^!(--;PS9Z-X;CMEEDF-K%)IDTAN'+-OA^SD  @E^/3[
M?H _,;_@L-\*)?V,OV5/ U_\%_BS\0;?6YO%,=AJOB"[^(&J37&H)]CG=F</
M<&-=SHK815 Q@ "OH?X'_LFCQ3\(/@3\?O!'Q$\8V?B.TTWP]K'B:.Z\<ZE<
M6NN036L372303SO'G,C2C:JY*[>A&/)/^#C?_DUGP/\ ]C^O_I#<U]A_L9_\
MF?\ PI_[)KH7_IO@H K?$K]L_P#9[^%7C>_^&WB'Q7?WNNZ/I)U37=,\.^'K
MW5)=*L0 3<70M(9!;H 0WSX)!! ((J#XI?MJ_ 3X9_LS3?M86_B@^(?"?V0R
MZ=<^'86NFOG^;;$NT?(VY65C)M$95MY7!KXL_P""4$FOS?M:_M:7OQ7+G7%O
MW&IB[^\%^U7_ )@&?X  @&.-NW'&*\H_8,D\9R_\$7?VBX=36<Z(EQ.=',@.
MWS?L\!N F>W$1..,D]\T ?='_!.?]O'1_P!J?X$Q^,OB)JSV/B+.L:KJ\,ND
M7,%AIVGQZA,L2"\DB6WD$4!A4D2%L*S,,A\=;>?\%%OV2-,UCP[IVL?$6]L+
M/Q;<&#PSXAU+PSJ%MI.IR!@N(;V6!8'7)&'#[""#NP17SQ^P'J7P9LO^"'\$
M?Q^U&>'PD_A_Q&/$ L9BMRUJ=2ND<1;3DN2Z*O8LZ@\&OC3]MG7K;Q!_P3?^
M$-Y\/[6#1OAY'XOU2#P-X>U#4C?ZTT,;W FN[VX!5%9I2P6WBC"QJRY=MP"@
M'U5_P78\8>-_AIX[^">O?#KQ]X@T&XUC6;VUU7^Q]=N;9+N*.2R,:R)&X5MO
MFR<D9PY!XQ7Z+U^9O_!?&1I)_P!G621RS-K5\2Q/4YTWFOTRH _+']N6[\2>
M&?\ @L5\-?@MX;^(/BO3O"GBB;0GUO0+#Q=?P6\YGO)8IL*DP\L,B*#LV\Y/
M4DUK?\%2_B+\3_\ @F_\=OAAXY_9;^+_ (N%OXB6\.L> =9\5WNJZ?<_9Y+<
M*1#=RRE/.$[IE2"#'E-K9-<[_P %'M'MO$/_  6_^#^A7EU=PQ7<?AR&2:PO
M9+>9 VH7 )26)E>-N>&4@@\@US7BZ#4_^">W_!5G3/$O[;,E[\1_!^KG_BDO
M&WC*>34)]+M3*##<QM(2!+:R';(H'"L9$4%DH _53XH_&OX:_!#P ?B5\8/%
M$&@:6ABC9[H,\C32?<@CCC#/-*3D".-68X. <5B^"_VK/@AX[_X2>UTCQ+>6
M^H^"X5F\4:%JFB7=IJ.GQM'YJ.UI+$LS*Z8*E%8-G R>*^(O^"XWC_5O#'QF
M_9M\8?V^D'A&R\5/JLNHB'[3:":*XL769T5@)0L19E&X;E:0 C)-?1_PV_9-
MA\-_MI0?MB^(?VDH-9U_Q3X2?3$T;2]%CM;74K)$B83+MGD+*F(6+Y*Y*#(W
M#(!Q7[%?_!4[P=^U5\>_B!HEQ#JVG:%!J&FZ;X"T\>'+N>2? N?/N+B2"%UM
MWD81X25E 5% ^8.3[5X!_;P_98^*-]XKTGP%\2+G4;WP/;27'BO3X_#.I)<Z
M>D;F.3="]N'9E96!159AM.1Q7QI_P;W30VMQ\=!<RK'_ ,51IB?.P'S%KY0.
M>Y/ ]36%_P $];BVTO\ ;M_;,GU*XCMXX9/$,DTDSA51%U.Z)8D\  <YZ4 ?
M>WPJ_;-_9N^.'POUSXR_"7XAOKOASPY,\6LWUCH=Z7@=(UE8"$PB63".K'8C
M<'V..)O_ /@JQ^P)I_PS7XNR?M"V;Z')K+Z5#-'I-[YTMTD<<DB) 81*RHDL
M;,X78N]06R0*^6O^"$F/^'?_ ,7<_P#0PZA_Z:H*J_\ ! KX _!KXJ_LJ>/;
M[XH_#31/$BWOCE;.:WUW3(KJ/RH+6WE0!9%('SRL>.I"^@H ^TO'?_!0#]D+
MX8?$6Q^%/Q$^,MOHNMZG8PWNGPZEI5Y%#<6TJLR3K<-#Y)C(5AOW[058$@@@
M6OV?OVX/V9/VH/%VN> ?@Q\1_P"T=:\.C=JFEW>EW5E.D8<(9%2XC1G0,0I(
M!VEESC<N?BO]O_3=.F_X+@?L\Z?-80O FA:/L@:(%%VZGJ)7"XP,$ CTP*G_
M &:#Y'_!P5\6XX3L5_#-QO"\!LP::QS^/- 'Z)>-O&6@?#WPEJ'C?Q3<2Q:=
MI=JUQ=R06LD\@11D[8XU9W;L%4$D\ 5\J?L _P#!3GPS^V)\1_&EG?0ZEIUK
M/XDCLO 6E'0;F4"RCMM[2W%S%$T,4LC!W*R2#;E4&[ +?6FO*S:'>JHR3:2
M ?[IK\UO^" 5UKEM^R/\6_\ A%)4&L-KK#1T9AE[K^S\Q 9ZG<!Q[&@#[0\8
M_M]_LL>!]=\0:'K'Q NIT\)7,5OXNU32O#U]>V&ARR-L2.[NH(7AA8M\I#-E
M2#NVX->M:%KNB^)]%M/$GAO5[;4-/O[9+BQOK.=98;B)U#)(CJ2&4@@@@X(-
M?D[_ ,$\&C/_  1]_:<N_$+.VHR3ZP+XW9/FF3^RX=I?=SN\PMUYSGO7UM_P
M1 F\92_\$Z_"7_"6^?Y2ZAJ2Z*9\Y-G]KDVXSSM\SS0/8#'&* .4_P""R/\
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MVGCWQ[XGU[3?#6K6*:;;7]]>:I):PK<:FI6&,F21B5C0;4!9MHX) K[ \+_
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M/TEFA'_ J\,_X*D>"M3^,NC?L6_#?PI&UQ=^(-$%M:K%R0)HM&4/QT4#+$]
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MX"^+?PSO/A!\0M(EU/P_J%O%!?6<][+NN(HW1PKR[O,.2@RV[<><G)S72T4
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MQ_\ ]B)I7_HQJ]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#POP#_P I
M!/'_ /V(FE?^C&KW2O"_ /\ RD$\?_\ 8B:5_P"C&KW2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /"_ /_*03Q__ -B)I7_HQJ]TKPOP#_RD$\?_ /8B
M:5_Z,:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BN._:#^.'@C]FOX)>*/CS\1KSR=&\*Z--
M?WF& :78OR0IGK)(Y6-1W9U'>OS9_P""!7_!4_QO^TI\;?B3\!OV@/$?G:SX
MJUF[\7>$/-E)6+>P^U:=%NZ1QH(Y(T'14F/:OK\GX)SK.^&L=G>&C>CA.7F[
MN[UY?\"M*7:+N>?B,RPV&QM+#3?O5+V^7?UV7F?JO1117R!Z 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7X
M!_Y2">/_ /L1-*_]&-7NE>%^ ?\ E()X_P#^Q$TK_P!&-7NE !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%?GC_P59_X+O?#']CM-1^!W[-LNG^+_B<@:"]N=_FZ;X=?H?.*G$]PI_Y8
M*<*1^\(QY;?0<,\+9YQ?FD<ORNBZE1[_ ,L5UE)[1BN[]%=M(Y,;CL+E]!U:
M\K+\7Y)=6>"_\'._[<'_ "+W[!O@76/^>6O^//)D^OV*T?'_  *X93_T[M7Y
M4?L^?'#QO^S7\;?"_P >?AS>>3K/A768;^SRQ"R[&^>%\=8Y$+1L.ZNP[UF?
M$_XG^/\ XT?$'5_BK\4_%=WKGB'7;U[O5M5OGW23RMWXP%  "JJ@*J@*H
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M4 %%%% !1110 4444 %%%% !1110!X7X!_Y2">/_ /L1-*_]&-7NE>%^ ?\
ME()X_P#^Q$TK_P!&-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\ _\I!/'_P#V(FE?^C&KW2O"_ /_ "D$\?\ _8B:5_Z,:O=* "BBB@ HHHH
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M[$EF9B2 /2Z "BBB@#P'PM%JTW[?WCU=(NXH7'@?2MS2Q[@1O?BO9OL7C?\
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MB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**
M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M5G[%XW_Z#=E_X#'_ !K8HK\8;<G=[GT:22,?[%XW_P"@W9?^ Q_QH^Q>-_\
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MH,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MKZ;'J,5J$U2XCEEW'+Q)M&.W%6*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \+\ _\ *03Q_P#]B)I7_HQJ]TKPOP#_ ,I!/'__ &(FE?\
MHQJ]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'=M\5/V?_B5IOB;1;C :XL9?WEO)C)BFB8"2"0 \I(JMR#C!%=S7XU_M"?\
M!'+]MW_@FO\ $2X_:E_X)2_%37M8TN#,E_X41UDU.. '<87@QY6J0#GY"OFC
M(PCD;Z][_P"">O\ P<(?!+]H&]MO@[^U_I]K\,?'R2_96OKIFCT?4)P=I7?*
M=UE)G(,<Q*Y&!(20H>=>&:Q.7RSCA.O]>PBUE%*U>CY5*>[M_-%6=F[*.HL-
MG7)56'Q\?95.C^S+T?Z/\S]&:*;%+'/&LT,BNCJ&1U.0P/0@]Z=7Y,>^%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHKYH[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWM:XX\3X"IBJ-&'VVT[Z.+Z)^KT/W>HHHK\2/I0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+\ _P#*03Q_
M_P!B)I7_ *,:O=*\+\ _\I!/'_\ V(FE?^C&KW2@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBOS]_X*F?\ !<OX;?L@37GP$_9LAM/&WQ7E8VLD<.9K#09C\H$^PYGN
M 3@6Z'(/^L*X"/[_  WPQG?%N:1P&5TG4J/?I&*ZRE+:,5W?HKMI')C,;AL!
M0=6O*R_%^275GT)^WS_P4>_9S_X)Y_#G_A+?C!KWVO7+V%CX=\':;*IO]4<<
M9"G_ %4(/WIG^5>@W-M0_EY\-?@#^W]_P<(?%RW^-?[1.NW7@3X):7>M_9%M
M:(RVX0$JT6GQ/_Q\SD95[R0%5.X#.T0CT[]@?_@B9\8?VH/B-_PV[_P5GUO5
M-8U35YEO;/P+JLY%S==XS?[<"WB48VV:;<#"OL ,1_6K1M&T?P[I%KH'A_2K
M:PL+*W2"RLK.!8H;>) %6-$4!44  !0  !@5^IUL]X;\*Z,L)P_*.*S-IJIB
MFDZ=&^CCAT]&^CJ/\4W&/AQPN-SV2J8M.%#I#K+SG_E_P[XG]FG]E[X'?LB?
M"NR^#GP!\!VNA:+9C=((ANFO)B &GN)3\TTK8&68G@ #"@ =_117XKBL5B<=
MB9XC$3<ZDVW*4FVVWNVWJV?24Z<*4%""LELD%%%%<Y84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%<=^T'X@^+?A;X)>*->^ O@+_A)_&D&C3?\(OH9O+>W6YOF7;%
MODN)(XUC5B';<PRJ,!DD [8>C+$XB%%-)R:5Y-1BKNUW)Z)+JWHEJR9R4(.3
MZ=M7]Q^&_P#P<D_M:^%_CG^V'8? OP79V$MK\+K"2QU35XK=#-<:E.5DG@\T
M#<8X0L:;,X$IFXK\]/#OB'6_"7B"Q\5^&=4FL=2TR\BN]/O;9]LEO/&X>.13
MV964$'U%?8GB+_@A3_P6&\6^(+[Q7XF_9BFOM2U.\EN]0O;GQ]H+27$\CEY)
M&/V[EF9B2?4U3_X<$_\ !6K_ *-/_P#+[T'_ .3J_P!'^$\]\-^%>&<-D]+-
ML+*-*'*W[>E[S>LW\?VI-NW2]C\=Q^%SG'8V>(EAYIR=_AEIVZ=$?N]_P3K_
M &O]$_;D_9$\)?M :>\*:E>V?V3Q/90GBSU6'"7,>/X5+8D0'GRY4/>O;J_+
M3_@@Q^R+_P %*_V$_B;XF^&W[17[/TVE?#GQ;9B[-^/%NDW:Z;JL(PDGE6]V
M\A66,M&Q52=R0DX521^I=?P?XA9-E&1\6XG#Y57A6PS?-3E3G&<5&6O*W%M7
M@[QL];)/JC]2RG$XC%8"$Z\'&>S333NNNO?<****^*/2"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_ /_*03Q__
M -B)I7_HQJ]TKPOP#_RD$\?_ /8B:5_Z,:O=* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GXB\
M0Z)X2\/WWBOQ-JD-CINF6<MWJ%[<OMCMX(T+R2,>RJJDD^@KXM_X)@?\%@O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >%^ ?^4@GC_\ [$32O_1C5[I7A?@'_E()X_\ ^Q$TK_T8U>Z4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%G^8ECSEN>>>:JU_29_PX)_X)*_]&G_^7WKW_P G4?\ #@G_ ()*_P#1I_\
MY?>O?_)U?O4?I.< QBDL-B=/[E+_ .7'RKX*S5OXX??+_P"1/'?^#;C]M_\
MX7C^S)>_LJ>-M7\WQ)\,MO\ 9'G29>YT25CY6,\GR)"T1[*C0"OTFKYX_9N_
MX)3_ +!?[(GQ-B^,7[.OP/F\-^(H;.:T%_%XOU>X5X)0 \;Q7%W)'(IPIPRG
M#*K#!4$?0]?R1X@9MP[GW%>(S+):<Z=&L^=QJ*,6IOX[*,IJS?O+5;M6LE?[
M[*</C,+@(4<2TY1TNFWITW2UZ!1117QAZ04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >%^ ?^4@GC_\ [$32O_1C5[I7
MA?@'_E()X_\ ^Q$TK_T8U>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"D%%%%?'GHA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P#
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M!?\ @HWXWM?C[_P5/^/&LZ%ITA\RU\->='+J:Q,03'% H^RZ8A&#@*SY!W1
M\U^G_P"RK^Q'^S!^Q9X1_P"$0_9T^$VG:$LL:K?ZH$,U_?D<YGN7S))SR%)V
M+GY54<5WW_"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5\AQ3XB\2\5TEAJTU2PL
M?AH4ER4HKHN5?%;HY-VZ6/0P.3X+ 2YXKFF]Y2UD_GT^1L45C_\ "#Z1_P _
M-[_X%M1_P@^D?\_-[_X%M7PAZAL45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_
M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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MP70_9"@TJVT;]J_P792NFY-)\6Y)8C_GUN"?SA)/_3$5\ ?!OX5>*OCC\5-
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M0V\33W$JQQHI9W=L!0.I)/2J7A[Q7X7\76LM]X3\26&J007#033:=>).D<H
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M )2">/\ _L1-*_\ 1C5[I0 4444 %%%% !1110 4444 %%%% !1110 4444
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M_6O<****^D.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M%^ ?^4@GC_\ [$32O_1C5[I7A?@'_E()X_\ ^Q$TK_T8U>Z4 %%%% !1110
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MXBM/#^H>*_&&H7>GQ:[I4MG!IB'!>&5"OFRJ?8Y53R.I]*V[']@OX50X:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /"_ /_*03Q__ -B)I7_HQJ]TKPOP#_RD$\?_ /8B
M:5_Z,:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M _\ Z&[QW_X5\]>]44 >"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\
MA7SU[U10!X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7SU[U10!X+_P
M[J^!_P#T-WCO_P *^>C_ (=U? __ *&[QW_X5\]>]44 >"_\.ZO@?_T-WCO_
M ,*^>C_AW5\#_P#H;O'?_A7SU[U10!X+_P .ZO@?_P!#=X[_ /"OGH_X=U?
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M4 >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO@?\
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M*^>O>J* /!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO_P *^>O>J* /!?\
MAW5\#_\ H;O'?_A7ST?\.ZO@?_T-WCO_ ,*^>O>J* /!?^'=7P/_ .AN\=_^
M%?/1_P .ZO@?_P!#=X[_ /"OGKWJB@#P7_AW5\#_ /H;O'?_ (5\]>6?LB?L
M<?#/XL_#/4/$GBKQ5XO6Y@\5:E91BR\331)Y4,Y1,@=6QU/>OLVO/OV:_@SJ
M?P,\!7OA#5=:@OY+KQ#?:BLUO&RJJSREPF#W .#0!PW_  [J^!__ $-WCO\
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M\>_"_P ;_'>I>,]!^!GB+4(=$\3:I,7O+RRM[0W+6TDASODC4)UR09=OW0H
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M7A'4]7N,>;J45M(5@NI,<%V3Y6/\31EOXJ^B* "BBB@ HHHH **** "BBB@
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M/& ZP0QG_5H1YCR9; B 8 ]WHKXX_8W\-?$[]FG]O;QU^QY8_$_Q!XL^'">
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MHE(9Y" JA?-"[5*D#ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (BWT,5TJ7 *6\4,;FVTJTR 9(X(Q*[, #(YFF(4$*GBG_!)/P]=_"V+XZ_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'0O%GQ8T*+2_$TR3Q:_IL PEK=PW$D,L2]<JK1D Y.0,Y.: .ZHHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZMXAU:XT?2[4'3/$#F,7MM>"=[A;E=JA01)(PVXY0E2>2U ')2?L;?&#P_\
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M5/$_A2P\"P>(_AE?ZM/YEUI<%R]Q;?8G?N!+"VP#  B+ +O*C4_X(BM9P?\
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919191880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 21, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEOGENOMICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2897368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9490 NeoGenomics Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort Myers<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">768-0600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NEO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,025,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s Proxy Statement for its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001077183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352923573352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352920887624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 316,827<span></span>
</td>
<td class="nump">$ 228,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">198,563<span></span>
</td>
<td class="nump">67,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">112,130<span></span>
</td>
<td class="nump">106,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">23,395<span></span>
</td>
<td class="nump">29,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">12,354<span></span>
</td>
<td class="nump">11,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">10,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">8,189<span></span>
</td>
<td class="nump">4,555<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">681,508<span></span>
</td>
<td class="nump">448,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment (net of accumulated depreciation of $109,952 and $92,895, respectively)</a></td>
<td class="nump">109,465<span></span>
</td>
<td class="nump">85,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">102,197<span></span>
</td>
<td class="nump">45,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">442,325<span></span>
</td>
<td class="nump">120,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">527,115<span></span>
</td>
<td class="nump">211,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investment in non-consolidated affiliate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PrepaidRentNoncurrent', window );">Prepaid lease asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">7,168<span></span>
</td>
<td class="nump">4,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,188,270<span></span>
</td>
<td class="nump">539,601<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,869,778<span></span>
</td>
<td class="nump">988,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,921<span></span>
</td>
<td class="nump">24,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">38,304<span></span>
</td>
<td class="nump">24,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">17,796<span></span>
</td>
<td class="nump">11,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of equipment financing obligations</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">2,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">6,884<span></span>
</td>
<td class="nump">4,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current pharma contract liabilities</a></td>
<td class="nump">5,192<span></span>
</td>
<td class="nump">4,029<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">87,232<span></span>
</td>
<td class="nump">73,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">532,483<span></span>
</td>
<td class="nump">168,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Equipment financing obligations</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">72,289<span></span>
</td>
<td class="nump">42,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities, net</a></td>
<td class="nump">55,475<span></span>
</td>
<td class="nump">5,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">13,951<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">674,269<span></span>
</td>
<td class="nump">220,854<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">761,501<span></span>
</td>
<td class="nump">294,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, (250,000,000 shares authorized; 124,107,500 and 112,075,474 shares issued and outstanding, respectively)</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,123,628<span></span>
</td>
<td class="nump">701,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(638)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(14,837)<span></span>
</td>
<td class="num">(7,185)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,108,277<span></span>
</td>
<td class="nump">694,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,869,778<span></span>
</td>
<td class="nump">$ 988,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PrepaidRentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Rent, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PrepaidRentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123398962&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919111240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation on property and equipment</a></td>
<td class="nump">$ 109,952<span></span>
</td>
<td class="nump">$ 92,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="nump">124,107,500<span></span>
</td>
<td class="nump">124,107,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="nump">112,075,474<span></span>
</td>
<td class="nump">112,075,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352920930312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 484,329<span></span>
</td>
<td class="nump">$ 444,448<span></span>
</td>
<td class="nump">$ 408,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">297,269<span></span>
</td>
<td class="nump">258,555<span></span>
</td>
<td class="nump">211,994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">187,060<span></span>
</td>
<td class="nump">185,893<span></span>
</td>
<td class="nump">196,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">221,347<span></span>
</td>
<td class="nump">143,794<span></span>
</td>
<td class="nump">127,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21,873<span></span>
</td>
<td class="nump">8,229<span></span>
</td>
<td class="nump">8,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">62,594<span></span>
</td>
<td class="nump">47,862<span></span>
</td>
<td class="nump">47,350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">305,814<span></span>
</td>
<td class="nump">199,885<span></span>
</td>
<td class="nump">183,830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(LOSS) INCOME FROM OPERATIONS</a></td>
<td class="num">(118,754)<span></span>
</td>
<td class="num">(13,992)<span></span>
</td>
<td class="nump">13,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">5,082<span></span>
</td>
<td class="nump">7,019<span></span>
</td>
<td class="nump">3,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">499<span></span>
</td>
<td class="num">(7,906)<span></span>
</td>
<td class="nump">4,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_GainLossOnInvestmentAndLoanReceivable', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="num">(109,260)<span></span>
</td>
<td class="num">(3,955)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_GainLossOnTerminationOfInterestRateSwap', window );">Loss on termination of cash flow hedge</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before taxes</a></td>
<td class="num">(15,075)<span></span>
</td>
<td class="num">(14,056)<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(6,728)<span></span>
</td>
<td class="num">(18,228)<span></span>
</td>
<td class="num">(4,361)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS) INCOME</a></td>
<td class="num">$ (8,347)<span></span>
</td>
<td class="nump">$ 4,172<span></span>
</td>
<td class="nump">$ 8,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>NET (LOSS) INCOME PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">119,962<span></span>
</td>
<td class="nump">108,579<span></span>
</td>
<td class="nump">100,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">119,962<span></span>
</td>
<td class="nump">111,794<span></span>
</td>
<td class="nump">103,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 404,172<span></span>
</td>
<td class="nump">$ 382,337<span></span>
</td>
<td class="nump">$ 361,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 80,157<span></span>
</td>
<td class="nump">$ 62,111<span></span>
</td>
<td class="nump">$ 47,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_GainLossOnInvestmentAndLoanReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Investment and Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_GainLossOnInvestmentAndLoanReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_GainLossOnTerminationOfInterestRateSwap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Termination Of Interest Rate Swap</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_GainLossOnTerminationOfInterestRateSwap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919109368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive (Loss) Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS) INCOME</a></td>
<td class="num">$ (8,347)<span></span>
</td>
<td class="nump">$ 4,172<span></span>
</td>
<td class="nump">$ 8,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>OTHER COMPREHENSIVE (LOSS) INCOME:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(648)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized loss on effective cash flow hedge, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Cash flow hedge termination reclassified to earnings, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive (loss) income, net of tax</a></td>
<td class="num">(648)<span></span>
</td>
<td class="nump">1,628<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE (LOSS) INCOME</a></td>
<td class="num">$ (8,995)<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 6,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352915548312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,465,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 320,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 340,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (579)<span></span>
</td>
<td class="num">$ (19,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP plan (in shares)</a></td>
<td class="nump">141,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issuance ESPP Plan</a></td>
<td class="nump">$ 2,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance fees and expenses</a></td>
<td class="num">(263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Loss on effective cash flow hedge</a></td>
<td class="num">(1,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_WorkingCapitalAdjustmentAcquisitionShares', window );">Working capital adjustment related to acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_WorkingCapitalAdjustmentAcquisitions', window );">Working capital adjustment related to acquisition</a></td>
<td class="num">(1,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts</a></td>
<td class="nump">$ 160,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">160,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="nump">2,309,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,054,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">$ 9,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">9,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">ESPP expense</a></td>
<td class="nump">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">9,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">8,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,781,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 507,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">520,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,618)<span></span>
</td>
<td class="num">(11,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP plan (in shares)</a></td>
<td class="nump">138,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issuance ESPP Plan</a></td>
<td class="nump">$ 3,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance fees and expenses</a></td>
<td class="num">(268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Loss on effective cash flow hedge</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(1,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination', window );">Cash flow hedge termination reclassified to earnings</a></td>
<td class="nump">2,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_WorkingCapitalAdjustmentAcquisitions', window );">Working capital adjustment related to acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,751,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts</a></td>
<td class="nump">$ 127,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">127,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="nump">2,310,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,306,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">$ 18,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">18,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">ESPP expense</a></td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">9,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of Convertible Senior Notes due 2025</a></td>
<td class="nump">30,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment', window );">Tax liability related to Convertible Senior Notes due 2025</a></td>
<td class="num">(7,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts', window );">Convertible note debt issuance costs</a></td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">4,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,075,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 694,294<span></span>
</td>
<td class="num">$ (22,576)<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">701,357<span></span>
</td>
<td class="num">$ (23,271)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(7,185)<span></span>
</td>
<td class="nump">$ 695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP plan (in shares)</a></td>
<td class="nump">112,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issuance ESPP Plan</a></td>
<td class="nump">$ 4,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt', window );">Premiums paid for capped call confirmations</a></td>
<td class="num">(29,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance fees and expenses</a></td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(2,817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(2,818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_WorkingCapitalAdjustmentAcquisitions', window );">Working capital adjustment related to acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,693,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock - public offering, net of underwriting discounts</a></td>
<td class="nump">$ 218,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">218,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="nump">1,372,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,372,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">$ 13,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">13,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement', window );">Issuance of common stock - private placement, net of private placement fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,444,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement', window );">Issuance of common stock - private placement, net of private placement fees</a></td>
<td class="nump">189,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">189,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">ESPP expense</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for acquisition</a></td>
<td class="nump">29,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">29,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">21,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(8,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,108,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 1,123,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (638)<span></span>
</td>
<td class="num">$ (14,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Convertible Stock Issued, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Tax Liability Component of Convertible Debt, Subsequent Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, New Issues, Private Placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, New Issues, Private Placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_WorkingCapitalAdjustmentAcquisitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital Adjustment, Acquisition, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_WorkingCapitalAdjustmentAcquisitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_WorkingCapitalAdjustmentAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital Adjustment, Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_WorkingCapitalAdjustmentAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352918845704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS) INCOME</a></td>
<td class="num">$ (8,347)<span></span>
</td>
<td class="nump">$ 4,172<span></span>
</td>
<td class="nump">$ 8,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net&#160;cash&#160;provided&#160;by operating&#160;activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">30,192<span></span>
</td>
<td class="nump">25,904<span></span>
</td>
<td class="nump">20,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">23,160<span></span>
</td>
<td class="nump">9,817<span></span>
</td>
<td class="nump">9,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">22,458<span></span>
</td>
<td class="nump">10,212<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">8,716<span></span>
</td>
<td class="nump">6,168<span></span>
</td>
<td class="nump">5,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible debt discount</a></td>
<td class="nump">2,563<span></span>
</td>
<td class="nump">4,358<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_GainLossOnTerminationOfInterestRateSwap', window );">Loss on termination of cash flow hedge</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="num">(109,260)<span></span>
</td>
<td class="num">(3,955)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates', window );">Interest on loan receivable from non-consolidated affiliate</a></td>
<td class="num">(391)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PolymeraseChainReactionTestingExitCostsCOVID19', window );">Write off of COVID-19 PCR testing inventory and equipment</a></td>
<td class="nump">6,061<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">2,547<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(4,691)<span></span>
</td>
<td class="num">(12,601)<span></span>
</td>
<td class="num">(17,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,634<span></span>
</td>
<td class="num">(15,197)<span></span>
</td>
<td class="num">(5,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_IncreaseDecreaseInPrepaidConstruction', window );">Prepaid lease asset</a></td>
<td class="num">(4,788)<span></span>
</td>
<td class="num">(20,229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Prepaid and other assets</a></td>
<td class="num">(1,906)<span></span>
</td>
<td class="num">(9,750)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable, operating lease liabilities, deferred taxes, accrued and other liabilities</a></td>
<td class="nump">5,151<span></span>
</td>
<td class="num">(3,970)<span></span>
</td>
<td class="num">(9,001)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(26,723)<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">23,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(196,791)<span></span>
</td>
<td class="num">(73,101)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">62,970<span></span>
</td>
<td class="nump">5,356<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(64,142)<span></span>
</td>
<td class="num">(29,096)<span></span>
</td>
<td class="num">(20,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="num">(419,404)<span></span>
</td>
<td class="num">(37,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Investment in non-consolidated affiliate</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Loan receivable from non-consolidated affiliate</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationWorkingCapitalAdjustment', window );">Acquisition working capital adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(632,367)<span></span>
</td>
<td class="num">(159,441)<span></span>
</td>
<td class="num">(19,630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of revolving credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_RepaymentsOfEquipmentAndOtherLoans', window );">Repayment of equipment financing obligations</a></td>
<td class="num">(3,047)<span></span>
</td>
<td class="num">(5,615)<span></span>
</td>
<td class="num">(7,201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(97,540)<span></span>
</td>
<td class="num">(99,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DerivativeTerminationFee', window );">Cash flow hedge termination</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,317)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs for term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="nump">15,080<span></span>
</td>
<td class="nump">20,310<span></span>
</td>
<td class="nump">11,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible debt, net of issuance costs</a></td>
<td class="nump">334,410<span></span>
</td>
<td class="nump">194,466<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PaymentsOfPremiumsForCappedCallConfirmations', window );">Premiums paid for capped call transactions</a></td>
<td class="num">(29,291)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ProceedsFromEquityOfferingNet', window );">Proceeds from equity offering, net of issuance costs</a></td>
<td class="nump">408,133<span></span>
</td>
<td class="nump">127,293<span></span>
</td>
<td class="nump">160,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">725,285<span></span>
</td>
<td class="nump">235,597<span></span>
</td>
<td class="nump">159,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">66,195<span></span>
</td>
<td class="nump">77,616<span></span>
</td>
<td class="nump">163,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">250,632<span></span>
</td>
<td class="nump">173,016<span></span>
</td>
<td class="nump">9,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">316,827<span></span>
</td>
<td class="nump">250,632<span></span>
</td>
<td class="nump">173,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">316,827<span></span>
</td>
<td class="nump">228,713<span></span>
</td>
<td class="nump">173,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,919<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">3,065<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
<td class="nump">4,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid, net</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_FairValueOfCommonStockIssuedToFundAcquisition', window );">Fair value of common stock issued to fund acquisition</a></td>
<td class="nump">29,174<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_WorkingCapitalAdjustmentAcquisitions', window );">Working capital adjustment related to acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Equipment acquired under financing obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">4,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">$ 1,315<span></span>
</td>
<td class="nump">$ 2,007<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationWorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Working Capital Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationWorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DerivativeTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Termination Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DerivativeTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_FairValueOfCommonStockIssuedToFundAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock issued to fund acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_FairValueOfCommonStockIssuedToFundAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_GainLossOnTerminationOfInterestRateSwap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Termination Of Interest Rate Swap</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_GainLossOnTerminationOfInterestRateSwap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_IncreaseDecreaseInPrepaidConstruction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Construction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_IncreaseDecreaseInPrepaidConstruction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PaymentsOfPremiumsForCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Premiums For Capped Call Confirmations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PaymentsOfPremiumsForCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PolymeraseChainReactionTestingExitCostsCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Polymerase Chain Reaction Testing, Exit Costs, COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PolymeraseChainReactionTestingExitCostsCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ProceedsFromEquityOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Equity Offering, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ProceedsFromEquityOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ReceivableWithImputedInterestNonConsolidatedAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable With Imputed Interest, Non-Consolidated Affiliates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ReceivableWithImputedInterestNonConsolidatedAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_RepaymentsOfEquipmentAndOtherLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of Equipment and Other Loans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_RepaymentsOfEquipmentAndOtherLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_WorkingCapitalAdjustmentAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital Adjustment, Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_WorkingCapitalAdjustmentAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352925924680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business</a></td>
<td class="text">Nature of Business<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Nature of the Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeoGenomics, Inc., a Nevada corporation (the &#8220;Parent,&#8221; &#8220;Company,&#8221; or &#8220;NeoGenomics&#8221;), and its subsidiaries, operate as a certified, high complexity clinical laboratory in accordance with the federal government&#8217;s Clinical Laboratory Improvement Act, as amended, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">COVID-19 Pandemic Update</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) was identified and the disease has since spread across the world, including the United States (&#8220;U.S.&#8221;). In March 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic. The outbreak of the pandemic is materially adversely affecting the Company&#8217;s employees, patients, communities, and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 outbreak will impact the Company&#8217;s business, results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#8217;s results of operations, financial condition, and cash flows may continue to be materially adversely affected, particularly if the pandemic continues to persist for a significant amount of time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the cash on hand, marketable securities, and expected cash collections are sufficient to fund near-term capital and operating needs for at least the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the first quarter 2021, due to the broad roll-out of the COVID-19 vaccine and a sharp decline in COVID-19 polymerase chain reaction (&#8220;PCR&#8221;) testing demand, the Company made the decision to exit COVID-19 PCR testing and the Company recorded a $6.1&#160;million loss related to the exit from COVID-19 PCR testing. This amount consisted of write-offs of $5.3&#160;million for all remaining COVID-19 PCR testing inventory recorded to cost of revenue and $0.8&#160;million for all remaining COVID-19 PCR testing laboratory equipment recorded to general and administrative expenses on the Consolidated Statements of Operations for the year ended December 31, 2021. There were no such amounts recorded for each of the years ended December 31, 2020 and 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Coronavirus Aid, Relief, and Economic Security Act</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal government passed legislation and the President of the United States signed into law on March 27, 2020, known as the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). On April 10, 2020, the U.S. Department of Health &amp; Human Services announced that Medicare-enrolled providers would receive a portion of a direct deposit disbursement totaling $50 billion. The $50 billion is part of a $100 billion Public Health and Social Service Emergency Fund created by the CARES Act. Payments made under the CARES Act are intended to reimburse healthcare providers for health care related expenses or lost revenues attributable to COVID-19 and are not required to be repaid provided that recipients attest to and comply with certain terms and conditions, including limitations on balance billing for COVID-19 patients. In the absence of specific guidance to account for government grants in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), the Company accounts for such grants in accordance with international accounting standards for government grants. Such amounts are recognized when there is reasonable assurance that the Company will (1) comply with the conditions associated with the grant and (2) receive the grant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company recognized $7.9&#160;million in grant income related to the CARES Act. No such amounts were recorded for the years ended December 31, 2021 and December 31, 2019. CARES Act grant income is classified in other income, net, on the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also permits the deferral of payment of the employer portion of social security taxes between March 27, 2020 and December 31, 2020. 50% of the deferred amount was due on December 31, 2021 and the remaining 50% is due on December 31, 2022. As of December 31, 2021, the total accrued deferred social security taxes, related to the CARES Act was $3.0&#160;million. This amount was recorded in accrued expenses and other liabilities on the Consolidated Balance Sheets. As of December 31, 2020, the total accrued deferred social security taxes, related to the CARES Act was $5.9&#160;million which was recorded evenly between accrued expenses and other liabilities and other long-term liabilities on the Consolidated Balance Sheets.</span></div>Additionally, the CARES Act included an Employee Retention Tax Credit (&#8220;ERTC&#8221;) provision designed to encourage employers to retain employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages paid between March 13, 2020 and September 30, 2021 that meet the requirements of the ERTC provision. For the year ended December 31, 2020, the Company recognized $1.9&#160;million in credits under the ERTC which was included in (loss) income from operations on the Consolidated Statements of Operations. In the fourth quarter of 2021 the Company recorded $4.4&#160;million and $1.9&#160;million in expense in (loss) income from operations related to non-reoccurring reversals and reserves against tax credits previously recorded in the nine months ended September 30, 2021 and in the year ended December 31, 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352925890216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of the Parent and its subsidiaries. All intercompany accounts and balances have been eliminated in consolidation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#8217;s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these Consolidated Financial Statements include, but are not limited to, those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether investments in affiliates are a Variable Interest Entity (&#8220;VIE&#8221;) at the start of each new venture and when a reconsideration event has occurred. A reporting entity must consolidate a VIE if that reporting entity has a variable interest (or combination of variable interests) and is determined to be the primary beneficiary. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its equity investments that are under 20% of the total equity outstanding and for which the Company does not have significant influence by applying the cost method. Investments that are under 20% of the total equity outstanding and for which the Company has significant influence are accounted for using the equity method unless a scope exception is applicable. Investments in which the Company holds a non-controlling interest and are between 20-50% equity are accounted for using the equity method. For any equity investments in which the Company holds over 50% of the outstanding stock, or for investments in which the Company controls the investee, the Company consolidates those entities into the Consolidated Financial Statements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Segment Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its activities in two reportable segments; (1) the Clinical Services segment and (2) the Pharma Services segment.&#160;These reportable segments deliver testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers and represent 100% of the Company&#8217;s consolidated assets, net revenue, and net (loss) income in each of the years ended December 31, 2021, 2020, and 2019. Please refer to Note 19. Segment Information, for further financial information about these segments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions of entities over which control is obtained that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent third-party valuations that use information and assumptions provided by management, which consider estimates of inputs and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired less liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives, and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the Company&#8217;s operating results from the date of acquisition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash, certain cash equivalents, accounts receivable, net, other current assets, accounts payable, accrued expenses and other liabilities, and Pharma contract liabilities are considered reasonable estimates of their respective fair values due to their short-term nature. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its marketable securities at fair value on a recurring basis. Please refer to Note 4. Fair Value Measurements, for further discussion.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with an original maturity of ninety days or less to be cash equivalents. The Company maintains its cash and cash equivalents with financial institutions that the Company believes to be of high credit standing. The Company believes that, as of December 31, 2021, its concentration of credit risk related to cash and cash equivalents was not significant.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all marketable securities as available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are carried at fair value, with the unrealized holding gains and losses, net of income taxes, reflected in accumulated other comprehensive income until realized. The Company evaluates its marketable securities for other-than-temporary impairment on a quarterly basis. Unrealized losses are charged against net earnings when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine whether a loss is other-than-temporary, such as the length and extent of the fair value decline, the financial condition and near-term prospects of the issuer, and whether there is the intent to sell or will more likely than not be required to sell before the securities&#8217; anticipated recovery. There were no other-than-temporary impairments for the years ended December 31, 2021, 2020 and 2019. Regardless of the intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are recorded when the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of computing realized and unrealized gains and losses, cost and fair value are determined on a specific identification basis.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounts Receivable, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are reported for all Clinical Services payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Pharma Services the Company negotiates billing schedules and payment terms on a contract-by-contract basis which can include payments based on certain milestones being achieved.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist principally of testing supplies and are valued at lower of cost or net realizable value, using the first-in, first-out method. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventories to their estimated net realizable value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Assets Held for Sale</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns 43,560 square feet of our Carlsbad, California facility. During the third quarter of 2021, the Company committed to selling this property and the associated land and concluded that these assets met the held for sale criteria. At December 31, 2021, $10.1 million was recorded as assets held for sale within current assets on the Consolidated Balance Sheets for this property and associated land and reflects its carrying value which was lower than the fair value less selling costs. We expect to sell this property within one year, however, there can be no assurance that the sale of this property will be completed in the time frame we expect or at all. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Prepaid Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a prepaid expense for costs paid but not yet incurred. Those expected to be incurred within one year are recorded as prepaid assets within total current assets on the Consolidated Balance Sheets. Any costs expected to be incurred outside of one year are recorded as other assets within total non-current assets on the Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Current Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, other current assets consisted primarily of receivables related to research and development (&#8220;R&amp;D&#8221;) tax credit receivables, pharma contract assets and other non-trade receivables.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on the straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the related lease terms or their estimated useful lives. Costs incurred in connection with the development of internal-use software are capitalized in accordance with the accounting standard for internal-use software, and are amortized over the expected useful life of the software.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews the estimated useful lives of property and equipment. Changes to the estimated useful lives are recorded prospectively from the date of the change. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts and any resulting gain or loss is included in income (loss) from operations. Repairs and maintenance costs are expensed as incurred and are included in cost of revenue, general and administrative expenses or R&amp;D expenses, as appropriate in the Consolidated Statements of Operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases corporate offices and laboratory spaces throughout the world, all of which are classified as operating leases expiring at various dates and generally having terms ranging from 1 to 20 years. Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s real estate lease agreements include options to either renew or early terminate the lease. Leases with renewal options allow the Company to extend the lease term typically between 1 and 5 years. When it is reasonably certain that the Company will exercise an option to renew or terminate a lease, these options are considered in determining the classification and measurement of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities are recorded based on the present value of the future lease payments over the lease term and assessed as of the commencement date. Incentives received from landlords, such as reimbursements for tenant improvements and rent abatement periods, effectively reduce the total lease payments owed for leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain real estate leases also include executory costs such as common area maintenance (non-lease component), as well as property insurance and property taxes (non-components). Lease payments, which may include lease components, non-lease components and non-components, are included in the measurement of the Company&#8217;s lease liabilities to the extent that such </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments are either fixed amounts or variable amounts based on a rate or index (fixed in substance), as stipulated in the lease contract. Any actual costs in excess of such amounts are expensed as incurred as variable lease cost.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes its incremental borrowing rate by lease term in order to calculate the present value of its future lease payments when the implicit rates in the leases agreements are not readily determinable. The discount rate represents a risk-adjusted rate on a secured basis and is the rate at which the Company would borrow funds to satisfy the scheduled lease liability payment streams commensurate with the lease term.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs represent fixed lease payments recognized on a straight-line basis over the lease term. Operating lease costs include an immaterial amount of variable lease costs and are recorded in cost of revenue, general and administrative, sales and marketing, and R&amp;D expenses (depending on the nature of the leased asset) in the Consolidated Statements of Operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Intangible Assets, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with determinable useful lives are recorded initially at acquired fair value or cost, less accumulated amortization. Each intangible asset with a determinable useful life is amortized over its estimated useful life using the straight-line method. The Company periodically reviews the estimated pattern in which the economic benefits will be consumed and adjusts the amortization period and pattern to match the estimate. Intangible assets with indefinite useful lives are recorded initially at fair value or cost and are tested annually for impairment or more frequently if management believes indicators of impairment exist. For the years ended December 31, 2021, 2020, and 2019, no impairment losses related to intangible assets with indefinite useful lives were recorded.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company&#8217;s intangible assets were comprised of customer relationships, trade names and trademarks, marketing assets, and developed technology. At December 31, 2020, the Company&#8217;s intangible assets were comprised of customer relationships and trademarks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#8217;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#8217; data. For the years ended December 31, 2021, 2020, and 2019, the Company&#8217;s evaluation of goodwill resulted in no impairment losses. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recoverability and Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the recoverability of its long-lived assets (including definite-lived intangible assets) if events or changes in circumstances indicate the assets may be impaired. Evaluation of possible impairment is based on the Company&#8217;s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value to the carrying amount of the asset.&#160;For the years ended December 31, 2021, 2020, and 2019, no impairment losses were recognized related to long-lived assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingencies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingent losses when estimated impacts of various conditions, situations or circumstances involve uncertain outcomes. Contingent losses are recorded based on management judgment along with internal and external advice from legal counsel and/or technical consultants. Estimated losses from contingencies are recorded when both of the following conditions are met: (i) information available before the financial statements are issued (or available to be issued) indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) the amount of loss can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, that amount shall be accrued. When no amount within the range is a better estimate than any other amount, however, the minimum amount in the range shall be accrued. Please refer to Note 17. Commitments and Contingencies, for further discussion.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Debt Issuance Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs related to convertible senior notes are recorded as deductions that net against the principal value of the debt and are amortized as interest expense over the life of the debt using the effective interest method. Debt issuance costs related to term loans are recorded as direct deductions from the carrying amount of the term loan and are amortized to interest expense over the life of the debt using the effective interest method.&#160;Debt issuance costs relating to line of credit arrangements are recorded as assets and amortized over the term of the credit arrangement regardless of whether any outstanding borrowing existed. The term loan and line of credit were terminated in 2020 and all debt issuance costs were expensed accordingly. Please refer to Note 9. Debt, for further information on debt issuance costs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Stock-based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures compensation expense for stock-based awards to employees, non-employee contracted physicians, and directors based upon the awards&#8217; initial grant-date fair values.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2021 the Company estimated the fair value of stock options using a trinomial lattice model. On January 1, 2021, the Company began applying the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) on a prospective basis to new awards. The Company expects the use of Black-Scholes to provide a more ubiquitous estimate of fair value. Like the prior trinomial lattice model, Black-Scholes is affected by the stock price on the date of the grant as well as assumptions regarding a number of highly complex and subjective variables. These variables include the expected term of the option, expected risk-free interest rate, the expected volatility of common stock, and expected dividend yield; each of which is described below. The assumptions for expected term and expected volatility are the two assumptions that significantly affect the grant date fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term: The expected term of an option is determined using the simplified method under SAB 107 which represents the average between the vesting term and the contractual term. The Company utilizes the simplified method to determine the expected life of the options due to insufficient exercise activity during recent years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free Interest Rate: The risk-free interest rate used in the Black-Scholes model is based on the implied yield at the grant date of the U.S. Treasury zero-coupon issue with an equivalent term to the stock-based award being valued. Where the expected term of a stock-based award does not correspond with the term for which a zero coupon interest rate is quoted, the Company uses the nearest interest rate from available maturities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Stock Price Volatility: The Company uses its own historical weekly volatility because that is more reflective of market conditions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend Yield: Because the Company has never paid a dividend and does not expect to begin doing so in the foreseeable future, the Company assumed no dividend yield in valuing the stock-based awards.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent. The performance obligation is satisfied and revenues are recognized at the point in time the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay patients and within 60 to 90 days of billing for client payers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharma Services segment generally enters into contracts with pharmaceutical and biotech customers as well as other Clinical Research Organizations (&#8220;CROs&#8221;) to provide research and clinical trial services ranging in duration from one month to several years. The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is recognized over time based on the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to sponsors at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics provides de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected for services provided in advance of revenue being recognized are deferred as contract liabilities. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently recognized. Contract assets are established for revenue that has been recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding account receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and are amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets and all others are classified as non-current assets. Contract assets are included in other current assets and other assets on the Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Cost of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payroll and payroll related costs for performing tests, project management, depreciation of laboratory equipment and laboratory leasehold improvements, rent for laboratory facilities, laboratory reagents, probes and supplies, delivery and courier costs relating to the transportation of specimens to be tested, and amortization for acquired Inivata developed technology intangible assets. The expenses related to shipping specimens to the facilities for testing, includes costs incurred for contract couriers, commercial airline flights, and courier charges. The Company also incurs expenses returning samples and slides to its customers.&#160;For the years ended December 31, 2021, 2020, and 2019, the Company recorded shipping expenses of approximately $16.5 million, $13.8 million, and $14.2 million, respectively as Cost of revenue in the Consolidated Statements of Operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of payroll and payroll related costs for the Company&#8217;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred. R&amp;D expenses consist of payroll and payroll related costs, laboratory supplies, depreciation of laboratory equipment, and costs for samples to complete validation studies. These expenses are primarily incurred to develop new genetic tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and are deemed immaterial for the years ended December 31, 2021, 2020 and 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods and lives for property and equipment, recognition of bad debts, compensation related expenses, and various other expenses that have been allowed for or accrued for financial statement purposes but are not currently deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations, and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company evaluates tax positions that have been taken or are expected to be taken in its tax returns and records a liability for uncertain tax positions, if deemed necessary. The Company follows a two-step approach to recognizing and measuring uncertain tax positions. First, tax positions are recognized if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon examination, including resolution of related appeals or litigation processes, if any. Second, the tax position is measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes on the Consolidated Balance Sheets. At December 31, 2021 and 2020, the Company has an uncertain tax position related to Federal and State R&amp;D tax credits, including a provision for interest and penalties related to such position as applicable. The Company does not expect a significant change in its uncertain tax positions in the next 12 months.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Net (Loss) Income per Common Share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic net (loss) income per share attributable to common stockholders by dividing net (loss) income by the weighted-average number of shares of common stock outstanding for the period. Diluted net (loss) income per share is computed using the weighted average number of common shares outstanding during the applicable period, plus the dilutive effect of potential common stock. Potential common stock consists of shares issuable pursuant to stock options and convertible notes, as well as non-vested restricted stock awards which are not considered outstanding with respect to the weighted average common shares outstanding in the calculation of basic net (loss) income per share. Potentially dilutive shares are determined by applying the treasury stock method to the Company&#8217;s outstanding stock options and restricted stock awards. Potentially dilutive shares issuable upon conversion of the 0.25% Convertible Senior Notes due 2028 and the 1.25% Convertible Senior Notes due 2025 are calculated using the if-converted method.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the FASB issued ASU No. 2021-06, Presentation of Financial Statements (Topic 205), Financial Services-Depository and Lending (Topic 942), and Financial Services-Investment Companies (Topic 946) (&#8220;ASU 2021-06&#8221;), Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10786, Amendments to Financial Disclosures About Acquired and Disposed Businesses, and No.33-10835, Update of Statistical Disclosures for Bank and Savings and Loan Registrants. This update amends certain SEC disclosure guidance that is included in the accounting standards codification to reflect the SEC&#8217;s recent issuance of rules intended to modernize and streamline disclosure requirements. The Company adopted this pronouncement upon issuance and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements, which updates various codification topics by clarifying disclosure requirements to align with the SEC&#8217;s regulations. The Company adopted this pronouncement on January 1, 2021 and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt&#8201;-&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;-&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8201;-&#8201;Accounting For Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible instruments by removing the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such convertible debt instruments. Similarly, the debt discount, that is equal to the carrying value of the embedded conversion feature upon issuance, will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible instrument was issued at a substantial premium. In addition, ASU 2020-06 requires the application of the if-converted method for calculating the impact of convertible instruments on diluted earnings </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. ASU 2020-06 can be adopted on either a fully retrospective or modified retrospective basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2020-06 on January 1, 2021 using the modified retrospective approach, and, accordingly, the Company recorded an adjustment that reflects the 1.25% Convertible Senior Notes due 2025 as if the embedded conversion feature had not been separated. The impact upon adoption on the Consolidated Balance Sheets included an increase of approximately $27.2&#160;million in convertible senior notes, net, a write-off of approximately $6.6&#160;million in deferred income tax liabilities, establishment of approximately $2.0&#160;million of valuation allowance against deferred income tax assets, and a decrease of approximately $23.3&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment to increase the beginning balance of retained earnings on the Consolidated Balance Sheets for previously recognized interest expense, net of tax effects, of approximately $2.7&#160;million for amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance, as well as a decrease to the beginning balance of retained earnings of approximately $2.0&#160;million for the establishment of valuation allowance against the Company&#8217;s deferred income tax assets. There was no impact to the Company&#8217;s earnings per share calculation. For further information regarding the 1.25% Convertible Senior Notes due 2025, please refer to Note 9. Debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance (&#8220;ASU 2021-10&#8221;). This update requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this pronouncement on January 1, 2022, and is currently evaluating the impact of this standard on its annual disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#8220;ASU 2021-08&#8221;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the planned adoption date and the impact of this standard on its Consolidated Financial Statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (&#8220;ASU 2020-04&#8221;) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (&#8220;LIBOR&#8221;) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) (&#8220;ASU 2021-01&#8221;) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of December 31, 2021, there was no impact to the Company&#8217;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352925981352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Trapelo Health</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2021 (the &#8220;Trapelo Acquisition Date&#8221;), the Company completed the acquisition of a 100% ownership interest in Intervention Insights, Inc. d/b/a Trapelo Health (&#8220;Trapelo&#8221;), an information technology company focused on precision oncology. The purchase price consisted of (i) cash consideration of $35.6&#160;million, which included a net adjustment of $0.6&#160;million for estimated cash on hand of Trapelo and estimated working capital adjustments on the Trapelo Acquisition Date, and (ii) equity consideration of $29.2&#160;million, consisting of 597,712 shares of the Company&#8217;s common stock, par value $0.001 per share, valued at $48.81 per share. The Company acquired control of Trapelo on the Trapelo Acquisition Date; therefore, the fair value of the common stock issued as part of consideration was determined on the basis of the closing market price of the Company&#8217;s common stock immediately prior to the Trapelo Acquisition Date. The Trapelo acquisition enhances the Company&#8217;s ability to provide customers clinical decision support to help answer complex questions related to precision oncology biomarker testing and treatment options as part of the Company&#8217;s comprehensive oncology offerings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Trapelo was determined to be a business combination and has been accounted for using the acquisition method. The purchase price and purchase price allocation are preliminary, are based upon management&#8217;s best estimates and assumptions, and are subject to future revision. The following table summarizes the estimated purchase consideration recorded for the acquisition of Trapelo, the estimated fair value of the net assets acquired and liabilities assumed, and the preliminary calculation of goodwill based on the excess of the estimated consideration transferred over the estimated fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.851%"><tr><td style="width:1.0%"/><td style="width:74.247%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued as consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share value of common stock issued as consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of common stock at Trapelo Acquisition Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Cash paid at closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of the purchase consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - marketing assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the timing of the acquisition, the following are considered preliminary and are subject to change:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amount of goodwill pending the completion of the amounts for income tax assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will finalize these amounts no later than one year from the acquisition date once it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in adjustments to the preliminary amounts disclosed above which may impact the reported results in the period those adjustments are identified. There have been no such adjustments to the preliminary amounts disclosed above subsequent to the Trapelo Acquisition Date through December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identified developed technology and marketing intangible assets are being amortized over ten years and four years, respectively, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Trapelo acquisition is 9.8 years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The marketing intangible assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the marketing intangible assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the marketing intangible assets had the intangible assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#8217;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized, all of which is assigned to the Clinical Services segment, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. None of the goodwill resulting from the acquisition of Trapelo is expected to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and integration costs related to Trapelo were approximately $1.8&#160;million for the year ended December 31, 2021 and are reported as general and administrative expenses in the Company&#8217;s Consolidated Statements of Operations. There were no such amounts recorded for the years ended December 31, 2020 and 2019. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of Trapelo are included in the Company&#8217;s Consolidated Financial Statements beginning on the Trapelo Acquisition Date. Revenue and net (loss) income of Trapelo included in the Consolidated Statements of Operations was not material for the period from the Trapelo Acquisition Date to December 31, 2021. No pro forma information has been included relating to the Trapelo acquisition, as this acquisition was not deemed to be material to the Company&#8217;s revenue or net (loss) income on a pro forma basis for the period from the Trapelo Acquisition Date to December 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Inivata Limited</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021 (the &#8220;Inivata Acquisition Date&#8221;), the Company completed the acquisition of the remaining equity interests in Inivata Limited, a private limited company incorporated in England and Wales (&#8220;Inivata&#8221;). Inivata is a global, commercial stage, liquid biopsy platform company. The acquisition follows a $25.0&#160;million minority equity investment by the Company in Series C1 Preference Shares (the &#8220;Preference Shares&#8221; or &#8220;previously-held equity interest&#8221;) in Inivata in May 2020, at which time the Company also acquired a fixed price option to purchase the remainder of equity interests in Inivata for $390.0&#160;million (the &#8220;Purchase Option&#8221;). The Company and Inivata also entered into a line of credit agreement in the amount of $15.0&#160;million (the &#8220;Line of Credit&#8221;) in May 2020. For further details regarding the previously-held equity investment in Inivata, the Purchase Option and the Line of Credit, please refer to Note 8. Investment in Non-Consolidated Affiliate. The Inivata acquisition adds liquid biopsy platform technology, including minimal residual disease testing capabilities, to the Company&#8217;s comprehensive portfolio of oncology testing solutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price consisted of cash consideration of $398.6&#160;million, which included a net adjustment of $8.6&#160;million for estimated cash on hand of Inivata and other adjustments on the Inivata Acquisition Date, and was funded through cash on hand and a private placement of equity. For further information regarding the private placement of equity, please refer to Note 11. Equity Transactions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the acquisition of the remaining equity interests in Inivata, the Company accounted for its previously-held equity interest and the Purchase Option in Inivata as equity securities without a readily determinable fair value. The equity interests were recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Therefore, the Company&#8217;s acquisition of control of Inivata on the Inivata Acquisition Date was accounted for as a business combination achieved in stages under the acquisition method. Accordingly, the Company used a discounted cash flow to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#8217;s previously-held equity interest and Purchase Option in Inivata. To determine the fair value of the previously-held equity interest, the fair value of Inivata&#8217;s total equity was allocated to its various classes of equity based on the respective rights and privileges of each class of stock in liquidation. The business enterprise value and a Black-Scholes model were then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at the fair value at the Inivata Acquisition Date based on its settlement value. This resulted in fair values of $64.9&#160;million in Preference Shares and a $74.3&#160;million Purchase Option, immediately prior to the acquisition. On the Inivata Acquisition Date, the $10.3&#160;million outstanding under the Line of Credit extended by the Company to Inivata was effectively settled as part of the acquisition of Inivata at the $15.0&#160;million principal amount and was recorded as part of the consideration transferred in the acquisition. The Company recorded a gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#8217;s Consolidated </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statements of Operations of $109.3&#160;million for the year ended December 31, 2021, including a measurement period adjustment of $17.8&#160;million recorded for the year ended December 31, 2021, for the excess of the acquisition-date fair value of the Company&#8217;s previously-held equity interest, Purchase Option, and Line of Credit over their carrying values. For further details regarding the previously-held equity investment and purchase option in Inivata, please refer to Note 8. Investment in Non-Consolidated Affiliate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and allocation of the business combination are preliminary, are based upon management&#8217;s best estimates and assumptions, and are subject to future revision. The following table summarizes the preliminary calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit and the estimated fair value of the previously-held equity interest and Purchase Option over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 18, 2021<br/>(as initially reported)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 18, 2021 <br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Line of Credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously-held equity interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Purchase Option</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of the fair value business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets - developed technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets - trademarks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - trade name</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,388)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to a change in legal settlement liabilities.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangible assets and related future amortization and the change in legal settlement liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the timing of the acquisition, the following are considered preliminary and are subject to change:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts for intangible assets, property and equipment, other current assets, current liabilities, and other long-term liabilities pending finalization of the valuation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts for income tax liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed and the reporting unit allocation of the goodwill; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acquisition-date fair value of the Company&#8217;s previously-held equity interest, Purchase Option, and the Line of Credit, and the gain on investment in and loan receivable from non-consolidated affiliate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will finalize these amounts no later than one year from the acquisition date, once it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in adjustments to the preliminary amounts disclosed above which may impact the reported results in the period those adjustments are identified.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identified developed technology intangible assets and the trademark intangible assets are both being amortized over fifteen years, and the trade name intangible asset is being amortized over five years, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Inivata acquisition is 14.9 years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The trademarks and trade name assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the trademarks and trade name assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the trademarks and trade name assets had the assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#8217;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized, of which $238.4 million and $33.0 million is assigned to the Clinical Services and Pharma Services segments, respectively, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of liquid biopsy technology for oncology testing. The recording of amortizable intangibles has given rise to a deferred tax liability upon the acquisition of Inivata which increased goodwill by $61.0 million. None of the goodwill resulting from the acquisition of Inivata is expected to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and integration costs related to Inivata were $-13.9&#160;million for the year ended December 31, 2021 and are reported as general and administrative expenses in the Company&#8217;s Consolidated Statements of Operations. There were no such amounts for the years ended December 31, 2020 and 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of the Company&#8217;s Inivata subsidiary are included in the Company&#8217;s Consolidated Financial Statements beginning on the Inivata Acquisition Date. For the period from the Inivata Acquisition Date to December 31, 2021, the Inivata subsidiary revenue was $1.5&#160;million, all of which was recorded in Pharma Services revenue. The Inivata subsidiary net loss was $27.6&#160;million for the period from the Inivata Acquisition Date to December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.583%"><tr><td style="width:1.0%"/><td style="width:47.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited pro forma results represent the combined results of operations of the Company and Inivata, on an unaudited pro forma basis, for the period in which the acquisition of Inivata occurred and the prior reporting period as though the companies had been combined as of the beginning of the earliest period presented. Therefore, the unaudited pro forma consolidated results have been prepared by adjusting the Company&#8217;s historical results to include the acquisition of Inivata as if it occurred on January 1, 2020. Acquisition-related transaction costs incurred by Inivata of $11.0&#160;million are included in net loss as if incurred on January 1, 2020. Acquisition-related transaction and retention costs incurred by the Company of $13.9&#160;million are included in net loss as if incurred on January 1, 2020. These unaudited pro forma consolidated historical results exclude $109.3&#160;million and $4.0&#160;million of gain on investment in and loan receivable from non-consolidated affiliate, net, recorded for the year ended December 31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926399032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.&#160;These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly.&#160;These are typically obtained from readily-available pricing sources for comparable instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs, where there is little or no market activity for the asset or liability.&#160;These inputs reflect the reporting entity&#8217;s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses, and fair values of the Company&#8217;s marketable securities accounted for as available-for-sale securities as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $0.6 million and $0.2 million of accrued interest receivable at December 31, 2021 and 2020, respectively, included in other assets on its Consolidated Balance Sheets related to its marketable securities. The amounts of realized gains and realized losses were immaterial for the years ended December 31, 2021 and 2020. There were no such amounts for the year ended December 31, 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of December 31, 2021 and 2020 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the years ended December 31, 2021 and 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash, certain cash equivalents, accounts receivable, net, other current assets, accounts payable, accrued expenses and other liabilities, and Pharma contract liabilities are considered reasonable estimates of their respective fair values at December 31, 2021 and 2020 due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and as such, these are considered Level 3 fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352925972504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lives in Years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - 13</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-17</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-9</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-10</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,895)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns 43,560 square feet of our Carlsbad, California facility. This facility, consisting of land and an office building, is not included in property and equipment, net, on the Consolidated Balance Sheets. At December 31, 2021, these assets are classified as assets held for sale within current assets on the Consolidated Balance Sheets with a carrying value of $3.2 million and $6.9 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December 31, 2021, 2020, and 2019, was as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,192&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926016376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the maturities of the operating lease liabilities and a reconciliation to the present value of lease liabilities were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.511%"><tr><td style="width:1.0%"/><td style="width:76.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.76</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional supplemental data related to the operating leases for the years ended December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company has entered into $4.9 million of contractually binding minimum lease payments for a lease executed but not yet commenced. This amount is excluded from the above tables and relates to the lease of an administrative space in Carlsbad, California that commenced in January 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company&#8217;s lease of its new laboratory and headquarters facility in Fort Myers, Florida commenced. As of December 31, 2021, the Company had paid approximately $25.0&#160;million to the landlord for the construction of the underlying assets which was classified as a prepaid lease asset until the lease commenced in the third quarter of 2021 at which time the prepaid lease asset was included in the calculation of the right-of-use asset. As of December 31, 2021, the Company had paid approximately $17.0&#160;million to the landlord for leasehold improvements, which are included in property and equipment, net, for its new laboratory and headquarters facility. As of </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all disbursements to the landlord had been completed. As of December 31, 2020, $21.9 million remained unpaid in a construction disbursement escrow account for final remaining disbursements to the landlord and remained in restricted cash on the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926132584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of Trapelo in April 2021, the Company recorded $44.7 million in goodwill, all of which was recorded in the Clinical Services segment. As a result of the acquisition of Inivata in June 2021, the Company recorded $271.4 million in goodwill, of which $238.4 million and $33.0 million are assigned to the Clinical Services and Pharma segments, respectively. For further information regarding the Trapelo and Inivata acquisitions, please refer to Note 3. Acquisitions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Services </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pharma Services </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired - Trapelo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired - Inivata</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.065%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.065%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7-15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt 0 13pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;7-15</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020, and 2019, amortization on the Consolidated Statements of Operations was recorded as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization recorded in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,160&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the estimated amortization expense related to amortizable intangible assets for each of the five following years and thereafter is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,898&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926029352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Non-consolidated Affiliate<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment in Non-Consolidated Affiliate</a></td>
<td class="text">Investment in Non-Consolidated Affiliate<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company formed a strategic alliance with Inivata and entered into a Strategic Alliance Agreement and Laboratory Services Agreement with Inivata&#8217;s laboratory subsidiary in the United States, Inivata, Inc., whereas Inivata&#8217;s laboratory rendered and performed certain laboratory testing which the Company made available to customers. The terms and conditions of the Laboratory Services Agreement were consistent with those that would be negotiated between willing parties on an arm&#8217;s length basis. For additional details on amounts paid related to the Laboratory Services Agreement, please refer to Note 18. Related Party Transactions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Laboratory Services Agreement, the Company also entered into an Investment Agreement with Inivata (the &#8220;Investment Agreement&#8221;), pursuant to which the Company acquired the Preference Shares for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25.0&#160;million in cash resulting in a minority interest in Inivata&#8217;s outstanding equity and an Option Deed which provided the Company with a Purchase Option to purchase Inivata. The Investment Agreement also granted the Company one seat on Inivata&#8217;s Board of Directors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company completed the acquisition of the remaining equity interests in Inivata. For further details regarding the acquisition of Inivata, please refer to Note 3. Acquisitions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Inivata Acquisition Date, Inivata was determined to be a variable interest entity (&#8220;VIE&#8221;) and the Company&#8217;s investment was under 20.0% of the total equity outstanding. The Company considered qualitative factors in assessing the primary beneficiary of the VIE which included understanding the purpose and design of the VIE, associated risks that the VIE created, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it was not the primary beneficiary of Inivata prior to the Inivata Acquisition Date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Inivata Acquisition Date, the power to control the activities that most significantly impacted Inivata&#8217;s economic performance was the sole responsibility of Inivata&#8217;s management and Board of Directors; however, the Company did have significant influence over Inivata. As the Preference Shares were determined to not be in-substance common stock, and because the Preference Shares and the Purchase Option did not have readily determinable fair values, prior to the Inivata Acquisition Date, the Company elected to measure the Preference Shares and the Purchase Option at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the initial $25.0&#160;million cost and $0.6&#160;million of associated transaction costs was allocated between the Preference Shares and the Purchase Option based on the relative fair value of each and was recorded as investment in non-consolidated affiliate on the Consolidated Balance Sheets. The initial relative fair value of the investment in non-consolidated affiliate was comprised of $19.6&#160;million in Preference Shares and a $6.0&#160;million Purchase Option. The Preference Shares were valued by determining the equity value of Inivata using the Backsolve Method and allocating the value of the Preference Shares using the Option-Pricing Method and the inputs used included the equity value based on the Series C1 capital raised by Inivata, a volatility rate of 84.0%, a risk-free interest rate of 0.17% and 0.0% dividend yield. The Purchase Option was valued using the Black-Scholes model with a volatility rate of 84.0%, a risk-free interest rate of 0.17% and 0.0% dividend yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, an observable transaction of an identical investment in Inivata Preference Shares occurred. This resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Purchase Option was also remeasured at fair value as a result of this observable transaction. As a result of these remeasurements, at December 31, 2020, the carrying value of the investment in non-consolidated affiliate is $29.6&#160;million, comprised of $25.0&#160;million in Preference Shares and a $4.6&#160;million Purchase Option. The Company recorded a net unrealized gain of $4.0&#160;million for these remeasurements for the year ended December 31, 2020 in gain on investment in and loan receivable from non-consolidated affiliate, net, on the Consolidated Statements of Operations. At December 31, 2020, the Purchase Option was valued using the Black-Scholes model with a volatility rate of 84.0%, a risk-free interest rate of 0.17% and 0.0% dividend yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company and Inivata also entered into the Line of Credit in the amount of $15.0&#160;million. In January 2021, the Line of Credit, in its entirety, was drawn by Inivata and recorded as a loan receivable from non-consolidated affiliate on the Consolidated Balance Sheets. Prior to the Inivata Acquisition Date, the Line of Credit contractually matured on December 1, 2025 and the unpaid principal balance was payable on January 1, 2026 and bore interest at 0.0% per annum. In January 2021, upon the draw of the Line of Credit by Inivata, the Company used an imputed interest rate of 8.33% to present value the Line of Credit. The Company recorded an imputed interest rate discount of $5.0&#160;million on the loan receivable from non-consolidated affiliate and an additional investment in non-consolidated affiliate of $5.0&#160;million, resulting in a $10.0&#160;million present value of the loan receivable from non-consolidated affiliate and increasing the value of the Preference Shares to $30.0&#160;million. For the year ended December 31, 2021 through the Inivata Acquisition Date $0.4 million of interest income was amortized to the loan receivable from non-consolidated affiliate. The interest income amortization is recorded in interest expense, net, on the Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, subsequent to Inivata&#8217;s draw on the Line of Credit, an observable transaction of an identical investment in Inivata Preference Shares occurred. This resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Company recorded a net unrealized loss of $5.0&#160;million for this remeasurement for the three months ended March 31, 2021. As of March 31, 2021, the carrying value of the investment in non-consolidated affiliate was $29.6&#160;million, comprised of $25.0&#160;million in Preference Shares and a $4.6&#160;million Purchase Option.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Inivata Acquisition Date the Company acquired all of the remaining equity interests of Inivata through the exercise of its Purchase Option. The Company&#8217;s carrying value of the investment in non-consolidated affiliate was $29.6&#160;million, comprised of $25.0&#160;million in Preference Shares and a $4.6&#160;million Purchase Option immediately prior to obtaining the remaining ownership of Inivata. The Company&#8217;s acquisition of control of Inivata on the Inivata Acquisition Date was accounted for as a business combination achieved in stages under the acquisition method. Accordingly, the Company </span></div>remeasured its Preference Shares and Purchase Option to their acquisition-date fair values. The Company used a discounted cash flow to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#8217;s Preference Shares and the Purchase Option. To determine the fair value of the Preference Shares, the fair value of equity was allocated to the various classes based on the respective rights and privileges of each class of stock in liquidation. The business enterprise value and a Black-Scholes model was then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at fair value at the Inivata Acquisition Date based on its settlement value. This resulted in fair values of $64.9&#160;million in Preference Shares and a $74.3&#160;million Purchase Option, immediately prior to the acquisition, resulting in a net gain of $104.6&#160;million for the year ended December 31, 2021, which includes the net loss of $5.0&#160;million for the remeasurement in the first quarter of 2021. In addition, on the Inivata Acquisition Date, the $10.3&#160;million outstanding under the Line of Credit extended by the Company to Inivata was effectively settled as part of the acquisition of Inivata at the $15.0&#160;million principal amount and was recorded as part of the consideration transferred in the acquisition resulting in a gain of $4.7&#160;million for the year ended December 31, 2021. The Company recorded a total gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#8217;s Consolidated Statements of Operations of $109.3&#160;million for the year ended December 31, 2021 for the excess of the acquisition-date fair value of the Company&#8217;s Preference Shares, Purchase Option, and Line of Credit over their carrying values. For further details regarding the acquisition of Inivata, please refer to Note 3. Acquisitions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352925988984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term debt, net, at December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25% Convertible Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total 0.25% Convertible Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25% Convertible Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(538)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total 1.25% Convertible Senior Notes due 2025, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of equipment financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,554&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the estimated fair value (Level 2) of the 0.25% Convertible Senior Notes due 2028 and the 1.25% Convertible Senior Notes due 2025 was $297.6&#160;million and $238.9&#160;million, respectively. There was no such estimated fair value as of December 31, 2020 related to the 0.25% Convertible Senior Notes due 2028. At December 31, 2020, the estimated fair value (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $320.9&#160;million. At December 31, 2021 and 2020, the carrying value of the Company&#8217;s equipment financing obligations approximated fair value based on the current market conditions for similar instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2028 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, the Company completed the sale of $345.0&#160;million of Convertible Senior Notes with a stated interest rate of 0.25% and a maturity date of January 15, 2028 (the &#8220;2028 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased. The 2028 Convertible Notes were issued at a discounted price of 97.0% of their principal amount. The total net proceeds from the issuance of the 2028 Convertible Notes and exercise of the over-allotment option was approximately $334.4&#160;million, which includes approximately $10.6&#160;million of discounts, commissions and offering expenses paid by the Company. On January 11, 2021, the Company entered into an Indenture (the &#8220;Indenture&#8221;), with U.S. Bank National Association, as trustee (the &#8220;Trustee&#8221;), governing the 2028 Convertible Notes. The Company used a portion of the net </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from the Offerings to enter into capped call transactions (as described below under the heading &#8220;Capped Call Transactions&#8221;).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to September 15, 2027, noteholders may convert their 2028 Convertible Notes at their option, only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130.0% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2028 Convertible Notes for each trading day of the measurement period was less than 98.0% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day; (3) if the Company calls any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after September 15, 2027 until the close of business on the second business day immediately preceding the maturity date, noteholders may convert their 2028 Convertible Notes at any time, regardless of the foregoing circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended September 30, 2021. Based on the terms of the 2028 Convertible Notes, the holders could not have converted all or a portion of their 2028 Convertible Notes in the fourth quarter of 2021. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended December 31, 2021. Based on the terms of the 2028 Convertible Notes, the holders cannot convert all or a portion of their 2028 Convertible Notes in the first quarter of 2022. When a conversion notice is received, the Company has the option to pay or deliver cash, shares of the Company&#8217;s common stock, or a combination thereof. As the Company is not required to settle the 2028 Convertible Notes in cash, the 2028 Convertible Notes are classified as long-term debt as of December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, the Company will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at its election. The initial conversion rate for the 2028 Convertible Notes is 15.1172 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to an initial conversion price of approximately $66.15 per share of common stock. The conversion rate is subject to adjustment as described in the Indenture. In addition, following certain corporate events that occur prior to the maturity date as described in the Indenture, the Company will pay a make-whole premium by increasing the conversion rate for a holder who elects to convert its 2028 Convertible Notes in connection with such a corporate event in certain circumstances. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $34.12 on December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2028 Convertible Notes prior to January 20, 2025. The Company may redeem for cash all or any portion of the 2028 Convertible Notes, at its option, on or after January 20, 2025 if the last reported sale price of its common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date of notice by the Company of redemption at a redemption price equal to 100.0% of the principal amount of the 2028 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2028 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event involving bankruptcy, insolvency or reorganization events with respect to the Company occurs, then the principal amount of, and all accrued and unpaid interest on, all of the 2028 Convertible Notes then outstanding will immediately become due and payable. If any other default event occurs and is continuing, then noteholders of at least 25.0% of the aggregate principal amount of the 2028 Convertible Notes then outstanding, by notice to the Company, may declare the principal amount of, and all accrued and unpaid interest on, all of the 2028 Convertible Notes then outstanding to become due and payable immediately. If the Company undergoes a Fundamental Change (as defined in the Indenture), then noteholders may require the Company to repurchase their 2028 Convertible Notes at a cash repurchase price equal to the principal amount of the 2028 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the Fundamental Change Repurchase Date (as defined in the Indenture).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes are the Company&#8217;s senior, unsecured obligations and will be equal in right of payment with its existing and future senior, unsecured indebtedness, senior in right of payment to its existing and future indebtedness that is expressly subordinated to the 2028 Convertible Notes and effectively junior to its existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness. The 2028 Convertible Notes will be structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of its subsidiaries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2028 Convertible Notes includes $0.8&#160;million, $1.4&#160;million and $32,000 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the year ended December 31, 2021. There were no such amounts for the year ended December 31, 2020. The effective interest rate on the 2028 Convertible Notes is 0.70%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of 0.25% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, which began on July 15, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the &#8220;Capped Call Transactions&#8221;) with option counterparties pursuant to capped call confirmations at a cost of approximately $29.3&#160;million. As the Capped Call Transactions meet certain accounting criteria, the Capped Call Transactions were classified as equity, are not accounted for as derivatives and were recorded as a reduction of the Company&#8217;s additional paid-in capital in the accompanying Consolidated Financial Statements. The Capped Call Transactions are not part of the terms of the 2028 Convertible Notes and will not affect any holders&#8217; rights under the 2028 Convertible Notes. The Capped Call Transactions cover, subject to customary anti-dilution adjustments, the number of shares of the Company&#8217;s common stock that initially underlie the 2028 Convertible Notes. The number of shares underlying the Capped Call Transactions is&#160;5.2&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cap price of the Capped Call Transactions is initially $85.75 per share of the Company&#8217;s common stock, which represents a premium of 75.0% over the public offering price of the common stock in the 2021 Common Stock Offering, which was $49.00 per share, and is subject to certain adjustments under the terms of the Capped Call Transactions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By entering into the Capped Call Transactions, the Company expects to reduce the potential dilution to its common stock (or, in the event a conversion of the 2028 Convertible Notes is settled in cash, to reduce its cash payment obligation) in the event that, at the time of conversion of the 2028 Convertible Notes, its common stock price exceeds the conversion price of the 2028 Convertible Notes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2025 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2020, the Company completed the sale of $201.3&#160;million of convertible senior notes with a stated interest rate of 1.25% and a maturity date of May 1, 2025 (the &#8220;2025 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased. The 2025 Convertible Notes were issued at a discounted price of 97.0% of their principal amount. The total net proceeds from the issuance of the 2025 Convertible Notes and exercise of the over-allotment option were approximately $194.5&#160;million, which includes approximately $6.9&#160;million of discounts, commissions and offering expenses paid by the Company. On May 4, 2020, the Company entered into an indenture (the &#8220;Indenture&#8221;), with U.S. Bank National Association, as trustee (the &#8220;Trustee&#8221;), governing the 2025 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to February 1, 2025, noteholders may convert their 2025 Convertible Notes at their option, only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130.0% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2025 Convertible Notes for each trading day of the measurement period was less than 98.0% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day; (3) if the Company calls any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after February 1, 2025 until the close of business on the business day immediately preceding the maturity date, noteholders may convert their 2025 Convertible Notes at any time, regardless of the foregoing circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended September 30, 2021. Based on the terms of the 2025 Convertible Notes, the holders could not have converted all or a portion of their 2025 Convertible Notes in the fourth quarter of 2021. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended December 31, 2021. Based on the terms of the 2025 Convertible Notes, the holders cannot convert all or a portion of their 2025 Convertible Notes in the first quarter of 2022. When a conversion notice is received, the Company has the option to pay or deliver cash, shares of the Company&#8217;s common stock, or a combination thereof. As the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company is not required to settle the 2025 Convertible Notes in cash, the 2025 Convertible Notes are classified as long-term debt as of December 31, 2021 and 2020. As of December 31, 2021, the Company had not received any conversion notices.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, the Company will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at its election. The initial conversion rate for the 2025 Convertible Notes is 27.5198 shares of common stock per $1,000 in principal amounts of 2025 Convertible Notes, equivalent to an initial conversion price of approximately $36.34 per share of common stock. The conversion rate is subject to adjustment as described in the Indenture. In addition, following certain corporate events that occur prior to the maturity date as described in the Indenture, the Company will pay a make-whole premium by increasing the conversion rate for a holder who elects to convert its 2025 Convertible Notes in connection with such a corporate event in certain circumstances. The value of the 2025 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $34.12 on December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2025 Convertible Notes prior to May 6, 2023. The Company may redeem for cash all or any portion of the 2025 Convertible Notes, at its option, on or after May 6, 2023 if the last reported sale price of its common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date of notice by the Company of redemption at a redemption price equal to 100.0% of the principal amount of the 2025 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2025 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event involving bankruptcy, insolvency or reorganization events with respect to the Company occurs, then the principal amount of, and all accrued and unpaid interest on, all of the 2025 Convertible Notes then outstanding will immediately become due and payable. If any other default event occurs and is continuing, then noteholders of at least 25.0% of the aggregate principal amount of the 2025 Convertible Notes then outstanding, by notice to the Company, may declare the principal amount of, and all accrued and unpaid interest on, all of the 2025 Convertible Notes then outstanding to become due and payable immediately. If the Company undergoes a &#8220;fundamental change&#8221; as defined in the Indenture, then noteholders may require the Company to repurchase their 2025 Convertible Notes at a cash repurchase price equal to the principal amount of the 2025 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Convertible Notes are the Company&#8217;s senior, unsecured obligations and will be equal in right of payment with its existing and future senior, unsecured indebtedness, senior in right of payment to its existing and future indebtedness that is expressly subordinated to the 2025 Convertible Notes and effectively junior to its existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness. The 2025 Convertible Notes will be structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of its subsidiaries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2025 Convertible Notes includes $2.5&#160;million, $1.2&#160;million and $0.15&#160;million, for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively for the year ended December 31, 2021. The interest expense recognized on the 2025 Convertible Notes includes $1.7&#160;million, $4.4&#160;million and $0.07 million, for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively for the year ended December 31, 2020. The effective interest rate on the 2025 Convertible Notes is 1.96%, which includes the interest on the 2025 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2025 Convertible Notes bear interest at a rate of 1.25% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, which began on November 1, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Maturities of Long-Term Debt</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of long-term debt at December 31, 2021 are summarized as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.25% Convertible Senior Notes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.25% Convertible Senior Notes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equipment Financing Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Long-Term Debt</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:&#160;Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:&#160;Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,554&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926135640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text">Derivative Instruments and Hedging Activities<div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021 and 2020, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company did not have any outstanding derivative instruments. In June of 2018, the Company entered into an interest rate swap agreement to reduce the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s exposure to interest rate fluctuations on the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s variable rate debt obligations.&#160;This derivative financial instrument was accounted for at fair value as a cash flow hedge to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effectively modify the Company&#8217;s exposure to interest rate risk by converting a portion of its prior floating rate debt to a fixed rate obligation, thus reducing the impact of interest rate changes on interest expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the swap agreement, the Company received a variable rate of interest based on LIBOR and paid a fixed rate of interest. The following table summarizes the previous interest rate swap agreement.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.767%"><tr><td style="width:1.0%"/><td style="width:47.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 2018 Hedge</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70 million</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 29, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One month LIBOR</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 9. Debt, concurrent with the closing of the 2025 Convertible Notes, the proceeds from this transaction were used to pay off all amounts outstanding under the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Prior Senior Secured Credit Agreement, after which the Company had no outstanding debt with variable rate interest. On May 1, 2020, the remaining obligation to make any further payments under the swap agreement was terminated. As a result of the termination, the Company paid $3.3&#160;million, which is included within loss on termination of cash flow hedge on the Consolidated Statements of Operations for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company did not have any such losses in the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value adjustments were historically recorded within other comprehensive income. Upon termination of the interest rate swap in 2020, the accumulated losses, net of tax of $2.7&#160;million, related to the interest rate swap were reclassified from accumulated other comprehensive income to loss on termination of cash flow hedge on the Consolidated Statements of Operations for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No such reclassifications were recorded during the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140353002991256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Transactions</a></td>
<td class="text">Equity Transactions<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement Transaction</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company completed a private placement (&#8220;Private Placement&#8221;) to certain accredited investors of an aggregate of 4,444,445 shares of the Company&#8217;s common stock at a price of $45.00 per share. The net proceeds to the Company from the Private Placement were approximately $189.9&#160;million, after deducting fees to the placement agents and other offering expenses of approximately $10.1&#160;million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock Issued for Acquisition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3. Acquisitions, the Company issued 597,712 shares of common stock as consideration for the acquisition of Trapelo in April 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Underwritten Public Equity Offerings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2021, the Company entered into an underwriting agreement relating to the issuance and sale of 4,081,632 shares of the Company&#8217;s common stock, $0.001 par value per share (the &#8220;2021 Common Stock Offering&#8221;). The price to the public in this offering was $49.00 per share. The net proceeds to the Company from the 2021 Common Stock Offering were approximately $189.9&#160;million, after deducting underwriting discounts, commissions and other offering expenses of approximately $10.1&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the underwriting agreement, the Company also granted the Underwriters a 30-day option to purchase up to 612,244 additional shares of common stock at the public offering price, less underwriting discounts and commissions. On January 6, 2021, the underwriters exercised their option in full and purchased all 612,244 shares. The net proceeds related to the option exercise were approximately $28.4&#160;million, after deducting underwriting discounts, commissions and other offering expenses of approximately $1.6&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2020, the Company entered into an underwriting agreement relating to the issuance and sale of 4.4&#160;million shares of the Company&#8217;s common stock, $0.001 par value per share (the &#8220;2020 Common Stock Offering&#8221;). The price to the public in this offering was $28.50 per share. The net proceeds to the Company from the 2020 Common Stock Offering were approximately $117.9&#160;million, after deducting underwriting discounts, commissions and other offering expenses of approximately $7.5&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the underwriting agreement, the Company also granted the underwriters a 30-day option to purchase up to 660,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. On May 29, 2020, the underwriters partially exercised their option and on June 3, 2020, purchased an additional 351,500 shares. The net proceeds related to the option exercise were approximately $9.4&#160;million, after deducting underwriting commissions and other offering expenses of approximately $0.6&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926114904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2021, the stockholders of the Company approved an amendment to the Equity Incentive Plan, originally effective as of October 14, 2003, and previously amended and restated and approved by the stockholders on December 21, 2015, and then again on May 25, 2017 (the &#8220;Amended Plan&#8221;). The Amended Plan allows for the award of equity incentives, including stock options, stock appreciation rights, restricted stock awards, stock bonus awards, deferred stock awards, and other stock-based awards to certain employees, directors, or officers of, or key non-employee advisers or consultants, including contracted physicians to the Company or its subsidiaries. The Amended Plan provides that the maximum aggregate number of shares of the Company&#8217;s common stock reserved and available for issuance under the Amended Plan is 25,625,000.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, stock options outstanding totaled 3.0 million and 3.8 million shares, respectively. As of December 31, 2021 and 2020, a total of approximately 6.8 million and 1.0 million shares, respectively, were available for future option and stock awards under the Amended Plan. Options typically expire after 5 or 7 years and generally vest over 3 or 4 years, but each grant&#8217;s expiration, vesting, and exercise price provisions are determined at the time the awards are granted by the Compensation Committee of the Board of Directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock award granted during the year ended December 31, 2021 was estimated as of the grant date using a Black-Scholes model. The fair value of each stock option award granted during the years ended December 31, 2020 and 2019 was estimated as of the grant date using a trinomial lattice model. Weighted average assumptions used during the years ended December 31, 2021, 2020, and 2019 are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 &#8211; 5.5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 &#8211; 5.5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 &#8211; 5.5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (%)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (%)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (%)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value/share at grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of the stock options are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:63.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,839,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,309,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,927)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,318,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,310,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,004)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,372,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(684,238)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668,356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number and weighted average grant-date fair values of options non-vested at the beginning and end of 2021, as well as options granted, vested, and forfeited during the year were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:63.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,421,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681,984)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the options outstanding at December 31, 2021:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:32.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prices ($)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life (Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life (Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27 &#8211; 8.21</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22 &#8211; 19.76</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.77 &#8211; 27.97</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.98 &#8211; 43.49</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.50 &#8211; 55.40</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the aggregate intrinsic value of all stock options outstanding and expected to vest was approximately $36.1 million and the aggregate intrinsic value of currently exercisable stock options was approximately $31.6 million. The intrinsic value of each option share is the difference between the fair market value of NeoGenomics&#8217; common stock and the exercise price of such option share to the extent it is &#8220;in-the-money.&#8221; Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $34.12 closing stock price of the Company&#8217;s common stock on December 31, 2021, the last trading day of 2021. The total number of in-the-money options outstanding and exercisable as of December 31, 2021 was approximately 1.7 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised during each of the years ended December 31, 2021, 2020, and 2019 was approximately $46.7 million, $68.6 million and $35.3 million, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options. The total cash proceeds received from the exercise of stock options were approximately $13.7 million, $18.4 million and $12.4 million for the years ended December 31, 2021, 2020, and 2019, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options granted during the years ended December 31, 2021, 2020, and 2019 was approximately $23.2 million, $7.5 million and $5.6 million, respectively. The total fair value of option shares vested during the years ended December 31, 2021, 2020, and 2019 was approximately $11.7 million, $5.2 million and $5.5 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense using the straight-line basis over the awards&#8217; requisite service periods. Stock compensation expense related to stock options for the years ended December 31, 2021, 2020, and 2019 was approximately $11.6 million, $6.0 million and $6.8 million, respectively, and is included in general and administrative expenses in the Consolidated Statements of Operations. As of December 31, 2021, there was approximately $10.8 million of total unrecognized stock-based compensation cost related to non-vested stock options granted under the Amended Plan. This cost is expected to be recognized over a weighted-average period of 2.1 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares and weighted average grant date fair values of restricted non-vested common stock at the beginning and end of 2021, 2020, and 2019, as well as stock awards granted, vested, and forfeited during the year were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:59.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.751%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2018</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,479)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,292)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,359)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense related to restricted stock for the years ended December 31, 2021, 2020, and 2019 was approximately $9.8 million, $3.4 million, and $2.6 million, respectively, and is included in general and administrative expenses in the Consolidated Statements of Operations. As of December 31, 2021, there was approximately $24.3 million of total unrecognized stock-based compensation cost related to non-vested restricted stock granted under the Amended Plan. This cost is expected to be recognized over a weighted-average period of 2.6 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company granted certain senior-level executives performance stock units (&#8220;PSUs&#8221;) representing 356,548 common shares with a weighted average grant date fair value of $44.87 to vest upon the achievement of time-based service conditions with vesting through June 30, 2024, and certain performance goals, including financial performance targets and operational milestones. As of December, 30, 2021, these certain senior-level executives agreed to forfeit all of the granted PSUs. For the year ended December 31, 2021, no stock-based compensation related to the PSUs was recorded in the Consolidated Statements of Operations and the cancellation of these awards had no impact on the Consolidated Financial Statements. Concurrent with this forfeiture, these certain senior-level executives were granted restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022. For the year ended December 31, 2021, expense related to these awards is included in stock-based compensation expense related to restricted stock.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Modification of Stock Option and Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, the Culture and Compensation Committee of the Company&#8217;s Board of Directors approved the accelerated vesting of 284,597 previously granted time-vesting stock option awards and 101,574 previously granted time-vesting restricted stock awards upon retirement of a director of the Company. The Company accounted for the effects of the stock awards as a modification, and recognized $6.6&#160;million of incremental stock-based compensation which consisted of $4.9&#160;million and $1.7&#160;million for the acceleration of stock option awards and restricted stock awards, respectively for the year ended December 31, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an Employee Stock Purchase Plan (&#8220;ESPP&#8221;), under which eligible employees can purchase common stock at a 15.0% discount from the fair market value.&#160;Stock-based compensation expense related to the ESPP for the years ended December 31, 2021, 2020 and 2019 was approximately $1.1 million, $0.9 million and $0.6 million, respectively.&#160;Shares issued pursuant to this plan were 112,094, 138,309 and 141,908 for each of the years ended December 31, 2021, 2020, and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926028232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s two reportable segments for which it recognizes revenue are (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s specialized diagnostic services are performed based on a written test requisition form or an electronic equivalent. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharma Services segment generally enters into contracts with pharmaceutical customers as well as other CROs to provide research and clinical trial services ranging in duration from one month to several years.&#160;The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, and/or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is usually recognized over time based on the number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to the sponsor(s) at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics is the sale of de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected in advance of services being provided are deferred as contract liabilities on the Consolidated Balance Sheets. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. Contract assets are established for revenue recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets. All others are classified as non-current assets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customers, either immediately or according to advance notice terms specified within the contracts.&#160;All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the values of contract assets, capitalized commissions, and contract liabilities for Pharma Services as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma capitalized commissions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma capitalized commissions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma capitalized commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded within other current assets on the Consolidated Balance Sheets. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Recorded within other assets on the Consolidated Balance Sheets. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Recorded within other long-term liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized for the years ended December 31, 2021, 2020, and 2019, related to Pharma contract liabilities outstanding at the beginning of each year was $4.4 million, $2.3 million, and $2.2 million, respectively. Amortization of capitalized commissions for the years ended December 31, 2021, 2020 and 2019 were $1.1&#160;million, $0.8&#160;million and $1.2&#160;million respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company signed approximately $172&#160;million in net new contracts. At year-end total backlog was approximately $267&#160;million, substantially all of which contain cancellation provisions. The Company applied the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The unsatisfied existing performance obligations under long-term contracts as defined by ASC Topic 606, Revenue from Contracts with Customers, differs from backlog in that these obligations do not include wholly unperformed contracts where the promised consideration is variable and/or the application of other practical expedients.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered various factors for both its Clinical Services and Pharma Services segments in determining appropriate levels of homogeneous data for its disaggregation of revenue; including the nature, amount, timing, and uncertainty of revenue and cash flows. Clinical Services categories align with the types of customers due to similarities of billing method, level of reimbursement, and timing of cash receipts. Unbilled amounts are accrued and allocated to payer categories based on historical experience. In future periods actual billings by payer category may differ from accrued amounts. Pharma Services relate to contracts with large pharmaceutical and biotech customers as well as other CROs. Because the nature, timing, and uncertainty of revenue and cash flows are similar and primarily driven by individual contract terms Pharma Services revenue is not further disaggregated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the disaggregation of net revenue for both the Clinical Services and Pharma Services Segments for the years ended December 31, 2021, 2020, and 2019 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.369%"><tr><td style="width:1.0%"/><td style="width:37.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Client direct billing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Medicare and other government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Self-pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140353003020712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act impacted a number of provisions of the tax code, including the eligibility of certain deductions and the treatment of net operating losses (&#8220;NOLs&#8221;) and tax credits. The CARES Act did not result in any material adjustments to the Company&#8217;s income tax provision for the year ended December 31, 2021, or to its deferred tax assets as of December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) income before income tax benefit for the years ended December 31, 2021, 2020, and 2019 is as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income tax expense (benefit): </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,075)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,056)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,645&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax (benefit) expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit provision</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,810)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,067)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,348)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax benefit provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,228)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,361)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the differences between the effective tax rate and the federal statutory tax rate for the years ended December 31, 2021, 2020 and 2019 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Penalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inivata acquisition fair value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision and other deferred tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.66)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, deferred income tax assets and liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry-forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in non-consolidated affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,076)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,994)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,238)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,415)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company has federal net operating loss carry forwards of approximately $231.5&#160;million, foreign net operating loss carryforwards of approximately $118.9&#160;million, including $96.4&#160;million in the United Kingdom, and state net operating loss carry forwards of approximately $112.8&#160;million. Federal net operating loss carry forwards will begin to expire in 2036. Under the Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, however, the deductibility of such federal net NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. State tax NOLs will begin to expire in 2022. NOLs in Switzerland and China begin to expire in 2024 and 2025, if not utilized in future periods. The NOLs in Singapore and the United Kingdom do not expire. As of December 31, 2021, the Company has federal R&amp;D credit carryforwards of </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $5.5&#160;million that begin to expire in 2036 and state research and investment credit carryforwards of approximately $3.8&#160;million that do not expire. An ownership change of more than 50 percent could result in a limitation of the use of net operating loss carryforwards and credit carryforwards under IRC Section 382 and the regulations thereunder. We have not conducted a formal study to determine whether there was an ownership change in prior periods that would limit the use of our net operating loss carryforwards and credit carryforwards under IRC Section 382. Management believes it is more likely than not that a limitation under Section 382 would not materially impact the realizability of the deferred tax assets related to federal and state net operating losses or credits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing all positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed. As of December 31, 2021 and 2020, management determined that sufficient positive evidence did not exist and concluded that it is more likely than not that a valuation allowance is required against foreign deferred tax assets. Accordingly, management established a full valuation allowance of $4.1&#160;million and $2.6&#160;million as of December 31, 2021 and 2020, respectively, related to the Company&#8217;s China, Switzerland and Singapore operations. As of December 31, 2021, management determined that sufficient positive evidence did not exist and conclude that it is more likely than not that a valuation allowance is required against certain domestic deferred tax assets. Accordingly, management established a valuation allowance of $28.9&#160;million related to the Company&#8217;s domestic operations as of December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States, as well as Singapore, Switzerland, China, United Kingdom and in various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment. For U.S. federal and most state purposes, the Company has open tax years ended December&#160;31, 2017 to December 31, 2020. For Switzerland, the Company has open tax years ended December 31, 2017 to December 31, 2020, for Singapore the Company has open tax years ended December 31, 2018 to December 31, 2020 and for United Kingdom the Company has open tax years ended April 5, 2018 to April 5, 2020. The 2017 U.S. Federal income tax filing is currently under examination by the IRS.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applied the accounting standard for uncertain tax positions and recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management&#8217;s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the unrecognized tax benefits as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits - January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in prior year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversals of prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions taken in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute expirations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits - December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits at December 31, 2021, if recognized would favorably affect the Company&#8217;s effective tax rate. These unrecognized tax benefits are classified as other long-term liabilities on the Consolidated Balance Sheets. The interest and penalties related to the unrecognized tax benefit are immaterial. Interest and tax penalties related to unrecognized tax benefits are included in income tax expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352925987304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income per Share</a></td>
<td class="text">Net (Loss) Income per ShareThe Company presents both basic earnings per share (&#8220;EPS&#8221;) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing &#8220;net (loss) income&#8221; by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised and if the 2028 Convertible Notes and 2025 Convertible Notes were converted. The potential dilution from stock awards is accounted for using the treasury <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock method based on the average market value of the Company&#8217;s common stock. The potential dilution from conversion of the 2028 Convertible Notes and 2025 Convertible Notes is accounted for using the if-converted method, which requires that all of the shares of the Company&#8217;s common stock issuable upon conversion of the 2028 Convertible Notes and the 2025 Convertible Notes will be included in the calculation of diluted EPS assuming conversion of the 2028 Convertible Notes and the 2025 Convertible Notes at the beginning of the reporting period (or at time of issuance, if later).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculations for the years ended December 31, 2021, 2020, and 2019 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,347)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,962&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive for the years ended December 31, 2021, 2020, and 2019:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential effect of the Capped Call Transactions entered into concurrently with the 2028 Convertible Notes were excluded from the calculation of diluted net (loss) income per share in 2021 as the Company&#8217;s closing price on December 31, 2021, did not exceed the conversion price of $85.75 per share. The Capped Call Transactions are not reflected in diluted net (loss) income per share as they are anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further details on the Capped Call Transactions, please refer to Note 9. Debt.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352925976552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text">Defined Contribution PlanThe Company maintains a defined-contribution 401(k) retirement plan covering substantially all U.S. based employees (as defined).&#160;The Company&#8217;s employees may make voluntary contributions to the plan, subject to limitations based on IRS regulations and compensation. The Company matches 100.0% of every dollar contributed up to 3.0% of the respective employee&#8217;s compensation and an additional 50.0% of every dollar contributed on the next 2% of compensation (4.0% maximum Company match).&#160;Matching contributions were approximately $6.1 million, $4.9 million and $4.4 million during the years ended December 31, 2021, 2020, and 2019, respectively, and are recorded in cost of revenue and operating expenses in the Consolidated Statements of Operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352925952936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Commitments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements in place to purchase a specified level of reagents from certain vendors. These purchase commitments expire at various dates through 2023. The purchase commitments as of December 31, 2021, are as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.428%"><tr><td style="width:1.0%"/><td style="width:68.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase commitments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceeding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2021, Natera, Inc. filed a patent infringement complaint against the Company&#8217;s newly-acquired subsidiary Inivata Limited and its subsidiary Inivata, Inc. in U.S. District Court for the district of Delaware, alleging Inivata&#8217;s InVisionFirst&#174;-Lung cancer diagnostic test of infringing two patents. The litigation is presently in the pleadings stage. The Company believes that it has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. At the time of filing the outcome of this matter is not estimable or probable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, the Company is voluntarily conducting an internal investigation that focuses on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;) of the Company&#8217;s internal investigation in November 2021. The Company&#8217;s review of this matter is ongoing. As of December 31, 2021, the Company has accrued a reserve of $11.2&#160;million in other long-term liabilities on the Consolidated Balance Sheets for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#8217;s best estimate of the minimum probable loss associated with this matter. As a result of the ongoing investigation and interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. At this time, the Company is unable to predict the duration, scope, result or related costs associated with any further investigation, including by the OIG, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Any determination that the Company&#8217;s operations or activities are not in compliance with existing laws or regulations, however, could result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, or other losses or conduct restrictions, which could be material to the Company&#8217;s financial results or business operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926012712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company formed a strategic alliance with Inivata and entered into a Strategic Alliance Agreement and Laboratory Services Agreement whereas Inivata, prior to the Inivata Acquisition Date, would render and perform certain laboratory testing which the Company made available to customers. In connection with this agreement, Inivata provided $0.8 million of testing services to the Company recorded in cost of revenue in the Consolidated Statements of Operations in 2021 through the Inivata Acquisition Date. Such services provided for the year ended December 31, 2020 were immaterial. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2020, the Company and Inivata also entered into a Line of Credit in the amount of $15.0&#160;million. The Company and Inivata settled the Line of Credit after the Inivata Acquisition Date and no amounts were outstanding as of December 31, 2021. For further details on the Line of Credit, please refer to Note 8. Investment in Non-Consolidated Affiliate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company completed its acquisition of all remaining equity interest in Inivata by exercising its Purchase Option. Beginning June 18, 2021, Inivata is a wholly-owned consolidated subsidiary of the Company. As of the Inivata Acquisition Date, Inivata&#8217;s financial statement activity is being consolidated within the Company&#8217;s Consolidated Financial Statements. For further details on the acquisition of Inivata, please refer to Note 3. Acquisitions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926011048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under two reportable segments, (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology and oncology practices, hospital pathology labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and self-pay patients. The Pharma Services segment supports pharmaceutical firms&#8217; drug development programs by assisting with various clinical trials and research as well as providing informatics related services often supporting pharmaceutical commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) includes revenues, cost of revenue, and gross profit for both reportable segments.&#160;Assets are not presented at the segment level as that information&#160;is not used by the CODM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,830&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,830&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,992)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on termination of cash flow hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,075)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,347)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical Services cost of revenue in 2021 includes $9.2 million of amortization of acquired Inivata developed technology intangible assets and write-offs of $5.3 million for COVID-19 PCR testing inventory.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharma Services cost of revenue in 2021 includes $1.2 million&#160;of amortization of acquired Inivata developed technology intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919947352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#8217;s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these Consolidated Financial Statements include, but are not limited to, those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether investments in affiliates are a Variable Interest Entity (&#8220;VIE&#8221;) at the start of each new venture and when a reconsideration event has occurred. A reporting entity must consolidate a VIE if that reporting entity has a variable interest (or combination of variable interests) and is determined to be the primary beneficiary. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></div>The Company accounts for its equity investments that are under 20% of the total equity outstanding and for which the Company does not have significant influence by applying the cost method. Investments that are under 20% of the total equity outstanding and for which the Company has significant influence are accounted for using the equity method unless a scope exception is applicable. Investments in which the Company holds a non-controlling interest and are between 20-50% equity are accounted for using the equity method. For any equity investments in which the Company holds over 50% of the outstanding stock, or for investments in which the Company controls the investee, the Company consolidates those entities into the Consolidated Financial Statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment ReportingThe Company reports its activities in two reportable segments; (1) the Clinical Services segment and (2) the Pharma Services segment.&#160;These reportable segments deliver testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers and represent 100% of the Company&#8217;s consolidated assets, net revenue, and net (loss) income in each of the years ended December 31, 2021, 2020, and 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions of entities over which control is obtained that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent third-party valuations that use information and assumptions provided by management, which consider estimates of inputs and </span></div>assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired less liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives, and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the Company&#8217;s operating results from the date of acquisition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash, certain cash equivalents, accounts receivable, net, other current assets, accounts payable, accrued expenses and other liabilities, and Pharma contract liabilities are considered reasonable estimates of their respective fair values due to their short-term nature. </span></div>The Company measures its marketable securities at fair value on a recurring basis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with an original maturity of ninety days or less to be cash equivalents. The Company maintains its cash and cash equivalents with financial institutions that the Company believes to be of high credit standing. The Company believes that, as of December 31, 2021, its concentration of credit risk related to cash and cash equivalents was not significant.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all marketable securities as available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are carried at fair value, with the unrealized holding gains and losses, net of income taxes, reflected in accumulated other comprehensive income until realized. The Company evaluates its marketable securities for other-than-temporary impairment on a quarterly basis. Unrealized losses are charged against net earnings when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine whether a loss is other-than-temporary, such as the length and extent of the fair value decline, the financial condition and near-term prospects of the issuer, and whether there is the intent to sell or will more likely than not be required to sell before the securities&#8217; anticipated recovery. There were no other-than-temporary impairments for the years ended December 31, 2021, 2020 and 2019. Regardless of the intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are recorded when the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</span></div>For the purposes of computing realized and unrealized gains and losses, cost and fair value are determined on a specific identification basis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, net</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounts Receivable, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are reported for all Clinical Services payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Pharma Services the Company negotiates billing schedules and payment terms on a contract-by-contract basis which can include payments based on certain milestones being achieved.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist principally of testing supplies and are valued at lower of cost or net realizable value, using the first-in, first-out method. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventories to their estimated net realizable value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_AssetsHeldForSalePolicyPolicyTextBlock', window );">Assets Held for Sale</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Assets Held for Sale</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Prepaid Assets</a></td>
<td class="text">The Company records a prepaid expense for costs paid but not yet incurred. Those expected to be incurred within one year are recorded as prepaid assets within total current assets on the Consolidated Balance Sheets. Any costs expected to be incurred outside of one year are recorded as other assets within total non-current assets on the Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock', window );">Other Current Assets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Current Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, other current assets consisted primarily of receivables related to research and development (&#8220;R&amp;D&#8221;) tax credit receivables, pharma contract assets and other non-trade receivables.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on the straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the related lease terms or their estimated useful lives. Costs incurred in connection with the development of internal-use software are capitalized in accordance with the accounting standard for internal-use software, and are amortized over the expected useful life of the software.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews the estimated useful lives of property and equipment. Changes to the estimated useful lives are recorded prospectively from the date of the change. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts and any resulting gain or loss is included in income (loss) from operations. Repairs and maintenance costs are expensed as incurred and are included in cost of revenue, general and administrative expenses or R&amp;D expenses, as appropriate in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases corporate offices and laboratory spaces throughout the world, all of which are classified as operating leases expiring at various dates and generally having terms ranging from 1 to 20 years. Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s real estate lease agreements include options to either renew or early terminate the lease. Leases with renewal options allow the Company to extend the lease term typically between 1 and 5 years. When it is reasonably certain that the Company will exercise an option to renew or terminate a lease, these options are considered in determining the classification and measurement of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities are recorded based on the present value of the future lease payments over the lease term and assessed as of the commencement date. Incentives received from landlords, such as reimbursements for tenant improvements and rent abatement periods, effectively reduce the total lease payments owed for leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain real estate leases also include executory costs such as common area maintenance (non-lease component), as well as property insurance and property taxes (non-components). Lease payments, which may include lease components, non-lease components and non-components, are included in the measurement of the Company&#8217;s lease liabilities to the extent that such </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments are either fixed amounts or variable amounts based on a rate or index (fixed in substance), as stipulated in the lease contract. Any actual costs in excess of such amounts are expensed as incurred as variable lease cost.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes its incremental borrowing rate by lease term in order to calculate the present value of its future lease payments when the implicit rates in the leases agreements are not readily determinable. The discount rate represents a risk-adjusted rate on a secured basis and is the rate at which the Company would borrow funds to satisfy the scheduled lease liability payment streams commensurate with the lease term.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs represent fixed lease payments recognized on a straight-line basis over the lease term. Operating lease costs include an immaterial amount of variable lease costs and are recorded in cost of revenue, general and administrative, sales and marketing, and R&amp;D expenses (depending on the nature of the leased asset) in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets, netIntangible assets with determinable useful lives are recorded initially at acquired fair value or cost, less accumulated amortization. Each intangible asset with a determinable useful life is amortized over its estimated useful life using the straight-line method. The Company periodically reviews the estimated pattern in which the economic benefits will be consumed and adjusts the amortization period and pattern to match the estimate. Intangible assets with indefinite useful lives are recorded initially at fair value or cost and are tested annually for impairment or more frequently if management believes indicators of impairment exist.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">GoodwillThe Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#8217;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#8217; data.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Recoverability and Impairment of Long-Lived Assets</a></td>
<td class="text">Recoverability and Impairment of Long-Lived AssetsThe Company reviews the recoverability of its long-lived assets (including definite-lived intangible assets) if events or changes in circumstances indicate the assets may be impaired. Evaluation of possible impairment is based on the Company&#8217;s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value to the carrying amount of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">We accrue contingent losses when estimated impacts of various conditions, situations or circumstances involve uncertain outcomes. Contingent losses are recorded based on management judgment along with internal and external advice from legal counsel and/or technical consultants. Estimated losses from contingencies are recorded when both of the following conditions are met: (i) information available before the financial statements are issued (or available to be issued) indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) the amount of loss can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, that amount shall be accrued. When no amount within the range is a better estimate than any other amount, however, the minimum amount in the range shall be accrued. Please refer to Note 17. Commitments and Contingencies, for further discussion.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text">Debt Issuance CostsDebt issuance costs related to convertible senior notes are recorded as deductions that net against the principal value of the debt and are amortized as interest expense over the life of the debt using the effective interest method. Debt issuance costs related to term loans are recorded as direct deductions from the carrying amount of the term loan and are amortized to interest expense over the life of the debt using the effective interest method.&#160;Debt issuance costs relating to line of credit arrangements are recorded as assets and amortized over the term of the credit arrangement regardless of whether any outstanding borrowing existed. The term loan and line of credit were terminated in 2020 and all debt issuance costs were expensed accordingly.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Stock-based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures compensation expense for stock-based awards to employees, non-employee contracted physicians, and directors based upon the awards&#8217; initial grant-date fair values.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2021 the Company estimated the fair value of stock options using a trinomial lattice model. On January 1, 2021, the Company began applying the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) on a prospective basis to new awards. The Company expects the use of Black-Scholes to provide a more ubiquitous estimate of fair value. Like the prior trinomial lattice model, Black-Scholes is affected by the stock price on the date of the grant as well as assumptions regarding a number of highly complex and subjective variables. These variables include the expected term of the option, expected risk-free interest rate, the expected volatility of common stock, and expected dividend yield; each of which is described below. The assumptions for expected term and expected volatility are the two assumptions that significantly affect the grant date fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term: The expected term of an option is determined using the simplified method under SAB 107 which represents the average between the vesting term and the contractual term. The Company utilizes the simplified method to determine the expected life of the options due to insufficient exercise activity during recent years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free Interest Rate: The risk-free interest rate used in the Black-Scholes model is based on the implied yield at the grant date of the U.S. Treasury zero-coupon issue with an equivalent term to the stock-based award being valued. Where the expected term of a stock-based award does not correspond with the term for which a zero coupon interest rate is quoted, the Company uses the nearest interest rate from available maturities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Stock Price Volatility: The Company uses its own historical weekly volatility because that is more reflective of market conditions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend Yield: Because the Company has never paid a dividend and does not expect to begin doing so in the foreseeable future, the Company assumed no dividend yield in valuing the stock-based awards.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent. The performance obligation is satisfied and revenues are recognized at the point in time the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay patients and within 60 to 90 days of billing for client payers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharma Services segment generally enters into contracts with pharmaceutical and biotech customers as well as other Clinical Research Organizations (&#8220;CROs&#8221;) to provide research and clinical trial services ranging in duration from one month to several years. The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is recognized over time based on the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to sponsors at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics provides de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected for services provided in advance of revenue being recognized are deferred as contract liabilities. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently recognized. Contract assets are established for revenue that has been recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding account receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and are amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets and all others are classified as non-current assets. Contract assets are included in other current assets and other assets on the Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text">Cost of RevenueCost of revenue includes payroll and payroll related costs for performing tests, project management, depreciation of laboratory equipment and laboratory leasehold improvements, rent for laboratory facilities, laboratory reagents, probes and supplies, delivery and courier costs relating to the transportation of specimens to be tested, and amortization for acquired Inivata developed technology intangible assets. The expenses related to shipping specimens to the facilities for testing, includes costs incurred for contract couriers, commercial airline flights, and courier charges. The Company also incurs expenses returning samples and slides to its customers.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of payroll and payroll related costs for the Company&#8217;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred. R&amp;D expenses consist of payroll and payroll related costs, laboratory supplies, depreciation of laboratory equipment, and costs for samples to complete validation studies. These expenses are primarily incurred to develop new genetic tests.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and are deemed immaterial for the years ended December 31, 2021, 2020 and 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegulatoryIncomeTaxesPolicy', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods and lives for property and equipment, recognition of bad debts, compensation related expenses, and various other expenses that have been allowed for or accrued for financial statement purposes but are not currently deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations, and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company evaluates tax positions that have been taken or are expected to be taken in its tax returns and records a liability for uncertain tax positions, if deemed necessary. The Company follows a two-step approach to recognizing and measuring uncertain tax positions. First, tax positions are recognized if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon examination, including resolution of related appeals or litigation processes, if any. Second, the tax position is measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes on the Consolidated Balance Sheets. At December 31, 2021 and 2020, the Company has an uncertain tax position related to Federal and State R&amp;D tax credits, including a provision for interest and penalties related to such position as applicable. The Company does not expect a significant change in its uncertain tax positions in the next 12 months.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Common Share</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Net (Loss) Income per Common Share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates basic net (loss) income per share attributable to common stockholders by dividing net (loss) income by the weighted-average number of shares of common stock outstanding for the period. Diluted net (loss) income per share is computed using the weighted average number of common shares outstanding during the applicable period, plus the dilutive effect of potential common stock. Potential common stock consists of shares issuable pursuant to stock options and convertible notes, as well as non-vested restricted stock awards which are not considered outstanding with respect to the weighted average common shares outstanding in the calculation of basic net (loss) income per share. Potentially dilutive shares are determined by applying the treasury stock method to the Company&#8217;s outstanding stock options and restricted stock awards. Potentially dilutive shares issuable upon conversion of the 0.25% Convertible Senior Notes due 2028 and the 1.25% Convertible Senior Notes due 2025 are calculated using the if-converted method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the FASB issued ASU No. 2021-06, Presentation of Financial Statements (Topic 205), Financial Services-Depository and Lending (Topic 942), and Financial Services-Investment Companies (Topic 946) (&#8220;ASU 2021-06&#8221;), Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10786, Amendments to Financial Disclosures About Acquired and Disposed Businesses, and No.33-10835, Update of Statistical Disclosures for Bank and Savings and Loan Registrants. This update amends certain SEC disclosure guidance that is included in the accounting standards codification to reflect the SEC&#8217;s recent issuance of rules intended to modernize and streamline disclosure requirements. The Company adopted this pronouncement upon issuance and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements, which updates various codification topics by clarifying disclosure requirements to align with the SEC&#8217;s regulations. The Company adopted this pronouncement on January 1, 2021 and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt&#8201;-&#8201;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8201;-&#8201;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8201;-&#8201;Accounting For Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible instruments by removing the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such convertible debt instruments. Similarly, the debt discount, that is equal to the carrying value of the embedded conversion feature upon issuance, will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible instrument was issued at a substantial premium. In addition, ASU 2020-06 requires the application of the if-converted method for calculating the impact of convertible instruments on diluted earnings </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. ASU 2020-06 can be adopted on either a fully retrospective or modified retrospective basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2020-06 on January 1, 2021 using the modified retrospective approach, and, accordingly, the Company recorded an adjustment that reflects the 1.25% Convertible Senior Notes due 2025 as if the embedded conversion feature had not been separated. The impact upon adoption on the Consolidated Balance Sheets included an increase of approximately $27.2&#160;million in convertible senior notes, net, a write-off of approximately $6.6&#160;million in deferred income tax liabilities, establishment of approximately $2.0&#160;million of valuation allowance against deferred income tax assets, and a decrease of approximately $23.3&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment to increase the beginning balance of retained earnings on the Consolidated Balance Sheets for previously recognized interest expense, net of tax effects, of approximately $2.7&#160;million for amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance, as well as a decrease to the beginning balance of retained earnings of approximately $2.0&#160;million for the establishment of valuation allowance against the Company&#8217;s deferred income tax assets. There was no impact to the Company&#8217;s earnings per share calculation. For further information regarding the 1.25% Convertible Senior Notes due 2025, please refer to Note 9. Debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance (&#8220;ASU 2021-10&#8221;). This update requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this pronouncement on January 1, 2022, and is currently evaluating the impact of this standard on its annual disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#8220;ASU 2021-08&#8221;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the planned adoption date and the impact of this standard on its Consolidated Financial Statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (&#8220;ASU 2020-04&#8221;) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (&#8220;LIBOR&#8221;) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) (&#8220;ASU 2021-01&#8221;) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of December 31, 2021, there was no impact to the Company&#8217;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AssetsHeldForSalePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets Held For Sale, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AssetsHeldForSalePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other current assets policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryIncomeTaxesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 740<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6501382&amp;loc=d3e54136-110423<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 740<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501382&amp;loc=d3e54053-110423<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryIncomeTaxesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352923551144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table summarizes the estimated purchase consideration recorded for the acquisition of Trapelo, the estimated fair value of the net assets acquired and liabilities assumed, and the preliminary calculation of goodwill based on the excess of the estimated consideration transferred over the estimated fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.851%"><tr><td style="width:1.0%"/><td style="width:74.247%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued as consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share value of common stock issued as consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of common stock at Trapelo Acquisition Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Cash paid at closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of the purchase consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - marketing assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table summarizes the preliminary calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit and the estimated fair value of the previously-held equity interest and Purchase Option over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 18, 2021<br/>(as initially reported)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 18, 2021 <br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid at closing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Line of Credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previously-held equity interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Purchase Option</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of the fair value business combination:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets - developed technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets - trademarks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible asset - trade name</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,388)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of business combination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to a change in legal settlement liabilities.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangible assets and related future amortization and the change in legal settlement liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.583%"><tr><td style="width:1.0%"/><td style="width:47.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140353003074888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value, Assets Measured on Recurring and Nonrecurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses, and fair values of the Company&#8217;s marketable securities accounted for as available-for-sale securities as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of December 31, 2021 and 2020 (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,686&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926411032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lives in Years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - 13</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-17</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-9</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-10</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,895)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,873&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December 31, 2021, 2020, and 2019, was as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,192&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352924516152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the maturities of the operating lease liabilities and a reconciliation to the present value of lease liabilities were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.511%"><tr><td style="width:1.0%"/><td style="width:76.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.76</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional supplemental data related to the operating leases for the years ended December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352923681864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Services </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pharma Services </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired - Trapelo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired - Inivata</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.065%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.065%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7-15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt 0 13pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;7-15</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,653&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Finite-lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020, and 2019, amortization on the Consolidated Statements of Operations was recorded as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization recorded in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,160&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the estimated amortization expense related to amortizable intangible assets for each of the five following years and thereafter is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,898&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926025432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term debt, net, at December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25% Convertible Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total 0.25% Convertible Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25% Convertible Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(538)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total 1.25% Convertible Senior Notes due 2025, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of equipment financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,554&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of long-term debt at December 31, 2021 are summarized as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.25% Convertible Senior Notes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.25% Convertible Senior Notes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equipment Financing Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Long-Term Debt</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:&#160;Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:&#160;Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,554&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926019944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Schedule of Interest Rate Derivatives</a></td>
<td class="text">The following table summarizes the previous interest rate swap agreement.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.767%"><tr><td style="width:1.0%"/><td style="width:47.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 2018 Hedge</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70 million</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 29, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One month LIBOR</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352915419432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</a></td>
<td class="text">The fair value of each stock option award granted during the years ended December 31, 2020 and 2019 was estimated as of the grant date using a trinomial lattice model. Weighted average assumptions used during the years ended December 31, 2021, 2020, and 2019 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 &#8211; 5.5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 &#8211; 5.5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 &#8211; 5.5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (%)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (%)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (%)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value/share at grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of the stock options are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:63.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,839,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,309,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,927)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,318,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,310,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,004)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,372,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(684,238)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668,356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number and weighted average grant-date fair values of options non-vested at the beginning and end of 2021, as well as options granted, vested, and forfeited during the year were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:63.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,421,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681,984)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the options outstanding at December 31, 2021:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:32.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prices ($)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life (Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life (Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27 &#8211; 8.21</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22 &#8211; 19.76</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.77 &#8211; 27.97</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.98 &#8211; 43.49</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.50 &#8211; 55.40</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares and weighted average grant date fair values of restricted non-vested common stock at the beginning and end of 2021, 2020, and 2019, as well as stock awards granted, vested, and forfeited during the year were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:59.050%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.751%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2018</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,479)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,292)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,777)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,359)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352916617048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with Customer, Asset and Liability</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the values of contract assets, capitalized commissions, and contract liabilities for Pharma Services as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma capitalized commissions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma capitalized commissions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma capitalized commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,109&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded within other current assets on the Consolidated Balance Sheets. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Recorded within other assets on the Consolidated Balance Sheets. </span></div>(3) Recorded within other long-term liabilities on the Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the disaggregation of net revenue for both the Clinical Services and Pharma Services Segments for the years ended December 31, 2021, 2020, and 2019 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.369%"><tr><td style="width:1.0%"/><td style="width:37.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Client direct billing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Medicare and other government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Self-pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352916700328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) income before income tax benefit for the years ended December 31, 2021, 2020, and 2019 is as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income tax expense (benefit): </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,075)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,056)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,645&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax (benefit) expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred benefit provision</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,810)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,067)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,348)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax benefit provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,228)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,361)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the differences between the effective tax rate and the federal statutory tax rate for the years ended December 31, 2021, 2020 and 2019 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Penalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inivata acquisition fair value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision and other deferred tax adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119.66)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, deferred income tax assets and liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry-forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in non-consolidated affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,076)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,994)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,238)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,415)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock', window );">Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits - January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in prior year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversals of prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in tax positions taken in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statute expirations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits - December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140353002994024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculations for the years ended December 31, 2021, 2020, and 2019 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET (LOSS) INCOME</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,347)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,962&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive for the years ended December 31, 2021, 2020, and 2019:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352926135640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock', window );">Purchase Commitment, Excluding Long-term Commitment</a></td>
<td class="text">The purchase commitments as of December 31, 2021, are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.428%"><tr><td style="width:1.0%"/><td style="width:68.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase commitments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of arrangements in which the entity has agreed to procure goods or services from one or more suppliers. May include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352925961144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484,329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,830&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,830&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,992)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in and loan receivable from non-consolidated affiliate, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on termination of cash flow hedge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,075)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,347)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical Services cost of revenue in 2021 includes $9.2 million of amortization of acquired Inivata developed technology intangible assets and write-offs of $5.3 million for COVID-19 PCR testing inventory.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharma Services cost of revenue in 2021 includes $1.2 million&#160;of amortization of acquired Inivata developed technology intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352916760856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PolymeraseChainReactionTestingExitCostsCOVID19', window );">Write off of COVID-19 PCR testing inventory and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="nump">$ 6,061<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PolymeraseChainReactionTestingWriteOffsCOVID19', window );">Write off of remaining COVID-19 PCR testing inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19', window );">PCR testing equipment, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ProceedsFromGovernmentAssistanceCARESAct', window );">Grant income recognized, COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_SocialSecurityTaxEmployerDeferralCARESAct', window );">Accrued deferred social security taxes, COVID-19</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_EmployeeRetentionTaxCreditCARESAct', window );">Amount of ERTC recognized, COVID-19</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_EmployeeRetentionTaxCreditCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Retention Tax Credit, CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_EmployeeRetentionTaxCreditCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PolymeraseChainReactionTestingExitCostsCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Polymerase Chain Reaction Testing, Exit Costs, COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PolymeraseChainReactionTestingExitCostsCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PolymeraseChainReactionTestingWriteOffsCOVID19">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Polymerase Chain Reaction Testing, Write-Offs, COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PolymeraseChainReactionTestingWriteOffsCOVID19</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ProceedsFromGovernmentAssistanceCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Government Assistance, CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ProceedsFromGovernmentAssistanceCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_SocialSecurityTaxEmployerDeferralCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Social Security Tax, Employer, Deferral, CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_SocialSecurityTaxEmployerDeferralCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914530456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="4"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Rate</div>
</th>
<th class="th">
<div>Jan. 11, 2021 </div>
<div>Rate</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 04, 2020 </div>
<div>Rate</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment', window );">Percentage of consolidated assets, net revenues and net income reported by reportable operating segment</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings', window );">Other than temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_AssetHeldForSaleSquareFeetOfFacilityOwned', window );">Square feet owned | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite lived intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets held-for-use</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Performance obligation, description of timing</a></td>
<td class="text">Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay patients and within 60 to 90 days of billing for client payers.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">$ 297,269,000<span></span>
</td>
<td class="nump">258,555,000<span></span>
</td>
<td class="nump">211,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,014,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,294,000<span></span>
</td>
<td class="nump">507,408,000<span></span>
</td>
<td class="nump">1,108,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,443,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,576,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,185,000)<span></span>
</td>
<td class="num">(11,357,000)<span></span>
</td>
<td class="num">(14,837,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,363,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,357,000<span></span>
</td>
<td class="nump">520,278,000<span></span>
</td>
<td class="nump">$ 1,123,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,291,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,271,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="nump">$ 14,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AssetHeldForSaleSquareFeetOfFacilityOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Held For Sale, Square Feet Of Facility Owned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AssetHeldForSaleSquareFeetOfFacilityOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated assets, net revenues and net income reported by reportable operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ScheduleOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ScheduleOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123398962&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security, recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352912624920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 18, 2021</div></th>
<th class="th"><div>Apr. 07, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,404,000<span></span>
</td>
<td class="nump">$ 37,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,260,000<span></span>
</td>
<td class="nump">$ 3,955,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527,115,000<span></span>
</td>
<td class="nump">211,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,603,000<span></span>
</td>
<td class="nump">179,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,512,000<span></span>
</td>
<td class="nump">31,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Investment in minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,600,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Consideration paid to other shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Identifiable intangible assets - developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments', window );">Payments to acquire business, adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common stock issued for consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts', window );">Acquisition and integration costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Identifiable intangible assets - developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Marketing Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments', window );">Payments to acquire business, adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts', window );">Acquisition and integration costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,900,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Lin of credit settled as consideration for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of previously-held equity interest</a></td>
<td class="nump">$ 64,900,000<span></span>
</td>
<td class="nump">64,906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue', window );">Fair value of Purchase Option</a></td>
<td class="nump">$ 74,300,000<span></span>
</td>
<td class="nump">74,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,300,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Measurement period adjustments, net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (60,994,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue from acquiree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Net loss from acquiree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Identifiable intangible assets - developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Trademarks | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquisition And Integration Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Step Acquisition, Purchase Option, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Acquired From Acquisition And Working Capital Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914756872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Schedule of Provisional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 18, 2021</div></th>
<th class="th"><div>Apr. 07, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Plus: Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,404<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527,115<span></span>
</td>
<td class="nump">$ 211,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common stock issued for consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Plus: Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Plus: Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Fair value of Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests', window );">Measurement period adjustments, fair value of previously-held equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of previously-held equity interest</a></td>
<td class="nump">$ 64,900<span></span>
</td>
<td class="nump">64,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue', window );">Measurement period adjustments, fair value of Purchase Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue', window );">Fair value of Purchase Option</a></td>
<td class="nump">$ 74,300<span></span>
</td>
<td class="nump">74,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Measurement period adjustments, net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Total fair value of business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther', window );">Measurement period adjustments, other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets', window );">Measurement period adjustments, total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities', window );">Measurement period adjustments, current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities', window );">Measurement period adjustments, deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet', window );">Measurement period adjustments, net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Plus: Cash paid at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Fair value of Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of previously-held equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue', window );">Fair value of Purchase Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1', window );">Total fair value of business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,680)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing Assets | Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Identifiable intangible assets - developed technology | Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Identifiable intangible assets - developed technology | Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Measurement period adjustments, identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Identifiable intangible assets - developed technology | Inivata | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Measurement period adjustments, identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Inivata | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name | Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Measurement period adjustments, identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name | Inivata | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Acquired and Liabilities Assumed, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Step Acquisition, Purchase Option, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to,  instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to equity interests acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to financial assets acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352923290744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Pro Forma Information (Details) - Inivata - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (129,251)<span></span>
</td>
<td class="num">$ (65,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenue</a></td>
<td class="nump">$ 484,231<span></span>
</td>
<td class="nump">$ 444,884<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914352328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Amortized Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 199,464<span></span>
</td>
<td class="nump">$ 67,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(923)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">198,563<span></span>
</td>
<td class="nump">67,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest receivable</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">52,791<span></span>
</td>
<td class="nump">21,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">52,664<span></span>
</td>
<td class="nump">21,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember', window );">Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">6,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">6,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_AgencyBondsMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">17,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">17,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">12,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">12,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">17,694<span></span>
</td>
<td class="nump">14,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">17,690<span></span>
</td>
<td class="nump">14,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">27,620<span></span>
</td>
<td class="nump">14,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">27,535<span></span>
</td>
<td class="nump">14,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">65,198<span></span>
</td>
<td class="nump">17,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(452)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 64,755<span></span>
</td>
<td class="nump">$ 17,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL121698322-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267856-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_AgencyBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_AgencyBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919827848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">$ 104,711<span></span>
</td>
<td class="nump">$ 27,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">93,852<span></span>
</td>
<td class="nump">40,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">198,563<span></span>
</td>
<td class="nump">67,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">22,550<span></span>
</td>
<td class="nump">6,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">30,114<span></span>
</td>
<td class="nump">15,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">52,664<span></span>
</td>
<td class="nump">21,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember', window );">Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">6,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_AgencyBondsMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">14,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">17,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">12,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">12,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">17,690<span></span>
</td>
<td class="nump">14,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">17,690<span></span>
</td>
<td class="nump">14,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">20,868<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">6,667<span></span>
</td>
<td class="nump">13,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">27,535<span></span>
</td>
<td class="nump">14,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">25,412<span></span>
</td>
<td class="nump">5,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">39,343<span></span>
</td>
<td class="nump">11,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">$ 64,755<span></span>
</td>
<td class="nump">$ 17,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_AgencyBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_AgencyBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352915355032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">$ 198,563<span></span>
</td>
<td class="nump">$ 67,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">17,690<span></span>
</td>
<td class="nump">14,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">52,664<span></span>
</td>
<td class="nump">21,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember', window );">Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">6,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_AgencyBondsMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">17,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">12,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">27,535<span></span>
</td>
<td class="nump">14,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">64,755<span></span>
</td>
<td class="nump">17,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">475,211<span></span>
</td>
<td class="nump">281,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">254,157<span></span>
</td>
<td class="nump">209,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">22,491<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">17,690<span></span>
</td>
<td class="nump">14,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">52,664<span></span>
</td>
<td class="nump">21,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">6,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">17,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">12,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">27,535<span></span>
</td>
<td class="nump">14,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">64,755<span></span>
</td>
<td class="nump">17,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">342,740<span></span>
</td>
<td class="nump">231,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">254,157<span></span>
</td>
<td class="nump">209,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">52,664<span></span>
</td>
<td class="nump">21,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">6,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">17,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">12,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">132,471<span></span>
</td>
<td class="nump">50,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">22,491<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">17,690<span></span>
</td>
<td class="nump">14,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">27,535<span></span>
</td>
<td class="nump">14,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">64,755<span></span>
</td>
<td class="nump">17,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_AgencyBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_AgencyBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914598856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 219,417<span></span>
</td>
<td class="nump">$ 178,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(109,952)<span></span>
</td>
<td class="num">(92,895)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">109,465<span></span>
</td>
<td class="nump">85,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 86,410<span></span>
</td>
<td class="nump">73,234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 43,251<span></span>
</td>
<td class="nump">27,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 11,141<span></span>
</td>
<td class="nump">7,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=neo_ComputerHardwareAndOfficeEquipmentMember', window );">Computer hardware and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 30,394<span></span>
</td>
<td class="nump">22,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=neo_ComputerHardwareAndOfficeEquipmentMember', window );">Computer hardware and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=neo_ComputerHardwareAndOfficeEquipmentMember', window );">Computer hardware and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 35,826<span></span>
</td>
<td class="nump">30,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in Years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 12,395<span></span>
</td>
<td class="nump">$ 6,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=neo_ComputerHardwareAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=neo_ComputerHardwareAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919289992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Depreciation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_AssetHeldForSaleSquareFeetOfFacilityOwned', window );">Square feet owned | ft&#178;</a></td>
<td class="nump">43,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">$ 10,050<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">30,192<span></span>
</td>
<td class="nump">25,904<span></span>
</td>
<td class="nump">$ 20,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">15,287<span></span>
</td>
<td class="nump">9,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">15,299<span></span>
</td>
<td class="nump">10,359<span></span>
</td>
<td class="nump">10,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_AssetHeldForSaleSquareFeetOfFacilityOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Held For Sale, Square Feet Of Facility Owned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_AssetHeldForSaleSquareFeetOfFacilityOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123398962&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352915464264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 9,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">10,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">10,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">6,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">5,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">59,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">102,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(23,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">79,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(6,884)<span></span>
</td>
<td class="num">$ (4,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 72,289<span></span>
</td>
<td class="nump">$ 42,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">12 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352920916504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Additional Supplemental Data (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 11,231<span></span>
</td>
<td class="nump">$ 8,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">39,785<span></span>
</td>
<td class="nump">25,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases</a></td>
<td class="nump">$ 10,165<span></span>
</td>
<td class="nump">$ 7,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352923083848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Minimum lease payments for leases executed but not commenced</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 21,919<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_FL', window );">Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Minimum lease payments for leases executed but not commenced</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_FL', window );">Florida | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Minimum lease payments for leases executed but not commenced</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352916695048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">$ 44,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">44,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health | Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">271,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">238,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata | Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">$ 32,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914476888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Rollforward of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 211,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">527,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">44,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">271,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">179,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">462,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">44,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">238,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">31,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">64,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services | Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services | Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">$ 32,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914393400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Classes of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 59,055<span></span>
</td>
<td class="nump">$ 35,895<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">428,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross (excluding goodwill)</a></td>
<td class="nump">501,380<span></span>
</td>
<td class="nump">156,548<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">442,325<span></span>
</td>
<td class="nump">120,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets, cost</a></td>
<td class="nump">13,447<span></span>
</td>
<td class="nump">13,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">143,101<span></span>
</td>
<td class="nump">143,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">45,756<span></span>
</td>
<td class="nump">35,895<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">97,345<span></span>
</td>
<td class="nump">$ 107,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">310,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">11,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 298,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 31,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 30,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 2,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919723272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Amortization Expense of Intangibles Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">$ 23,160<span></span>
</td>
<td class="nump">$ 9,817<span></span>
</td>
<td class="nump">$ 9,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">10,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">$ 12,753<span></span>
</td>
<td class="nump">$ 9,817<span></span>
</td>
<td class="nump">$ 9,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919913464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 33,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">33,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">33,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">33,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">33,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">259,898<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 428,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352916091544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Non-Consolidated Affiliate (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 22, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Carrying amount of investment in non-consolidated affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,869,778<span></span>
</td>
<td class="nump">$ 988,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investment in non-consolidated affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongTermLineOfCreditSettlementGainLoss', window );">Gain on settlement under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,260<span></span>
</td>
<td class="nump">3,955<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember', window );">Inivata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Fair value of previously-held equity interest</a></td>
<td class="nump">$ 64,900<span></span>
</td>
<td class="nump">$ 64,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue', window );">Fair value of Purchase Option</a></td>
<td class="nump">$ 74,300<span></span>
</td>
<td class="nump">74,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss', window );">Unrealized gain on investment in non-consolidated affiliate, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Measurement period adjustments, net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,300<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Carrying amount of investment in non-consolidated affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=neo_PreferenceSharesMember', window );">Preference Shares | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Carrying amount of investment in non-consolidated affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investment in non-consolidated affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=neo_PreferenceSharesMember', window );">Preference Shares | Variable Interest Entity, Not Primary Beneficiary | Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PurchaseOptionMeasurementInput', window );">Purchase option, measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=neo_PreferenceSharesMember', window );">Preference Shares | Variable Interest Entity, Not Primary Beneficiary | Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PurchaseOptionMeasurementInput', window );">Purchase option, measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=neo_PreferenceSharesMember', window );">Preference Shares | Variable Interest Entity, Not Primary Beneficiary | Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PurchaseOptionMeasurementInput', window );">Purchase option, measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=neo_PurchaseOptionMember', window );">Purchase Option | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Carrying amount of investment in non-consolidated affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=neo_PurchaseOptionMember', window );">Purchase Option | Variable Interest Entity, Not Primary Beneficiary | Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PurchaseOptionMeasurementInput', window );">Purchase option, measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0017<span></span>
</td>
<td class="nump">0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=neo_PurchaseOptionMember', window );">Purchase Option | Variable Interest Entity, Not Primary Beneficiary | Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PurchaseOptionMeasurementInput', window );">Purchase option, measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.840<span></span>
</td>
<td class="nump">0.840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=neo_PurchaseOptionMember', window );">Purchase Option | Variable Interest Entity, Not Primary Beneficiary | Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PurchaseOptionMeasurementInput', window );">Purchase option, measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Net unrealized loss from remeasurement of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate per annum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Imputed interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestDiscount', window );">Loan with imputed interest, discount)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment', window );">Additional investment in non-consolidated affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestNetAmount', window );">Present value of loan receivable with imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Investment in minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Variable Interest Entity, Not Primary Beneficiary | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndFeeIncomeLoansAndLeases', window );">Interest income from loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Preference Shares | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Investment in minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">19,600<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Purchase Option | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Investment in minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Step Acquisition, Purchase Option, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Additional Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LongTermLineOfCreditSettlementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Line of Credit, Settlement, Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LongTermLineOfCreditSettlementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Variable Interest Entities, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_PurchaseOptionMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Option, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_PurchaseOptionMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndFeeIncomeLoansAndLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndFeeIncomeLoansAndLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the receivable or loan. The discount or premium is the difference between the present value and the face amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The receivable or note face amount less the unamortized discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_InivataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_InivataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=neo_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=neo_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=neo_PurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=neo_PurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352912546376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Long Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">$ (13,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="num">(714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Equipment financing obligations</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">533,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: Current portion of equipment financing obligations</a></td>
<td class="num">(1,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt, net</a></td>
<td class="nump">532,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(8,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="num">(208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">335,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">201,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(4,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="num">(506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">196,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=neo_FinanceObligationsMember', window );">Finance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: Current portion of equipment financing obligations</a></td>
<td class="num">$ (1,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=neo_FinanceObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=neo_FinanceObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352913767272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="3"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 11, 2021 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>Rate </div>
<div>shares</div>
</th>
<th class="th">
<div>May 04, 2020 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>Rate</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>day </div>
<div>Rate</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>day</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Rate</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,080,000<span></span>
</td>
<td class="nump">$ 20,310,000<span></span>
</td>
<td class="nump">$ 11,202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt', window );">Ownership of convertible notes (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 334,410,000<span></span>
</td>
<td class="nump">194,466,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (714,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="nump">$ 334,400,000<span></span>
</td>
<td class="nump">$ 194,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember', window );">Capped Call Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible debt, net of issuance costs</a></td>
<td class="nump">$ 29,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_CappedCallTransactionsNumberOfUnderlyingShares', window );">Capped call transaction, number of underlying shares | shares</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 85.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_SaleOfStockPremiumOnOfferingPrice', window );">Premium on offering price (as a percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_SaleOfStockPricePerSharePublicOfferingPrice', window );">Public offering price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 49.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 345,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DiscountedPriceOfAggregatePrincipleRate', window );">Discount on principal amount (as a percent) | Rate</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDiscountOnShares', window );">Discount on shares</a></td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Conversion price on applicable trading day (as a percent)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible Notes, conversion ratio | Rate</a></td>
<td class="nump">1.51172%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible Notes, conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 66.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price of principal (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt', window );">Ownership of convertible notes (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_InterestExpenseDebtContractualCouponInterest', window );">Interest expense, contractual coupon interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_InterestExpenseDebtAccretionOfDebtDiscount', window );">Interest expense, accretion of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts', window );">Interest expense, amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate on Convertible Notes (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes | Convertible Debt | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes | Convertible Debt | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Conversion price on applicable trading day (as a percent)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes | Convertible Debt | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | day</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate', window );">Principal amount priced to investors (as a percent) | Rate</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DiscountedPriceOfAggregatePrincipleRate', window );">Discount on principal amount (as a percent) | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDiscountOnShares', window );">Discount on shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Conversion price on applicable trading day (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible Notes, conversion ratio | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75198%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible Notes, conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price of principal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_InterestExpenseDebtContractualCouponInterest', window );">Interest expense, contractual coupon interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_InterestExpenseDebtAccretionOfDebtDiscount', window );">Interest expense, accretion of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts', window );">Interest expense, amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">70,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate on Convertible Notes (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(538,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(506,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Convertible Debt | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Convertible Debt | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Conversion price on applicable trading day (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Convertible Debt | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate', window );">Principal amount priced to investors (as a percent) | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_CappedCallTransactionsNumberOfUnderlyingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capped Call Transactions, Number Of Underlying Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_CappedCallTransactionsNumberOfUnderlyingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Notes, Aggregate Principle Amount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Threshold of Default, Percent Of Owners Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DiscountedPriceOfAggregatePrincipleRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discounted Price of Aggregate Principle Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DiscountedPriceOfAggregatePrincipleRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_InterestExpenseDebtAccretionOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Accretion Of Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_InterestExpenseDebtAccretionOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Amortization Of Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_InterestExpenseDebtContractualCouponInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Contractual Coupon Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_InterestExpenseDebtContractualCouponInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_SaleOfStockPremiumOnOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Premium On Offering Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_SaleOfStockPremiumOnOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_SaleOfStockPricePerSharePublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Price Per Share, Public Offering Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_SaleOfStockPricePerSharePublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187103-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914085608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Maturities of Long Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Term Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="num">$ (714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsAbstract', window );"><strong>Financing Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="num">(1,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Total Long-Term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne', window );">2022</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">201,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities', window );">Total Debt</a></td>
<td class="nump">547,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="num">(714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less:&#160;Current portion of long-term debt</a></td>
<td class="num">(1,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(13,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt, net</a></td>
<td class="nump">532,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Term Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongTermDebtIncludingCurrentMaturitiesDue', window );">Total Debt</a></td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less:&#160;Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="num">(208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">335,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Total Long-Term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="num">(208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(8,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Term Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">201,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_LongTermDebtIncludingCurrentMaturitiesDue', window );">Total Debt</a></td>
<td class="nump">201,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less:&#160;Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="num">(506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">196,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Total Long-Term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="num">(506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(4,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=neo_FinanceObligationsMember', window );">Finance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract', window );"><strong>Term Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsAbstract', window );"><strong>Financing Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total Debt</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="num">(1,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Total Long-Term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less:&#160;Unamortized debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal After Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LongTermDebtIncludingCurrentMaturitiesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt including current maturities due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LongTermDebtIncludingCurrentMaturitiesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt and Finance Lease Obligations, Including Current Maturities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=neo_FinanceObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=neo_FinanceObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914644520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount', window );">Outstanding derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DerivativeTerminationFee', window );">Termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,317,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Cash flow hedge termination reclassified to earnings, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,661,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=neo_InterestRateSwapDecember2016Member', window );">Previous interest rate swap agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DerivativeTerminationFee', window );">Termination fee</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Swap June 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Fixed Rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Cash flow hedge termination reclassified to earnings, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DerivativeTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Termination Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DerivativeTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtPercentageBearingVariableInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtPercentageBearingVariableInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=neo_InterestRateSwapDecember2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=neo_InterestRateSwapDecember2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=neo_InterestRateSwapJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=neo_InterestRateSwapJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352918872968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 18, 2021</div></th>
<th class="th"><div>Apr. 07, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Jun. 03, 2020</div></th>
<th class="th"><div>Apr. 29, 2020</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="nump">4,444,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received</a></td>
<td class="nump">$ 189.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CommonStockOfferingMember', window );">Common Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,081,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_SaleOfStockOptionTerm', window );">Sale of stock, option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,244<span></span>
</td>
<td class="nump">351,500<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.4<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_SaleOfStockOptionTerm', window );">Sale of stock, option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember', window );">Trapelo Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_SaleOfStockOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Option, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_SaleOfStockOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=neo_CommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=neo_TrapeloHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352915279256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 25, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,625,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,961,195<span></span>
</td>
<td class="nump">3,785,941<span></span>
</td>
<td class="nump">5,318,759<span></span>
</td>
<td class="nump">6,839,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options, exercisable, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_CommonStockClosingPrice', window );">Common stock closing price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber', window );">Options outstanding and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised during period, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.7<span></span>
</td>
<td class="nump">$ 68.6<span></span>
</td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue', window );">Fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issuance ESPP plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,094<span></span>
</td>
<td class="nump">138,309<span></span>
</td>
<td class="nump">141,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock based compensation, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock based compensation, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">936,648<span></span>
</td>
<td class="nump">149,012<span></span>
</td>
<td class="nump">230,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of shares granted during period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.52<span></span>
</td>
<td class="nump">$ 28.45<span></span>
</td>
<td class="nump">$ 19.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of shares granted during period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=neo_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount from market price (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_CommonStockClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock closing price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_CommonStockClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grants in period aggregate grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of in-the-money options outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to adjust previously recorded stockholders' equity balances to the actual aggregate amounts paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchaseProgramAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=neo_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=neo_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914402680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted Average Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">45.10%<span></span>
</td>
<td class="nump">42.70%<span></span>
</td>
<td class="nump">43.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average fair value per share at grant date (in dollars per share)</a></td>
<td class="nump">$ 18.87<span></span>
</td>
<td class="nump">$ 8.88<span></span>
</td>
<td class="nump">$ 5.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352918836456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Status of Our Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,785,941<span></span>
</td>
<td class="nump">5,318,759<span></span>
</td>
<td class="nump">6,839,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,232,056<span></span>
</td>
<td class="nump">845,120<span></span>
</td>
<td class="nump">969,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,372,564)<span></span>
</td>
<td class="num">(2,310,934)<span></span>
</td>
<td class="num">(2,309,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(684,238)<span></span>
</td>
<td class="num">(67,004)<span></span>
</td>
<td class="num">(180,927)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">2,961,195<span></span>
</td>
<td class="nump">3,785,941<span></span>
</td>
<td class="nump">5,318,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">1,668,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding , beginning balance (in dollars per share)</a></td>
<td class="nump">$ 15.21<span></span>
</td>
<td class="nump">$ 9.97<span></span>
</td>
<td class="nump">$ 7.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">42.13<span></span>
</td>
<td class="nump">28.33<span></span>
</td>
<td class="nump">19.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">9.97<span></span>
</td>
<td class="nump">7.96<span></span>
</td>
<td class="nump">6.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">29.70<span></span>
</td>
<td class="nump">16.37<span></span>
</td>
<td class="nump">13.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">25.46<span></span>
</td>
<td class="nump">$ 15.21<span></span>
</td>
<td class="nump">$ 9.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 15.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352915898088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Roll Forward of Non-Vested Stock Options Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,163,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,232,056<span></span>
</td>
<td class="nump">845,120<span></span>
</td>
<td class="nump">969,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="num">(1,421,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited (in shares)</a></td>
<td class="num">(681,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">1,292,839<span></span>
</td>
<td class="nump">2,163,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">18.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">8.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">9.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 13.93<span></span>
</td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352915284104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Information about our Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding (in shares) | shares</a></td>
<td class="nump">2,961,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">3 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 25.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable (in shares) | shares</a></td>
<td class="nump">1,668,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">2 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeOneMember', window );">7.27 &#8211; 8.21</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, lower limit (in dollars per share)</a></td>
<td class="nump">7.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, upper limit (in dollars per share)</a></td>
<td class="nump">$ 8.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding (in shares) | shares</a></td>
<td class="nump">638,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">11 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable (in shares) | shares</a></td>
<td class="nump">638,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">11 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeTwoMember', window );">8.22 &#8211; 19.76</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, lower limit (in dollars per share)</a></td>
<td class="nump">8.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, upper limit (in dollars per share)</a></td>
<td class="nump">$ 19.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding (in shares) | shares</a></td>
<td class="nump">701,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">1 year 10 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable (in shares) | shares</a></td>
<td class="nump">618,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeThreeMember', window );">19.77 &#8211; 27.97</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, lower limit (in dollars per share)</a></td>
<td class="nump">19.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, upper limit (in dollars per share)</a></td>
<td class="nump">$ 27.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding (in shares) | shares</a></td>
<td class="nump">359,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 24.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable (in shares) | shares</a></td>
<td class="nump">112,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 23.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeFourMember', window );">27.98 &#8211; 43.49</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, lower limit (in dollars per share)</a></td>
<td class="nump">27.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, upper limit (in dollars per share)</a></td>
<td class="nump">$ 43.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding (in shares) | shares</a></td>
<td class="nump">612,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 31.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable (in shares) | shares</a></td>
<td class="nump">298,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">5 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 28.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeFiveMember', window );">43.50 &#8211; 55.40</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, lower limit (in dollars per share)</a></td>
<td class="nump">43.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, upper limit (in dollars per share)</a></td>
<td class="nump">$ 55.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding (in shares) | shares</a></td>
<td class="nump">650,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">6 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 48.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable (in shares) | shares</a></td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 55.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=neo_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914328200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning balance (in shares)</a></td>
<td class="nump">291,891<span></span>
</td>
<td class="nump">335,298<span></span>
</td>
<td class="nump">282,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">936,648<span></span>
</td>
<td class="nump">149,012<span></span>
</td>
<td class="nump">230,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(213,777)<span></span>
</td>
<td class="num">(184,127)<span></span>
</td>
<td class="num">(115,711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(163,359)<span></span>
</td>
<td class="num">(8,292)<span></span>
</td>
<td class="num">(62,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, ending balance (in shares)</a></td>
<td class="nump">851,403<span></span>
</td>
<td class="nump">291,891<span></span>
</td>
<td class="nump">335,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 23.82<span></span>
</td>
<td class="nump">$ 15.75<span></span>
</td>
<td class="nump">$ 9.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">39.52<span></span>
</td>
<td class="nump">28.45<span></span>
</td>
<td class="nump">19.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">32.83<span></span>
</td>
<td class="nump">12.90<span></span>
</td>
<td class="nump">9.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">38.58<span></span>
</td>
<td class="nump">20.75<span></span>
</td>
<td class="nump">12.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, ending balance (in dollars per share)</a></td>
<td class="nump">$ 36.00<span></span>
</td>
<td class="nump">$ 23.82<span></span>
</td>
<td class="nump">$ 15.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352915501512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Revenue payment terms</a></td>
<td class="text">Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Pharma contract liability, revenue recognized</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract commissions</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount', window );">Amount of new contracts signed</a></td>
<td class="nump">172.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 267.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Increase From New Contracts, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352912547992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract with Customer, Asset, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Current pharma contract asset</a></td>
<td class="nump">$ 1,738<span></span>
</td>
<td class="nump">$ 1,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Long-term pharma contract asset</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Total pharma contract assets</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAbstract', window );"><strong>Capitalized Contract Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetCurrent', window );">Current pharma capitalized commissions</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Long-term pharma capitalized commissions</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Total pharma capitalized commissions</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current pharma contract liabilities</a></td>
<td class="nump">5,192<span></span>
</td>
<td class="nump">4,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term pharma contract liability</a></td>
<td class="nump">917<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total pharma contract liabilities</a></td>
<td class="nump">$ 6,109<span></span>
</td>
<td class="nump">$ 4,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919742024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 484,329<span></span>
</td>
<td class="nump">$ 444,448<span></span>
</td>
<td class="nump">$ 408,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">404,172<span></span>
</td>
<td class="nump">382,337<span></span>
</td>
<td class="nump">361,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">80,157<span></span>
</td>
<td class="nump">62,111<span></span>
</td>
<td class="nump">47,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=neo_ClientDirectBillingMember', window );">Client direct billing | Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">252,617<span></span>
</td>
<td class="nump">240,535<span></span>
</td>
<td class="nump">212,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=neo_CommercialInsuranceMember', window );">Commercial insurance | Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">78,773<span></span>
</td>
<td class="nump">76,550<span></span>
</td>
<td class="nump">83,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=neo_MedicareAndMedicaidMember', window );">Medicare and other government | Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">72,010<span></span>
</td>
<td class="nump">64,776<span></span>
</td>
<td class="nump">64,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=neo_SelfPayServicesMember', window );">Self-pay | Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_ClientDirectBillingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_ClientDirectBillingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_CommercialInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_CommercialInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_MedicareAndMedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_MedicareAndMedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_SelfPayServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_SelfPayServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919090584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Significant Components of the Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income tax (benefit) expense</a></td>
<td class="num">$ (15,075)<span></span>
</td>
<td class="num">$ (14,056)<span></span>
</td>
<td class="nump">$ 3,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">41<span></span>
</td>
<td class="num">(434)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax (benefit) expense</a></td>
<td class="nump">82<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(575)<span></span>
</td>
<td class="num">(12,856)<span></span>
</td>
<td class="num">(3,409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="num">(5,211)<span></span>
</td>
<td class="num">(939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(7,476)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred benefit provision</a></td>
<td class="num">(6,810)<span></span>
</td>
<td class="num">(18,067)<span></span>
</td>
<td class="num">(4,348)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax benefit provision</a></td>
<td class="num">(6,728)<span></span>
</td>
<td class="num">(18,228)<span></span>
</td>
<td class="num">(4,361)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income tax (benefit) expense</a></td>
<td class="nump">24,761<span></span>
</td>
<td class="num">(6,954)<span></span>
</td>
<td class="nump">7,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income tax (benefit) expense</a></td>
<td class="num">$ (39,836)<span></span>
</td>
<td class="num">$ (7,102)<span></span>
</td>
<td class="num">$ (3,408)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919972856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Tax Rate and the Federal Statutory Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal income tax benefit (as a percent)</a></td>
<td class="nump">17.77%<span></span>
</td>
<td class="nump">14.29%<span></span>
</td>
<td class="num">(19.47%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent', window );">Transaction Costs (as a percent)</a></td>
<td class="num">(10.11%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent', window );">Penalties (as a percent)</a></td>
<td class="num">(15.61%)<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses (as a percent)</a></td>
<td class="num">(3.29%)<span></span>
</td>
<td class="num">(1.41%)<span></span>
</td>
<td class="nump">7.41%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Compensation expense (as a percent)</a></td>
<td class="num">(0.96%)<span></span>
</td>
<td class="nump">65.78%<span></span>
</td>
<td class="num">(135.12%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses', window );">Transaction expenses (as a percent)</a></td>
<td class="nump">159.14%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent', window );">Tax credits (as a percent)</a></td>
<td class="nump">11.63%<span></span>
</td>
<td class="nump">32.11%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent', window );">Uncertain tax position (as a percent)</a></td>
<td class="nump">0.22%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="num">(3.32%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent', window );">Return to provision (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">7.38%<span></span>
</td>
<td class="num">(13.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign Tax Rate Differential (as a percent)</a></td>
<td class="nump">2.74%<span></span>
</td>
<td class="num">(1.64%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net (as a percent)</a></td>
<td class="nump">0.16%<span></span>
</td>
<td class="num">(0.06%)<span></span>
</td>
<td class="num">(2.78%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance (as a percent)</a></td>
<td class="num">(138.07%)<span></span>
</td>
<td class="num">(8.97%)<span></span>
</td>
<td class="nump">25.74%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate (as a percent)</a></td>
<td class="nump">44.62%<span></span>
</td>
<td class="nump">129.68%<span></span>
</td>
<td class="num">(119.66%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Tax Credits, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Penalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Return To Provision, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Transaction Costs, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Transaction Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919266696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Current and Non-current Deferred Income Tax Assets And Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of Deferred Tax Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Accounts receivable, net</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">6,171<span></span>
</td>
<td class="nump">5,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">81,903<span></span>
</td>
<td class="nump">33,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">6,596<span></span>
</td>
<td class="nump">4,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,355<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">19,978<span></span>
</td>
<td class="nump">11,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DeferredTaxAssetsInterestExpense', window );">Interest expense</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,668<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">120,852<span></span>
</td>
<td class="nump">60,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(33,014)<span></span>
</td>
<td class="num">(2,631)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">87,838<span></span>
</td>
<td class="nump">57,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="num">(19,094)<span></span>
</td>
<td class="num">(11,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Investment in non-consolidated affiliate</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts', window );">Convertible debt discount</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(108,592)<span></span>
</td>
<td class="num">(29,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(15,389)<span></span>
</td>
<td class="num">(14,678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(292)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(143,076)<span></span>
</td>
<td class="num">(62,994)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income tax liabilities</a></td>
<td class="num">$ (55,238)<span></span>
</td>
<td class="num">$ (5,415)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DeferredTaxAssetsInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DeferredTaxAssetsInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352923097032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 231,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">33,014<span></span>
</td>
<td class="nump">$ 2,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">118,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">96,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">112,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards that do not expire</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards that expire</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 28,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_HerMajestysRevenueAndCustomsHMRCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_HerMajestysRevenueAndCustomsHMRCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352916705128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits - January 1</a></td>
<td class="nump">$ 1,670<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Increases in prior year positions</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reversals of prior year positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases in tax positions taken in current year</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute expirations</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits - December 31</a></td>
<td class="nump">$ 2,351<span></span>
</td>
<td class="nump">$ 1,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352923333784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share - Computation of Basic and Diluted Net (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Income (Loss) Available to Common Stockholders, Basic</a></td>
<td class="num">$ (8,347)<span></span>
</td>
<td class="nump">$ 4,172<span></span>
</td>
<td class="nump">$ 8,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">119,962<span></span>
</td>
<td class="nump">108,579<span></span>
</td>
<td class="nump">100,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding (in dollars per share)</a></td>
<td class="nump">119,962<span></span>
</td>
<td class="nump">111,794<span></span>
</td>
<td class="nump">103,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net (loss) income per share(in dollars per share)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net (loss) income per share (in dollars per share)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and restricted stock awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">2,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and restricted stock awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919257672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share - Schedule of Antidilutive Shares (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember', window );">Capped Call Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from EPS calculation (in shares)</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from EPS calculation (in shares)</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | 1.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from EPS calculation (in shares)</a></td>
<td class="nump">5,538<span></span>
</td>
<td class="nump">3,723<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | 0.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from EPS calculation (in shares)</a></td>
<td class="nump">5,130<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352927229400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Matching percentage of company of every dollar contributed (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contribution (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Additional matching contribution (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent', window );">Additional percentage of compensation subject to matching contribution (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent', window );">Maximum company match (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company contributions</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan additional maximum annual contributions per employee percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employer matching additional contribution upon employee percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919966056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jan. 20, 2021 </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_PatentInfringementComplaintMember', window );">Patent Infringement Complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents allegedly infringed upon | patent</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_FederalHealthcareProgramRevenueMember', window );">Federal Healthcare Program Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_PatentInfringementComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_PatentInfringementComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_FederalHealthcareProgramRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_FederalHealthcareProgramRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352919972520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Affiliated Entity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 22, 2021</div></th>
<th class="th"><div>May 22, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt outstanding</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Strategic Alliance With Inivata Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction, expenses from transactions with related party</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=neo_StrategicAllianceWithInivataLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=neo_StrategicAllianceWithInivataLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140352914672200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 484,329<span></span>
</td>
<td class="nump">$ 444,448<span></span>
</td>
<td class="nump">$ 408,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">297,269<span></span>
</td>
<td class="nump">258,555<span></span>
</td>
<td class="nump">211,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>Gross profit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">187,060<span></span>
</td>
<td class="nump">185,893<span></span>
</td>
<td class="nump">196,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">221,347<span></span>
</td>
<td class="nump">143,794<span></span>
</td>
<td class="nump">127,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21,873<span></span>
</td>
<td class="nump">8,229<span></span>
</td>
<td class="nump">8,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">62,594<span></span>
</td>
<td class="nump">47,862<span></span>
</td>
<td class="nump">47,350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">305,814<span></span>
</td>
<td class="nump">199,885<span></span>
</td>
<td class="nump">183,830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(LOSS) INCOME FROM OPERATIONS</a></td>
<td class="num">(118,754)<span></span>
</td>
<td class="num">(13,992)<span></span>
</td>
<td class="nump">13,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">5,082<span></span>
</td>
<td class="nump">7,019<span></span>
</td>
<td class="nump">3,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">499<span></span>
</td>
<td class="num">(7,906)<span></span>
</td>
<td class="nump">4,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_GainLossOnInvestmentAndLoanReceivable', window );">Gain on investment in and loan receivable from non-consolidated affiliate, net</a></td>
<td class="num">(109,260)<span></span>
</td>
<td class="num">(3,955)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_neo_GainLossOnTerminationOfInterestRateSwap', window );">Loss on termination of cash flow hedge</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before taxes</a></td>
<td class="num">(15,075)<span></span>
</td>
<td class="num">(14,056)<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(6,728)<span></span>
</td>
<td class="num">(18,228)<span></span>
</td>
<td class="num">(4,361)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS) INCOME</a></td>
<td class="num">(8,347)<span></span>
</td>
<td class="nump">4,172<span></span>
</td>
<td class="nump">8,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesSegmentMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">404,172<span></span>
</td>
<td class="nump">382,337<span></span>
</td>
<td class="nump">361,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">244,360<span></span>
</td>
<td class="nump">215,529<span></span>
</td>
<td class="nump">185,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>Gross profit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">159,812<span></span>
</td>
<td class="nump">166,808<span></span>
</td>
<td class="nump">175,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesSegmentMember', window );">Clinical Services | Amortization of acquired developed technology intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesSegmentMember', window );">Clinical Services | Write Off For COVID-19 PCR Testing Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesSegmentMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">80,157<span></span>
</td>
<td class="nump">62,111<span></span>
</td>
<td class="nump">47,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">52,909<span></span>
</td>
<td class="nump">43,026<span></span>
</td>
<td class="nump">26,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>Gross profit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">27,248<span></span>
</td>
<td class="nump">$ 19,085<span></span>
</td>
<td class="nump">$ 21,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesSegmentMember', window );">Pharma Services | Amortization of acquired developed technology intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_GainLossOnInvestmentAndLoanReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Investment and Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_GainLossOnInvestmentAndLoanReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_GainLossOnTerminationOfInterestRateSwap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Termination Of Interest Rate Swap</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_GainLossOnTerminationOfInterestRateSwap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_WriteOffForCOVID19PCRTestingInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_WriteOffForCOVID19PCRTestingInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>neo-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:neo="http://neogenomics.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="neo-20211231.xsd" xlink:type="simple"/>
    <context id="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16bc87396d614913bb00f167e8f21276_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i46c8412ab640433d99f2e270ea75b9ff_I20220221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2022-02-21</instant>
        </period>
    </context>
    <context id="i306577667f484778bf45986f95823aa8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97aa2adfd61943129250ed16f5aef4cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70ebc9da32df40f79360ad5da5aef714_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79d415270f85409cb33c97966be628d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b900d497a954a51b916af633f093d2d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81e7e38bca0a483382014babf710343a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d041f360e72469b85c9fb255e34af5c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4187c911d534ee0a8aa9f97ffb938b1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7fa4741509064ec490975a24aa59cd1f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie78002a692994bf9a3d0e7bbfb10684e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id547d59cc8974dcda13cff3fd0b89721_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i73a0530d49904cd080aff3e02d8c44dc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i91b950b832fa47e2a4081c8b4e114d98_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib8efe0d97fc1406cb5ef0d9c377ce77d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09eaaff3cf3e4c139b248da5aa23a90d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff84eeb2c41c49b5bfd127f0c4245c57_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i84d2ab56c92948dfbdbcf7f735be5cea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i688fe6bfb720405dbb35c980f41b1802_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ecbb3fba22b4fce8d7cab8d90245383_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e73e76fb9d740ce9295635957e3246e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9052537da8546a7aa1dbd81390401be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f9645b439ad4fc3b4c672c2c734a7e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i57d0917029a34ef29e913c208110630e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id918e17d65804ec2aaddb4bddbbe04de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2dd25891418746beaebca51736f0026a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04d0596343524d0a9e26d27762aa2791_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83026cc4bc5d41b4ad74488ad2199f77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f50257a2f734bc48f00930c77961bc5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice51bbf0728a42838fa6df2fe01bcc47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if407078fb14144a49b4fde832c9c9fd0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82ac84e649b24f039e093f75604210c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib815884d2c9841e7b4cf247a74f794da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fe82c466a4049f6ad31f72b2eb34e2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8eb531e73f524c3299d26ea0b0cc94f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79509cebd90244a19cdc2cf04c78f592_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18eda084cbb54f798854f0d69e97920e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i17a51adbb970403990c2ec023fc31d62_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id8fa1647fb744e689ec47a53eb568d0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e0ce2e60c5f48469d701fa7b04e3fdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i254845f3a44141fc942661d21925077a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3530310efa1a411da896298ef26d7531_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib644839f440545ae8408c532800708e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d57451dc3554d079ea8b73a036cab7f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i703a879602c940af8370fab4717a800c_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i62ee856eea894002ad4ee9f50ed2417f_I20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-07</instant>
        </period>
    </context>
    <context id="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-07</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="i8259a282355a443fa5a631a8aff168d8_I20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-07</instant>
        </period>
    </context>
    <context id="ie972fa406763417d8f2c25acd458f794_I20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-07</instant>
        </period>
    </context>
    <context id="i58e1304c1c784732a549e74c73206cf7_D20210407-20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-07</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="i3b120b1a036d4eb488cfbc0aaf1ae278_D20210407-20210407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-07</startDate>
            <endDate>2021-04-07</endDate>
        </period>
    </context>
    <context id="i1f7ed50e5ea746629e2bf83cd1f470c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide651db4d96d4bcdb658a4ec18230410_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5dd1dfb285c4701b75adf82d4eff717_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i50f0b20cb9b84704a2839897bfab2b29_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i3f4da2d058964b75bd9d1986bbd5843b_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if0bf694fe7e54138828b3af7f759dc6b_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i056163c254b84758b521f7190d147b16_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i60818069430f4235a500d9ef12d9797d_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="ic894cd7e3581485ea84cafa3847d68c3_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i53250a94560e4680a9724632efeb9b7b_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i09d7da96f3244a2ca7446eb12f52373a_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i26e3bddf7f4f43deac1e105c9da91f6b_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i8a298c3d0be247f28f61c6f6bc44daec_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i4a906e75b19e4b31bb630f84fb76671b_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i241e751eb6ae41b0a89e6a8d1860ded0_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i8fa897a9364d4ba0bb0ed58d1af8a907_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="if693f0a2a745494496eeae35fb96dea0_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="ia6cc8a93c1f0462e8fac56d280a8d2fe_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i41d155bca1e34d069f969cab67f80b2f_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ic5d9574696644e1f9309d0cfefa33d29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb76b6a1b0eb453db2e735dd98b1f29f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71ca084f388f4e8697369585c4417521_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie43d3909305b4bfa99fb106a2a366787_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:InivataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6716adac8aa646019b124b8d827b9826_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3652099553bf4bfeb2731eeab20bbca8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab89ab574c9d401982c77a3b962e16c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24d2c1e8a5f54322b16d387e79522764_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff47caf8efa84cd9b3978e89517a4e53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic54d50e147b9488787c8e53018d0c7a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia677c5c475564da488a50b112b59dccb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if89815183f42497fa9138d9ca4e8f7b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2bcfcbd104942f4850c679c537fde09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7ab7a0601cb455db099d018b5e7ee2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3fa8f61db574f89a67fc8c16cf3711d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76224457309a40699695790b0f50e4f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffbb9a38583e4074b4296919f28d1a77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i638518a143ae4d87a72a11c64fcc3765_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8dc964799b214b28aed62721500a4078_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i697bd4c12c7545578588a80fd60c5a2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fff7b93030247d7a7ec551b5888bba9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ec309e8b8ca4034bede264e6e054708_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if66997f44a6d49358fc4baf034b07e2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i704a124a4a974f0fa8f723461b30609a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie93f36a0218f438aaa218be2623ebb81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i746a7393ab77458f87d791a8c09ccaa7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42b094c7c0f04992a913df6000efec8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf91dd30bbfd452691bc71a1f3018647_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5abf1dd36ab74c1ab535b08da51fd03e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1fc88b8c4af4d838d278264c23593de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb1df97244f7467cb5339af566fe6b01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4ad6cd969fd4b7995ef71a5a45c8429_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4cc69c67cfe341499445ae00f2e71e27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:AgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie66912a44f91463f9626b1399dcc65b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i374016e58cd24f058ea5bda9bf666837_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i558037007551470fb27b3d37558ce693_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51cad3ea1be84d3fafc2dceed5c35c13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ec189eb73b74704b15fcb292ea00266_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b095f6dcdbc4f00abc2c61aefa9f5bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54c09dd584b74333a5ee8cfd4907e771_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02504c45cdee431f96d72f6ef0b3b993_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i819a50dc28e74d5181cf147448558684_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie905db35afe34f1baf538346e1229ce2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4854e1e15ce44e82986165ed1c077b3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib160d83770f74b9b8af5700509a86741_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee0c00ad27f2434d8b93b095e710a55f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id904fbd917124e16bb45e001aecb4dd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9633971e98a74fa18caf2e387613ffcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50a6890d5edf4d9894153bf7442085c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf875c7bc1374e99ae736ce591a58b2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04f461e673034df49706dbcf7f464bbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b59437edee2408ca9c79c95d8d4ab63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4317cec7404a430cbea079ef5f61f530_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0773373ae2a84f8e978c278d271d8702_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida715c03157f4228b0751ab8b032c92f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa881d72ef684b53bc9c3d9157e723c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f8469e26fb441bd917912f9f3502f1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i998bda56c93d4dd6a54740477cd3e347_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic657212cfb3b42ed8189daaa3097f436_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4421d3ac76904ead8fadef3b2ee78bdf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbe0ac1d20e94e4c8366764e3173c3f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbde1cab9dcf4d98a6860b20663b33c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia43aad3092004bd7b9ca33e6dee09b34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ea7bec6dbe545609392aa55eb5b135a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d680608e3bb4da6945d179588c188ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9af0c8ccd543458fa9a3298f3d4ce64d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icdf8f52ad9b840b585d5bd5a88b2922f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a7bf89c9ebb4ba3a93af970a63499c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c8bd802f0224b98af017ab422589382_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7609acc1e0564279a18161c77ee0a661_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c926b150cdc41c987af0ca6157a147b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic11934a2c2474130860676bb9c52078b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i882fb0fa1ed04909a0884aa6e36e11d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc5bdf0bd65547809e7e35cef332ded7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52a20a06d1fb4012ab3ed6acefa4763e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia08a6bbb0803484290d41e899ab2e80c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76551b3aac0541058270850f80fddc5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if012ec1a006545bd8bc701a1f1a66681_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i636c4a523c7044148f591fa542ca2a22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e0ff94327434437bddf706a1455ce54_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d92940bce5d4fc1a139df4991f04954_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff03a902a6dc4195b028b950ecde4819_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieadec132a5f64c42a09fbe4ba6114c84_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if418afdb92d045b3a3f7ed0f7f4d1122_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1c7ceda81e3493eb7227ddc4cd896f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e2cb12c76b947e78ab4acbe3ee1f639_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54d9161759f74b8f932b20183ffd720f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia73a0aa5156842af960bcd14bd338f8e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i84d1f59ac1cd467a8d62d4b587435dc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">neo:ComputerHardwareAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7d1a2450d964986952b0cb1d7a972d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">neo:ComputerHardwareAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i880abad5544f42bc928b73e22ab0195b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">neo:ComputerHardwareAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie96c96643a9a49e897b82d45077534e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">neo:ComputerHardwareAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9ea353bc69b4538a77ec069769583e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc1b463b713a4a888492c941c54b0d54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0af911d8233f4962aafb743c2dd6a5f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e31541c268a47789bfebfdbfe3302c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea2775d83b054b66a7b7488b3b99b796_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib569323910c44cd88620b55283478461_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22d7d272d9234119b3defb42cd98b2ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie55f1b1da3e0488c9a6e5f436542cf5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81cc823b18b445a48f1d7b22e1ae4708_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95ed315fe6ca4ac4b52bb55b50e60ce8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d27cc71a1714b4ebf592be7df20c267_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic20fd6415e784db381b4c4dc75be37e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i291ce8a7f66b4b84a5b2060a8fcc1069_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i151d387283274e48b13d8617c7cb5641_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5b8f4e448e449b8833a37c30148dc54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6385c3880aa64c458d744783c9ed5858_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74fa1e58d23f4919baa197fafbd39ade_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia467e61d4253433b840909b9672e06a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c550d928cb64f8baa867e835a056792_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic957ae942d964cf9b7a556c4a93531fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ac08cc60a5e4cdab6616035137f9346_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if28d75b24f2140639b3049878575785f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6711068bbac647fc86549e4223bb1234_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1de0a4a163954f2cb05b76ae300bf20b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8170c0aaa5d7434fa9c612d65b268c2e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i637576e87f3d47aa8bf8b7d26b13ccaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic98525a6e8714275ab1c829b7a50b6e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if411244f1e50462093c1aae195efef2f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if43301d85c4e4b128360590c43b56712_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04841638dcb14d26aca6ddbca52a8008_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84706daee59246f5ab9cf3fb66b19a70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b0eadb39e524028b1b5befa8894385c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5dd218dd4ac047aabdc29a8180d928bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a9e3c3f614b4a54a8fa244038abc68c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a182d543fcb4f498a67a90731372126_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9eff1173507945b488259b30471cc6bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a929c3ad7fd4b79ac34b701ad8c5f50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie027d3283ba246829bb5659c80860729_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie9911279c90843e3b12761e1e6b7cd04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id70e96f3c16a456f80d98d1ca756c591_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i626362dd9a22429d9bb4e5026984bc8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i211b3436a4454faea569497baa14b01c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i724957d1dba34eadb214d693374d40ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8e67a3847ca48b39b6ee1a91b870b20_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15b55aa860d546afb934b299f66c83bc_I20200522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-22</instant>
        </period>
    </context>
    <context id="idc5c1aae3c584667a244f89cd8a59dce_D20200522-20200522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-22</startDate>
            <endDate>2020-05-22</endDate>
        </period>
    </context>
    <context id="id3649585fd6c4174aa308719cf6e9e80_I20200522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-22</instant>
        </period>
    </context>
    <context id="i1b0aa1a691324c869b66196ee345f501_I20200522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-22</instant>
        </period>
    </context>
    <context id="i4115d538e4cb482997d79b54d6ea7e82_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81ef4e3b7e4349c09dfb58d45e01d6a3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2746f4168df4e39b0b9c9c32fab75aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i55719c5ae1624deeab13abbd59d52c69_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a973dc561984ddf97bf05e50b7774cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0bd3a8ae9bd414ab4804e5744d62945_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd5b0ed6e13f4301a82540f21d96736e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0157f74f12948d5b65dae57eda95f7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie482047107814fcebaeb573c8d125f94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic34c607907124e1797f9b2a94c22f26c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia67744929d544b18bcea0c016670b483_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3c717cc90b34c8396331da311fbc8a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e5bb53850794a1bb9fe4a1d9392f790_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i21e0442b30f14bb3be7f6da7309905fa_I20210522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-22</instant>
        </period>
    </context>
    <context id="id5bd8263f7e1453fae593718fb321be8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i33e7531437724368b82772116041a856_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i562c64b34e6c47f5ac6fe747404a6e3a_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i93dce16f064a42eabc5af5199673306a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icedf740a0317452ea709d14ef5bf92f4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9aa9ea29f0bc44568dcd39d50b79abda_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id314aeaf3a3e4fd28f10f5c449698ad4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2d9fb9ddce7e450f8b051082329851b8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifcc7b5e165b64262a42245b5258953e1_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i8e6ac5e675db4ac6837f4c1270b3e2de_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i6f1df0f3964f4e5f8fec10eac6e0e19d_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">neo:PurchaseOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="ie4c011915eac47c0998bdadb7a8c7b5c_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i808a9ed8cc11448da4c70680cd987939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41a23e34f1f24675a50fd9548060e01b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">neo:FinanceObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f65e6d59d9d4339974d98eb93610ffa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">neo:FinanceObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9236c81b3c974578a313916abc4fb1f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8457e19cdaef435383fa565c271d3716_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88a97a83c09a4c2fb216eb170e5f0549_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07b91282517d4c9ca4fef081647caa7a_I20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="icc25a561b9d845e1a4b085174856869d_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="i5c92183f6c1545059fe96165a77e5108_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="id52cd4fd62d54923a9542f08f3e9e0b5_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="ibc0c47f77f104125b2614b3cc70b4781_I20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8316e135f82444fd960aa45a363a320e_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i317802a689f346709fdb8f5e9f54cf2b_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="ic3e44ba920e9419596aae3ab89649f48_I20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="i34af75623b2843a0a57023612b0339a8_I20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="ia164ece2fda645d18a4614a36f3dde97_D20200504-20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="i9736d15d029c4d79a63118c242b0a06d_D20200504-20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="i8c8fa3e8e2304733b69c9fd8dc90960b_D20200504-20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="i80ffbe19f2b94211b4716f57813e319e_I20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="i7e141e5dc5ac4d099c050eacf32e2ce1_D20200504-20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib2e710b5650c4cd790dff15ccb7d0cc9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47acf3b6354b4627a7978853e4d3e47f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapJune2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fa5b7dff3c2469793b45a7b9c0a39e3_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapDecember2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="i872473cddd404138b10ac6c363634e0c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapJune2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f2d85c36fbe4f798381a1b1b4a59d9d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapJune2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25aa5942e458401b9ff510cbfb4e37f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">neo:InterestRateSwapJune2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i46a03a2c735740e0a62ec8fcfd378af4_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i5d84ea5eee6f466492f6a5f7b9c99c5f_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i909533f6893842af88add72e0b80061e_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">neo:TrapeloHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i6f0072740fba4f1f957dc041083ebbbf_D20210106-20210106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-06</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="if7813f0e28ca47909409d4d71f3f0cc2_I20210106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-06</instant>
        </period>
    </context>
    <context id="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-06</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="i9b6939f2ae8d44b0b65a46676533cb9a_I20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="i59836b2a553946d0a448161d3100d995_D20200429-20200429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="i9f5d1a3736b248a992304f0788d7d8b5_D20200603-20200603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-03</startDate>
            <endDate>2020-06-03</endDate>
        </period>
    </context>
    <context id="i681790e0336945d58f151a6d5808acd9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i831056d6c8b04c6c8f9562bb6f5192df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie255c1c51fd744cca5a778a0da0a5155_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a253449c87943b39413bdd71acbf134_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4be580f98fbf4b08bfe75fadf6a6c0a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic76afff429474a7f9ebd89074d5938d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib552bd7af98f40b89fa495c675994501_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i85dd1e5d4a554aae80eca8c6f52b6874_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i971c2719748f46e78600d16ad130da2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b827dae344b4efeb7a3cec6f619da89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i657183ed33254a23a110400913bd73a3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1ebf39f1a9949e98894465429e942a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e0d681c2fc34b14bac44c4021fc624f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">neo:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c7e18a3aebc410cb31023371db1e1f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0be2f6f601ad4f47b7a64f324453f4ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f7aefd0c1144fcda962a595d1d326e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44f2175697164b01b2aab1f8ff1898cb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83965d652d1d423f8ca32d729d617473_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec0d080a2339420d89dc78184ef8b898_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcea204956134004ac776ab4422f61d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if16aafa54e7c4291827eb4a4a779b7fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d981c543aef4926ad686ff97522008d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4bb9f08a180f4313aa2080d8df018f76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ed4a1d011e94710823acf48d3e17a2e_D20170525-20170525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">neo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-25</startDate>
            <endDate>2017-05-25</endDate>
        </period>
    </context>
    <context id="i2b45da9a6c9a4f8c9594977540bd40f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">neo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i679ecadf68b64358a44f898cebaed8f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">neo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e4de4fe398a4353b1bfc64e3f2090b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">neo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i667bb3b470c64da985250798b766a649_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d47d42a743b474492f4e32571a3f05e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55f72e0eca1d419dab353fa6c8a23098_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i321637f0a7b540bdbb4033a0247f471f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if213c108cbd74502ad64e78f83030eaf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id558c0253e714d4fa8959f36f7ace8af_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a5278b10f214b99ae816d90c219b11f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib515a6110c0c4a03b0ab671c0fd68174_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie847e09d489543aea8789c0dfbead017_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2e0e7f7754324dedae9666c62419ea78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67fff1172685496bbaf7a54a6396eb92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73e92c7aad5c4209a4df55556c23b848_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95ccf651c92142fb87ac4f3feb892173_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaeeb6ff7726a404aa5ab12499665bd21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id37460a8ce1e41cfbb99f9a168dcda88_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia2a4237d1df945f78f4dd92cf2d83177_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i83dc4513b1f24e378f0be8c6c7f73c50_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42ba577adb2b4ee4a77b0a9e0248c94e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6dccccc0a21b4ef3be05781945900129_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24a99cf2affb44979b10edd8cc9305bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:HerMajestysRevenueAndCustomsHMRCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7819d6cd0da4e4da9a9fdcae4fb87ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if495aff7c41d4b8aad8f6a3241978f33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe0dff7a9994470f9689008656bb381b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c214db41910419cb07bdbcc42d83756_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia87bb3f8d04745f2889e0a2f39c141d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife334d7e97604dfb939dddee1cd879c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1225c352b00e4cb690a7adb7cdcbedde_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a9dd7cfafdc43d091c918725cbc192d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f155818af974561b4f8f18784fa25f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i57a16efa8cab4c0c99d0598296108afd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i091d1f087aa54fdfb74ce0705a97ff6b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87d1360a007c47328b217b42d2e1ff65_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e3dba7dbe87474f82bf542453f20492_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i383f1d1042d44cf1b819e519a1682405_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a0708e137d04355b6f919e001c59cce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf2957894b7a4d2f897b45f006d71ee4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4fedbf43609e4de1a63dab08b8a57324_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74606006218e4bd29582caf14fce1a54_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaeda459a54ed4faf87cd1bc16a70d854_D20210120-20210120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:PatentInfringementComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-20</startDate>
            <endDate>2021-01-20</endDate>
        </period>
    </context>
    <context id="i4f4073899af34688810e3b224590c74f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13a97ccd6ccc4b63a539db53fa7f8e61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:StrategicAllianceWithInivataLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie359835360d14552b460dfe2e09d74a4_I20200522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-22</instant>
        </period>
    </context>
    <context id="ie1bd7c4a65e8470fb2e0bcb4e07683c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i837dec7e8fdd48c7a1722bf1b1f3b0e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9dd5c1eb69c64cc799674374d18d6cc0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if43b0047444b401e8e1b445dd63adc4b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8c1b9b8d04e54ea9b259cbdf629ff3dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib2d0d6a9a7bd4a269a7535713c120fbd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd350be96f284665bf09aeefccfc73cb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83673f0de9224acfae001662ab57801f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i627f74b4ec984553bf1664500f452ad0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:WriteOffForCOVID19PCRTestingInventoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7798d7199db145cf9eee4dd9052c2e1b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>neo:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="day">
        <measure>neo:day</measure>
    </unit>
    <unit id="patent">
        <measure>neo:patent</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV80L2ZyYWc6Yjc4N2ZkYzRlMGZiNDk4Y2FhZTI2ZWIwODI2OWFiMDgvdGFibGU6ZmU2ZTZkOTU4NzNlNDY0ZThjZWE2NDVlNjE3NDYwYTQvdGFibGVyYW5nZTpmZTZlNmQ5NTg3M2U0NjRlOGNlYTY0NWU2MTc0NjBhNF80LTEtMS0xLTMwNTcy_398bec22-73fd-4d8a-b23f-0a149f9ace2a">0001077183</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV80L2ZyYWc6Yjc4N2ZkYzRlMGZiNDk4Y2FhZTI2ZWIwODI2OWFiMDgvdGFibGU6ZmU2ZTZkOTU4NzNlNDY0ZThjZWE2NDVlNjE3NDYwYTQvdGFibGVyYW5nZTpmZTZlNmQ5NTg3M2U0NjRlOGNlYTY0NWU2MTc0NjBhNF81LTEtMS0xLTMwNTcy_26417d5d-877a-405e-8968-296d40f554d0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV80L2ZyYWc6Yjc4N2ZkYzRlMGZiNDk4Y2FhZTI2ZWIwODI2OWFiMDgvdGFibGU6ZmU2ZTZkOTU4NzNlNDY0ZThjZWE2NDVlNjE3NDYwYTQvdGFibGVyYW5nZTpmZTZlNmQ5NTg3M2U0NjRlOGNlYTY0NWU2MTc0NjBhNF82LTEtMS0xLTMwNTcy_17ca2c2c-cb98-4c6a-996d-ecc689136777">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV80L2ZyYWc6Yjc4N2ZkYzRlMGZiNDk4Y2FhZTI2ZWIwODI2OWFiMDgvdGFibGU6ZmU2ZTZkOTU4NzNlNDY0ZThjZWE2NDVlNjE3NDYwYTQvdGFibGVyYW5nZTpmZTZlNmQ5NTg3M2U0NjRlOGNlYTY0NWU2MTc0NjBhNF83LTEtMS0xLTMwNTcy_c37f700d-b6c2-4867-b2cc-6a1812c6457a">false</dei:AmendmentFlag>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDkvZnJhZzphMWI3YmRiZGMwOWM0NDZkODg4ZGNlZTJlODAwZTdmYS90ZXh0cmVnaW9uOmExYjdiZGJkYzA5YzQ0NmQ4ODhkY2VlMmU4MDBlN2ZhXzkzNDU4NDg4MzYxNzE_3abe204f-2ab3-4a36-a712-176a29c29383"
      unitRef="rate">0.0151172</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDkvZnJhZzphMWI3YmRiZGMwOWM0NDZkODg4ZGNlZTJlODAwZTdmYS90ZXh0cmVnaW9uOmExYjdiZGJkYzA5YzQ0NmQ4ODhkY2VlMmU4MDBlN2ZhXzMz_86d6751e-70e8-4d23-a1f1-365b34121927"
      unitRef="rate">0.0275198</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV84NA_3b14177c-437e-486e-9bfc-3324d9cd8a69">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6NjQyNDQ3MTlhMzBhNGFhYTk2NWZkNjU4YTFhZThkMjgvdGFibGVyYW5nZTo2NDI0NDcxOWEzMGE0YWFhOTY1ZmQ2NThhMWFlOGQyOF8wLTAtMS0xLTMwNTcy_c135a572-3c08-4ac5-b4d3-5b9673953dec">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8xNjQ5MjY3NDQ1NTIy_f4c62f32-ae18-4ca5-a0be-d62a514031e4">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8xNjQ5MjY3NDQ1NTIy_ddf6511c-72ab-418e-8066-6bade8e3e507">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6MzBlYzJiNGFiYzc1NDk4NTg4YmU4MzEyNmZlNzEzZWYvdGFibGVyYW5nZTozMGVjMmI0YWJjNzU0OTg1ODhiZTgzMTI2ZmU3MTNlZl8wLTAtMS0xLTMwNTcy_6ea81aa3-9726-40ce-bf64-ff7576aad72c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yMDY_7f63959a-37bf-443c-9a9d-2260c63afd12">001-35756</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yMTE_78d20d25-0824-4113-84d4-4b455ae816a1">NEOGENOMICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YWExZDg0NTFlZDcxNGNlZmE5OGY3ZGU5N2Q3NTI2NDYvdGFibGVyYW5nZTphYTFkODQ1MWVkNzE0Y2VmYTk4ZjdkZTk3ZDc1MjY0Nl8wLTAtMS0xLTMwNTcy_a0546f9f-3442-4a57-b1ae-d5482c03f872">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YWExZDg0NTFlZDcxNGNlZmE5OGY3ZGU5N2Q3NTI2NDYvdGFibGVyYW5nZTphYTFkODQ1MWVkNzE0Y2VmYTk4ZjdkZTk3ZDc1MjY0Nl8wLTItMS0xLTMwNTcy_ed6802fc-bf60-4af8-acdf-06a043fe85a7">74-2897368</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yNzQ_0aca73b0-7698-4458-a54a-e25e1725df9b">9490 NeoGenomics Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yODI_8f34a45b-7daa-4de8-ae3e-0ebf2faf5b46">Fort Myers</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yODY_66e88b67-1be8-4008-8e7e-afbc7ecb3fda">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yODk_4dd3caab-696e-4f9d-a3b6-a5577f147b21">33912</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8zNDM_709ec07d-bce0-4d58-bdd1-8afa495b288c">(239)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8zNDY_b08b9746-b138-4e26-8152-b24efe35d8e9">768-0600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6ZGNiMDdkOGU3MDdmNDZmMzk1Yzk4MGExZGEyZTRhYjcvdGFibGVyYW5nZTpkY2IwN2Q4ZTcwN2Y0NmYzOTVjOTgwYTFkYTJlNGFiN18xLTAtMS0xLTMwNTcy_7cbd30a8-ada5-4530-bdb5-3703a39d7a9c">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6ZGNiMDdkOGU3MDdmNDZmMzk1Yzk4MGExZGEyZTRhYjcvdGFibGVyYW5nZTpkY2IwN2Q4ZTcwN2Y0NmYzOTVjOTgwYTFkYTJlNGFiN18xLTItMS0xLTMwNTcy_91102c49-cf89-4dce-b8db-2d7ec50d7270">NEO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6ZGNiMDdkOGU3MDdmNDZmMzk1Yzk4MGExZGEyZTRhYjcvdGFibGVyYW5nZTpkY2IwN2Q4ZTcwN2Y0NmYzOTVjOTgwYTFkYTJlNGFiN18xLTQtMS0xLTMwNTcy_180000df-95ea-4ba7-b6a2-b5688af3356c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV82Mjc_a5a83d14-8a68-461d-abf7-1f74bc7b3d2f">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV83Nzc_2ffc1aa3-f6a9-4aae-a2ec-deb3fc4afbdc">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8xMTMy_8599e90b-c18d-40e0-bd91-8cdbbbee810f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8xNDYy_1c65f964-6648-4629-b83c-7acc25ea303f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YmU5ZmZlZjQ3ODE4NGQ0OTkxMDg5OWIzNjI1ZmE5YTAvdGFibGVyYW5nZTpiZTlmZmVmNDc4MTg0ZDQ5OTEwODk5YjM2MjVmYTlhMF8wLTAtMS0xLTMwNTcy_fb3f3b38-a82c-4f01-9ee8-21ac7d96cd4e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YmU5ZmZlZjQ3ODE4NGQ0OTkxMDg5OWIzNjI1ZmE5YTAvdGFibGVyYW5nZTpiZTlmZmVmNDc4MTg0ZDQ5OTEwODk5YjM2MjVmYTlhMF8xLTQtMS0xLTMwNTcy_5f1d4b26-160f-4d02-8ac5-14eaa364336f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGFibGU6YmU5ZmZlZjQ3ODE4NGQ0OTkxMDg5OWIzNjI1ZmE5YTAvdGFibGVyYW5nZTpiZTlmZmVmNDc4MTg0ZDQ5OTEwODk5YjM2MjVmYTlhMF8yLTQtMS0xLTMwNTcy_e9688f98-c271-40d6-b422-252c28f93850">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8zMDg2_35717111-9c72-433b-8809-2c2ddd29240e">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yNTQ3_6f151634-4478-40d0-a654-5bbace0bfbba">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i16bc87396d614913bb00f167e8f21276_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yNjgy_ad7a9f9f-4603-4dbe-af9e-6d90368c3391"
      unitRef="usd">4100000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i46c8412ab640433d99f2e270ea75b9ff_I20220221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8yODc4_69e914cd-085b-481b-bf1d-3237ab031673"
      unitRef="shares">124025766</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xL2ZyYWc6OGYyNzQwODZhODA4NDExODk4MDFmNzM3Mjc0NGJiMWUvdGV4dHJlZ2lvbjo4ZjI3NDA4NmE4MDg0MTE4OTgwMWY3MzcyNzQ0YmIxZV8zMDg4_420766c4-18e3-414d-996c-5110fa0a6d0b">Portions of the registrant&#x2019;s Proxy Statement for its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV81NS9mcmFnOjIxZGQxM2U2Y2VhZjRhOTZiMzc3NGQxM2ZmYzYwNTg0L3RhYmxlOmY2NWMxNjFmNzhiNzRhODE4NzQ4ODk4MzYwYTQyMmQxL3RhYmxlcmFuZ2U6ZjY1YzE2MWY3OGI3NGE4MTg3NDg4OTgzNjBhNDIyZDFfMi0wLTEtMS03NzUyMi90ZXh0cmVnaW9uOjdkYzkyY2U5YjdiNjQyMWFiZjc2ZDUzYzAwNDdjNjVmXzE2NDkyNjc0NDI0Mzg_d3da63ce-adbc-49dc-81f4-4f2999608750">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV81NS9mcmFnOjIxZGQxM2U2Y2VhZjRhOTZiMzc3NGQxM2ZmYzYwNTg0L3RhYmxlOmY2NWMxNjFmNzhiNzRhODE4NzQ4ODk4MzYwYTQyMmQxL3RhYmxlcmFuZ2U6ZjY1YzE2MWY3OGI3NGE4MTg3NDg4OTgzNjBhNDIyZDFfMi0wLTEtMS03NzUyMi90ZXh0cmVnaW9uOjdkYzkyY2U5YjdiNjQyMWFiZjc2ZDUzYzAwNDdjNjVmXzE2NDkyNjc0NDIzNjY_ff819ee5-055b-4e2b-9612-2f847f98e761">34</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV81OC9mcmFnOjI5Y2U0ZjY5MDFlMTRiNWViNWM5NmNhNzY4OTJiOGM5L3RleHRyZWdpb246MjljZTRmNjkwMWUxNGI1ZWI1Yzk2Y2E3Njg5MmI4YzlfMTY0OTI2NzQ1ODM3Mg_5eeff2ec-8a1c-4ed0-ad5e-97d5add0e4c4">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNC0xLTEtMS0zMDU3Mg_40fcad2b-4dd6-465c-903e-acd6afbb5942"
      unitRef="usd">316827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNC0zLTEtMS0zMDU3Mg_e5fc6d04-8a58-48f3-9069-cc74ac81c53b"
      unitRef="usd">228713000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNS0xLTEtMS0zMDU3Mg_e8b9d36a-5832-44e4-b512-1936665fbe34"
      unitRef="usd">198563000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNS0zLTEtMS0zMDU3Mg_affc5ebf-6cc0-4583-b596-d893de5435ba"
      unitRef="usd">67546000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNi0xLTEtMS0zMDU3Mg_eedadbf8-49ef-4867-9ce8-5d406ad84daa"
      unitRef="usd">112130000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNi0zLTEtMS0zMDU3Mg_d60068fe-a2d9-4bc0-bce4-986395769875"
      unitRef="usd">106843000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNy0xLTEtMS0zMDU3Mg_6be9a3b0-0662-4191-806d-b1d7863b404a"
      unitRef="usd">23395000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNy0zLTEtMS0zMDU3Mg_cf10cacc-fe34-4183-bd4a-d6b6f94f3877"
      unitRef="usd">29526000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOC0xLTEtMS0zMDU3Mg_5c423e6d-38d8-48ec-89d8-ff724e7e6034"
      unitRef="usd">12354000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOC0zLTEtMS0zMDU3Mg_f247620a-e623-45b0-8318-a0be2bb40ae3"
      unitRef="usd">11547000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOS0xLTEtMS00MDg4OQ_56d8d31e-7bd2-4652-bc9a-922277f982d1"
      unitRef="usd">10050000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOS0zLTEtMS00MDg4OQ_44b5de32-fbbe-4781-b6d1-d6e842031a78"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOS0xLTEtMS0zMDU3Mg_31b98ac2-ec4b-46b1-b05d-06d739efdc76"
      unitRef="usd">8189000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfOS0zLTEtMS0zMDU3Mg_749787eb-c66a-4f72-9c01-39153dcb602b"
      unitRef="usd">4555000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTAtMS0xLTEtMzA1NzI_3f679ec7-d363-484f-a731-1d5afc2a95cd"
      unitRef="usd">681508000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTAtMy0xLTEtMzA1NzI_8672e59e-465d-4cdc-9a58-8eedc50c46e7"
      unitRef="usd">448730000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjpiNjk4MTQwMzk3OTU0NzhhYjBjMjNhZDY5NTE1MTg1Y18yMTk5MDIzMjU1NjU4_7322545a-9505-4d03-b601-765d45a32031"
      unitRef="usd">109952000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjpiNjk4MTQwMzk3OTU0NzhhYjBjMjNhZDY5NTE1MTg1Y18yMTk5MDIzMjU1Njgx_08fe9643-49c5-4e6b-82ec-76171c0f4601"
      unitRef="usd">92895000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTEtMS0xLTEtMzA1NzI_b43614c7-554f-4067-8ffb-426c04d1915e"
      unitRef="usd">109465000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTEtMy0xLTEtMzA1NzI_b64d3e6f-9e38-4ca3-a6ba-30b57ad3d920"
      unitRef="usd">85873000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTItMS0xLTEtMzA1NzI_d475b38b-c54e-4653-b457-9973ec9eb1ad"
      unitRef="usd">102197000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTItMy0xLTEtMzA1NzI_380361d1-0487-42ba-bef7-60b63641a0e9"
      unitRef="usd">45786000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTMtMS0xLTEtMzA1NzI_834db1c9-d1cd-4660-a013-84cd024e109d"
      unitRef="usd">442325000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTMtMy0xLTEtMzA1NzI_f3d2647c-089a-4212-9df3-8cef84589ab7"
      unitRef="usd">120653000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTQtMS0xLTEtMzA1NzI_c831c70a-83e1-4157-a51e-796a09c7492b"
      unitRef="usd">527115000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTQtMy0xLTEtMzA1NzI_b979dd14-0ecf-44e7-ba95-7ea37e83cead"
      unitRef="usd">211083000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTUtMS0xLTEtMzA1NzI_ff185f29-cad1-44da-a489-94e8fffd0467"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTUtMy0xLTEtMzA1NzI_aa4e4b6e-3c61-47f0-9af4-6ccaf6297d96"
      unitRef="usd">21919000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTctMS0xLTEtNDc2Mzg_d41c2aee-4129-41a8-8526-9f4f4fde2852"
      unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTctMy0xLTEtNDc2Mzg_4e50d9d4-1f38-46fe-9eb3-5c1685a73072"
      unitRef="usd">29555000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <neo:PrepaidRentNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTYtMS0xLTEtMzA1NzI_6e00af3f-5833-4741-ad39-55a6f1032db5"
      unitRef="usd">0</neo:PrepaidRentNoncurrent>
    <neo:PrepaidRentNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTYtMy0xLTEtMzA1NzI_61af4a64-6fcb-4f3c-ae84-ce9764196594"
      unitRef="usd">20229000</neo:PrepaidRentNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTgtMS0xLTEtMzA1NzI_7182d8e9-2044-4b69-9a43-8ee900c2b7fd"
      unitRef="usd">7168000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTgtMy0xLTEtMzA1NzI_d501d413-86ea-4914-8201-c2fbad2ed8de"
      unitRef="usd">4503000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTktMS0xLTEtMzA1NzI_6c5ca8f3-1435-4cf2-9d38-7b0b8d9b07c8"
      unitRef="usd">1188270000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMTktMy0xLTEtMzA1NzI_29471560-0d9f-4535-8b9b-212f9c326a82"
      unitRef="usd">539601000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjAtMS0xLTEtMzA1NzI_35e6ddcd-652d-4ba8-b64c-7c5474985859"
      unitRef="usd">1869778000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjAtMy0xLTEtMzA1NzI_9bda9206-a281-4741-8e9d-e9cea140deb5"
      unitRef="usd">988331000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjMtMS0xLTEtMzA1NzI_850f6a17-bd37-464d-b4f9-671201377f1c"
      unitRef="usd">17921000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjMtMy0xLTEtMzA1NzI_2f883586-f58d-47c3-89d0-f843217fef1c"
      unitRef="usd">24965000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjQtMS0xLTEtMzA1NzI_7345fa04-df2f-4b46-a890-d8180afc3068"
      unitRef="usd">38304000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjQtMy0xLTEtMzA1NzI_271f12b8-1e91-46b5-aa54-4b87b9a76112"
      unitRef="usd">24727000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjUtMS0xLTEtMzA1NzI_2637aebb-5ac9-43e9-af6c-021f0028e888"
      unitRef="usd">17796000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjUtMy0xLTEtMzA1NzI_9b4e7e22-ea77-4c50-9d09-c85bcaf588f6"
      unitRef="usd">11654000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjYtMS0xLTEtMzA1NzI_72d8f26c-ab9d-4cf5-a53f-eb58c4a2cb6c"
      unitRef="usd">1135000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjYtMy0xLTEtMzA1NzI_516679cf-df69-4fbb-b4ad-5d3a3c012dd9"
      unitRef="usd">2841000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjctMS0xLTEtMzA1NzI_8324b0b5-884c-41b9-81a1-15d61b5c22de"
      unitRef="usd">6884000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjctMy0xLTEtMzA1NzI_d85d17c1-e3f2-4931-a5ce-73820b0c14df"
      unitRef="usd">4967000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjktMS0xLTEtMzA1NzI_a101fcea-1910-4e9c-936e-1592d579de5a"
      unitRef="usd">5192000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMjktMy0xLTEtMzA1NzI_b7f3259d-e80d-406c-bf39-5e70f87ad0a3"
      unitRef="usd">4029000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzAtMS0xLTEtMzA1NzI_e89c27f2-2543-439e-82da-5c4e8448bcc4"
      unitRef="usd">87232000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzAtMy0xLTEtMzA1NzI_eb428583-15b6-4ee6-9f98-a15c467f1d4d"
      unitRef="usd">73183000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzItMS0xLTEtMzA1NzI_899a11ac-c0a3-46c6-a54f-cc6488f9caad"
      unitRef="usd">532483000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzItMy0xLTEtMzA1NzI_935379b5-c581-4d91-8686-25499e2ab753"
      unitRef="usd">168120000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzMtMS0xLTEtMzA1NzI_e2acf1d1-dbac-4217-aefb-c77295b986eb"
      unitRef="usd">71000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzMtMy0xLTEtMzA1NzI_9ec8432e-ca6b-4f91-9b75-fb95088bd42f"
      unitRef="usd">967000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzQtMS0xLTEtMzA1NzI_1eea9e20-4fa5-4369-b5b5-bee6d59d4870"
      unitRef="usd">72289000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzQtMy0xLTEtMzA1NzI_854106b3-86c9-436c-b234-e4a3ebeed02e"
      unitRef="usd">42296000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzYtMS0xLTEtMzA1NzI_8747a71f-5a39-4083-9ff7-a60c151fb590"
      unitRef="usd">55475000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzYtMy0xLTEtMzA1NzI_fe4a1a9e-0e77-430f-8b39-1ea471de92d9"
      unitRef="usd">5415000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzctMS0xLTEtMzA1NzI_9cbcb6f0-d769-4ccf-beb0-c4805a8377e6"
      unitRef="usd">13951000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzctMy0xLTEtMzA1NzI_6fc1eeac-6581-4252-a9ef-e43f367ae017"
      unitRef="usd">4056000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzgtMS0xLTEtMzA1NzI_9ade6f64-8c12-401e-bb02-dadde889a0c5"
      unitRef="usd">674269000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzgtMy0xLTEtMzA1NzI_6917ef04-edd8-4362-9b82-07a3c618a2e8"
      unitRef="usd">220854000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzktMS0xLTEtMzA1NzI_b6f7ca60-5557-4416-92f3-dffd619e6a09"
      unitRef="usd">761501000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzktMy0xLTEtMzA1NzI_5d77d574-8ac8-4dc9-9119-4cbdac5e9a7f"
      unitRef="usd">294037000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzktMS0xLTEtNzc0Nzk_cfe9a0fb-0af8-4e99-942b-8d214dd47e4b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfMzktMy0xLTEtNzc0ODE_0883dfb7-a228-4988-82fe-ef531cef7cb0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV8xOA_4addb2dc-dfde-4300-a13b-c50a41b16136"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV8xOA_bfaca6e4-f148-448c-ab8d-d7271e4cc38c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV8zMw_7927d83f-6fab-43c4-85f7-57e9187aa44c"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV8zMw_942f7489-ca75-4ef0-999c-03e627402aab"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV81NQ_6b9cd9fe-5bdc-447c-87fd-4b447124376d"
      unitRef="shares">124107500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV81NQ_6f0b8999-3e7d-4387-bb3d-2b44cd51b3c3"
      unitRef="shares">124107500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV82Mg_7f0ffc17-9ca6-4c69-adef-b42caeedefcb"
      unitRef="shares">112075474</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5NzJiOWI3MjViZDk0MThlOGFhMWQzYjA5MWI3NzhmMV82Mg_85d4f6ec-4bf9-43c7-ba19-4bb6d9965361"
      unitRef="shares">112075474</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMS0xLTEtMzA1NzI_afd19707-24bc-4c76-8eb7-ec2a1e9bd2e5"
      unitRef="usd">124000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDEtMy0xLTEtMzA1NzI_2fc2afc6-e80d-4521-983c-5786227dbef4"
      unitRef="usd">112000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDItMS0xLTEtMzA1NzI_c5b1ebfa-ca21-4557-a2ce-bef4392796f7"
      unitRef="usd">1123628000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDItMy0xLTEtMzA1NzI_b8ec7742-e991-40ad-8eea-6de3e7aac717"
      unitRef="usd">701357000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDMtMS0xLTEtMzA1NzI_bab77008-e581-4307-9e25-cf154dc76ffd"
      unitRef="usd">-638000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDMtMy0xLTEtMzA1NzI_d1f9eefa-03a5-4407-b8d2-ce2584f761bc"
      unitRef="usd">10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDQtMS0xLTEtMzA1NzI_d22d52a5-09b3-4870-bc9f-dee47bbb5f31"
      unitRef="usd">-14837000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDQtMy0xLTEtMzA1NzI_42c10169-a191-4be0-a9fa-10c815bc759d"
      unitRef="usd">-7185000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDUtMS0xLTEtMzA1NzI_e643cc03-bff7-4fd9-8b03-ac6511e5992a"
      unitRef="usd">1108277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDUtMy0xLTEtMzA1NzI_162cdd3b-459f-4e0d-a4e6-bab66259509b"
      unitRef="usd">694294000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDYtMS0xLTEtMzA1NzI_ef727e31-49aa-4700-a83f-53d5aa643765"
      unitRef="usd">1869778000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82NC9mcmFnOjE1YTg0MDBiZGQ2MDQ3NGQ4NTZiMDdlYWIyYjAxMTliL3RhYmxlOjM2ZDgwZDk1ZjI5MDQyYmFiYTMwNDgzZTAyYzg1Nzc4L3RhYmxlcmFuZ2U6MzZkODBkOTVmMjkwNDJiYWJhMzA0ODNlMDJjODU3NzhfNDYtMy0xLTEtMzA1NzI_44fa145e-6a37-4b7f-8cfe-52e83a53b46c"
      unitRef="usd">988331000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i70ebc9da32df40f79360ad5da5aef714_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMy0xLTEtMS0zMDU3Mg_8fab6d18-f2a6-46d2-a9ad-69a16e6991ef"
      unitRef="usd">404172000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i79d415270f85409cb33c97966be628d9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMy0zLTEtMS0zMDU3Mg_bfaf55ff-0311-47f7-98f5-233b608d570a"
      unitRef="usd">382337000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9b900d497a954a51b916af633f093d2d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMy01LTEtMS0zMDU3Mg_65549b50-ac61-4f4d-af05-eb7e33e06e55"
      unitRef="usd">361161000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i81e7e38bca0a483382014babf710343a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNC0xLTEtMS0zMDU3Mg_0d841b9b-0ebd-4160-9854-69f75cbfe547"
      unitRef="usd">80157000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9d041f360e72469b85c9fb255e34af5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNC0zLTEtMS0zMDU3Mg_2ba7bce0-b4cb-457e-afb5-444ced712ebe"
      unitRef="usd">62111000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id4187c911d534ee0a8aa9f97ffb938b1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNC01LTEtMS0zMDU3Mg_ed91c185-7d55-4e29-8ea9-de765b1b2961"
      unitRef="usd">47669000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNS0xLTEtMS0zMDU3Mg_d8f328a3-0047-42e2-8fb0-ed3d4dfbb20e"
      unitRef="usd">484329000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNS0zLTEtMS0zMDU3Mg_eb0a08dd-e541-4b74-8a3b-8948eb115e13"
      unitRef="usd">444448000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNS01LTEtMS0zMDU3Mg_832329a8-f9d0-4acd-abf6-e1a11f8cf79e"
      unitRef="usd">408830000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNy0xLTEtMS0zMDU3Mg_005eb7dd-1733-435b-ae3d-6e9471c4906a"
      unitRef="usd">297269000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNy0zLTEtMS0zMDU3Mg_8bc3f444-603c-49df-ba03-a40a3ac53ca0"
      unitRef="usd">258555000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfNy01LTEtMS0zMDU3Mg_3904072b-56b4-4430-8a4c-7e206c02de68"
      unitRef="usd">211994000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfOS0xLTEtMS0zMDU3Mg_d842ea56-c414-4b10-bffd-b5ae70c83c9d"
      unitRef="usd">187060000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfOS0zLTEtMS0zMDU3Mg_4cf89ac4-abd0-48de-9ca5-82feab4250f6"
      unitRef="usd">185893000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfOS01LTEtMS0zMDU3Mg_00634ebe-6733-457e-99b1-8989698413a3"
      unitRef="usd">196836000</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTEtMS0xLTEtMzA1NzI_93637123-6e4d-49bf-8ca1-e86d2c2550b5"
      unitRef="usd">221347000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTEtMy0xLTEtMzA1NzI_9bc3b184-56a3-48de-989e-6b22eb8ac139"
      unitRef="usd">143794000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTEtNS0xLTEtMzA1NzI_12a887e7-2b6c-4292-bb1a-a1328fa890b7"
      unitRef="usd">127993000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTItMS0xLTEtMzA1NzI_ad5db4ed-fc96-48e7-8387-dbb8cc12acee"
      unitRef="usd">21873000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTItMy0xLTEtMzA1NzI_ceaea8cc-8466-41ef-bbdc-4fa9175a3b29"
      unitRef="usd">8229000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTItNS0xLTEtMzA1NzI_1e18f228-107d-48b0-b467-c4f5fcc04057"
      unitRef="usd">8487000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTMtMS0xLTEtMzA1NzI_a43833ce-1727-4470-9bbf-3705b998e7f7"
      unitRef="usd">62594000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTMtMy0xLTEtMzA1NzI_46771ccf-f826-4eec-8777-ee12079c7d67"
      unitRef="usd">47862000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTMtNS0xLTEtMzA1NzI_3d960a1b-9b77-4f84-8d58-ab21436d2e4c"
      unitRef="usd">47350000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OperatingExpenses
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTQtMS0xLTEtMzA1NzI_10be26eb-09b6-4fec-a784-a3ce76b301cb"
      unitRef="usd">305814000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTQtMy0xLTEtMzA1NzI_77d99c6d-0c79-4403-9800-908b52b29412"
      unitRef="usd">199885000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTQtNS0xLTEtMzA1NzI_3174eb12-9ea6-4029-b509-4e196c71d347"
      unitRef="usd">183830000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTUtMS0xLTEtMzA1NzI_98ec2464-6282-4cf4-89a7-77177febefeb"
      unitRef="usd">-118754000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTUtMy0xLTEtMzA1NzI_32d0f3d5-831c-4874-8212-8005bd630e49"
      unitRef="usd">-13992000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTUtNS0xLTEtMzA1NzI_30023162-a00e-440e-ab7a-39dfab22f022"
      unitRef="usd">13006000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTYtMS0xLTEtMzA1NzI_7df35995-03cb-41bc-baff-12c47ff47371"
      unitRef="usd">5082000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTYtMy0xLTEtMzA1NzI_2e58f105-9fae-416f-a1b4-2630ae2d5261"
      unitRef="usd">7019000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTYtNS0xLTEtMzA1NzI_74c4573b-9807-44d4-bc0f-ff4f27d7b10b"
      unitRef="usd">3713000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTctMS0xLTEtMzA1NzI_2ab09a54-e621-4d35-91e3-68dc80a05014"
      unitRef="usd">-499000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTctMy0xLTEtMzA1NzI_426375d7-f1d5-4da4-af8e-5edd3ffd244b"
      unitRef="usd">7906000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTctNS0xLTEtMzA1NzI_32e2ae9a-c76c-4a9d-bf00-00224425a0d1"
      unitRef="usd">-4630000</us-gaap:OtherNonoperatingIncomeExpense>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtMS0xLTEtNTA4NzE_914b1a7d-c2b9-46f6-9b42-fcfbd1a2990b"
      unitRef="usd">109260000</neo:GainLossOnInvestmentAndLoanReceivable>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtMy0xLTEtNTA4Nzk_32b8429f-6b0a-4d2d-9c76-72217bca3c37"
      unitRef="usd">3955000</neo:GainLossOnInvestmentAndLoanReceivable>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtNS0xLTEtNTA4OTQ_6481a8c1-d047-496e-9252-7c66fd3dbdc1"
      unitRef="usd">0</neo:GainLossOnInvestmentAndLoanReceivable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtMS0xLTEtMzA1NzI_785215b4-dff6-43e5-be64-a0d7436167c6"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtMy0xLTEtMzA1NzI_a600d601-25bd-43d4-b1bb-edb76dcbd780"
      unitRef="usd">-1400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTgtNS0xLTEtMzA1NzI_fbefaf75-30a3-4c77-8b84-da1677ae5e72"
      unitRef="usd">-1018000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <neo:GainLossOnTerminationOfInterestRateSwap
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTktMS0xLTEtMzA1NzI_cba57844-9458-41ff-9a5f-192465ee9963"
      unitRef="usd">0</neo:GainLossOnTerminationOfInterestRateSwap>
    <neo:GainLossOnTerminationOfInterestRateSwap
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTktMy0xLTEtMzA1NzI_723c8e74-bd9a-422f-a059-da573395e40c"
      unitRef="usd">-3506000</neo:GainLossOnTerminationOfInterestRateSwap>
    <neo:GainLossOnTerminationOfInterestRateSwap
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMTktNS0xLTEtMzA1NzI_35040701-04b8-48d3-80b7-ab66896f2e92"
      unitRef="usd">0</neo:GainLossOnTerminationOfInterestRateSwap>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjAtMS0xLTEtMzA1NzI_f568677a-d773-4d41-8d6b-3efaddc64f10"
      unitRef="usd">-15075000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjAtMy0xLTEtMzA1NzI_cd1249a0-0e10-4e64-a79a-cd70c03e30ca"
      unitRef="usd">-14056000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjAtNS0xLTEtMzA1NzI_c8d6acb9-8ade-4100-aa59-ff33cb422ca1"
      unitRef="usd">3645000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjEtMS0xLTEtMzA1NzI_18c6a1fc-1d11-4845-99ab-2ce37cba686e"
      unitRef="usd">-6728000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjEtMy0xLTEtMzA1NzI_e099c199-f40f-444b-a0de-9394845d900a"
      unitRef="usd">-18228000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjEtNS0xLTEtMzA1NzI_e52cc0b4-a8f6-4114-a77a-c1f5e5fc6f05"
      unitRef="usd">-4361000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjItMS0xLTEtMzA1NzI_e4d6b368-80f3-42a5-b00e-3be40a7acbfe"
      unitRef="usd">-8347000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjItMy0xLTEtMzA1NzI_64df1ef4-a5a9-4fd8-a0f2-b5767e70cbd2"
      unitRef="usd">4172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMjItNS0xLTEtMzA1NzI_f7f92092-9cae-4e49-afc8-43c4ea640902"
      unitRef="usd">8006000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzMtMS0xLTEtMzA1NzI_8c6f5aeb-2914-46c4-b00b-b1d6724a87fc"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzMtMy0xLTEtMzA1NzI_09c157bc-b377-4a0e-b493-50103e5a86fd"
      unitRef="usdPerShare">0.04</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzMtNS0xLTEtMzA1NzI_04b0ba43-1514-4e42-a0a0-585f91e792f5"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzQtMS0xLTEtMzA1NzI_56cf0e92-1501-470b-af08-fd863c511319"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzQtMy0xLTEtMzA1NzI_74441f65-fa00-431c-b72a-2255e52f7b68"
      unitRef="usdPerShare">0.04</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzQtNS0xLTEtMzA1NzI_fd7e62f0-b3e0-474a-8166-e99e03c55553"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzctMS0xLTEtMzA1NzI_592f56e1-b2e5-46c9-bd4f-16eb4b723585"
      unitRef="shares">119962000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzctMy0xLTEtMzA1NzI_62d78830-029d-49a1-9d87-005db5f9a68c"
      unitRef="shares">108579000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzctNS0xLTEtMzA1NzI_a117d89a-10f5-4d1f-9439-f11eefda93f1"
      unitRef="shares">100470000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzgtMS0xLTEtMzA1NzI_6bda4676-f997-4261-8c56-eff09779b2f6"
      unitRef="shares">119962000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzgtMy0xLTEtMzA1NzI_ae986b8a-2050-4475-80c2-5572f120a8c9"
      unitRef="shares">111794000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV82Ny9mcmFnOjAyNTI1ZGIxNzZhMzRkZGI4OWE0ZjE1MTM0ZDVhMjRiL3RhYmxlOmJhZjg0YjcyY2UzMzQ5ODliMzQ4YjIzMTQ4NWE5ZWUzL3RhYmxlcmFuZ2U6YmFmODRiNzJjZTMzNDk4OWIzNDhiMjMxNDg1YTllZTNfMzgtNS0xLTEtMzA1NzI_4d194ca0-3ccb-4c17-87a2-03a81bfe10b6"
      unitRef="shares">103615000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMi0xLTEtMS0zMDU3Mg_c9d32abe-2c58-4b0c-996b-bf938a27aac4"
      unitRef="usd">-8347000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMi0zLTEtMS0zMDU3Mg_d58023f1-18e0-429c-9df0-e19c9bdd1bb7"
      unitRef="usd">4172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMi01LTEtMS0zMDU3Mg_196bc182-139e-412d-803b-eb795bb918b6"
      unitRef="usd">8006000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNS0xLTEtMS0zMDU3Mg_b3c08451-1075-48ed-987e-087fcf36cd91"
      unitRef="usd">-648000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNS0zLTEtMS0zMDU3Mg_346cfa36-37da-42a6-bc56-8b0cda78000a"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNS01LTEtMS0zMDU3Mg_97a6e77e-1a34-48f5-82b3-be6ab11fcede"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNi0xLTEtMS0zMDU3Mg_6b784425-1300-4aa0-9494-6e428caa4e58"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNi0zLTEtMS0zMDU3Mg_a0608759-daef-4582-8c4f-394917157edf"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfNi01LTEtMS0zMDU3Mg_cf01fac0-a4c7-4ece-bd25-32cc039627b8"
      unitRef="usd">-1039000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOC0xLTEtMS0zMDU3Mg_2e4fabd3-27c5-4e76-87dd-4c05798f301c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOC0zLTEtMS0zMDU3Mg_c5021104-e56d-4770-9b1f-6397e058dac6"
      unitRef="usd">-2661000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOC01LTEtMS0zMDU3Mg_665f8ba7-e414-4a54-b3aa-7a29c0cdd747"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOS0xLTEtMS0zMDU3Mg_93eda72c-6946-40d1-95d3-c65b4a181799"
      unitRef="usd">-648000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOS0zLTEtMS0zMDU3Mg_5f8b1e22-201d-4eef-979e-ce0431bf9580"
      unitRef="usd">1628000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfOS01LTEtMS0zMDU3Mg_4a79e566-0ace-4e42-9ca0-8276eb59eb9c"
      unitRef="usd">-1039000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMTAtMS0xLTEtMzA1NzI_a8896ff4-183b-48a2-8d82-48d9c973f9b1"
      unitRef="usd">-8995000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMTAtMy0xLTEtMzA1NzI_e5879a28-eb43-486d-a213-53809a02f516"
      unitRef="usd">5800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83MC9mcmFnOjUyY2M5OGI0MGNlODQ1MGRhMjk5YzlhNmVkMDMwZmI2L3RhYmxlOjY0YmIxMzUwNzNjMTRiYTY4YmVkMzEzMzAyYzk4ZjlkL3RhYmxlcmFuZ2U6NjRiYjEzNTA3M2MxNGJhNjhiZWQzMTMzMDJjOThmOWRfMTAtNS0xLTEtMzA1NzI_3aa11aea-5681-4d7a-a8da-c2b437c2e006"
      unitRef="usd">6967000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i7fa4741509064ec490975a24aa59cd1f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtNi0xLTEtMzA1NzI_e8bd32ba-aa54-46db-93c4-a52575a03a24"
      unitRef="shares">94465440</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7fa4741509064ec490975a24aa59cd1f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtOC0xLTEtMzA1NzI_8ab5396e-d121-4a9f-a57e-65819a6881f0"
      unitRef="usd">94000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie78002a692994bf9a3d0e7bbfb10684e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtMTAtMS0xLTMwNTcy_b884b7d7-b8aa-4494-85ec-3e550de74cde"
      unitRef="usd">340291000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id547d59cc8974dcda13cff3fd0b89721_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtMTItMS0xLTMwNTcy_111efe5d-682d-42a5-876d-3859ef30882d"
      unitRef="usd">-579000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73a0530d49904cd080aff3e02d8c44dc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtMTQtMS0xLTMwNTcy_fa498221-2e35-4047-bacf-bee0399172bf"
      unitRef="usd">-19363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTgtMTYtMS0xLTMwNTcy_9aacb1fb-8f4d-43b8-8aa3-880bdfcb641e"
      unitRef="usd">320443000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTktNi0xLTEtMzA1NzI_6c7db819-ff53-404f-b053-8665ab5ee54b"
      unitRef="shares">141908</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTktMTAtMS0xLTMwNTcy_615bca09-d173-4387-83e5-d216e02e5b8a"
      unitRef="usd">2332000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMTktMTYtMS0xLTMwNTcy_aba33fe7-8017-43d1-95c9-6ce624f7c774"
      unitRef="usd">2332000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjMtNi0xLTEtMzA1NzI_009dd1b5-8b6c-465c-a960-1665b646b016"
      unitRef="shares">168501</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjMtMTAtMS0xLTMwNTcy_9c11d46b-b0ff-4677-a983-39741d67aff3"
      unitRef="usd">-837000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjMtMTYtMS0xLTMwNTcy_3d71b455-6bde-4de3-8e9b-23437fb9a6c1"
      unitRef="usd">-837000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjYtNi0xLTEtMzA1NzI_d8c17b5f-f48a-4c0a-a32c-dde992a924f8"
      unitRef="shares">2054911</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjYtOC0xLTEtMzA1NzI_98417077-4043-4252-9f6f-b731adf97240"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjYtMTAtMS0xLTMwNTcy_6ad96d4d-23a0-4c86-a15d-e3be4a9396d6"
      unitRef="usd">9971000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjYtMTYtMS0xLTMwNTcy_1b193133-447f-411f-b89a-f90345c703ba"
      unitRef="usd">9974000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjUtNi0xLTEtMzA1NzI_15b9d1a1-b8b5-4888-9fe2-d826bd6b5137"
      unitRef="shares">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjUtOC0xLTEtMzA1NzI_d9c35ff9-4a83-42c7-aca8-d1e85292204b"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjUtMTAtMS0xLTMwNTcy_8ac09c09-47d1-4e5c-b5ef-ac18fb10f168"
      unitRef="usd">160766000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjUtMTYtMS0xLTMwNTcy_35b9c9e0-3168-48db-828e-7c2f02d6546f"
      unitRef="usd">160774000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <neo:WorkingCapitalAdjustmentAcquisitionShares
      contextRef="i44adf6073142485195d6ddd3b89f9a8c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjQtNi0xLTEtMzA1NzI_cd1a0bad-d57e-4012-b817-39bf3aa877c1"
      unitRef="shares">99524</neo:WorkingCapitalAdjustmentAcquisitionShares>
    <neo:WorkingCapitalAdjustmentAcquisitions
      contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjQtMTAtMS0xLTMwNTcy_9c3e9f49-12fd-4d27-af49-bbca216e0f88"
      unitRef="usd">1977000</neo:WorkingCapitalAdjustmentAcquisitions>
    <neo:WorkingCapitalAdjustmentAcquisitions
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjQtMTYtMS0xLTMwNTcy_0f00128d-704a-44cd-9ec2-39500d465c40"
      unitRef="usd">1977000</neo:WorkingCapitalAdjustmentAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjAtMTAtMS0xLTMwNTcy_8f6e0497-4d16-46e6-812b-8b34443bc4cc"
      unitRef="usd">263000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjAtMTYtMS0xLTMwNTcy_d61525c4-eef0-4528-a52c-502b171af1a5"
      unitRef="usd">263000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjctMTAtMS0xLTMwNTcy_8e15a733-9786-4b73-b091-5010214026dc"
      unitRef="usd">609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjctMTYtMS0xLTMwNTcy_f8eabf50-d7d9-4d4b-b7fa-707ceb702bf1"
      unitRef="usd">609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i298f0c22f01f4bedba53f5dd55be36cc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjgtMTAtMS0xLTMwNTcy_141f9101-e0b5-468b-aa17-d4e3b85fac75"
      unitRef="usd">9386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjgtMTYtMS0xLTMwNTcy_0d6e37c8-cf09-496b-953f-43ce2f69bb29"
      unitRef="usd">9386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ib8efe0d97fc1406cb5ef0d9c377ce77d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjItMTItMS0xLTMwNTcy_9ed9029c-b9d5-4e93-8ba1-ef14ef28604f"
      unitRef="usd">-1039000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjItMTYtMS0xLTMwNTcy_8c67202d-dc15-43e2-b7d6-fba6aa96e007"
      unitRef="usd">-1039000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:NetIncomeLoss
      contextRef="i09eaaff3cf3e4c139b248da5aa23a90d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTQtMS0xLTMwNTcy_4860e2fb-11d5-43cc-a3eb-5a9bfae07e2d"
      unitRef="usd">8006000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTYtMS0xLTMwNTcy_08037828-0ecc-46a1-82f6-a707e71afc2b"
      unitRef="usd">8006000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iff84eeb2c41c49b5bfd127f0c4245c57_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtNi0xLTEtMzA1NzI_91eeef8d-ed02-40ea-b56a-487582ce1607"
      unitRef="shares">104781236</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iff84eeb2c41c49b5bfd127f0c4245c57_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtOC0xLTEtMzA1NzI_933a8368-57ba-48ca-bd1a-ed8e99a3345e"
      unitRef="usd">105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84d2ab56c92948dfbdbcf7f735be5cea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTAtMS0xLTMwNTcy_6b3cbb73-10e5-4294-a57e-e4c8444c7f7a"
      unitRef="usd">520278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i688fe6bfb720405dbb35c980f41b1802_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTItMS0xLTMwNTcy_61418455-7c4c-4384-a9de-95a3be79273f"
      unitRef="usd">-1618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ecbb3fba22b4fce8d7cab8d90245383_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTQtMS0xLTMwNTcy_2a83e27f-ad3b-4c44-a59a-bc371d583dba"
      unitRef="usd">-11357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTYtMS0xLTMwNTcy_53770167-b3ed-448d-a004-0cf895b6dd0f"
      unitRef="usd">507408000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtNi0xLTEtMzA1NzI_910aa17e-215e-409f-b95b-709323ef6775"
      unitRef="shares">138309</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtMTAtMS0xLTMwNTcy_f225c5a5-dde1-4176-91fe-8423eb8aa628"
      unitRef="usd">3579000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtMTYtMS0xLTMwNTcy_33fe8805-1aa5-4a12-86af-9876067c4106"
      unitRef="usd">3579000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtNi0xLTEtMzA1NzI_897349d5-ed8f-43a1-ac72-7018e61cbefd"
      unitRef="shares">97478</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtMTAtMS0xLTMwNTcy_12764d0c-7c7a-4846-924a-28c7f7047735"
      unitRef="usd">-1276000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtMTYtMS0xLTMwNTcy_8562e33a-2ec2-4cba-a853-dbb9c67ab967"
      unitRef="usd">-1276000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktNi0xLTEtMzA1NzI_b41f1e19-e7f3-4faf-93e9-8cd7734917a0"
      unitRef="shares">2306951</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktOC0xLTEtMzA1NzI_f1c2b2d4-cd39-4707-8545-31d155917721"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktMTAtMS0xLTMwNTcy_3fd26d76-afad-4f8b-a2e3-e2e4235bcca0"
      unitRef="usd">18273000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktMTYtMS0xLTMwNTcy_e5ceadd1-021d-45ae-ac88-a49b27c510d4"
      unitRef="usd">18275000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtNi0xLTEtMzA1NzI_c50a6785-aa08-456b-a78a-fe5428acf717"
      unitRef="shares">4751500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie85ba41aeab04f21b497cb8665c6989b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtOC0xLTEtMzA1NzI_f9b00242-7647-4431-aa0c-21a596362cc6"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtMTAtMS0xLTMwNTcy_c7f5b5c3-62cb-484e-9430-33b5250fb9b7"
      unitRef="usd">127288000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtMTYtMS0xLTMwNTcy_306d32ec-2fa6-4527-a6f9-b2a931da714b"
      unitRef="usd">127293000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItMTAtMS0xLTMwNTcy_9f9a62fe-851b-4d40-b3be-e645988334c7"
      unitRef="usd">268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItMTYtMS0xLTMwNTcy_fddcf924-6c2e-4619-ac62-6fd7b13d40a6"
      unitRef="usd">268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDEtMTAtMS0xLTMwNTcy_c22bb3e9-8279-4c55-a743-e64e397cbbd4"
      unitRef="usd">875000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDEtMTYtMS0xLTMwNTcy_b3c88f87-7a00-4c6e-8aad-f2883ce615b6"
      unitRef="usd">875000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDItMTAtMS0xLTMwNTcy_7ad8db40-5e2c-4292-9704-b727b43aba03"
      unitRef="usd">9337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDItMTYtMS0xLTMwNTcy_c8b7dadb-30c2-4983-b045-325dd9f4c524"
      unitRef="usd">9337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTAtMS0xLTMwNTcy_c2855314-bec5-4012-8b08-9ebb0aef6296"
      unitRef="usd">30912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTYtMS0xLTMwNTcy_97d1d3e4-d793-41d8-acbc-7b102a5eff63"
      unitRef="usd">30912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <neo:AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDQtMTAtMS0xLTMwNTcy_338499b5-7cd0-4893-af5e-4eb3ad4fa8a0"
      unitRef="usd">-7504000</neo:AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment>
    <neo:AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDQtMTYtMS0xLTMwNTcy_4170821b-de52-4b19-a883-a51ce9cb4359"
      unitRef="usd">-7504000</neo:AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment>
    <neo:AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts
      contextRef="i92286c00f7f84b6f9feee29af41d8eb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDUtMTAtMS0xLTMwNTcy_26155a78-4b12-4ec1-bde8-4cd8f9763169"
      unitRef="usd">137000</neo:AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts>
    <neo:AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDUtMTYtMS0xLTMwNTcy_903bfa00-d8dc-4394-a89e-b55f180ac769"
      unitRef="usd">137000</neo:AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ie9052537da8546a7aa1dbd81390401be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtMTItMS0xLTMwNTcy_825f363b-a4e8-4d4e-890e-84510068199c"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtMTYtMS0xLTMwNTcy_c426e666-7455-487e-9602-e85c93309dbf"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <neo:OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination
      contextRef="ie9052537da8546a7aa1dbd81390401be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtMTItMS0xLTMwNTcy_7b4c6ab6-1319-43a4-a6b9-9b4a373d2246"
      unitRef="usd">-2661000</neo:OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination>
    <neo:OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtMTYtMS0xLTMwNTcy_b7512147-3a55-4b65-803e-d00becf79928"
      unitRef="usd">-2661000</neo:OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie9052537da8546a7aa1dbd81390401be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctMTItMS0xLTMwNTcy_0cf583c2-e763-4b09-80d2-c494ede0e444"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctMTYtMS0xLTMwNTcy_81e6bebb-e4e8-46c9-afd9-e295194abcce"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i5f9645b439ad4fc3b4c672c2c734a7e0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDYtMTQtMS0xLTMwNTcy_5f07c74d-b928-45c5-a391-9e1b3eb8f62e"
      unitRef="usd">4172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDYtMTYtMS0xLTMwNTcy_8fb2458e-e460-45d9-9b55-b93c3acb4813"
      unitRef="usd">4172000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i57d0917029a34ef29e913c208110630e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktNi0xLTEtNDgxMjE_56c66167-d55e-41dd-8d94-d74713e85737"
      unitRef="shares">112075474</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i57d0917029a34ef29e913c208110630e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktOC0xLTEtNDgxMjE_1dd9f1c9-7c3f-4bfc-9dc1-19b37fb1b7da"
      unitRef="usd">112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id918e17d65804ec2aaddb4bddbbe04de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTAtMS0xLTQ4MTIx_a64d5d0c-2fc8-4783-b696-903239b08d20"
      unitRef="usd">701357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2dd25891418746beaebca51736f0026a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTItMS0xLTQ4MTIx_2a849d85-9eec-4e62-8732-71597d20f9fc"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i04d0596343524d0a9e26d27762aa2791_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTQtMS0xLTQ4MTIx_67f362cd-1a6e-407c-a899-244bfc3eee97"
      unitRef="usd">-7185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMjktMTYtMS0xLTQ4MTIx_84cc517c-308c-4e5b-b855-e04e8e6edaac"
      unitRef="usd">694294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83026cc4bc5d41b4ad74488ad2199f77_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTAtMS0xLTQ4MjAy_20f6012f-a92a-4de4-b3aa-b400bfaa9e02"
      unitRef="usd">-23271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f50257a2f734bc48f00930c77961bc5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTQtMS0xLTQ4MjAy_6b83b6f7-fd7d-4b51-8c9c-384c9d8fca30"
      unitRef="usd">695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice51bbf0728a42838fa6df2fe01bcc47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzAtMTYtMS0xLTQ4MjAy_6c010d36-d810-4039-9bca-48b084483345"
      unitRef="usd">-22576000</us-gaap:StockholdersEquity>
    <neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtMTAtMS0xLTQ4MjAy_73b9fe4f-a267-4372-9907-85f541717e05"
      unitRef="usd">29291000</neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt>
    <neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzEtMTYtMS0xLTQ4MjAy_b5ac1632-75fa-43c5-9e38-fcc05bf1d385"
      unitRef="usd">29291000</neo:AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItNi0xLTEtNDgyMDI_8880ea19-6ee9-4448-a7f1-bc4f37022b5c"
      unitRef="shares">112094</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItMTAtMS0xLTQ4MjAy_3075a0ca-9a54-49b8-a67f-53984d2b7d64"
      unitRef="usd">4360000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzItMTYtMS0xLTQ4MjAy_62125cde-5947-4bef-af0a-3485bc002d30"
      unitRef="usd">4360000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzMtNi0xLTEtNDgyMDI_6d35bb4c-5319-4600-8f93-788d577747e1"
      unitRef="shares">811335</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzMtOC0xLTEtNDgyMDI_e96bffbd-2973-4fbf-9ac0-667c307e218b"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzMtMTAtMS0xLTQ4MjAy_883cfdaa-2b2d-4ce1-959e-1504a1c0d9cf"
      unitRef="usd">-2818000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzMtMTYtMS0xLTQ4MjAy_0dfd4f5b-4029-48b7-b2c6-2a076afb6905"
      unitRef="usd">-2817000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzQtNi0xLTEtNDgyMDI_c07c1c2f-c397-42bc-96e7-b6028b21546d"
      unitRef="shares">1372564</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzQtOC0xLTEtNDgyMDI_a8c17ffb-cfb8-4319-8a45-831666c1665f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzQtMTAtMS0xLTQ4MjAy_a20e3e13-605f-40a6-aa40-2a37365c197a"
      unitRef="usd">13677000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzQtMTYtMS0xLTQ4MjAy_96aef084-0be7-4ff3-8c1a-4ca1eacb88ac"
      unitRef="usd">13678000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <neo:StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtNi0xLTEtNDgyMDI_9ad376d2-42be-48cd-bd5e-c3ffbe70c3ca"
      unitRef="shares">4444445</neo:StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement>
    <neo:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtOC0xLTEtNDgyMDI_a76b1bed-bf69-4b89-9f76-4ee5cbc3ba2a"
      unitRef="usd">4000</neo:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement>
    <neo:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtMTAtMS0xLTQ4MjAy_ecc68e0a-6d4f-40a5-b118-bf4b9d5cf39d"
      unitRef="usd">189859000</neo:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement>
    <neo:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzUtMTYtMS0xLTQ4MjAy_cf340f78-e5d4-4ac5-a96e-08af72d3fbf3"
      unitRef="usd">189863000</neo:StockIssuedDuringPeriodValueNewIssuesPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtNi0xLTEtNDgyMDI_eb6452b7-ff31-4749-9f0f-19d63e37041b"
      unitRef="shares">4693876</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtOC0xLTEtNDgyMDI_bc24b4cd-23ec-4b18-a027-d1356eca0d45"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtMTAtMS0xLTQ4MjAy_6cd378bd-6791-4a77-ba44-49dc556e23a3"
      unitRef="usd">218495000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzYtMTYtMS0xLTQ4MjAy_1fdc4df8-6ca6-4f76-9e34-e11e16d396cf"
      unitRef="usd">218500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctNi0xLTEtNDgyMDI_6a7a24a6-a257-4276-80c8-3bbd02abc07e"
      unitRef="shares">597712</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ibd56523806d247648cc2152b5a10b1b6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctOC0xLTEtNDgyMDI_cc4caf73-5968-443d-8582-5496ec70d055"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctMTAtMS0xLTQ4MjAy_85e65766-89d4-4578-aae4-22e6591871a8"
      unitRef="usd">29174000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzctMTYtMS0xLTQ4MjAy_1fbe0344-5d59-4d15-b4b5-0cb94b55036d"
      unitRef="usd">29175000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtMTAtMS0xLTQ4MjAy_6bd9fd6b-98b4-4a79-9883-ec8a576b687b"
      unitRef="usd">372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzgtMTYtMS0xLTQ4MjAy_a1549f00-7eac-469c-9eb6-309ac3d830e3"
      unitRef="usd">372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktMTAtMS0xLTQ4MjAy_5ad9b126-12ff-4d01-8b4e-7db8595d7f23"
      unitRef="usd">1052000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfMzktMTYtMS0xLTQ4MjAy_ffbd9bf8-974d-4bd2-97ee-0c3e64c98e41"
      unitRef="usd">1052000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia71a04da731e4d1ea48c0ac107ce5092_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtMTAtMS0xLTQ4MjAy_7b439271-25bd-4743-b764-38bc7c0ee611"
      unitRef="usd">21406000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDAtMTYtMS0xLTQ4MjAy_82811149-fa2f-4b72-ba21-a0a1e073a57c"
      unitRef="usd">21406000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if407078fb14144a49b4fde832c9c9fd0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDEtMTItMS0xLTQ4MjAy_a40998e9-497f-4f6e-abaf-3bf3d4b6fe7d"
      unitRef="usd">-648000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDEtMTYtMS0xLTQ4MjAy_16c3c23f-3163-4ac5-8805-56e515767f3f"
      unitRef="usd">-648000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i82ac84e649b24f039e093f75604210c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDItMTQtMS0xLTQ4MjAy_5aadab1c-96e9-4994-8462-4814fe9ee99f"
      unitRef="usd">-8347000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDItMTYtMS0xLTQ4MjAy_10420406-8a86-4bd6-bea8-c47835b14013"
      unitRef="usd">-8347000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib815884d2c9841e7b4cf247a74f794da_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtNi0xLTEtNDgyMDI_a087d649-5d34-4001-8cb1-621298669059"
      unitRef="shares">124107500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib815884d2c9841e7b4cf247a74f794da_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtOC0xLTEtNDgyMDI_50ef5c18-717e-473d-bf07-5524704e1913"
      unitRef="usd">124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0fe82c466a4049f6ad31f72b2eb34e2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTAtMS0xLTQ4MjAy_e5b401c5-22a4-4afd-af48-344ba4598abe"
      unitRef="usd">1123628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8eb531e73f524c3299d26ea0b0cc94f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTItMS0xLTQ4MjAy_18252df4-bf0d-498d-991d-7abc8c705997"
      unitRef="usd">-638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i79509cebd90244a19cdc2cf04c78f592_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTQtMS0xLTQ4MjAy_9b38826c-895c-436d-b077-ed4f28d2df3c"
      unitRef="usd">-14837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83My9mcmFnOjkwMWE3NzRlZmUzODRkZDE4NTkyNmYwNTM5NDI1MzlkL3RhYmxlOmQ5ZmUwN2E0ZTg1OTRmZjJiZDk4NGRmMGY4YTY1ZWFlL3RhYmxlcmFuZ2U6ZDlmZTA3YTRlODU5NGZmMmJkOTg0ZGYwZjhhNjVlYWVfNDMtMTYtMS0xLTQ4MjAy_a599903b-ee9e-47db-a07c-44ce828a4213"
      unitRef="usd">1108277000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMy0xLTEtMS0zMDU3Mg_2afdbdd6-93de-4c38-815b-92dc41242afd"
      unitRef="usd">-8347000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMy0zLTEtMS0zMDU3Mg_79dc1126-05c0-4d7d-b1d7-caf76f86c338"
      unitRef="usd">4172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMy01LTEtMS0zMDU3Mg_735c0175-961b-4706-8087-8348af0d4c98"
      unitRef="usd">8006000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNS0xLTEtMS0zMDU3Mg_54dda617-a3cc-42c4-ac6a-f72a97fa6949"
      unitRef="usd">30192000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNS0zLTEtMS0zMDU3Mg_8f942b4e-5ce8-45b3-9425-453334f5f799"
      unitRef="usd">25904000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNS01LTEtMS0zMDU3Mg_316f7db4-3e4f-4040-8df7-89c3987dc2fc"
      unitRef="usd">20346000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNi0xLTEtMS0zMDU3Mg_ed63edac-a250-4755-9f00-9469b33e0c86"
      unitRef="usd">23160000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNi0zLTEtMS0zMDU3Mg_32e9516e-ca72-488c-871f-3b34eda0c3db"
      unitRef="usd">9817000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNi01LTEtMS0zMDU3Mg_2db782f0-7a79-49f5-9e69-4a91ff6d2589"
      unitRef="usd">9925000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNy0xLTEtMS0zMDU3Mg_433d0da2-b468-4989-a8bf-36b743c8e867"
      unitRef="usd">22458000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNy0zLTEtMS0zMDU3Mg_8d38aa11-4f8d-4198-863e-441626b23b4d"
      unitRef="usd">10212000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNy01LTEtMS0zMDU3Mg_782c05a9-e976-4e65-bddf-d9e5be0530ba"
      unitRef="usd">10000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOC0xLTEtMS0zMDU3Mg_ca0349a5-b291-481e-b830-71eda137c4f4"
      unitRef="usd">8716000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOC0zLTEtMS0zMDU3Mg_15d13bba-f5af-4c36-b172-f02ac39b01ec"
      unitRef="usd">6168000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOC01LTEtMS0zMDU3Mg_8314f6c8-1cc0-4eb6-80df-f13ab9c2f3d8"
      unitRef="usd">5635000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOS0xLTEtMS0zMDU3Mg_db18231c-a8b8-4ef7-b2e6-3d83f4282dd9"
      unitRef="usd">2563000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOS0zLTEtMS0zMDU3Mg_bb81d762-c9f7-49f7-bc0e-5a646b8c118b"
      unitRef="usd">4358000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfOS01LTEtMS0zMDU3Mg_9d2ea96c-b089-4c71-9fcd-28ab8941f4c2"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTAtMS0xLTEtMzA1NzI_74fdc1e6-3364-483c-aedd-36c81963acfb"
      unitRef="usd">178000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTAtMy0xLTEtMzA1NzI_62b441e3-db5d-47c9-872a-a515029472ca"
      unitRef="usd">165000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTAtNS0xLTEtMzA1NzI_15384752-40b1-498b-8d81-0c220be3ef87"
      unitRef="usd">390000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTEtMS0xLTEtMzA1NzI_60f2e327-994a-4b2c-86ee-5d1ce179f30a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTEtMy0xLTEtMzA1NzI_b4698d5a-c96b-4019-b5e3-429340b2de1a"
      unitRef="usd">-1400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTEtNS0xLTEtMzA1NzI_0b002233-3b1e-46ec-b6f6-e9c9b0e36822"
      unitRef="usd">-1018000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <neo:GainLossOnTerminationOfInterestRateSwap
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTItMS0xLTEtMzA1NzI_a58eba1f-eaec-4615-81ec-fb2266d129b0"
      unitRef="usd">0</neo:GainLossOnTerminationOfInterestRateSwap>
    <neo:GainLossOnTerminationOfInterestRateSwap
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTItMy0xLTEtMzA1NzI_d1647d9c-b33b-40ce-9b7c-22bd0a7f488f"
      unitRef="usd">-3506000</neo:GainLossOnTerminationOfInterestRateSwap>
    <neo:GainLossOnTerminationOfInterestRateSwap
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTItNS0xLTEtMzA1NzI_d48b236a-4a49-48fc-b5d4-d7be41aca397"
      unitRef="usd">0</neo:GainLossOnTerminationOfInterestRateSwap>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTMtMS0xLTEtNDc3Nzk_6399a283-55ed-4d47-a110-04035dbc0eb9"
      unitRef="usd">109260000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTMtMy0xLTEtNDc3Nzk_cacdf68a-d867-42d9-8837-764e7c90f98d"
      unitRef="usd">3955000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTMtNS0xLTEtNDc3Nzk_b159f8ba-d83a-4a92-a38d-2e08c1b8f528"
      unitRef="usd">0</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <neo:ReceivableWithImputedInterestNonConsolidatedAffiliates
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtMS0xLTEtNDc3Nzk_c6627e27-5027-45b5-8fd8-ba5f6532daab"
      unitRef="usd">391000</neo:ReceivableWithImputedInterestNonConsolidatedAffiliates>
    <neo:ReceivableWithImputedInterestNonConsolidatedAffiliates
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtMy0xLTEtNDc3Nzk_2dc1f869-547a-4b14-bfad-e2fa2872bab8"
      unitRef="usd">0</neo:ReceivableWithImputedInterestNonConsolidatedAffiliates>
    <neo:ReceivableWithImputedInterestNonConsolidatedAffiliates
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtNS0xLTEtNDc3Nzk_56c8c830-674f-4445-a79f-1b6335bc9a82"
      unitRef="usd">0</neo:ReceivableWithImputedInterestNonConsolidatedAffiliates>
    <neo:PolymeraseChainReactionTestingExitCostsCOVID19
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtMS0xLTEtNDc4MDQ_f909724a-748d-43d7-9392-2b65c2788680"
      unitRef="usd">6061000</neo:PolymeraseChainReactionTestingExitCostsCOVID19>
    <neo:PolymeraseChainReactionTestingExitCostsCOVID19
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtMy0xLTEtNDc4MDQ_7f3301c6-7df1-4f51-84c9-89eb9e24a743"
      unitRef="usd">0</neo:PolymeraseChainReactionTestingExitCostsCOVID19>
    <neo:PolymeraseChainReactionTestingExitCostsCOVID19
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtNS0xLTEtNDc4MDQ_fdd8ba28-0a27-4b69-80a2-5a6d5f71dc25"
      unitRef="usd">0</neo:PolymeraseChainReactionTestingExitCostsCOVID19>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtMS0xLTEtMzA1NzI_b4eae17d-c5ae-47df-b4f4-306a5eae63f4"
      unitRef="usd">-2547000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtMy0xLTEtMzA1NzI_38dab966-d40f-4ff7-a3d3-acb113c80a56"
      unitRef="usd">-1460000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTQtNS0xLTEtMzA1NzI_41630718-6542-438e-a71f-bcb01ff1583b"
      unitRef="usd">-472000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtMS0xLTEtMzA1NzI_c84ee165-2d95-4f2f-83eb-264647f64c05"
      unitRef="usd">4691000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtMy0xLTEtMzA1NzI_3a04eace-e648-4c47-9226-db9dd2a99ab6"
      unitRef="usd">12601000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTYtNS0xLTEtMzA1NzI_4710ab31-c047-447f-8920-f21f86127833"
      unitRef="usd">17301000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTctMS0xLTEtMzA1NzI_32aebefc-8899-4be5-8aef-66a1295c3e15"
      unitRef="usd">-1634000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTctMy0xLTEtMzA1NzI_a55791f9-742b-4d9e-95a4-e9b5a7721e2f"
      unitRef="usd">15197000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTctNS0xLTEtMzA1NzI_fc303e1e-f05e-43ce-ac9b-e458ca5b57c5"
      unitRef="usd">5754000</us-gaap:IncreaseDecreaseInInventories>
    <neo:IncreaseDecreaseInPrepaidConstruction
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTktMS0xLTEtMzA1NzI_5906ad66-9dc8-4918-96cd-72e3a425f0d0"
      unitRef="usd">4788000</neo:IncreaseDecreaseInPrepaidConstruction>
    <neo:IncreaseDecreaseInPrepaidConstruction
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTktMy0xLTEtMzA1NzI_30cad26b-9c5d-48c1-9cec-03d085a3f124"
      unitRef="usd">20229000</neo:IncreaseDecreaseInPrepaidConstruction>
    <neo:IncreaseDecreaseInPrepaidConstruction
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMTktNS0xLTEtMzA1NzI_e32c407f-6bc8-47d8-81b5-0395ec72204f"
      unitRef="usd">0</neo:IncreaseDecreaseInPrepaidConstruction>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjAtMS0xLTEtMzA1NzI_e8bac7f2-31d4-45f5-ac19-17fbbc9d3d21"
      unitRef="usd">1906000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjAtMy0xLTEtMzA1NzI_3490cfc6-50e5-418a-8559-8ef67fc87362"
      unitRef="usd">9750000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjAtNS0xLTEtMzA1NzI_96451942-62ca-49fb-b9d2-3c7aab80e28e"
      unitRef="usd">367000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjItMS0xLTEtMzA1NzI_f691ca07-cbd5-48f8-91df-92cda6c3ff04"
      unitRef="usd">5151000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjItMy0xLTEtMzA1NzI_1e19dc87-fd27-4ce2-a5a3-9988c55f8682"
      unitRef="usd">-3970000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjItNS0xLTEtMzA1NzI_e4762bb4-a241-448b-a586-3b08bafad72b"
      unitRef="usd">-9001000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjMtMS0xLTEtMzA1NzI_124b9bad-7694-4cf1-87c8-837cebb597b1"
      unitRef="usd">-26723000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjMtMy0xLTEtMzA1NzI_0b464538-3c56-4256-aed0-1539fe1c6e8d"
      unitRef="usd">1460000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjMtNS0xLTEtMzA1NzI_3396e024-377f-4c73-9834-dd9a1fe0718b"
      unitRef="usd">23369000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjUtMS0xLTEtMzA1NzI_e150c2eb-b38b-412f-9583-6085f31e12ce"
      unitRef="usd">196791000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjUtMy0xLTEtMzA1NzI_a0863e68-cef8-4604-884b-7d26b6de769d"
      unitRef="usd">73101000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjUtNS0xLTEtMzA1NzI_2e39f7fb-3523-494e-a65a-884da9aef0ca"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjYtMS0xLTEtMzA1NzI_4a909b03-2921-4457-9e94-f4367b2c373f"
      unitRef="usd">62970000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjYtMy0xLTEtMzA1NzI_e3eb37a2-aa5a-430e-ab29-e58c5c38eb9c"
      unitRef="usd">5356000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjYtNS0xLTEtMzA1NzI_b29a069f-94c0-4201-a73c-764d5d09bf3d"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjgtMS0xLTEtMzA1NzI_4b78a923-65e4-4e35-a16b-9f25c3de4705"
      unitRef="usd">64142000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjgtMy0xLTEtMzA1NzI_3e88436c-6744-416d-b6f0-6b100dc23555"
      unitRef="usd">29096000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjgtNS0xLTEtMzA1NzI_9e2da64c-4f0d-4e38-96f0-0eefa8290942"
      unitRef="usd">20029000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjktMS0xLTEtMzA1NzI_53fd27a6-5166-4d5f-8756-1ab59af55275"
      unitRef="usd">419404000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjktMy0xLTEtMzA1NzI_e03d147c-d903-4296-b114-bbe2ddff358b"
      unitRef="usd">37000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMjktNS0xLTEtMzA1NzI_6a19a471-6373-4318-9e58-ef42e2239a13"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzAtMS0xLTEtMzA1NzI_f3b3ba4a-6619-4aa2-867b-1ad784a364d0"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzAtMy0xLTEtMzA1NzI_629e5de4-0aa2-48e3-a7e0-ac458b6cbeaf"
      unitRef="usd">25600000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzAtNS0xLTEtMzA1NzI_b4a33cbe-c2f9-4c46-915b-ca8dd515cec4"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzQtMS0xLTEtNjQ0Njc_18dc9b98-ee2e-4c8d-b271-0ca446f69b68"
      unitRef="usd">15000000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzQtMy0xLTEtNjQ0Njc_dca53bb8-cdaf-4465-af1e-195c4ec67a43"
      unitRef="usd">0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzQtNS0xLTEtNjQ0Njc_ccbcf9ff-bd3a-405b-8f39-7c1ee8ab0f46"
      unitRef="usd">0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <neo:BusinessCombinationWorkingCapitalAdjustment
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzEtMS0xLTEtMzA1NzI_cb4dfbc4-ef1c-417c-a513-3cee749c7210"
      unitRef="usd">0</neo:BusinessCombinationWorkingCapitalAdjustment>
    <neo:BusinessCombinationWorkingCapitalAdjustment
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzEtMy0xLTEtMzA1NzI_3199390d-06c9-4f84-a2b3-560425ab0f26"
      unitRef="usd">0</neo:BusinessCombinationWorkingCapitalAdjustment>
    <neo:BusinessCombinationWorkingCapitalAdjustment
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzEtNS0xLTEtMzA1NzI_6b69a7de-edd4-4de4-aa00-613323d93774"
      unitRef="usd">399000</neo:BusinessCombinationWorkingCapitalAdjustment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzItMS0xLTEtMzA1NzI_c329c022-58ee-4376-bc0d-133add15dc2e"
      unitRef="usd">-632367000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzItMy0xLTEtMzA1NzI_9db29e16-6463-4a03-9eb8-d233ffec33ab"
      unitRef="usd">-159441000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzItNS0xLTEtMzA1NzI_03449a45-7c8c-42f6-a42f-a940563d2e0c"
      unitRef="usd">-19630000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzUtMS0xLTEtMzA1NzI_d1e799ba-b336-4a07-8a24-ff441fc7f187"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzUtMy0xLTEtMzA1NzI_91a9335f-6750-40d5-868f-1494af0ccc47"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzUtNS0xLTEtMzA1NzI_8d102f69-cfaa-4b83-a4db-4bd78448691f"
      unitRef="usd">5000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <neo:RepaymentsOfEquipmentAndOtherLoans
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzctMS0xLTEtMzA1NzI_a7f7489a-7b5f-4ffd-87b3-9faf9aaa56d8"
      unitRef="usd">3047000</neo:RepaymentsOfEquipmentAndOtherLoans>
    <neo:RepaymentsOfEquipmentAndOtherLoans
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzctMy0xLTEtMzA1NzI_297f037d-4348-41da-8d6f-86e2dc07c443"
      unitRef="usd">5615000</neo:RepaymentsOfEquipmentAndOtherLoans>
    <neo:RepaymentsOfEquipmentAndOtherLoans
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzctNS0xLTEtMzA1NzI_e6301b30-4ea3-4cc2-b7d7-b2a9f24b3851"
      unitRef="usd">7201000</neo:RepaymentsOfEquipmentAndOtherLoans>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzgtMS0xLTEtMzA1NzI_1d1570a9-130f-4c4f-8349-22a587c81145"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzgtMy0xLTEtMzA1NzI_bab77c95-f6b5-480f-9a22-b7995ffb1b69"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzgtNS0xLTEtMzA1NzI_8d63f12f-51be-44a4-8b7e-07e1082c8b6e"
      unitRef="usd">100000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzktMS0xLTEtMzA1NzI_8ceda06c-f367-4226-ad6a-4e4ac1a1a424"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzktMy0xLTEtMzA1NzI_e6ead933-7d8a-4865-a7ca-81ab800fdef3"
      unitRef="usd">97540000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfMzktNS0xLTEtMzA1NzI_b246917d-6913-47bf-a520-414cd953aeba"
      unitRef="usd">99250000</us-gaap:RepaymentsOfSecuredDebt>
    <neo:DerivativeTerminationFee
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDAtMS0xLTEtMzA1NzI_678c91f8-ad06-4c67-bc87-279414fab8bf"
      unitRef="usd">0</neo:DerivativeTerminationFee>
    <neo:DerivativeTerminationFee
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDAtMy0xLTEtMzA1NzI_33f9323c-f8c9-434b-9206-5bb5747fe21f"
      unitRef="usd">3317000</neo:DerivativeTerminationFee>
    <neo:DerivativeTerminationFee
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDAtNS0xLTEtMzA1NzI_835c5b60-2af0-4e24-b3b0-cf461425e6c0"
      unitRef="usd">0</neo:DerivativeTerminationFee>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDEtMS0xLTEtMzA1NzI_52823b05-3592-4b69-a7bd-1a7842fffc37"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDEtMy0xLTEtMzA1NzI_c1af376d-923f-4ebb-9f3f-f84522b392cf"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDEtNS0xLTEtMzA1NzI_8b122d8c-88e7-4256-b31a-0a3a1f4b3bb1"
      unitRef="usd">1059000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDItMS0xLTEtMzA1NzI_d3586fce-cbcb-4fa1-8a2b-c6d397b59cf9"
      unitRef="usd">15080000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDItMy0xLTEtMzA1NzI_0d08dcab-474c-4ee5-8d2e-33b70500a86f"
      unitRef="usd">20310000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDItNS0xLTEtMzA1NzI_cf10d085-1d29-4a02-a8f7-11281bdd2abe"
      unitRef="usd">11202000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDMtMS0xLTEtMzA1NzI_deaafea6-a0ef-4160-b6b3-a84b6656484a"
      unitRef="usd">334410000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDMtMy0xLTEtMzA1NzI_3210085c-1033-4759-acb1-e72f76c0a05c"
      unitRef="usd">194466000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDMtNS0xLTEtMzA1NzI_d4c57567-0c8a-46ed-b203-c25fa808113f"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <neo:PaymentsOfPremiumsForCappedCallConfirmations
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctMS0xLTEtNDc5MDg_f2b0bef6-d5c5-4673-bd59-04812d2faec8"
      unitRef="usd">29291000</neo:PaymentsOfPremiumsForCappedCallConfirmations>
    <neo:PaymentsOfPremiumsForCappedCallConfirmations
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctMy0xLTEtNDc5MDg_6a212bba-b2f5-4561-b486-2901420e37e6"
      unitRef="usd">0</neo:PaymentsOfPremiumsForCappedCallConfirmations>
    <neo:PaymentsOfPremiumsForCappedCallConfirmations
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctNS0xLTEtNDc5MDg_ff7df7fc-a044-48a3-8ab6-c8dde1200da3"
      unitRef="usd">0</neo:PaymentsOfPremiumsForCappedCallConfirmations>
    <neo:ProceedsFromEquityOfferingNet
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDQtMS0xLTEtMzA1NzI_df5614c4-b853-4e22-9108-d090bacf4e6f"
      unitRef="usd">408133000</neo:ProceedsFromEquityOfferingNet>
    <neo:ProceedsFromEquityOfferingNet
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDQtMy0xLTEtMzA1NzI_7e4e9033-1846-4601-b08f-30c18e81f16e"
      unitRef="usd">127293000</neo:ProceedsFromEquityOfferingNet>
    <neo:ProceedsFromEquityOfferingNet
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDQtNS0xLTEtMzA1NzI_79f0b9d3-fcf8-43fc-a863-e8d768234a1d"
      unitRef="usd">160774000</neo:ProceedsFromEquityOfferingNet>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDUtMS0xLTEtMzA1NzI_85736a66-ef45-418f-b5c9-ed4995744986"
      unitRef="usd">725285000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDUtMy0xLTEtMzA1NzI_c9877375-2005-42bc-a06b-6bc41a53b36a"
      unitRef="usd">235597000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDUtNS0xLTEtMzA1NzI_cf00972e-e988-447c-95a5-9760754b1902"
      unitRef="usd">159466000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctMS0xLTEtMzA1NzI_5c0856df-f254-4bab-8ee9-45f5ef6e7b0c"
      unitRef="usd">66195000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctMy0xLTEtMzA1NzI_b29d5abe-4db4-4c3e-91f2-cd59950f9923"
      unitRef="usd">77616000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDctNS0xLTEtMzA1NzI_5bab8467-a42f-498d-841f-186782f873d3"
      unitRef="usd">163205000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDgtMS0xLTEtMzA1NzI_03f56cb9-050b-4e90-bba4-2f2b59a78585"
      unitRef="usd">250632000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDgtMy0xLTEtMzA1NzI_d74e8978-4907-42d7-945c-3bb87da9a296"
      unitRef="usd">173016000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDgtNS0xLTEtMzA1NzI_4d73c27e-6ebd-4025-86c9-2286df871c7e"
      unitRef="usd">9811000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDktMS0xLTEtMzA1NzI_fe7476a5-425d-4c02-b31f-fab4da4cc54d"
      unitRef="usd">316827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDktMy0xLTEtMzA1NzI_60303392-3911-4208-9965-c8128c16feb7"
      unitRef="usd">250632000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjVmOWI0MDE1NjhjZTQ5ZDFiMzkyN2YzNzI5YzJkODYyL3RhYmxlcmFuZ2U6NWY5YjQwMTU2OGNlNDlkMWIzOTI3ZjM3MjljMmQ4NjJfNDktNS0xLTEtMzA1NzI_7d967eee-b191-4c2e-a6bb-802f116cd53d"
      unitRef="usd">173016000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMS0xLTEtMS0zMDU3Mg_70ab0efb-8c8b-4ac1-9c08-c127558c5d24"
      unitRef="usd">316827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMS0zLTEtMS0zMDU3Mg_677d5435-8965-4cd9-aa03-6f0795fd4b11"
      unitRef="usd">228713000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMS01LTEtMS0zMDU3Mg_a3b16760-8349-4490-88cd-1dbcf814e265"
      unitRef="usd">173016000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMi0xLTEtMS0zMDU3Mg_88161477-a70f-4171-975a-cb4e91315143"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMi0zLTEtMS0zMDU3Mg_df256b8f-45a3-46c9-8014-cebc9cbb6eb6"
      unitRef="usd">21919000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMi01LTEtMS0zMDU3Mg_68d66e15-8827-4ea2-9063-9f5a65fe6eee"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMy0xLTEtMS0zMDU3Mg_a5e56d72-1653-4b71-841e-65a308bae7d5"
      unitRef="usd">316827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMy0zLTEtMS0zMDU3Mg_9ebefb80-166d-4c45-8816-4dc2c7cb0c90"
      unitRef="usd">250632000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMy01LTEtMS0zMDU3Mg_65633075-418b-4e38-8dbd-c5fcc14c9092"
      unitRef="usd">173016000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNi0xLTEtMS0zMDU3Mg_a4c5b2e6-d374-47fb-9568-0639415192bb"
      unitRef="usd">3065000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNi0zLTEtMS0zMDU3Mg_7e819478-7ee7-47f1-990f-3035d9a880f1"
      unitRef="usd">2926000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNi01LTEtMS0zMDU3Mg_90003fc8-bf54-4803-b336-ea8f805a25d0"
      unitRef="usd">4775000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNy0xLTEtMS0zMDU3Mg_898cc25e-f855-4346-ab24-ce7b0747fee9"
      unitRef="usd">148000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNy0zLTEtMS0zMDU3Mg_8369dfa6-606c-4ed7-8cad-11fded53b2ed"
      unitRef="usd">246000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfNy01LTEtMS0zMDU3Mg_ee3050d9-2a9c-440a-9af8-3a4558a92dda"
      unitRef="usd">319000</us-gaap:IncomeTaxesPaidNet>
    <neo:FairValueOfCommonStockIssuedToFundAcquisition
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfOS0xLTEtMS0zMDU3Mg_5c014568-2798-4958-b992-2bbb9ab7adf6"
      unitRef="usd">29174000</neo:FairValueOfCommonStockIssuedToFundAcquisition>
    <neo:FairValueOfCommonStockIssuedToFundAcquisition
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfOS0zLTEtMS0zMDU3Mg_e2ebefdd-5486-4e2b-88ec-2fdc0e6e4e13"
      unitRef="usd">0</neo:FairValueOfCommonStockIssuedToFundAcquisition>
    <neo:FairValueOfCommonStockIssuedToFundAcquisition
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfOS01LTEtMS0zMDU3Mg_fbc39632-155a-4938-aabc-e1a503d42113"
      unitRef="usd">0</neo:FairValueOfCommonStockIssuedToFundAcquisition>
    <neo:WorkingCapitalAdjustmentAcquisitions
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTEtMS0xLTEtMzA1NzI_dc2a8727-bf0e-471e-b5de-a2141b02615c"
      unitRef="usd">0</neo:WorkingCapitalAdjustmentAcquisitions>
    <neo:WorkingCapitalAdjustmentAcquisitions
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTEtMy0xLTEtMzA1NzI_9bfe5c5d-f69d-4f46-bc3f-d5506145be1f"
      unitRef="usd">0</neo:WorkingCapitalAdjustmentAcquisitions>
    <neo:WorkingCapitalAdjustmentAcquisitions
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTEtNS0xLTEtMzA1NzI_a0e0f9e6-ed0f-4153-ae3c-72278972e1a1"
      unitRef="usd">1977000</neo:WorkingCapitalAdjustmentAcquisitions>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTItMS0xLTEtMzA1NzI_213d8ebf-9e19-400f-9c22-58d9c886ee59"
      unitRef="usd">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTItMy0xLTEtMzA1NzI_e13d18b7-9b9e-4d74-bec0-fd013a03032d"
      unitRef="usd">428000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTItNS0xLTEtMzA1NzI_59d41713-0279-433c-8e7e-75aeb1e35ecf"
      unitRef="usd">4283000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTMtMS0xLTEtMzA1NzI_d3ef7dd4-499b-4758-a23a-ecf47f1d2a5c"
      unitRef="usd">1315000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTMtMy0xLTEtMzA1NzI_ddd2395f-7eca-4bbc-90d4-cd52a9cca4f9"
      unitRef="usd">2007000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV83Ni9mcmFnOjNhY2NhYjU3ZGVjZTQzZjBhMzkyZGRkMDkwYjAyZjc3L3RhYmxlOjFiMmI1MWM1N2Y2ZDQ3ZDM4YTBlODRmM2NlODNkZDAwL3RhYmxlcmFuZ2U6MWIyYjUxYzU3ZjZkNDdkMzhhMGU4NGYzY2U4M2RkMDBfMTMtNS0xLTEtMzA1NzI_1855230a-2fff-4fb0-8425-42eef6d66bc5"
      unitRef="usd">1034000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTM5NA_fe820508-529d-4ad5-bdb4-bbf64db84eba">Nature of Business&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Nature of the Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NeoGenomics, Inc., a Nevada corporation (the &#x201c;Parent,&#x201d; &#x201c;Company,&#x201d; or &#x201c;NeoGenomics&#x201d;), and its subsidiaries, operate as a certified, high complexity clinical laboratory in accordance with the federal government&#x2019;s Clinical Laboratory Improvement Act, as amended, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;COVID-19 Pandemic Update&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, a novel strain of coronavirus (&#x201c;COVID-19&#x201d;) was identified and the disease has since spread across the world, including the United States (&#x201c;U.S.&#x201d;). In March 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic. The outbreak of the pandemic is materially adversely affecting the Company&#x2019;s employees, patients, communities, and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 outbreak will impact the Company&#x2019;s business, results of operations, financial condition, and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national, and international markets. As the COVID-19 pandemic continues, the Company&#x2019;s results of operations, financial condition, and cash flows may continue to be materially adversely affected, particularly if the pandemic continues to persist for a significant amount of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates that the cash on hand, marketable securities, and expected cash collections are sufficient to fund near-term capital and operating needs for at least the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of the first quarter 2021, due to the broad roll-out of the COVID-19 vaccine and a sharp decline in COVID-19 polymerase chain reaction (&#x201c;PCR&#x201d;) testing demand, the Company made the decision to exit COVID-19 PCR testing and the Company recorded a $6.1&#160;million loss related to the exit from COVID-19 PCR testing. This amount consisted of write-offs of $5.3&#160;million for all remaining COVID-19 PCR testing inventory recorded to cost of revenue and $0.8&#160;million for all remaining COVID-19 PCR testing laboratory equipment recorded to general and administrative expenses on the Consolidated Statements of Operations for the year ended December 31, 2021. There were no such amounts recorded for each of the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Coronavirus Aid, Relief, and Economic Security Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Federal government passed legislation and the President of the United States signed into law on March 27, 2020, known as the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;). On April 10, 2020, the U.S. Department of Health &amp;amp; Human Services announced that Medicare-enrolled providers would receive a portion of a direct deposit disbursement totaling $50 billion. The $50 billion is part of a $100 billion Public Health and Social Service Emergency Fund created by the CARES Act. Payments made under the CARES Act are intended to reimburse healthcare providers for health care related expenses or lost revenues attributable to COVID-19 and are not required to be repaid provided that recipients attest to and comply with certain terms and conditions, including limitations on balance billing for COVID-19 patients. In the absence of specific guidance to account for government grants in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;), the Company accounts for such grants in accordance with international accounting standards for government grants. Such amounts are recognized when there is reasonable assurance that the Company will (1) comply with the conditions associated with the grant and (2) receive the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, the Company recognized $7.9&#160;million in grant income related to the CARES Act. No such amounts were recorded for the years ended December 31, 2021 and December 31, 2019. CARES Act grant income is classified in other income, net, on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act also permits the deferral of payment of the employer portion of social security taxes between March 27, 2020 and December 31, 2020. 50% of the deferred amount was due on December 31, 2021 and the remaining 50% is due on December 31, 2022. As of December 31, 2021, the total accrued deferred social security taxes, related to the CARES Act was $3.0&#160;million. This amount was recorded in accrued expenses and other liabilities on the Consolidated Balance Sheets. As of December 31, 2020, the total accrued deferred social security taxes, related to the CARES Act was $5.9&#160;million which was recorded evenly between accrued expenses and other liabilities and other long-term liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;Additionally, the CARES Act included an Employee Retention Tax Credit (&#x201c;ERTC&#x201d;) provision designed to encourage employers to retain employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages paid between March 13, 2020 and September 30, 2021 that meet the requirements of the ERTC provision. For the year ended December 31, 2020, the Company recognized $1.9&#160;million in credits under the ERTC which was included in (loss) income from operations on the Consolidated Statements of Operations. In the fourth quarter of 2021 the Company recorded $4.4&#160;million and $1.9&#160;million in expense in (loss) income from operations related to non-reoccurring reversals and reserves against tax credits previously recorded in the nine months ended September 30, 2021 and in the year ended December 31, 2020, respectively.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <neo:PolymeraseChainReactionTestingExitCostsCOVID19
      contextRef="i18eda084cbb54f798854f0d69e97920e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDQ3OA_66859e04-1b52-4be0-ae32-1ab9a3341ec8"
      unitRef="usd">6100000</neo:PolymeraseChainReactionTestingExitCostsCOVID19>
    <neo:PolymeraseChainReactionTestingWriteOffsCOVID19
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDQ5Mg_5807a833-9699-40a3-a20d-7e0317c901f0"
      unitRef="usd">5300000</neo:PolymeraseChainReactionTestingWriteOffsCOVID19>
    <neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDUwNg_2538f730-6d63-4d09-81ee-16f150c1f422"
      unitRef="usd">800000</neo:PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19>
    <neo:ProceedsFromGovernmentAssistanceCARESAct
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDUyMA_bcba9233-5022-49ee-895a-39cc8c2d51e0"
      unitRef="usd">7900000</neo:ProceedsFromGovernmentAssistanceCARESAct>
    <neo:ProceedsFromGovernmentAssistanceCARESAct
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDUzNw_467040f0-34d4-4690-9b3d-e963436395ef"
      unitRef="usd">0</neo:ProceedsFromGovernmentAssistanceCARESAct>
    <neo:ProceedsFromGovernmentAssistanceCARESAct
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDUzNw_adb7388d-ac73-4d6e-a534-d5fa96898936"
      unitRef="usd">0</neo:ProceedsFromGovernmentAssistanceCARESAct>
    <neo:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDU0Mw_ff8d27b7-86cb-4899-aea9-b1b085ededfc"
      unitRef="usd">3000000</neo:SocialSecurityTaxEmployerDeferralCARESAct>
    <neo:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ2MDU1Nw_07dc349d-8bbc-452c-b2b5-2846a58576de"
      unitRef="usd">5900000</neo:SocialSecurityTaxEmployerDeferralCARESAct>
    <neo:EmployeeRetentionTaxCreditCARESAct
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ3NDU1Nw_66d56c97-b45e-49ca-9d76-e43f89c933fe"
      unitRef="usd">1900000</neo:EmployeeRetentionTaxCreditCARESAct>
    <neo:EmployeeRetentionTaxCreditCARESAct
      contextRef="i17a51adbb970403990c2ec023fc31d62_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ3NDU3MQ_91276501-a5fa-4a58-ae9e-d3c85fbef4c7"
      unitRef="usd">4400000</neo:EmployeeRetentionTaxCreditCARESAct>
    <neo:EmployeeRetentionTaxCreditCARESAct
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84Mi9mcmFnOjVhNjNmZDk1NDI0YTQ4M2U5NzA5MDg1NTU3MTllZjdmL3RleHRyZWdpb246NWE2M2ZkOTU0MjRhNDgzZTk3MDkwODU1NTcxOWVmN2ZfMTY0OTI2NzQ3NDU4NQ_bc2fa111-e789-41b0-a9c9-76c4ca513718"
      unitRef="usd">1900000</neo:EmployeeRetentionTaxCreditCARESAct>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjI_069ce4d6-1f77-4888-914f-fc7a915b62d4">Summary of Significant Accounting Policies&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements include the accounts of the Parent and its subsidiaries. All intercompany accounts and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#x2019;s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these Consolidated Financial Statements include, but are not limited to, those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether investments in affiliates are a Variable Interest Entity (&#x201c;VIE&#x201d;) at the start of each new venture and when a reconsideration event has occurred. A reporting entity must consolidate a VIE if that reporting entity has a variable interest (or combination of variable interests) and is determined to be the primary beneficiary. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity&#x2019;s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its equity investments that are under 20% of the total equity outstanding and for which the Company does not have significant influence by applying the cost method. Investments that are under 20% of the total equity outstanding and for which the Company has significant influence are accounted for using the equity method unless a scope exception is applicable. Investments in which the Company holds a non-controlling interest and are between 20-50% equity are accounted for using the equity method. For any equity investments in which the Company holds over 50% of the outstanding stock, or for investments in which the Company controls the investee, the Company consolidates those entities into the Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reports its activities in two reportable segments; (1) the Clinical Services segment and (2) the Pharma Services segment.&#160;These reportable segments deliver testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers and represent 100% of the Company&#x2019;s consolidated assets, net revenue, and net (loss) income in each of the years ended December 31, 2021, 2020, and 2019. Please refer to Note 19. Segment Information, for further financial information about these segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions of entities over which control is obtained that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent third-party valuations that use information and assumptions provided by management, which consider estimates of inputs and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired less liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives, and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the Company&#x2019;s operating results from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash, certain cash equivalents, accounts receivable, net, other current assets, accounts payable, accrued expenses and other liabilities, and Pharma contract liabilities are considered reasonable estimates of their respective fair values due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures its marketable securities at fair value on a recurring basis. Please refer to Note 4. Fair Value Measurements, for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with an original maturity of ninety days or less to be cash equivalents. The Company maintains its cash and cash equivalents with financial institutions that the Company believes to be of high credit standing. The Company believes that, as of December 31, 2021, its concentration of credit risk related to cash and cash equivalents was not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all marketable securities as available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are carried at fair value, with the unrealized holding gains and losses, net of income taxes, reflected in accumulated other comprehensive income until realized. The Company evaluates its marketable securities for other-than-temporary impairment on a quarterly basis. Unrealized losses are charged against net earnings when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine whether a loss is other-than-temporary, such as the length and extent of the fair value decline, the financial condition and near-term prospects of the issuer, and whether there is the intent to sell or will more likely than not be required to sell before the securities&#x2019; anticipated recovery. There were no other-than-temporary impairments for the years ended December 31, 2021, 2020 and 2019. Regardless of the intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are recorded when the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the purposes of computing realized and unrealized gains and losses, cost and fair value are determined on a specific identification basis.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are reported for all Clinical Services payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For Pharma Services the Company negotiates billing schedules and payment terms on a contract-by-contract basis which can include payments based on certain milestones being achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist principally of testing supplies and are valued at lower of cost or net realizable value, using the first-in, first-out method. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventories to their estimated net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns 43,560 square feet of our Carlsbad, California facility. During the third quarter of 2021, the Company committed to selling this property and the associated land and concluded that these assets met the held for sale criteria. At December 31, 2021, $10.1 million was recorded as assets held for sale within current assets on the Consolidated Balance Sheets for this property and associated land and reflects its carrying value which was lower than the fair value less selling costs. We expect to sell this property within one year, however, there can be no assurance that the sale of this property will be completed in the time frame we expect or at all. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Prepaid Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a prepaid expense for costs paid but not yet incurred. Those expected to be incurred within one year are recorded as prepaid assets within total current assets on the Consolidated Balance Sheets. Any costs expected to be incurred outside of one year are recorded as other assets within total non-current assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, other current assets consisted primarily of receivables related to research and development (&#x201c;R&amp;amp;D&#x201d;) tax credit receivables, pharma contract assets and other non-trade receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on the straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the related lease terms or their estimated useful lives. Costs incurred in connection with the development of internal-use software are capitalized in accordance with the accounting standard for internal-use software, and are amortized over the expected useful life of the software.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews the estimated useful lives of property and equipment. Changes to the estimated useful lives are recorded prospectively from the date of the change. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts and any resulting gain or loss is included in income (loss) from operations. Repairs and maintenance costs are expensed as incurred and are included in cost of revenue, general and administrative expenses or R&amp;amp;D expenses, as appropriate in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases corporate offices and laboratory spaces throughout the world, all of which are classified as operating leases expiring at various dates and generally having terms ranging from 1 to 20 years. Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s real estate lease agreements include options to either renew or early terminate the lease. Leases with renewal options allow the Company to extend the lease term typically between 1 and 5 years. When it is reasonably certain that the Company will exercise an option to renew or terminate a lease, these options are considered in determining the classification and measurement of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities are recorded based on the present value of the future lease payments over the lease term and assessed as of the commencement date. Incentives received from landlords, such as reimbursements for tenant improvements and rent abatement periods, effectively reduce the total lease payments owed for leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain real estate leases also include executory costs such as common area maintenance (non-lease component), as well as property insurance and property taxes (non-components). Lease payments, which may include lease components, non-lease components and non-components, are included in the measurement of the Company&#x2019;s lease liabilities to the extent that such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payments are either fixed amounts or variable amounts based on a rate or index (fixed in substance), as stipulated in the lease contract. Any actual costs in excess of such amounts are expensed as incurred as variable lease cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes its incremental borrowing rate by lease term in order to calculate the present value of its future lease payments when the implicit rates in the leases agreements are not readily determinable. The discount rate represents a risk-adjusted rate on a secured basis and is the rate at which the Company would borrow funds to satisfy the scheduled lease liability payment streams commensurate with the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs represent fixed lease payments recognized on a straight-line basis over the lease term. Operating lease costs include an immaterial amount of variable lease costs and are recorded in cost of revenue, general and administrative, sales and marketing, and R&amp;amp;D expenses (depending on the nature of the leased asset) in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with determinable useful lives are recorded initially at acquired fair value or cost, less accumulated amortization. Each intangible asset with a determinable useful life is amortized over its estimated useful life using the straight-line method. The Company periodically reviews the estimated pattern in which the economic benefits will be consumed and adjusts the amortization period and pattern to match the estimate. Intangible assets with indefinite useful lives are recorded initially at fair value or cost and are tested annually for impairment or more frequently if management believes indicators of impairment exist. For the years ended December 31, 2021, 2020, and 2019, no impairment losses related to intangible assets with indefinite useful lives were recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, the Company&#x2019;s intangible assets were comprised of customer relationships, trade names and trademarks, marketing assets, and developed technology. At December 31, 2020, the Company&#x2019;s intangible assets were comprised of customer relationships and trademarks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#x2019;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#x2019; data. For the years ended December 31, 2021, 2020, and 2019, the Company&#x2019;s evaluation of goodwill resulted in no impairment losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recoverability and Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the recoverability of its long-lived assets (including definite-lived intangible assets) if events or changes in circumstances indicate the assets may be impaired. Evaluation of possible impairment is based on the Company&#x2019;s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value to the carrying amount of the asset.&#160;For the years ended December 31, 2021, 2020, and 2019, no impairment losses were recognized related to long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingent losses when estimated impacts of various conditions, situations or circumstances involve uncertain outcomes. Contingent losses are recorded based on management judgment along with internal and external advice from legal counsel and/or technical consultants. Estimated losses from contingencies are recorded when both of the following conditions are met: (i) information available before the financial statements are issued (or available to be issued) indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) the amount of loss can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, that amount shall be accrued. When no amount within the range is a better estimate than any other amount, however, the minimum amount in the range shall be accrued. Please refer to Note 17. Commitments and Contingencies, for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs related to convertible senior notes are recorded as deductions that net against the principal value of the debt and are amortized as interest expense over the life of the debt using the effective interest method. Debt issuance costs related to term loans are recorded as direct deductions from the carrying amount of the term loan and are amortized to interest expense over the life of the debt using the effective interest method.&#160;Debt issuance costs relating to line of credit arrangements are recorded as assets and amortized over the term of the credit arrangement regardless of whether any outstanding borrowing existed. The term loan and line of credit were terminated in 2020 and all debt issuance costs were expensed accordingly. Please refer to Note 9. Debt, for further information on debt issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures compensation expense for stock-based awards to employees, non-employee contracted physicians, and directors based upon the awards&#x2019; initial grant-date fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2021 the Company estimated the fair value of stock options using a trinomial lattice model. On January 1, 2021, the Company began applying the Black-Scholes option valuation model (&#x201c;Black-Scholes&#x201d;) on a prospective basis to new awards. The Company expects the use of Black-Scholes to provide a more ubiquitous estimate of fair value. Like the prior trinomial lattice model, Black-Scholes is affected by the stock price on the date of the grant as well as assumptions regarding a number of highly complex and subjective variables. These variables include the expected term of the option, expected risk-free interest rate, the expected volatility of common stock, and expected dividend yield; each of which is described below. The assumptions for expected term and expected volatility are the two assumptions that significantly affect the grant date fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Term: The expected term of an option is determined using the simplified method under SAB 107 which represents the average between the vesting term and the contractual term. The Company utilizes the simplified method to determine the expected life of the options due to insufficient exercise activity during recent years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free Interest Rate: The risk-free interest rate used in the Black-Scholes model is based on the implied yield at the grant date of the U.S. Treasury zero-coupon issue with an equivalent term to the stock-based award being valued. Where the expected term of a stock-based award does not correspond with the term for which a zero coupon interest rate is quoted, the Company uses the nearest interest rate from available maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Stock Price Volatility: The Company uses its own historical weekly volatility because that is more reflective of market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend Yield: Because the Company has never paid a dividend and does not expect to begin doing so in the foreseeable future, the Company assumed no dividend yield in valuing the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent. The performance obligation is satisfied and revenues are recognized at the point in time the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay patients and within 60 to 90 days of billing for client payers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pharma Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Pharma Services segment generally enters into contracts with pharmaceutical and biotech customers as well as other Clinical Research Organizations (&#x201c;CROs&#x201d;) to provide research and clinical trial services ranging in duration from one month to several years. The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is recognized over time based on the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to sponsors at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics provides de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts collected for services provided in advance of revenue being recognized are deferred as contract liabilities. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently recognized. Contract assets are established for revenue that has been recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding account receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and are amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets and all others are classified as non-current assets. Contract assets are included in other current assets and other assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue includes payroll and payroll related costs for performing tests, project management, depreciation of laboratory equipment and laboratory leasehold improvements, rent for laboratory facilities, laboratory reagents, probes and supplies, delivery and courier costs relating to the transportation of specimens to be tested, and amortization for acquired Inivata developed technology intangible assets. The expenses related to shipping specimens to the facilities for testing, includes costs incurred for contract couriers, commercial airline flights, and courier charges. The Company also incurs expenses returning samples and slides to its customers.&#160;For the years ended December 31, 2021, 2020, and 2019, the Company recorded shipping expenses of approximately $16.5 million, $13.8 million, and $14.2 million, respectively as Cost of revenue in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist of payroll and payroll related costs for the Company&#x2019;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred. R&amp;amp;D expenses consist of payroll and payroll related costs, laboratory supplies, depreciation of laboratory equipment, and costs for samples to complete validation studies. These expenses are primarily incurred to develop new genetic tests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and are deemed immaterial for the years ended December 31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods and lives for property and equipment, recognition of bad debts, compensation related expenses, and various other expenses that have been allowed for or accrued for financial statement purposes but are not currently deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations, and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company evaluates tax positions that have been taken or are expected to be taken in its tax returns and records a liability for uncertain tax positions, if deemed necessary. The Company follows a two-step approach to recognizing and measuring uncertain tax positions. First, tax positions are recognized if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon examination, including resolution of related appeals or litigation processes, if any. Second, the tax position is measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes on the Consolidated Balance Sheets. At December 31, 2021 and 2020, the Company has an uncertain tax position related to Federal and State R&amp;amp;D tax credits, including a provision for interest and penalties related to such position as applicable. The Company does not expect a significant change in its uncertain tax positions in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Net (Loss) Income per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates basic net (loss) income per share attributable to common stockholders by dividing net (loss) income by the weighted-average number of shares of common stock outstanding for the period. Diluted net (loss) income per share is computed using the weighted average number of common shares outstanding during the applicable period, plus the dilutive effect of potential common stock. Potential common stock consists of shares issuable pursuant to stock options and convertible notes, as well as non-vested restricted stock awards which are not considered outstanding with respect to the weighted average common shares outstanding in the calculation of basic net (loss) income per share. Potentially dilutive shares are determined by applying the treasury stock method to the Company&#x2019;s outstanding stock options and restricted stock awards. Potentially dilutive shares issuable upon conversion of the 0.25% Convertible Senior Notes due 2028 and the 1.25% Convertible Senior Notes due 2025 are calculated using the if-converted method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the FASB issued ASU No. 2021-06, Presentation of Financial Statements (Topic 205), Financial Services-Depository and Lending (Topic 942), and Financial Services-Investment Companies (Topic 946) (&#x201c;ASU 2021-06&#x201d;), Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10786, Amendments to Financial Disclosures About Acquired and Disposed Businesses, and No.33-10835, Update of Statistical Disclosures for Bank and Savings and Loan Registrants. This update amends certain SEC disclosure guidance that is included in the accounting standards codification to reflect the SEC&#x2019;s recent issuance of rules intended to modernize and streamline disclosure requirements. The Company adopted this pronouncement upon issuance and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements, which updates various codification topics by clarifying disclosure requirements to align with the SEC&#x2019;s regulations. The Company adopted this pronouncement on January 1, 2021 and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, Debt&#x2009;-&#x2009;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2009;-&#x2009;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x2009;-&#x2009;Accounting For Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible instruments by removing the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such convertible debt instruments. Similarly, the debt discount, that is equal to the carrying value of the embedded conversion feature upon issuance, will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible instrument was issued at a substantial premium. In addition, ASU 2020-06 requires the application of the if-converted method for calculating the impact of convertible instruments on diluted earnings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. ASU 2020-06 can be adopted on either a fully retrospective or modified retrospective basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASU 2020-06 on January 1, 2021 using the modified retrospective approach, and, accordingly, the Company recorded an adjustment that reflects the 1.25% Convertible Senior Notes due 2025 as if the embedded conversion feature had not been separated. The impact upon adoption on the Consolidated Balance Sheets included an increase of approximately $27.2&#160;million in convertible senior notes, net, a write-off of approximately $6.6&#160;million in deferred income tax liabilities, establishment of approximately $2.0&#160;million of valuation allowance against deferred income tax assets, and a decrease of approximately $23.3&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment to increase the beginning balance of retained earnings on the Consolidated Balance Sheets for previously recognized interest expense, net of tax effects, of approximately $2.7&#160;million for amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance, as well as a decrease to the beginning balance of retained earnings of approximately $2.0&#160;million for the establishment of valuation allowance against the Company&#x2019;s deferred income tax assets. There was no impact to the Company&#x2019;s earnings per share calculation. For further information regarding the 1.25% Convertible Senior Notes due 2025, please refer to Note 9. Debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance (&#x201c;ASU 2021-10&#x201d;). This update requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this pronouncement on January 1, 2022, and is currently evaluating the impact of this standard on its annual disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#x201c;ASU 2021-08&#x201d;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the planned adoption date and the impact of this standard on its Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (&#x201c;ASU 2020-04&#x201d;) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (&#x201c;LIBOR&#x201d;) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) (&#x201c;ASU 2021-01&#x201d;) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of December 31, 2021, there was no impact to the Company&#x2019;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjM_df485d6b-20c4-4c3b-8339-9c6f8795fe92">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#x2019;s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these Consolidated Financial Statements include, but are not limited to, those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDE_5b89be1d-60d5-417a-9f25-234ecc88f301">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether investments in affiliates are a Variable Interest Entity (&#x201c;VIE&#x201d;) at the start of each new venture and when a reconsideration event has occurred. A reporting entity must consolidate a VIE if that reporting entity has a variable interest (or combination of variable interests) and is determined to be the primary beneficiary. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity&#x2019;s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;The Company accounts for its equity investments that are under 20% of the total equity outstanding and for which the Company does not have significant influence by applying the cost method. Investments that are under 20% of the total equity outstanding and for which the Company has significant influence are accounted for using the equity method unless a scope exception is applicable. Investments in which the Company holds a non-controlling interest and are between 20-50% equity are accounted for using the equity method. For any equity investments in which the Company holds over 50% of the outstanding stock, or for investments in which the Company controls the investee, the Company consolidates those entities into the Consolidated Financial Statements.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU2Mjg4Mg_7e27b754-4399-4adb-a987-92ad1fee5f8b">Segment ReportingThe Company reports its activities in two reportable segments; (1) the Clinical Services segment and (2) the Pharma Services segment.&#160;These reportable segments deliver testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers and represent 100% of the Company&#x2019;s consolidated assets, net revenue, and net (loss) income in each of the years ended December 31, 2021, 2020, and 2019.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzI5NA_02f06d13-433d-4765-bb62-11960cfcf322"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzI5NA_b2e00182-3d12-4980-8464-6cce9c362eff"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <neo:PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzU2MQ_266e2bb8-12fd-4b3c-b6eb-a13fe665782b"
      unitRef="number">1</neo:PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment>
    <neo:PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzU2MQ_4204abfa-b37d-4ae9-afc2-b3f0844545cc"
      unitRef="number">1</neo:PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment>
    <neo:PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzI5ODUzNTAwMzU2MQ_905d6e65-898c-452a-a590-e0ea29a0477a"
      unitRef="number">1</neo:PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDAwNw_ea98f009-0bd7-4500-917c-cbcc126517e0">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions of entities over which control is obtained that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent third-party valuations that use information and assumptions provided by management, which consider estimates of inputs and &lt;/span&gt;&lt;/div&gt;assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired less liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives, and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the Company&#x2019;s operating results from the date of acquisition.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDk_7a792a75-8a82-4485-960c-39359dca3e27">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash, certain cash equivalents, accounts receivable, net, other current assets, accounts payable, accrued expenses and other liabilities, and Pharma contract liabilities are considered reasonable estimates of their respective fair values due to their short-term nature. &lt;/span&gt;&lt;/div&gt;The Company measures its marketable securities at fair value on a recurring basis.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTM_03d13f6f-4837-4ad4-b2ef-5217032601a1">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with an original maturity of ninety days or less to be cash equivalents. The Company maintains its cash and cash equivalents with financial institutions that the Company believes to be of high credit standing. The Company believes that, as of December 31, 2021, its concentration of credit risk related to cash and cash equivalents was not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTA_0b4ab91e-202d-4b8c-ba18-e59e84d9c4fa">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all marketable securities as available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are carried at fair value, with the unrealized holding gains and losses, net of income taxes, reflected in accumulated other comprehensive income until realized. The Company evaluates its marketable securities for other-than-temporary impairment on a quarterly basis. Unrealized losses are charged against net earnings when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine whether a loss is other-than-temporary, such as the length and extent of the fair value decline, the financial condition and near-term prospects of the issuer, and whether there is the intent to sell or will more likely than not be required to sell before the securities&#x2019; anticipated recovery. There were no other-than-temporary impairments for the years ended December 31, 2021, 2020 and 2019. Regardless of the intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are recorded when the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/span&gt;&lt;/div&gt;For the purposes of computing realized and unrealized gains and losses, cost and fair value are determined on a specific identification basis.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU5MDY3MQ_0dd6ecde-065a-49dd-a987-c09aa3c2b09c"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU5MDY3MQ_768153d4-c130-4999-b94c-d88bf4577e98"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU5MDY3MQ_f8dd6dac-5856-4724-b4d1-18ae9058aefa"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTE_f9f6bb72-21ea-48bb-8805-ea88d432744b">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are reported for all Clinical Services payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For Pharma Services the Company negotiates billing schedules and payment terms on a contract-by-contract basis which can include payments based on certain milestones being achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjQ_c8f9701a-5847-4c90-96ee-f885b255eaff">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist principally of testing supplies and are valued at lower of cost or net realizable value, using the first-in, first-out method. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventories to their estimated net realizable value.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <neo:AssetsHeldForSalePolicyPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDAwOQ_a5234236-161a-44ae-aeb4-dfa39960d870">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets to be disposed of by sale are reclassified as held for sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use and when the Company commits to a plan to sell the assets. Assets classified as held for sale are measured at the lower of their carrying value or fair value less selling costs. Such assets are classified within current assets if there is reasonable certainty that the sale and collection of consideration will take place within one year. Upon reclassification as held for sale, long-lived assets are no longer depreciated or amortized and a measurement for impairment is performed to determine if there is an excess of carrying value over fair value less costs to sell. Any remeasurement is reported as an adjustment to the carrying value of the assets. Subsequent changes to estimated fair value less the selling costs will impact the measurement of assets held for sale if the fair value is determined to be less than the carrying value of the assets.&lt;/span&gt;&lt;/div&gt;</neo:AssetsHeldForSalePolicyPolicyTextBlock>
    <neo:AssetHeldForSaleSquareFeetOfFacilityOwned
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDAxMQ_f5355dca-acd6-4732-b09c-f3841b8f9738"
      unitRef="sqft">43560</neo:AssetHeldForSaleSquareFeetOfFacilityOwned>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU2MjkxMg_4ea1919e-b685-47b4-b47b-2baeaf0216b0"
      unitRef="usd">10100000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU4MDM5Nw_08cd435f-9281-45b6-9540-6d3ddc973d8e">The Company records a prepaid expense for costs paid but not yet incurred. Those expected to be incurred within one year are recorded as prepaid assets within total current assets on the Consolidated Balance Sheets. Any costs expected to be incurred outside of one year are recorded as other assets within total non-current assets on the Consolidated Balance Sheets.</us-gaap:DeferredChargesPolicyTextBlock>
    <neo:OtherCurrentAssetsPolicyPolicyPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjU_590a8d6f-0792-467f-9cf5-83a1130b7d15">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, other current assets consisted primarily of receivables related to research and development (&#x201c;R&amp;amp;D&#x201d;) tax credit receivables, pharma contract assets and other non-trade receivables.&lt;/span&gt;&lt;/div&gt;</neo:OtherCurrentAssetsPolicyPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTU_d4bcb145-0bdc-4e41-9ef6-5977daf2dcf1">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on the straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the related lease terms or their estimated useful lives. Costs incurred in connection with the development of internal-use software are capitalized in accordance with the accounting standard for internal-use software, and are amortized over the expected useful life of the software.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews the estimated useful lives of property and equipment. Changes to the estimated useful lives are recorded prospectively from the date of the change. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts and any resulting gain or loss is included in income (loss) from operations. Repairs and maintenance costs are expensed as incurred and are included in cost of revenue, general and administrative expenses or R&amp;amp;D expenses, as appropriate in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTY_b286d371-3c94-4842-86af-fb246b41980a">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases corporate offices and laboratory spaces throughout the world, all of which are classified as operating leases expiring at various dates and generally having terms ranging from 1 to 20 years. Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s real estate lease agreements include options to either renew or early terminate the lease. Leases with renewal options allow the Company to extend the lease term typically between 1 and 5 years. When it is reasonably certain that the Company will exercise an option to renew or terminate a lease, these options are considered in determining the classification and measurement of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities are recorded based on the present value of the future lease payments over the lease term and assessed as of the commencement date. Incentives received from landlords, such as reimbursements for tenant improvements and rent abatement periods, effectively reduce the total lease payments owed for leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain real estate leases also include executory costs such as common area maintenance (non-lease component), as well as property insurance and property taxes (non-components). Lease payments, which may include lease components, non-lease components and non-components, are included in the measurement of the Company&#x2019;s lease liabilities to the extent that such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payments are either fixed amounts or variable amounts based on a rate or index (fixed in substance), as stipulated in the lease contract. Any actual costs in excess of such amounts are expensed as incurred as variable lease cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes its incremental borrowing rate by lease term in order to calculate the present value of its future lease payments when the implicit rates in the leases agreements are not readily determinable. The discount rate represents a risk-adjusted rate on a secured basis and is the rate at which the Company would borrow funds to satisfy the scheduled lease liability payment streams commensurate with the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs represent fixed lease payments recognized on a straight-line basis over the lease term. Operating lease costs include an immaterial amount of variable lease costs and are recorded in cost of revenue, general and administrative, sales and marketing, and R&amp;amp;D expenses (depending on the nature of the leased asset) in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="id8fa1647fb744e689ec47a53eb568d0b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTIwMzE_a4a84daa-7d03-49c4-8b05-f7c1ffee11b5">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i9e0ce2e60c5f48469d701fa7b04e3fdb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTIwMzc_ab494235-c0b6-4acf-a7c8-acb11c3a4770">P20Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="id8fa1647fb744e689ec47a53eb568d0b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTIzMzI_8e2f963a-e861-4802-9180-535ce1ca5f6d">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9e0ce2e60c5f48469d701fa7b04e3fdb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTIzMzk_2ea797b1-1452-449f-981f-3477aafad2f8">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDc_0b89b8b7-98f3-4dae-8252-6546250213ee">Intangible Assets, netIntangible assets with determinable useful lives are recorded initially at acquired fair value or cost, less accumulated amortization. Each intangible asset with a determinable useful life is amortized over its estimated useful life using the straight-line method. The Company periodically reviews the estimated pattern in which the economic benefits will be consumed and adjusts the amortization period and pattern to match the estimate. Intangible assets with indefinite useful lives are recorded initially at fair value or cost and are tested annually for impairment or more frequently if management believes indicators of impairment exist.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTUwNDk_2df870e2-302a-4532-9fce-949c8bd17bc7"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTUwNDk_8f193cb6-e94e-41e4-9bbb-f40fa703377d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTUwNDk_cb762ee9-d1f9-4e47-8d27-0ea114bd37fd"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDU_8078cd1b-e31b-4c9a-bed5-dc4d84a4f388">GoodwillThe Company evaluates goodwill on an annual basis in the fourth quarter or more frequently if management believes indicators of impairment exist. Such indicators could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management performs a quantitative goodwill impairment test. The quantitative analysis is performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit&#x2019;s fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies&#x2019; data.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjA_7f557173-806d-406b-bed2-11fd42bce90a">Recoverability and Impairment of Long-Lived AssetsThe Company reviews the recoverability of its long-lived assets (including definite-lived intangible assets) if events or changes in circumstances indicate the assets may be impaired. Evaluation of possible impairment is based on the Company&#x2019;s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value to the carrying amount of the asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTc0MzM_9acd79ff-743b-4f35-8d86-4703a56a24d4"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTc0MzM_a1e83a4c-4c29-4183-abda-f9a4ed8029be"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTc0MzM_f7664fbe-aea4-4a8e-8852-27f4f505904f"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU4MDM5OA_05cebf55-4258-4f54-8c2c-e6658151badc">We accrue contingent losses when estimated impacts of various conditions, situations or circumstances involve uncertain outcomes. Contingent losses are recorded based on management judgment along with internal and external advice from legal counsel and/or technical consultants. Estimated losses from contingencies are recorded when both of the following conditions are met: (i) information available before the financial statements are issued (or available to be issued) indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) the amount of loss can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, that amount shall be accrued. When no amount within the range is a better estimate than any other amount, however, the minimum amount in the range shall be accrued. Please refer to Note 17. Commitments and Contingencies, for further discussion.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDI_c29a5557-8cc4-4924-b95d-86be89d63f3a">Debt Issuance CostsDebt issuance costs related to convertible senior notes are recorded as deductions that net against the principal value of the debt and are amortized as interest expense over the life of the debt using the effective interest method. Debt issuance costs related to term loans are recorded as direct deductions from the carrying amount of the term loan and are amortized to interest expense over the life of the debt using the effective interest method.&#160;Debt issuance costs relating to line of credit arrangements are recorded as assets and amortized over the term of the credit arrangement regardless of whether any outstanding borrowing existed. The term loan and line of credit were terminated in 2020 and all debt issuance costs were expensed accordingly.</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE2OTk_4c650d77-f9c3-4043-8011-e59b76557027">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures compensation expense for stock-based awards to employees, non-employee contracted physicians, and directors based upon the awards&#x2019; initial grant-date fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2021 the Company estimated the fair value of stock options using a trinomial lattice model. On January 1, 2021, the Company began applying the Black-Scholes option valuation model (&#x201c;Black-Scholes&#x201d;) on a prospective basis to new awards. The Company expects the use of Black-Scholes to provide a more ubiquitous estimate of fair value. Like the prior trinomial lattice model, Black-Scholes is affected by the stock price on the date of the grant as well as assumptions regarding a number of highly complex and subjective variables. These variables include the expected term of the option, expected risk-free interest rate, the expected volatility of common stock, and expected dividend yield; each of which is described below. The assumptions for expected term and expected volatility are the two assumptions that significantly affect the grant date fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Term: The expected term of an option is determined using the simplified method under SAB 107 which represents the average between the vesting term and the contractual term. The Company utilizes the simplified method to determine the expected life of the options due to insufficient exercise activity during recent years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free Interest Rate: The risk-free interest rate used in the Black-Scholes model is based on the implied yield at the grant date of the U.S. Treasury zero-coupon issue with an equivalent term to the stock-based award being valued. Where the expected term of a stock-based award does not correspond with the term for which a zero coupon interest rate is quoted, the Company uses the nearest interest rate from available maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Stock Price Volatility: The Company uses its own historical weekly volatility because that is more reflective of market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend Yield: Because the Company has never paid a dividend and does not expect to begin doing so in the foreseeable future, the Company assumed no dividend yield in valuing the stock-based awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDA_0bb8ceb7-373f-45dd-8db7-86d7419ca805">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent. The performance obligation is satisfied and revenues are recognized at the point in time the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay patients and within 60 to 90 days of billing for client payers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pharma Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Pharma Services segment generally enters into contracts with pharmaceutical and biotech customers as well as other Clinical Research Organizations (&#x201c;CROs&#x201d;) to provide research and clinical trial services ranging in duration from one month to several years. The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is recognized over time based on the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to sponsors at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics provides de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts collected for services provided in advance of revenue being recognized are deferred as contract liabilities. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently recognized. Contract assets are established for revenue that has been recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding account receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and are amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets and all others are classified as non-current assets. Contract assets are included in other current assets and other assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDY_198c1d11-439a-4eb8-a109-2ef2108d092d">Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay patients and within 60 to 90 days of billing for client payers.</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDM_5efa417e-cc3b-4ecd-a813-0471d81a06cf">Cost of RevenueCost of revenue includes payroll and payroll related costs for performing tests, project management, depreciation of laboratory equipment and laboratory leasehold improvements, rent for laboratory facilities, laboratory reagents, probes and supplies, delivery and courier costs relating to the transportation of specimens to be tested, and amortization for acquired Inivata developed technology intangible assets. The expenses related to shipping specimens to the facilities for testing, includes costs incurred for contract couriers, commercial airline flights, and courier charges. The Company also incurs expenses returning samples and slides to its customers.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i254845f3a44141fc942661d21925077a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMjYwNjA_fcce48a9-457a-41c7-b07c-5f49045c6575"
      unitRef="usd">16500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3530310efa1a411da896298ef26d7531_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMjYwNjQ_40f715a5-07da-4a76-8f91-005c5a93a02c"
      unitRef="usd">13800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib644839f440545ae8408c532800708e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMjYwNzE_96403c0b-9b74-4fd1-93e6-7f157e11c3c4"
      unitRef="usd">14200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTk_63bbf187-3830-4cd4-ba90-8fb44b3a5c1f">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist of payroll and payroll related costs for the Company&#x2019;s billing, finance, human resources, information technology, and other administrative personnel as well as stock-based compensation. The Company also includes professional services, facilities expense, IT infrastructure costs, depreciation, amortization, and other administrative-related costs in general and administrative expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MTc_72bbee32-6a97-4ebc-8a76-7f6e3f2857f5">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred. R&amp;amp;D expenses consist of payroll and payroll related costs, laboratory supplies, depreciation of laboratory equipment, and costs for samples to complete validation studies. These expenses are primarily incurred to develop new genetic tests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and are deemed immaterial for the years ended December 31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RegulatoryIncomeTaxesPolicy
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MjE_b2e9fc8d-91b8-480d-9023-94952f96a2bb">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods and lives for property and equipment, recognition of bad debts, compensation related expenses, and various other expenses that have been allowed for or accrued for financial statement purposes but are not currently deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations, and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company evaluates tax positions that have been taken or are expected to be taken in its tax returns and records a liability for uncertain tax positions, if deemed necessary. The Company follows a two-step approach to recognizing and measuring uncertain tax positions. First, tax positions are recognized if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon examination, including resolution of related appeals or litigation processes, if any. Second, the tax position is measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes on the Consolidated Balance Sheets. At December 31, 2021 and 2020, the Company has an uncertain tax position related to Federal and State R&amp;amp;D tax credits, including a provision for interest and penalties related to such position as applicable. The Company does not expect a significant change in its uncertain tax positions in the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:RegulatoryIncomeTaxesPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDQ_b1a2d74d-63d5-4210-a925-c51af36e9118">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Net (Loss) Income per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates basic net (loss) income per share attributable to common stockholders by dividing net (loss) income by the weighted-average number of shares of common stock outstanding for the period. Diluted net (loss) income per share is computed using the weighted average number of common shares outstanding during the applicable period, plus the dilutive effect of potential common stock. Potential common stock consists of shares issuable pursuant to stock options and convertible notes, as well as non-vested restricted stock awards which are not considered outstanding with respect to the weighted average common shares outstanding in the calculation of basic net (loss) income per share. Potentially dilutive shares are determined by applying the treasury stock method to the Company&#x2019;s outstanding stock options and restricted stock awards. Potentially dilutive shares issuable upon conversion of the 0.25% Convertible Senior Notes due 2028 and the 1.25% Convertible Senior Notes due 2025 are calculated using the if-converted method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDAzNQ_8e3cbf4e-7c14-4408-8509-dfb225d0f239"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMzExODA_5ee97888-b995-4659-839a-b69bfd456c72"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfNDE3MDg_5009c4a0-3853-4b80-a841-248492fd1d40">&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the FASB issued ASU No. 2021-06, Presentation of Financial Statements (Topic 205), Financial Services-Depository and Lending (Topic 942), and Financial Services-Investment Companies (Topic 946) (&#x201c;ASU 2021-06&#x201d;), Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10786, Amendments to Financial Disclosures About Acquired and Disposed Businesses, and No.33-10835, Update of Statistical Disclosures for Bank and Savings and Loan Registrants. This update amends certain SEC disclosure guidance that is included in the accounting standards codification to reflect the SEC&#x2019;s recent issuance of rules intended to modernize and streamline disclosure requirements. The Company adopted this pronouncement upon issuance and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements, which updates various codification topics by clarifying disclosure requirements to align with the SEC&#x2019;s regulations. The Company adopted this pronouncement on January 1, 2021 and the impact of the provisions of this standard on its Consolidated Financial Statements was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, Debt&#x2009;-&#x2009;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2009;-&#x2009;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x2009;-&#x2009;Accounting For Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible instruments by removing the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such convertible debt instruments. Similarly, the debt discount, that is equal to the carrying value of the embedded conversion feature upon issuance, will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible instrument was issued at a substantial premium. In addition, ASU 2020-06 requires the application of the if-converted method for calculating the impact of convertible instruments on diluted earnings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. ASU 2020-06 can be adopted on either a fully retrospective or modified retrospective basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASU 2020-06 on January 1, 2021 using the modified retrospective approach, and, accordingly, the Company recorded an adjustment that reflects the 1.25% Convertible Senior Notes due 2025 as if the embedded conversion feature had not been separated. The impact upon adoption on the Consolidated Balance Sheets included an increase of approximately $27.2&#160;million in convertible senior notes, net, a write-off of approximately $6.6&#160;million in deferred income tax liabilities, establishment of approximately $2.0&#160;million of valuation allowance against deferred income tax assets, and a decrease of approximately $23.3&#160;million in additional paid-in capital. In addition, upon adoption, there was an adjustment to increase the beginning balance of retained earnings on the Consolidated Balance Sheets for previously recognized interest expense, net of tax effects, of approximately $2.7&#160;million for amortization of debt discount related to the carrying value of the embedded conversion feature upon issuance, as well as a decrease to the beginning balance of retained earnings of approximately $2.0&#160;million for the establishment of valuation allowance against the Company&#x2019;s deferred income tax assets. There was no impact to the Company&#x2019;s earnings per share calculation. For further information regarding the 1.25% Convertible Senior Notes due 2025, please refer to Note 9. Debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance (&#x201c;ASU 2021-10&#x201d;). This update requires business entities to disclose information about certain government assistance they receive. Such disclosure requirements include the nature of the transactions and the related accounting policy used, the line items on the balance sheet and income statement that are affected and the amounts applicable to each financial statement line item and significant terms and conditions of the transactions. ASU 2021-10 is effective for annual periods beginning after December 15, 2021, with early adoption permitted. ASU 2021-10 should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company will adopt this pronouncement on January 1, 2022, and is currently evaluating the impact of this standard on its annual disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#x201c;ASU 2021-08&#x201d;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the planned adoption date and the impact of this standard on its Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (&#x201c;ASU 2020-04&#x201d;) which provides for temporary optional expedients and exceptions to the current guidance on certain contract modifications and hedging relationships to ease the burdens related to the expected market transition from the London Inter-bank Offered Rate (&#x201c;LIBOR&#x201d;) or other reference rates to alternative reference rates. In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) (&#x201c;ASU 2021-01&#x201d;) to clarify that certain optional expedients and exceptions apply to modifications of derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements, and for calculating price alignment interest. ASU 2020-04 was effective beginning on March 12, 2020 and may be applied prospectively to such transactions through December 31, 2022 and ASU 2021-01 was effective beginning on January 7, 2021 and may be applied retrospectively or prospectively to such transactions through December 31, 2022. The Company will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. As of December 31, 2021, there was no impact to the Company&#x2019;s Consolidated Financial Statements related to ASU 2020-04 or ASU 2021-01.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA0Mg_165cc6ee-68ae-4b60-b5ef-ecf93e2bfea4"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i0d57451dc3554d079ea8b73a036cab7f_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA0OQ_4a337db4-b2f0-4db6-a133-2b021459702c"
      unitRef="usd">27200000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0d57451dc3554d079ea8b73a036cab7f_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDEwNQ_6fb0b885-78d0-4db5-9dea-974b08ba3c7a"
      unitRef="usd">-6600000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0d57451dc3554d079ea8b73a036cab7f_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA2NA_fe6372d9-e877-4a3a-a1f0-0fe24ba60913"
      unitRef="usd">2000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:StockholdersEquity
      contextRef="i83026cc4bc5d41b4ad74488ad2199f77_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA3Ng_94d58871-f5d3-4299-a4ac-d666ebae9d55"
      unitRef="usd">-23300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i703a879602c940af8370fab4717a800c_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDA5MQ_415fbdff-fb69-402a-bafc-7c040243d681"
      unitRef="usd">2700000</us-gaap:StockholdersEquity>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0d57451dc3554d079ea8b73a036cab7f_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDEyNg_a1760171-0a8f-4f32-ae0d-b57cc0b895ac"
      unitRef="usd">2000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84NS9mcmFnOjUyOWM4ZmJlZjM5YjRmMmI5ZDdiOGFhYjQ0ZWZiMDQ4L3RleHRyZWdpb246NTI5YzhmYmVmMzliNGYyYjlkN2I4YWFiNDRlZmIwNDhfMTY0OTI2NzU0NDExOQ_dde437b4-f13b-421b-90db-305b437e9f6d"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTk2Mw_fc866e1f-a738-4213-a472-771297c08201">Acquisitions &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Trapelo Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 7, 2021 (the &#x201c;Trapelo Acquisition Date&#x201d;), the Company completed the acquisition of a 100% ownership interest in Intervention Insights, Inc. d/b/a Trapelo Health (&#x201c;Trapelo&#x201d;), an information technology company focused on precision oncology. The purchase price consisted of (i) cash consideration of $35.6&#160;million, which included a net adjustment of $0.6&#160;million for estimated cash on hand of Trapelo and estimated working capital adjustments on the Trapelo Acquisition Date, and (ii) equity consideration of $29.2&#160;million, consisting of 597,712 shares of the Company&#x2019;s common stock, par value $0.001 per share, valued at $48.81 per share. The Company acquired control of Trapelo on the Trapelo Acquisition Date; therefore, the fair value of the common stock issued as part of consideration was determined on the basis of the closing market price of the Company&#x2019;s common stock immediately prior to the Trapelo Acquisition Date. The Trapelo acquisition enhances the Company&#x2019;s ability to provide customers clinical decision support to help answer complex questions related to precision oncology biomarker testing and treatment options as part of the Company&#x2019;s comprehensive oncology offerings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Trapelo was determined to be a business combination and has been accounted for using the acquisition method. The purchase price and purchase price allocation are preliminary, are based upon management&#x2019;s best estimates and assumptions, and are subject to future revision. The following table summarizes the estimated purchase consideration recorded for the acquisition of Trapelo, the estimated fair value of the net assets acquired and liabilities assumed, and the preliminary calculation of goodwill based on the excess of the estimated consideration transferred over the estimated fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Per share value of common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of common stock at Trapelo Acquisition Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of the purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - marketing assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the timing of the acquisition, the following are considered preliminary and are subject to change:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;amount of goodwill pending the completion of the amounts for income tax assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will finalize these amounts no later than one year from the acquisition date once it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in adjustments to the preliminary amounts disclosed above which may impact the reported results in the period those adjustments are identified. There have been no such adjustments to the preliminary amounts disclosed above subsequent to the Trapelo Acquisition Date through December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The identified developed technology and marketing intangible assets are being amortized over ten years and four years, respectively, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Trapelo acquisition is 9.8 years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The marketing intangible assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the marketing intangible assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the marketing intangible assets had the intangible assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#x2019;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The goodwill recognized, all of which is assigned to the Clinical Services segment, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. None of the goodwill resulting from the acquisition of Trapelo is expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition and integration costs related to Trapelo were approximately $1.8&#160;million for the year ended December 31, 2021 and are reported as general and administrative expenses in the Company&#x2019;s Consolidated Statements of Operations. There were no such amounts recorded for the years ended December 31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations of Trapelo are included in the Company&#x2019;s Consolidated Financial Statements beginning on the Trapelo Acquisition Date. Revenue and net (loss) income of Trapelo included in the Consolidated Statements of Operations was not material for the period from the Trapelo Acquisition Date to December 31, 2021. No pro forma information has been included relating to the Trapelo acquisition, as this acquisition was not deemed to be material to the Company&#x2019;s revenue or net (loss) income on a pro forma basis for the period from the Trapelo Acquisition Date to December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Inivata Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021 (the &#x201c;Inivata Acquisition Date&#x201d;), the Company completed the acquisition of the remaining equity interests in Inivata Limited, a private limited company incorporated in England and Wales (&#x201c;Inivata&#x201d;). Inivata is a global, commercial stage, liquid biopsy platform company. The acquisition follows a $25.0&#160;million minority equity investment by the Company in Series C1 Preference Shares (the &#x201c;Preference Shares&#x201d; or &#x201c;previously-held equity interest&#x201d;) in Inivata in May 2020, at which time the Company also acquired a fixed price option to purchase the remainder of equity interests in Inivata for $390.0&#160;million (the &#x201c;Purchase Option&#x201d;). The Company and Inivata also entered into a line of credit agreement in the amount of $15.0&#160;million (the &#x201c;Line of Credit&#x201d;) in May 2020. For further details regarding the previously-held equity investment in Inivata, the Purchase Option and the Line of Credit, please refer to Note 8. Investment in Non-Consolidated Affiliate. The Inivata acquisition adds liquid biopsy platform technology, including minimal residual disease testing capabilities, to the Company&#x2019;s comprehensive portfolio of oncology testing solutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price consisted of cash consideration of $398.6&#160;million, which included a net adjustment of $8.6&#160;million for estimated cash on hand of Inivata and other adjustments on the Inivata Acquisition Date, and was funded through cash on hand and a private placement of equity. For further information regarding the private placement of equity, please refer to Note 11. Equity Transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the acquisition of the remaining equity interests in Inivata, the Company accounted for its previously-held equity interest and the Purchase Option in Inivata as equity securities without a readily determinable fair value. The equity interests were recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Therefore, the Company&#x2019;s acquisition of control of Inivata on the Inivata Acquisition Date was accounted for as a business combination achieved in stages under the acquisition method. Accordingly, the Company used a discounted cash flow to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#x2019;s previously-held equity interest and Purchase Option in Inivata. To determine the fair value of the previously-held equity interest, the fair value of Inivata&#x2019;s total equity was allocated to its various classes of equity based on the respective rights and privileges of each class of stock in liquidation. The business enterprise value and a Black-Scholes model were then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at the fair value at the Inivata Acquisition Date based on its settlement value. This resulted in fair values of $64.9&#160;million in Preference Shares and a $74.3&#160;million Purchase Option, immediately prior to the acquisition. On the Inivata Acquisition Date, the $10.3&#160;million outstanding under the Line of Credit extended by the Company to Inivata was effectively settled as part of the acquisition of Inivata at the $15.0&#160;million principal amount and was recorded as part of the consideration transferred in the acquisition. The Company recorded a gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#x2019;s Consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statements of Operations of $109.3&#160;million for the year ended December 31, 2021, including a measurement period adjustment of $17.8&#160;million recorded for the year ended December 31, 2021, for the excess of the acquisition-date fair value of the Company&#x2019;s previously-held equity interest, Purchase Option, and Line of Credit over their carrying values. For further details regarding the previously-held equity investment and purchase option in Inivata, please refer to Note 8. Investment in Non-Consolidated Affiliate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and allocation of the business combination are preliminary, are based upon management&#x2019;s best estimates and assumptions, and are subject to future revision. The following table summarizes the preliminary calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit and the estimated fair value of the previously-held equity interest and Purchase Option over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 18, 2021&lt;br/&gt;(as initially reported)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 18, 2021 &lt;br/&gt;(as adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value of business combination:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Line of Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of previously-held equity interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Purchase Option&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total fair value of business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of the fair value business combination:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets - developed technology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets - trademarks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - trade name&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total fair value of business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to a change in legal settlement liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangible assets and related future amortization and the change in legal settlement liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the timing of the acquisition, the following are considered preliminary and are subject to change:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;amounts for intangible assets, property and equipment, other current assets, current liabilities, and other long-term liabilities pending finalization of the valuation;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;amounts for income tax liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed and the reporting unit allocation of the goodwill; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the acquisition-date fair value of the Company&#x2019;s previously-held equity interest, Purchase Option, and the Line of Credit, and the gain on investment in and loan receivable from non-consolidated affiliate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will finalize these amounts no later than one year from the acquisition date, once it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in adjustments to the preliminary amounts disclosed above which may impact the reported results in the period those adjustments are identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The identified developed technology intangible assets and the trademark intangible assets are both being amortized over fifteen years, and the trade name intangible asset is being amortized over five years, based on their estimated useful lives. The weighted-average amortization period in total for all classes of intangible assets from the Inivata acquisition is 14.9 years. The developed technology was valued using the income approach, specifically, the multi-period excess earnings method, which measures the after-tax cash flows attributable to the developed technology. The trademarks and trade name assets were valued using the income approach, specifically, the relief from royalty method, which measures the cash flow streams attributable to the trademarks and trade name assets in the form of the avoided royalty payment that would be paid to the owner in return for the rights to use the trademarks and trade name assets had the assets not been acquired. The values of the identifiable intangible assets represent Level 3 measurements as they were based on unobservable inputs reflecting the Company&#x2019;s assumptions used in pricing the assets at fair value. These inputs required significant judgments and estimates at the time of the valuation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The goodwill recognized, of which $238.4 million and $33.0 million is assigned to the Clinical Services and Pharma Services segments, respectively, was primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of liquid biopsy technology for oncology testing. The recording of amortizable intangibles has given rise to a deferred tax liability upon the acquisition of Inivata which increased goodwill by $61.0 million. None of the goodwill resulting from the acquisition of Inivata is expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition and integration costs related to Inivata were $-13.9&#160;million for the year ended December 31, 2021 and are reported as general and administrative expenses in the Company&#x2019;s Consolidated Statements of Operations. There were no such amounts for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations of the Company&#x2019;s Inivata subsidiary are included in the Company&#x2019;s Consolidated Financial Statements beginning on the Inivata Acquisition Date. For the period from the Inivata Acquisition Date to December 31, 2021, the Inivata subsidiary revenue was $1.5&#160;million, all of which was recorded in Pharma Services revenue. The Inivata subsidiary net loss was $27.6&#160;million for the period from the Inivata Acquisition Date to December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited pro forma results represent the combined results of operations of the Company and Inivata, on an unaudited pro forma basis, for the period in which the acquisition of Inivata occurred and the prior reporting period as though the companies had been combined as of the beginning of the earliest period presented. Therefore, the unaudited pro forma consolidated results have been prepared by adjusting the Company&#x2019;s historical results to include the acquisition of Inivata as if it occurred on January 1, 2020. Acquisition-related transaction costs incurred by Inivata of $11.0&#160;million are included in net loss as if incurred on January 1, 2020. Acquisition-related transaction and retention costs incurred by the Company of $13.9&#160;million are included in net loss as if incurred on January 1, 2020. These unaudited pro forma consolidated historical results exclude $109.3&#160;million and $4.0&#160;million of gain on investment in and loan receivable from non-consolidated affiliate, net, recorded for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg0Nw_441ea546-34af-4eef-abb2-4312c638daa1"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NjgzMg_2fb68294-21f0-4277-a995-1e2248704af2"
      unitRef="usd">35600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments
      contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg5Mw_0067be10-f44e-4265-829a-f442f4ad656f"
      unitRef="usd">600000</neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg1Mw_c20e8894-1c2c-4538-b342-e63b0b1da763"
      unitRef="usd">29200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg2OA_66701302-1bac-4957-90ad-556b573d12fe"
      unitRef="shares">597712</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg4NQ_cf4fbfa3-8204-4562-a09a-93d8e8594213"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njg3Nw_2f264074-9b2d-4323-9d2d-152cf10cef22"
      unitRef="usdPerShare">48.81</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTk2NA_fcabd832-7d2f-4dfe-92fb-bf3ff088a53a">The following table summarizes the estimated purchase consideration recorded for the acquisition of Trapelo, the estimated fair value of the net assets acquired and liabilities assumed, and the preliminary calculation of goodwill based on the excess of the estimated consideration transferred over the estimated fair value of the net assets acquired and liabilities assumed at the Trapelo Acquisition Date (in thousands, except per share data):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Per share value of common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of common stock at Trapelo Acquisition Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of the purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - marketing assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The following table summarizes the preliminary calculation of goodwill based on the excess of the estimated fair value of the consideration transferred including the fair value of the Line of Credit and the estimated fair value of the previously-held equity interest and Purchase Option over the estimated fair value of the net assets acquired and liabilities assumed at the Inivata Acquisition Date and includes measurement period adjustments recorded during 2021 (in thousands):&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 18, 2021&lt;br/&gt;(as initially reported)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 18, 2021 &lt;br/&gt;(as adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value of business combination:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Line of Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of previously-held equity interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Purchase Option&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total fair value of business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of the fair value business combination:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets - developed technology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets - trademarks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible asset - trade name&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total fair value of business combination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment primarily relates to a change in estimated taxes based on jurisdictions in which forecasted profits are expected to be generated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to the recognition of a credit which Inivata is entitled to claim for certain research and development expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to a change in legal settlement liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment relates to a change in estimated deferred income tax liabilities as a result of the reduction in the amounts for intangible assets and related future amortization and the change in legal settlement liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMi0yLTEtMS00NDI2OQ_452875a7-a624-4ab6-903f-663d76af09c6"
      unitRef="shares">597712</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMy0yLTEtMS00NDI2OQ_ce647117-51aa-4f4e-b80f-b251c3adcb1f"
      unitRef="usdPerShare">48.81</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfNC0yLTEtMS00NDI2OQ_93bb1757-efc4-4cab-82a8-142dadfd7f62"
      unitRef="usd">29174000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfNS0yLTEtMS00NDI2OQ_ce54131a-23ac-4f29-88c8-5b87af297f6c"
      unitRef="usd">35591000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfNi0yLTEtMS00NDI2OQ_843c8731-ac32-49fd-92ac-e87316f87490"
      unitRef="usd">64765000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfOS0yLTEtMS00NDI2OQ_6d69b8aa-6f5f-42c3-85f1-62a0a499589d"
      unitRef="usd">713000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTAtMi0xLTEtNDQyNjk_edfb843b-a9c9-4b53-9e04-f30d03aade20"
      unitRef="usd">282000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8259a282355a443fa5a631a8aff168d8_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTEtMi0xLTEtNDQyNjk_878d9c11-cc9f-4c8a-b016-d60beab20e65"
      unitRef="usd">549000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie972fa406763417d8f2c25acd458f794_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTItMi0xLTEtNDQyNjk_26302607-bb21-4bf3-8bcc-ed313ed5fc30"
      unitRef="usd">19040000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTMtMi0xLTEtNDQyNjk_d383f634-73f9-4dde-831b-780047d3babc"
      unitRef="usd">268000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTQtMi0xLTEtNDQyNjk_ed5e4e53-5135-4ec0-bb49-f428310e435c"
      unitRef="usd">20852000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTUtMi0xLTEtNDQyNjk_a287727c-0da7-481b-8562-bee8fc6e7ce3"
      unitRef="usd">751000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTYtMi0xLTEtNDQyNjk_c97f2155-6655-48a8-924b-19351167064b"
      unitRef="usd">20101000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTctMi0xLTEtNDQyNjk_2e34e35d-da97-4d06-b226-127d363639a2"
      unitRef="usd">44664000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjhjZDg0OTE1YmJkNzRhNDU4MTg1MGM2MjBhYmQ4ZjI1L3RhYmxlcmFuZ2U6OGNkODQ5MTViYmQ3NGE0NTgxODUwYzYyMGFiZDhmMjVfMTgtMi0xLTEtNDQyNjk_d2851a4c-4774-43cf-82ae-f3c00a299228"
      unitRef="usd">64765000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i58e1304c1c784732a549e74c73206cf7_D20210407-20210407"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njk1MQ_138bb283-2a82-42ac-83dc-bea15b8323d1">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3b120b1a036d4eb488cfbc0aaf1ae278_D20210407-20210407"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njk3MQ_6ff66356-b9b4-4c1c-a920-30e99b71849b">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NjkyNw_18d0a52c-8aff-41dd-b887-35f2051ea81c">P9Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i62ee856eea894002ad4ee9f50ed2417f_I20210407"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4Njk4MA_afd78d51-d279-4444-b2fb-fdc68d6b5bf9"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="i1f7ed50e5ea746629e2bf83cd1f470c3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMzI5ODUzNDkyOTIyMg_67ae8e09-6fde-4569-9404-dd87dfd518dc"
      unitRef="usd">1800000</neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="ide651db4d96d4bcdb658a4ec18230410_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAwMw_50642599-0246-429a-a57d-e5219775467d"
      unitRef="usd">0</neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="ib5dd1dfb285c4701b75adf82d4eff717_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAwMw_880abd45-6160-410a-b5d2-fbaf56a8d4ea"
      unitRef="usd">0</neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i50f0b20cb9b84704a2839897bfab2b29_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAwOA_57d47251-2b1a-4229-a18a-ef954b804cf4"
      unitRef="usd">25000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i3f4da2d058964b75bd9d1986bbd5843b_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAyMQ_cac913d9-0e9b-4316-acd1-4902e4e451d4"
      unitRef="usd">390000000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzAzNQ_82abe24d-6f51-45b0-aa93-0ae5eccdfce0"
      unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzA0OA_ecac454e-c557-47e0-b9fa-25cb334b5109"
      unitRef="usd">398600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzA2NA_7dc88bec-4273-4bf3-93a7-44b87352170f"
      unitRef="usd">8600000</neo:CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzA3OA_1ae54e1a-2cf8-409d-b6bd-ecc2f333264b"
      unitRef="usd">64900000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue
      contextRef="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzA5Mw_33d06b9d-f58e-4fa6-882f-d429553c15d3"
      unitRef="usd">74300000</neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue>
    <us-gaap:LineOfCredit
      contextRef="if0bf694fe7e54138828b3af7f759dc6b_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzEwOA_a330593d-40c7-4258-988c-b2006a14bc10"
      unitRef="usd">10300000</us-gaap:LineOfCredit>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzEyMw_a85750b7-6063-4837-83d9-781d798e4670"
      unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzE1MQ_f6699c86-7681-4ce1-9232-f92d3a3c765e"
      unitRef="usd">109300000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzEzNg_59753004-1aa3-4c80-a256-697dedf71916"
      unitRef="usd">17800000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMi0yLTEtMS00NDQ3Mg_91748e51-00b9-4c35-8378-13efb9e9a424"
      unitRef="usd">398594000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMi02LTEtMS00NDQ3Mg_d0e83326-ae64-4ea9-a52b-883e5f72a603"
      unitRef="usd">398594000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMy0yLTEtMS00NDQ3Mg_08e2a83e-7f47-4370-a55e-83b24be7a765"
      unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMy02LTEtMS00NDQ3Mg_d60b4bc1-7c7f-492d-827b-71bebbe2da4a"
      unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNC0yLTEtMS00NDQ3Mg_0ebae49c-989c-4ceb-b01b-2e382897ded9"
      unitRef="usd">413594000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNC02LTEtMS00NDQ3Mg_9f15879d-1993-437a-ab5e-75baf89ed789"
      unitRef="usd">413594000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNS0yLTEtMS00NDQ3Mg_7f2b6928-0c92-4653-bfb0-12f8bfdf6d34"
      unitRef="usd">62919000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNS00LTEtMS00NDQ3Mg_c1479d04-4fc5-4112-8e9d-4755e8f00164"
      unitRef="usd">1987000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNS02LTEtMS00NDQ3Mg_fab585bc-7f19-4811-800e-fa1300cef2a9"
      unitRef="usd">64906000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue
      contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNi0yLTEtMS00NDQ3Mg_10b928f2-d913-40eb-b28d-2a4fcbd32468"
      unitRef="usd">58537000</neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNi00LTEtMS00NDQ3Mg_361978e3-da30-40bc-9cfc-3e8165adacab"
      unitRef="usd">15763000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue>
    <neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNi02LTEtMS00NDQ3Mg_b9c09994-9399-4a57-ad34-f8d4e97f4430"
      unitRef="usd">74300000</neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="i056163c254b84758b521f7190d147b16_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNy0yLTEtMS00NDQ3Mg_c0317f2a-2506-4c3c-a6ff-fce0bf42be18"
      unitRef="usd">535050000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNy00LTEtMS00NDQ3Mg_8f3df1e8-1d30-4fa1-b7a3-fc4702e8c516"
      unitRef="usd">17750000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfNy02LTEtMS00NDQ3Mg_70c504ac-e95a-468c-bbfb-372fd16b04e9"
      unitRef="usd">552800000</us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTAtMi0xLTEtNDQ0NzI_03d8cb73-9bf8-4253-b275-2cfcf1ec51fb"
      unitRef="usd">14068000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTAtNi0xLTEtNDQ0NzI_08d310ec-9f16-4281-91f8-fac4a7630bc3"
      unitRef="usd">14068000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTEtMi0xLTEtNDQ0NzI_46eb49bf-381e-428a-82be-ee4a4e8af9ac"
      unitRef="usd">5366000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTEtNC0xLTEtNDQ0NzI_f545221e-0acd-4327-825c-f3523c4b1db8"
      unitRef="usd">345000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTEtNi0xLTEtNDQ0NzI_f64b894e-5a2c-4b0e-a62b-5487bb0382a7"
      unitRef="usd">5711000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTItMi0xLTEtNDQ0NzI_1c8e5516-b395-4333-8abe-a0051767cd06"
      unitRef="usd">1753000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTItNi0xLTEtNDQ0NzI_0de12679-1a34-4b27-baf9-bbdb428443fa"
      unitRef="usd">1753000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ic894cd7e3581485ea84cafa3847d68c3_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTMtMi0xLTEtNDQ0NzI_a125db50-d50d-464e-9402-349e8f9aee2c"
      unitRef="usd">302982000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="i53250a94560e4680a9724632efeb9b7b_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTMtNC0xLTEtNDQ0NzI_f1debad7-9668-4086-927c-e8df3af35917"
      unitRef="usd">-11796000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i09d7da96f3244a2ca7446eb12f52373a_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTMtNi0xLTEtNDQ0NzI_4fc1ff48-dff6-4662-91b7-3887af0a5b57"
      unitRef="usd">291186000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i26e3bddf7f4f43deac1e105c9da91f6b_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTQtMi0xLTEtNDQ0NzI_6a3225bf-9deb-49a2-aa28-d7d5f20e48ab"
      unitRef="usd">31700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="i8a298c3d0be247f28f61c6f6bc44daec_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTQtNC0xLTEtNDQ0NzI_d860e95b-e6a4-466c-add5-318f6fa1df3d"
      unitRef="usd">-226000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4a906e75b19e4b31bb630f84fb76671b_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTQtNi0xLTEtNDQ0NzI_0b6149ed-c382-4e05-8780-6cfcf34d956e"
      unitRef="usd">31474000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i241e751eb6ae41b0a89e6a8d1860ded0_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTUtMi0xLTEtNDQ0NzI_0be59029-c599-404a-9625-3b50d9278247"
      unitRef="usd">2322000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="i8fa897a9364d4ba0bb0ed58d1af8a907_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTUtNC0xLTEtNDQ0NzI_8b9520fc-fd62-4af8-86ba-8427e9bbe5ba"
      unitRef="usd">253000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="if693f0a2a745494496eeae35fb96dea0_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTUtNi0xLTEtNDQ0NzI_6f24eb76-5ad9-4955-86f0-7501a3f510c1"
      unitRef="usd">2575000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTYtMi0xLTEtNDQ0NzI_9d006b31-b0ce-420c-ba91-e3caeb74103c"
      unitRef="usd">6240000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTYtNi0xLTEtNDQ0NzI_9e3659bf-5a98-432a-83a1-8e0e02460154"
      unitRef="usd">6240000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTctMi0xLTEtNDQ0NzI_185f7ee6-2a05-40a1-b0dc-b658fbd25f8e"
      unitRef="usd">364431000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTctNC0xLTEtNDQ0NzI_9d1e7ed6-a29e-4d10-945f-c123f77337e4"
      unitRef="usd">-11424000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTctNi0xLTEtNDQ0NzI_9c9eef69-7429-4667-bc0e-95f044f940f5"
      unitRef="usd">353007000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTgtMi0xLTEtNDQ0NzI_0df5e3da-27d4-4fd8-bb58-ab7ed7323c2d"
      unitRef="usd">4241000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTgtNC0xLTEtNDQ0NzI_5806ef4a-ca5b-4b1b-91d4-241430919761"
      unitRef="usd">-1650000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTgtNi0xLTEtNDQ0NzI_fb164949-7566-4b8e-9576-58efde639433"
      unitRef="usd">5891000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTktMi0xLTEtNDQ0NzI_d8e8dc1e-7efc-4979-85e4-ed92e9b5e877"
      unitRef="usd">64680000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTktNC0xLTEtNDQ0NzI_78296606-33b1-4304-b8aa-c3bb09793308"
      unitRef="usd">3686000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMTktNi0xLTEtNDQ0NzI_8751112c-2646-4849-9918-65ee7ec77bee"
      unitRef="usd">60994000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjAtMi0xLTEtNDQ0NzI_a81f5588-031a-4ba1-a86c-fcea75bbef15"
      unitRef="usd">4690000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjAtNi0xLTEtNDQ0NzI_27162501-5532-436c-a8b5-649e882c1e7d"
      unitRef="usd">4690000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjEtMi0xLTEtNDQ0NzI_5b0fb89d-6d96-40dd-bbaf-d7934f5e2eb3"
      unitRef="usd">290820000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjEtNC0xLTEtNDQ0NzI_d9e8df82-807a-48e4-a36c-a496a3d9ccbc"
      unitRef="usd">-9388000</neo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjEtNi0xLTEtNDQ0NzI_0cc8060d-cb8c-45e8-9763-d3710a14db19"
      unitRef="usd">281432000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjItMi0xLTEtNDQ0NzI_b26bc431-a1e5-49d5-b260-11c541695021"
      unitRef="usd">244230000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjItNC0xLTEtNDQ0NzI_6e5f60d1-d734-46de-9fff-1bef9015f853"
      unitRef="usd">27138000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjItNi0xLTEtNDQ0NzI_04da9623-e7cc-4608-a860-abd8dba7a3e6"
      unitRef="usd">271368000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ie09dd33dffad4d3488554bf8c6d26e6f_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjMtMi0xLTEtNDQ0NzI_b2009f77-be95-4eca-9af1-033d52c88ce8"
      unitRef="usd">535050000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjMtNC0xLTEtNDQ0NzI_55bf0025-f6c0-444e-a001-6f2d973de0aa"
      unitRef="usd">17750000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjE5ZTdlNjUyYjRlODRiZWZhYjhhMjMyNWQ4NjEzZDZkL3RhYmxlcmFuZ2U6MTllN2U2NTJiNGU4NGJlZmFiOGEyMzI1ZDg2MTNkNmRfMjMtNi0xLTEtNDQ0NzI_d81e603e-5a0a-4231-ab88-f93315e4a70a"
      unitRef="usd">552800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia6cc8a93c1f0462e8fac56d280a8d2fe_D20210618-20210618"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1Mzg3NA_8cb2a0de-d681-4e46-800c-caad91f740a6">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i41d155bca1e34d069f969cab67f80b2f_D20210618-20210618"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1Mzg3NA_ab7b7845-1978-4795-8eb5-802859f3ca4b">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8fa897a9364d4ba0bb0ed58d1af8a907_D20210618-20210618"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1Mzg5NA_6d3fc171-f5fa-4f5d-93ac-51abcf36b9e8">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic5ec072b3f2149f9841f0efdd06bc306_D20210618-20210618"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1MzkyMA_5d9009b3-6554-4581-a374-ec1807696f6c">P14Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic5d9574696644e1f9309d0cfefa33d29_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzYyOA_865742fa-3537-47df-ac75-dacdc553ca7e"
      unitRef="usd">238400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ibb76b6a1b0eb453db2e735dd98b1f29f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzY1NQ_61396f7b-f858-43cb-b9c0-40ddb707a86d"
      unitRef="usd">33000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ4NzY4Ng_235aba77-0f6c-4306-8bd2-a716bd180202"
      unitRef="usd">61000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i60818069430f4235a500d9ef12d9797d_I20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1Mzk4Mg_f5b5ce02-2613-4e7b-bb9c-026658365c9f"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMzI5ODUzNDkyOTI0Ng_1114320e-c408-436e-bf8d-0bc7e1bac66c"
      unitRef="usd">-13900000</neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="i71ca084f388f4e8697369585c4417521_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDA5NQ_beac7252-a8d8-4e0f-b2d7-277a2a1a72cf"
      unitRef="usd">0</neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="ie43d3909305b4bfa99fb106a2a366787_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDA5NQ_e633c066-e21d-4bea-a807-74f6c5b30680"
      unitRef="usd">0</neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDAwMw_9cafa869-1ab4-4f51-9626-4b2613c194ea"
      unitRef="usd">1500000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDAxNw_a50b3d6a-df0a-41a6-8f10-e15b95273763"
      unitRef="usd">27600000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDA5MA_1ff53a11-84f9-4071-b32d-5fa1c0a1c4e2">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma information has been provided for illustrative purposes only and is not necessarily indicative of results that would have occurred had the acquisition of Inivata occurred on January 1, 2020, nor are they necessarily indicative of future results (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjFhNmMyNTg1OTBhMjQxZGNiMDdkZmEzOTcxOGI0NWRjL3RhYmxlcmFuZ2U6MWE2YzI1ODU5MGEyNDFkY2IwN2RmYTM5NzE4YjQ1ZGNfMi0yLTEtMS00NDY0NA_63a1067d-398c-4ac6-86ec-f7093c434276"
      unitRef="usd">484231000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i71ca084f388f4e8697369585c4417521_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjFhNmMyNTg1OTBhMjQxZGNiMDdkZmEzOTcxOGI0NWRjL3RhYmxlcmFuZ2U6MWE2YzI1ODU5MGEyNDFkY2IwN2RmYTM5NzE4YjQ1ZGNfMi00LTEtMS00NDY0NA_0c2c1e71-0029-4290-a417-99aed4868cdf"
      unitRef="usd">444884000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjFhNmMyNTg1OTBhMjQxZGNiMDdkZmEzOTcxOGI0NWRjL3RhYmxlcmFuZ2U6MWE2YzI1ODU5MGEyNDFkY2IwN2RmYTM5NzE4YjQ1ZGNfMy0yLTEtMS00NDY0NA_80611738-2e5b-4490-973c-0cd98c51838c"
      unitRef="usd">-129251000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i71ca084f388f4e8697369585c4417521_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RhYmxlOjFhNmMyNTg1OTBhMjQxZGNiMDdkZmEzOTcxOGI0NWRjL3RhYmxlcmFuZ2U6MWE2YzI1ODU5MGEyNDFkY2IwN2RmYTM5NzE4YjQ1ZGNfMy00LTEtMS00NDY0NA_af387b09-b12f-497b-b788-654216b9bbe2"
      unitRef="usd">-65387000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMzI5ODUzNDkyOTIzMA_8a488566-3c4f-4889-90ed-6bef1e51f71a"
      unitRef="usd">11000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMzI5ODUzNDkyOTIzOA_1114320e-c408-436e-bf8d-0bc7e1bac66c"
      unitRef="usd">-13900000</neo:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfODI0NjMzNzI1NDA2MA_019a4a7f-f1ca-4cd1-9833-f27dd743a98a"
      unitRef="usd">109300000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i71ca084f388f4e8697369585c4417521_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85Ny9mcmFnOjUzZTdmNWU2YjliMzRmNWJiNGI2MTEyNTgwOWM4NzRiL3RleHRyZWdpb246NTNlN2Y1ZTZiOWIzNGY1YmI0YjYxMTI1ODA5Yzg3NGJfMTY0OTI2NzQ5MDUyNg_da7775fa-b66d-44c1-9034-7ae9ed6958a2"
      unitRef="usd">4000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfNDAzNQ_dc0e023b-e18a-4784-a340-ffe13492e7b4">Fair Value Measurements&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities.&#160;These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly.&#160;These are typically obtained from readily-available pricing sources for comparable instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs, where there is little or no market activity for the asset or liability.&#160;These inputs reflect the reporting entity&#x2019;s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets and Liabilities that are Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses, and fair values of the Company&#x2019;s marketable securities accounted for as available-for-sale securities as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had $0.6 million and $0.2 million of accrued interest receivable at December 31, 2021 and 2020, respectively, included in other assets on its Consolidated Balance Sheets related to its marketable securities. The amounts of realized gains and realized losses were immaterial for the years ended December 31, 2021 and 2020. There were no such amounts for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the Company&#x2019;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of December 31, 2021 and 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash, certain cash equivalents, accounts receivable, net, other current assets, accounts payable, accrued expenses and other liabilities, and Pharma contract liabilities are considered reasonable estimates of their respective fair values at December 31, 2021 and 2020 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and as such, these are considered Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfNDAzNg_d82c20e4-7cdd-40f7-9b11-cdf9577cc9c8">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses, and fair values of the Company&#x2019;s marketable securities accounted for as available-for-sale securities as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNC0yLTEtMS0zMDU3Mg_4d0df595-3351-4c95-9325-d7d15f867878"
      unitRef="usd">52791000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNC00LTEtMS0zMDU3Mg_2afb4d1e-c01f-4a56-8ba9-025525420bb2"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNC02LTEtMS0zMDU3Mg_b1f1485a-b80d-4a91-a899-39167a639537"
      unitRef="usd">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNC04LTEtMS0zMDU3Mg_d0bba0a4-3361-42b4-835e-4eee61c997d0"
      unitRef="usd">52664000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i6716adac8aa646019b124b8d827b9826_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS0yLTEtMS01NTIyNw_aba86d2e-cdaf-410d-ae9f-e0b7afdd99a4"
      unitRef="usd">6175000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6716adac8aa646019b124b8d827b9826_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS00LTEtMS02MTY0MA_f256b934-3877-433b-9d6e-b12fbad2533d"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6716adac8aa646019b124b8d827b9826_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS02LTEtMS02MTY0Nw_8ec1a23a-88a8-47f0-b7c5-2bbb329e2d8a"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6716adac8aa646019b124b8d827b9826_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS04LTEtMS02MTY0Nw_3ec15392-4f0a-4465-821d-706f396e742b"
      unitRef="usd">6160000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi0yLTEtMS01NTIyNw_7e31a067-73f2-41ff-a848-b89e0d1681e8"
      unitRef="usd">17546000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi00LTEtMS02MTY0MA_69861a40-a107-4a54-823b-9a13ad71a87e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi02LTEtMS02MTY0Nw_008e0823-d5a2-4e51-879d-29ed44d5f2dd"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi04LTEtMS02MTY0Nw_d3ec4d5e-636e-4e17-9c9a-641ff6321cc5"
      unitRef="usd">17530000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS0yLTEtMS0zMDU3Mg_cd431e28-f704-40a1-b646-86682804b204"
      unitRef="usd">12440000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS00LTEtMS0zMDU3Mg_5ca8369b-0b46-4709-8ef8-a62adcd23d03"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS02LTEtMS0zMDU3Mg_a15130d0-72a6-4e72-b11d-f7b2099c7b9f"
      unitRef="usd">211000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNS04LTEtMS0zMDU3Mg_c74c90d9-ced3-41eb-b0bc-4bbf8f0d9737"
      unitRef="usd">12229000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi0yLTEtMS0zMDU3Mg_c3bf03bf-04ad-4dcf-8c9e-74a660c62c70"
      unitRef="usd">17694000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi00LTEtMS0zMDU3Mg_80dde007-fa2f-4df1-8a25-0f88b541b658"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi02LTEtMS0zMDU3Mg_7c021839-d2bf-45d6-acb6-b75bd711f50b"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNi04LTEtMS0zMDU3Mg_b89fd4b0-120d-44dc-b5bb-a2a8ca14d559"
      unitRef="usd">17690000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNy0yLTEtMS0zMDU3Mg_bb4af3f1-b64d-42f9-a005-5f3001de1a24"
      unitRef="usd">27620000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNy00LTEtMS0zMDU3Mg_7c28e3cb-a33f-4b25-9018-3874fe5b4ff8"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNy02LTEtMS0zMDU3Mg_97ca3d7c-dc36-416b-92a0-bbc4b580fe16"
      unitRef="usd">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfNy04LTEtMS0zMDU3Mg_0951761b-58b1-4eff-b44b-14efe8b77ab1"
      unitRef="usd">27535000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOC0yLTEtMS0zMDU3Mg_7241ad0f-b542-4f38-a329-7e9a5ebffed0"
      unitRef="usd">65198000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOC00LTEtMS0zMDU3Mg_73e7116f-3e5d-4c26-8613-7a86ce50731c"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOC02LTEtMS0zMDU3Mg_a2192750-7d57-4bf8-8cbd-d698ee41b2af"
      unitRef="usd">452000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOC04LTEtMS0zMDU3Mg_530b569f-e193-4023-869b-dd48ddb752f1"
      unitRef="usd">64755000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOS0yLTEtMS0zMDU3Mg_f6e0b1c8-9a67-4450-b704-ebd0d8b4648c"
      unitRef="usd">199464000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOS00LTEtMS0zMDU3Mg_0c5c49b1-dc81-400d-b1a8-126e93a365aa"
      unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOS02LTEtMS0zMDU3Mg_e972ee5b-be2f-4073-925e-4c596ddef8ac"
      unitRef="usd">923000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjA4YWVhNzgwOTIyNTRkYjVhNmJkMjFmMzg5YjRlMTc0L3RhYmxlcmFuZ2U6MDhhZWE3ODA5MjI1NGRiNWE2YmQyMWYzODliNGUxNzRfOS04LTEtMS0zMDU3Mg_1360e07a-d77b-4332-bcb2-8f4407ca2d0f"
      unitRef="usd">198563000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNC0yLTEtMS00NDkyOQ_7f0b8531-a4a3-4a29-99c4-ed4b9bcb4625"
      unitRef="usd">21357000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNC00LTEtMS00NDkyOQ_1eb8ba91-eb47-49cb-8347-85114ff9730d"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNC02LTEtMS00NDkyOQ_c4d87949-cf4c-4a75-837c-bef4d1d0b66c"
      unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNC04LTEtMS00NDkyOQ_af681bae-a15d-4a22-8285-8b9474821bf1"
      unitRef="usd">21340000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ia677c5c475564da488a50b112b59dccb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNi0yLTEtMS00NDkyOQ_887b28f9-3874-40b7-a534-a6fbc0eda89b"
      unitRef="usd">14543000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia677c5c475564da488a50b112b59dccb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNi00LTEtMS00NDkyOQ_571dbb12-b94d-462d-8d6a-13e69756d6ab"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia677c5c475564da488a50b112b59dccb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNi02LTEtMS00NDkyOQ_d388db97-61ef-43a1-b5b7-0aa641e69580"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia677c5c475564da488a50b112b59dccb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNi04LTEtMS00NDkyOQ_dc0b83a8-5c6b-4b3b-bcb6-c7d08ec5a996"
      unitRef="usd">14543000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNy0yLTEtMS00NDkyOQ_8f8e1672-9625-4675-873d-751c7b0ad9ae"
      unitRef="usd">14546000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNy00LTEtMS00NDkyOQ_2c78f24f-5a36-43ef-aea7-913148be7048"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNy02LTEtMS00NDkyOQ_c790c75a-4b2d-4686-bec5-ebee4ce8a7f4"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfNy04LTEtMS00NDkyOQ_b1fcc47b-cb6a-44e7-a6e2-a0e38ebfbb7e"
      unitRef="usd">14538000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOC0yLTEtMS00NDkyOQ_83c2a223-3935-427d-bc6e-b728e08e1c68"
      unitRef="usd">17144000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOC00LTEtMS00NDkyOQ_4424b65f-466a-4f58-803e-7aceb8714968"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOC02LTEtMS00NDkyOQ_98427967-03a0-48e3-a4a7-ec284526a932"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOC04LTEtMS00NDkyOQ_b142347c-aa80-4a39-8bd2-90184bcc287f"
      unitRef="usd">17125000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOS0yLTEtMS00NDkyOQ_5d1c1d35-34cd-490a-a431-e870c5008bda"
      unitRef="usd">67590000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOS00LTEtMS00NDkyOQ_2e44eeb9-7e7a-4cc6-b11d-91e9260bef00"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOS02LTEtMS00NDkyOQ_611932b9-91a6-4738-b9c4-b331690dd327"
      unitRef="usd">45000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmNlNDlkMmM0ODVlNDQ1MjhiMjMyMzM5YTYxNjc0OThkL3RhYmxlcmFuZ2U6Y2U0OWQyYzQ4NWU0NDUyOGIyMzIzMzlhNjE2NzQ5OGRfOS04LTEtMS00NDkyOQ_e66f4e58-48c0-4cb1-a969-e5e6baea4188"
      unitRef="usd">67546000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfMjc0ODc3OTA4NDAzOQ_aab5c51f-75ad-49d5-90c4-fa0b6c4160a0"
      unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfMjc0ODc3OTA4NDAyMA_81a94423-a621-4e6f-94c8-1ff57d31ee30"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfNDAzNw_e13cd8be-ac2a-4a26-8821-cebe8262c820">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNC0yLTEtMS0zMDU3Mg_0d2394bc-7ebd-49f6-abcf-6755a9827451"
      unitRef="usd">22550000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNC00LTEtMS0zMDU3Mg_3d63ddbe-0b29-4639-910a-647f17b08b0e"
      unitRef="usd">30114000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNC02LTEtMS0zMDU3Mg_8f52c58a-d14e-4f89-a988-d54ccdd8ad24"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idc922c5f4bae4c03a613ec6c8a22ef64_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNC04LTEtMS0zMDU3Mg_ca268fc1-904c-4b4c-8854-1b6701b56b41"
      unitRef="usd">52664000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i6716adac8aa646019b124b8d827b9826_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNS0yLTEtMS01NTM4OA_43434d2a-fdd3-435d-95c1-290e66ac9327"
      unitRef="usd">4150000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i6716adac8aa646019b124b8d827b9826_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNS00LTEtMS01NTM4OA_7dbf2057-117f-4a24-889d-f49c9a829978"
      unitRef="usd">2010000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i6716adac8aa646019b124b8d827b9826_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNS02LTEtMS01NTM4OA_45f99524-753f-45b5-87a0-052eb020ef5b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6716adac8aa646019b124b8d827b9826_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNS04LTEtMS01NTM4OA_6349d7f3-63d4-4358-98aa-850a0a58ce35"
      unitRef="usd">6160000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi0yLTEtMS01NTM4OA_8e11b4fc-f1b9-417b-8353-37639edbc327"
      unitRef="usd">14041000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi00LTEtMS01NTM4OA_7e45085e-9985-4435-8d8f-603777f25853"
      unitRef="usd">3489000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi02LTEtMS01NTM4OA_99e31c54-11af-4b10-b16f-016cbed48b97"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8bce6a8a3ff54e77b96545b34c50da9e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi04LTEtMS01NTM4OA_3cb7d762-e4d5-4d30-a41a-a003e4e9be42"
      unitRef="usd">17530000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy0yLTEtMS01NTM4OA_53407cbb-7be3-4eae-9b16-5b0de93ccc8f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy00LTEtMS01NTM4OA_566456b3-ace4-4ff6-9531-7438d10d7d55"
      unitRef="usd">12229000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy02LTEtMS01NTM4OA_71fb6c92-df54-47b6-9300-d2c9579102fc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3652099553bf4bfeb2731eeab20bbca8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy04LTEtMS01NTM4OA_f0ea8a7b-f413-4780-b670-3599caddfca5"
      unitRef="usd">12229000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi0yLTEtMS0zMDU3Mg_87902a19-2cd5-4d9a-a5a7-49214a6de487"
      unitRef="usd">17690000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi00LTEtMS0zMDU3Mg_a573491c-0abd-44ed-ab9d-136e26558ed8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi02LTEtMS0zMDU3Mg_cda2bfb8-f333-4e55-a3b3-c3c89bba49ed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab89ab574c9d401982c77a3b962e16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNi04LTEtMS0zMDU3Mg_12c8cc0f-28bb-4c6a-add5-96ab584a8e02"
      unitRef="usd">17690000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy0yLTEtMS0zMDU3Mg_b44f8a76-6d39-48ab-8fa7-cf5e289e8fa5"
      unitRef="usd">20868000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy00LTEtMS0zMDU3Mg_9fbeda79-6004-47d3-b305-2cc3c6ac38b2"
      unitRef="usd">6667000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy02LTEtMS0zMDU3Mg_3c879067-d8d5-4814-bd1d-6532fdbf17dc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i24d2c1e8a5f54322b16d387e79522764_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfNy04LTEtMS0zMDU3Mg_7ecc23ac-9801-40c2-a3ae-d73838f4b4e7"
      unitRef="usd">27535000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOC0yLTEtMS0zMDU3Mg_45c5cce2-5e8f-4972-84f6-caffdd3823f2"
      unitRef="usd">25412000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOC00LTEtMS0zMDU3Mg_3ae6fc96-48c6-42d5-ad2b-d4110fa5e6ea"
      unitRef="usd">39343000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOC02LTEtMS0zMDU3Mg_a3611c03-3ed7-405f-afcf-ab93da588224"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iff47caf8efa84cd9b3978e89517a4e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOC04LTEtMS0zMDU3Mg_eb29e7ec-c474-47df-989d-765a4a1a3a10"
      unitRef="usd">64755000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOS0yLTEtMS0zMDU3Mg_501d0256-42a2-4bcc-88a4-e019b8f1302f"
      unitRef="usd">104711000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOS00LTEtMS0zMDU3Mg_93e26198-6315-4d1b-93b6-d9114cd2e737"
      unitRef="usd">93852000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOS02LTEtMS0zMDU3Mg_beebfa6b-1bbf-4707-8903-a990fdfe76a3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjQzMjVkODg5MTljNDRjNWNhOGMyNTc0Y2JlYzI5YjI5L3RhYmxlcmFuZ2U6NDMyNWQ4ODkxOWM0NGM1Y2E4YzI1NzRjYmVjMjliMjlfOS04LTEtMS0zMDU3Mg_98fb68d4-3a07-4970-8ed6-983be80ee650"
      unitRef="usd">198563000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNC0yLTEtMS00NTAzNg_c85afa9f-755b-4970-a057-a914c84449ab"
      unitRef="usd">6075000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNC00LTEtMS00NTAzNg_e7807991-f253-43df-a07b-5274d356b6c7"
      unitRef="usd">15265000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNC02LTEtMS00NTAzNg_55bb275d-6b4e-44d0-8ddc-43f3f06598d4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic54d50e147b9488787c8e53018d0c7a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNC04LTEtMS00NTAzNg_21f626f2-9853-4219-915b-9abcef5b5c93"
      unitRef="usd">21340000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ia677c5c475564da488a50b112b59dccb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNi0yLTEtMS00NTAzNg_c0508af4-abc2-4757-9617-5353444eb9ce"
      unitRef="usd">14543000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ia677c5c475564da488a50b112b59dccb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNi00LTEtMS00NTAzNg_b3e4f6ac-6704-46e1-9a69-11a8d538466d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ia677c5c475564da488a50b112b59dccb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNi02LTEtMS00NTAzNg_1b909dd5-368c-46c6-a982-f0e8c6996049"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia677c5c475564da488a50b112b59dccb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNi04LTEtMS00NTAzNg_a720a401-7652-4c2b-aa24-18784e5a1a80"
      unitRef="usd">14543000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNy0yLTEtMS00NTAzNg_a0766c74-5897-4355-ac8b-4f5bb0ad98af"
      unitRef="usd">560000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNy00LTEtMS00NTAzNg_a93d921c-6119-48c0-a2a2-1ed5490f80a4"
      unitRef="usd">13978000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNy02LTEtMS00NTAzNg_aac70cb3-4bc0-4305-a669-4d0f973786e8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if89815183f42497fa9138d9ca4e8f7b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfNy04LTEtMS00NTAzNg_2b8b17ce-ee44-4bc4-b56f-6de131e16ccd"
      unitRef="usd">14538000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOC0yLTEtMS00NTAzNg_ee696e3c-c3ee-43ad-8440-933e11df6c4a"
      unitRef="usd">5863000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOC00LTEtMS00NTAzNg_2dfeef17-de3d-43c9-969b-5acf59adce35"
      unitRef="usd">11262000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOC02LTEtMS00NTAzNg_d90309fa-677b-4f68-b2da-9c7909729c4b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id2bcfcbd104942f4850c679c537fde09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOC04LTEtMS00NTAzNg_42068ddf-a13e-4bc0-b7cd-95a8dc1e4b70"
      unitRef="usd">17125000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOS0yLTEtMS00NTAzNg_e5014502-963a-4778-86a7-645cfd926eaa"
      unitRef="usd">27041000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOS00LTEtMS00NTAzNg_68768bbb-8785-497a-98c2-47f1c916dff9"
      unitRef="usd">40505000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOS02LTEtMS00NTAzNg_9fa44164-2dad-4d7f-b704-bfabca58812f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjAxMTc3MmUxYTVhMzQwMDc4OTc4ODZkY2M3NzM2MDNjL3RhYmxlcmFuZ2U6MDExNzcyZTFhNWEzNDAwNzg5Nzg4NmRjYzc3MzYwM2NfOS04LTEtMS00NTAzNg_0a65d4db-f442-49ba-89e4-1ec78157e3f3"
      unitRef="usd">67546000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RleHRyZWdpb246M2UwNWNkY2E3M2YzNDgzOWFkMWI4OWY2ODMyZTVmZDZfNDAzNA_4b5dae32-5f08-4ab8-909f-6a7fbd899b0d">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the Company&#x2019;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of December 31, 2021 and 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.463%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7ab7a0601cb455db099d018b5e7ee2e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNC0yLTEtMS0zMDU3Mg_3d32f02f-edf8-4014-b48a-31e4f3f66b8e"
      unitRef="usd">254157000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3fa8f61db574f89a67fc8c16cf3711d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNC00LTEtMS0zMDU3Mg_7c4ea760-bf97-4ce1-aa0a-8d773250f726"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i76224457309a40699695790b0f50e4f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNC02LTEtMS0zMDU3Mg_846dfc45-dfcc-4071-a2b5-01894e72a993"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iffbb9a38583e4074b4296919f28d1a77_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNC04LTEtMS0zMDU3Mg_b78753fe-c972-4f9e-8628-7d4f4834e549"
      unitRef="usd">254157000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i638518a143ae4d87a72a11c64fcc3765_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNi0yLTEtMS0zMDU3Mg_83ba8081-a523-447a-8676-5ea1069c7b6c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8dc964799b214b28aed62721500a4078_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNi00LTEtMS0zMDU3Mg_8b6b77f1-8504-4ef8-8846-9b880b544615"
      unitRef="usd">22491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i697bd4c12c7545578588a80fd60c5a2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNi02LTEtMS0zMDU3Mg_2e620e05-d160-4fe9-8cd8-1f4c10578b8a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4fff7b93030247d7a7ec551b5888bba9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfNi04LTEtMS0zMDU3Mg_aac1697b-12f9-4c63-ba44-8b3940892509"
      unitRef="usd">22491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7ec309e8b8ca4034bede264e6e054708_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC0yLTEtMS0zMDU3Mg_979ee31e-12fe-4063-a4b8-c1876fa51488"
      unitRef="usd">52664000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if66997f44a6d49358fc4baf034b07e2c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC00LTEtMS0zMDU3Mg_0502e5ee-5eae-4f06-bcc2-a5e9e71b2bc3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i704a124a4a974f0fa8f723461b30609a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC02LTEtMS0zMDU3Mg_4d2b01c9-878f-4e85-9db2-6ead77bf0078"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie93f36a0218f438aaa218be2623ebb81_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC04LTEtMS0zMDU3Mg_dfac5dfc-aadb-4cab-bb4d-2560c54abd75"
      unitRef="usd">52664000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i746a7393ab77458f87d791a8c09ccaa7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC0yLTEtMS01NTQ0Mg_a58cd036-9717-4567-9730-0c264b7028c3"
      unitRef="usd">6160000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i42b094c7c0f04992a913df6000efec8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC00LTEtMS01NTQ0Mg_d4f0443c-c0a6-4a87-a361-1303ff564545"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icf91dd30bbfd452691bc71a1f3018647_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC02LTEtMS01NTQ0Mg_6b404d36-5bed-47fc-b7bf-16b975bb855c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5abf1dd36ab74c1ab535b08da51fd03e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOC04LTEtMS01NTQ0Mg_7838c64d-9fcc-4e89-91e7-ac663e229ad8"
      unitRef="usd">6160000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie1fc88b8c4af4d838d278264c23593de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOS0yLTEtMS01NTQ0Mg_9c35991d-5560-4215-a1fb-7310e4430119"
      unitRef="usd">17530000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibb1df97244f7467cb5339af566fe6b01_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOS00LTEtMS01NTQ0Mg_e2822fa7-304a-422b-89e4-7d6fb1e0d4ed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia4ad6cd969fd4b7995ef71a5a45c8429_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOS02LTEtMS01NTQ0Mg_c3c3fdcf-293f-4a1a-870b-7a753ad0166d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4cc69c67cfe341499445ae00f2e71e27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfOS04LTEtMS01NTQ0Mg_628bcf7d-ca06-49b9-99c6-d10f4312c567"
      unitRef="usd">17530000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie66912a44f91463f9626b1399dcc65b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtMi0xLTEtNTU0NDI_ad240757-add5-4dd8-a9c3-89dadbc38c1b"
      unitRef="usd">12229000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i374016e58cd24f058ea5bda9bf666837_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtNC0xLTEtNTU0NDI_d49d2f56-ab9a-42fc-9d99-a52f5d497286"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i558037007551470fb27b3d37558ce693_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtNi0xLTEtNTU0NDI_1f13b8d9-2d72-4d99-956a-f33cf3156cc7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i51cad3ea1be84d3fafc2dceed5c35c13_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtOC0xLTEtNTU0NDI_01fc2d67-3620-46ee-9755-7c15944547e4"
      unitRef="usd">12229000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i638518a143ae4d87a72a11c64fcc3765_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtMi0xLTEtMzA1NzI_989ff59b-fb10-4245-94cf-9a1074fbd7cd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8dc964799b214b28aed62721500a4078_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtNC0xLTEtMzA1NzI_d55d31d2-de9f-4360-a27d-bc5ee3b71212"
      unitRef="usd">17690000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i697bd4c12c7545578588a80fd60c5a2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtNi0xLTEtMzA1NzI_8bfa1891-580a-4c80-90de-bcc01707551d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4fff7b93030247d7a7ec551b5888bba9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTAtOC0xLTEtMzA1NzI_df839c57-1c34-4b5a-a6ad-706d52a0ac9c"
      unitRef="usd">17690000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0ec189eb73b74704b15fcb292ea00266_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTEtMi0xLTEtMzA1NzI_a1352de2-bf85-4eaf-a4db-4ad364bfba7c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0b095f6dcdbc4f00abc2c61aefa9f5bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTEtNC0xLTEtMzA1NzI_491035e9-5029-4e6e-8689-aa1616fff683"
      unitRef="usd">27535000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i54c09dd584b74333a5ee8cfd4907e771_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTEtNi0xLTEtMzA1NzI_a9de093d-2c22-4f3e-aaa7-4af7dbd78199"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i02504c45cdee431f96d72f6ef0b3b993_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTEtOC0xLTEtMzA1NzI_b07736c0-7512-45e0-9ef9-a7a7964b6a77"
      unitRef="usd">27535000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i819a50dc28e74d5181cf147448558684_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTItMi0xLTEtMzA1NzI_6f51025a-25fc-4dc0-bf0f-ef9c9df4eab9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie905db35afe34f1baf538346e1229ce2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTItNC0xLTEtMzA1NzI_f5649e49-e05b-4c63-bb18-c487b97d13b4"
      unitRef="usd">64755000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4854e1e15ce44e82986165ed1c077b3a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTItNi0xLTEtMzA1NzI_d593412b-bfc2-4598-b802-0a714a6b6ce4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib160d83770f74b9b8af5700509a86741_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTItOC0xLTEtMzA1NzI_58e25991-9d85-40cd-ab6b-0bae4a9f422d"
      unitRef="usd">64755000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee0c00ad27f2434d8b93b095e710a55f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTMtMi0xLTEtMzA1NzI_2da8852a-b412-4cf0-9a36-753ec3271556"
      unitRef="usd">342740000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id904fbd917124e16bb45e001aecb4dd5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTMtNC0xLTEtMzA1NzI_8b0da9b1-fd7f-4393-b1f7-6815cc8466f3"
      unitRef="usd">132471000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9633971e98a74fa18caf2e387613ffcc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTMtNi0xLTEtMzA1NzI_f2ecad15-2205-49c8-933b-da37ec249108"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i50a6890d5edf4d9894153bf7442085c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOmFhZGUwYTRjNDRkYzRmZjQ4NGQ1MThmOTNlM2MwY2Q4L3RhYmxlcmFuZ2U6YWFkZTBhNGM0NGRjNGZmNDg0ZDUxOGY5M2UzYzBjZDhfMTMtOC0xLTEtMzA1NzI_001cde18-1d66-42fd-aa81-9006b4cbbbca"
      unitRef="usd">475211000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibf875c7bc1374e99ae736ce591a58b2e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNC0yLTEtMS00NTA1Mg_f6923b6f-30bb-4daa-a1ce-7fad3e64ae03"
      unitRef="usd">209141000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i04f461e673034df49706dbcf7f464bbb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNC00LTEtMS00NTA1Mg_b681d8a5-c3f0-4c2e-ae59-c8e8faf41d09"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2b59437edee2408ca9c79c95d8d4ab63_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNC02LTEtMS00NTA1Mg_9d15699d-2ffe-41c3-94f4-fb6d9528cbf3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4317cec7404a430cbea079ef5f61f530_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNC04LTEtMS00NTA1Mg_4bf9cb74-df41-41e7-95eb-13d51c7d15fd"
      unitRef="usd">209141000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0773373ae2a84f8e978c278d271d8702_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNS0yLTEtMS00NTA1Mg_c7569650-f0f3-46c1-80bb-29ccb33f842c"
      unitRef="usd">1000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ida715c03157f4228b0751ab8b032c92f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNS00LTEtMS01NDI5MQ_dd82828f-2daf-4d50-a881-112b45973eb1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifa881d72ef684b53bc9c3d9157e723c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNS02LTEtMS01NDI5MQ_a0385ff6-3d70-46be-90a8-3cf818180ab9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f8469e26fb441bd917912f9f3502f1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNS04LTEtMS00NTA1Mg_93baa7a6-ec2a-41d5-a6f0-2edbf4cbcb4f"
      unitRef="usd">1000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i998bda56c93d4dd6a54740477cd3e347_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNi0yLTEtMS00NTA1Mg_486bd4e1-c510-4996-8f8a-0af46b9185c6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic657212cfb3b42ed8189daaa3097f436_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNi00LTEtMS00NTA1Mg_c116a54b-7a91-4c98-bfd2-b989a0f1c9ee"
      unitRef="usd">3999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4421d3ac76904ead8fadef3b2ee78bdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNi02LTEtMS00NTA1Mg_63df8adf-0282-41c8-aa44-04fbfb64604e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifbe0ac1d20e94e4c8366764e3173c3f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfNi04LTEtMS00NTA1Mg_b7cfad87-a11a-446b-9f9b-0e828178bf3c"
      unitRef="usd">3999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0773373ae2a84f8e978c278d271d8702_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfOC0yLTEtMS00NTA1Mg_48a2f725-3f5b-4a3b-a959-1725e2161a94"
      unitRef="usd">21340000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ida715c03157f4228b0751ab8b032c92f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfOC00LTEtMS00NTA1Mg_e25282cf-6666-48e7-bf23-e2d9a4a59b7a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifa881d72ef684b53bc9c3d9157e723c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfOC02LTEtMS00NTA1Mg_57247283-ae93-4c6d-8c9f-049de6003783"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2f8469e26fb441bd917912f9f3502f1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfOC04LTEtMS00NTA1Mg_df674c83-1431-43af-8f16-f00600d42937"
      unitRef="usd">21340000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i998bda56c93d4dd6a54740477cd3e347_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTAtMi0xLTEtNDUwNTI_feea3b30-473d-4edb-ba74-fa7145f5d326"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic657212cfb3b42ed8189daaa3097f436_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTAtNC0xLTEtNDUwNTI_f4d95f98-c880-4981-b136-16baa57e29f0"
      unitRef="usd">14543000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4421d3ac76904ead8fadef3b2ee78bdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTAtNi0xLTEtNDUwNTI_ecba294f-b46e-4917-a739-d874535d78ba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifbe0ac1d20e94e4c8366764e3173c3f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTAtOC0xLTEtNDUwNTI_d77f1bc0-3d60-45f9-880d-a8d3cf7b7e91"
      unitRef="usd">14543000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibbde1cab9dcf4d98a6860b20663b33c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTEtMi0xLTEtNDUwNTI_45330a30-5c99-4a98-a0f7-05a77eda7d5e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia43aad3092004bd7b9ca33e6dee09b34_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTEtNC0xLTEtNDUwNTI_fdc9ceea-9032-4000-b9a0-09569dd13add"
      unitRef="usd">14538000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7ea7bec6dbe545609392aa55eb5b135a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTEtNi0xLTEtNDUwNTI_01e84ac3-e68a-4aa1-9aa4-569e72ddc5a9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8d680608e3bb4da6945d179588c188ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTEtOC0xLTEtNDUwNTI_854a96cd-b4c2-49f1-8404-4c53d237dcb7"
      unitRef="usd">14538000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9af0c8ccd543458fa9a3298f3d4ce64d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTItMi0xLTEtNDUwNTI_129f774e-f28a-4b45-b1c1-42a031fc576b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icdf8f52ad9b840b585d5bd5a88b2922f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTItNC0xLTEtNDUwNTI_52972b0a-9e66-4836-af9b-dc99cf2555bc"
      unitRef="usd">17125000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7a7bf89c9ebb4ba3a93af970a63499c0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTItNi0xLTEtNDUwNTI_6dda18b1-ee59-4918-a828-dc3b5b08d3be"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3c8bd802f0224b98af017ab422589382_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTItOC0xLTEtNDUwNTI_8aefebb4-28a0-43f7-a052-068eb656a5ad"
      unitRef="usd">17125000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7609acc1e0564279a18161c77ee0a661_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTMtMi0xLTEtNDUwNTI_eb0f292a-d8c4-489c-80b2-9d561b00ef63"
      unitRef="usd">231481000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9c926b150cdc41c987af0ca6157a147b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTMtNC0xLTEtNDUwNTI_30c72ac4-801b-4082-a7bc-992a307db6da"
      unitRef="usd">50205000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic11934a2c2474130860676bb9c52078b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTMtNi0xLTEtNDUwNTI_4317baf4-acd5-4e7c-8d1a-e7f3d25ea491"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i882fb0fa1ed04909a0884aa6e36e11d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV84OC9mcmFnOjNlMDVjZGNhNzNmMzQ4MzlhZDFiODlmNjgzMmU1ZmQ2L3RhYmxlOjg1NWEyMzdhM2FjMDRhMDU5YjQzYmUzN2IyZGYyYTBmL3RhYmxlcmFuZ2U6ODU1YTIzN2EzYWMwNGEwNTliNDNiZTM3YjJkZjJhMGZfMTMtOC0xLTEtNDUwNTI_2cbfaae4-29d1-48a0-9af9-0768911a8b53"
      unitRef="usd">281686000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfNjI2_6550bdbc-e79c-4fae-89c5-199c85761e56">Property and Equipment, Net&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lives in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 - 13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1-17&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1-9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns 43,560 square feet of our Carlsbad, California facility. This facility, consisting of land and an office building, is not included in property and equipment, net, on the Consolidated Balance Sheets. At December 31, 2021, these assets are classified as assets held for sale within current assets on the Consolidated Balance Sheets with a carrying value of $3.2 million and $6.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December 31, 2021, 2020, and 2019, was as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfNjI3_428273e5-633d-491b-bd4d-24360486d535">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lives in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 - 13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1-17&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1-9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December 31, 2021, 2020, and 2019, was as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifc5bdf0bd65547809e7e35cef332ded7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMS0xLTEtMS0zMDU3Mg_be554bd5-b1c6-4aad-bf72-09447dbd87ab"
      unitRef="usd">86410000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i52a20a06d1fb4012ab3ed6acefa4763e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMS0zLTEtMS0zMDU3Mg_36ea077c-e894-4e6d-a51d-a69eeab64d2e"
      unitRef="usd">73234000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia08a6bbb0803484290d41e899ab2e80c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMS01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjljODY0MWZiNTc3MzQ1ZDdhMzczMWE4NGY3MWE5NDhmXzEwOTk1MTE2Mjc3ODQ_53cbb625-3fc6-42f7-af2c-31a537766ff4">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i76551b3aac0541058270850f80fddc5d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMS01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjljODY0MWZiNTc3MzQ1ZDdhMzczMWE4NGY3MWE5NDhmXzEwOTk1MTE2Mjc3OTA_2657d842-14a4-4777-8429-039af1babc02">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if012ec1a006545bd8bc701a1f1a66681_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMi0xLTEtMS0zMDU3Mg_d414ff51-56a3-4149-b1ad-6e0c90dcc0c5"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i636c4a523c7044148f591fa542ca2a22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMi0zLTEtMS0zMDU3Mg_fb23c28c-c7d6-450d-962f-75b6277a3afe"
      unitRef="usd">7400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8e0ff94327434437bddf706a1455ce54_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMi01LTEtMS0zMDU3Mg_f5e73f94-2c09-4db2-91b6-5339860ff7fe">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7d92940bce5d4fc1a139df4991f04954_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMy0xLTEtMS0zMDU3Mg_b441684f-f3e4-4c92-a450-5b8ac839c822"
      unitRef="usd">43251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iff03a902a6dc4195b028b950ecde4819_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMy0zLTEtMS0zMDU3Mg_bb1bc089-6ea8-41af-93f6-c76bd31de44a"
      unitRef="usd">27688000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ieadec132a5f64c42a09fbe4ba6114c84_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMy01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjRjZDM0Y2ZkZDIwODRhNjg5YzdiNDc1NmVkNzljMWE0XzIxOTkwMjMyNTU1NTY_4042217d-b670-474f-83bf-0c57d11b86f1">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if418afdb92d045b3a3f7ed0f7f4d1122_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMy01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjRjZDM0Y2ZkZDIwODRhNjg5YzdiNDc1NmVkNzljMWE0XzIxOTkwMjMyNTU1NjA_2cdea8d9-fc02-4e13-b04c-8c3df914757d">P17Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic1c7ceda81e3493eb7227ddc4cd896f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNC0xLTEtMS0zMDU3Mg_156b9061-3c99-4f13-a580-8ba31b6ea256"
      unitRef="usd">11141000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e2cb12c76b947e78ab4acbe3ee1f639_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNC0zLTEtMS0zMDU3Mg_7b3ae04c-5417-4ad1-b9cc-0567d75872ff"
      unitRef="usd">7425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i54d9161759f74b8f932b20183ffd720f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNC01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjQzN2U4NWRjMWViODRmMzI4NWY5MjU1NjFlNjhkNjMzXzIxOTkwMjMyNTU1NTY_cc00233c-235b-4763-8cae-d075f9e5e4af">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia73a0aa5156842af960bcd14bd338f8e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNC01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjQzN2U4NWRjMWViODRmMzI4NWY5MjU1NjFlNjhkNjMzXzIxOTkwMjMyNTU1NjA_a41a72aa-2adb-4007-910f-2f6a61acc270">P9Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i84d1f59ac1cd467a8d62d4b587435dc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNS0xLTEtMS0zMDU3Mg_48663088-63c1-426b-b4df-947db81123cd"
      unitRef="usd">30394000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib7d1a2450d964986952b0cb1d7a972d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNS0zLTEtMS0zMDU3Mg_4648ba54-c519-46de-9b1a-ff83d5241676"
      unitRef="usd">22843000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i880abad5544f42bc928b73e22ab0195b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNS01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOmEzODU0MjBkNGNlZDQyMDlhNzljYmQ0MDE1YzVkYzEwXzIxOTkwMjMyNTU1NTY_3d2b8645-7a9a-46a6-a961-c1565edf2003">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie96c96643a9a49e897b82d45077534e9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNS01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOmEzODU0MjBkNGNlZDQyMDlhNzljYmQ0MDE1YzVkYzEwXzIxOTkwMjMyNTU1NjA_63a8edf8-2ce4-402c-836e-e2e5e181bd5c">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if9ea353bc69b4538a77ec069769583e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNi0xLTEtMS0zMDU3Mg_7fb8e1a3-2304-4699-b7cd-ba7e996478a7"
      unitRef="usd">35826000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icc1b463b713a4a888492c941c54b0d54_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNi0zLTEtMS0zMDU3Mg_23596519-031f-43f7-880b-8843eaddf9bc"
      unitRef="usd">30718000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0af911d8233f4962aafb743c2dd6a5f0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNi01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjU5YmVmMmViYTlkMzQzMGY5OTNhYmYzMzlmNjFmOTY1XzIxOTkwMjMyNTU1NTY_211b27aa-864b-427e-be09-41a003a8818a">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6e31541c268a47789bfebfdbfe3302c7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNi01LTEtMS0zMDU3Mi90ZXh0cmVnaW9uOjU5YmVmMmViYTlkMzQzMGY5OTNhYmYzMzlmNjFmOTY1XzIxOTkwMjMyNTU1NjA_fbb5aa75-9b04-4449-b53d-671a012e77af">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iea2775d83b054b66a7b7488b3b99b796_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNy0xLTEtMS0zMDU3Mg_ccaaa911-4001-4196-bd90-237345b78f41"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib569323910c44cd88620b55283478461_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfNy0zLTEtMS0zMDU3Mg_6682a16f-1e25-4379-bf75-fb2760383e86"
      unitRef="usd">3170000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i22d7d272d9234119b3defb42cd98b2ed_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfOC0xLTEtMS0zMDU3Mg_4620aba7-b69f-4c97-ad28-6bcef9c0fedf"
      unitRef="usd">12395000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie55f1b1da3e0488c9a6e5f436542cf5a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfOC0zLTEtMS0zMDU3Mg_744acc1f-2c38-4cfa-a20e-996d39b63fb3"
      unitRef="usd">6290000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfOS0xLTEtMS0zMDU3Mg_ebcb8516-d423-4b03-84b7-e6b76b3c4d2f"
      unitRef="usd">219417000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfOS0zLTEtMS0zMDU3Mg_44514722-730e-4310-94fe-448fa083d6fe"
      unitRef="usd">178768000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMTAtMS0xLTEtMzA1NzI_7322545a-9505-4d03-b601-765d45a32031"
      unitRef="usd">109952000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMTAtMy0xLTEtMzA1NzI_08fe9643-49c5-4e6b-82ec-76171c0f4601"
      unitRef="usd">92895000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMTEtMS0xLTEtMzA1NzI_20f0d62f-10ca-4412-9065-dedb68745e32"
      unitRef="usd">109465000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjg4OGIyZjhjMjYxNjRmNGI4YTE3ZjIzNDk2M2RmYWRkL3RhYmxlcmFuZ2U6ODg4YjJmOGMyNjE2NGY0YjhhMTdmMjM0OTYzZGZhZGRfMTEtMy0xLTEtMzA1NzI_cee5f204-68f1-4792-a364-29fef63f1e05"
      unitRef="usd">85873000</us-gaap:PropertyPlantAndEquipmentNet>
    <neo:AssetHeldForSaleSquareFeetOfFacilityOwned
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfMzI5ODUzNDg4NjAxNA_f5355dca-acd6-4732-b09c-f3841b8f9738"
      unitRef="sqft">43560</neo:AssetHeldForSaleSquareFeetOfFacilityOwned>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i81cc823b18b445a48f1d7b22e1ae4708_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfMjE5OTAyMzI1NzgyMQ_26af1b72-bcc2-4a9e-a669-fe7ecec6f1ab"
      unitRef="usd">3200000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="i95ed315fe6ca4ac4b52bb55b50e60ce8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RleHRyZWdpb246MjkzOWU2MGUwNzBmNGJlYWE5YTAyN2YxZmQxZDk2MTFfMjE5OTAyMzI1Nzg0MA_a07448b2-5405-4f05-a379-4a8c5c3c2edd"
      unitRef="usd">6900000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:Depreciation
      contextRef="i9d27cc71a1714b4ebf592be7df20c267_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMS0xLTEtMS04NDU5Mw_699a51d1-8de3-429f-95e1-b11a2c13951b"
      unitRef="usd">14200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic20fd6415e784db381b4c4dc75be37e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMS0zLTEtMS04NDY2Nw_a24cc798-5e56-47b7-b05b-94d7f6f08c09"
      unitRef="usd">15287000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i291ce8a7f66b4b84a5b2060a8fcc1069_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMS01LTEtMS04NDY2Nw_7ed87d47-1c71-4697-ba4d-9b7ba7568d37"
      unitRef="usd">9386000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i151d387283274e48b13d8617c7cb5641_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMi0xLTEtMS04NDU5OA_09df9a8a-5b48-4719-90a5-e9254d054261"
      unitRef="usd">15299000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if5b8f4e448e449b8833a37c30148dc54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMi0zLTEtMS04NDY2Nw_2280a358-2913-496c-8d64-8ef6aa34ccf4"
      unitRef="usd">10359000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6385c3880aa64c458d744783c9ed5858_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMi01LTEtMS04NDY2Mw_aa770519-bb2a-4219-89b7-535cfb298dcf"
      unitRef="usd">10825000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i74fa1e58d23f4919baa197fafbd39ade_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMy0xLTEtMS04NDYwMw_1dd14852-1cbe-4e7b-bfca-1db9713c28cf"
      unitRef="usd">693000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia467e61d4253433b840909b9672e06a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMy0zLTEtMS04NDY2Nw_2f688020-0a5f-4474-9407-80199969bbf0"
      unitRef="usd">258000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6c550d928cb64f8baa867e835a056792_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfMy01LTEtMS04NDY2Nw_88c25081-426c-411c-b336-2a8ae07f9758"
      unitRef="usd">135000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfNC0xLTEtMS04NDY3NA_55ed3a6b-4be7-4085-abdb-a09b96319063"
      unitRef="usd">30192000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfNC0zLTEtMS04NDY2Nw_ed99c7b3-f39d-49fa-80da-42a056de38b8"
      unitRef="usd">25904000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85MS9mcmFnOjI5MzllNjBlMDcwZjRiZWFhOWEwMjdmMWZkMWQ5NjExL3RhYmxlOjk0ZDUyNGNlYjRhZjQ5MjA4NzZjNWE2ODBhYzIzYTgyL3RhYmxlcmFuZ2U6OTRkNTI0Y2ViNGFmNDkyMDg3NmM1YTY4MGFjMjNhODJfNC01LTEtMS04NDY2Nw_3db81bc4-7bc7-46da-a27e-18e455e869e9"
      unitRef="usd">20346000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTcxOQ_0efa3c5f-1c79-4b86-b978-6528bcd5746f">Leases&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the maturities of the operating lease liabilities and a reconciliation to the present value of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.511%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional supplemental data related to the operating leases for the years ended December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company has entered into $4.9 million of contractually binding minimum lease payments for a lease executed but not yet commenced. This amount is excluded from the above tables and relates to the lease of an administrative space in Carlsbad, California that commenced in January 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company&#x2019;s lease of its new laboratory and headquarters facility in Fort Myers, Florida commenced. As of December 31, 2021, the Company had paid approximately $25.0&#160;million to the landlord for the construction of the underlying assets which was classified as a prepaid lease asset until the lease commenced in the third quarter of 2021 at which time the prepaid lease asset was included in the calculation of the right-of-use asset. As of December 31, 2021, the Company had paid approximately $17.0&#160;million to the landlord for leasehold improvements, which are included in property and equipment, net, for its new laboratory and headquarters facility. As of &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, all disbursements to the landlord had been completed. As of December 31, 2020, $21.9 million remained unpaid in a construction disbursement escrow account for final remaining disbursements to the landlord and remained in restricted cash on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTcxNg_de21a776-c294-49dc-a5b2-8f613bf98280">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the maturities of the operating lease liabilities and a reconciliation to the present value of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.511%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMS0xLTEtMS0zMDU3Mg_5d6b4ab3-76f6-4e76-8b58-36924858c24c"
      unitRef="usd">9752000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMi0xLTEtMS0zMDU3Mg_e2fe8b40-7b1c-453b-8bd3-b89b60b2d73e"
      unitRef="usd">10313000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMy0xLTEtMS0zMDU3Mg_dcf61088-0016-4e4c-9f26-76eb3a85059c"
      unitRef="usd">10388000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfNC0xLTEtMS0zMDU3Mg_9f55fc3a-ce47-4d17-9dbc-29d9372de8d6"
      unitRef="usd">6929000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfNS0xLTEtMS0zMDU3Mg_83d7aeae-1c83-4a60-9b05-dd8daa6525cc"
      unitRef="usd">5904000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfNi0xLTEtMS0zMDU3Mg_7f35a3f3-1a1b-49cc-a64a-14a84fe718ae"
      unitRef="usd">59496000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfNy0xLTEtMS0zMDU3Mg_503ebd6c-7416-4ac8-9251-483005767cfd"
      unitRef="usd">102782000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfOC0xLTEtMS0zMDU3Mg_f98a54f1-5e57-4412-bb19-a7800b5d0871"
      unitRef="usd">23609000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfOS0xLTEtMS0zMDU3Mg_5f9fc317-a8d0-4318-86f2-eb6e05a797cb"
      unitRef="usd">79173000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMTAtMS0xLTEtMzA1NzI_a12b76c4-1f6c-4a35-b1e6-60c19db506cf"
      unitRef="usd">6884000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMTEtMS0xLTEtMzA1NzI_9c94ca74-2a21-42b6-bd81-bfc281fe6ba9"
      unitRef="usd">72289000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMTItMS0xLTEtMzA1NzI_2326eb04-791f-44c2-8950-e32525eae9f5">P12Y9M3D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOmFlZGExNjRiYmE5NTQ3ZjU5NWY5MTA3MTA0MWM1MDIxL3RhYmxlcmFuZ2U6YWVkYTE2NGJiYTk1NDdmNTk1ZjkxMDcxMDQxYzUwMjFfMTMtMS0xLTEtMzA1NzI_beaa564f-5cc0-4242-8aef-de7cb4001408"
      unitRef="number">0.039</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTcxNw_792ab530-7aa5-45c8-a7ce-7f5fddfcfbd8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional supplemental data related to the operating leases for the years ended December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMi0yLTEtMS01NjIwNA_71a4bb17-9af3-46c8-b8b8-9af87350b568"
      unitRef="usd">11231000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMi00LTEtMS01NjIxMQ_97fd0560-1462-4da0-bcae-114a1f0c8173"
      unitRef="usd">8371000</us-gaap:OperatingLeaseCost>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMi0yLTEtMS0zMDU3Mg_488af37c-2f6d-41ce-8604-c15c24b9cbba"
      unitRef="usd">39785000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMi00LTEtMS0zMDU3Mg_210bd941-7ec3-4eed-a813-4f3045e2b150"
      unitRef="usd">25461000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMy0yLTEtMS0zMDU3Mg_bf47da85-5488-49ae-b832-f90f3826f4bd"
      unitRef="usd">10165000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RhYmxlOjcxMzU3MWZiY2JiMTRkYTRhNGVjY2RhYmM0ODhkZTc4L3RhYmxlcmFuZ2U6NzEzNTcxZmJjYmIxNGRhNGE0ZWNjZGFiYzQ4OGRlNzhfMy00LTEtMS0zMDU3Mg_3265e365-9b46-43d0-8421-2f9f155dd18a"
      unitRef="usd">7116000</us-gaap:OperatingLeasePayments>
    <neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMjE5OTAyMzI2NTE2NA_63fea18c-4c5b-43cb-bcb2-dbee1e1d930a"
      unitRef="usd">4900000</neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="ic957ae942d964cf9b7a556c4a93531fb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTY0OTI2NzQ1Njg2OQ_b8232d0c-9a0a-4775-925e-c269102481eb"
      unitRef="usd">25000000</neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i9ac08cc60a5e4cdab6616035137f9346_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTY0OTI2NzQ1Njg4NA_dedbf6f7-55cc-4064-8e5f-7817c0cc437a"
      unitRef="usd">17000000</neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV85NC9mcmFnOjBhMmRhZTk0MmZjNzRmMjE4MjFiZGQwYjFhYjYxMGIxL3RleHRyZWdpb246MGEyZGFlOTQyZmM3NGYyMTgyMWJkZDBiMWFiNjEwYjFfMTY0OTI2NzQ1Njg2NQ_3f8eee22-befe-4154-ae04-ec31c64b96f6"
      unitRef="usd">21900000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkyNw_f17ea80c-bca9-4d11-a669-c88f94aeebfa">Goodwill and Intangible Assets&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of Trapelo in April 2021, the Company recorded $44.7 million in goodwill, all of which was recorded in the Clinical Services segment. As a result of the acquisition of Inivata in June 2021, the Company recorded $271.4 million in goodwill, of which $238.4 million and $33.0 million are assigned to the Clinical Services and Pharma segments, respectively. For further information regarding the Trapelo and Inivata acquisitions, please refer to Note 3. Acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pharma Services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired - Trapelo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired - Inivata&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 13pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;7-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2021, 2020, and 2019, amortization on the Consolidated Statements of Operations was recorded as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization recorded in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the estimated amortization expense related to amortizable intangible assets for each of the five following years and thereafter is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if28d75b24f2140639b3049878575785f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzgyNDYzMzcyMTE1OTY_d6d613b6-a08f-44ba-a456-9e6c49cd1da3"
      unitRef="usd">44700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzgyNDYzMzcyMTE2Mjk_dabb4098-bba0-445f-81b5-98a6168d6874"
      unitRef="usd">271400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic5d9574696644e1f9309d0cfefa33d29_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzgyNDYzMzcyMTE2NjI_55dce7f5-de8c-4ad9-bf84-4f4d041bcbe9"
      unitRef="usd">238400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ibb76b6a1b0eb453db2e735dd98b1f29f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzgyNDYzMzcyMTE2ODk_8865e4a2-f001-40b6-bacf-b766c92b9eb1"
      unitRef="usd">33000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkyOA_1e21e670-750e-48bd-a593-7be1b59e1f36">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pharma Services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired - Trapelo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired - Inivata&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i6711068bbac647fc86549e4223bb1234_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzEtMS0xLTEtMzA1NzI_1d04c677-9191-47c2-a383-112466384b1e"
      unitRef="usd">179534000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1de0a4a163954f2cb05b76ae300bf20b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzEtMy0xLTEtMzA1NzI_8a875527-4461-49b9-9d7d-62647b090602"
      unitRef="usd">31549000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzEtNS0xLTEtMzA1NzI_ef0347d9-90b6-4b2e-a18d-f73dee87e65a"
      unitRef="usd">211083000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if28d75b24f2140639b3049878575785f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzItMS0xLTEtNDk1NjE_79f84620-8ea8-4161-974f-2547e09cc1c9"
      unitRef="usd">44664000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8170c0aaa5d7434fa9c612d65b268c2e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzItMy0xLTEtNDk1NjE_35f03699-6bae-402a-b4e6-0d29ada056ad"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i1f7ed50e5ea746629e2bf83cd1f470c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzItNS0xLTEtNDk1NjE_9b03d984-221b-47fa-865d-ef3739693586"
      unitRef="usd">44664000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic5d9574696644e1f9309d0cfefa33d29_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzMtMS0xLTEtNDk1NjE_c9ecdea4-64be-41a4-bc20-fd87528d31b0"
      unitRef="usd">238405000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ibb76b6a1b0eb453db2e735dd98b1f29f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzMtMy0xLTEtNDk1NjE_93aff3df-d7de-48f8-a735-a25c39f93138"
      unitRef="usd">32963000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzMtNS0xLTEtNDk1NjE_3b2b060f-5977-4bbf-949a-e8c09b2b9b7d"
      unitRef="usd">271368000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i637576e87f3d47aa8bf8b7d26b13ccaf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzQtMS0xLTEtNDk1Njg_21760519-838e-4bd3-9e45-e51cab6587c8"
      unitRef="usd">462603000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic98525a6e8714275ab1c829b7a50b6e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzQtMy0xLTEtNDk1Njg_8ad09115-fd56-4246-8f92-6f5d687f6565"
      unitRef="usd">64512000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo3YjgzNTAxM2ZjMjQ0YzIwOTRjMTIxNThkNWI4YWUyNS90YWJsZXJhbmdlOjdiODM1MDEzZmMyNDRjMjA5NGMxMjE1OGQ1YjhhZTI1XzQtNS0xLTEtNDk1Njg_59d0862f-7099-446f-a68c-aa0c3b6806d5"
      unitRef="usd">527115000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkzMg_6631f926-4d2b-41f4-9008-54031f387493">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 13pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;7-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if411244f1e50462093c1aae195efef2f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjplZjI3YzYxZDAzYjI0NThlODNhYjQ4N2Q5NzBlNmEyM18yNzQ4Nzc5MDY5NDQ0_96cda091-ac8d-42aa-be3a-797294d4e901">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if43301d85c4e4b128360590c43b56712_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjplZjI3YzYxZDAzYjI0NThlODNhYjQ4N2Q5NzBlNmEyM18yNzQ4Nzc5MDY5NDQ4_de342048-3fd1-4c9c-bea0-0b84ba3baa4e">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i04841638dcb14d26aca6ddbca52a8008_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItMy0xLTEtMzA1NzI_92a31186-1737-4907-a6af-784910c9de8b"
      unitRef="usd">143101000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i04841638dcb14d26aca6ddbca52a8008_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItNS0xLTEtMzA1NzI_c967cc55-6c85-4b68-9b07-e3734c52b990"
      unitRef="usd">45756000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i04841638dcb14d26aca6ddbca52a8008_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzItNy0xLTEtMzA1NzI_ac948c7a-d7f1-4961-861d-10e2606c1b0f"
      unitRef="usd">97345000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i84706daee59246f5ab9cf3fb66b19a70_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjowNzdhMzAzOWM1MjI0YjgwOWFiMDRkODkxNDQyYzVjZl8yNzQ4Nzc5MDY5NDQ0_5b064e09-fa95-417c-a731-bec822f224fc">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i2b0eadb39e524028b1b5befa8894385c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjowNzdhMzAzOWM1MjI0YjgwOWFiMDRkODkxNDQyYzVjZl8yNzQ4Nzc5MDY5NDQ4_0b4eb127-33e6-4364-bddf-41abaeb0d8a8">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5dd218dd4ac047aabdc29a8180d928bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtMy0xLTEtMzA1NzI_744b4e04-4d00-480f-b7b1-3ebef60107d5"
      unitRef="usd">310226000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5dd218dd4ac047aabdc29a8180d928bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtNS0xLTEtMzA1NzI_bd0cc009-905b-4ec1-8276-07fc07ba5a11"
      unitRef="usd">11798000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5dd218dd4ac047aabdc29a8180d928bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzMtNy0xLTEtMzA1NzI_b5c5d5dc-cf37-4c4d-900a-08184d14bfa2"
      unitRef="usd">298428000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4a9e3c3f614b4a54a8fa244038abc68c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtMS0xLTEtNDkxODI_d4e47074-ec5a-470e-8276-f0c784252475">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7a182d543fcb4f498a67a90731372126_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtMy0xLTEtNDkyNDQ_a2332a94-646d-482f-ab61-5ed99f166d93"
      unitRef="usd">549000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7a182d543fcb4f498a67a90731372126_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtNS0xLTEtNDkyMjY_8bc5334e-aec4-41a1-8204-47ab8f2910a3"
      unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7a182d543fcb4f498a67a90731372126_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtNy0xLTEtNDkyMzM_ed167cfc-2f91-4ad8-aa84-a6b5e48f08c9"
      unitRef="usd">449000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i9eff1173507945b488259b30471cc6bf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtMS0xLTEtMzA1NzI_09cf90f5-d317-4e73-a017-431968d60f1c">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0a929c3ad7fd4b79ac34b701ad8c5f50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtMy0xLTEtMzA1NzI_fe9ed354-c37c-46b0-bba4-54a5890fdbe9"
      unitRef="usd">31473000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a929c3ad7fd4b79ac34b701ad8c5f50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtNS0xLTEtMzA1NzI_8ad9acc4-0860-4842-803c-ee2908e00631"
      unitRef="usd">1125000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0a929c3ad7fd4b79ac34b701ad8c5f50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzQtNy0xLTEtMzA1NzI_21c6f1a0-877f-4f70-8c83-03e189c16c57"
      unitRef="usd">30348000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie027d3283ba246829bb5659c80860729_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtMS0xLTEtNDkxODI_e77b1439-fe00-451a-aac3-4f9313afae6c">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie9911279c90843e3b12761e1e6b7cd04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtMy0xLTEtNDkyNTE_08d01ecd-c3a9-498c-8c73-1d1b39b081c4"
      unitRef="usd">2584000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie9911279c90843e3b12761e1e6b7cd04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtNS0xLTEtNDkyMjY_ee7ef848-ff6b-44b7-9443-319687226786"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie9911279c90843e3b12761e1e6b7cd04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtNy0xLTEtNDkyMzM_02c53770-7b89-4777-b82c-2c73241c5170"
      unitRef="usd">2308000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id70e96f3c16a456f80d98d1ca756c591_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzUtMy0xLTEtMzA1NzI_05f30d36-c717-4b37-8d29-3edea06a4b38"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id70e96f3c16a456f80d98d1ca756c591_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzUtNy0xLTEtMzA1NzI_eff48e94-3b2b-4454-9458-82a4a30ab9a4"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtMy0xLTEtMzA1NzI_eea2ef19-216f-4d71-ac8f-a808d47d8ecc"
      unitRef="usd">501380000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtNS0xLTEtMzA1NzI_9a677908-0d84-4908-84ed-13118a778f49"
      unitRef="usd">59055000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzYtNy0xLTEtMzA1NzI_56e9ba9c-d2b3-4ec7-b4e0-f530e063abbe"
      unitRef="usd">442325000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i626362dd9a22429d9bb4e5026984bc8b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTEtMS0xLTMwNTcyL3RleHRyZWdpb246NmJmOTU5OGExZWIyNDliYWJhOGYxYjk3NjkwMjI3MjRfMjc0ODc3OTA2OTQ0NQ_10a63cf9-1b2b-4ceb-b9c3-46f8fcb66872">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i211b3436a4454faea569497baa14b01c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTEtMS0xLTMwNTcyL3RleHRyZWdpb246NmJmOTU5OGExZWIyNDliYWJhOGYxYjk3NjkwMjI3MjRfMjc0ODc3OTA2OTQ0OQ_0053aa37-756f-4859-bcf0-66b671685081">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i724957d1dba34eadb214d693374d40ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTMtMS0xLTMwNTcy_96647ec2-0a5a-4c77-bc3f-1e10b777cfcb"
      unitRef="usd">143101000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i724957d1dba34eadb214d693374d40ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTUtMS0xLTMwNTcy_5df2bc71-8a3a-42c5-a8c2-ac059b08bba1"
      unitRef="usd">35895000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i724957d1dba34eadb214d693374d40ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEwLTctMS0xLTMwNTcy_77d9faee-0274-48eb-9047-684537e7117d"
      unitRef="usd">107206000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id8e67a3847ca48b39b6ee1a91b870b20_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEzLTMtMS0xLTMwNTcy_d0109e52-509a-4205-be0b-eee1cc9dc857"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id8e67a3847ca48b39b6ee1a91b870b20_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzEzLTctMS0xLTMwNTcy_8b9a3c15-059d-4d11-a417-fc18396a4a2f"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzE0LTMtMS0xLTMwNTcy_2a9c0314-3dfa-49f3-86fd-323c5daf30a4"
      unitRef="usd">156548000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzE0LTUtMS0xLTMwNTcy_1c9d51e0-5cb4-4bda-a912-c88d0a77daf6"
      unitRef="usd">35895000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTphMGFmMTk0ZTYxNWU0OTUwODI2YTJkOWNiNmY0ZDc4ZS90YWJsZXJhbmdlOmEwYWYxOTRlNjE1ZTQ5NTA4MjZhMmQ5Y2I2ZjRkNzhlXzE0LTctMS0xLTMwNTcy_2041abc2-fb86-4cae-84f9-6597e82c1550"
      unitRef="usd">120653000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkzMw_75ec7c89-fa8b-4095-8527-2f11148a7f3e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2021, 2020, and 2019, amortization on the Consolidated Statements of Operations was recorded as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization recorded in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9d27cc71a1714b4ebf592be7df20c267_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzEtMS0xLTEtNDg4MDM_405d5aca-7ae2-4625-9801-91d79973a25d"
      unitRef="usd">10407000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic20fd6415e784db381b4c4dc75be37e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzEtMy0xLTEtNDg4NDU_6b117663-ad71-40c5-9b82-f2f8412c2db6"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i291ce8a7f66b4b84a5b2060a8fcc1069_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzEtNS0xLTEtNDg4NTI_2bb39547-00e3-4833-a1a9-82692094325a"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i151d387283274e48b13d8617c7cb5641_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItMS0xLTEtNDg4MDM_6fa8fc3e-cb2f-427d-818a-6233972af217"
      unitRef="usd">12753000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if5b8f4e448e449b8833a37c30148dc54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItMy0xLTEtNDg4NDU_5454b5bb-9a71-43da-a82f-995ed0f9f90e"
      unitRef="usd">9817000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6385c3880aa64c458d744783c9ed5858_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItNS0xLTEtNDg4NTI_5dc03dd5-be0b-4580-953c-181af0d2df77"
      unitRef="usd">9925000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItMS0xLTEtMzA1NzI_71ea2b2f-0e3c-4cd7-9f78-5b2fff5ff018"
      unitRef="usd">23160000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItMy0xLTEtMzA1NzI_82e4488c-5d83-4c24-b335-5ff549e5a7b4"
      unitRef="usd">9817000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTpkY2Y4MTE4ZTU4ZjI0YTQ0YTI4NzA5MjU2YjdhZDk4OS90YWJsZXJhbmdlOmRjZjgxMThlNThmMjRhNDRhMjg3MDkyNTZiN2FkOTg5XzItNS0xLTEtMzA1NzI_7a6b5db3-381e-4cfe-a700-e2d36d178b3b"
      unitRef="usd">9925000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90ZXh0cmVnaW9uOmEzMzBmMWEyMGI0ZTQ2ZTJhZTRkOGQzNjcwM2JlMGUxXzkzMA_cc90dc06-4c8e-49e0-9d2f-968180ea7342">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the estimated amortization expense related to amortizable intangible assets for each of the five following years and thereafter is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzEtMi0xLTEtMzA1NzI_1c5ef8a3-41f8-4c15-a929-3ea406b49b9b"
      unitRef="usd">33899000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzItMi0xLTEtMzA1NzI_bce2d669-a331-431f-a170-174bc6d57bb6"
      unitRef="usd">33899000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzMtMi0xLTEtMzA1NzI_0c66fc8f-6cb4-4062-a7e3-e1b7c8c44f72"
      unitRef="usd">33899000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzQtMi0xLTEtMzA1NzI_16a2f7c2-2463-4471-b767-31783bc4ce10"
      unitRef="usd">33798000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzUtMi0xLTEtMzA1NzI_bde6ed53-e5f5-4a09-9d34-6f7611df784b"
      unitRef="usd">33485000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzYtMi0xLTEtMzA1NzI_edffe8cd-c9f0-4005-b684-c9d20ade13f2"
      unitRef="usd">259898000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDAvZnJhZzphMzMwZjFhMjBiNGU0NmUyYWU0ZDhkMzY3MDNiZTBlMS90YWJsZTo2NjkyOTFiZjViZDg0YmM4YWZhN2FiMjQ3YzE2Njc5My90YWJsZXJhbmdlOjY2OTI5MWJmNWJkODRiYzhhZmE3YWIyNDdjMTY2NzkzXzctMi0xLTEtMzA1NzI_f112fb7d-3d04-46b2-bfb8-eee7a315ac08"
      unitRef="usd">428878000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzU1NDM_fe2622f3-fffe-4d81-b335-870b7862dd13">Investment in Non-Consolidated Affiliate&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2020, the Company formed a strategic alliance with Inivata and entered into a Strategic Alliance Agreement and Laboratory Services Agreement with Inivata&#x2019;s laboratory subsidiary in the United States, Inivata, Inc., whereas Inivata&#x2019;s laboratory rendered and performed certain laboratory testing which the Company made available to customers. The terms and conditions of the Laboratory Services Agreement were consistent with those that would be negotiated between willing parties on an arm&#x2019;s length basis. For additional details on amounts paid related to the Laboratory Services Agreement, please refer to Note 18. Related Party Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Laboratory Services Agreement, the Company also entered into an Investment Agreement with Inivata (the &#x201c;Investment Agreement&#x201d;), pursuant to which the Company acquired the Preference Shares for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$25.0&#160;million in cash resulting in a minority interest in Inivata&#x2019;s outstanding equity and an Option Deed which provided the Company with a Purchase Option to purchase Inivata. The Investment Agreement also granted the Company one seat on Inivata&#x2019;s Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021, the Company completed the acquisition of the remaining equity interests in Inivata. For further details regarding the acquisition of Inivata, please refer to Note 3. Acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Inivata Acquisition Date, Inivata was determined to be a variable interest entity (&#x201c;VIE&#x201d;) and the Company&#x2019;s investment was under 20.0% of the total equity outstanding. The Company considered qualitative factors in assessing the primary beneficiary of the VIE which included understanding the purpose and design of the VIE, associated risks that the VIE created, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it was not the primary beneficiary of Inivata prior to the Inivata Acquisition Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Inivata Acquisition Date, the power to control the activities that most significantly impacted Inivata&#x2019;s economic performance was the sole responsibility of Inivata&#x2019;s management and Board of Directors; however, the Company did have significant influence over Inivata. As the Preference Shares were determined to not be in-substance common stock, and because the Preference Shares and the Purchase Option did not have readily determinable fair values, prior to the Inivata Acquisition Date, the Company elected to measure the Preference Shares and the Purchase Option at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2020, the initial $25.0&#160;million cost and $0.6&#160;million of associated transaction costs was allocated between the Preference Shares and the Purchase Option based on the relative fair value of each and was recorded as investment in non-consolidated affiliate on the Consolidated Balance Sheets. The initial relative fair value of the investment in non-consolidated affiliate was comprised of $19.6&#160;million in Preference Shares and a $6.0&#160;million Purchase Option. The Preference Shares were valued by determining the equity value of Inivata using the Backsolve Method and allocating the value of the Preference Shares using the Option-Pricing Method and the inputs used included the equity value based on the Series C1 capital raised by Inivata, a volatility rate of 84.0%, a risk-free interest rate of 0.17% and 0.0% dividend yield. The Purchase Option was valued using the Black-Scholes model with a volatility rate of 84.0%, a risk-free interest rate of 0.17% and 0.0% dividend yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2020, an observable transaction of an identical investment in Inivata Preference Shares occurred. This resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Purchase Option was also remeasured at fair value as a result of this observable transaction. As a result of these remeasurements, at December 31, 2020, the carrying value of the investment in non-consolidated affiliate is $29.6&#160;million, comprised of $25.0&#160;million in Preference Shares and a $4.6&#160;million Purchase Option. The Company recorded a net unrealized gain of $4.0&#160;million for these remeasurements for the year ended December 31, 2020 in gain on investment in and loan receivable from non-consolidated affiliate, net, on the Consolidated Statements of Operations. At December 31, 2020, the Purchase Option was valued using the Black-Scholes model with a volatility rate of 84.0%, a risk-free interest rate of 0.17% and 0.0% dividend yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2020, the Company and Inivata also entered into the Line of Credit in the amount of $15.0&#160;million. In January 2021, the Line of Credit, in its entirety, was drawn by Inivata and recorded as a loan receivable from non-consolidated affiliate on the Consolidated Balance Sheets. Prior to the Inivata Acquisition Date, the Line of Credit contractually matured on December 1, 2025 and the unpaid principal balance was payable on January 1, 2026 and bore interest at 0.0% per annum. In January 2021, upon the draw of the Line of Credit by Inivata, the Company used an imputed interest rate of 8.33% to present value the Line of Credit. The Company recorded an imputed interest rate discount of $5.0&#160;million on the loan receivable from non-consolidated affiliate and an additional investment in non-consolidated affiliate of $5.0&#160;million, resulting in a $10.0&#160;million present value of the loan receivable from non-consolidated affiliate and increasing the value of the Preference Shares to $30.0&#160;million. For the year ended December 31, 2021 through the Inivata Acquisition Date $0.4 million of interest income was amortized to the loan receivable from non-consolidated affiliate. The interest income amortization is recorded in interest expense, net, on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2021, subsequent to Inivata&#x2019;s draw on the Line of Credit, an observable transaction of an identical investment in Inivata Preference Shares occurred. This resulted in a remeasurement of the Preference Shares to the value of this observable transaction. The Company recorded a net unrealized loss of $5.0&#160;million for this remeasurement for the three months ended March 31, 2021. As of March 31, 2021, the carrying value of the investment in non-consolidated affiliate was $29.6&#160;million, comprised of $25.0&#160;million in Preference Shares and a $4.6&#160;million Purchase Option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Inivata Acquisition Date the Company acquired all of the remaining equity interests of Inivata through the exercise of its Purchase Option. The Company&#x2019;s carrying value of the investment in non-consolidated affiliate was $29.6&#160;million, comprised of $25.0&#160;million in Preference Shares and a $4.6&#160;million Purchase Option immediately prior to obtaining the remaining ownership of Inivata. The Company&#x2019;s acquisition of control of Inivata on the Inivata Acquisition Date was accounted for as a business combination achieved in stages under the acquisition method. Accordingly, the Company &lt;/span&gt;&lt;/div&gt;remeasured its Preference Shares and Purchase Option to their acquisition-date fair values. The Company used a discounted cash flow to derive a business enterprise value of Inivata in order to determine the acquisition-date fair value of the Company&#x2019;s Preference Shares and the Purchase Option. To determine the fair value of the Preference Shares, the fair value of equity was allocated to the various classes based on the respective rights and privileges of each class of stock in liquidation. The business enterprise value and a Black-Scholes model was then used to determine the fair value of the remaining equity acquired through the exercise of the Purchase Option. The Purchase Option was recorded at fair value at the Inivata Acquisition Date based on its settlement value. This resulted in fair values of $64.9&#160;million in Preference Shares and a $74.3&#160;million Purchase Option, immediately prior to the acquisition, resulting in a net gain of $104.6&#160;million for the year ended December 31, 2021, which includes the net loss of $5.0&#160;million for the remeasurement in the first quarter of 2021. In addition, on the Inivata Acquisition Date, the $10.3&#160;million outstanding under the Line of Credit extended by the Company to Inivata was effectively settled as part of the acquisition of Inivata at the $15.0&#160;million principal amount and was recorded as part of the consideration transferred in the acquisition resulting in a gain of $4.7&#160;million for the year ended December 31, 2021. The Company recorded a total gain on investment in and loan receivable from non-consolidated affiliate, net, within the Company&#x2019;s Consolidated Statements of Operations of $109.3&#160;million for the year ended December 31, 2021 for the excess of the acquisition-date fair value of the Company&#x2019;s Preference Shares, Purchase Option, and Line of Credit over their carrying values. For further details regarding the acquisition of Inivata, please refer to Note 3. Acquisitions.</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i15b55aa860d546afb934b299f66c83bc_I20200522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzExMTA_1981a2a2-a032-4d33-954a-f811edd0456f"
      unitRef="usd">25000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i15b55aa860d546afb934b299f66c83bc_I20200522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzI2NDQ_1e19541b-9504-44c6-8e95-4a5975ce3abf"
      unitRef="usd">25000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <neo:PaymentsToAcquireVariableInterestEntitiesTransactionCosts
      contextRef="idc5c1aae3c584667a244f89cd8a59dce_D20200522-20200522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzI2NTY_49b26379-2c10-44cd-a47f-ed04c3735581"
      unitRef="usd">600000</neo:PaymentsToAcquireVariableInterestEntitiesTransactionCosts>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="id3649585fd6c4174aa308719cf6e9e80_I20200522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzMwMTU_1d6a0756-e31f-4b67-8f73-7f8baaea39a2"
      unitRef="usd">19600000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i1b0aa1a691324c869b66196ee345f501_I20200522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzMwNDU_04831a49-df19-478d-b6ab-5925001fa10a"
      unitRef="usd">6000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <neo:PurchaseOptionMeasurementInput
      contextRef="i4115d538e4cb482997d79b54d6ea7e82_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzMzNjg_00e52521-80d0-4d49-a120-60b3f625da89"
      unitRef="number">0.840</neo:PurchaseOptionMeasurementInput>
    <neo:PurchaseOptionMeasurementInput
      contextRef="i81ef4e3b7e4349c09dfb58d45e01d6a3_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM0MDE_856e5342-c1a9-4a12-9fbc-bd462fdd4358"
      unitRef="number">0.0017</neo:PurchaseOptionMeasurementInput>
    <neo:PurchaseOptionMeasurementInput
      contextRef="ia2746f4168df4e39b0b9c9c32fab75aa_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM0MDg_0c582e49-be93-4dc0-b0a1-2d8e39cf8120"
      unitRef="number">0.000</neo:PurchaseOptionMeasurementInput>
    <neo:PurchaseOptionMeasurementInput
      contextRef="i55719c5ae1624deeab13abbd59d52c69_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM1MTQ_d95820d4-f838-4c80-ac3c-739d7e149aad"
      unitRef="number">0.840</neo:PurchaseOptionMeasurementInput>
    <neo:PurchaseOptionMeasurementInput
      contextRef="i7a973dc561984ddf97bf05e50b7774cc_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM1NDc_5209f3a9-2aaf-4e94-8804-3522da4e5a08"
      unitRef="number">0.0017</neo:PurchaseOptionMeasurementInput>
    <neo:PurchaseOptionMeasurementInput
      contextRef="ib0bd3a8ae9bd414ab4804e5744d62945_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM1NTQ_44347442-ef99-4679-b528-e912c677bf55"
      unitRef="number">0.000</neo:PurchaseOptionMeasurementInput>
    <us-gaap:Assets
      contextRef="ibd5b0ed6e13f4301a82540f21d96736e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQyNDE_1d38aa14-37b0-47f8-a439-aa8af937ce88"
      unitRef="usd">29600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic0157f74f12948d5b65dae57eda95f7c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQyNTg_0f892b8b-b760-4d1d-98be-ac12b4b8d253"
      unitRef="usd">25000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie482047107814fcebaeb573c8d125f94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQyODg_ce724b64-2a86-4bb3-9d98-b1ed4f3bc8fd"
      unitRef="usd">4600000</us-gaap:Assets>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic34c607907124e1797f9b2a94c22f26c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQzNTQ_0c949d04-edba-47d6-859d-a56bc8063c82"
      unitRef="usd">4000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <neo:PurchaseOptionMeasurementInput
      contextRef="ia67744929d544b18bcea0c016670b483_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQ1ODc_6a85d177-2e34-4b05-ba8f-328fc75766df"
      unitRef="number">0.840</neo:PurchaseOptionMeasurementInput>
    <neo:PurchaseOptionMeasurementInput
      contextRef="ic3c717cc90b34c8396331da311fbc8a6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQ2MjA_9b6c1150-906a-40ca-950f-1a4faf94f73a"
      unitRef="number">0.0017</neo:PurchaseOptionMeasurementInput>
    <neo:PurchaseOptionMeasurementInput
      contextRef="i3e5bb53850794a1bb9fe4a1d9392f790_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzQ2Mjc_ea7fbded-af9c-4c1a-89fb-2032acd5641f"
      unitRef="number">0.000</neo:PurchaseOptionMeasurementInput>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i21e0442b30f14bb3be7f6da7309905fa_I20210522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM1OTk_e775bd91-5178-481f-aeb7-ae8261211900"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="id5bd8263f7e1453fae593718fb321be8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2MTI_c4467156-71ac-45d4-82e6-22b31656781a"
      unitRef="number">0.000</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i33e7531437724368b82772116041a856_I20210131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2MTc_f7209749-5acd-4c15-b332-7e1e844b1ddd"
      unitRef="number">0.0833</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:ReceivableWithImputedInterestDiscount
      contextRef="i33e7531437724368b82772116041a856_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2MjQ_595b36fb-3f52-4c3b-9a9b-0c67aff762dd"
      unitRef="usd">5000000</us-gaap:ReceivableWithImputedInterestDiscount>
    <neo:EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment
      contextRef="i33e7531437724368b82772116041a856_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2MzY_e5decf4c-9bcf-43d0-a1d6-5025e87a7a76"
      unitRef="usd">5000000</neo:EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment>
    <us-gaap:ReceivableWithImputedInterestNetAmount
      contextRef="i33e7531437724368b82772116041a856_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2NDg_35f3f073-f9e2-49ff-983e-dd2896dbf830"
      unitRef="usd">10000000</us-gaap:ReceivableWithImputedInterestNetAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i562c64b34e6c47f5ac6fe747404a6e3a_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM2NjE_f8771ab1-6e55-48c6-89f1-0f224d56baf1"
      unitRef="usd">30000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:InterestAndFeeIncomeLoansAndLeases
      contextRef="i93dce16f064a42eabc5af5199673306a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzM4NDgyOTA3MTc5NDg_63457d29-df4e-4100-97ab-aa1564e3a13e"
      unitRef="usd">400000</us-gaap:InterestAndFeeIncomeLoansAndLeases>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="icedf740a0317452ea709d14ef5bf92f4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0ODk3MTM_460f0a9c-1e30-426c-b14a-5633e3d7251f"
      unitRef="usd">5000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i9aa9ea29f0bc44568dcd39d50b79abda_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0ODk3NDE_3a4308c8-8609-4354-91f3-2769f1b26300"
      unitRef="usd">29600000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="id314aeaf3a3e4fd28f10f5c449698ad4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0ODk3NTY_5c1c993c-8a8d-4c55-947b-c94b8a8fb204"
      unitRef="usd">25000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i2d9fb9ddce7e450f8b051082329851b8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0ODk3Mjc_219af94a-4595-429e-8862-ca9859dbbfb6"
      unitRef="usd">4600000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="ifcc7b5e165b64262a42245b5258953e1_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0NTA_fbcfc429-e3ef-4ba4-af93-fbf5bd25f45e"
      unitRef="usd">29600000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i8e6ac5e675db4ac6837f4c1270b3e2de_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0MjM_c7f0d019-942a-44bc-b595-ea6b0a308af3"
      unitRef="usd">25000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="i6f1df0f3964f4e5f8fec10eac6e0e19d_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0MzY_86f55e41-6051-4ab6-bbab-a2ff61a52532"
      unitRef="usd">4600000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0NjU_3a3e78be-842e-4c9c-8ae0-00bcae97b5ed"
      unitRef="usd">64900000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue
      contextRef="i5342d7cb695b49708ece5ba35894eb3d_D20210930-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0ODA_01ba7281-6c30-4be9-b175-dfc0633edb44"
      unitRef="usd">74300000</neo:BusinessCombinationStepAcquisitionPurchaseOptionFairValue>
    <us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzE2NDkyNjc0OTE1MjM_cf81a14b-f0b4-4ab6-9742-178d0bb014b8"
      unitRef="usd">104600000</us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="icedf740a0317452ea709d14ef5bf92f4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzExNTQ0ODcyMTQxMzMx_460f0a9c-1e30-426c-b14a-5633e3d7251f"
      unitRef="usd">5000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:LineOfCredit
      contextRef="ie4c011915eac47c0998bdadb7a8c7b5c_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM0OTU_c7353078-bfcf-4096-8833-740afc956a92"
      unitRef="usd">10300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i21e0442b30f14bb3be7f6da7309905fa_I20210522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM1NDE_c03d79e7-a3eb-4410-b169-b4837e4dbda4"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <neo:LongTermLineOfCreditSettlementGainLoss
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM1NTQ_77ba9851-5a7a-4062-ad0a-297c605cd4b9"
      unitRef="usd">4700000</neo:LongTermLineOfCreditSettlementGainLoss>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
      contextRef="i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDMvZnJhZzozYTIyYWU3YzY1NGE0ZTc4YWQ3ZTVmNWFmMTI0YzVkMi90ZXh0cmVnaW9uOjNhMjJhZTdjNjU0YTRlNzhhZDdlNWY1YWYxMjRjNWQyXzgyNDYzMzcyNTM1Njg_946c1dc7-efc5-4a32-9a6f-2c8d69a32ff1"
      unitRef="usd">109300000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEyNTE5_35c7c5b7-95a4-4dd8-a8dd-2cafda71f10d">Debt&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-term debt, net, at December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25% Convertible Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total 0.25% Convertible Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25% Convertible Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total 1.25% Convertible Senior Notes due 2025, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of equipment financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, the estimated fair value (Level 2) of the 0.25% Convertible Senior Notes due 2028 and the 1.25% Convertible Senior Notes due 2025 was $297.6&#160;million and $238.9&#160;million, respectively. There was no such estimated fair value as of December 31, 2020 related to the 0.25% Convertible Senior Notes due 2028. At December 31, 2020, the estimated fair value (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $320.9&#160;million. At December 31, 2021 and 2020, the carrying value of the Company&#x2019;s equipment financing obligations approximated fair value based on the current market conditions for similar instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;2028 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2021, the Company completed the sale of $345.0&#160;million of Convertible Senior Notes with a stated interest rate of 0.25% and a maturity date of January 15, 2028 (the &#x201c;2028 Convertible Notes&#x201d;), unless earlier converted, redeemed, or repurchased. The 2028 Convertible Notes were issued at a discounted price of 97.0% of their principal amount. The total net proceeds from the issuance of the 2028 Convertible Notes and exercise of the over-allotment option was approximately $334.4&#160;million, which includes approximately $10.6&#160;million of discounts, commissions and offering expenses paid by the Company. On January 11, 2021, the Company entered into an Indenture (the &#x201c;Indenture&#x201d;), with U.S. Bank National Association, as trustee (the &#x201c;Trustee&#x201d;), governing the 2028 Convertible Notes. The Company used a portion of the net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;proceeds from the Offerings to enter into capped call transactions (as described below under the heading &#x201c;Capped Call Transactions&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to September 15, 2027, noteholders may convert their 2028 Convertible Notes at their option, only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130.0% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2028 Convertible Notes for each trading day of the measurement period was less than 98.0% of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate on each such trading day; (3) if the Company calls any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after September 15, 2027 until the close of business on the second business day immediately preceding the maturity date, noteholders may convert their 2028 Convertible Notes at any time, regardless of the foregoing circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended September 30, 2021. Based on the terms of the 2028 Convertible Notes, the holders could not have converted all or a portion of their 2028 Convertible Notes in the fourth quarter of 2021. The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended December 31, 2021. Based on the terms of the 2028 Convertible Notes, the holders cannot convert all or a portion of their 2028 Convertible Notes in the first quarter of 2022. When a conversion notice is received, the Company has the option to pay or deliver cash, shares of the Company&#x2019;s common stock, or a combination thereof. As the Company is not required to settle the 2028 Convertible Notes in cash, the 2028 Convertible Notes are classified as long-term debt as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, the Company will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at its election. The initial conversion rate for the 2028 Convertible Notes is 15.1172 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to an initial conversion price of approximately $66.15 per share of common stock. The conversion rate is subject to adjustment as described in the Indenture. In addition, following certain corporate events that occur prior to the maturity date as described in the Indenture, the Company will pay a make-whole premium by increasing the conversion rate for a holder who elects to convert its 2028 Convertible Notes in connection with such a corporate event in certain circumstances. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $34.12 on December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the 2028 Convertible Notes prior to January 20, 2025. The Company may redeem for cash all or any portion of the 2028 Convertible Notes, at its option, on or after January 20, 2025 if the last reported sale price of its common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date of notice by the Company of redemption at a redemption price equal to 100.0% of the principal amount of the 2028 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2028 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an event involving bankruptcy, insolvency or reorganization events with respect to the Company occurs, then the principal amount of, and all accrued and unpaid interest on, all of the 2028 Convertible Notes then outstanding will immediately become due and payable. If any other default event occurs and is continuing, then noteholders of at least 25.0% of the aggregate principal amount of the 2028 Convertible Notes then outstanding, by notice to the Company, may declare the principal amount of, and all accrued and unpaid interest on, all of the 2028 Convertible Notes then outstanding to become due and payable immediately. If the Company undergoes a Fundamental Change (as defined in the Indenture), then noteholders may require the Company to repurchase their 2028 Convertible Notes at a cash repurchase price equal to the principal amount of the 2028 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the Fundamental Change Repurchase Date (as defined in the Indenture).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Convertible Notes are the Company&#x2019;s senior, unsecured obligations and will be equal in right of payment with its existing and future senior, unsecured indebtedness, senior in right of payment to its existing and future indebtedness that is expressly subordinated to the 2028 Convertible Notes and effectively junior to its existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness. The 2028 Convertible Notes will be structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized on the 2028 Convertible Notes includes $0.8&#160;million, $1.4&#160;million and $32,000 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the year ended December 31, 2021. There were no such amounts for the year ended December 31, 2020. The effective interest rate on the 2028 Convertible Notes is 0.70%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of 0.25% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, which began on July 15, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Capped Call Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the &#x201c;Capped Call Transactions&#x201d;) with option counterparties pursuant to capped call confirmations at a cost of approximately $29.3&#160;million. As the Capped Call Transactions meet certain accounting criteria, the Capped Call Transactions were classified as equity, are not accounted for as derivatives and were recorded as a reduction of the Company&#x2019;s additional paid-in capital in the accompanying Consolidated Financial Statements. The Capped Call Transactions are not part of the terms of the 2028 Convertible Notes and will not affect any holders&#x2019; rights under the 2028 Convertible Notes. The Capped Call Transactions cover, subject to customary anti-dilution adjustments, the number of shares of the Company&#x2019;s common stock that initially underlie the 2028 Convertible Notes. The number of shares underlying the Capped Call Transactions is&#160;5.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cap price of the Capped Call Transactions is initially $85.75 per share of the Company&#x2019;s common stock, which represents a premium of 75.0% over the public offering price of the common stock in the 2021 Common Stock Offering, which was $49.00 per share, and is subject to certain adjustments under the terms of the Capped Call Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;By entering into the Capped Call Transactions, the Company expects to reduce the potential dilution to its common stock (or, in the event a conversion of the 2028 Convertible Notes is settled in cash, to reduce its cash payment obligation) in the event that, at the time of conversion of the 2028 Convertible Notes, its common stock price exceeds the conversion price of the 2028 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;2025 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2020, the Company completed the sale of $201.3&#160;million of convertible senior notes with a stated interest rate of 1.25% and a maturity date of May 1, 2025 (the &#x201c;2025 Convertible Notes&#x201d;), unless earlier converted, redeemed, or repurchased. The 2025 Convertible Notes were issued at a discounted price of 97.0% of their principal amount. The total net proceeds from the issuance of the 2025 Convertible Notes and exercise of the over-allotment option were approximately $194.5&#160;million, which includes approximately $6.9&#160;million of discounts, commissions and offering expenses paid by the Company. On May 4, 2020, the Company entered into an indenture (the &#x201c;Indenture&#x201d;), with U.S. Bank National Association, as trustee (the &#x201c;Trustee&#x201d;), governing the 2025 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to February 1, 2025, noteholders may convert their 2025 Convertible Notes at their option, only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130.0% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of 2025 Convertible Notes for each trading day of the measurement period was less than 98.0% of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate on each such trading day; (3) if the Company calls any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after February 1, 2025 until the close of business on the business day immediately preceding the maturity date, noteholders may convert their 2025 Convertible Notes at any time, regardless of the foregoing circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended September 30, 2021. Based on the terms of the 2025 Convertible Notes, the holders could not have converted all or a portion of their 2025 Convertible Notes in the fourth quarter of 2021. The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended December 31, 2021. Based on the terms of the 2025 Convertible Notes, the holders cannot convert all or a portion of their 2025 Convertible Notes in the first quarter of 2022. When a conversion notice is received, the Company has the option to pay or deliver cash, shares of the Company&#x2019;s common stock, or a combination thereof. As the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company is not required to settle the 2025 Convertible Notes in cash, the 2025 Convertible Notes are classified as long-term debt as of December 31, 2021 and 2020. As of December 31, 2021, the Company had not received any conversion notices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, the Company will pay or deliver, as applicable, cash, shares of common stock or a combination of cash and shares of common stock, at its election. The initial conversion rate for the 2025 Convertible Notes is 27.5198 shares of common stock per $1,000 in principal amounts of 2025 Convertible Notes, equivalent to an initial conversion price of approximately $36.34 per share of common stock. The conversion rate is subject to adjustment as described in the Indenture. In addition, following certain corporate events that occur prior to the maturity date as described in the Indenture, the Company will pay a make-whole premium by increasing the conversion rate for a holder who elects to convert its 2025 Convertible Notes in connection with such a corporate event in certain circumstances. The value of the 2025 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $34.12 on December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the 2025 Convertible Notes prior to May 6, 2023. The Company may redeem for cash all or any portion of the 2025 Convertible Notes, at its option, on or after May 6, 2023 if the last reported sale price of its common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date of notice by the Company of redemption at a redemption price equal to 100.0% of the principal amount of the 2025 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2025 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an event involving bankruptcy, insolvency or reorganization events with respect to the Company occurs, then the principal amount of, and all accrued and unpaid interest on, all of the 2025 Convertible Notes then outstanding will immediately become due and payable. If any other default event occurs and is continuing, then noteholders of at least 25.0% of the aggregate principal amount of the 2025 Convertible Notes then outstanding, by notice to the Company, may declare the principal amount of, and all accrued and unpaid interest on, all of the 2025 Convertible Notes then outstanding to become due and payable immediately. If the Company undergoes a &#x201c;fundamental change&#x201d; as defined in the Indenture, then noteholders may require the Company to repurchase their 2025 Convertible Notes at a cash repurchase price equal to the principal amount of the 2025 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Convertible Notes are the Company&#x2019;s senior, unsecured obligations and will be equal in right of payment with its existing and future senior, unsecured indebtedness, senior in right of payment to its existing and future indebtedness that is expressly subordinated to the 2025 Convertible Notes and effectively junior to its existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness. The 2025 Convertible Notes will be structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized on the 2025 Convertible Notes includes $2.5&#160;million, $1.2&#160;million and $0.15&#160;million, for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively for the year ended December 31, 2021. The interest expense recognized on the 2025 Convertible Notes includes $1.7&#160;million, $4.4&#160;million and $0.07 million, for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively for the year ended December 31, 2020. The effective interest rate on the 2025 Convertible Notes is 1.96%, which includes the interest on the 2025 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2025 Convertible Notes bear interest at a rate of 1.25% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, which began on November 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Maturities of Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of long-term debt at December 31, 2021 are summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.25% Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.25% Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equipment Financing Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Long-Term Debt&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&#160;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&#160;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEyNTIw_a07e6498-a704-4109-9a44-9ea9f01b2890">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-term debt, net, at December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25% Convertible Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total 0.25% Convertible Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25% Convertible Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total 1.25% Convertible Senior Notes due 2025, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of equipment financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzEtMC0xLTEtNDU2MDQvdGV4dHJlZ2lvbjo5Y2Y1MTJjOWE2MTk0NmRjYjJmNzdiZDM2M2U1YWVlZF85MzQ1ODQ4ODM2MTQ0_5ae48d67-81d6-4e18-b93a-820661377100"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzItMS0xLTEtNDU3NzE_be7a78dd-ec0c-4c78-894f-7c0c7a61034c"
      unitRef="usd">345000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzItMy0xLTEtNDU3OTQ_1e4721c5-106f-44dc-ba07-48ec2e08f7c6"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzMtMS0xLTEtNDU3NzE_04f677cb-c5b3-4e7d-b110-7b95e840f15d"
      unitRef="usd">8963000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzMtMy0xLTEtNDU3OTQ_53540c6a-db52-4b30-9c33-39bd3f1c7640"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzQtMS0xLTEtNDU3NzE_7abd2466-40e9-4800-b769-dc16233aa5ae"
      unitRef="usd">208000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzQtMy0xLTEtNDU3OTQ_2b972e4e-87b5-40b6-a08f-155ad5c482d6"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMC0xLTEtNDU2MDQvdGV4dHJlZ2lvbjo5N2UwMjM1MzhlNmI0NDY4YjU0YzNkM2E0YjVhYzMyNl85MzQ1ODQ4ODM2MTUw_5ae48d67-81d6-4e18-b93a-820661377100"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMS0xLTEtNDU3NzE_ff5afe65-4bfb-4b32-80a9-979ed06f2e8f"
      unitRef="usd">335829000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i92ecf7fc383c449c8e228b4b6dfc78bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMy0xLTEtNDU3OTQ_35ea7afc-8219-4253-bfe5-e2aa7860f44d"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzEtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjoyZGZiZWFjOWY0OTI0NjM1YWRlYzRhMzEwN2JhMGVkZV80_e665d9b6-aa68-4920-aa61-94070387d716"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzItMS0xLTEtMzA1NzI_1718ce6a-e277-456d-9c06-a339685f76e8"
      unitRef="usd">201250000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i808a9ed8cc11448da4c70680cd987939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzItMy0xLTEtMzA1NzI_901b26ea-54b8-4880-9e7c-1696368d9c59"
      unitRef="usd">201250000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzMtMS0xLTEtMzA1NzI_55f6310a-1ce1-42c2-8079-f8343056cdc9"
      unitRef="usd">4090000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i808a9ed8cc11448da4c70680cd987939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzMtMy0xLTEtMzA1NzI_631ba16f-996a-4a51-87a9-2bf1b63aa024"
      unitRef="usd">32592000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzQtMS0xLTEtMzA1NzI_a7687bec-1cab-4906-b8a9-d58dc1bf8ea8"
      unitRef="usd">506000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i808a9ed8cc11448da4c70680cd987939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzQtMy0xLTEtMzA1NzI_f54e8923-7262-494d-af03-54ff49e42ee4"
      unitRef="usd">538000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjphNzA4NTYyODM0ZTM0YzE2YjU1YmFiYzY3YzBjMTVkZF8xMA_e665d9b6-aa68-4920-aa61-94070387d716"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMS0xLTEtMzA1NzI_1007a4ec-44df-411d-97c5-49690bf79ccf"
      unitRef="usd">196654000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i808a9ed8cc11448da4c70680cd987939_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzUtMy0xLTEtMzA1NzI_f71dac9d-f05a-4e27-8f96-98d135eaa95b"
      unitRef="usd">168120000</us-gaap:LongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzEyLTEtMS0xLTMwNTcy_58807e70-f225-48d7-a0f5-83b4c3d90308"
      unitRef="usd">1206000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzEyLTMtMS0xLTMwNTcy_4c2bcf6e-f3cd-4f7e-bb1d-6b38215dba86"
      unitRef="usd">3808000</us-gaap:OtherLongTermDebt>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE0LTEtMS0xLTMwNTcy_b5f4d521-75b4-428d-93c2-77fe73c6c66e"
      unitRef="usd">533689000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE0LTMtMS0xLTMwNTcy_b2dda87c-8c06-4751-9b5e-c18d9d5174b8"
      unitRef="usd">171928000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE2LTEtMS0xLTMwNTcy_58897518-12d2-43b3-ae2c-0169bf662b79"
      unitRef="usd">1135000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2f65e6d59d9d4339974d98eb93610ffa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE2LTMtMS0xLTMwNTcy_b60bf467-dbe3-48fc-9bad-a996440ef96f"
      unitRef="usd">2841000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE3LTEtMS0xLTMwNTcy_abc72659-afc2-45a0-acb3-8589d6c08718"
      unitRef="usd">532554000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTo4ZmU2NmFkYzhhNDE0Y2JjOTYxOTM2NzcyZjY2MzljYy90YWJsZXJhbmdlOjhmZTY2YWRjOGE0MTRjYmM5NjE5MzY3NzJmNjYzOWNjXzE3LTMtMS0xLTMwNTcy_e10e7fe1-1666-40e2-93b6-47f155098601"
      unitRef="usd">169087000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5MDk_ff47dd21-00ef-439d-a270-48be9624f908"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE1Mw_bc74f162-de7b-4ef4-83f7-b9aa4a8e05f6"
      unitRef="rate">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9236c81b3c974578a313916abc4fb1f9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE5NA_d02d8084-a070-4cdd-98c0-63445ad6eedf"
      unitRef="usd">297600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i8457e19cdaef435383fa565c271d3716_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzgyNDYzMzcyNjM1MjI_f4c5e7d0-7622-4a85-a578-fa3ec1d75305"
      unitRef="usd">238900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5Mzk_5c0dbb9f-85ac-4b5a-8e70-e0a114ab810e"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5MTY_021973cb-d3e4-46e0-b8ef-95bf66e43f11"
      unitRef="rate">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i88a97a83c09a4c2fb216eb170e5f0549_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5MjM_fce4b947-b77b-483e-a5fe-1b0178727876"
      unitRef="usd">320900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5NzQ_6b94ba52-49de-44d8-9b7d-c80b55d06c0d"
      unitRef="usd">345000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5NTE_442e6a77-f9ba-498e-9a15-7d5edf0071d0"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <neo:DiscountedPriceOfAggregatePrincipleRate
      contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5NDY_204580b1-7b66-41ab-8470-1cde51430bd5"
      unitRef="rate">0.970</neo:DiscountedPriceOfAggregatePrincipleRate>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icc25a561b9d845e1a4b085174856869d_D20210111-20210111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5NTg_125e99b3-8871-4753-9993-cb0b864d0056"
      unitRef="usd">334400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockDiscountOnShares
      contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTA5ODg_ae0fa4f9-c2d4-4519-8bfd-c5044f597488"
      unitRef="usd">10600000</us-gaap:CommonStockDiscountOnShares>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i5c92183f6c1545059fe96165a77e5108_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMTg_ec3b6735-fa13-49c5-9fa3-afd27fcdae5a"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i5c92183f6c1545059fe96165a77e5108_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMTQ_8cf07d97-e338-4680-b39d-1a0d33ba08fa"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i5c92183f6c1545059fe96165a77e5108_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMDM_f05b7cc5-1907-428f-9c7e-7a0af3f860fe"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="id52cd4fd62d54923a9542f08f3e9e0b5_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMjc_3a41f8e5-730e-40fb-8066-c2a42d8401a6"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="id52cd4fd62d54923a9542f08f3e9e0b5_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMzY_f3382dc5-4718-46d7-85cd-e68e11ca2ce8"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <neo:DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate
      contextRef="ibc0c47f77f104125b2614b3cc70b4781_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwMDk_20dd5be7-06ca-43bb-b7f8-f818d51b972e"
      unitRef="rate">0.980</neo:DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwNTQ_2abbb0ee-8c47-4ce6-ac03-4a6caeebe4a4"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwNjA_7865bbb1-767b-4897-b243-fd5b9c42fd1b"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwNjQ_0126c52b-1800-48f0-966a-b5c1f0fcdc5f"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODYyOTU_76b6f9db-0ead-4294-9f57-ce88e9027fc6"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODYzNjU_e71cdf44-eb51-400f-84fd-75b6fcc80578"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODYzODE_c16b5bf6-f2d8-446e-b083-fbac07df663e"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i07b91282517d4c9ca4fef081647caa7a_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwNjg_c31c7ff3-844d-4f18-a558-cca2724d1bb7"
      unitRef="usdPerShare">66.15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDkyNjc0OTc3NzY_a8fc00c5-b443-4579-ac66-9a2f35dc8bb0"
      unitRef="usdPerShare">34.12</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEwOTU_ea29b145-37e4-4a3f-af55-3b8055ef4618"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMTE_a8a60c54-18e8-4c2f-a992-97181ce0b511"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMDE_f66bc178-93fb-4e70-9e4f-450d69a0571f"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMDU_c17dc497-d695-4bd0-8959-3ad517bba43e"
      unitRef="number">1.000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <neo:DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt
      contextRef="i8316e135f82444fd960aa45a363a320e_D20210111-20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMTU_222845ad-9ae9-4401-bba4-f471f5cafd2c"
      unitRef="number">0.250</neo:DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMjA_6236e036-6f4f-42ae-96c8-3e34b2decaff"
      unitRef="usd">800000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExMzQ_bbde7572-be65-45e5-991c-7b3848a110bd"
      unitRef="usd">1400000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExNDg_df1e1c11-2ac9-4b01-8369-24787fcfeb8c"
      unitRef="usd">32000</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i04c72e19bac545378b3cb9a3982f9ce9_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExNTY_8a8cbf59-7dbb-4055-9e64-01e03def838c"
      unitRef="number">0.0070</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExNzg_6305f52a-ffe4-4a81-bae8-b3695f15c1f1"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i317802a689f346709fdb8f5e9f54cf2b_D20210111-20210111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExNjM_0e8defe2-14d1-4c17-a0dd-208b0a8b1c05"
      unitRef="usd">29300000</us-gaap:ProceedsFromConvertibleDebt>
    <neo:CappedCallTransactionsNumberOfUnderlyingShares
      contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExODU_926b77a3-cb2d-4780-98df-91596604bed7"
      unitRef="shares">5200000</neo:CappedCallTransactionsNumberOfUnderlyingShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTExOTg_df2cd10e-d0ae-4e08-b40e-d6fa5064f36d"
      unitRef="usdPerShare">85.75</us-gaap:SaleOfStockPricePerShare>
    <neo:SaleOfStockPremiumOnOfferingPrice
      contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyMDY_72643e16-2044-4392-bf93-5915b0771b04"
      unitRef="number">0.750</neo:SaleOfStockPremiumOnOfferingPrice>
    <neo:SaleOfStockPricePerSharePublicOfferingPrice
      contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyMTE_83a364ef-9c77-4e75-87b3-04eb65dde1ce"
      unitRef="usdPerShare">49.00</neo:SaleOfStockPricePerSharePublicOfferingPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i34af75623b2843a0a57023612b0339a8_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzYxMQ_4a07a2c9-bb93-44b6-b984-b4079df7c219"
      unitRef="usd">201300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i34af75623b2843a0a57023612b0339a8_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY3Mw_622b03e3-2ee0-4b19-8a3e-65bd28cd0c85"
      unitRef="rate">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <neo:DiscountedPriceOfAggregatePrincipleRate
      contextRef="i34af75623b2843a0a57023612b0339a8_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3Xzg1OQ_fabc3782-ba6e-4bc4-af96-3c23ec624960"
      unitRef="rate">0.970</neo:DiscountedPriceOfAggregatePrincipleRate>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia164ece2fda645d18a4614a36f3dde97_D20200504-20200504"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwMjE_f189d451-692f-4118-a8ff-d1c9939321c2"
      unitRef="usd">194500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockDiscountOnShares
      contextRef="i34af75623b2843a0a57023612b0339a8_I20200504"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwNTQ_845c0249-b89d-4bd7-accc-5bce06cb986c"
      unitRef="usd">6900000</us-gaap:CommonStockDiscountOnShares>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i9736d15d029c4d79a63118c242b0a06d_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDE_ccfbd43e-2f5a-475e-8a10-df7047249a07"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i9736d15d029c4d79a63118c242b0a06d_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE3MDU_66c71d6e-f732-4362-bedc-b7d4f9a80c06"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i9736d15d029c4d79a63118c242b0a06d_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE4NTQ_7543efc5-e5f9-479d-805b-a9753431031f"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i8c8fa3e8e2304733b69c9fd8dc90960b_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE5Mjg_7dd89bd4-c16c-4946-a3a2-e2f0077b5e43"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i8c8fa3e8e2304733b69c9fd8dc90960b_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE5NjE_f0465a86-6f2e-44e1-8f35-a13e90462b92"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <neo:DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate
      contextRef="i80ffbe19f2b94211b4716f57813e319e_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzIxMzc_e47ae969-76bb-4111-9b51-8db5877e517b"
      unitRef="rate">0.980</neo:DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyNDE_50e3a83c-c630-488b-abbd-3c52cd38a06b"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyMzM_0a60da41-7c7b-4785-83ef-dca309c00238"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i798397e8b5bb425aa43fdb4d3e169c49_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyMzc_3f9e0435-6892-4963-b762-8aba7bbe71fe"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODU2NDA_929f474b-aabd-4d31-9380-a010b7b43641"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODU3MTA_81e3e4e1-b665-449c-89da-7ccc28c5054b"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i2f3bb5de8aa140eaa080c87d1186324b_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEwOTk1MTE2ODU3MjY_f0937242-0519-4aa1-93df-2b1f94cb7b7a"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i34af75623b2843a0a57023612b0339a8_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzMxMDc_8c1ac056-c711-461d-a13e-83ff3da87eff"
      unitRef="usdPerShare">36.34</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzM2NjA_ffb4a36f-6f03-458b-9852-ab7462a118e8"
      unitRef="usdPerShare">34.12</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzQzMjY_4b955904-85ca-4b23-81ae-83636590bd9f"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzQzODE_caabddf8-7965-4329-b143-bf03be68a5fe"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzQ0Mzc_fbde7c50-fb7c-4b17-ac3e-4f5944976055"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i89873e20554549fb87c7f5d521489f5d_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzQ2NjI_6e147508-a558-4a0e-a26d-b24697910246"
      unitRef="number">1.000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <neo:DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt
      contextRef="i7e141e5dc5ac4d099c050eacf32e2ce1_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzUyMTg_7ae83524-27a0-49de-8eb0-6a0f59d09640"
      unitRef="number">0.250</neo:DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDkyNjc0OTc3ODQ_4cee7c7d-82d5-4b4d-b873-e347edc88afd"
      unitRef="usd">2500000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDkyNjc0OTc3OTg_d8489857-7828-472f-bea1-08cc62b04cf6"
      unitRef="usd">1200000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzE2NDkyNjc0OTc4MTI_03008c29-b9ee-46e0-8ef6-fb446b076c91"
      unitRef="usd">150000</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="ib2e710b5650c4cd790dff15ccb7d0cc9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY2OTY_90f3179b-5a25-47ab-8039-7a57cccaf43f"
      unitRef="usd">1700000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="ib2e710b5650c4cd790dff15ccb7d0cc9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY3MDA_6f611d20-8807-4576-884a-af18b7f3792d"
      unitRef="usd">4400000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="ib2e710b5650c4cd790dff15ccb7d0cc9_D20200101-20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY3MDc_1d5911d3-f552-4a4b-ade2-0aca05c0ab62"
      unitRef="usd">70000.00</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i96dc3123b65d44fbb8eedd626efe6bb9_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzY3ODY_7804c3fc-cfce-4bd9-8742-c2525f47cc73"
      unitRef="number">0.0196</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzkzNDU4NDg4OTEyNDc_c5cf4263-c680-4f50-a6ef-8c2f6e0d902f"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90ZXh0cmVnaW9uOjJhNGY0ZWI3NTAzMzRkOWJiMGU5NWU1ZGU3MDA1MjI3XzEyNTIy_b351fc9c-f006-4d57-bd76-488e38992b60">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of long-term debt at December 31, 2021 are summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.25% Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.25% Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equipment Financing Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Long-Term Debt&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&#160;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&#160;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzAtMi0xLTEtNTQ5NjcvdGV4dHJlZ2lvbjplNzk1MzFmNzA4MmQ0YmZjOTA2MjAwMDg4YjI1ODE2OV85MzQ1ODQ4ODM2MTM1_5ae48d67-81d6-4e18-b93a-820661377100"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzAtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjowZjlmMjdmNzk3NWM0OGQ0YTcyNDg5NDYwOWFiOGE1Ml80_e665d9b6-aa68-4920-aa61-94070387d716"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEtMi0xLTEtNDY4OTI_5464bcd9-d04b-496d-a07b-98e871789352"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEtMS0xLTEtMzA1NzI_8bb020eb-3d29-4229-84ef-a9412c50234c"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEtMy0xLTEtMzA1NzI_03af2d6a-0b1a-4786-9520-bbe7a7d28180"
      unitRef="usd">1135000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEtNS0xLTEtMzA1NzI_f8b5f5f0-fd3c-420b-9ce7-1292db4b95b5"
      unitRef="usd">1135000</neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzItMi0xLTEtNDY4OTI_9e3248ab-0b75-4da1-9451-8270450aa6c5"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzItMS0xLTEtMzA1NzI_6fd2dba9-52ad-411b-b9fb-ae1ddd20e226"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzItMy0xLTEtMzA1NzI_f2dcfc5b-bd1e-475e-837a-72811a103db1"
      unitRef="usd">69000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <neo:LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzItNS0xLTEtMzA1NzI_cc7759d3-56d7-4a33-87de-3191ddc00f1b"
      unitRef="usd">69000</neo:LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzMtMi0xLTEtNDY4OTI_3794ec29-a3f1-42b3-83ed-7ede494c04ea"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzMtMS0xLTEtMzA1NzI_8fd3f124-e72e-49c2-ad07-296ca826bfb2"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzMtMy0xLTEtMzA1NzI_369b9695-17a6-4579-bb3d-33531d8efaec"
      unitRef="usd">2000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <neo:LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzMtNS0xLTEtMzA1NzI_94fc541e-ee92-4465-a00b-41e71c7759f2"
      unitRef="usd">2000</neo:LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzQtMi0xLTEtNDY4OTI_c69b1ed5-5098-43e6-87e0-9c5a7097ad50"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzQtMS0xLTEtMzA1NzI_c177b344-9837-4231-912e-b15b7135f941"
      unitRef="usd">201250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzQtMy0xLTEtMzA1NzI_2cb30602-b494-4084-b51f-ae67a8e9631e"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <neo:LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzQtNS0xLTEtMzA1NzI_8365137d-86e3-4b58-bde8-fdb2ba4a1beb"
      unitRef="usd">201250000</neo:LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzUtMi0xLTEtNDY4OTI_cdafba0e-eeed-4856-8a5b-a0b2dff46149"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzUtMS0xLTEtMzA1NzI_2a1142d4-2fe2-4949-84c6-1d97aa525fbf"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzUtMy0xLTEtMzA1NzI_a7f6af6c-8c51-4f05-b7e4-21080f42b1c1"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzUtNS0xLTEtMzA1NzI_0da076c3-a6a0-404d-a6f9-bfce6b7300ea"
      unitRef="usd">0</neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtMi0xLTEtNDY4OTI_f8613eb1-5f0b-4b62-b6fa-f70786239aed"
      unitRef="usd">345000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtNC0xLTEtNzAwODQ_65fa3b0d-9362-4adf-ba6a-6e23e0579352"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtNi0xLTEtNzAwODQ_14ef1293-437e-4bf6-8f92-a555171a7472"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtOC0xLTEtNzAwODQ_1eb6c6a5-585a-4148-98db-d3536777e9ca"
      unitRef="usd">345000000</neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <neo:LongTermDebtIncludingCurrentMaturitiesDue
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzctMi0xLTEtNDY4OTI_db741992-4c2f-4bf4-9cf5-e1c9fc60cc52"
      unitRef="usd">345000000</neo:LongTermDebtIncludingCurrentMaturitiesDue>
    <neo:LongTermDebtIncludingCurrentMaturitiesDue
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtMS0xLTEtMzA1NzI_a10f018b-f56a-4958-8b29-861638988b83"
      unitRef="usd">201250000</neo:LongTermDebtIncludingCurrentMaturitiesDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtMy0xLTEtMzA1NzI_f537aaf8-5456-4a57-88ea-fa590b0af011"
      unitRef="usd">1206000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <neo:LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzYtNS0xLTEtMzA1NzI_0f09072b-e851-47ea-90b8-24f6333ea5ad"
      unitRef="usd">547456000</neo:LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtCurrent
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtMi0xLTEtNDY4OTI_a11f55c7-ff43-45e7-ae8f-002a5af99d33"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtNC0xLTEtNDY5MDc_ee5abe4d-d64e-4252-9896-801ebfe7cdf5"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtNi0xLTEtNDY5MDc_d8fc0589-8045-4b1a-997d-cec431681dd8"
      unitRef="usd">1135000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtOC0xLTEtNDY5MDc_981dcd12-4202-4e56-94ed-2e79257aa78d"
      unitRef="usd">1135000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzktMi0xLTEtNDY4OTI_dcf7df30-1d31-4d85-849d-1453d281e8c0"
      unitRef="usd">8963000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzctMS0xLTEtMzA1NzI_07a504ea-05d3-4c77-9795-21271cc00db7"
      unitRef="usd">4090000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzctMy0xLTEtMzA1NzI_9e43a472-eaf7-4849-9daa-a46f0471716b"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzctNS0xLTEtMzA1NzI_0c72de7d-4dd5-489a-9167-8dbfb76866b5"
      unitRef="usd">13053000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzEwLTItMS0xLTQ2ODky_8dc92b83-68d9-4eee-8d7e-9e738ca54206"
      unitRef="usd">208000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtMS0xLTEtMzA1NzI_8d0a3104-6a3f-4977-907c-9828ea2e607d"
      unitRef="usd">506000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtMy0xLTEtMzA1NzI_93ea2a7f-b2e2-4a24-8310-f272b1d65d92"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzgtNS0xLTEtMzA1NzI_e14318d1-6b8b-481b-b262-60e43d03ab3a"
      unitRef="usd">714000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if57d4d112e3b41fa9a22f25e4cc7ae0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzExLTItMS0xLTQ2ODky_17a618e0-29e2-4b27-83b1-14b4d38acede"
      unitRef="usd">335829000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib3edaa3f9e0a4edb8fa7bef6ac3003ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzktMS0xLTEtMzA1NzI_7235ed4d-1f70-4eb8-baee-10a38e5a8ae5"
      unitRef="usd">196654000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i41a23e34f1f24675a50fd9548060e01b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzktMy0xLTEtMzA1NzI_f752a93a-ace4-4795-918f-390c8ed29e7d"
      unitRef="usd">71000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMDYvZnJhZzoyYTRmNGViNzUwMzM0ZDliYjBlOTVlNWRlNzAwNTIyNy90YWJsZTplMTYyM2NmOTIzYzg0ZjMzODAwMjhkYjY4YTA3MWVlZi90YWJsZXJhbmdlOmUxNjIzY2Y5MjNjODRmMzM4MDAyOGRiNjhhMDcxZWVmXzktNS0xLTEtMzA1NzI_22853711-c42a-4575-a428-173cb82e61c1"
      unitRef="usd">532554000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzIxMTQ_35008f57-c700-46ef-83f4-3758e3575f46">Derivative Instruments and Hedging Activities&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021 and 2020, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company did not have any outstanding derivative instruments. In June of 2018, the Company entered into an interest rate swap agreement to reduce the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s exposure to interest rate fluctuations on the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s variable rate debt obligations.&#160;This derivative financial instrument was accounted for at fair value as a cash flow hedge to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; effectively modify the Company&#x2019;s exposure to interest rate risk by converting a portion of its prior floating rate debt to a fixed rate obligation, thus reducing the impact of interest rate changes on interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the swap agreement, the Company received a variable rate of interest based on LIBOR and paid a fixed rate of interest. The following table summarizes the previous interest rate swap agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.767%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 2018 Hedge&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 29, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Index&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One month LIBOR&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 9. Debt, concurrent with the closing of the 2025 Convertible Notes, the proceeds from this transaction were used to pay off all amounts outstanding under the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s Prior Senior Secured Credit Agreement, after which the Company had no outstanding debt with variable rate interest. On May 1, 2020, the remaining obligation to make any further payments under the swap agreement was terminated. As a result of the termination, the Company paid $3.3&#160;million, which is included within loss on termination of cash flow hedge on the Consolidated Statements of Operations for the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company did not have any such losses in the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value adjustments were historically recorded within other comprehensive income. Upon termination of the interest rate swap in 2020, the accumulated losses, net of tax of $2.7&#160;million, related to the interest rate swap were reclassified from accumulated other comprehensive income to loss on termination of cash flow hedge on the Consolidated Statements of Operations for the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. No such reclassifications were recorded during the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:LongtermDebtPercentageBearingVariableInterestAmount
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzE2NDkyNjc0NDQxNDY_5156d0fc-c598-4706-a914-468428dccbc3"
      unitRef="usd">0</us-gaap:LongtermDebtPercentageBearingVariableInterestAmount>
    <us-gaap:LongtermDebtPercentageBearingVariableInterestAmount
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzE2NDkyNjc0NDQxNDY_df230200-d66d-463a-97c4-35ea1388eca2"
      unitRef="usd">0</us-gaap:LongtermDebtPercentageBearingVariableInterestAmount>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzIxMTU_218e3405-54b1-4444-bbb5-2a76c5ea019e">The following table summarizes the previous interest rate swap agreement.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.767%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 2018 Hedge&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 29, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Index&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One month LIBOR&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i47acf3b6354b4627a7978853e4d3e47f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90YWJsZTowMGUzNTQ5OWJiODE0ZjUzODE2M2IzYTAzMTk2Njg2ZS90YWJsZXJhbmdlOjAwZTM1NDk5YmI4MTRmNTM4MTYzYjNhMDMxOTY2ODZlXzEtMi0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo3YWM4OTJhODlmNzg0MDhiODU5YjA4ODA3YjQyYTdhZF80_bc0b5847-8470-448a-9155-24e3cd9cee5f"
      unitRef="usd">70000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i47acf3b6354b4627a7978853e4d3e47f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90YWJsZTowMGUzNTQ5OWJiODE0ZjUzODE2M2IzYTAzMTk2Njg2ZS90YWJsZXJhbmdlOjAwZTM1NDk5YmI4MTRmNTM4MTYzYjNhMDMxOTY2ODZlXzUtMi0xLTEtMzA1NzI_01738699-4220-45e5-803f-a947bbbc2502"
      unitRef="number">0.0298</us-gaap:DerivativeFixedInterestRate>
    <neo:DerivativeTerminationFee
      contextRef="i0fa5b7dff3c2469793b45a7b9c0a39e3_D20200501-20200501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzEzMDQ_691972aa-2c63-4b8f-a1d3-a204e92a3d15"
      unitRef="usd">3300000</neo:DerivativeTerminationFee>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i872473cddd404138b10ac6c363634e0c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzE4MjE_2bab34b7-d7fa-4ce2-94ec-50d449241c41"
      unitRef="usd">-2700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i0f2d85c36fbe4f798381a1b1b4a59d9d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzIwMzE_27d0abc1-9917-4778-adae-a06585956db8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i25aa5942e458401b9ff510cbfb4e37f8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTIvZnJhZzoxZDg3Mzg1YWNjYzI0ZWJlYjBkOTdhYWUyNWM1OTU4OC90ZXh0cmVnaW9uOjFkODczODVhY2NjMjRlYmViMGQ5N2FhZTI1YzU5NTg4XzIwMzE_a984bfbd-cd03-435b-ac0e-0d896fc005e1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzE4OTU_009a0636-4b63-4318-8e4f-c35887f01741">Equity Transactions&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Private Placement Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021, the Company completed a private placement (&#x201c;Private Placement&#x201d;) to certain accredited investors of an aggregate of 4,444,445 shares of the Company&#x2019;s common stock at a price of $45.00 per share. The net proceeds to the Company from the Private Placement were approximately $189.9&#160;million, after deducting fees to the placement agents and other offering expenses of approximately $10.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common Stock Issued for Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3. Acquisitions, the Company issued 597,712 shares of common stock as consideration for the acquisition of Trapelo in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Underwritten Public Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 6, 2021, the Company entered into an underwriting agreement relating to the issuance and sale of 4,081,632 shares of the Company&#x2019;s common stock, $0.001 par value per share (the &#x201c;2021 Common Stock Offering&#x201d;). The price to the public in this offering was $49.00 per share. The net proceeds to the Company from the 2021 Common Stock Offering were approximately $189.9&#160;million, after deducting underwriting discounts, commissions and other offering expenses of approximately $10.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the underwriting agreement, the Company also granted the Underwriters a 30-day option to purchase up to 612,244 additional shares of common stock at the public offering price, less underwriting discounts and commissions. On January 6, 2021, the underwriters exercised their option in full and purchased all 612,244 shares. The net proceeds related to the option exercise were approximately $28.4&#160;million, after deducting underwriting discounts, commissions and other offering expenses of approximately $1.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 29, 2020, the Company entered into an underwriting agreement relating to the issuance and sale of 4.4&#160;million shares of the Company&#x2019;s common stock, $0.001 par value per share (the &#x201c;2020 Common Stock Offering&#x201d;). The price to the public in this offering was $28.50 per share. The net proceeds to the Company from the 2020 Common Stock Offering were approximately $117.9&#160;million, after deducting underwriting discounts, commissions and other offering expenses of approximately $7.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the underwriting agreement, the Company also granted the underwriters a 30-day option to purchase up to 660,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. On May 29, 2020, the underwriters partially exercised their option and on June 3, 2020, purchased an additional 351,500 shares. The net proceeds related to the option exercise were approximately $9.4&#160;million, after deducting underwriting commissions and other offering expenses of approximately $0.6&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i46a03a2c735740e0a62ec8fcfd378af4_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE3OTc_ff990096-e40f-4776-88c2-26f55ff70376"
      unitRef="shares">4444445</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5d84ea5eee6f466492f6a5f7b9c99c5f_I20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4Mzk_9143cdd9-7dd9-43c8-b898-8b3c4e058f1d"
      unitRef="usdPerShare">45.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i46a03a2c735740e0a62ec8fcfd378af4_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4MjM_4502770b-285a-4d72-bd85-1fa11486fa3d"
      unitRef="usd">189900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i46a03a2c735740e0a62ec8fcfd378af4_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4MDg_f995f037-26da-4770-b922-85d65b62d5a2"
      unitRef="usd">10100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i909533f6893842af88add72e0b80061e_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4NDc_5e160b85-5752-41c2-b334-94d1e7345d21"
      unitRef="shares">597712</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6f0072740fba4f1f957dc041083ebbbf_D20210106-20210106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4NTY_147b22f5-6091-4dc1-9597-cd6d968f64bf"
      unitRef="shares">4081632</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if7813f0e28ca47909409d4d71f3f0cc2_I20210106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4Njc_878685d7-d9e6-40c7-b829-28589469732b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if7813f0e28ca47909409d4d71f3f0cc2_I20210106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4NzU_46426a1c-dacd-401a-af99-79bdade0d4a5"
      unitRef="usdPerShare">49.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6f0072740fba4f1f957dc041083ebbbf_D20210106-20210106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4ODM_aecc16cc-057b-4ec5-829a-767c9556a517"
      unitRef="usd">189900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6f0072740fba4f1f957dc041083ebbbf_D20210106-20210106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE4OTk_9eef15ad-d327-46a8-b8f0-d4948cb7e2b0"
      unitRef="usd">10100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <neo:SaleOfStockOptionTerm
      contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5MjU_a6bd43dc-9df3-4de9-b96f-7a542f3ab038">P30D</neo:SaleOfStockOptionTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5MTQ_45133de9-5045-4363-82b1-0889503ca0a7"
      unitRef="shares">612244</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5MzE_a597f648-9326-4c9b-823c-ab4b24b98cc9"
      unitRef="shares">612244</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5NDA_db633c38-0e37-41fe-8744-51496af77f5f"
      unitRef="usd">28400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i93cc8079775843dc9f0ff312808ddc7e_D20210106-20210106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzNDU4NDg4NTE5NTU_1da7adda-9c20-4bdd-960e-a466a462d292"
      unitRef="usd">1600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzQ1Nw_af9c3cd6-1cda-41b3-ada2-9ae2ff4146a1"
      unitRef="shares">4400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9b6939f2ae8d44b0b65a46676533cb9a_I20200429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzQ5OA_6bd14ab2-6481-44a3-9558-bc0c0397ae7c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9b6939f2ae8d44b0b65a46676533cb9a_I20200429"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzYwMg_fbab19b2-0444-4c72-8542-f8a5fe87b4e2"
      unitRef="usdPerShare">28.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzcwMw_efbe9d38-745a-47c7-bbc7-c62de2ed98bd"
      unitRef="usd">117900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzgwNA_182eb1c8-4953-4b27-8774-7549eb40a339"
      unitRef="usd">7500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <neo:SaleOfStockOptionTerm
      contextRef="i2f14c01a6dc14d788222ae605116c5c2_D20200429-20200429"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzg5OQ_7997cf05-7c39-45d5-b187-bfe32cd43ab7">P30D</neo:SaleOfStockOptionTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i59836b2a553946d0a448161d3100d995_D20200429-20200429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzkzMQ_fa770917-59af-413f-980b-fa3c73413edb"
      unitRef="shares">660000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9f5d1a3736b248a992304f0788d7d8b5_D20200603-20200603"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzExNTU_0a73af93-150d-4491-99b9-b2a2ec33069a"
      unitRef="shares">351500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9f5d1a3736b248a992304f0788d7d8b5_D20200603-20200603"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzEyMzM_6a303601-bdf6-4a1b-8c79-8972b9656477"
      unitRef="usd">9400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i9f5d1a3736b248a992304f0788d7d8b5_D20200603-20200603"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMTUvZnJhZzo2ZWM5ZDE1MjU3NWM0YTk5ODllNTkxY2JkZTUzNDZlZS90ZXh0cmVnaW9uOjZlYzlkMTUyNTc1YzRhOTk4OWU1OTFjYmRlNTM0NmVlXzEzMjM_8cf42dad-c0ce-4737-808a-a16bfa9b31b8"
      unitRef="usd">600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMTI_7f1fd595-03bb-4c7f-b891-d15978dd16d6">Stock-Based Compensation&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2021, the stockholders of the Company approved an amendment to the Equity Incentive Plan, originally effective as of October 14, 2003, and previously amended and restated and approved by the stockholders on December 21, 2015, and then again on May 25, 2017 (the &#x201c;Amended Plan&#x201d;). The Amended Plan allows for the award of equity incentives, including stock options, stock appreciation rights, restricted stock awards, stock bonus awards, deferred stock awards, and other stock-based awards to certain employees, directors, or officers of, or key non-employee advisers or consultants, including contracted physicians to the Company or its subsidiaries. The Amended Plan provides that the maximum aggregate number of shares of the Company&#x2019;s common stock reserved and available for issuance under the Amended Plan is 25,625,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, stock options outstanding totaled 3.0 million and 3.8 million shares, respectively. As of December 31, 2021 and 2020, a total of approximately 6.8 million and 1.0 million shares, respectively, were available for future option and stock awards under the Amended Plan. Options typically expire after 5 or 7 years and generally vest over 3 or 4 years, but each grant&#x2019;s expiration, vesting, and exercise price provisions are determined at the time the awards are granted by the Compensation Committee of the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock award granted during the year ended December 31, 2021 was estimated as of the grant date using a Black-Scholes model. The fair value of each stock option award granted during the years ended December 31, 2020 and 2019 was estimated as of the grant date using a trinomial lattice model. Weighted average assumptions used during the years ended December 31, 2021, 2020, and 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2 &#x2013; 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8 &#x2013; 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 &#x2013; 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value/share at grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The status of the stock options are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;of Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,839,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,309,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,318,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,310,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,372,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(684,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,961,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number and weighted average grant-date fair values of options non-vested at the beginning and end of 2021, as well as options granted, vested, and forfeited during the year were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,163,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,421,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the options outstanding at December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prices ($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27 &#x2013; 8.21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22 &#x2013; 19.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.77 &#x2013; 27.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.98 &#x2013; 43.49&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.50 &#x2013; 55.40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,961,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the aggregate intrinsic value of all stock options outstanding and expected to vest was approximately $36.1 million and the aggregate intrinsic value of currently exercisable stock options was approximately $31.6 million. The intrinsic value of each option share is the difference between the fair market value of NeoGenomics&#x2019; common stock and the exercise price of such option share to the extent it is &#x201c;in-the-money.&#x201d; Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $34.12 closing stock price of the Company&#x2019;s common stock on December 31, 2021, the last trading day of 2021. The total number of in-the-money options outstanding and exercisable as of December 31, 2021 was approximately 1.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised during each of the years ended December 31, 2021, 2020, and 2019 was approximately $46.7 million, $68.6 million and $35.3 million, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options. The total cash proceeds received from the exercise of stock options were approximately $13.7 million, $18.4 million and $12.4 million for the years ended December 31, 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of options granted during the years ended December 31, 2021, 2020, and 2019 was approximately $23.2 million, $7.5 million and $5.6 million, respectively. The total fair value of option shares vested during the years ended December 31, 2021, 2020, and 2019 was approximately $11.7 million, $5.2 million and $5.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense using the straight-line basis over the awards&#x2019; requisite service periods. Stock compensation expense related to stock options for the years ended December 31, 2021, 2020, and 2019 was approximately $11.6 million, $6.0 million and $6.8 million, respectively, and is included in general and administrative expenses in the Consolidated Statements of Operations. As of December 31, 2021, there was approximately $10.8 million of total unrecognized stock-based compensation cost related to non-vested stock options granted under the Amended Plan. This cost is expected to be recognized over a weighted-average period of 2.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares and weighted average grant date fair values of restricted non-vested common stock at the beginning and end of 2021, 2020, and 2019, as well as stock awards granted, vested, and forfeited during the year were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock compensation expense related to restricted stock for the years ended December 31, 2021, 2020, and 2019 was approximately $9.8 million, $3.4 million, and $2.6 million, respectively, and is included in general and administrative expenses in the Consolidated Statements of Operations. As of December 31, 2021, there was approximately $24.3 million of total unrecognized stock-based compensation cost related to non-vested restricted stock granted under the Amended Plan. This cost is expected to be recognized over a weighted-average period of 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2021, the Company granted certain senior-level executives performance stock units (&#x201c;PSUs&#x201d;) representing 356,548 common shares with a weighted average grant date fair value of $44.87 to vest upon the achievement of time-based service conditions with vesting through June 30, 2024, and certain performance goals, including financial performance targets and operational milestones. As of December, 30, 2021, these certain senior-level executives agreed to forfeit all of the granted PSUs. For the year ended December 31, 2021, no stock-based compensation related to the PSUs was recorded in the Consolidated Statements of Operations and the cancellation of these awards had no impact on the Consolidated Financial Statements. Concurrent with this forfeiture, these certain senior-level executives were granted restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022. For the year ended December 31, 2021, expense related to these awards is included in stock-based compensation expense related to restricted stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Modification of Stock Option and Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2021, the Culture and Compensation Committee of the Company&#x2019;s Board of Directors approved the accelerated vesting of 284,597 previously granted time-vesting stock option awards and 101,574 previously granted time-vesting restricted stock awards upon retirement of a director of the Company. The Company accounted for the effects of the stock awards as a modification, and recognized $6.6&#160;million of incremental stock-based compensation which consisted of $4.9&#160;million and $1.7&#160;million for the acceleration of stock option awards and restricted stock awards, respectively for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors an Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), under which eligible employees can purchase common stock at a 15.0% discount from the fair market value.&#160;Stock-based compensation expense related to the ESPP for the years ended December 31, 2021, 2020 and 2019 was approximately $1.1 million, $0.9 million and $0.6 million, respectively.&#160;Shares issued pursuant to this plan were 112,094, 138,309 and 141,908 for each of the years ended December 31, 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzg0OQ_1c2523c0-444e-46b9-843e-1fe49fb37495"
      unitRef="shares">25625000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzkwNA_b4830abf-7db7-4139-b60e-4f1aa8885d84"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzkxMQ_f38dc419-dbd0-4b65-8d87-9ca6096e4f31"
      unitRef="shares">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzk3OA_638b3eb6-4527-4618-aea7-50b6cb905120"
      unitRef="shares">6800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzk4NQ_358ad6dc-0bc8-41cb-b54f-f401658b170c"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i681790e0336945d58f151a6d5808acd9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzExMTU_528f45c9-5dca-4658-8318-9e5915a038bc">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i831056d6c8b04c6c8f9562bb6f5192df_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzExMjE_d3035432-d42e-4d4a-8916-53be8c8a9223">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie255c1c51fd744cca5a778a0da0a5155_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzExNTQ_d6743759-0187-4516-934d-de42f54bc992">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9a253449c87943b39413bdd71acbf134_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzExNjA_411f9e88-ec05-4f8c-a465-58b28e7180f6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMDU_448da517-2982-40d1-9be9-e471c8b62e32">The fair value of each stock option award granted during the years ended December 31, 2020 and 2019 was estimated as of the grant date using a trinomial lattice model. Weighted average assumptions used during the years ended December 31, 2021, 2020, and 2019 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2 &#x2013; 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8 &#x2013; 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 &#x2013; 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value/share at grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie255c1c51fd744cca5a778a0da0a5155_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo0YmM1Y2QzNTJjMDE0NGQzYTkyMmFiZmJjYTE3ZjY4Nl80_df3fee80-749e-43f2-a3b3-d498e7d43618">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9a253449c87943b39413bdd71acbf134_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtMS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo0YmM1Y2QzNTJjMDE0NGQzYTkyMmFiZmJjYTE3ZjY4Nl85_f13f4874-935b-4188-b046-0c5ed431ae8a">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4be580f98fbf4b08bfe75fadf6a6c0a0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtMy0xLTEtMzA1NzIvdGV4dHJlZ2lvbjozNjk5ZWQwZjgwZmQ0ZDg5ODA2YWY0NDU3M2VmNjY4Ml80_cc26de99-91c7-4666-8801-99f3fbde23f3">P3Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic76afff429474a7f9ebd89074d5938d6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtMy0xLTEtMzA1NzIvdGV4dHJlZ2lvbjozNjk5ZWQwZjgwZmQ0ZDg5ODA2YWY0NDU3M2VmNjY4Ml85_07d17880-cc73-41bc-adc0-3048872e4ce6">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib552bd7af98f40b89fa495c675994501_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtNS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjozNjNkZDBkZTZlNGQ0NTdhOWQ2YjFiNjM0ZDU3ZjFmNl80_102fbbed-a6a1-42ed-beda-4cd8d97dd37c">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i85dd1e5d4a554aae80eca8c6f52b6874_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzEtNS0xLTEtMzA1NzIvdGV4dHJlZ2lvbjozNjNkZDBkZTZlNGQ0NTdhOWQ2YjFiNjM0ZDU3ZjFmNl85_12c6481c-9007-4efb-a4b6-8944febfc672">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzItMS0xLTEtMzA1NzI_42c63142-3814-4eb7-b009-16d4a0e91045"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzItMy0xLTEtMzA1NzI_e71c3857-8bf8-4228-8555-56d461b8b2cf"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzItNS0xLTEtMzA1NzI_72167283-4c94-4024-877e-afe64b2f7818"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzMtMS0xLTEtMzA1NzI_b0dcaaf7-ace2-462f-a309-0990548b1ae6"
      unitRef="number">0.451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzMtMy0xLTEtMzA1NzI_de64cef0-d517-4326-9148-dbf5f0281860"
      unitRef="number">0.427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzMtNS0xLTEtMzA1NzI_588dcb3f-22ae-4ec6-af98-008534910934"
      unitRef="number">0.432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzQtMS0xLTEtMzA1NzI_d7b9dbce-1b63-44a3-b9ba-e59a8970bf8e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzQtMy0xLTEtMzA1NzI_c133ba45-56dc-48f5-833a-492b0d32d9b3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzQtNS0xLTEtMzA1NzI_92744a98-cb9e-403f-8a79-7c4a83269b4a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzUtMS0xLTEtMzA1NzI_b0612148-71c1-41e4-a7e2-3728ec3cb0f4"
      unitRef="usdPerShare">18.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzUtMy0xLTEtMzA1NzI_5c4bfbcf-bdce-4349-a790-ca2b9f34d1ff"
      unitRef="usdPerShare">8.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxOTdjMzAwZTdhZWQ0NzM2OGJjYjFmMzNlOTNjNzhjYi90YWJsZXJhbmdlOjE5N2MzMDBlN2FlZDQ3MzY4YmNiMWYzM2U5M2M3OGNiXzUtNS0xLTEtMzA1NzI_284f2356-88f3-42b0-b854-ea48e1ae2491"
      unitRef="usdPerShare">5.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMDY_5fe3dec5-bc33-404d-9c16-b8ab133afb2b">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The status of the stock options are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;of Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,839,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,309,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,318,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,310,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,372,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(684,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,961,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEtMS0xLTEtMzA1NzI_048a5195-78e3-4e1d-ae08-b6162a65eb03"
      unitRef="shares">6839417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i91b950b832fa47e2a4081c8b4e114d98_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEtMy0xLTEtMzA1NzI_db467ca7-9a92-49f7-911d-52813d0c7222"
      unitRef="usdPerShare">7.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzItMS0xLTEtMzA1NzI_1c270574-3c24-484b-a447-56392fa39308"
      unitRef="shares">969720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzItMy0xLTEtMzA1NzI_2c22a362-91f6-4eea-866b-8c3e30713d21"
      unitRef="usdPerShare">19.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzMtMS0xLTEtMzA1NzI_d0b226e5-8a29-407f-83fe-c9c8635654cc"
      unitRef="shares">2309451</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzMtMy0xLTEtMzA1NzI_53983478-6d80-4062-9c1a-75ba3ac94647"
      unitRef="usdPerShare">6.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzQtMS0xLTEtMzA1NzI_3df756c7-b6c7-4043-bc74-ae2625afbdd6"
      unitRef="shares">180927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzQtMy0xLTEtMzA1NzI_c0bfb96f-f75d-4b11-a5f7-a186d6fd912c"
      unitRef="usdPerShare">13.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzUtMS0xLTEtMzA1NzI_cbf694fd-5be4-464c-8fb7-e655535bad50"
      unitRef="shares">5318759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzUtMy0xLTEtMzA1NzI_d1b24107-148f-4965-8fea-8fd8f88041ab"
      unitRef="usdPerShare">9.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzYtMS0xLTEtMzA1NzI_beec8459-3050-4fea-9275-fa286767a903"
      unitRef="shares">845120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzYtMy0xLTEtMzA1NzI_113a1b57-cecc-41f6-8168-3436aed09f0d"
      unitRef="usdPerShare">28.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzctMS0xLTEtMzA1NzI_5fea29e4-628f-4be5-81cd-bdf4b577ef43"
      unitRef="shares">2310934</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzctMy0xLTEtMzA1NzI_a9a5060d-a458-495a-82cb-ae8e1759174d"
      unitRef="usdPerShare">7.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzgtMS0xLTEtMzA1NzI_9c68456a-878b-42a4-92f4-6f764f0f22d8"
      unitRef="shares">67004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzgtMy0xLTEtMzA1NzI_1c9da70a-85ff-4def-b678-45caba76f9d0"
      unitRef="usdPerShare">16.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzktMS0xLTEtMzA1NzI_ae69451d-ac76-4f3e-bc15-21c795548144"
      unitRef="shares">3785941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzktMy0xLTEtMzA1NzI_64ae3e78-b109-4a54-b4ef-807146a82027"
      unitRef="usdPerShare">15.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEwLTEtMS0xLTMwNTcy_72fcaa4d-bbfe-4814-b80a-b2e4fcd6b586"
      unitRef="shares">1232056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEwLTMtMS0xLTMwNTcy_3e4f913c-ba3c-40b4-b93e-e17bf360a815"
      unitRef="usdPerShare">42.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzExLTEtMS0xLTMwNTcy_c04388d2-9453-4bf0-ace8-f8421e272669"
      unitRef="shares">1372564</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzExLTMtMS0xLTMwNTcy_2871130b-6037-4d23-af98-16a8653df0bb"
      unitRef="usdPerShare">9.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEyLTEtMS0xLTMwNTcy_55607cd6-6f5e-48ff-8eb0-488da1f32229"
      unitRef="shares">684238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEyLTMtMS0xLTMwNTcy_78c476c6-c85f-4066-b83d-f06bce1ade61"
      unitRef="usdPerShare">29.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEzLTEtMS0xLTMwNTcy_c8d66552-5b6d-414e-a612-9e3eb1b8f268"
      unitRef="shares">2961195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzEzLTMtMS0xLTMwNTcy_6c53de8d-7196-44c2-a9d2-9b7af78ec6d9"
      unitRef="usdPerShare">25.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzE0LTEtMS0xLTMwNTcy_5cee1865-240b-4a02-8a08-f7a04cb46222"
      unitRef="shares">1668356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4Y2Y3MTk2Y2EyMjE0ZGU2YjNmOWVjOTExMWQyY2ZlOS90YWJsZXJhbmdlOjhjZjcxOTZjYTIyMTRkZTZiM2Y5ZWM5MTExZDJjZmU5XzE0LTMtMS0xLTMwNTcy_57c12d73-e6f3-4dee-ba00-faeeeb14ba7f"
      unitRef="usdPerShare">15.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMDg_40ccb855-35f3-49bd-9878-a2975dfcae4b">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number and weighted average grant-date fair values of options non-vested at the beginning and end of 2021, as well as options granted, vested, and forfeited during the year were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,163,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,421,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzEtMS0xLTEtMzA1NzI_380fdd55-b573-484c-9b02-45c35c50b028"
      unitRef="shares">2163809</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzEtMy0xLTEtMzA1NzI_ae828293-dfb9-4c5b-8bba-2310b68c400c"
      unitRef="usdPerShare">6.07</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzItMS0xLTEtMzA1NzI_35c887ce-1096-4390-b267-70aa1b19bcfe"
      unitRef="shares">1232056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzItMy0xLTEtMzA1NzI_80f9f87b-d56b-43c0-bc11-6e0ec7c2a86e"
      unitRef="usdPerShare">18.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzMtMS0xLTEtMzA1NzI_0ec034d4-f138-47bb-b0b1-09eba4eff272"
      unitRef="shares">1421042</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzMtMy0xLTEtMzA1NzI_91c53556-11b5-44fd-80fe-866b88a4ea2d"
      unitRef="usdPerShare">8.17</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzQtMS0xLTEtMzA1NzI_dfa3aa61-8f7f-4479-ac50-f69cf3ca6047"
      unitRef="shares">681984</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzQtMy0xLTEtMzA1NzI_1475499d-12be-4991-a0a1-edb2da6d6376"
      unitRef="usdPerShare">9.58</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzUtMS0xLTEtMzA1NzI_efdfc583-4522-4089-a7bc-f97096ee9c28"
      unitRef="shares">1292839</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTo4ZmY1MmU3ZTcxMzA0ZWIzYmNhYzM5YTNiOGU5NTVmNS90YWJsZXJhbmdlOjhmZjUyZTdlNzEzMDRlYjNiY2FjMzlhM2I4ZTk1NWY1XzUtMy0xLTEtMzA1NzI_1c352141-2fd4-4f01-ad2a-ee3c1a5abb47"
      unitRef="usdPerShare">13.93</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzUyMTA_ba42eb3b-04ad-46db-acf0-3ec4e8f5792c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the options outstanding at December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prices ($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27 &#x2013; 8.21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22 &#x2013; 19.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.77 &#x2013; 27.97&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.98 &#x2013; 43.49&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.50 &#x2013; 55.40&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,961,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo0ODY3YzRjMTU1ODg0ZTFmYjAxMTY5NTI3YTQyYWIwZl80_f58ad63e-ddf5-44e2-ae2b-b0ce1a438a6a"
      unitRef="usdPerShare">7.27</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo0ODY3YzRjMTU1ODg0ZTFmYjAxMTY5NTI3YTQyYWIwZl85_644d61d3-7386-41d2-9514-da040b2da3c8"
      unitRef="usdPerShare">8.21</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i971c2719748f46e78600d16ad130da2f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMi0xLTEtMzA1NzI_d86aeda3-17c5-4790-acac-6cbd1e1b8a05"
      unitRef="shares">638040</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItNC0xLTEtMzA1NzI_058144a5-b3d2-423c-a267-cb1c825df380">P0Y11M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i971c2719748f46e78600d16ad130da2f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItNi0xLTEtMzA1NzI_d3807f32-b0ab-4edd-8111-87c978d56dc1"
      unitRef="usdPerShare">7.86</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i971c2719748f46e78600d16ad130da2f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItOC0xLTEtMzA1NzI_7ea215c8-2491-4fb8-aa7e-68ab2207b2ec"
      unitRef="shares">638040</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i2a7daf9dafcc4632bbbcadcfd2ab0a56_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMTAtMS0xLTMwNTcy_94c93aa7-46b0-4672-8f66-e2b2514b60c5">P0Y11M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i971c2719748f46e78600d16ad130da2f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzItMTItMS0xLTMwNTcy_615cd5bb-ae6f-463c-ba51-d2c7be42fb9c"
      unitRef="usdPerShare">7.86</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo4MjE2ZjVkODcwOGU0YjkwOGYyMDk2ZmUxNTliODVhM180_4ef6544c-2363-48ca-a1a6-d86454400d3b"
      unitRef="usdPerShare">8.22</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo4MjE2ZjVkODcwOGU0YjkwOGYyMDk2ZmUxNTliODVhM185_8a6aaa95-bc22-4fd2-82af-84d84e6097f7"
      unitRef="usdPerShare">19.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8b827dae344b4efeb7a3cec6f619da89_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMi0xLTEtMzA1NzI_bbfaca35-e5de-44e6-a9b0-b7de8093bad9"
      unitRef="shares">701148</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtNC0xLTEtMzA1NzI_1fe969dd-2abd-45c6-b5a8-f68ff5345571">P1Y10M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i8b827dae344b4efeb7a3cec6f619da89_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtNi0xLTEtMzA1NzI_0b6065a3-5ec3-41d1-98ef-10b726b10045"
      unitRef="usdPerShare">15.53</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i8b827dae344b4efeb7a3cec6f619da89_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtOC0xLTEtMzA1NzI_a6c75564-b53b-4f9b-8836-097e675e2622"
      unitRef="shares">618439</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i979cda9aa01446559b674ce997b1fcba_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMTAtMS0xLTMwNTcy_59edafc5-4d1c-4bc6-a6a7-ffb344475d33">P1Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i8b827dae344b4efeb7a3cec6f619da89_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzMtMTItMS0xLTMwNTcy_8b7dd06a-9507-4661-a766-3748d8581768"
      unitRef="usdPerShare">15.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i657183ed33254a23a110400913bd73a3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjpjYmEzMWMwMDg4MDI0Y2RkYmNiZTA0NDdiNDNiMTQ5Ml80_c537eb12-ff09-44d0-8a79-29c52245d2a7"
      unitRef="usdPerShare">19.77</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i657183ed33254a23a110400913bd73a3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjpjYmEzMWMwMDg4MDI0Y2RkYmNiZTA0NDdiNDNiMTQ5Ml85_96d0ba0d-cea2-4c57-bbab-051b39f167a2"
      unitRef="usdPerShare">27.97</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="id1ebf39f1a9949e98894465429e942a8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMi0xLTEtMzA1NzI_6b31cd60-da91-4b44-ac71-081764602aa8"
      unitRef="shares">359217</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i657183ed33254a23a110400913bd73a3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtNC0xLTEtMzA1NzI_c6782e53-fb4d-47d4-80fe-00ef4666fdba">P4Y10M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="id1ebf39f1a9949e98894465429e942a8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtNi0xLTEtMzA1NzI_51cc4754-c3d6-4330-9666-10ac2044f9f4"
      unitRef="usdPerShare">24.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="id1ebf39f1a9949e98894465429e942a8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtOC0xLTEtMzA1NzI_b290e764-6958-4e0d-9fef-ea7342a95ae5"
      unitRef="shares">112799</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i657183ed33254a23a110400913bd73a3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMTAtMS0xLTMwNTcy_2460fcac-1087-49d3-9e75-5074167b148b">P4Y8M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="id1ebf39f1a9949e98894465429e942a8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzQtMTItMS0xLTMwNTcy_23e9eb14-adef-43dd-9d65-3a7678f8954c"
      unitRef="usdPerShare">23.30</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5OGJhOTllNjJiODc0Y2JkOWQ0MWZkM2ZkMjVhYjllZV80_b595504a-ada0-4dd7-bf2b-aac6f9991406"
      unitRef="usdPerShare">27.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo5OGJhOTllNjJiODc0Y2JkOWQ0MWZkM2ZkMjVhYjllZV85_20ceb19b-53d2-4a80-9ebc-d2d6e5a2b0fc"
      unitRef="usdPerShare">43.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8e0d681c2fc34b14bac44c4021fc624f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMi0xLTEtMzA1NzI_38e00fa5-e7a5-4c61-920f-4302b8ebbc56"
      unitRef="shares">612500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtNC0xLTEtMzA1NzI_08afcc65-952f-446b-ac3c-f446381e694f">P5Y7M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i8e0d681c2fc34b14bac44c4021fc624f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtNi0xLTEtMzA1NzI_68b78ae5-1e63-434f-80c5-6c48c915a8a0"
      unitRef="usdPerShare">31.47</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i8e0d681c2fc34b14bac44c4021fc624f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtOC0xLTEtMzA1NzI_78db9f28-f35a-4a09-a5af-37c551f2ad54"
      unitRef="shares">298980</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ic026775faf6a4dc3ba868b533c7c818b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMTAtMS0xLTMwNTcy_f1fc68d9-0ef8-4a7e-b1fb-93b0985f90db">P5Y2M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i8e0d681c2fc34b14bac44c4021fc624f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzUtMTItMS0xLTMwNTcy_5d371170-28f3-4711-ab4b-ed3da3ec0d64"
      unitRef="usdPerShare">28.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo3YWM0NjljMzU2YWU0NzBjYjQ4ZDk5ZTMwZTIxMzE3Ml80_8c497739-409d-4864-b5bb-695c3acd1790"
      unitRef="usdPerShare">43.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMC0xLTEtMzA1NzIvdGV4dHJlZ2lvbjo3YWM0NjljMzU2YWU0NzBjYjQ4ZDk5ZTMwZTIxMzE3Ml85_13c9964c-490a-4c23-a77c-42b10214edc2"
      unitRef="usdPerShare">55.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMi0xLTEtMzA1NzI_1ad2c12e-c8df-4b9b-ac91-86783d5c5f09"
      unitRef="shares">650290</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtNC0xLTEtMzA1NzI_1958b782-e793-4d51-9f4a-829470a36984">P6Y3M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtNi0xLTEtMzA1NzI_6c90ade3-35ef-4436-907b-34d66b13628d"
      unitRef="usdPerShare">48.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtOC0xLTEtMzA1NzI_9e0c210f-8448-4aba-8dac-28c786546c28"
      unitRef="shares">98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i5a648c5df90546a88d262e86802c7e48_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMTAtMS0xLTMwNTcy_3b887460-509a-4b35-b7c6-2db1cc7717b6">P5Y11M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ifb2e9e9d5d534dc1bdaf5f8b04aec807_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzYtMTItMS0xLTMwNTcy_47fdbd91-8246-4291-a784-95311277b07f"
      unitRef="usdPerShare">55.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctMi0xLTEtMzA1NzI_d812cfe4-8401-4fdd-9c37-178c74737ea9"
      unitRef="shares">2961195</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctNC0xLTEtMzA1NzI_41fb8c19-b9d0-4625-8869-9e3680307b24">P3Y9M14D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctNi0xLTEtMzA1NzI_067c3087-7894-412c-9e32-50a6aba14e36"
      unitRef="usdPerShare">25.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctOC0xLTEtMzA1NzI_e6be3b4f-8bf4-4b47-ba71-5007ebf5b128"
      unitRef="shares">1668356</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctMTAtMS0xLTMwNTcy_16fddc4a-144e-4e98-9371-63f24ad67c43">P2Y3M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZTpjMTRhM2NhMDkyZjQ0OGExODc0M2E0NDAxZjFiZTQwZS90YWJsZXJhbmdlOmMxNGEzY2EwOTJmNDQ4YTE4NzQzYTQ0MDFmMWJlNDBlXzctMTItMS0xLTMwNTcy_2f930d86-0ade-43d4-987a-1d5602f92437"
      unitRef="usdPerShare">15.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzIwMDc_ea6a14a7-189f-4ebd-b416-6a61939a916f"
      unitRef="usd">36100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzIxMDE_5b82de54-638c-4985-8520-8dea316ba54c"
      unitRef="usd">31600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <neo:CommonStockClosingPrice
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI2MDc_21654615-86f6-4b9f-81ed-1b33eedeeb3d"
      unitRef="usdPerShare">34.12</neo:CommonStockClosingPrice>
    <neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI3ODk_6f7b163a-2844-4808-ba6f-8d07d838d57b"
      unitRef="shares">1700000</neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI5MDQ_b277d9ac-2e4d-4aa9-97a1-2b7dcaac1d90"
      unitRef="usd">46700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI5MDg_2067700b-c71a-49a1-a108-8aad53841503"
      unitRef="usd">68600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzI5MTU_117d42d4-7c92-4457-92f5-5ec5def40562"
      unitRef="usd">35300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMxODU_eddf83d7-8ebb-4f5c-bb8f-e3b87b6e5bdd"
      unitRef="usd">13700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMxODk_1bfa0a1a-7e7b-4189-a734-770e0b4277cf"
      unitRef="usd">18400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMxOTY_9ba58c8a-b8d5-4885-a93a-1f0389f35858"
      unitRef="usd">12400000</us-gaap:ProceedsFromStockOptionsExercised>
    <neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMzNDM_b4067974-239d-41e5-ab59-cfe8aff2899d"
      unitRef="usd">23200000</neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue>
    <neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMzNDc_17fb3b92-895d-40c8-93cc-56910ef84590"
      unitRef="usd">7500000</neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue>
    <neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzMzNTQ_39444cb0-9c30-4a8e-8777-62f1cd22a87f"
      unitRef="usd">5600000</neo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM0NzI_8a7b7c43-b6d1-4652-b6d2-ddd9d7daa404"
      unitRef="usd">11700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM0NzY_f0fe9465-84a5-4594-bad8-d9655126d8db"
      unitRef="usd">5200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM0ODM_01233582-9d0b-4d41-baf2-54ff85235c54"
      unitRef="usd">5500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM3MzU_77154a54-df02-4587-93bc-7e57db9b52c0"
      unitRef="usd">11600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c7e18a3aebc410cb31023371db1e1f0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM3Mzk_922e503a-01f9-4370-bf29-18666f459594"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0be2f6f601ad4f47b7a64f324453f4ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM3NDY_bd1cafdf-53e6-4c64-8fe8-29bf3b41d7d9"
      unitRef="usd">6800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i4f7aefd0c1144fcda962a595d1d326e5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NTQ_afe0fb10-1849-4c6e-8cd7-72cdeefd51ba"
      unitRef="usd">10800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQwNTA_6cb11938-da40-4b62-9a76-31b3b0825176">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzE2NDkyNjc0NTc4NzI_6cfc556c-3289-4785-9b65-22d303465022">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares and weighted average grant date fair values of restricted non-vested common stock at the beginning and end of 2021, 2020, and 2019, as well as stock awards granted, vested, and forfeited during the year were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i44f2175697164b01b2aab1f8ff1898cb_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEtMS0xLTEtNDk0MTg_0d471a6f-7edd-4c6f-b106-c471b7015932"
      unitRef="shares">282508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i44f2175697164b01b2aab1f8ff1898cb_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEtMy0xLTEtNDk0MTg_7eef14bc-2c73-4254-b8aa-5b5c54ee3ce5"
      unitRef="usdPerShare">9.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzItMS0xLTEtNDk0MTg_68c9396d-364e-40e4-9a0f-59d6fc474ebb"
      unitRef="shares">230980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzItMy0xLTEtNDk0MTg_1a4cb312-804d-44c8-a682-ca091e5fc4a5"
      unitRef="usdPerShare">19.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzMtMS0xLTEtNDk0MTg_8af7f6f4-44c2-4a9b-85fa-daa7cf5f72e9"
      unitRef="shares">115711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzMtMy0xLTEtNDk0MTg_8f338193-4117-4323-b4dd-5ed8b03a6bd4"
      unitRef="usdPerShare">9.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzQtMS0xLTEtNDk0MTg_0dd82e77-d1a2-4c57-990e-38239df4a7b4"
      unitRef="shares">62479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzQtMy0xLTEtNDk0MTg_53a1063a-e2a9-4433-886f-7afdabe42d3f"
      unitRef="usdPerShare">12.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i83965d652d1d423f8ca32d729d617473_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzUtMS0xLTEtNDk0MTg_4500cc53-8424-45ac-a0c6-1202f4eec97f"
      unitRef="shares">335298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i83965d652d1d423f8ca32d729d617473_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzUtMy0xLTEtNDk0MTg_c04bc743-1df4-4336-8fb4-db1dbdf5a9d0"
      unitRef="usdPerShare">15.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzYtMS0xLTEtNDk0MTg_303b2b53-03dc-48eb-af1f-c32a5a45cc74"
      unitRef="shares">149012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzYtMy0xLTEtNDk0MTg_e2c73f7c-b777-429a-8c7e-00a8444cd154"
      unitRef="usdPerShare">28.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzctMS0xLTEtNDk0MTg_3cfc1fe0-9ede-489c-aa2e-270ff816864b"
      unitRef="shares">184127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzctMy0xLTEtNDk0MTg_97f91c12-8a5c-4dd3-a7ec-9236d645386d"
      unitRef="usdPerShare">12.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzgtMS0xLTEtNDk0MTg_30cc4641-76de-4017-9112-8ada873617a0"
      unitRef="shares">8292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzgtMy0xLTEtNDk0MTg_0f23da39-af46-457d-b20f-d6596a8b3471"
      unitRef="usdPerShare">20.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iec0d080a2339420d89dc78184ef8b898_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzktMS0xLTEtNDk0MTg_737fa22d-f723-4b7e-9184-c800423269b8"
      unitRef="shares">291891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iec0d080a2339420d89dc78184ef8b898_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzktMy0xLTEtNDk0MTg_bfebe679-3651-49ad-822f-02e572eb0a8c"
      unitRef="usdPerShare">23.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEwLTEtMS0xLTQ5NDE4_d87adb12-6eed-4f24-9951-7a7d57bbd707"
      unitRef="shares">936648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEwLTMtMS0xLTQ5NDE4_694dcf76-dcee-4bf3-bd5a-4177f39d1b0a"
      unitRef="usdPerShare">39.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzExLTEtMS0xLTQ5NDE4_4ba9d128-3cba-42f3-814b-2c779825c899"
      unitRef="shares">213777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzExLTMtMS0xLTQ5NDE4_9f6f92d6-112c-4fc0-8db2-d3138e3e8f68"
      unitRef="usdPerShare">32.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEyLTEtMS0xLTQ5NDE4_61b94e7f-9aa9-402f-af12-406e0cfcf11a"
      unitRef="shares">163359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEyLTMtMS0xLTQ5NDE4_2a9a9b13-d11a-454f-9b9b-0bbe701f51f5"
      unitRef="usdPerShare">38.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if16aafa54e7c4291827eb4a4a779b7fb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEzLTEtMS0xLTQ5NDE4_2bf4da74-eaae-47fe-82bd-8bb28929d010"
      unitRef="shares">851403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if16aafa54e7c4291827eb4a4a779b7fb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90YWJsZToxN2RiZjcxNTIzZWY0NzczOWIxYmJmYjM1NzA4ZjNhMC90YWJsZXJhbmdlOjE3ZGJmNzE1MjNlZjQ3NzM5YjFiYmZiMzU3MDhmM2EwXzEzLTMtMS0xLTQ5NDE4_a5f785c2-cca2-4546-8691-58a55116a30b"
      unitRef="usdPerShare">36.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQxMDY_8489648d-e600-4673-a7b7-5a27fb7e7f0e"
      unitRef="usd">9800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQxMTE_d19f4026-275b-41bc-93b6-416842e81585"
      unitRef="usd">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQxMjA_4f69823e-f172-4a09-b869-35eb26960b00"
      unitRef="usd">2600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="if16aafa54e7c4291827eb4a4a779b7fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQyMzA_36005950-4dc6-49f7-9c4d-a338f90bf7d2"
      unitRef="usd">24300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzM4NDgyOTA3MDQ0MzA_92f2112d-eeb8-4259-ac81-1a5ee17e8875">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7d981c543aef4926ad686ff97522008d_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzkzNDU4NDg4NDU1Mjg_05d062af-b644-4c23-9e72-76896e118421"
      unitRef="shares">356548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7d981c543aef4926ad686ff97522008d_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDMxMDU_56f1cd3c-5eeb-40d0-bd3e-e1c2d693ba2d"
      unitRef="usdPerShare">44.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4bb9f08a180f4313aa2080d8df018f76_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzE2NDkyNjc0NTgxMTc_3a413eb9-afa5-46a8-a283-7fd94ae79417">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1NjY_a3347345-3bfa-4b66-bf6b-e2ae13e4e7b6"
      unitRef="shares">284597</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1NTc_5b1630c9-ea7b-4467-aa2e-62703d91eac3"
      unitRef="shares">101574</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1NDM_4e1a54ea-6d18-4f92-ac1f-b2f23af4f192"
      unitRef="usd">6600000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i849a0cb2d79e42ca99ce777af2ddbb1d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1MTU_170bdc3c-a12f-4855-bc2d-1bd66b414e55"
      unitRef="usd">4900000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzEwOTk1MTE2NDY1Mjk_ca704ee9-38fc-436e-a029-653e82121afd"
      unitRef="usd">1700000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i5ed4a1d011e94710823acf48d3e17a2e_D20170525-20170525"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQyMTY_39bfa8dd-074b-435e-b270-8fba50ebd11f"
      unitRef="number">0.150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b45da9a6c9a4f8c9594977540bd40f9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQzNjE_48a7eb05-c495-4108-bde4-bd7267f49249"
      unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i679ecadf68b64358a44f898cebaed8f9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQzNjU_2599a7b8-17e4-4671-977c-94439bdd5861"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e4de4fe398a4353b1bfc64e3f2090b9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQzNzI_1d44bad3-51ed-4098-a0c8-92096effa3a9"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQ0MzE_06cd597d-4649-41c1-9749-670744b73f2a"
      unitRef="shares">112094</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQ0MzU_1a23e509-78c9-457e-ab7c-58e1f03f8f91"
      unitRef="shares">138309</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjEvZnJhZzo1NjUxZTc5NTkwOTU0MDgzOTU1YmNmYzgzZDU2Yzk1ZC90ZXh0cmVnaW9uOjU2NTFlNzk1OTA5NTQwODM5NTViY2ZjODNkNTZjOTVkXzQ0NDI_e7e1be9d-9142-4b48-8603-558cac6ac6a6"
      unitRef="shares">141908</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgwNzE_bf211c05-ef26-4dfb-8dae-66ceaff65608">Revenue Recognition &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s two reportable segments for which it recognizes revenue are (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s specialized diagnostic services are performed based on a written test requisition form or an electronic equivalent. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials. Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pharma Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Pharma Services segment generally enters into contracts with pharmaceutical customers as well as other CROs to provide research and clinical trial services ranging in duration from one month to several years.&#160;The Company records revenue on a unit-of-service basis based on number of units completed and the total expected contract value. The total expected contract value is estimated based on historical experience of total contracted units compared to realized units as well as known factors on a specific contract-by-contract basis. Certain contracts include upfront fees, final settlement amounts, and/or billing milestones that may not align with the completion of performance obligations. The value of these upfront fees or final settlement amounts is usually recognized over time based on the number of units completed, which aligns with the progress of the Company towards fulfilling its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into other contracts, such as validation studies and informatics. Revenue for validation studies for which the sole deliverable may be a final report that is sent to the sponsor(s) at the completion of contracted activities, is recognized at a point in time upon delivery of the final report to the sponsor. Informatics is the sale of de-identified data for which deliverables typically consist of retrospective records or prospective deliveries of data. Informatics revenue is recognized upon delivery of retrospective data or over time for prospective data feeds. Any contracts that contain multiple performance obligations and include both units-of-service and point in time deliverables are accounted for as separate performance obligations and revenue is recognized as previously disclosed. The Company negotiates billing schedules and payment terms on a contract-by-contract basis. While the contract terms generally provide for payments based on a unit-of-service arrangement, the billing schedules, payment terms, and related cash payments may not align with the performance of services and, as such, may not correspond to revenue recognized in any given period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts collected in advance of services being provided are deferred as contract liabilities on the Consolidated Balance Sheets. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. Contract assets are established for revenue recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding receivable is recorded. Additionally, certain costs to obtain contracts, primarily for sales commissions, are capitalized when incurred and amortized over the term of the contract. Amounts capitalized for contracts with an initial contract term of twelve months or less are classified as current assets. All others are classified as non-current assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most contracts are terminable by the customers, either immediately or according to advance notice terms specified within the contracts.&#160;All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the values of contract assets, capitalized commissions, and contract liabilities for Pharma Services as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma capitalized commissions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma capitalized commissions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma capitalized commissions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded within other current assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Recorded within other assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Recorded within other long-term liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized for the years ended December 31, 2021, 2020, and 2019, related to Pharma contract liabilities outstanding at the beginning of each year was $4.4 million, $2.3 million, and $2.2 million, respectively. Amortization of capitalized commissions for the years ended December 31, 2021, 2020 and 2019 were $1.1&#160;million, $0.8&#160;million and $1.2&#160;million respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the Company signed approximately $172&#160;million in net new contracts. At year-end total backlog was approximately $267&#160;million, substantially all of which contain cancellation provisions. The Company applied the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The unsatisfied existing performance obligations under long-term contracts as defined by ASC Topic 606, Revenue from Contracts with Customers, differs from backlog in that these obligations do not include wholly unperformed contracts where the promised consideration is variable and/or the application of other practical expedients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered various factors for both its Clinical Services and Pharma Services segments in determining appropriate levels of homogeneous data for its disaggregation of revenue; including the nature, amount, timing, and uncertainty of revenue and cash flows. Clinical Services categories align with the types of customers due to similarities of billing method, level of reimbursement, and timing of cash receipts. Unbilled amounts are accrued and allocated to payer categories based on historical experience. In future periods actual billings by payer category may differ from accrued amounts. Pharma Services relate to contracts with large pharmaceutical and biotech customers as well as other CROs. Because the nature, timing, and uncertainty of revenue and cash flows are similar and primarily driven by individual contract terms Pharma Services revenue is not further disaggregated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the disaggregation of net revenue for both the Clinical Services and Pharma Services Segments for the years ended December 31, 2021, 2020, and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.369%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Client direct billing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Medicare and other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Self-pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgyNDYzMzcyMTY2MzY_224d7d61-7314-49c0-99e5-cfeb47447454"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgyNDYzMzcyMTY2Mzk_c698fd18-7163-4480-8ebb-4a80ee76eebe">Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgwNzI_8600ab1a-9ff2-439c-a3f9-917064fc765c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the values of contract assets, capitalized commissions, and contract liabilities for Pharma Services as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma capitalized commissions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma capitalized commissions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma capitalized commissions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded within other current assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Recorded within other assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;(3) Recorded within other long-term liabilities on the Consolidated Balance Sheets.</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzEtMS0xLTEtMzA1NzI_8ff74ecf-b520-4fab-877e-ac1b1ee79c2e"
      unitRef="usd">1738000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzEtMy0xLTEtMzA1NzI_8a4fba86-6a7a-4fd8-b2ef-512604bf9065"
      unitRef="usd">1643000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzItMS0xLTEtMzA1NzI_7d85ffdb-8091-4c77-a692-c88b2f8d5a3e"
      unitRef="usd">236000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzItMy0xLTEtMzA1NzI_1ada9798-cb3c-49a4-9559-0a29c813b2a9"
      unitRef="usd">290000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzMtMS0xLTEtMzA1NzI_20ea7322-e185-492f-b54f-343f4aa0bb23"
      unitRef="usd">1974000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzMtMy0xLTEtMzA1NzI_5f01ad9b-f4cd-4004-b1f0-832ca6b1ecb5"
      unitRef="usd">1933000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzUtMS0xLTEtMzA1NzI_00d1e0b5-e49f-47d7-81a4-e07ec9bddac6"
      unitRef="usd">109000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzUtMy0xLTEtMzA1NzI_430a4552-f885-4022-80ce-7a4eb937af47"
      unitRef="usd">185000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzYtMS0xLTEtMzA1NzI_ed21a1e2-6e27-41c1-93bd-1a8eb6648f52"
      unitRef="usd">882000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzYtMy0xLTEtMzA1NzI_ff37bf89-d47e-4f15-ba20-a7d09dba538f"
      unitRef="usd">970000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostGross
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzctMS0xLTEtMzA1NzI_1ea1f922-a20c-4901-a498-8a69b8b46bcd"
      unitRef="usd">991000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzctMy0xLTEtMzA1NzI_8fc7f86f-9195-427f-a4e0-c35fb28fa246"
      unitRef="usd">1155000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzktMS0xLTEtMzA1NzI_17df48fe-9942-4a2d-8902-62aa45117d1b"
      unitRef="usd">5192000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzktMy0xLTEtMzA1NzI_521904d8-7965-429a-a64e-795afe7eee6d"
      unitRef="usd">4029000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzEwLTEtMS0xLTMwNTcy_405e6dd9-d112-47e3-b95f-60c10d9bc354"
      unitRef="usd">917000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzEwLTMtMS0xLTMwNTcy_4bb603ed-a7f8-4cc4-a4f8-3a2fbb09d553"
      unitRef="usd">712000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzExLTEtMS0xLTMwNTcy_0e705834-6041-464c-849b-f91d5e0e8629"
      unitRef="usd">6109000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTo3ZjFlNjI0MWY1ODQ0ZmRmOTFjNGVkMzcxOWZhZGE1OS90YWJsZXJhbmdlOjdmMWU2MjQxZjU4NDRmZGY5MWM0ZWQzNzE5ZmFkYTU5XzExLTMtMS0xLTMwNTcy_25f35f95-7575-4098-8112-ac31cf3d4798"
      unitRef="usd">4741000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYxNjY_f3758756-a90e-45f4-94cb-f246e9aa20ca"
      unitRef="usd">4400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYxNzM_d4986cc5-8f4f-4aae-a35c-3d4d0bac7394"
      unitRef="usd">2300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzIxOTkwMjMyNjYxNzA_11afe809-796f-46f5-b616-005964446022"
      unitRef="usd">2200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYyNzA_45fd3ace-36f8-48ab-9632-443ad20f3375"
      unitRef="usd">1100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYyNzQ_fec6af43-3748-4d9a-9ddf-6ec706728696"
      unitRef="usd">800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYyODE_e7524103-b5b8-4ea6-b878-3143150b7fbc"
      unitRef="usd">1200000</us-gaap:CapitalizedContractCostAmortization>
    <neo:RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzYzNTc_366ec393-e654-4d9b-8fd1-f2ec6c66489c"
      unitRef="usd">172000000</neo:RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzY0NDI_ccd18126-b26b-43a9-bc86-7fa0f7f47cc1"
      unitRef="usd">267000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90ZXh0cmVnaW9uOmY4YTgwNzI3ZWE1ZjQ0ODI5YzYyNTE3ODlkYjVmYjA0XzgwNzA_aace6c02-065c-4bcd-95b5-d983cbc54d2a">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the disaggregation of net revenue for both the Clinical Services and Pharma Services Segments for the years ended December 31, 2021, 2020, and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.369%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Client direct billing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Medicare and other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Self-pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i667bb3b470c64da985250798b766a649_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzItMi0xLTEtMzA1NzI_e46c4ca9-eccf-4958-98dc-cfca00e139aa"
      unitRef="usd">252617000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8d47d42a743b474492f4e32571a3f05e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzItNC0xLTEtMzA1NzI_0001c4b3-cf9c-4250-a110-576d934ba8f0"
      unitRef="usd">240535000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i55f72e0eca1d419dab353fa6c8a23098_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzItNi0xLTEtMzA1NzI_02e3744d-9670-46de-aa5c-9f4641ba5767"
      unitRef="usd">212703000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i321637f0a7b540bdbb4033a0247f471f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzMtMi0xLTEtMzA1NzI_c86a91ba-b1c3-4e73-99a7-b19b92ed0e45"
      unitRef="usd">78773000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if213c108cbd74502ad64e78f83030eaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzMtNC0xLTEtMzA1NzI_2445f0a5-ce2b-4d62-8fe2-bfbc2ee76210"
      unitRef="usd">76550000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id558c0253e714d4fa8959f36f7ace8af_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzMtNi0xLTEtMzA1NzI_b6557800-c4a4-4765-b3d2-db1ce9772965"
      unitRef="usd">83107000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4a5278b10f214b99ae816d90c219b11f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzQtMi0xLTEtMzA1NzI_15de31e4-19fc-44f2-af31-93cbd9c1704b"
      unitRef="usd">72010000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib515a6110c0c4a03b0ab671c0fd68174_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzQtNC0xLTEtMzA1NzI_c263cbab-85f1-45c5-a6de-df4350f79ed8"
      unitRef="usd">64776000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie847e09d489543aea8789c0dfbead017_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzQtNi0xLTEtMzA1NzI_d4fdda24-cfd9-4fe8-a8e7-e8ae6b225924"
      unitRef="usd">64745000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2e0e7f7754324dedae9666c62419ea78_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzUtMi0xLTEtMzA1NzI_3e93c4a5-9355-4eaa-bc31-a292aef56e53"
      unitRef="usd">772000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i67fff1172685496bbaf7a54a6396eb92_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzUtNC0xLTEtMzA1NzI_926e9060-88d7-44e6-ab65-6f659d956d2c"
      unitRef="usd">476000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i73e92c7aad5c4209a4df55556c23b848_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzUtNi0xLTEtMzA1NzI_771ca7c5-feac-4f08-a937-c8ab16be1bfe"
      unitRef="usd">606000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i70ebc9da32df40f79360ad5da5aef714_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzYtMi0xLTEtMzA1NzI_8f16d2dd-15a0-4c21-9c42-2a9c4c218801"
      unitRef="usd">404172000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i79d415270f85409cb33c97966be628d9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzYtNC0xLTEtMzA1NzI_5276b1ac-d21c-4300-9086-93825ec2eeb8"
      unitRef="usd">382337000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9b900d497a954a51b916af633f093d2d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzYtNi0xLTEtMzA1NzI_9c3ed9d1-5638-4b64-ae5c-ae7527c66ed7"
      unitRef="usd">361161000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i81e7e38bca0a483382014babf710343a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzctMi0xLTEtMzA1NzI_68bc80c7-f777-4530-96aa-28c89ae8b9a7"
      unitRef="usd">80157000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9d041f360e72469b85c9fb255e34af5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzctNC0xLTEtMzA1NzI_fabce891-25e6-4d45-aefe-845d78ca5300"
      unitRef="usd">62111000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id4187c911d534ee0a8aa9f97ffb938b1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzctNi0xLTEtMzA1NzI_3879a177-cfe4-4639-83c9-c20779aa7d6a"
      unitRef="usd">47669000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzgtMi0xLTEtMzA1NzI_63eab7bf-f623-469c-9c96-17980a384cd1"
      unitRef="usd">484329000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzgtNC0xLTEtMzA1NzI_adf6059d-a2cb-4c5e-be6a-f2accf609ed2"
      unitRef="usd">444448000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjQvZnJhZzpmOGE4MDcyN2VhNWY0NDgyOWM2MjUxNzg5ZGI1ZmIwNC90YWJsZTowNmY1ZjA3Y2IxZWQ0NWFiOWM4ZTlhYTRkODIyZTYwOS90YWJsZXJhbmdlOjA2ZjVmMDdjYjFlZDQ1YWI5YzhlOWFhNGQ4MjJlNjA5XzgtNi0xLTEtMzA1NzI_a8ab81e6-c2b6-4981-a2b5-2e7f86c5be1f"
      unitRef="usd">408830000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3MzI_23cb07f9-7402-4b73-a6f4-1656ffb39a59">Income Taxes&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act impacted a number of provisions of the tax code, including the eligibility of certain deductions and the treatment of net operating losses (&#x201c;NOLs&#x201d;) and tax credits. The CARES Act did not result in any material adjustments to the Company&#x2019;s income tax provision for the year ended December 31, 2021, or to its deferred tax assets as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Loss) income before income tax benefit for the years ended December 31, 2021, 2020, and 2019 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income before income tax expense (benefit): &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred benefit provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax benefit provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the differences between the effective tax rate and the federal statutory tax rate for the years ended December 31, 2021, 2020 and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Penalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inivata acquisition fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision and other deferred tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021 and 2020, deferred income tax assets and liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carry-forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in non-consolidated affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, the Company has federal net operating loss carry forwards of approximately $231.5&#160;million, foreign net operating loss carryforwards of approximately $118.9&#160;million, including $96.4&#160;million in the United Kingdom, and state net operating loss carry forwards of approximately $112.8&#160;million. Federal net operating loss carry forwards will begin to expire in 2036. Under the Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, however, the deductibility of such federal net NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. State tax NOLs will begin to expire in 2022. NOLs in Switzerland and China begin to expire in 2024 and 2025, if not utilized in future periods. The NOLs in Singapore and the United Kingdom do not expire. As of December 31, 2021, the Company has federal R&amp;amp;D credit carryforwards of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately $5.5&#160;million that begin to expire in 2036 and state research and investment credit carryforwards of approximately $3.8&#160;million that do not expire. An ownership change of more than 50 percent could result in a limitation of the use of net operating loss carryforwards and credit carryforwards under IRC Section 382 and the regulations thereunder. We have not conducted a formal study to determine whether there was an ownership change in prior periods that would limit the use of our net operating loss carryforwards and credit carryforwards under IRC Section 382. Management believes it is more likely than not that a limitation under Section 382 would not materially impact the realizability of the deferred tax assets related to federal and state net operating losses or credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing all positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed. As of December 31, 2021 and 2020, management determined that sufficient positive evidence did not exist and concluded that it is more likely than not that a valuation allowance is required against foreign deferred tax assets. Accordingly, management established a full valuation allowance of $4.1&#160;million and $2.6&#160;million as of December 31, 2021 and 2020, respectively, related to the Company&#x2019;s China, Switzerland and Singapore operations. As of December 31, 2021, management determined that sufficient positive evidence did not exist and conclude that it is more likely than not that a valuation allowance is required against certain domestic deferred tax assets. Accordingly, management established a valuation allowance of $28.9&#160;million related to the Company&#x2019;s domestic operations as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the United States, as well as Singapore, Switzerland, China, United Kingdom and in various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment. For U.S. federal and most state purposes, the Company has open tax years ended December&#160;31, 2017 to December 31, 2020. For Switzerland, the Company has open tax years ended December 31, 2017 to December 31, 2020, for Singapore the Company has open tax years ended December 31, 2018 to December 31, 2020 and for United Kingdom the Company has open tax years ended April 5, 2018 to April 5, 2020. The 2017 U.S. Federal income tax filing is currently under examination by the IRS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applied the accounting standard for uncertain tax positions and recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management&#x2019;s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the unrecognized tax benefits as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits - January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reversals of prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in tax positions taken in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statute expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits - December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of unrecognized tax benefits at December 31, 2021, if recognized would favorably affect the Company&#x2019;s effective tax rate. These unrecognized tax benefits are classified as other long-term liabilities on the Consolidated Balance Sheets. The interest and penalties related to the unrecognized tax benefit are immaterial. Interest and tax penalties related to unrecognized tax benefits are included in income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3Mjc_ec8fb0e3-c695-4ae7-84ac-176bd4010580">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Loss) income before income tax benefit for the years ended December 31, 2021, 2020, and 2019 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income before income tax expense (benefit): &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred benefit provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax benefit provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i95ccf651c92142fb87ac4f3feb892173_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzItMS0xLTEtMzA1NzI_da0723fc-1f53-4c0b-aa5b-d9116315e827"
      unitRef="usd">24761000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaeeb6ff7726a404aa5ab12499665bd21_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzItMy0xLTEtMzA1NzI_a6ea2d7e-6440-451d-a609-d4075c232cc8"
      unitRef="usd">-6954000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id37460a8ce1e41cfbb99f9a168dcda88_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzItNS0xLTEtMzA1NzI_96e6a9b4-cec2-4b86-aa20-be43ec8a1729"
      unitRef="usd">7053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia2a4237d1df945f78f4dd92cf2d83177_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzMtMS0xLTEtMzA1NzI_f760f51f-d3c2-4029-95ae-56eba6c865e5"
      unitRef="usd">-39836000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i83dc4513b1f24e378f0be8c6c7f73c50_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzMtMy0xLTEtMzA1NzI_52f0d078-efad-4f23-9527-0ef2a167cee5"
      unitRef="usd">-7102000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i42ba577adb2b4ee4a77b0a9e0248c94e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzMtNS0xLTEtMzA1NzI_a68028af-a90f-4a47-8a43-88cec3002d35"
      unitRef="usd">-3408000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzQtMS0xLTEtMzA1NzI_a8fbd86d-b2bb-46b2-9280-c8a3ecb8cd93"
      unitRef="usd">-15075000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzQtMy0xLTEtMzA1NzI_ddc81225-8a60-4423-a74d-7696e1474198"
      unitRef="usd">-14056000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzQtNS0xLTEtMzA1NzI_3ee51c0c-b393-4f39-a763-2916f9d0b93f"
      unitRef="usd">3645000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzgtMS0xLTEtMzA1NzI_260db9fd-91e7-4f70-89aa-4b260def0cf7"
      unitRef="usd">41000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzgtMy0xLTEtMzA1NzI_fc9532a8-7814-4d56-979a-528454f5ae41"
      unitRef="usd">-434000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzgtNS0xLTEtMzA1NzI_2a75bdd9-007c-4baf-a070-b05c1a2ee183"
      unitRef="usd">-303000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzktMS0xLTEtMzA1NzI_405e2c86-9906-4cb1-aa53-db2c7d851d9b"
      unitRef="usd">41000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzktMy0xLTEtMzA1NzI_627fee47-c056-4e66-a10a-c99ded6f3ed9"
      unitRef="usd">273000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzktNS0xLTEtMzA1NzI_4f24f67f-b7db-4e57-ad0d-ece6ff113dc9"
      unitRef="usd">290000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEwLTEtMS0xLTMwNTcy_1dae19ce-0bc2-492a-89da-ec7aee7df8b1"
      unitRef="usd">82000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEwLTMtMS0xLTMwNTcy_eba8b3f4-3511-4152-84fd-a3e777188e0c"
      unitRef="usd">-161000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEwLTUtMS0xLTMwNTcy_ec365ade-10ff-429b-a82b-d71b6284879d"
      unitRef="usd">-13000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEyLTEtMS0xLTMwNTcy_18c6974e-9248-4ea5-84c4-6910f6ac9ac7"
      unitRef="usd">-575000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEyLTMtMS0xLTMwNTcy_e98af8ca-dcc8-45ff-b2b8-1f4bc177f062"
      unitRef="usd">-12856000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEyLTUtMS0xLTMwNTcy_020f7a20-d6e0-4dec-a233-35cdb3d139b5"
      unitRef="usd">-3409000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEzLTEtMS0xLTMwNTcy_b5ce06bd-e5b1-4730-aceb-ea900074c8c6"
      unitRef="usd">1241000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEzLTMtMS0xLTMwNTcy_95927d83-b045-4254-a2eb-c723e449ff1d"
      unitRef="usd">-5211000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzEzLTUtMS0xLTMwNTcy_8f73bbb8-20ad-42f1-9289-529cfa95db28"
      unitRef="usd">-939000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE0LTEtMS0xLTMwNTcy_24fd849c-fe22-4a88-aa61-9f0b862643de"
      unitRef="usd">-7476000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE0LTMtMS0xLTMwNTcy_414403ab-d877-4ff8-a383-4792d35a8e21"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE0LTUtMS0xLTMwNTcy_73bd231c-e7e9-4682-b7a2-f7041bbf3f3c"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE1LTEtMS0xLTMwNTcy_3e5a2f3a-e7fd-4a5d-9891-f8404608123a"
      unitRef="usd">-6810000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE1LTMtMS0xLTMwNTcy_c8ccf1d3-80ea-480b-8c88-98f8480f7504"
      unitRef="usd">-18067000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE1LTUtMS0xLTMwNTcy_b395fe5b-f12c-49a0-85d4-271a0540a0c2"
      unitRef="usd">-4348000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE2LTEtMS0xLTMwNTcy_4f4f1862-ec15-44d7-a426-4ce61cb4ae2c"
      unitRef="usd">-6728000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE2LTMtMS0xLTMwNTcy_77b482b1-9ae2-4efa-af6a-24fb4794895f"
      unitRef="usd">-18228000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTo3OTY5OTAyN2U0OWI0MTRkYWI3YjVhZmRjOGY2MGIyYy90YWJsZXJhbmdlOjc5Njk5MDI3ZTQ5YjQxNGRhYjdiNWFmZGM4ZjYwYjJjXzE2LTUtMS0xLTMwNTcy_5aa08925-200e-4e25-9296-fd2780d581c8"
      unitRef="usd">-4361000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3MzQ_685601fa-2ca3-437a-9026-7eb8b35d5df6">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the differences between the effective tax rate and the federal statutory tax rate for the years ended December 31, 2021, 2020 and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Penalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inivata acquisition fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision and other deferred tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEtMS0xLTEtMzA1NzI_29b7b154-3f42-4575-9074-dfa4a31c8bb9"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEtMy0xLTEtMzA1NzI_5e0e024a-e254-4dde-a29f-fdd9762dee4e"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEtNS0xLTEtMzA1NzI_ec6094c1-2d11-4e9d-9b72-909dd9101cab"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzItMS0xLTEtMzA1NzI_5b502a4b-7b4f-42de-bf89-218a19c2cd2e"
      unitRef="number">0.1777</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzItMy0xLTEtMzA1NzI_89d86896-c38f-4e9f-8f41-5750b4914893"
      unitRef="number">0.1429</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzItNS0xLTEtMzA1NzI_48230148-9632-4032-9a6c-851ed074d492"
      unitRef="number">-0.1947</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <neo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtMS0xLTEtODQ5NDk_8e98d9d2-e857-44f0-b6e3-8633e5408c2a"
      unitRef="number">-0.1011</neo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <neo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtMy0xLTEtODQ5NDk_cddb94ad-c059-448b-b7ca-13488a6941ae"
      unitRef="number">0</neo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <neo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtNS0xLTEtODQ5NDk_9e6c7b5b-38cc-4825-8c40-f6a642d93b2d"
      unitRef="number">0</neo:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <neo:EffectiveIncomeTaxRateReconciliationPenaltiesPercent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtMS0xLTEtODQ5NDk_ba62d00c-8ad4-44e4-ba31-64bd7c70e997"
      unitRef="number">-0.1561</neo:EffectiveIncomeTaxRateReconciliationPenaltiesPercent>
    <neo:EffectiveIncomeTaxRateReconciliationPenaltiesPercent
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtMy0xLTEtODQ5NDk_e7e17c2b-bc3f-4c5f-b909-1e0fc61c1f98"
      unitRef="number">-0.0001</neo:EffectiveIncomeTaxRateReconciliationPenaltiesPercent>
    <neo:EffectiveIncomeTaxRateReconciliationPenaltiesPercent
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtNS0xLTEtODQ5NDk_09844c69-e443-42b6-a868-bab893831bb6"
      unitRef="number">0.0008</neo:EffectiveIncomeTaxRateReconciliationPenaltiesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtMS0xLTEtMzA1NzI_28b8f649-f275-4a82-954d-a7a78c5bba74"
      unitRef="number">-0.0329</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtMy0xLTEtMzA1NzI_3ead7abf-2e4a-4cc6-9090-fa66228576cb"
      unitRef="number">-0.0141</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzMtNS0xLTEtMzA1NzI_76745b17-5c1d-4aba-abca-373ade35a0dd"
      unitRef="number">0.0741</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtMS0xLTEtMzA1NzI_f411746c-27d1-4cf8-8faa-0d300023b975"
      unitRef="number">-0.0096</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtMy0xLTEtMzA1NzI_0b3f1317-6021-4f0a-9e71-2d5876afa7a2"
      unitRef="number">0.6578</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzQtNS0xLTEtMzA1NzI_87998ec9-8da0-4e15-a6e6-189569897fa2"
      unitRef="number">-1.3512</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <neo:EffectiveIncomeTaxRateReconciliationTransactionExpenses
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzUtMS0xLTEtMzA1NzI_86e611ff-e0a3-4802-9579-775904ffd2a8"
      unitRef="number">1.5914</neo:EffectiveIncomeTaxRateReconciliationTransactionExpenses>
    <neo:EffectiveIncomeTaxRateReconciliationTransactionExpenses
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzUtMy0xLTEtMzA1NzI_23f1e190-f05e-4924-b492-3aa8c275780a"
      unitRef="number">0</neo:EffectiveIncomeTaxRateReconciliationTransactionExpenses>
    <neo:EffectiveIncomeTaxRateReconciliationTransactionExpenses
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzUtNS0xLTEtMzA1NzI_c6e1667e-fd31-496f-a3aa-03aa5ab038cc"
      unitRef="number">0</neo:EffectiveIncomeTaxRateReconciliationTransactionExpenses>
    <neo:EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzYtMS0xLTEtMzA1NzI_3e368cd6-8232-44b1-81d2-32d5a7c9bc1c"
      unitRef="number">0.1163</neo:EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent>
    <neo:EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzYtMy0xLTEtMzA1NzI_1756de7d-7b0d-4560-a10f-4202690d12c3"
      unitRef="number">0.3211</neo:EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent>
    <neo:EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzYtNS0xLTEtMzA1NzI_a909fb19-93cb-47cd-9329-31d05de08c2e"
      unitRef="number">0</neo:EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent>
    <neo:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzgtMS0xLTEtMzA1NzI_e8ce3a33-c226-4cce-a7d9-dc128ad5f5f9"
      unitRef="number">0.0022</neo:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent>
    <neo:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzgtMy0xLTEtMzA1NzI_1917a485-8ef7-4e8e-933d-b192f3d4ecda"
      unitRef="number">0.0121</neo:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent>
    <neo:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzgtNS0xLTEtMzA1NzI_cee452a1-5244-4f50-91f5-a5b107ed7195"
      unitRef="number">-0.0332</neo:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent>
    <neo:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzktMS0xLTEtMzA1NzI_29e46b6d-8b1f-4817-a98f-9b57f8346d53"
      unitRef="number">0</neo:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <neo:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzktMy0xLTEtMzA1NzI_39d45dc3-02be-4b4d-ba08-83bf9f6b46d4"
      unitRef="number">0.0738</neo:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <neo:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzktNS0xLTEtMzA1NzI_1b864dab-e971-4353-a04b-c96577b16a6a"
      unitRef="number">-0.1320</neo:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEwLTEtMS0xLTMwNTcy_f3a1b415-a585-4a6e-8343-7f37b58d7fa0"
      unitRef="number">0.0274</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEwLTMtMS0xLTMwNTcy_26210d4c-9008-4491-8e4b-0844c08794d9"
      unitRef="number">-0.0164</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEwLTUtMS0xLTMwNTcy_dafb83b7-1ab4-4592-863e-8a8cbf775ed8"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzExLTEtMS0xLTMwNTcy_2efce88a-473e-49db-b3e3-d2dd2ae5b6e9"
      unitRef="number">0.0016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzExLTMtMS0xLTMwNTcy_1b0e31b2-bc31-491a-9e78-f491f842261d"
      unitRef="number">-0.0006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzExLTUtMS0xLTMwNTcy_0b0f8428-3f0f-49a4-89b8-7775106cbd2f"
      unitRef="number">-0.0278</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEyLTEtMS0xLTMwNTcy_1990518a-5d46-4798-9f3a-00c2bb132137"
      unitRef="number">-1.3807</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEyLTMtMS0xLTMwNTcy_0d4ad6a4-88ef-4c0e-8b19-82319eab01a5"
      unitRef="number">-0.0897</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEyLTUtMS0xLTMwNTcy_73aab69b-a115-445d-978b-18348b941b0e"
      unitRef="number">0.2574</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEzLTEtMS0xLTMwNTcy_faa52a3b-66e5-4106-abd0-54eed7213b5e"
      unitRef="number">0.4462</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEzLTMtMS0xLTMwNTcy_6c715ab4-b3e3-4745-9075-6fe9c7c4722f"
      unitRef="number">1.2968</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTpkZjI1MDExMzliMTY0ODE1ODc5M2Q4OThlZjY0YTJmMS90YWJsZXJhbmdlOmRmMjUwMTEzOWIxNjQ4MTU4NzkzZDg5OGVmNjRhMmYxXzEzLTUtMS0xLTMwNTcy_84eb73c5-4777-4466-839a-bd124742af7b"
      unitRef="number">-1.1966</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3Mjk_596c404b-f694-4424-9959-6719e99ab139">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021 and 2020, deferred income tax assets and liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carry-forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in non-consolidated affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzItMS0xLTEtMzA1NzI_a2c2f144-9891-4fb3-8cd6-5af78f186e71"
      unitRef="usd">295000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzItMy0xLTEtMzA1NzI_cae80814-a63f-4edf-8302-13d67f78cc8b"
      unitRef="usd">1286000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzMtMS0xLTEtMzA1NzI_d3cc74a8-c85b-4565-9f8e-673e14c2f24d"
      unitRef="usd">6171000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzMtMy0xLTEtMzA1NzI_a20a8043-534b-4840-9001-997227408939"
      unitRef="usd">5403000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzQtMS0xLTEtMzA1NzI_60e06839-6ab2-4679-85c6-9b6c6a269506"
      unitRef="usd">81903000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzQtMy0xLTEtMzA1NzI_5ed36733-983a-44b7-a6a9-a29815397c14"
      unitRef="usd">33888000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzUtMS0xLTEtMzA1NzI_d8887bd1-ec31-4566-b65c-4744430ba6ed"
      unitRef="usd">6596000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzUtMy0xLTEtMzA1NzI_676044b5-2a6c-413f-85c7-690354d0a6a1"
      unitRef="usd">4575000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzYtMS0xLTEtMzA1NzI_b41f28c4-ae6d-4013-ac40-cbeee1a9368d"
      unitRef="usd">2355000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzYtMy0xLTEtMzA1NzI_20c5048a-2fe1-463e-9ec5-8a1744f13dd6"
      unitRef="usd">1999000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <neo:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzctMS0xLTEtMzA1NzI_9fa7746c-e614-46a7-9831-35bbfbe28cb0"
      unitRef="usd">19978000</neo:DeferredTaxAssetsOperatingLeaseLiability>
    <neo:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzctMy0xLTEtMzA1NzI_fad8beb1-e2d6-4cfb-91d8-d0f440c2988e"
      unitRef="usd">11589000</neo:DeferredTaxAssetsOperatingLeaseLiability>
    <neo:DeferredTaxAssetsInterestExpense
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzgtMS0xLTEtODAyNTM_4d9c513d-2734-4046-82ba-d5a9ec44f689"
      unitRef="usd">886000</neo:DeferredTaxAssetsInterestExpense>
    <neo:DeferredTaxAssetsInterestExpense
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzgtMy0xLTEtODAyNTM_e5d98487-0272-4628-ae9c-1cfe70ebf2d3"
      unitRef="usd">0</neo:DeferredTaxAssetsInterestExpense>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzgtMS0xLTEtMzA1NzI_2e302243-46ec-4161-9772-489e2476e410"
      unitRef="usd">2668000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzgtMy0xLTEtMzA1NzI_da7e1dec-cc38-4889-8112-81b5d51566a6"
      unitRef="usd">1470000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzktMS0xLTEtMzA1NzI_e04690d7-a33e-4cdf-833e-1fa51cb2a4e9"
      unitRef="usd">120852000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzktMy0xLTEtMzA1NzI_468ff168-b344-4f46-9a76-9c6395cff0d8"
      unitRef="usd">60210000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzEwLTEtMS0xLTMwNTcy_41cb3b2e-c07d-4464-b032-42cec8d6de71"
      unitRef="usd">33014000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzEwLTMtMS0xLTMwNTcy_8ef304f1-59e8-493d-898d-48b428802df7"
      unitRef="usd">2631000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzExLTEtMS0xLTMwNTcy_e8f631fc-fcc4-4586-843e-450bec1ed052"
      unitRef="usd">87838000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzExLTMtMS0xLTMwNTcy_18d06098-b69e-4fbd-a1c0-ea85f55b5f05"
      unitRef="usd">57579000</us-gaap:DeferredTaxAssetsNet>
    <neo:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzEzLTEtMS0xLTMwNTcy_57eda328-2d10-4c67-b5e1-ff18da4b4b07"
      unitRef="usd">19094000</neo:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <neo:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzEzLTMtMS0xLTMwNTcy_35cc1567-d59c-48da-8ab6-aab0754b7b93"
      unitRef="usd">11120000</neo:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE0LTEtMS0xLTMwNTcy_c3c6d9e3-8d96-4e36-ab2c-3bc3f0df1991"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE0LTMtMS0xLTMwNTcy_c672b542-7142-4705-9f4d-7ffedee1f775"
      unitRef="usd">1000000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE1LTEtMS0xLTMwNTcy_d86ddb4d-d81b-4c01-9a9f-94b6a8f0623f"
      unitRef="usd">1000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE1LTMtMS0xLTMwNTcy_4954083c-ed72-4e85-8b05-a16dd8344596"
      unitRef="usd">6636000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE2LTEtMS0xLTMwNTcy_6d1f5abd-8945-4e58-bb3b-37531646a032"
      unitRef="usd">108592000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE2LTMtMS0xLTMwNTcy_b2abc8fa-8f30-4a4a-b192-0885ceffdb5d"
      unitRef="usd">29268000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE3LTEtMS0xLTMwNTcy_a2c68b5d-aa83-4e35-9632-119e92b3aa07"
      unitRef="usd">15389000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE3LTMtMS0xLTMwNTcy_d00215dd-b92f-4dbe-ac9f-3da5d921d51f"
      unitRef="usd">14678000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE4LTEtMS0xLTMwNTcy_4038249c-6d99-4ff9-9dab-fc3ed42db7e3"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE4LTMtMS0xLTMwNTcy_310e0e37-a2f0-4d42-97e8-39f327cd5fc6"
      unitRef="usd">292000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE5LTEtMS0xLTMwNTcy_74180a00-0524-4d86-8191-d8076030f891"
      unitRef="usd">143076000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzE5LTMtMS0xLTMwNTcy_fc24d4d3-53f6-4ec2-8d28-0db7f19c3959"
      unitRef="usd">62994000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzIwLTEtMS0xLTMwNTcy_8f66c71d-db09-4544-8230-130a37edb379"
      unitRef="usd">55238000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZTozOTMwMGJjN2RlZGQ0ZmYyYTY4YTk0OTE2OTVmNjNiMi90YWJsZXJhbmdlOjM5MzAwYmM3ZGVkZDRmZjJhNjhhOTQ5MTY5NWY2M2IyXzIwLTMtMS0xLTMwNTcy_2c913921-630c-4bd1-b616-7f638e873e9c"
      unitRef="usd">5415000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzgxOA_6d48d97b-94ba-445a-b8fe-a30ce39528ea"
      unitRef="usd">231500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i6dccccc0a21b4ef3be05781945900129_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1Xzg4MA_636bcde4-d8ab-4388-9aeb-d245a83e4c6f"
      unitRef="usd">118900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i24a99cf2affb44979b10edd8cc9305bf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE2NDkyNjc0NjI0NzI_1abf866b-fdae-4926-b9dd-2e6450b183ca"
      unitRef="usd">96400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id7819d6cd0da4e4da9a9fdcae4fb87ed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1Xzk0NA_5c0084f9-6e8d-4984-953b-638a1690516f"
      unitRef="usd">112800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="if495aff7c41d4b8aad8f6a3241978f33_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE4ODM_e22120f2-16bc-4664-b798-f501856568f9"
      unitRef="usd">5500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="id7819d6cd0da4e4da9a9fdcae4fb87ed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE5ODc_3320143a-21d1-4f8b-a45f-dde30162b05e"
      unitRef="usd">3800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6dccccc0a21b4ef3be05781945900129_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzMzMDQ_181f9c16-94fd-4b36-b88b-7f912a5d0698"
      unitRef="usd">4100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibe0dff7a9994470f9689008656bb381b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE2NDkyNjc0NTQ0NTU_6a52a8e9-88ba-43d5-8cfb-b12fa68a2a4d"
      unitRef="usd">2600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if495aff7c41d4b8aad8f6a3241978f33_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzE2NDkyNjc0NTQ0NDA_476e8cb8-b917-4c3c-b643-3d127d0ed2b0"
      unitRef="usd">28900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90ZXh0cmVnaW9uOmU3YmU0OGY3NWQwYjQ1ODk5YWUyMWI4NTEwYmJkYmQ1XzU3MjU_20598b4d-4d45-47d3-bdb4-28cce3d34ce5">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits - January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reversals of prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in tax positions taken in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statute expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits - December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzItMS0xLTEtMzA1NzI_0f12b6f0-caaf-4b5b-8239-e9f7b87aadc9"
      unitRef="usd">1670000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0e73e76fb9d740ce9295635957e3246e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzItMy0xLTEtMzA1NzI_1b814656-54b9-4f1f-a147-12baab2500ad"
      unitRef="usd">444000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzMtMS0xLTEtMzA1NzI_f69c23b6-3947-40fd-a529-612a5ac62412"
      unitRef="usd">83000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzMtMy0xLTEtMzA1NzI_2609e56f-2fb8-4902-b409-ca53adbcb39d"
      unitRef="usd">1020000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzQtMS0xLTEtMzA1NzI_25e8b143-0955-49e7-8cfe-cc92cabe76cd"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzQtMy0xLTEtMzA1NzI_ffe311ed-aaec-424d-a7bc-116bdef757a1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzUtMS0xLTEtMzA1NzI_fcc9008f-45f2-45d2-806d-8f5d02efb26e"
      unitRef="usd">632000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzUtMy0xLTEtMzA1NzI_e8d9db40-b4cc-49a4-91dd-3d089488ebc1"
      unitRef="usd">378000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzYtMS0xLTEtMzA1NzI_deff07c7-42c3-4368-88a4-9fe0eca1934e"
      unitRef="usd">34000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzYtMy0xLTEtMzA1NzI_a9b2f0a9-d907-4f89-8c5d-2e34b875fd8b"
      unitRef="usd">172000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzctMS0xLTEtMzA1NzI_a66319eb-0c2d-40f8-a6fc-0de7a616eb07"
      unitRef="usd">2351000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i97aa2adfd61943129250ed16f5aef4cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMjcvZnJhZzplN2JlNDhmNzVkMGI0NTg5OWFlMjFiODUxMGJiZGJkNS90YWJsZToyMzE5NmQ1MTY3MDc0MWEzOTZiMDc0MDc0MmU4NTBlZC90YWJsZXJhbmdlOjIzMTk2ZDUxNjcwNzQxYTM5NmIwNzQwNzQyZTg1MGVkXzctMy0xLTEtMzA1NzI_469fa267-598b-45f2-886f-2d8868d91bf5"
      unitRef="usd">1670000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90ZXh0cmVnaW9uOjc5MDc0ZTc2MjljZTRjMGU4MmFmMjgxMDEzZDExZjRlXzI2OTU_c34c0d72-f26f-49b1-975f-ad3309f025f3">Net (Loss) Income per ShareThe Company presents both basic earnings per share (&#x201c;EPS&#x201d;) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing &#x201c;net (loss) income&#x201d; by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock awards were exercised and if the 2028 Convertible Notes and 2025 Convertible Notes were converted. The potential dilution from stock awards is accounted for using the treasury &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock method based on the average market value of the Company&#x2019;s common stock. The potential dilution from conversion of the 2028 Convertible Notes and 2025 Convertible Notes is accounted for using the if-converted method, which requires that all of the shares of the Company&#x2019;s common stock issuable upon conversion of the 2028 Convertible Notes and the 2025 Convertible Notes will be included in the calculation of diluted EPS assuming conversion of the 2028 Convertible Notes and the 2025 Convertible Notes at the beginning of the reporting period (or at time of issuance, if later).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculations for the years ended December 31, 2021, 2020, and 2019 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NET (LOSS) INCOME&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive for the years ended December 31, 2021, 2020, and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potential effect of the Capped Call Transactions entered into concurrently with the 2028 Convertible Notes were excluded from the calculation of diluted net (loss) income per share in 2021 as the Company&#x2019;s closing price on December 31, 2021, did not exceed the conversion price of $85.75 per share. The Capped Call Transactions are not reflected in diluted net (loss) income per share as they are anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further details on the Capped Call Transactions, please refer to Note 9. Debt.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90ZXh0cmVnaW9uOjc5MDc0ZTc2MjljZTRjMGU4MmFmMjgxMDEzZDExZjRlXzI2OTI_20841527-8852-4416-95c9-9eb8bab86d1c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculations for the years ended December 31, 2021, 2020, and 2019 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NET (LOSS) INCOME&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net (loss) income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzMtMS0xLTEtMzA1NzI_448b75ad-8392-4335-be68-9ae2be63bfd2"
      unitRef="usd">-8347000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzMtMy0xLTEtMzA1NzI_9e4fc407-b4ea-4111-a937-34cfa36d18a3"
      unitRef="usd">4172000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzMtNS0xLTEtMzA1NzI_5f81d88b-d839-4892-9154-fbd53825d29a"
      unitRef="usd">8006000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE0LTEtMS0xLTMwNTcy_b9b2d7b8-f793-45f2-8829-b8259d4983a1"
      unitRef="shares">119962000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE0LTMtMS0xLTMwNTcy_c6c21d28-6980-40b5-bfd8-9cb830ea6f1b"
      unitRef="shares">108579000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE0LTUtMS0xLTMwNTcy_ecfc5f31-9f62-41f2-a0a1-1e952d0ff8d4"
      unitRef="shares">100470000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6c214db41910419cb07bdbcc42d83756_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE1LTEtMS0xLTMwNTcy_06778e39-5cb6-4717-9d24-c2fa6482e918"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia87bb3f8d04745f2889e0a2f39c141d2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE1LTMtMS0xLTMwNTcy_ae464660-f4d4-40b6-9a4f-ca0af5e16ada"
      unitRef="shares">3010000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ife334d7e97604dfb939dddee1cd879c4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE1LTUtMS0xLTMwNTcy_6dbfc9a9-6bdc-4376-9cae-f4b930667c88"
      unitRef="shares">2862000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibcea204956134004ac776ab4422f61d3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE2LTEtMS0xLTMwNTcy_75315111-4d50-40c5-9760-18c87340e3b8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ib49e57f9c3d34b1197865431886bc4cc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE2LTMtMS0xLTMwNTcy_b32c17ea-5bbf-4a54-9a7a-f8399f1ab3a4"
      unitRef="shares">205000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i987c789d69ad4dc794c68a60eba50de3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE2LTUtMS0xLTMwNTcy_184b5272-2361-4b85-9779-6a2f9675d59a"
      unitRef="shares">283000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE5LTEtMS0xLTMwNTcy_85bd4989-a2db-462d-886b-c25175cbdeb6"
      unitRef="shares">119962000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE5LTMtMS0xLTMwNTcy_c660e1d9-124f-4c24-b47f-96cd771ada19"
      unitRef="shares">111794000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzE5LTUtMS0xLTMwNTcy_d4bc0fb0-5c5e-4029-9433-5e9b51193731"
      unitRef="shares">103615000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIxLTEtMS0xLTMwNTcy_ac548789-24ca-406d-b900-0ed99ebb9514"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIxLTMtMS0xLTMwNTcy_adeb0212-025d-4380-b0d2-e8491e9ae989"
      unitRef="usdPerShare">0.04</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIxLTUtMS0xLTMwNTcy_64341c99-d7f7-4271-8106-e77ec20087c7"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIyLTEtMS0xLTMwNTcy_c18f3948-2546-44ce-bfa0-c8d417397258"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIyLTMtMS0xLTMwNTcy_bd18a777-fc8b-46ae-b83f-29ff04d7033e"
      unitRef="usdPerShare">0.04</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpmM2JmMzNjODQ1Mjc0MmJiYmU3NDc1ZjJkNGFjMDcwYi90YWJsZXJhbmdlOmYzYmYzM2M4NDUyNzQyYmJiZTc0NzVmMmQ0YWMwNzBiXzIyLTUtMS0xLTMwNTcy_d4f35249-8e77-4153-9966-5f6724c11980"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90ZXh0cmVnaW9uOjc5MDc0ZTc2MjljZTRjMGU4MmFmMjgxMDEzZDExZjRlXzI2OTM_8ea5f04a-2e0e-4417-bf5a-f5d1710b317c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potential dilutive shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive for the years ended December 31, 2021, 2020, and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1225c352b00e4cb690a7adb7cdcbedde_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzItMS0xLTEtMzA1NzI_4beaf9fd-a05c-4b72-8d9c-4290c7a17cfd"
      unitRef="shares">1892000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3a9dd7cfafdc43d091c918725cbc192d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzItMy0xLTEtMzA1NzI_c35e868d-4df2-4207-be16-2e1079163b04"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f155818af974561b4f8f18784fa25f0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzItNS0xLTEtMzA1NzI_b9537113-a0b1-4f28-b03b-f86c9a31a9c6"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i57a16efa8cab4c0c99d0598296108afd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtMS0xLTEtMzA1NzI_f7592cef-0efd-495e-95f2-e0d6e6e8a987"
      unitRef="shares">194000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i091d1f087aa54fdfb74ce0705a97ff6b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtMy0xLTEtMzA1NzI_789d2c0e-ed6e-4166-8186-fcb5bc4f0c5d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i87d1360a007c47328b217b42d2e1ff65_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtNS0xLTEtMzA1NzI_2a8c6e34-f68f-4876-8848-30484a500bf9"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8e3dba7dbe87474f82bf542453f20492_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtMS0xLTEtNDczMDE_481ffb95-2cd4-48ef-b13d-c03c8067e68b"
      unitRef="shares">5538000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i383f1d1042d44cf1b819e519a1682405_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtMy0xLTEtNDcyNzQ_1120e48e-ebf7-4362-a5cf-9cbae344cb0a"
      unitRef="shares">3723000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2a0708e137d04355b6f919e001c59cce_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzMtNS0xLTEtNDcyNzk_21e9b3dc-744b-4981-be9b-1e2b9b128242"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf2957894b7a4d2f897b45f006d71ee4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzQtMS0xLTEtMzA1NzI_f848cf69-923d-45ab-b209-cb293ab5d884"
      unitRef="shares">5130000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4fedbf43609e4de1a63dab08b8a57324_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzQtMy0xLTEtMzA1NzI_d41ddcb6-c686-4994-b42b-52c6c5981482"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i74606006218e4bd29582caf14fce1a54_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90YWJsZTpiNmI4NzY4NmZlMjM0OWIyYWQwNTE0ZGEwNjU3YzJkMy90YWJsZXJhbmdlOmI2Yjg3Njg2ZmUyMzQ5YjJhZDA1MTRkYTA2NTdjMmQzXzQtNS0xLTEtMzA1NzI_142f52b1-2282-4796-bfd1-d0be2a44148f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic3e44ba920e9419596aae3ab89649f48_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzAvZnJhZzo3OTA3NGU3NjI5Y2U0YzBlODJhZjI4MTAxM2QxMWY0ZS90ZXh0cmVnaW9uOjc5MDc0ZTc2MjljZTRjMGU4MmFmMjgxMDEzZDExZjRlXzIxOTkwMjMyNjYzMjU_6cf8d81a-c72a-4599-a50c-87374e284f34"
      unitRef="usdPerShare">85.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzY0NA_b5d4552b-366f-480e-89d9-ddbd0657b925">Defined Contribution PlanThe Company maintains a defined-contribution 401(k) retirement plan covering substantially all U.S. based employees (as defined).&#160;The Company&#x2019;s employees may make voluntary contributions to the plan, subject to limitations based on IRS regulations and compensation. The Company matches 100.0% of every dollar contributed up to 3.0% of the respective employee&#x2019;s compensation and an additional 50.0% of every dollar contributed on the next 2% of compensation (4.0% maximum Company match).&#160;Matching contributions were approximately $6.1 million, $4.9 million and $4.4 million during the years ended December 31, 2021, 2020, and 2019, respectively, and are recorded in cost of revenue and operating expenses in the Consolidated Statements of Operations.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzMzMQ_235b99d9-9a90-4789-ab66-30fc75779332"
      unitRef="number">1.000</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzM2OA_cf64593c-c6d5-4ac7-8740-59dd65dac858"
      unitRef="number">0.030</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzQzMQ_f7649f15-3bec-4b0d-8744-3302a7265578"
      unitRef="number">0.500</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <neo:DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzQ3NA_798a9882-b293-453b-b7ab-e7517fdb8700"
      unitRef="number">0.02</neo:DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent>
    <neo:DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzQ5NA_8565b6c0-386e-4f98-9526-83e46b484bf1"
      unitRef="number">0.040</neo:DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzU3OA_fce51885-ac62-4a41-a7ae-79bcec474943"
      unitRef="usd">6100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzU4Mg_79e42fe3-c55e-45df-b3be-02bf80b3e2f7"
      unitRef="usd">4900000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzMvZnJhZzoxMjlhNGVkOGQ3NTg0MmIzYmY2NDNmNzY1ODFjMTJiZi90ZXh0cmVnaW9uOjEyOWE0ZWQ4ZDc1ODQyYjNiZjY0M2Y3NjU4MWMxMmJmXzU4OQ_eff40a82-07ec-496c-8f8d-3cfa22acb109"
      unitRef="usd">4400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90ZXh0cmVnaW9uOjhiZmE3NTRiOGIyMjRkYjJhMWY0MDYwODY1ODU1YWE5XzI5Ng_89eb2101-708f-426f-9e52-dceefb17f083">Commitments and Contingencies&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements in place to purchase a specified level of reagents from certain vendors. These purchase commitments expire at various dates through 2023. The purchase commitments as of December 31, 2021, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.428%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Legal Proceeding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2021, Natera, Inc. filed a patent infringement complaint against the Company&#x2019;s newly-acquired subsidiary Inivata Limited and its subsidiary Inivata, Inc. in U.S. District Court for the district of Delaware, alleging Inivata&#x2019;s InVisionFirst&#xae;-Lung cancer diagnostic test of infringing two patents. The litigation is presently in the pleadings stage. The Company believes that it has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. At the time of filing the outcome of this matter is not estimable or probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Regulatory Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the assistance of outside counsel, the Company is voluntarily conducting an internal investigation that focuses on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#x201c;OIG&#x201d;) of the Company&#x2019;s internal investigation in November 2021. The Company&#x2019;s review of this matter is ongoing. As of December 31, 2021, the Company has accrued a reserve of $11.2&#160;million in other long-term liabilities on the Consolidated Balance Sheets for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#x2019;s best estimate of the minimum probable loss associated with this matter. As a result of the ongoing investigation and interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. At this time, the Company is unable to predict the duration, scope, result or related costs associated with any further investigation, including by the OIG, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Any determination that the Company&#x2019;s operations or activities are not in compliance with existing laws or regulations, however, could result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, or other losses or conduct restrictions, which could be material to the Company&#x2019;s financial results or business operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90ZXh0cmVnaW9uOjhiZmE3NTRiOGIyMjRkYjJhMWY0MDYwODY1ODU1YWE5XzI5Nw_c7edcb77-b9d0-4cb2-94ae-23058aed947f">The purchase commitments as of December 31, 2021, are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.428%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90YWJsZTo2MTRhMDFkNjE0ZTY0MTczOTIwZjFkNmUwYWI4MjI2Ny90YWJsZXJhbmdlOjYxNGEwMWQ2MTRlNjQxNzM5MjBmMWQ2ZTBhYjgyMjY3XzEtMS0xLTEtMzA1NzI_f68202e5-f72a-4b7d-b1c8-89ab6bef7f51"
      unitRef="usd">1005000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90YWJsZTo2MTRhMDFkNjE0ZTY0MTczOTIwZjFkNmUwYWI4MjI2Ny90YWJsZXJhbmdlOjYxNGEwMWQ2MTRlNjQxNzM5MjBmMWQ2ZTBhYjgyMjY3XzItMS0xLTEtMzA1NzI_c5c26b3d-af8e-42e6-8efa-ccde6cca25d4"
      unitRef="usd">1005000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligation
      contextRef="i306577667f484778bf45986f95823aa8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90YWJsZTo2MTRhMDFkNjE0ZTY0MTczOTIwZjFkNmUwYWI4MjI2Ny90YWJsZXJhbmdlOjYxNGEwMWQ2MTRlNjQxNzM5MjBmMWQ2ZTBhYjgyMjY3XzQtMS0xLTEtMzA1NzI_78da70bc-2c37-4805-9e7b-d451f773ab0f"
      unitRef="usd">2010000</us-gaap:PurchaseObligation>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="iaeda459a54ed4faf87cd1bc16a70d854_D20210120-20210120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90ZXh0cmVnaW9uOjhiZmE3NTRiOGIyMjRkYjJhMWY0MDYwODY1ODU1YWE5XzIxOTkwMjMyNTYxODk_00dc71df-5be2-4340-ac34-67175299ac26"
      unitRef="patent">2</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i4f4073899af34688810e3b224590c74f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzYvZnJhZzo4YmZhNzU0YjhiMjI0ZGIyYTFmNDA2MDg2NTg1NWFhOS90ZXh0cmVnaW9uOjhiZmE3NTRiOGIyMjRkYjJhMWY0MDYwODY1ODU1YWE5XzMyOTg1MzQ4ODc3NTY_a29b0125-c1c4-44c7-8337-a808470c4380"
      unitRef="usd">11200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzkvZnJhZzozMTMyMTMxYTQwZDA0NjIxOWFjZDQ2NTJkZjEwYWJlOS90ZXh0cmVnaW9uOjMxMzIxMzFhNDBkMDQ2MjE5YWNkNDY1MmRmMTBhYmU5XzU3Nw_65092b7b-c969-4623-bd70-c9f3762c89ec">Related Party Transactions&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2020, the Company formed a strategic alliance with Inivata and entered into a Strategic Alliance Agreement and Laboratory Services Agreement whereas Inivata, prior to the Inivata Acquisition Date, would render and perform certain laboratory testing which the Company made available to customers. In connection with this agreement, Inivata provided $0.8 million of testing services to the Company recorded in cost of revenue in the Consolidated Statements of Operations in 2021 through the Inivata Acquisition Date. Such services provided for the year ended December 31, 2020 were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2020, the Company and Inivata also entered into a Line of Credit in the amount of $15.0&#160;million. The Company and Inivata settled the Line of Credit after the Inivata Acquisition Date and no amounts were outstanding as of December 31, 2021. For further details on the Line of Credit, please refer to Note 8. Investment in Non-Consolidated Affiliate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021, the Company completed its acquisition of all remaining equity interest in Inivata by exercising its Purchase Option. Beginning June 18, 2021, Inivata is a wholly-owned consolidated subsidiary of the Company. As of the Inivata Acquisition Date, Inivata&#x2019;s financial statement activity is being consolidated within the Company&#x2019;s Consolidated Financial Statements. For further details on the acquisition of Inivata, please refer to Note 3. Acquisitions.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i13a97ccd6ccc4b63a539db53fa7f8e61_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzkvZnJhZzozMTMyMTMxYTQwZDA0NjIxOWFjZDQ2NTJkZjEwYWJlOS90ZXh0cmVnaW9uOjMxMzIxMzFhNDBkMDQ2MjE5YWNkNDY1MmRmMTBhYmU5XzIxOTkwMjMyNTY1MDk_00df8d1b-329c-42fb-a1f8-fe4265c51bf1"
      unitRef="usd">800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie359835360d14552b460dfe2e09d74a4_I20200522"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzkvZnJhZzozMTMyMTMxYTQwZDA0NjIxOWFjZDQ2NTJkZjEwYWJlOS90ZXh0cmVnaW9uOjMxMzIxMzFhNDBkMDQ2MjE5YWNkNDY1MmRmMTBhYmU5XzIxOTkwMjMyNTY4NjY_caf3883e-7476-40a5-a61f-4aa2702630e4"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LongTermDebt
      contextRef="ie1bd7c4a65e8470fb2e0bcb4e07683c8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xMzkvZnJhZzozMTMyMTMxYTQwZDA0NjIxOWFjZDQ2NTJkZjEwYWJlOS90ZXh0cmVnaW9uOjMxMzIxMzFhNDBkMDQ2MjE5YWNkNDY1MmRmMTBhYmU5XzE2NDkyNjc0NDc0Mjc_ca1b2533-e259-42be-b6db-878c7fb73647"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzEwODY_e731f304-5f41-4e91-9544-86b1cd30f67d">Segment Information&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under two reportable segments, (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology and oncology practices, hospital pathology labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and self-pay patients. The Pharma Services segment supports pharmaceutical firms&#x2019; drug development programs by assisting with various clinical trials and research as well as providing informatics related services often supporting pharmaceutical commercialization efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial information reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) includes revenues, cost of revenue, and gross profit for both reportable segments.&#160;Assets are not presented at the segment level as that information&#160;is not used by the CODM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost of revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Loss) income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on investment in and loan receivable from non-consolidated affiliate, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on termination of cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Clinical Services cost of revenue in 2021 includes $9.2 million of amortization of acquired Inivata developed technology intangible assets and write-offs of $5.3 million for COVID-19 PCR testing inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharma Services cost of revenue in 2021 includes $1.2 million&#160;of amortization of acquired Inivata developed technology intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzgyNDYzMzcyMTM1NzM_a633da5e-3cfb-4e90-8325-89f664f83f04"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzEwODc_aeaad366-c948-46fb-8704-269b95ca4f6a">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost of revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Loss) income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on investment in and loan receivable from non-consolidated affiliate, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on termination of cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Clinical Services cost of revenue in 2021 includes $9.2 million of amortization of acquired Inivata developed technology intangible assets and write-offs of $5.3 million for COVID-19 PCR testing inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharma Services cost of revenue in 2021 includes $1.2 million&#160;of amortization of acquired Inivata developed technology intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i837dec7e8fdd48c7a1722bf1b1f3b0e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMtMS0xLTEtMzA1NzI_0c100457-d1e9-4401-911a-3ae40cfb7967"
      unitRef="usd">404172000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9dd5c1eb69c64cc799674374d18d6cc0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMtMy0xLTEtMzA1NzI_4a3ed6f0-f8a5-40e9-ab7a-2211c085bcd8"
      unitRef="usd">382337000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if43b0047444b401e8e1b445dd63adc4b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMtNS0xLTEtMzA1NzI_31d5c510-e536-4036-b4ad-01f1560c7894"
      unitRef="usd">361161000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8c1b9b8d04e54ea9b259cbdf629ff3dd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzQtMS0xLTEtMzA1NzI_902d911d-d8f8-4a30-9ad5-8a86f8061823"
      unitRef="usd">80157000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib2d0d6a9a7bd4a269a7535713c120fbd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzQtMy0xLTEtMzA1NzI_0caf2fe9-96fd-4763-a6f5-6b00a1da21e3"
      unitRef="usd">62111000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibd350be96f284665bf09aeefccfc73cb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzQtNS0xLTEtMzA1NzI_868f4a0c-5b00-4c4f-8692-b6fac1a4463d"
      unitRef="usd">47669000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzUtMS0xLTEtMzA1NzI_4a353eb7-cdc0-4497-8fe9-edb5c9ea866a"
      unitRef="usd">484329000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzUtMy0xLTEtMzA1NzI_5dc2a469-efea-4193-a0fc-fe89246543cf"
      unitRef="usd">444448000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzUtNS0xLTEtMzA1NzI_345c342c-06a3-4c64-88b7-5b41ef6b301d"
      unitRef="usd">408830000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i837dec7e8fdd48c7a1722bf1b1f3b0e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzgtMS0xLTEtMzA1NzI_9e315fa3-d005-4184-9eec-52ed4231aa5a"
      unitRef="usd">244360000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9dd5c1eb69c64cc799674374d18d6cc0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzgtMy0xLTEtMzA1NzI_bcf02b37-6cdd-4ed4-81b2-557163f6687f"
      unitRef="usd">215529000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if43b0047444b401e8e1b445dd63adc4b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzgtNS0xLTEtMzA1NzI_651535a1-78c9-4d4f-82fb-a8891c78ac8b"
      unitRef="usd">185612000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8c1b9b8d04e54ea9b259cbdf629ff3dd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzktMS0xLTEtMzA1NzI_a2f363be-233c-41de-8dae-e0737817dc16"
      unitRef="usd">52909000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib2d0d6a9a7bd4a269a7535713c120fbd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzktMy0xLTEtMzA1NzI_f0c816e8-8cf7-4334-a2d9-4a217c0e8545"
      unitRef="usd">43026000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibd350be96f284665bf09aeefccfc73cb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzktNS0xLTEtMzA1NzI_7a777606-e086-4190-906b-3c826b21e3aa"
      unitRef="usd">26382000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEwLTEtMS0xLTMwNTcy_90468bcb-dc32-4cb0-96dc-648538a05ced"
      unitRef="usd">297269000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEwLTMtMS0xLTMwNTcy_3e5daead-b070-460e-85ee-428c949e2b53"
      unitRef="usd">258555000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEwLTUtMS0xLTMwNTcy_e3b6b385-724c-4d7f-b1a0-0ee3ec072514"
      unitRef="usd">211994000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i837dec7e8fdd48c7a1722bf1b1f3b0e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEzLTEtMS0xLTMwNTcy_ebec178f-cb24-42d0-8562-e0b970b7870d"
      unitRef="usd">159812000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i9dd5c1eb69c64cc799674374d18d6cc0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEzLTMtMS0xLTMwNTcy_f61d0b73-96e1-42b5-98ad-3d4fff845cb6"
      unitRef="usd">166808000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if43b0047444b401e8e1b445dd63adc4b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzEzLTUtMS0xLTMwNTcy_81510dd4-a93a-4981-9e97-da40f9e868de"
      unitRef="usd">175549000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i8c1b9b8d04e54ea9b259cbdf629ff3dd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE0LTEtMS0xLTMwNTcy_c879185b-dbe7-4c23-8a59-7f5b0a4c9b0c"
      unitRef="usd">27248000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib2d0d6a9a7bd4a269a7535713c120fbd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE0LTMtMS0xLTMwNTcy_e40f371f-3745-4aa8-a7fc-85fad109b576"
      unitRef="usd">19085000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ibd350be96f284665bf09aeefccfc73cb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE0LTUtMS0xLTMwNTcy_bdf8ae62-c04f-471e-8a33-1de43ec7a2c2"
      unitRef="usd">21287000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE1LTEtMS0xLTMwNTcy_7e5253e4-bf51-448c-8ffc-904a7af3bc9c"
      unitRef="usd">187060000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE1LTMtMS0xLTMwNTcy_bf416814-273e-4c73-ad2c-5b9ba3070363"
      unitRef="usd">185893000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE1LTUtMS0xLTMwNTcy_2292ca8e-a582-4e17-8a29-2a3f97a91119"
      unitRef="usd">196836000</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE4LTEtMS0xLTMwNTcy_3cd0033c-5842-4229-ace5-c9339f9ee8de"
      unitRef="usd">221347000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE4LTMtMS0xLTMwNTcy_f3ca9269-9a5d-4b8b-bdf5-d8b771aaee88"
      unitRef="usd">143794000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE4LTUtMS0xLTMwNTcy_e6338950-ec3e-4473-8848-8924c10ea993"
      unitRef="usd">127993000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE5LTEtMS0xLTMwNTcy_d034dfac-1949-42b8-8220-5dd428000152"
      unitRef="usd">21873000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE5LTMtMS0xLTMwNTcy_5cf504ee-35c9-4136-a6ba-00669ca001dd"
      unitRef="usd">8229000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzE5LTUtMS0xLTMwNTcy_81dfe844-9027-4e30-866f-8e6f734185b8"
      unitRef="usd">8487000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIwLTEtMS0xLTMwNTcy_84835d9e-836f-4937-a37a-85a66eb441e5"
      unitRef="usd">62594000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIwLTMtMS0xLTMwNTcy_19e81398-39c9-4a6e-80cf-8a70fea4b76b"
      unitRef="usd">47862000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIwLTUtMS0xLTMwNTcy_992935f3-5e99-4aee-aa2d-ef7a2122491b"
      unitRef="usd">47350000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OperatingExpenses
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIyLTEtMS0xLTMwNTcy_2c3050f6-20dd-4683-9401-fc0eddf05d40"
      unitRef="usd">305814000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIyLTMtMS0xLTMwNTcy_5474d547-9c6b-4999-8b61-95b2604682cc"
      unitRef="usd">199885000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIyLTUtMS0xLTMwNTcy_1a3e7d92-701e-4623-b346-d34aebe87cf7"
      unitRef="usd">183830000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIzLTEtMS0xLTMwNTcy_590114a2-1655-467e-bff6-c81d87342bcb"
      unitRef="usd">-118754000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIzLTMtMS0xLTMwNTcy_29699726-4b6a-437b-8d72-16c7a9c386b7"
      unitRef="usd">-13992000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzIzLTUtMS0xLTMwNTcy_dc91817d-2bda-4246-a843-1f074243f145"
      unitRef="usd">13006000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI0LTEtMS0xLTMwNTcy_86c8d6f2-5cad-4cce-83e9-df1f20b7a352"
      unitRef="usd">5082000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI0LTMtMS0xLTMwNTcy_62efc069-842b-4451-88d3-26e339fa89e7"
      unitRef="usd">7019000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI0LTUtMS0xLTMwNTcy_5852f9f7-9b11-45b0-b4ef-09451a39bfe3"
      unitRef="usd">3713000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTEtMS0xLTMwNTcy_da80cf80-9dc3-4bcb-9127-a0ca6157baf3"
      unitRef="usd">-499000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTMtMS0xLTMwNTcy_91a68dfc-79e9-43cd-a9fd-5462b314c461"
      unitRef="usd">7906000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTUtMS0xLTMwNTcy_e1f80808-a1a3-441f-a718-8352fa3e3055"
      unitRef="usd">-4630000</us-gaap:OtherNonoperatingIncomeExpense>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTEtMS0xLTQ3NTcz_c01529da-5de7-40ec-a969-d22e3675bec6"
      unitRef="usd">109260000</neo:GainLossOnInvestmentAndLoanReceivable>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTMtMS0xLTQ3NTUw_f0f4f16a-0137-42d7-8509-232a6b9cf11f"
      unitRef="usd">3955000</neo:GainLossOnInvestmentAndLoanReceivable>
    <neo:GainLossOnInvestmentAndLoanReceivable
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI1LTUtMS0xLTQ3NTUw_f413755a-bfb1-477b-a882-f32a01425c23"
      unitRef="usd">0</neo:GainLossOnInvestmentAndLoanReceivable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI2LTEtMS0xLTMwNTcy_aa876043-7ba7-4329-b27f-8128e1d2df69"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI2LTMtMS0xLTMwNTcy_03a0dd2b-d2c2-4f3c-a97e-ab8ba014233a"
      unitRef="usd">-1400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI2LTUtMS0xLTMwNTcy_6c522b81-fa16-4c9e-954c-3a252523cff6"
      unitRef="usd">-1018000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <neo:GainLossOnTerminationOfInterestRateSwap
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI3LTEtMS0xLTMwNTcy_512c824d-6a2b-40bb-b437-5cc9a78eab93"
      unitRef="usd">0</neo:GainLossOnTerminationOfInterestRateSwap>
    <neo:GainLossOnTerminationOfInterestRateSwap
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI3LTMtMS0xLTMwNTcy_be4ec4b4-1df8-4516-aaba-aac5376dae3d"
      unitRef="usd">-3506000</neo:GainLossOnTerminationOfInterestRateSwap>
    <neo:GainLossOnTerminationOfInterestRateSwap
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI3LTUtMS0xLTMwNTcy_62eb997b-73de-4dda-a931-b5e3455f67af"
      unitRef="usd">0</neo:GainLossOnTerminationOfInterestRateSwap>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI4LTEtMS0xLTMwNTcy_25cf0e67-c10c-4d67-b643-aa977ae0e518"
      unitRef="usd">-15075000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI4LTMtMS0xLTMwNTcy_70383002-a99c-48fb-b2d4-521ec7fe5ab3"
      unitRef="usd">-14056000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI4LTUtMS0xLTMwNTcy_dfc69bd6-49ca-4c8d-9de7-04bb9e186c01"
      unitRef="usd">3645000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI5LTEtMS0xLTMwNTcy_8aab509c-ef9f-409c-9492-38a4cd9df34d"
      unitRef="usd">-6728000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI5LTMtMS0xLTMwNTcy_1012dc97-494e-44ba-a44d-02d360db9414"
      unitRef="usd">-18228000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzI5LTUtMS0xLTMwNTcy_a1ecb0b6-efff-4cad-ab45-85bca65bb2f7"
      unitRef="usd">-4361000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMwLTEtMS0xLTMwNTcy_2c902fc5-ff34-49b3-8e35-3d3d6f80a747"
      unitRef="usd">-8347000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02c816429e874bce96c4b9dd6ee42ffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMwLTMtMS0xLTMwNTcy_0def2ada-652c-458c-85a4-a1439ea1fcaf"
      unitRef="usd">4172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i113f1b3301b24f6ebefea5fcf65b6930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90YWJsZTpjZjI3MjljMjc0MjI0ZDYwYTk2ZjlhYzU5MjlhMzdjOS90YWJsZXJhbmdlOmNmMjcyOWMyNzQyMjRkNjBhOTZmOWFjNTkyOWEzN2M5XzMwLTUtMS0xLTMwNTcy_d154042f-a7d4-45ad-b769-2be520134586"
      unitRef="usd">8006000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i83673f0de9224acfae001662ab57801f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzMyOTg1MzQ4ODg3MjU_2e6abf7f-e690-4d54-b045-16af499cd98f"
      unitRef="usd">9200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i627f74b4ec984553bf1664500f452ad0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzMyOTg1MzQ4ODg4MjI_8cb38e91-cd11-4c43-9710-7d2bb6f60ec6"
      unitRef="usd">5300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7798d7199db145cf9eee4dd9052c2e1b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExODU0YTc2MDA4NDQ2OTU4MWE3Y2VhYjQ2M2Q2YzhlL3NlYzphMTg1NGE3NjAwODQ0Njk1ODFhN2NlYWI0NjNkNmM4ZV8xNDIvZnJhZzpiYjMwYWI4Mjc2MmU0N2U3OGNhMTdiYWUwMGY3ZTE0OC90ZXh0cmVnaW9uOmJiMzBhYjgyNzYyZTQ3ZTc4Y2ExN2JhZTAwZjdlMTQ4XzMyOTg1MzQ4ODkyODQ_0e9e2c15-0cc9-4d8d-89eb-6208aa6bc26c"
      unitRef="usd">1200000</us-gaap:CostOfGoodsAndServicesSold>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MMPF]B?"E@J%C=A2/R-S W")2D9%,A%%;^!]4<\;1I]\PDK0D29N0?& O9!+
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MM'1J@;HFU<1PQ)I4E7)/&\G]1!BNLH.]W=>R'=5*9CAB#;-2[6DCM4^'CHS
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MY!E_-:^TMI5G7W#NC39P =-WQL$5\^R\Z+SH\1D1ZE]S?"(GCY/SXWI=6>)
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M4KT&:-Q4;R6>2/&6YAQD="U=.E>!K"=%M=%?G0BV*[>^7YD0;%L>;BA):*$
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MEQP?FMP<.HNE$!T1Q1YUZ=_%>>"( L5"T'<0#;@9R>M@9PY%4 _ZQW$X%3%
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MW6Y A'<]L6M<+<8R'4%*?LW"PBN@$+ VF7Y [+3;82?IB$%,%/S"@"P'X:!
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M$V8<:C2O--19,B9A5U N?7='"0L\T_IHN8W4=L5E#2#$2CK+,AM32?HB&\?
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MD5O!T7'065#<8Z&7" :>B]+-4=0H,&1UG%,R>Q3&#QNNQ3&(/0[.<]\[^0%
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M=R+ ^X6&1YL'$M#]1X,7_P502P,$%     @ 2(995!D^K?*%!   E D  !D
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ME20(?4+8:]=OOO?CZ;&SG=\'QAF$U#TM>GN%4$6KQ'X,]J#E_F<VD]E_9#.
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M$V9*-./UGL,:O;3-UOJTIV$[:4DD%KRB)>+6Y:2$DF!7$D '(@4(*S0%:^4
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M%)@7F)$R)*$.I=S2-T"9REV>!ANB,@OX/L$L'B3Z9.F !5R07QI(_-ZE*F"
MH4_N=U8"P,%=:6YA,3'4;)"Q 2&# 8X'4H;@7IILF<"E*;52U ,,T4O>RC10
MNAR:8,PC'[XT8RE+=FS@2*9KHA7=@7>3Z6A:J?C-1D&1 6B4AW)OL.?6+ 1V
M*K#6#HG&%O :Z05 R6HE4Q)K>8O(66.MG:]"L;RK"]3HL,A)EA&6E00+B[\C
MTHHSBF7J["^?5AQG4?MU]&XD7OKQ!_$3:Q9(_4+K)%#\RR'C!.70F6PN]]X\
MJQ9;$SUC#DMZ^6#X6<"=DZ+Z===",[OY_-;22I,Q9(0-N@'(CU4"\!%@^K'V
M ^N% #?8$Z1JB?=+RBD@X2'FT7(;9"4$JD7FE5GE%:WROK9*@=V( @'(/C9\
M)W>9L6Y6R2[ARX#;)HFPN(9.WA6J8X6Z3R2+]T;PH%LQY$<9NU7%>(%*@WP+
M:P AAS\^@T,-<Y8:MC:P+W$($_8[Y"-CK=U"FME8^JO,8KLW"K_8G$*R\EB*
MB6OM]!F+)<%A]V"?U9X.9BO#J\@GRR2)@R ?&[M2M7EC0(--D)L$']CB NE(
MTB1X-["+H0C].[#K9B,Q(R4+ W(2";4,<G*D%<)B!QE(2'$ <GU(<ZT2.X?5
MS&@JGC@5S+7Q!:P*A N5T6)$W8'D 7ND4UJLD=,:TD+9 "\\%90&LN%-W,J<
M62G@G-02)89Q!3TA;)$*.':OP?$$ 5.)*LL (;;,-9(#F&6"U*)O&$OLYR$]
M="A&0Z*,Q:(UB_<&((R P>* O6UY"8D>P24^,AX=1-R"N3 Q;%#M_F10V;$P
MN:X6-0I!S<,\R(J?AZ2I'2$TI*N(YVI4-R[3$ITEN4ENY!YJU73>, ":*4NR
M"F-0V*02<7*%6ZNPY-4P%!$5 VKL \. 5)*A+KEGPQ&JE(1Y1,%!C7;=DD?C
MJ]W8Q3\AL,ZFYR+?V063P$0XAD@4>JJ5(GN8I" CX8_0CL.:MRRJ1G3V;1A,
M8Z:B \!+"I^:$MD/>B,V^7@361"8@I"UGX8L298KX(=<)WM&TCB9?6'2]Y F
M$[)G'Z_J@]$(Y0XU0U@7_R&[9L?5C#@PJWA96''RYK40F'(N/0R0,8P%>Q"N
M1"%CO_&O914'&H5(]SQV/_]*9Y:G"#0*N(UE\?Z_V+27$SV82WYL_23KT4?S
M1J5 I\F:\4C\:R.!?)U@V(PH!O=':@ZDPV80NJ$XD2R2,5>@_<YG,QK*"*,1
MF?AZXPB]\5.ICV&N8_#!HR7R/[,HI=/)"DFF;NRMC!2DE#*F)E_6,LO(O_9S
M%P0P( VE#2G90Q\Q.UM5OUUAZ\G<P=Q?R4)7Y&O2Z@;I08L\'&=7@8&S1ZZ&
MW.]1A@9@ GO![CGLKE2&Z,B6N8W^J1CY,'2E[3;)UPT13\-UC#SO<MP'8BVV
M4/$]P@N'$_]K"KLR8?*9#AA+]6UE7_/YR)OQW@Q6&RJ#<QM7(*/SY6\@"V\8
M_H;,AB.81@IA%:9,HT;XBL&FGN#4(W;@XY-TM7PP6:?,>.QFN-!,XP<W[9$C
M*@5\D(]N8!PH%)%;E6\ICP3181EUX9.[F.Q;BX(@,3&RP2E685=(8@84*(EC
M>VC"N20'67X;<QY9$&7?4S>J0'U"H5:/:@6),)%&Y>4MY8DVF&R)6%D(\CFF
MX73&B&8A/*=([+TQ#>G0X'JF2A&+L3!4"!E2C)*Q1<H^-EYYMK^@78R88'37
MFG"\;J7$?42Q&ETED%6(U][^F(R-UFKH,-GTI90U-WC GV;D-L!EB6P=VO3P
MC ^TZ'>U189Q5F9XO0D>"Z89?GX@/SPN,B\J;M8M-FLV]*(6NG/UJ_;;T*J*
M45RWD1/M6\H!></\I:P5Z'91#C\2!"F7W8!='G-1J:PC9HF#$)XUIXYU*],8
M87D!E?E ^*YRHA+)=G*M*)@9=@XPC"LRVX7N7R?1-2VS].,/:;[+@CN'*JYX
MBKSESI04DW3MQ^H/X\RLN62+8NOIA:DL"4Q6U$1$<1_9#'=)JX;HP5)097I]
M9*9]DCPCP\4RP*:W+AY+9$?( ZDV3MO *I,?M[0 P"SJ]A#8DL8@8620- \I
M6)P7'(D;*1-YNE*19C5Q\==K2HRR^PM."R.'9-A*<Y/8#ENK4"(02N5G(38+
M>1=YZQQ@4M=EA*M]:_(4OGB#'S[Y=,#\"DG"6MH"X0JY[+Z;/>]@@3'9'&$V
MM@%P54G\<#YK;'UM1LL:/, &E'7YPV: *WC,VQY[T$&P7RJ87Y/ #1)P\&C
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MM MYNX36Y7!30^@%)66[)N=8+C91G%7Q2VR5>DC-KF@=[)P$FWIJNZ.B8P_
M4CC#L6S>ESPIX'M<'Y;*+S]W.VP=3RSD5_O]_645[75!:ZG,S+0X6V-PR#>2
MF=K9&DSPGW>75<.KO34Z%TYT'_!(8<#CIF'7=4?I6&*]8.70GF6UYZ4XI+2A
M=AX+O@5?(<?"^5MPR]-FA,J]VFB4^5^X$R6*L=A0@<$ZG:'(8I^P;D,*&U.3
M@9'C4BZ2\1C"6#I/\Z5&L8U]N=&!M*X(M/&V:DW4*T6S1S6G%*HG>;P:]X_6
M>7*<;%$T.^!C'*!NE/>ZT') R.;:7&AW((+[/V;\DTUY7=//.H!E5"DA.?I7
M=TX(HO]VUK]VJ1ILW',K=K-XF_<4S]5TY5W-KOXP3-(]>6V>_FU\5 [7'D^&
M"[@.^T>'/1R6\0:?!L$V\=8\M0%W\/A:XD\/.S' ]\*B*W8#66#U-^KL7U!+
M P04    " !(AEE48*WF5:<$   Y#P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q.2YX;6R]5]MNVT80_96!:A0IP%(D15T<RP)D)T%3P+40)^U#T8<U.9(6
M7G*9W:5E_7UGEQ=1C6343NP'6^1>SLR</7.DG6ZDNM-K1 ,/F<CU>6]M3/&V
MW]?)&C.F?5E@3C-+J3)FZ%6M^KI0R%*W*1/]* A&_8SQO#>;NK&%FDUE:03/
M<:% EUG&U/8"A=R<]\)>,_")K];&#O1GTX*M\ ;-EV*AZ*W?HJ0\PUQSF8/"
MY7EO'KZ]B.UZM^!/CAO=>09;R:V4=_;E8WK>"VQ"*# Q%H'1QSU>HA 6B-+X
M6F/VVI!V8_>Y0?_@:J=:;IG&2RG^XJE9G_<F/4AQR4IA/LG-;UC7,[1XB13:
M_8=-M38*>I"4VLBLWDP99#RO/ME#S4-GP^38AJC>$+F\JT NRW?,L-E4R0TH
MNYK0[(,KU>VFY'AN#^7&*)KEM,_,WG\MN=G"9\5RS1Q1>MHW!&RG^TD-<E&!
M1$= P@BN9&[6&M[G*:;[ 'W*J$TK:M*ZB!Y%?(>)#X/0@RB(PD?P!FV9 X<W
M>+S,O^>WVBBJ\Y]',.,6,W:8\?=1]V006"A^SPS"0K $J0%,=QJN<_B]S!'"
M2<6.!V:-<"FS@N5;2.A3H,$4&!0U3M'BO/GYITD4!6??1'#CX=DO8"0DJ QU
M,S5,HC#E%HOG]TA25!KD$AA-K58*5Q:!WF,OCNW?$/2:*71K.BE9Z'!\IFUJ
M&>5/.,D=,%,EF#B(DWCH!P$4J"H,'SX30$Z>5"B9(*;:)M:M<ZEDY@:^)6N#
M"H$5M/.!4]NBV,)).#GU3ZE_A" */6!+0Z%(JB5QFJ]@B=A&V+%%II0;3?6F
M(&E&4:9+5'8]/I IZJK4_T8*_+ )Y-MT;<TWKN:/6I=$)CDIS!,Z=\W=@<XU
MI%Q3KVO'-/PAJ9R!WUVC]P^95T##T[$WIM[;T;Y/L:6<W#-%Q5P@&]C"L$YP
MVD3B*LB<;>@YG8APJO+A"[6RVBAN#.:P*&\%3Z!6ZW7-@W9B9'E)=@ZC0W(D
M NDT;%G$+@FG;$ MBXQ$5#&M4# W5)^!+9#EI W+O6:BUEDP";W1('J"SCPX
M"4A9(11,P3T3)>Y$!F_L[KHC;.K[I]44V;1&I<E*LHU4*E:(.+/F>B>/#5%_
M$I\^5]+'<WF.MO<HMT*3):G:<S01S\YQOD?B3B<N;XJ;M:=R^*3WU<&$EK B
M;[,>8R=:S2%9#8-!\&O*MB +)U6BJRA5LJ;O8"@+^SH*(R^*8V!IZM3,Q-%>
M,-T#:XMTI^F!0*V/\.2HZ5#E'Y5\V<T='U E7%=E<=640$I9ED(XT*86<FH:
M:4JI\C\@%M<B%J\230W8Q#DHC&CBQZ^J"W^TD\5UZR:GCJ7@!8UA5^8+64/P
M8ZV!#F;X;&LXDLMA:PC'KVL-8W_X,LY0/M$91H$7D/V^MC-<45+[@M]+G*1F
M.+7[]IA!.+;K'WB#!J;C%'FWHL$P](94Y(_TC-/_;1G/%TG0\8E#O\/[G>M,
MAFKE+FVV>8GVZF;3CK;WPGEU'=HMKRZ55TRM."4H<$E; W\\[(&J+FK5BY&%
MNQS=2D-7+?>XIKLM*KN YI>2?HW5+S9 >UN>_0M02P,$%     @ 2(995((9
MW)(Z#@  W"L  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULS5IY;]S&
M%?\J U4N+("B>!^^ /E(FJ))!"L'BJ)_4-Q9[<!<<L-#Z^VG[^^]X?!8[4JR
MX10%$J](SKS[GGFUK>I/S4K*5GQ>%V7S^F35MIL7%Q=-OI+KK+&KC2SQ95G5
MZZS%8WU[T6QJF2UXT[JX\!PGNEAGJCQY\XK?7=5O7E5=6ZA27M6BZ=;KK-Z]
ME46U?7WBGI@7']7MJJ47%V]>;;);>2W;7S=7-9XN!B@+M99EHZI2U'+Y^N32
M??$VH/6\X#<EM\WD;T&<W%35)WKX8?'ZQ"&"9"'SEB!D^+F3[V11$""0\4</
M\V1 21NG?QOHWS'OX.4F:^2[JOA=+=K5ZY/D1"SD,NN*]F.U_9OL^0D)7EX5
M#?\KMGIMX)^(O&O::MUO!@5K5>K?[',OA\F&Q#FRP>LW>$RW1L14OL_:[,VK
MNMJ*FE8#&OW!K/)N$*=*4LIU6^.KPK[VS75;Y9_.WX*OA7A7K:'K)B-QO;IH
M 9W67.0]I+<:DG<$DNN)'ZNR737B0[F0BSF "Y UT.89VMYZ#T)\+W-;^*XE
M/,=S'X#G#[SZ#,\_QNLJJ^7Y#?-ZE>U@6JVXK.NLO)7\][\N;YJVAIW\^P%D
MP8 L8&3!-Q#LUT$2_$'\O*&'1OQ<BA^SG?!B+2]+M"LI&EJRJHJ%K!M1+?D=
MP<C*G<@VF[JZ ] ,S@$!+%@(;<6+/OS1J78G?BASO(3?B*LB*RU1U>I6E5E1
M[(1<+B6[E,@8],]Y6]W(6K@!$>#X%N N!"+%G:JZ!AL8!Z-;P)V;-FO[AX&0
MF]T!HDL!.Y!K NVQ+;BA!HVE(/P6@8<6,>\A?X_%<P+SU[\DGN>\O.S1$@/\
MRGUY9HM?L&#Z18"G:ML(A#FF(=MF]8+8DEH0R@BBL>COHENH\E93*BJM :M_
M)'9DKK2.:HH*^$0,URHGEOM5A&#8<U.573.\0U21=7UO*3%=@;A:O^\M67\E
MO>6R;DD:<KTIJITD4A<*I+15W9#JP,Y2Y=H2^/F3W(FR*L_-!I$M[E3#"VJ1
M@R6$MJQL9RSC-?L(,&]6NT:!T;(Q5F-,"]M5VR#2WS1JH;):R>: R$GK:B&Q
M>Y6UO!^!3:V[-;1Z6\M;&(@H.]8\%-&0]^X;,2G4C5\V(&N]AKBUP+!.UG?&
MNNXR560WA63=JJ;I,NA2=*!#JWI&DVK(BB+\[SB.+2X9X6" )A@Q8/SA6',3
M$$A[,.R2)=56;58 KF\[B-Q%P4FHI.=D>-9,L7ELM#<5NZ=@S31T6L;> [%!
M6G"R: *<EKL3Y(>066(K:[DGI&77=GBIF6(P4T,\(CI[B$3M;J-R'2,^;Q1!
M7[;8$))9Q&(G,Q@8 ;V5I:QY'=RJ%0@!X)46!7J1)6ZZ5L@L7XE;1.EV4#:#
M9?^R>"NDK;U#?I9U#@N&:<'0M8$U3!,XAUN!#.10,@QM;RWJB]'=]2I&-0:C
M6<3%PUJU+3RE-\.W51\FWAM'TW:^S%0M[K*BXY7,PD2$ XY%5[.E8 =Q++0T
M[RM^BQ!+?*YUS!R\@.&(!3E*UQ"D3+PM,H2&ZQSQ$]ZRKA:R>(0DH^:'*&N.
MD.;T-NFF7T(C(F%9K17LM\C:EC35T_D[%U&T';: FA!@4"WV9M4U3Z>KI\X:
MR2/59A3?.<Z_T')E#OCSA\_D$H!$)B*>(XHR^#,XD,>9Q'5?BM .V7OGS\[L
M^:-J/ITO:YB(@B I[(N:>'_^[$PX=BR>]?]Z=H!_![1W%42A"DHUM#((;1>?
M X_7!CZ(> 8;HW )AG9*%@M>QYB]E_=^[PERU/X%AP'R@(EF3H6;V$F,7_PD
M^ GM.&:SH3S=#<J<1SN"HZMY]1^M\T&\/PUQ^UK'[8&BRYZB#\97K]A7?YY$
M3M"VIU W$9&5^*D5N$1D;$>^^+XWU31*K1AZ=%,[=@:PD(]G^0YVA.X9A45?
MH(Q?2D5;GKN)8Z5>#/7ZMA\\ACP5H>6[B16'J4CM-!Y0)T%HN61"B>W[>ZA=
M8/"#,]":1E/448S4@O=N9/OQ(Y@!VK?B)+32P!5N:,-D#6K7\GS/<L*(C,2=
M(7<M/_:L, (2IG:*/ FP+SD3'@OK$>QP$"N-7,M-0V1%.X@,%LX4!S>X5A0E
ME@^RB-R43:C/X>2*VWV[9!L\9QL<393-S1@9%2@4Y,>H?2-1@Y9,,\7\D@.P
M=GJ8X!8='H>??G\?T72FH%_:M!Q$LA^"=3H\:,DFO]TS9=:)>$],?$=,_,91
M]J<9X?<UZUENY%N)D\*@(]N)#ZA6.^5O&@CT&H!')_#.X*7NGEY=*TU8X6'R
M"&92DI=ZY$YD_JFOTP/SRZ)@[0Y^W2"0Z>:?L\0-2AR6UJ&2YQ"V%V.',EEI
MWDT-ZB-U8B3H>6AHQ//3,Z.&*8Q[>O@H:0Q!G][U56J''/,/M43X_:<.YX^%
MH1[-E*P_ TUL>_&0-A+RZ\A/H%H'V0'.1A$NB0Z^P^(Q(5'(BT3LP$6#!*DJ
M2<GM0E]$B%8!Z==.''H%ZZ*U(TXOILC@AZF%DDH$=@(/#PBTZWI6G*9X%27"
M0W1T>.V8])",@A0($&$<AU)>"E7;08R0DL &Z14")B)B&-/:<)(>$4(<$84.
MS ^_%#*#A*(*H(<V<.H%8\SQ[3CM \\85SS;2_K@<J1.UJWOV$,@$</'T:J,
MY0^JS@<J=UU*FH*@TN4IU3?S6OO4CY"EI]7VHWCS#GU=V7)I/%K8G))#B%P[
M,HAT-7< -I=T?3&G<[QJF**%0JL.M#F%SG8KT3:WIB"$CW^2[0CD)UE]+ZDX
MRYN^W)ZW5H;+O4J;^K-N'WW?%,K/+0T65$OT]$VY*L_QZ1QPY<[NNW)Q>51R
MM=Q03X=6E"'JE]PU;JL.I= *Z02\29H3YE)-9@F3V<<4YR#L5<;\#/J0_ C!
M#':AA55D, 'X.MO'(MN9@HAS!G=(0,1ON#LJ=CP>T*5/G[;RHFK&H4$OMU++
M#1 /ZQ5]5-X5.O9"?+KE[VDZ]0/;]0[#?4*7/)VLS%WG$+/T59.H.\^Q,3\H
MU_ON-"D<CK2W]PW?1?D[,WN-^X#Q&[RC&OO$KKUB^14=PP$_#**1($N<1LGH
MEKSOU ]M?UPP[^I_.."R [6]J?0>J]D<EK&)F/F'UCU73!,( MV>WIMGS6IT
M@V5=K2?INO<'<LUAYR293X7,<,!]+B4ZX_L A_U$X#R <0DUEQP*C:GD4-@$
M<\FYWN2-F<)]D<+VY3VR,F]]]PK#KV\I#QB(1YW:R&:,AG#&93@:S)>1:]3?
MEW7?DF;7G:DF'#DP-(</T6QF?K"0ZK;D@G$ZGLRG\Q-*JF5C!@&ZH:PS*I7.
M:>I-X0T>P(.@<2IC\E!-H]@&]:Z@Z1[/=V2MJ@6L5D_"#Z*J99'U:7QNI5]E
M8T?D%TV#PMZX[W0RDMN?O=%WU?335>!7I1F*Z='E8HTZDT3$<_:>)5K?1_<2
M64<MF+]KFJ>O.45RJR+U@*PY.DWD4 ]'/<21,YDB4NQDL^S*0<6+XRK.*YIX
MC$*?M&]S^1OW.S9-_&6E&@U--;-J[$:*"2%L+-G06)Z;QE+;!F<N%&FL9!N5
M^S"%UR9SJ>=^DRYUG#0?[U?%H7YU,N&?\#POGA[M7_<CVJ2?G8U@OUU3.Q7)
MD4G-T?;V:(_IHG5(J$&@45)J.^/8PO,=;A+0C:#Q'#I;-[1BUZ7VU9\/2SPK
MB-,S@>R KN9!E&A#_!"=!3<'<3AVTT%J.2B3T)$$X8@Q"2R7!T">C69D@C*A
MYO@,$ G(0QBIA4]=*TE=ZI,2;QQ(^9$5H1_ST8Q[ T;/]:TX!D;?VQ]&13XZ
M&W#I)WWW_E#SGH2N%3B^0/.!_NMID>_>Z=,W"W[I-+B=^F,.U]M.O6,)[_\V
M^*$-]O^$X'=/!?_#^!>9^/=^C OM2M4+\4>7U:T.!&/Y;S*ZH="<*Z(!4U5]
M7DCHC\J_O.,#44+% R)J,#5O74G'?\_[9N_J^M?&G+R.K1P1@G[>"N$I)DKJ
M +15[6K"TL.QET@_#0*:DYE.O=OT13)*?P5B^5R;-*G6YOC?5!!YA1:EKUH)
M:W^:A-UUU=VNQ-\[5"4(622=0)NLD<:4Z]LJ*V:GI$M5X@.=<$R7M5E]*UN=
M62ICI%@#:P->]$_W#-8RR+5JX-6/*2-##ZWMI$\'/.N8GL60A4$C-H6@1X^>
M+-CP<7N?F#H!(K#L4F2?=>_33W;68;:0D["*ONG5E#?#$1TU["!)P43SUG1#
M,_C?#;(?,=FTI!^^:$VWY%Z]B+I:/E6\G$F-&(\<ZG-=/%)\UY\!H??=F=J6
MSH=T[.V)@4FK6G?=94XCCMX0#S3IWE,U=R 1S$2Y%WP?K=H?2"BV^+%:J*7*
M!Z5-+Z>P9H_57D_CA;7<%7PN3= >/I;=GWO</Z8=+YWH0 &#(SNDDS@C>81$
M% EA&D\OL1C5<RPQ2^^?HVIC=AW7"N/@T?U'[$@'LEJV(-K$L&RXTK''Z[P9
M T-5QXA,IM?7=?8.\@RM^(^.8 <%6OTEG2'+H(F)IDD1=J-IRHKC=K-=J7S%
M]T@4IT".U':ZU_>/S>=X^<:HH\=V3+Y'+]5,"XU9K7/,P&SQP=R!T<9YU=7Y
M*FOTO:>9:)L-!1N^PO#P)I/^/EQ?79GT9_7I7HM&%NI6T41LN+%#L4]L#)C]
MYB'C4?XSF$##ZAV',?=FN7U/_$1WYAM?(/-+ZL*'>^)Q,(ZRT-E7NG-\#')M
M!F%-!]P0!=W7Z:^E(6!M2+(<A.F@PDF1E%T_H8->[7&!:Z7H.HB/KY[\[9%T
MZ#+@Q>3&Y5HBJ].]4BK7H!5]^7)X.UQ=O=0W-L?E^M[KCR@*%+)?(9?82EW'
MB;XU9A[::L/W-V^JMJW6_.=*9K B6H#ORZIJS0,A&"[TOODO4$L#!!0    (
M $B&651GUV06?@T  +LE   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;+U:;6\;N1'^*X1K% FPMJ65+,FY)$#BM.@!#1HD=[T/13]0NY26O=5RC^1:
M47]]GQERW_3BJU&@7VQIEQS.^SPSU-N]L;^Z0BDOON_*RKV[*KROW]S=N:Q0
M.^EN3:TJO-D8NY,>7^WVSM56R9PW[<J[=#)9W.VDKJ[>O^5G7^S[MZ;QI:[4
M%RM<L]M)>_BH2K-_=S6]:A]\U=O"TX.[]V]KN57?E/^Y_F+Q[:ZCDNN=JIPV
ME;!J\^[JP_3-QSFMYP5_UVKO!I\%2;(VYE?Z\F/^[FI"#*E299XH2/Q[4H^J
M+(D0V/@MTKSJCJ2-P\\M]3^S[)!E+9UZ-.4O.O?%NZO5E<C51C:E_VKV?U%1
MGGNBEYG2\5^Q#VOGRRN1-<Z;7=P,#G:Z"O_E]ZB'P8;5Y,*&-&Y(F>]P$'/Y
M27KY_JTU>V%I-:C1!Q:5=X,Y79%1OGF+MQK[_/NOZDE5C1)?56:VE29-O;WS
M($RO[[)(Y&,@DEX@,DW%9U/YPHD_5;G*QP3NP%''5MJR]3%]EN(GE=V*V301
MZ22=/D-OUHDY8WJSWQ%S8\U./()7"W> JGTA'EG)RHI_?%@[?O[/9PZ<=P?.
M^<#Y_Z;79XE00+YQM<S4NRM$G%/V25V=HRQ^*A2DVM6R.OSQ#ZMTNOS!";\W
MB)K:6"_7I1).;1%+W@D$LM@7.BN$]EC 1/ZM'#X&NM(J\6KZ6CR"&YW)4GS#
MN3K#"EGEXE7Z6GPI).*A>WX;CC]9'D\4M35/.L>#)VFU:9S(VJ5>.:^KK7#M
M%F]$9G:[!F(=;BC8<E%+7YC2; ^@0R&,98DP57;RK#"NUAY4^QVE7.,%PEQ9
M564J?B<Q9"9SM=.9R,"ALBZX@E5ZMVZL4\PW^TK+<RT/M$Q76=GDQ#.$H$6Y
MA@J]6.L20FT39E_93(,/7;G&2IR;B,\JA\!0+)UM? %OVYHG9:N@(*8=& /S
M1#<J]4C3G4I=4Y-AP18OR%3C6:$;;7?$I, 1VHK<-ENDJ">DWKHUQ=9*+%D?
MHEE(E!,S$",YL@D^R/( TL%K>KM9R!>6D5M*FQ6W9QR@]=1SWNEJ14J"Y^$H
M+;>5 0_9@ 4HJU:6J@Y6!%>@)"[V5GNO*F8:I__6:!=B@)8*<"DKP3G?&K C
M:,&3+"%\T&BD26819EWJK>3-&ASAD]MHG!/D8MX#(UV4$ _8".V>9;J03TJL
M%;CK62=BM!Z*0J$8KLE5B8)DL09N3TN,S94E0]3%P6FHIV*>W?G#B#%RN[!_
M[*?)_]-16S-KQXJ"$#F[BRS+-FPZ^Y&8<F<:$%/?X0(^<+]6X*<L^7L2LU-F
M4/ES#KI=74(=Y+Z0G%Y ?D(%./S'B^\H^9%WLNR;F + BO)[TG[@PK4J;,U$
MH8!:CR?M^<%!?._#D7/.5A!8:3)H*V"EML9K)I!KE_$9R$T:-<9R=$0YB2;1
ML5JQXGM]RPIFUC63D/F_4)TX;P]-.ES"&H8O5122B,*>O-F\3 9_J(G#\B!,
MEC4Q)R*7S":T:C%!2C@XHAI]*.2$E[L1EM)C(+/-#;AO?82>Q1,7?.+#A1.#
M/X==MR<I\KFD<RF=;E4%'9'DL1KHBBM1@ FQ.!REVBS"!C".!4"5]#^(^OCU
M;ZS86/BZ',DBCI-H'\[0W)9$A/AY$PW&%<A42NP(71%)!^G J3B 8%MXHT5#
M[/5UG+,E5=(;L[F)QY"?ZD$X5LUN#8:A85KHR)IUJ?P@'KPA>W6QVNH$^:9L
M5&#@V264%?J8Z@X>!$0?!<1'(-;2P.*>,1E3)7J/4#?"JX'Z?ZW,'EK#1@.[
ML *XSFRHT$>2-^O#3<<BJP-!HP"2H/C>XB'6E&AJV("P@"*(L=$5F\S[,D"$
MF$0X?._@FZV?[G0)H6$Y^$$A/0#[050&ZU%PJN!.I-RH[ABLYTM3M')0)BF(
M"\*0+RIZES@C]3>N8=\>5C%XD8!1U#@S7W2'-B<S_ZX7@/$$\FUDK/-%;_:2
M?''3E)NH$J(WD HGY,0#:R%H?>S.R&9F%(XAMCH3)0!!Q!'!RE+G(6"<1X*,
M $97H64%>NEK%"60,^M[3$P,.0.\'*LS8V<R'TJ4C&H.J#I8EH #Z3N6<%=#
M-F-?N=="^C,V'C@V]Z. +N18L71&ZV"G%+6!U SER$P-Z+8L'5IMC[D9,8#"
MV(M/Y/D=<!#MS=4-TA)J"*,=!GJ] @9RNT%)X$H"Q(7M5@%;45Q1/]VE'1"H
M!X\C&5(NG8@SQBS9,6B(DI^(.3Z+6<5!O?MNCH]E893*8?,/U6$0T6PM^DJ!
MO@,4TS#+I9B+#A1RP!J>%P)BF$D9 XUL--(<%[^,ZW\+A\A3D,20")\]]KQF
ML!MHYHDP'JQ!T*(TB-QQS'3@PW69B*8X>5/&F$#1Y.R J-K%!/E<7ORE0!X;
MQ6C<V1?,ML:Q(0)U-X3KQP5(6BITG*,2IGS":#+F,HE**0,HDZ[HS[F05D?:
MW8S:FH3-@,21=)OAODAA<+Q87(+V!ZJ'?4FY6QB7@;TV4/N'F%\[V,K+\J>3
M0]>*$7U04\Y^D5-#:H-1.\666D(5G ]$A]40RIRKL/:C+)GV-QKUQ*(@G3-9
M )L7O"96\9-3#F%AWF2!C>$BE8^;#->L'=HH:)SLW38VM_T8!6PH']:BZL'_
MM2NBTY]1Y[KQK/>#\A%\MUU.=H9@RV/7=[6XBP30U9/16913#BQ)*@^PEO/W
MH#.!Y?*<&T9R7[1!7>EW 0V;]1@*)-19[-!=07B2B)(H5\:=#GU&PGQFDH</
M+.&^@*,@>S3!R,3;#BEZ4'D)-2EJ5S='%;!SJP&Y +-'6%02?4@Q@$H]0:"A
MIP@9.2V75*"9QQ**#4F?/(_8JUIEXVA@**ZQYQ97IKHYWO 9*ALP1IN(!Q0E
MTOGZ,#(7U*0T5W"-AB$GIZ5&PW*2M&$,8;H @G]0L@C))D(XU;4'0Y5%QGLV
M>"1 PX.81* 1!DFQ/K:IDDW986]%8(3096%-LPU9A,*.]1ED"C-DV)+RQO$A
M3*T+DYYPI:@;E?80)ENQH' M!O)@^3F/"]/X,UAH@^1B]JR;,,/CR3E/ZWR+
M"=T05D3;)"/_&?MJE9_/.23"<7\DF?@G",&XL)W',A%\F(A7; W4)#QQK]^$
MM_SF,3I+Z)I.0IL&C-=BFBQG*_Z_F,_$7TVUO6$OOK0I?2W2V4*DZ Q_XC[A
MPD*B^+"<A_^SV0DSYY73,C5YH+^K^S,,7=H(QE:K5#PLCQF[L.%:/#Q,F;WI
M_?U%70W-<RWND^E#BO_S9)(^/*.LX:Y7L]?B8;H4RVEZ06/C,Q9)D'Z>+.=3
MUL?7=J(38R^B\%$J^*_J%>GH/+&7$)E=(E)V^GAI(?UZ6J(H%F@?=]F"DD-^
M&@7\=Y+$8)@^)!U(0:Q_>4;-B'54R5"D8I.P5NC]*WJ >%,2,)R.%GL$X/7\
M=D[]9 G'2<1U>COKO]'1>)+V3ZC^!2A<'KB:4-F17?=QP1U?(&\G+IIN),#K
MZ>UTP-WD=M5^"\Q->^:.>/O4\*BS/?;RJ<.L[8#SJ"#5P%/?>:: (G(]7?:'
M:!K! 6"H_:A$>#[D1C'(HSA8R^S7TFQ9Q4?DTL6R%XFRNJ=Y&Z-=&FE"C]V
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MO-L[]G^J*78P0^2X]&>OO<_%Y;?AY?N+D<4S,)M?G_#PAAZ=7OH!V*7W:;(
M(,2G^22YG]W3IVF:+"<S2DDG5SEBN4J6RYE8+I+[^XE8S0 0E[]S2[A,D\ET
M(A8 D<L%_YO?@[5XV[-$L9[3\\DB0M)3%<XG\X2*^FR5)K/94LP6 ,J+Z8E:
M5Q/@YZ58I,ET.@759+%XB$2'!@.>7<V36<K(=CY/YG-J.N:35;*:3<2Y'WO<
M#7Y0 YUL^6=#U/4CR,)O:[JGW2^3/H0?Y/3+P\^:/B/.H$YDH VV3FZ7]U?"
MAI\*A2_>U/SS'+@4XHT_%DJB)- "O-\8Q&/\0@=TO]=Z_Q]02P,$%     @
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M^;N3\_#UAS&=YP._:+6Q@VM!DMP:\Y6^7.;O3@)B2!4JJPF#Q,>=NE!%08C
MQN\MSI.>) $.KSOLGUAVR'(KK;HPQ:\ZKY?O3M(3D:NY;(KZRFS^H5IY)H0O
M,X7E_V+CSL;QB<@:6YM5"PP.5KITG_*^U<, ( V. $0M0,1\.T+,Y4=9R_=O
M*[,1%9T&-KI@41D:S.F2C')=5WBJ 5>_ORPSLU+B1MXK^_:L!D:Z?Y:UT!\<
M='0$.HS$CZ:LEU9\7^8JWT5P!E9Z?J*.GP_1DQ@_JLP7<>B)*(C")_#%O7PQ
MXXN?E4]\U#8KC&TJ)?Y]?FOK"A[QGR=(C'L28R8Q_HLJ_//0XF:IQ,7YU??7
MXCRKA5ZMP:+*A11EL[I5E3!SL:[,G::0L/2M!D -V3*3*T_H,BN:7)<+OJ\*
MO="WNM#U QW-5%4C2.&R><,1884L<X<!X5PCTFHZ5R(3(.8K61,B*,R"L=%W
M?TNC*'CST\\_6+X,WYPZ<")>J5PC-3QB/]>Y*$V-T+4($3 '@ ?X;JTJ+0LA
M\]_@WD35BMHP'Q<&$I</1""<OK$D#^F&:/1B"R0B/OR@9"44N9V TRC63^<X
MGJ!#1H K"E%5@4-&(R$-[DE6WAZ8+T8_0-[3CO"M C$U9.-6E6JNZQTF['$N
M\#_P6$]1$,Z$9LIS4R 50J?02+TTC<5S>_J:01C"'7Z.%76/Q&R5&+4\ <-'
M/+.USL0+$8V]:1+B8I1XL\GX%%=3+YC$ KD,F:H4HWCFI7%R*D93+PPB?,;>
M.$A/Q8VI81T AA,OF$Y.^7(,V(0N8R\93\3E$VR(BP;J+NO7XI/*X4:$:\R<
MC&/F8Q0'\:FXKN$(]"":QB*:!2W=S $SZBW*CL@+D4;,3Q(ZOH#H8VO?(;W1
MI&,\\E+'.(LWZ^B&7@32HXD7A< TFL5XTFMFZHVG@&$WC-[TGX[!WITZ5]AZ
M)BL[#0-'.?6"9,J78R\>]XH=>M$CT&F4=J!1>PE0$O4<0929,D,P2RYF;>CG
M>@YN5)DA1&]5O5&J=*&/VUSNF%Q%$G>Q/F^59*&'IC;5P_;(_^#41WQZSXD_
M':>&< L"\7+OTQEHZ^C*>BXGS7O>#P1D./6G4T"'8S^:X7,4SOPQU/]2W%2R
MM-+U !?&(OI'8>"3V5_VIAU>?5:E+&I-22^<^ F?&P5^P!?X3/'QDRE?M7GT
MME"=>P(B!G4&"/TQ TSQB0_*;#CBC->'3.#/$CJ43/QIRE#QQ \CNG59ZCO4
M<W0MOS=P$8:;2UV).UDT:I \13B9^>'XB# WV_0LPM!/8MR+(TB_<^I+V14'
M3K6FI1?X440J]2,Z#MEB9NU*U4U54GK=^B^Y@X'O5(_2[2#';\E-_;B5UH\"
MPMA%7N\;G5_75"@B?SIV*DW&NT;[F2@Z[X!%D]90K-(1H%*Z^ 7Z<FJ7Y*(2
MHA+EU _8.T:I/^.+:.+(?+\?.N.QG[ BHIF?.,[A70G3.:_W0Z0-#DK]O38&
M+MO5(!Q".'.!)F]#?%MMJ=RWP>UBBHKP\4KQ<;^XO4;QS4Q#*D?24' CN*A3
M$LK";(+_R'YI0L>J!J#9T#<3+YR&8H)<&8N?]CH!D<FJ>GB%1+&156Y%&GHS
M'(QC+TW3'6=+O,DL$6,/B1@1;;*OKZAW?D0L\N+)!-S,9C/Q\Y:0PLD=U80S
M;X8 "4-ODLX0&N@@4.?Z.$HA3.<4[!) G,!0(?)X(/Y>$>.'NH 0%DHGD4@"
ME(% _* LE'=WR%\@8!#"^49 '(>GCTO! &<Z155-Q60*R6>[YAE(]'I/W(JF
MAU=F_JK!EQ87<I@7S(@L) \I5"[+.]6&/5RB1!8BKS&%SB7WB?,Y5PC5JV,4
M>D$ P L#R,IEJUS=4G-FV4EPXI1J3T*M #0KRP4?ZED(4EB2VH-HYD4)0NIS
M13Z!GI(<6"$[K9D?:A?B=';*S4)"L>=,T7,2$98#BAL:&K#0-!7?41+!+2 [
M.>&A*!J"4<%'*8]=S83SAJC^AR+3&[:98DF%JRTI^UVO\W71^SJB4JZ1\>XU
MM;#%@W@1Q:$_P5!6%' 7CTYR%CN&Z@E,88@TM,6T[>-?S!)_W#T0VE7W+Z4F
M:_\+!W*S<OVEY:KY5Z0(P\A/.Q)^7[&?1[4!".KO0G,M0#!J;E"AZ#CQP23P
M,+N4%C />-0GK Q2NZ;NZ<&9HIL6T+$W56\-&C/$ J6]8K]N"U/?EQ!'<HXL
M\-C"X13SQ0.88EZ)3LLM4,")-"FN>/#$TFS4'94.;J+:0MY/2K;)ECN.P>SL
M,,%BET?YH-2/QJC0*[84U),&+SFORWM*QZTC^VVS0WB9QG&51I'?LW&]T?4?
MJBK([O1WL=2E/ (V[HK1!!S->1YK:DCZAU/KO*EI'H:=M<G;":XG _'DFJ:.
MKG?<=3R1&\;GZ/GB_/!0=3SFKKZ3J_6;CVW->#9()MM@ TI9'_.]03R@3,!<
ML";=TMOD^2<IQMO <!0?2XQ&? ,GM4N]%MD2N5,1EA7I#.=+,0E(M1F3-$V1
M#V=AYQT[[3SE_H,3^"-.29J#(C0<=)=7%^*ZW7K%&)@Z\U5JT132C?Z4FQ4?
M]\6O"F9!PT.BH9Y0-/#2@5=^U+LW^0.I.5=P]94NE=@L%2=WQB(VDEC:5P6D
M7,.OJLZ]G XWK @6?B@TA?\W%MP7/\I2+A2;_%85&C$/SZXI--E&A?Y*=F93
MD?#,WXYA'-ZA,AW[=+K;9 "#V]2T2I:(+KG-)B[%['<*E2IDFQRZ@'@JD8-S
M:+)?M0PD(WS\W)'/##+;@/[3.Q">%DON.95$H/S>R*JFS+BA?28G.*0D-Q+<
MN4Q0JH7D+^I.YS1[N@JD222T Y63":&&3*>MBSU:#_. (0\V6.WDN6U]]/Q9
M.UGJ! !'_#VA9DZI!'3;V4;E+L^QA+580)2RVT!U(A%I9&C:/C<\ R#E+MV)
M^YKW$P9!H+/E+E0&!D''W/[F9@@P#6-PQ?/%Y7Q?=4"'GA\3;J_A(0<E<JFU
MLN+HL\T:R9C\DS8!16/[K'18IP0/L4L%Y\J/9N?!K++:NE0?Z7FKZP:=9:;I
MT3ZCW9Z/17$AR@SF'?3S$7>$_]Z?Y *^8^N^Q3I@:)_'GHIZ ZKP V%Z3W1)
MK8$_'*('[;P8^V&?\$F0%Y&?;&\\JT%D]W5G>&\8X(>6FURUO;UBOJVZ;?PC
M6S]16[^]T;ZUS?J]<[><_#^,=\QNT:!]?D[O/1];_1[?!]\,6A?,5FIG)UWQ
M(L0^:LNYI;/<[6X4? V?O4UWS.UU+O"HK7*]"F1%T6QL6Q!^:RIM<YVU_G##
MY+?EG-(38#B%#X\*"0/:AO-1IQ!-\_,:S._T'KW6:+:2&U=KAR3<=S:NL A"
M9#6DNQKD\@69RJ<UCOCB7_L[]6QEX -.AG53P1%)-X\[0GK'N-OB[Z\>T=M#
M@+U&VY'=4>LWQ,Y3W2 F_Q+J]"!JU@YA?V3^/T7B'(U5(29;](,;I!/R6Q:*
M[?%I?V]*BP(4=RIS;N.."'?-CKJ72"+.-]HI[?+J>C<4T"<76KFN4KIM$V&#
MF<N<IBT2JSFX5.S\*#/PH#_:I@6#&4)9MWOBKE]SBUWJRG?7DJ8$KV[LZE*>
M>^4ENPZL4'>R?8<@FWII*FJ%7.-V,*/9QCI& =V3V:[?<$IB'&\]?%>:E5)U
M]\+M2+9$55B:HO5+N>*M2Z^ O,L>!W1@R3STK)#5@A9>G4Y85/(-*1;TZHX[
M\=UQ@]G02V.XM;M5Q&/7_HAF3:UM4?.@(Y" Z\(IO>]R#NO0IQ<_%>VKN!G-
M5?>ES2Q-.9!KL)VWN]//O(*;;W-\GYFY19]W]:4W!#55U/K*LFWC6G-U@NPX
M+"\9<8&<9Y&LW*;,_7:!?0?#B*G;Q7(AUV[V8,.02V<\G+N7%?QD, J03Q_T
M:!<: W=I\\1Q;3S723RQ\/UR%.DK\4]9-M0LAKSB3:8!O7D;CP=&ZR<R?GFZ
M]>(T!@"AOZ*UB)6%=:^:#QQ]_%9L!_EN;-3RJ^*E5?=2CU$E<23B:<IUDK3,
MPW1;8T8Q;SNGT>F3@@XT1SMM+YYL1;[9!AE$>,(&!]>#F#L& "YES.6=P4#%
M26>NVC'O<5>Q_\:-W<(^Z09PE*Q !^168N05/%47IER\HL2VL^0T94MXL/#]
M( ON@:[I]Q^M(^IN/4[>M.Y?9CWJBHYQQ4SI53?;^MMM>_>V_R#*IX74W3B@
MRP-OL/U#O\$X&_RD9:60_NB'.YQ'RMK]NJ6_V_\VZ-S])&9[W/VPZ$=D3W2B
MHE!S@ ;^='+BUNW=E]JL^0<RMZ:NS8HOETJB%M(!/)\;I(SV"Q'H?S'U_K]0
M2P,$%     @ 2(995 &UW,%8!0  ? X  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&ULK5=;;]LV%/XK!UXQ)(!J2[)=R[D!39IA!=8TJ+/M8=@#+1U%
M1"11):DX_O<[A[K$3FQO"_IBR>2Y?.?V43Q;*?U@,D0+3T5>FO-!9FUU,AJ9
M.,-"F*&JL*2=5.E"6/JK[T>FTB@2IU3DH]#W/XP*(<O!Q9E;N]479ZJVN2SQ
M5H.IBT+H]27F:G4^" ;=PC=YGUE>&%V<5>(>%VA_KVXU_1OU5A)98&FD*D%C
M>C[X&)Q<3EC>"?PA<64VWH$C62KUP'\^)^<#GP%ACK%E"X(>CWB%><Z&",;W
MUN:@=\F*F^^=]5]<[!3+4AB\4OF?,K'9^2 :0(*IJ'/[3:U^Q3:>*=N+56[<
M+ZP:V;$_@+@V5A6M,B$H9-D\Q5.;APV%:)]"V"J$#G?CR*'\)*RX.--J!9JE
MR1J_N%"=-H&3)1=E837M2M*S%S=4]Z/?E#''\+F,58%0H89%)C2>C2PY8+%1
MW!J[;(R%>XP%(7Q1I<T,7)<))ML&1H2LAQ=V\"[#@Q8_83R$<>!!Z(?! 7OC
M/MRQLS?>8^]:Z%*6]P9NNRCAKX]+8S5UQ]\'[$]Z^Q-G?_)CTOEF8W<9PI4J
M*E&N@8;18&D-+)7-N$5E#-C%R1K&Q7GT\T]1&/JGU[<+]Q:<'H,H$TAD7EM,
M@-:'<.FTZ17P*<[K!,F"LF1=BKR1=*-$:M( 0:J<ZG)->X\R(8_0>BD9>^ZP
M2X>]]<FREL"OW+A@\EX\HJ;IA[(NEH15I6RV("<.M0$B$F/)(=LF#G+*%)14
MR1 ^/4-G@N!)-XW :\PV$Y9,UWD"*HYK#3(%FJ[X <1*Z,00(DH2/J&.I2&;
M+L;46:/>BRC;)2&U<IDCW)!YXR1H:[ICR]F*FV4DH'>[,:5:%=L@**LB)I0E
MA\7AUH8#9Q26.-?4>MTJ%&@SE3A&HHA*)]+EDNCU@?+_*/(:.:/VN5NX#,'L
MU/199F.' 39Q.!96;TW(@;AD^K[/5!N5!ZM,QAG5]'LMN0E<\42>=P"ZWOCW
MT,BSJ04#J2M:^U^QM-L["RP)S!*YMWE*J%6:"L0BC^M<V-;!QFR!(" %!_VC
M,%!*>'>)][+D8>^L::P4"=)",R=P1/EF83I,6<9EI(S1X_XFK*B/FP9(54YG
MM*N+RYC)U,J\#,OT4[@FDC& S/1 /(UN?CNN=K^^U_9$,(<CER%5&UHQ'M,+
M5G:#GD3!W6&.3YRZTVX4;Z[OB 6_+A;$@C=77[]<PSLXBKSQ9'9,;Q,OF(7T
MC#SZ"FGIJ^.6?A[V,TH0S+WYAQ "/_*FLSD]?6\R\QMFH<\%P#0E5N&T->VD
MJB8)KMG"4QA[?D! O8B,[% B?U;+F,%LS7FG'OI3"*-QSV2OH!_"' 3>;#XA
MS&/O0S!M@W]%O!LYIL3Y0]_EC9Z3YA'USM^@NMTV+QGDL<??DFL[+(Y6#HS+
M(2!+C$5MD-6E[C*]<KQ.\RC(_?O>^9LZ]54#+K8*'WC1/.SKUSV_[:ES0/5Y
M*;MGG*?>=!Q1/\W"\:;H+F*8>L'8?V5WF\.?>]!1I*@JPG;%''JG16E$W(1#
MTE0:YB^KF)GH9-2TEJ^)XNAKX@ [_;B2$C.XE NSF\Y)S747)1CYJ-M1PD22
M"V4=K6##FALTVVJF\"Z:#F?39]<-[^U-#H-CJ^VW14/S_R6B)I*U,[#5DD.@
MNP2DM:9M3;<'*V1NNN-['PX/JIS.?F;VE+2H4%P!F-,'$"[M<-=GZVCC1E"@
MOG?W'CX9B6.;RT&_VE^M/C8WBF?QYE[V16@Z8 SDF)*J3_D;@&[N.LT?JRIW
MOZ#/3[JMN->,KH>H68#V4T5HVS_LH+]P7OP#4$L#!!0    ( $B&651X$24(
M40,  &X'   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;*U5;6_;1@S^
M*X3:%2G@Z<U.FK:V@3C9T'X(%L3K^F'8A[-$V[?<BW9WBN-_7_)DJS*P9,#0
M#Y9%BGSXD$?RICOK'OP6,<"35L;/DFT(S8<L\]46M?"I;=#0E[5U6@02W2;S
MC4-11R>MLC+/+S(MI$GFTZB[<_.I;8.2!N\<^%9KX?8+5'8W2XKDJ+B7FVU@
M13:?-F*#2PQ?FCM'4M:CU%*C\=(:<+B>)5?%A\6$[:/!'Q)W?O .G,G*V@<6
M/M>S)&="J+ *C"#H[Q&O42D&(AK_'#"3/B0[#M^/Z+_&W"F7E?!X;=5768?M
M++E,H,:U:%6XM[M/>,CGG/$JJWQ\PJZS'5/$JO7!ZH,SR5J:[E\\'>HP<+C,
MGW$H#PYEY-T%BBQO1!#SJ;,[<&Q-:/P24XW>1$X:/I1E</15DE^8W^":-#5<
M6Q.<7+6Q5'=*F&D6")Z-LNH M>B@RF>@BA)N"67KX1=38WT*D!&OGEQY)+<H
M7T2\P2J%<3&",B^+%_#&?;+CB#=^!N\>@W1(+15@@88R#Q[^O%KYX*@Y_GHA
MP*0/,(D!)C^BFO\3ZO<MDE(WPNR!IR[0SX/@5F2'GZNAPR0OSA[>TO3TB3<$
M 95]1"?-AF:1LA<F2*'4'N@!7])E&ON\!M2-LGM$#V?"'_'?IF]>%1?YQP&-
M-Z\NR^+=1S]PT(+)/2 \6M421;>'(2\/P4(@!&8S8A9_TY2R4DDM@^AL.A:4
MQ>?[):6P:=7A@S UP6E:3#YJ4C@M2J#5Y:'(\S3_">P:D++=0VV5$NX[#\)N
M&XXY/I@Q(8>^P;@I^FSZ](8A(P>JI*AKR;)0</Z?X<B-8QA\"E!&TQ/(LPD#
MT'!+W>K3=(Y5OV6!#^ZTFCMT"*)IG"5?$9#.\O5%6M#"4(H,1O!ZDKX_2I$Z
M*2:]HFYC,S"W/0I'!\D###1^J%?H^A&,SWP4 <J\>#\:E$OM.[UP7,3*.D:0
MW&H^<*:.JF):C#9TI3A*F4+B$Z=/AR6[TE"W>ZMD+;A<2VJ$V+2> 7[KG,@@
M_;=)S08[4*/;Q$W/9T;MUZW#7MM?)E?=#OUNWMU$M\)M>*84KLDU3]^=)^"Z
M[=X)P39QHZYLH/T<7[=T(:)C _J^MC8<!0[07['S;U!+ P04    " !(AEE4
M'[7X@ 8'  !:$   &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6RM6-MN
M'+D1_15BUEAD@?'<),>&+0FP[.Q:"WLM6'M!$.2!PZ[I)LPF9TGVC/3W.57L
M;HUN3I#DQ9KN)D]5G3I51?ID'^+7U!!E==TZGTXG3<[;U_-Y,@VU.LW"ECR^
M;$)L=<9CK.=I&TE7LJEU\]5B\==YJZV?G)W(N\MX=A*Z[*RGRZA2U[8ZWIR3
M"_O3R7(RO/ABZR;SB_G9R5;7=$7YM^UEQ--\1*EL2S[9X%6DS>GD[?+U^3&O
MEP6_6]JG@]^*(UF'\)4?+JK3R8(=(D<F,X+&GQV](^<8"&[\V6-.1I.\\?#W
M@/ZCQ(Y8UCK1N^#^L%5N3B>O)JJBC>Y<_A+V'ZB/YP7CF>"2_*OV9>V+U429
M+N70]IOA06M]^:NO>QX.-KQ:/+%AU6]8B=_%D'CY7F=]=A+#7D5>#33^(:'*
M;CAG/2?E*D=\M=B7S]Z%MK49+.>DM*_4N^"S]35Y8RF=S#-,\,*YZ>'."]SJ
M";CE2GT"0I/4WWQ%U5V .7P;'5P-#IZOOHGXGLQ,'2VG:K58+;^!=S0&?"1X
M1_]-P.J]3<:%U$52_WB[3CE"-?_\AM7CT>JQ6#W^?]'\/\"IRRZ:!DI5A\M^
M;>1YJ_V-PD>EZTA4/EFOMDX;4CFH[;!7J[0E8S>6*N5H1TZ%#:H0A<I;-C&T
MRE#,*'NU(U^%F&9L SM'"'-@GJZW%J3JK'8ZVM E5>D,7W,30U<WG-TC 7A\
M.QR&>6B!VC7%40]3I1D4_@2']I+47^!.;@ /5M(/K]7?24<8]Q78>;!]I9ZI
MY72Q>"'6^Y^_AJS=XTX\4ZOI8KE0'ZG&DLL8#)$ ?_;J9^T[-#4@#9[]@OBB
MGJH+#P%OK ./6FWQTF<POHF<+\9E$Z#?XI>N\2=E1##FZOOO7JV6+]\DY6GO
M;IYK\V<''BLTT76RE663%][N4/KJHX6G; 6"L'#WX9+>&7#TV^QJQF+/T9H,
M6UW,X#"*Y6IX+8P[O0?'(-HYJCG8'FMT[,+_;KE%_VACRM]_MWQY_.;YQPX+
MC?90".!T[4/*UB@D7%#[\!DM[T-/2M&/<C;;6DO'MDEAT"1\<S=*$@MU.$P>
M;$1X&5J<W='UFIR%5%E5$)K-(O0ZA,()\Y$U"@7)0]_&8.&506 -$M"F$B0H
M[(VESN:I6G>2$0@-#OF@:B0:,$3%S$&RT+N=8Y]WVKJ9>EL^9@PQCAH:D(CQ
M"M,169>WN0$JI@O$4O"S DNVU6N'[Q%H8<V_9^H+U9W3.2"?G\KZ/VQN!$^G
M9#DV(Y! 1^)9NQUB=-,[+L+&+KC.9Y0A:#7!5YWAY@&.$#=@/?BQ?L=>](F0
M.#<!XPB,A<*-J-8.)H=6 +B$>5C@0#G%G<6*@V:S9Y\W5*$VG&I(N]P8+F+H
MK/2R6,*$W32%'\9U5:$MH!PC\2=^#.A!NJNF:J]3)MFIUW!PILY1MU5QTZ8G
M0KK+R2$A2$!I>KS@\V9C2X 7GMLAR%<_D1??)7?45Q)M=90NP:\_2%3BTH>N
M!:U7A0:T)ZZ:U>+-YXN?Y-?RS0\#SOUZ?R(5X/B7L"MMC/O,G0(8-T.!?"!Z
M**_@ZP#ZH,VG&FJ^/R>,B9WT+B[%N!,VGBV7LQ6.(\[U/@4N$.4 _QR66E2Q
M7ELNY5O!8$:EX"RW_0HY<B*=*SZX)&D]V\!=0(I3MRCMHH9#H&U$64B2H/=@
MK"#MAQIX1%.HG3KJEND@W[%Z#.$,6*GUS=V:$.'Z_J X(AZHEMM)2EU?\GMI
M!A6[*U*INCA4-FHNIMO"?CR+G#2;1D)Q#N5#*N?)ZS(4QDRNN666AI!IT K.
M@;;MVK$W@/B4'B%E3+WD6S*(XAQ0>BW<$YA,#_9:"QM]P<;;WJ,[E&*4C-Q5
M2ZMO>K4H7566=R/P/LB28UXF)0P?_WV^D>O$#J*?W9-RWUOQS,WU08/KO+#"
MQQG,2AYE,M>ZV-=^,KC43$<ZXNB3P9QZ2"2C;C A6>+WNLAM?^HEA<J>JC[2
M4A0URC5Z3BI"'<B[D45[%A.N5Q"L% H[TL)A7MBS#XC";"+ZBK"-"9'M.2#H
M_XR#43T0@,:A@[G<0C!V5 [T3]?H3VF0AFXQ.O*0NPIV 5H1E[;U!S/AL<8%
M:@O/$I#<NH9TDHPWJ;9Q> C#=(WQQ2S*%! >#H9 $_8HX#CEXG+5D+9^1ML6
ML8C89 [!F&, @UYA67\;')V!,;(\Y?--C5NLU)F((-O<E7023E=9>(M\E-A(
MEH;>EE+)43\R92>?DXJ3^\::IO=P3:Q3BIS(_H!QGR6XA?!M*1"$(\B87^SM
M(8>SQRX?\X/[7DL(A6^U2>9]+E>_\>UX<7Y;[HNWR\NM^Y...(<E'/$WV+J8
MO7PQ4;'<9,M##ENY/:Y#QEU4?J+#HM7R GS?!-1Q_\ &QO]../L74$L#!!0
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MW8PFQS WBI"YUR\<SYL0M(<!-<[R-ZO3!)=;',E]W**C4^?KR(,H?]WAW*Z
M&RGRXE#2V/&R;'1_6U#:"[U1E$$QC'0D]]XJ+T],7=.AQM[DI^GHB4;MU>>?
M/WTX04G=7-V.%QDJ$>V-?3Q][:+T!^*)_R_QG+YV4YT?W?UQ)&_"%PYAW&G?
M?P:,N^-'U+O^V^%)O/\"NQ9V@TL0#KH:JM'I,I\PVW_5] _>;,.7!,Y2?)>$
M98,/06E) .]K8_SA@1R,GY:7OP%02P,$%     @ 2(995.[ <SWP+@  -*,
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MVML2!*P^0ZA_/.>G/FYRN)"#9\[^_!\7+\Z_8]DYL@V0'ZH$N!^40$#;7A<
M_((BVI5=7I'2!^7J\+XKN-I9MLM!357-NO0H?AO0"^&')<%;YBC8=P35TO4=
MG6 % EZD-3"!RUOP9EI51SO\%9SJXOS\3TJG@KY @4LK=54KU:Y3'<EKXR\>
M(^F=J,9""8L"0Y;=P]9 SFCS9F"QNNT",*!6*_W_.:\T/[_X9HJ\7@;R>CE)
M&Z]5[UT9O3=&8I/+H"_XK0?N=#\\(FRUM^[1^-J); YF S M_ "&HR_Y*12D
MR.,D&I ,[C8EH EMAQ:<'E3!BRYGX81<*<8+_'?7BYD :@[(Q8M!L,EO68*Q
MP;A',EJ"7XHZK^_X)3]N!K" BS8'BL<"H5L%T9G:(WR4%BD!GC4V*IL";);E
MHYN)3E\V+9( 6RJLV,LVZ.(B6X%%0C8.K:G4,[H@DN1,\(-\= _HC&=7DJ($
MY0#<23(P9]SG;.S"=55NC98)24Z\O19Y%UP*6I=>22RD<.=X)L]"?.0X>)2'
M(O<X$N%_)?#0#AD))?*F;(M3@ VN/1B&XFB ^0G/<KB"\#\PV("*;DNZB[VQ
MWF>1'DF=&Z,,#Q")<()%7P46?37)HN\0.;\I<J)%=UV#L]F3L!QCV,E%QQGV
M 3O152[SMMTC+84K6^9^ P+6M<B3]%.&;B#\7<S@0_^ Q"-(:"(T,GY0<8CD
M#,_O\CT_#+]I>Q?=.O:SZ.7$"<1?B\I1@DTY$.A4;\VA=,]]4Q.E)5?(# >8
M$4,YX;@"#LU:'G[G-Z"ZV$<!Z@.#[VSJTK\)E_[-Y*5?(0KQ+$-<CEWU Y>B
M?[R-2R5LJ3CQZ#!E&V!KL&RJ$IXN$GMYUX-N)+'$WC0P&\@ ()4*W96^1=$*
M^*L!"/A7D>\]"POOQ8H<'BB5#A@81!IB@V1Y# N\^2I0*+P RJ(W?-U9D0.F
MA+MU"@& A^=#\5^4'5KN-4K&@9@*[\!J,Q&R(RJ9P 0SPR&MJ54M*X/T_&S]
MY8GCP/KH;AL[<DJ[7YS'<-WYY.7_G+>?'5M6-VZ)UU..AY)^SSHI 57 O "[
M8PK:QA=\? $=D]N\K/#WIR!T3WU>)=J)8PQTNX&<"F+*A=LW@+J+.;@&&!F<
MJ8$/%F#3.@ESV+V0TQ4H)E>438FD&76:7^<5.1 W&"4EF.&1/?N&"CQ>I^]W
M:+:&)9N=^'5Y)9R#T-?.%4#D/X_CHV5IB@ "T48A,V,<(&Q]#4*J*O\)CX!E
M2UA:$X>0<4%^#)N:I'EB'&1F8@.H*L'#W/9,BR)TX>9:M\&0^:W35S&FB0$'
MWC'E"<?*4X*&XS>,EAPM?PJ,4X-<W *.T!DT8114L]D_>M#'KJW((B@!0[_&
M<XIW1M@!6;Y&[-"9.SHH&,D@7]9>W>K"H6E/QK2Q),9<V#'(TC-R< ;=%+ Z
MT3, !=*T)#K":B&0D!.D9(V.+#P#"@$;@>D'1&"][C82FNP(#6RU&9#E(#/^
M?9!N(%^*,E@G-1R?]8T&<H(!6(+AXMJ9AAP(1N(0!)$>J#L)R'I7D1F'!AIP
M%#Q2E9\Q'H1G(%FT<!K++<(+B\!KYL[%"8)=P9DJ=T1A&L0CY,(;=XX"BO>1
M!M// SVAZ B!:[O.VX*TC*(B/6FN\.YGB6J0@ '06L$H!G3'*!]%#RUU$U/V
M!X0*NRAO!-KUOEF6A(O R:P6[D!F;-AF%5@5M+/LBA6'H?_@"Q"M6]"+QK'2
M0)-HF80O2+^LJ@;IN%]A.$9P(=?"CM 6HP'_I% H,!9Q(<76(SQ3*LADC"XF
M5<>EVG*?4MMO5 O]OJ6RR['X<VMR!^1@PET>QBS PD2KQ[I:DB,0Q ;AL6PJ
M%J=#Z]\C!6,.J,,PV-*Q0> ].X_71_]F8@N<), X!FJZ[LZA8)-,!=BNE?B2
MJ=N4!A,M;3#D/@EIZ0%KMVXZIDS,@= >,["(/,@Y0HV<DP*47S!&C6#-C,%M
M&3TO_MZ+;6CUN'V$, RRK099!OAX!U<Q# I9V -\?'**_2PWKN@KL?IA/4XK
M.61<4B9JZI\N]J?![&>*EJO*ZQ CD/?-G:OCLBUACZZIZ1+H&,L-6H'%)"?,
M(R?,)\GWNL9X+V#YB GVX+<S^V^B M]I#HY"DBA8-&X&5DI5"NJ0)TC5D+E1
M44@6[544 ' M'+!"V48<))8(>MAK44FM[T[+>B;_:OHNVX*::0:&0I+84(U:
M4K0]PHTLZ;XL20X"% LPP)Q?.@W=WH$$<OZT:.YJ^2.&:L2XN,.X1%\;$\2N
M''RSR"IC)YN\U)@'OG@Z+9/8D/R+JUC*W(!%.WJ[7[],)K]D\0/,NJ-\)5S8
M8I^AY:P:(EJY8&QL= EZHE1?-CCM*E;PW8&$$_5 0;6VZ<%'RGD58*C:YRP3
M0-RP79'7X3'.Z?6X/ 940LJC2SS,[;;DT^39KLKKH)Q)Y-)1S_3(4T="P+?@
MM_<MDS%95TK*@\-*A**U5A:9";@Q/H"DC^E5MM0XP/00QX'QRI:5"2*().GV
MT0MEF-'KBW*5>,X*;S+#.DR2 V:63C<%4426$%C'.RIK4;B6$JT:X&;&&5.,
MG!?V.&!YX1](#(/*$<,$=6(P D@\*%Y)ON*BQFJ'@XJUQ/02S6&+B[P.3+TZ
MN 8T/88701>@I #W3S:X!8,0K"4 M$'4.9IL.8Q(69JZZ1<>+%E\GA.;;+&-
MA1\Y4$$VF:$/OAZ3?[+PA7*$4<Z[SR.1#?/Z_G-,B:M857(Q713R$>L^RD+X
M;%1032^0.DMHG&*R<2?+2GB.L,"HHU]C20&:JGM'H7I)=?Y"SOY !NF?ARR0
M6L.Y#UMJX)H?[YH.39BO]?*9\!CB8P"!MD..Q5LY"I082",@U4U]^O5@3=UY
M3+M?3*?*/Q!05[+YQ,U__3+PG]' F/AFF*X:B_"JT8+6(26.2S9:HOGNTT(3
MSLG1J@489%6S(][3A/RG/^?;W7=O0E*^R[^$(%Q<4M-^,3)LJDH83+PE^%/A
M['N3MQ 3N1?3:=B/+0:(.J[TP##LCC,)QURAW[U:EOS-Z=\&M-H1M8?(D0T/
M!1T1$B*L)>@79W#9$W^6 /MVUYN:%*R*PT31*85IQ--4/S3*X:04:"##WX/$
M=1C_0C'<PLMLPE-0+NBPL"8%Y8-!$$BIPD74;V@/C$2[/_CB) P"]W,%7"T*
M//CTEAHI  >KUWEUBF:0;U;='4%(83Y*61.<'(Z#BR!6#VOEL::0@M)YR^ID
M=-%9,.A'SA]$6#C2*F@37> !)OOT]>Q&R0P0%W7LQ ()-3ZX)"D80EVIZE<M
M'WJ('!E+.=9L#B'C6)=VA.IG MZV04,JP!/24H1Z4H!8]*<A6<IT2$!0G$VZ
M:PFM2N:?5@NQ8H_!*[2Q>%'*?[B:Z(*UD9KIM6<-$PA2K]_NI.</50=K5U,8
MDQXNP/ H/>4I;EW,I '4(C]-T21:6CN\X19M1:V13%25*2F#+3_$$TV)RUB8
M<#%=F4 ,/ZZF'O)B0MP5_PJ(#2..1%,KBCM0"#U?X"^;%GPJS(AZ]6K0N\5#
MWS5M5<PH? 3GY'C"P$= S<_G!U*0W0"794L.5T=E5DWO)96!N\K%5%@E=4O^
M-4FE%I/=\!,1R06RT/R<8Z$B GW(N\%=8@$2O8B A<Q(2+AI$6=@,Q''"[$Q
MJ P<S&,DSB-U+>@S(P=39).D9[YN75HQ"D>7Q%NCA0.@ZMT=P@&08TR9;%Y<
M@R/AL$YZ''H>ZPJT3!*+-A/O$=?&L'D1E^"3=_N=2"V-F['Q\5S1]C=T1,LN
M<=3V(>1SD"PD4]]]<>VR)$]68&(S1$X5SY,S*#-)/S6FS--DF6$?-?PUE#)T
MY)#W4Z=BB*J#-/9HF4BF$<7$@UCU5(K(: OQKZ N##JE_@$+9PI36H+..X9F
M"#BDXK/LFI*>),LEQBB2$HBKJ- OB F0UI7;1=]Z9X+\*.6Z@3:G>BLT518B
M6D0OP5)<%\L* G#:+YF8V+@>'NQ.0K[,BJ"2Y+8/R!E)S3>!DN'>ESV) A:^
M"C\>GVV;/!'1C]%>Y,W1Y@&WH.Y.2'C>4=;!1R59UG"YH3 Q_)I+EFF=L((_
MT2O7$VG$&>O)%=;!MI@$/ 2&<9JN/CM0&R,N[9@PJ [(4%4\)[2(EPAEX29(
M>[%,6)5?;!%_&VM/0Z!;Z3C/6$JW5,;S)7O,[P*D'ESY#K'(6 ;38B?J6XZA
MYV<#G]TZ*5I:BD%G A1\OX. V*&F]1%67=]WJ?W4=R7:=AKF7#(F85=0+J#[
MD.WI3(N]Y3:R&0JNBP4AMJ2SC+,Q5:..LG&(M(4L1,M)6H,1;^5VU MY@8Z7
MRB8\()]*$P,,<TA3H*>/10VG'('!/!_=4ZU)(Q9&I=<:8K*U2$YV0L&)J*52
M6D80G*TN. X$$M&O]FRK2N"_&-#>/B0!P)QQ^=:+@$(6ZXQ%'5%]I@:**F@A
MAYB"81H;X!9E[+IFXYI..>7)W+^;\BZJ[VTH[Y=TDRW'MB^IH1?D_=<9>C.R
MC]6\Q( Y0,6F\-#LRQYST1R"+>J$:YH2?20AEY,_SBB,I7 7T[5PU[$:<"*,
M\95KD ]\?5@)B41D66/"?Q%;#-LXNEB@:,L:6W&WV3 S;D?J6[_%8N!AS:.8
M?$> 67'<-74"45J,.%XK9[(Y*2T_.(^3^G2[O$/G%&DA,GBHQP]U]&15+=@H
MH@I8IE.4(MYFH]D:XGTEV<?K4P]9I^MK4TIVY-I0;:SP4AY\:8=W%?@.,VD$
M<=W3TX.X./Q$]1.KEF/,V*FPLNUOH90,H$)[#\M)4*#')=P7X-9)#HEU@Q?3
MU7X_2='M*&,\[-7QDA^MYB4Y6 LV1 **(%@U?0O(E\J>/PXQG)TQ#W$/QKT-
M:]BHD">]&7D!S.%M?Q.7,6N5#UD<IJ:X(C*;43-#7]ND-K6/=24'"^"UQT]/
M.#7!&TBNK&G%F.;S[JD':(V<W[0IJU%"52UOCS@$-9=+Z>E$"1([-J,%/,&U
M2<NK<],PU-?\?LQ"<-EEDBJT>?U8TWV=7"56->!E2/7EOP4JLWTLXT',8>,
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MA\4!7/5ZLP$V';7C[E]45I.UAXNF7UW1H3&4? &'X? 3<_B^IQ>'UK\MT,5
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M3,5B))>"T9G9E*4C8MO^**-)/KBZ,+3WXNJ"%RI-<O9>(%ED&16;&Y;R]>4
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M*\J'I'*B^-(\WDRY4CPSPYC1&1.: =;GG*OM1"NH7_.N_@502P,$%     @
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M8=W!-O>;D,-;& 2 S\@AJ\)KB)>2O V6Y#&%+(PP"."RZ';0!]X(2BEB:9$
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MR&3H!=$V"DG>\0F"1Y'F"FE1NLD8^J,!_=%W"\.GNGI"-<!2'*Q& 3_J]6W
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M-<D6&BV?G(Q%)'%-!->)(,YJN6ML5<0CU 8%F91#1"G0$L:(J.3+IA8"C:J
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M,WC)+M_$XR7_DN]"JP[NB:NFOJ":VR7<^VJCAC]OY\;/_W4F8+H+F/J Z8F
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M\Z%V!K2^4,IN/UR W2UR]@]02P,$%     @ 2(995*_D(D=-!P  G!$  !D
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MM0^R'G79H<8?H$8Q7,O*;#5<53GFKP$"HCCPC'<\E_%!Q$O,3B")?(C#.#J
MEPS[3AQ>\@'>%5,5KS8:;H?M_G.^UD91F?Q[ '\TX(\<_N@#_!6I)V\$@BS@
M?2P?EDSS#%B5PR47C7F;HRXE!T-8N9[IFF4X]TB/&M4C>HO[+4(A!6F-(H*Q
M!PAZ*UL-AE8R)K)&,*L'36;*37Y'IC2@/2B@-&.Y)IJ[5+MOZ#NF<1A-X8A7
MY"4;33/:!WS*L#:N:+3+(BME4QE]?.;<G7?G>'-U3Y7V;;6B2KNY^'9]!3_#
M4>HGH\DQ]49^-(FI37VZ3?KLM$Y2Q(H]HJ(; J@^2U*R"Z2!KAAMB(7=:!1-
M_>EI#%&8^N/)E-K0'TW"+KDD>\"BH'O G@9)*GL 67=)^.6G-([BWR#QPXB(
M^BF!['&B>$;QS)+I_%G+5/[L'H=CB--D=YCOJ1_B'$7^9#HBSHE_&HW[S5=6
MF,()DS\+L\LQ)2X\"5W>J!UU33H$_P'7 Q4_'BI^_.F*/Z\,SW=97&'6*&XX
M;?_J*1.-K;-"R1(N9%DWQE7C?IGLT\1!$I_11"T-$CTF8&#8'TZ+E"!\1?&-
M:"S-_!-97F/&&HW6G:M=&;6R$3DMD98,_W4(_D,R?*>NU:NJCOQT&@_%N6OO
M/BCBB(KOK2TAC^F *BI?P^TE<D-ITS#VQTE*8IG$R4O3=*]IE(3O</<56O#B
M^2I1;=PCK4GM=)%T+]DP._P'G'?/W[-Y]Q-QS=2&4P($%N0:GDRH7%3W,'<#
M(VOW&*ZEH:?5=;?T+X/*&M!Z(8E\/[ !AK^CQ?]02P,$%     @ 2(995*HA
MO)=C @  204  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULG53=;],P
M$/]73M$>F%26C[8P56VDM1L"B4G5-D (\> FE\2:/X+MK.6_Y^RT64%;'WAI
M?/;]/N[J\WRKS:-M$!WLI%!V$37.M;,XMD6#DMD+W:*BDTH;R1R%IHYM:Y"5
M 21%G"7)NU@RKJ)\'O;6)I_KS@FN<&W =E(R\WN)0F\741H=-NYXW3B_$>?S
MEM5XC^Y+NS84Q0-+R24JR[4"@]4BNDIGRXG/#PE?.6[MT1I\)1NM'WWPJ5Q$
MB3>$ @OG&1A]GG"%0G@BLO%KSQD-DAYXO#ZP?PBU4RT;9G&EQ3=>NF817490
M8L4ZX>[T]B/NZYEZOD(+&WYAV^=.LPB*SCHM]V!R(+GJOVRW[\,1X#)Y!9#M
M 5GPW0L%E]?,L7QN]!:,SR8VOPBE!C29X\K_*??.T"DGG,M76DKNJ,O. E,E
MK+1R7-6H"HX6WCRPC4![/H\=:7E$7.QYESUO]@IOFL$M4346;E2)Y=\$,9D<
MG&8'I\OL).,U%A<P3D>0)5EZ@F\\5#X.?./_JOR:VT)HVQF$'U<;ZPQ=GY\G
M5">#ZB2H3EY177>F:.@6P;/\"&YVA>A*$H?/6M5O'1IY=/Y2\T^*^$&>V985
MN(AH4BV:)XSRAP:A/:@7Q\5;T!50>U%NT PM'@&CXNFPTH)&ERX#5^ :W5GJ
MECV?P7=DQ@*J8/Q?> 9GD(Z29.J#\7[YH!T3+YLX@VR4I F\U.+XZ'I+-'48
M8DOP3KG^I@^[PSMQU8_'<WK_R-PR4W-E06!%T.3B_30"TP]N'SC=AF'9:$>C
M%Y8-O75H? *=5UJ[0^ %AM<S_P-02P,$%     @ 2(995'="G[,,!0  O@H
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MF-)X 7Q?:>T.&V]@O+*>_P=02P,$%     @ 2(995#Y'IL]R P  WPH  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULI5;=;]HP$/]7K&@/F]0U'T"
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MF9XI";>'.FYY$(T#LENV386W14,O#KR195]M48R]$8GCENPM;G,/GWA!X"A
M0T*PFX5,ZA!H4+R:SP$GCQ#@-A>IAHB+5*QJS+Y(_[>6JLTY=U<UK ./#WUB
M(89/$#>?>"]6W#3V=N PKI"B(_S$3'_BGOX?[/\;TI[7QU'D<LF,;>(>J_]'
M6]\TIG?:VG-Y9:86<4^MGLU*VC/FF) PCKI=,#.&N&?,M@M3FPN[=LT,(.'!
MF\& .'&#>-^XMF'X.,8CRY2W26+LAVU<N[**PERU0*!5=.Q'W1!(S!P@_>=
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M0]M=AM;C8<]X%ZM:?U/7H+/=P'_^H;\#-THNZO\&YL#;.?!Z#N*9XS9?U9]
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M0=D O%]):?:&3=!N[/0W4$L#!!0    ( $B&652ZWI&\;@4  -T=   9
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MC"Z8J 7T[[><JZ>7^H:ON]&=_ ]02P,$%     @ 2(995&'X_%4^!0  .!T
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M!A;'@S!J06Q8G!S=F)/NQMPILHW,+ 7DP,:<-'3<NF+S=S'98CH#<9O'S I
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M-1"5@7Z_Y5P]#JH [=5O^3]02P,$%     @ 2(995!3-DG!9 P  NPH  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULE5;;;MLX$/T50N@"";".1,K6
M); -M F*+I "0=/+PV(?:&ML$95$E:3BYN\[HA79K2@E^V*+$L^<,T/R<)8'
MJ;[K',"0GV51Z967&U-?^[[>YE!R?25KJ/#+3JJ2&QRJO:]K!3RSH++P61!$
M?LE%Y:V7]MV]6B]E8PI1P;TBNBE+KI[>02$/*X]ZSR\^B7UNVA?^>EGS/3R
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M,,[3R$V9]I3I-*4TO$ K;LU>5'M2V&->=\?<)2-UK"B+DY'-2H.3!P632NY
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M*8/K$591M>VP#8QL7$=928/]R0TK_(. L@GXO9#2; .[0/]/2O\!4$L#!!0
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M-Z"6+ '=4EZG#M+9 LQN':W[<9BE1/PVF$=UY*/WP1QGU#:DMZ#$0=,'@BW
MQ&M]!W\<9Z6QSC-XG24F36#2&G@DV-)VRK8BFO: PVU :[H'CCX!6O0"&NG@
M,.YN(-=T$]S>3BIR[_R:<=,S<+P-FDW[P)U/H-EY23/L1L'A!II-.\'M_:2A
M^8[/N6D9^&@++$G3/DCP<9:5QOI_34B.XO 92G]MG,E!S8JA3:-$+H0I)YOZ
MM!X,3\IQJ#$OI\HKJF9,:,1A:EV#@XY]PU4YJ)4;(^?%<#21QHY:Q3*SPRTH
M9V#O3Z4T3QL7H!Z7!_\ 4$L#!!0    ( $B&6503"44FC@,  '8/   9
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MK^HFKQX8N:L:JP=I;)M6/1:V,:;*+;#O-U*:QX%ST+;:JQ]02P,$%     @
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M.'_[._\@^"9[:?>&"\'#['%-"90AL@'\ON)</'Z0[P&7[^ ?_0]02P,$%
M  @ 2(995,F/2WZ2!   _Q0  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N
M>&ULO5A=;]LV%/TKA-<-"=!$)/7IS#&PQDF:(=V".MD>ACW0-FT3E4B7I.-V
MZ(\O):N2;5&,\[476Y3NN3R\O#I'4F\EY"<UIU2#+UG*U6EGKO7BQ//4>$XS
MHH[%@G)S92ID1K09RIFG%I*220'*4@]#&'D98;S3[Q7G;F2_)Y8Z99S>2*"6
M64;DUW<T%:O3#NK\./&1S>8Z/^'U>PLRHT.J[Q8WTHR\*LN$990K)CB0='K:
M^0V=7.(X!Q01?S&Z4AO'(%_*2(A/^>!J<MJ!.2.:TK'.4Q#S=T_/:)KFF0R/
MSV723C5G#MP\_I']HEB\6<R(*'HFTK_91,]/.TD'3.B4+%/]4:S>TW)!89YO
M+%)5_(+5.C8RP>.ETB(KP89!QOCZGWPI"[$!0$$+ )< O"_ +P'^OH"@! 3[
M L(2$.X+B$I M OP6P!Q"2AVWUM7M]B: =&DWY-B!60>;;+E!\7^%FBS(XSG
MK3C4TEQE!J?[ SK2X @,UYT(Q!1<"SX#MU1FH+AV,*":L%0=FJB[X0 <O#D$
M;P#CX'8NEHKPB>IYVA#)TWGC<M)WZTEQZZ3C8^"CMP!#C"SPL^?!!\^#G[OA
MOQ-^#% [_&+_V:$%?NF&?R!? 0QL:,_L?+7]N-I^7*3S7=M_Q9662Z,O&OQS
M;0+ E::9^M>1WJ_2^T7ZH"7]'2>9D)K]1R=&'\Q4$Z;&8LFUK6?6J>(B5:Z@
M]_TCY,/0[WGW%@I!12%P4KBF2IW\\A.*X*\--DRI)>%C"L9":6L?KW-'FYQB
M%-@9A16CT,GH_/.2+8IJ3QDWTS-SOXE1RF8D%V<KC;!! V$85336?1<VZN<G
M,+%SC2JND9/KK= D+8IEHQ4U:(6^'R7='6+-,!2C+FZA%E?4XH<W%IPMI<Q+
MN<@WUEB;$3#Z^/K&S6U&R ]WUF&)PDF [,M(JF4D>U0X-:)[I'/1S6O]%G!J
M+7AB*3@.PV"':#,,15V8Q':FW8IIU\D4'N/P9W F^#TUM1ZE% PI9T*"/X2F
M"GS;NC1HM,S6G C6_@1?0Z'0A@$BY[*&FF@C"(R;\E.E@31#<$ 4(&!!Y=C,
M>6BU*'?6HEA6;WH:[OSQN.UZU(Z L#/3C63FGEF0U.KKN-%:?A!""'<ZT!('
M[=V':B]!+V@F9:ZMFS7I1OXNSV98&\_:<-!K.@ZR6 [>D/&2=S.JC7=M2\CM
M2]=;&F3EUO0AWP\3O"OXEK@V=K41(;<3H9=4G]IC4/PJZE.K/W++_U/5QYT5
MM:K/TW"7C\=MUZ/V&.0V&;?Z=!M]A2'"84-]'HS;?EBNS0C#EY.@,M?6G1S
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M+"L&B,^7B2CI^D7QHYG-#];._P502P,$%     @ 2(995$LU@;.J!@  J28
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M?M*#O9<+W\+U1J87K.DXP6NR(/(AF7-U9N4LRS BL0A9##A937H7\/,=<E.
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M\R.:YDV9;^K?<-SE99FG]>6:LR47E8#\_#[/R]V;ZF<A^Y\RG?X/4$L#!!0
M   ( $B&653.2,6\DP,  %@-   9    >&PO=V]R:W-H965T<R]S:&5E=#8W
M+GAM;,U7WX_:.!#^5T913VJE;G[" A4@ >GI*G6EU:[N^G"Z!Y,,8&T2<[:!
MY;_OV,D&V V!:^^A^[#$SGR?9[Z9V./A3L@GM4+4\)QGA1HY*ZW7GSQ/)2O,
MF7+%&@MZLQ R9YJ&<NFIM4266E">>:'OWWHYXX4S'MJY>SD>BHW.>('W$M0F
MSYG<3S$3NY$3."\3#WRYTF;"&P_7;(F/J/]<WTL:>35+RG,L%!<%2%R,G$GP
M*0XB [ 6?W'<J:-G,*',A7@R@R_IR/&-1YAAH@T%HY\MSC#+#!/Y\6]%ZM1K
M&N#Q\PO[[S9X"F;.%,Y$]HVG>C5R^@ZDN&";3#^(W1]8!=0U?(G(E/T/N]*V
M-W @V2@M\@I,'N2\*'_9<R7$$2#LG &$%2!\#>B> 405('H%"'IG )T*T+'*
ME*%8'6*FV7@HQ0ZDL28V\V#%M&@*GQ<F[X]:TEM..#U^U")YNIF2<BG,1$[E
MI)A-R U\LYK1_&2+DFH )HJJ8VW>*G@?HV8\4Q_(\!UXH%9,HAIZFGPRS%Y2
MK3\MUP_/K!^$<"<*O5+PN4@Q/27P*)@ZHO EHFG8RAACXD(4?(30#X,&AV;7
MP_T&>'PU/!BT1!/5^8DL7W0N/T;7F_G;_$RD9,42Z1/4,-_#L=T]V]OIR8[)
M%/[^2I3P16.N_FEQJ%,[U+$.=<XX],#5T\U"(@(O-%+.-4BF$=XS!0S6*!-:
M^D-3(;3S^F[/_ZTI73\&B]MAH=MY#3M1HUNKT6WE^?R\I@V,--^*C/*2<;V_
M0HEVSD[7#9JEN( +SVEQ 1>Y8:L8M[48MZU$,=_R%(L4]ARS] H=VNE\UV^6
MX<=@\7^&G8C0JT7HM?+4NR:K=LT%XQ*V+-N@T:+<*(%I6-+WJR&UWPXO(!59
MQJ0ZV#0J5JX]L&N;(WT[#OINOS?TML<"O;4BH[Y_]!><(N*WB*[;.]">*-&O
ME>BW*G''"YYO\A9-!S73X-?8! /_<&SZUWWXM ?F-H%[I/0U)NT"56"A$$)>
M'H1T)*9LWW26SBXP1:43,*BI^N>HXNNHVK0Z:C&"]D)@SQ<*(0@/7.$O4@J'
M$SJ(_K]2:*?J5@F\K1+86 ,_31'_%$6IDG?4<N8HE[9U5Y"(3:'+7JV>K:\'
M$]L4OYJ?FFN#;64/-.6=XX[)):=6,\,%4=)!3\>8+-OX<J#%VC:V<Z&I3;:/
M*[KZH#0&]'XAA'X9F 7JR]3X.U!+ P04    " !(AEE4MV8'_0\$   ^#P
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M_;EI;RZL+#(8N4G4BZI%EKG^R/2'5QLRG%R8)F*U6WQPG>#,C09<%AU*W7
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M[]G^3V@2<K6_D&6B^D;[1FL9*"R%9'ECK"+(TZ+^I3^;0AP98.^, 6D,2-_
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M;?@64=U5S>VIXH:O<$,8?!%<;Q7XE:<TO73@&J&-6GQ2^X0'/29T]0 \] O
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M5!8 \_M:"'VZ*0(TJ__L7U!+ P04    " !(AEE47DS3-X $   ,%   &0
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M,ZT?=XQNF#0&\/M6"/TR,-?3]M\1R_\!4$L#!!0    ( $B&653%5M4+*P,
M -X+   9    >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;+56R6[;,!#]E8&0
M0P*DD2AY#6P#38RB:=,TR-(>BAX8:6P3H4B7I)< _?B2DB(YL"6XJ'NQQ&4>
MW[PQGV:PDNI9SQ -K%,N]-";&3,_]WT=SS"E^DS.4=B5B50I-7:HIKZ>*Z1)
M%I1R/PR"CI]2)KS1()N[5:.!7!C.!-XJT(LTI>KE KE<#3WBO4[<L>G,N E_
M-)C3*=ZC>9S?*COR2Y2$I2@TDP(43H;>>W)^2?HN(-OQC>%*;[R#2^5)RF<W
MN$J&7N 8(<?8. AJ'TN\1,X=DN7QJP#URC-=X.;[*_J'+'F;S!/5>"GY=Y:8
MV=#K>9#@A"ZXN9.KCU@DU'9XL>0Z^X55OK<3>! OM)%I$6P9I$SD3[HNA-@(
M(*V:@+ ("/<-B(J *$LT9Y:E-::&C@9*KD"YW1;-O63:9-$V&R9<&>^-LJO,
MQIG1E8AEBO! UZCA'=Q0I:@3%H[':"CC^L3./MZ/X?CH!(Z "7B8R86F(M$#
MWU@"#L:/B\,N\L/"FL/&&)]!1$XA#$*R(_QR__#@;;AOTRYS#\O<PPPOVB?W
M']=V%:X,IOIG W948D<9=JL&^^L<G9!B"EQJ#;'5]<5>NA55NX7+T;H9FKMZ
MRU$8D79@TUSN8-$J6;0:68QQ@DIA H:N@6J-1I_"DO(%S>\0M[>8BAAW,<J1
M.QN,HB@@K9)07K'6-N].1':S;I>LVXVL[?VTMT\T5*%3(G4.7N%NB=T]:(6[
M6WH2TNO75;A7LNC]MPKWMABUR :?O,"]'06N(]TO2??W*3#\AD?!C"7_V<J8
MR+2A*B2H#"TX>,W)AEV2@U:]@-L4N=]IU0E(*NLB82./>T,-@K5AN)8QY?!I
MH9A.6/9M;$JT\B\2'5[&RI=(LS']M8S;;D1(V*O5L;(:TNPU-[93D@UDP,RH
M@42"D 9P/6=JYU4J3GGCEO7L*OLBG>:+@HFEQILDK^R*= ]?T,J&2+,/[:=C
M@X#;9M2N_?R1RFA(L]/\BST6T&^L;X=A^QO-E^M\OU U94(#QXF-"\ZZ]J^A
M\F8R'Q@YS_JQ)VEL=Y>]SFP#CLIML.L3*<WKP+5X94L_^@-02P,$%     @
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MCB?$Q&P2$]MDH X<;'%,*S&Q5F!!. B'R22F'J;:71EN)T),*S&Q5M#BBQW
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M837KLJFJ,[_ON[K4O'SY6=K+3^J^_ M02P,$%     @ 2(995" 5OA"$ @
M)C(  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:36ZC0!"&X:M8
M'"#MKNJJ[HSBK&:3[2@70$[[1[&-!8PFN?U8SL+^T"QF$_&M4(,HW@V/$/#T
MJQ[:<=^=AMW^/"P^CH?3L&IVXWC^$<*PWM5C.SQTYWJZ'-ET_;$=+\M^&\[M
M^KW=UB#+I8?^?D;S_'0_<_'Z>:[_,[';;/;K^K-;_S[6T_B/P>%/U[\/NUK'
M9O':]MLZKIKP<;CM'L)U$Q\NDYO%R]NJZ5_>8A/F#A((DOF#%()T_J $06G^
M((,@FS_((<CG#\H0E.</*A!4Y@]ZA*#'^8/B$F5<$B1-L";0.B+7D<#KB&!'
M K$CDAT)S(Z(=B10.R+;D<#MB'!' KDCTAT)[(Z(=R306U!O(=!;4&\AT%LF
M#]L$>@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z*^JM!'HK
MZJT$>BOJK01ZZ^1E"8'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>
M"?5.!'HGU#L1Z)U0[T2@=T*]$X'>:?*RFT#OA'HG KT3ZIT(]$ZH=R+0.Z'>
MB4#OA'HG KT-]38"O0WU-@*]#?4V KT-]38"O0WU-@*];?*QDD!O0[V-0&]#
MO8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0&^?
M_&Q"H+>CWDZ@MZ/>3J"WH]Y.H'=&O3.!WAGUS@1Z9]0[$^B=4>],H'=&O3.!
MWAGUS@1Z9]0[$^B=)S\+$NB=4>],H'=&O3.!W@7U+@1Z%]2[$.A=4.]"H'=!
MO0N!W@7U+@1Z%]2[?*?>P_AYJ,.MYVN-U_].JL?+N?5V^>OR:^?DAKKB'.XK
MAN>_4$L#!!0    ( $B&652);LQ^*P(  +LP   3    6T-O;G1E;G1?5'EP
M97-=+GAM;,W;36[;,!"&X:L8V@:6+%*DU"+.INVVS:(78"4Z%JP_D$SJW+Z4
MG 1HD1H)7*#OQH)-<KX1!WAVOO[^.%F_.O;=X+?)/H3I8Y;Y>F][X]-QLD-<
MV8VN-R%^=7?99.J#N;.9V&QT5H]#L$-8A[E&<G/]V>[,?1=67X[Q9]^.PS9Q
MMO/)ZM-IXYRU3<PT=6UM0ES/'H;FCY3U4T(:3RY[_+Z=_%7<D&2O)LPK?P]X
M.O?MP3K7-G9U:USX:OJX*SMVF0^/G?7I^1*O]#CN=FUMF[&^[^.1U$_.FL;O
MK0U]EYZ*7IU/#O&&[>DSOSA_*7,N,.Z\=>/DX\2<?7_<\TCFT^LI%K(NM.=?
M\24QEK[X_>P\[<8V;\R.U_MS=(=E'CY;'I??\>\S?JG_SCX$I \)Z:. ]*$@
M?6A('R6DCPK2QP=('_F&T@A%U)Q":DXQ-:>@FE-4S2FLYA17<PJL.45609%5
M4&05%%D%159!D5509!44605%5D&155!DE119)45629%54F25%%DE159)D552
M9)44625%UH(B:T&1M:#(6E!D+2BR%A19"XJL!476@B)K09%54615%%D5159%
MD5519%44615%5D6155%D5119-45639%54V35%%DU159-D5539-44635%5DV1
MM:3(6E)D+2FREA192XJL)476DB)K29&UI,A:4F2M*+)6%%DKBJP51=:*(FOU
M/V7],8Z'?QR_/-/>M,-S?K;\9^'F%U!+ 0(4 Q0    ( $B&650'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 2(995 LQMHCO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 2(995)E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !(
MAEE4UKF/XT &  !O&0  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ 2(995-!$":DA @  = 4  !@
M         ("!A X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( $B&6533(30EKP<   \@   8              " @=L0  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !(AEE4!4LL-=4"  #;!P
M&               @(' &   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ 2(995')/&7]4!@  >AD  !@              ("!RQL  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $B&650D>KR&=0,
M )X*   8              " @54B  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !(AEE4":X[S"D*  !+.   &               @($
M)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 2(995,D6
M5B+V"@  "S(  !@              ("!7S   'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( $B&652#/+>BK D  &X8   8
M  " @8L[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !(
MAEE4.'7!JQ<I   YA0  &0              @(%M10  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $B&653#3UE7]A,  )1+   9
M          " @;MN  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#
M%     @ 2(995+ FI.1S"@  ="   !D              ("!Z((  'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !(AEE4&3ZM\H4$  "4
M"0  &0              @(&2C0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+ 0(4 Q0    ( $B&6518"FIE3P4  *$,   9              " @4Z2
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 2(995(B=
MHCED!0  ! T  !D              ("!U)<  'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6Q02P$"% ,4    " !(AEE4PEH2P5H*  !@(0  &0
M    @(%OG0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M $B&653FC]=20Q$  !91   9              " @0"H  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ 2(995-#-52HS!0  4@T  !D
M             ("!>KD  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !(AEE48*WF5:<$   Y#P  &0              @('DO@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $B&652"&=R2.@X
M -PK   9              " @<+#  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ 2(995&?79!9^#0  NR4  !D              ("!
M,](  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !(AEE4
MF;/W6EL-   ])0  &0              @('HWP  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( $B&650!M=S!6 4  'P.   9
M      " @7KM  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ 2(995'@1)0A1 P  ;@<  !D              ("!"?,  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !(AEE4'[7X@ 8'  !:$
M&0              @(&1]@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( $B&653@1T?%, 0  !@*   9              " @<[]  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 2(995-*]/*B/
M!@  9@X  !D              ("!-0(! 'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !(AEE4[L!S/? N   THP  &0
M@('[" $ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( $B&
M6505@:G,* <  )P2   9              " @2(X 0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ 2(995,MF?%/W!0  V1,  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( $B&653I8,K"C0(  '4%   9
M  " @1U7 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M2(995*IE@CX4!P  F1,  !D              ("!X5D! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !(AEE4ISDI-C@$  !1"@  &0
M            @($L80$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( $B&652OY")'30<  )P1   9              " @9ME 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 2(995)29[OV^ P
M*0D  !D              ("!'VT! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !(AEE4JB&\EV,"  !)!0  &0              @($4
M<0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( $B&651W
M0I^S# 4  +X*   9              " @:YS 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ 2(995#Y'IL]R P  WPH  !D
M     ("!\7@! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $B&652ZWI&\;@4  -T=   9              "
M@=R: 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 2(99
M5&'X_%4^!0  .!T  !D              ("!@: ! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " !(AEE4R!(8#PL)  !N4@  &0
M        @('VI0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( $B&651^DV@IF04  )$@   9              " @3BO 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 2(995->8N8NN P  !@X
M !D              ("!"+4! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " !(AEE4%,V2<%D#  "["@  &0              @('MN $
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( $B&653#SU;&
MHP(  )\&   9              " @7V\ 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ 2(995 0L#)_4 @  ^@@  !D
M ("!5[\! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !(
MAEE4^%^"AOH"   Z"P  &0              @(%BP@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( $B&6503"44FC@,  '8/   9
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M970V,"YX;6Q02P$"% ,4    " !(AEE4R8]+?I($  #_%   &0
M    @(&QW $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M $B&650W6)*(_@@  +PV   9              " @7KA 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ 2(995$LU@;.J!@  J28  !D
M             ("!K^H! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " !(AEE4K8MNJ5(#  !""P  &0              @(&0\0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( $B&652;(LHVH00
M "05   9              " @1GU 0!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ 2(995-M>/XM'!P  UB0  !D              ("!
M\?D! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " !(AEE4
MSDC%O),#  !8#0  &0              @(%O 0( >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( $B&652W9@?]#P0  #X/   9
M      " @3D% @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ 2(995%?%Q9YK P  ?PL  !D              ("!?PD" 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !(AEE4K>#L3.$%   &)P
M&0              @($A#0( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( $B&6523]<#RTP,   4.   9              " @3D3 @!X
M;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ 2(995$"TB@2D
M P  V D  !D              ("!0Q<" 'AL+W=O<FMS:&5E=',O<VAE970W
M,BYX;6Q02P$"% ,4    " !(AEE4<(69@2@#   ""P  &0
M@($>&P( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( $B&
M653,@+[:Y@,  &L0   9              " @7T> @!X;"]W;W)K<VAE971S
M+W-H965T-S0N>&UL4$L! A0#%     @ 2(995%F6 HTE!   !A   !D
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M=#<Y+GAM;%!+ 0(4 Q0    ( $B&652YW?BI\P,  !,.   9
M  " @4(W @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @
M2(995/MD!1:N P  <0X  !D              ("!;#L" 'AL+W=O<FMS:&5E
M=',O<VAE970X,2YX;6Q02P$"% ,4    " !(AEE4/AY1*^X"   B"0  &0
M            @(%1/P( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4
M Q0    ( $B&653\BX$#U (  .@'   9              " @79" @!X;"]W
M;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ 2(995'9_--77 @
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M96QS+RYR96QS4$L! A0#%     @ 2(995-,%HA0W!@  UC<   \
M     ( !1U0" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $B&650@%;X0
MA (  "8R   :              "  :M: @!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( $B&652);LQ^*P(  +LP   3
M  "  6== @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    != %T @AD  ,-?
$ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>383</ContextCount>
  <ElementCount>632</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Investment in Non-consolidated Affiliate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/InvestmentinNonconsolidatedAffiliate</Role>
      <ShortName>Investment in Non-consolidated Affiliate</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Derivative Instruments and Hedging Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivities</Role>
      <ShortName>Derivative Instruments and Hedging Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Equity Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/EquityTransactions</Role>
      <ShortName>Equity Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2157114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2164115 - Disclosure - Net (Loss) Income per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossIncomeperShare</Role>
      <ShortName>Net (Loss) Income per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2168116 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2170117 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2173118 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2175119 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/Acquisitions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2335306 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/Debt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2340307 - Disclosure - Derivative Instruments and Hedging Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesTables</Role>
      <ShortName>Derivative Instruments and Hedging Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2345308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/RevenueRecognition</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2358310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2365311 - Disclosure - Net (Loss) Income per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossIncomeperShareTables</Role>
      <ShortName>Net (Loss) Income per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/NetLossIncomeperShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2371312 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2376313 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SegmentInformation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NatureofBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/NatureofBusiness</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Acquisitions - Schedule of Provisional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails</Role>
      <ShortName>Acquisitions - Schedule of Provisional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Acquisitions - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/AcquisitionsProFormaInformationDetails</Role>
      <ShortName>Acquisitions - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Amortized Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Fair Value by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Property and Equipment, Net - Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails</Role>
      <ShortName>Property and Equipment, Net - Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Leases - Summary of Additional Supplemental Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/LeasesSummaryofAdditionalSupplementalDataDetails</Role>
      <ShortName>Leases - Summary of Additional Supplemental Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Goodwill and Intangible Assets - Rollforward of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Rollforward of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Goodwill and Intangible Assets - Amortization Expense of Intangibles Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Amortization Expense of Intangibles Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Goodwill and Intangible Assets - Estimated Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Investment in Non-Consolidated Affiliate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails</Role>
      <ShortName>Investment in Non-Consolidated Affiliate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Debt - Summary of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails</Role>
      <ShortName>Debt - Summary of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Debt - Schedule of Maturities of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails</Role>
      <ShortName>Debt - Schedule of Maturities of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Derivative Instruments and Hedging Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Equity Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/EquityTransactionsDetails</Role>
      <ShortName>Equity Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/EquityTransactions</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Stock-Based Compensation - Status of Our Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Status of Our Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Stock-Based Compensation - Roll Forward of Non-Vested Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Roll Forward of Non-Vested Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Stock-Based Compensation - Summary of Information about our Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Information about our Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Revenue Recognition - Summary of Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenue Recognition - Summary of Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2456433 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Income Taxes - Significant Components of the Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Significant Components of the Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2460435 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate and the Federal Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Tax Rate and the Federal Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2461436 - Disclosure - Income Taxes - Current and Non-current Deferred Income Tax Assets And Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Current and Non-current Deferred Income Tax Assets And Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2462437 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2463438 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2466439 - Disclosure - Net (Loss) Income per Share - Computation of Basic and Diluted Net (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net (Loss) Income per Share - Computation of Basic and Diluted Net (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/NetLossIncomeperShareTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2467440 - Disclosure - Net (Loss) Income per Share - Schedule of Antidilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails</Role>
      <ShortName>Net (Loss) Income per Share - Schedule of Antidilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/NetLossIncomeperShareTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2469441 - Disclosure - Defined Contribution Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DefinedContributionPlanDetails</Role>
      <ShortName>Defined Contribution Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/DefinedContributionPlan</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2472442 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2474443 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="neo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2477444 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SegmentInformationTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="neo-20211231.htm">neo-20211231.htm</File>
    <File>neo-20211231.xsd</File>
    <File>neo-20211231_cal.xml</File>
    <File>neo-20211231_def.xml</File>
    <File>neo-20211231_lab.xml</File>
    <File>neo-20211231_pre.xml</File>
    <File>neoex1011executiveemployme.htm</File>
    <File>neoex211listofsubsidiaries.htm</File>
    <File>neoexhibit23112312021.htm</File>
    <File>neoexhibit31112312021.htm</File>
    <File>neoexhibit31212312021.htm</File>
    <File>neoexhibit32112312021.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>neo-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1527">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "neo-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 35,
   "contextCount": 383,
   "dts": {
    "calculationLink": {
     "local": [
      "neo-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "neo-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "neo-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "neo-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "neo-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "neo-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 813,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 6
   },
   "keyCustom": 75,
   "keyStandard": 557,
   "memberCustom": 33,
   "memberStandard": 58,
   "nsprefix": "neo",
   "nsuri": "http://neogenomics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://neogenomics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://neogenomics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Acquisitions",
     "role": "http://neogenomics.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Fair Value Measurements",
     "role": "http://neogenomics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Property and Equipment, Net",
     "role": "http://neogenomics.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Leases",
     "role": "http://neogenomics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Investment in Non-consolidated Affiliate",
     "role": "http://neogenomics.com/role/InvestmentinNonconsolidatedAffiliate",
     "shortName": "Investment in Non-consolidated Affiliate",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Debt",
     "role": "http://neogenomics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Derivative Instruments and Hedging Activities",
     "role": "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivities",
     "shortName": "Derivative Instruments and Hedging Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Equity Transactions",
     "role": "http://neogenomics.com/role/EquityTransactions",
     "shortName": "Equity Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorLocation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://neogenomics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorLocation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - Stock-Based Compensation",
     "role": "http://neogenomics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Revenue Recognition",
     "role": "http://neogenomics.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157114 - Disclosure - Income Taxes",
     "role": "http://neogenomics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164115 - Disclosure - Net (Loss) Income per Share",
     "role": "http://neogenomics.com/role/NetLossIncomeperShare",
     "shortName": "Net (Loss) Income per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168116 - Disclosure - Defined Contribution Plan",
     "role": "http://neogenomics.com/role/DefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170117 - Disclosure - Commitments and Contingencies",
     "role": "http://neogenomics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173118 - Disclosure - Related Party Transactions",
     "role": "http://neogenomics.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175119 - Disclosure - Segment Information",
     "role": "http://neogenomics.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Acquisitions (Tables)",
     "role": "http://neogenomics.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://neogenomics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://neogenomics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://neogenomics.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Leases (Tables)",
     "role": "http://neogenomics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335306 - Disclosure - Debt (Tables)",
     "role": "http://neogenomics.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340307 - Disclosure - Derivative Instruments and Hedging Activities (Tables)",
     "role": "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesTables",
     "shortName": "Derivative Instruments and Hedging Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://neogenomics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://neogenomics.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358310 - Disclosure - Income Taxes (Tables)",
     "role": "http://neogenomics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365311 - Disclosure - Net (Loss) Income per Share (Tables)",
     "role": "http://neogenomics.com/role/NetLossIncomeperShareTables",
     "shortName": "Net (Loss) Income per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2371312 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://neogenomics.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2376313 - Disclosure - Segment Information (Tables)",
     "role": "http://neogenomics.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i18eda084cbb54f798854f0d69e97920e_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "neo:PolymeraseChainReactionTestingExitCostsCOVID19",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business (Details)",
     "role": "http://neogenomics.com/role/NatureofBusinessDetails",
     "shortName": "Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "neo:PolymeraseChainReactionTestingWriteOffsCOVID19",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i3f4da2d058964b75bd9d1986bbd5843b_D20210618-20210618",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Acquisitions - Schedule of Provisional Information (Details)",
     "role": "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
     "shortName": "Acquisitions - Schedule of Provisional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i94946a5a004045d9b69b4dbf7ab60669_D20210407-20210407",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Acquisitions - Pro Forma Information (Details)",
     "role": "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
     "shortName": "Acquisitions - Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i670a6ed6de274faa9bcd9efbb0050959_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost (Details)",
     "role": "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails",
     "shortName": "Fair Value Measurements - Schedule of Amortized Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Fair Value by Contractual Maturity (Details)",
     "role": "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
     "shortName": "Fair Value Measurements - Fair Value by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis (Details)",
     "role": "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i50a6890d5edf4d9894153bf7442085c2_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "role": "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "neo:AssetHeldForSaleSquareFeetOfFacilityOwned",
      "reportCount": 1,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Property and Equipment, Net - Depreciation (Details)",
     "role": "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails",
     "shortName": "Property and Equipment, Net - Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i9d27cc71a1714b4ebf592be7df20c267_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Leases - Schedule of Future Minimum Lease Payments (Details)",
     "role": "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Schedule of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Leases - Summary of Additional Supplemental Data (Details)",
     "role": "http://neogenomics.com/role/LeasesSummaryofAdditionalSupplementalDataDetails",
     "shortName": "Leases - Summary of Additional Supplemental Data (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Leases - Narrative (Details)",
     "role": "http://neogenomics.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "neo:LesseeOperatingLeaseLeaseNotYetCommencedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i1f7ed50e5ea746629e2bf83cd1f470c3_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i97aa2adfd61943129250ed16f5aef4cf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Goodwill and Intangible Assets - Rollforward of Goodwill (Details)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Rollforward of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Classes of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Goodwill and Intangible Assets - Amortization Expense of Intangibles Assets (Details)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Amortization Expense of Intangibles Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i9d27cc71a1714b4ebf592be7df20c267_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Goodwill and Intangible Assets - Estimated Amortization Expense (Details)",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive (Loss) Income",
     "role": "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome",
     "shortName": "Consolidated Statements of Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Investment in Non-Consolidated Affiliate (Details)",
     "role": "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
     "shortName": "Investment in Non-Consolidated Affiliate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "neo:LongTermLineOfCreditSettlementGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Debt - Summary of Long Term Debt (Details)",
     "role": "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
     "shortName": "Debt - Summary of Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Debt - Narrative (Details)",
     "role": "http://neogenomics.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i7e141e5dc5ac4d099c050eacf32e2ce1_D20200504-20200504",
      "decimals": "INF",
      "lang": "en-US",
      "name": "neo:DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Debt - Schedule of Maturities of Long Term Debt (Details)",
     "role": "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
     "shortName": "Debt - Schedule of Maturities of Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "neo:LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongtermDebtPercentageBearingVariableInterestAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongtermDebtPercentageBearingVariableInterestAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Derivative Instruments and Hedging Activities (Details)",
     "role": "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails",
     "shortName": "Derivative Instruments and Hedging Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongtermDebtPercentageBearingVariableInterestAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongtermDebtPercentageBearingVariableInterestAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Equity Transactions (Details)",
     "role": "http://neogenomics.com/role/EquityTransactionsDetails",
     "shortName": "Equity Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i46a03a2c735740e0a62ec8fcfd378af4_D20210618-20210618",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i91b950b832fa47e2a4081c8b4e114d98_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i91b950b832fa47e2a4081c8b4e114d98_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i97aa2adfd61943129250ed16f5aef4cf_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Stock-Based Compensation - Status of Our Stock Options (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Status of Our Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i97aa2adfd61943129250ed16f5aef4cf_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Stock-Based Compensation - Roll Forward of Non-Vested Stock Options Activity (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Roll Forward of Non-Vested Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i7fa4741509064ec490975a24aa59cd1f_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i7fa4741509064ec490975a24aa59cd1f_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Stock-Based Compensation - Summary of Information about our Options Outstanding (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails",
     "shortName": "Stock-Based Compensation - Summary of Information about our Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "iec0d080a2339420d89dc78184ef8b898_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "role": "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i44f2175697164b01b2aab1f8ff1898cb_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Revenue Recognition - Narrative (Details)",
     "role": "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Revenue Recognition - Summary of Contract Assets and Liabilities (Details)",
     "role": "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails",
     "shortName": "Revenue Recognition - Summary of Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456433 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "role": "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i667bb3b470c64da985250798b766a649_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Income Taxes - Significant Components of the Provision for Income Taxes (Details)",
     "role": "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Significant Components of the Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460435 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate and the Federal Statutory Tax Rate (Details)",
     "role": "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Tax Rate and the Federal Statutory Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461436 - Disclosure - Income Taxes - Current and Non-current Deferred Income Tax Assets And Liabilities (Details)",
     "role": "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Current and Non-current Deferred Income Tax Assets And Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462437 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://neogenomics.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i97aa2adfd61943129250ed16f5aef4cf_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463438 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "role": "http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i0e73e76fb9d740ce9295635957e3246e_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466439 - Disclosure - Net (Loss) Income per Share - Computation of Basic and Diluted Net (Loss) Per Share (Details)",
     "role": "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails",
     "shortName": "Net (Loss) Income per Share - Computation of Basic and Diluted Net (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "ic3e44ba920e9419596aae3ab89649f48_I20210111",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467440 - Disclosure - Net (Loss) Income per Share - Schedule of Antidilutive Shares (Details)",
     "role": "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails",
     "shortName": "Net (Loss) Income per Share - Schedule of Antidilutive Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i1225c352b00e4cb690a7adb7cdcbedde_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469441 - Disclosure - Defined Contribution Plan (Details)",
     "role": "http://neogenomics.com/role/DefinedContributionPlanDetails",
     "shortName": "Defined Contribution Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472442 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://neogenomics.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i306577667f484778bf45986f95823aa8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i21e0442b30f14bb3be7f6da7309905fa_I20210522",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474443 - Disclosure - Related Party Transactions (Details)",
     "role": "http://neogenomics.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "ie1bd7c4a65e8470fb2e0bcb4e07683c8_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477444 - Disclosure - Segment Information (Details)",
     "role": "http://neogenomics.com/role/SegmentInformationDetails",
     "shortName": "Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "i837dec7e8fdd48c7a1722bf1b1f3b0e0_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business",
     "role": "http://neogenomics.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20211231.htm",
      "contextRef": "id1bbbcec8d4c4d43bca7205d5ecefcff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 96,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "verboseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "verboseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "verboseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "verboseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "verboseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "verboseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "verboseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "verboseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://neogenomics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "neo_AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Convertible Stock Issued, Issuance Costs",
        "label": "Adjustments to Additional Paid in Capital, Convertible Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Convertible note debt issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleStockIssuedIssuanceCosts",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt",
        "label": "Adjustments to Additional Paid in Capital, Decrease From Purchase Of Calls Related To Convertible Debt",
        "negatedTerseLabel": "Premiums paid for capped call confirmations"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Tax Liability Component of Convertible Debt, Subsequent Adjustment",
        "label": "Adjustments to Additional Paid in Capital, Tax Liability Component of Convertible Debt, Subsequent Adjustment",
        "terseLabel": "Tax liability related to Convertible Senior Notes due 2025"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTaxLiabilityComponentOfConvertibleDebtSubsequentAdjustment",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_AgencyBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency Bonds",
        "label": "Agency Bonds [Member]",
        "terseLabel": "Agency bonds"
       }
      }
     },
     "localname": "AgencyBondsMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Acquired Developed Technology Intangible Assets",
        "label": "Amortization Of Acquired Developed Technology Intangible Assets [Member]",
        "terseLabel": "Amortization of acquired developed technology intangible assets"
       }
      }
     },
     "localname": "AmortizationOfAcquiredDevelopedTechnologyIntangibleAssetsMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_AssetHeldForSaleSquareFeetOfFacilityOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Held For Sale, Square Feet Of Facility Owned",
        "label": "Asset Held For Sale, Square Feet Of Facility Owned",
        "terseLabel": "Square feet owned"
       }
      }
     },
     "localname": "AssetHeldForSaleSquareFeetOfFacilityOwned",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "neo_AssetsHeldForSalePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Held For Sale, Policy",
        "label": "Assets Held For Sale, Policy [Policy Text Block]",
        "terseLabel": "Assets Held for Sale"
       }
      }
     },
     "localname": "AssetsHeldForSalePolicyPolicyTextBlock",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "neo_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://neogenomics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "neo_BusinessCombinationAcquisitionAndIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Acquisition And Integration Related Costs",
        "label": "Business Combination, Acquisition And Integration Related Costs",
        "terseLabel": "Acquisition and integration costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionAndIntegrationRelatedCosts",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Acquired and Liabilities Assumed, Net",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Measurement period adjustments, net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Assets, Other",
        "terseLabel": "Measurement period adjustments, other current assets"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAssetsOther",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities",
        "terseLabel": "Measurement period adjustments, current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liabilities",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liabilities",
        "terseLabel": "Measurement period adjustments, deferred income tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Purchase Option, Fair Value",
        "terseLabel": "Measurement period adjustments, fair value of Purchase Option"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPurchaseOptionFairValue",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationStepAcquisitionPurchaseOptionFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Step Acquisition, Purchase Option, Fair Value",
        "label": "Business Combination, Step Acquisition, Purchase Option, Fair Value",
        "terseLabel": "Fair value of Purchase Option"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionPurchaseOptionFairValue",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_BusinessCombinationWorkingCapitalAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Working Capital Adjustment",
        "label": "Business Combination, Working Capital Adjustment",
        "terseLabel": "Acquisition working capital adjustment"
       }
      }
     },
     "localname": "BusinessCombinationWorkingCapitalAdjustment",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_CappedCallTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped Call Transactions",
        "label": "Capped Call Transactions [Member]",
        "terseLabel": "Capped Call Transactions"
       }
      }
     },
     "localname": "CappedCallTransactionsMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_CappedCallTransactionsNumberOfUnderlyingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped Call Transactions, Number Of Underlying Shares",
        "label": "Capped Call Transactions, Number Of Underlying Shares",
        "terseLabel": "Capped call transaction, number of underlying shares"
       }
      }
     },
     "localname": "CappedCallTransactionsNumberOfUnderlyingShares",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "neo_CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Acquired From Acquisition And Working Capital Adjustments",
        "label": "Cash Acquired From Acquisition And Working Capital Adjustments",
        "terseLabel": "Payments to acquire business, adjustments"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisitionAndWorkingCapitalAdjustments",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_ClientDirectBillingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client Direct Billing",
        "label": "Client Direct Billing [Member]",
        "terseLabel": "Client direct billing"
       }
      }
     },
     "localname": "ClientDirectBillingMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Services [Member]",
        "label": "Clinical Services [Member]",
        "terseLabel": "Clinical Services"
       }
      }
     },
     "localname": "ClinicalServicesMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ClinicalServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical services segment.",
        "label": "Clinical Services Segment [Member]",
        "verboseLabel": "Clinical Services"
       }
      }
     },
     "localname": "ClinicalServicesSegmentMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_CommercialInsuranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Insurance",
        "label": "Commercial Insurance [Member]",
        "terseLabel": "Commercial insurance"
       }
      }
     },
     "localname": "CommercialInsuranceMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_CommonStockClosingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock closing price.",
        "label": "Common Stock Closing Price",
        "verboseLabel": "Common stock closing price (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockClosingPrice",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "neo_CommonStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Offering",
        "label": "Common Stock Offering [Member]",
        "terseLabel": "Common Stock Offering"
       }
      }
     },
     "localname": "CommonStockOfferingMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ComputerHardwareAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer hardware and office equipment.",
        "label": "Computer Hardware And Office Equipment [Member]",
        "terseLabel": "Computer hardware and office equipment"
       }
      }
     },
     "localname": "ComputerHardwareAndOfficeEquipmentMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Notes, Aggregate Principle Amount Rate",
        "label": "Debt Instrument, Convertible Notes, Aggregate Principle Amount Rate",
        "terseLabel": "Principal amount priced to investors (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNotesAggregatePrincipleAmountRate",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "neo_DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Threshold of Default, Percent Of Owners Of Debt",
        "label": "Debt Instrument, Covenant, Threshold of Default, Percent Of Owners Of Debt",
        "terseLabel": "Ownership of convertible notes (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantThresholdOfDefaultPercentOfOwnersOfDebt",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_DeferredTaxAssetsInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest Expense",
        "label": "Deferred Tax Assets, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestExpense",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-of-Use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-of-Use Asset",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan additional maximum annual contributions per employee percent.",
        "label": "Defined Contribution Plan Additional Maximum Annual Contributions Per Employee Percent",
        "verboseLabel": "Maximum company match (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanAdditionalMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employer matching additional contribution upon employee percent.",
        "label": "Defined Contribution Plan Employer Matching Additional Contribution Upon Employee Percent",
        "verboseLabel": "Additional percentage of compensation subject to matching contribution (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_DerivativeTerminationFee": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Termination Fee",
        "label": "Derivative, Termination Fee",
        "negatedTerseLabel": "Cash flow hedge termination",
        "terseLabel": "Termination fee"
       }
      }
     },
     "localname": "DerivativeTerminationFee",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_DiscountedPriceOfAggregatePrincipleRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounted Price of Aggregate Principle Rate",
        "label": "Discounted Price of Aggregate Principle Rate",
        "terseLabel": "Discount on principal amount (as a percent)"
       }
      }
     },
     "localname": "DiscountedPriceOfAggregatePrincipleRate",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "neo_EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Other Tax Credits, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Other Tax Credits, Percent",
        "terseLabel": "Tax credits (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherTaxCreditsPercent",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_EffectiveIncomeTaxRateReconciliationPenaltiesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Penalties, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Penalties, Percent",
        "terseLabel": "Penalties (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPenaltiesPercent",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Return To Provision, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Return To Provision, Percent",
        "terseLabel": "Return to provision (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent",
        "terseLabel": "Transaction Costs (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTransactionCostsPercent",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_EffectiveIncomeTaxRateReconciliationTransactionExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Transaction Expenses",
        "label": "Effective Income Tax Rate Reconciliation, Transaction Expenses",
        "verboseLabel": "Transaction expenses (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTransactionExpenses",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Positions, Percent",
        "terseLabel": "Uncertain tax position (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_EmployeeRetentionTaxCreditCARESAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Retention Tax Credit, CARES Act",
        "label": "Employee Retention Tax Credit, CARES Act",
        "terseLabel": "Amount of ERTC recognized, COVID-19"
       }
      }
     },
     "localname": "EmployeeRetentionTaxCreditCARESAct",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Additional Investment",
        "label": "Equity Securities without Readily Determinable Fair Value, Additional Investment",
        "terseLabel": "Additional investment in non-consolidated affiliate"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAdditionalInvestment",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_FairValueOfCommonStockIssuedToFundAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock issued to fund acquisition.",
        "label": "Fair Value Of Common Stock Issued To Fund Acquisition",
        "terseLabel": "Fair value of common stock issued to fund acquisition"
       }
      }
     },
     "localname": "FairValueOfCommonStockIssuedToFundAcquisition",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_FederalHealthcareProgramRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Healthcare Program Revenue",
        "label": "Federal Healthcare Program Revenue [Member]",
        "terseLabel": "Federal Healthcare Program Revenue"
       }
      }
     },
     "localname": "FederalHealthcareProgramRevenueMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_FinanceObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Obligations [Member]",
        "label": "Finance Obligations [Member]",
        "terseLabel": "Finance Obligations"
       }
      }
     },
     "localname": "FinanceObligationsMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_GainLossOnInvestmentAndLoanReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Investment and Loan Receivable",
        "label": "Gain (Loss) On Investment and Loan Receivable",
        "negatedTerseLabel": "Gain on investment in and loan receivable from non-consolidated affiliate, net"
       }
      }
     },
     "localname": "GainLossOnInvestmentAndLoanReceivable",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_GainLossOnTerminationOfInterestRateSwap": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Termination Of Interest Rate Swap",
        "label": "Gain (Loss) On Termination Of Interest Rate Swap",
        "negatedTerseLabel": "Loss on termination of cash flow hedge"
       }
      }
     },
     "localname": "GainLossOnTerminationOfInterestRateSwap",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "verboseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "verboseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_IncreaseDecreaseInPrepaidConstruction": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Construction",
        "label": "Increase (Decrease) in Prepaid Construction",
        "negatedTerseLabel": "Prepaid lease asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidConstruction",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InivataMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inivata",
        "label": "Inivata [Member]",
        "terseLabel": "Inivata"
       }
      }
     },
     "localname": "InivataMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_InterestExpenseDebtAccretionOfDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Accretion Of Debt Discount",
        "label": "Interest Expense, Debt, Accretion Of Debt Discount",
        "terseLabel": "Interest expense, accretion of debt discount"
       }
      }
     },
     "localname": "InterestExpenseDebtAccretionOfDebtDiscount",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Amortization Of Debt Issuance Costs",
        "label": "Interest Expense, Debt, Amortization Of Debt Issuance Costs",
        "terseLabel": "Interest expense, amortization of debt issuance costs"
       }
      }
     },
     "localname": "InterestExpenseDebtAmortizationOfDebtIssuanceCosts",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InterestExpenseDebtContractualCouponInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Contractual Coupon Interest",
        "label": "Interest Expense, Debt, Contractual Coupon Interest",
        "terseLabel": "Interest expense, contractual coupon interest"
       }
      }
     },
     "localname": "InterestExpenseDebtContractualCouponInterest",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InterestRateSwapDecember2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap December 2016 [Member]",
        "label": "Interest Rate Swap December 2016 [Member]",
        "terseLabel": "Previous interest rate swap agreement"
       }
      }
     },
     "localname": "InterestRateSwapDecember2016Member",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_InterestRateSwapJune2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Swap June 2018",
        "label": "Interest Rate Swap June 2018 [Member]",
        "terseLabel": "Interest Rate Swap June 2018"
       }
      }
     },
     "localname": "InterestRateSwapJune2018Member",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_LesseeOperatingLeaseLeaseNotYetCommencedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "terseLabel": "Minimum lease payments for leases executed but not commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal After Year Five",
        "label": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Five",
        "label": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year One",
        "label": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearOne",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_LongTermDebtIncludingCurrentMaturitiesDue": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt including current maturities due.",
        "label": "Long Term Debt Including Current Maturities Due",
        "totalLabel": "Total Debt"
       }
      }
     },
     "localname": "LongTermDebtIncludingCurrentMaturitiesDue",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_LongTermLineOfCreditSettlementGainLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Line of Credit, Settlement, Gain (Loss)",
        "label": "Long Term Line of Credit, Settlement, Gain (Loss)",
        "terseLabel": "Gain on settlement under line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCreditSettlementGainLoss",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt and Finance Lease Obligations, Including Current Maturities",
        "label": "Long-term Debt and Finance Lease Obligations, Including Current Maturities",
        "totalLabel": "Total Debt"
       }
      }
     },
     "localname": "LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Four",
        "label": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Three",
        "label": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "neo_LongtermDebtAndFinanceLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Two",
        "label": "Long-term Debt and Finance Lease Obligations, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongtermDebtAndFinanceLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_MedicareAndMedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare and Medicaid",
        "label": "Medicare and Medicaid [Member]",
        "terseLabel": "Medicare and other government"
       }
      }
     },
     "localname": "MedicareAndMedicaidMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_OnePointTwoFivePercentConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Five Percent Convertible Senior Notes",
        "label": "One Point Two Five Percent Convertible Senior Notes [Member]",
        "terseLabel": "1.25% Convertible Senior Notes"
       }
      }
     },
     "localname": "OnePointTwoFivePercentConvertibleSeniorNotesMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Termination",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Termination",
        "negatedTerseLabel": "Cash flow hedge termination reclassified to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossTermination",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_OtherCurrentAssetsPolicyPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current assets policy.",
        "label": "Other Current Assets Policy Policy [Policy Text Block]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsPolicyPolicyPolicyTextBlock",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "neo_PatentInfringementComplaintMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement Complaint",
        "label": "Patent Infringement Complaint [Member]",
        "terseLabel": "Patent Infringement Complaint"
       }
      }
     },
     "localname": "PatentInfringementComplaintMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PaymentsOfPremiumsForCappedCallConfirmations": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Premiums For Capped Call Confirmations",
        "label": "Payments Of Premiums For Capped Call Confirmations",
        "negatedTerseLabel": "Premiums paid for capped call transactions"
       }
      }
     },
     "localname": "PaymentsOfPremiumsForCappedCallConfirmations",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_PaymentsToAcquireVariableInterestEntitiesTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Variable Interest Entities, Transaction Costs",
        "label": "Payments To Acquire Variable Interest Entities, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "PaymentsToAcquireVariableInterestEntitiesTransactionCosts",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated assets, net revenues and net income reported by reportable operating segment.",
        "label": "Percentage Of Consolidated Assets Net Revenues And Net Income Reported By Reportable Operating Segment",
        "verboseLabel": "Percentage of consolidated assets, net revenues and net income reported by reportable operating segment"
       }
      }
     },
     "localname": "PercentageOfConsolidatedAssetsNetRevenuesAndNetIncomeReportedByReportableOperatingSegment",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_PharmaServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Services [Member]",
        "label": "Pharma Services [Member]",
        "terseLabel": "Pharma Services"
       }
      }
     },
     "localname": "PharmaServicesMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PharmaServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma services segment.",
        "label": "Pharma Services Segment [Member]",
        "verboseLabel": "Pharma Services"
       }
      }
     },
     "localname": "PharmaServicesSegmentMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PolymeraseChainReactionTestingExitCostsCOVID19": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Polymerase Chain Reaction Testing, Exit Costs, COVID-19",
        "label": "Polymerase Chain Reaction Testing, Exit Costs, COVID-19",
        "terseLabel": "Write off of COVID-19 PCR testing inventory and equipment"
       }
      }
     },
     "localname": "PolymeraseChainReactionTestingExitCostsCOVID19",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19",
        "label": "Polymerase Chain Reaction Testing, General and Administrative Expenses, COVID-19",
        "terseLabel": "PCR testing equipment, general and administrative"
       }
      }
     },
     "localname": "PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_PolymeraseChainReactionTestingWriteOffsCOVID19": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Polymerase Chain Reaction Testing, Write-Offs, COVID-19",
        "label": "Polymerase Chain Reaction Testing, Write-Offs, COVID-19",
        "terseLabel": "Write off of remaining COVID-19 PCR testing inventory"
       }
      }
     },
     "localname": "PolymeraseChainReactionTestingWriteOffsCOVID19",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_PreferenceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preference Shares",
        "label": "Preference Shares [Member]",
        "terseLabel": "Preference Shares"
       }
      }
     },
     "localname": "PreferenceSharesMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PrepaidRentNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Rent, Noncurrent",
        "label": "Prepaid Rent, Noncurrent",
        "terseLabel": "Prepaid lease asset"
       }
      }
     },
     "localname": "PrepaidRentNoncurrent",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_ProceedsFromEquityOfferingNet": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Equity Offering, Net",
        "label": "Proceeds From Equity Offering, Net",
        "terseLabel": "Proceeds from equity offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromEquityOfferingNet",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_ProceedsFromGovernmentAssistanceCARESAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Government Assistance, CARES Act",
        "label": "Proceeds from Government Assistance, CARES Act",
        "terseLabel": "Grant income recognized, COVID-19"
       }
      }
     },
     "localname": "ProceedsFromGovernmentAssistanceCARESAct",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_PurchaseOptionMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Option, Measurement Input",
        "label": "Purchase Option, Measurement Input",
        "terseLabel": "Purchase option, measurement input (as a percent)"
       }
      }
     },
     "localname": "PurchaseOptionMeasurementInput",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "neo_PurchaseOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Option",
        "label": "Purchase Option [Member]",
        "terseLabel": "Purchase Option"
       }
      }
     },
     "localname": "PurchaseOptionMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_RangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range five.",
        "label": "Range Five [Member]",
        "verboseLabel": "43.50 \u2013 55.40"
       }
      }
     },
     "localname": "RangeFiveMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_RangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range four.",
        "label": "Range Four [Member]",
        "verboseLabel": "27.98 \u2013 43.49"
       }
      }
     },
     "localname": "RangeFourMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_RangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range one.",
        "label": "Range One [Member]",
        "verboseLabel": "7.27 \u2013 8.21"
       }
      }
     },
     "localname": "RangeOneMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_RangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range three.",
        "label": "Range Three [Member]",
        "verboseLabel": "19.77 \u2013 27.97"
       }
      }
     },
     "localname": "RangeThreeMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_RangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range two.",
        "label": "Range Two [Member]",
        "verboseLabel": "8.22 \u2013 19.76"
       }
      }
     },
     "localname": "RangeTwoMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ReceivableWithImputedInterestNonConsolidatedAffiliates": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable With Imputed Interest, Non-Consolidated Affiliates",
        "label": "Receivable With Imputed Interest, Non-Consolidated Affiliates",
        "negatedTerseLabel": "Interest on loan receivable from non-consolidated affiliate"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestNonConsolidatedAffiliates",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_RepaymentsOfEquipmentAndOtherLoans": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of Equipment and Other Loans",
        "label": "Repayments of Equipment and Other Loans",
        "negatedLabel": "Repayment of equipment financing obligations"
       }
      }
     },
     "localname": "RepaymentsOfEquipmentAndOtherLoans",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Increase From New Contracts, Amount",
        "label": "Revenue, Remaining Performance Obligation, Increase From New Contracts, Amount",
        "terseLabel": "Amount of new contracts signed"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationIncreaseFromNewContractsAmount",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_SaleOfStockOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Option, Term",
        "label": "Sale Of Stock, Option, Term",
        "terseLabel": "Sale of stock, option term"
       }
      }
     },
     "localname": "SaleOfStockOptionTerm",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "neo_SaleOfStockPremiumOnOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Premium On Offering Price",
        "label": "Sale of Stock, Premium On Offering Price",
        "terseLabel": "Premium on offering price (as a percent)"
       }
      }
     },
     "localname": "SaleOfStockPremiumOnOfferingPrice",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "neo_SaleOfStockPricePerSharePublicOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Price Per Share, Public Offering Price",
        "label": "Sale of Stock, Price Per Share, Public Offering Price",
        "terseLabel": "Public offering price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerSharePublicOfferingPrice",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "neo_ScheduleOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of significant accounting policies.",
        "label": "Schedule Of Significant Accounting Policies [Line Items]",
        "verboseLabel": "Schedule Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_ScheduleOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of significant accounting policies.",
        "label": "Schedule Of Significant Accounting Policies [Table]",
        "verboseLabel": "Schedule Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "ScheduleOfSignificantAccountingPoliciesTable",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_SelfPayServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Self Pay Services",
        "label": "Self Pay Services [Member]",
        "terseLabel": "Self-pay"
       }
      }
     },
     "localname": "SelfPayServicesMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options grants in period aggregate grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Aggregate Grant Date Fair Value",
        "verboseLabel": "Fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateGrantDateFairValue",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of in-the-money options outstanding and exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Number",
        "verboseLabel": "Options outstanding and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "neo_SocialSecurityTaxEmployerDeferralCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Social Security Tax, Employer, Deferral, CARES Act",
        "label": "Social Security Tax, Employer, Deferral, CARES Act",
        "terseLabel": "Accrued deferred social security taxes, COVID-19"
       }
      }
     },
     "localname": "SocialSecurityTaxEmployerDeferralCARESAct",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, New Issues, Private Placement",
        "label": "Stock Issued During Period, Shares, New Issues, Private Placement",
        "terseLabel": "Issuance of common stock - private placement, net of private placement fees (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "neo_StockIssuedDuringPeriodValueNewIssuesPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, New Issues, Private Placement",
        "label": "Stock Issued During Period, Value, New Issues, Private Placement",
        "terseLabel": "Issuance of common stock - private placement, net of private placement fees"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesPrivatePlacement",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_StrategicAllianceWithInivataLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Alliance With Inivata Limited",
        "label": "Strategic Alliance With Inivata Limited [Member]",
        "terseLabel": "Strategic Alliance With Inivata Limited"
       }
      }
     },
     "localname": "StrategicAllianceWithInivataLimitedMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_TrapeloHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trapelo Health",
        "label": "Trapelo Health [Member]",
        "terseLabel": "Trapelo Health"
       }
      }
     },
     "localname": "TrapeloHealthMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/EquityTransactionsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_WorkingCapitalAdjustmentAcquisitionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital Adjustment, Acquisition, Shares",
        "label": "Working Capital Adjustment, Acquisition, Shares",
        "negatedTerseLabel": "Working capital adjustment related to acquisition (in shares)"
       }
      }
     },
     "localname": "WorkingCapitalAdjustmentAcquisitionShares",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "neo_WorkingCapitalAdjustmentAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital Adjustment, Acquisitions",
        "label": "Working Capital Adjustment, Acquisitions",
        "negatedLabel": "Working capital adjustment related to acquisition",
        "terseLabel": "Working capital adjustment related to acquisition"
       }
      }
     },
     "localname": "WorkingCapitalAdjustmentAcquisitions",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_WriteOffForCOVID19PCRTestingInventoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write Off For COVID-19 PCR Testing Inventory",
        "label": "Write Off For COVID-19 PCR Testing Inventory [Member]",
        "terseLabel": "Write Off For COVID-19 PCR Testing Inventory"
       }
      }
     },
     "localname": "WriteOffForCOVID19PCRTestingInventoryMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_YankeeBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yankee Bonds",
        "label": "Yankee Bonds [Member]",
        "terseLabel": "Yankee bonds"
       }
      }
     },
     "localname": "YankeeBondsMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Two Five Percent Convertible Senior Notes",
        "label": "Zero Point Two Five Percent Convertible Senior Notes [Member]",
        "terseLabel": "0.25% Convertible Senior Notes"
       }
      }
     },
     "localname": "ZeroPointTwoFivePercentConvertibleSeniorNotesMember",
     "nsuri": "http://neogenomics.com/20211231",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r437",
      "r648",
      "r649",
      "r651",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r131",
      "r323",
      "r327",
      "r332",
      "r570",
      "r571",
      "r575",
      "r576",
      "r654",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r131",
      "r323",
      "r327",
      "r332",
      "r570",
      "r571",
      "r575",
      "r576",
      "r654",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r0",
      "r136",
      "r142",
      "r149",
      "r250",
      "r491",
      "r492",
      "r493",
      "r527",
      "r528",
      "r596",
      "r598",
      "r599",
      "r600",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r0",
      "r136",
      "r142",
      "r149",
      "r250",
      "r491",
      "r492",
      "r493",
      "r527",
      "r528",
      "r596",
      "r598",
      "r599",
      "r600",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r0",
      "r136",
      "r142",
      "r149",
      "r250",
      "r491",
      "r492",
      "r493",
      "r527",
      "r528",
      "r596",
      "r598",
      "r599",
      "r600",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r339",
      "r375",
      "r448",
      "r450",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r688",
      "r756",
      "r759",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r339",
      "r375",
      "r448",
      "r450",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r688",
      "r756",
      "r759",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r215",
      "r418",
      "r422",
      "r694",
      "r755",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r215",
      "r418",
      "r422",
      "r694",
      "r755",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r339",
      "r375",
      "r427",
      "r448",
      "r450",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r688",
      "r756",
      "r759",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]",
        "verboseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r339",
      "r375",
      "r427",
      "r448",
      "r450",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r688",
      "r756",
      "r759",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]",
        "verboseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r133",
      "r134",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r166",
      "r251",
      "r252",
      "r494",
      "r528",
      "r597",
      "r599",
      "r600",
      "r601",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r825",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r133",
      "r134",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r166",
      "r251",
      "r252",
      "r494",
      "r528",
      "r597",
      "r599",
      "r600",
      "r601",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r825",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r1",
      "r133",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r144",
      "r145",
      "r147",
      "r148",
      "r166",
      "r251",
      "r252",
      "r494",
      "r528",
      "r597",
      "r599",
      "r600",
      "r601",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r825",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r216",
      "r217",
      "r418",
      "r423",
      "r758",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r418",
      "r423",
      "r758",
      "r785",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://neogenomics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchaseProgramAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to adjust previously recorded stockholders' equity balances to the actual aggregate amounts paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.",
        "label": "Accelerated Share Repurchase Program, Adjustment",
        "terseLabel": "Incremental stock-based compensation for accelerated vesting"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseProgramAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r48",
      "r657"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r36",
      "r221",
      "r222"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r46",
      "r297"
     ],
     "calculation": {
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization",
        "verboseLabel": "Accumulated depreciation on property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r39",
      "r68",
      "r69",
      "r70",
      "r741",
      "r765",
      "r769"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r67",
      "r70",
      "r78",
      "r79",
      "r80",
      "r133",
      "r134",
      "r135",
      "r574",
      "r760",
      "r761",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "verboseLabel": "Amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r491",
      "r492",
      "r493",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of Convertible Senior Notes due 2025"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "verboseLabel": "ESPP expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r452",
      "r454",
      "r497",
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation expense - options and restricted stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r388",
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Stock issuance fees and expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net\u00a0cash\u00a0provided\u00a0by operating\u00a0activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r454",
      "r487",
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r92",
      "r109",
      "r359",
      "r624"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of convertible debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r88",
      "r109",
      "r359",
      "r626"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r109",
      "r279",
      "r287"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities excluded from EPS calculation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "verboseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "verboseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r241",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r191",
      "r204",
      "r211",
      "r248",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r570",
      "r575",
      "r615",
      "r655",
      "r657",
      "r711",
      "r738"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Carrying amount of investment in non-consolidated affiliate",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r63",
      "r126",
      "r248",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r570",
      "r575",
      "r615",
      "r655",
      "r657"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r293",
      "r657"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r126",
      "r248",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r570",
      "r575",
      "r615",
      "r655"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r236",
      "r240",
      "r731"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Over Five Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r236",
      "r239",
      "r730"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Over One Year Through Five Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r236",
      "r238",
      "r729"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "One Year or Less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r231",
      "r258"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities, at fair value",
        "totalLabel": "Total",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r455",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r447",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "verboseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/EquityTransactionsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r447",
      "r449",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]",
        "verboseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/EquityTransactionsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Voting interests acquired (as a percent)"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill, expected tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r561",
      "r562",
      "r563"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r561",
      "r562"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Common stock issued for consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": {
     "auth_ref": [
      "r544",
      "r563"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to,  instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination",
        "totalLabel": "Total fair value of business combination"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.",
        "label": "Business Combination, Consideration Transferred, Other",
        "terseLabel": "Lin of credit settled as consideration for acquisition",
        "verboseLabel": "Fair value of Line of Credit"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Net loss from acquiree"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue from acquiree"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred",
        "terseLabel": "Measurement period adjustments, net assets acquired",
        "totalLabel": "Measurement period adjustments, net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to equity interests acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests",
        "terseLabel": "Measurement period adjustments, fair value of previously-held equity interest"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "neo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to financial assets acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets",
        "totalLabel": "Measurement period adjustments, total identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "terseLabel": "Measurement period adjustments, identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedTerseLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r552",
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r552",
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total purchase consideration"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Fair value of previously-held equity interest"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "negatedTerseLabel": "Gain on investment in and loan receivable from non-consolidated affiliate, net",
        "terseLabel": "Gain on investment in and loan receivable from non-consolidated affiliate, net"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r114",
      "r115",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Lease Obligations [Abstract]",
        "terseLabel": "Financing Obligations [Abstract]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Lease Obligation Incurred",
        "terseLabel": "Equipment acquired under financing obligations"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Abstract]",
        "terseLabel": "Capitalized Contract Cost [Abstract]"
       }
      }
     },
     "localname": "CapitalizedContractCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "totalLabel": "Total pharma capitalized commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetCurrent": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalizedContractCostGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.",
        "label": "Capitalized Contract Cost, Net, Current",
        "terseLabel": "Current pharma capitalized commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalizedContractCostGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Long-term pharma capitalized commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r43",
      "r111"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r18",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r105",
      "r111",
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r105",
      "r616"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r58",
      "r309",
      "r718",
      "r745"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 17)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r316",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r319",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDiscountOnShares": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.",
        "label": "Common Stock, Discount on Shares",
        "terseLabel": "Discount on shares"
       }
      }
     },
     "localname": "CommonStockDiscountOnShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://neogenomics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common Stock, Shares, Issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r35",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common Stock, Shares, Outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, (250,000,000 shares authorized; 124,107,500 and 112,075,474 shares issued and outstanding, respectively)"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "verboseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r74",
      "r76",
      "r77",
      "r85",
      "r723",
      "r750"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "COMPREHENSIVE (LOSS) INCOME"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r280",
      "r285",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Contract with Customer, Asset and Liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r397",
      "r399",
      "r419"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "totalLabel": "Total pharma contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Contract with Customer, Asset, Net [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r397",
      "r399",
      "r419"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Current pharma contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r397",
      "r399",
      "r419"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term pharma contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r397",
      "r398",
      "r419"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total pharma contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r397",
      "r398",
      "r419"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current pharma contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r397",
      "r398",
      "r419"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term pharma contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Pharma contract liability, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r334",
      "r336",
      "r337",
      "r339",
      "r349",
      "r350",
      "r351",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r367",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debt Securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r90",
      "r694"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold [Abstract]",
        "verboseLabel": "Cost of revenue:"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]",
        "verboseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]",
        "verboseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r524",
      "r531"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r524",
      "r531",
      "r533"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax (benefit) expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r524",
      "r531"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r717",
      "r746"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "terseLabel": "Total debt"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r353",
      "r360",
      "r361",
      "r363",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r125",
      "r131",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r367",
      "r368",
      "r369",
      "r370",
      "r627",
      "r712",
      "r714",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r29",
      "r364",
      "r714",
      "r737"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r338",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Convertible Notes, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r55",
      "r338",
      "r389",
      "r390",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Convertible Notes, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Conversion price on applicable trading day (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r336",
      "r367",
      "r368",
      "r625",
      "r627",
      "r628"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r351",
      "r367",
      "r368",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r54",
      "r356",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Effective interest rate on Convertible Notes (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r54",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "verboseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r56",
      "r125",
      "r131",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r367",
      "r368",
      "r369",
      "r370",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price of principal (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r56",
      "r125",
      "r131",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r367",
      "r368",
      "r369",
      "r370",
      "r389",
      "r391",
      "r392",
      "r393",
      "r624",
      "r625",
      "r627",
      "r628",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "verboseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r349",
      "r624",
      "r628"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r237",
      "r258",
      "r259",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r233",
      "r258"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Prepaid Assets"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r525",
      "r531"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r47",
      "r349",
      "r626"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Less:\u00a0Unamortized debt issuance costs",
        "negatedTerseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r525",
      "r531"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "verboseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r109",
      "r127",
      "r525",
      "r531",
      "r532",
      "r533"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred benefit provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r32",
      "r33",
      "r515",
      "r713",
      "r736"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r525",
      "r531"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carry-forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards that do not expire"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards that expire"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r520",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails",
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r504",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedLabel": "Net deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs",
        "negatedTerseLabel": "Convertible debt discount"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.",
        "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates",
        "negatedTerseLabel": "Investment in non-consolidated affiliate"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r522",
      "r523"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesCurrentandNoncurrentDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "verboseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "verboseLabel": "Matching percentage of company of every dollar contributed (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "verboseLabel": "Additional matching contribution (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "verboseLabel": "Maximum annual contribution (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r109",
      "r295"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "verboseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Fixed Rate (as a percent)"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r64",
      "r586",
      "r587",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "verboseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r595",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r584",
      "r586",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "verboseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r580",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount of derivative"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r579",
      "r581",
      "r582",
      "r584",
      "r585",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "verboseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Identifiable intangible assets - developed technology",
        "verboseLabel": "Developed Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "verboseLabel": "NET (LOSS) INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net (Loss) Income per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r128",
      "r506",
      "r534"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Federal statutory rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r506",
      "r534"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Valuation allowance (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r506",
      "r534"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Foreign Tax Rate Differential (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r506",
      "r534"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "verboseLabel": "Non-deductible expenses (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r506",
      "r534"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "verboseLabel": "Compensation expense (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r506",
      "r534"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other, net (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r506",
      "r534"
     ],
     "calculation": {
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal income tax benefit (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesReconciliationofEffectiveTaxRateandtheFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Unrecognized stock based compensation, weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r78",
      "r79",
      "r80",
      "r133",
      "r134",
      "r135",
      "r138",
      "r145",
      "r148",
      "r170",
      "r250",
      "r388",
      "r394",
      "r491",
      "r492",
      "r493",
      "r527",
      "r528",
      "r599",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r760",
      "r761",
      "r762",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "verboseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investment in Non-Consolidated Affiliate"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonconsolidatedAffiliate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r246",
      "r752"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain on remeasurement"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Investment in non-consolidated affiliate"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "terseLabel": "Net unrealized loss from remeasurement of investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r351",
      "r367",
      "r368",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r443",
      "r604",
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r603",
      "r604",
      "r607",
      "r608",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r351",
      "r428",
      "r430",
      "r435",
      "r443",
      "r604",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r351",
      "r367",
      "r368",
      "r428",
      "r430",
      "r435",
      "r443",
      "r604",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r351",
      "r367",
      "r368",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r443",
      "r604",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r351",
      "r367",
      "r368",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r443",
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r609",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Current portion",
        "negatedTerseLabel": "Less: Current portion of equipment financing obligations",
        "terseLabel": "Current portion of equipment financing obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Equipment financing obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total Debt"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r263",
      "r264",
      "r362",
      "r386",
      "r595",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Finite-lived Intangible Assets Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r280",
      "r283",
      "r286",
      "r290",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "verboseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r286",
      "r696"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "verboseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r280",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r286",
      "r695"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails",
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r109",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on debt extinguishment",
        "negatedTerseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r272",
      "r273",
      "r657",
      "r710"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r275",
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Measurement period adjustments, goodwill"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r89",
      "r126",
      "r191",
      "r203",
      "r207",
      "r210",
      "r213",
      "r248",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r615"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "GROSS PROFIT",
        "verboseLabel": "Gross Profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit [Abstract]",
        "verboseLabel": "Gross profit:"
       }
      }
     },
     "localname": "GrossProfitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r584",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HerMajestysRevenueAndCustomsHMRCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of United Kingdom.",
        "label": "Her Majesty's Revenue and Customs (HMRC) [Member]",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "HerMajestysRevenueAndCustomsHMRCMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r109",
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r109",
      "r294",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "verboseLabel": "Impairment of long-lived assets held-for-use"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Recoverability and Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r191",
      "r203",
      "r207",
      "r210",
      "r213",
      "r709",
      "r720",
      "r727",
      "r753"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "(Loss) income before income tax (benefit) expense",
        "totalLabel": "(Loss) income before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r81",
      "r86",
      "r137",
      "r139",
      "r140",
      "r142",
      "r143",
      "r153",
      "r160",
      "r161",
      "r601",
      "r719",
      "r721",
      "r724",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net (loss) income per share(in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r81",
      "r86",
      "r137",
      "r139",
      "r140",
      "r142",
      "r143",
      "r153",
      "r160",
      "r161",
      "r162",
      "r601",
      "r724",
      "r747",
      "r749",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net (loss) income per share (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r300",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]",
        "verboseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails",
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]",
        "verboseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails",
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r507",
      "r514",
      "r519",
      "r529",
      "r535",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r147",
      "r148",
      "r189",
      "r505",
      "r530",
      "r536",
      "r754"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Total tax benefit provision",
        "verboseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid, net"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable, operating lease liabilities, deferred taxes, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options and restricted stock awards (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r282",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets, cost"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r282",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r120",
      "r285",
      "r691",
      "r692",
      "r693",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross (excluding goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r278",
      "r284"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndFeeIncomeLoansAndLeases": {
     "auth_ref": [
      "r725"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases.",
        "label": "Interest and Fee Income, Loans and Leases",
        "terseLabel": "Interest income from loan receivable"
       }
      }
     },
     "localname": "InterestAndFeeIncomeLoansAndLeases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r82",
      "r185",
      "r623",
      "r626",
      "r726"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r104",
      "r106",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r60",
      "r657"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r61",
      "r121",
      "r169",
      "r265",
      "r266",
      "r267",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesNarrativeDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r126",
      "r205",
      "r248",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r571",
      "r575",
      "r576",
      "r615",
      "r655",
      "r656"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r42",
      "r126",
      "r248",
      "r615",
      "r657",
      "r716",
      "r743"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r53",
      "r126",
      "r248",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r571",
      "r575",
      "r576",
      "r615",
      "r655",
      "r656",
      "r657"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r29",
      "r30",
      "r126",
      "r248",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r571",
      "r575",
      "r576",
      "r615",
      "r655",
      "r656"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r29",
      "r714",
      "r737"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amount outstanding under line of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Imputed interest rate (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Interest rate per annum (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]",
        "verboseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r49",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "verboseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the assets held for sale.",
        "label": "Long Lived Assets Held-for-sale by Asset Type [Axis]",
        "terseLabel": "Long Lived Assets Held-for-sale by Asset Type [Axis]"
       }
      }
     },
     "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongLivedAssetsHeldForSaleNameDomain": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A name of the assets to be disposed.",
        "label": "Long Lived Assets Held-for-sale, Name [Domain]",
        "terseLabel": "Long Lived Assets Held-for-sale, Name [Domain]"
       }
      }
     },
     "localname": "LongLivedAssetsHeldForSaleNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r29",
      "r350",
      "r365",
      "r367",
      "r368",
      "r714",
      "r739"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long term debt outstanding",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Total long-term debt, net",
        "verboseLabel": "Total long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt and Lease Obligation [Abstract]",
        "terseLabel": "Total Long-Term Debt [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "negatedLabel": "Less:\u00a0Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, by Current and Noncurrent [Abstract]",
        "terseLabel": "Term Loan [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less:\u00a0Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r131",
      "r321",
      "r355"
     ],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "neo_LongTermDebtIncludingCurrentMaturitiesDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r131",
      "r321",
      "r355"
     ],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "neo_LongTermDebtIncludingCurrentMaturitiesDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r131",
      "r321",
      "r355"
     ],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "neo_LongTermDebtIncludingCurrentMaturitiesDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r131",
      "r321",
      "r355"
     ],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "neo_LongTermDebtIncludingCurrentMaturitiesDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r131",
      "r321",
      "r355"
     ],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "neo_LongTermDebtIncludingCurrentMaturitiesDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r131",
      "r321",
      "r355"
     ],
     "calculation": {
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "neo_LongTermDebtIncludingCurrentMaturitiesDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtPercentageBearingVariableInterestAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-term Debt, Percentage Bearing Variable Interest, Amount",
        "terseLabel": "Outstanding derivative instruments"
       }
      }
     },
     "localname": "LongtermDebtPercentageBearingVariableInterestAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r56",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails",
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.",
        "label": "Marketing-Related Intangible Assets [Member]",
        "terseLabel": "Marketing Assets"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Measurement Input, Expected Dividend Rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Measurement Input, Price Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r105",
      "r107",
      "r110"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r4",
      "r72",
      "r75",
      "r80",
      "r84",
      "r110",
      "r126",
      "r137",
      "r139",
      "r140",
      "r142",
      "r143",
      "r147",
      "r148",
      "r158",
      "r191",
      "r203",
      "r207",
      "r210",
      "r213",
      "r248",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r601",
      "r615",
      "r722",
      "r748"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "NET (LOSS) INCOME",
        "verboseLabel": "NET (LOSS) INCOME"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome",
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r139",
      "r140",
      "r142",
      "r143",
      "r150",
      "r151",
      "r159",
      "r162",
      "r191",
      "r203",
      "r207",
      "r210",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestInVariableInterestEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).",
        "label": "Noncontrolling Interest in Variable Interest Entity",
        "terseLabel": "Investment in minority interest"
       }
      }
     },
     "localname": "NoncontrollingInterestInVariableInterestEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "verboseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://neogenomics.com/role/SegmentInformationDetails",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r191",
      "r203",
      "r207",
      "r210",
      "r213"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "(LOSS) INCOME FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r637",
      "r644"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesSummaryofAdditionalSupplementalDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r631"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r632",
      "r638"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesSummaryofAdditionalSupplementalDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r641",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r640",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesSignificantComponentsoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r5",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r62",
      "r657"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r65",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Loss on effective cash flow hedge"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r65",
      "r68"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized loss on effective cash flow hedge, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r68",
      "r71"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Cash flow hedge termination reclassified to earnings, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome",
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r73",
      "r76",
      "r568",
      "r569",
      "r573"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive (loss) income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "OTHER COMPREHENSIVE (LOSS) INCOME:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofComprehensiveLossIncome",
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r29",
      "r714",
      "r739"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-term Debt",
        "terseLabel": "Equipment financing obligations"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense (income), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security, recognized in earnings.",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Portion Recognized in Earnings",
        "terseLabel": "Other than temporary impairment losses"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of debt issuance costs for term loan"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "terseLabel": "Consideration paid to other shareholders"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r94",
      "r96",
      "r230"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      },
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Business acquisitions, net of cash acquired",
        "terseLabel": "Plus: Cash paid at closing",
        "verboseLabel": "Cash paid at closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedTerseLabel": "Investment in non-consolidated affiliate"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r96",
      "r648"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.",
        "label": "Payments to Fund Long-term Loans to Related Parties",
        "negatedTerseLabel": "Loan receivable from non-consolidated affiliate"
       }
      }
     },
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r427",
      "r429",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r268",
      "r269"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r94",
      "r95",
      "r230"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r99",
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r46",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "verboseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesNarrativeDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r302",
      "r789",
      "r790",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r45",
      "r296"
     ],
     "calculation": {
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r22",
      "r23",
      "r298",
      "r657",
      "r733",
      "r744"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment (net of accumulated depreciation of $109,952 and $92,895, respectively)",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r298",
      "r789",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r22",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r22",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "verboseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesNarrativeDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated Useful Lives in Years"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock": {
     "auth_ref": [
      "r31",
      "r715",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of arrangements in which the entity has agreed to procure goods or services from one or more suppliers. May include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Table Text Block]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "totalLabel": "Total purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableWithImputedInterestDiscount": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the receivable or loan. The discount or premium is the difference between the present value and the face amount.",
        "label": "Receivable with Imputed Interest, Discount",
        "terseLabel": "Loan with imputed interest, discount)"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableWithImputedInterestNetAmount": {
     "auth_ref": [
      "r624"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The receivable or note face amount less the unamortized discount or premium.",
        "label": "Receivable with Imputed Interest, Net Amount",
        "terseLabel": "Present value of loan receivable with imputed interest"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestNetAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RegulatoryIncomeTaxesPolicy": {
     "auth_ref": [
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making).",
        "label": "Regulatory Income Taxes, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "RegulatoryIncomeTaxesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r437",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r437",
      "r648",
      "r649",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r648"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party transaction, expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "verboseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r437",
      "r648",
      "r651",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails",
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r646",
      "r647",
      "r649",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "negatedLabel": "Repayment of revolving credit facility"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedLabel": "Repayment of term loan"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r501",
      "r690",
      "r806"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r13",
      "r26",
      "r117",
      "r786"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://neogenomics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r38",
      "r394",
      "r494",
      "r657",
      "r742",
      "r764",
      "r769"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r133",
      "r134",
      "r135",
      "r138",
      "r145",
      "r148",
      "r250",
      "r491",
      "r492",
      "r493",
      "r527",
      "r528",
      "r599",
      "r760",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r182",
      "r183",
      "r202",
      "r208",
      "r209",
      "r215",
      "r216",
      "r219",
      "r417",
      "r418",
      "r694"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r421",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "verboseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "terseLabel": "Revenue payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Performance obligation, description of timing"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r639",
      "r644"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/LeasesSummaryofAdditionalSupplementalDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Sale of stock, consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/EquityTransactionsDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/EquityTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share (in dollars per share)",
        "verboseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/EquityTransactionsDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "verboseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r56",
      "r131",
      "r367",
      "r369",
      "r389",
      "r391",
      "r392",
      "r393",
      "r624",
      "r625",
      "r628",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r153",
      "r157",
      "r160",
      "r162",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r4",
      "r126",
      "r247",
      "r248",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r280",
      "r285",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "verboseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsAmortizationExpenseofIntangiblesAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Schedule of Interest Rate Derivatives"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DerivativeInstrumentsandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "verboseLabel": "Schedule of Nonvested Share Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r46",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]",
        "verboseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/PropertyandEquipmentNetDepreciationDetails",
      "http://neogenomics.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "verboseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r191",
      "r194",
      "r206",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "verboseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r191",
      "r194",
      "r206",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r455",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "verboseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/EquityTransactionsDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r462",
      "r474",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r178",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r304",
      "r305",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "verboseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r178",
      "r180",
      "r181",
      "r191",
      "r195",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "verboseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "verboseLabel": "Discount from market price (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value of shares granted during period (in dollars per share)",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested, ending balance (in shares)",
        "periodStartLabel": "Nonvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Restricted Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, ending balance (in dollars per share)",
        "periodStartLabel": "Nonvested, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Weighted average fair value per share at grant date (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/EquityTransactionsDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Options exercised during period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails",
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r464",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "verboseLabel": "Number of shares, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding , beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Options, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r453",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]",
        "verboseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r455",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "verboseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "verboseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "verboseLabel": "Range of Exercise Prices, lower limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "verboseLabel": "Number Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "verboseLabel": "Number Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "verboseLabel": "Range of Exercise Prices, upper limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number",
        "terseLabel": "Accelerated vesting (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r482",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Options, exercisable, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails",
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "verboseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationRollForwardofNonVestedStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofInformationaboutourOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r396",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping costs"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r118",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r2",
      "r178",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r276",
      "r301",
      "r304",
      "r305",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsRollforwardofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r59",
      "r78",
      "r79",
      "r80",
      "r133",
      "r134",
      "r135",
      "r138",
      "r145",
      "r148",
      "r170",
      "r250",
      "r388",
      "r394",
      "r491",
      "r492",
      "r493",
      "r527",
      "r528",
      "r599",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r760",
      "r761",
      "r762",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "verboseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r170",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "verboseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r34",
      "r35",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "verboseLabel": "Issuance of common stock for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r34",
      "r35",
      "r388",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Common stock issuance ESPP plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r388",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock - public offering, net of underwriting discounts (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r388",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "Issuance of restricted stock, net of forfeitures (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r35",
      "r388",
      "r394",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock for stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/StockBasedCompensationStatusofOurStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r59",
      "r388",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "verboseLabel": "Issuance of common stock for acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r34",
      "r35",
      "r388",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "verboseLabel": "Common stock issuance ESPP Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r388",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock - public offering, net of underwriting discounts"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r34",
      "r35",
      "r388",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "verboseLabel": "Issuance of restricted stock, net of forfeitures"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r59",
      "r388",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Issuance of common stock for stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r40",
      "r41",
      "r126",
      "r228",
      "r248",
      "r615",
      "r657"
     ],
     "calculation": {
      "http://neogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedBalanceSheets",
      "http://neogenomics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity Transactions"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/EquityTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/DebtNarrativeDetails",
      "http://neogenomics.com/role/EquityTransactionsDetails",
      "http://neogenomics.com/role/NetLossIncomeperShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.",
        "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]",
        "terseLabel": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible"
       }
      }
     },
     "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/AcquisitionsScheduleofProvisionalInformationDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r362",
      "r386",
      "r595",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r130",
      "r428",
      "r443",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r502",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits - December 31",
        "periodStartLabel": "Unrecognized tax benefits - January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reversals of prior year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "terseLabel": "Increases in prior year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases in tax positions taken in current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Statute expirations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).",
        "label": "Variable Interest Entity, Initial Consolidation, Gain (Loss)",
        "terseLabel": "Unrealized gain on investment in non-consolidated affiliate, net"
       }
      }
     },
     "localname": "VariableInterestEntityInitialConsolidationGainOrLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/AcquisitionsNarrativeDetails",
      "http://neogenomics.com/role/InvestmentinNonConsolidatedAffiliateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r152",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Diluted weighted average shares outstanding (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r150",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://neogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://neogenomics.com/role/NetLossIncomeperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL121698322-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123398962&loc=d3e400-110220"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-07)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=6501382&loc=d3e54053-110423"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=6501382&loc=d3e54136-110423"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r807": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r808": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r809": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r810": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r811": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r812": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r813": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r814": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r815": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r816": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r817": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r818": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r819": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r820": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r821": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r822": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r823": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001077183-22-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001077183-22-000017-xbrl.zip
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M?3L0?R&"X,Y]40 #$6Q/>?)Z($'^[&+?W_[3>[QKO'>/THM8&U(![20<U.A
M)<K64@K)^\S>Q)+.U? YHM=BTJN#J+H\HFIAB*:<)'$&<=') 3J=D_98O;55
M)5O,/+_1Z1Q1G=:(?@&B.ET:43EU48A&S8%ME/1!(41KHUP=,F;QN,J"Q=7R
MNH\E@AWA*OO<5!3H*J&3@P&?<G24:C;.L06LCE;+YUXKGDOQN!)!8Z"D=7$6
MF!5&Q%13J#4G,5N]6A[W.O%<CK]5AJ+V8!+' )DX>8*<2O',8 34)=AG+^Q
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M'9F@BPVZ!WO;K/G:>1&R0+J*2I5TUDIR*PK5U&RTYZR#8E>5@[5,7=.U2VI
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M11:4AJ.W(.W< & %=6N6T[N2.;[\+H97PVN#%*:684#V-C9D>:<J#6.58%
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M]7F$&B# D\1F4:.8,@SA6<T6/\E)A[V-4X)(<)[9^O;@7\Q-H:=&@OHQ WG
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MP*WJ>P#@;X9;8#_"VVY5A,#N?";G.'C!,0B&F8!/']_&D1 =<@9;C*QSL&[
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MP',ZOB@G 8P/)1U/#)XHXQ2/.U$TGBKJ1JK2ZEKVX<?D+"-C'*45MH)+JQ1
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M"1(^PY]27ERD2,5B5T$@I'H<%P[C:[/YU$G18X&2MK)5T2H-C@0X*QS[.4X
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ML*SV8=B'].7P[LT.Z("P.B*AROAI@_G\ )9^U$K82>S)"AQY@3XR7"YYWC!
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M>)344$06:Y^XT(Q00A-N\Z^8BC'AZ9N;F'*QDS\Y=C1_=6=EU N6,81Z0&&
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M .^G>BAC.-:BHF\6[@<=F3YSQETW6Q$KEL[-T:]8"!#N*80G??E16C.>?#^
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MF"+?W15I! 5D8MYEOL6R43%#M@Q6A08:Q()N#7B!, J\=SMV[Z!I):"@8LH
MQHP_:N;4B8.D[\#C1O4 V:!.5@4E3QE[9UFL8J2LX;"]E+/$V\UV2[)^C65-
M>/+:<*Y)B@99?JC(<+<!"PLXQDT' 079)9: \W EJ&HL4DG,&'B2TP%N/G@^
MH7G-->"4L["09T-X:QQN\9?<+)P:-&5LY6*O+S%3$N3N!DQ#68/\QKCSX(4H
M8W_JM4P'IZ[CSQI6S[HVQWF>>TT5OW&4YBGQISJ/!T;\6=OX9.?*VB)7%!MG
M:D^\H2. 6%=7]=@>EG4QV\UNJ\';YG<$1002FZLG,HA<=4V-"]RMJN0K$\.B
MGQ5Y"Q6EZ5T49&-97X7&:B.E&3Y'-]7<9PI;C,C3)(CCSH&C"F^G&- VO=[H
M(:VCV'D4NUM'L>LH=AW%WH:^U%'L.HJ]U)[3Z32FT6;EN$?B;=8F6:%:D>,A
MR)OBKGE%#?KM@#Q"TK13AS3?2P=Y;3%6QV25$%"\^"J\M:K?LKF(M\R?%'#4
MME\4H2/NXP:&]"N="H>MQM%A;Y-# 7YY?+2:FEU/L[>[QT]^)K2[C<[!X2N<
M"<^C4XY64BE?I;1NJDFV6JVN-@4WM"_99O_,F[,P&P\L=M]Q?PS!^ ^]?=EA
MK+4$)Z?<EV3>P2V0+AD6CN;35LC'2J?TN[_#C2ZUODW)HR?#%"O(RL))>5"(
MVD\UL4VK9'K)3;=5\]LZ[-D@ERQ^LS/[9")&<]%<?28V$_P!_4^EQ/LD\)/(
M^K<O_HA,!\Q&(CXS_(U$O&0*JR+(G9;=7EN0RT7F9<1U1B5505S+G(6OK8ZK
M**O-W@:R6BXOM6I=,,F_1I@N&]K6K?CI)+5&77L".VW[J%:HSSO'7QWKGWA?
MKA7JHZ:QW;.[M3Y][K-_W(?K%\)W)1;K7]!U+QK7JG5] Z!M]VK5^KQS?);%
M(V=L,X(0P]QP.PUKY;K^1![9Q[5N?=XIQJ+R=XZU]QT+IGVPK9M[/_U3Q(B)
MJ+7K!@+;K)7K\T[QI9.,[K"H 5ZO0N)L$K5J77L:#S>X8=6J=:TIOG7&$^=Q
ML8/=UJ8]^Z#6IL\<!4CAI$]!2K^(*![6'H"-I'3],[_6I&M-\?4H$J'_T[9.
M8O_/:,.KU&[KTNX&L=9:EZXUQ3?046<2Q;4YNHEXUDKTN<4S^W,49;9U.MK4
M&;7;&K2S@:._UJ!K3?$_,L1!#REV^LU)$L<=98E(T\UBJ+NM43M;$.<O JTK
M +'&?*>RP.@GB_RC!??H)TL?^(1X+NC7(D ;"4@03;B$(@I3YH(L(1H.SKLJ
M<W1]LHI.A4_6[ 6.J4MF#68C^<KLRRG, *57+^_-"8++*;/-: ;KAUBPYB/U
M&UVS)^<D,)/B<A*)\O0XU<J"E+C6<0-ZR9V[*)9WWB2S;>.\U5X5\E8[#>OK
M^9>3KYB]>GI^?G9Q^:5ZZ:N?YWE2L"HU4Y0CV;* W3=D1ASD[Y7%<@6JK@*+
MO_&QY+>-?61[8<$A?AG,M'21O9P2:LH%V!3;J/25Y8)[V,!.C_V4-PEN3\S8
MP2SXT)5EUEY4A(^J(,+=AO7MXO+<NCGY?'[['^OLXN;TZ]7-;]]7SL-^M:SX
M%'-? E"K</1MO$B=UIJ$!B^40UJ^;-<GWV^MBXN-!]O=;HFT>B",)]__=7YK
M?;[Z;MW^>FY]/_]R<7/[_>3R]O^[(;Z&JTOK_/_]=G'['QN^^WIR2V0.5Z?_
M^O7JZ]GY=_CY[>WY]QOKY/+,NKBY^0T^NO[M^^FO)S?G-];59_E;Z^;\]+?O
M%VNP#;S2K'QC+B;C(*[<\<)$!^,Q53N,W!]XH@1^@NH6/L+D-S# /.>_H'+Q
M6SGBKU]/+<K79%ZTZ;@?!1;5A6A^NCR_:M!?6RM5^]DJ*J1?H\"391=/>5)H
MV%L\C@55J&D(GT4_SN!,ERP>+1LI(MI$O0K&^CW^Y^"XR>L^RD>.]>*1Q&B@
M. *U<' V9)B-^\PX(9]4O_4BI,B-4EVEP:@F']V'LOF"M-V/H@2I[IQ84F<0
M/82R!)PQ5]#L.R%2\?3CZ ?E(2$%82B$P?PZ\+T,WA-O.7%4N=2=^7=(O.0E
M6]SSA;FX1!@6(M$Q<O,%#M8@B9#TR)<ENCTU.D6V5Y2HWX7DQ>/"$936BVF\
MDH9-.''()FLD[TYBEJE6/BDIB(D:@R1\$,G2%+*PB$$0.G&FOJSY.M-'Q<G*
MA6(HS9;;Y]NHO+[A;^/8D0Q.";%S8L<5=2'\.(U]54ADKF+:Q)D^-"TU,X=F
MYNC5S!PU,T?-S+$-?:F9.6IFCL5V#!)MP0%WJMG\X3B[#J ?Q@6I>E76'B
MH0N0<+-8TK]EZ2C";YCDS$^2C&P6OBT)GB'7G"$X'IBS&G;*F7 %&=<=-M9;
MF["$Y-/ULD?4\6'CN'6PR0G5/6JTNHN_WO0H:?4:G=9F)]3R[WJ]IV<?:74W
M)C5YA<X>-#I'JRW8VZ%*(55VBO5:HGBZAGZO! G*)5WJV5,0#?A/0ZW!I:4O
M2)N!8B.F8?%3Q*Z?R-H1:9(Z3'D?321E^CW=D*2KG^EQ=YADYG?ZA_!X9N'.
M'",9NYY$Y+J?G4JY&/5\;B"OL4".,+JG:P;, 46QN#S2BL=RS0.D)_Q\L>F"
M'&=W6.%SJBRAJ?()?GP,9&7AQ#TP=]N'0BD'H#PI?*>>SWH^GW(^7QH+.NMY
ME(7.6]W7B&%S4LB8JK70>?M=)"EA$*0:O CQ2$0&2;0*%U[2MF0D>S(T5]IY
M&:O[\"SUW ^P-OO#'J=Y1S9NJOU.H^3BB?6?V#&VU_KP@#OI;4)PV_;Q0<MN
M'?=>#X;[1%CI1R_.UIE)[Q^S&FNLPJO(7:_1/:B\S+UQY7!@'S4/[5;K>'<P
M^L:!*YO8Q^=?!B^UX+8D*R-)V,QU%KLC!$62#TD?QS?7UQ4^?=N/.7VKFU%
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M/;8\9*5'U>R&GQ0/?CX<"R<FCW>1A$]X&>B^$J%)U+3 PHCO?-AF^. (]DR
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M(7E]'O@INURFM<I^X;4Y$QC7@O,39@EO03(2\O7BVXV.I-8<6CG0_Z@&^M=
M_QKHOPU]J8'^-=!_$UO]FMDDK3/T1X;6:18@:*,V.E[0Z"!/,/1%A$-*?5!Q
M-0Z:8# 4[ Y7U-;@2P.'HP24&;MG$UXCSQ*# <:O,&8A'(QSC?P)HOZ+< J7
MMQ&J6/ES&2XPPJ?XG(1(R::JY@,@2I!DB8^:4")](4+EYW Y')HG\D1Y_C[%
M/.@721IG;DH1+D\@:QHZL*!Y2;,A+[#T:O4FCK#="1GI@74:3X)H*@AF)"F<
MF9O##Z7;75#VD7Z.HBT,:['&PD%ZAT$6&#]'ASM%7GF0JR[6*X'7OHLA,O<A
M?N\\QPQ54<"LSV<G&/9SB4@[#:9T>\88,\62B.PBD6LZ=J8JG&($$6.>"QFG
M^GIVF^".3;EI"BNK*N7M9JNKOK!R>FHD2X.;.1Z42+#HC 5!5!SI1Y$LSQ3&
M\J2,^REH;F1G&3,/-?&4#$DX8Z(+27"4JC],58,OQ3 QLL8@:5] /(H4%=+O
M)+R1T;.0^DR#@+\<ZLZ#7AJDLNN4B.+ ]""4:?;5MF9E4_R+] KN?([$ 4L1
M>I\D"K"5@P]0LY'+.1!#/Y&,<L5)0AP7W/EH"S&=W2Q!A1K D1Y 7PQ!W )_
M3%E^(J0SD#S<&&N]8T0*O3O)^D@MHY;V1XA!543N,;HOFJ%@T&PHUU]^*C:4
M8BH_D7&,A:+2QAY)>D@C7\N@DCR1>$B3:N7D].N):ET%^G!M21MBA)8/D9QC
M)LD975CXO'S.<U0"?C6[A"J^VK!^C>X%8>1BX=),#276@<6% 6C$GZG=SR%N
M=37*TZM_7YSMMXXE4:<,IX..%#&W)+E+D;0'#166,@)S1/ \AHM"+W$="5 :
M9#%16N;,1=/B4'1D.(X"ZI/:J? UKN5'_.PD&X(*DEETO_YZ8T@_B2M."4LK
M[AO)EH\N=XFJB05E32KQ</I(O(K/^J[8=Z@DQ9CD*LX"^ T2"=E6/R,0@"[(
MRQRI^'8_23(>NR(;HH7S8N=>[Z!)[*.D&]->V&6.P>QJS@+"%Z%5-B/,3<ME
M +028Y1LOB%0B*!%!BLR(1+IE).4V9101U&&@(M=PNYA% +9YB5.0*I6R_'&
M(-V$2R)H )S+^!B>C'VAJ%]S\<-^E.A69'4<,&&7_BT";TV<N-3:")>0[\;9
M3V::K*!%A @ Y'^%8VH<A4C^J@=+H!^I(N4JHA[5K(ZD$RC1.=)X+5YK&!!F
M$3)I%B\*PA#+V[W'M+8[Q$A'H%CH9$K4G**V4C]#;>:0-5L,X!9A848>@"8.
M0D/-BVB[Y31BA90 8WTE=I9;4ZYN.K;:;<E6AN).>$U6W>7CVGI[BZ!(.-TW
M8CAFITKU9#>6A&.P:,8QBZ?%?22_9.>J'*-"RN+A,9?)+"=",_G-(E_E][GA
MG[-BD]%3REO,ZIP)6^FU(U\,K"NB5$)!.E.AUF^PMV(CUTG*'A@\"FPE/V%\
MWI"PQ;PTM 4$*E\)IRT9>6,9/U.[A__[G+D="9@\B2;6S2=.:G392P*<4AH#
MG4O&/+YJL1^?;5Q"X:MEO#K[5C5MO\RO-K<;*C8VOGIIQ3T#V=.P_GO!D"!+
M8N4)R[#/9-!F>@QG&E%XC8' :!-8H0-F$,'<4Z'@Z[;R?TT".HZ0GS"-;"G5
M*IM WU,D\S/98&S4^F"TPRFB,9FD7A30E#>SM"Y&_H12?: C4;AO(D/1Z1 N
M']4T?P-E2VHJE/P!.#LE^)= DT7R%/0\$.H52=@-=">/ .-E7CHRD:\&NIJN
M)V%&=7Z,! O8V:BR8B*1EDJ4%4#^(*BVC DET"3CON#7(L=LY X6QF\VB$KR
M@3E@#TSY'-"UG,)PFM9T3I#H)H<XV_TH!-L)WN-K@*2LK*4F2E>!2O4]QKA0
M2I@MU;!BV5!H[NM3XJ&)05FFBI%4B3%(#[JC9$TN7$Z\1)B\BQJFC=+,99BX
M8!4)9C1!FE=Y]\<K"(.QD%6'Y5W)*56HPK9TQED4BAR@FV>1.$$2:;@]X8?U
MG*I\&+HPS@R)-T^(9A7?Q/48LT1Y'7%[Y!22GLZF*FQ82O;P!V#005,X8$E,
M":I 89B5-.*-8,!\N@NF%TQ2NIDQ^KVOAU UC?] !M0WC9;&Z:'D&N7>8$\I
M+:_,?I13Q?-AN!_D=3#/<=.-<B9(HBGUHT&*V2>XL40YTS*7E%";;1QY#J?R
M-*AS,'TBX.Y(S#;YI)V$H)Z8L,0)"E+_H#>-Y4O*']X@N _H;R />3$Q> R*
MA$2[[T=T&X\+IAS9_.2%56Z>Q$$9TUFD,]GGW%VZMZ!&X"1CAYST&N>H4U5D
M=HI*[)AAXB4:5/(@@6;TD9"2 !\S>'=TU]"FD5.<H C#C0>Q_85C11'TDQ5K
MX-\Y0P@F,U]$5-Q)SH!L)"D0KI\06? J$(C;_UR?JT$KIR9VD@HWB#M=S8_U
M(36NCNGI1-AF$BO+P<RA*BAM56<(H8J/B*S:!47KZVXA^RDNB)_,K <=0>@J
ME^>QZ4+#1<(C?DTS\P0S?;:QDN0ZD:SF)Y" ?9C'"9*A3Q03M8H?:.T]BFB:
M8+U5Q41IO<P2*S W&Q<R]%E?8$/YZ227!_V6:1I+U^),WBHZ1'DSJ%VF[O"A
MT"99,@']H.YKH29CDXF7B:QS8Y*HFAF/^+I<T(W#4VG#0C:A,@)_@!7'' &<
M%!,;V%@<_50X50R-783:X86:P0-[PL7@!7'NZ36V05^A.E3)1:@&>*^2Y>T[
MH9E<Q+Y%Q1LN@U7<<L&J9>7O%$@<=.[\_FR>SZPM1DL**D36&>$.<[@-%0L7
MGC1-$&=&,=0(.8V0.ZX1<C5"KD;(;4-?:H1<C9!;K*F5>T0EN.&=%>-7NK88
MTR\4K^\*L2\H@FO>YY/"A5Y=(#B%7;I _!!C?>0^HHJ Y6>^A- ,,XH6TJV1
M@0&&/V#1M3M/%E9NE;E1YJZ51"SK!EXTT"'Q#+X7^/OMJ39"Y._8RLU4D8J+
M4';1F+1[&5W,+17M'=/6--SGF($ /1=V23:SMGDJ9E\NA706PRP5&QG7=%G$
M=DO0GT1M+TR05M\@IZ<S3E9*AZX1DD^#D-1!#DD>PM%[YMRID\I><"'^[5 R
M&>K5DH!]C1Q^X>6XR,F JG:PE*M?%4Z6\8AD(=6^9,>99>>"DWD8@W;&0UVV
M@:?OG1/[49;,D1"9>D1: .3@HM_E)%>:.8N=T'YXASQ(":$6?<4$1^&9">9;
M,E8Q23-O*D.1!9Z_HL$B<62>]N#GU;(HAQL[RPYZ?+7CW?F)9/"0+Z-!4&$#
M#0A2_1E3S68,P,#DL/]=.M ]5:)/6"*,L0 17"']5!?K4G$A0E8BR58.)V=#
MDQW1$G1%\77R^W'A:4V\-D//A40E8)N-,2]=.<Q5% *6 <<C34#3UXR+++MU
MDM"THE<O ]$/O"+J1Y.K.6.)I$AR:B,R4FD2-0??#X*XRFI[#*LEP!GSK"M
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MI%DE(_&2P(4T!JO9B0+DE3(*.RRC!*ZA3&#J^*R@$[\C*MY\?@P&4L*:H%$
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MKMVP;K+Q&'&8T-*-<9,KV4&Z&M.I21N7U[6[R6>8,JQEP#.EC LW]B>FT[0
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MH_I! <#?_A4>\L0DAJN/3I(*G#Y.;11/+?'?S*=RIS8T#H*';1I?#QS7#\"
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M7=-N6#?9>(P,.3#(FQP/"1UQP9:FD_H:=HOK2W35\MUJ#O#!0[K2N^B+ U(
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M_R)?P*@/HL\MO24-D7/P_/_LO6M7&[FV+OQ7/-C][K=[#"LMJ5154K(.8]!
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MM#- X:);4M[+!:8+HO03G/,K*SV7F>GHW.GLC8;3W*]@#XI.L/9]=N0P-MN
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M<,K@N[2U32/FAL!FY#-W^).=VU@4)*+H:F<GZ$)+L*L;)Q('UTYFJ@.XSE(
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MQBG+G ),"3[(R?P8%K_R%U]17_*Q>0@8]@#2RP\Z>>MT>N-R5 LIW\$5M/Z
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MA-UQ!ZT'(:M0S.*3#]7T';P"KUN!YYV(E+(XHE@B$]$ L1#" !X0CB1.#$W
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M F$0IUJB4#'#&>.)4FQKF\=U&CS8[?!\6<]*Y5?EJGB57[/*SSDF)F&4ASR
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M7J4?2:47(@E#>$HI1P3'&LQT8FF%HA@IEL*.*LQP:%G#ZHQ7B33L11U.'(&
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MPABQ@$"8&E.)* U#$](T3B*^FN#4PY.'IY<0G'IX>@ \+52UZ=A$-,4H"0S
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M>OC[T:]_'3Y__?'WYWOBX.W'KP='OWT^>/M2'CS?IR__^E9^/CSZ19;O_7S
M]LCOY7<>OGU]]/N'_QO\_ORC./CI]='+GWX3O[W]C?[^GQ?#^9+U[\^'1[^_
MW>&_O7T]+-<G#W[Z_>CET?]]/'S[COS^TV^??__P_OW!AW^7S_OO7*YG=C&'
M\;SUQ_C(F7?@ZM%CH:('RX, )YDL!B2\V'!KVXJ^4+(OQ-+]/W<"RJ9N'.M2
M#\_MP-[>MK%.-.DLR7"+/3KWH[?%UIPFQ_%^/"SW;KKWY\E@]K4[33<;PF 7
M8Y3.&,PX+[E5"2)E%(2SN9"73J"DH=8I8V@FE<&0N9"YGB!SI;HW@CEEF;7"
M9^MX)$E[GSTERHBT#'-M1"_AAM#:MZ,M+\MG"5__\,8(KZ,&;YP#42=C&YD"
M\"0EB4F+4+<!<$'ZS"X]% K)#<FM*Q=]I_-\4NA80K!@K!8Q1$=YR)GG2'SY
M"J,WL]L-Q_@P0&N!R?:O,AFE-.4D(RC#8MUK),%H%8$;:5/FQ)0O;VU+O<J3
MV4A@2&!=)##-'9&<1&$M*1Z=&.(*?R7"H@FB,%HK!(9Q6IOL]LM5=LM.6,.*
M]&2)2Q!$E(C-A0P^)<*MI9KYNK; ]KE:9G,;$AP27%<N^@[\9JFWL@1CG-4,
M6F).$$.#\2)1*J(U*#^[0FN_7:4UZUSP-'LP692@C7L#18=R,(;XF(-7@E;Y
MR4A?B$5>ZZ+\W.BA.K<#YEDGW;2"I3>83D]JG;2W]^;5J][QT(WN51Y=^_#F
M3C+=M450(5S,BFA.!1-&4BNCBC$6[-ALG0G?.<E[736T6G*_&#+%RYLX3XND
M>T?'P_'7E)IO>G4R">_=-+TJ=IYBS;0];ORX4#-504=OJ(6<):\17PGV2A /
M1BGIO$Q)"E\B/D'[EBP]I? I;FU8;S=V,VH;K=1I*]TA F769!(8JTNEA$_1
M.\FSC%%*G[@*WR/E&T+114[^MQN>I!LI&:/5-AEYH5BBJ/3!$0N1ZD+)W&@P
M/$F(C*I$6)+>N+H_@W.&A+Q94$="1BNAE1[<;;8^E0C=9@?<YER2QWG'>4[%
M61*JB]MLEC($"RHD5:RN@]:B>V[S4;6X7P_4_?/<S3CWBM*?30:AGMIJ$CL7
M:V8*-'(:S$YN>7#EJ>PE?@29G=<7)F^^;>>SF\2?)N,I)G;:X\,/+Q<2.X38
M&*F78+P*()0,X*PB0%5U>D)Y4N=@4F7ZDK35<M6ALMWC!OS](E2T4G=[)UK(
M[/Q=$\4-L>K?<#.&HW>BWX4LC@V4QD*SX$G.A7^U+OQK.'"K!8U*U]:8K6W#
M%Z=GKF7M.P(::1>MA%;JI'-<W1HL=(X/XQSG<C4\:NJ%E*!\3"!BXF"2]<"X
MX#I[ZU2@'7*.3Z#;YG*2)ESNO"D:_>S5^+A:X'[I&<Q4=S4]T[QY>&K:O2]I
M$@;3%#$UTQ[]_;:0FHDF4.UEABR, Q&( \=9@!B3M<S9XN-,S503*?J6+IV<
MP<)41^"^&-@LB?6[%:9N0#K&,G<"\_R1?6L$U:2H>T'JOB$F&=BL,OABU&)<
MJYD@6]M+=Q4CB#L+X@=MREK"72/";X?PQ88L%ZV*(A9YXDCQUT:!HS)"XCX)
M9WEY4VUMV[[5Z*LW#.;8ZH-60BL][H8L=)D/X#+G$GS44\LI+P&QT!D$I24@
M-M9!MH0+&33AWIVZS*5G66$S5BMY/N@=G_CA()0W<JH(NFC-:O8I?9X,9G69
M7!Q,0[-4!KNT'E4:L%QB\Q9V9;5(C+\NI/ZH]#921PL;>@G"& ,V)P;1,.6C
M\I)R71>\$TGZ9/D-Q5C4[ C$UYSZNX1NC&SN!.#Y=%^T@<N<+0AG:KHO:'#!
M&8@T&<DL8Z2>EUWZI"P"M[/ ?=!TWQW=,J+Z=JA>2/$9%X@M_P.A(P619  O
M4R[8IJ9.%\U4F=HM3?I:*03W9H$;&\+02FBEQYWD0T>Y(D<YW[E7!&RPB0 O
M'K$(V.C!,)- AQ(0L:BD4/G,42Z?VL,6OKM \S_CR<>:H@NGRQ5[+GXXF<Z.
MTFC6FZ3337FS<<^%/T\&TV8A(W;RM=>TO.(<WBB-?SBS[]GNS)T+Z^Y\L^B;
MLT^!*;RV*/"7A11>B-01[R+$NIE#$,K &ZJ!6Y^Y<T;KVKML;5^R10*\??LR
M5B\W(?Q$*W6%@%>8J+DE^6+HV2KO7G.BDB>;A07*<@01F097_^I]<,UHK&QJ
MCJ9O]3+'1A#1R+MH);32)EKI@<]4HG=<IW><2\R03(H4,1$T$77%5HA@4V!%
MEDA"8IW_4L\A=,@[/H%FJS=79Y?G5'ZR&\5>^G*<1E.<=(5% K026FD3HH76
MFQZ^Q0C3M^.=<NOJ)W##5VX0]T=G<<2E>L]YV^KN>#K#)J:[!0L[U[0[E("/
M"*N+BJ8*A$H*#&4>C.="".Z#"&%KF[6QY GAC*2+5D(K;925UB*DT36NQ37.
MZ>BHJ&1%+$-Y= D(R0PXR0)(PCS5U&7J9(=<XQ/H:VA6?IU)9FQ9P,PM6@FM
MU/GFQ_4(YMK^\Z.;IK@[/JI\Z>HW7;^08C)^-W%'K]-I@CZ]29-/@Y!..RI?
MIS!^-VI^ P84=PHHPC5:.U'I-.=@M2E:VVL.GEA: @I*&!6$J5BTMB*+&^.1
M#3K-!LC9:"6TTN8?*T#/NBF>=4ZJ9Y.<SY) U-&"B,*#U]F!)CHDKXM@S[1K
MGO6I5+W!5[#4$2,7:#G7\#TX'R7<%,/G5T)A41QSRF@EM%+G Y'U27P_'XA\
M-]AHSDAB!UY[X<B[1:%/!<VV6CN1.MM'&0_.40U1).Z-S"YH66>><8,3!#:,
M%9"[T4IHI2<D]='#=L+#SO>X1Y6X#@9"KJ-ZK/)@2\P%@H?$LK+>,]L]#_L$
M2O0_CZ?37E7X.:=RNS^E7G#3][T\''_NO4_Q'=;M,6^-5D(KH9702JTT77I3
M0D$2K<Z!"J)"'=9'ZFQ.K4/2.MY_(^3A['V:U,AODMZ7X*_XLOU1&!^EZN)V
MBU-[47S:OZI+^\D-1O6+.WF6)B40'+KI=)#+O:R??6<4W[HO& ZV%P[NEW!P
M?VX@0(J6,!O VRA!),O!>$<A92I29D8146=1]0E?K #A0("NT@"2]298J1OK
M>Y&LNTO6<]K=!*4981%BH(6L>6+@=520O5/.694(T9TBZR=0J3](L]Z@ 0P6
MW3'9C%9"*Z&5T$IHI4VVTAWB<F*3<SGSD'D2@7);PG,3G72.<6?);9(H5\/Q
M$D]\B[\QGFXOGOY8XNE?KL;3PBB26/9 :4U^\!# \>1!.NNS2T0G%IM-4J1+
MM3"$<,<KY CA%4)XOIQM"->&&2"IH%<H1\&PK,#I@MYZU#PPWST(/ZIRMKX6
M@#^Z89VHT.\]3R$=^33I<=KO50"MNX[MQY.8)C ;'_]0[3<=#P>Q5^_'8Z*Y
M:V?IYVQ$2IX%08.P7OH<*=.9!,&$#%+_L7_;-9C-3S\\F4UG;E1O&8[+;XWE
M_MI9&)=O:2K48R*D2!@(DAQXJ1P(HZ5A(14:JWD_(OK:T#[C2U/=G9"RYAK!
M"N'>M5SC?ZW&@'<P7)<H;C&2NQ^_W; DZ?UX6.[==._/D\'L*P9J=Z2P^9V?
MEG-GN#(@M:_$%0J%1>H*HYEDK>-<R%0I3")U(74]0>HR(C)7G'JPS H3LX\^
M9)TUES[)D-PRU(4"M#U>6SBQI#P/O@XDH21)$,5ZX.I2HR2"$4*$8D.WM2T9
MZ3.]]$IC)#<DMZY<]%VZ5Y0Q.2F?O69$$!F]YS)80[*@GAK";F:W&YI6D.96
M37-S?8**"FJ$E*"#"""X*31G8P(K'?=)6Z9YTR>HZ"+)W;GU!/D-^6WM%WT7
M?C.IQ  \>\>8%SDD$W5PWM366B&YX<AOG>.WN5(@*^HT,9W!1>Y!!%'#.%M$
M:N":1FEX]"6,H[3/90N[7Y#@D.#6?M%WZ7)(FB>MLK=1"Q)2$:E2<6F+T.%,
MJ(3JM"NT-E<>E5QK0I4&SU,$(4P$1X@ $K*QTJL820G;)-%]039#G3Z!EN+=
M\='1>'0ZR>O;YJMFA/>KH;O?RG%L!KEUE309Z9V@+CE/1&;4"ZN#-TK)H*RQ
MOO:#,'+6#U)X[Q;ETF^;!IZ?3,J].YU\<%I%O7X 8K$S[B!OD1OWKBFJDCI:
M* &CLNX@MQE\H430Q'+&4U:ZCAJBW/3Y\M,/L?T+^VS12DM$H)8QHP(A66<C
MO,HVIY28=5G0:)*7WR'E&T+114YN1M#<2,D8K;;)R NUE,R8#-))B#%1$%0K
ML#0G,*(0LC?.*6:VMGE?:B3D#8,Z$C):":WT\(D;%@Q5@MEDM/ A616$MS&J
ME 3+^7M:!MUF)]WF7)*'\YR,(1*H*[Y3.,K *)?!&JV(TD%0HKKG-A]5#_SU
M0#U?*]@;YX41[?W>*,WJ&P4:.0UF)Y-[[C)_TB,T.IW9>7UA\N;;=CZ[2?QI
M<NLS09C8N0T?OEM([!BKN:C3C%(T=:ZEH^""9J )-4G1X%..6]M6]T5K#5D=
MJMH];KSC8*--L-)=6B=:2.S\70_%#:'JDM2,H>KMJ'EQOC_32D020 ==CP$(
M!98)!\S41EDBM.8UZ=XOW]:-"4:(=V1EM!):J9.^LX7L#OK.[OK.^>E_4K'$
M>7&6*3 0P3MP1G*(WMN@M/-6Z4[YSB?0JG,YPQ,NM^T4))R].MO3AUT[CRJW
MT[QY>&K:O2]I$@;3%#&OTQX!?ES(ZWA!,TW40M*9@\@UP\V3!1.BKAD?JAW9
MVF9]3E3?2MJA5#?"O=VJUI)8OUM5ZP:D8S1S)S#/SP/(-##/HH 0N06AB08C
MA01.(Y6R8%DS6L",('ZT('[0CJXEW#4B_'8(7\CU\1R9BEJ!RRX6?UUW>18!
M XD5=<JE#Z'Z:VJ*8.&(\\W".38*H9702H^[G0M]Y@/XS+D<7S/K)T8*A-'B
M,Z5+X((QX(3U3 =)211G/G/I25G8R]5*I@]ZQR=^. CEC9PJA"XZN\KUILGG
MR6!6OMB+@VDH=V"&35Z/*Q%8+K%Y"YNZ6F/&@^>+(U"#)$YI(\$Y8@HQJB(F
MM'&0DQ3,N) UU5O;HJ\E[4M"L*_KD4!\S<F_2^C&T.9. %Y(^%E/"!,,M!(:
MA."T0CD HTY:Q14+06UMMS7^$X';/> ^:,+OCFX947T[5"\D^8+.TLO H0#8
MUX:^!%9P IQ[R23)WOK:E,!TGQGLMMXP<&/'&%H)K?2XLWSH*%?D*.</:1(5
M.4LEX,U.%0'+-+@2 X%GSG(:G:;"GSE*NW0Y#)OX[@+--U<';96P=-ISH]A+
M7X[3:'K/8YE/NJ2!A2>T$EII(P_378T<=N*'D^GL*(UFT[?CG7+KZB=PPU=N
M$/='N^YX,'/#2]'%>9%D=SR=8<KL;M7 _45Q;;-UBM4!2)(6<1T% <]]@J2$
MM,9P+D(1UTPM,W(=X8RDBU9"*VVBE1[XK!RZQC6ZQCDYG6,,V3(!*K $0E$+
M+B@&*D?M*2^NTJD.N<8GT"#3S*<^D\S8XX))7+026JGSJ?;U".;:./:CFZ:X
M.SZJ?.GJ-UT_/7$R?C=Q1Z_3GR>#Z6"6WJ3)IT%(I_G[URF,WXV:WX !Q9WR
M\]?,'@Z,>=\<)V7:@@A2@M."5ZV=>.TP\K7SUBS?=HML@)R-5D(K;:*5.J^W
MT;-VP+/.277/@S'9:-".D.)950+C7(3,C.$A*2J]ZIIG?2I5;_ 5+/5 RP5:
MSC5\#\Y'US3%\/GYQ5@4QYPR6@FMU/E 9'T2W\\'(M\--IJ./&S$:R\<N::H
MKETTT0L",K$ )4!E8#41X#737G#G'>%;V[;/^>*B7V2%3K,"<C=:":WTA*0^
M>MA.>-@YP1^,U]%%#YS40;76</"DSG9C,D:;19!,=,_#/H42?;-RO5'[XU%!
M5QU2L3L>-9_0#U/O31H-QI/>P7A6?F4\2;T"5XFU?,QEHY702IT/0]8B]$\I
M=?><40_S)3Y]GOP,0XWV0HV7UU7MC92<%O6>@@1!ZNI#3PS8Y#UQ*2MFZ^I#
MTK=TZ5FR"'TD:+026FD3K=1U-8]N]&'=Z)QBMSK2R). J"V'&B^!"SZ ]I0P
M)XO$5KR#;O0)5.G?NB^]X<#YP; J]TD:NEJ!GXU7I-N?=,H3$]-H);321IY:
MGUMC-TKC6X4=A5U_/B?7FX./-R=^FOX\*6]]^YD8D+07D/QRS>X(;H2U7H(.
MD8 P)2IQ6280R7,717:F[H[0?4E$-P[X(2D@=:.5T$J==+#M[XE%![MI#G9.
M\0NJ28&Y+W=4,A"^GI\WIGA92<OS$;S@TG;*P3Z!\OQE23\J6KY T,^^S:4+
M=7($5N,Q08U60BMU/^AHK1Q_VUCC$GWBW)U6XH9?%X4Y4U1*ITT-&4K<D (%
M'U/Y:X@F6ZTX525NH-=T]JUE!3VB&KD7K816ZJ2';*W2CAYRG1YROI9.N,_U
MI'LT,8#@5A1E;1-X*3,UQ 7=*0_Y'5T=!]/CH?M:/V?Z>R+ [WSLW_D$VBU^
M'D^GO3H#(>=40/DI]8*;ON_EX?AS[WV*[U*SW!-;*["F@%9"*Z&5T$IM"(%D
MB622Z^B,%,IIYVCTT5!NB2#4I[O7Y\Y[;P]G[].D%MXFZ7T:38M#VQ^%\5&J
M?FZW>+87Q;']J_JUG]Q@5+^XDV=I\CJ%H9M.![G<R_K9=T;QK?N"%;GV)EI7
MW;!_53<8)C-7W(,3-9\610)C2?E#R/)$*4.M#44W],DUVXVQY:6K-(!DO0E6
M6F\S!9)U]\EZ?L2!8"HII4 +*4$8G< JPB 9&2SGQ$:?.T763Z%]XJI2[Q5L
M' U&IS,-)Q<@.3T]D=QD5"X+VRFP#(%60BNAE=!*;9R=;5_(U]+>G>/"M]\\
M'\:![<6!ORV*=NU%4,XKH)Q:$-P)<,I;L%XXKGED3-0U5'VE:(?.S2+LD9P?
MB976?@H"R;D[Y#R_>$!+RJC0P%T5Z5Y),(0GB(3X%+*VEIGND?,3J+(?I%D!
MZB253_)7T>/#LZ+[D9M\3#-7CS],4SB9#&:#-&T*[G50X<Q]P;H[II_12F@E
MM!)::3/K[K]>>+U_C8?USIY'A8>C-Q<N;V<RF):WGI>_CMZ=3K N'O,P-V4=
M# KO$!2&1<5.0I:&!P9)*UZ"0F)+4!@9!&%%BHDD(<36-N?=*-L@Y)&8'XF5
MNEUC1V)^<&*>4^N&)N63]Y":_B<5++@<+21F);7"^?+D=X>8GT ]O:KT00,.
MK))C\ABMA%9"*Z&5T$J;;*4[Q. R6R6D%]S6@8N!UTJW9H$%S873B=QY#GB)
M)[Z5QK#TU=XAY%KZ^N5J,"TST4&+"-ZR$DS+(,%Q2\$FZGGR)BM6@FG1I[I+
M\[P1PIVK>".$'PS"\WHX>R:D244/*U(@'&M7D90%T3QP%[PPE'</PH^J>JVO
M!>"/;EC'9?1[SU-(1SY->ISVZ\A]LN[ZM!]/8IK ;'S\0[7?=#P<Q%Z]'X^)
MYJ9U\>=T/EC1D5BJ";..BY0+XUG* R.&4J(X27_L7T=P^P<OYAFN62LZ/3R9
M36=N5&_9[5B.(,M]/^OWX>/L8% 9;F]V\/S=EY<?]OZ0*BA%E88HZW1O&B.8
M:.L>$J$I3T9JKK>V*65]HF5?Z,5AI/?+^M\.*6NN!ZP0[EW+-?[7:@QX!\-U
MB>*N$6/WXK?% *X9^_1^/"SW;GJZ<PD#M3M2V.'N50JC=:<Q#19TX!F$SP%L
M#!2H]5QG3^LNY(;"D+J0NIX@=45+3:(Z*FF(2(&Y<I%>^/*'3T3$I:@+!6A[
MO/9MU.LOXN7;_2]_."6BC"0 R\& T'6-N[(*+.&,6T],9'4'"Z%]+MM:Y([D
MAN2V]HN^ [FQ&)DTE@IJM% ^N>2#DU1SE0EARF%<]H#\M7^5OY@SPD8CP:84
M0"3%P&C.0%-I=>&N;',=J+,XH &I"ZEK0ZGK3DUV(A)I%1=<LO+2V<149%JK
M$J(Q;>G-W'5#;QU&:*MFN%^N,IS2F2L6(E"G$@BB0QTU;(&)*D-Y2LGJNL2'
M&KE\UQSR&_+;VB_Z+OM'=*$Q%W-4U I.F662I$A5EBYE$3+JSJZPVF]76<V(
M$$H('8 34^,VZ<$;*2$1D4Q2*3I7XC9E19_9S:@'/(%FX=V3HY.AJQ.SX71V
M=L]=+"3HY<GXJ!?>N]&[U!N,>BZ$<K&S<F6]X\E@% ;'0VPQQH8[M!)::0-D
MD^&$J1"$#S(*ZH6+6@AC7&34VJPURJ8N!1A_[5Q-;'_8^?H'(UD5 V5PECD0
M,0GPW#GPY>'PV14A3-C6-N-]IA<'@^ :LZZ"&*EV$ZQT%Z;-DC"I'<N:%[H5
M)A-B.0E:6T4+_6)R_0$Y])>K'*J\X5YE#3GJ",)+"B;8HMF*>K/1Y. XJ2)M
M,?&$^.PT/N\2"H4DJ?>9:&:<8(:;[%3,+"=2X!D$AD+=@_%O<S .A)+(%41#
M"0C":Y-Y*$&1\<24L)9S(4LHQ/I2JVZ$0H^JP?QZ"+Z:I*/!R=&T=^P&L3[_
MO>".CU.Y7C<<5@3F085$,<']YI<_Z3$4."P$K816>OA8P6GJB(A.<YI$I,D)
M$X@+E.@211#+FK-H]/PL&EU^V>WS%";)3=.+R?CHU<DDO"^O#_-NH=#IZS1T
MLQ3?CB\MQ'V>_ R#C?:"C;W%O(OFWN8D,CBF- BN&5A+-!B9I:":ZD1JL&'[
MS"Z3=T$60*Y&*Z&5-M%*=_&HL6AO'U(P4001!2^Z33,BHTPAY9 S>M3'YU'G
MY+N7)8)2M:=5YB+:>:C-KMQ #H%(GVGDIF,>]2FT0HR/CL;UEX[#Q]Y@.CVI
MI\5[>V]>O>J]&KH1=CJL]BBXCU))Q@U1D0FMBLP(C$I6H$*)IUY]AQ:O.Q->
M+;E?#)GBY=&/IT?%]XZ.A^.O*37?=,Z*U<ZWG(^!)\=OPWW[ET^.?WWY?/\/
M8PQ)CEI0*5D00AAP.E/P062N"2L&#V<GQY?O$L,BQ"8$JVBECO#R"K,_W^'D
M?[OA2;J1DC$:;9.1%_([G&CI2'!@G10@K"^4K'0&R:T1D7D=E:@3B[A:^LP5
M0AT)&:V$5MI$*ZTCQ8-NLT-N<[X'HV!6AIA 6J%!^)3!9>* "R-]((3%VDK5
M-;?Y!/HP]L]S-^/<*TI_-AF$68JGB9V+M70%&CD-9B?E&[ 9XU%E=EY?F+SY
MMIW/;A)_FMQZ\"DF=F[#AR\7$CLJ<NF]"$4VU)7*BA PV7+0QD2IM18ZT:UM
M0VF?\Z6[2[&^U1' +\8^2Z+];K'/WV =PYL[P?G2>+P&SLDJG[./P*SF(++/
M8%T@H)0.G.C$J/%;VTLOX$4@=[=0W4+R[^_ZQ>\.:90S[>%](0MH# \Y.@?,
MLP@B) I6V@14$N%H(-&&7+=N&VJZ49)&O&/[$%H)K=1)W]E"!A!]9W=]YUPJ
MD,0<198>!&&V'L+2X%E0P!S1RF6O;-,A77SGXL!5;.=:?18P7&[MJ@>S3E^-
MC^]_& M+(5W-_S5O'IZ:=N]+FH3!-$7,_;5'@+\LY/Y"D80TL R!6PV"^0!6
MI4*"BC#CB[&%BEO;M,\UZTN%;5V/!>YKSO[=@'2,9NX$YOG,GS.!ZIP]A.P-
MB)K--TY(,)PJI4+Y0^86,G\(XLZ"^$&[_I9PUXCPVR%\(=?G&$D\40Z*R%Q$
MBU/@G"!%KW#-E0S4ZKK[AO>57GI#!.)\$W)):"6T$EII4UK^T&<^@,^<R_%9
MY5(F1@#Q1=F*G#F40-F!"*Y$2,$;4\=;-SYSL4"&_7[KR/1!G5/]R<U2[WCH
M0JJGI"_Z_Q;>Z>6$K8";DPJLA]__-@U8+J]Y:_KJU-*OS@V-J<#V>/+7A52@
M=9'K8MV:!4Q0#!RA&#U!X#D7XB2!!U>[HH6H_\=&P,<"]Q6F O\&ZDTT]#=(
MQZ#G3F!>2 5J52R5"H2SLB"\L6"S5B!2DL$'[AVK8$80/UH0MSK^[9X@1EG3
M'L(74H$I!&42<:"B:%*!$CREIB!>>!MER-S6TIVQ?2,M GVS@(Y]96@EM-+F
MY@+1:7;$:<[E HM7%"1K TE& <(%"<ZJ!,2XK%GDV6=^YC05[Y#3?,IM?] [
M/O'#02AOY%1Q=)$*+->;)I\G@V:S71Q,FRUWV!6X,:G 6W4%7E EIO_:H\;?
M%M)_R2M1C*@A9TY!:%$S!B0#M5'QQ#41U-?TG[*\;Z[938$%T<V$^)H[ 2^A
M&V.;.P%X/N7G Q->A B,IP#"4P.., V1<JE2<"36S3*X'NKQ O=!N__NZ)81
MU;=#]4*:3X7(M?$1E+;%+SNMP3M1I_W%( NP&7=%L3!J^@)WOVT:N+&9#*V$
M5MK<-!\ZRC4ZRKG4'LVQ&#,;4,$I$+7:;1,7D"A-5$5N53,&HSA*27"N7S=2
M>_5$KPM_G@RFS?H3;.)[5)F[G6^6Q>1=B^07%D?X.>V8J(>!F*S'> OW&1(,
M<.\C8<X'HE/1_E;W-64=*FL@QC<X=7<5WAB^W G!\]F[$$1P67.05AD0@D<P
MTC"0PJH4-(E$2IS:]YBQ^Z#9N[N[9@3V[8"].)Y/)B6U*A[9UI8#J0TXEP0P
M5KYNJ2EF-\W*.*JQ'W?#X(T-8&@EM-+CSM^AJUR=JUQ(X?E$N!!03&FA!$$2
MO/ 22/"V_%<27J=1-:ZR2^?/GD!SWINKNU7KB=N>&\5>^G*<1M-['K]]TN4*
M+"JAE=!*&SD;_VKL<)M%[I?BB_-:R.YX.L.TV=U"AG?7M,?X:'-4'JSQM:%?
MV_+*<"C!H2NJVRNC_=8VUXM9[]N/[T4X(^FBE=!*FVBE!QY]CZYQC:YQ3DT[
M*H7-A(!.+H!0-H!-7@$GU@4>#2>)=\@U/H$^F+TWKUZ=2V;L=<$T+EH)K=3Y
M9/MZ!'-M(/O135/<'1]5OG3UFZY?F#T9OYNXH]?I-$V?WJ3)IT%(IQG\URF,
MWXV:WX"Y^_:BC8^+0ERZ:#UE"BC+&40LCT-1Y ET]$9:&75F]61]GTAL0-LP
MLD!*1RNAE3:_RHV.]U$XWCF97W<]6Y\-6"TB"!]9>942D,"3$L&:)&CW'.]3
MJ9F#KUBJIUXNP'2> >C!^1Z[II0^N5@!>7HX!DOJF)%&*Z&5.A^GK"]!X.?C
ME._&(DU''P8D;04D!\]W%C,!V@MNF2[6EC[625(<O%8"N/%!!Y*2HK0>Q.T+
M@F.D-HP6D+S12FBE)Y0*0!?;"1<[I_D-,Y128<MSR7+1_)H5G<DH..)H(IH[
MJ4,'7>P3*/$?I%D!\B253_)74?+#\73:*]@^<I./:>;\,/6F*9S4D;5I>C''
M=N:^8#L YKO12F@EM!):J8U>SBR()MID3P45P@GK18[)<!9LL#F26T2,TW*]
MY=5\Z'@X>Y\F-2*<I/<E*!Q\2ONC,#Y*OUYXO7^-A_7._N0&HY^+_SL<O;EP
M>3N3$CN.WET^9%D\YF%^Z[Y@5'BGJ'"O1(7[<PV?@EAKD@5A=8D*LTK@O,O
M?>91>)63CEO;2BQN.;U]PR=B'ID9K;3F+GMDYJXS\_S!=A5X8+Q0,57\=.V,
M,42"5$E2J97./'>(F9] <;[J]"K.L<J.R66T$EH)K8160BMMLI7N$H,;YH(1
M20GKF<B$VT0LSUHJ(DKH'?C]8_ 25YP&W36^QBI8>U'U?HFJ?YD_<N*B\S2
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MVWW^^X>7_.6'X8>71[^(@P__EU]^/6U??_F&_/7R^:_\Y;L_F,O1QZC \IA
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MW!O=&) L"?$YO1&+776T)0SAO.J-D,!Z'8 Q'XG361B3M[9Y7RZ_I  !WEF
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M"O#914@L.V8T\\ZW%Y<@QCN+\5;++(CQM6)\7GM(%4RH4R"5KAOSA)#@M,U
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M2+AHN=+N2CTAB&9B'S]:&U@%!^02]-R5S5(')PWD[)W F Q.H%K"=T#24+_
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M%/!2&7S=G97PTSX%0-^H4/DO5[W6'!\K<W*8_T,?'; ^?C_UXUCX>9XRSZ]
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MJ[+Z'.M,;QV^#W<<Z[0=R'>KVA0[@H]6Q;+KOG8EY0LX$;NS$O_O97\N?FR
M'-TC)P>G;E!Z0157+$R#!%%Q(<M]4;$([ 4W\&/7X][W=2^@&)"BHG]8 O$H
M;P,;B"N;HV#C*-5H=EK#[,H!T%?;T]K2G3E-6\/LJ&'K0K*[@@9&0@SX5\FO
M9#,5]&1D.</X>AD&@I%?&6\AJ7@*O=3C+\F7VPD]6,?%TG+N;)!QCDU[W@L]
M AB>;&<N2< TNGD4D3;?@:=-5#Q]3<*2AHE]<V>+UI1WJ">W=??.KD2\9CI<
M0N<ME/HW+64[,!K_V"C\']=</MD]=7.X,S-/X(HA!"<M6,Z]E(DH$VE89D58
M\;&Y+"K.HP#^ZZ=^*$H?F9"0TSFI7)%Z;OI]J<5>9)Q>9AZW2M3T_5(G;K""
MX'_O>3W%WS.P55C'IV+8MQV+&DA?&04IRQUR<=6 ,C#MAR>Z=@J,HZ85!I/0
MOPNMW[ZG #[3#E7(Z-'-',:JN9FJ)=&#1P75+><(P#&/-!$$/E5W 8Z>>BD_
MOG8$!^OWKY4>$2[HP**=]/V7EC-P-*9$IH@U,KBK1 \E,[E4TB:A,)3FZVN\
M)U;=L^1@7UXLY6V@'">0M%:<@TN$3HKZ*I+>8#&U?./P5A(RDG>M78X&,SV>
MP=4%^R N8$^Q+M J$2=K75'P3:^4M>[\T<]3%>K1ZH _=H:KHRBQ<**"4YOX
M3E=86CVB+9]@737CNI$-YR@+SQ&1^YYB8Q4X@8VD_31/,S6E7+;WQ=3_F@=/
M5-,/F5J&J_9,=:(#F;3:35A#5A.114IK.L4KD)-N-JZ+U$VVO>ZZI6@GNOJ4
MQKC07<)D&=1"D4UT8DHY<^H*=H$'?EJ_PUIWG -9 [EA!RW-%W*C&ZP]5^$Y
MJ^EZ3U P:*?Y]?CSUD#HCW A3F!R)WI_]HU$_@:[N"?RA6UN4.N/-X;(='_V
M4DG=@V^<\PV14]'!WEND771QIXI2,#>.. MAXV2U4N%FG >%G[O9=5C1>V^1
MM)6';RL/29QZ40#>>>$%+LA#EK$\"PM6IM0&)DE$EMY)'NX/.+R5AV\@#U4*
M"J+D!8O2*&9AXH<L#TN/>2D7F1O!?\&A>3Z[137.:GG.#=9'=[M^6^/6S<X;
M<<;;DD()^K8=7J;<-)@9%ADK>@(P9PQ]N4620^0[M@%%=M]RQ19"-G)E?AGS
M:$VS3NG[7X)TGDL,FAJK'MJ.9D&W3"R3S-5=15>+ZC%R7@S($JQ\7K>LD/Q!
MK86Z^67V5.8W=:XVU_1__5)]KVP)-WK?SS6K^GS9SIM.9@[0(E^J_*;:?A1
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M".W1[Z<A#X*DS$.6^Y7+PC*/&?>"@,$M[GMAE"5$$N<G:VC") >EX@ISZMG
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MF&[3[;"_.'(%V4+B:K&-?_U[LJJT2R",  EJ>MJ-42DKEW.>L^8Y5C ['U[
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M,8CD&2B6Q#2!*FK=\A&,Z7:W<X;RM?-:@WRFYG1!!\?=CI\VJVO@NQ7P'2T
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MIIVCFB%J-44\5U'2+'CDHB7":499 #H&P"FTZ?Y\#Z>",JX[9.: RARQF,G
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M[B'"TD::ZW@A(XMP[G!ZU7[",I=L)VB&4_-VMM_J;VA'UF$'\\#L4(SXHC6
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M8>>Z/7@E'$MAUW9\&5L:#5BD0Q?>P9W3VT^GVW*5<K>X-E5DZ6<8RX'QF2O
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M42[UWH'03<'NK+)MWV6%FM4WKK*M8/4[&' U+-P_+,P;<DP2HW1D*%B& 19
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MHYQ;ZJWB.0!.:!*4*69KA>'IH\)\ D3R)"6N44A)@L(@*3+$*<2T5C9A*YP
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MC@!_*OMUE@!'65.K";'_OEKTRW+--Q!FWN1G395?KHY>?A+!8&P<0U((CK@
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MF&3(SHO%<4YK_PJDUEEK(D?*:]KPR>CB=ISX6Z95V9P[V2G@_,+E+$DP8+Z
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MO;Q@DD&5'C?NU9337YJ-LUY.4AAVLDE5_#K'\_I+?I^3&48]XB?B9V65N!5
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M'JC6($R%H()3[!S-=^1K?*KQ:5?*+3TV0&7O: U0/PE0= Z@'$F$:V&1TS@
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M=7FTVQCAY1?]?6S8\=@D-K\/&P&&NXWTW\/.%]29D1,:T(N-_>\U@[YG!&A
M"*B[C5(LCVL OG&FM1-\@PSA_,='NS!J'*5!:NR?KL(&OI%Q@3:^E!7:0-!
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M1V>PCW^M-G[LV/?)+ZSV8\/':V%XUJ;&X; T_GNK#WM]CP,[7M+8IH/#4VZ
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M&6VQX)K@7X=^U!]!]S9NO]M5)5F\%?@+LD10K4KB=9.E+5L,/DOEK,Y.62X
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MPR;;NS1,, B[8VL@IB^IVZ_UO*^D(2,SL(3LPTN%%^8\ ',F0_91.(CIEJ9
M99KK,\WQC]K^]A$R#8L1]3G%"0L^$9F,)SX'("QZ9Y@(W!:FT>XIU_9=>H2"
MU"9I%B570@KAK:2..N^TX27>3]Q2U:\(_16$SFCS6:,*QRE!(SP35. D<9(:
M8E%E<TX[[S-=6>-J7JFI*D(7$*$Z*$6C0S;V6F:+(M0B9*U00)4VCM]2E:\(
M_16$3OOTK0U<4<M044=36S(6B!="$PX6$C79&6516Q?S.BM=_?;7P]=6R6Y[
M98*SG_7VRB.42[KE.L^A>3+\')GW/J1@8PDSD<(',)RJJ%)(.>1<MSL6@KS;
M+\X90**]_E&5XT^@/9$^&2*I501\] 3&"K! H:K%N!XM<[.'KF[F:ID'=![8
MR5J)LQ+G7(B3\F"9EMPE:R0RJ--!>A>C3DGRG'W=95H4XIRV2U-T+A@O2!8N
M$NDRH$D:B[>ZV"0Q">MML4N;CLI*G)4X*W'.-\"&B<S0S*3,<YEU\BDG4*AK
M:N6U$[1N[BT*<4Z["T3TEOD@B?$!-4X=2P4CDPBS2:(V:K5+KIQ@:PIYZQC
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M'=Y:H^A_E8QDC9A?*#+:':14Z6AN='0\0T<Q9,VHM8125I0F&8C+7*,.E;P
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MB*&0U$ON&(_2<Y6 #<@4%5<<<RLCL\N*X7TPK)+,Y27SY&TS:07^@"-(1B'
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M!20O4JY)_2L4;1(ABM+FHQQ(L[5W\(O- @MC?G-L.T=Q5 V= +KFHY"_+E#
M,G!0; U-/08&=]T![>Z$V#+B,/&-&9[R Q;KJ@W;W4:K*/\MUO8&Z[5@PCY>
MCWDW"]RM$_C\3-8MG>OL]))?[3/VBU:,N5%>)LYYRW"JXRM,>V$DW'AY89:*
MXV7R>H($%R'XPL85^U/?6_#ZA2,&?&!8M/:9?T"KDS<,8\@IW%NCSQ?>%X3B
MIKM.WJ.,V;?RA4"]^WVP8_UA;NR2=]BN>[#?UFBMB#84G=]K)\/.* AW\QLM
M>H_14T 4XK6T3X7-B]XR(+LPB\4M2@\A#WWB1K>W'QPM139='L8".#3_KAF<
M[IRRHL*^L.;MT9&LK2*"?^T?@7,3QQ@%GXPB?/"P?@O0JM>:HW15]Z.I[D>D
MZGY4=3^JNA]MPEBJ[D>;U?WHSFY&,]V/)%A#ST/ UB7XCS8FQ$BYQ]IC1[E^
M'MV/RI2=D1<QZJ28,\BZ1QVXRU7ZVXT;^:/6G2LUZ^1>T4B,LUYPP91VS#MC
MF=$T&1_'U0_DAE3+ZZZ=V6L>=\%^6PX]^\)91?(P@!B^Z>:*P/$U50O/I1SH
MDYVFI$Q&S"22*4>XJ8W( !0A%AEW%&;,II0[9NN[.KQNDESL@-<6\R#*D,FX
MP6LE%4M)Q>6'IG,A_O_L?6E3&\FR]E]1<.]]XYP(BE/[,G.""&:P?>T8H?&,
M;!_XHJ@5! )Q); -O_[-ZI9 : $! B3HF3";I.ZJKLPG]TPE%$4N2H&XB (9
M0SQ2CFFN+2'8A3PUYHZ^O_>>:_98PF!W$<9QSDTH/:0E;0Q;1/_>[9_-V?GW
MK8?(X'LK)!*)S^Y.ZPWB#@Y$,VD0Y4JKY%-TVN?Q,3F)<S),-G35^VO\SG5-
M.>_UVKM2N.9&SFMHQA;9OL-NP5=%[S/?>=7OW.<3OCEF;?UJ)1?1WI(?WBR'
ML>4OPVELI5>I/\\%<&E37QGYXS,F;I>[_7NZJA_)0GS^413;A0OASR)667FE
MK[BCN=O25GN7A$$J.(<X%@"?47*$"8C:$)-FF3OPAIKBE9[HE7XVJK?=3BR%
M_W@NEIG"&K=Z?EPLAB8-5E'&B1\P(*6:+?B2E'FYWY(,BR2H10!&.6M*$^1L
MU,BQW .6Y.I7,G- RFG1>0E09_TJ>-"/QVV4_U:X ML@\7L]()6B,N]Z<$I!
M<I_..\7/0#)%.Y*,F$-B=W$_EX:>#-]TC[1+LZJ3N69UAUTYK__'R1SOVTHV
M!RUWUV^0R-W]^OOQU/:*1BJGO?;W,EQ\$O>[9^W"\>Q';I1#3K6#&/;C6//>
M[%^\EOUGUTWZ[^K46^YJ4%!5SKKIP7*RT[IV>M[+,%J$"T;[!L.*4CMKDV4D
MHXA;=?MG]ZP\&0-01I3&U$IM$N-289/R3$T131+<)^H>-2YEY+#*2'-E+LV!
MJH?U%HX:I'JDB(!P0]P3A2P. 8Y .VRU([Z8 FPVV)VS% ?E=#/HL78<\TS#
M09V$]04I%O4DO3:09-NNW_[Q0H6]64:7P[%GP VV4&[/AA<=)-04\<F"WX!I
M!O&X?(WL-^J%\@I%RMBY'U4XQJ-\PQ(8VRE&=Z"BXN\T@^@P[)EO6WPF[R8G
M*78[[5!P]OMR%B2\M1#MY<S&,A]]UC:'>\DL.ES2'&6=U^'&XD&4*<!%1649
MOQYLIPP4]D?Z?M\ZQ&/6(GVWJ-T;J2KR ., QX"' "=M%-J=\S(M[ZK::%!Y
M6BK^1;K@W$6<PU!?40_7&83V.^W;"C/+#4S<K/SDQ3#!<.8&V_V2N&?"6W\P
M;N<&PGD6.7?64!P-)T88:6UDUFDCN4E<WS7@)UO^Y9+RBD87M%-LI)&^7*V_
MFO<S/\[!WEJ&2J>4S1.@:$!@ZF-D=$C($#@FB;F+0:UMBHW)LIJ;,+=R*DY1
M$6A/QWJ?S";\$3Y[2/W8PWA@BIGT-Y#N:"7)]?TJ7U9)U<WLRZ(^$!Q1P#8B
M'C&80SS_FL-"6/+$9%C;U&)#W55&>G<A?6GN]&).%"GR,^U5*>9MIO143\^C
MJ21#Y0T**1;2.!E.Q2A(IK*?![1R ?=O*2IY[MT%JAT'^YD9BEPR# F 0(>5
M(@[SM4TU(]_P^T!?.#UW8#U>SS6;/2VB?>7O(;5R9%VM.*NKR25#DKIS$/M3
M0<T$$8W S)_%/J>3TQM'GHM<FJ2999+'HM6ZRH4F FGE&,(\.BE"B 0>V"8W
M&].<Z%?(LSY,?AY5)8<FPK7J.**OWM"%9XFQU9/2OPU<!IFE"I_!;=L;<S7\
M/!U6M1?&S"!)MYLS,++I<:6+#_+R;C#I/W)^X8!3RZ3T&_U:;K<Y\KD5'5+"
M2!^4JU44]\K9KL.<Q.OLR'_>O&56[]<'XW3*AKQ%7X/Y5K$^N:E!3NW/<F+2
M_7MSO6[G75&5/+KGT9'B*\<XC9-:W5[4>!FNNLD9V2SOQ+-! X6BYOJNK@CC
M/BMNDQ*2,D<U9Q9;H3!EDE"'&3.V%#$8"Y"<]W'ZO[=^T)J\,N"F"YS=G_7/
M+6ZQLM0;Y!SH*2#K)7)&\ZSB*A.2\I283,_D+N?4-9Z4%#](G#X99 :?Y:8>
M_2+X,A[@O%^,Z(G(I8H1S2 25O_1DC0_W<@0C1$C[O(@7\LBDL(%JGW 7HN<
M[S$U+%1$'<<:U,"99T0A@_X-HP-Q)Z"SP,SK^;CG)T6'\VBS=ZIWW>!T?:2@
ML"AWNZK5N(I<3KENZ:[,D<[LK,R2.5Q-J[\68\]*GT4)V-4B"JVXD2;'+KSU
M@0O[I/&YE:SS3&FPLJP$V]QYCFPR$C%/6?22<B/QVJ91M]1WM7L3Q4 EP9QU
ML_\YCU&>' QY%1J_UG&F$5=1O/$3<*3=OWIKMO) JG>Z97^H0="H(,.'QWTL
M 3O!1YJ"E5P$HBV7A(/UD!B8"485<9^"Z- TZKL][C/,@6JDD:GHE5"=U;BR
M?OBNE8@V@0N"I*$)<9);C^F44"#>&&88)9X"8!J^,8F88XF38^D>CX@-/@B8
M)DECA B&,-4XJ5SEMQ-%'DJ@N? 8( DY((Y<:J^0]=XCX7S$TH/:)?W:IMPP
M=RM:0R$%EEFVR@".KNKAKKQ&@QSN?A%2&VOL4$P[F:G3WPBL%UT2!S6'-P3U
M527BM6PNU+PO&W_GEJDG1[4=.PCJ;?7[7=^V@Z$P8"Z60^]O7*Y9_NWZ8OL9
M*4^&8:3I"+MZ3HBK$;GOH^N5R0VE$C3'!)BI(F8I!N1.]+''RSDEUR@F Q$!
M4^-Y4,9*!MCL*0<0M%B&.^1DU7CI46WXWK6\3RYPL!QH$A9Q)2(8$@0C,#0Q
M5X"-8(V^[&3<EZ"0JNG2!+6PW)M&2J]( ,4^*4819S(7' 2/G H\@<:"/9:O
M<QKN2U!AU5QP%C'RK+TI ;B5O$!1) /0!2J<QL(A:Y1@G!',<M>OY9F J[U.
MED4=*0-H9<Q)XTT*.GB#P2IV3R[JJD&FTVA)U _W6RI7B8(@1)Y(C[CA$EEF
M*0(#'F.EG(B</?G4VY<@D)F2KB*6J<2RDWT)F$MA=2[!I!%Q'@G2B0ED"8L&
M7J/.T)>8=#O-&GFV2;<:I^0B,0EVSRDACBLBDU :'@HC)L[G9:TFW3Z *C_^
MK%_Z5N3*1B,-4C+7,.6,<I,G].C@A%8JYN:!U73;Y9QN.^YZF&>V[1,-M9WA
MTJB&VE9#;=^XU7$S'2P[3P2.S&KFD9<L#Z748'PX%Q#S@OK -!B&[C$3]*;Q
M8C74=J7)!N[3PE;B8#E!RN>AMDH+I,&21<%;AHW'F++%3M"KAMHN(R'X%DLF
M8@Z6@]2&@M4I&7)*4J2ML\JYJ$A:R 2]>P^UG0(\BQAJ.PW/JJ&VE4A>R%#*
M+W1G>ZMEJ$E<<1#$%@0Q0!Q804QC9#'!3CG.)"=+(I*KH;9+03:LWMQJ:1)9
MS(X<)W/_)&X\TB98D-#>4^T%%GRQ<^:KH;9+2 B'NZT$RH^BG"(LB$$<3@?P
M(R1$'4F&>X 095]BJ.W=$OD>0VUOD\.K/-2VZB]\2W]A6O47KOH+5_V%EV$M
M57_AY>HO?&>_X+'^PM%(E2Q7-EG/8Z(NT6"))Y@$Y0/'J]%?>.X1\#/4A1LC
MX*>&#1XX KX('95]&+>FOV-<U0B#'92*2)E!.:ZJK& \XA4-EI]*0_T:51N@
M9^N'#9;OSXY[/_MD^2<J@AO9V._5!.FAV5:'>_J6]L1Z+"3RBA#$)0E%!@;2
M+"46K%8Q=\)F<H--=CVNILDO?)K\+"GQ%-/DIW+\TDR3=RP&:POGON4Q]_NS
MRL4DK6<8L^BK:?*+Q (*ZVJEY(KB.B03SA/DM4-&"XJL4UQ22_(HX3<_07X:
MAUZA3*X]DL7>V2.'QT]ESEN&QX_<^67FQANM6*18""ZX24XKKY((@A*N#?Q0
MI78_(SM_OLQ>6.Z,$ 8>N!;>(NXH0V :9]$NF8077# /2.T^6]"L^!>@ERIN
M4Q)'(Y<LY=!>2!HIDV,UC!KD"&?( ?2[*+45*;[0?/@7H(PJJ#-!)3CG5J0\
M$<4+C))3/G?(R+6]8!WP) SG1DDXI6HF_$O+QFHF_#0"!I7V8TM&PI7 &EDA
M-.(61V2I#,A1+HTR!,/WQ\R!GZ8-OO0<^%=14+[:<^"GDL7*SH%7P$0DBN"%
M]3Q@8SQ 5+0^,1HI&,[SXU<U!_X1B/;E M;74C9J)B@\:F4QXB: 0A\=1M)B
M$,IP.C*'3A8P^WT>&GZAV>]SL=?C9[\/6GBDD8GFOIAH/NCF4;MECOGCY\#/
MJB%YY!SXVR36(N? 3SZUT347 FWEA-(M#=>J2>^W-0M;PDGO4[OF+?.D]Q7A
MC_F&[4Z/<SQ@V*Z1P3-"6>X<S7ER3L<8@J0RIBB=JX;MOD1'G*.+G4./&TW/
M8'TM[F,$BS<@38- W'$PO\ @1I%Q%8/7VJ8 &LO=/>.6B2ZJ8;N/H8H\?T)S
M;;102&D*EKFB";EH"<+:>TD=YC[)HOGJ@H?M/I8P^%V$L8AANV^<0'B]^;&%
M&09:R'YI$R/B,F(P=))$R7$N'5;2FV)H([D3-Y9E\.[\<W>?6XHZ&A7!3DB!
M/?=!&1Q2GHOIG0K8>S.P\ =,@2LI^N3]J6']NRV#$R/*."0L!<FIK$,:,X.4
M%;FFQB;.<@1O0RU2<CXU+522\[Z=RK>W6C))0@(%"-18(2Z4A)^X1381[51B
MRE#0H?C"1],_EA@J:?ED1.%;) @#5,%0$H(B;G/!9H@48>LM%AY;)VF6D'@2
M'VHK*1SGGBD_(U'VGMT*'Z<I5C/E'T#6C3QM3(/RSY)'/OG<_3X8I!6GR%-!
M1>(@^13+4L_(A\^1G^6I>OP<^6E7?L@<^:DD^41)D=64D/F:U?B6%SYQ*AGR
M4N.<!H&1!3Q 8*@DL%""P33-'!ERSTGRQ2B1@MYVNM]+'"2WSY&_?M\ +JM:
MSEMJ.5E5RUG5<E:UG,NPEJJ6<[EJ.1]<F_G<HPUO0?C;2+]>5@*URVJY/W)!
M93,75&:UZ"8EE4)\!]2D7MO?5,8"<<[YZ'7@G@?.G+>*8A$$6"W)IS35/AB;
M5#WHG-E(URMJI+R>O)R\FH+8FW#/WSK%>*(WIH&!U@77:#DF2/+&HX2Q1#P(
MA5Q0,G<+C$P;0YW$:[4(FNIIUC!ZYW$UJH=OTN%X8>_9M*K>'" _/X8-%;Y@
MVQ\4Q/5S2BV8*]US6$_H__.71P6/5T<'X1M4SW[Y-F7A]M>8GD]7N,]B"=]@
M1KWUQ0KVL/-Z38OE>+X%/5P3?5%=9IKVMS;P1#]4@5F(+GZU_^>T1_5<FM[]
M'$%)J, #Z!21.4Z2-9;21$7DWBL;L:T<05/4D-UOG_I[S=-.O;E[4:<[QXWF
MQ\O=RWV\=UB_;&QO_:@?'ASM'N[RW>86JW_[VMEK#S[SGT\'[CAT&L=??NX<
MPF?HKJ@?[APVMO\ZAGMRV.-%X\-?[9W#@X/ZMO^Y]^WK\7\NM\[J;?SSC^:[
MLYWF9[%SZ+^'#U]Y^-]/G3W:^>X.3V%M1Z1^^?X8ULCKQY_Q[O'>8:.Y1>OP
M#.K;^WSW\",\@W>T\56+^N5G^/DS;VS7:;U9)RUA(]=!*J1) $4H$HV<819I
MBJ4D3"D@J^S\G^J)&G51SI[A7;'H8UBT\M6N HO^7;)H_7*+[%Q^'&/1[H^]
MP\YQ_3  BQZQG6]UW/CP.3^SBYWM?;&SO?NC\>U]&RQT4N]HW(I2BF"<1-9*
MC;BA./]$D.%88:954$3.= XO"4L^I]XP']>]^[_S]FF1K_R^?6++Z8V-ZQSJ
M9],GEN_)-(M1SC.\%W.HC\[ZH_U>]_PDH,&*O8\QI5\?"MDOH57FUIIST,"=
M>QTGCKL^-["*"U?^Z5FMW^VT0RUO]\;3P[55>(;_/?X %[3YT4T7U0=+M>M[
MI,$\3-U&;%R4CWKVKGT_?\5!14:_D?X<5NY\/-F!VS=_Q,[W6(>U'(PEPZ3V
MSQC09>QUKZ0^JX3^'$+_W;5>OKW+X5XMP25W/A@4,'=Y@D! %JO<_"9J190V
M3-!LOFI*Z*\S$JR>AH/R2_?DI H#*PQ\$@Q\F#U38>"28N!-PZ>EG<,41X=8
MH 9Q"E\TCPE9PPGU E/&?86!%0:^;0SDQ%(6&4\D42Z5L *G8 376.*(B9L7
M TM+-OX1;3_^,2@0O?AS (#;Y_%VV)N5!UUAWYS8=W$3^S"SB09I$7;$YE%B
M$AE!,<K#HZP*5!.-US;).F&S2HTJY*N0[W4C'\-2*"6E2EQSI;1+7!@MDQ&:
M,CMHS7P+\N7ZCU'-;^LDC(+@B$/O3IUP-]I>(R>-59BX.$S<&=,'DW8BB811
M"LR#/HC!'/91(4(-#2ZWEG1BE3#QWJ[05/RW:JY0]B!7Z-A>9_K)Z?V>UU3H
M7VD4?!$_8,:[YH]N9?HN!.H^3KC_3&24:^M _5,"\9"GE?$\\YTJS 6V5GJQ
M,--W.JP\J9I7<?<R>[@J[EXP=X\I,C(%4%BL08+:@#@A#CF3'+*1A! HCI3*
MBKO? '<_E^_FBJ$KQKT?XXYY91(-/GD![!I(1%R)W+E>6:2H)L02S((C:YO2
M5#S[>GEV45Z'L\5X'2JVOC];CSL6P%)2P@2&A P*<<L8TBI$Q(@!@>PQ3L0M
M&5N_D30J_A1I5'-AV93G]?JP[.5\!P>]&"O[8B%X5I_P'C!E>,QMZL!P)(A3
M!W@&=B12,41NN,<\VD4'SI<H2%3Q]\M[#RK^7B1_CR?&I ",33F*BH(98CQ%
M-F"%J)'>:BI=<@M/#JSX>PGY^UG]!R5+5ZQ[/]8=\R P:9R11B"BK,Q-$PUR
MC@7$F& DZ)AL]*#Y5DS[>IEVV1P(%5\_@*_'70B&)R\XB2A&0Q'G4B"+L4/P
M)T4*]T*BR\77;R3[0%39!Z_2@_"^>]ZK#(R%H-GG"0>"!RV%Q""0P$8CSJ)$
M6D6,C!=68:-L$+@*4+X!]GXQ!\(D>U?9E(_D\?&@!U'*,<Z1T4PA#D>(#, X
M<D0X19A(AI,L0<DZ%9-S^RH>?S4\_IQ.A$IJ+Y*CQWP+U#NP+3%%CAN..-8<
M.4$2LE$JJZ.1C,1*:K\!CEXR#T,ERQ?-^>/>!\VD("R/LY.1(>Z$1BY$C5)P
MU%ENB8MN&67Y&\EBD%46P^OT0;2_5T'.Q6#:ETD?1+#)69P]JO!(N182:2L<
MLMC1D!*7A)LJR/D&V/OE?! 5>R^0O<=4%FH)X31P1%.D" R6W-S#2T2"4=;F
MJ4HN5>S]!MC[6=T/%4<OD*/'W ]6 28GZ9'V@B">L$!.16!P@C5.G#KB2<71
M;X"CEZPO0\7T"V3Z<<\##C:/O6;(2HL1QSS 3\D@EWR43H&&MIRIQF\A^Z%Y
M$'NQF!!7Y4"\,O_#5C[5Z>!6^58?@W"[$WZ(I"5AT1$D4L[G<I(B)Y-%26&E
M)67&QK"VR;A8!X)<(M]JQ>:K[X>XA<TK'>;!'+[S^X##+XL]M:1(ECD<D&$R
MSRP/"3E09Y",8)ABH1;::[GB\.7E\.=R151L_21LW;[)UH3'1*AAB#.59[8G
MB70R%%DA!%'$*JXJMGX+;+TT_HA*:W\RYF^,R702G?32"B2TL(@3KI'1P:'
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MIV>U8M!Y;;B5ASZ<Z0-TBOR=%WITS^'I>8C?[STHH$7S@!$+8'C,N?SLU7D
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M^T<H]6+,35J+:92U7HXQ_N-_9OL(Z?T> :Y->1"%Q%NJ)S$S#_ED4(GP^!R
MZX1DMK 4H&GPE _U/9SI<,#H7W"B5[G'B%:X- <N?1SWO[0X0 LCG"*F"0=H
M<0HYC TB$N02CH9@+G)S!#6C.<(X/]T31@HNPLO-0__SH+C"V'YGZNP5[JRU
M,?6:2#"^(Z@] $!&>NY,"#+F+,;DIEK?%>ZL%.[<M,%;41'/M%!(NZ1!M:8:
M:2$$$H [DCCMJ$\5[E2X\Z2X0PA+Q#&&B:,\R>ABBE: IB-%[FR-IUI@%>ZL
M$NZ,V6$M10D82YKEX3R@[V#*<R_:B&R*DCN:A[[JM4TZL\78F\.=-Y50\KV;
MAW9T<G>6A]J*4[;_*K%SJ6W%X8%^O3K/"CWOCY[U"6O1X>"M30I9'RGBDB9D
M&5B+V!@LN';$YN '%S-GF,X-G]-19/7@<]$AG@IZEMQ<K*!G0= S9C &T,]
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M1(E.6>:CETD2L)ZUJ5(77C6WCWGMG4O66R90%"'F5#F)K $KV:D0-3;,V6!
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M!]<&Z"Q/^2P#SQ0B"GP;KIB*UNSLTJ:1I$F,6%.ZR[U7*Z^S5V_O_@3BG/-
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M\$_Z2^-/X ]G=O)YM4Z_<'OUQD;.?&H'^."K[>><@88?WSH<YZ>,OP+^5HY
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MSE);%,HI3<P!@J_@L&1-J AS)4Y%?MMY#WI=N,Q9KHK]"563+L?B,=N:F08
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MS@JFT\ZN4?4Z_":LP_^8]]0K5?5*U4/SIS_ZO<&@1N$;H;!?X$TD6I(,.)T
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M'B8(>#],3*=3^@$@.U_;!>]O-0ZG  RDJM/.82SX[+QX%TQ0(WX[CZ%=K$"
M+(8>H&RW-VR$]L!W>H,(\EM.<F'_76\T!.ROA*)Q?B45C=Y$+'(-=SMLG-JO
M\&F_#1:@>HW/0;0PZE=W02]ZW0J!P3_IQ$'5X%%W +<,4FYL_-8&2_&#=XT
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MA1V'C[UZ<H?J?ML->C@Z;X)E-"2>8V],8@# 8',I.T5XO:ZR78AXM."EZ$2
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MED#;_AR+,S)*:QQ'/OJ\ZJLEL#B*D8N<1:\M4=3L[*HF%D^P6N5V^-B_@]Y
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MXNCL/U^.SMZ1_W[_P/:^OSN66L#D@&M)O66(,V61P50B%9UV#$8_)+G3B$!
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M@N+81T.-D$P8H2*C7,:,=,0\ .DJ,+L;F)U?!3/B-.%22"2XR]5P24*6<(4
MXJQUL"UA&S:V.+\N*6_EH&Q)!3A7&G@NG7"3^+KLR[[T2+VR3B%W"=F]CU/I
M'L T6:(/A<L3)O3/7K>][?\S;)9K5"'7G9"K,6>&)6D\94XB9@"O.$X!64$-
MDCF$QGI).:$;6YH]%+BJ[B"KJ\V8>DTDIR9JQ4&MC?0\)Y7+&#E-R17:C,?:
M?']"=0MMKAC7$E5]QDBA$ILH9$(T.8VXP10YC@T0,,%L<-XQ$XHN[O3!C&OU
M.H:LM"7R(:>6]T&9\OG0TBR1]6T_L(*6R$Y<A%W_Y+7ZITC*@,].CL=>>MN1
M)X*P]W/6"A51.\(9PD8(@+"H<I1G1-X;ZJT#BNQ#U77D%:C]4YDLE=H_B]K/
M6"XI149(S!T,HT><<GBEG$>$2!=B4D)9LHIJ_^J\*%>#N@;V6RP*38UB^0JC
MIG*J/+<ILYB&O2G7:!&J5>AU!_3Z-.]B >L$8YT0%XG"CT"1QC(@G43 -"9'
M9=S8DFR^]U+E8WDQROV\/I9*N9>FW#.F2=3!!,<Q<MR#:6(L1X:$@%C VG"M
MH_-@FK %_5<KE\ICJN;'4?!QG%3W>&U.E+N4@G\JT^-#63@1%N,*//V=8U;W
MT_8D=GRT>OOI[TG@> 55=X.JPSD[!)A2PLHK(%">(<ZD1EIGO$H11V^)83P7
M<'E(0Z7*9;+"2OY4)DBEY$^IY#/VB#6.)FP-"@:K7*7)(.U%K@_-N--*I*#=
MQA91+ZO1ZTJ;(C>%.T\E ]VS:UW5Z.>1IF:U@?\9^J-58=*/CN=^SFBS4C)B
MHD/8TY#C<S2R,GF$0U16$AD=5AM;M,[$=65NGD-YGMGM5$%G!9U5ALFK@\X9
M4YA+DRR5"N4LV]+YKG4.?PKP'QT,<4DL*<-D!:#S:L'KF0YI:Y52/ZKMT$TW
MI=(O[*?63-,5(<I*%<E^[_9RUGG-IA1'M45G2P;%XJU<.ZNHHF,'L:A5TK\Q
MF[\7:[YE^_VR/4E.[B]*N;:ZG2.4ZVE,=S^N=3NC&W>*=2\*V_QA6T5QJX_'
ML2B/=3 NA1-'U;I.8\>VBJ_/E#RZ;E3%H)KM<4'57&ABZG+%Z>RB2][\D,UQ
M3<=F9[I42_P!U^K'F;(-BWMN%/CUTUKWA.&-FV4U-Y%X^LKTA63N=0>Q1L1F
M[9&++;RUO5R'I?]/['T\ANE?F2()%]NC7:#+]@^VV=Z[3_"]77%(X9X7?[3V
M=^"]DUW>.-C^ ??YT?A\B+_,%DDX\2(C_I<\QI/6R9>##R>-=S#&]I_MQLG1
MC\;.VXLO.V]_?#GYT/KWQ6X>_U?/N,=!490H8#<WCB"C1$(V,(9-PE0D5N[:
M('(Q;.?-U '=\<Q@9J7F/G)-8Z2&IV2Y2MC[V:(*N7WY+[E(^*^Y,DL6\--<
MK#A/_SR4KEF1DL4-#WX^0U=G-$3'-(Z&1T% AX6#+RO'#?.41L[)U;I&I[EX
M?"Z\ UO4<2XF WH21W)=3&T_3VWMEXR_%/_^]I^/Q2OR^Z\%3H5F;J@3:O#W
M30#)_&UX"8!3X%!_JO1,\<EQ#<^R<N]I\55W#N]];Q9]GT9WR96@?VD5BURB
MV.B>XVI2Y2SF(*-<1ODHUL >R]L+[$.Y(' NAI-'#5 ^'!05FO*U1_6+1X6Y
M-VL[ET,'@$TMV%7ZHWI(<V,N"O24%7VZW@][>?OJ#T#3:W;4+BO7!(\_8L\W
M<SF>XAG+*CL 'CKO)85%D V,C$[]2>.F!6\5U_+EG\=UD!>,J:@I=&40,*NC
MTE1Q5)"J/R[4-,@GS</>>6T!ZE^G)J^O[1*MVBY5;9>JMDNK,):J[=)JM5WZ
MN56Q#A96N5VVX^"X&RXKYQ7%\$:6!(S\&U@?N;#QI%#>+ 4=VQCY8C=OS^4N
MWI^JE'IW<^"&7;V9T,1.&#U5?=3R8%1L==1_9*K_PM@R^OFCP9W[PT*SBJ*#
M=WJ6T=L+S9NR#>85KIH_#OKE1_5B\PVF+,M<E'K8S@^]K#&,ZF9>-OJ<U+'-
M[1OR'THKL?9+;EX!'VZV"VDH9J3HI@'67>;DO5]G2/4CE_?SQS$,6W$_S7+/
MPO;>[H2155L@XNOFH[M?*6P91%"%M!84 4A)9(0WR$2GG75:!C+'+]<!Q:X6
MLQQ9A\?=L_ZL'O4GI.>&XL)T4JBX!"%BKA:WK&<V%T\'4VRP=/O=J>SEVMBP
M0FYR29=?7I!N"G&_$HLWOR=N:<*^[,'J1S;C5Z\<X>)CCW5_JJK&)'[5CT_,
M74ILCK<+L+CBS=.PSI]\63D U[':@]HO?^]__/AKYK3[C;=+*[/UHB-![O;P
MJQWK\<1)$+D+";R:95A[<5">*^4SINWOMMDJF%3W34&,/V9>G%L;  DM&->:
MA(7<DX"582&G[0;]J]VXV#N!^Y#&20X#^:MYV(9K['CRY>2O;WOO_CP!<G9V
MV)P)"VD?7AS"OP9MP#-].L]A((?P72!Q>._B7^U&^SU\OG&V=_%'<U'%*\ZU
M4\(&I)D! L>80"Y*C8R-%%XPET*N>%5G7#T\1GHUPN4>J^!H!8-K H//F252
M@=]S@M],3)R)/'F.%7(\6L0)(<@:IA#C/EDF ]&6;6SQ^J($D267*JT0L$+
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M$+74 ?&0*$!$;G@8B00N3[ R1#*'^;+K.E5P\7+@0B0BA"8:=AS%A22.)YT
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M/)"FX6F6LA45C8;]T6P/V]L=@(36])N93(_D)E8R<M&@^]M??0* -,PC+X-
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M/ )5^QY;W=/QU.? G'ZFW&7D8G'^DZ=@?C&RIWH<&-B/%AAY]J&<1:#U=NP
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MHH(G<F-+T+K!RSJB7M.3II>MT$L/H:T4^HD4>H;P))SC!J)&VB>%.&,<61K
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MYC+=SH.*U;TH'/OE:4E,'QX87EV+:+O%:N65JS!MB9@V7^!:P(9#N*6(2"$
MTU1$+@&] 4,U:,4X=3XW3B>ZKL0\G_EUM=IO5%UXG@X$EL!E*A!X+A"8H374
M2&,4E8@[:1%GRB$=5,8$KZSQ3$N7#1M6-V;^7*7"@!>% 2M!:"K-?RS-GZ$T
MP1NBB0J(N@":3X'-6,T9(@DK^ W6-S<&!\W'^,&U*YZR ]>+S@C9!1WLQ?Y@
M?!)3KW5BE0[R=&<NX_FOCHB7#U'SI;>UA)63B2+A;4 <4 1I%@T*B22*G;(L
M)X"(.EZI3N=5K/BJGYU46ORH6CQ#,20%K,72(,VI0YP+@O[_]JZ].6UDRW\5
MU>S>+6<+83T!);.IPI@DS-C& \[,O?>?J9;4,IH(B=$C#O?3[SG=DGC;^(F
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M<LNBMMS0E!8A#=O1&LY/']5[] .W.5].22S)>O[:JVP,/.WPOQU>7<G>Q-&
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ME']E#!9@]H)EN7#_E=N83$;2B?T.=X"*[I[1$EV5=<&YO KA*Y$V+2D^*S1
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MEF4V$6-A=KKZ9T,U<FSEZ,ERV0.:'TU^-L5-ZI^-KH+1]T0)_,9/^@RF:_3
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MTBLD:GUY;(J0U H@,GE'._J!/'K:6J^$4-7IP_[)L*C99";&SPF;K@[S+R3
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M'W9/NG@9,X3ZS<F'G_X?4$L#!!0    ( $B&650YIIK:XS4  $4^ @ 4
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M4J"O:O,%?/UIE7,V_;!Z[GD.]]<+ D[)M&.U47)(X&.J> @(P7D-A2SYPGG
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M5JZ_L?O5PSY/:Z WFRVVD?Z\_JQ?<4D@6<\\OQSUPZU(PD@P(J_D$WF/@BE
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MN@P!ZV@#RR4XK078K(5EB3&CP_'!N(TCT3MX,E 0[L31XX%O[7,S)731'NN
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M609G)?N+>XJ?<B@F^N1!&,])&10!(00!,4?DB=-;\D"Q[0:K&:)KW%-<'1H
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MI3=">O1V'T;9=UD@>K_A,$5D$UQWGJ5SU&I!M1A_ABN<(XX[D762$8@I$8F
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MI;<7LWB&^GD[\=/Y*#.@1G)'M"Y='[)U)</7$.ZX"(9J[F!-VZJA*+,]X"?
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M/>/L$K$F:2(I.!8T<U;52OO9 >Z3Y-V %ARP]+7XPELOW+>*>$?.2^&DCZ7
MK=RYY4Q<=NCU"D9QU08(LDL5=!\,ITFGO5JF1@'J)O#_F*+.)N/_A?1WU!>^
M'S?5X>\AXANS&,/\V6P\QQ_=?H%>P^)-+KX!S<+Q: -AR6",!981IZTGQN7
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MQVG;D:P4D\?FHLQ%_?BVF8SC&.:_%'=L,O\66:>)#=M]?O^A#3WD69G;X$-
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M<7UKTR[#MY"^;A9O_6Q1YH;//S5S/_EMUEQ\>GXQFY4UEZ.\!OU#PHQ1ET?
MS@,G67-4D-1"^DIWK5OA/$%6[<%@%<8ZO *$>[-UORIYRN^@:'3YM]+X=821
M.86,AA=1(\JD<6G,$14B5):<RR14G13N;OA.F$X5#%1A(L-ZE%/XTT\NX>E
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M3=,_F]D?2/VK\XF;[7P^4HX'KLO-*I3Y*XIY$F114)91FI"83O*!S;+'XT^
M*/M2?H6)$4M=/&_.PWC:=CTI$S'&J>VAVTP_S/QT?MD?Y?+L['KI?#F?7T!"
MV<H7E[,X [,>+"<H4R82/$I1^@46KT3DA&)5NK,<4(@38..A35LA5W^-CM9"
M?C-;(EX.$GI_YO'GES\=1>="$F593NTP/@RQ0SF[LTDRD7D,FM7)K1D&_PER
M<X\&K9#5AV_6>3-M6P2]];,WL\M.AJ5]5$E3;9&.RIE- &,)E304?R 1S\L
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M5_;U$=?62AT]P5T[HA8-16<3_P@I@? <K-X?\X83Z[2I>B#S5[A(&V04E@4
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M(ATX$HR5!+*E.<2L5*B3Z=0)W@G1:WASK"%-[RNZZTMQ!@&=B1@).A&EWE
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M$JH@:.;K+,Q=(3[V6_9M&'EGE:YBQ[TGX=U-!\!82+.<*5&2.B(C1:2RG:,
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M\)/%V;*RS(84E#$D:=R;I;$H+,.5U#&'>"0U3,H'XK0-'[U_3W9@Y3?#:6Y
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MQ?%&I9)1U6D'. XSWM-*?U@K;J.V@:WW.VKJ_.+\"HA"89@KJXE,%$/A&$@
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MD443@?SLFA>EK/2MAO0\S63@+J1II)93)P-_MV'HVL+;;GY_U']PT_L%1 )
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MZQ9#5'] ]+W%ZDY,3?MH;T-UFG;9737V* $ZB'LH*FA0"HL&EI6/M;M5M9&
M;"0EC0]@ZTS9)TZ!'?VLAV# (5+N^85\[6QO!LC6,R,4A&(,W9 NFMH-0S+
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M)49TY"=52IUG4=,IB[/,8[+,>;+YI9)2BS8=XENMZ-EL@+.BQA;.=W[NJ]F
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M9V!<9J&D@AZM"'FO_*R]9GMN0W"J4-&0RI_VJ(2>A_6N\<S)I%XCFJ]-ZGU
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MDEC@; )7ZY9+ZT8,O[][OX:G.(]"&\X(!B>S*5>O)<KZSA-KCWP77)NID#N
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M=0%L5<^<.0,9O<-"9*5:.BIIH0,1$#VE5%/GNVS0['W(V93I,<:?U+#<P"T
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MC2%/"!B&?0=;9TN#)[0^+@W(%TLLOV.&K$)X!<C>BNBKA":@[J,&NM7!2AK
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M5?PJ[3(ZCN=@>K__EPG)KVW:I=1]7X//[N8QP.@<*,#A$/)Q=N8IS2I(CL1
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MAD)SKM3BY$V59+R#H1UF*Q&3QADISA))75>3[F)A-]33'O"N6FBV5GE\A_\
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MNNGS(@W9<"F"?,,,Y0Q.AG65\*[!,=[N?//2.'LQ%^U+_E. .R0"RX1TD[E
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M3J;9T"/?.!JQ1V?%DWW-.DX!1WRMOJ> 4/C^CO$S>MK*=C>WTY\"?LPO82C
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M&F</H49]KQB>\=#<>CH'?'''P@)RSC D,BOCONG8CN**N@8%31!DU''JD-[
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MLNZYE%3[ZW;7?:-!_GN,ZT6_)[VVC94^F+B2CF0(,+$T%J.)KDIU9BESQQY
M$WSH(W9U:? S9*1P2ZE/F#I?\M-!D^LB9K?:]NEV 0/OR:"ET8O/$5IT;-IO
MWEN!>R#-%DVOV,$-)?!BX]9QDKO&ATO[W WJG0[6JZ>7AEGUZ48G0)^=XF_5
MZ?VHLXA='ZR!"5ZC2[56<7)Z6[V6'>DB3:$/HZ)/-_M$O\V.NB\H.=\<\B@'
MQ=</S^1A%Y5IQC*'A_#0TH;I_+?OZ@PLK)<@FJSYITINF$%#;;GE-E<7E/VX
MGM5*F#BY(?CXA%D#!"!E^X>WMX2N?=QQ05H,A+;<)TJPP-ZDER3?*_BRV2=M
M*CY7,3.W;6_1,.>""3V\3Z]ZR>)I4\X3@[@;T'4=EA:S@V' %"U'8'=:^]U%
M)?T?*.5KE<UC2/FX9;L+??DB2BH_?. F=6G[*?*AG_@]6 9L (TG_6G6%YEB
M-)*O$3B1ZG:JO",$=]-J8\):+PY@:)*Q'@*0JP< !#YQWJ*](;-HQH=Z5#T/
M66D+6C$L(S5OG&K@ZF(>=F3N8ZE?462VW:&UHM+S>R57_WP''D7(<*<*B/T/
M-09+]J#]M10Q.TJROK/Z$'YF9D^L?5-;_LA=EOW0$=KUNN8G5/']VWP;]_E(
MZ$;?QXC3W!&B=)<:HH<.V[Q!!\5KF@CR)W%E(#]PV_EN-Z5U0H,8JHA%:\%[
M>P$'4P$=G]/!S),:KG_GY!)I]]3WA;G_D.V%: @=>1K@S"^\<NG(&L2,K<XT
MD\90S9WIF4DFEMIH<IV8GJH'?KG%!3X9[WJ[-4'YTY.%XYN-)@TC&2-?-D;@
M!#SC(GT0LP8^QE1=!/9W (5A#N0#E6'OB"X>?L(1$6\\/(Y;M^*^2;PYGB,W
MI63I\E;YD8^I!P 1"=? 162QQ+E83XW)-Q&TK\3F/F>!$=$\+<+#]PN/HRSO
MZ^*4,OXP0&RI%HUY\T5I3#J_A3VAN)3>:M8ZD66Z_4$MHC7X/):);X;5,528
MBF30["4BP[0)IZVWR2.&X:?]\ ;9CZ-NAPHFG^R\<G 7X*FL<-OK],CH4W,Q
M1_[U00HR"2W&EJ'S,YXR4\M@Z0C@U2W$,9P>6/1CFNZ/(&">OER6TJ_@+.G0
M##U"0U.33Y?M*X7Q_W$- J+'UF?FLB)_0%J#T8L0>1C_.D\:UW"G..E_V<?)
MZ$*[:Y"/PA^^IT8N2_YNENQ)[P%+&]FGNYIG7[6Y/'N5>->#O%.:+Y:8&VU6
M^>%GQRJCLR3K.[$%LDYZBY@J:2I)X@H'"(I[+!"B=Y2_EJ:Z,[M@2MC;'X+N
MW;?[&E77K15E/L4^4^L)@_;)PEOR=QY^S<-/YV@KR)1Z9:09'^Z.W=#8N5XW
MNCE'Y!Y*K6*[<] FBF3(7O_[&%)=$M[3-TV;FB-887/O=>T=U3<O7@/*$;\[
M?DVC3].MX]:6?J]XUX<LO2^H4&JO-.9)HKG&R-^Y#,M^>LME9Z  [*4)5&_2
M;:,0MP'=0%A&\^+)Y+\?_XEV<M[ '<K7ISO#XB;8?9B>,@NBFOQ@T7'M&$FK
M] =(#"29YZXR5N0:=S\=_PB!I:40J9 9 I9AK_JB^4@_:VPNPZ4U.!1BX>>F
MD$5*%\=B$$ <&56/HRJV-*#B0YYB9./^L9O9#Q"][52U<79!KB+/!W9-7J#Q
MR1L<O'9AG%.F3<\)FAO;N:D /J8@D*#P[*NC06'+2VP-NW!2XSN4J85DEYJ3
M#3GAX[N WW0?R U\&F(>THA-1=ZK>RR;WRVL0:Y)C __&&!]=TI[B3;\0Z+^
M"=DX3BPK0J#<4^F+>8CH-?KOP<9H;!]Q!D<F4E_0W'N @J9GV('CZR9\0= *
MR)JL<SQ;7T^:T)VB?*;WUVC$R>[8\\9VR;=$C_&)9C0'.9/SJ>A*Q+!3B1!;
M@PP6A$F3:N*I^;%PQUIKW]LFK1(F0??'RHH^ST?;O14[^:G#2WO]+#9WQYQD
M& _W6$0FMCO'L@/)5<(!6]<:$O LR^L3"OTJ5I0;0E[12R>2[:\#CU'V'F.B
MJ4$L(5@)!=1?)\K%@9HV!^70";L <;;Q+<*#P%#_X>C 2I<\7Y;^B%#W.:$1
M,^/$<^HA\0"3J &$'*<4O?@2U$@<+$F:]M0<J^X$13'<T8F>DA,1@47F7#&9
MX%K[::C:AA:%\_G%Q#\7"X\,;D4'S:OV;<Y44423(#TEXKL 7ZPP_ (S@EPG
M%#"]$\<U::*/_ODSW7%+K',M9LLHW.9!DX_'VQ=?:?-%57CX!19PGMFTR!,4
M7"!W"B*IS3WY@WM^8J"$+'_'?]Q_W#R@<.0TP;W_V2.+GWJ/ORS[BRPI[7?\
MM?D85 ^AZM,($X,DU3[H7*8='=Q;<^QMI"=/9L1Y'M2!:AV.E<_M7_5].O=H
M3Z/:-D[MF7G+HW.@(PBLJ1!SB*?U/>G+O:!C@5U*'VA?ZFBF&J,.5R$2"UY1
M^;;_^$V-E)'C)"U_EJH7EMY,;W-@0'IW 8F>"DQ+VMH_3 CIO/;<M3&]3_?N
MR7*I%<_[9>,]?AIJAAAQ+PH)_$Q795QGYI9QO\IF4E-W 8)5EC!]'8$*GF)I
M99_(?M)R**2I\K]I$(^V4/3PW!-DU,3'Z4>F/)KYY"KDJS^D.9'JN(B6;0 ?
M*4D&!K6Y,K-CG#Y\_#D?-I06O,_[D3+8SI.GHO=?8F[3"QDNG/P_0!Z@'C"Q
M]H;&E$)<,:9%[_VMP_9_!AOU7K]?G2;XY*#2+;&,^P9=NMQ^*806<]6;Y007
M828:/NI2(K@^3&$Y95YW'Q:^C\W\'<.RIV]W[[>5OV/I435TJC!T%^"O,VM(
MP5+3:2W@QTBY+G4FV)+63YU'[0PSP9@HE9W-H5P?QQ3KU+R,&2G;*V=&8F+&
M^)]Q%[H.TPT:R)!9I!V^2SFP9,Z-V$<U&'::U!O>#GKMDZVK!JMQ'#GSJ=KT
MBL$+Z;V:,Y4($-N$9KB>2X'$0QJA/8'4J,NTS0%BJ@,$UO^-+CPY<:'S3+=/
M8X;_L2'QF\;_U)I#;W=*G4B/T:&"6,=A% H^F2=V% XSA\N9P7.DS&2MB(^F
M!%8O^-V5F#  H4HI-1H@EOOIA'/D=7.1W%:6*V+H 8CJ3MNR&(^ 2F-?P:IZ
M=_I;FDA@Z56G1T-E/T*>.ODDSVRF98U<WN9#W'L7 *!AYZ0Q;E'K=G3<8MW
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MBX'--!YZ!Q/0&J=K<KU+^\M.R*>A?[(:X[4M]0R_9\T"]#KCZG1G#,C$YXE
MSQGZ+D4U<>8^3R3N9_3S]>"724?QYKO<\+S<G6ZNRTR^,X6PUV7.FT1L2C*5
M9!F'F<1:F87DD*$D@PD)&:.4R(2YQAE/ 'M^V[@M>"!;] *(ATU=%:&V8:']
MNM: (:5M)WD51M[5':E[Y[^M^W&WC]N:OLMP40\O[7LQER1Z SIJ'INZ+L!_
M&[NZ [K"=Y8,I[:'#73=D/I)?[2W&L:N9LGNI$ZYQ)F@+$M#&.*(ZY&*FDQ*
MDD"6<D;-V7'$I<L:D56K<UO_^5G2\F'3J$XSLO0.2VJ)N6F-<AM>[#K ;GSP
M3NO( M_A78 .<;^F5 ^S/V5VHLBKM-JU/*DV.I'Q7-S<;O;IAK=QFP_5;;$Q
MBRU_6>LG]NJ/?-(OV58[Z\3?GXW@OB^^R4WS4WZ75TM*$Z+".(&2$BUJ42R-
M(\ZAC 3!488HPI$/]]L/W/FYW34V$\_=86^2Y6LE7!GH8&5@CY@XV]-K<(GK
M/7W73NAR;UWIG;^R*X_TM,]!;<P"U(8U_P"U:6.[U'X[8 )7VA/@&;C0?JFW
M<YT]MSDPRD26I91UMJ;7LN2;O&[Z_:XV)5<HS#B'J8R%*==*(4O2%+((JRB,
M,LPS[A10<KJ]N;G)#=Q%E]6L!WE <5!;SBTC2?PQ.7;0R(4DND>.V%'C-TCD
M3)O3QH/8$; 7^F%YF[<:][T]1J%'Y%SE=+OH7:?4V$C1R]*<:[DTH>%2'%Y2
M7\8I99HO 6,E3?A;%D"*M6Y1%0<1$S)$43)@>W!\Y#/=/]QN9N5-4&M%OVM/
M>(O:3?8FZ'\[Y9Q)=TXCOIVQH&?MHA\GTC>XW9@$G<E/*A68BMBMU4;$#V]S
M^A/QZ7K)ZS@P >Q)AY+INN'Y:#1AR\,&M*L[$RGS7TT(N-J+?0@4I;'  4QQ
MI@<CKA1D"BD8,)RF,H@9XXY+,J<;G-^B2A^O65O)MX@=AXXS3-O)OC_V1I;L
MY[2-&#ABQXE7@3S3Y*3B9F?^<V&RO.OEO>3GT+9Q@-UR]S*+$0T3C* ,TL!4
M7T204AE!E24X#&E(4IZY3.\G13^WQ8(+H^VF[?GI766O_?G;])KWE'S1KYGX
MYW-[KB_J0UMWWVS=Z?,6_&8]:^O.&=/)M@<QT-]N&W^;K_-*OL^_[C?YK!S!
M7TJI'E;O<R67248CC,($,DR0]L9%#$DF.%2<A$H1A!!/';WQ"^#,W%>_/UTU
MR7_O6'KP$S$^MG_?C1.-'7!E##DT-NP546G, <8>CW, #ZSZG2%< FC:^8,'
MZO9F%SZ>.5!@M=J+?/5@CKOOS@.]^<Y7#T(#TN:;_<N'JIWY=*>"/LE-O9>I
M)>3!9(! &:,\P9 (ILR<(H!93 ,8T%C&6(94)HX5W;W@FJ'D]LP"Y=8N(%O#
M@'GAP)M/7P"G*_ZP:K1Y</5"/[UKJ=13]]C8DMWOJIU!X,V3KNK95(<2M5:9
M$.TFKGL!&LL\BK=/HOVJN!=DT\JY3S+W=-WKPT>H*_@Z+^N@1Y/?I,OFDV7:
M.R9Q A&A,<1$*$B4R*"2@4J92GB$W<[3.P*8VQ+/7EU!T6(&FU-Y]/QTAIWT
MCDGQR"I[OHI@A[].K>0Q<=*EY$U71_ 0B/G4$3Q!D5,=P5//&29]AZJ ;ZM_
M?Y9?Y?I![E8^EC)#2D59 )' $F*4(DAC;LH*QCP2&$O*L(OPN34_-]G[I$>@
M.PIX:\0V!N1Q 38-=OW?#KR;"CKVBYT&CL?VR K8 0??-'+005]L5Y,?S2)T
M0_CG\X0[R]\PWKR*GR.$2:5O&#W/A6_@4X;)WF=92GW3[=5:O-:/7A7W)O3=
M9%5=E_)G69?G3%(I&,H0%"$Q,;ZI"9I'"11(RI32-)68N6B=19MS$[@.<KUU
M(W:@W;3,AFP[ ?-,X<BJ]82]'E[0 @:_-) ]AO@Z$.15GFS:G523'(AX+D0N
MMPX\\O; 2CWII9O'+[0NH&-.-UQ]S\LE2N*(Q(Q"$9CMF!2ED#!F:@#P+(TQ
MYBI,G&J3'6MI;DICX-5U0PQ \(N!Z%HI["BI=MKBA:J1%<6))??C5^<8\'MV
MZFAKTQY\.F?TWJFELS=<G 6LV<[X(*LEUFH0IRJ%:9"8^193D(0LA5E 4Q8&
M$4DCOJQ,Q@ [/3C4B),4;)L:[R6O$R!H;Z.-I#;!]1=FZ=KQ:2<%E[(TL@H\
M"3+O-D4U1*,,)E]$FT!EM2J^4?T-C))/:X^7L5)D[1IZJ:Q7>Z:>2&2U?ZVW
M<$?MCM1/[]74O6)E/64:'K5VXJ$S>N$/A9W53G6-O5_R68^)+7R/X^(PWL:.
M]SH%X:4#MBSHL8BXLGG*99]7_\G&4\1$R2 2"0PHP1"K.(5,:A\\3HE $6=Q
M%#.W/?HC+<UOUWW[C3W]FMS]\*/<BBC&*% PX;'A%L4PRS($%<<IB3..LLRI
M[+('9J>8V(S.JYOV7\#65"+O0-1@*3]"PRB:_;RM%Q'G(P8?4^%CEP_<9*+E
M[5OMC?Z'%#?Y^J9=\F-!()0D*2244HCC,(,LT_J@9!K&2"H>!\)I+^E0*W.3
M P,2&)2@A>FX+7202<O=GTOY&7N3YSDU(ZR/GN3 [X;-P9:FW9<Y9>S>]LO)
MBX=]]]O:0&TVE^KQ@^[_>M0*E(K2*.&0!VD(<89#2$E"(*9Q$D9(A4G@M+ER
MO*FY*4"O$-86JYZ^ZSL&N04G.+:3!3_,C:P-PTESEHCS?'C5B1/-32H6Y\U^
MKA@6=XR4F+L\EE.U_I]KW:J>.IH\40;0Z^*.YNLE86DB8YF:,YS:VV#$Y$#!
M&<PX"YD441;(T',B[@$PYS<O?*,=P>JQR;4,?FE0NN[,C-*?*2-Q' O]72&F
MO4<N(*,B@$HIC#GC:98XE71[Z=Z<8NB9:U]:;M"]< ^-/,0UO6)0GN\:_\G*
M+^!NVN3D0X#.().B'ZJ=DX]?TI;;X"UDOGROW\/5I]MB+3\\U!/3F! E0IY"
M[<VG$"<1AC1*)!2"JI0(C,(XL!'I0P^?F[C6^$ -$#0([93U('&G%?%2.D96
M,@<FK(7LE,D'!*B4_(\WQ=<?]6VU]OP#FQ]A\V,M. <?.(E0G#*E^\!/7G/I
M(9>B+%_1S>91%1NC N7[;8I-(F444(5@DB2F3F2,848Q@@'3#K(0DFO?:MBY
MEJ-MSNTS[AVV*,R.8Q_T!<E-;=BW<X,\<SJR%EQ.YP6'5<X2--+YE./MOM"1
ME+-$'#^%<O[6%ZV^97)PM&,FYG%*9)S D$3:V< 1A0QG#"8B("&-" X%>I%2
M6SN,,YS>[R ./T+MOR\]S0C'[)^1A7.$PEC&SH4WCVST3IACT:L>RGE-*H>2
M/%(YJP,-#=U"^BK;.C.O5K0L<Y5+\=-C=UCH@:[:8NR/KVDEKTV[U_)[]9,F
M[]=E0$,6A4A//PD3$$=20I(F>EC(:" #$<8Q<G)G+P$S-S^W9PO8&6,4I6<.
MZ.P!KYW/<5_4<[9;5]/TQ^B;6\Y= 7ZIK0'&'%#;XW4'['):/>^170!HXEVT
MRZG;WV?S\,RA9Q)8]6Y=5IL'T[QN43NEE4FX=*W[M[PM5GJ46)L4/29[Q_6&
M"CUC>$T?RW 99 0E&48PB40 ,=,B3"7"4/$(IT(BL^OF(KV#D<Q-=WLP0=7@
M!$(#=3W<,+1C[)1U$KI'EE5C ]@9L0 ],Q9@:PCH]TAK"GA]JD<&G)NXD$W/
MARN&HIGX!,:%I.T?T[CT@<-$]*]T4Z<*?;?6^J*5_,VZ,K$21?5ID]_1S>-/
M<BU5SLV)LC:>+\,)8T1$4'(20DQ4;%S6"&+.8TD"Q!1U*L7JC&!NHMD9 #H+
M0&."GLT6%6BM #TSW-34O8?L5'14WD=63V?*1XC6',R?5[UT1S&I3@XFZ;D^
M#G_0T!P<%<W74G0IW=I/"Q%,><@X##*.( XBDY$X0! )GBD9T"!23F'AAYN9
MF\)=<?YP9W)92I,JPM#LG&3C()MV0G4Y1R.K40=PESQRC-P9ITCPG"[C8%,3
M9\@X9>Y^4HR35[LIP%H6VAO;Y%]I[6K)S5U[XN^ME$N5<BEHQF <BQ3B#(60
M!OI_N.+2I.1)XI@Y%*L[U9;5"SY]>;GZ((0R!R%NI;C1T\0=:#M-.,DOI8*G
M21! %2;:I10F][O,3"!LB (:TUA&5J5++R9V0G7MH0-*6BYDGF3QM*[ZXF;T
M&7('4<^'>Q2]]4*1*'@]TZI_,3I53UJ;%V76(Y$-%\TXI*^LQY8P:D>6D[=.
M,J[8@.]&%:MK?2Q9OJ7YQJ3$D,LPX"E.4P03AB3$D@N8)5S!6&4R$AFA-'5*
MV7NDG;DIGP$&OAID)CN(T* O66C<T3ED&7$025,O$M:$U2CKK+JKHGS8>$VA
M<I*1$1?Z=FV]X#+>GL&G%^GV+[\@V(B=W]5F1W:U/Q3U'HP4S9[V1]44J?]<
MK%9OF[BH)44RP5@2&&=FPR/&*61I&$$EF%!<48ZDTU[S^)#G)E4-T#J]60UU
M0 S2N%ULIWGSZKB1Y=-GE-+6\"Y&:?<J@%^,^:"UW_>YF$DZRW\TT[BPIP]O
MFJ0;#L8[3=.RMTQ@GS;%U[S4/]#5N[4J-G?U;]^M\RJGJRM>9XC/US?U^=S[
ME:SDE?C/AR:"H#D!V*WPELN0(R(0BR#"H?:*M8L,,Z6=9)HAD:6,)JF;5SPJ
MVKD-6#]+:IS#6LR:TG" ;K%K05-/?._[C?R:%P_EZA'>RI4 LCF,F;?675P4
MU>-;83?0S::O1Q[C#A<][9D*>K::8J:UM6!G+MC9NP [BQ>@/8^[-7K4E'7^
M^V;L#'<>$;]T0CS_Y%ODSQNAT8'3+WXKQ8-)EGMAM:<ZN,U4YQ8)$Q2F(D(0
M,TY@%H4,!FF08!1$5&;$\:"'5X NVC7-*8_./C,.>:K9UD:@NJ8/\/LF6,[(
M7JQWQYY]O4"WND^Q1F'?[W3*+\1IITZCT+LW31JG%?=MX^V*X$>EV[DKUG7Z
M]7=E^2#%=?'V82UZJ0N7%(612F(&A?Z (,8H@UDB0D@3%G,B!!?2JIR"<\MS
MFZH\W0;@-7Y0UE4$\MH"4!5 :1L W1EAOP?HUBOG]TY'XWID0>YM'GQ4H('>
M%FMHP(/K ACX_22G8]%LO_\Z&MT3;<H.>KO_Z&>_=A!W)S9QW9XWV<[N(#/[
MV[W#'N ^0'RL;N7&#$$;>2O7I1ZEFCQUS4'V78Y+^6>:K\TO>[O/RY#0+&29
M@OH'W(P7E*42QDHF,4H#P;%TC#VZ!,]O+S[)U#O<G6#37YULQW][D;NH \\/
M+:/WQT1Y-8P9X(D=H$V2^8-!_8<%>)I/5RZ L6C[U^LA0647]8W]>#15'TTT
M/$W25TZ#E@^"3XQA%SU^LB'-!PG]$<[+\P8G6MZ8<L&O9?/?=^MV>:_\++G,
MO]:+)9)%08("!!56"<1!FD"&$@+U2XNB, A9K"=#[3!BMVQFT^R ,6SDX:O#
M:,:J%N0"K*7C#HP5Y7;K4]YHG"P7<PT3_- !_@/08K6E=0?::U)F:XI\IV<^
MW_#4B9JMJ3B0LMG^WHO+V'75>W-9[LZPOUM_T'::L^O%:B7%E5+Z$OW5E\L(
M$_W"!0$,4Q) 3&0 26Q6^6-.:$RD".+$P?F^&-!,O>\=<O/5K8LUU.#+8I6+
M^O 0[? /KI;GV&UV&C=N+[Q W;V>%6;/M]\G3RP!.U-&*<0WC,VQJO4YHGFI
MDG[#2#M1]V_@ X>6T[G/*[JJ*Q*+O'K8F$;Y@X'RTT/UH:C^+JM/-!?+&$LA
MPE"+:6+.D6=40)K$%$8AH4&$4:A8Z%9AQZ[AN:U^?]H4]W)3/=8U TW<S7W[
MJ;9;8_J;I9WW<D\?3[HNE_6(G5B.P?/(VMA"!GW,H ,-V$-5'QM_E!4PP'T6
M]'&CRG.-'\O&)R[[XT;)?B4@Q_N'J=C/=/.K-/$GGV5][/G=NM(OE,G'T111
M;0\PQU@$5*09C-*,0*RPA!G*))0AQHHCPE)FE4+<K=FY*=@6=5OOUTV>+*FV
M$R?_!(XL35O L$4,=I!;.D<X3>Y&DU=9LFQZ4E%RH^.Y)#G>/73FVAU(W!U
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M\L.)?,6>TDF.'4O:;VH&B2 M8C\/73TPIM.L0YDC@;2\;;*$=^&'(<YBQ),
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MEURD&>(D@2R.F7']8TBE,O5!HSB1"6$R'7Q@<FY>OL$&MJ2!XJ$J*UJ?WK^
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M&.%(02'3&&))&:2AC"'*6, 40Y0+IU)#-HW.38\;S+ &#7:HN[KVPXML6/4
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M#$U$!*:TKF**9%FF$J>$[5Y0S<U?;.:..[# H'6<./KI+CNO9_).F&)'8F?
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MI$IF,,]3PC*&<Y$[]88>2+ZIL4>CGOE>=@J"G89-7G.CH]VQM+0$M9J>N\3
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M(YG@H(YTX'+&"^IU?N*%3\?IB-MS1CO[\%*K?;+A=V,_<_+-T[I<:$OV:OG
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MD-_IW$3HS5B.<URD*4PCE$)4X!A2F9DVD9BF0J0JPE[-0TZ,-S63SLH'5I6
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M4S-ZVSW"MH+JEUF+ZNFE< '<S0T1&,:!Z;,7@OV;=I_&9)CFW1WCODX3[]-
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ME?WCJNX7U>^X]MPBAH<3<;]LM U6)]1>FMRSLBZ>N-LE))H*5*[I 4<Q-O9
M FFB"DT9(I%)3N(<QWU+Q/85:GKVP['Z A? :K,K#] HU+?N8>]Y=*.G<>=F
M8#([6,QAEWK>5!K?34I=,W:8<]UPT Y44;&W6*]4:?%<&(]78#S[R?[-_+YL
M3&;\?<DOY_/29#"9X^B/B_(;W=!/Y4.I+<(Z2X))F7-),)0HB2"*\E2_XB8$
M1N9"YGF$&79JM^0UZM1,N:W@H)$<&-%!+3NHA7?O'N>.?S>1#H;JT%SI!NCI
M')4SD'7OQC<(PB/UX#OWU?7JMN<-5$>//?=GC=99SUN]=C\]_YO]:?UFM>12
MBK4)-*I*VEPK)5?EXOZSW,Q(DJ=YG&H"+R@RG?,0Q%P6,&&8\2)E-$Z<NK^?
M'&EJ]-T(6T79R:JRUK*6]P(LI$U1Z5-YX33HI_D[&)0#<_8612-H4Y_L>HOB
M9Y_NJ=V8N3-S,.Q&8N,S,/0B8B=<.LBW^_[1"-=)C3;)NMW0LXZ-^.^GNCCZ
MW?)2"!O[3.<FW.WCXHH^EALZK\8T9OQRH2^\5E>F;MAJ4VJ[W3A:9D5$4(:+
M# J<$X@RA2##40(E2UDBL-2_=^+@D$)-C:[KSX(W AMR;HD,OLA%N5R!S\N-
M7 /Q)(%^?3//2CDAYM+-QS'V# V\"K34,?&>.X5LW"<H%Z#6:5O"\NK8/!K-
M E;I"8ASV&H^(00;M^I/0"CWJ@.%?'9/-[5>Y:U+3C^8KK^^GR^_^^:B=CUB
M0A_K5DS[Z6E!@95TF!JP#I"$=25V#3BND]!!]3WWG\L]H1) 9AEF"<T*":,B
MTUL_Q"6D*$IAIO3&+\\C(97TJ0^Z/X27$3%"'= [,P9X;-(4M#&AM]B6=LY-
M].B=TS$A8CB0OC%DHL8@W_^!85XY_>+8M]YQ9<^2+;;4V'MJ"J]N?MIX (:*
ME$M%8"&4,!N+%.*8(R@0BR*5QBB/O;)4]X>8VC:AKK?6B-@KM.( D)DHLEBF
M J8JS: F205I+C6:6:09-,DIR95GK9NSH!RIMLTP8+I1Y7D #4R5GLCX5ZLY
MJGS8ZC3[PXQ;C>:HFGO59XY?V8\MWY>+<B,_E=^DWF)L]-R:?82M^[?^G?[W
M<F6[^'S6KT =1AE+EF8IRJ&,30I:EB209E+ ),]H+I@BE#G5 NDY_M1XMA(?
M6OG!3H&J%.;Z E@=ZE9(1HN>\:R^LY1E+!8YQY!$>M5#N"@@R26%,2*,8U(4
MLI!^/#W@/(U#XA.=*;=%8$#T!UXAPL/NO8CT!"_H"N,KPZC+3T^ 7JY-?1]S
M9JVJ^H]/Y4+&,YH1D6-MY%-A B,SDD-*3*H:RM.8TU1$V"E#NG.4J2U"+\LO
MU7\!1ECW$K'=P';S5#"X!F:CWDCUKU1U"(DPA:J>/?EUZE0=4NYHF:J#%_?U
M4B_Y_YB6!E*\?3(GF%755]MCZ-W#XWSY4TI[3>-=N-&OP8Q@%16HX%"(0D'$
MC1N X!BJ))8\2U6$J.?NM9<<T[.-ZC:>:QL?O0WU>/?EY@88@3T#I'O-C>O1
MPL!X#W[F8!"N% "5!G75Z8NJ ]T%:-2HH]6WSLC.B>AQ('$&D(%/*OI(,O(1
MQAE@[9]MG/.PGM$9G#\]/-E<MK?R<25YU9%*_WTN;1.XA6@W)KE9+1_E:O/3
MC+S1OS-'CH_F>& 6Q3R*BU1!+H7>5YHF(C2)"L@S6F#C1\T*[,>@H42;'JFV
M- .BI1K0_W^LU;!%GV6C@V>81JA)57DB)14(\E0H4\.102KS"&)<2*%BQ85(
M9PMY;T:Z\XB^&7-F236S>U(.-[V?M"GS'X >FV0SL;2EWBO-K=NR^AH?X< K
M;?OK:^MT ;9:V3EJZW4!&LTN[')K>MGH2]Z=_#[]XW$" QXV)B>4<./&Y02&
M="\V)_3S^RWE;Y[6>O^T7FN3G94+.U1=;?9?4GP4>H!2E73K>+GD>MR5%%J"
M3_K'YM2@E&O]NZ<'*>JV/M65MJGK+%,8\8+FD/&"091D>HN$N8 926(6J4@D
MU,N]/ZRX4W/$5$VH>=UAS'84\XRH&'AZW9:#Z4S:P(M$HRAH:7H!=KJ"MK*U
MRQHTZMJUH:4PJ#7>]C?;^KBMVN$6CW&F)^B2,K#(HRXTX\#_<OD9:=0>V;+4
MING:'>M*/I1/#]>+)J_@9E5R.5,X34F4,"B25.A-([4)LA1*HA1)!1,T<:H7
MYS3:U):$6DI@6[%6<NK=GQ:T5^=M-\"[63XXC$/[S+2LMIRED=:8Z!6@UXMM
M;A"P(H=$T"/]-2228Z6]GHNH7]ZK*T)=^:XGGS%>GJNK.L_R6YUOZK<K^" 7
M<D7G9@\B'LI%:4*E3?OR=S],R82FJ6.6R4QJFQYF%%.(5"8@CDVF%:)4Y2IA
MF?(JW.DTZM0(N1:Z<M \$]O/4G>#W,W@#@[DP)3<QO"YQ* 6>8 &FEX@!;5>
MW48>U0CU N.E+>EW<^]NY.OEO!25,^1EUR"B*%$%AQ'!'"**,&0D3J#$C&/.
M..=1XMF&_.A@4^,?3?<+7C[.36UTF_*WD]R[^_AQA-UX)Q1N ]/-,S%-=S';
M\6?0SC\NR(1N)7Y\P+%[B)]4_4#S\-/W](WS^O)5SN<FX9$N?LXRKN(T1SF,
M\[C0FTF50"*B' HDE-Y+LCQRHX[#CY\:6=3Q2E9$4,OH&\WU#+YN7C@?E(&9
MP N/'C%;A]0^,UCKV2-'CM(ZI,Y^>-;!J_P=05?T\5&**SJ?WZWH8DVYK<[6
M-"KX^T(_9?Y3[W>J7@4S21(D42HT%T811 6.($L4T2 6DB:%))1&KEXAOZ&G
M]I%7T@.NQ0>;G?P78+%MY?&T5:'NJ^+N[/"<EM.^H^' 'MJ,J' VDH.VZ!=-
MSY1K!7;BU^U3!@/:W<4T'. C^9O" N_E?.J'78<GRO.!H[FE^BG:]E'U?$+/
M %[S$/:RK&>K(NR;G[M+ZH*QE]_I2KRGY<K&RMFSC*H"J-FW\BKLYR&>%5&2
M90F1,#5!3(@4*<2)3*&,<RZC% E*/%LW#B?L]*+6&O& K3QN.G;]E'3EVUAM
MP.EUV]E.8\J&/ADY4NFZ75D9L)_@8/%EH^P%,.I6D<>@I? %V+X&1N> 8<>#
M3TO8V.3AQ!TW@'EPV/>BG(<?L6<'CMUI>'T,/E.2\K10""+).40\EI!$*8<X
MHO+_9^]->R/'L;31OR)@@+G5@-FO%HK+S"=7+M5Y495.9+J[,:@/ :Y.S80C
MW!'AK,SY]9?4$B''2BI(6?7B HUJIRV)YSR4'AX>GH7",H5E@7SJOQP.X;7C
M&*W^2Q>G--_)Z]E[XQ!+-W:^#J'(K-H3;AO*$[#AQDG5P[;;.!QFW&8;)]4\
M:+5Q^LIA7_B+)(KV&(YQRC'$&9#<?-V0HP)05E# 59&Q3*>*""=GPYDQIN95
M:-*'E@V#^GW7QQ!T^["OQ"6V]_!E:E7X(\HSZ@?]NH^-,^KG?4;1_>_[W*77
M%?'^96FV1(O')I*MLIU/A7IS^_G=EUNQF7&L!)2\!!E!$D!9<K.>$P7,6E[D
M6):XP'1(/>]S@TZ- GXQUM8FJ9IVG*MMM*!9U>[^\>$MR.BPFM1G<;_L/XR!
M9F3B>%DC?2=TLI/:@&KEMOUK(J ZK.AW*'3'KO]]'<J#:X&[P.58%OSLHUZE
M0KB+<J>*A3O=.X#+N\I_M8W2VAE82Z4E9T 18GB[H"7@:<J!RG(H>"F(PM"9
MMX\,,#6.WA6;?'(/ 3F)G@/[7HE);*9]"<> 'C='<?'@SROQ&8LK'5\;/S(\
MH_LYXCMVVW@D=T;H%X1V[KJ!,6Y-1>Y?U8ORI>L/B]JS(F<L33/(-02%S#B
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M_TBI &4I!6F9:\:U%'F&W'S7+YX[/5=U+9IY[8UPCD3R$BA)8<Z$R$&*R@Q
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MU!PHK.^7M^)?S]5*_8.M*EO:X,/"?(9JO7FWV-3)B[T84^O+6\\XE$61I2E
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MZVBFTR7A^R;1Q6O]F:]K"V2[2'SY@SW]O\\+E:<9:=](GFHFH5DPN! 2P*+
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M8]7<QHN\7ZZ^L+GZHD37,;B4')5(%+9):6Y[&Q# 2L@!QT6><HEMJ+.?NSZ
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ME4@C$VT(^ YI.,A3KR_=O0O6^;R-U;G3G[JNL1\6_Z78ZM[,OIJ5AIWSLE0
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MXM&>XTZ-MFK1;7DE6W8^J:4WFXW$R)^T"B1;#=QK5?E,Q'D:BPAO9!;S079
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MRU!=Q"MVC:G3 KQV :F+T#A4A[K\C*'!PB^ZB=B(/YO*^+A\7FQF,"4<,<)
MFA<20,PQ((1F(&.:<&$&+W+L%R%\>K"IF53;1&_?H. S>+J142B41K".P&97
M$N&7U7(=-,SW,@J!8WO/##AR0.]EU0^C>!WN&481ORR7\H]J/N^GB6:9+" N
M<J YL[9,6@*N,@XXS"$71<H5]JH-=V2,J1%")Z)K]J4SEFZL<"5"D<G %QQO
M.CBC?E 6.#;.J!__&47WO_ESEPYM_&NKI?]JB/R]$:PI1/QL>*1U-QL;Y)-:
MO:WFSUT"TZRDK"QAB@"&N3$1A#1$ *D&,DT%(I*(LO0Z*/*68&HTT<J6_%0M
M$FDFAJW6MD%E$P'@&7WG/QU88U)*E@&D;9@&,^3,I<:@A(@3S77&F&>81M0)
M&:MX7S,E"[5)?IH;3?Z25$T;A>W$O-)TN5%_U"F(O#"T_2I^^K6&W=)=LE,@
MV6E0MZ-,NIFJM0C9?GD@@(&;+_M*,7+KY8$@'39>'OJ@88M6X][;1M._K=;"
M?.3/=G%B.4Z179P(,XM362C H): \MPL4@+17&@?C]O)D:;F7KNW8_B1UVD4
MW4@J"#:1R:A+4NVE&NWD#$<W%Z$(2BNG1QN5/BXJO4\3EV\8&L5@):[F55NG
M].^+U;:R^CW[_K-:*%UMUN^^B_FSW.Z1+2=MFEC<^^6[[^RQ6M27?U:;Y]5B
MW=^OP50S6L(<4&T+94$L "M2"J@46 L,F9+(+P0BKL!3LY!?ZFNC)_L:UQGD
MG<XV Z'5.FG53G9ZVPZOG>;U;:WN5^W0H[\^;G0ZI9<B,BM/YGT8$$4RSB0%
M#D&)+/3(\2OC3,%A\,M(XPZ,G.EU"5G(.E/%-H<W[-Y4X9IIP;5"$($RY[:V
M+*& 0Z9!GJ6I3HG*&"E]3.-+ T[20D[FO88]-AYMW9/[W_^-Y!G^ST35\GO&
MS%R"WVT1" EJ[-.@/23?G4?-/R;&$8JP\3"7!ATW%L81@H,X&-?[AE'-.ZV5
M+6.EMJTV/[.-VN-'6^GO5O[W\[KI<C?C# L!RQ1 7"H M2H HRD!N"C-XQ#1
M6F=^?LHA8DS/55E+>--X*IGYDJPO4AA1/3V1@^;$C9-BXQR9I[;B)[N6PXG5
M('FIPDU;E+6G1>VB%$%['ET#9E"F&R3(J.QW#53[C'C5LP8Z*850<^O_;'V>
MG]53&P+W:;5\6+''W5 SK4K$=8D T=2Z+4L,N)0"4%+(#.M<<NT5T>PQ]M1\
M!6:"5G5:G#'6:N.L3<04_81-FZS%=CHFMNR*L; ]_9\>$^3H$8T#>VP?:0_(
MI@SI3NZD%?RF1XL!W:;^>(5UI'J,/ZYKU1^8 V?K@$<,3"BUO&ES6U?JJ_E"
MMR1KSX-L?N7[^?*/ORGYH'XQ^V#[RUMMB,1P[YRMUY6N1),0N[#;XAE760YA
M9BS$DE, .13V["8#4.*<(,8E1%[99B&%FQI56G$3PX9J:^$(F\ZJC4K)5ZN3
M9_YJR'ET(\S7FIW(C-H8DB_T2EX<B]\D=>*Q52^I];M)K(;;OS*K9K*O9[W-
M-IH&S+B-@'_8/-V0 HZ;W1L!VH.<X!AC#%L$NG(V_ZPV7]^8=<5(L>K<$#^Z
MQK@P1VD.-0,9U:D]1U. 9-3,.RHEU9BG!<]]R-UET*F1=BM6\F06Y4=FS-I&
MA;YCTH^VG9!WH^/0>$:FV4[<Y \C;]()?+-MROXC0L]B'XB",J'3P*,RG \4
M^\SE=>_UG44-Q;UA3Y4]9+#5$^[XO&J:FJZW)8*1RG5NVW\P)8@U-R5@7!/
M*<(%UA)2/V[R&WYJ+-4<EKSL@>E2I#?$3#B>E$3#-_:YR8LLFMJFJZ5.=F)'
M*8<\#+!HS44=1'BUKJ+N\)QK)^KQE($,I]9KI5X6AMF2:%<AYNVSVG;N9:+,
MA,P@T##- <19!HCD)2AQ*7214:9RYL5QG@),C>4&=$SVA=R1S"("&9O.:M%O
MDH/Z4#TK;+-,N$H^L4K&Z9X\$+VPW.8KQ+CL-A"B WX;^IQ(54W7IXKGM=57
MNPJMZP^+3VI5+?=+L[^HX#K3/,^P/9[&9IMJZYAK0* Q!"G-A:*9QD*%+GD:
M5('IG6YWXH7)CAKY=7#C[NE.<63F=RFGNG9M&;(%(3'O20/#D?KC+VN6CUAQ
M-<H<CEN.-:P*TZK5&F5ZO NYQI'BFKU!O3Z_56NQJFH1ZJZ#,TQT#C.M 8)(
MF&U +@"A$ .$4YU"5A0"2_]MP-&QIF;Q=]9J:Z/VQ&U;;OJZ-L[ [&/Z7PW>
M2%;^ -P&FO-G$8E@N1\?[Q6,]+.*'[?'S]\RT/1^?GJ:MX$XW5G2N^87.U==
MCEA9%H@#E=FX)2H98$9Q@ E'A!.D<^25&.4RZ-0HI2]S(K<Y;3:K97<<7RWT
M<O58+QC_X6GSNLR#HZ4:&-W8]F4?V-UY>2=QG)YQ'A"%-=]<!A[7Z/* XL!4
M\KEW:!FS5?6-V:B77ZN%^K!1C^N9*E1>9K P)"0P@&8[#PB6*3 []U0QCC&D
MVF__?F24Z6VR=T(FOULQDUI.3TOF&)YNM'(E1I%9Q!>< 67+3JH?N%K9X3@C
M%RD[J>AA;;+3E_X96AV^N"6;I1BK-!4:,)GE ")#*333"DA;<X>4!:-23+F_
MX4MUID=@%_P\X7R'K_4">7@2_P0OQ8A^Q> =#*-Z$%]Y[O[$K0KW%/J_N#_A
M\:E[W::$)V0:ME)_5!MK\G]:+;]54LF??_S=:/%AL3TSO+6AZG6<X[%"4=LM
M;5H(2JQ_4JL<V;.X$A"F2E!@J!B"D&68^+@6PH@U->?#F]LO?TO>_WKWSR_)
M^\]WOR5WG]Y]OKW_\/&7Y/;-_8=_?+C_\.Z+WSH9:/K<5KSQ)R7RVF44:EP5
MG4KV_.LGJU52+?[2"Y+8:79SO#Q>%/=&6+R#KC>!1!MUY0@+Y_X:$/CI W/]
MV<K6+K%E3.K5Q_9FJELSS03$J"@T!(3KPA T)(!+S$"FN%0IRHC4J0]!GQQI
M:IQKO_&VNN6'75'1\P4L/;%U8\\@B$4FQ$[&NMAGDUWZ>Y3^7A?!")L]?W*T
M<5/D+RE]D =_\08_FEBHY?&8,/N?C\O-?QD.6SZ:;9LPQF;3$H%J"756$H T
MSP#D0@&B<@X$DQG,4\9R[!2$ZC_TU(CDMVI1/3X_-LU&DZ<V>JY.;F_ZCR;J
MNQ)U>5S^O$D6RXW-@F\T<F.: =-SGGKB@C[2(?9AJ&H] 4;\Y+^L_=8I<--6
MG(N&M5R*NGE#O6*_$N8O9/@38>^\0 R'KUDQS/WU*I#E[1HPX(&C+ K#%>U6
MB2N><&4OZK:'9"^RH)2*E;0 DN3&NH0H!YRH%)1$%Y+S#,G,JQ'1R9&FMBCL
M/A#52NH9,' :4S>K,@A2D9E\!U(G9)3M\D4HXO2D/ACM==I2GU+Z9&?JDS?X
MVY1OS.\KP>9?U.I;)=3ZBWJPB]1OZI&KU0SQTFPW4P)8J3F )<* 0JZ!80R4
M8U)FC"BW\[B+8TWOL*P3-^GD=3=/SJ-ZV?(+AE1D>CB *&DE37YO9'6,C;B,
MF;L%%PR[D0RV+8;K#L-U(_%?PYAD3GB<L<#.WS^:P>6D1M^^<KO!CS'7J\VL
MW4RV[Z66U*#%%+ !46:3C;7M/,L HSDLF2I(ECHYYPZ>/#5SJ17.[7L^Q.D\
MYUVE?62.ZYP'%QG-^:L\J>TY*\?<U+-PS+_VK9O#IX[R;9Y4IOL63U\PL&>B
M;8;Y:;74U6;&1:ZS,A- (20!5"P#)*4"()4Q:FR3+,?8I]1V[]E>W]\(5;5_
M^7SWY4ORZ?/=^P_WGHT1>X!E@A08:\-40@M@3#L,."H(0%RE-$L+S@7S"[ :
M"-DX)EPM7-)(-QPTM^W<0" BLY<3 OXM(P]U#=LJLO?\<5M$'BIVT!KRR"7Q
MRTK<_[&<%9#D&:<8"&-=&%N#,D *E!G3@Z1FHU9D>38@G<QY_*E9).;=*>(5
ME;" NWWX$6%\-3_]F9(21H77J2C1P^[5"DI8&29;3Z('T#7E)/J/&=HB9:'N
M])N5DF;UE 1+!(4 @B!;ZP%*P+'Y9TEA3C.$6*Z\',S]AT^-DAI??;)\WJPW
M;%'W4GJVH8/)W"9$V$2U6FS?CB<]-!TI:2!&L?EF6Y'KUQ:/-^?Q&-#+Y%#Q
MP'U+>@.,W*/D4+7#?B1'KO%W"G]6W1GYG;:-3)[J!/N%K,N@_KIDB_6,"9SF
MJ3+&!Y<40&P]P\J8)CE1,I524(%+\ZP'6Q;[LF?X\H!.;S%MWN+^L/%>YJW,
M]CU6G=")KA9L(>R7O]S5(7/W@CI ?]E]' C.L7K4;0,R#)!;<>MZ?4U]YUKB
MH!"Z>Y/#0CF22_E:2+W\R^X(G7$R.SQD-$^SNT)]=[/'74/S<+5:&69_7Q.,
M>K-<;]8?U6:6<X:R' J04V*8&+$4$$TD*""E4J,LU02[,?&%D:9'P=:J_8]_
M_[<,I?_Y=W/=<K6IVUI*6^ZS6J^?K?2)L.+[IN@>ASHUVVQ2\ )(G94&:FP6
M/8TA(%+EDN)4(YIU4-^[6[3A\+X?P<9]&PM=-]/V&K#&2H0V 'WH *H%O$F,
MB"$SH<]B$#@;^OA8(V=$GU7X,"OZ_.7#"/B#V<D9ZZ[:F)WS-YL@8+9X#Q6?
MJZ;=]L\_?F/_O5R]L27_;[]7QD26+&4PHP94&W]+" .L$"E@&$.D\A1*[-5K
MRG/\J>V-=^*#N94_V2F0-!HDOUNY/<LI^,Z*&\M$Q#HR^UP/LS<=#00K*$WY
MRC J?0T$:)_6ACXF?+<I0Z9W^IY]_V1-KN7B=K-95?QY8Q-?[Y>?F&TJL LP
MI05DC.1 \B(%D!O[E%%8  U+GE-9*BY%J$93'G)-C1[O[O_V[G/RYNZW3Y_?
M_>W=QR\?_O$N^>G7NR]?_I)\^&A^_<XW.C70]+GQY2M,2F0>=6@M9?/3S/[:
MJ':3M,HE?>WLV4FC7YR@V;"8C]9.RD>VR722&@"H3Q.I(8_W#UU[\_SX/*^K
M!35M6IOBJ'?Z5B[K<@6U@:0))3Q7$DB6(0"5*@$I"@)*C0H,)14*4M>(-I<!
MIT;$.YF31NB;MDRR_=8[P;U,56?HSW-M#$ CDV@0++WBZGP NCK<SFFPT:+P
M?%3O!^=YW3?,EOSY>5TME#%+Q;^>JW55EU!I&GZS!W6G_[&TA]+&GE7FY=LT
M5YGM^ZP0!<6849#)3 *891PP A%@"D*)<B0SXF4Z#A-C:@35B)E4G9P):P6]
MJJ_]P"ER,P_C Q^9R#H%DIX&VZ;UMMR5X;-V7K9J))T>X4R^ZW ,:N$-%&54
M@^XZN/;MMRN?=GUSO=_8YGE5UR'I'S9]6E4+43VQ^8=%W0S&O/,S6$![[&-L
M.,%R &TG4 YS!42F&2LY+TGN53)DD!13XTWS(I?#^^FY@^]&B=$AC<R(+UL6
MWB2M#C^ZQE-FH#@M];S!BM99SUV25VNPYPW6N3Y[_@\;6(+6%MJS!VA*OC4#
M+AX:B_0?;/ZL/JH_ZK^L9UE*$%.E B4T=B&T<=&4EA0@E2)2%MC\U:\DOLNH
M4^.T[3&CC2U</CZ:W=3:ZI& Y.F9SRMA_J"5U>8F633NJCH@\0\[C\98L67T
M;<BBYQ&NVPRY$6%PW",37RUOT@B<-!)O^RC50EO'X!_-!0%"; ;!%+9 J=/(
MXU82]0'CH.2GU\W#**P+J;Y?MG9@9SRJQM5GZ\UM]U TS62I40Z$+7@-62D
M+R@!-*-9@6@J4P7](GA\AI]>6,]VL\5VEO9ZRU]UKP]V:6MU_:QPGN<IS#E
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MS-] L[5AVDXY=</>3VI59W=_JENTW+4=6NH_S0I*8$IE"7C!<[-G+"D@.2I
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M+;$\[/!1>>4+EU]7%.QF7ZY*;1%N7[I0\+HI2W9;Z;!-LN)=&8=&'JCY[3)
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MO_\AE^_?N!P/9)OWLB4Y5ORS*K?\5HCZ_>U_?_X0%LLH+80(> $Y*B*(@C"
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MHXZ>.E)=9+-^^"(77JR1XOP'7[%/FTIE;;Y[T?]T+Y^K\_U$1'$0YQ&,LCR
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M^:7M.*%*+'WG\OO1Y-0K:OUKM:GKW]<5QRN5T*(V(]YQ.5E049#+@(A4)8)
MFF(,42(DX0=9#(7\]RP*4XS2J..=>W/>=V+<"(ZZGV"4T":#O<U &6T['+CI
M/3-&FZXSIMHY(%NP=V !=@[NYL#RW_9N@9,]M@!$^Z9BQ-WQI%.LG=*I&\LF
M95VG8!Z2L]N'CPX6*;=<S_L_K[?R'2^E/<T*X.91S8#^HT.8VEAU=1)\_^=F
MF10D$")%,-+!X(&JEDF$FC!2QK#@$46!W6;N*#OFMX=KG^@WK@/,:-<[J)YI
MMK$?-AL->P^:O86%3JO1A<G[SOC($KP*1]<!*",LF3H:93Q8)T)3KGB8?;3U
M+CFG+3V\Y+F0T]*DD-26**EF$L$B2D,89305*,\3Q V/K4X]?GX$ML]:VY78
MMA!4/X)OF*>NA<0S_3C&PCPN^1I,)HH\;K'9*AL=:<R?\WH@8OCHELEB@L\9
MVX_Z/7O-N*G:/SA[D"OY#[PN'YH\E.;H)X_ERCG/((LD32&"U%R,9#",$B:"
M&(=)(FPV3$\W,[>-TM9*T#-SU&G.&5#-YE?70^69P4:@9#TY&@;!Z>SG3%.3
M3F^&W3V<OURX^@KMM7>'LC'+""597J@@_CQ3\NFQ) (>%;"@69IB4J \C&R(
MX'0S<R."KYLUU(6VM+9EJSY%>P:/T" [QM:,#ZY'S#,?7%3HDFAJ,-L)M6-I
MK;/0N%>Z.FYJ>N&IL^Z>U($Z?_6894R3B]IVH]I8ZHD^O=\\/VW6W35+Q (5
M(R(@SW ,4<PXE).&&$9,%$&:%DFDHG;-4D9M&IX;D^PROWEC_**)Q&N5YJBV
MW3)[W[HO3-9+?A#VOI9JP?W8@:LL7[P2\VN,WV7@>X+89AGF!^K)EFCN(+=<
MR-GC-KC(LWC<A M >R=?+PY'W.^R=NO-]CVNJA<Y.]4:!<LL5!(N-(8D0ARB
M(N,PQQ&#(D HQ$7.!;82>#%J=6YC@-?:K8>(FTTJG>/HF>D':K?B+>BL=BVF
M8H72!"5;#UN>0<G6,V"8E6P]=_/87)*GBM.R&8)CS)C (8$8*ZD^2340QT$&
M0\)(*)*8I139$$__X7/CE[YMMJD=/<C,F&,L$)X)P@B#$=D3Q\XZSH7H-3!Q
M9L.Q:\=Y"B>N&:GGVV9^WV]:(:/#.(5]C(*:M<CO-RLR0;@$+&8099& ),\1
M3#/Y^1*!"1)L1 "7I1E&+_CTH5J=1&JM0GD?<?4OOE4N@'IGO*4NL&7GF#&%
M#ZPG$A]J+5>R$ZWMP" ZRZ&"\#CHW.H)6]HPK;KP.(".M(9'/F;D%CO]P=FS
MKHYW<F_NFUR55:4*/M$9];^O2SE%^A-7[(9NRY_E]D4?^.TJW"]1+C E(8=9
MP&*((H$A%K(O,Q23@/(@S+E1:5-/]LUMFM2YMZMUU.Y9]UU<@+V3K8:$=A-H
M/T'GJ.7VO^-^-SPW>+O>?.L#AY-]N-CU7AMV 91O0#OG\.32$^QN#S,<VSCM
M*8@?@(^.3SPU,W9M6\E%LWPP_[K1B<&K-KL^S@D6J" P%+E0H63RPT!9#-,<
M)U%(\SR.+=>YIQN:&YEWU@&LS5.<SG:FVRZ"SV!KNB"^'C'OB^/.1'48VP+G
M7FE@& ?'Z^8SC4V\AAYV^7@]?>%Z^T/9_\'K?W'^;K-F=2OA520%2R(<P+Q0
M*^=0TD*1BPR&,:81%YP'*38]>3UZ^MQHH#$0$&6A^='>,6B7CTBO@L+S]]VB
MH(V[K'EF (?Y<>95L$QT9MF'Q\UAY%FO!TX<C^^9[%CQK+G]L\/S%SG:\;NK
M5-;Y]D5)G6QOUDP=!#RI2Y91G'(4%P@*6B00!:I6>Q)(\F(9HDDBL""Q79:X
M>>,CMOBFW-U[:NW6AU^\,_K*[;WS/3%R9^\Z=-]N4Z^S>Z$5FN024:'\\2+*
MU^_G703,[U;>^>;?=A?O(BP7-_ N/V&D:E*YEDO!]Q5GY?83ICKAO8ND^"9)
MX69[)R=W&_9QS9:(IRA@E$&6L12BC*E"PK& (J4HXB''06 T QO1]MSF9Y\?
MGY[5-DP7X08J:2_X!=<  ]E/5':,93U?FXXP8S-/\'JF,V6U&B :NT%G^&)?
M:T;9KJ(C&NN!--^A6I(]9F[UDBS:GU8QR1Z8(\VD$8^P7SCJ7:NF:ON'YZI<
M/S0/;>K$?N5_ZE_5=WK!RB6;4KVWNLP+RDD@&$QI$,G5)<&2V[(<)A$/2%AP
MPF.C?(#Q)LR.XJ256K5>?HRT$9_660, RLF;-AT\=;8OP)IOFVG=P6^ 7)C7
MX)=2WJS=-V3%*WKR\I+7?__X/BC0_=!X !H76C9<-"= ]0)(/YHKY,^M*V#G
MB_=.,%]H^^^,B5;C_CK%:@E_'9X#Z_R1#YYL,^ ZQ_L[!E<^R6[,JK=/U?+3
MER4-Y.A#2 *#'"F5D"*&F 7RCY@7B&0A2_/ 9 !JGS>WT>33:E.5#)L13X?)
M,)6/\-0S+W_Z<OOM\X>;ZS_D ]=.3#%K3O_^L/GY?]25S?12_:2_6OW%=D^8
MY/,[,+?[E@[_>>P*=2?AN*0QCI.897(%FLI9&B$,8DYC&&11QK(B8 '*;6HF
M])YM]<%,4"OA7K4Q7K^RCYKI<G$4%MZ7@Y<!&+'*.W+5\2IN__R)5VE'CAVO
MPHXOF4(-ZRO_:WO_)U_]Y+]MUML?]3+A*4L3@55E9"&_9;GV*F@<P!C%11*'
M:9QQY%,6Z] @FY=^,GVLR*<^UE&7F!'%=##['J['*V;=KMU6:7, Z!M*9QV9
M-&,-K7/P72>F=?:I+D4K>K& ];N7_37M88&.TKI]TI50?I57;NO/ZV;E\D]>
M/OR0;_*-Y"W\P#_^Q2M:UERN8"A?<A$F28Y5X&%"E)YU)'F88XC3,$0AID5$
M0SL>GM#Z^9&VMEV2AMKR8IO5"E>U.A%HMK\LSP2F? W,N'^F7>M[O^U,5'4_
M.K=6=1Q.1O J[Q>@]7\!&@2 ?#VZW:$.!=#" #H<@ ;"MZZ(U]Z;0*S$C_TS
M4$#QVC%FLBI^31@W./[&<?U<:9L^KY^>]R5D$,Y$)L(8$A&IW%B6RD^1$IAG
M.,<HIEQ0*TVG<PW-;6^M9R?0AHZOUW,66[/AP05BGKE\'%C65'L)":>\>+:Q
M24GLDLN'C'/Q^FM+YFSJ6N?ABTVE>*I>XB+$/&()C.(DA2B6\]T\+C+(@X"(
M/,\*'N=V4]WSC<UO9KHO0+)2^OJT;^W8PBU'$)OQA!O8/#-%KV"+PNN]$5Y7
M5&HY!X6G*BU'S;U1A99S;I^OSG+VCI&*/_MBS\T17W/TM\SR(!2(!E HCD T
MC6&>YQSF-,A3$494OD!V;'&FI?E11;_8^/[TNCW;M@[FN 2T&6<X ,\S80RA
MYJ52^RD<?-5K?]766U5M/^7P0.WVDY?;D03CY?+C>EMN7VX8DP^KW\L?;ZO[
MS9_KI6 4!1D-8910+@E"%6.*6 QICA!+$4VR-#99;PRT,;>E1F,F:.U< &6I
MQ!$H6\W(8 C082)P!)-G$AB%D#$)&& P$"P@[];?_K^1^A$V/^H/?NBYDWSL
M!HYU'[K)I>-F K_B<ETWY<%NUQ__4I.-Y[+^H58HMT(KQ'!<!)G( YBR#$.4
MIPAB+G\B(4\8Q6F4TF*$?,_%AHU>\.D%>_3$6 YY_)7)3=(RL<SFN0P^"8*,
M%TD.TR3()=_& 2RPB"!)0RR",,,B">S2J7S@/A'D"N #W%WC;38O<X/A-.2L
M; 6_*&/_IC#\>/3:?AAZ;:VG:L;0.)VT76YUTNF;,0B'$SGS&^VS!%3]9DF0
MC^HQ-VOVJ5RK4'==]_.6K,H'O?E=_X:WK4K2-_[49F3=BKNJ7-/R":]NA)QR
MJ7" 3^5/OLQS$2=<2$X*1 P1SAG$*HHSCY(8)U$2L<0X@\"]>7.;2-[_X!7'
MRD+S6'0/G39,<6_?%9[Y4#D'I6F/C0R<RA)M'6R*%(.>BPNP=U))$75N*MK<
M.0JTITV,S"=CQ1)/G6N>A/"VG3Q1@L+;=;95 H._OAA(;O#0Z&2)#_X ZR=%
M>&QE1)+?7L2J?%B7HJ0J*YI2)3JC\C4VJY*672DYFC"&U3I!1"2$2,@A.J=1
M+D?G&&<H$2A/8O.JA#9-SV]C=Z<5>"M SWZP=P!T'M@7\;/JE<LCKR^D/8^I
M\X'8(@G/$]13I=[U%##K'N1X#_E3ZX*C\HMC !O*K;-YW'09=2.<?)5'-^;^
MD;D(N*RTUGXOJ.!3Q?_]S-?TY</F42XEER0)BTB0 LIE6@11'J60<!1 $K"T
M"%(41#FQ"0\R:'-NJZY^\,O.5/!'8ZQEJ) )Y&8[2(Z!],SO(S&TSPHP1\5M
MZ+]!N]/&]YL#<13$;W'K..(YJ$RT#%%.XR(F,,4TAZC@<K(9%AE,\Y0)G"AI
M:Z/Z<&>>/S=".2X#M^:6^]"'")IQQA6X>.:'PTIB[ACAC,].O_[#-B;]TL\X
M>/A5G[ML=!KC;B7;)4>^=/I;'YZ/L^1X40B2%_(3CWD,$4E4E7M"8,AP'"84
M96%A)4]O:\#<.&!4FJ(=Y(;S"(] >B:-5QMQ"["S?J%4_0@'=[ADGE(/1T'F
M.MG0SHBITPM'070BH7#<<\;1VN_KBM.-7';]A[-[_-<[ON:B5/D9M%(6U-]X
M_;Q2R[!/TF,M,EB7>I\@I'F21DD":282N4QB%.8Q3F"4IA&F**8QLIK!C#5D
M;C2W,UBE;CU5Y:8"+^I[?-HT]EK&4(_N'S,NG )USYS8=P%('T#GA-(";-P
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M<KH0RO.FS">"\B)<5@&4EY\V>I)W;C[Y[N4W_+^;ZOU*KM>T!![!08@13V!
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MFH8B3W(8A7D D2"J0%"8PR#+D@+Q@A)FN)5ZOI'Y[:?N;+PBZ>P$F(8SAZL
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MU<;;D8EMSYC1C$>\/1-0:_D"]#&_[6'^X37F]\.86_/22.2<,I:M#9-RV4B
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ME8[;V%3?\8KO0SS4;O]O>-O^[48M&3Z5/_G]CVKS_/#CGJ__A^.JWAUO+K'
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MR068D!.7(.(J2B5+89&)#'*L,$<I)2BV"U@_T]+\(E0.OI KSD;.@6M&-@X
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M 2!:#?R"8R_#N,6YL>".[$=W2#>"@YWD,]#*#O;"@[>O0>T=;0[!+&C@Z"7
MJ#'@$&A^#N<&/6/@'H6Z-?/9[^K!G/Y=W'Y8Z&7/O9W>C!0?-NI^?9,+1@3&
M*<P+DD',*P1I43*8*D92F=**(^F9*G48=GI9S%9JL!<;=.0&_[:?I!7=MY6
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M:H7"O>954.LA6D-"N=N7/% 2F$;H.P<<ST$(ZKD,]NZ\WJ5C''^B&BJVMF4
MH8]XR-RE_JIB[)J)C.Y0I%02T3UJ"8IC^.L2H4IJYX1@63Q7>K4O<NZ1,RZ
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MQ=.N:A@05/528-<>ZFJ1KQX(X$_W3'\]\:%#I[[ZT#Y0VFMS)7B]X,V[UZ#
MRI (Y49N6@G;;#,!R33SR>)156=;/D'0_L'=U0=^+:V:)BIQE3*NCE^4_J>*
ME2&1BF2EN Y D?,Z@QGNTC&N;SV$[A_&;3O+N8FSZIK^7RY6TSFL5E_@9%/5
M^'VZFD1F.67"D!@,.G!4960'CUZ>0QFI%1VD.J7)SY(U=H2VN\:? L_>PF\#
M2QOJWRW._'0^\<9$R84CP@0@TB#E06 L$$QD)F49M:QD<FZ3T0A6]E?P?>CL
M+.M1H5)ZNK_%;Y9KK2^P_#:-L/H5S@(L)S8!1)<<"2#*W#[TR&P20#R70;*<
M- CS ]?EZ4\?&0:[*VLQJ-S&'H* ;OB9OT>_D0D,%YI$QPR1R5 2@D9Q".,]
MDU;$^V?,XS,0'OGLD1,N@VA];YDUD!*^-H,8(<!'_'(UD<!B9 F(2<7G8AY(
MH+X\ Q,V)<.]J90!?DC+V&FYX=V)W<3<A ]Q#-]@?@$W=WN:I<!I="09%8B4
MT1)7!CE80%.78O*:NBI N4])(Y[$CKI]4,2XAYA; LH'E-1C[<LPUML,Q"M7
MQ?B_5(I_%0WH:7%):"H.5W**H*=5[FEU4 'Y-:XJEEY"[+APVP\?CX.MFJH:
M..'>+E;KHUPF[G4%=U>G]9?%+$VD$(Z[((DSJ0RIHIP$:Q/A1H*@GJ.W7^LF
MZBF:&CGQAC%E XF^ 1#]9;E8K3XO%WE:<E(N1BXQ(C0J$IGQ*UL>DKKHA.'!
M.6/K=-6Y1<38MTR#PF17X390:GW=[^?]]W.8KVY99>IS\,FB>R@C>HL:U6E3
M=H0&EX1Q*ME4IT[G29+&ODD:%#/#"+X%RP)SY&16:MG2V70^+5RLI]_@BJ\)
MQ]/6.LD(Q%1JS5T9%IQ*'XT<M!.>N5P'1S\@;%PG:"#UWS=$ ^JB 6@=HTZ0
M@%/DYQWZ>;-%5PUYS8SE+,1<NE*;\MS. O$8P1(E05(64@!1YVWDLV2-Z__4
M@=5P>F@ 5%]@-BL!P3S]ZI?_@%O"FB2J542_C3!C5'E,S(G%:("HI'+.#M'
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M'9:D&(W,H^L8HBA3J#/QV@6B$XT<=.9<]$K6#F.Y[E'7+NQV0<9++-L^:FK
MV7KD)5GDCCE><BTF!=RCT1%G0B)2J&2UX\'Q.GUF=IQI5?]J;\#$YFYB;B(5
MA3'%$OP*WL'FOQ_G#Z\0CA>SV8?%\@^_3!.NG*3* H&8);J.952<PWUG8RG_
MX,(*4\=A?R&AC61 =T3&PS?%U934@KEZ\)A*1.\E^$2TT$58DA(GO2,Q9@Q]
M-,^^UFS?G5Z\U9P*74_Q]ZW97EK8&4;GW=F+&V:Y'NCLNR^@28PZXP9C1'-M
MB8RNS =3%-7O!4:Z#"2M<S?S5!G"6('A0>&TGQ[:PM/'U>H"TNVZ^,UN>7]V
M/EM< G2_]/EB&4]1JI]G?KZ:9 ;42.Z(UF6^5[:NM,LTA#LN@J&:.ZCUA&\G
M@L?UR@Z.S,H:;<*W>X+1O_O9!3S)Y\3Z,H)%1G1/#. N+7W,C0?" P?@*/98
M:2;@3N2.F[%M +8#:G/TZ>LW<??JZ^*).[>MJ$MWG2VG1_FMG\U6Q]!=G'Q=
MO%W,D:3U% .\KF&QI<D;%X!8YW.9"H-?:<T(LY+9E#WNW7NMNQYMZUN)O'%G
M9AP"PJWHMIUW!WVD<6O#ES_]/$*9)XJAI/2:>LI)XJE+>WGBP$7"%?4J0!96
M5KJ6W8/J<2=^'-)0'TRW[<#YQ<^(NF=##]X2S;OQR@E#SFP,)RJ92"1SDE@H
M@YU!\: 8S5S5<4"&Y&+<\22'A/MHNF\A<_5<*'$,J_5R&KNW OAK;XJDNTF_
M$VTXS]0FDDM+(NE#($&80*Q0VC'.(9A*Z:V=Z!UW?DH#/O:0^FP^,GR:35 )
M*(V6*,8QEL@N$6M2>>4$C@7-G%6U'EOL0.ZX0UD:0.V VAP],GSQ(7-K#LG$
M>2F<]+'TR#<HVYR)RP[C!,$HGC  0?:9ZK(/#2./>CE4D'<P-;7O^N[=<(5F
MX7BT@;!D<GG<S(C3UA-3VDH81JDWA^TX<ICF//\4=VE-@&)$_[C8@M\7RW\@
M U<![TU0_":BJ%==4+SQJR::!9LU+:5C%%W];&P9VJR)<CYF+03CJ<\LP-X+
MCCP>YE#&N(X"QK>\/7E#MF))F@A>N@1#"28#\<EGPB17(C(IJ&7#X&KL,3(-
M0>IE8A]U6FFOJ.\W^*/[T6KB) ,5(:&H;.E!+27:7F13@$S.9$E%I3Z1_>@;
M>>Q, P'//@IK-YG4A7$W3 E+->ZF1#0M4\AI<B0H;@G5'*(SP*RK,X:F%WDC
MCU!H (1[J*M=#&YV5O?#HZY">O7^.RSC= 5I0KFVW 1&DM9H[GT92)><0)&R
M8"B 2Y6&S[R<UG[H_*>XA*JLR':AVNV_QQD,/!NM:=K,2I1,>&*#",1$PYDP
MVOA8L0[P):3V ^H_Q?51736.GKCLYZI\7DZ_H3O[>>9C5S8^24P(Z4K/+QDP
M(A-.$R] $<07QOM" 15]4I:[K=X/?:_ZPN= JADY!=/+17G 8*E 2"YQ0G/
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MJ^=RXS:,;09SM1343@76+Q>KZ1Q6*XR^PA5O7]9P?NMIR.8:?LONQWGWHR7
M,9RAYWRQ[*[+BI!0PMDYXQ5Q70$1$DV<*:7QVHG2JM2B&*J8T &9&+?G;#/
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MWL0N_;NZ\6(F%C<*]2*3Q$N;Y^),!RT2$=0'SV762AT*H@^I:VW0\C#(^"$
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M3H+N6?Y#>RQ3M,%;H@(WN'$@DQ"I(,KJ''.FVHDZ+<Z?(:H?NEY;$GXH+30
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M>+C:>M%0A\K/Q)D0<>M!)$[;TN ;!2>5=C'7<9$>)6=<ZS2@NN_7H>XM^P8
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M)G,CH[RM8OOK[+K'JGZL[Z@IS!;&/3!3S[X34FA L2C8F*SW18<<[T5N0[O
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M_">>?,??EXOUU[-9]MZB-1S()R1+ZWT$SY'5"N^2G/5)R7+X+?$)BOO:%[=
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M-=H!=*_6WHM%?E/+<>I(]'?+L*C-B]]A.,,S\EPLI]580/A$?K.MU^<ITW;
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MRK39R79LJMH4,WLI^/D.JMO(ND.\7';2XC$;C28 RMJET:"JXT0T)!%"XA2
M.MLFN#B*'JI;Z7A(#]5MQ#TI:.I!^YOYHHYB>Q]/YE\V6K@:09LB#XR51&37
M1OM)%PA2>U!9,LO( *,;TG+NL>?W!(-=]+8<680=Q%1W[>EF;11E \-$=%=I
M*,49N&P=L)"PCN@K1;29$/XS+=/'16/N-7O*NCNT_!%.K_HV<K*CD3,'W-!:
M4M)GLJ>A=G9RVB5IDF.'P,P-13UY*=MK^DG@["CVB:_4_W]<+3\LY[2._ER^
MF7_'#[A*%QDFM*NMY[2V/N%BOES]L5Q?3T37(F;IBP&9!>W2MB9LUV0M*464
M,H;(S9#>6CN\NB?X[*KOY>&$/S&VWB]P6^Z"EID79L#:3$$F1P&!*PNQ)(?(
MC'!I2"KQ]F_N:4L; 5F-1=_!GE=/Q-97AY8W4]8"BD)^HK2)?#N9B'R5'?D"
MGLN<I(VQ36NWAZB9MCO@V%[2WO+N$#.7BRPG$Y.AL,#5B7PJE0#16@XF"*N+
MC"GZPZ"F!Q]I?ST_ YP=A-X!=&Z9SLK(I<W,,2$FA>"]JC/8E0,?. (6DXKR
M7N;2YES\07+Z LXN>KY_I+.WT#M SEU#_.XZC4V$G(VT H23M-_6F<*QUN@8
MBCQ4%&234YNSXT<(FK8O:=N@?C>I=W&*?)>1VQVS/JWK<.Q+URY\P9FLT]9]
MT+6S8!U5+9#DI3Q@CM8X'D)H-)]K.(T]!7 [@N))H(VFG^X,UZNP6OV8+[Y<
M%FT'-+3SEPCH?9W&&0,$7X=/(6<Z%1-#/@36[E+54Q#7 EU[Z* [//UC$4Z7
MM+?_=YVW>=EY387 -!>& D^L1_.\>I@4C'IE*"8M,?C8IBO$LZ3U%,NU0-:^
MVM@>7OX"7@O\4JWDYQ%1=O'VRYN@S5R#/W ]8RPI*7("D^I)RJ8(7]1;()\+
MYLRT;Q3D/4)03^[66(C:7_+[XFBT8X*K9*M9R8YYQ4FM!E,M:RH4;3"RN48S
M7D(F&;69&G>;BFE;NK< R\XR[L(I?[_^BJL[+' *.[FKDPX(T20+B^ ,9Y!U
M4"5YY%&WZ4'P$RG3=EQO@97]I-V)Y_-BD5^%;_-U.-DT KN5H3 +VE!48!*1
M7^%O*$((5@M0(F$N3EB%;<H'GZ9KVC[IK7R>D?30 :HN]]D-&^_F(6[R9UZ=
MKZITR:1J&R-/8*TC#J*BV" $!5X:$T3B2?HVF'J*JFD;G;= U&@ZZ,>!OFUH
MGU@L)B>=!1E>KGV]CTP)G,\&R ++XK) GAJU:QA$W[3]S%M[3"/I941?:OR:
MC3_"JC8X^8[[U6G\])BQ:C.>IJ]M/09WSD:M$402D4)S,BJN%L,GEVMWKQP,
MMLOK&K\>X]T#LR$NK@!$\)8E2_#U68'"Q.N$.0.\"&&0*V2F?5.8.R1-?X*]
M)QZ&#.;87OA=A&4/Y?<YIT/F"I(Q2#QDBAFT,36;F"0FG$!]B+*>Z2LT1E+S
M@-S9+23>@1?]:.I54BKDVI$V>Z]K>P\& :T'*P(Y;M):@8<XC.XY=W8;30_-
MG=U&[$>8.YL$9HO*0JYEM"JZ1#(3IO8XU%%DH23R9[R:7RMW=BM][YD[NXWP
MCR]W-LF(V1L!5F8*-Z7SM;4)!W+Y51#9D3#] &C],KFSNR*KL>@[V/,>S/$K
M7$F6=0%7"O&@0YWDXAD4Z7U@BF57VL04.^?.-H-4&U]I;ZEWB)S+I1:BTDJ0
M.=4<<ZVI4Q 812+">6(D&^UL&U_I:#)HM]+SL S:;83> 70>3N9,4F:MF 7I
M$S'!I0<GO0.FG9"I&.-SFP#_>#)HM]+SH S:;83> 7(^G<>S>9Z'U8]/H?:N
M^;1>IG]N5I5UPNI,EIBEVG,T*0;18JP=&7E2:(TMJ@EZ'B5IVD2A-AO7./+O
M 4@WY%<_\7W9],X.J:KG<K$)QU,0IJZSF$ IBQ#"Y@JGJ.**B#RQ-HAZEK9I
MC=-((+@/K7$UT@'&WI.]?7%RLMQTK;V8QG%58"=0ZV "6+*OQ A%"HYS!X8K
MY[G50?/4)D7D,9(F1M3(NK^?-3**(B8^!G@5OGW#_"J<G-P2SE74:9)$%VK6
M;]&<HDY;Z!.)"$..V2N10KCG.ST8\#_UCFGCL$8(&56P'9B<NR<@'S'CZ0;N
M%P/5-S8Z2J8T"QRR9B0KU (\LQ*RD1&E*LRG=@W<GJ9MVD380UR+[*V1[C%V
MN1@I<$"5K87B1$V@,AJ\2A3D:JXQ(N>HVR6R/4==3^??^R-B*\#MH)[N(?=^
M@5<=,8H6AB-YG4Y'4-88"-97N1G,,>C"79O)S ,)[!EXNR!C*^CMIJ;NT??Y
MS^4E6\4G3%98T%BG4:B:TF5+#8&B2*EX6K13V+QK GNZG#DX^G934P?HNQ[@
M^/+']<>_SW%%1'W]\0Z_X\EFRW F,11>D6>*EM84>2O19T_[!DM*<\<H^FZ3
MY3N(OFG+5MJX=@TTTQ/>?K\9<G/V,W^7"]8%QS21 <66FOCA:T-PD2GH2EK%
M4+SC;5H7;$7FM/MN"YP\!L71E=83(M\NOIVOSS82$Y?&W,4LM0Z%A"8$;1C*
M01!U2D*M%.-"HV[4J_L)HCI!V_A0> QT>^JE X@]M$&\N\[55X&"+YX#<%JA
MQ$PI$**/$(V*.16,0;4!V9-D35O=UV9+'4\/'68A/]D1A#FM=<X25$IU9J)E
MQ%N]DBW",NN-(Q?X ,%#OQU;1H3&[GU;MM%2!V;M+F<WH^"+\Y*;),%G5@>>
M20:^U%'PV9/;(4B2X1 M6ZX)ZB_'JP6R=I-_AS!*>-EV)@<94^TXDR(C4U\2
M0M#.0%(EU]F;ANLV21>/4=1?SD4;(.VD@<FG&ESUDR&3NIHG$M6++U]6FZ)5
M^GJ1YM].L%K=&2)CWD8.FUPGE6SU&X6K)=A:2L=1^R%##@:^KK];I_TPTTK2
M'1BB#ZME0LQG;TB,;\_.SC<#'LJKY>EI'=Y;IY1)+7-(CM%2<)O[6@5!%0M8
MNP<R);*(;2S2LZ3U=P(VCFD:5R<=@.P6Z5?+Z/WBTU<2\]F,%ZF"I_7",]8A
M>(;7DFH/)M"RH85$2ZE-=O,31/47!XX#K+'TT &D[O7NN\G$_4P@.?NZ/,F?
M5R'/%U]>AQ]G,Z:,5"5$, PUJ"@T>,X98/0,N=<F\$.,ZGB&S&E[PAS*U1I3
M5T<!1/K>&:;SVLW@%I]\I@WY!5EQ2*)&O@DM!*<4R"RC%A;IIX=(&]J"Y&E;
MS$P)T#%T>!1@O3F9N<P-W'B[GU?S+U]JFH&T++-,3"(:4'I3<A/)^4B%ONO(
M\Q6'*/C?FO!I&]9,"=SQ]#EQLNZCK&Y*17\.QBZB^4U(5E/H!7I!2W-32B\,
MQ"IKI]%[2R(.ZM[N_W#PNS,%PXYYV?'@[X *Z=EJ7GP\(SU^K-KDLY"4XB@]
MB! %*)Y9G<P0('F*_6-TC(1Y6/MXG\1A4#SZ*X>QE'0<Z-O8=#XS0FO-.7G.
MFTZORB-$EA+D%#D*:9T2;6I@!I,X#'U'?RTQEI*Z0]^M%,#*S:UK/*Y=,62V
MR1&V-060&? 1&1CI5 Y,>R7:C%X>2. PY!W]/<8X"NK,U?N.B[!87[NT[\MK
M+.'\9'W)W?OR_L\%O;A^/ZYG2:,Q-CI@)M=V;<2H8Q<SM;(S"E,T0SJU[$7$
M,+0=VPW(P=0R,?ZN\A5^^^L;4MA?R2<SOFD&>!Y.7BW/ORT75_]G)HO3N2A3
M6<JU6W:B=:43&*UTR4R(;(<$%]N\<QBZCNCBHZG0^P/3BY166-5UL32N9X*X
MI)RI/8YX\<2:=_7FV91-GVPFHXS"I]V@],@;AP'IB"XZ&@J\0QA=#)4)-XQ=
M719NIH/,4F"*,R?!AZA 1?*='/,<A#:: FU3' ZI8-[^S<-@=407&0=00'>N
M_NVDO=?GJ_GBRT75SXQ9\A:-,)"TE;1H# 4P2M52?T\66=%2RFUFM@RC;QCX
MCOZ28A3U= "ZV[D.]_HIS12KZ3/9@M12U4R^##%K"9(($45$QQH58#U!U#!X
M'>%5PEB*Z+*GQQ_GM83B??G'@O1S4J?\768]T XO5=(>T'!=HV(!3I&QSB:&
M8)DE$QX&[)';O758;NZ170<T%'P'9NI6LY2K@Y4-(S/+,LJL(D@9B(]0CU6"
M+V YR9 [4SQK8Z,>HV@8N([P@'\4%4QLG>[P@*?S\]/WY#D2&77_KDS-4BI2
M\N! ED3,B" @!*^ JQP\5S+F8@<8I&=?- PF1W02/[YX>\+*+;Q_.(\G\W27
M+9%$T"(Q2(%[H*"6(@U)4DO<"H_2Y7)_DL?SJ'GZE</P<T3GZ2U%WL$&]MC\
MT'KCKGV*$(RWH!BY=JXV<6=%<G1HZMRD1M'<[I-;Q1&=G(^I@+'GF(T_5^I3
M^HKY_ 27Y?>PIK!T/<>S9;D]76N_@5/#GS_6)*H=.6H[HBK03L4BQ6*$< ;_
ME[TW:W(S.<Y&?U%&U+Y<<C@S\GPQ(AGD2 Z?&T0M622L)D #:&JH7W^RT.@=
MW8WE+;R%EAPV3;(Y0"Y/9F56Y:(T8^ YLV!M?4$VGF-ILQ#U]"NJR*9X0$HU
M92(OJR-XLV8Y.S(:SK1OP^B3)(T_<.I(/.RSHFIWX7?1''Z?B:L1(,%)D;P!
MD6L[5A&)W&MVQ$A6W@AEDVO47O*(EOZ:O0]0\\..DN,DWB%J-E,\5) 2BPJ0
MI8M7=_<D)@]<"NU\,+6[[P2XZ6'8SK$Z?A8R!XA[]*;;30AW9S'H]1PT&7RI
M1=3!1LHN"Q.UL)I!1,%0QN#$PUZVK6G84Y_?$PP.T=M\8!%VD58]6MS&C/4^
MN$#&4.<;:VTI,0P!ZC"+0-;AM&RS=./ I8BC+/HY_,0Y4N+=8>;.3BU."'?,
M<A!1!#*F@N"B#6!X%&A\ENEAY5H3Y'2\%'$O3>^Z%'$?L9_A4D1IA3922C!%
M$WL^B-KC@Y U<:8569S;Y4;Y]2Q%W$O?1RY%W$?XY[<44<BL8Y0:'%.6)!DI
M[70H@,[P4%"25>:R [1>S5+$0Y'56/0=G'E;U[8)SXMDI1:B9UL;<3)$72-(
MCL;9R)CA;<Z[@Y<BCK);ZO!8Z6BI=XB<C:EE6UP,F$!BY2(F"5$E6R>]NN1,
M1!W;Y.=GLQ1Q+SWOMA1Q'Z%W )WM^_F"4RS:*(&7Z$@N%$AZ43S4QBP1$S<Z
MM%E"=CY+$??2\TY+$?<1>@?(>?X9T#"C(POU\6\MGL#!61ZAF"B2ELZ)1GG:
MLV3U-W1M@ -L,#UT *I]AJ(FRF^+36LA4=I0'$1C"P@7,]/<*_NP=/\_HVL/
M!<81HVOWT%('^+O[9OW3C[>7BRKH-[/\;CY+FS]<OR?Z@)8YIX%+YD&Q+,$)
MKB&KX#DZ895J%YGO1F-_=YO#X*^1ECK#WVTMQ4?\%GZL)^J_+YM9(>'BM]D[
M_)/28;SXCG^=SU9?EL0L#T(YI#2W5GGZA!!=R!"D\BPG84UN,V#Y*++'#^]:
M8.D9R+95[+FA^'\P+/[XYWP2<PC%U]8O(Q!4$)25\;J.*3(AC=5<8ILJ\4.H
M'=FS=HC90]1XEE E[.$DB(Q9*@2F95V5Z#)$633HS.H&WZ++PYZ8T<!:Z1WY
MXJY7N.ZMRG,$[*_SR\7$*,59)/ZXP?K&@AH\"P),S)YQ49@,[:X"]R9WY#2]
M4[CNK<BS1.OT.TZXXMR5%*"H0$FC(79C,0C2T__3QIO,&FT^.H3<D4>L]XK6
M?15Y7FA]4^AK;_B4TF93O(9HZA-V8<1G-()R6U4GF1F#MLU,PT,I'GEZ>W>8
M/5R=(U<DW.7QMUFZN*QSES<2O>7YYTN<&"X+9SQ *!A!Z92 @G,!3 @50XQQ
MMU$G.W_AR)/:VT*LG>@/Q]-\%2X&=X,;?B8Q<+0I*>!!U;0NY+H[*H#/R+37
M24;59E'<%F)&'K%^>N=UB!*.[8-KVE%9ES(Z;0NP4NK^*)O!>>M Z%QTS"A,
MAQV5[0:6G 910RBC"U3=E=>MC";1A'I2)=)]+'558@$G(P=7B(?BI8JF31O3
M=GK&'FA^>C=UH"XZ"/S?AF_3>GIB6-[MM[B1D&',":0#/"E1MW 6#CYR!]&2
M(_9%%MEHW_@+A/57D#?, ]^0^N@ 7AN/NV;G]VF(:TE]V&0A%" ^>N\QKA3C
M68T5)>7-(1HZXQ6C?"3(HGTFXVJTWWY/2D=NMQH2)@_7C+?4V1E@\OH]1Y/L
M=) <% _$FW5UKW9)8'Q4MO H<FQ3"K@C@>.^Q(V)P$,T="[ 6[_,4$9#9X?A
M(*18;]Y)$(5'$,Y$'XK1/K29HKDSB>.>OZ.#;V\MG0G\UB\M*?/L% H@^R&^
M"B_@I4R0K;$L::PC'4=#W_BO9&.#;V\=G0OVZ@5TK*]Y'@-PQ>J"9!D@",_K
M*'<GI P"!8Z'O='?O$;'WKXZ.@/LW7\!";XN3#812(YU+K*HK7.4RZGH*,3E
M*$08!X =O6*-B<+#M74&4)P4BF&U,P%RM2]E1"33T@ID0.F9U9Z7<=+?<=^T
MQ@3<7CKIX UK*S_7[R@<G8Y<"V VU;0I)_#<6M#<2BM8$,&V:1UYCJIQ7[5.
MCJU#=-'%Z\-6;NY<?0<32BXN ;I:\^)JK;;' EJ+$(LJFN$)G=>>[Q'-WKA.
MCJ\#-=+!\7CW2>7-++\DN3KRJ<[V)NX224[7]=JR.$B&F\B<5NH$+_,OT]E?
MZ^4P3Q4-M=51:1%Q=M?*[LXDVZ48\/T,)\8(+Z*Q4+=W4I:4%%FX=&"4U*I$
MSOA#G+Y8?W0\5?WT'@V-G2<*E4ZLR X@O!J&\WK3GAC7*0H'SB3R$X)\8LQ2
M@R1]V!3)7<A=UF8.2U4_K4B-(3R2(E\1A-?W]=%:'U(-K;+EM=R' FZ-#%!$
MIM!XPW"766=#T]5/B]*9P'AO9;X>(*_O_HN+1ABKP1@G*&@3"%[9 )A-TLZB
M%4&=%L?C/\J<'XSW5F4'*!XHEKKJD(D4,=6E7DFPFGJ( ('X70^DRAZ3D657
M% ](5C\M3><1%N^MRM> XOMO$(Z)E+1BD)".(X48P'EIP5N?E(C92"].!>2.
M'HG."<N'*[0#.+]\'CW=HS.QTAIMF8<4%(51DF7PD@O@(2?4K) DAHLEGJ:C
MGY:IT8.'@935P4O44VT7!K,T1A6@,#V2?1%#(=D(A3O&Z;AP*K1I<CZF!^8D
M756-P#>D0KIXB=I-9M</;<)J##9FL (+L><I/(F.>#32$&NBH&U3S[87F?UT
M8C5&83OE=8'-^R,"_S8+7^>+U?1?F.MFKOEE??CEWHE@'<14'UU\J&M1D@?.
M77+<V.Q*;N3_7B"MH\ZMYJYP2"T-O7JQM6><\*"1&U^@2$Z1A+&^1K<6C/'!
M%9Z"L8TVY^U$WVXX/.?7J8;Z&BPE&7H!Z&+ZG3[D.][:W3+,\G]A_DS1[IM$
M/[K*!>[QL>/RSUT_>YC%GP=Q,MC2SRW?_F;+MV_9!,FQA"2POOXX!<HJ#9%B
M/RB8B^!>U^*V1B?/P40??Q[O_=5_D*I^HL_XQR09+S X Q8M"4QF#2XJRKB$
M(V,OT:38IK/Z&*K'WJQS&GP^/M%/I.=S]Z_KP>M-O>SF&T[J:[=QU8''C5Z)
MQ)F"J$*@V,!XB(;2%Y2Z7HT7)D2;3KX1/>[U4NSWY>Z ]%N"KG1U:WPQ6Y44
MUR"RH4A;DM5[*PM%VDKPR!%1MQG>O">AY^M7]T'A0[_:4IOG[DJ/65>_YU><
MU)FV75I_.(Y-*21%R8$;51N^K83 ?0)/6(N&_B@:C7GO(GZ]VIBBD)4L3 *7
M.=E70@I5- M <M$F.L9L;C5!ZAXAY^L-]T'1TU'F_MKH8I_Y5L'])4QGO\^7
MRY]^;.3W$2^N;AZ^3+^M]X5%68\.7<"1#P/%HH*@:]."C5AR+D6IUJC;A]Y>
MP'D 2'9):X;55P>='UO8V&P;"S+[X+D''Y,C1E! $$E#*<4KEXO1K$T _21)
MO6"K'1[F+933 <K>AN677R_F_]PPM-D^9XU+*DD-&K$N:B(3]=$PH+ 8LS4E
M.-;F+GPK.>.B:R!5/QIJ=JS<.P#/AOB?<3G]/+M22#4L2G!<R.3,K8\UW7$.
MO#$<HH_:"]0JA39-C]OI&7OW\7 'WP#R[A(U-_;$E?;9@169@4(;ZP)65==P
M%.^R%S*UF3/Q%$5=.)ZCM/TB@ X0?0<0NF8 \YOEAJ?;HW_C2Q5/ @WQ(&/A
MY)VE 5>XK*42*A1RW++96.$7B>L-6(>@X%%0/JQ*ND#9X[CRXW3YC[49EIBY
M5H'8\-J#<BY#R([\.%>%3G[')&^S1.<YJL;MFVJ=XQTD^\YN&-[.9^L;ESO+
MHZ--.K$ZD4#6:0=!UD$'%L$XRY0*FIG89G?H<U3UE]$=IOTG876D(D:%5:V<
MOK=H]Y_AV_^[G*%@W-UD$D0NQ0(02A(U2J#<Q&M>E^U(2GJED?I!0=W6(O;G
MOZ47D!RKRWD3L8[<!_&0DY\QK7D@;LSUDGF6(T]$O@AHB!LZE.G/!3)SG)7D
MC<B[=/^^_$V]I& -@7*D>+L*=WZ_&8:BR=5Z;>L"Q&)K'$C)1A %BM=H%6/<
MI];543?$C-M-VR:X.4S27<0T=UMW;G>\_X1A0:'_W^G7*J9K*WGS=5U ['B(
M29 =D*U1@F&2!*\- TZQ?Q0BN^3:K?7=D]A>#K<#(;*EJ+:EMKKR7^_F54WA
M8L.'*$'D4A"$5PX4MXK26NOK;'ZN4T*K66LG=I^B7H[#8: UB-R[PL^OTS\Q
MWSW@)R$;5$Q$<,BQ>GL)T:M(H4(TPHI4#+;IEWJ&J%Z2_:%1=)ST1XZZ[X0)
MY&VG5]=KOR).M Y%4)X*6=8;M5K1&QARL#%[)";P49:_-=9^ZO-["8Z. \-@
M$NS G;Q??<'%V_E7^OXO.%NN[S+2_"O61^F[KW]X_5+]$=-%6"ZG99JN%%<[
M\/\(?TZ2BT('IR&&H*[\J ^V0-V8FSB3MI@V5XV#L3#N")&A7=4XFAVZH6[8
M^M!?_N]RNOKQQR+,EI1?KQO6]J\ W?(A0]1XOD3;0%6<5U]S4U(GE-#.I016
M13JT+*L31<E=&4H/>3*6<]>FI?4^'4=7KJ_FZ1]?YA=DHLNK3Z8H#[<UC(1(
MF-5"0'%&DDF%NN8OU8=)*S$6SQQO$V;O3.*X*=T1^'A4@-Y$*9V6GC\VW\-K
MS)_^K#:.IF75^ ,\<:=TT(0BS+4YN]1R-E,$6.3!8J% V;=Y1AK8W]ST5GSZ
M0F;U4UABKF<M';0;2R7Q?L9UC=]//V[_S68]P9M_AD6^NJ%#X71=1@5.2T.'
M*Z.$ 7D&Y0+EGQS1AS:SL =CH2M_M0^^GFZ8.:52N[@F_>ER24'G<ODFD3B7
MTYLR'A:5UMK+VEG)KXH'77(*6-(I:&32V39%O$\0-"[61@+(?'A==0NZ^ML%
M7C][60HXN)49F.4!E,H4%V PM0R:L^*S\ZI-C>:+I(T+Q$$@L .L#M?&Z)4'
M%-]\PXOY?V&X6'W9/'5RDWG6=!ID4S2H6+=J!&8@:X'<>N>\W&7@XY:/[@\.
M1ZAN/IP4.[CA^G09E],\#8L?G\+:==>L9&TMW$8A1,F0%'.@LE'@-7GB0H(J
M-OFD19O<]TF2QGURZ>-X&T9?/0#OEOQWX2O]]D[*M3'+$AC+& D@BI.<3*TR
MS8R,RB@5R"Z=56T>;%ZF;>1(:Q@0/(36L!KI &,?UG?&^.$B)+Q3PBR-T)Z3
M?Y>VOHE;24)**4%4EGR]"41LFTNN[?2,C*6!M3X?7 4COP:2C_\ZGZT%]+[0
MM]]V>GDMG&>Z@-$*R7NO=S58A%(210%)&QM?NLMZ]@M&/N_: &,XD7;@8-Y3
M//[FXF*^JM!^_ZV*YAK@A9O$92%'7-LPE-,44FH)-B<AA<[*Q397 T^2-&ZI
M06,W,XPB.D#4B['E4Z'E[;-H(K-17 B(V;%:#1L@KIM;HPP^\<),HUNIXVD?
M&:-]1/BG14 7=UUWO<-E-=N-"I:_+9>7M9#HCK>8%*4=KVW5#&,"Y94$G[,
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M0O_BPT68U=#TRM=0LO1U'78\W)C!G%!>%PM8/.5/$BEUPNQ HE'>Y<2];U1
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MC@+\AFLF3\-D![??K\@R1P+?>02I+PGGT>:L9^539!;<&P9<N7K-ZC2EMYA
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M[.425V_HT)R&.+V@$W^MASLVP;FKLY @6$LVH9( +QV%\<2*LE;'[-HLZCB
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ML "-MLH4D+&:DT22FI%D4YR;Q$I.1;69S+ +=?U=KQT)BGU@=XB&>D?=W?C
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M51:L,,R\31+W'%7C^J"A\/'0N0RFA_Z]R,&3SA]_QL >I>%L\^=PP[B1+*L
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MK+5*M%E<^P)A(\_".Q%"M@-S$&7UXS/7[4WUI9+^@RU,!<ZQSK0'%\QZ4K,
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MQBN9/&MOKNZZSV\@)^VC/7\.&K9?KJ"18-U\$9V]P$Q+4(6O;6)X_P."@J_
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MFA[Q53&T,XR%UJ(8N]]-6*Q$7NG7)O]0/SU=NVJNK2NGWP!02P,$%     @
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ME =>TU>?\4<#X><+IW\"4$L#!!0    ( $B&650#F,4SF@8   0E   9
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M)IR(R(/75N[5SB ,_=%$9CD3:W<7C'X!4G4L50:!W_H7)%(YG0G7$>E<(U.
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M7RH=_ =02P$"% ,4    " !(AEE4HF]ZH*ZC!  +Q#  $
M@ $     ;F5O+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( $B&650(Q I2Z1@
M !<3 0 0              "  =RC! !N96\M,C R,3$R,S$N>'-D4$L! A0#
M%     @ 2(995#FFFMKC-0  13X" !0              ( !\[P$ &YE;RTR
M,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ 2(995*5FF2A&J   OX$' !0
M             ( !"/,$ &YE;RTR,#(Q,3(S,5]D968N>&UL4$L! A0#%
M  @ 2(995/.%FB"<Z0  $BP! !,              ( !@)L% &YE;RTR,#(Q
M,3(S,5]G,2YJ<&=02P$"% ,4    " !(AEE4T>1@/^Z( 0!);A  %
M        @ %-A08 ;F5O+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !(
MAEE4E'BF7'CZ   BN L %               @ %M#@@ ;F5O+3(P,C$Q,C,Q
M7W!R92YX;6Q02P$"% ,4    " !(AEE49E,HO_<P  ##-P$ '@
M    @ $7"0D ;F5O97@Q,#$Q97AE8W5T:79E96UP;&]Y;64N:'1M4$L! A0#
M%     @ 2(995(RW@J@: P  L@X  !X              ( !2CH) &YE;V5X
M,C$Q;&ES=&]F<W5B<VED:6%R:65S+FAT;5!+ 0(4 Q0    ( $B&652X\868
M80,  +8*   9              "  : ]"0!N96]E>&AI8FET,C,Q,3(S,3(P
M,C$N:'1M4$L! A0#%     @ 2(995..O!S"T!P  &R$  !D
M ( !.$$) &YE;V5X:&EB:70S,3$Q,C,Q,C R,2YH=&U02P$"% ,4    " !(
MAEE4$0J2.K4'   9(0  &0              @ $C20D ;F5O97AH:6)I=#,Q
M,C$R,S$R,#(Q+FAT;5!+ 0(4 Q0    ( $B&650#F,4SF@8   0E   9
M          "  0]1"0!N96]E>&AI8FET,S(Q,3(S,3(P,C$N:'1M4$L%!@
0   -  T >0,  .!7"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
